[{"CaseStudyId":"1857","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"2264397","Name":"Portugal"},{"GeoNamesId":"927384","Name":"Malawi"},{"GeoNamesId":"3996063","Name":"Mexico"},{"GeoNamesId":"2413451","Name":"Gambia"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d    South Africa has the largest number of HIV infections of any country. Out\u000d      of a population of 50 million people, 5.6 million are HIV+. On World Aids\u000d      Day in September 2009, South African President Jacob Zuma announced the\u000d      most significant government-led interventions to stem the AIDS epidemic\u000d      since its emergence more than 20 years ago, stating that extraordinary\u000d      measures are needed. He said that \"In order to meet the need for\u000d        testing and treatment, we will work to ensure that all the health\u000d        institutions in the country are ready to receive and assist patients and\u000d        not just a few accredited antiretroviral centres. Any citizen should be\u000d        able to move into any health centre and ask for counselling, testing and\u000d        even treatment if needed\". This research has had major impact on the\u000d      health policy to achieve this. The policy developments are all landmarks\u000d      in primary health policy and provision in South Africa, and have also been\u000d      applied in Gambia, Malawi, Brazil, Mexico and Portugal.\u000d    Because our research had shown PALSA PLUS to be both effective and\u000d      cost-effective, in 2010 the South African National Department of Health\u000d      adopted PALSA PLUS as the primary method of in- service training for nurse\u000d      practitioners in public sector primary care facilities throughout the\u000d      country. To implement this policy it contracted our partner, the Knowledge\u000d      Translation Unit at the University of Cape Town Medical School, to provide\u000d      the training, clinical guidelines and training materials (see\u000d      corroborating source C). By January 2013 the KTU had trained 1500 trainers\u000d      in all 8 provinces in South Africa, who had in turn trained 18,000 primary\u000d      care professionals in 1900 health facilities (of a total of 3500\u000d      nationwide). Supported by the STRETCH trial's evidence, in 2011 the South\u000d      African National Department of Health adopted Nurse-Initiated\u000d      Antiretroviral Treatment (NIMART) as national policy for the nationwide\u000d      expansion of ART in primary care.\u000d    The research programme started in 2000 with a WHO initiative to improve\u000d      tuberculosis control worldwide by increasing detection of infectious\u000d      cases. WHO's Practical Approach to Lung Health (PAL) programme encouraged\u000d      low and middle income countries to implement PAL guidelines for the\u000d      diagnosis and treatment of chronic lung diseases among primary health care\u000d      workers. In collaboration with WHO and South African health departments,\u000d      and with local primary care doctors and nurses, the researchers completely\u000d      redesigned the guidelines and educational methods and implemented them\u000d      throughout one province as PALSA (corroborating source A). After the PALSA\u000d      trial showed that the intervention was effective and highly popular, and\u000d      that large scale expansion was feasible, it became standard practice in\u000d      the Free State province from 2002 on. PALSA was then expanded, as PALSA\u000d      PLUS, to cover nurse-provided care of HIV and sexually transmitted\u000d      infections. After the second trial showed that PALSA PLUS was effective,\u000d      it became standard practice in two provinces in 2009\/10 and then\u000d      nationally in 2011. Subsequently, the researchers were commissioned by the\u000d      South African National Department of Health to expand the clinical\u000d      guidelines and training to include diabetes, hypertension, chronic lung\u000d      disease and depression, and started to evaluate it as the PC101 trial in\u000d      the Western Cape. Preliminary evidence from PC101 and engagement with the\u000d      National Department of Health led to it becoming the standard guidelines\u000d      and educational method for primary care nursing in South Africa\u000d      (corroborating source C).\u000d    Meanwhile the research programme addressed controversial policies on\u000d      antiretroviral treatment (ART) for HIV\/AIDS. KTU was contracted to monitor\u000d      and evaluate the Free State's HIV\/AIDS programme the programme, and to\u000d      manage all electronic medical patient records. Our finding that 53% of\u000d      patients died while awaiting ART but that when ART was received it reduced\u000d      mortality by 87% increased pressure on South African authorities to\u000d      accelerate ART roll-out and to initiate ART promptly in eligible patients.\u000d      A key problem though was the lack of doctors to provide ART, which only\u000d      doctors were authorised to prescribe. The researchers therefore developed\u000d      and helped the Free State provincial Health Department to implement\u000d      STRETCH - a radical breakthrough in enabling primary nurses to treat\u000d      HIV\/AIDS by training and authorising them to prescribe ART, in the face of\u000d      objections by the national Department of Health, HIV physicians, and the\u000d      South African Nursing Council. This intervention was at first permitted\u000d      only because it was implemented as a randomised trial (corroborating\u000d      source B). Nurse Initiated ART (NIMART) became national policy within\u000d      months of the end of the trial and is expected to greatly enhance access\u000d      to ART in South Africa. Any nurse needs to complete our training to be\u000d      authorised to prescribe ART. Between 2010 and 2011, 300,000 more people\u000d      started ART. ART expansion will greatly reduce morbidity and mortality due\u000d      to HIV\/AIDS, and help control the rampant tuberculosis epidemic.\u000d    Our research has also had wider international impact. In 2010 the\u000d      Malawian Ministry of Health began implementing PALM PLUS, a local\u000d      adaptation of PALSA PLUS. In 2011 the Gambian Department of Health &amp;\u000d      Social Welfare began to implement its adaptation of PALSA PLUS, and in\u000d      2012 started implementing NIMART based on the STRETCH model. PALSA PLUS\u000d      guidelines and training materials are also being used in Brazil, Mexico\u000d      and Portugal.\u000d    ","ImpactSummary":"\u000d    In order to reduce morbidity and mortality from HIV\/AIDS, tuberculosis\u000d      and other chronic diseases, effective and cost-effective interventions to\u000d      strengthen primary care through in-service nurse training were put in\u000d      place as standard practice throughout South Africa (population 50\u000d      million), based on our research. This programme has so far trained 1500\u000d      trainers in all 8 provinces, who in turn have trained 18,000 primary care\u000d      professionals in 1900 of all 3500 clinics nationally. South Africa, with\u000d      5.8 million HIV+ people, and 500,000 newly infected with tuberculosis each\u000d      year, based its Nurse Initiation and Monitoring of Antiretroviral\u000d      Treatment policy on our training package and trials. These were landmark\u000d      changes in primary health policy and provision in South Africa. The\u000d      training methods and materials are also being used in Gambia, Malawi,\u000d      Brazil and Portugal.\u000d    ","ImpactType":"Societal","Institution":"\u000d    University of East Anglia\u000d    ","Institutions":[{"AlternativeName":"East Anglia (University of)","InstitutionName":"University of East Anglia","PeerGroup":"B","Region":"East","UKPRN":10007789}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"1085599","Name":"Province of the Western Cape"},{"GeoNamesId":"967573","Name":"Free State"},{"GeoNamesId":"3369157","Name":"Cape Town"}],"References":"\u000d    (UEA authors in bold)\u000d    \u000a1. Fairall L, Zwarenstein M, Bateman, Bachmann MO, Lombard C,\u000d      Majara B, Joubert G, English R, Bheekie A, van Rensburg D, Mayers P,\u000d      Peters A, Chapman R Effect of educational outreach to nurses on\u000d      tuberculosis case detection and primary care of respiratory illness:\u000d      pragmatic cluster randomised controlled trial BMJ 2005\u000d      331:750-754 doi: 10.1136\/bmj.331.7519.750\u000d    \u000a\u000a2. Fairall LR, Bachmann MO, Zwarenstein M, Bateman ED, Niessen\u000a        LW, Lombard C, Majara B, English R, Bheekie A, van Rensburg D,\u000d      Mayers P, Peters A, Chapman R Cost effectiveness of educational outreach\u000d      to primary care nurses to increase tuberculosis case detection and improve\u000d      respiratory care: economic evaluation alongside a randomised trial Tropical\u000a        Medicine and International Health 2010 15: 277-286 doi:\u000d      10.1111\/j.1365-3156.2009.02455.x\u000d    \u000a\u000a3. Zwarenstein M, Fairall LR, Lombard C, Mayers P, Bheekie A, English RG,\u000d      Lewin S, Bachmann MO, Bateman E Outreach education for integration\u000d      of HIV\/AIDS care, antiretroviral treatment, and tuberculosis care in\u000d      primary care clinics in South Africa: PALSA PLUS pragmatic cluster\u000d      randomised trial. BMJ 2011 342:d2022 doi:\u000d      10.1136\/bmj.d2022\u000d    \u000a\u000a4. Fairall LR, Bachmann MO, Louwagie G, Janse van Vuuren C,\u000d      Chikobvu P, Steyn D, Staniland G, Timmerman V, Msimanga M. Seebrechts CJ,\u000d      Boulle A, Nhiwatiwa R, Bateman ED, Zwarenstein MF, Chapman RD\u000d      Effectiveness of antiretroviral treatment in a South African program: a\u000d      cohort study Archives of Internal Medicine 2008 168:86-93\u000d      doi: 10.1001\/archinternmed.2007.10\u000d    \u000a\u000a5. Fairall L, Bachmann MO, Lombard C, Timmerman V, Uebel K,\u000d      Zwarenstein M, Boulle A, Georgeu D, Colvin CJ, Lewin S, Faris G, Cornick\u000d      R, Draper B, Tshabalala M. Kotze E, van Vuuren C, Steyn D, Chapman R.\u000d      Bateman E Task shifting of antiretroviral treatment from doctors to\u000d      primary-care nurses in South Africa (STRETCH): a pragmatic, parallel,\u000d      cluster-randomised trial Lancet 2012 380:889-898 doi:\u000d      10.1016\/S0140-6736(12)60730-2\u000d    \u000a\u000a6. Barton GR, Fairall L, Bachmann MO, Uebel K, Timmerman\u000d      V, Lombard C, Zwarenstein M Cost-effectiveness of nurse-led versus\u000d      doctor-led antiretroviral treatment in South Africa: pragmatic cluster\u000d      randomised trial Tropical Medicine and International Health 2013\u000d      18:769-77 doi: 10.1111\/tmi.12093\u000d    \u000aKey grants supporting this research:\u000d    Bachmann (PI, grant awarded to UEA) \"Streamlining tasks and roles to\u000d      expand treatment and care for HIV: randomised controlled trial, economic\u000d      evaluation and qualitative process evaluation (STRETCH)\" &#163;820,000 Medical\u000d      Research Council (UK) 2008-10.\u000d    Fairall (PI, grant awarded to University of Cape Town; Bachmann\u000d      co-applicant). \"Evaluation of antiretroviral provision in Free State\u000d      clinics\" $800,000 Canadian IDRC\/CIDA 2004-7.\u000d    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d    A. Practical approach to lung health. Manual on initiating PAL\u000d      implementation World Health Organisation (2008)\u000d      http:\/\/whqlibdoc.who.int\/hq\/2008\/WHO_HTM_TB_2008.410_eng.pdf\u000d    This manual explains why PAL is a cornerstone of WHO TB policy. On pages\u000d      122 and 123 it cites the Practical Approach to Lung Health in South Africa\u000d      (PALSA) guidelines and supporting research (English et al 2004, Bheekie et\u000d      al 2006, English et al 2006).\u000d    B. S-T-R-E-T-C-H! Streamlining Tasks and Roles to Expand Treatment\u000d      and Care for HIV. In: Tried and Tested. In Models for the Scale Up for\u000d        HIV Prevention, Treatment and Care from South Africa and Beyond. (pp\u000d      208-212) Department of Health (2010)\u000d      http:\/\/www.hst.org.za\/sites\/default\/files\/TriedandTested_ModelsforScaleUpHIVPrevention_Book.pdf\u000d    This book, published online by the South African National Department of\u000d      Health, describes exemplary evidence-based models for expansion of\u000d      HIV\/AIDS care, with a chapter advocating STRETCH (pp. 209-212).\u000d      It cites the STRETCH randomised trial as supporting evidence (Fairall et\u000d      al., 2008, which is the study protocol for the trial described in\u000d      reference 6 of underpinning research).\u000d    C. Knowledge Translation Unit, University of Cape Town Lung\u000d      Institute\u000d      http:\/\/www.knowledgetranslation.co.za\/index.htm\u000d    This website describes the whole programme, including activity data on\u000d      national implementation, guidelines, training methods and materials, and\u000d      research publications. It confirms that:\u000d    \"The Department [of Health] has supported the Knowledge Translation Unit\u000d      to introduce rapid and effective training to all nurse practitioners and\u000d      other health care providers in primary health care clinics in South Africa\u000d      using the methodology of PALSA PLUS. Legal provision for nurses to\u000d      prescribe ART has been provided using Section 56(6) of the Nursing Act of\u000d      2005.\" ... \"PALSA PLUS is now a national training requirement for any\u000d      nurse prior to authorization to prescribe NIMART\"\u000d    \" The KTU has updated and revised the Primary Care 101 guideline\u000d      for national use, following input from the Colleges of Medicine of South\u000d      Africa, the Medicines Control Council, the South African Pharmacy Council,\u000d      the South African Nursing Council and the National Department of Health\u000d      Chronic Disease Cluster.\"\u000d    D. Letter from the Deputy Director General (formerly Director of\u000d      Primary Health Care) of the South African National Department of Health,\u000d      confirming the impact of the research. He has been involved in national\u000d      implementation on the basis of this research since the beginning. (letter\u000d      held on file at UEA) \u000d    ","Title":"\u000d    Implementation of effective clinical practice in African primary care\u000d    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d    The research that led to the impact in this case study is the development\u000d      and evaluation of educational methods to improve primary care in low and\u000d      middle income countries. For over ten years this research provided\u000d      evidence that these educational methods strengthen primary care in African\u000d      countries, with particular focus on HIV\/AIDS, tuberculosis and other\u000d      chronic diseases.\u000d    Practical Approach to Lung Health in South Africa (PALSA)\u000d      (2000-2010): UEA and South African researchers radically changed World\u000d      Health Organisation (WHO) clinical practice guidelines and educational\u000d      methods, aimed at integrating primary care of tuberculosis and other lung\u000d      diseases. A large pragmatic cluster randomised trial showed that the PALSA\u000d      education package, was effective, significantly increasing tuberculosis\u000d      case detection and appropriate emergency referrals and asthma treatment,\u000d      and was cost effective (research references 1-2).\u000d    PALSA PLUS (2004-2011): PALSA was expanded to cover HIV\/AIDS and\u000d      other sexually transmitted infections. A large pragmatic randomised trial\u000d      (research reference 3) showed that PALSA PLUS improved the quality of\u000d      HIV\/AIDS care provided by primary care nurses. The research also showed\u000d      that PALSA and PALSA PLUS increased tuberculosis cure and treatment\u000d      completion rates and reduced patient dropout.\u000d    Antiretroviral treatment (ART) expansion in South African primary care\u000d      (2004-2011): Novel statistical methods were used to evaluate ART\u000d      effectiveness using patient cohort data (research reference 4). This\u000d      provided the first rigorous evidence that ART in Africa could be highly\u000d      effective even when implemented on a large scale. These studies also\u000d      showed extremely high mortality rates among patients because of delays in\u000d      their starting ART.\u000d    Streamlining Tasks and Roles to Expand Treatment and Care for HIV\/AIDS\u000d        (STRETCH) (2007-2012): The PALSA PLUS guidelines and training\u000d      package was extended to cover initiation, monitoring and prescribing of\u000d      ART, and nurse-led HIV\/AIDS care which did not need doctors. This complex\u000d      intervention was compared with South African standard of care in a\u000d      MRC-funded pragmatic randomised trial (research reference 5). The trial\u000d      showed that nurse-led ART was as effective as doctor-led ART in preventing\u000d      deaths and in viral suppression, but was more effective in increasing\u000d      patients' weight and immunity, detecting tuberculosis and improving\u000d      treatment adherence. The cost effectiveness analysis (research reference\u000d      6) showed that STRETCH cost more than standard of care but was reasonably\u000d      cost effective. Qualitative research identified barriers to implementation\u000d      but showed how nurses were able to adopt this intervention.\u000d    Integrated primary care of diabetes, hypertension, chronic respiratory\u000d        disease and depression (Primary Care 101) (2010-2013): The PALSA\u000d      PLUS guidelines and training package was expanded to include diagnosis and\u000d      treatment of these chronic diseases in adults and, diagnosis and treatment\u000d      of depression in adults with chronic disease. This intervention was\u000d      evaluated in a fourth NIH-funded pragmatic randomised trial, which\u000d      currently is being analysed.\u000d    UEA researcher involvement:\u000d    M Bachmann - (Professor of Health Services Research, at UEA since\u000d      2003) has had lead roles in all the studies, especially trial design\u000d      (PALSA, STRETCH, PC101), ART cohort studies, and economic evaluation\u000d      (PALSA). He has supervised 5 South African PhDs based on this research.\u000d    A Clark - (Senior Lecturer in Medical Statistics, at UEA since\u000d      2005) had lead roles in developing statistical methodology for cluster\u000d      randomised trials and economic evaluations.\u000d    L Niessen - (Professor of Public Health Economics &amp; Public\u000d      Health Modelling, at UEA since 2008) contributed to economic evaluation of\u000d      PALSA.\u000d    G Barton - (Reader in Health Economics, at UEA since 2007) led the\u000d      economic evaluation of STRETCH.\u000d    "},{"CaseStudyId":"1858","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Natural Environment Research Council"],"ImpactDetails":"\u000d\u000a    This research has led to changes in national and international health\u000d\u000a      policy, including policies of the World Health Organisation, other\u000d\u000a      international bodies such as the European Commission, and the United\u000d\u000a      Nations Economic Commission for Europe, and the USA Environmental\u000d\u000a      Protection Agency. It also led to changes in European Union and UK\u000d\u000a      legislation. The impact of the research was strengthened by Hunter's\u000d\u000a      participation in expert panels advising these public health agencies.\u000d\u000a    Small and very small drinking water systems\u000d\u000a    The research showing that small water systems in both developed and\u000d\u000a      developing countries are far more likely to be prone to microbiological\u000d\u000a      contamination than large mains systems influenced the recommendations of\u000d\u000a      international expert groups and task forces, leading to changes in policy.\u000d\u000a      Hunter was an expert member of the joint task force of the United Nations\u000d\u000a      Economic Commission for Europe and the World Health Organisation Regional\u000d\u000a      Office for Europe. These organisations jointly published guidance, \"Small-scale\u000a        water supplies in the pan-European region\" (corroborating source A),\u000d\u000a      which appraised policy-makers and regulators in the drinking-water sector\u000d\u000a      of the need to address failings in the monitoring of small-scale water\u000d\u000a      supplies. There is little objective research evidence on which to base\u000d\u000a      policy and regulations. WHO cited two UEA studies as providing \"exemplary\u000d\u000a      drinking-water quality data\" for England and Wales (corroborating source\u000d\u000a      B). These studies were used to show that compliance with microbial\u000d\u000a      indicators is a problem in many small- scale water supplies, resulting in\u000d\u000a      water of a quality that is not safe for consumption and a risk to public\u000d\u000a      health. Their economic assessment of the health benefits of improvements\u000d\u000a      to small water supplies (research reference 3) led directly to WHO\u000d\u000a      publishing guidance on social cost-benefit analysis of drinking-water\u000d\u000a      interventions (corroborating source B).\u000d\u000a    Bathing water legislation\u000d\u000a    It is estimated that, globally, over 120 million gastrointestinal\u000d\u000a      illnesses per year are caused by swimming and bathing in\u000d\u000a      wastewater-polluted coastal waters. Hunter has been a member of two\u000d\u000a      separate WHO expert groups to deliver improved guidance on bathing water\u000d\u000a      quality. Hunter's methodological research was used\u000d\u000a      specifically to underpin the WHO guidance documents on classification of\u000d\u000a      bathing water quality, to avoid misclassification of recreational waters\u000d\u000a      through inappropriate choice of methods of calculation (corroborating\u000d\u000a      sources C, D, E). These WHO guidance documents form the basis of current\u000d\u000a      European Union Bathing Water Directives (corroborating source F), which\u000d\u000a      were consequently enacted into UK law in 2008 (corroborating source G).\u000d\u000a    Hunter worked with epidemiologists from the USA Environmental Protection\u000d\u000a      Agency, identifying the uncertainties and shortcomings of current US EPA\u000d\u000a      recreational water quality criteria, setting research priorities to\u000d\u000a      support the development of better criteria, and advocating better methods\u000d\u000a      for developing new criteria (corroborating source H). This work then led\u000d\u000a      to EPA changing the criteria for regulating the microbiological quality of\u000d\u000a      US bathing waters (corroborating source I). \u000d\u000a    ","ImpactSummary":"\u000d\u000a    Diarrhoeal disease is the world's second most common cause of death in\u000d\u000a      children under five years old, killing 760,000 children each year\u000d\u000a      according to the World Health Organisation (WHO). Microbial contamination\u000d\u000a      of drinking water is one of the most important causes. In England and\u000d\u000a      Wales acute diarrhoeal disease is estimated to cost the country &#163;1.5\u000d\u000a      billion annually. UEA epidemiologists have shown the important role of\u000d\u000a      water supply systems in spreading diarrhoeal disease in developed and\u000d\u000a      developing countries; led WHO research projects on small scale drinking\u000d\u000a      water systems; and influenced WHO policy on small scale drinking water\u000d\u000a      systems in developed and developing countries. Methodological research on\u000d\u000a      epidemiological methods for monitoring and regulating bathing water\u000d\u000a      quality has led to changes in WHO guidance on bathing water quality\u000d\u000a      standards and influenced US Environmental Protection Agency criteria.\u000d\u000a      Hunter's participation in international expert panels facilitated the\u000d\u000a      impact of this research on policy.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of East Anglia\u000d\u000a    ","Institutions":[{"AlternativeName":"East Anglia (University of)","InstitutionName":"University of East Anglia","PeerGroup":"B","Region":"East","UKPRN":10007789}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    Key publications (UEA authors in bold)\u000d\u000a    Small and very small drinking water systems\u000d\u000a    \u000a1. Risebro HL, Breton L, Aird H, Hooper A, Hunter PR\u000d\u000a      Contaminated small drinking water supplies and risk of infectious\u000d\u000a      intestinal disease: a prospective cohort study PLoS One 2012\u000d\u000a      7:article no. 42762 doi: 10.1371\/journal.pone.0042762\u000d\u000a    \u000a\u000a2. Richardson HY, Nichols G, Lane C, Lake IR, Hunter\u000d\u000a        PR Microbiological surveillance of private water supplies in\u000d\u000a      England: the impact of environmental and climate factors on water quality\u000d\u000a      Water Res 2009 43:2159-68 doi: 10.1016\/j.watres.2009.02.035\u000d\u000a    \u000a\u000a3. Hunter PR, Pond K, Jagals P, Cameron J An assessment\u000d\u000a      of the costs and benefits of interventions aimed at improving rural\u000d\u000a      community water supplies in developed countries Sci Total Environ\u000d\u000a      2009 407:3681-5 doi: 10.1016\/j.scitotenv.2009.03.013\u000d\u000a    \u000a\u000a4. Hunter PR, Zmirou-Navier D, Hartemann P Estimating the impact\u000d\u000a      on health of poor reliability of drinking water interventions in\u000d\u000a      developing countries Sci Total Environ 2009 407:2621-4\u000d\u000a      doi: 10.1016\/j.scitotenv.2009.01.018\u000d\u000a    \u000aRecreational water quality\u000d\u000a    \u000a5. Hunter PR Does calculation of the 95th percentile of\u000d\u000a      microbiological results offer any advantage over percentage exceedence in\u000d\u000a      determining compliance with bathing water quality standards? Lett Appl\u000d\u000a        Microbiol 2002 34:283-6 doi:\u000d\u000a      10.1046\/j.1472-765x.2002.01081.x\u000d\u000a    \u000a\u000a6. Chawla R, Hunter PR Classification of bathing water quality\u000d\u000a      based on the parametric calculation of percentiles is unsound Water\u000d\u000a        Res 2005 39:4552-8. doi: 10.1016\/j.watres.2005.08.022\u000d\u000a    \u000aKey research grants\u000d\u000a    &#8226; AQUAVALENS: Programme grant to develop low cost rapid methods of\u000d\u000a        detecting viruses, bacteria and parasites in drinking water Hunter\u000d\u000a      (PI), Tyler; EU FP7 2013-2018; &#8364;9M\u000d\u000a    &#8226; Assessment of human health impacts from emerging microbial\u000d\u000a        pathogens in drinking water by molecular and epidemiological studies\u000d\u000a        (Healthy-Water) Hunter, Lake, Hofle, Kasimir, Figueras, Bosch,\u000d\u000a      Courtois, Torokne; EU FP6 2006 - 2009; &#8364;2,908,065\u000d\u000a    &#8226; EpiBathe - Assessment of Human Health Effects caused by bathing\u000d\u000a        waters Kay (University of Wales, PI), Hunter; EU FP6 2005 -2007; &#8364;2M\u000d\u000a    &#8226; Evaluation of the Costs &amp; Benefits of Water and Sanitation\u000d\u000a        Improvements Cameron (PI), Hunter (PI); World Health Organisation\u000d\u000a      2006 -2007; US$251,933\u000d\u000a    &#8226; Seasonal environmental hazards: a multi-disciplinary approach to\u000d\u000a        the analysis of health risks in lower-income countries Few (PI),\u000d\u000a      Lake, Hunter; NERC 2007 - 2009; &#163;204K\u000d\u000a    &#8226; Human health risks from contaminated tap water. Can we use\u000d\u000a        microbial ecology to assess the integrity of water distribution systems?\u000d\u000a      Grant (PI), Hunter; NERC 2007 - 2008; &#163;120K\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    A. Small-scale water supplies in the pan-European region United\u000d\u000a      Nations Economic Commission for Europe and World Health Organisation for\u000d\u000a      Regional Office for Europe (2011) \u000d\u000a    Available at :http:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0018\/140355\/e94968.pdf\u000d\u000a References to UEA research: p.22 (Hunter et al., 2009a; Richardson et\u000d\u000a      al., 2009), pp.24-25 &amp; p.30 (Hunter et al., 2009a)\u000d\u000a    B. Valuing water, valuing livelihoods. Guidance on social\u000d\u000a        cost-benefit analysis of drinking-water interventions, with special\u000d\u000a        reference to small community water supplies\u000d\u000aWorld Health Organisation (2011)\u000d\u000aAvailable at: http:\/\/whqlibdoc.who.int\/publications\/2011\/9781843393108_eng.pdf\u000d\u000a      References to UEA contributions to the development of this guidance: John\u000d\u000a      Cameron and Paul Hunter were editors. John Cameron authored four chapters\u000d\u000a      (2, 3, 6 and 11). Paul Hunter authored two chapters (5 and 9)\u000d\u000a    C. Guidelines for safe recreational water environments Volume 1:\u000d\u000a        Coastal And Fresh Waters\u000d\u000a World Health Organisation (2003)\u000d\u000aAvailable at: http:\/\/whqlibdoc.who.int\/publications\/2003\/9241545801.pdf\u000d\u000a      References to UEA research: p.83 (Hunter 2002)\u000d\u000a    D. Guidelines for safe recreational water environments: Addendum to\u000d\u000a        volume 1\u000d\u000aWorld Health Organisation (2009)\u000d\u000a      Available at: http:\/\/whqlibdoc.who.int\/hq\/2010\/WHO_HSE_WSH_10.04_eng.pdf\u000d\u000a      References to UEA research: p.18 (Hunter 2002; Chawla &amp; Hunter 2005).\u000d\u000a      Page 8 of this document also cites reference H below (Boehm et al, 2009).\u000d\u000a    E. Guidelines for safe recreational water environments Volume 2:\u000d\u000a        Swimming Pools And Similar Environments\u000d\u000a      World Health Organisation (2006)\u000d\u000a      Available at: http:\/\/whqlibdoc.who.int\/publications\/2006\/9241546808_eng.pdf\u000d\u000a    F. Directive 2006\/7\/EC of the European Parliament and of the Council\u000d\u000a        of 15 February 2006 concerning the management of bathing water quality\u000d\u000a        and repealing Directive 76\/160\/EEC\u000d\u000a      Available at: http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=CELEX:32006L0007:EN:NOT\u000d\u000a    G. Statutory Instrument, Bathing Water Regulations 2008, SI 2008\/1097\u000d\u000a      Available at: http:\/\/www.legislation.gov.uk\/uksi\/2008\/1097\/contents\/made\u000d\u000a    H. A sea change ahead for recreational water quality criteria\u000d\u000a      Boehm AB, Ashbolt NJ, Colford JM Jr, Dunbar LE, Fleming LE, Gold MA,\u000d\u000a      Hansel JA, Hunter PR, Ichida AM, McGee CD, Soller JA, Weisberg SB.\u000d\u000a      J Water Health. 2009:9-20 doi: 10.2166\/wh.2009.122\u000d\u000a    I. Recreational Water Quality Criteria 2012\u000d\u000a      US Environmental Protection Agency OFFICE OF WATER 820-F-12-058\u000d\u000a      Available at:\u000d\u000a      http:\/\/water.epa.gov\/scitech\/swguidance\/standards\/criteria\/health\/recreation\/upload\/RWQC2012.pdf\u000d\u000a    ","Title":"\u000d\u000a    Influencing international health policy to reduce acute waterborne\u000d\u000a        diarrhoeal disease\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Underpinning the impacts described in this case study is epidemiological\u000d\u000a      research on infectious diarrhoeal disease associated with drinking and\u000d\u000a      recreational water exposure. This research was led by Professor Hunter of\u000d\u000a      UEA Norwich Medical School, working with epidemiologists from UEA's\u000d\u000a      Schools of Environmental Science and International Development, and from\u000d\u000a      Europe, the USA and Africa.\u000d\u000a    Small and very small drinking water systems\u000d\u000a    Small and very small drinking water systems supply water from well,\u000d\u000a      borehole, spring or surface water sources instead of from large scale\u000d\u000a      public utilities. Hunter and colleagues at UEA completed a large cohort\u000d\u000a      study that demonstrated that children under 10 years of age in England who\u000d\u000a      are reliant on contaminated private small water supplies have more than 5\u000d\u000a      times the risk of diarrhoea than children whose water is not contaminated\u000d\u000a      (research reference 1). They have also shown that a high proportion of\u000d\u000a      such water systems suffer from microbiological contamination which is much\u000d\u000a      worse than in large, mains drinking water systems (research reference 2).\u000d\u000a      This contamination is highly correlated with environmental and climatic\u000d\u000a      variables.\u000d\u000a    Hunter and colleagues' economic analyses of water interventions to\u000d\u000a      improve small-scale water supplies in developed countries showed that they\u000d\u000a      reduce the direct and indirect costs of illness, outweighing the costs of\u000d\u000a      improving the supplies (research reference 3). Their epidemiological\u000d\u000a      modelling research quantified the impact of community water systems on\u000d\u000a      health in developing countries and highlighted the problems caused by the\u000d\u000a      unreliability of these supplies. It showed that even occasional days of\u000d\u000a      water treatment failure could lead to an almost total loss of the health\u000d\u000a      benefits of setting up these water sytems (research refererence 4).\u000d\u000a      Similar epidemiological modelling was also applied to developed countries\u000d\u000a      such as the UK and France, also highlighting the risks of small water\u000d\u000a      systems.\u000d\u000a    Recreational water quality\u000d\u000a    Hunter and colleagues' epidemiological research on recreational water\u000d\u000a      exposure has included case control and cohort studies, and methodological\u000d\u000a      research on methods of monitoring water quality. The methodological\u000d\u000a      research has shown that the statistical methods used by regulatory\u000d\u000a      agencies to assess compliance with bathing water quality standards were\u000d\u000a      flawed, and that more valid methods were preferable (research references 5\u000d\u000a      and 6).\u000d\u000a    UEA Researcher Involvement\u000d\u000a    This work was led by Hunter (Professor of Health Protection, at UEA since\u000d\u000a      2001) in collaboration with Lake (Senior Lecturer in Environmental\u000d\u000a      Science, at UEA since 2002 (UOA7)), Roger Few (Senior Research Fellow in\u000d\u000a      International Development, at UEA since 2002 (UOA7)), and Helen Risebro\u000d\u000a      (Senior Research Associate, at UEA since 2004), as well as with colleagues\u000d\u000a      elsewhere in the UK, Europe, US and Africa.\u000d\u000a    "},{"CaseStudyId":"2394","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2661886","Name":"Sweden"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    The assessment of cost-effectiveness, primarily undertaken by Buxton and\u000a      colleagues, was a major part of the evidence provided by the MASS trial.\u000a      This underpinned policies and guidelines that introduced and promoted AAA\u000a      screening in the UK and internationally. AAAs affect more than 4% of\u000a      British men aged 65-74 and are responsible for over 6,800 deaths annually.\u000a      The MASS trial showed that screening could reduce AAA-related mortality by\u000a      42%. Implementation of the NHS AAA screening programme in started in 2009.\u000a      It was fully implemented in England by Spring 2013, offering `screening to\u000a      around 300,000 men every year during the year they turn 65' (1). Uptake in\u000a      the 2011-12 cohort of men invited for screening was 75%, according to the\u000a      latest report (1). In 2008 the Department of Health's (DH's) Impact\u000a      Assessment considered policy options for AAA screening and estimated that\u000a      each would provide a gain of at least 130,000 quality adjusted life years\u000a      (QALYS) over a 20 year period, and that the net value of the option\u000a      adopted was &#163;3,884million over 20 years, valuing the health benefit at a\u000a      social value of &#163;40,000 per QALY gained (p.3) (2).\u000a    The ministerial commitment to introduce a national AAA screening policy\u000a      was announced in 2008 as part of a statement by the UK Prime Minister on\u000a      the changes that would be made in what was the sixtieth year of the NHS\u000a      (3). The timescales throughout the UK varied slightly. The decision to\u000a      introduce a national screening programme in England had to be subject to\u000a      an Impact Assessment produced by the DH, and signed off by the relevant\u000a      minister (2). Published in July 2008 it explored the options and explained\u000a      why the preferred option was a screening policy for all men aged 65. Major\u000a      evidence references used in the Impact Assessment were the four RCTs\u000a      included in the Cochrane review, but especially the findings from the MASS\u000a      trial. The DH's Impact Assessment's analysis of costs relied heavily on\u000a      work primarily led by HERG in the MASS study: Buxton et al (2002), Kim et\u000a      al (2007). Highlighting the importance of MASS, the Impact Assessment\u000a      stated:\u000a    `The main elements of the cost analysis are therefore based on the\u000a      outputs and subsequent analysis from MASS....The unit costs for screening\u000a      and elective and emergency surgery operations are based on MASS\u000a      trials....An alternative cost base ... was also considered. However, the\u000a      MASS unit costs are more comprehensive and reliable, and are based on a\u000a      detailed bottom-up costing, taking into account patient-specific costs.'\u000a      (paras 44, 48) (3).\u000a    Further evidence to support the importance of the MASS study, and HERG's\u000a      contribution, in the policy decisions to set up a national screening\u000a      programme comes from the DH and MRC. The DH sent a letter on 15 June 2011\u000a      congratulating HERG on the work for Policy Research Programme: `This has\u000a      made a significant contribution to strengthening the evidence-base for\u000a      policymaking through a range of applied economic research. This has\u000a      included important contributions to the consideration of abdominal aortic\u000a      aneurysm (AAA) screening;' (DH, Head of Policy Research Programme) (4). In\u000a      2010 the MRC reported on findings from its first collection of data on\u000a      research impacts. The impact of the MASS stream of work on the\u000a      introduction of the national AAA screening programme was one of just eight\u000a      examples of policy impact that the MRC highlighted (5).\u000a    To get to the position in 2008 where ministers announced the decision to\u000a      introduce the screening policy, Buxton and other MASS team members had\u000a      undertaken extensive dissemination of the findings, both to the National\u000a      Screening Committee, which analysed the data and options in detail, and\u000a      also to relevant clinicians. Following the contribution made by Buxton to\u000a      the AAA screening decision, he was invited to become a member of the UK\u000a      National Screening Committee from 2009. On 31 March 2004 Buxton and others\u000a      addressed many stakeholders at a meeting, `Aneurysm Screening: The Facts\u000a      and the Future' called by the Vascular Surgical Society of Great Britain\u000a      and Ireland. It was widely covered by UK TV and print media, and the\u000a      proceedings were published (6).\u000a    In addition to documented evidence of influence on health policy, and\u000a      cost-effective, improved health services and clinical outcomes in the UK,\u000a      the MASS trial also had extensive international impact on advisory\u000a      committees, guidelines, and policies and helped generate improvements in\u000a      both publicly and privately funded healthcare services. This includes in\u000a      the USA and Europe.\u000a    A 2009 practice guideline from the US Society for Vascular Surgery drew\u000a      on the same four studies as the Cochrane review, and so again the MASS\u000a      study, contributing 67,800 of the 127,891 men included, had the most\u000a      influence. The guideline stated: `We recommend one-time ultrasound\u000a      screening for AAA for all men at or older than age 65' (p.11S). It\u000a      described the level of recommendation as `Strong' and the quality of\u000a      evidence as `High' (7). AAA screening is now widely available in the USA.\u000a      Many of the policies and practices in the period from 2008 drew on a key\u000a      2005 evidence synthesis and Recommendation Statement from the US\u000a      Preventive Services Task Force in its public advisory role. The MASS\u000a      study's importance was highlighted in both the recommendation and the\u000a      synthesis, which have remained in place throughout 2008-13. The latter\u000a      stated: `the detailed micro-costing approach used in the MASS CEA...\u000a      justified a \"good\" quality rating.' (p.3) (8). That review formed the\u000a      basis both for the legislation under which Medicare has offered AAA\u000a      screening throughout the 2008-13 period, and for clinical policy\u000a      statements issued by the healthcare companies, such as Aetna which for its\u000a      22 million members says: `Aetna considers one-time ultrasound screening\u000a      for abdominal aortic aneurysms (AAA) medically necessary for men 65 years\u000a      of age or older.' (8). Originally published in 2005 the policy was\u000a      reviewed annually and republished, the last time being in December 2012,\u000a      and continues to inform healthcare practice.\u000a    In Sweden, health policy is decided by counties. An assessment by the\u000a      Swedish Council on Health Technology Assessment (SBU) in 2008 came after\u000a      some counties had introduced screening. But it strongly recommended\u000a      screening and drew heavily on `The largest study, the MASS study' (p.2),\u000a      showing over 50% of the men in the review came from the MASS study (9).\u000a      Screening was later adopted by most counties. The 2011 European Society\u000a      for Vascular Surgery guidelines also drew on the four studies in the\u000a      Cochrane study, with the MASS study the largest. It supported population\u000a      screening of older men to reduce `aneurysm-related mortality by almost\u000a      half'. (p.S5) (10).\u000a    ","ImpactSummary":"\u000a    Abdominal aortic aneurysms (AAAs) affect more than 4% of British men aged\u000a      65-74 and are responsible for over 6,800 deaths annually. The MASS trial\u000a      showed that screening could reduce AAA-related mortality by 42%, and the\u000a      Health Economics Research Group (HERG) demonstrated, through the MASS\u000a      trial, that AAA screening was cost-effective. HERG thus helped inform the\u000a      policy announced by UK ministers in 2008 to introduce a national screening\u000a      programme for all men reaching 65. By Spring 2013 it was fully introduced\u000a      in England &#8212; offering screening to 300,000 men annually; the latest Annual\u000a      Report (2011-12) claimed an uptake rate of 75%. In 2008 the DH estimated\u000a      the health gain from a screening programme would be at least 130,000 QALYS\u000a      over 20 years. Internationally, MASS is the most significant trial of AAA\u000a      screening, and provides the most robust evidence-based model of its\u000a      cost-effectiveness. It extensively influenced AAA screening guidelines,\u000a      policies and services, including in the USA and Europe.\u000a    ","ImpactType":"Health","Institution":"\u000a    BRUNEL UNIVERSITY (H0113)\u000a    ","Institutions":[{"AlternativeName":"Brunel University","InstitutionName":"Brunel University","PeerGroup":"C","Region":"London","UKPRN":10000961}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1) Scott RAP, Ashton HA, Buxton M, Day NE, Kim LG, Marteau TM, Thompson\u000a      SG, Walker NM (on behalf of the Multicentre Aneurysm Screening Study\u000a      Group) (2002) The Multicentre Aneurysm Screening Study (MASS) into the\u000a      effect of abdominal aortic aneurysm screening on mortality in men: a\u000a      randomised controlled trial. Lancet, 360:1531-9 http:\/\/dx.doi.org\/10.1016\/S0140-6736(02)11522-4\u000a      Scopus: 522 citations.\u000a    \u000a\u000a2) Buxton M, Ashton H, Campbell H, Day NE, Kim LG, Marteau TM, Scott RAP,\u000a      Thompson SG (2002) Multicentre aneurysm screening study (MASS): cost\u000a      effectiveness analysis of screening for abdominal aortic aneurysms based\u000a      on four year results from randomised controlled trial. BMJ,\u000a      325:1135-8. DOI: http:\/\/dx.doi.org\/10.1136\/bmj.325.7373.1135\u000a      Scopus: 150 Citations. An accompanying editorial in the BMJ\u000a      described the trial as `a job well done.'\u000a    \u000a\u000a3) Bryan S, Buxton MJ, McKenna M, Ashton H, Scott A (1995) Private costs\u000a      associated with abdominal aortic aneurysm screening: the importance of\u000a      private travel and time costs. J Med Screening, 2:62-6 http:\/\/msc.sagepub.com\/content\/2\/2\/62\u000a    \u000a\u000a4) Kim L, Thompson S, Briggs A, Buxton M, Campbell H (2007) How\u000a      cost-effective is screening for abdominal aortic aneurysms? J Med\u000a        Screening,14:46-52. http:\/\/dx.doi.org\/10.1258\/096914107780154477\u000a    \u000a\u000a5) Campbell HE, Briggs AH, Buxton M, Kim LG, Thompson SG (2007) The\u000a      credibility of health economic models for health policy decision-making:\u000a      the case of population screening for abdominal aortic aneurysm. J\u000a        Health Serv Res Policy, 12:11-7 http:\/\/dx.doi.org\/10.1258\/135581907779497594\u000a    \u000a\u000a6) Thompson SG, Ashton HA, Gao L, Buxton MJ, Scott RAP on behalf of the\u000a      Multicentre Aneurysm Screening Study (MASS) Group (2012) Final follow-up\u000a      of the Multicentre Aneurysm Screening Study (MASS) randomized trial of\u000a      abdominal aortic aneurysm screening. Brit J Surg, 99:1649-56. http:\/\/dx.doi.org\/10.1002\/bjs.8897\u000a    \u000a\u000a7) Thompson, S. G., L. C. Brown, M. B. Sweeting, M. J. Bown, L. G. Kim,\u000a      M. J. Glover, M. J. Buxton, J. T. Powell (2013) Systematic review and\u000a      meta-analysis of the growth and rupture rates of small abdominal aortic\u000a      aneurysms: implications for surveillance intervals and their cost-\u000a      effectiveness. Health Technol Assess, 17:41. http:\/\/dx.doi.org\/10.3310\/hta17410\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"}],"Sources":"\u000a    1) The NHS AAA Screening Programme's web site provides data about the\u000a      programme being fully introduced in England by Spring 2013 with around\u000a      300,000 men annually being offered screening, and considerable progress in\u000a      the rest of the UK: http:\/\/aaa.screening.nhs.uk\/questions\u000a      The latest Annual Report (2011-12) showed a 75% uptake: http:\/\/aaa.screening.nhs.uk\/annualreport\u000a    2) The DH formal analysis of the benefits from the introduction of AAA\u000a      screening and the ministerial sign-off of the introduction of the policy\u000a      came in the Impact Assessment of a national Screening Programme for\u000a        Abdominal Aortic Aneurysms. July 2008, Department of Health. http:\/\/webarchive.nationalarchives.gov.uk\/20080726153931\/http:\/\/dh.gov.uk\/en\/Publicationsandstat\u000a        istics\/Publications\/PublicationsLegislation\/DH_086050 (Key\u000a      references to MASS, paras: 44,48)\u000a    3) The Prime Minister made a speech to celebrate the 60th\u000a      anniversary of the foundation of the NHS; in that he made various\u000a      commitments, including on the introduction of AAA screening. Reference:\u000a      Prime Minister's health speech 7 January 2008 accessed online at: http:\/\/webarchive.nationalarchives.gov.uk\/20090114000528\/number10.gov.uk\/page14171\u000a    4) DH recognition of the major importance of HERG's role in informing\u000a      policy development in AAA screening is contained in a letter to Professor\u000a      Buxton on 15 June 2011 from Dr Sandra Williams, Head of Policy Research\u000a      Programme, DH. Pdf available from Brunel University.\u000a    5) The MASS study was highlighted in the MRC's impact report: MRC:\u000a        outputs, outcomes and impact of MRC Research: Analysis of MRC e-Val Data\u000a        2010, but because it related to funding that came after the main\u000a      MRC-funding, the reference here was to the MRC Biostatistics Unit part of\u000a      the MASS collaboration who had recently received some continued funding\u000a      for part of the research. http:\/\/www.mrc.ac.uk\/Achievementsimpact\/Outputsoutcomes\/MRCe-Val2009\/Policy\/index.htm\u000a    6) The Vascular Surgical Society of GB and Ireland's report on the 2004\u000a      meeting addressed by Buxton and other MASS team members highlighted the\u000a      range of stakeholders attending, including the PM's health advisor, and\u000a      the media coverage. Pdf available from Brunel.\u000a    7) In the USA the Society for Vascular Surgery 2009 guidelines drew\u000a      heavily on the four trials in the Cochrane review, but in the relevant\u000a      text named only the MASS study. It recommended screening and stated: `Level\u000a      of recommendation: Strong; Quality of evidence: High' (p.11S). Chaikof EL\u000a      et al. The care of patients with an abdominal aortic aneurysm: the Society\u000a      for Vascular Surgery practice guidelines. J Vasc Surg 2009;50: 2S-49S\u000a      (October 2009 Supplement). doi:10.1016\/j.jvs.2009.07.002 http:\/\/www.jvascsurg.org\/article\/S0741-5214(09)01368-8\/fulltext\u000a    8) The US Preventive Services Task Force published a review in 2005 that\u000a      has influenced the policies and practices of a wide range of healthcare\u000a      providers throughout the 2008-13 period. It contains several elements\u000a      including: Screening for Abdominal Aortic Aneurysm: Recommendation\u000a        Statement. http:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/uspsaneu.htm\u000a      and Cost-Effectiveness Analyses of Population-Based Screening for\u000a        Abdominal Aortic Aneurysm. Evidence Synthesis. http:\/\/www.uspreventiveservicestaskforce.org\/uspstf05\/aaascr\/aaacost.htm\u000a      . Both use the same four trials as the Cochrane review, with the MASS\u000a      trial, `A good-quality RCT' (p.3), providing half the participants. The\u000a      cost-effectiveness analysis in MASS was influential because of its\u000a      quality: the Task Force's recommendation remained the official public\u000a      advice throughout 2008-13. The AAA screening policy of Aetna, a major US\u000a      healthcare provider, is regularly updated. The review in December 2012\u000a      repeated the strong recommendation for screening, based on the Task Force\u000a      review above. Clinical Policy Bulletin: Abdominal Aortic Aneurysm\u000a      Screening. Number 0702, last reviewed 11\/29\/2012. http:\/\/www.aetna.com\/cpb\/medical\/data\/700_799\/0702.html\u000a      Similarly, the Screening Abdominal Aortic Aneurysms Very Efficiently\u000a      (SAAAVE) Act that introduced screening into Medicare's services in 2007\u000a      was based on the MASS-informed Preventive Services Task Force\u000a      Recommendation and has been in force throughout the 2008-13 period with\u000a      all new entrants to Medicare who meet the criteria being eligible for\u000a      screening.\u000a    9) In Sweden the strong recommendation for AAA screening in the SBU\u000a      Report 2008-04 drew heavily on MASS: http:\/\/www.sbu.se\/en\/Published\/Alert\/Screening-for-Abdominal-Aortic-Aneurysm\/\u000a    10) The European Society for Vascular Surgery guidelines also drew on the\u000a      4 studies included in the Cochrane review, with MASS therefore the\u000a      largest, and concluded: `Population screening of older men for AAA, in\u000a      regions where the population prevalence is 4% or more, reduces aneurysm-\u000a      related mortality by almost half within 4 years of screening, principally\u000a      by reducing the incidence of aneurysm rupture. Level 1a, Recommendation\u000a      A.' (p. S5) Reference: Moll FL et al.; Management of abdominal aortic\u000a      aneurysms clinical practice guidelines of the European Society for\u000a      Vascular Surgery. Eur JVasc Endovasc Surg 2011; 41(Suppl):S1-S58.\u000a      http:\/\/dx.doi.org\/10.1016\/j.ejvs.2010.09.011\u000a    \u000a    ","Title":"\u000a    Informing the policy and implementation of screening for abdominal\u000a        aortic aneurysms (AAA)\u000a    ","UKLocation":[{"GeoNamesId":"2654141","Name":"Buxton"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    In November 1993 Professor Martin Buxton, then Director of the Health\u000a      Economics Research Group (HERG) at Brunel University, was a co-applicant\u000a      to the MRC for the Multi-centre Aneurysm Screening Study (MASS). He had\u000a      already started working on the costs and cost-effectiveness of AAA\u000a      screening with Alan Scott's leading clinical team at Chichester. For the\u000a      MASS application, the initial collaboration was expanded to include\u000a      trialists and statisticians at the MRC Biostatistics Unit in Cambridge and\u000a      the Psychology and Genetics Research Group at the United Medical and\u000a      Dental School. The comprehensive aims of the MASS trial included:\u000a      estimating the reduction in mortality from rupture of AAA that could be\u000a      achieved by population based screening; assessing the impact of the\u000a      screening programme and treatment criteria on NHS costs, and on patients'\u000a      quality of life; and producing data to allow assessment of the potential\u000a      for a national screening programme.\u000a    The trial was funded in 1996. Buxton was a co-applicant and also a member\u000a      of the Trial Steering Committee. A population based sample of 67,800 men\u000a      aged between 65-74 was recruited from Jan 1997-May 1999, with an initial\u000a      four-year follow-up period. During the stream of work, Buxton and\u000a      colleagues at HERG (principally Stirling Bryan, a named applicant, until\u000a      1997; Helen Campbell,1998-2002; Mathew Glover, 2010-) were responsible for\u000a      analysing the detailed cost data. Buxton was an author on the main\u000a      clinical effectiveness paper, published in Nov 2002 in the Lancet (1),\u000a      which provided `reliable evidence of benefit' from AAA screening aimed at\u000a      reducing the 6,800 annual deaths in England and Wales alone. Buxton was\u000a      lead author on the BMJ cost-effectiveness paper published simultaneously.\u000a      It stated: `Even at four years the cost effectiveness of screening for\u000a      abdominal aortic aneurysms is at the margin of acceptability according to\u000a      current NHS thresholds. Over a longer period the cost effectiveness will\u000a      improve substantially, the predicted ratio at 10 years falling to around a\u000a      quarter of the four year figure.' (p.1135) (2)\u000a    A 2007 Cochrane review included four studies; the MASS study contributed\u000a      67,800 of the 127,891 men. Findings from the Chichester study, one of the\u000a      other three studies, were published in 1995 and described as the first\u000a      ever report of an RCT of a screening programme for AAA; the HERG team led\u000a      on a paper assessing costs to patients (3). The Cochrane review concluded\u000a      that there was significant reduction in mortality from AAA in men who\u000a      undergo ultrasound screening and the cost effectiveness may be acceptable\u000a      but needed further expert analysis. Buxton and Campbell were also\u000a      co-authors on subsequent papers developing Markov modelling of the\u000a      cost-effectiveness of screening, and using the cost data collected in the\u000a      original study (4,5). The continuing follow-up work retained the aim of\u000a      supplying data for a national screening programme &#8212; but increasingly\u000a      helping inform its implementation. The 13-year, and final, follow-up paper\u000a      on the effectiveness shown in the MASS trial, was published in 2012 with\u000a      Buxton as a co-author. It reported `a 42 (95 per cent confidence interval\u000a      31 to 51) per cent reduction' in the AAA-related mortality rate by\u000a      screening men aged 65-74 years (p.1649) (6). Research to assist in\u000a      refinement of the policy has continued with HERG's cost-effectiveness\u000a      modelling of potential alternative recall intervals (7).\u000a    "},{"CaseStudyId":"2398","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"1210997","Name":"Bangladesh"},{"GeoNamesId":"2510769","Name":"Spain"},{"GeoNamesId":"6251999","Name":"Canada"}],"Funders":["Wellcome Trust","Medical Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    HERG's payback research has produced significant and cumulative impacts,\u000d\u000a      including on public debates and policy, and on the organisation of public\u000d\u000a      services and medical charities. The Payback research provides new\u000d\u000a      evaluation processes that have been applied by organisations nationally\u000d\u000a      and internationally. The impacts were partly generated by extensive\u000d\u000a      stakeholder engagement and dissemination activities by team members (see\u000d\u000a      below). Many stakeholders, in turn, promoted the HERG findings showing the\u000d\u000a      benefits that come from health research, and used this to support their\u000d\u000a      case for continued and\/or increased funding. For example, those attending\u000d\u000a      the seminar in Nov 2008 at the Wellcome Trust to launch HERG's Medical\u000d\u000a        Research: What's it Worth report to key stakeholders included: the\u000d\u000a      Chief Executive of the MRC and the Director Generals of R&amp;D at the DH\u000d\u000a      and at the science department. In 2010 the UK Science Minister\u000d\u000a      demonstrated the report's considerable importance: `The report on Medical\u000d\u000a      Research, What's it Worth? is regarded by BIS Analysis teams as very\u000d\u000a      comprehensive and rigorous. It was used as evidence as part of the\u000d\u000a      preparations for the Spending Review and it will continue to be cited in\u000d\u000a      the foreseeable future.' [1]\u000d\u000a    Examples of the detailed impact of HERG's Payback stream are organised\u000d\u000a      into three sections below to demonstrate both the research's wide reach\u000d\u000a      and its cumulative significance.\u000d\u000a    1) Adoption of HERG's payback framework in organisations' evaluation\u000d\u000a        strategies or approaches: The wide use of the Payback Framework\u000d\u000a      arises partly from the decisions of many public and charitable research\u000d\u000a      funders either explicitly to request that specific impact studies be\u000d\u000a      organised according to the Payback Framework and\/or to include it in their\u000d\u000a      strategies. Examples include:\u000d\u000a    \u000d\u000a      The main Canadian public sector, charitable, and commercial\u000d\u000a        organisations funding health research combined to sponsor an expert\u000d\u000a        panel including Buxton. Tasked with identifying a best method to\u000d\u000a        evaluate impacts, it proposed a framework that `builds on the combined\u000d\u000a        logic model and impacts approach of the \"payback model\"'(p.18). The\u000d\u000a        President of Alberta's main health research funding body has described\u000d\u000a        its adoption in provinces of Canada and in Spain. [2]\u000d\u000a      In 2009 ICDDR,B in Bangladesh, one of the leading research centres in\u000d\u000a        low-and-middle- income countries, incorporated the Payback Framework\u000d\u000a        prominantly into its `Strategic Plan 2020' covering 2010-2020 and\u000d\u000a        set out how it would be put into practice. [3]\u000d\u000a    \u000d\u000a    2) Impact of HERG's payback work on stakeholders' political campaigns\u000d\u000a        to support public funding: A wide and international range of\u000d\u000a      (health) research stakeholders (including public bodies, charities and\u000d\u000a      public campaigns) have quoted findings from HERG's payback studies as key\u000d\u000a      evidence when advocating support for medical research. Here we give just a\u000d\u000a      few of the many examples of stakeholders who cited the HERG et al (2008)\u000d\u000a      report: Medical Research: What's it Worth.\u000d\u000a    \u000d\u000a      In 2010 the Spending Review was intended to make major cuts in\u000d\u000a        Government expenditure. In their evidence to the Spending Review many\u000d\u000a        medical research stakeholders cited the HERG 2008 report prominently in\u000d\u000a        their arguments in defence of investment in medical research, eg the\u000d\u000a        Association of Medical Research Charities (AMRC), specific charities,\u000d\u000a        public funders. [4,1]\u000d\u000a      The report was also cited in policy debates as key evidence in\u000d\u000a        submissions to the government Spending Review by stakeholders concerned\u000d\u000a        to defend investment in publicly funded research in general, including\u000d\u000a        by the Commons Science and Technology Committee and by a public campaign\u000d\u000a        (Science is Vital) that engaged thousands of scientists and\u000d\u000a        others [5].\u000d\u000a      More generally, diverse UK, European and international organisations\u000d\u000a        used the HERG 2008 report to promote investment in medical research,\u000d\u000a        including investment in research for international development; it was\u000d\u000a        the first reference in a Royal Society submission on this [6].\u000d\u000a    \u000d\u000a    3) Impact of the HERG payback work on policy decisions by governments\u000d\u000a        and charities to sustain and increase health research funding and\u000d\u000a        enhance the organisation of research systems: The findings from\u000d\u000a      various payback studies are not only used in policy debates, but in a\u000d\u000a      range of ways have been cited as influencing the policy decisions of\u000d\u000a      governments and other research funders in relation to issues about the\u000d\u000a      level and organisation of medical research funding.\u000d\u000a    \u000d\u000a      When the results of the UK Government's 2010 Spending Review were\u000d\u000a        announced medical research had done comparatively well; various\u000d\u000a        stakeholders identified the HERG 2008 report as a key part of the\u000d\u000a        evidence that had been successfully used to influence the decision\u000d\u000a        [4,7].\u000d\u000a      In 2012 the MRC launched a research programme on understanding the\u000d\u000a        link between research and economic impact and demonstrated the\u000d\u000a        continuing policy-relevance of the HERG 2008 report: `Internationally\u000d\u000a        there has been little new evidence that could assist funding policy in\u000d\u000a        the UK since the \"Medical Research: What's it Worth?\" report'. [8].\u000d\u000a      In 2011\/12 HERG worked with a local team from RSM McClure Watters to\u000d\u000a        apply the Payback Framework to assess the impact of health research\u000d\u000a        funded by the Northern Ireland Executive. Based on that study the\u000d\u000a        Executive changed its policy and announced: `Following consideration of\u000d\u000a        the report, and the benefits outlined in it, the Health Minister has\u000d\u000a        decided to invest &#163;2.6 million' to become a full partner of the National\u000d\u000a        Institute of Health Research (NIHR). [9].\u000d\u000a      Asthma UK funded HERG to lead an evaluation of the impacts of their\u000d\u000a        research funding. They used the analysis of how different funding\u000d\u000a        streams had contributed to impacts to help revise their funding\u000d\u000a        strategies, and hoped the report's publication would boost research\u000d\u000a        funding. [10]\u000d\u000a      When in April 2013 the NBCF in Australia launched the impact\u000d\u000a        assessment conducted by HERG it received a high media profile, which was\u000d\u000a        important to increase public understanding of the charity's\u000d\u000a        achievements, provide accountability for past expenditure, and\u000d\u000a        justification for future funding by supporters. On policies it also\u000d\u000a        stated: `As a consequence of this evaluation process NBCF has decided to\u000d\u000a        take three actions in terms of future investment in research....we have\u000d\u000a        decided to substantially boost our investment in translational\u000d\u000a        research.' [11]\u000d\u000a    \u000d\u000a    Extensive dissemination helped generate the full range of these impacts.\u000d\u000a      It included publications, invited presentations, seminars, and advice\u000d\u000a      directly to stakeholders, eg on committees in Canada [2], the EU, Ireland,\u000d\u000a      WHO and the UK. The resulting impact, illustrated by the key examples\u000d\u000a      above, has potentially had even wider implications. The additional\/better\u000d\u000a      organised health research that arose (at least partially) as an impact\u000d\u000a      from HERG's work might, itself, reasonably be expected on occasions to\u000d\u000a      have generated some of the range of wider impacts including on health and\u000d\u000a      welfare.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Globally, many health research-funding organisations, public and\u000d\u000a      charitable, felt the need to demonstrate to policymakers and the public\u000d\u000a      how their investments in research were benefitting society. HERG's\u000d\u000a      research on developing techniques for assessing the payback (or impact)\u000d\u000a      from health research tackled this need. The payback stream of research\u000d\u000a      itself has had significant, wide- reaching and cumulative impacts. First,\u000d\u000a      internationally, health research funding bodies adopted the framework in\u000d\u000a      their evaluation strategies, including to provide accountability. Second,\u000d\u000a      many stakeholders made extensive use the findings of payback studies in\u000d\u000a      public debate and private lobbying for public expenditure on health\u000d\u000a      research. Third, governments, public research funding bodies and medical\u000d\u000a      research charities, from the UK to Australia, used the findings from\u000d\u000a      payback studies to inform decisions regarding the levels and distribution\u000d\u000a      of health research funding, with the aim of increasing the health and\u000d\u000a      economic benefits that come from investments in research.\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    BRUNEL UNIVERSITY (H0113)\u000d\u000a    ","Institutions":[{"AlternativeName":"Brunel University","InstitutionName":"Brunel University","PeerGroup":"C","Region":"London","UKPRN":10000961}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. Buxton M, Hanney S (1996) How can payback from health services\u000d\u000a      research be assessed? J Health Serv Res Policy, 1:35-43.\u000d\u000a      URL: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10180843 (Scopus: 118 citations).\u000d\u000a    \u000a\u000a2. Wooding S, Hanney S, Buxton M, Grant J (2005) Payback arising from\u000d\u000a      research funding: Evaluation of the Arthritis Research Campaign.\u000d\u000a        Rheumatology, 44:1145-56. DOI: 10.1093\/rheumatology\/keh708\u000d\u000a      (33 citations).\u000d\u000a    \u000a\u000a3. Hanney S, Buxton M, Green C, Coulson D, Raftery J.(2007) An assessment\u000d\u000a      of the impact of the NHS Health Technology Assessment Programme. Health\u000d\u000a        Technol Assess, 11:53. URL:\u000d\u000a      http:\/\/ushamp-build.squiz.co.uk\/jl\/hta\/volume-11\/issue-53 (37 citations,\u000d\u000a      summary and main report).\u000d\u000a    \u000a\u000a4. Oortwijn WJ, Hanney SR, Ligtvoet A et al. 2008. Assessing the impact\u000d\u000a      of health technology assessment in the Netherlands. Int J Technol\u000d\u000a        Assess Health Care, 24:259-69. doi:\u000d\u000a      10.1017\/S0266462308080355 (19 citations)\u000d\u000a    \u000a\u000a5. Buxton MJ, Hanney S, Jones T (2004) Estimating the economic value to\u000d\u000a      societies of the impact of health research: a critical review. Bull\u000d\u000a        WHO, 82:733-739. URL:\u000d\u000a      http:\/\/www.who.int\/bulletin\/volumes\/82\/10\/buxton1004abstract\/en\/index.html\u000d\u000a      (42 citations).\u000d\u000a    \u000a\u000a6. HERG, RAND Europe, OHE. Medical Research- What's it Worth?\u000d\u000a        Estimating the economic benefits from medical research in the UK. UK\u000d\u000a      Evaluation Forum (AMS, MRC, Wellcome Trust), London 2008. URL:\u000d\u000a      http:\/\/www.wellcome.ac.uk\/About-us\/Publications\/Reports\/Biomedical-science\/WTX052113.htm\u000d\u000a\u0009  This report was rigorously peer-reviewed prior to\u000d\u000a      publication by the AMS, Wellcome Trust, and MRC. As a report this has no\u000d\u000a      official citations on Scopus, but the study was highlighted in an\u000d\u000a      editorial in Nature on 11 June 2010 as one of the few studies\u000d\u000a      `that have made a genuine attempt objectively to assess the economic\u000d\u000a      outcomes of research'. In 2012 the MRC call for further work in the field\u000d\u000a      said of this HERG (2008) study: `This work is considered an exemplar\u000d\u000a      study, providing credible estimates of economic return and recommendations\u000d\u000a      for future research.'\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"16","Level2":"5","Subject":"Policy and Administration"}],"Sources":"\u000d\u000a    1) In 2010 the Science Minister, David Willetts, wrote to one of our\u000d\u000a      colleagues describing how the Medical Research: What's it Worth\u000d\u000a      (HERG, et al, 2008) report had been used in by BIS in their preparations\u000d\u000a      for the Spending Review. A pdf copy of the letter is available from\u000d\u000a      Brunel.\u000d\u000a    2) A Canadian report from the CAHS's Panel on the Return on Investments\u000d\u000a      in Health Research,\u000d\u000a      www.cahs-acss.ca\/making-an-impact-a-preferred-framework-and-indicators-to-measure-returns-on-nvestment-in-health-research-8\/\u000a      (2009) set out the impact of the Payback Framework on its recommendations.\u000d\u000a      Also in a corroborative statement (available from Brunel) the chair of the\u000d\u000a      Panel and current President of Alberta Innovates-Health Solutions (AIHS),\u000d\u000a      wrote to Martin Buxton: `confirming the major impact of your work on the\u000d\u000a      panel that led to our CAHS framework, and on its adoption by AIHS and a\u000d\u000a      number of other health research funders in Canada and abroad.'\u000d\u000a    3) ICDDR,B. Strategic Plan 2020. Almost a whole page (17) of the\u000d\u000a      28 page plan is devoted to a slightly adapted version of the HERG\u000d\u000a      multidimensional categorisation of benefits and a description of proposed\u000d\u000a      use, although unlike in the drafts the final version does not carry\u000d\u000a      references. Available:\u000d\u000ahttp:\/\/www.icddrb.org\/what-we-do\/publications\/doc_download\/107-strategic-plan-2020\u000d\u000a    4) Many major medical research funding organisations used the HERG 2008\u000d\u000a      report as key evidence in the 2010 Spending Review including Cancer\u000d\u000a      Research UK (2010) Available:\u000d\u000a      http:\/\/info.cancerresearchuk.org\/prod_consump\/groups\/cr_common\/@nre\/@pol\/documents\/generalcontent\/cr_048533.pdf\u000a      The chair of the AMRC had previously chaired the Commons Science and\u000d\u000a      Technology Committee until 2010. His corroborative statement (available\u000d\u000a      from Brunel) highlights the significance of HERG's report: a) in AMRC's\u000d\u000a      many submissions to the government in support of medical research funding\u000d\u000a      and to protect the Charity Research Support Fund (CRSF), and b) in\u000d\u000a      lobbying by others groups. He stated: `It is my belief that this\u000d\u000a      contributed to the Treasury's decision to ring-fence the Science Budget,\u000d\u000a      which includes the CRSF, for the 2010-15 financial period'\u000d\u000a    5) Many stakeholders used HERG's 2008 report as key evidence, in the\u000d\u000a      policy debate prior to the 2010 Spending Review, to support research\u000d\u000a      funding in general, eg the Commons Science and Technology Committee: Committee\u000d\u000a        contribute to 2010 Spending Review consultation: Letter from the Chair\u000d\u000a        of the Committee to the Chancellor of the Exchequer, 27 July 2010, available:\u000a      http:\/\/www.parliament.uk\/business\/committees\/committees-a-z\/commons-select\/science-and-technology-committee\/news\/100729-letter-to-chancellor\/\u000a      and the grassroots public campaign: Science is Vital (2010) Key\u000d\u000a        messages. http:\/\/scienceisvital.org.uk\/2010\/09\/28\/key-messages\/\u000d\u000a    6) Organisations using the 2008 HERG report for more general campaigns\u000d\u000a      for research investment include the European Commission Science Advisory\u000d\u000a      Board in Health. It issued a call in The Lancet `for more and\u000d\u000a      better investment in health research'; the only reference was HERG 2008. [Lancet\u000d\u000a      377:719-720]. The Royal Society used it in a submission to\u000d\u000a      DFID's 2009 Consultation: \"Eliminating World Poverty: Assuring our\u000d\u000a        Common Future\". See RS Policy Document 07\/09. Available:\u000d\u000a     http:\/\/royalsociety.org\/uploadedFiles\/Royal_Society_Content\/policy\/publications\/2009\/7876.pdf\u000d\u000a    7) The importance of HERG's 2008 report in influencing the decision to\u000d\u000a      protect medical research funding was emphasised in a corroborative\u000d\u000a      statement from a Deputy Director, R&amp;D Directorate, DH (available from\u000d\u000a      Brunel) that says HERG's 2008 report `was an important factor in\u000d\u000a      convincing the Government to protect the science budget in the 2010 and\u000d\u000a      2013 Spending Reviews, and in 2010 to raise the health research budget in\u000d\u000a      real terms...and is still referred to in Government itself.'\u000d\u000a    8) The 2012 MRC research call Understanding the link between research\u000d\u000a        and economic impact highlighted the international importance of the\u000d\u000a      HERG 2008 report in informing policy. Available: www.mrc.ac.uk\/Fundingopportunities\/Highlightnotices\/Research_economicimpact\/MRC008598\u000d\u000a    9) The Northern Ireland Executive press release of 5 July 2012 explained\u000d\u000a      how the report on the impact of its research (based on the HERG Payback\u000d\u000a      Framework) led to the Health Minister's decision to invest &#163;2.6 million by\u000d\u000a      subscribing Northern Ireland to the NIHR . Available:\u000d\u000a      http:\/\/www.northernireland.gov.uk\/news-dhssps-050712-we-expect-four?WT.mc_id=rss-news\u000d\u000a    10) In creating its 2011-16 Strategy, Asthma UK stated the HERG impact\u000d\u000a      analysis: `has given us a unique insight into our research and provided\u000d\u000a      powerful information to guide our future strategy.'(p3) Available\u000d\u000a      http:\/\/www.asthma.org.uk\/Handlers\/Download.ashx?IDMF=392dba83-7a51-4b1a-b23c-7190df76fa30\u000d\u000a      Asthma UK also said of the article on the study: `The charity\u000d\u000a      hopes that proving its impact will help generate further funding\u000d\u000a      opportunities towards their search for new knowledge, treatments and,\u000d\u000a      ultimately, a cure': http:\/\/www.asthma.org.uk\/News\/where-does-my-money-go\u000d\u000a    11) In April 2013 NBCF launched HERG's report assessing the impact of the\u000d\u000a      charity's research. Pp5\/6 of the speaking notes explain how the findings\u000d\u000a      had already made an impact on its funding strategies. Available:\u000d\u000a      http:\/\/www.nbcf.org.au\/Stories\/Research\/HERG-Evaluation-Report.aspx\u000d\u000a    ","Title":"\u000d\u000a    How the development and application of techniques for assessing the\u000d\u000a        payback (or impact) from health research informs policies to support\u000d\u000a        health research\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    In 1993 the Director NHS R&amp;D wanted to develop methods of showing the\u000d\u000a    benefits from, and thus justifying, spending NHS resources on health\u000d\u000a    research. He asked Martin Buxton, the Director of the Health Economics\u000d\u000a    Research Group (HERG) at Brunel University, to explore this area. Buxton\u000d\u000a    recruited Stephen Hanney to HERG to work with him on what became an\u000d\u000a    extensive research programme to develop and apply the Payback Framework.\u000d\u000a    They worked on this, inter alia, at HERG from 1993 to 2013; from\u000d\u000a    2000 an information scientist, Teresa Jones, joined the HERG Payback team,\u000d\u000a    as did Claire Donovan in 2010 as Reader in the Assessment of Research\u000d\u000a    Impact. The Payback Framework consists of a multidimensional categorisation\u000d\u000a    of benefits, and a logic model to help organise assessment of benefits. The\u000d\u000a    HERG team tested and applied it in various case studies [1]. Diverse\u000d\u000a    organisations funded further developments and applications of the framework.\u000d\u000a    HERG conducted studies independently, or, more often, worked with\u000d\u000a    collaborators, principally RAND Europe (Jonathan Grant, Steve Wooding, Wija\u000d\u000a    Oortwijn and others) and people associated with funding bodies. Bodies that\u000d\u000a    funded studies led by, or involving, HERG include:\u000d\u000a    1) Medical research charities both in the UK (eg the Arthritis Research\u000d\u000a      Campaign [2]; Asthma UK) and overseas (eg Heart and Stroke Foundation of\u000d\u000a      Canada and the National Heart Foundation of Australia; and, in 2012, the\u000d\u000a      National Breast Cancer Foundation - NBCF - in Australia)\u000d\u000a    2) Publically funded health research programmes both in the UK (eg the\u000d\u000a      NHS Health Technology Assessment (HTA) programme [3]; Northern Ireland's\u000d\u000a      health department - DHSSPS) and overseas (eg ZonMW's HTA programme in\u000d\u000a      Holland [4]; a major NIH programme in the USA).\u000d\u000a    Such applications facilitated methodological developments, including\u000d\u000a      increasingly sophisticated consensus scoring of levels of impact achieved\u000d\u000a      (first by the Payback team alone [2], then with HTA experts [4]) and\u000d\u000a      analysis of medical research charities' whole portfolios (eg Asthma UK,\u000d\u000a      NBCF).\u000d\u000a    HERG conducted further methodological work, including with the WHO, on\u000d\u000a      how the economic benefits from health research could be better identified\u000d\u000a      [5]. Building on this, in 2007\/8 Buxton led a team including RAND Europe\u000d\u000a      and the Office of Health Economics (OHE) (Jon Sussex and team) in a study\u000d\u000a      for the UK Evaluation Forum and funded by MRC\/Wellcome Trust\/Academy of\u000d\u000a      Medical Sciences (AMS). This research, secured following a competitive\u000d\u000a      process organised by the MRC, developed and applied new ways to assess the\u000d\u000a      economic impact of UK publicly and charitably funded health research. We\u000d\u000a      focussed on two major elements of the economic returns: health gains net\u000d\u000a      of the health care costs of delivering them; and the GDP gains, ie the UK\u000d\u000a      national income that results from the medical research and the further\u000d\u000a      research stimulated by it. The extensive and original `bottom-up' research\u000d\u000a      calculating the value of health gains from research in two major health\u000d\u000a      care fields (cardiovascular disease (CVD) and mental health), plus the GDP\u000d\u000a      gains from the same research, required publication as a major\u000d\u000a      peer-reviewed report to allow presentation in sufficient detail for full\u000d\u000a      public scrutiny [6]. The study showed that every GBP1.00 invested in CVD\u000d\u000a      research will yield approximately GBP0.39 worth of total benefits - health\u000d\u000a      gain plus GDP - every year.\u000d\u000a    "},{"CaseStudyId":"3067","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"290557","Name":"United Arab Emirates"},{"GeoNamesId":"3144096","Name":"Norway"},{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Our research has informed guidelines that address the very early phase of\u000d\u000a      emergency care plus the policy and organisation of that care.\u000d\u000a    Reduced use of 03b2-agonists in patients with ARDS. \u000d\u000a      A UK survey of practice in 2010 (Scally JICS 2010:11, 36-39) reported that\u000d\u000a      `all ITUs regularly prescribed 03b2-agonists for their patients'. A\u000d\u000a      Canadian study (2001-2003) found that at least a quarter of patients with\u000d\u000a      acute lung injury (ALI) received high dose 03b2-agonists. Following the\u000d\u000a      announcement of our results from the BALTI study in December 2011, the\u000d\u000a      Lancet journal editorial concluded `For now, the results of the\u000d\u000a        truncated BALTI-2 trial are sufficient to change practice. 03b2-2\u000d\u000a        agonist treatment in patients with ARDS should be limited to the\u000d\u000a        treatment of clinically important reversible airway obstruction and\u000d\u000a        should not be part of routine care'. a The impact of our\u000d\u000a      study on reducing drug use was demonstrated in an international\u000d\u000a      point-prevalence survey, performed in 2012, which showed that 03b2-agonist\u000d\u000a      use in patients with ARDS had fallen to 7.9% in the UK and 13.9% in China.\u000d\u000a      This study concluded that, based on our extrapolation of study results,\u000d\u000a      389 potential deaths per year could be avoided in the UK alone by ceasing\u000d\u000a      usage of 03b22-agonists for ARDS.b The impact of our research\u000d\u000a      has been further extended through personal communication with the\u000d\u000a      International Surviving Sepsis Guideline group who have now published\u000d\u000a      guidelines, which `recommend against the routine use of beta agonists in\u000d\u000a      ARDS' (Feb 2013). c These guidelines have been endorsed by 30\u000d\u000a      organisations, translated into six different languages and are widely\u000d\u000a      implemented around the world.\u000d\u000a     \u000d\u000a    Improvements to CPR feedback devices. Perkins led the\u000d\u000a      International Liaison Committee for Resuscitation (ILCOR) review of CPR\u000d\u000a      feedback devices (sensor devices that optimize the quality of CPR). The\u000d\u000a      resulting international recommendations, which were published by ILCOR and\u000d\u000a      adopted by the American Heart Association, European, Asian, South Africa,\u000d\u000a      and Australian Resuscitation Councils, drew substantially on the\u000d\u000a      systematic review and primary research undertaken at Warwickd,\u000d\u000a      Implementation of CPR feedback devices into clinical practice has been\u000d\u000a      associated with improved CPR performance and increased survival (adjusted\u000d\u000a      odds ratio of 2.72 (95% CI 1.15 to 6.41). e Our finding that\u000d\u000a      accelerometer-based CPR feedback devices were inaccurate when used on a\u000d\u000a      patient lying on a bed were described as having `an enduring impact on\u000d\u000a        the fundamental understanding of current CPR technology\".e\u000d\u000a      and led to the development (with a Medical Technology Company -\u000d\u000a      PhysioControl) of the new technology TrueCPRTM, which uses\u000d\u000a      magnetic fields to overcome the limitations we identified with\u000d\u000a      accelerometers. TrueCPRTM has been granted CE (Conformit&#233;\u000d\u000a      Europ&#233;enne) mark approval from the EU and approval from the US Food and\u000d\u000a      Drug Administration (USFDA). It is now available for sale in most\u000d\u000a      countries.f Since learning about our findings, Laerdal Medical\u000d\u000a      (Norway) has started developing a smart backboard to overcome the\u000d\u000a      limitations we identified in our research. \u000d\u000a     \u000d\u000a    Improvements to training in CPR. Our research on training\u000d\u000a      and assessment methods for CPR has led to direct changes to the\u000d\u000a      competency-based performance tests used within the Advanced Life Support\u000d\u000a      (ALS) and have been implemented in the UK, Europe and Australia,\u000d\u000a      facilitated by Perkins' leadership of the UK Resuscitation Council ALS\u000d\u000a      Working Group. Our development work on e-learning showed that it was\u000d\u000a      possible to replace face-to-face training with e-learning material, thus\u000d\u000a      reducing the cost of delivering the course without compromising learning\u000d\u000a      quality. This led to the launch of a new course, which draws heavily on\u000d\u000a      the e-learning material developed by our research.g The new\u000d\u000a      course has been delivered to more than 10,000 doctors and nurses in the UK\u000d\u000a      and reduced costs by approximately &#163;3 million in the first 18 months.\u000d\u000a     \u000d\u000a    Improvements to guidelines for emergency care. Our\u000d\u000a      systematic review of emergency care, underpins the Joint Royal College\u000d\u000a      Ambulance Liaison Committee Clinical Guidelines, published in 2013h,\u000d\u000a      for which Matthew Cooke acted as the academic director. These guidelines\u000d\u000a      are used by all NHS ambulance staff (approx. 5000 paramedics) and have\u000d\u000a      been adopted in United Arab Emirates. The Royal National Lifeboat\u000d\u000a      Institute reversed a national policy decision to limit the duration of\u000d\u000a      search and rescue operations to 20 minutes when our evidence showed that\u000d\u000a      survival was possible beyond that time (2011). The new evidence from our\u000d\u000a      systematic review and scoping exercise on falls prevention informed the\u000d\u000a      decision, in 2013, to revise the NICE guidelines for falls prevention by\u000d\u000a      demonstrating the new evidence and the variability in practice.i\u000d\u000a      Our research from the team at Warwick has influenced the evolution of new\u000d\u000a      roles in emergency care, such as emergency care practitioners (Adams,\u000d\u000a      2005) and Advanced Clinical Practitioners (Cooke, in progress, 2013) and\u000d\u000a      an expansion of the workforce by using non-doctors. Our evaluation of the\u000d\u000a      National Emergency Care Practitioner (ECP) Programme demonstrated the\u000d\u000a      safety and clinical effectiveness of this new role led to the\u000d\u000a      dissemination of ECP programmes throughout the UK, with the majority of\u000d\u000a      ambulance services adopting such roles. This programme is widely linked to\u000d\u000a      improved efficiencies such as reduced ambulance transport to the emergency\u000d\u000a      department reducing cost and improving efficiency.\u000d\u000a     \u000d\u000a    Changes to national policy on A&amp;E departments. As\u000d\u000a      National Clinical Director Urgent and Emergency Care, Cooke led the\u000d\u000a      development of new National Quality Indicators for A&amp;E 2010j\u000d\u000a      based on his Warwick research. Many of the results were utilised before\u000d\u000a      publication because of Professor Cooke's national role. Reviews of\u000d\u000a      patients who leave AEDs without being seen (Clarey &amp; Cooke, 2012) and\u000d\u000a      reattend (Trivedy, 2013) informed the development of two of the eight\u000d\u000a      national indicators (i.e. per cent reattending A&amp;E and per cent\u000d\u000a      leaving without being seen). National guidance on reducing waits was\u000d\u000a      informed by a systematic review of effective approaches to wait- time\u000d\u000a      reduction (Cooke et al, 2004), by research on the use of observation wards\u000d\u000a      (Sibly, 2007) and by understanding the types of patients who suffer long\u000d\u000a      delays (Downing, 2004). Work conducted with Bristol University, on walk-in\u000d\u000a      centres (Chalder et al, 2007; Salisbury et al, 2007) has changed policy\u000d\u000a      whereby walk-in centres are no longer considered to be effective in\u000d\u000a      diverting care. The changes implemented on the basis of this research have\u000d\u000a      led to a substantial reduction in waiting times: Department of Health\u000d\u000a      statistics show number of patients seen within four hours increasing from\u000d\u000a      60% in 2002 to 95% in 2013. Others have demonstrated the link between the\u000d\u000a      waiting time and mortality. Cooke's work (2002) provided guidance and\u000d\u000a      support for the implementation of fast- track systems in A&amp;E and is\u000d\u000a      now standard practicek, Multiple studies have showed that this\u000d\u000a      system can reduce waits for those with minor injuries by 50%. l\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The emergency care team at Warwick Medical School has a strong track\u000d\u000a      record of high-quality health sciences research encompassing evidence\u000d\u000a      synthesis, health-services research and clinical trials. Our trials of a\u000d\u000a      03b2-agonist (salbutamol) in acute respiratory distress syndrome (ARDS)\u000d\u000a      have influenced therapeutic recommendations in the International Sepsis\u000d\u000a      Guidelines (2013), reducing the use of this potentially detrimental\u000d\u000a      therapy. Our cardiac arrest research informed the 2010 international\u000d\u000a      guidelines on cardiopulmonary resuscitation (CPR) led to the generation of\u000d\u000a      new intellectual property, and prompted industrial collaborations to build\u000d\u000a      new technologies, such as TrueCPRTM (2013). These have led to\u000d\u000a      improved CPR practice and improved patient survival. Furthermore, our\u000d\u000a      research has led to major policy changes and to a redesign of UK emergency\u000d\u000a      healthcare, improving cost efficiency, the patient experience and clinical\u000d\u000a      outcomes (e.g. 95% of patients were treated within 4 hours - up from 65%;\u000d\u000a      and people leaving without been seen reduced to less than 5%).\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Warwick and Liverpool School of Tropical Medicine\u000d\u000a    ","Institutions":[{"AlternativeName":"Warwick (University of)","InstitutionName":"University of Warwick","PeerGroup":"A","Region":"West Midlands","UKPRN":10007163},{"AlternativeName":"Liverpool School of Tropical Medicine","InstitutionName":"Liverpool School of Tropical Medicine","PeerGroup":"G","Region":"North West","UKPRN":10003958}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"1105844","Name":"Harare Province"}],"References":"\u000d\u000a    \u000a1. Smith FG, et al. Effect of intravenous 03b2-2 agonist\u000d\u000a      treatment on clinical outcomes in acute respiratory distress syndrome\u000d\u000a      (BALTI-2): a multicentre randomised controlled trial. Lancet 2012;\u000d\u000a      379:229-35. doi:10.1016\/S0140-6736 (11) 61623-1. (REF2 UoA2\u000d\u000a        Submission)\u000d\u000a    \u000a\u000a2. Yeung J, et al. The use of CPR feedback\/prompt devices during\u000d\u000a      training and CPR performance: A systematic review. Resuscitation\u000d\u000a      2009; 80:743-51. doi:10.1016\/j.resuscitation.2009.04.012\u000d\u000a    \u000a\u000a3. Perkins GD, et al. Improving the efficiency of advanced life\u000d\u000a      support training: a randomized, controlled trial. Ann. Intern. Med.\u000d\u000a      2012; 157:19-28. doi:10.7326\/0003-4819-157-1-201207030- 00005. (REF2\u000d\u000a        UoA2 Submission)\u000d\u000a    \u000a\u000a4. Cooke, et al. Reducing attendances and waits in emergency\u000d\u000a      departments: a systematic review of present innovations. [National\u000d\u000a      Co-ordinating Centre for NHS Service Delivery and Organisation R &amp; D]\u000d\u000a      2004.\u000d\u000a    \u000a\u000a5. Adams A, et al. Evaluation of the NHS Changing Workforce\u000d\u000a      Programme's Emergency Care Practitioners Pilot Study in Warwickshire.\u000d\u000a      University of Warwick. 2005.\u000d\u000a    \u000a\u000a6. Snooks H, et al. NHS Emergency response to 999 calls:\u000d\u000a      alternatives for cases that are neither life-threatening nor serious BMJ\u000d\u000a      2002; 325,330-33. doi:http:\/\/dx.doi.org\/10.1136\/bmj.325.7359.330\u000d\u000a    \u000a\u000a7. Trivedy CR, Cooke MW. Unscheduled return visits (URV) in adults to the\u000d\u000a      emergency department (ED): a rapid evidence assessment policy review.\u000d\u000a      Emerg Med J. 2013 Oct 28. doi: 10.1136\/emermed-2013-202719. [Epub ahead of\u000d\u000a      print]\u000d\u000a    \u000aFunding:\u000d\u000a    &#8226; National Institute for Health Research Service Delivery and\u000d\u000a      Organisation (SDO292002). Reducing attendance and waits in A&amp;E\u000d\u000a      departments: A review and survey of present innovations. Cooke (PI),\u000d\u000a      &#163;76,016 [2002-03].\u000d\u000a    &#8226; NHS Modernisation Agency International emergency department overload\u000d\u000a      study. Cooke (PI), &#163;30,000 [2003-04].\u000d\u000a    &#8226; Department of Health Policy Research Programme. Cooke (Co-app)\u000d\u000a      Evaluation of walk-in centres phase 2 &#163;151,264 [2004-05].\u000d\u000a    &#8226; Department of Health. National Survey of Secondary Emergency Care. Cooke\u000a        (PI) Principal Applicant, &#163;8,322 [2005].\u000d\u000a    &#8226; National Ambulance Paramedic guidelines, Cooke (PI) JRCALC\u000d\u000a      &#163;298,388. [2006-12].\u000d\u000a    &#8226; Intensive Care Foundation, Beta Agonist Lung Injury Trial - Gold Medal\u000d\u000a      Award. Perkins\/Gao (PI), &#163;50,000. Co-sponsors: Heart of England\u000d\u000a      NHS Foundation Trust and University of Warwick. [2007].\u000d\u000a    &#8226; National Institute for Health Research Clinician Scientist Award\u000d\u000a      (DHCS\/06\/06\/101). Perkins (PI), &#163;683,211. Sponsor: University of\u000d\u000a      Warwick. [2007-13].\u000d\u000a    &#8226; Canadian Health Services Research Foundation. Waiting with an\u000d\u000a      emergency. Cooke (Co-app) Can$1.4m [2007-13].\u000d\u000a    &#8226; Resuscitation Council (UK). E-learning evaluation. Perkins (PI),\u000d\u000a      &#163; 250,000. Co-sponsors: Heart of England NHS Foundation Trust and\u000d\u000a      University of Warwick. [2008-10].\u000d\u000a    &#8226; National Institute for Health Research, 03b2-Agonist Lung Injury Trial\u000d\u000a      Prevention. Perkins (PI), &#163;121,446. Co-sponsors: Heart of England\u000d\u000a      NHS Foundation Trust and University of Warwick. [2008-11].\u000d\u000a    &#8226; Medical Research Council (G0700478). 03b2-Agonist Lung Injury Trial. Lamb\/Gao\u000a        (co-PIs), &#163;1,985,025. Co-sponsors: Heart of England NHS Foundation\u000d\u000a      Trust and University of Warwick. [2008-12].\u000d\u000a    &#8226; Resuscitation Council (UK) PhD Fellowship. Perkins (PI),\u000d\u000a      &#163;80,000. Sponsor: University of Warwick. [2009-12].\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    a. Thompson BT. 03b2-agonists for ARDS: the dark side of adrenergic\u000d\u000a      stimulation? Lancet 2012; 379:196-8.\u000d\u000a    b. Howes, M. I. et al. The Use of Beta 2 Agonists for the\u000d\u000a      Treatment of Acute Respiratory Distress Syndrome. J. Int. Care Soc. 2013;\u000d\u000a      3:2-3 (http:\/\/bit.ly\/19BaYAv)\u000d\u000a    c. Surviving Sepsis International Guidelines (2012)\u000d\u000a      (http:\/\/bit.ly\/VeQJor)\u000d\u000a    d. Mancini M. E. et al 2010 International Consensus on\u000d\u000a      Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science\u000d\u000a      With Treatment Recommendations. Circulation 2010; 122:S539-S581.\u000d\u000a      (http:\/\/bit.ly\/19BcItv)\u000d\u000a    e. Bobrow BJ.J. et al. The influence of scenario-based training\u000d\u000a      and real-time audio-visual feedback on out-of-hospital cardiopulmonary\u000d\u000a      resuscitation quality and survival from out-of- hospital cardiac arrest.\u000d\u000a      Ann Emerg Med. 2013; 62:47-56.e1.\u000d\u000a    f. Supporting Statement: Vice President, Physio-Control, Inc.\u000d\u000a      (Identifier 1).\u000d\u000a    g. Resuscitation Council (UK): e-learning programme \u000d\u000a\u0009   http:\/\/bit.ly\/HhSKe3\u000d\u000a    h. UK ambulance services clinical practice guidelines. Eds Fisher, Brown,\u000d\u000a      Cooke: London 2013\u000d\u000a      http:\/\/aace.org.uk\/the-clinical-practice-guidelines-2013-are-on-their-way\/\u000d\u000a    i. Lamb, S. et al. Report to the National Co-ordinating Centre\u000d\u000a      for NHS Service Delivery and Organisation R&amp;D (NCCSDO), 2008\u000d\u000a      (http:\/\/bit.ly\/1igK2rz). Supporting Statement from NICE\u000d\u000a      Communications Executive (Identifier 2).\u000d\u000a    j. Dept. of Health Checklists to help achieve four hour A&amp;E target.\u000d\u000a      http:\/\/bit.ly\/Hel2WF\u000d\u000a    k. Supporting Statement: Deputy Director Acute Episodes of Care,\u000d\u000a      NHS England (formerly Policy Lead, Urgent &amp; Emergency Care, Department\u000d\u000a      of Health, Whitehall). (Identifier 3).\u000d\u000a    l. Total time spent in A&amp;E. Dept of Health Statistics archive. \u000d\u000a    ","Title":"\u000d\u000a    Influencing Emergency Healthcare Policy and Practice\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Intravenous salbutamol in acute respiratory distress syndrome\u000d\u000a      Severe sepsis can lead to the life-threatening condition ARDS. Our phase\u000d\u000a      II trial in patients with ARDS (03b2-agonist lung injury trial [BALTI-1])\u000d\u000a      found an apparent benefit from the 03b22-adrenergic receptor\u000d\u000a      agonist salbutamol and led to an increase in its use internationally\u000d\u000a      [BALTI-1 was principally conducted elsewhere]. Our subsequent phase III\u000d\u000a      multi-centre, double-blind, randomised controlled trial of intravenous\u000d\u000a      salbutamol in ARDS (a Warwick study) ran from December 2006 to March 2010\u000d\u000a      (Gates, Perkins, Gao, Lamb). 1 It was stopped early after\u000d\u000a      treatment with salbutamol was, found to be poorly tolerated by patients\u000d\u000a      and associated with increased organ failure and mortality (RR 1&#183;47, 95% CI\u000d\u000a      1&#183;03-2&#183;08), leading to calls to discontinue the routine use of\u000d\u000a      03b2-agonists in this condition.\u000d\u000a    Improving the effectiveness of cardiopulmonary resuscitation (CPR)\u000d\u000a      Cardiac arrest is the final common event prior to death in a wide range of\u000d\u000a      emergency conditions. To improve patient survival, our team evaluated\u000d\u000a      strategies to improve the effectiveness of CPR. We did an in-depth\u000d\u000a      analysis, which found that the quality of CPR was suboptimal during\u000d\u000a      in-hospital CPR due to compression of the underlying mattress during chest\u000d\u000a      compression (Perkins, Benny, Tweed, 2001 and 2004). We found that\u000d\u000a      recalibration of a device that provides CPR pressure feedback could\u000d\u000a      overcome this problem (Perkins, 2005). Our subsequent systematic review\u000d\u000a      found that such devices could improve CPR quality in a number of settings\u000d\u000a      (Perkins, Yeung, Gao, 2009 and 2010). 2 Furthermore, we\u000d\u000a      identified that a commonly used accelerometer based feedback device failed\u000d\u000a      to differentiate between chest and mattress compression (Perkins, 2009),\u000d\u000a      which led to its redesign, and improvement.\u000d\u000a    CPR education has a key role in transferring the results of research into\u000d\u000a      clinical practice. Our research has played a central role in the\u000d\u000a      development of the Advanced Life Support Course, which is taught to over\u000d\u000a      20,000 healthcare professionals each year in the UK, Europe and Australia.\u000d\u000a      We developed and evaluated the formal examinations for this course\u000d\u000a      (Perkins, Stallard 2007; Napier, Perkins 2009) and conducted a multicentre\u000d\u000a      randomised trial to evaluate a novel e-learning programme (Perkins,\u000d\u000a      Kimani, Stallard 2012). 3 We found that the quality of learning\u000d\u000a      was maintained, while reducing the cost of delivering the course from &#163;585\u000d\u000a      to &#163;275 per person.\u000d\u000a    Development of new clinical guidelines for ambulance services \u000d\u000a      Warwick is the academic centre for the Joint Royal College Ambulance\u000d\u000a      Liaison Committee undertaking the literature reviews, statistical\u000d\u000a      modelling, consensus work and drafting of the clinical guidelines for\u000d\u000a      ambulance services that form the basis of clinical practice for all\u000d\u000a      paramedics in the UK (Cooke, Fisher 2001-2013). Warwick is currently\u000d\u000a      undergoing the rigorous National Institute for Health and Social Care\u000d\u000a      Excellence (NICE) accreditation process for these guidelines.\u000d\u000a    UK emergency care policy\u000d\u000a      Our research has had a major influence on emergency care policy over many\u000d\u000a      years. Specific projects have addressed the causes behind delays in care\u000d\u000a      and the means for reducing delays, such as the introduction of observation\u000d\u000a      wards (Cooke, 2004) 4, and fast-tracking of individuals with\u000d\u000a      minor injuries (Cooke, 2002). We have also demonstrated more efficient and\u000d\u000a      clinically effective utilisation of new roles for clinicians. For example,\u000d\u000a      1) the development and introduction of emergency care practitioners\u000d\u000a      (Adams, 2005) 5 and Advanced Clinical Practitioners (Cooke, in\u000d\u000a      progress, 2013 but already being across all Accident and Emergency\u000d\u000a      Departments (AEDs) across the West Midlands in 2014 in a project led by\u000d\u000a      Cooke &amp; Swann), and 2) how improved facilities such as walk-in centres\u000d\u000a      can change emergency patient flow (Cooke, 2007) by reducing AED\u000d\u000a      attendances in specific circumstances and by reducing the patients\u000d\u000a      transported to AED by ambulance.6 In an evaluation of these\u000d\u000a      changes, we found a reduction in the number of patients who leave AEDs\u000d\u000a      without being seen (Cooke, 2012) and changes in the causes of reattendance\u000d\u000a      related to initial quality of care and improved access to community\u000d\u000a      services for follow up care.7\u000d\u000a    University of Warwick Medical School staff:\u000d\u000a     \u000d\u000a    Professor Matthew Cooke (Professor of Emergency Medicine,\u000d\u000a      2000-present), Professor Gavin Perkins (Professor of Critical Care\u000d\u000a      Medicine, 2007-present), Dr Mike Tweed (Senior Lecturer in Medical\u000d\u000a      Education, 2000-2003), Professor Jeremy Dale (Professor of Primary\u000d\u000a      Care, 1997- present), Professor Fang Gao (Professor of\u000d\u000a      Anaesthesia, Critical Care and Pain, 2009-2011), Dr Joyce Yeung\u000d\u000a      (PhD Student, 2008-2011), Professor Sallie Lamb (Professor of\u000d\u000a      Rehabilitation and Director of Warwick Clinical Trials Unit,\u000d\u000a      2003-present), Professor Simon Gates (Professor of Clinical\u000d\u000a      Trials, May 2005-present), Dr Chetan Trivedy (Academic Clinical\u000d\u000a      Lecturer in Emergency Medicine, 2012-present) Professor Nigel Stallard\u000d\u000a      (Professor of Medical Statistics, 2005-present), Dr Ann Adams\u000d\u000a      (Principal Research Fellow &amp; Director Research Degrees, 2000-present).\u000d\u000a    "},{"CaseStudyId":"3139","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":[],"ImpactDetails":"\u000a    The Preventing Child Deaths project1 carried out from\u000a      2006 to 2007 was the focal point of an ongoing programme of research into\u000a      child death review processes being carried out by the Warwick team. This\u000a      work has had a direct influence on national policy and practice in\u000a      interagency working to safeguard children and has formed the basis of a\u000a      national training programme and templates for use by CDOPs. A\u000a      The basic procedures to be followed in response to a child's death were\u000a      outlined in statutory national guidance (Working Together to Safeguard\u000a        Children) in 2006. This guidance was expanded in 2010B\u000a      and incorporated the templates and tools developed through the `Preventing\u000a      Child Deaths' Warwick research. A further revision in 2013, again draws on\u000a      these research findings, and Dr Sidebotham was involved in the\u000a      consultation on this guidance, and provided advice directly to the DfE. C\u000a    CDOPs have now been established by all 152 Local Safeguarding Children\u000a      Boards (LSCBs) in England, as well as a national panel for Wales. The\u000a      governments in Scotland and Northern Ireland are currently developing\u000a      similar processes, and Dr Sidebotham is currently supporting the\u000a      Safeguarding Board for Northern Ireland as they seek to develop their\u000a      processes. D The research report on Preventing Child Deaths1\u000a      included a series of appendices with examples of terms of reference\u000a      for CDOPs, forms for notification and data collection, a pro forma\u000a      for data analysis, and audit tools for the child death review processes.\u000a      To assist LSCBs in carrying out child death reviews, the DfE commissioned\u000a      Warwick Medical School to lead development work on national templates for\u000a      these reviewsA, recognising the expertise of the research team\u000a      and the learning from this research. These templates, which are available\u000a      on the DfE website A, are now used as the primary data\u000a      collection tools for all 93 CDOPs in England, and form the basis of annual\u000a      returns by CDOPs to the DfE. The website A includes the\u000a      following citation: `In accordance with Working Together to Safeguard\u000a      Children (paragraph 7.2) all Local Safeguarding Children Boards (LSCBs)\u000a      need to keep information about each child's death... `In order to\u000a        assist LSCBs in this task, the Department commissioned Warwick\u000a        University to lead development work on the templates, which can be used\u000a        by all LSCBs.'\u000a    The Preventing Child Deaths research identified a number of learning\u000a      needs for practitioners from all agencies involved in child welfare and\u000a      CDOP members, and in light of this, the government commissioned Warwick\u000a      Medical School to develop national training materials to support the\u000a      introduction of these child death review processes. This led to the\u000a      production of a training CD, which was distributed to all LSCBs in England\u000a      and made available on the DfE website. A In addition, over 800\u000a      professionals from health, police and social care agencies across England\u000a      have attended training courses in child death review at Warwick Medical\u000a      School since it was established in 2007. The outcomes of this work are\u000a      therefore embedded in professional practice in responding to and learning\u000a      from childhood deaths across the country, and are reflected in local\u000a      protocols and in annual reports from the CDOPs. Dr. Sidebotham has helped\u000a      child death review experts from European countries, Australia and the\u000a      United StatesC, and has been invited to deliver seminars in the\u000a      Netherlands, Australia and Northern Ireland on this topic. These seminars\u000a      have contributed to the development of similar processes in the\u000a      Netherlands and Northern Ireland. D\u000a    In 2011, as a result of his expertise in this area, Dr Sidebotham was\u000a      appointed the academic lead for the Health Quality Improvement\u000a      Partnership-commissioned Clinical Outcomes Review Programme, Child Health\u000a      Reviews-UK. E In 2013, he was appointed to a Royal College of\u000a      Paediatrics and Child Health (RCPCH) working group on child mortality, and\u000a      has presented work from this at a RCPCH policy breakfast (April, 2013),\u000a      and at the Conservative Party conference (September 2013).\u000a    Dr Sidebotham's work with Professor Marion Brandon of UEA on fatal child\u000a      maltreatment and Serious Case Reviews has an ongoing influence on wider\u000a      aspects of child protection. This work is cited in Working Together, 2010B,\u000a      is frequently cited in local Serious Case Reviews across the country, and\u000a      features regularly in local and national training programmes in child\u000a      protection. It is cited in the RCPCH Child Protection Companion,\u000a      and the NICE guidance, When to suspect child maltreatment, which\u000a      forms the basis of clinical guidance for paediatricians, GPs and other\u000a      clinicians in recognising and responding to child maltreatment. In 2010 to\u000a      2011, Professor Eileen Munro undertook a review of Children's\u000a        Safeguarding in England, which influenced subsequent Government\u000a      revisions of safeguarding children guidance in England (Working Together,\u000a      2013). Dr Sidebotham contributed evidence to this review and was a member\u000a      of the Learning from Practice review stream. F In 2012 Dr\u000a      Sidebotham was invited by the RCPCH to contribute to its Child Protection\u000a      CompanionF, a working guide for paediatricians, which cites the\u000a      Sidebotham and Brandon research on Serious Case Reviews and other work by\u000a      Sidebotham and his colleagues. The recent review into the death from abuse\u000a      of Daniel Pelka, which cites the Brandon &amp; Sidebotham research, has\u000a      generated a lot of media interest into how we learn from Serious Case\u000a      Reviews. As a result of this, Dr Sidebotham's research was featured in a\u000a      BBC `Inside Out' documentary (9 September 2013, available on request).\u000a    ","ImpactSummary":"\u000a    Every year over 5,000 children and young people in the UK die. Previous\u000a      research suggests that 20-25% of these deaths may be preventable, and in\u000a      comparison to many other European countries, the UK has higher child\u000a      mortality rates. Child Death Review processes, introduced in the USA in\u000a      the 1970s have been proposed as a means of learning from child deaths and\u000a      driving prevention initiatives. Prior to 2008, the UK had no national\u000a      system for reviewing and learning from children's deaths.\u000a    From 2006 to 2007, a team from Warwick Medical School led by Dr Peter\u000a      Sidebotham undertook government-funded research examining a number of\u000a      Local Authorities across England who had set up pilot Child Death Overview\u000a      Panels (CDOPs). The findings from this research were instrumental in\u000a      developing national policy and procedures for child death reviews. The\u000a      Warwick research emphasised the importance of a multi-agency approach to\u000a      reviewing all child deaths, with a strong public health focus on learning\u000a      lessons for prevention, and robust systems for notification and gathering\u000a      information. This, together with other research by Warwick Medical School\u000a      on fatal child maltreatment published between 2009 and 2011, has\u000a      contributed to updated national policy and interagency practice to\u000a      safeguard children.\u000a    Although it is too early in the process to demonstrate any impact on the\u000a      ultimate goal of reducing preventable child deaths, CDOPs have now been\u000a      established in every Local Authority in England, as well as an all-Wales\u000a      panel, and current work in Scotland and Northern Ireland is considering\u000a      how best to implement such reviews. These panels are reviewing all child\u000a      deaths in England, resulting in local prevention initiatives, and national\u000a      returns enabling a clearer picture of the nature of preventable child\u000a      deaths.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Warwick and Liverpool School of Tropical Medicine\u000a    ","Institutions":[{"AlternativeName":"Warwick (University of)","InstitutionName":"University of Warwick","PeerGroup":"A","Region":"West Midlands","UKPRN":10007163},{"AlternativeName":"Liverpool School of Tropical Medicine","InstitutionName":"Liverpool School of Tropical Medicine","PeerGroup":"G","Region":"North West","UKPRN":10003958}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. P. Sidebotham et al. Preventing Childhood Deaths: a\u000a          study of \"Early Starter\" Child Death Overview Panels in England.\u000a      London: Department for Children Schools and Families, 2008\u000a    \u000a\u000a2. P. Sidebotham et al. Responding to unexpected infant deaths:\u000a      experience in one English region. Archives of Disease in Childhood\u000a      2010; 95:291-295. doi:10.1136\/adc.2009.167619\u000a    \u000a\u000a3. Sidebotham P, Atkins B, Hutton JL. Changes in\u000a      rates of violent child deaths in England and Wales between 1974 and 2008:\u000a      an analysis of national mortality data. Archives of Disease in\u000a        Childhood 2012; 97:193-199. doi: 10.1136\/adc.2010.207647.\u000a      (REF2 UoA2 submission)\u000a    \u000a\u000a4. M. Brandon et al., Understanding Serious Case Reviews and their\u000a          impact &#8212; a biennial analysis of Serious Case Reviews 2005-07.\u000a      London, Department for Children, Schools and Families, 2009. (Cited in\u000a      `When to suspect child maltreatment, NICE, 2009'; Working Together to\u000a      Safeguard Children, HM Government, 2010; the Munro review of child\u000a      protection in England, 2011; Child Protection Companion, RCPCH, 2013)\u000a    \u000a\u000a5. M. Brandon et al., New learning from Serious Case Reviews: a\u000a          two-year report for 2009-2011. London: Department for\u000a        Education, 2011. (Cited in the Munro review of child protection in\u000a      England, 2011; Child Protection Companion, RCPCH, 2013)\u000a    \u000a\u000a6. Sidebotham P, Bailey S, Belderson P, Brandon M. Fatal child\u000a      maltreatment in England, 2005- 9. Child Abuse and Neglect 2011;\u000a        35: 299-306.\u000a        http:\/\/dx.doi.org\/10.1016\/j.chiabu.2011.01.005 (REF2 UoA2\u000a        submission).\u000a    \u000a\u000a7. P. Sidebotham et al. Learning from Serious Case Reviews:\u000a        report of a research study on the methods of learning lessons nationally\u000a        from Serious Case Reviews. London, Department for Education, 2010\u000a    \u000aGrants\u000a    \u000a      Preventing future child deaths. 2006-2007 (16 months); funded by\u000a        Department for Education and Skills (EOR\/SBU\/2006\/045; &#163;185,209). Dr\u000a          Peter Sidebotham (PI); Shahid Perwez.\u000a      Learning from Serious Case Reviews. 2009 (6 months); funded by\u000a        Department for Children, Schools and Families (EOR\/SBU\/2007\/016;\u000a        &#163;36,945). Dr Peter Sidebotham (PI); Dr Colette Solebo; Dr Janice\u000a        Koistenen; Catherine Ellis.\u000a      Biennial analysis of Serious Case Reviews, 2005-7. 2007-2009 (24\u000a        months); funded by Department for Children, Schools and Families\u000a        (EOR\/SBU\/2007\/016; &#163;70,673). Dr Peter Sidebotham, co-applicant\u000a        with Dr Marian Brandon, University of East Anglia.\u000a      Biennial Analysis of Serious Case Reviews, 2009-11. 2010-2011 (16\u000a        months); funded by Department for Children, Schools and Families\u000a        (EOR\/SBU\/2010\/045; &#163;118,261). Dr Peter Sidebotham, co-applicant\u000a        with Dr Marian Brandon, UEA; Dr Carol Hawley, Catherine Ellis.\u000a    \u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    A. Research reports from this research programme and related\u000a    government-funded research, along with the national templates and training\u000a    materials, can be found on the Department for Education website (www.education.gov.uk), including National\u000a      templates for LSCBs to use when collecting information about child deaths.\u000a    B.Working Together (2010) contains the current national statutory\u000a    guidelines on safeguarding children. Chapter 7 outlines the procedures for\u000a    child death review, and draws on the work of the Warwick Medical School.\u000a    This guidance has recently been superseded by Working Together (2013),\u000a    which retains the procedures for child death review covered in the previous\u000a    guidance. C. Supporting Letter available from: Former Safeguarding\u000a    Children Policy Advisor, Department for Education until 2012), currently\u000a    Social Worker and President of the International Society for the Prevention\u000a    of Child Abuse and Neglect (ISPCAN). (Identifier 1). D. Supporting\u000a      Letter available from: Chairman, Safeguarding Board for Northern\u000a    Ireland. (Identifier 2). E. The Child Health Reviews-UK programme was one of\u000a    a series of Clinical Outcomes Review Programmes commissioned by HQIP (RCPCH).\u000a    This incorporated a themed review of mortality and serious morbidity in\u000a    children and young people with epilepsies for which Dr Sidebotham was the\u000a    academic lead. The study findings were published in September 2013.\u000a    F. The Munro review of child protection for which Dr Sidebotham was\u000a    a member of the Learning from Practice group, cites the work of Warwick\u000a    Medical School in all three reports. F. Dr Sidebotham was a contributing\u000a    author for the RCPCH Child Protection Companion, 2013, a working\u000a    guide for all paediatricians. Dr Sidebotham's work is repeatedly cited\u000a    throughout this Companion.\u000a    ","Title":"\u000a    Improving Child Death Reviews Nationwide\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"2641364","Name":"Northern Ireland"},{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Annually, over 5,000 children and young people aged 0-19 die in the UK.\u000a      Although numbers of child deaths have fallen in all age groups, the rate\u000a      of decline has slowed in the past 30 years, and in comparison to many\u000a      other European countries, child mortality in the UK remains high. A recent\u000a      analysis of WHO data concluded that if the UK health system performed as\u000a      well as that of Sweden, as many as 1,500 children's lives might be saved\u000a      each year. Recent National data indicate that 20% of deaths reviewed have\u000a      identified modifiable factors &#8212; a finding that is in keeping with other\u000a      internationally reported studies. The aim of child death review is to\u000a      examine the circumstances of all children's deaths in order to identify\u000a      such modifiable factors, to learn from them, and to inform local and\u000a      national prevention initiatives. Prior to 2006, there were no standardised\u000a      approaches to reviewing child deaths in the UK.\u000a    From 2006 to 2007, we evaluated four basic components of the child death\u000a      review process1: how Local Safeguarding Children Boards (LSCBs)\u000a      went about establishing the overview panels; the systems for notification\u000a      of deaths and data collection; processes for analysing case data; and the\u000a      outputs of the process. The research team identified the importance of\u000a      using multiple sources for notification of child deaths and for gathering\u000a      information about the circumstances and any contributory factors. We made\u000a      recommendations on the structure and membership of panels and developed\u000a      templates for notification, data collection and analysis, and the\u000a      involvement of parents in the process. We identified potential barriers to\u000a      effective working including lack of understanding and cross-boundary\u000a      issues, and how some panels had attempted to overcome these barriers. This\u000a      research tied in with previous research carried out from 2003-2007 by Dr\u000a      Sidebotham with Professor Peter Fleming at the University of Bristol on\u000a      the epidemiology of sudden unexpected death in infancy. As part of this\u000a      research, we developed coordinated procedures for health, police and\u000a      social services in responding to unexpected child deaths. Dr Sidebotham\u000a      analysed further data on how these processes worked at Warwick Medical\u000a      School between 2005 and 2007, focusing in particular on how police\u000a      officers and health professionals could effectively work together in\u000a      investigating unexpected deaths.2 The analysis showed that it\u000a      was possible for police officers and health professionals to respond\u000a      promptly to unexpected child deaths, gather comprehensive information\u000a      about the circumstances of those deaths, and provide ongoing support to\u000a      bereaved families. The approaches used in this research have been adopted\u000a      as national policy in responding to unexpected child deaths (Section 5,\u000a      source B). Since 2010, the Warwick team has been carrying out further\u000a      research through an NIHR doctoral research fellowship to assess how\u000a      parents and professionals perceive these processes, their utility in\u000a      investigating unexpected deaths, and their impact on bereaved parents.\u000a    In 2009 Dr Sidebotham carried out further research at Warwick exploring\u000a      nationwide data on violent child deaths.3 Between 2005 and\u000a      2011, he collaborated with Professor Marian Brandon at the University of\u000a      East Anglia (UEA), carrying out national analyses of data from Serious\u000a      Case Reviews (statutory inter-agency reviews which take place following\u000a      any child death or serious injury from abuse and neglect). 4-7\u000a      Dr Sidebotham was the PI for work looking at the patterns of child\u000a      maltreatment fatalities, comparing different national data sets (from the\u000a      Home Office, Office for National Statistics, and Department for Education)\u000a      to determine the incidence of fatal child maltreatment, and analysing the\u000a      case characteristics of different types of fatal maltreatment. Both these\u000a      pieces of work have been important in providing government with measures\u000a      of the overall incidence and changing patterns of violent child deaths.\u000a      This work has demonstrated that overall numbers and rates of violent child\u000a      deaths have fallen; that declines in rates have plateaued over recent\u000a      years, particularly among teenagers; that different data sources are\u000a      needed for a full understanding of national rates; and that there are\u000a      heterogeneous patterns of violent child deaths requiring different\u000a      approaches to identification and prevention. This work has been widely\u000a      reported in the media and has helped develop our understanding of how we\u000a      learn from Serious Case Reviews. The research has emphasised the\u000a      importance of professionals having an understanding of child development,\u000a      and of taking account of the full context of cases of abuse and neglect,\u000a      including parental characteristics such as domestic violence, mental\u000a      ill-health and substance misuse.\u000a    In 2009, Dr Sidebotham led an assessment of the approaches to carrying\u000a      out Serious Case Reviews.7 This research highlighted the\u000a      ongoing value of Serious Case Reviews in both local and national learning;\u000a      the importance of broadening the scope of national analysis of such\u000a      reviews; and of focusing such reviews on underlying systems issues, not\u000a      just individual practice. It highlighted the value of learning from good\u000a      practice as well as when things go wrong, and that learning should be\u000a      embedded as an ongoing process throughout the review.\u000a    University of Warwick researchers:\u000a    Dr Peter Sidebotham, Associate Professor in Child Health (2005-13) - PI 1,\u000a        3, 7; joint PI 4-6; Collaborator 2\u000a    Catherine Ellis (2010-12) - Research Assistant 5, 7 \u000a    Shahid Perwez (2007-8) - Research Fellow 1\u000a    Janice Koistenen (2007-8) - Project Manager 1\u000a    Ben Atkins (2009) - Medical Student 3\u000a    Jane Hutton, Professor of Statistics (2009) - Collaborator 3\u000a    Colette Solebo (2010) - Research Assistant 7\u000a    External collaborators:\u000a    Professor Jan Howarth, Professor of Child Welfare, Department of\u000a      Sociological Studies. University of Sheffield (2007-8) 1 (2010)\u000a        7\u000a    Dr. Catherine Powell, Senior Lecturer, University of Southampton (2007-8)\u000a        1 (2010)7\u000a    Professor Peter Fleming, Professor of Infant Health &amp; Developmental\u000a      Physiology, University of Bristol (2003-7, PI) 2\u000a    Professor Marian Brandon, Director for the Centre for Research on\u000a      Children and Families, University of East Anglia (2005-11, Joint PI)\u000a        4-7\u000a    "},{"CaseStudyId":"3147","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"51537","Name":"Somalia"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"337996","Name":"Ethiopia"},{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"1282988","Name":"Nepal"},{"GeoNamesId":"934841","Name":"Swaziland"},{"GeoNamesId":"2328926","Name":"Nigeria"},{"GeoNamesId":"927384","Name":"Malawi"},{"GeoNamesId":"69543","Name":"Yemen"},{"GeoNamesId":"102358","Name":"Saudi Arabia"},{"GeoNamesId":"149590","Name":"Tanzania"},{"GeoNamesId":"3175395","Name":"Italy"}],"Funders":["Economic and Social Research Council"],"ImpactDetails":"\u000d\u000a    The LSTM's work on strategies to improve access to TB diagnosis and\u000d\u000a      treatment was driven by\u000d\u000a      our pro-poor and equity perspectives and our understanding of the barriers\u000d\u000a      that prevent\u000d\u000a      disenfranchised populations accessing healthcare services. These research\u000d\u000a      programmes have\u000d\u000a      directly influenced policy and local TB control programmes practice.\u000d\u000a    Policy: Achieving policy change in TB healthcare at the\u000d\u000a      international level requires primary\u000d\u000a      research evidence, time and extensive engagement with researchers,\u000d\u000a      policymakers and funding\u000d\u000a      agencies. Squire and Cuevas were invited to the WHO's\u000d\u000a      annual Strategic and Technical Advisory\u000d\u000a      Group (STAG-TB) meetings to discuss new evidence and give perspectives on\u000d\u000a      TB, SM, poverty\u000d\u000a      and access to services in 2009, 2010, 2011 2012 and 2013. Cuevas\u000d\u000a      served as the Chair of the\u000d\u000a      Stop TB Partnership New Diagnostics Working Group on SM (2007-2011). These\u000d\u000a      contributions\u000d\u000a      yielded numerous contributions to policy and practice. Including the STOP\u000d\u000a      TB Departments\u000d\u000a      adoption of a new milestone within its End of TB strategy, `No families\u000d\u000a      should face catastrophic\u000d\u000a      health costs as a result of TB'. As documented in the slides of the 65th\u000d\u000a      World Health Assembly in\u000d\u000a      May 2012, when Member States including Brazil, UK, Italy, Swaziland, Saudi\u000d\u000a      Arabia and others,\u000d\u000a      called upon the WHO to develop a new post-2015 TB strategy.a\u000d\u000a    As a member of the WHO Advisory Committee for TB and Poverty Squire\u000d\u000a      co-wrote the WHO\u000d\u000a      Options for National TB Control Programmes `Addressing the Poverty in TB\u000d\u000a      control' not previously\u000d\u000a      documented within WHO guidelines.b This document addresses the\u000d\u000a      integration of pro-poor\u000d\u000a      measures in TB control programmes and offers guidance for national TB\u000d\u000a      control programmes on\u000d\u000a      the practical issues involved such as engagement of close-to-community\u000d\u000a      providers. The LSTM also\u000d\u000a      facilitated, through the work of the TB &amp; Poverty Subgroup of the Stop\u000d\u000a      TB Partnership the further\u000d\u000a      development and publication of the patient costing tool, c used\u000d\u000a      to estimate patients' costs to assess\u000d\u000a      the impact of TB on the welfare of households and individuals. Squire\u000d\u000a      was the Secretary from\u000d\u000a      2007 to 2009.\u000d\u000a    The LSTM were commissioned as members of the core writing team of the\u000d\u000a      2011 normative guide\u000d\u000a      `Priorities in operational research to improve TB care and control',\u000d\u000a      jointly sponsored by the WHO,\u000d\u000a      Stop TB, and the Global Fund for AIDS, TB &amp; Malaria. The opening\u000d\u000a      statement on the WHO\u000d\u000a      website refers to evidence from operational research projects paving the\u000d\u000a      way for ensuring many\u000d\u000a      more people have access to vital TB health services. The LSTM research\u000d\u000a      findings are referenced\u000d\u000a      within the documented linking the LSTM operational research to recommended\u000d\u000a      practice.d\u000d\u000a      The WHO revised the SM definitions for smear-positive TB in 2007e,\u000d\u000a      recommending that the third\u000d\u000a      smear examination could be dropped, based on the evidence presented. The\u000d\u000a      findings of LSTM\u000d\u000a      systematic reviews commissioned in 2010 by the WHO were sent to the expert\u000d\u000a      group who\u000d\u000a      considered available options. Cuevas and Squire were\u000d\u000a      members of the expert groups convened\u000d\u000a      to examine the evidence. The LSTM supported the group as most of the\u000d\u000a      relevant data came from\u000d\u000a      LSTM studies. Cuevas attended the meeting in September 2009, where\u000d\u000a      the evidence was\u000d\u000a      discussed and then again at the STAG with Squire where the expert\u000d\u000a      committee report was\u000d\u000a      approved as policy.f The revised policy for same-day diagnosis\u000d\u000a      includes the revised definitions and\u000d\u000a      an accelerated method for collecting specimens as conducted in the LSTM\u000d\u000a      studies. Although\u000d\u000a      implementation of policies takes time, several countries (for example,\u000d\u000a      Nigeria, Somalia and\u000d\u000a      Tanzania) and international organisations (for example, Doctors Without\u000d\u000a      Borders (Medicins Sans\u000d\u000a      Frontieres)) are already implementing this approach. Although it is too\u000d\u000a      early to document impact at\u000d\u000a      the population level, the US Agency for International Development (USAID)\u000d\u000a      has funded the LSTM\u000d\u000a      (2010-present) to model the medium-to-long-term cost and\/or health\u000d\u000a      benefits of these approaches.\u000d\u000a    Practice: The National TB Programme in Malawi is currently\u000d\u000a      engaging informal providers in\u000d\u000a      recognising disease and referring patients as part of national policy. The\u000d\u000a      Nigerian National TB and\u000d\u000a      Leprosy Control programme is exploring whether the Global Fund could\u000d\u000a      provide financial support\u000d\u000a      to include Community-based approaches within its programme, a\u000d\u000a      statement can be provided from\u000d\u000a      the National Coordinator to corroborate Nigerian approaches.g\u000d\u000a      The Ethiopian Regional and\u000d\u000a      National Health services are expanding a Community-based approach from a\u000d\u000a      base of three million\u000d\u000a      to seven million population as a package of the regional and national\u000d\u000a      Health Extension\u000d\u000a      Programme. Our work engaging community health workers has been described\u000d\u000a      as a `pathfinder for\u000d\u000a      TB' by the WHO. Work in Ethiopia was highlighted on the WHO website in\u000d\u000a      2013, where the,\u000d\u000a      Executive Secretary of the Stop TB Partnership said: \"To stop TB, we\u000d\u000a        must bring quality TB care to\u000d\u000a        poor and marginalized communities we can capitalize on two of the\u000d\u000a        world's greatest resources -\u000d\u000a        people and communities - to ensure that no one gets left behind. I am\u000d\u000a        particularly pleased to see\u000d\u000a        that this project has served as a pathfinder, encouraging further\u000d\u000a        investment and scale up from the\u000d\u000a        Ethiopian government and the Global Fund\". h\u000d\u000a    The successes of these approaches have received international publicity,\u000d\u000a      and were promoted in\u000d\u000a      2013 by the WHO Stop TB Partnership as `leading the way'. During the\u000d\u000a      United Nations General\u000d\u000a      Assembly in New York in 2013 the governments of the UK and USA hosted the\u000d\u000a      `Millennium\u000d\u000a      Development Goal Countdown 2013'. For Millennium Development Goal (MDG) 6,\u000d\u000a      a single case\u000d\u000a      study was selected; the case study was the LSTM `TB REACH Ethiopia'\u000d\u000a      project on community\u000d\u000a      level health extension workers, which Theobald (LSTM) presented on\u000d\u000a      behalf of the Global fund, i\u000d\u000a      as case detection more than doubled in south Ethiopia in the 2 years after\u000d\u000a      the project was\u000d\u000a      implemented. A figure illustrating this can be corroborated in reference.j\u000d\u000a    ","ImpactSummary":"\u000d\u000a    This case study describes the impact on national and global tuberculosis\u000d\u000a      (TB) control policy of\u000d\u000a      research led by Cuevas, Squire and Theobald at the\u000d\u000a      Liverpool School of Tropical Medicine\u000d\u000a      (LSTM). Early research led to the publication of the World Health\u000d\u000a      Organisation (WHO) Options for\u000d\u000a      National TB Control Programmes `Addressing the Poverty in TB control' in\u000d\u000a      2005. Further research\u000d\u000a      led to WHO endorsement of same-day diagnosis of TB by smear microscopy\u000d\u000a      (SM) in 2010. This\u000d\u000a      strategy has been implemented in Malawi, Nigeria, Yemen, Ethiopia and\u000d\u000a      Nepal. Alongside this we\u000d\u000a      have developed and tested approaches to bring diagnosis and treatment for\u000d\u000a      TB closer to the\u000d\u000a      community. Same-day diagnosis and close-to-community approaches have led\u000d\u000a      to improvements in\u000d\u000a      access to TB care and treatment, and reductions in costs incurred during\u000d\u000a      care-seeking by poor\u000d\u000a      patients in these countries and elsewhere.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Warwick and Liverpool School of Tropical Medicine\u000d\u000a    ","Institutions":[{"AlternativeName":"Warwick (University of)","InstitutionName":"University of Warwick","PeerGroup":"A","Region":"West Midlands","UKPRN":10007163},{"AlternativeName":"Liverpool School of Tropical Medicine","InstitutionName":"Liverpool School of Tropical Medicine","PeerGroup":"G","Region":"North West","UKPRN":10003958}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"5128638","Name":"New York"}],"References":"\u000d\u000a    \u000a1. Kemp JR, Mann G , Nhlema Simwaka B, Salaniponi\u000d\u000a      FML, Squire SB. Can Malawi's poor afford\u000d\u000a        free TB services? Patient and household costs associated with a TB\u000d\u000a        diagnosis in Lilongwe.\u000d\u000a      Bulletin of the World Health Organisation 2007 85; 580-585.\u000d\u000a    \u000a\u000a2. Nhlema-Simwaka B, Benson T, Kishindo P, Salaniponi FML, Theobald S,\u000d\u000a      Squire SB, Kemp\u000d\u000a        JR. Developing socio-economic measures to monitor access to\u000d\u000a        tuberculosis services in urban\u000d\u000a        Lilongwe, Malawi. Int J Tuberc Lung Dis. 2007\u000d\u000a      11(1):65-71.\u000d\u000a    \u000a\u000a3. Yassin MA, Cuevas LE. How many sputum smears are\u000d\u000a        necessary for case finding in\u000d\u000a        pulmonary tuberculosis? Tropical Medicine and International Health\u000d\u000a      Volume 8, Issue 10,\u000d\u000a      October 2003, Pages 927-932.\u000d\u000a    \u000a\u000a4. Lawson L, Yassin MA, Ramsay A ,\u000d\u000a      Olajide I, Thacher TD, Davies PDO, Squire SB, Cuevas L.\u000d\u000a        Microbiological validation of smear microscopy after sputum digestion\u000d\u000a        with bleach; A step\u000d\u000a        closer to a one-stop diagnosis of pulmonary tuberculosis.\u000d\u000a      Tuberculosis Volume 86, Issue 1,\u000d\u000a      January 2006, Pages 34-40.\u000d\u000a    \u000a\u000a5. Cuevas LE, A multi-country non-inferiority cluster\u000d\u000a        randomized trial of frontloaded smear\u000d\u000a        microscopy for the diagnosis of pulmonary tuberculosis. PLoS Med. 8,\u000d\u000a      e1000443 (2011).\u000d\u000a      (Submitted in UoA2 REF2).\u000d\u000a    \u000a\u000a6. Cuevas LE, Al-Sonboli N, Lawson L, Yassin MA, Arbide\u000d\u000a      I, Al-Aghbari N, Sherchand JB, Al-Absi\u000d\u000a      A, Emenyonu EN, Merid Y, Okobi MI, Onuoha JO, Aschalew M, Aseffa A, Harper\u000d\u000a        G, de\u000d\u000a        Cuevas RMA, Theobald SJ, Nathanson CM, Joly J, Faragher\u000d\u000a        B, Squire SB, Ramsay A. LED\u000d\u000a        fluorescence microscopy for the diagnosis of pulmonary tuberculosis: A\u000d\u000a        multi-country cross-\u000d\u000a        sectional evaluation. PLoS Medicine. Volume 8, Issue 7, July 2011,\u000d\u000a      Article number\u000d\u000a      e1001057J. (Submitted in UoA2 REF2).\u000d\u000a    \u000a\u000a7. Davis JL, Cattamanchi A, Cuevas LE, Hopewell PC, Steingart KR.\u000d\u000a      Diagnostic accuracy of\u000d\u000a        same-day microscopy versus standard microscopy for pulmonary\u000d\u000a        tuberculosis: a systematic\u000d\u000a        review and meta-analysis. Lancet Infect. Dis. 13, 147-154 (2013). (Submitted\u000d\u000a        in UoA2\u000d\u000a        REF2).\u000d\u000a    \u000a\u000a8. Ramsay A, Cuevas LE, Mundy CJF, Nathanson CM, Chirambo P, Dacombe\u000d\u000a        R, Squire SB,\u000d\u000a      Salaniponi FML, Munthali S. New policies, new technologies: modelling\u000d\u000a        the potential for\u000d\u000a        improved smear microscopy services in Malawi. PLoS ONE 4, e7760\u000d\u000a      (2009).\u000d\u000a    \u000a\u000a9. Simwaka BN, Theobald S, Willets A, Salaniponi FML, Nkhonjera\u000d\u000a      P, Bello G, Squire SB.\u000d\u000a      Acceptability and effectiveness of the storekeeper-based TB referral\u000d\u000a        system for TB suspects in\u000d\u000a        sub-districts of Lilongwe in Malawi. PLoS ONE 7, e39746 (2012).\u000d\u000a    \u000a\u000a10. Yassin MA, Datiko DG, Tulloch O, Markos P,\u000d\u000a      Aschalew M, Shargie EB, Dangisso MH,\u000d\u000a      Komatsu R, Sahu S, Blok L, Cuevas LE, Theobald S. Innovative\u000d\u000a        community-based approaches\u000d\u000a        doubled tuberculosis case notification and improve treatment outcome in\u000d\u000a        southern Ethiopia.\u000d\u000a      PLoS ONE 8, e63174 (2013).\u000d\u000a    \u000aResearch Funding\u000d\u000a    &#8226; World Health Organization (Switzerland) - Tuberculosis Poverty\u000d\u000a      Secretariat, PI: Squire.\u000d\u000a      &#163;218,827. [2006-2010].\u000d\u000a    &#8226; World Health Organization (Switzerland) - A Multi-centric Trial of\u000d\u000a      Front-Loaded Smear\u000d\u000a      Microscopy in the Diagnosis of Tuberculosis. PI: Cuevas. &#163;169,462.\u000d\u000a      [2007-2008].\u000d\u000a    &#8226; Department for International Development (DFID)\/Economic and Social\u000d\u000a      Research Council\u000d\u000a      (ESRC). Identifying Barriers to TB Diagnosis and Amp. Treatment Under a\u000d\u000a      new Rapid\u000d\u000a      Diagnostic Scheme. PI: Theobald. &#163;237,584. [2008-2012].\u000d\u000a    &#8226; US Agency for International Development (USAID). TREAT TB: Technology,\u000d\u000a      Research,\u000d\u000a      Education and Technical Assistance for TB Project. PI: Squire.\u000d\u000a      &#163;1,068,390. [2009-2014].\u000d\u000a    &#8226; World Health Organization - Innovative Community-based Approaches for\u000d\u000a      Enhanced\u000d\u000a      Tuberculosis Case Finding &amp; Amp; Outcome in Southern Ethiopia - Part\u000d\u000a      1. PI: Theobald.\u000d\u000a      &#163;446,291. [2010-2012].\u000d\u000a    &#8226; STOP TB Partnership. Innovative Community-based Approaches for Enhanced\u000d\u000a      Tuberculosis\u000d\u000a      Case Finding &amp; Treatment Outcome in Southern Ethiopia - Part 2. PI:\u000d\u000a        Theobald. &#163;388,917.\u000d\u000a      [2012-2013].\u000d\u000a    &#8226; The European and Developing Countries Clinical Trials Partnership\u000d\u000a      (EDCTP) - Innovative\u000d\u000a      approaches to diagnose and monitor patients with TB to facilitate\u000d\u000a      conducting clinical trials for\u000d\u000a      the community-based treatment of MDR-TB. PI: Cuevas. &#163;686,353.\u000d\u000a      [2012-14].\u000d\u000a    &#8226; TB Reach - Scaling up innovative community-based approaches to improve\u000d\u000a      TB diagnosis and\u000d\u000a      treatment among vulnerable and high-risk populations in Ethiopia. PI:\u000d\u000a        Cuevas. &#163;576,796.\u000d\u000a      [2013-14].\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    a) WHO\/Global TB Programme. Post 2015 Strategy and Targets, 23rd Stop TB\u000d\u000a      Partnership\u000d\u000a      Coordinating Board Meeting, 11 - 12 July 2013, Ottawa, Canada\u000d\u000a      http:\/\/www.stoptb.org\/assets\/documents\/about\/cb\/meetings\/23\/1.13-\u000d\u000a      0%20Presentations\/Session%2006_Post%202015%20Strategy_Raviglione.pdf\u000d\u000a    b) The WHO Options for National Control Programmes, published in 2005,\u000d\u000a      implemented\u000d\u000a      between 2008 and 2013.\u000d\u000a      http:\/\/whqlibdoc.who.int\/hq\/2005\/WHO_HTM_TB_2005.352.pdf\u000d\u000a    c) STOP TB, TB &amp; Poverty Sub Group, Patient Costing Tool\u000d\u000a      http:\/\/tinyurl.com\/o7rhpq6\u000d\u000a    d) 2011 normative guide \"Priorities in operational research to improve TB\u000d\u000a      care and control\",\u000d\u000a      (WHO, Stop TB, and the Global Fund for AIDS, TB &amp; Malaria.)\u000d\u000a      http:\/\/www.who.int\/tb\/features_archive\/operational_research_priorities\/en\/\u000d\u000a    e) The WHO 2007 policy statement on Same-day diagnosis of tuberculosis by\u000d\u000a      microscopy is\u000d\u000a      available at http:\/\/tinyurl.com\/pjlwfmu.\u000d\u000a    f) The revised WHO policy for same-day diagnosis, which included the\u000d\u000a      revised SM definitions\u000d\u000a      plus an accelerated method for collecting specimens, was issued in 2011:\u000d\u000a      http:\/\/tinyurl.com\/oxaaxae.\u000d\u000a    g) Person who can be contacted: National Manager, Nigeria\u000d\u000a      Tuberculosis and Leprosy\u000d\u000a      Control Programme &#8212; to indicate that the programme wants to expand ACF to\u000d\u000a      selected\u000d\u000a      Nigerian states. (Identifier 1).\u000d\u000a    h) http:\/\/www.stoptb.org\/news\/stories\/2013\/ns13_035.asp Quote from the\u000d\u000a      Executive Secretary\u000d\u000a      of the Stop TB Partnership with reference to LSTM project in Ethiopia.\u000d\u000a    i) United Nations General Assembly MGD6 countdown case study, \"Tackling\u000d\u000a      TB in Ethiopia\".\u000d\u000a      (http:\/\/tinyurl.com\/ml96kgq). \"Ethiopian community health workers help\u000d\u000a      double the number\u000d\u000a      of vulnerable people provided with TB Care\"\u000d\u000a    j) A figure illustrating this, based on data from the Regional TB Control\u000d\u000a      programme, is at:\u000d\u000a      http:\/\/tinyurl.com\/omr7vwl.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Improving Access to Tuberculosis Care for the Poor in Developing\u000d\u000a        Countries\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Background\u000d\u000a    Tuberculosis (TB) is a contagious and often severe airborne disease\u000d\u000a      caused by a bacterial\u000d\u000a      infection. In 2012, an estimated 8.6 million people developed TB and 1.3\u000d\u000a      million died from the\u000d\u000a      disease. Three million of the annually estimated 8.6 million cases of TB\u000d\u000a      are missed by healthcare\u000d\u000a      services. National surveys establish the population prevalence of TB. Data\u000d\u000a      are also collected at\u000d\u000a      health centres on cases diagnosed and treated. The gap of three million\u000d\u000a      cases is the difference\u000d\u000a      between the expected prevalence and the reported number of diagnoses\u000d\u000a      (surveillance data). It is\u000d\u000a      thus a combination of cases missed and cases not notified. Increasing case\u000d\u000a      detection is therefore\u000d\u000a      an international priority. Smear microscopy tests (the main test used for\u000d\u000a      diagnosis) have a low\u000d\u000a      acquisition cost and have low sensitivity. For several decades, because of\u000d\u000a      the low sensitivity of\u000d\u000a      SM, patients have had to provide three separate sputum samples for\u000d\u000a      examination. This process\u000d\u000a      requires several visits and substantial out-of-pocket expenditure.\u000d\u000a      According to WHO definitions,\u000d\u000a      sputum smears had to contain at least 10 bacilli (bacteria) and at least\u000d\u000a      two of the three smears had\u000d\u000a      to yield a positive result in order for a patient to be considered\u000d\u000a      smear-positive.\u000d\u000a    Problems with diagnosis and access to service\u000d\u000a    Work in Malawi led by Squire (Professor of Tropical Medicine,\u000d\u000a      1995-present) assessed patient\u000d\u000a      and household direct and opportunity costs of accessing TB services. To do\u000d\u000a      this his team surveyed\u000d\u000a      TB patients, sampled from all health facilities in Lilongwe. This\u000d\u000a      demonstrated that poor patients (an\u000d\u000a      income of &lt;US$0.25\/day) needed to spend 244% of their monthly income\u000d\u000a      accessing TB healthcare\u000d\u000a      services. In contrast, non-poor patients (an average income of US$1.23 per\u000d\u000a      day) `only' needed to\u000d\u000a      spend 129% of their income accessing TB services.1 The LSTM\u000d\u000a      were the first to use a validated\u000d\u000a      measure of poverty based on questions regarding a limited range of assets\u000d\u000a      as a proxy for income.2\u000d\u000a      Research in Ethiopia and Nigeria led by Cuevas (Professor of\u000d\u000a      Epidemiology, 1993-present)\u000d\u000a      reported similar difficulties in accessing services in Ethiopia,\u000d\u000a      concluding that patient and household\u000d\u000a      costs of TB diagnosis are prohibitively high even where services are free.\u000d\u000a      In both settings, many\u000d\u000a      patients stopped attending the services before achieving a diagnosis.\u000d\u000a    Solution 1: Improving case definitions, diagnosis and detection of\u000d\u000a          TB\u000d\u000a    Studies to improve SM-based diagnosis with the goal of diagnosis in a\u000d\u000a      single day were conducted\u000d\u000a      by Cuevas, Squire, Theobald (LSTM Reader in Social Science,\u000d\u000a      1999-present), Yassin (LSTM\u000d\u000a      Epidemiologist 2003-2010) and Ramsay (LSTM Fellow 2001-2008,) in\u000d\u000a      Nigeria, Ethiopia, Nepal,\u000d\u000a      Yemen, Brazil, Cameroon and Malawi (2006-2013). The LSTM demonstrated that\u000d\u000a      most patients\u000d\u000a      are diagnosed by the first two smears3; smears with low\u000d\u000a      numbers (1-10) of bacilli are true-positive\u000d\u000a      results; SM has high specificity.4 One positive smear is\u000d\u000a      sufficient for a positive SM diagnosis; and\u000d\u000a      that diagnosis can be reached in one day (same-day diagnosis).\u000d\u000a        4 Previous to these studies, it was\u000d\u000a      perceived that smears with very few bacilli could be false positive, and\u000d\u000a      thus the control\u000d\u000a      programmes required that patients have at least two smears with few\u000d\u000a      bacilli. By demonstrating\u000d\u000a      this, control programmes could consider one smear with few bacilli as true\u000d\u000a      positive. The LSTM\u000d\u000a      conducted multi-country evaluations in Nepal, Nigeria, the Yemen and\u000d\u000a      Ethiopia, which\u000d\u000a      demonstrated that single-day diagnosis had the same level of performance\u000d\u000a      as older schemes. In\u000d\u000a      total, 6,627 patients were enrolled; 6,466 had culture tests of which\u000d\u000a      1,526 were positive.5 We also\u000d\u000a      demonstrated that this approach could be used in conjunction with the new\u000d\u000a      LED fluorescence\u000d\u000a      microscopes.6 We conducted a systematic review of same-day SM\u000d\u000a      and presented data to the\u000d\u000a      WHO to inform development of policy guidance.7 A study in 2009\u000d\u000a      modelled that the implementation\u000d\u000a      of the new WHO recommendations on smear microscopy and LED based\u000d\u000a      fluorescence microscopy\u000d\u000a      combined would result in substantial increases in smear positive\u000d\u000a      case-detection using existing\u000d\u000a      human resources.8\u000d\u000a    Solution 2: Community-based approaches to improve access to\u000d\u000a          diagnosis and treatment\u000d\u000a    From 2008 to 2013, Squire and Theobald led work in Malawi\u000d\u000a      demonstrating that engaging\u000d\u000a      informal providers (shopkeepers) in recognising disease and referring\u000d\u000a      patients doubled TB case\u000d\u000a      detection and reduced the time delay to diagnosis by 75%. 9\u000d\u000a      Since 2009, Cuevas and Theobald\u000d\u000a      have led studies engaging village-based health extension workers (HEWs) to\u000d\u000a      facilitate access to\u000d\u000a      diagnosis and treatment in Ethiopia. HEWs identify individuals with\u000d\u000a      symptoms of TB and collect\u000d\u000a      and prepare smears and transport to the diagnostic laboratories.10\u000d\u000a      In the Yemen, HEWs visited the\u000d\u000a      homes of adults with TB to identify secondary cases that had not consulted\u000d\u000a      healthcare services\u000d\u000a      and, in Nigeria, HEWs visited households in slums and tested specimens. In\u000d\u000a      Ethiopia these\u000d\u000a      approaches have led to a greater than 100%, increase in case detection3,\u000d\u000a      and in Nigeria, to a 70%\u000d\u000a      increase.\u000d\u000a    "},{"CaseStudyId":"3148","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"934841","Name":"Swaziland"},{"GeoNamesId":"3374766","Name":"Cape Verde"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000aSeveral factors have made malaria control difficult in sub-Saharan Africa and led to substantial\u000d\u000aincreases in malaria burden on the continent during the 1980s and 1990s. The first was the\u000d\u000awidespread emergence of resistance of P. falciparum, particularly to chloroquine (CQ), then the\u000d\u000amost commonly used anti-malarial drug. This has been managed by changing treatment policy to\u000d\u000aACTs in most sub-Saharan African countries.\u000d\u000aRe-introduction of amodiaquine for treating uncomplicated malaria in Africa.\u000d\u000aThe results of the joint studies of the LSTM and the WHO on the efficacy and safety of\u000d\u000aamodiaquine, led to it being reintroduced for uncomplicated malaria in 2003, and has had an\u000d\u000aenduring impact since. The WHO technical report (page10) refers to the reviews leading to the\u000d\u000arecommendation that amodiaquine be added to the Model List as a core list medicine.a, b In 2006,\u000d\u000aWHO guidelines recommended amodiaquine combined with artesunate as one of the three ACTs\u000d\u000afor malaria treatment in Africa.c As a result, it is currently estimated that amodiaquine-containing\u000d\u000aACT accounts for 30% of ACTs taken by adults with malaria in Africa. The 2008 Global Malaria\u000d\u000aAction Plan states \"There has been a remarkable adoption of ACTs in sub-Saharan African\u000d\u000acountries: in 2003, only two sub-Saharan African countries had adopted ACTs; as of September\u000d\u000a2007, all sub-Saharan African countries except Swaziland and Cape Verde have adopted ACT\u000d\u000apolicy.\"d This is having an on-going impact on the treatment of uncomplicated malaria across\u000d\u000aAfrica.\u000d\u000aWHO recommendation for replacement of monotherapy with ACTs in P. falciparum malaria.\u000d\u000aThe analysis of ACT safety and efficacy in 2004 provided unequivocal evidence (70% more\u000d\u000apatients cured with artesunate combination treatments than with monotherapy; meta-analysis of 16\u000d\u000atrials) that ACT was more effective in treating malaria than the single antimalarial drugs alone. This\u000d\u000aled the WHO Expert Panel to recommend strongly in its 2006 guidelines that countries should stop\u000d\u000ausing monotherapy.c Garner was the methodologist on the WHO Guideline Panel and drafted the\u000d\u000aevidence box for these guidelines. Evidence provided by the LSTM team led to the Global\u000d\u000aRecommendation in 2010 to replace monotherapy with combination therapy and also supported\u000d\u000aother WHO recommendations for treating uncomplicated and complicated malaria.e, f Introduction\u000d\u000aof ACTs is the most important treatment advance in malaria this century. This decision led to a\u000d\u000amassive increase in the manufacture and testing of co-formulated products and has probably been\u000d\u000acritical in reducing mortality from malaria globally. There were an estimated 11 million ACT\u000d\u000atreatment courses purchased in 2005, an estimated 287 million ACT treatments were purchased in\u000d\u000a2011 as documented in UNITAID's Malaria Response.g (UNITAID is a global health organisation\u000d\u000ahosted by the WHO that uses innovative financing to increase funding for greater access to\u000d\u000atreatments and diagnostics for HIV\/AIDS, malaria and tuberculosis in low-income countries).\u000d\u000aDihydroartemisinin-piperaquine added as a treatment option for malaria. During the\u000d\u000adevelopment of the WHO malaria guidelines, the LSTM team was commissioned to assess new\u000d\u000aACT treatment options. In the Cochrane review prepared for the WHO Guidelines panel, the\u000d\u000aanalysis showed clearly that the dihydroartemisinin-piperaquine combination drug had failure rates\u000d\u000aof less than 10% and consistently performed as well as and often better than other ACTs, which\u000d\u000aled the panel to recommend it as a new option for treating malaria. The Medical Officer from the\u000d\u000aWHO's Global Malaria Programme confirms the new recommendations in the 2010 addition of the\u000d\u000aMalaria Treatment Guidelines, are based on the findings of these systematic reviews. h\u000d\u000aArtesunate recommended for severe malaria. At the 2010 Guideline review panel, the Cochrane\u000d\u000aReview of artesunate versus quinine was considered; this review showed that artesunate produced\u000d\u000aa 38% reduction in mortality in adults with malaria, when compared with quinine. Thus, the WHO\u000d\u000aMalaria Guidelines Panel in 2010 recommended that artesunate be used instead of quinine for\u000d\u000asevere malaria in adults. In 2011 a trial of artesunate in children was published and quickly added\u000d\u000ato the meta-analysis, providing additional data on children; this summary was considered by the\u000d\u000aPanel, who then recommended its adoption in children. f, i\u000d\u000aDirect impact on the decision-making process of the technical expert group on malaria\u000d\u000achemotherapy and beyond.\u000d\u000aPaul Garner introduced systematic reviews and meta-analysis to malaria, against all the advice of\u000d\u000aexperts in the field (who said that malaria was so varied that the methods were not appropriate).\u000d\u000aThe early reviews on the efficacy and safety of amodiaquine and ACT indicated that rigorous up-to-date\u000d\u000ascientific reviews could drive policy and led the WHO to move from consensus decision\u000d\u000amaking to evidence-informed approaches. Whilst this is part of a global movement, the LSTM team\u000d\u000awas instrumental in the introduction of evidence-informed approaches to decision making on\u000d\u000amalaria guidelines.h, j This is reflected by the fact that WHO routinely turns to the LSTM for\u000d\u000aCochrane reviews, summaries and GRADE analyses. Importantly, malaria guidelines that are\u000d\u000abased on an externally validated tool have been demonstrated to be among some of the best WHO\u000d\u000aguidelines in terms of quality, as indicated by high quality scores using an international assessment\u000d\u000atool (AGREE).j\u000d\u000aThe reputation of the LSTM led the Director-General's office of the WHO to ask the team to\u000d\u000aevaluate progress in evidence-based guideline development across the whole organization. The\u000d\u000afindings of the WHO guideline development evaluation were presented in 2013. In addition, the\u000d\u000apaper was presented to the WHO Senior Management Team, which is the highest decision-making\u000d\u000abody in the organization, and includes the Director General. This was then used to help refine and\u000d\u000areinforce policies within the organization in relation to guidelines, and to extend quality assurance\u000d\u000aprocesses to other aspects of WHO publications.j\u000d\u000a","ImpactSummary":"\u000d\u000aThe World Health Organization (WHO) estimate 3.3 billion people are at risk of malaria, with 219\u000d\u000amillion cases and over half a million deaths annually. The Liverpool School of Tropical Medicine\u000d\u000a(LSTM) has applied new methods of research synthesis to malaria, and the results of this work\u000d\u000ahave directly influenced important global decisions on malaria policies, including the adoption of\u000d\u000anew antimalarial drugs. In this case study, we report on the influence of the LSTM on malaria\u000d\u000acontrol over the last 15 years by preparing rigorous, up-to-date, timely systematic reviews on\u000d\u000amalaria. This work has also contributed to substantive improvements in the methodological rigor\u000d\u000aand transparency of the WHO malaria policy group in evidence-based policy formulation and\u000d\u000aguideline development.\u000d\u000a","ImpactType":"Health","Institution":"\u000d\u000aUniversity of Warwick and Liverpool School of Tropical Medicine\u000d\u000a","Institutions":[{"AlternativeName":"Warwick (University of)","InstitutionName":"University of Warwick","PeerGroup":"A","Region":"West Midlands","UKPRN":10007163},{"AlternativeName":"Liverpool School of Tropical Medicine","InstitutionName":"Liverpool School of Tropical Medicine","PeerGroup":"G","Region":"North West","UKPRN":10003958}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a\u000a1. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, Brasseur P. Systematic review\u000d\u000aof amodiaquine treatment in uncomplicated malaria. Lancet [1996]; 348:1196-201. [DOI:\u000d\u000a10.1016\/S0140-6736(96)06217-4].\u000d\u000a\u000a\u000a2. MacLehose H, Klaes D, Garner P. Amodiaquine: a systematic review of adverse events\u000d\u000a(unpublished document available on WHO website) [2003]\u000d\u000a\u000a\u000a3. International Artemisinin Study Group Artesunate combinations for treatment of malaria: meta-analysis.\u000d\u000aLancet [2004]; 363 (9402):9-17 [DOI: 10.1016\/S0140-6736(03)15162-8]\u000d\u000a(corresponding author: P Garner).\u000d\u000a\u000a\u000a4. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for\u000d\u000atreating uncomplicated malaria. Cochrane Database of Systematic Reviews [2009]; 3: Art. No.\u000d\u000aCD007483 [DOI: 10.1002\/14651858.CD007483.pub2 ]. (Submitted in UoA2 REF2).\u000d\u000a\u000a\u000a5. Sinclair D, Gyansa-Lutterodt M, Asare B, Koduah A, Andrews, E, Garner P. Integrating Global\u000d\u000aand National Knowledge to Select Medicines for Children: The Ghana National Drugs\u000d\u000aProgramme. PLoS Med [2013]; 10(5): e1001449. [DOI:10.1371\/journal.pmed.1001449].\u000d\u000a\u000a\u000a6. Sinclair D, Donegan S, Isba R, Lalloo DG. Artesunate versus quinine for treating severe\u000d\u000amalaria. Cochrane Database of Systematic Reviews [2012]; 6: Art. No. CD005967. [DOI:\u000d\u000a10.1002\/14651858.CD005967.pub4].\u000d\u000a\u000a\u000a7. Sinclair D, Isba R, Kredo T, Zani B, Smith H, Garner P. World Health Organization Guideline\u000d\u000aDevelopment: An Evaluation. PLoS One [2013]; 8(5):e63715 [DOI:\u000d\u000a10.1371\/journal.pone.0063715].\u000d\u000a\u000aKey Research Grants\u000d\u000a&#8226; DFID (UK) Effective Health Care Research Consortium (HD26) &#163;6 Million. PI Garner P. 2010-16.\u000d\u000a&#8226; DFID (UK) Effective Health Care Alliance Programme (EHCAP) (HD7). Increase in decisions\u000d\u000arelated to the health sector based on best available evidence in middle and low-income\u000d\u000acountries, &#163;4,022,649, PI Garner P. 2005-10\u000d\u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"15","Subject":"Pharmacology and Pharmaceutical Sciences"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000aa. WHO technical report that informed the decisions on the essential medicine list, 2003, page\u000d\u000a10. http:\/\/tinyurl.com\/kh9khf2\u000d\u000ab. WHO essential medicines list reintroduced amodiaquine in 2003 http:\/\/tinyurl.com\/m4mqknf\u000d\u000ac. WHO Guideline 2006 stating the meta-analysis of 11 RCTs found clear benefit of adding\u000d\u000aACTs it significantly reduces treatment failure, recrudescence and gametocyte carriage.\u000d\u000aAnnex 1 of the first edition of the guidelines.\u000d\u000ahttp:\/\/whqlibdoc.who.int\/publications\/2006\/9241546948_eng.pdf\u000d\u000ad. Roll Back Malaria Global Malaria Action Plan http:\/\/www.rollbackmalaria.org\/gmap\/3-2.html)\u000d\u000aPart III: Regional Strategies 2. Africa.\u000d\u000ae. LSTM are part of the WHO Malaria Treatment Guidelines Panel and contributed towards\u000d\u000athis new edition 2010. http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241547925_eng.pdf\u000d\u000af. 2010 WHO Guidelines for the treatment of malaria:\u000d\u000ahttp:\/\/www.who.int\/malaria\/publications\/atoz\/9789241547925\/en\/index.html\u000d\u000ag. UNITAID's Malaria Response http:\/\/www.unitaid.eu\/en\/what\/malaria?id=1151\u000d\u000ah. Medical Officer from the WHO's Global Malaria Programme talking about the new edition of\u000d\u000aMalaria Treatment Guidelines: YouTube video: Http:\/\/Tinyurl.Com\/Mb5zety\u000d\u000ai. WHO Recommendation: Intravenous artesunate should be used in preference to quinine\u000d\u000afor the treatment of serve malaria.\u000d\u000ahttp:\/\/www.who.int\/malaria\/areas\/high_risk_groups\/children\/en\/index.html\u000d\u000aj. Person who can be contacted: A statement can be provided from the Director of\u000d\u000aStrategy, Office of the Director General, confirming that processes in the WHO have\u000d\u000achanged due to the evaluation. (Identifier 1).\u000d\u000a\u000d\u000a","Title":"\u000d\u000aEnduring Impact on WHO Guidelines for Malaria Treatment\u000d\u000a","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000aSince 1994, the LSTM has been preparing systematic reviews on the benefits and harms of\u000d\u000ahealthcare interventions for tropical diseases. Meta-analysis can generate new knowledge by\u000d\u000acombining data from a number of smaller studies; and can demonstrate consistency of findings\u000d\u000aleading to unequivocal global policy recommendations. Before this period, the World Health\u000d\u000aOrganization and other guideline groups rarely used systematic reviews and concise summaries of\u000d\u000afindings for developing recommendations. Instead, processes usually relied heavily on experts in a\u000d\u000aparticular specialty, rather than methodologists specialising in synthesis and interpreting evidence,\u000d\u000aor representatives of those who will have to live with the recommendations. The LSTM have forged\u000d\u000aa relationship with the World Health Organization (WHO) in tropical diseases to ensure that the\u000d\u000aright policy questions are being addressed by LSTM reviews. LSTM staff who conducted this body\u000d\u000aof research has included Professor Paul Garner the Co-ordinating Editor of the Cochrane\u000d\u000aInfectious Diseases Group CIDG and the LSTM Evidence Synthesis for Global Health Group since\u000d\u000a(1994 - present,) David Sinclair, Clinical Lecturer, Author and Editor with the Cochrane Infectious\u000d\u000aDiseases Group (2007-present) and Helen Smith, Lecturer in Research Methods (1998 - present.)\u000d\u000aIn 1994 Paul Garner engaged Dr Piero Olliaro at WHO in a meta-analysis of data from 40 malaria\u000d\u000atrials to compare the therapeutic efficacy of amodiaquine with that of chloroquine in patients with\u000d\u000amalaria. Chloroquine was failing as a treatment due to parasite drug resistance in Africa and\u000d\u000aamodiaquine was a cheap potential alternative. Garner and Olliaro wrote a protocol and identified\u000d\u000aall available malaria trials, including trials published in French, and unpublished studies obtained\u000d\u000afrom pharmaceutical companies. These approaches were ground-breaking, and the analysis\u000d\u000arevealed new findings from combining many small studies-that amodiaquine was clearly much\u000d\u000amore effective than chloroquine, the results published in the Cochrane Library and the Lancet.1\u000d\u000aLSTM was also commissioned to evaluate amodiaquine safety as it had been suggested it had\u000d\u000aserious adverse effects. In 2003, the systematic review of over 370 studies (in all languages)\u000d\u000ashowed that the risk of severe adverse effects in patients treated with amodiaquine is not higher\u000d\u000athan that in patients treated with chloroquine.2\u000d\u000aSubsequently, the LSTM worked with Dr Olliaro and Abdel Babiker (MRC Trials Unit in London) to\u000d\u000acarry out a prospective meta-analysis of individual patient data from all trials that compared\u000d\u000aartemisinin-based combination therapies (ACTs) with existing antimalarial treatments given by\u000d\u000athemselves. The LSTM research team contributed to the WHO template used by investigators to\u000d\u000aplan each randomised controlled trial (RCTs). The LSTM organised the individual patient data\u000d\u000aanalysis across all these studies, a much more substantive analysis were all the data are managed\u000d\u000ain a single data base and analysed together; they engaged the researchers in the analytical plan\u000d\u000aand co-ordinated the analysis and interpretation of the data. The LSTM organised the investigators\u000d\u000ameeting of the International Artemisinin Study Group in WHO Geneva in 2002 to discuss the\u000d\u000afindings and their interpretation.3 The analysis included results from a number of trials that had not\u000d\u000apreviously been published. The overall analysis showed there was no doubt that adding artesunate\u000d\u000asubstantially increased cure rate, whatever drug it was added to.\u000d\u000aIn 2008, the WHO asked the LSTM to summarise the relative effectiveness of various ACTs. The\u000d\u000aanalysis showed that a new ACT, dihydroartemisinin piperaquine, which at that time was not pre-qualified,\u000d\u000awas at least as good as, and probably better than, the other ACTs that were currently in\u000d\u000ause. Cochrane methods combined with the grades of recommendation, assessment, development\u000d\u000aand evaluation (GRADE) approach were used to assess the quality of evidence.4 Subsequently,\u000d\u000anew evidence on the efficacy of ACTs in children with severe malaria was published, and the WHO\u000d\u000aasked the LSTM to rapidly incorporate this with existing trials of ACT for severe malaria in children\u000d\u000aso that the WHO were able to change its global guidelines to strongly recommend ACTs rather\u000d\u000athan quinine for treating severe malaria in children.5, 6\u000d\u000aIn 2012, the LSTM's reputation with the malaria panel led the WHO Director Generals' office\u000d\u000aasking LSTM to evaluate how well the organization was meeting current methodological standards\u000d\u000afor guideline development.7 This analysis showed that WHO guideline development methods in all\u000d\u000atopic areas had become more transparent since 2007, but that some departments were bypassing\u000d\u000aprocedures, and that the quality assurance standards set were not fully embedded in the\u000d\u000aorganization.\u000d\u000a"},{"CaseStudyId":"3349","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    Three sets of impact has been established by this research:\u000a    1) Changes to DoH guidelines. In June 1998, the UK government's Committee\u000a      on Toxicity of Chemicals in Food, Consumer Products and the Environment\u000a      (COT) published a report on recommending that ``pregnant women who are\u000a      atopic or for whom the father or any sibling of the unborn child has an\u000a      atopic disease, may wish to avoid eating peanuts and peanut products\u000a      during pregnancy and breast feeding.'' This advice was given in the\u000a      absence of any robust studies on the prevalence of peanut allergy and its\u000a      trend, and in the absence of any link between maternal peanut consumption\u000a      and peanut allergy in their offspring. The House of Lords, Science and\u000a      Technology Committee report on Allergy (6th Report, Session\u000a      2006-7) reviewed the evidence in the area and recommended \"that this\u000a      advice should be withdrawn immediately pending a comprehensive review by\u000a      the Food Standards Agency and the COT\". COT's Statement on the review of\u000a      the 1998 COT recommendation on peanut avoidance stated that \"Since the COT\u000a      recommendations were made, there have also been several studies published\u000a      on the frequency of sensitisation and allergy to peanuts, which could\u000a      inform understanding of whether the prevalence of this allergy is\u000a      increasing. It was therefore considered timely to re-assess the current\u000a      state of scientific knowledge in this area and, based on the evidence now\u000a      available, to re-consider whether the 1998 COT dietary recommendations\u000a      remain appropriate\" (CS1: http:\/\/cot.food.gov.uk\/pdfs\/cotstatement200807peanut.pdf).\u000a      Nine out of the 14 UK studies examined, originated from the Isle of Wight\u000a      Team (http:\/\/cot.food.gov.uk\/pdfs\/cotstatement200807peanut.pdf\u000a      page 12) illustrating the major contribution the team has made to the\u000a      evidence base. Following this review COT Committee concluded that \"the\u000a      previous dietary recommendations are no longer appropriate because of a\u000a      shift in the evidence base (CS2)\". The roll out of their revised guideline\u000a      and advice has benefitted groups along the entire healthcare supply chain:\u000a      individual parents, GPs and allergy services. The revised advice is also\u000a      being included within general advice given to mothers about pregnancy and\u000a      development of their baby, including the `Pregnancy' and `Birth to Five'\u000a      books (http:\/\/www.nhs.uk\/Conditions\/pregnancy-and-baby\/pages\/foods-to-avoid-\u000a      pregnant.aspx#Peanuts)\u000a      (CS3).\u000a    2) Provision of evidence that food allergy levels have not increased. The\u000a      birth cohort established by Professor Dean is the only birth cohort\u000a      worldwide set up specifically to investigate epidemiology of food allergy\u000a      using objective measures and her findings provided the first demonstration\u000a      that unlike other manifestations of allergic disorders (eg Asthma) the\u000a      rates of food allergy has not increased. This key evidence has informed\u000a      policy (CS4,5) as well as the advice that allergic consumers receive from\u000a      healthcare professionals and supporting organisations. As a result Prof\u000a      Dean and Dr Venter have delivered expert advice to bodies including the\u000a      European Food Safety Authority, the National Institute of Clinical\u000a      Excellence, the Royal College of Paediatrics and the European Academy of\u000a      Allergy and Clinical Immunology. Their prevalence data has significant\u000a      reach and has been included in 2010 US Food Allergy Guidelines (CS6). The\u000a      impact of this work has been confirmed by the chief executive of\u000a      Anaphylaxis Campaign (CS7): \"Their research is in these areas is world\u000a      leading in part because they are in a unique position to perform\u000a      longitudinal cohort studies with very little attrition. In the Allergy\u000a      world `Isle of Wight cohorts' are recognised by all\".\u000a    3) Changes in public awareness with respect to the prevalence of food\u000a      allergy. Since the publication of their findings Professor Dean and Dr\u000a      Venter have contributed to numerous public engagement exercises (e.g.\u000a      Focus on Health: Asthma and Allergy in your Family, http:\/\/www.port.ac.uk\/uopnews\/2012\/11\/29\/expert-advice-for-asthma-and-allergy-sufferers\/)\u000a      and training events for healthcare professionals (e.g. Allergy Academy\u000a      flagship training event for all healthcare professionals http:\/\/allergyacademy.org\/),\u000a      ensuring there is widespread awareness that prevalence of food allergy has\u000a      not increased. As stated in a letter by the director of Allergy Academy\u000a      (CS8), which has led the delivery of education in Allergy to over 5000\u000a      healthcare professionals, \"The information on prevalence of food allergies\u000a      as provided by Professor Taraneh Dean and her team has been used to inform\u000a      many of the educational sessions given at the Allergy Meeting.\u000a    4) The paper: Venter, C.; Pereira, B.; Voigt, K.; Grundy, J.; Clayton, C.\u000a      B.; Higgins, B.; Arshad, S. H.; Dean, T. Prevalence and Cumulative\u000a      Incidence of Food Hypersensitivity in the First 3 Years of Life. Allergy\u000a      2008, 63, 354-359, was included in the 2008 version of the \"If you only\u000a      read five papers this year...\" session thus reflecting its value to the\u000a      clinical allergy community.\u000a      Our work on raising the awareness has also been subject of critical media\u000a      review (CS9).\u000a    ","ImpactSummary":"\u000a    Our research has led to a change in DoH guidelines on maternal\u000a      consumption of peanut during pregnancy\/breastfeeding.\u000a    Guidelines until 2009 advocated the avoidance of peanut in allergic\u000a      families. However evidence base for this advice was poor and the advice\u000a      was adopted by families regardless of their allergy status leading to\u000a      significant constraints on their lifestyles. Our research revealed that\u000a      peanut allergy is not associated with maternal peanut consumption, and\u000a      that there was no need for pregnant women to avoid peanut during\u000a      pregnancy. On the basis of our research DoH concluded that previous\u000a      guidance was inappropriate and it was thus withdrawn.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Portsmouth\u000a    ","Institutions":[{"AlternativeName":"Portsmouth (University of)","InstitutionName":"University of Portsmouth","PeerGroup":"D","Region":"South East","UKPRN":10007155}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Food Standards Agency (sponsor), awarded to: Prof Taraneh Dean (PI), Prevalence\u000a        and Incidence of Food Allergy and Intolerance in British Population,\u000a        grant period: 2001-2006; &#163;603,605 (Grant ref.T07023). Food Standards\u000a      Agency (sponsor), awarded to: Prof Taraneh Dean (PI), Trends in\u000a        incidence of peanut allergy in England in the last 15 years, grant\u000a      period: 2003-2006, &#163;115,758 (Grant ref. T07034). Professor Dean was the\u000a      single applicant for both awards.\u000a    \u000a\u000a2. Venter C, Pereira B, Grundy J, Clayton B, Roberts G, Higgins\u000a        B, Dean T. Incidence of parentally reported\u000a        and clinically diagnosed food hypersensitivity in the first year of\u000a        life. Journal of Allergy and Clinical Immunology 2006; 117:\u000a      1118-1124. DOI: 10.1016\/j.jaci.2005.12.1352.\u000a      \u000a      Web:\u000a        http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0091674906001680\u000a      \u000a      Web of Science citation count: 76 (rated in the top 5% of outputs for\u000a      Immunology and\u000a      Allergy journals); Impact factor: 12.047\u000a    \u000a\u000a3. Venter C, Pereira B, Voigt K, Grundy J, Clayton CB, Higgins\u000a        B, Arshad SH, Dean T. Prevalence and cumulative\u000a        incidence of food hypersensitivity in the first 3 years of life.\u000a      Allergy 2008; 63: 354-359. DOI: 10.1111\/j.1398-9995.2007.01570.x.\u000a      \u000a      Web:\u000a        http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2007.01570.x\/abstract\u000a      \u000a      REF 2 output: 2-TD-002 Scopus citation count: 75 (rated in the top 5% of\u000a      outputs for\u000a      Immunology and Allergy journals); Impact factor: 6.271.\u000a    \u000a\u000a4. Venter C, Pereira B, Voigt K, Grundy J, Clayton CB, Higgins\u000a        B,Arshad SH, Dean T. Factors associated with maternal\u000a        dietary intake, feeding and weaning practices, and the development of\u000a        food hypersensitivity in the infant. Pediatr Allergy Immunol 2009;\u000a      20: 320- 327. DOI: 10.1111\/j.1399-3038.2008.00832. REF 2 output: 2-BH-004\u000a      \u000a      Web:\u000a        http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3038.2008.00832.x\/abstract\u000a      \u000a      Web of Science citation count: 14 (rated in the top 25% of outputs for\u000a      immunology and allergy journals); Impact factor: 3.376\u000a    \u000a\u000a5. Dean T, Venter C, Pereira B, Grundy J, Clayton CB, Higgins\u000a        B. Government advice on peanut avoidance during pregnancy - Is\u000a        it followed correctly and what is the impact on sensitization?\u000a      Journal of Human Nutrition and Dietetics 2007; 20: 95-99. DOI:\u000a      10.1111\/j.1365-277X.2007.00751.x.\u000a      \u000a      Web:\u000a        http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-277X.2007.00751.x\/abstract\u000a      \u000a      Web of Science citation count: 14; Impact factor: 1.972\u000a    \u000a\u000a6. Venter C, Arshad H, Grundy J, Pereira B, Clayton C, Voigt K, Higgins\u000a        B, Dean T. Time trends in the prevalence of peanut\u000a        allergy: three cohorts of children from the same geographical location\u000a        in the UK. Allergy, 2010; 65: 103-108. DOI:\u000a      10.1111\/j.1398-9995.2009.02176.x.\u000a      \u000a      Web:\u000a        http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2009.02176.x\/abstract.\u000a      \u000a      \u000a      REF 2 output: 2-TD-001\u000a      \u000a      Scopus citation count: 48 (rated in the top 5% of outputs for Immunology\u000a      and Allergy journals); Impact factor: 6.271\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"7","Subject":"Immunology"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    CS1. http:\/\/cot.food.gov.uk\/pdfs\/cotstatement200807peanut.pdf\u000a    Department of Health's Revised COT statement\u000a    \u000a    CS2. Letter from Head of Food Allergy Branch, Food Standards Agency UK to a\u000a    British Dietetic Association, Royal College of Midwives,Community\u000a    Practitioners and Health Visitors Association and British Society of Allergy\u000a    and Clinical Immunology\u000a    \u000a    CS3. http:\/\/www.nhs.uk\/Conditions\/pregnancy-and-baby\/pages\/foods-to-avoid-\u000a      pregnant.aspx#Peanuts Pregnancy and childbirth handbook\u000a    \u000a    CS4. Letter from Head of Food Allergy Branch, Food Standards Agency UK re.\u000a    Dean et al. Prevalence studies.\u000a    \u000a    CS5. Buck, J., Hattersley, S., &amp; Kimber, I. (2010). Food allergy-science\u000a    and policy needs-The UK Food Standards Agency Research Programme. Toxicology,278(3),\u000a    319-325.\u000a    \u000a    DOI: 10.1016\/j.tox.2010.08.007\u000a    \u000a    CS6. Letter from Professor of Pediatrics and Division Chief, Food Allergy\u000a    Institute, Mount Sinai Medical Center, USA and Lead author of the American\u000a    Academy of Pediatrics (AAP) guidance on allergy prevention and Associate\u000a    Editor of the Journal of Allergy and Clinical Immunology\u000a    \u000a    CS7. Letter from Chief Executive Officer of The Anaphylaxis Campaign UK re\u000a    Dean et al. Prevalence studies.\u000a    \u000a    CS8. Letter from Joint Clinical Lead for Allergy at Guy's &amp; St Thomas'\u000a    Hospitals NHS Foundation Trust, the UK's largest specialist allergy service,\u000a    since 2007 and Director of the King's College London Allergy Academy\u000a    \u000a    CS9. http:\/\/news.bbc.co.uk\/1\/hi\/health\/7218276.stm\u000a    Baby allergy fears 'over the top' (31\/01\/2008), BBC News\u000a    ","Title":"\u000a    University of Portsmouth allergy research leads to overturn of\u000a      inappropriate Department of Health guidelines on maternal feeding during\u000a      pregnancy and breastfeeding\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The underpinning research was carried out under the leadership of\u000a      Professor Taraneh Dean (Professor of Health Sciences, University of\u000a      Portsmouth; Honorary Deputy Director of Asthma and Allergy Research\u000a      Centre, Isle of Wight) during the period 2001-2010. The main\u000a      co-investigator for this research is Dr Carina Venter (University of\u000a      Portsmouth)\u000a    Food hypersensitivity (FHS) is an adverse reaction following food\u000a      ingestion that can be either a food allergy (if immunologically mediated)\u000a      or a non-allergic FHS. It is important that those producing guidance or\u000a      developing education programmes have robust population-based\u000a      epidemiological data regarding prevalence and risk factors of FHS to key\u000a      food allergens in children and other age groups.\u000a    Whilst there is evidence demonstrating increasing prevalence of other\u000a      manifestations of allergies such as asthma and atopic dermatitis, there\u000a      had been a paucity of studies, investigating the prevalence of FHS.\u000a    Following a competitive call Professor Dean was commissioned1\u000a      by the Food Standards Agency to establish the first UK birth cohort with\u000a      the specific aim of establishing prevalence of FHS using the objective\u000a      outcome measure of food challenges2. The team specifically\u000a      investigated the prevalence of peanut allergy, which is the most common\u000a      cause of food induced anaphylaxis in children, in a whole population birth\u000a      cohort (total 969 children) born between 2001 and 2002. This cohort was\u000a      compared with previous cohorts of children born in the same geographical\u000a      location, Isle of Wight, UK. The cohort was recruited ante-natally and\u000a      followed up at 1, 2 and 3 years of age: the 10 year follow up is the\u000a      subject of a current NIHR Fellowship. Prevalence of FHS to peanuts and\u000a      other foods was 1.9%, 3.8% and 4.5% at ages 1, 2 and 3 respectively. Based\u000a      on double-blinded, placebo-controlled, food challenge (DBPCFC), a gold\u000a      standard methodology used for such studies, and a good clinical history,\u000a      the cumulative incidence of FHS was 5.0% (48\/969, 95% CI: 3.7-6.5).3\u000a    The research team also established, using a validated food frequency\u000a      questionnaire for consumption of allergenic foods, that maternal dietary\u000a      intake of food allergens, and peanut in particular, during pregnancy and\u000a      breast-feeding did not influence subsequent development of FHS in children4.\u000a      We also discovered that the governmental advice to avoid peanuts was\u000a      actually followed by mothers regardless of their family history of\u000a      allergy, which could have had a detrimental effect and actually increase\u000a      the prevalence of allergic disorders in children5. The team was\u000a      able to use this evidence, based on their robust methodology, to call into\u000a      question results from previous studies. Overall, 33.7% of parents reported\u000a      a food-related problem and, of these, only 12.9% were diagnosed with FHS\u000a      by DBPCFC and history. Consequently, the results from this study\u000a      challenged the previously-held perception that peanut allergy and other\u000a      food allergies are increasing.6 The team demonstrated that\u000a      peanut allergy prevalence has changed over time, with a peak in peanut\u000a      sensitisation and reported allergy in children born in 1994-1996, but,\u000a      since the late 1990's, this seems to have stabilised.\u000a    "},{"CaseStudyId":"3408","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a      The first UK child protection clinical guidelines\u000a      The Cardiff systematic reviews have directly informed five national\u000a        guidelines in the field child `protection:\u000a      \u000a        The first NICE evidence-based maltreatment guidelines (2009)[5.1].\u000a        The first joint guidelines published by the Royal College of\u000a          Radiology and Royal College of Paediatrics and Child Health (RCPCH) in\u000a          2008. As a direct consequence of these guidelines, skeletal surveys\u000a          now routinely include oblique views of the ribs for all children in\u000a          the UK under the age of two years where physical abuse is suspected\u000a          [5.2].\u000a        The RCPCH Child Protection Companion &#8212; the clinical guidance for\u000a          all paediatricians (2006) across UK and the second edition of the\u000a          Companion (Kemp co-edited), published in 2013, to include evidence\u000a          from all 21 of CCPSR's systematic reviews [5.3].\u000a        National standards for ophthalmological examination in suspected\u000a          abusive head trauma (2013). The Royal College of Ophthalmologists were\u000a          preparing guidelines as of July 2013.\u000a        \u000a`Child Protection and the Dental Team: an introduction to\u000a            safeguarding children in dental practice' published 2006,\u000a          updated in 2009 with new developments in the Cardiff research. This\u000a          live document accessible online (and supported by a website) was\u000a          commissioned by the Department of Health and distributed to all dental\u000a          practitioners in the UK to highlight their role and responsibility in\u000a          child safeguarding, with information on how to recognise suspected\u000a          child abuse or neglect [5.4].\u000a      \u000a      National compulsory training programme\u000a      Cardiff's evidence base informs the national child protection training\u000a        programme which meets the Intercollegiate National Safeguarding six\u000a        levels of competences. This training is delivered to all healthcare\u000a        staff across the UK. Cardiff's research informs the training manuals\u000a        [5.3] for the RCPCH\/NSPCC\/ALSG training programmes at:\u000a      \u000a        Level 2: Child Protection Recognition and Response (accessed by 400\u000a          trainers and 4000 trained health practitioners who work with children)\u000a          [5.7].\u000a        Level 3: Child Protection in Practice (1700 Child protection\u000a          clinicians registered).\u000a      \u000a      Since 2008 Kemp and Maguire have also delivered over 100 invited\u000a        lectures to present CCPSR findings and recommendations, reaching an\u000a        estimated 15-20,000 child protection practitioners in the UK, Europe and\u000a        US.\u000a      International reach &#8212; online training and information resources\u000a      The publication of national guidelines and the delivery of compulsory\u000a        training into evidence-based clinical assessment of child abuse has\u000a        embedded Cardiff's research into UK clinical child protection practice.\u000a      Since 2008 the Cardiff group has also disseminated its findings to\u000a        professionals and practitioners through the Core-Info website\u000a        (www.core-info.cf.ac.uk) which hosts the findings from the 21 systematic\u000a        reviews and meta-analyses that are updated annually. Commenting on\u000a        Core-Info, the former president of the Royal College of Paediatrics and\u000a        Child Health noted: \"This resource does not only allow easy access\u000a          for improved clinical decision-making, the evidence base also\u000a          underpins improved expert evidence in courts around the world\"\u000a        [5.7]. The influence of Cardiff's work has also been highlighted by the\u000a        American Academy of Pediatrics [5.6].\u000a      Core-Info analytics show that the website is used by 100,000 health\u000a        professionals, social workers, law enforcement, the judiciary and\u000a        researchers from 40 countries annually. A recent survey of child\u000a        protection paediatricians in the UK and Australia confirms that\u000a        Core-Info is used by 60% of these professionals to inform clinical\u000a        decisions, provide continuing professional development and education\u000a        material, inform legal reports and give scientific validation to expert\u000a        opinion. It is considered to be \"one of the most important\u000a          developments in the field, supporting better clinical decision making,\u000a          training and expert opinion in court, and increasing overall\u000a          confidence of paediatricians\" [5.5].\u000a      Six Core-Info leaflets developed jointly by the Cardiff team and the\u000a        NSPCC (2007-2013) translate key research findings into practice for\u000a        allied professionals in child protection. Since 2008, approximately\u000a        200,000 hard copies (plus numerous downloaded copies) have been sold to\u000a        non-specialists who work with, or come into contact, with children. The\u000a        Core-Info leaflets are regularly updated to reflect the latest evidence\u000a        and are widely used for national training (Levels 1-2) and as a quick\u000a        reference source for health visitors, social services, general\u000a        practitioners and police.\u000a      Impact on practitioners and services &#8212; an evidence base for clinical\u000a          practice\u000a      As a consequence of the wide-spread national and international\u000a        dissemination of CCPSR's research findings through national guidelines\u000a        and training, child health professionals now base assessments, diagnoses\u000a        and court evidence on scientifically informed and clinically validated\u000a        models and practices. The significance of this shift in practice is\u000a        summarised by the National Clinical Director for Children at the\u000a        Department of Health: \"This work is at the forefront in supporting\u000a          evidence based practice in a sensitive clinical field of great\u000a          importance\" [5.8].\u000a      The evidence base provided by the Cardiff group has helped child\u000a        protection professionals and expert witnesses to re-establish trust. The\u000a        standardised evidence-based practice means that convictions in court and\u000a        child-protection interventions are more reliable, with a lower\u000a        likelihood of wrongful convictions.\u000a      Impact on child health and welfare\u000a      The ultimate beneficiaries of this work are the children who are being\u000a        abused. Through the adoption of national guidelines and the\u000a        implementation of standardised evidence-based practice across the UK, it\u000a        is now more likely that abuse will be recognised and appropriately\u000a        investigated and abused children are more likely to be protected from\u000a        future harm.\u000a      The Deputy High Court Judge in the Family Division and Recorder in the\u000a        Crown and County Court states that one of the major benefits of\u000a        Cardiff's work has been the improvement in the scientific validation and\u000a        quality of expert opinion presented in Family and Criminal Child\u000a        Protection Court Cases, in particular the eradication of police and\u000a        paediatricians using colour to estimate the age of a bruise [5.9].\u000a      In 2013 the CCPSR group won the BMJ Child Health Team of the Year in\u000a        the BMJ Improving Health Awards [5.10].\u000a      ","ImpactSummary":"\u000a    Responding to the crisis in confidence amongst clinicians involved in\u000a      child protection, Cardiff University developed the world's first research\u000a      programme to provide the scientific basis for more reliable clinical\u000a      assessments of child abuse and neglect. The programme, which involves 21\u000a      systematic reviews (updated annually) and related primary studies, has\u000a      directly informed five national clinical guidelines, the National Child\u000a      Protection training program and the first NICE guidance on child\u000a      maltreatment. Through the Core-Info website, the evidence base created by\u000a      the Cardiff team is accessed each year by 100,000 users. Key messages from\u000a      their research have been published in a series of Core-Info leaflets which\u000a      have reached more than 250,000 allied professionals nationally. The\u000a      Cardiff research informs standardised national clinical practice, training\u000a      and legal decisions, ultimately improving the recognition and protection\u000a      of children from abuse or neglect.\u000a    ","ImpactType":"Societal","Institution":"\u000a    Cardiff University\u000a    ","Institutions":[{"AlternativeName":"Cardiff University","InstitutionName":"Cardiff University","PeerGroup":"A","Region":"Wales","UKPRN":10007814}],"Panel":"A         ","PlaceName":[],"References":"\u000a      \u000a1. Maguire S, Mann MK, Sibert J, Kemp A.\u000a        Can you age bruises accurately in children? Archives of Disease in\u000a          Childhood. 2005;90(2):187-189.\u000a        http:\/\/dx.doi.org\/10.1136\/adc.2003.044073\u000a      \u000a\u000a2. Prosser I, Lawson Z, Evans A, Harrison S, Morris S, Maguire S,\u000a        Kemp AM. A timetable for the radiologic features of fracture\u000a        healing in young children. American Journal of Roentgenology.\u000a        2012;198(5):1014-1020. http:\/\/dx.doi.org\/10.2214\/AJR.11.6734\u000a      \u000a\u000a3. Maguire S, Mann MK, Sibert J, Kemp A.\u000a        Are there patterns of bruising in childhood which are diagnostic or\u000a        suggestive of abuse? Archives of Disease in Childhood. 2005;90(2):182-186.\u000a        http:\/\/dx.doi.org\/10.1136\/adc.2003.044065\u000a      \u000a\u000a4. Kemp AM, Dunstan F, Harrison S, Morris S, Mann M,\u000a        Rolfe K, Datta S, Thomas DP, Sibert JR, Maguire S.\u000a        Patterns of skeletal fractures in child abuse: systematic review. British\u000a          Medical Journal. 2008;337:a1518.\u000a          http:\/\/dx.doi.org\/10.1136\/bmj.a1518\u000a      \u000a\u000a5. Maguire SA, Kemp AM, Lumb RC, Farewell DM.\u000a        Estimating the probability of abusive head trauma: A pooled analysis. Pediatrics.\u000a        2011;128(3):e550-e564.\u000a        http:\/\/dx.doi.org\/10.1542\/peds.2010-2949\u000a      6. Ng WS, Watts P, Lawson Z, Kemp A, Maguire S.\u000a        Development and validation of a standardized tool for reporting retinal\u000a        findings in abusive head trauma. American Journal of Ophthalmology.\u000a        2012;154(2):333-339. http:\/\/dx.doi.org\/10.1016\/j.ajo.2012.02.007\u000a      \u000aNote: CCPSR researchers in bold. All publications available on\u000a        request from the HEI.\u000a      Key funding sources\u000a      &#8226; Systematic review of physical abuse. National Society for the\u000a        Prevention of Cruelty to Children (NSPCC). A Kemp (PI). &#163;788,971.\u000a        2003-2013.\u000a      &#8226; Developing diagnostic tools for clinicians to improve diagnostic\u000a        accuracy and identify patterns of bruising in physical. Medical Research\u000a        Council. Research grant ref: G0601638. A Kemp (PI). &#163;1.12 million.\u000a        2007-2012.\u000a      ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"16","Level2":"7","Subject":"Social Work"},{"Level1":"17","Level2":"1","Subject":"Psychology"}],"Sources":"\u000a      \u000a         NICE guideline 2009: When to Suspect Child Maltreatment,\u000a          http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG89FullGuideline.pdf\u000a          (pp v, 107, 142-143) [Also saved as a pdf on 24.04.13 and available\u000a          from HEI on request].\u000a         Standards for the radiological investigation of suspected Non\u000a          Accidental Injury 2008\u000a          http:\/\/www.rcr.ac.uk\/docs\/radiology\/pdf\/RCPCH_RCR_final.pdf\u000a            (pp 5, 6, 51, 52, 55) [Also saved as a pdf on 24.04.13 and\u000a          available from HEI on request].\u000a         Child Protection Companion: RCPCH 2013 (2nd edition) http:\/\/www.rcpch.ac.uk\/child-health\/standards-care\/child-protection\/publications\/child-protection-publications\u000a          (pp 238, 244, 245, 246, 247, 248, 249, 260, 261) [Also saved as a pdf\u000a          on 24.04.13 and available from HEI on request].\u000a         Child Protection and the Dental Team: An introduction to\u000a          safeguarding children in dental practice. Cardiff research directly\u000a          cited pp 5.2, 5.5. [Also saved as a pdf on 24.04.13 and available from\u000a          HEI on request].\u000a         Individual corroboration from the President Royal College of\u000a          Paediatrics and Child Health. Confirms the Core-Info website has been\u000a          used to improve clinical decision making and the standard of expert\u000a          testimony.\u000a         Contactable individual: Chair, Committee for Child Abuse and\u000a          Neglect, American Academy of Pediatrics. Can confirm the Core-Info\u000a          website has been used to improve clinical decision making and the\u000a          standard of expert testimony internationally.\u000a         Individual corroboration from the President RCPCH. Confirms the\u000a          Core-Info website has been used to improve clinical decision making\u000a          and the standard of expert testimony.\u000a         Individual corroboration from the National Clinical Director for\u000a          Children, Young People and Maternity, Department of Health. Confirms\u000a          the importance of the research in supporting evidence based practice\u000a          in UK and internationally.\u000a         Contactable individual: Deputy High Court Judge in the Family\u000a          Division and Recorder in the Crown and County Court. Can confirm the\u000a          use of the research in several court cases regarding the colour of\u000a          bruises over time and the inability to age bruises accurately due to\u000a          their colour has been crucial to the case outcome and the future care\u000a          of the child.\u000a         BMJ Improving Health Awards: http:\/\/thebmjawards.bmj.com\/previous-winners\/2013\/child-\u000a            health-team-of-the-year [Also saved as a pdf on 17.06.13 and\u000a          available from HEI on request].\u000a      \u000a      ","Title":"\u000a    A scientific foundation for the first national clinical standards in the\u000a      assessment of child abuse.\u000a    ","UKLocation":[{"GeoNamesId":"2653822","Name":"Cardiff"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Ten years ago there were no evidence-based standards or clinical\u000a      guidelines to inform clinical assessments of suspected child abuse or\u000a      neglect. When cases went to court, expert medical opinions were provided\u000a      by a handful of clinicians who relied on their clinical experience, rather\u000a      than scientific evidence. Clinicians were accused of misrepresenting\u000a      evidence and being instrumental in the wrongful prosecution of mothers for\u000a      causing the deaths of their babies. Media and legal criticism led to a\u000a      lack of confidence in and amongst clinicians working in child protection.\u000a    An evidence base for the recognition and assessment of child abuse.\u000a    In 2002 Professor Alison Kemp (Senior Clinical Lecturer 1993-2005, Reader\u000a      2005-2009, Professor \/ Program Director 2009-present) and Dr Sabine\u000a      Maguire (Clinical Lecturer 2002-2008, 2008-present Principle Investigator)\u000a      established Cardiff Child Protection Systematic Reviews (CCPSR), funded by\u000a      the National Society for the Prevention of Cruelty to Children, to develop\u000a      a scientific foundation for child protection policies and practice. The\u000a      research team includes two researchers, an information specialist from\u000a      SURE (Support Unit for Research Evidence at Cardiff University), a\u000a      statistician and a national panel of expert reviewers trained in critical\u000a      appraisal methods.\u000a    By 2013, CCPSR had completed 21 systematic reviews critically appraising\u000a      the world literature relating to the recognition and investigation of\u000a      child abuse. The group has published 28 peer- reviewed papers.\u000a    Methodological developments have included a novel ranking system for the\u000a      security of diagnosis of child abuse; this system has been adopted\u000a      internationally by other child protection research groups.\u000a    Key findings\u000a    Some of the most significant findings into clinical approaches and\u000a      practices regarding suspected cases of child abuse and neglect, are\u000a      summarised below:\u000a    \u000a      Ageing of bruises: In 2005 Maguire and colleagues from CCPSR\u000a        concluded that it is not possible to age bruises in children\u000a        accurately with the naked eye [3.1].\u000a      Ageing of fractures: Responding to the paucity of scientific\u000a        evidence, CCPSR carried out a primary study (2010-12) which concluded\u000a        that it is possible to age fractures within broad time frames\u000a        [3.2].\u000a      Characteristics of abusive bruises: In 2005 the Cardiff team showed\u000a        that in non-mobile infants, bruises over soft tissue areas that carry\u000a        the imprint of an implement were indicators of abuse, as were multiple\u000a        bruises of uniform shape [3.3]. This review led to the group's\u000a        successful application for the first MRC-funded study on bruising in\u000a        children (2007-12).\u000a      Abusive fractures: A CCPSR review (2008) found that rib fractures,\u000a        fractures to the shaft of the humerus in infants and femoral fractures\u000a        in non-mobile babies have a high probability of being caused by abuse\u000a        [3.4].\u000a      Abusive head trauma (AHT): The CCPSR created a database of\u000a        individual patient data collected from six international studies\u000a        (2009-11). The team developed a method for `individual patient data\u000a        analysis' and proposed a model to estimate the probability of AHT (a\u000a        contentious diagnosis) from clinical features [3.5]. The model has\u000a        subsequently been validated in clinical practice to improve the early\u000a        recognition of cases of suspected AHT.\u000a      Retinal haemorrhages are important features of AHT; the AHT\u000a        systematic reviews identified a lack of internationally recognised\u000a        reporting standards for haemorrhagic retinopathy in cases of AHT.\u000a        The CCPSR researchers developed and validated such a tool (2010-12)\u000a        [3.6].\u000a    \u000a      The quality of the group's work on bruising was cited in a Lancet\u000a        editorial (Cabinum-Foeller, E. and L. Frasier. 2005. Bruising in\u000a        Children. The Lancet 365(9468), pp1369-1370): \"The\u000a          conclusions are clinically intuitive, but provide a more empiric\u000a          literature-based review that provides an essential framework for any\u000a          clinician attempting to determine the cause of bruising.\" The\u000a        independent validation and application of several methodologies\u000a        developed by CCPSR (e.g. the diagnosis security ranking system, the AHT\u000a        probability model, etc.) also demonstrate the quality of the group's\u000a        research output.\u000a      "},{"CaseStudyId":"3409","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"933860","Name":"Botswana"},{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"934841","Name":"Swaziland"},{"GeoNamesId":"49518","Name":"Rwanda"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"4566966","Name":"Puerto Rico"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Between 2008 and December 2012, Motivational Interviewing in Health\u000d\u000a        Care by Rollnick, Miller &amp; Butler sold 71,748\u000d\u000a      copies and was translated into 11 languages, prompting the senior\u000d\u000a      commissioning editor at Guilford Press to note: \"Rollnick &amp;\u000d\u000a        Butler's Cardiff research provided the fuel for a book that has\u000d\u000a        surpassed all expectations. It continues to find avid readers from\u000d\u000a        across medicine and related professions, and has established itself as\u000d\u000a        the primary source for teachers and practitioners wanting to learn about\u000d\u000a        the application of MI in different health care settings.\" [5.2]\u000d\u000a    Specific strategies developed in Cardiff have also been integrated into\u000d\u000a      the 2nd &amp; 3rd editions of the standard Miller\/Rollnick\u000d\u000a      text on motivational interviewing [5.1]. Between 2008 and December 2012,\u000d\u000a      these texts sold 77,028 copies and have been translated into over 25\u000d\u000a      languages [5.2].\u000d\u000a    The impact of the above Cardiff research on clinical strategies is very\u000d\u000a      diverse and widely disseminated worldwide, embracing guidelines and policy\u000d\u000a      documents in many countries and continents. The following examples have\u000d\u000a      been selected because they provide precise links between Cardiff research\u000d\u000a      and impact.\u000d\u000a    Example 1: AETNA Health Insurance Organisation: Prof. K. Resnicow\u000d\u000a      (Michigan, USA, 2010) used Cardiff health care textbooks, and the\u000d\u000a      agenda-setting and importance-confidence strategies within them, in the\u000d\u000a      training of trainers within AETNA, a company with over 36 million members.\u000d\u000a      The focus was on behaviour change among members with a chronic disease.\u000d\u000a      Between 2010 and September 2012, 83+ trainers in health care MI were\u000d\u000a      trained, along with 2,210 clinical staff worldwide, with a reported 43%\u000d\u000a      increase in engagement in the disease management programme and a 55%\u000d\u000a      decrease in drop-outs [5.3]. Professor Resnicow notes, \"The impact of\u000d\u000a        Rollnick and Butler's seminal research in Cardiff goes beyond the\u000d\u000a        private sector and is all but immeasurable. Leading US government and\u000d\u000a        professional bodies, e.g. the American Medical Association, the American\u000d\u000a        Academy of Pediatrics, and the US Preventive Task Force, have adopted\u000d\u000a        healthcare MI for the prevention and management of chronic disease\"\u000d\u000a      [5.4].\u000d\u000a    Example 2: Emergency &amp; Public Health Medicine in USA:\u000d\u000a      Healthcare strategies evaluated in Cardiff (\"pros and cons\", \"elicit-provide-elicit\")\u000a      for very brief emergency room consultations with alcohol and drug problems\u000d\u000a      were used in 1994 by Bernstein (Boston, USA) and Rollnick to\u000d\u000a      develop a 3-5 minute intervention, Brief Negotiation Interview\u000d\u000a      (BNI) [5.5]. Bernstein established effectiveness in numerous randomised\u000d\u000a      trials, and set up a BNI ART Institute. Since 2008 they\u000d\u000a      have trained 1525 clinicians across North and Central America. Data\u000d\u000a      obtained by Bernstein from the small Boston-based cohort of 52\/1525\u000d\u000a      clinicians (only 3.4% of the total), reveal that in 2011 alone,\u000d\u000a      BNI was used with 5,158 patients. For the longer period 2008-2012,\u000d\u000a      Bernstein estimates that these 52 clinicians saw a total of 44,983\u000d\u000a      patients, all of whom received BNI, a method of proven effectiveness. The\u000d\u000a      programme has been endorsed by the National Registry of Evidence-based\u000d\u000a      Programs [5.6]. Bernstein notes, \"Rollnick's research on brief MI has\u000d\u000a        had a direct and measurable impact on the delivery of brief intervention\u000d\u000a        in emergency room settings in North America from Bethel Alaska to\u000d\u000a        Bayamon Puerto Rico to Yale New Haven and Boston Medical Centers. The\u000d\u000a        benefit to patients emerged from our numerous controlled trials.\u000d\u000a        Implementation of this respectful and effective intervention now extends\u000d\u000a        way beyond the boundaries of our work here in Boston to many scores of\u000d\u000a        thousands of patients across the USA and in other countries.\" [5.7]\u000d\u000a    Example 3: Swedish Quitlines for tobacco and alcohol: Dr Astri\u000d\u000a      Brandell Eklund and colleagues, used a health care text and the strategies\u000d\u000a      of \"agenda-setting\" and \"importance and confidence\" in the training of\u000d\u000a      staff of these two national telephone services. Between January 2008 and\u000d\u000a      June 2012 counselling contact was made with 8,066 people on the alcohol\u000d\u000a      line, and 17,407 on the smoking line, with a reported quit rate of 36% for\u000d\u000a      the latter [5.8].\u000d\u000a    Example 4 - UK Family Nurse Partnership Programme [5.9]: The\u000d\u000a      founder of this intensive home-visiting programme for pregnant teens in\u000d\u000a      deprived settings bought 2,500 copies of the Rollnick\/Miller\/Butler Motivational\u000a        Interviewing in Health Care book for distribution among its home\u000d\u000a      visiting nurses tackling a wide range of behavioural issues (alcohol;\u000d\u000a      drugs; safe sex). Rollnick was contracted to provide training and support\u000d\u000a      to the UK rollout of this programme. Since 2008, the strategies developed\u000d\u000a      in Cardiff have been integrated into the training and supervision of 1000+\u000d\u000a      nurses who have delivered the programme to 9,207 families up to the end of\u000d\u000a      2012.\u000d\u000a    Example 5: African low resource settings [5.10] Paediatric Aids\u000d\u000a      Treatment in Africa (PATA &#8212;www.teampata.org) brings together HIV-AIDS\u000d\u000a      treatment teams for training from across the Continent. It covers over 30%\u000d\u000a      of children in treatment in Africa. Rollnick was a founding member and\u000d\u000a      currently a Director, and since 2008, he has integrated health care MI for\u000d\u000a      medication adherence into training provided in Mbabane, Swaziland (40\u000d\u000a      teams, 20 countries), Kigali. Rwanda (40 teams), Gaborone, Botswana (41\u000d\u000a      teams; 18 countries; 65,142 children in treatment), Cape Town (South\u000d\u000a      Africa; 20 teams; 10 countries) [5.10].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research carried out at Cardiff University refined an addiction\u000d\u000a      counselling method, motivational interviewing, co-founded\u000d\u000a      previously by Rollnick, to improve the consultation for changing\u000d\u000a      health behaviour (e.g. diet, exercise, smoking and drinking). Their\u000d\u000a      published findings and resulting method are now used in health care\u000d\u000a      worldwide, with good evidence for effectiveness. The impact of this work\u000d\u000a      has been described as `immeasurable' and is reflected in industry\u000d\u000a      guidelines and policy documents, and diverse clinical efforts that include\u000d\u000a      the treatment of children with HIV-AIDS in Africa.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    Cardiff University\u000d\u000a    ","Institutions":[{"AlternativeName":"Cardiff University","InstitutionName":"Cardiff University","PeerGroup":"A","Region":"Wales","UKPRN":10007814}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"934985","Name":"Mbabane"},{"GeoNamesId":"4930956","Name":"Boston"},{"GeoNamesId":"5879092","Name":"Alaska"},{"GeoNamesId":"202061","Name":"Kigali"},{"GeoNamesId":"933773","Name":"Gaborone"},{"GeoNamesId":"933773","Name":"Gabarone"}],"References":"\u000d\u000a    \u000a1. Rollnick S, Butler C, Stott N, (1997) Helping\u000d\u000a      smokers make decisions: The enhancement of brief intervention for general\u000d\u000a      medical practice. Pt Educ Couns 31: 191-203.\u000d\u000a      http:\/\/dx.doi.org\/10.1016\/S0738-3991(97)01004-5\u000d\u000a    \u000a\u000a2. Butler C, Rollnick S, Cohen D, Russell I,\u000d\u000a      Bachmann M, Stott N. (1999) Motivational consulting versus brief\u000d\u000a      advice for smokers in general practice: A randomized trial. Brit J Gen\u000d\u000a        Pract ;49:611-616.\u000d\u000a      http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1316198\/pdf\/brjgenprac004944500611.pdf\u000d\u000a    \u000a\u000a3. Butler C, Simpson SA, Hood K, Cohen D,\u000d\u000a      Pickles T, Spanou C, McCambridge J, Moore L, Randell\u000a        E, Alam FM, Kinnersley P, Edwards A, Smith C, Rollnick\u000a        S. Training practitioners to deliver opportunistic multiple\u000d\u000a      behaviour change counselling in primary care (MRC\/NPRI Pre-Empt): a\u000d\u000a      cluster randomized trial. BMJ 2013;346:f1191 (Published 19 March 2013).\u000d\u000a      http:\/\/dx.doi.org\/10.1136\/bmj.f1191\u000d\u000a    \u000a\u000a4. Pill R, Stott N, Rollnick S, Rees M. (1998) A\u000d\u000a      randomized controlled trial of an intervention to improve the care given\u000d\u000a      in general practice to Type II diabetic patients: patient outcomes and\u000d\u000a      professional ability to change behaviour. Fam Pract 15: 229-235.\u000d\u000a      DOI: 10.1093\/fampra\/15.3.229\u000d\u000a      http:\/\/fampra.oxfordjournals.org\/content\/15\/3\/229.long\u000d\u000a    \u000a\u000a5. Channon S, Huws-Thomas M, Rollnick S, Hood K,\u000d\u000a      Cannings-John R, Rogers C, Gregory J A Multi-Centre\u000d\u000a      Randomised Controlled Trial Of Motivational Interviewing In Teenagers With\u000d\u000a      Diabetes. Diabetes Care 2007; 30:1390-1395. DOI: 10.2337\/dc06-2260\u000d\u000a      http:\/\/care.diabetesjournals.org\/content\/30\/6\/1390.long\u000d\u000a    \u000a\u000a6. Robling M, McNamara R, Bennert K, Butler C, Channon\u000a        S, Cohen D, Crowne L, Hambly H, Hawthorne C, Hood K,\u000d\u000a      Longo M, Pickles T, Playle R, Rollnick S, Thomas-Jones\u000a        E, Gregory J. The effect of the Talking Diabetes consulting\u000d\u000a      skills intervention on glycaemic control and quality of life in children\u000d\u000a      with type 1 diabetes: cluster randomised controlled trial (DEPICTED\u000d\u000a      study). BMJ 2012; 344, e2359. DOI: 10.1136\/bmj.e2359\u000d\u000a      http:\/\/www.bmj.com\/content\/344\/bmj.e2359\u000d\u000a    \u000aResearch funding:\u000d\u000a    Preventing disease through opportunistic, rapid engagement by primary\u000d\u000a        care teams using behaviour change counselling (PRE-EMPT). C\u000d\u000a        Butler, S Simpson, K Hood, S Rollnick.\u000d\u000a      &#163;846,667, MRC. Sep 2006 - Sep 2010.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    \u000d\u000a      Miller W, Rollnick S. (2012) Motivational Interviewing: Helping People\u000d\u000a        Change. 3rd Edition. New York: Guilford Press. ISBN-13: 978-1609182274.\u000d\u000a        Corroborates the integration of specific strategies developed in Cardiff\u000d\u000a        (see pages 105-116, 139-145). [Hard copy available from HEI upon\u000d\u000a        request].\u000d\u000a      Individual corroboration from Senior Commissioning Editor of Guildford\u000d\u000a        Press on the importance and success of the text book as the primary\u000d\u000a        source for teachers and practitioners wanting to learn about the\u000d\u000a        application of the research in different health care settings. Can also\u000d\u000a        confirm sales figures for the books.\u000d\u000a      AETNA news release: `Aetna Members More Motivated to Make Healthy\u000d\u000a        Changes', 15 Feb 2012: http:\/\/www.aetna.com\/news\/newsReleases\/2012\/0215-Aetna-Members-More-\u000a          Motivated.html [saved as a pdf on 24.07.2013 and available on\u000d\u000a        request from HEI]. Confirms the integration of motivational interviewing\u000d\u000a        into AETNA's Care Management Disease Management programs, and numbers of\u000d\u000a        clinicians and support staff who have received training in MI.\u000d\u000a      Individual corroboration from Professor of Health Behavior &amp;\u000d\u000a        Health Education, School of Public Health, University of Michigan who\u000d\u000a        worked with AETNA Health Insurance Company in the delivery of staff\u000d\u000a        training in MI. Details of staff training were obtained directly from\u000d\u000a        Professor and the company. Confirms the influence of Cardiff research on\u000d\u000a        the policy and practice of the leading US government and professional\u000d\u000a        bodies, as well as in the private sector.\u000d\u000a      The Brief Negotiated Interview, Boston School of Public Health: http:\/\/www.bu.edu\/bniart\/sbirt-\u000a          in-health-care\/sbirt-brief-negotiated-interview-bni\/ [saved as a\u000d\u000a        pdf on 13.08.2013 and available on request from HEI]. Confirms Cardiff\u000d\u000a        strategies at centre of intervention.\u000d\u000a      Project ASSERT: SRIRT in Emergency Care, Boston School of Public\u000d\u000a        Health: http:\/\/www.bu.edu\/bniart\/sbirt-experience\/sbirt-programs\/sbirt-project-assert\/\u000d\u000a        [saved as a pdf on 07.11.2013and available on request from HEI].\u000d\u000a        Confirms programme has been endorsed by the National Registry of\u000d\u000a        Evidence-based Programs.\u000d\u000a      Individual corroboration from Consultant in Emergency Medicine, Boston\u000d\u000a        Medical Centre, Boston. Confirms the successful application of the\u000d\u000a        research within emergency and public health medicine in the USA.\u000d\u000a      Individual corroboration from MD, The Karolinska Insititute &amp;\u000d\u000a        Swedish National Institute Of Public Health. Confirms the successful\u000d\u000a        application of research in Swedish Quitlines for tobacco and alcohol.\u000d\u000a      Report: `Healthy Child Programme: The two year review', Department of\u000d\u000a        Health, 2009. Available to download at:\u000d\u000a        http:\/\/www.inspiredbybabies.org.uk\/Page2NationalrelevantDocsresources\/Department%20of%\u000a20Health%20The%202%20year%20old%20review%20108329.pdf\u000a          Corroborates the research as the evidence base for the Nurse\u000d\u000a        Partnership Programme (see pages 16, 44) [saved as a pdf on 24.07.2013\u000d\u000a        and available on request from HEI].\u000d\u000a      Individual corroboration from Executive Director, Paediatric AIDS\u000d\u000a        Treatment for Africa. Can confirm the application of the research in\u000d\u000a        this African low resource setting.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Motivational interviewing in health care - worldwide uptake\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The research question\u000d\u000a    Research on the best way to encourage patients to change their lifestyle\u000d\u000a      or medication use has a long history, with mixed results. People don't\u000d\u000a      respond uniformly well to being advised to change. This challenge is even\u000d\u000a      more marked in specialist addiction treatment, where a counselling method\u000d\u000a      was developed with a different goal - to avoid direct persuasion and\u000d\u000a      elicit peoples' own motivation to change.\u000d\u000a    Rollnick was the co-founder of this specialist method, Motivational\u000a        Interviewing (MI), defined as a counselling style for helping people\u000d\u000a      resolve ambivalence about behaviour change. In 1993,\u000d\u000a      Rollnick (Research Fellow [1993] - current Professor [2013]) and Stott\u000d\u000a      (Professor [1993] - current retired [2013]) considered this question for a\u000d\u000a      programme of research: Can MI be simplified for everyday practice in\u000d\u000a        hospitals and clinics, in which patients clarify for themselves why and\u000d\u000a        how they might change their behaviour?\u000d\u000a    20 years of research\u000d\u000a    Butler (1993, Clinical Fellow &#8212; current Professor) joined the team,\u000d\u000a      and for the first time, a careful study of the consultation on health\u000d\u000a      behaviour change emerged. All research was conceived and executed\u000d\u000a      in the Cardiff University's School of Medicine Cochrane Institute of\u000d\u000a      Primary Care and Public Health (CIPCPH).\u000d\u000a      There followed 20 years of research on specific brief consultation\u000d\u000a      strategies:\u000d\u000a    \u000d\u000a      \"Pros &amp; Cons\" The patient describes the benefits and\u000d\u000a        drawbacks of change\u000d\u000a      \"Importance &amp; Confidence\" Specific questions to address the\u000d\u000a        \"why\" and \"how\" of change\u000d\u000a      \"Elicit-Provide-Elicit\" A new framework for exchanging\u000d\u000a        information with patients\u000d\u000a      \"Agenda-setting\" A method for deciding with patients which\u000d\u000a        behaviour change to focus on\u000d\u000a        These strategies were developed, tested, and published in papers and\u000d\u000a        textbooks for clinicians.\u000d\u000a    \u000d\u000a    Smoking &amp; lifestyle change\u000d\u000a    Butler &amp; Rollnick (mid-1990s) conceived the \"importance\u000d\u000a        &amp; confidence\" strategy in experimental consultations with\u000d\u000a      smokers [3.1]. Its use by GPs achieved significantly better outcomes when\u000d\u000a      compared to advice-giving [3.2]. It was integrated into a larger\u000d\u000a      counselling method, along with \"pros and cons\" and the \"elicit-provide-elicit\"\u000d\u000a      strategy, published in two textbooks for clinicians, and then evaluated in\u000d\u000a      a MRC-funded, multi-site trial of effectiveness for promoting lifestyle\u000d\u000a      change [3.3].\u000d\u000a    Diabetes: Agenda-setting &amp; multiple-behaviour consultations\u000d\u000a    In 1993 Rollnick, Stott &amp; colleagues used a MRC grant\u000d\u000a      to develop and evaluate \"agenda-setting\" in adults with poorly\u000d\u000a      controlled diabetes [3.4]. This strategy for deciding what\u000d\u000a      behaviour change to focus on was then applied to children with Type 1\u000d\u000a      diabetes: Gregory (2002, Reader- current Professor), Rollnick,\u000d\u000a      Channon (2002 Consultant Clinical Psychologist &#8212; current, the same)\u000d\u000a      &amp; Robling (2003 Research Fellow &#8212; current Reader) began with a\u000d\u000a      pilot and successful trial of MI delivered by a psychologist [3.5]; they\u000d\u000a      then worked with parents and children to develop a child-friendly visual\u000d\u000a      agenda-setting chart and evaluated its use by doctors and nurses in a\u000d\u000a      multi-site controlled trial across UK services [3.6].\u000d\u000a    Integrating the research\u000d\u000a    This research on brief strategies for helping patients with behaviour\u000d\u000a      change was not only reported in journals, but integrated into the first\u000d\u000a      (and only) two MI healthcare textbooks for clinicians, and two subsequent\u000d\u000a      editions of the parent text of the broader MI method (2002 &amp; 2012).\u000d\u000a    "},{"CaseStudyId":"3410","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2750405","Name":"Netherlands"}],"Funders":["Wellcome Trust","Medical Research Council"],"ImpactDetails":"\u000d\u000a    The findings and recommendations of the Cardiff research team have\u000d\u000a      provided the basis for new educational materials, training programmes and\u000d\u000a      other decision management tools used by clinicians in the UK and abroad.\u000d\u000a      The Cardiff research has also informed new clinical guidelines in the UK\u000d\u000a      and elsewhere on the management of RTI. The widespread dissemination of\u000d\u000a      Cardiff's research is helping to improve antibiotic stewardship across\u000d\u000a      Europe. Our four trials (see Section 3) all demonstrated the effectiveness\u000d\u000a      of different tools to reduce antibiotic prescribing. The reductions ranged\u000d\u000a      from 32% to 67% in trial participants and a 4.2% reduction in overall\u000d\u000a      antibiotic prescribing (and a 5.5% reduction in antibiotic dispensing\u000d\u000a      costs) over a one-year period at the whole general practice level. This\u000d\u000a      equates to a saving of &#163;830 per annum for an average sized UK general\u000d\u000a      practice. Given the widespread adoption of Cardiff's tools and training in\u000d\u000a      NHS initiatives to reduce GP antibiotic prescribing (see below), if 50% of\u000d\u000a      all UK GP practices achieved just half of the average savings observed in\u000d\u000a      the trials, the direct costs savings across the country since publication\u000d\u000a      of the NICE guidelines would total &#163;9 million.\u000d\u000a    Guidelines\u000d\u000a    The NICE guidelines on managing acute RTI were published in 2009 and were\u000d\u000a      distributed to all GPs in the UK. They highlighted the importance of\u000d\u000a      eliciting patient expectations; GPs are encouraged to achieve a shared\u000d\u000a      understanding regarding the management and treatment of the infection.\u000d\u000a      This recommendation stems directly from the Cardiff research, which is\u000d\u000a      cited in the NICE publication [5.1]. Aspects of Cardiff's research have\u000d\u000a      also informed a revision of the Dutch national guidelines on RTIs [5.4].\u000d\u000a    Patient educational materials\u000d\u000a    In 2009 the Cardiff team published the results of a trial revealing that\u000d\u000a      use of the interactive booklet for children about RTIs, which was\u000d\u000a      developed by the Cardiff team, resulted in a two-thirds reduction in\u000d\u000a      antibiotic use [3.5, see `What this study adds' summary, p7]. The results\u000d\u000a      were picked up by the UK medical media, including Pulse, Healthcare Today\u000d\u000a      and Onmedica; the publicity stimulated widespread uptake of the booklet\u000d\u000a      around the UK. The booklet has been available for purchase at the Royal\u000d\u000a      College of GPs bookshop since 2010. Over 90,000 copies have been purchased\u000d\u000a      by or sent to general practices since 2009. In September 2009, for\u000d\u000a      example, NHS Forth Valley highlighted the `When Should I Worry?' booklet\u000d\u000a      as a potential aid to management of self- limiting upper respiratory\u000d\u000a      infections through the Whole System Working initiative in 2009-10. 27,000\u000d\u000a      copies of the booklet have been distributed to practices to date [5.2]. In\u000d\u000a      2012, Welsh Government sent 30,000 copies to all general practices in\u000d\u000a      Wales as part of European Antibiotic Awareness Day activities [5.3].\u000d\u000a    Training clinicians\u000d\u000a    The evaluation of Cardiff's training package showed that communication\u000d\u000a      skills training (to improve interactions with patients and enhance their\u000d\u000a      experience) and the promotion of a point-of-care blood test, used alone or\u000d\u000a      in combination, led to significant reductions in antibiotic prescribing.\u000d\u000a      The results of this study led directly to a change in the Dutch national\u000d\u000a      guidelines on lower respiratory tract infections; a training package on\u000d\u000a      the updated guidelines was sent to 11,000 GPs [5.6] and made freely\u000d\u000a      available online [5.4, 5.5]. The study also helped convince the Dutch\u000d\u000a      health insurance system to pay for C-reactive protein (CRP) point of care\u000d\u000a      testing [5.6].\u000d\u000aCardiff developed a blended learning package (e-learning,\u000d\u000a      practice based outreach, experiential learning, and reflections) about\u000d\u000a      antibiotic prescribing for RTIs. Research demonstrated this approach\u000d\u000a      reduced practice-level antibiotic prescribing, not just in those patients\u000d\u000a      included in the trial. The Cardiff team's research, including the learning\u000d\u000a      package, formed the basis of the Royal College of General Practitioners\u000d\u000a      Managing Acute Respiratory Tract Infections (MARTI) course, which by\u000d\u000a      December 2012 had been completed by over 4,300 clinical users and results\u000d\u000a      in an average 24% increase in test scores between pre and post course\u000d\u000a      evaluation [5.7]. A contract has just been signed where Cardiff's SME\u000d\u000a      partners involved in the trial of the blended learning are investing\u000d\u000a      &#163;50,000 in further development and its commercialisation. Cardiff's\u000d\u000a      research has influenced national and international antimicrobial\u000d\u000a      stewardship programmes and campaigns. For example, Cardiff's interactive\u000d\u000a      booklet for children and training in its use, and the MARTI module form\u000d\u000a      part of the TARGET antibiotic toolkit [5.8], which was developed in 2012\u000d\u000a      by the Antimicrobial Stewardship in Primary Care collaboration (ASPIC) and\u000d\u000a      has been accessed by more than 5,400 unique users since November 2012.\u000d\u000a    Public awareness and policy\u000d\u000a    The Cardiff team's development and trial of the blended learning package\u000d\u000a      were picked up by local and national media. Articles in The Telegraph\u000d\u000a      [5.9] and Professor Chris Butler's contributions to discussions on Radio\u000d\u000a      4's Women's Hour [5.10], Radio 4's Inside Health, and BBC Wales's Jason\u000d\u000a      Mohammed Show all helped to disseminate the message about reducing\u000d\u000a      antibiotic prescribing for RTIs to the general public. Butler, Francis and\u000d\u000a      Stanton also advise the Health Protection Agency, the Department of\u000d\u000a      Health, the Advisory Committee on Antimicrobial Resistance and Healthcare\u000d\u000a      Associated Infection, and the Welsh Antimicrobial Resistance Programme.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research by Cardiff University is contributing to initiatives within the\u000d\u000a      NHS and across Europe to safely reduce unnecessary antibiotic prescribing\u000d\u000a      and thus help contain antimicrobial resistant bacteria. Our researchers\u000d\u000a      conducted observational studies of prescribing patterns linked to local\u000d\u000a      resistance data and qualitative research with GPs and patients on their\u000d\u000a      perceptions of acute respiratory tract infections and antibiotic use and\u000d\u000a      resistance. This enabled the Cardiff team to develop clinician training\u000d\u000a      and patient education resources (covering issues such as communication\u000d\u000a      skills, point of care testing, and typical duration of infections) to\u000d\u000a      reduce unnecessary prescribing. Our trials proved these interventions were\u000d\u000a      effective, at times cutting prescribing by as much as two-thirds. Our\u000d\u000a      research has provided the basis for new clinical guidelines, antibiotic\u000d\u000a      stewardship initiatives and policies, and educational tools for clinicians\u000d\u000a      and patients that are being used in the UK and internationally.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    Cardiff University\u000d\u000a    ","Institutions":[{"AlternativeName":"Cardiff University","InstitutionName":"Cardiff University","PeerGroup":"A","Region":"Wales","UKPRN":10007814}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    Note: All Cardiff researchers in bold\u000d\u000a    Key References\u000d\u000a    \u000a1. Butler CC, Rollnick S, Pill R, Maggs-Rapport F,\u000d\u000a        Stott N. Understanding the culture of prescribing: Qualitative study\u000d\u000a      of general practitioners' and patients' perceptions of antibiotics for\u000d\u000a      sore throats. British Medical Journal. 1998;317(7159):637-42. doi:\u000d\u000a      http:\/\/dx.doi.org\/10.1136\/bmj.317.7159.637\u000d\u000a    \u000a\u000a2. Butler CC, Dunstan F, Heginbothom M, Mason B,\u000d\u000a        Roberts Z, Hillier S, et al. Containing antibiotic resistance:\u000d\u000a      decreased antibiotic-resistant coliform urinary tract infections with\u000d\u000a      reduction in antibiotic prescribing by general practices. The British\u000d\u000a      Journal of General Practice. 2007;57(543):785-92\u000d\u000a      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17925135\u000d\u000a    \u000a\u000a3. Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ.\u000d\u000a      Effect of point of care testing for C reactive protein and training in\u000d\u000a      communication skills on antibiotic use in lower respiratory tract\u000d\u000a      infections: cluster randomised trial. BMJ. 2009;338:b1374 doi:\u000d\u000a      http:\/\/dx.doi.org\/10.1136\/bmj.b1374\u000d\u000a    \u000a\u000a4. Butler CC, Hood K, Verheij TJ, Little P, Melbye H, Nuttall\u000a        J, et al. Variation in antibiotic prescribing and its impact on\u000d\u000a      recovery in patients with acute cough in primary care: prospective study\u000d\u000a      in 13 countries. British Medical Journal. 2009;338:b2242 doi:\u000d\u000a      http:\/\/dx.doi.org\/10.1136\/bmj.b2242\u000d\u000a    \u000a\u000a5. Francis NA, Butler CC, Hood K, Simpson S,\u000d\u000a      Wood F, Nuttall J. Effect of using an interactive booklet\u000d\u000a      about childhood respiratory tract infections in primary care consultations\u000d\u000a      on reconsulting and antibiotic prescribing: a cluster randomised\u000d\u000a      controlled trial. BMJ. 2009;339:b2885 doi:\u000d\u000a      http:\/\/dx.doi.org\/10.1136\/bmj.b2885\u000d\u000a    \u000a\u000a6. Butler CC, Simpson SA, Dunstan F, Rollnick\u000d\u000a        S, Cohen D, Gillespie D, et al. Effectiveness of\u000d\u000a      multifaceted educational programme to reduce antibiotic dispensing in\u000d\u000a      primary care: practice based randomised controlled trial. BMJ.\u000d\u000a      2012;344:d8173. doi: http:\/\/dx.doi.org\/10.1136\/bmj.d8173\u000d\u000a    \u000a\u000a7. Little P, Stuart B, Francis N, Douglas E, Tonkin-Crine S,\u000d\u000a      Anthierens S, Cals JW, Melbye H, Santer M, Moore M, Coenen S, Butler C,\u000d\u000a      Hood K, Kelly M, Godycki-Cwirko M, Mierzecki A, Torres A,\u000d\u000a      Llor C, Davies M, Mullee M, O'Reilly G, van der Velden A, Geraghty AW,\u000d\u000a      Goossens H, Verheij T, Yardley L; on behalf of the GRACE consortium.\u000d\u000a      Effects of internet-based training on antibiotic prescribing rates for\u000d\u000a      acute respiratory-tract infections: a multinational, cluster, randomised,\u000d\u000a      factorial, controlled trial. Lancet. 2013 Oct 5;382(9899):1175-1182. doi:\u000d\u000a      http:\/\/dx.doi.org\/10.1016\/S0140-6736(13)60994-0 Epub 2013 Jul 31.\u000d\u000a    \u000aKey funding\u000d\u000a    SAVIT Study: The effect of intranasal sodium cromoglycate on symptoms of\u000d\u000a      suspected acute viral URTI in children. Butler. MRC (1999-2000).\u000d\u000a      &#163;98,012. www.controlled- trials.com\/ISRCTN21562211\/\u000d\u000a    The link between antibiotic prescribing and resistance in the community:\u000d\u000a      definition, dynamics, and influences. Howard, Palmer, Magee, Dunstan\u000d\u000a      (2000-2003). NHS Wales Office of Research and Development for Health and\u000d\u000a      Social Care. &#163;199,713.\u000d\u000a    Antibiotic Resistance in Community Urinary Tract Infection. Palmer,\u000d\u000a      Butler, Dunstan. Wellcome Trust (2002-2005). &#163;271,9320.\u000d\u000a    The development and evaluation of an interactive leaflet for children\u000d\u000a      with acute respiratory tract infections. Butler, Simpson,\u000d\u000a      Hood, Francis. MRC (2005-2009). &#163;307,860.\u000d\u000aSTAR: Stemming\u000d\u000a      the Tide of Antimicrobial Resistance. Butler, Evans, Hood,\u000d\u000a      Simpson, Palmer, Rollnick, Dunstan. MRC\u000d\u000a      (2006-2009). &#163;509,753.\u000d\u000a    GRACE: Genomics to combat resistance against antibiotics in\u000d\u000a      community-acquired lower respiratory tract infections in Europe. Butler,\u000d\u000a      Hood. EC FP6 project (2006-2011). Total project grant &#8364;11.5\u000d\u000a      million; &#163;804,740 to Cardiff University.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"}],"Sources":"\u000d\u000a    \u000d\u000a      NICE clinical guideline on Respiratory Tract Infections, July 2008:\u000d\u000a        www.nice.org.uk\/nicemedia\/pdf\/CG69FullGuideline.pdf Corroborates the\u000d\u000a        importance of Cardiff research in informing UK clinical guidelines.\u000d\u000a        Cardiff research directly cited (pp.14, 88, 93).\u000d\u000a      Statement from Clinical Lead, NHS Forth Valley. Confirms the use and\u000d\u000a        usefulness of the `When should I worry?' interactive booklet developed\u000d\u000a        by Cardiff in NHS Forth Valley.\u000d\u000a      Corroborative statement from Head of Welsh Antimicrobial Resistance\u000d\u000a        Programme, Public Health Wales, about the use of the interactive booklet\u000d\u000a        in Welsh General Practice.\u000d\u000a      Dutch Primary Care Guideline on Acute Cough 2013:\u000d\u000a        http:\/\/nhg.artsennet.nl\/kenniscentrum\/k_richtlijnen\/k_nhgstandaarden\/Samenvattingskaartje-NHGStandaard\/M78_svk.htm Confirms the influence of the Cardiff research in the updating of\u000d\u000a        guidelines for training Dutch GPs. Cardiff research directly cited\u000d\u000a        (Notes 18, 34, 37 and references). [Translated version saved as a pdf on\u000d\u000a        11\/04\/2013].\u000d\u000a      Educational website for Dutch GPs: http:\/\/www.acutehoest.nl\/praktijk.\u000d\u000a        Confirms Cardiff research as informing the education and training for\u000d\u000a        Dutch GPs on antibiotic prescribing for respiratory tract infections.\u000d\u000a        Cardiff research directly cited in Literature section. [Translated\u000d\u000a        version saved as a pdf on 11\/04\/2013].\u000d\u000a      Corroborative statement from Assistant Professor, Maastricht\u000d\u000a        University Medical Centre about the impact of the Cardiff research on\u000d\u000a        Dutch clinical guidelines on lower respiratory tract infections and\u000d\u000a        health insurance reimbursements.\u000d\u000a      RCGP online course - Managing Acute Respiratory Tract Infections\u000d\u000a        http:\/\/elearning.rcgp.org.uk\/course\/info.php?id=17&amp;nopopup=1\u000d\u000a        Confirms Cardiff research informed Royal College of General Practitioner\u000d\u000a        guidance on patients presenting with acute ear pain, acute sore throat,\u000d\u000a        sinusitis and acute cough. Cardiff research directly cited in References\u000d\u000a        section. [Saved as a pdf on 11\/04\/2013].\u000d\u000a      RCGP TARGET antibiotic prescribing toolkit:\u000d\u000a        http:\/\/www.rcgp.org.uk\/clinical-and-research\/target-\u000d\u000a        antibiotics-toolkit\/training-resources.aspx. Corroborates the use of\u000d\u000a        Cardiff research in the antibiotics training and resources for UK GPs.\u000d\u000a        Cardiff research directly cited in `Training Resources' and `Patient\u000d\u000a        information leaflet'\u000d\u000a        http:\/\/www.rcgp.org.uk\/clinical-and-research\/target-\u000d\u000a        antibiotics-toolkit\/patient-information-leaflets.aspx sections [Saved as\u000d\u000a        a pdf on 11\/04\/2013].\u000d\u000a      `GPs could prescribe 1.6m fewer antibiotics' The Telegraph, 09\u000d\u000a        Feb 2012. Article in The Telegraph reporting Cardiff research:\u000d\u000a        www.telegraph.co.uk\/health\/healthnews\/9071706\/GPs-\u000d\u000a        could-prescribe-1.6m-fewer-antibiotics.html [Saved as a pdf on\u000d\u000a        11\/04\/2013].\u000d\u000a      Woman's Hour, Radio 4, 16\/08\/2011.\u000d\u000a        http:\/\/www.bbc.co.uk\/programmes\/b0135z1k Professor Butler provides\u000d\u000a        expert comment on antibiotic resistance.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Safely reducing antibiotic prescriptions to help contain antibiotic\u000d\u000a      resistance.\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Antibiotic prescribing practices and perceptions\u000d\u000a    Cardiff University researchers, including Chris Butler (Clinical Fellow,\u000d\u000a      1993; Professor of Primary Care Medicine, 2001-present), Nick Francis\u000d\u000a      (Clinical Lecturer, 2003-2010; Senior Clinical Research Fellow,\u000d\u000a      2010-present), Fiona Wood (Lecturer, 2003-2013; Senior Lecturer 2013-\u000d\u000a      present), Kerry Hood (Senior Lecturer 2002-2007; Reader, 2007-2009,\u000d\u000a      Professor, 2009-present), Frank Dunstan (Professor of Medical Statistics,\u000d\u000a      2002-present) and Stephen Rollnick (Research Fellow, 1993; Professor of\u000d\u000a      Healthcare Communication, 2013-present), have developed and evaluated\u000d\u000a      effective, evidence-based tools which improve the clinical management of\u000d\u000a      respiratory tract infections (RTIs) and help to reduce inappropriate\u000d\u000a      antibiotic use.\u000d\u000a    Butler and Rollnick provided the earliest insights into clinicians' and\u000d\u000a      patients' perspectives on why antibiotics were prescribed for sore throats\u000d\u000a      [3.1]. This research, published in the British Medical Journal (BMJ) in\u000d\u000a      1998, revealed several drivers for inappropriate prescribing, including GP\u000d\u000a      perceptions that community antibiotic prescribing was incidental to\u000d\u000a      resistance (`resistance is not a problem in my practice') and a lack of\u000d\u000a      tools to support clinicians to change their prescribing habits.\u000d\u000a    Butler, Dunstan and colleagues then produced the first ever evidence that\u000d\u000a      showed antibiotic use was linked to antibiotic resistance at a local\u000d\u000a      (practice) level. Analysing data from urine samples submitted by Welsh\u000d\u000a      GPs, they found that antibiotic resistance was common in primary care;\u000d\u000a      patients infected with resistant strains were sicker for longer and\u000d\u000a      consumed more healthcare resources compared to patients infected with\u000d\u000a      bacteria sensitive to antibiotic treatment. The research also revealed\u000d\u000a      that reducing antibiotic prescribing was associated with reduced\u000d\u000a      resistance at the general practice level [3.2].\u000d\u000a    In 2003 and 2006 Butler and Francis produced new data on the normal\u000d\u000a      illness course of upper RTIs in children and acute sore throat in adults.\u000d\u000a      This data is used to help set realistic expectations about likely illness\u000d\u000a      course. Butler, Francis, Wood and colleagues also conducted qualitative\u000d\u000a      research to describe the perceptions of both general practitioners (GPs)\u000d\u000a      and the general public regarding antibiotic use and resistance, including\u000d\u000a      interviews with GPs about their rationale for using broad-spectrum\u000d\u000a      antibiotics (which generally cause greater `collateral damage') and\u000d\u000a      parents about their information needs regarding their child's RTI.\u000d\u000a    Butler (as a work package leader), supported by others from Cardiff,\u000d\u000a      played a central role in the EU-funded FP6 project `Genomics to combat\u000d\u000a      resistance to antibiotics in Community-acquired lower respiratory tract\u000d\u000a      infections in Europe' which ran from 2006 to 2011. This project provided\u000d\u000a      evidence that there is `unhelpful' variation in the antibiotic prescribing\u000d\u000a      practices of doctors between 14 European sites. The project has produced\u000d\u000a      the most reliable data so far on the prognostic value of signs, symptoms\u000d\u000a      and point of care testing for RTIs in primary care [3.3], as well as trial\u000d\u000a      data on the effectiveness of antibiotics in adults with acute cough [3.4].\u000d\u000a    Evaluation of tools\u000d\u000a    From 2005-2011 the Cardiff team collated the insights from their\u000d\u000a      empirical investigations. Informed by complementary research strengths in\u000d\u000a      motivational interviewing, shared decision making, and other behaviour\u000d\u000a      change theories, the team developed a set of communication skills\u000d\u000a      strategies to help clinicians adopt a non-prescribing approach while\u000d\u000a      enhancing patient empowerment and maintaining patient satisfaction. Output\u000d\u000a      from this work included a communications skills training programme [3.3],\u000d\u000a      a blended learning package (http:\/\/www.stemmingthetide.org\/) [3.6], and\u000d\u000a      interactive patient information booklets, supported by online clinician\u000d\u000a      training, for children (www.whenshouldiworry.com) [3.5] and adults [3.7]\u000d\u000a      with RTIs.\u000d\u000a    The team also led or played a central role in four major trials of the\u000d\u000a      tools developed by the research. The tools under investigation included\u000d\u000a      `blended learning' (combining multi-media and interactive learning),\u000d\u000a      enhanced communication skills training, point of care testing, and\u000d\u000a      interactive booklets. The trials demonstrated statistically significant,\u000d\u000a      clinically important, safe, and acceptable reductions in antibiotic\u000d\u000a      prescribing through use of the tools [3.3, 3.5-3.7]. The paper describing\u000d\u000a      the blended learning (STAR) study was one of six papers internationally\u000d\u000a      shortlisted for the BMJ Research Paper of the Year Award 2013.\u000d\u000a    "},{"CaseStudyId":"3865","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2464461","Name":"Tunisia"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    The process through which the research led to the impact\u000d\u000a      Since 2000, this University of Liverpool programme led by Capewell has\u000d\u000a      provided innovative and\u000d\u000a      robust analyses consistently showing that upward or downward trends in\u000d\u000a      death rates from heart\u000d\u000a      disease and stroke mainly reflect changes in powerful cardiovascular risk\u000d\u000a      factors, particularly\u000d\u000a      smoking and diet. The contributions from specific medical treatments have\u000d\u000a      also been consistently\u000d\u000a      quantified. This and subsequent work enabled Capewell and Liverpool\u000d\u000a      colleagues to widely\u000d\u000a      disseminate evidence-base key messages on strategies for the prevention of\u000d\u000a      cardiovascular\u000d\u000a      disease and non-communicable diseases. Notably, that population-wide\u000d\u000a        preventive policies\u000d\u000a        can be powerful, rapid, equitable and cost saving.\u000d\u000a    This cutting edge IMPACT CHD Policy research has influenced public policy\u000d\u000a      debate in the UK and\u000d\u000a      internationally. It has provided scientific evidence endorsing UK policies\u000d\u000a      on tobacco control and\u000d\u000a      healthy diet. It has informed the evaluation of the subsequent\u000d\u000a      interventions in Europe and beyond.\u000d\u000a      Furthermore, Professor Capewell has shared his findings with policy makers\u000d\u000a      in numerous countries\u000d\u000a      developing CVD prevention strategies, including Sweden, Tunisia, China and\u000d\u000a      the USA.\u000d\u000a    The principal beneficiaries have been policy makers and the general\u000d\u000a      public through improved\u000d\u000a      public health polices and information that reduces CVD and improves\u000d\u000a      health. Capewell's seminal\u000d\u000a      work has been widely cited. He has also received invitations to talk to\u000d\u000a      politicians and policy\u000d\u000a      makers in London, the European Parliament in Brussels and the World Health\u000d\u000a      Organisation\u000d\u000a      (details below), plus presentations to lecture in prestigious academic\u000d\u000a      settings in the UK, Europe,\u000d\u000a      the USA (Harvard, Yale etc), and Australia (Sydney &amp; Melbourne\u000d\u000a      universities).\u000d\u000a    Proof of contribution\u000d\u000a      Capewell's research has been seen as a key contributor to CVD prevention\u000d\u000a      policy for well over a\u000d\u000a      decade. Capewell and colleagues have extensively disseminated their\u000d\u000a      findings internationally\u000d\u000a      including to policy makers and politicians. This led in 2008 to an\u000d\u000a      invitation to Capewell from NICE\u000d\u000a      (The National Institute of Health and Clinical Excellence) to write a\u000d\u000a      specification for a full guidance\u000d\u000a      review on Cardiovascular disease prevention at the population level.\u000d\u000a      [7]. This was subsequently\u000d\u000a      supported by the NICE Topic Review Group, and then approved by ministers.\u000d\u000a      This then led to the\u000d\u000a      formation of the NICE Programme Development Group (PDG) in 2009. Capewell\u000d\u000a      was appointed\u000d\u000a      as PDG Vice Chair. He also served as a topic expert, authoring three NICE\u000d\u000a      evidence papers which\u000d\u000a      were subsequently cited as evidence in the final NICE publication in 2010\u000d\u000a      [8].\u000d\u000a    The NICE Guidance was published in June 2010 [8]. Fully implemented, the\u000d\u000a      recommendations\u000d\u000a      could prevent up to 40,000 premature cardiovascular deaths each year. The\u000d\u000a      NICE Guidance\u000d\u000a      received extensive positive media coverage including the Telegraph (front\u000d\u000a      page), The Times, BBC,\u000d\u000a      ITV etc. Altogether totaling over 150 separate news items, plus invited\u000d\u000a      editorials for Capewell in\u000d\u000a      the New Scientist, JAMA, European Heart J and Heart (all 2010), thus\u000d\u000a      influencing the wider clinical\u000d\u000a      community.\u000d\u000a    The 2010 NICE guidance has now been endorsed and extended in the 2012\u000d\u000a      NICE Commissioning\u000d\u000a      Guide on CVD prevention [9]. This has informed Primary Health Care Trusts\u000d\u000a      and Clinical\u000d\u000a      Commissioning Groups and Wellbeing Boards. Thus, directly influencing NHS\u000d\u000a      and local authority CVD\u000d\u000a      budgets which exceed &#163;10 billion per year.\u000d\u000a    The NICE Report has also been endorsed by the European Society of\u000d\u000a      Cardiology [10].\u000d\u000a      We also reinforced the nutrition messages in a BMJ editorial [11], which\u000d\u000a      then fed into recent\u000d\u000a      American Heart Association Guidelines on CVD prevention [12].\u000d\u000a    These publications also increased the weight of scientific evidence and\u000d\u000a      political pressure acting on\u000d\u000a      the policy makers and officials planning the UN High Level Meeting on\u000d\u000a      Non-communicable Disease\u000d\u000a      Prevention and Control in Sept 2011. That specifically recommended\u000d\u000a      reductions in dietary salt and\u000d\u000a      tobacco which were subsequently actioned by the World Health Organisation\u000d\u000a      [11, 12].\u000d\u000a    Capewell's research has also translated into UK Faculty of Public\u000d\u000a        Health Position papers.\u000d\u000a      These are used as authoritative guidance by public health practitioners\u000d\u000a      across the UK. Capewell\u000d\u000a      has been notably active in co-authoring and advocating improvements in\u000d\u000a      food policy, specifically\u000d\u000a      around European subsidies from the Common Agricultural Policy, and front\u000d\u000a      of pack Traffic Light\u000d\u000a      Labelling to better inform consumers [13, 14].\u000d\u000a    Capewell was also invited as the sole public health expert on the Academy\u000d\u000a      of Medical Royal\u000d\u000a      Colleges Obesity Review [15]. He was thus able to advise on the most\u000d\u000a      effective and cost-effective\u000d\u000a      interventions. As well as dissemination to the AoMRC membership of over\u000d\u000a      200,000 doctors, the\u000d\u000a      report, Measuring Up: the medical profession's prescription for the\u000d\u000a        nation's obesity crisis received\u000d\u000a      extensive positive media coverage, raising public awareness, and\u000d\u000a      influencing policy makers and\u000d\u000a      politicians. The recommendations highlighted the crucial need for\u000d\u000a      effective policy interventions to\u000d\u000a      prevent obesity (and subsequent chronic diseases), notably protecting\u000d\u000a      children from the\u000d\u000a      aggressive marketing of junk food and sugary drinks, putting a duty on\u000d\u000a      sugary drinks, and ensuring\u000d\u000a      that healthy food was routinely provided in ALL UK schools [15].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Capewell's MRC\/EU\/NIHR funded IMPACT programme has been developed at the\u000d\u000a      University of\u000d\u000a      Liverpool (UoL) since 1999. It examines why cardiovascular disease (CVD)\u000d\u000a      death rates have\u000d\u000a      recently halved in the UK, USA and Europe (mainly risk factor improvements\u000d\u000a      plus modern\u000d\u000a      treatments), and why CVD rates are increasing in China and most developing\u000d\u000a      countries (adverse\u000d\u000a      risk factor trends reflecting a Westernised diet). Results have informed\u000d\u000a      CVD prevention strategies\u000d\u000a      in the UK and beyond, notably NICE Guidance on CVD prevention in whole\u000d\u000a      populations. The\u000d\u000a      strong NICE recommendations on diet and tobacco were recently endorsed in\u000d\u000a      NICE\u000d\u000a      Commissioning Guidance and European and American guidance.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    UNIVERSITY OF LIVERPOOL\u000d\u000a    ","Institutions":[{"AlternativeName":"Liverpool (University of)","InstitutionName":"University of Liverpool","PeerGroup":"A","Region":"North West","UKPRN":10006842}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2158177","Name":"Melbourne"},{"GeoNamesId":"2800867","Name":"Bruxelles-Capitale"}],"References":"\u000d\u000a    These references report Capewell's coronary heart disease modelling to\u000d\u000a      explain past mortality\u000d\u000a      trends and to inform CVD prevention policies in the UK and beyond.\u000d\u000a    \u000a1. Ford ES, Ajani US, Croft JB, Critchley JA, Labarthe DR, Kottke DE,\u000d\u000a      Giles WH, Capewell S.\u000d\u000a      Explaining the Decrease in U.S. deaths from Coronary Disease, 1980-2000.\u000d\u000a      New England\u000d\u000a      Journal of Medicine 2007; 356: 2388-2398. PMID: 17554120 Citations: 961\u000d\u000a      Impact\u000d\u000a      Factor: 51.658\u000d\u000a    \u000a\u000a2. Huffman MD, Ning H, Shay CM, Ford ES, Lloyd-Jones BM, Guzman M, O'Flaherty\u000d\u000a        M,\u000d\u000a      Capewell S. Quantifying Options For Reducing Coronary Heart Disease\u000d\u000a      Mortality By 2020.\u000d\u000a      Circulation. 2013 127 2477. Citations: 0 Impact Factor: 15.202\u000d\u000a    \u000a\u000a3. Taylor-Robinson DC et al. Policy-makers' attitudes to decision\u000d\u000a      support models for\u000d\u000a      coronary disease: a qualitative study. BMC Public Health. 2008, 8:415\u000d\u000a      Citations: 9\u000d\u000a      Impact Factors: 2.076\u000d\u000a    \u000a\u000a4. Bajekal M, Scholes S, Love H, Hawkins N, O'Flaherty M, Raine\u000d\u000a      R, Capewell S. Analysing\u000d\u000a      recent socioeconomic trends in coronary heart disease mortality in\u000d\u000a      England, 2000-2007: a\u000d\u000a      population modelling study. PLoS Medicine 2012; 9(6): e1001237.\u000d\u000a      doi:10.1371\/journal.pmed.1001237 Citations: 9 Impact Factor: 15.253\u000d\u000a    \u000a\u000a5. Saidi O, Ben Mansour N, O'Flaherty M, Capewell S,\u000d\u000a      Critchley J, Ben Romdhan H.\u000d\u000a      Analyzing recent coronary heart disease mortality trends in Tunisia\u000d\u000a      between 1997 and\u000d\u000a      2009. PLoS ONE 2013 8(5): e63202. doi:10.1371\/journal.pone.0063202\u000d\u000a      Citations: 0\u000d\u000a      Impact Factor: 3.730\u000d\u000a    \u000a\u000a6. O'Flaherty M, Flores-Mateo G, Nnoaham K, Lloyd-Williams F, Capewell\u000d\u000a        S. Potential\u000d\u000a      cardiovascular mortality reductions with different food policy options in\u000d\u000a      the UK.\u000d\u000a      Bulletin of WHO 2012, 90: 522-531. PMID: 22807598 Citations 8 Impact\u000d\u000a      Factor 5.25\u000d\u000a    \u000aKey grant awards relating to this work\u000d\u000a    2006-2008. Medical Research Council MRC. (&#163;405,000). Extending the\u000d\u000a      IMPACT\u000d\u000a      coronary heart disease model to different health policy contexts\u000d\u000a      [G0500920], PI S Capewell\u000d\u000a    2008-2012. Liverpool Primary Care Trust, MerseyBEAT, &#163;2m,\u000d\u000a      S Capewell (PI and\u000d\u000a      Programme Director), M Gabbay, J Wilding, M Pearson, M\u000d\u000a        Whitehead, J Neilson, T\u000d\u000a        Walley, K Wilson; Liverpool Institute for Health\u000d\u000a      Inequalities Research (LivHIR).\u000d\u000a    2009-2012. Medical Research Council. (NPRI3).\u000d\u000a        (&#163;500,700) Prevention IMPACT:\u000d\u000a      developing and evaluating economic models for planning optimal\u000d\u000a      cardiovascular prevention\u000d\u000a      strategies, &#163;500k, PI S Capewell\u000d\u000a    2008-2012. European Commission PHEA. 2008 -2012. (2,800,000 Euros).\u000d\u000a      \"MedCHAMPS &#8212; MEDiterranean studies of Cardiovascular\u000d\u000a      disease and Hyperglycaemia:\u000d\u000a      Analytical Modelling of Population Socio-economic\u000d\u000a      transitions. &#8364;2.8m. N Unwin, JA\u000d\u000a      Critchley, S Capewell, K Bennett, B Ahmad, P Phillimore, B Unal, Y\u000d\u000a      Demiral, B Kilic; W\u000d\u000a      Maziak; A Mataria, A Husseini, N Abu-Rmeileh, R Khatib, H Rhomdane &amp; H\u000d\u000a      Aounallah).\u000d\u000a    2012-2016. NIHR School for Public Health Research Liverpool &amp;\u000d\u000a      Lancaster Collaboration\u000d\u000a      (&#163;2.5m) M Whitehead , J Popay, S Capewell, P Diggle and C\u000d\u000a        Dowrick;\u000d\u000a      (including: Modelling preventive interventions to address inequalities in\u000d\u000a      chronic disease.\u000d\u000a      PI S Capewell).\u000d\u000a    2012-2017 British Heart Foundation Programme Grant (&#163;1,507,000)\u000d\u000a      Vascular risk and\u000d\u000a        functional decline in old age. E Brunner (PI), M Kivimaki, A\u000d\u000a      Singh-Manoux, M Marmot, &amp; S\u000d\u000a        Capewell.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"}],"Sources":"\u000d\u000a    Each source listed below provides evidence for the corresponding numbered\u000d\u000a      claim made in section\u000d\u000a      4 (details of the impact).\u000d\u000a    \u000d\u000a    \u000d\u000a      Capewell S, Blamey A, Lincoln P, Mwatsama M, Lloyd\u000d\u000a        Williams F; Critchley JA,\u000d\u000a        Ireland R, Birt C, Platt S, Summerton N, Miller C, Field\u000d\u000a        J. Cardiovascular disease\u000d\u000a          prevention at the population level. NICE Potential Public Health\u000d\u000a        Programme Guidance, 2179.\u000d\u000a        2008. NICE, London.\u000d\u000a      NICE Public Health Guidance: Prevention of cardiovascular disease at\u000d\u000a        population level.\u000d\u000a        2010 (PH25). http:\/\/guidance.nice.org.uk\/PH25\u000a\u000d\u000a      NICE CMG45: Integrated commissioning for the prevention of\u000d\u000a        cardiovascular disease. (2012).\u000d\u000a        http:\/\/www.nice.org.uk\/usingguidance\/commissioningguides\/integratedcommissioningforpreventionofcvd\/CardiovascularDisease.jsp\u000a\u000d\u000a      J&#248;rgensen T et al. Population level changes to promote\u000d\u000a        cardiovascular health. European\u000d\u000a          Journal of Preventive Cardiology (2013); 20 (3): 409-21\u000a\u000d\u000a      Mozaffarian D. United Nations dietary policies to prevent\u000d\u000a        cardiovascular disease. Modest\u000d\u000a        diet changes could halve the global burden. BMJ 2011; 343: d5747 PMIB:\u000d\u000a        21933831\u000d\u000a      Mozaffarian D et al. American Heart Association Council on\u000d\u000a        Epidemiology and Prevention,\u000d\u000a        Council on Nutrition, Physical Activity and Metabolism, Council on\u000d\u000a        Clinical Cardiology,\u000d\u000a        Council on Cardiovascular Disease in the Young.\u000d\u000a        Population approaches to improve diet, physical activity, and smoking\u000d\u000a        habits: a scientific\u000d\u000a        statement from the American Heart Association. Circulation.\u000d\u000a          2012;126:1514-1563.\u000a\u000d\u000a      Birt C, Maryon-Davis A, Stewart L, Parkin C, Mwatswama M, Capewell\u000d\u000a          S.\u000d\u000a        A CAP on Health. UK Faculty of Public Health. 2008. ISBN: 1-900273-25-X\u000d\u000a      UK Faculty of Public Health. Position statement: Traffic-light food\u000d\u000a        labelling. August 2008.\u000d\u000a        ISBN: 1-900273-35-7\u000d\u000a      Stephenson T, Bhui K, Capewell S et al. Measuring Up:\u000d\u000a        the medical profession's\u000d\u000a        prescription for the nation's obesity crisis. Academy of Medical\u000d\u000a          Royal Colleges, London.\u000d\u000a          February 2013.\u000a\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    IMPACT Coronary Heart Disease Policy Model and Prevention Policies\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Cardiovascular disease (CVD) mainly comprises coronary heart disease and\u000d\u000a      stroke. CVD\u000d\u000a      generates a huge and unequal burden of premature mortality globally. In\u000d\u000a      the UK, annually causing\u000d\u000a      over 100,000 deaths and costing over &#163;30 billion in the UK. However, CVD\u000d\u000a      is eminently\u000d\u000a      preventable.\u000d\u000a    Capewell has been Professor of Clinical Epidemiology in the University of\u000d\u000a      Liverpool (UoL) from 1999.\u000d\u000a      Research funding has come from the MRC, EU, BHF, NHS, NIH, NIHR and a\u000d\u000a      variety of foreign\u000d\u000a      sources. His team has included UoL Senior Lecturers Martin O'Flaherty and\u000d\u000a      David Taylor-Robinson\u000d\u000a      (since 2006), plus many other UK and international colleagues.\u000d\u000a    Capewell's policy model, IMPACT, has been progressively developed and\u000d\u000a      refined at the UoL since\u000d\u000a      2000. The IMPACT model is comprehensive, synthesising data on all standard\u000d\u000a      treatments in all\u000d\u000a      patient groups, plus changes in all the major risk factors. It has been\u000d\u000a      tested, refined and validated,\u000d\u000a      particularly since 2008. IMPACT is the most widely used comprehensive CVD\u000d\u000a      policy model in the\u000d\u000a      world. It can now estimate deaths prevented or postponed,\u000d\u000a      life-years-gained, the cost-effectiveness of\u000d\u000a      different interventions, and the future deaths prevented by different\u000d\u000a      prevention policies (such as\u000d\u000a      increases in specific treatments or decreases in particular risk factors\u000d\u000a      [1,2] ).\u000d\u000a    IMPACT results have now been used to help to explain Coronary Heart\u000d\u000a      Disease (CHD) mortality\u000d\u000a      trends in over twenty very different populations, including England and\u000d\u000a      Wales, Scotland, Northern\u000d\u000a      Ireland, Ireland, Finland, Sweden, Iceland, Poland, the Czech Republic,\u000d\u000a      Italy, Spain, Syria,\u000d\u000a      Palestine, Tunisia, Turkey, China, New Zealand, Canada and the USA\u000d\u000a      [1,4,5].\u000d\u000a    The consistent findings from the IMPACT studies are that the largest\u000d\u000a      component of the widespread\u000d\u000a      declines in cardiovascular mortality rates reflects population-wide\u000d\u000a      improvements in major risk factors &#8212; notably\u000d\u000a      smoking, blood pressure and cholesterol (mainly reflecting diet).\u000d\u000a      Additional important\u000d\u000a      contributions then coming from specific medical treatments for acute cases\u000d\u000a      and thereafter for patients\u000d\u000a      with chronic cardiovascular disease [1-6].\u000d\u000a    Worryingly, the recent rises in obesity and diabetes prevalence have\u000d\u000a      generated additional deaths in the\u000d\u000a      UK and far beyond [4]. Westernisation of diet has been particularly\u000d\u000a      powerful and damaging in low and\u000d\u000a      middle income countries (such as China, Syria &amp; Tunisia) which are now\u000d\u000a      suffering dramatic and costly\u000d\u000a      increases in non-communicable disease burdens (notably cardiovascular\u000d\u000a      disease and diabetes) [5].\u000d\u000a    Since 2006, this MRC-funded research programme has been exploring the\u000d\u000a      complex relationships\u000d\u000a      between evidence, policy makers and decision making [3]. Collaborations\u000d\u000a      with UCL since 2010 have\u000d\u000a      produced IMPACTsec. This is the first comprehensive CHD policy model able\u000d\u000a      to quantify trends in\u000d\u000a      specific socio-economic groups. These studies confirmed the more powerful\u000d\u000a      effects of major risk\u000d\u000a      factors in deprived groups. Happily, they also demonstrated remarkably\u000d\u000a      equitable treatments across\u000d\u000a      all socioeconomic groups [4]. From 2010 onwards, Capewell's group has also\u000d\u000a      developed increasingly\u000d\u000a      refined food policy models. Results suggest that reducing dietary intake\u000d\u000a      of salt, transfats and saturated\u000d\u000a      fats and increasing fruit and vegetable consumption could massively reduce\u000d\u000a      death rates [6].\u000d\u000a    "},{"CaseStudyId":"3866","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"298795","Name":"Turkey"},{"GeoNamesId":"1643084","Name":"Indonesia"},{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"3077311","Name":"Czech Republic"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"192950","Name":"Kenya"},{"GeoNamesId":"3996063","Name":"Mexico"},{"GeoNamesId":"290557","Name":"United Arab Emirates"},{"GeoNamesId":"798544","Name":"Poland"},{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"1269750","Name":"India"}],"Funders":["Wellcome Trust","Medical Research Council"],"ImpactDetails":"\u000d\u000a    The team not only conducted high quality research on misoprostol, but\u000d\u000a      have also provided practitioners worldwide with high-quality,\u000d\u000a      evidence-based guidelines to ensure effective and safe misoprostol use in\u000d\u000a      pregnancy.\u000d\u000a    National and International Guidelines\u000d\u000a    The `Bellagio guidelines' that came out of the UoL led expert reviews in\u000d\u000a      2007 were the first international guidelines to address the appropriate\u000d\u000a      dosages of misoprostol in pregnancy. A recognition of their importance led\u000d\u000a      to their adoption by the International Federation of Gynecology and\u000d\u000a      Obstetrics (FIGO) in 2009. This is the only organisation that brings\u000d\u000a      together professional societies of obstetricians and gynaecologists on a\u000d\u000a      global basis. The adopted guidelines were disseminated at the 2009 FIGO\u000d\u000a      World Congress in South Africa at a special session chaired by Prof Weeks.\u000d\u000a      The congress was attended by 6,400 delegates from 158 countries, and\u000d\u000a      misoprostol dosage packs, produced for the event, were placed in the\u000d\u000a      delegates' conference bags. Each of the 10,000 packs contained a\u000d\u000a      gestational calendar, credit card sized memory aid and an A4 sticker [9]\u000d\u000a      with the FIGO misoprostol doses printed on them. Those remaining were\u000d\u000a      distributed to regional conferences in Africa and South Asia. Although\u000d\u000a      funded by FIGO, the summary graph on misoprostol dosage and marketing\u000d\u000a      packs was designed by Prof Weeks and produced by a local printer in\u000d\u000a      Liverpool. The FIGO misoprostol dosage guidelines were subsequently\u000d\u000a      updated and presented at a special session at the FIGO World Congress in\u000d\u000a      Rome in 2012 (8,000 delegates from 170 countries). This time 13,000\u000d\u000a      updated marketing packs in English, French and Spanish were produced for\u000d\u000a      distribution in delegate packs. Those remaining were distributed at\u000d\u000a      regional conferences. These findings have also been used by many\u000d\u000a      international organisations including Gynuity Health Projects (www.gynuity.org),\u000a      the Postabortion Care Consortium (www.pac-\u000a        consortium.org), and PATH (www.path.org).\u000d\u000a    The UoL team has also used their expertise on misoprostol to impact on\u000d\u000a      national and international guideline development groups. Prof Alfirevic\u000d\u000a      was on the expert group that developed the 2008 NICE Guidelines for\u000d\u000a        Induction of Labour [10] (and his work referenced in the final\u000d\u000a      report), Prof Weeks was on the committee that developed the WHO\u000d\u000a        recommendations for induction of labour [11] (3 of his publications\u000d\u000a      are referenced in the final report), and Prof Neilson chaired the expert\u000d\u000a      group that developed the WHO Recommendations for the prevention of\u000d\u000a        postpartum haemorrhage (WHO 2006, updated in 2012 [12]). The team's\u000d\u000a      work has also been heavily cited in the successful application to place\u000d\u000a      misoprostol on the core list of the 18th WHO Model List of\u000d\u000a      Essential Medicines for use in postpartum haemorrhage. Profs Weeks or\u000d\u000a      Alfirevic were cited 4 times in the original application [13], and 6 times\u000d\u000a      in the formal safety review commissioned by WHO [14].\u000d\u000a    Website\u000d\u000a    In 2002 Prof Weeks set up a website (www.misoprostol.org)\u000d\u000a      to disseminate information related to misoprostol in pregnancy. The\u000d\u000a      University of Liverpool has subsequently funded multiple revisions and\u000d\u000a      updates. It now contains 169 documents and 58 pages and includes the FIGO\u000d\u000a      guidelines, an extensive bibliography of over 1800 references, and\u000d\u000a      information on availability, dangers and protocols. Dosage posters are\u000d\u000a      also available for download and the main pages are translated into Dutch,\u000d\u000a      Spanish and Russian.\u000d\u000a    The website is used extensively throughout the world. It currently\u000d\u000a      receives around 16,500 visits per month (an increase of 45% from 2011) and\u000d\u000a      tops the Google search for misoprostol. Visitors to the site come from all\u000d\u000a      over the world: for example in September 2013 the top 15 countries were\u000d\u000a      India, Mexico, Australia, Brazil, Germany, Canada, UK, South Africa, Czech\u000d\u000a      Republic, Turkey, Indonesia, United Arab Emirates, Poland, Columbia and\u000d\u000a      Kenya. Most visitors are directed from search engines, but 10% directly\u000d\u000a      type `www.misoprostol.org'. 74% of the visits are to the home page or main\u000d\u000a      dosage page. The website is also referenced in guidelines including the\u000d\u000a      Royal College of Obstetricians and Gynaecologists guideline on Late\u000d\u000a      Intrauterine Fetal Death and Stillbirth [15].\u000d\u000a    Leading opinion change amongst practitioners\u000d\u000a    The guidelines have also been spread to practitioners through the\u000d\u000a      production of highly cited articles. Prof Weeks has authored important BMJ\u000d\u000a      editorials on the topic of misoprostol use (Elati &amp; Weeks BMJ\u000d\u000a      2011;342:d2877; Aflaifel &amp; Weeks BMJ 2012;345:e4546; together\u000d\u000a      accessed from www.bmj.com 22,031 times)\u000d\u000a      and has written influential reviews on the subject. His review in BJOG was\u000d\u000a      one of the 10 most downloaded articles of 2009 (Elati &amp; Weeks BJOG\u000d\u000a      2009;116(supp1):61). The team's work on misoprostol is frequently\u000d\u000a      referenced in textbooks including the Oxford Handbook of Clinical\u000d\u000a      Specialities [16], Williams Obstetrics (22nd edition),\u000d\u000a      Dewhurst's Textbook of Obstetrics and Gynaecology, Obstetrics: Normal and\u000d\u000a      Problem Pregnancies, Protocols for High- Risk Pregnancies, and Oxford Desk\u000d\u000a      Reference: Obstetrics and Gynaecology.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    This University of Liverpool (UoL) research programme has provided the\u000d\u000a      first international guidance on pregnancy dosage regimes for the drug\u000d\u000a      misoprostol. Although commonly used, its use in pregnancy is off-label.\u000d\u000a      This has led to a wide variety of different dosage regimens. Professors\u000d\u000a      Weeks, Alfirevic and Neilson (all UoL) have been at the forefront of\u000d\u000a      research into its correct use since 1998. In 2007 they initiated a WHO\u000d\u000a      expert conference to conduct dosage reviews, thus establishing an\u000d\u000a      international consensus. These regimens were adopted by the International\u000d\u000a      Federation of Gynecology and Obstetrics (FIGO) in 2009, and updated in\u000d\u000a      2012. Examples of resulting guidelines with social marketing are provided.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    UNIVERSITY OF LIVERPOOL\u000d\u000a    ","Institutions":[{"AlternativeName":"Liverpool (University of)","InstitutionName":"University of Liverpool","PeerGroup":"A","Region":"North West","UKPRN":10006842}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. Weeks A, Alia G, Blum J, Winikoff B, Ekwaru P, Durocher J,\u000d\u000a      Mirembe F. A randomized trial of misoprostol compared with manual vacuum\u000d\u000a      aspiration for incomplete abortion. Obstet Gynecol 2005;106:540-7\u000d\u000a      Citations: 40 Impact Factor: 4.798\u000d\u000a    \u000a\u000a2. Ewert K, Powers B, Robertson S, Alfirevic Z.\u000d\u000a      Controlled-release misoprostol vaginal insert in parous women for labor\u000d\u000a      induction: a randomized controlled trial. Obstet Gynecol\u000d\u000a      2006;108:1130.DOI: 10.1097\/01.AOG.0000239100.16166.5a Citations: 8 Impact\u000d\u000a      Factor: 4.798\u000d\u000a    \u000a\u000a3. Bricker L, Peden H, Tomlinson AJ, Al-Hussaini TK, Idama T, Candelier\u000d\u000a      C, Luckas M, Furniss H, Davies A, Kumar B, Roberts J, Alfirevic Z.\u000d\u000a      Titrated low-dose vaginal and\/or oral misoprostol to induce labour for\u000d\u000a      prelabour membrane rupture: a randomised trial. BJOG. 2008\u000d\u000a      Nov;115(12):1503-11. doi: 10.1111\/j.1471-0528.2008.01890.x Citations: 3\u000d\u000a      Impact Factor: 3.760\u000d\u000a    \u000a\u000a4. Elati A, Elmahaishi M, Elmahaishi M, Elsraiti O, Weeks A. The\u000d\u000a      effect of misoprostol on postpartum contractions: a randomised comparison\u000d\u000a      of three sublingual doses. BJOG 2011;118(4):466-73. doi:\u000d\u000a      10.1111\/j.1471-0528.2010.02821.x Citations: 3 Impact Factor: 3.760\u000d\u000a    \u000a\u000a5. Kundodyiwa T, Alfirevic Z and Weeks AD. Low Dose Oral\u000d\u000a      Misoprostol for Induction of Labor: A Systematic Review. Obstetrics and\u000d\u000a      Gynecology 2009;113(2):374-383.doi: 10.1097\/AOG.0b013e3181945859\u000d\u000a      Citations: 14 Impact Factor: 4.798\u000d\u000a    \u000a\u000a6. Elati A, Weeks AD. Risk of fever after Misoprostol for the\u000d\u000a      prevention of postpartum hemorrhage: a meta-analysis. Obstetrics and\u000d\u000a      Gynaecology 2012;120(5):1140-8. doi: 10.1097\/AOG.0b013e3182707341\u000d\u000a      Citations: 0 Impact Factor: 4.798\u000d\u000a    \u000a\u000a7. Weeks A and Faundes A. Misoprostol in obstetrics and gynecology. International\u000a        Journal of Gynecology and Obstetrics, 2007;99(2):S156-9. Doi: http:\/\/dx.doi.org\/10.1016\/j.ijgo.2007.09.003\u000d\u000a      Citations: 23 Impact Factor: 3.760\u000d\u000a    \u000a\u000a8. Hofmeyr GJ, G&#252;lmezoglu AM, Alfirevic Z. Misoprostol for induction of\u000d\u000a      labour: a systematic review. Br J Obstet Gynaecol. 1999\u000d\u000a      Aug;106(8):798-803. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10453829\u000d\u000a      Citations: 95 Impact Factor: 3.760\u000d\u000a    \u000aKey Research Grants\u000d\u000a    2011 - 2016. DFID\/MRC\/Wellcome Trust Joint Global Health Trial\u000d\u000a      Grant. Induction of labour in pre-eclamptic women: a randomised trial\u000d\u000a      comparing balloon catheter with oral misoprostol, &#163;699,651. PI AD\u000d\u000a        Weeks.\u000d\u000a    2010 - 2013. Gynuity Health Projects. MamaMiso: a pilot study of self-\u000d\u000a      administered misoprostol to prevent bleeding after childbirth. $ 238,986,\u000d\u000a      PI AD Weeks. UoL (funds supplied by Bill &amp; Melinda Gates\u000d\u000a      Foundation)\u000d\u000a    2013 - 2014. NIHR HTA. Which method is best for the induction of\u000d\u000a      labour: A network meta- analysis and cost effectiveness review, &#163;141,759,\u000d\u000a      PI Alfirevic Z.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"14","Subject":"Paediatrics and Reproductive Medicine"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    Each source listed below provides evidence for the corresponding numbered\u000d\u000a      claim made in section 4.\u000d\u000a    \u000d\u000a      \u000aProf Weeks's design of the A4 sticker was first published in a\u000d\u000a        review article (BJOG 2009;116(supp1):61) and subsequently used at the\u000d\u000a        FIGO congresses in 2009 and 2012. The latest version is downloadable\u000d\u000a        from the FIGO website (http:\/\/www.figo.org\/files\/figo-\u000a          corp\/Misoprostol_Recommended%20Dosages%202012.pdf\u000a\u000d\u000a      National Institute for Health and Clinical Excellence. Clinical\u000d\u000a        guideline no. 70: Induction of labour. London: National Institute for\u000d\u000a        Health and Clinical Excellence; 2008\u000d\u000a      World Health Organization. WHO recommendations for induction of\u000d\u000a        labour. Geneva: WHO Press; 2011\u000d\u000a      World Health Organization. WHO Recommendations for the prevention and\u000d\u000a        treatment of postpartum haemorrhage. Geneva: WHO Press; 2012\u000d\u000a      Blum J, Durocher J &amp; Abbas D (on behalf of Gynuity Health\u000d\u000a        Projects, NY). Proposal for the inclusion of misoprostol in the WHO\u000d\u000a        Model List of Essential Medicines (2010). Available at: http:\/\/www.who.int\/selection_medicines\/committees\/expert\/18\/applications\/Misoprostol_app\u000a          lication.pdf\u000a\u000d\u000a      Wannmacher L. Safety profile of misoprostol for obstetrical\u000d\u000a        indications. Commissioned report for the 18thWHO Expert\u000d\u000a        Committee on the Selection and use of Essential Medicines (March 2011).\u000d\u000a        Report available at: http:\/\/www.who.int\/selection_medicines\/committees\/expert\/18\/applications\/Misoprostol_saf\u000a          ety_review.pdf\u000a\u000d\u000a      Collier J, Longmore M, Turmezei T, Mafi A. Oxford Handbook of Clinical\u000d\u000a        Specialities (8th Edition). OUP Oxford, 2009, pp62. The\u000d\u000a        reference list can be accessed at http:\/\/www.oup.co.uk\/academic\/series\/oxhmed\/links\/ohcs8weblinks\/ch1\/\u000a\u000d\u000a      Royal College of Obstetricians and Gynaecologists. Green-Top Guideline\u000d\u000a        no 55. Late Intrauterine Fetal Death and Stillbirth. 2010. Available at\u000d\u000a        http:\/\/www.rcog.org.uk\/files\/rcog-\u000a          corp\/GTG 55 31072013.pdf\u000a\u000d\u000a    \u000d\u000a    Key individuals able to verify the information provided above:\u000d\u000a    Contact:, Karolinska Institutet, Stockholm, Sweden. Collaborator on the\u000d\u000a      Bellagio review panel and co-author of several published guidelines.\u000d\u000a    Contact: FIGO; and Department of Obstetrics &amp; Gynaecology, University\u000d\u000a      of British Columbia, Canada.\u000d\u000a    Contact: Department of Reproductive Health and Research, World Health\u000d\u000a      Organization, Geneva.\u000d\u000a    Contact: NICE Guideline Development Group for Induction of Labour,\u000d\u000a      Simpson Centre for Reproductive Health, University of Edinburgh, Scotland.\u000d\u000a    Contact: Royal College of Obstetricians and Gynaecologists; FIGO; and St\u000d\u000a      George's, University of London, UK. \u000d\u000a    ","Title":"\u000d\u000a    Making Pregnancy Safer in Low Resource Settings Through the Development\u000d\u000a      of Safe Misoprostol Use\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Misoprostol research has been undertaken in the UoL Department of Women's\u000d\u000a      and Children's Health since 1998. The Cochrane Pregnancy and Childbirth\u000d\u000a      Group is based in the department with Profs Neilson and Alfirevic as\u000d\u000a      co-ordinating editors. Prof Weeks joined the Department in 2003.\u000d\u000a    Misoprostol was originally developed for the prevention of stomach\u000d\u000a      ulcers, but is used world-wide in pregnancy off-label for miscarriage\u000d\u000a      management, labour induction and bleeding after childbirth. The\u000d\u000a      sensitivity of the uterus to misoprostol increases markedly through\u000d\u000a      pregnancy. In early pregnancy 800mcg is often needed, whilst in late\u000d\u000a      pregnancy the as little as 50 mcg may be too high dose. Thus the use of\u000d\u000a      the correct dose, route and frequency of administration is very important.\u000d\u000a      However, the lack of a mainstream licensed product for reproductive health\u000d\u000a      use and its wide availability on the black market mean that it is commonly\u000d\u000a      used at inappropriate or dangerous dosages (Deole &amp; Weeks, Int J\u000d\u000a        Gynecol Obstet 2010;109:71). The use of excessive doses has been\u000d\u000a      responsible for many maternal deaths from ruptured uterus in South Africa\u000d\u000a      (see 5th report into Confidential Enquiries in Maternal Deaths\u000d\u000a      in South Africa). A review in 2005 reported that in 1998 over 700,000\u000d\u000a      pregnancies were induced with misoprostol in the USA despite causing\u000d\u000a      uterine rupture, maternal and fetal deaths, and brain damage in newborn\u000d\u000a      infants.\u000d\u000a    For many indications, the appropriate dosage remained unknown. This\u000d\u000a      prompted the UoL to conduct randomised trials to find the optimal regimens\u000d\u000a      in terms of efficacy and safety for incomplete miscarriage (Uganda,\u000d\u000a      2001-5) [1] and three more to define the optimal dosage and route for\u000d\u000a      labour induction (multicentre 2003-6 [2] and 2006-8 [3], Libya\u000d\u000a      2009-11 [4]). These studies have clarified that low doses of oral and\u000d\u000a      vaginal misoprostol (20-25mcg) are not only effective for labour\u000d\u000a      induction, but reduce the rate of uterine over-contraction and fetal heart\u000d\u000a      rate abnormalities.\u000d\u000a    These trials feed into Cochrane reviews that address misoprostol use,\u000d\u000a      including those on oral misoprostol for induction of labour (Alfirevic\u000d\u000a      &amp; Weeks, 2006, under active revision in 2013), medical treatment for\u000d\u000a      early fetal death (Neilson et al, 2006) and medical treatments for\u000d\u000a      incomplete miscarriage (Neilson et al 2013). Other systematic reviews have\u000d\u000a      also been conducted by the UoL on misoprostol for the induction of labour\u000d\u000a      [5,8] and on the effect of dosage variation on misoprostol side effects\u000d\u000a      [6].\u000d\u000a    In 2007, Prof Weeks set up and chaired an international expert conference\u000d\u000a      to develop consensus guidelines on misoprostol dosages jointly funded by\u000d\u000a      the World Health Organisation and Rockefeller Foundation. Key\u000d\u000a      international researchers from 13 countries undertook data synthesis and\u000d\u000a      held a joint meeting to produce robust and high quality evidence. This\u000d\u000a      research and resulting policy papers drew heavily on primary research and\u000d\u000a      systematic reviews generated by Alfirevic, Nielson and Weeks. The\u000d\u000a      proceedings of the `Bellagio meeting' with dosage recommendations were\u000d\u000a      published with Prof Weeks as editor; Profs Alfirevic and Weeks were\u000d\u000a      authors on 5 of the 10 policy papers [7].\u000d\u000a    Current work includes randomised trial of self-administered oral\u000d\u000a      misoprostol versus placebo in rural Uganda (funded by Bill and Melinda\u000d\u000a      Gates Foundation \/ Gynuity Health Projects) and a randomised trial of oral\u000d\u000a      misoprostol versus Foley catheter for labour induction\u000d\u000a      (MRC\/DFID\/Wellcome).\u000d\u000a    "},{"CaseStudyId":"3869","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council","Royal Society"],"ImpactDetails":"\u000a    The SANAD Trial identified lamotrigine as first line treatment for\u000a      patients with focal epilepsy. This drug was demonstrated to be clinically\u000a      and cost effective to the NHS. SANAD also identified valproate as the most\u000a      effective treatment for patients with generalised epilepsy. A network\u000a      meta-analysis of similar antiepileptic drug trials provides the best\u000a      overview of currently available evidence. Prognostic modelling of these\u000a      data allow the identification of patients at differing risk of seizure\u000a      remission, allowing stratification for outcomes in patient consultations.\u000a    This work had the following impacts:\u000a    \u000a      SANAD triggered an update of the NICE epilepsy guideline which was\u000a        published in 2012 [7]. This provides impact on the health and wellbeing\u000a        of over 32,000 people per year who are newly diagnosed with epilepsy as\u000a        well as over half of the 600,000 prevalent population that are treated\u000a        with antiepileptic drug monotherapy.\u000a      Data from SANAD and the network meta-analysis underpins the 2012\u000a        guidance provided by NICE. Lamotrigine is recommended as a first line\u000a        treatment for focal epilepsy while gabapentin and topiramate are not.\u000a        Valproate is recommended as a first line treatment for generalised\u000a        epilepsy while topiramate is not. Identifying topiramate and gabapentin\u000a        as poor choices for monotherapy has resulted in significant savings for\u000a        the NHS.\u000a      SANAD underpins guidance in other countries (e.g. German epilepsy\u000a        guidelines [8], International League Against Epilepsy (ILAE guidelines)\u000a        [9].\u000a      SANAD allows better understanding of the impacts of taking\u000a        antiepileptic drugs, including: that there are few important differences\u000a        between drugs in quality of life outcomes; and that cognitive impairment\u000a        associated with epilepsy is more likely related to underlying pathology\u000a        than the drugs. This understanding will be important in devising future\u000a        intervention programmes.\u000a    \u000a    The MESS trial compared antiepileptic drug treatment versus no treatment\u000a      following a first seizure and for early epilepsy and identified a subgroup\u000a      of patients likely to benefit from treatment. Further prognostic modelling\u000a      identifies patients at risk of recurrence to inform driving policy.\u000a    This work had the following impacts:\u000a    \u000a      MESS data underpin NICE guidance (2012) for patients with first\u000a        seizures [7]. The guidance highlights the prognostic modelling to inform\u000a        risk stratification and decision making. This informs the management,\u000a        impacting on the health and wellbeing, of over 60,000 people who\u000a        experience a first unprovoked seizure per annum in the UK.\u000a      Prognostic modelling of data from MESS informed UK and EU driving\u000a        policy (2012) [9,10]. Regulations changed for patients with a first\u000a        seizure who are allowed to drive once 6 months seizure free rather than\u000a        12 months, unless in a high risk group. Designation of `high risk' was\u000a        informed by prognostic modelling of MESS.\u000a    \u000a    The aforementioned cohort studies assessing outcomes associated with in\u000a      utero exposure to antiepileptic drugs treatment inform treatment decisions\u000a      by providing reliable and valid information about the risks to the unborn\u000a      children. These studies have quantified risk to cognitive development\u000a      associated with a number of antiepileptic drugs and identify sodium\u000a      valproate as the drug with the greatest risk. Data allow better informed\u000a      decision making and have informed guidelines, and regulators.\u000a    This work has had the following impacts:\u000a    \u000a      Altered prescribing practices in the UK and US: There has been a\u000a        substantial reduction in the prescribing of valproate to women with\u000a        epilepsy of child bearing age and a subsequent increase in alternative\u000a        drugs including lamotrigine and levitaricatem [5,6,15].\u000a      The recommendations of the Federal Drugs Administration [13] \"The\u000a          U.S. Food and Drug Administration (FDA) is informing the public that\u000a          children born to mothers who take the anti-seizure medication\u000a          valproate sodium or related products (valproic acid and divalproex\u000a          sodium) during pregnancy have an increased risk of lower cognitive\u000a          test scores than children exposed to other anti-seizure medications\u000a          during pregnancy. This conclusion is based on the results of\u000a          epidemiologic studies that show that children born to mothers who took\u000a          valproate sodium or related products throughout their pregnancy tend\u000a          to score lower on cognitive tests (IQ and other tests) than children\u000a          born to mothers who took other anti-seizure medications during\u000a          pregnancy.\"\u000a      Updating of patient information leaflet for the drug Epilim (sodium\u000a        valproate), warning of the risks associated following feotal exposures\u000a        [15].\u000a      The publication of guidelines for preconceptual counselling for WWE\u000a        both in the UK and US [12,13,14].\u000a    \u000a    Beneficiaries of this work include\u000a    \u000a      People with new onset first seizures (60,000 per annum) and epilepsy\u000a        (32,000 per annum). The work has identified treatment options with the\u000a        best outcomes and has identified benefit harm trade-offs, leading to\u000a        better informed treatment choices and a focus on outcomes of importance\u000a        and relevance to them.\u000a      The NHS and other health systems caring for people with epilepsy,\u000a        through providing effective and cost effective care. Topiramate and\u000a        gabapentin were found to be both less effective and more costly and are\u000a        rarely used a monotherapy in epilepsy.\u000a      Guideline developers including NICE.\u000a      DVLA and similar EU bodies currently harmonising regulations across EU\u000a        member states.\u000a    \u000a    ","ImpactSummary":"\u000a    The epilepsy research group at the University of Liverpool (UoL) has\u000a      undertaken a programme of work assessing treatment outcomes associated\u000a      with antiepileptic drug treatment in patients with epilepsy. This includes\u000a      two large pragmatic trials in patients with first seizures and newly\u000a      diagnosed epilepsy, and cohort studies assessing malformations and\u000a      cognitive development in children exposed to antiepileptic drugs in utero,\u000a      and the work of the Cochrane Epilepsy Group.\u000a    This work has influenced prescribing in the UK and worldwide through the\u000a      following impacts:\u000a    \u000a      Triggered NICE guidelines update (2012), underpinning guidance on\u000a        management of first seizures, new epilepsy, women with epilepsy\u000a      Changes to drug labelling (SPC) for sodium valproate (2011)\u000a      Informed guidance in other countries (e.g. German guidelines,\u000a        International League Against Epilepsy Guidelines; US Medicine\u000a        guidelines)\u000a      Underpinned UK and EU policy on driving following first seizures and\u000a        antiepileptic drug withdrawal\u000a    \u000a    ","ImpactType":"Health","Institution":"\u000a    UNIVERSITY OF LIVERPOOL\u000a    ","Institutions":[{"AlternativeName":"Liverpool (University of)","InstitutionName":"University of Liverpool","PeerGroup":"A","Region":"North West","UKPRN":10006842}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Marson A, Jacoby A, Johnson A, Kim L, Gamble C,\u000a      and Chadwick D. Medical Research Council MESS Study Group.\u000a      Immediate versus deferred antiepileptic drug treatment for early epilepsy\u000a      and single seizures: a randomised controlled trial. Lancet 2005.\u000a      365(9476):2007-13 Citations: 155 Impact Factor: 39.060\u000a    \u000a\u000a2. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA,\u000a      et al. The SANAD study of effectiveness of carbamazepine, gabapentin,\u000a      lamotrigine, oxcarbazepine, or topiramate for treatment of partial\u000a      epilepsy: an unblinded randomised controlled trial. Lancet\u000a      2007;369:1000-1015. Citations: 266 Impact Factor: 39.060\u000a    \u000a\u000a3. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA,\u000a      et al. Valproate, lamotrigine or topiramate for generalized and\u000a      unclassifiable epilepsy: results from the SANAD trial. Lancet\u000a      2007;369:1016-1026. Citations: 285 Impact Factor: 39.060\u000a    \u000a\u000a4. Bonnet LJ, Tudur Smith C, Williamson PR, Marson\u000a        AG. Risk of recurrence after a first seizure and implications for\u000a      driving. Further analysis of the MESS study. BMJ 2010;341:c6477 Citations:\u000a      10 Impact Factor: 17.215\u000a    \u000a\u000a5. Meador K, Baker GA, et al. On behalf of the NEAD Study Group.\u000a      Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic\u000a      Drugs. New England Journal of Medicine (2009) 360 (16), 1597-1605\u000a      Citations: 258 Impact Factor: 51.658\u000a    \u000a\u000a6. Meador KJ, Baker GA, et al on behalf of the NEAD Study Group.\u000a      Fetal antiepileptic\u000a        drug exposure and cognitive outcomes at age 6 years (NEAD study): a\u000a        prospective observational study. Lancet Neurol. 2013\u000a      Mar;12(3):244-52. Citations: 13 Impact Factor: 23.917\u000a    \u000aKey Research Grants\u000a      1993-2002. MRC. Title, &#163;1.3m, PIs Chadwick , Jacoby,\u000a      Johnson\u000a    1998-2006. NIHR Health Technology Assessment Programme. Title,\u000a      &#163;1.3m, PIs Chadwick, Jacoby, Donaldson\u000a    2007-2013. NIHR Programme Grant. Title, &#163;515k, PIs Marson AG,\u000a      Jacoby A, Baker GA, Williamson PR, Tudur Smith\u000a        C\u000a    2003 to 2013. US NIH Grant. Neurodevelopmental study of children\u000a      exposed in utero &#163;708,187. PI Baker GA\u000a    2009 to 2012 Epilepsy Research Foundation Cognitive consequences\u000a      of in utero exposure to second generation antiepileptic drugs &#163;100,000.00\u000a      PI Baker GA\u000a    2009 to2013. Sanofi Sythelabo Educational Grant. Support for the\u000a      NEADS study: Antiepileptic Drugs exposure in utero &#163;166,501.00 PI Baker\u000a        GA\u000a    2011-2016. NIHR. Core support for the Cochrane Epilepsy Group.\u000a      &#163;500k. A Marson.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"9","Subject":"Neurosciences"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    Each source listed below provides evidence for the corresponding numbered\u000a      claim made in section 4 (details of the impact).\u000a\u0009  \u000a    NICE Guidelines. The diagnosis and management of the epilepsies in\u000a      adults and children in primary and secondary care. Clinical Guideline 137,\u000a      NICE 2012.\u000a      http:\/\/guidance.nice.org.uk\/CG137\u000a\u000a    German guidelines. Elger CE, Beyenburg S, Dengg D et al. Erster\u000a      epileptischer Anfall und Epilepsien im Erwachsenenalter. In: Diener HC,\u000a      Putzki N (eds) Leitlinien f&#252;r Diagnostik und Therapie im der Neurologie.\u000a      Stuttgart: Georg Thieme Verlag, 2008.\u000a    ILAE Guidelines http:\/\/www.ilae.org\/Visitors\/Documents\/Guidelines-epilepsia-12074-2013.pdf\u000a\u000a    DVLA decision to adopt EU recommendations for single seizures. DfT\u000a      advisory panel minutes and at a glance guidance: http:\/\/webarchive.nationalarchives.gov.uk\/20130411225420\/http:\/\/dft.gov.uk\/dvla\/medical\/medical_advisory_information\/medicaladvisory_meetings\/minutes\/~\/media\/pdf\/medical\/mins_\u000a        10032011%20Neuro.ashx\u000a\u000a    American Academy of Neurology and American Epilepsy Society\u000a      guidelines Management Issues for Women with Epilepsy Neurology 2009\u000a    Royal Society of Medicine Primary Care Guidelines [Managing epilepsy\u000a      in women: new guidelines 2004, 2011].\u000a    FDA alert June 2011, http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm261543.htm\u000a\u000a    Updating of patient information leaflet for the drug Epilim [Sodium\u000a      Valproate], warning of the risks associated following feotal exposures. http:\/\/www.medicines.org.uk\/emc\/medicine\/10913\/PIL\/Epilim+100mg+crushable+tablets\/\u000a\u000a    Ackers R, Besag FM, Wade A, Murray ML, Wong IC Changing\u000a        trends in antiepileptic drug prescribing\u000a        in girls of child-bearing potential. Arch Dis Child. 2009\u000a      Jun;94(6):443-7. \u000a\u0009  \u000a    ","Title":"\u000a    Treatment Outcomes in Epilepsy\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The underpinning research was undertaken at the UoL between 1993 and 2013\u000a      and informs treatment decisions, guidelines and policy for people with\u000a      epilepsy through randomized controlled trials, cohort studies, systematic\u000a      review, prognostic modelling and statistical method development. It\u000a      addresses the key clinical questions: when to start treatment and which is\u000a      the appropriate treatment. These questions require assessment of both\u000a      benefit and harm.\u000a    Key researchers from the UoL are Profs A Marson, G Baker, P Williamson, A\u000a      Jacoby, D Chadwick (retired) and Dr C Tudur-Smith. The MRC Multicentre\u000a      Study of Early Epilepsy and Single Seizures (MESS 1993-2000) recruited\u000a      1,400 patients and compared the policies of immediate and deferred\u000a      treatment for patients presenting with single seizures and early epilepsy.\u000a      This trial provides the best evidence worldwide to inform decisions about\u000a      when to start treatment. Results showed that early treatment reduced the\u000a      risk of a recurrence but had no effect on longer term seizure outcome or\u000a      quality of life; and ends the long-standing debate that `seizures beget\u000a      seizures' in early epilepsy. Predictive modelling of data identified\u000a      patients at low, medium and high risk of recurrence, informing risk\u000a      prediction and thus clinical decisions. Data have also been modelled to\u000a      underpin driving policy in the UK and EU following a process to harmonise\u000a      legislation across the EU. Models identified time points at which it is\u000a      appropriate to allow patients to return to driving and identified patients\u000a      at higher risk.\u000a    The NIHR Health Technology Assessment Programme funded study of Standard\u000a      and New Antiepileptic Drugs (SANAD 1998-2006) compared clinical, quality\u000a      of life and cost effectiveness outcomes for standard and new antiepileptic\u000a      drugs for patients with newly diagnosed epilepsy. This trial provides the\u000a      best evidence worldwide to inform decisions about which is the drug of\u000a      choice for particular patients. This trial identified lamotrigine, a new\u000a      drug, as a first line treatment for newly diagnosed focal epilepsy, being\u000a      as effective as the standard treatment, carbamazepine, but better\u000a      tolerated, and cost effective. For generalised epilepsy patients,\u000a      valproate, the standard treatment, was identified as the most effective\u000a      treatment. This poses a significant challenge for the management of a\u000a      particular patient subgroup, women of child bearing potential, for whom\u000a      there is growing evidence that valproate is associated with a higher\u000a      teratogenic risk.\u000a    This challenge is being addressed through the Liverpool group's\u000a      collaboration with colleagues in Manchester and the US in a series of\u000a      cohort studies assessing outcomes in children exposed to antiepileptic\u000a      drugs in utero. In their large prospective study the Liverpool Manchester\u000a      Neurodevelopment Group found a significant impact of sodium valproate\u000a      exposure on cognitive development, particularly verbal IQ, in children\u000a      assessed up to the age of 2 years. The NEAD study group (a UK\/US NIH\u000a      funded collaboration) found that in utero exposure to sodium valproate had\u000a      a significant and negative impact on the IQ of children when assessed at\u000a      age 3 and 6 years in comparison to children exposed to other antiepileptic\u000a      drugs (carbamazepine, lamotrigine, and phenytoin). Further, the UoL UK\u000a      study demonstrated significant risks associated with in utero exposure to\u000a      Sodium Valproate in comparison with control children across key areas of\u000a      neuropsychological functioning, as well as an association with autism.\u000a    The Cochrane Epilepsy Group has its editorial base in Liverpool (NIHR\u000a      funded, Marson Coordinating Editor, Tudur Smith Statistical Editor) has\u000a      produced over 60 systematic reviews, focussing on drug treatments and\u000a      other interventions for epilepsy. These reviews also underpin guidance\u000a      provided by NICE in their 2012 epilepsy guidelines.\u000a    "},{"CaseStudyId":"6239","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"2623032","Name":"Denmark"}],"Funders":["Wellcome Trust"],"ImpactDetails":"\u000d\u000a    Key impact: Incorporating prognostic information in clinical care for\u000d\u000a        back pain\u000d\u000a    The prognostic information identified by our research, particularly\u000d\u000a      information about the course of back pain and key predictors of poor\u000d\u000a      outcome, has been incorporated into Evidence Based Medicine resources: BMJ\u000d\u000a      Best Practice, e-Guidelines; UpToDate; and NICE Clinical Knowledge\u000d\u000a      Summaries in the UK [1] and internationally.[e.g. 2] Our novel approach to\u000d\u000a      bringing together key predictors of outcome in a brief prognostic\u000d\u000a      screening tool (STarTBack Tool) has been adopted by at least 85 clinical\u000d\u000a      services across the world to classify and inform patients regarding the\u000d\u000a      likely course of their symptoms.[e.g. 3,4] We have developed a website (www.keele.ac.uk\/sbst\/) including\u000d\u000a      free and open access to the tool, and information to encourage\u000d\u000a      implementation into clinical practice. The website has been accessed by\u000d\u000a      30,000 unique visitors since inception in 2009. Research groups in\u000d\u000a      Denmark, Sweden and the USA are collaborating with our team to test its\u000d\u000a      generalizability to other patient populations and healthcare settings,\u000d\u000a      and its use in children with back pain. Use of the tool to identify\u000d\u000a      high-risk patients has been recommended by key professional groups; the\u000d\u000a      Royal College of General Practitioners (RCGP Online MSK Module) [5];\u000d\u000a      Department of Health National Spinal Taskforce [6]; British Pain Society\u000d\u000a      (2013); and other national guidelines. \u000d\u000a    Key impact: Implementing psychosocial approaches in primary care for\u000d\u000a        back pain\u000d\u000a    We pioneered the application of psychosocial approaches to chronic pain\u000d\u000a      management, on the basis of our findings that psychosocial factors are\u000d\u000a      predictors and consequences of chronic pain. These approaches were\u000d\u000a      developed by specialist teams of psychologists and physiotherapists, and\u000d\u000a      applied more broadly to primary care. Our back pain trial (Hay et al.\u000d\u000a      2005) showed that our training and mentoring programme enable primary care\u000d\u000a      physiotherapists to successfully deliver psychologically informed\u000d\u000a      physiotherapy, encouraging patients to alter unhelpful attitudes and pain-\u000d\u000a      related fears, increasing activity, and supporting self-management and\u000d\u000a      return-to-work. By integrating these research findings into routine health\u000d\u000a      services, we have ensured more immediate improvements in the care provided\u000d\u000a      for back pain patients. Our staff have led and collaborated on the\u000d\u000a      development of back pain and chronic pain management (`IMPACT') services,\u000d\u000a      which continue to offer enhanced approaches to pain management. In 2013\u000d\u000a      the IMPACT service won the national Care Integration Award for pain\u000d\u000a      management. Since 2007 we have trained over 230 healthcare professionals\u000d\u000a      from the UK, Denmark, Australia, Germany, USA and Ireland to adopt and\u000d\u000a      deliver psychologically informed physiotherapy, and have developed a\u000d\u000a      cascade training model for wider dissemination. Healthcare services [e.g.\u000d\u000a      7] now incorporate such models of care. This pioneering work contributed\u000d\u000a      substantially to the Centre's receipt of the Queen's Anniversary Prize\u000d\u000a      (2009).\u000d\u000a    Key impact: Providing a novel cost-effective model of stratified care\u000d\u000a        for back pain\u000d\u000a    In a randomised trial and impact study, we combined our expertise in\u000d\u000a      prognostic stratification with matched interventions to produce a new\u000d\u000a      model of stratified care for back pain. This demonstrated improved patient\u000d\u000a      outcomes and reduced work loss compared to current best care, together\u000d\u000a      with cost savings for the NHS. Public and professional awareness of the\u000d\u000a      benefits of stratified care has been increased via radio and patient\u000d\u000a      magazines (BBC Health News Sept 2011, Arthritis Today October 2011) and\u000d\u000a      professional forums (Frontline CSP Sept 2011, RCGP Conference 2012, RCGP\u000d\u000a      on line training). We held workshops with leading UK musculoskeletal\u000d\u000a      clinicians in November 2009 and June 2012, plus a conference in April 2012\u000d\u000a      with &gt;120 delegates, including representatives from the Department of\u000d\u000a      Health, professional bodies and key charities, leading to adoption of the\u000d\u000a      StarTBack approach in at least 23 healthcare organisations. Change in\u000d\u000a      healthcare delivery and patient outcome has been achieved through our team\u000d\u000a      working with expert groups to revise the Department of Health's Any\u000d\u000a      Qualified Provider documentation (March 2012) and the Map of Medicine care\u000d\u000a      pathway for back pain (April 2012)[8], which provide evidence-based\u000d\u000a      guidance and clinical decision support at the point of care, and enable\u000d\u000a      commissioners to develop efficient and effective development of new\u000d\u000a      services. Through the Keele Primary Care Musculoskeletal Research\u000d\u000a      Consortium, considered a national exemplar model for academic- healthcare\u000d\u000a      collaboration, we have facilitated implementation of the stratified care\u000d\u000a      model within community physiotherapy services in Cheshire and\u000d\u000a      Staffordshire. It has been incorporated into commissioning plans for Vale\u000d\u000a      Royal, South Cheshire, North Staffordshire and Stoke Clinical\u000d\u000a      Commissioning Groups, as part of General Practice QP plans, service\u000d\u000a      providers QiPP initiatives and commissioning CQUIN targets [9], which\u000d\u000a      allows for the new approach to become sustainable and serve as good\u000d\u000a      practice model for the wider NHS. Multiple services in the UK have changed\u000d\u000a      their clinical pathways to implement stratified care [e.g. 4,7].\u000d\u000a      Internationally, prognostic stratification in patients with back pain has\u000d\u000a      been advocated on government websites, recommended in international\u000d\u000a      guidelines [e.g. 10], and several healthcare organisations are\u000d\u000a      adopting stratified care for back pain (e.g. Fairview Healthcare,\u000d\u000a      Minnesota and Intermountain Healthcare, Utah).\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Our research has produced a paradigm shift in the primary care management\u000d\u000a      for back pain, by expanding traditional diagnostic approaches to attending\u000d\u000a      to physical and psychosocial factors shown to influence future outcome\u000d\u000a      (`prognosis'). We have developed screening tools (freely available, widely\u000d\u000a      accessed, translated and adopted), to distinguish groups at low or high\u000d\u000a      risk of long-term disability, and developed primary care interventions\u000d\u000a      tailored to these groups. Through improved clinical outcomes and\u000d\u000a      cost-effectiveness, we have changed back care at national and\u000d\u000a      international levels, evidenced by inclusion in official guidelines, into\u000d\u000a      training of health professionals, adoption by spine and pain services, and\u000d\u000a      active engagement of health care commissioners, clinicians and educators.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    Keele University\u000d\u000a    ","Institutions":[{"AlternativeName":"Keele University","InstitutionName":"Keele University","PeerGroup":"B","Region":"West Midlands","UKPRN":10007767}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[Reference 1]. Croft PR, Macfarlane GJ, Papageorgiou AC, Thomas E, Silman\u000d\u000a      AJ. Outcome of low back pain in general practice: a prospective study. BMJ\u000d\u000a      1998;316(7141):1356-9. (604 citations Google Scholar)\u000d\u000a    \u000a\u000a[Reference 2]. Thomas E, Silman AJ, Croft PR, Papageorgiou AC, Jayson MI,\u000d\u000a      Macfarlane G. Predicting who develops chronic low back pain in primary\u000d\u000a      care: a prospective study. BMJ 1999;318(7199):1662-7. (428 citations\u000d\u000a      Google Scholar)\u000d\u000a    \u000a\u000a[Reference 3]. Dunn KM, Jordan K, Croft PR. Characterising the course of\u000d\u000a      low back pain: a latent class analysis. Am J Epidemiol\u000d\u000a      2006;163(8):754-61. (119 citations Google Scholar)\u000d\u000a    \u000a\u000a[Reference 4]. Hill JC, Dunn KM, Lewis M, Mullis R, Main CJ, Foster NE,\u000d\u000a      Hay EM. A primary care back pain screening tool: identifying patient\u000d\u000a      subgroups for initial treatment. Arthritis Rheum 2008;59(5):632-41.\u000d\u000a      DOI:10.1002\/art.23563 (117 citations Google Scholar)\u000d\u000a    \u000a\u000a[Reference 5]. Hay EM, Mullis R, Lewis M, Vohora K, Main CJ, Watson P,\u000d\u000a      Dziedzic KS, Sim J, Minns Lowe C, Croft PR. Comparison of physical\u000d\u000a      treatment versus a brief pain management programme for back pain in\u000d\u000a      primary care: a randomised clinical trial in physiotherapy practice.\u000d\u000a      Lancet 2005;365(9476):2023-30. (129 citations Google Scholar)\u000d\u000a    \u000a\u000a[Reference 6]. Hill JC, Whitehurst DG, Lewis M, Bryan S, Dunn KM, Foster\u000d\u000a      NE, Konstantinou K, Main CJ, Mason E, Somerville S, Sowden G, Vohora K,\u000d\u000a      Hay EM. Comparison\u000d\u000a        of stratified primary care management for low back pain with current\u000d\u000a        best practice (STarT Back): a randomised controlled trial. Lancet\u000d\u000a      2011;378(9802):1560-71. DOI: 10.1016\/S0140-6736(11)60937-9. (110 citations\u000d\u000a      Google Scholar)\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    [Source 1]: National Institute for Health and Clinical Excellence (NICE)\u000d\u000a      Clinical Knowledge Summaries (CKS). Back Pain &#8212; low (without\u000d\u000a      radiculopathy). November 2009. http:\/\/cks.nice.org.uk\/back-pain-low-without-radiculopathy\u000d\u000a      (Last accessed 17-Oct-13)\u000d\u000a    [Source 2]: Therapeutic Guidelines: Rheumatology (revised October 2010,\u000d\u000a      Key References &#8212; non-specific low back pain). In: eTG complete [Internet].\u000d\u000a      Melbourne: Therapeutic Guidelines Limited (Last accessed 17-Oct-13) http:\/\/www.tg.org.au\/etg_demo\/desktop\/tgc\/rhg\/rheumatology,_version_2.htm\u000d\u000a    [Source 3]: STarTBack Tool implemented in Region of Southern Denmark\u000d\u000a      (STarT skema in Danish): since June 2012. Available at http:\/\/www.regionsyddanmark.dk\/wm370018\u000d\u000a      (Last accessed 17-Oct-13)\u000d\u000a    [Source 4]: Sheffield back pain services: http:\/\/www.sheffieldbackpain.com\/professional-resources\/resources\/keele-start.\u000d\u000a      (Last accessed 17-Oct-13)\u000d\u000a    [Source 5]: Royal College of General Practitioners (RCGP) Musculoskeletal\u000d\u000a      online module and 2012 Curriculum for Care of People with for\u000d\u000a      Musculoskeletal Problems, page 8 (http:\/\/www.rcgp.org.uk\/gp-training-and-exams\/gp-curriculum-overview.aspx)\u000d\u000a      (Last accessed 17-Oct-13)\u000d\u000a    [Source 6]: National Spinal Taskforce January 2013: Commissioning Spinal\u000d\u000a      Services: Getting the service back on track: a guide for commissioners of\u000d\u000a      spinal services (page 15, 16). Available at http:\/\/www.nationalspinaltaskforce.co.uk\/\u000d\u000a      (Last accessed 17-Oct-13)\u000d\u000a    [Source 7]: Back Rehabilitation Programme in Department of Physiotherapy,\u000d\u000a      Ipswich Hospital. Available at http:\/\/www2.ipswichhospital.net\/microsites\/physiotherapy\/gp_backrehab.asp\u000d\u000a      (Last accessed 17-Oct-13)\u000d\u000a    [Source 8]: Map of Medicine: Low back and radicular pain: a pathway for\u000d\u000a      care developed by the British Pain Society. Lee J, Gupta S, Price C,\u000d\u000a      Baranowski AP. Br J Anaesthesia 2013; 111: 112-120. http:\/\/healthguides.mapofmedicine.com\/choices\/map\/low_back_and_radicular_pain1.ht\u000a        ml (Last accessed 17-Oct-13)\u000d\u000a    [Source 9]: CQUIN and AHP Musculoskeletal Care Toolkit, March 2012.\u000d\u000a      Quality and Productivity (QP) indicator by the North Staffordshire CCG,\u000d\u000a      used in 36 practices covering a population of 220,000. Available at http:\/\/www.networks.nhs.uk\/nhs-networks\/ahp-networks\/ahp-qipp-toolkits\u000d\u000a      (Last accessed 17-Oct-13)\u000d\u000a    [Source 10]:Goertz M, Thorson D, Bonsell J, Bonte B, Campbell R, Haake B,\u000d\u000a      Johnson K, Kramer C, Mueller B, Peterson S, Setterlund L, Timming R. Adult\u000d\u000a      acute and subacute low back pain. Bloomington (MN): Institute for Clinical\u000d\u000a      Systems Improvement (ICSI); Nov 2012. https:\/\/www.icsi.org\/_asset\/bjvqrj\/LBP.pdf\u000d\u000a      (page 25-26 and Appendix E) (Last accessed 17-Oct-13) \u000d\u000a    ","Title":"\u000d\u000a    Optimising clinical outcomes and cost-effectiveness of primary care\u000d\u000a        for patients with back pain\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2636841","Name":"Stoke-on-Trent"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The Global Burden of Disease Project highlighted back pain as the leading\u000d\u000a      cause of years lived with disability. This is strong justification for the\u000d\u000a      focus of our research on the impact, long-term outcomes, and optimal\u000d\u000a      management of back pain, strongly supported by patient and public\u000d\u000a      involvement from our dedicated Research User Group. This research has\u000d\u000a      generated over 190 peer-reviewed publications since 1994. Based on large\u000d\u000a      primary care-based cohort studies funded by Arthritis Research UK,\u000d\u000a      Wellcome Trust and National Institute of Health Research (NIHR), we have\u000d\u000a      improved current understanding of the impact and prognosis of back pain.\u000d\u000a      The research outputs overturned the commonly held belief that back pain\u000d\u000a      patients have a good prognosis and highlighted the multidimensional\u000d\u000a      consequences of pain. Croft (Keele University, Professor of Primary Care\u000d\u000a      Epidemiology, 1995-present) conducted one of the first population-based\u000d\u000a      studies of back pain using linked medical record data, and demonstrated\u000d\u000a      that 75% of patients still experience pain and disability one year after\u000d\u000a      consultation in primary care, with psychological and social factors\u000d\u000a      predicting poor long-term outcome (references 1,2). Using novel\u000d\u000a      statistical approaches to analysing longitudinal data, Dunn (Wellcome\u000d\u000a      Trust Reader in Epidemiology, Keele University, 2008-2014) identified\u000d\u000a      distinct back pain trajectories characterised by increasing psychosocial\u000d\u000a      consequences and risk of poor long-term outcome (reference 3). These\u000d\u000a      insights instigated a shift in the classification of back pain from a\u000d\u000a      focus on current pain duration and diagnosis to a prognostic definition\u000d\u000a      based on assessment of key physical and psychosocial factors to estimate\u000d\u000a      risk of poor outcome, and initiated the development and validation of a\u000d\u000a      brief screening tool for use in clinical practice (STarTBack Tool,\u000d\u000a      reference 4). This research has been pivotal in the development of new\u000d\u000a      approaches to the management of back pain.\u000d\u000a    In a National Lottery funded randomised trial Hay (Professor in Community\u000d\u000a      Rheumatology, Keele University, 1994-present) demonstrated that\u000d\u000a      appropriately trained physiotherapists can adopt and incorporate\u000d\u000a      psychosocial approaches in the management of back pain, and that such a\u000d\u000a      pain management approach can be delivered in fewer sessions and with equal\u000d\u000a      effectiveness compared to a standard package of physiotherapy (reference\u000d\u000a      5). Key findings from this trial and our prognostic studies underpinned a\u000d\u000a      new programme of research funded by Arthritis Research UK, the Health\u000d\u000a      Foundation and the NIHR, developing and testing a model of stratified care\u000d\u000a      based on patients' prognosis. In this model, patients at low risk of poor\u000d\u000a      outcome are supported to self- manage, while those at medium and high risk\u000d\u000a      access treatment that target their key physical and psychosocial obstacles\u000d\u000a      to recovery. We provided robust evidence that stratified care is superior\u000d\u000a      to best current care in a large randomised trial (STarTBack trial,\u000d\u000a      reference 6) where subgrouping using the STarTBack screening tool and\u000d\u000a      matched treatments improved patients' clinical and work outcomes with\u000d\u000a      clear cost-savings for the NHS and society. A subsequent impact study\u000d\u000a      (Foster, NIHR Professor of Musculoskeletal Health in Primary Care, Keele\u000d\u000a      University, 2012-17) confirmed that stratified care can be implemented in\u000d\u000a      primary care, leading to improvements in patient outcomes including\u000d\u000a      disability and days lost from work at similar healthcare costs.\u000d\u000a    "},{"CaseStudyId":"6284","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d    Key insight: Osteoarthritis as a clinical syndrome of persistent joint\u000d        pain and disability\u000d    Our epidemiologic estimates of joint pain, osteoarthritis, and severity of\u000d    disability have informed central government and directed the\u000d      commissioning of clinical services for osteoarthritis across England\u000d    by underpinning the costing reports and templates produced by NICE and\u000d    rolled out nationally [1]. In specially commissioned work that Jordan, Peat\u000d    &amp; Croft undertook for the Policy &amp; Public Affairs Unit of Arthritis\u000d    Research UK in 2012-2013 presented in the report \"Osteoarthritis in General\u000d    Practice\" to Parliament in June 2013, cited in national health economic\u000d    reports, and in national press releases in July 2013, we have provided\u000d    information for policy-makers and third- sector organisations that has\u000d    helped advance the policy debate on health priorities for the nation\u000d    and the NHS, specifically towards greater recognition of the disability\u000d    attributed to musculoskeletal disorders and osteoarthritis in particular\u000d    [2].\u000d    Our research has also directly influenced health professional\u000d        guidelines and training on clinical assessment, diagnosis and prognosis.\u000d      Members of our research team sat on national (NICE - Dziedzic, 2008; NICE\u000d      Update - Dziedzic, Porcheret 2013) and European (EULAR Hand - Dziedzic,\u000d      2009; EULAR Knee - Peat, 2010) guideline development groups where, in\u000d      addition to our epidemiologic estimates, our research on clinical\u000d      diagnosis and assessment underpinned recommendations for clinical (as\u000d      opposed to x-ray) diagnosis of osteoarthritis in routine practice [3].\u000d      Dissemination of this core message for practitioners has been actively\u000d      pursued by us through advising on the national Map of Medicine (Peat [4])\u000d      and NHS Patient Decision Aids (Wood, Myers) with these in turn forming the\u000d      basis for national knowledge summaries used by clinicians at the point of\u000d      care [5] as well as featuring in NHS Evidence and Osteoarthritis Research\u000d      Society International's OA Primer - an online educational resource for\u000d      practitioners and patients worldwide.\u000d    Key insight: High-risk occupations and causal exposures\u000d      The research on physical occupational exposures associated with knee\u000d      osteoarthritis was frequently cited and highly influential in the\u000d      Industrial Injuries Advisory Council's (IIAC) 2008 report on\u000d      osteoarthritis of the knee in miners [6] and in helping advance the\u000d        national policy debate to consider other similarly affected\u000d      occupational groups, notably carpet fitters and carpet and floor layers -\u000d      the subject of a later IIAC report in 2010. Both IIAC reports were\u000d      presented to Parliament by the Secretary of State for Work and Pensions\u000d      and resulted in a change in legislation with Parliament approving\u000d      the addition of osteoarthritis of the knee in these occupational groups to\u000d      the prescribed list of industrial injuries (PDA14) with effect from 13\u000d      July 2009 [7] and 30 March 2012 respectively, resulting in benefits to\u000d        health and welfare for over 16,000 coalminers who were successfully\u000d      awarded claims [8].\u000d    Key insight: central importance of self-management and active\u000d          nonpharmacological management and the effective contribution of allied\u000d          health professionals to delivering these in primary care\u000d      Our research on the effectiveness of high-quality advice and supervised\u000d      exercise programmes for osteoarthritis and our commitment to seeing the\u000d      implementation of these in routine primary care contributed to exercise\u000d      becoming a core treatment recommended in successive NICE [3] and European\u000d      guidelines for all persons with osteoarthritis and directly challenging\u000d      both the belief that exercise is bad for joints with osteoarthritis by\u000d      accelerating `wear and tear' and the idea that `nothing can be done'.\u000d      Members of our research team sat on these guideline development groups\u000d      (Dziedzic, Porcheret, Mallen).\u000d    Our impact has extended beyond influencing health professional\u000d        guidelines to training health professionals to support the\u000d      implementation of these evidence-based changes to care. Working with\u000d      Arthritis Research UK and the Royal College of General Practitioners,\u000d      Porcheret (GP research fellow and RCGP Clinical Champion for\u000d      Osteoarthritis 2008-2011) and co-workers at Keele developed\u000d    (i) a new e-learning module on osteoarthritis for primary care health\u000d      professionals [9] that to date has been completed by 606 individuals since\u000d      its launch in February 2013\u000d    (ii) a series of all-day workshops run across UK sites training 230 GPs\u000d      to date, and\u000d    (iii) a series of health care professional leaflets and topical evidence\u000d      digests [circulated to &gt;44,000 GPs] [10].\u000d    Regionally, our clinical researchers have provided practical,\u000d      face-to-face training for 44 GPs, 141 physiotherapists, 12 occupational\u000d      therapists, and 17 practice nurses from across the West Midlands and\u000d      Cheshire on the practical delivery of best evidence treatment for\u000d      osteoarthritis as part of our osteoarthritis studies, organised and run\u000d      `Sharing Best Practice' days, hosted a series of clinical appraisal topic\u000d      sessions with local health professionals, and shaping local clinical\u000d      algorithms and patient pathways. Our Osteoarthritis Guidebook, developed\u000d      and co-authored with members of the public together with health\u000d      professionals and researchers at our Centre, has been made available\u000d      through our institutional website and that of Arthritis Research UK. In a\u000d      set of local general practices it has been provided to over 500 people\u000d      consulting with osteoarthritis.\u000d    ","ImpactSummary":"\u000d    Osteoarthritis affects 8.5 million people in the United Kingdom,\u000d      accounting for a third of all years lived with disability. Our research\u000d      has provided commissioners and third-sector organisations with accurate\u000d      estimates of the size of the problem, policy-makers with evidence on\u000d      groups at particularly high-risk, and clinicians with original evidence on\u000d      better approaches to assessing and managing osteoarthritis in patients\u000d      presenting to primary care. These key insights have supported advances in\u000d      public health and health care policy debate, changes in legislation, and\u000d      improvements in the quality of patient care through training and new\u000d      national, European, and global guidelines for health professionals.\u000d    ","ImpactType":"Political","Institution":"\u000d    Keele University\u000d    ","Institutions":[{"AlternativeName":"Keele University","InstitutionName":"Keele University","PeerGroup":"B","Region":"West Midlands","UKPRN":10007767}],"Panel":"A         ","PlaceName":[],"References":"\u000d    \u000a1. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older\u000d      adults: a review of community burden and current use of primary health\u000d      care. Annals of the Rheumatic Diseases 2001;60(2): 91-7. DOI:\u000d      10.1136\/ard.60.2.91\u000d    \u000a\u000a2. Coggon D, Croft P, Kellingray S, Barrett D, McLaren M, Cooper C.\u000d      Occupational physical activities and osteoarthritis of the knee. Arthritis\u000a        Rheum. 2000;43(7):1443-9. DOI:\u000d      10.1002\/1529-0131(200007)43:7&lt;1443::AID-ANR5&gt;3.0.CO;2-1\u000d    \u000a\u000a3. Mallen CD, Thomas E, Belcher J, Rathod T, Croft P, Peat G.\u000d      Point-of-Care Prognosis for Common Musculoskeletal Pain in Older Adults. JAMA\u000a        Internal Medicine. 2013;173(112):1119- 25. DOI:\u000d      10.1001\/jamainternmed.2013.962\u000d    \u000a\u000a4. Hay EM, Foster NE, Thomas E, Peat G, Phelan M, Yates HE, Blenkinsopp\u000d      A, Sim J. Effectiveness of community physiotherapy and enhanced pharmacy\u000d      review for knee pain in people aged over 55 presenting to primary care:\u000d      pragmatic randomised trial. BMJ 2006;333:995. DOI:\u000d      10.1136\/bmj.38977.590752.0B\u000d    \u000a\u000a5. Foster NE, Thomas E, Barlas P, Hill JC, Young J, Mason E, et al.\u000d      Acupuncture as an adjunct to exercise based physiotherapy for\u000d      osteoarthritis of the knee: randomised controlled trial. BMJ 2007;\u000d      335(7617):436-48. DOI: 10.1136\/bmj.39280.509803.BE\u000d    \u000a\u000a6. Dziedzic K, Nicholls E, Hill S, Hammond A, Handy J, Thomas E, Hay E.\u000d      Self-management approaches for osteoarthritis in the hand: a 2x2 factorial\u000d      randomized trial. Annals of the Rheumatic Diseases 2013; DOI:\u000d      10.1136\/annrheumdis-2013-203938\u000d    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d    \u000d      National Institute for Health and Clinical Excellence. Osteoarthritis.\u000d        Costing report. Implementing NICE guidance. February 2008. Available at:\u000d        http:\/\/www.nice.org.uk\/nicemedia\/live\/11926\/39712\/39712.pdf.\u000d        Last accessed: 4 October 2013.\u000d      Medical Director. Tel: 0300 790 0400. Arthritis Research UK. Copeman\u000d        House, St Mary's Gate, Chesterfield, Derbyshire S41 7TD, UK.\u000d      National Collaborating Centre for Chronic Conditions. (2008).\u000d        Osteoarthritis: national clinical guideline for care and management in\u000d        adults [NICE guideline CG59]. London: Royal College of Physicians.\u000d        Available at: http:\/\/guidance.nice.org.uk\/CG59.\u000d        Last accessed: 4 October 2013.\u000d      Map of Medicine - Osteoarthritis suspected. Available at: http:\/\/healthguides.mapofmedicine.com\/choices\/map\/osteoarthritis1.html\u000d        Last accessed: 4 October 2013. http:\/\/healthguides.mapofmedicine.com\/choices\/map\/osteoarthritis2.html\u000d        Last accessed: 4 October 2013.\u000d      Clinical Knowledge Summaries - Osteoarthritis. Available at: http:\/\/cks.nice.org.uk\/osteoarthritis#!references\u000d        Last accessed: 4 October 2013.\u000d      Industrial Injuries Advisory Council. Osteoarthritis of the knee in\u000d        coal miners. Report by the Industrial Injuries Advisory Council in\u000d        accordance with Section 171 of the Social Security Administration Act\u000d        1992 considering prescription for osteoarthritis of the knee in coal\u000d        miners. Aug 2008. Available at: http:\/\/iiac.independent.gov.uk\/pdf\/command_papers\/Cm7440.pdf\u000d        Last accessed: 4 October 2013.\u000d      The Social Security (Industrial Injuries) (Prescribed Diseases)\u000d        Amendment Regulations 2009. Available at: http:\/\/www.legislation.gov.uk\/uksi\/2009\/1396\/contents\/made\u000d        Last accessed: 4 October 2013.\u000d      Hansard Written Answers (17 January 2012, Column 648W). Available at:\u000d        http:\/\/www.publications.parliament.uk\/pa\/cm201212\/cmhansrd\/cm120117\/text\/120117w0001.h\u000d        tm\u000d        Last accessed: 4 October 2013.\u000d      Royal College of General Practitioners, Arthritis Research UK, and\u000d        Arthritis Research UK Primary Care Centre. E-Learning course on\u000d        Musculoskeletal Care, February 2013. Available at: http:\/\/elearning.rcgp.org.uk\/course\/view.php?id=118\u000a\u000d      Porcheret M, Healey E, Dziedzic K, Corp N, Howells N, Birrell F.\u000d        Osteoarthritis: a modern approach to diagnosis and management. Hands On\u000d        Series 6, Issue 10, Autumn 2011. Available at: http:\/\/www.arthritisresearchuk.org\/health-professionals-and-\u000d        students\/reports\/hands-on\/hands-on-autumn-2011.aspx\u000a\u000d    \u000d    ","Title":"\u000d    Improving health outcomes and primary care services for osteoarthritis in\u000d      primary care\u000d    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d    The key insights from our Centre's research have led a shift in the\u000d      concept of osteoarthritis from a structural disease characterised by\u000d      changes on an x-ray to a clinical syndrome of persistent joint pain and\u000d      disability, and provided rigorous evidence on the effective contributions\u000d      of a range of active nonpharmacological treatments.\u000d    Specifically, our multidisciplinary team has combined quantitative and\u000d      qualitative methods with public involvement in our studies to:\u000d    (i) Describe the nature and scale of the problem in the population\u000d        and how it is currently managed in primary care. We have combined\u000d      evidence synthesis, analysis of routine recording in a network of general\u000d      practices (registered population=100,000) with new population surveys of\u000d      35,959 residents of North Staffordshire, to provide accurate, national\u000d      estimates of the burden of painful osteoarthritis and associated\u000d      disability [1]. [Programme Grants from the Medical Research Council\u000d      (Croft) and Arthritis Research UK (Peat); 2000-2012].\u000d    (ii) Identify possible contributing causes. Our studies have\u000d      focused on lifestyle factors. Between 1993 and 2001, Croft (Professor of\u000d      Primary Care Epidemiology, Keele University, 1995-) and collaborators in\u000d      Southampton University discovered several high-risk occupations (farming,\u000d      mining, carpet-fitting) and demonstrated that prolonged kneeling and\u000d      squatting were specific, potentially modifiable exposures associated with\u000d      developing knee osteoarthritis [2].\u000d    (iii) Develop and test new methods for improving patient assessment\u000d        in primary care. Pain and its effects on individuals with\u000d      osteoarthritis are often under-recognised in general practice. Our\u000d      clinical studies, using intensive clinical and imaging assessments in over\u000d      2000 adults with joint pain, developed and validated new and practical\u000d      tools to support assessment in primary care. We recently demonstrated that\u000d      3 simple questions asked by the GP during the consultation can improve\u000d      their judgement of whose symptoms are unlikely to respond to routine care\u000d      [3] [402 patients, 5 GP practices, ARUK Primary Care Fellowship,\u000d      2004-2008: Mallen].\u000d    (iv) Evaluate and implement new interventions aimed at more effective\u000d        primary care management.\u000d      Care was traditionally focussed on what the general practitioner and the\u000d      orthopaedic surgeon could offer. Our TOPIK trial [325 patients, 15 GP\u000d      practices, 2001-2004; ARUK project grant: Hay] was undertaken in response\u000d      to gaps in evidence identified by local clinicians. Short-term\u000d      improvements in health outcomes, reduced use of anti-inflammatory drugs,\u000d      and high patient satisfaction were achieved by giving patients with knee\u000d      osteoarthritis greater access to community physiotherapy (individualised\u000d      exercise programme; advice on activity and pacing), and pharmacists\u000d      (face-to-face medication review and advice) [4]. In separate trials we\u000d      have confirmed the benefits of advice and exercise for knee\u000d      osteoarthritis, that acupuncture yields no additional benefit [5] [352\u000d      patients, 37 NHS physiotherapy centres, 2003-2005; ARUK project grant:\u000d      Hay], and that for hand osteoarthritis joint protection education offered\u000d      by occupational therapists is beneficial [6] [257 patients, 5 general\u000d      practices, 2008-2009; ARUK project grant: Dziedzic].\u000d    We are now combining qualitative interviews and observations with\u000d      practitioners and patients with large-scale trials to evaluate approaches\u000d      to enhance adherence to exercise [526 patients, 55 NHS physiotherapists],\u000d      and implement NICE recommended management into everyday routine primary\u000d      care [525 patients, 8 GP practices] [2008-2013; NIHR Programme Grant for\u000d      Applied Research: Hay].\u000d    "},{"CaseStudyId":"6304","Continent":[{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"6251999","Name":"Canada"}],"Funders":[],"ImpactDetails":"\u000a    It has been estimated that globally there are almost as many mobile phone\u000a      subscriptions as there are people. Rigorous, high quality, independent\u000a      research is vital for governments and agencies responsible for\u000a      safeguarding public health against a background of increasing concern over\u000a      potential harms.\u000a    Impacts on health and welfare and public policy and services\u000a     \u000a    International policy\u000a    The International Agency for Research on Cancer (IARC) produces\u000a      monographs on environmental factors and the risk of human cancer providing\u000a      scientific support for action taken by national health agencies tasked\u000a      with preventing exposure to potential carcinogens. The long-awaited\u000a      monograph evaluating the carcinogenicity of mobile phone exposure was\u000a      delayed more than two years to ensure the inclusion of evidence from\u000a      Interphone [A].\u000a    Primary evidence from Interphone showed that overall, mobile phone users\u000a      had no increased risk of brain tumours (although in a single small\u000a      subgroup of those with the highest cumulative call time, a raised glioma\u000a      risk was seen). No trend in increasing risk was observed for cumulative\u000a      call time or for increasing numbers of calls or years of mobile use. The\u000a      World Health Organization (WHO) website [B] notes `Based largely\u000a        on these [Interphone] data, IARC has classified radiofrequency\u000a        electromagnetic fields as possibly carcinogenic to humans (Group 2B)',\u000a      a low risk category which also includes coffee consumption. It also cites\u000a      Interphone (the only individual study discussed) as `the largest\u000a        retrospective case-control study to date ... showing no increased risk\u000a        of glioma or meningioma with mobile phone use of more than 10 years'.\u000a    The International Commission on Non-Ionizing Radiation Protection\u000a      (ICNIRP) is an independent international body that publishes Exposure\u000a        Guidelines for Non-Ionising Radiation, endorsed by the WHO, and\u000a      which includes radiofrequency fields from mobile phones. These guidelines\u000a      are on the radiation protection agenda of virtually every country\u000a      worldwide. They have been formally adopted as national standards in over\u000a      50 countries including Australia, Canada, many countries in Europe, Latin\u000a      America and SE Asia, and form the basis of the US and Japanese guidelines.\u000a      In 2010\/11, ICNIRP published specifically on Interphone [C],\u000a      commenting on its large size and noting that `Interphone added greatly\u000a        to the volume of evidence available' and that the outcomes include\u000a      an important contribution to the evidence base for the ongoing review of\u000a      international exposure guidelines.\u000a    The ICNIRP Standing Committee on Epidemiology states `the accumulating\u000a        evidence is increasingly against the hypothesis that mobile phones cause\u000a        brain tumours in adults'. It adds, \"importantly, Interphone has\u000a        provided valuable methodological insights aiding the interpretation of\u000a        epidemiological research into mobile phones and health\" [D].\u000a    UK Government policy\u000a    The Health Protection Agency (HPA), now part of Public Health England,\u000a      has a statutory responsibility to advise the Department of Health on\u000a      health effects related to mobile phones and has adopted the ICNIRP\u000a      standards on radiation protection exposure for mobile phones. In their\u000a      public health advice, the HPA quote their independent Advisory Group on\u000a      Non-Ionising Radiation (AGNIR) which states: `T he INTERPHONE\u000a        study ... has contributed importantly to our understanding of possible\u000a        health risks from use of mobile phones' [E]. A dedicated web\u000a      section on Interphone on the HPA website has seen approximate 200 visitors\u000a      a month since April 2010 (E). A major HPA report on radiofrequency\u000a      electromagnetic fields published in 2012 addresses Interphone in detail\u000a      and concludes there is no convincing evidence that mobile phone\u000a      technologies cause adverse effects on human health [F].\u000a    Public debate and awareness\u000a    A measure of the significance of the impact of both the UK and the\u000a      Interphone studies for the general public was the management of media\u000a      dissemination by the Science Media Centre, London [G], an\u000a      organisation that independently promotes the voices and views of the\u000a      scientific community to the news media. McKinney gave press and TV (BBC,\u000a      ITV, Sky News) briefings (e.g. Mobile phones 'unlikely' to cause\u000a        cancer, BBC News), and we are aware of over 75 news articles,\u000a      including articles in all the UK national broadsheets (e.g. Mobile\u000a        phone study finds no solid link to brain tumours, The Guardian) and\u000a      across the international press (including the New York Times and Reuters)\u000a      that reported on Interphone.\u000a    Impact on commerce\u000a    Reassurance for industry\u000a    Interphone has enabled governments in over 50 countries worldwide to\u000a      adopt scientifically validated exposure guidelines that have allowed\u000a      continued expansion of the mobile phone industry, leading to major\u000a      economic benefits. Without Interphone results, as one UK AGNIR committee\u000a      member points out: `There would have been pressures to restrict\u000a        exposures to the radiofrequency radiation from mobile phones on a\u000a        precautionary basis' [H]. He added that Interphone\u000a      results have `helped to allay public anxieties about mobile phone\u000a        technology' potentially increasing their commercial value.\u000a    The mobile phone industry is forecast to have a global market value of\u000a      $334.8 billion in 2015. Mobile phone network operators and manufacturers\u000a      both in the UK and worldwide have committed over $13.4 billion since 2000\u000a      towards investigating health impacts of mobile phone usage. Funding to the\u000a      University of Leeds and Interphone was `firewalled' to ensure the\u000a      independence of the academic researchers but the results were\u000a      unsurprisingly welcomed by the industry [I]. The UK Mobile\u000a      Operators Association, a consortium of all UK network operators, stated\u000a      that `Interphone is likely to be recognised as an important part of the\u000a        wider scientific evidence' underpinning the WHO policy advice on RF\u000a      Environmental Health Criteria [J].\u000a    ","ImpactSummary":"\u000a    More than 6.5 billion people worldwide use mobile phones, and\u000a      identification of any associated health risks is of vital importance to\u000a      global public health. Researchers at Leeds have had a central role in the\u000a      design, scientific direction, conduct, and dissemination of Interphone,\u000a      the largest and most comprehensive case-control study of mobile phone use,\u000a      which showed that mobile phone use is not associated with an increased\u000a      risk of brain tumours. Interphone, for which Leeds was the largest study\u000a      centre from 13 countries, along with a concurrently run UK North study,\u000a      has made a major contribution to government policy recommendations,\u000a      international exposure guidelines for non-ionising radiation, and\u000a      international assessment of carcinogenicity.\u000a    ","ImpactType":"Political","Institution":"\u000a    University of Leeds\u000a    ","Institutions":[{"AlternativeName":"Leeds (University of)","InstitutionName":"University of Leeds","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007795}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Cardis E, et al (including McKinney PA and Hepworth SJ). The\u000a      INTERPHONE Study: Design, Epidemiological Methods, and Description of the\u000a      Study Population. Eur J Epid 2007; 22: 647- 664. DOI:\u000a      10.1007\/s10654-007-9152-z. McKinney and Hepworth worked at IARC on this\u000a      publication; McKinney made a substantial contribution to the concept and\u000a      design and was a member of the Epidemiology Sub-committee (named in\u000a      alphabetical order as the 1st group of non-IARC authors) who wrote and\u000a      critiqued the output for important intellectual content.\u000a    \u000a\u000a2. Parslow RC, Hepworth SJ, McKinney PA. Recall of past use of mobile\u000a      phone handsets. Rad Protect Dosim 2003; 106: 233-40. A novel paper on how\u000a      (in)accurately individuals recall their true mobile phone use.\u000a    \u000a\u000a3. Vrijheid M, et al for the Interphone Study Group (including McKinney\u000a      PA, Hepworth SJ and Parslow RC). Validation of Short-Term Recall of Mobile\u000a      Phone Use for the Interphone Study. Occ Environ Med 2006; 63: 237-43. DOI:\u000a      10.1136\/oem.2004.019281. First international paper on the validation of\u000a      recall of mobile phone use. Parslow worked as a Technical Advisor at IARC\u000a      advising on analyses, interpretation and output: Leeds was the largest\u000a      contributor of data. McKinney, Hepworth and Parslow critiqued the paper\u000a      and UK North was the only centre to provide 3 authors on the paper.\u000a    \u000a\u000a4. Vrijheid M, et al (including Hepworth SJ and Parslow RC). Determinants\u000a      of mobile phone output power in a multinational study: implications for\u000a      exposure assessment. Occ Environ Med 2009; 66: 664-71. DOI:\u000a      10.1136\/oem.2008.043380 First international exposure assessment of mobile\u000a      phone power output by direct measurement. Parslow was a member of the\u000a      Interphone Expert Working Group on RF radiation measurement. Hepworth\u000a      advised on statistical analyses and all Leeds authors contributed to study\u000a      design, conduct and critiqued the paper.\u000a    \u000a\u000a5. SJ Hepworth, MJ Schoemaker, KR Muir, AJ Swerdlow, MJA van Tongeren, PA\u000a      McKinney. Mobile phone use and risk of glioma in adults: a UK case-control\u000a      study. BMJ 2006; 332: 883-86. DOI: 10.1136\/bmj.38720.687975.55 (full\u000a      paper). The largest (over 950 brain tumour cases) published study with\u000a      significant international impact for academia, commerce, media and the\u000a      general public.\u000a    \u000a\u000a6. The INTERPHONE Study Group (including McKinney PA and Hepworth SJ).\u000a      Brain tumour risk in relation to mobile telephone use: results of the\u000a      INTERPHONE international case-control study. International Journal of\u000a      Epidemiology 2010; 39: 675-94. doi:10.1093\/ije\/dyq079 Final results paper\u000a      of Interphone. McKinney had a major input into the intellectual content\u000a      and interpretation of results.\u000a    \u000aMcKinney was principal investigator of the UK North study which received\u000a      &#163;1.7 million total funding from i) the EU European 5th Framework\u000a      programme `Quality of Life and Management of Living Resources' FP5 (26%);\u000a      ii) IARC (2%); iii) the UK Government (44%, including the Health and\u000a      Safety Executive 22%, the Department of Health 7%, and the Mobile\u000a      Telecommunications and Health Research Programme 15%); and iv) the mobile\u000a      phone industry (28%).\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [A] Letter from Head IARC Monographs Section, International Agency\u000a      for Research on Cancer (IARC), confirming Non-Ionizing Radiation, Part\u000a        II: Radiofrequency Electromagnetic Fields http:\/\/monographs.iarc.fr\/ENG\/Monographs\/vol102\/mono102.pdf\u000a      was scheduled immediately after the release of the Interphone results to\u000a      ensure their contribution to the evidence base.\u000a    [B] World Health Organisation. Electromagnetic fields and\u000a        public health: mobile phones. June 2011 Fact sheet 193 http:\/\/www.who.int\/mediacentre\/factsheets\/fs193\/en\/\u000a    [C] International Commission on Non-Ionising Radiation Protection\u000a      (ICNIRP). (i) `Guidance on Radiofrequency' specifically\u000a      noting Interphone http:\/\/www.icnirp.de\/documents\/ICNIRPnote.pdf\u000a      (ii) Swerdlow AJ, et al, ICNIRP Radiation Protection Standing Committee on\u000a      Epidemiology. Mobile Phones, Brain Tumours and the Interphone Study:\u000a        Where Are We Now? Environmental Health Perspectives 2011; 119:\u000a      1534-38. http:\/\/www.icnirp.de\/documents\/SCIreview2011.pdf\u000a    [D] Letter from Vice Chair of ICNIRP, corroborating the important\u000a      contribution of Interphone to on-going work on ICNIRP's guidelines on\u000a      exposure to mobile phones.\u000a    [E] Health Protection Agency. (i) Health advice on mobile phones\u000a      following the Interphone study. http:\/\/www.hpa.org.uk\/Topics\/Radiation\/UnderstandingRadiation\/UnderstandingRadiationTopic\u000a        s\/ElectromagneticFields\/RadioWaves\/MobilePhones\/info_HealthAdvice\/\u000a      (ii) HPA Advisory Group on Non Ionising Radiation (AGNIR) statement on\u000a      Interphone.\u000ahttp:\/\/www.hpa.org.uk\/web\/HPAweb&amp;HPAwebStandard\/HPAweb_C\/1274088317073\u000a    [F] Health Protection Agency. Health Effects from Radiofrequency\u000a      Electromagnetic Fields: a report of the independent Advisory Group on\u000a      Non-ionising Radiation. April 2012. \u000a        http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1317133827077\u000a    [G] Letter from Chief Executive of the Science Media Centre,\u000a      attesting to the media impact and widespread national and international\u000a      coverage of the Interphone results. This included: Mobile\u000a        phones 'unlikely' to cause cancer, BBC News http:\/\/www.bbc.co.uk\/news\/health-13988882;\u000a      Mobile phone study finds no solid link to brain tumours, The\u000a      Guardian http:\/\/www.guardian.co.uk\/science\/2010\/may\/17\/mobile-phones-brain-cancer-study;\u000a      No link found between mobile phones and cancer, Nature News http:\/\/www.nature.com\/news\/2010\/100517\/full\/news.2010.246.html.Portfolio\u000a      of full media coverage available on request.\u000a    [H] Letter from member of the DH Stewart Committee on Mobile\u000a      Phones and AGNIR (2001-09) stating that Interphone has been pivotal in\u000a      managing health risks from mobile phones.\u000a    [I] Mobile Operators Association statement on Interphone http:\/\/www.mobilemastinfo.com\/2010\/mobile-operators-welcome-publication-of-interphone-study.html\u000a    [J] Letter from the Chair of the UK Mobile Operators Association\u000a      Science Working Group confirming that identifying health risks of mobiles\u000a      has global significance to the industry. \u000a    ","Title":"\u000a    Guiding international policy on mobile phone exposure and adult brain\u000a        tumours: the UK North and Interphone study\u000a    ","UKLocation":[{"GeoNamesId":"2644688","Name":"Leeds"},{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    In the late 1990s the International Commission on Non-Ionizing Radiation\u000a      Protection (ICNIRP) and the World Health Organization (WHO) recommended\u000a      research into the possible adverse health effects of mobile phone use.\u000a    In 1999, Leeds researchers - Principal Investigator Patricia McKinney\u000a      (Senior Research Fellow, 1993-2001, Reader, 2001-2005, Professor\u000a      2005-date) and Roger Parslow (Research Associate, 1996-2001,\u000a      Senior Research Fellow, 2001-2007, Senior Lecturer, 2007-date) - designed\u000a      and obtained funding for an independent `UK North' (Scotland, West\u000a      Yorkshire, Trent and West Midlands) epidemiological case-control study\u000a      investigating risk factors for adult brain tumours, including mobile phone\u000a      use.\u000a    At the same time, McKinney and Parslow collaborated with the\u000a      International Agency for Research on Cancer (IARC) in Lyon to assess the\u000a      feasibility of an international study combining multiple national data\u000a      sets. Once shown to be viable, the multinational Interphone study was set\u000a      up to determine whether mobile phone use increased the risk of brain\u000a      tumours. McKinney played a key role in establishing and implementing\u000a      Interphone from its inception in 2000 and was one of five scientists on\u000a      the epidemiology committee, formulating the scientific direction and\u000a      conduct of the research (1). Also in 2000 in Leeds, Parslow managed the\u000a      design and programming of the common data collection tool (the computer\u000a      assisted personal interview (CAPI)) used by all 13 countries in Europe,\u000a      North America, Asia and Australia contributing to Interphone.\u000a    As part of the UK North study in Leeds, work was done to validate how\u000a      accurately individuals remember their past use of mobile phones by\u000a      comparing individual `recall' with mobile phone records (2). The results\u000a      showed reported use may not represent actual use, a finding replicated in\u000a      Interphone, using validation data from Leeds and 10 other international\u000a      centres (3). Leeds also ran a pilot study, provided the only UK data, and\u000a      consulted on data analysis, for Interphone research of mobile phone power\u000a      output, leading to a new exposure assessment for mobile phone radio-\u000a      frequency radiation (4). Through this key validation work, Parslow and\u000a      Sarah Hepworth (University of Leeds; Research Fellow, 2002-05,\u000a      Senior Research Fellow 2005-date) made the only UK contribution to a\u000a      series of studies (2,3,4) that enhanced the scientific robustness of\u000a      Interphone.\u000a    In 2006, independently of Interphone, an academic collaboration between\u000a      the UK North study in Leeds and the UK South study (run by Professor\u000a      Anthony Swerdlow, Institute of Cancer Research, London) published national\u000a      results showing that overall mobile phone use was not associated with an\u000a      increased risk of developing a brain tumour (5). This was led by Leeds\u000a      (Hepworth and McKinney, first and last authors) who contributed 60% of the\u000a      brain tumour cases in the study.\u000a    This UK data combined with that from 12 other countries was used to\u000a      create an Interphone dataset on over 5,000 brain tumours. Leeds was the\u000a      largest Interphone study centre contributing 23% of overall cases. Results\u000a      from Interphone published in 2010 showed no evidence of an increase in\u000a      risk of developing a brain tumour as a result of using a mobile phone (6).\u000a      Interphone remains the largest and most comprehensive case control study\u000a      of different independent populations.\u000a    "},{"CaseStudyId":"6305","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1168579","Name":"Pakistan"},{"GeoNamesId":"1282988","Name":"Nepal"}],"Funders":[],"ImpactDetails":"\u000a    Our work has directly led to changes to government policy and public\u000a      service guidelines and\u000a      practices for TB control across Nepal and Pakistan, improving care for\u000a      more than 300,000 people\u000a      with TB annually, and helping to protect nearly 200 million people from TB\u000a      annually. The strategies\u000a      we developed and demonstrated were effective, which have been rolled out\u000a      since 2008, have led\u000a      to improved quality of life for patients through reduced financial burden,\u000a      better treatment outcomes,\u000a      reducing risk of TB spread and development of drug resistant strains of\u000a      TB. Without our research,\u000a      and development support, it is unlikely that any change to care would have\u000a      occurred. These\u000a      strategies have also been adopted in other low-income countries, such as\u000a      Swaziland.\u000a    Impacts on international development\u000a      From the outset, to ensure our research influenced policy and practice at\u000a      large scale, we adopted\u000a      a deliberate strategy of working closely with National TB Programmes. This\u000a      strategy develops\u000a      trust; ensures our research addresses national priorities; ensures\u000a      findings are relevant for policy\u000a      makers; promotes policy-makers' ownership of the research findings; and\u000a      encourages joint\u000a      development of subsequent policy, operational guidelines and training\u000a      methods and materials.\u000a      Much of our research uptake was made possible through our partnership with\u000a      in-country research\u000a      and development NGOs, set up by ex-students\/employees of the University of\u000a      Leeds. TB\u000a      Programme Managers and members of their teams were involved from\u000a      conception (responding to\u000a      their prioritisation of the problems) to completion. This included joint\u000a      development of the\u000a      interventions to be tested, regular briefings and discussions of likely\u000a      implications of findings.\u000a    Our research and research uptake strategy have together led directly to\u000a      better, evidence-informed,\u000a      public policy and improved public services in Nepal and Pakistan for\u000a      people with TB. We were\u000a      involved in the development of draft national policy and operational plans\u000a      published since 2008.\u000a      National guidelines adopted since 2008 have been revised to take account\u000a      of our findings, and our\u000a      patient-friendly approaches have been implemented in both in Nepal (A-G)\u000a      and Pakistan (H-J).\u000a    We have also jointly developed training materials and courses that have\u000a      been used by the TB\u000a      Programmes from 2008 onwards to train health workers in the new\u000a      strategies. Walley and Newell\u000a      have provided on-going advice and support to the NTPs throughout the\u000a      assessment period.\u000a      More widely, the research influenced key WHO\/Stop TB Partnership (www.stopTB.org)\u000a      documents\u000a      (K-M) (including the Stop TB strategy 2006), in which the\u000a      requirement for DOT has been replaced\u000a      by a more patient-centred approach of `supervision and patient support'.\u000a      Although publication of\u000a      these documents falls outside the assessment period, their influence in\u000a      encouraging adoption of\u000a      this strategy across low-income countries has continued throughout the\u000a      assessment period.\u000a    Impacts on health and welfare\u000a      Our research and our research uptake strategy have together led to 100%\u000a        reach across our\u000a        intended target populations - the (overwhelmingly poor) people of\u000a      Nepal and Pakistan receiving\u000a      care for TB - starting in 2008 and continuing to date. This means improved\u000a      care for 30,000 people\u000a      with TB in the mountain\/hill districts of Nepal annually, helping protect\u000a      30 million people from TB\u000a      infection in Nepal (A-G); and improved care for 300,000 people with\u000a      TB in Pakistan annually,\u000a      helping protect 177 million people in Pakistan (H-J) (based on WHO\u000a      statistics on numbers at risk).\u000a    Our research has also contributed to improved TB treatment outcomes in\u000a      both countries (N).\u000a    \u000a      in Nepal, the TB treatment success rate was 48% (case detection 56%)\u000a        in 1995 prior to our\u000a        research, and 85% (case detection 71%) in 2011: mortality fell by 900 to\u000a        7,000.\u000a      in Pakistan, the TB treatment success rate was 70% (case detection\u000a        4.5%) in 1995, and 91%\u000a        (case detection 65%) in 2011: mortality fell by 31,000 to 59,000.\u000a    \u000a    Our research has also led to significantly improved quality of life\u000a        for people with TB in Nepal and\u000a      Pakistan, who no longer need to attend a clinic daily, and can therefore\u000a      continue their usual\u000a      employment\/duties and follow normal lives (4), reducing the burden\u000a      and costs of TB.\u000a    \u000a      In Nepal, we estimated costs to patients using family\/community health\u000a        worker DOT were\u000a        US$32 lower than using standard health centre DOT (a reduction of nearly\u000a        50%) (5). To put this\u000a        in context, the average annual income (2001) was US$400 and 55% of the\u000a        population earned\u000a        less than the international poverty line (IPL) of US$1.25 per day.\u000a      in Pakistan, we estimated costs to patients using family\/community\u000a        health worker DOT were\u000a        US$27 lower than using standard health centre DOT (a reduction of 50%) (3).\u000a        The average\u000a        annual income (2001) was US$750 and 23% of the population earned less\u000a        than the IPL.\u000a    \u000a    ","ImpactSummary":"\u000a    Leeds research has led to adoption of effective, patient-friendly\u000a      tuberculosis (TB) care delivery in\u000a      Nepal and Pakistan, relaxing the global TB treatment strategy's\u000a      requirement that (generally very\u000a      poor) patients attend a health centre every day for 2 months for\u000a      supervision and support that led to\u000a      unemployment, poverty and debt. This impact has reach across the more than\u000a      300,000 people a\u000a      year treated for TB in Nepal and Pakistan; and its significance is that\u000a      patients can retain their usual\u000a      employment yet still have a high likelihood of cure. Our research\u000a      demonstrated that home-based\u000a      care was feasible under routine low-income country TB programme\u000a      conditions, was as effective as\u000a      health centre-based care, and was much more acceptable than health\u000a      centre-based care.\u000a    ","ImpactType":"Political","Institution":"\u000a    University of Leeds\u000a    ","Institutions":[{"AlternativeName":"Leeds (University of)","InstitutionName":"University of Leeds","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007795}],"Panel":"A         ","PlaceName":[],"References":"\u000a    [University of Leeds staff at the time of the research in bold]\u000a    \u000a1. Walley JD, Khan MA, Newell JN, Khan MH (2001).\u000a      Effectiveness of the direct observation\u000a      component of DOTS for tuberculosis: a randomised controlled trial in\u000a      Pakistan. Lancet, 357,\u000a      664-669. doi:10.1016\/S0140-6736(00)04129-5. Cited 110 times.\u000a      Results from the first trial to show that more patient-friendly\u000a        approaches to DOT are effective.\u000a    \u000a\u000a2. Khan MA, Walley J, Newell J, Imdad N (2000).\u000a      Tuberculosis in Pakistan: socio-cultural\u000a      constraints and opportunities in treatment. Social Science and Medicine,\u000a      50, 247-254.\u000a      doi: 10.1016\/S0277-9536(99)00279-8.\u000a      Identification of problems of daily health centre DOT from\u000a        patient\/health provider perspectives.\u000a    \u000a\u000a3. Khan MA, Walley JD, Witter SN, Imran A, Safdar N\u000a      (2002). Costs and cost effectiveness of\u000a      different DOT strategies for the treatment of tuberculosis in Pakistan.\u000a      Health Policy and\u000a      Planning 17(2), 178-186. doi: 10.1093\/heapol\/17.2.178.\u000a      Analysis of the trial (1) showing that the patient-friendly DOT\u000a        strategies we developed are\u000a        more cost effective than daily health centre DOT.\u000a    \u000a\u000a4. Newell JN, Baral SC, Pande SB, Bam DS, Malla P\u000a      (2006). Family member DOTS and\u000a      community DOTS for TB control in Nepal: district randomised trial. Lancet,\u000a      367 (9514), 903-\u000a      909. doi:10.1016\/S0140-6736(06)68380-3.\u000a      Results from a large cluster-randomised trial showing effectiveness of\u000a        our strategies within\u000a        usual health service care.\u000a    \u000a\u000a5. Mirzoev T, Baral SC, Karki D, Green AT, Newell\u000a        JN (2008). Community-based DOTS and\u000a      family member DOTS for TB control in Nepal: costs and cost-effectiveness.\u000a      Cost Effectiveness\u000a      and Resource Allocation 2008, 6:20. doi:10.1186\/1478-7547-6-20\u000a      Analysis showing the two approaches tested in Nepal (4) were affordable\u000a        and comparable.\u000a    \u000aGrant support (open competition peer-reviewed grants)\u000a      Walley - TB DOT project trial in Pakistan (DFID 1995-98 &#163;313,824); Newell\u000a      - TB service delivery\u000a      in areas with poor access to health facilities in Nepal (DFID 2000-3\u000a      &#163;247,094).\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    Key external outputs\u000a\u0009  Nepal Ministry of Health and Population (2010). National\u000a      Strategic Plan - Implementation of\u000a      Stop TB Strategy 2067\/68-2071\/71 (16 July 2010-15 July 2015). Kathmandu:\u000a      National\u000a      Tuberculosis Centre. (See section 2.9, p50, and acknowledgement on page\u000a      16.) Available at\u000a      www.nepalccm.org\/resources\/tuberculosis\/pdf\/nationalstrategicplan2010-15.pdf\u000a    Nepal Ministry of Health and Population (2012). Nepal NTP\u000a      General Manual 3rd edition. (See\u000a      pages 4, 9, 10, 31 for role of family members in TB patient support.)\u000a      Available at\u000a      http:\/\/nepalntp.gov.np\/theme\/images\/uploads\/1373865242eneral_Manual_en.pdf\u000a    C. Nepal Ministry of Health and Population (2009). Tuberculosis\u000a      Case Management Guideline 1st\u000a      edition. (Also in Nepali.) (See page 18 for role of family members in TB\u000a      patient support.)\u000a      http:\/\/library.elibrary-mohp.gov.np\/mohp\/collect\/mohpcoll\/archives\/mohp:204\/9.dir\/doc.pdf\u000a    D. Annual Report 2008\/09, Ministry of Health and Population,\u000a      National Tuberculosis Programme,\u000a      Nepal. Available at http:\/\/www.docstoc.com\/docs\/140273075\/Department-of-Health-Services---\u000a      Ministry-of-Health-and-Population\u000a    E. Annual Report 2008\/09, Ministry of Health and Population,\u000a      National Tuberculosis Programme,\u000a      Nepal. (See pages 2, 9 for role of family members in TB patient support;\u000a      and\u000a      acknowledgement on page 32.) Available at\u000a      http:\/\/nepalntp.gov.np\/theme\/images\/uploads\/1359021203l_Report_NTP_2011.pdf\u000a    F. The current Chief of the Policy Planning and International\u000a      Cooperation Division of the Nepal\u000a      Ministry of Health and Population can confirm the impact of our research\u000a      on TB service\u000a      delivery in Nepal.\u000a    G. The Deputy Director of the Nepal National Tuberculosis\u000a      Programme during the period when\u000a      our findings were incorporated into Nepal national policy can confirm the\u000a      influence of our\u000a      research on national health policy in Nepal.\u000a    H. National TB Control Programme Pakistan (2008). Desk guide for\u000a      doctors. (See pp8-9 for role\u000a      of family members and community health workers in TB patient support; p20\u000a      for\u000a      acknowledgement of input from Nuffield Institute for Health, University of\u000a      Leeds.)\u000a    I. National TB Control Programme, Ministry of Health, Government\u000a      of Pakistan (2008). Refresher\u000a      module for doctors. (See p18 for role of community health workers in TB\u000a      patient support.)\u000a      http:\/\/ntp.gov.pk\/uploads\/ntp_1369816170_Doctor_Module_Nov_2008.pdf\u000a    J. Letter from the Programme Manager of the Pakistan National TB\u000a      Programme during the period\u000a      when our findings were incorporated into Pakistan national policy\u000a      confirming the impact of our\u000a      research on national health policy in Pakistan.\u000a    K. The Stop TB Strategy. WHO and the Stop TB Partnership 2006 (WHO\u000a      document number\u000a      WHO\/HTM\/STB\/2006.37). (See p2 for acknowledgement of input from John\u000a      Walley.)\u000a      http:\/\/www.who.int\/tb\/strategy\/en\/\u000a    L. The Global Plan to Stop TB 2011-2015. WHO and the Stop TB\u000a      Partnership (WHO document\u000a      number WHO\/HTM\/STB\/2006.35). (See p7 for acknowledgement of input from\u000a      James Newell.)\u000a      http:\/\/www.stoptb.org\/global\/plan\/\u000a    M. An Expanded DOTS Framework for Effective Tuberculosis Control.\u000a      WHO (WHO document\u000a      number WHO\/CDS\/TB\/2002.297). (See p2 for acknowledgement of input from\u000a      John Walley.)\u000a      http:\/\/www.who.int\/tb\/publications\/expanded_dots_framework\/en\/\u000a    N. Global Tuberculosis Control: WHO Report 2012. (WHO document\u000a      WHO\/HTM\/TB\/2012.6).\u000a      http:\/\/www.who.int\/tb\/publications\/global_report\/en\/\u000a    All manuals, guidelines and training materials listed above have been\u000a      developed by the national\u000a      bodies responsible in the relevant countries (National Tuberculosis\u000a      Control Programmes, etc).\u000a      (NB WHO rules prohibit staff from providing letters of support that could\u000a      be perceived as favouring\u000a      any individual or establishment.)\u000a    \u000a    ","Title":"\u000a    Making tuberculosis care more patient-centred in Nepal and Pakistan\u000a    ","UKLocation":[{"GeoNamesId":"2644688","Name":"Leeds"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    TB is a major global cause of illness and death: the World Health\u000a      Organisation (WHO) reports that\u000a      in 2011, 8.7 million people fell ill with TB, and 1.4 million people died\u000a      from TB; and over 95% of TB\u000a      deaths occur in low- and middle-income countries. Until 2006, the TB\u000a      control policy recommended\u000a      by WHO included Direct Observation of Treatment (DOT) by a health worker\u000a      at a health centre\u000a      daily for at least the first 2 months of treatment. We observed that this\u000a      strategy caused substantial\u000a      hardship to poor patients, severely disrupting their ability to work,\u000a      since health centres are\u000a      generally only open during working hours. During treatment, many employed\u000a      TB patients lost their\u000a      jobs; daily labourers could not get work; farmers struggled to access\u000a      clinics; household duties\u000a      including childcare were disrupted; and school and college students had\u000a      difficulties continuing their\u000a      studies. Health centre DOT ignores the imperatives of daily survival for\u000a      poor people, and forces\u000a      many people to seek care in the private sector, which has poor treatment\u000a      outcomes, leading to\u000a      further illness and death, and continuing transmission of TB.\u000a    Despite being part of global policy, there was no evidence to support the\u000a      use of health centre DOT\u000a      rather than more flexible ways of encouraging continuation and completion\u000a      of treatment. We\u000a      hypothesised that flexible strategies could produce cure rates as good as\u000a      or better than daily\u000a      health centre DOT and be more patient-friendly. We planned from the outset\u000a      that if the context-\u000a      appropriate strategies we developed proved effective, we would use our\u000a      good relationships with\u000a      National TB Programmes to encourage changes in policy and help implement\u000a      such strategies.\u000a    From 1996 to 2000, our research team at the University of Leeds carried\u000a      out an individually\u000a      randomised controlled trial in Pakistan to compare treatment outcomes and\u000a      patient satisfaction\u000a      using daily health centre DOT with those obtained using more\u000a      patient-friendly strategies of\u000a      treatment supervision and patient support by community health volunteers\u000a      or family members at or\u000a      near the patient's home. The team was led by John Walley\u000a      (Professor of International Public\u000a      Health, employed by UoL 1992-) with James Newell (Professor of\u000a      International Public Health,\u000a      1995-) and Amir Khan (UoL PhD graduate, who set up a Pakistani NGO - the\u000a      Association for\u000a      Social Development - to operationalize the research and development).\u000a    The trial demonstrated that patient-friendly approaches led to higher\u000a      cure rates than daily health\u000a      worker DOT (1). Our development of these approaches was guided by a\u000a      social science study\u000a      identifying constraints to TB control from patients' and providers'\u000a      perspectives (2); and we also\u000a      carried out a study demonstrating the cost-effectiveness of the approaches\u000a      (3).\u000a    We then carried out the first cluster-randomised controlled trial to\u000a      investigate the impact of patient-\u000a      friendly strategies for treatment supervision and patient support. The\u000a      trial randomised districts in\u000a      hill and mountain areas of Nepal, where standard daily health centre DOT\u000a      was clearly not feasible\u000a      because of the unavailability of accessible clinics. This trial\u000a      demonstrated that under normal health\u000a      service conditions, patient supervision at home by a family member or by a\u000a      community health\u000a      volunteer achieved cure rates of 89% and 85% respectively (4),\u000a      higher than the international target\u000a      of 85%; and patient satisfaction was high. A subsequent costing analysis\u000a      demonstrated that the\u000a      costs of the two strategies were similar, and affordable to the Nepal NTP\u000a      (5). The research team\u000a      was led by James Newell and included Sushil Baral (UoL PhD\u000a      graduate, who set up a Nepali\u000a      NGO - the Health Research and Development Forum - to operationalize the\u000a      research and\u000a      development); Tolib Mirzoev (Senior Lecturer, 2004-) and Andrew\u000a        Green (Professor of\u000a      International Health Planning, 1983-2004).\u000a    Our contribution to the field of study was that, at the time, although\u000a      there had been a small number\u000a      of studies comparing DOT to non-DOT (unsupervised self-administered) TB\u000a      care, our studies were\u000a      the only ones comparing different DOT strategies and demonstrating their\u000a      effectiveness.\u000a    "},{"CaseStudyId":"9535","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"149590","Name":"Tanzania"},{"GeoNamesId":"1168579","Name":"Pakistan"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"2328926","Name":"Nigeria"},{"GeoNamesId":"1210997","Name":"Bangladesh"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    National Impact:\u000d\u000a      The Royal College of Obstetricians &amp; Gynaecologists incorporated the\u000d\u000a      findings into their clinical guidelines (2006) for the management of both\u000d\u000a      severe pre-eclampsia and eclampsia, and these continued to be the national\u000d\u000a      guidance followed until 2010 [A]. This guidance was superseded by NICE\u000d\u000a      guidelines which cite the studies and recommend use of magnesium sulphate\u000d\u000a      for treatment of both eclampsia and severe pre-eclampsia [A]. We estimate\u000d\u000a      that two hundred cases of eclampsia per year are now prevented in the UK\u000d\u000a      amongst an estimated 40,000 pre-eclamptic women treated with magnesium\u000d\u000a      sulphate, and whilst deaths do occur, they are now extremely rare [B].\u000d\u000a    Global Impact:\u000d\u000a      WHO recommendations for the prevention and treatment of pre-eclampsia and\u000d\u000a      eclampsia recommend magnesium sulphate for the prevention and treatment of\u000d\u000a      eclampsia, specifically citing these studies [C]. Other national\u000d\u000a      guidelines in high resource countries also cite the studies while making\u000d\u000a      the same recommendations [D]. The Pre-Eclampsia\/Eclampsia: Prevention,\u000d\u000a        Detection and Management toolkit for Developing Countries was\u000d\u000a      developed by the USAID-funded Maternal and Child Health Integrated Program\u000d\u000a      (MCHIP) as a resource of current evidence, materials and experiences from\u000d\u000a      around the world and cites the studies as the key evidence behind the\u000d\u000a      recommendation to use magnesium sulphate for the prevention and treatment\u000d\u000a      of pre-eclampsia and eclampsia [E].\u000d\u000a    A recent systematic review [F] demonstrated that in Bangladesh, India,\u000d\u000a      Pakistan, and Nigeria in addition to the UK, the introduction of treatment\u000d\u000a      for eclampsia with magnesium sulphate as a result of these trials\u000d\u000a      consistently results in a halving of the rates of maternal death.\u000d\u000a      Magnesium sulphate is now included on the WHO Model List of Essential\u000d\u000a      Medicines [G] and was recently added to the Interagency Emergency Health\u000d\u000a      Kit of recommended medicines and medical devices for 10,000 people for\u000d\u000a      approximately three months [H].\u000d\u000a    Magnesium sulphate continues to be introduced in low resource countries\u000d\u000a      internationally, as part of initiatives aimed at reaching Millennium\u000d\u000a      Development Goal 5, to reduce maternal mortality by three-quarters by\u000d\u000a      2015. For example, a recent Department for International Development\u000d\u000a      intervention in Tanzania included the provision of magnesium sulphate as\u000d\u000a      one of four key actions [I].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    International obstetric practice has been changed by two large randomised\u000d\u000a      controlled trials led from the University of Oxford's National Perinatal\u000d\u000a      Epidemiology Unit, which demonstrated the efficacy of magnesium sulphate\u000d\u000a      for both treatment and prevention of eclampsia during pregnancy, a\u000d\u000a      condition characterised by fits in association with hypertension, and an\u000d\u000a      important cause of maternal morbidity and mortality. Until the 1990s there\u000d\u000a      was widespread geographical variation in the management of the condition,\u000d\u000a      with magnesium sulphate used almost exclusively in North America.\u000d\u000a      Following the publication of the results of these two trials magnesium\u000d\u000a      sulphate is now in routine use globally, widely recommended in guidelines,\u000d\u000a      and has been placed on the WHO Model List of Essential Medicines.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    The University of Oxford\u000d\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1]. Douglas KA, Redman CW. Eclampsia in the United Kingdom. Br Med J\u000d\u000a      1994;309:1395-400. doi: 10.1136\/bmj.309.6966.1395. PubMed ID: 7819845. This\u000a          paper reports the first UK national study estimating the incidence of\u000d\u000a          eclampsia prior to the publication of the eclampsia trials and is\u000d\u000a          provided for background.\u000d\u000a    \u000a\u000a[2]. The Eclampsia Trial Collaborative Group. Which anticonvulsant for\u000d\u000a      women with eclampsia? Evidence from the Collaborative Eclampsia Trial.\u000d\u000a      Lancet 1995; 345: 1455-63.\u000d\u000a      PubMed ID: 7769899. The first of two key papers, the Collaborative\u000a        Eclampsia Trial demonstrates the clinical effectiveness of\u000d\u000a          magnesium sulphate for the treatment of eclampsia compared\u000d\u000a          with standard treatment.\u000d\u000a    \u000a\u000a[3]. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith\u000d\u000a      D, Magpie Trial Collaboration Group. Do women with pre-eclampsia, and\u000d\u000a      their babies, benefit from magnesium sulphate? The Magpie Trial: a\u000d\u000a      randomised placebo-controlled trial. Lancet 2002; 359: 1877-90.\u000d\u000a      PubMed ID: 12057549. This is second of the two key papers and\u000d\u000a          demonstrates the clinical effectiveness of magnesium sulphate for the\u000d\u000a          prevention of eclampsia compared with placebo.\u000d\u000a    \u000a\u000a[4]. Simon J, Gray A, Duley L; Magpie Trial Collaborative Group.\u000d\u000a      Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with\u000d\u000a      pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial.\u000d\u000a      Br J Obstet Gynaecol 2006;113:144-51.\u000d\u000a      PubMed ID: 16411990. This paper reports the economic evaluation\u000d\u000a          demonstrating the particular value of treatment in low resource\u000d\u000a          settings.\u000d\u000a    \u000a\u000a[5]. Knight M on behalf of UKOSS. Eclampsia in the United Kingdom 2005.\u000d\u000a      BJOG. 2007;114(9):1072-8.\u000d\u000a      PubMed ID: 17617191. This paper reports the second and most recent\u000d\u000a          UK national study estimating the incidence of eclampsia following the\u000d\u000a          introduction of magnesium sulphate into clinical practice for the\u000d\u000a          prevention and management of eclampsia and is provided to complete the\u000d\u000a          picture of evidence.\u000d\u000a    \u000aThis research was funded by the UK Medical Research Council, the UK\u000d\u000a      Department for International Development, the UNDP\/UNFPA\/WHO\/World Bank\u000d\u000a      Special Programme of Research, Development and Research Training in Human\u000d\u000a      Reproduction (HRP) and the European Commission.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"14","Subject":"Paediatrics and Reproductive Medicine"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [A]. NICE Guideline CG107 (issued August 2010). The management of\u000d\u000a      hypertensive disorders during pregnancy. http:\/\/www.nice.org.uk\/nicemedia\/live\/13098\/50418\/50418.pdf\u000d\u000a      [Accessed 6\/9\/2013]. This is the current UK national guidance\u000d\u000a          recommending use of magnesium sulphate to prevent eclampsia and\u000d\u000a          referencing the studies in the supporting evidence. See section 1.8.\u000d\u000a    [B]. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, et al.\u000d\u000a      (2011) Saving Mothers' Lives: Reviewing maternal deaths to make motherhood\u000d\u000a      safer: 2006-2008. The Eighth Report of the Confidential Enquiries into\u000d\u000a      Maternal Deaths in the United Kingdom. BJOG 118 Suppl 1: 1-203. PubMed ID:\u000d\u000a      21356004. This reports cases of maternal death in the UK and shows\u000d\u000a          the rarity of deaths from eclampsia. It nevertheless cites the Oxford\u000d\u000a          University research to emphasise the importance of magnesium sulphate\u000d\u000a          to prevent eclampsia. See pages 68 &amp; 70.\u000d\u000a    [C]. WHO recommendations for the prevention and treatment of\u000d\u000a      pre-eclampsia and eclampsia (2011). http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241548335_eng.pdf\u000d\u000a      [Accessed 06\/09\/2013]. WHO guidance recommending magnesium sulphate\u000d\u000a          for the management and prevention of eclampsia. See pages, 2, 20-24.\u000d\u000a    [D]. Society of Obstetricians and Gynecologists of Canada Clinical\u000d\u000a      Practice Guideline. Diagnosis, Evaluation, and Management of the\u000d\u000a      Hypertensive Disorders of Pregnancy (2008). http:\/\/sogc.org\/wp-content\/uploads\/2013\/01\/gui206CPG0803hypertensioncorrection.pdf\u000d\u000a      [Accessed 06\/09\/2013]. An example of a national guideline also\u000d\u000a          recommending magnesium sulphate for the management and prevention of\u000d\u000a          eclampsia. See sections S5 &amp; S32.\u000d\u000a    [E]. Pre-Eclampsia\/Eclampsia: Prevention, Detection and Management\u000d\u000a      toolkit (2011) http:\/\/archive.k4health.org\/sites\/default\/files\/PEE%20Bibliography%20nov2011_0.pdf\u000d\u000a      [Accessed 28\/10\/2013]. A toolkit for developing countries\u000d\u000a          highlighting the importance of magnesium sulphate for preventing and\u000d\u000a          treating eclampsia and pre-eclampsia for developing countries.\u000d\u000a    [F]. McDonald SD, Lutsiv O, Dzaja N, Duley L. A systematic review of\u000d\u000a      maternal and infant outcomes following magnesium sulfate for\u000d\u000a      pre-eclampsia\/eclampsia in real-world use. Int J Gynaecol Obstet.\u000d\u000a      2012;118(2):90-6. PubMed ID: 22703834. This systematic review\u000d\u000a          identifies studies documenting the efficacy of magnesium sulphate in\u000d\u000a          \"real-life\" cohort studies and shows a consistent halving in maternal\u000d\u000a          death amongst women with eclampsia treated with magnesium sulphate.\u000d\u000a    [G]. WHO Model List of Essential Medicines (2011). http:\/\/whqlibdoc.who.int\/hq\/2011\/a95053_eng.pdf\u000d\u000a      [Accessed 06\/09\/2013]. WHO list of recommended essential medicines\u000d\u000a          for health services listing magnesium sulphate for the treatment of\u000d\u000a          eclampsia and management of severe pre-eclampsia. See p 4.\u000d\u000a    [H]. WHO Interagency Emergency Health Kit (2011). http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241502115_eng.pdf\u000d\u000a      [Accessed 06\/09\/2013]. Details of WHO Interagency Emergency Health\u000d\u000a          Kit 2011 &#8212; Medicines and medical devices for 10,000 people for\u000d\u000a          approximately three months. Magnesium sulphate included in 2011\u000d\u000a          version for treatment of eclampsia\/pre-eclampsia. See page 6.\u000d\u000a    [I]. Department for International Development (2011). Business Case and\u000d\u000a      Intervention Summary &#8212; Reproductive and Maternal Health Supplies in\u000d\u000a      Tanzania. http:\/\/devtracker.dfid.gov.uk\/projects\/GB-1-202959\/documents\/\u000a        [Accessed 06\/09\/2013]. This describes the DFID intervention\u000d\u000a          for 2012-14 in Tanzania, citing the Magpie study as evidence for the\u000d\u000a          provision of magnesium sulphate to prevent maternal death. See\u000d\u000a          Evidence section &#8212; Clinical effectiveness of maternal health supplies.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    EVIDENCE BASED TREATMENT AND PREVENTION OF ECLAMPSIA\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Eclampsia represents the gravest end of the spectrum of hypertensive\u000d\u000a      disorders in pregnancy. Usually preceded by pre-eclampsia, eclampsia is\u000d\u000a      characterised by grand mal seizures, coma, hypertension, proteinuria and\u000d\u000a      oedema, and can lead to maternal death. In 1992, with 383 affected women\u000d\u000a      nationally, an Oxford-led study demonstrated that the rate of eclampsia\u000d\u000a      was 5 per 10,000 women delivering in the UK. One in 50 of these affected\u000d\u000a      women died from the disorder [1]. During this period eclampsia was a\u000d\u000a      leading cause of maternal morbidity and mortality globally, responsible\u000d\u000a      for an estimated 50,000 maternal deaths annually worldwide. Standard\u000d\u000a      treatment at that time in the UK and many other countries was with an\u000d\u000a      anticonvulsant such as diazepam or phenytoin, whereas in North America,\u000d\u000a      magnesium sulphate was principally used. Clinicians elsewhere were\u000d\u000a      sceptical about the efficacy of magnesium sulphate as there was\u000d\u000a      insufficient randomised controlled trial evidence to support its use.\u000d\u000a    In 1995, the Collaborative Eclampsia trial of magnesium sulphate for the\u000d\u000a      treatment of women having an eclamptic fit was led by Dr Lelia\u000d\u000a      Duley and co-ordinated from the National Perinatal Epidemiology Unit\u000d\u000a      (NPEU), University of Oxford. In this international multi-centre\u000d\u000a      randomised controlled trial, conducted in nine countries, 1,687 women\u000d\u000a      having an eclamptic fit were randomised to receive magnesium sulphate,\u000d\u000a      diazepam or phenytoin [2]. The trial demonstrated a statistically\u000d\u000a      significant halving in the recurrence of seizures for women treated with\u000d\u000a      magnesium sulphate compared with diazepam and phenytoin. There were also\u000d\u000a      non-significant reductions in maternal mortality, severe maternal\u000d\u000a      morbidity, and fetal and neonatal effects.\u000d\u000a    The Oxford-led `Magpie Trial', published in 2002, was a multi-centre\u000d\u000a      international randomised controlled trial of magnesium sulphate for the prevention\u000d\u000a      of eclampsia. This trial also demonstrated the benefits of magnesium\u000d\u000a      sulphate in halving the risk of eclampsia in women with pre-eclampsia who\u000d\u000a      were treated with magnesium sulphate [3]. In the absence of an existing\u000d\u000a      preventive therapy, 10,141 women with pre-eclampsia across 33 countries\u000d\u000a      were randomised to receive either magnesium sulphate or placebo. A\u000d\u000a      cost-effectiveness study was subsequently conducted, using the Magpie\u000d\u000a      Trial data. This demonstrated that the number of women with pre-eclampsia\u000d\u000a      who needed to be treated to prevent one case of eclampsia was 324 in high\u000d\u000a      resource settings, 184 in medium and 43 in low resource settings [4]. When\u000d\u000a      treatment was used for severe pre-eclampsia the incremental cost (that is\u000d\u000a      the amount of additional spending on magnesium needed) of preventing one\u000d\u000a      case of eclampsia was $12,942 in high resource settings, $1,179 in medium\u000d\u000a      resource settings and $263 in low resource settings.\u000d\u000a    A national study conducted by the NPEU in 2005 demonstrated a halving in\u000d\u000a      the observed incidence of eclampsia in the UK following the introduction\u000d\u000a      of magnesium sulphate treatment for severe pre-eclampsia, with a\u000d\u000a      two-thirds reduction in the incidence of the associated severe maternal\u000d\u000a      morbidity [5]; the effect sizes were at the level predicted by the\u000d\u000a      original Eclampsia Collaborative and Magpie trials.\u000d\u000a    "},{"CaseStudyId":"9536","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Wellcome Trust","Medical Research Council"],"ImpactDetails":"\u000a    Research into the benefits and risks of antiplatelet therapy has shown\u000a      that long-term antiplatelet therapy reduces the risk of heart attacks,\u000a      strokes and deaths due to vascular disease in a wide range of high-risk\u000a      people. It has also shown that the benefits of aspirin do not clearly\u000a      outweigh the bleeding risks in healthy people. This work has influenced\u000a      treatment guidelines nationally and internationally, and has led to\u000a      changes to medication labelling worldwide. The 3 Aspirin Papers published\u000a      in the BMJ in 2004 have been cited over 4000 times, and the 2009 ATT paper\u000a      is listed amongst the most cited articles (793 citations) in The Lancet\u000a      since 2008 [A].\u000a    Public Policy\u000a    A number of national and international healthcare policy guidelines for\u000a      people at high risk of vascular disease have been influenced by CTSU's\u000a      work on antiplatelet therapy. In particular, the 8th American\u000a      College of Chest Physicians (ACCP) guidelines [B], published\u000a      in 2008, are heavily dependent on the ATT for their data synthesis and\u000a      recommendations as is the report on European Society of Cardiology's Task\u000a      Force on Antiplatelet Drugs in 2010 [C]. These guidelines were developed\u000a      with CTSU's assistance (Professor Colin Baigent was a member of both\u000a      groups) and, taken together, these guidelines have had a major impact on\u000a      antiplatelet drug use since either the US or the European guidelines are\u000a      adopted in most countries. The ATT work is also referenced as 'level A'\u000a      evidence in the 2013 American College of Cardiology Foundation\/American\u000a      Heart Association (ACCF\/AHA) guideline for the management of ST-elevation\u000a      myocardial infarction [D].\u000a    NICE guidance for secondary prevention of myocardial infarction\u000a      references the ATT collaboration results. This was originally published in\u000a      2007 and is planned to be updated before the end of 2013. The draft update\u000a      (July 2013) references an ATT meta-analysis as the key source of data for\u000a      antiplatelet trials [E]. The Scottish Intercollegiate Guidelines Network\u000a      (SIGN) has referenced CTSU's work in a 2013 update to its national\u000a      clinical guideline on antithrombotics [F], and the 2009 ATT paper is also\u000a      referenced in a British Hypertension Society 2010 statement regarding the\u000a      use of aspirin in primary prevention of CVD [G].\u000a    Drug Regulation\u000a    Following the publication of CTSU's 2009 \"aspirin in primary prevention\"\u000a      paper, the UK Medicines and Healthcare products Regulatory Agency (MHRA)\u000a      issued an update to their guidance on aspirin use for primary prevention\u000a      of thrombotic vascular disease [H]. Directly citing CTSU's research as the\u000a      motivating factor behind the new guidance, this update warned against the\u000a      routine use of aspirin in patients at low risk because the benefits of\u000a      aspirin in these circumstances may not exceed the bleeding risks.\u000a    ","ImpactSummary":"\u000a    Over the past 20 years, the University of Oxford's Clinical Trial Service\u000a      Unit (CTSU), within the Nuffield Department of Population Health (NDPH),\u000a      has conducted some of the world's largest trials and collaborative\u000a      meta-analyses of trials of antiplatelet therapy, including aspirin, that\u000a      have together had a major ongoing and incremental impact on the treatment\u000a      and prevention of cardiovascular disease. They have helped ensure that\u000a      antiplatelet therapy is widely used both in the acute care of patients\u000a      with heart attacks and for the secondary prevention of heart attacks and\u000a      strokes in high-risk patients. This research has been recognised as the\u000a      gold standard for international guidelines, and has been instrumental in\u000a      changing prescribing labelling for aspirin.\u000a    ","ImpactType":"Political","Institution":"\u000a    The University of Oxford\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a[1]. Collins R, Peto R, Baigent C, Sandercock P, Warlow C. Collaborative\u000a      overview of randomised trials of antiplatelet therapy--I: Prevention of\u000a      death, myocardial infarction, and stroke by prolonged antiplatelet therapy\u000a      in various categories of patients. Antiplatelet Trialists' Collaboration.\u000a      BMJ 308, 81-106 (1994).\u000a      PubMed ID: 8298418. The first `Aspirin Paper' showing that a\u000a          prolonged course of antiplatelet therapy could reduce the risk of\u000a          serious vascular events by about one quarter among a wide range of\u000a          patients at high risk of vascular disease.\u000a    \u000a\u000a[2]. Collins R, Peto R, Baigent C, Sandercock P, Warlow C. Collaborative\u000a      overview of randomised trials of antiplatelet therapy--II: Maintenance of\u000a      vascular graft or arterial patency by antiplatelet therapy. Antiplatelet\u000a      Trialists' Collaboration. BMJ 1994; 308: 159-168.\u000a      PubMed ID: 8312766. The second `Aspirin Paper' showing that\u000a          antiplatelet therapy reduces the risk of vascular occlusion among\u000a          patients undergoing a vascular procedure.\u000a    \u000a\u000a[3]. Collins R, Peto R, Baigent C, Sandercock P, Warlow C. Collaborative\u000a      overview of randomised trials of antiplatelet therapy--III: Reduction in\u000a      venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among\u000a      surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ\u000a      1994; 308: 235-246.\u000a      PubMed ID: 8054013. The third `Aspirin Paper' showing that aspirin\u000a          reduces the risk of deep venous thrombosis and pulmonary embolism in\u000a          patients at risk of venous thromboembolism.\u000a    \u000a\u000a[4]. Baigent C, Sudlow C, Collins R, Peto R. Antithrombotic Trialists'\u000a      Collaboration Collaborative meta-analysis of randomised trials of\u000a      antiplatelet therapy for prevention of death, myocardial infarction, and\u000a      stroke in high risk patients. BMJ 2002;324: 71-86.\u000a      PubMed ID: 11786451. A paper from the ATT collaboration showing the\u000a          benefits of a prolonged course of antiplatelet therapy for the\u000a          prevention of serious vascular events. This paper also demonstrated\u000a          that intensification of antiplatelet therapy (by adding a second\u000a          antiplatelet agent to aspirin) yielded further benefits that exceeded\u000a          any additional risks of bleeding.\u000a    \u000a\u000a[5]. Chen, Z. M. et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial\u000a      Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin\u000a      in 45,852 patients with acute myocardial infarction: randomised\u000a      placebo-controlled trial. Lancet 2005;366: 1607-1621.\u000a      PubMed ID: 16271642. CTSU's CCS2-COMMIT trial of clopidogrel plus\u000a          aspirin versus aspirin alone, which showed that adding clopidogrel to\u000a          aspirin therapy resulted in additional benefits in patients with an\u000a          acute myocardial infarction.\u000a    \u000a\u000a[6]. Antithrombotic Trialists' (ATT) Collaboration (Writing Committee:\u000a      Baigent C, Blackwell L, Buring J, Collins R, Emberson J, Godwin J,\u000a      Hennekens C, Kearney P, Meade T, Patrono C, Peto R, Roncaglioni MC,\u000a      Zanchetti A.) Aspirin in the primary and secondary prevention of vascular\u000a      disease: collaborative meta-analysis of individual participant data from\u000a      randomised trials. Lancet 2009; 373: 1849-1860.]\u000a      PubMed ID: 19482214. A meta-analysis of six primary prevention\u000a          trials of aspirin versus placebo, which showed that the vascular\u000a          benefits of aspirin do not clearly exceed any bleeding hazards, even\u000a          among those with risk factors for cardiovascular disease.\u000a    \u000aThe ATT Collaboration's work has been supported by funding from the UK\u000a      Medical Research Council, the British Heart Foundation, Cancer Research\u000a      UK, the European Community Biomed Programme, the Stroke Association,\u000a      Chest, Heart and Stroke Scotland, Edinburgh University (Sir Stanley and\u000a      Lady Davidson Fund), by a Wellcome Training Fellowship, and by Sanofi-\u000a      Aventis, Bristol-Myers Squibb and AstraZeneca.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [A]. Most cited articles in The Lancet since 2008, extracted from Scopus.\u000a      Elsevier website:\u000a      http:\/\/www.journals.elsevier.com\/the-lancet\/most-cited-articles\/.\u000a      Accessed 5th November 2013. The 2009 ATT paper has been\u000a          cited &gt; 790 times in Scopus since it was published.\u000a    [B]. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American\u000a      College of Chest Physicians Evidence-Based Clinical Practice Guidelines\u000a      (8th edition). Chest 2008;133:199S- 233S. PubMed ID: 18574266. The\u000a          8th American College of Chest\u000a          Physicians (ACCP) guidelines, which rely heavily on the ATT for their\u000a          data synthesis and recommendations. See page 203S.\u000a    [C]. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet J-P,\u000a      et al. Antiplatelet agents for the treatment and prevention of\u000a      atherothrombosis. Doi:10.1093\/eurheartj\/ehr373.\u000a      PubMed ID: 22019823. The European Society of Cardiology's Task\u000a          Force on Antiplatelet Drugs guidelines from 2010 continue to use the\u000a          ATT study for their recommendations. Pages 2925-2926.\u000a    [D]. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF\/AHA guideline for\u000a      the management of ST-elevation myocardial infarction: a report of the\u000a      American College of Cardiology Foundation\/American Heart Association Task\u000a      Force on Practice Guidelines. J Am Coll Cardiol.\u000a      2013 Jan 29;61(4):e78-140. PubMed ID: 23256914. These guidelines\u000a          reference the 2002 ATT paper, referring to it as `Level A' evidence.\u000a    [E]. C48 MI: secondary prevention: Full guideline. NICE, London 2007\u000a      \u000a        http:\/\/guidance.nice.org.uk\/CG48\/Guidance\/pdf\/English Draft Updated\u000a      Guidance (June 2013):\u000a      http:\/\/www.nice.org.uk\/guidance\/index.jsp?action=download&amp;o=64153\u000a      (Accessed 17th September 2013). This is the original\u000a          NICE guideline and the proposed update. The ATT, led by CTSU, provided\u000a          key evidence for antiplatelet therapy in secondary prevention in the\u000a          guidelines: see page 318.\u000a    [F]. Scottish Intercollegiate Guidelines Network. Antithrombotics:\u000a      indication and management. A national clinical guideline. August 2012\u000a      (updated June 2013).\u000a      http:\/\/www.sign.ac.uk\/pdf\/SIGN129.pdf\u000a      (Accessed 31st October 2013). This recently updated SIGN guideline\u000a          references the 2009 ATT paper.\u000a    [G].The use of aspirin in primary prevention of cardiovascular disease.\u000a      Statement from the British Hypertension Society. January 2010.\u000a      http:\/\/www.bhsoc.org\/pdfs\/Statement%20on%20Aspirin%20Jan10.pdf\u000a      (Accessed 31st October 2013). This BHS\u000a          statement refers to the 2009 ATT collaborative meta-analysis.\u000a    [H]. MHRA Drug Safety update October 2009: Aspirin: not licensed for\u000a      primary prevention of thrombotic vascular disease -\u000a      http:\/\/www.mhra.gov.uk\/Safetyinformation\/DrugSafetyUpdate\/CON087716.\u000a      The UK Medicines and Healthcare products Regulatory Agency (MHRA)\u000a          directly cite CTSUs research in this 2009 guidance update on aspirin\u000a          use for primary prevention of thrombotic vascular disease. \u000a    ","Title":"\u000a    ANTIPLATELET THERAPY FOR PREVENTING HEART ATTACKS AND STROKES\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    In the 1980s a number of trials assessed the effects of antiplatelet\u000a      drugs (especially aspirin) for the prevention of heart attacks and\u000a      strokes, but in many cases these trials gave apparently conflicting\u000a      results. As a consequence there was considerable uncertainty about which\u000a      types of patients benefited from such treatment. In order to provide\u000a      better guidance for doctors and patients, the University of Oxford's CTSU\u000a      initiated collaborative meta-analyses (studies which combine data from a\u000a      group of original studies) of all trials involving an antiplatelet regimen\u000a      for the prevention of serious vascular events (heart attacks, strokes and\u000a      of deaths from vascular disease). The outcome of this effort was the\u000a      publication by the Antiplatelet Trialists' (APT) Collaboration in 1994 of\u000a      a series of three important papers, dubbed \"The Aspirin Papers\" [1-3] by\u000a      the British Medical Journal. The first of these papers showed conclusively\u000a      that a prolonged course of antiplatelet therapy could reduce the risk of\u000a      serious vascular events by about one quarter among a wide range of\u000a      patients at high risk of vascular disease [1]. The other papers\u000a      supplemented this evidence by showing also that antiplatelet therapy\u000a      reduced the risk of vascular occlusion among patients undergoing a\u000a      vascular procedure [2], and that it reduced the risk of deep venous\u000a      thrombosis and pulmonary embolism in patients at risk of venous\u000a      thromboembolism [3].\u000a    The recognition of the importance of arterial thrombosis as a cause of\u000a      death and disability led to a substantial increase in the number of trials\u000a      involving antithrombotic agents. In 2002, the Antiplatelet Trialists'\u000a      Collaboration, renamed the Antithrombotic Trialists' (ATT) Collaboration,\u000a      updated the worldwide evidence from these trials [4]. The ATT\u000a      Collaboration's analyses reaffirmed the benefits of a prolonged course of\u000a      antiplatelet therapy for the prevention of serious vascular events, and\u000a      also demonstrated that intensification of antiplatelet therapy (by adding\u000a      a second antiplatelet agent to aspirin) yielded further benefits that\u000a      exceeded any additional risks of bleeding [4]. This strategy was studied,\u000a      for example, in CTSU's own CCS2-COMMIT (2005) trial of clopidogrel plus\u000a      aspirin versus aspirin alone among Chinese patients with suspected acute\u000a      heart attack, which showed that adding clopidogrel to aspirin therapy\u000a      resulted in additional benefits [5].\u000a    Whereas these studies showed clearly that the benefits of aspirin greatly\u000a      exceed the bleeding risks among patients at high risk of a heart attack or\u000a      stroke, considerable controversy remained as to whether the benefits\u000a      exceeded any risks among healthy people. In 2009, the ATT Collaboration\u000a      published a meta-analysis of six primary prevention trials of aspirin\u000a      versus placebo, using detailed data on individual participants, in order\u000a      to quantify the benefits and risks of aspirin at different levels of\u000a      predicted vascular disease risk [6]. This research showed clearly that the\u000a      vascular benefits of aspirin do not clearly exceed any bleeding hazards,\u000a      even among those with risk factors for cardiovascular disease. One reason\u000a      for this is that the risks of bleeding in an individual tend to mirror\u000a      their risks of coronary heart disease, so patients deriving greater\u000a      coronary benefits from aspirin also tend to suffer from greater risks of\u000a      bleeding [6]. Like earlier work from the ATT, this research has been\u000a      influential in guiding clinical practice and has been incorporated into\u000a      clinical guidelines.\u000a    "},{"CaseStudyId":"9537","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Taken together, the CTSU's Heart Protection Study, Cholesterol Treatment\u000d\u000a      Trialists' Collaboration, SEARCH and SHARP studies have shown that\u000d\u000a      lowering low-density lipoprotein (LDL), or `bad' cholesterol with a statin\u000d\u000a      regimen, or a statin-based regimen, reduces the risk of heart attacks,\u000d\u000a      strokes and revascularisation procedures in both high-risk and healthy\u000d\u000a      people, and that more intensive statin regimens lead to further reductions\u000d\u000a      in risk. This work has influenced treatment guidelines and statin\u000d\u000a      medication labelling internationally. Given the known benefits of statins\u000d\u000a      on vascular mortality, and their widespread use, it is likely that CTSU's\u000d\u000a      work has contributed to the continuing decline in vascular mortality that\u000d\u000a      has been observed in developed countries over the past decade.\u000d\u000a    All the major national and international healthcare policy guidelines on\u000d\u000a      cardiovascular disease prevention have been influenced by CTSU's work on\u000d\u000a      cholesterol-lowering statin therapy. For example, the National Heart Lung\u000d\u000a      and Blood Institute's (NCEP) ATPIII North American guidelines [A], which\u000d\u000a      are the main guidelines used in the US, specifically refer to the Heart\u000d\u000a      Protection Study results. The UK National Institute of Health and Care\u000d\u000a      Excellence (NICE) guidelines on cardiovascular disease and statins [B],\u000d\u000a      and European Society of Cardiology guidelines for the management of\u000d\u000a      dyslipidaemias [C], refer to CTSU's trials (HPS and SHARP) as well as the\u000d\u000a      CTT meta-analyses throughout. By providing unique information about the\u000d\u000a      safety of simvastatin 80mg daily, the SEARCH study significantly\u000d\u000a      influenced both FDA [D] and MHRA [E] guidance on prescription of statins.\u000d\u000a    The SHARP results provide definitive evidence for the efficacy and safety\u000d\u000a      of a statin-based regimen for the prevention of atherosclerotic events\u000d\u000a      among patients with chronic kidney disease. The Kidney Disease Improving\u000d\u000a      Global Outcomes (KDIGO) group generates internationally recognised\u000d\u000a      guidelines for the care of kidney patients, and a KDIGO Work Group (in\u000d\u000a      which 5 of the 11 members were also members of the SHARP Steering\u000d\u000a      Committee) has recently published updated guidance for the use of\u000d\u000a      statin-based regimens that is based chiefly on the SHARP trial [F]. SHARP\u000d\u000a      has also strongly influenced other guidelines, including the Canadian\u000d\u000a      Cardiovascular Society (CCS) Guidelines for the Diagnosis and Treatment of\u000d\u000a      Dyslipidaemia [G], most particularly by helping to identify CKD as an\u000d\u000a      important risk factor for cardiovascular disease.\u000d\u000a    The NHS reports that there has been a 40% reduction in deaths from heart\u000d\u000a      disease in people under 75 since 2000, and estimates that statins\u000d\u000a      currently save around 7,000 lives a year in the UK [H]. CTSU's work on\u000d\u000a      ensuring that statin therapy is used appropriately widely has undoubtedly\u000d\u000a      contributed to this saving of lives during the REF 2014 period. Indeed,\u000d\u000a      NICE guidance throughout the REF period recommended the HPS regimen of\u000d\u000a      simvastatin 40mg as their first line treatment for cardiovascular disease\u000d\u000a      prevention in high-risk patients [B]. Due to the major public health\u000d\u000a      impacts of CTSU's research into the safety and benefits of statin use,\u000d\u000a      this work has also been featured prominently both on the internet and in\u000d\u000a      print versions of mainstream newspapers. Recent articles include publicity\u000d\u000a      surrounding the CTT's work on the effects of reducing cholesterol among\u000d\u000a      apparently healthy people, for example in the Daily Mail [I] and on the\u000d\u000a      effects of more intensive statin regimens in the Daily Telegraph [J].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Studies coordinated by the University of Oxford's Clinical Trial Service\u000d\u000a      Unit (CTSU) within the Nuffield Department of Population Health (NDPH)\u000d\u000a      have strongly influenced the labelling of statin medication\u000d\u000a      internationally, treatment guidelines, and the resulting changes in\u000d\u000a      prescribing have contributed to reductions in mortality and morbidity from\u000d\u000a      heart attack and ischaemic stroke in many countries. CTSU's randomised\u000d\u000a      trials and meta-analyses of trials have shown that lowering low-density\u000d\u000a      lipoprotein (LDL) cholesterol safely reduces the risk of heart attacks,\u000d\u000a      strokes and revascularisation procedures in a wide range of people, and\u000d\u000a      work conducted in collaboration with the NDPH's Health Economic Research\u000d\u000a      Centre has provided clear evidence of cost-effectiveness of statins.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    The University of Oxford\u000d\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1]. Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection\u000d\u000a      Study of cholesterol lowering with simvastatin in 20,536 high-risk\u000d\u000a      individuals: a randomised placebo-controlled trial. Lancet 360,\u000d\u000a      7-22 (2002). PubMed ID: 12114036. Primary paper from the Heart\u000d\u000a          Protection Study, showing that simvastatin 40mg daily reduced\u000d\u000a          the overall risk of death in a wide range of people at high\u000d\u000a          risk of cardiovascular disease.\u000d\u000a    \u000a\u000a[2]. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and\u000d\u000a      safety of cholesterol-lowering treatment: prospective meta-analysis of\u000d\u000a      data from 90,056 participants in 14 randomised trials of statins. Lancet\u000d\u000a      366, 1267-1278 (2005). PubMed ID: 1621459. The first CTT\u000a          study indicating that statins reduce the risk of heart attacks,\u000d\u000a          strokes and coronary revascularisation. This study also showed\u000d\u000a          that statin therapy does not increase the risk of cancer or\u000d\u000a          non-cardiovascular causes of death.\u000d\u000a    \u000a\u000a[3]. Study of the Effectiveness of Additional Reductions in Cholesterol\u000d\u000a      and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL\u000d\u000a      cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors\u000d\u000a      of myocardial infarction: a double-blind randomised trial. Lancet 2010;\u000d\u000a      376: 1658-69. PubMed ID: 21067805. This trial demonstrated that\u000d\u000a          larger reductions in cholesterol, with a regimen of 80 mg\u000d\u000a          daily simvastatin, produced worthwhile further reductions in\u000d\u000a          CHD compared with a standard 20 mg daily regimen.\u000d\u000a    \u000a\u000a[4]. Cholesterol Treatment Trialists' (CTT) Collaboration et al.\u000d\u000a      Efficacy and safety of more intensive lowering of LDL cholesterol: a\u000d\u000a      meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet\u000d\u000a      376, 1670-1681 (2010). PubMed ID: 21067804. A meta-analysis\u000d\u000a        showing that more intensive regimens of statins yield additional\u000d\u000a          benefits without any additional safety concerns.\u000d\u000a    \u000a\u000a[5]. Cholesterol Treatment Trialists' (CTT) Collaborators et al.\u000d\u000a      The effects of lowering LDL cholesterol with statin therapy in people at\u000d\u000a      low risk of vascular disease: meta-analysis of individual data from 27\u000d\u000a      randomised trials. Lancet 380, 581-590 (2012). PubMed ID:\u000d\u000a      22607822. A meta-analysis showing definitively that the benefits of\u000d\u000a          statin therapy clearly outweigh the hazards in healthy people.\u000d\u000a    \u000a\u000a[6]. Baigent, C. Landray MJ, Reith C, et al. The effects of\u000d\u000a      lowering LDL cholesterol with simvastatin plus ezetimibe in patients with\u000d\u000a      chronic kidney disease (Study of Heart and Renal Protection): a randomised\u000d\u000a      placebo-controlled trial. Lancet 377, 2181-2192 (2011).\u000d\u000a      PubMed ID: 21663949. The SHARP study from NDPH provided the first\u000d\u000a          reliable evidence that lowering cholesterol reduces the risk\u000d\u000a          of heart attacks and strokes among kidney patients.\u000d\u000a    \u000aThe CTT Collaborative Group's work has been supported by funding from the\u000d\u000a      UK Medical Research Council, the British Heart Foundation, the European\u000d\u000a      Community Biomed Programme, the Australian National Health and Medical\u000d\u000a      Research Council and National Heart Foundation, and grants from Merck and\u000d\u000a      Schering Plough.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"}],"Sources":"\u000d\u000a    [A]. ATP 3 Cholesterol Guidelines, NHLBI. nhlbi.nih.gov at http:\/\/www.nhlbi.nih.gov\/guidelines\/cholesterol\/atp3full.pdf\u000d\u000a      [Accessed 6th September 2013]\u000d\u000a      National Heart Lung and Blood Institute's (NCEP) ATPIII North\u000d\u000a          American guidelines on statin use, published in 2002 and still\u000d\u000a          current as of September 2013. See page II-61.\u000d\u000a    [B]. NICE Guidelines: Lipid modification: Cardiovascular risk assessment\u000d\u000a      and the modification of blood lipids for the primary and secondary\u000d\u000a      prevention of cardiovascular disease. http:\/\/www.nice.org.uk\/nicemedia\/live\/11982\/40742\/40742.pdf\u000d\u000a      [Accessed 6th September 2013]\u000d\u000a        UK National Institute of Health and Care Excellence guidelines on\u000d\u000a          lipid modification quote the CTT Lancet meta-analysis widely\u000d\u000a          in their guidance. See pages 147, 168 (HPS), 166, 167, 168,\u000d\u000a          205, 206, 208 (CTT).\u000d\u000a    [C]. ESC\/EAS Guidelines for the management of dyslipidaemias (2011) http:\/\/www.escardio.org\/guidelines-surveys\/esc-guidelines\/GuidelinesDocuments\/guidelines-dyslipidemias-FT.pdf\u000d\u000a      [Accessed 6th September 2013].\u000d\u000a    The European Society of Cardiology guidelines for the management of\u000d\u000a        dyslipidaemias. See pages 1792, 1806 (SHARP); 1783 (CTT)\u000d\u000a    [D]. US Food and Drug Administration website: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProvide\u000a        rs\/ucm204882.htm [Accessed 31st October 2013]. This\u000a          FDA guidance specifically refers to the SEARCH results in\u000d\u000a          relation to the risk of muscle injury with high dose statins.\u000d\u000a    [E]. Medicine and Healthcare products Regulatory Agency Drug Safety\u000d\u000a      Update Volume 3, Issue 10, May 2010. http:\/\/www.mhra.gov.uk\/Safetyinformation\/DrugSafetyUpdate\/CON085169\u000d\u000a      [Accessed 31st October 2013]. This MHRA update comments\u000d\u000a          on the implications of the SEARCH results.\u000d\u000a    [F]. KDIGO Clinical Practice Guideline for Lipid Management in Chronic\u000d\u000a      Kidney Disease Kidney International Supplements (2013) 3, 261;\u000d\u000a      doi:10.1038\/kisup.2013.29 http:\/\/www.kdigo.org\/clinical_practice_guidelines\/pdf\/LIPIDS\/KDIGO\u000a        Lipid GL.pdf [Accessed 5th November 2013]. The\u000d\u000a          KDIGO guidelines are the main guidelines used internationally by\u000a          nephrologists, and this update is based chiefly on the results of\u000d\u000a          SHARP.\u000d\u000a    [G]. 2012 update of the Canadian Cardiovascular Society guidelines for\u000d\u000a      the diagnosis and treatment of dyslipidemia for the prevention of\u000d\u000a      cardiovascular disease in the adult. Can J Cardiol. 2013\u000d\u000a      Feb;29(2):151-67. doi: 10.1016\/j.cjca.2012.11.032. PubMed ID 23351925.\u000d\u000a      These guidelines specifically refer to the SHARP results and\u000d\u000a          highlight the important role of CKD as a significant CV risk\u000d\u000a          factor.\u000d\u000a    [H]. NHS Choices. Coronary Heart Disease-Treatment. http:\/\/www.nhs.uk\/Conditions\/Coronary-heart-disease\/Pages\/Treatment.aspx\u000d\u000a      [Accessed 6th September 2013]. NHS Choices information\u000a          page, reporting statistics about reduction in Coronary Heart Disease\u000d\u000a          and statin use in the UK.\u000d\u000a    [I]. `All over-50s should take statins regardless of their health\u000d\u000a      history,' says Oxford professor | Mail Online 2012. dailymail.co.uk\u000d\u000a      at http:\/\/www.dailymail.co.uk\/health\/article-2194892\/All-50s-statins-regardless-health-history-says-Oxford-professor.html\u000d\u000a      [Accessed 6th September 2013].\u000d\u000a        Daily Mail article about CTSU's statin research featuring an\u000d\u000a          interview with Rory Collins.\u000d\u000a    [J]. More potent statins `could save thousands' &#8212; Telegraph 2010. http:\/\/www.telegraph.co.uk\/health\/8117635\/More-potent-statins-could-save-thousands.html\u000d\u000a      [Accessed 6th September 2013]. Daily Telegraph article about CTSU's\u000d\u000a          statin research featuring an interview with Colin Baigent.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    STATIN THERAPY FOR PREVENTING HEART ATTACKS AND STROKES\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    CTSU's Heart Protection Study (HPS), which commenced in 1994 and included\u000d\u000a      over 20,000 patients, showed that simvastatin 40mg daily reduced the risk\u000d\u000a      of heart attacks, strokes, and the need for arterial revascularisation\u000d\u000a      procedures in a wide range of people at high risk of cardiovascular\u000d\u000a      disease [1]. At about the same time that the HPS began, CTSU set up a\u000d\u000a      collaborative meta-analysis called the Cholesterol Treatment Trialists'\u000d\u000a      (CTT) Collaboration, with the aim of providing more reliable information\u000d\u000a      about the effects of lowering LDL cholesterol on vascular and non-vascular\u000d\u000a      outcomes. The first CTT report in 2005 included data from around 90,000\u000d\u000a      patients in 14 randomised trials, and provided comprehensive information\u000d\u000a      that has helped to guide the use of statin therapy internationally [2]. It\u000d\u000a      showed that treatment with a statin reduces the risk of heart attacks,\u000d\u000a      strokes and coronary revascularisation procedures, as well as the overall\u000d\u000a      risk of death, in a wide range of patients at risk of cardiovascular\u000d\u000a      disease. It also refuted previous concerns that statin therapy might\u000d\u000a      increase the risk of cancer, and non-cardiovascular causes of death [2].\u000d\u000a    In 2010, CTSU published the results of its Study of the Effectiveness of\u000d\u000a      Additional Reductions in Cholesterol and Homocysteine [SEARCH] trial [3]\u000d\u000a      comparing 80 mg versus 20 mg simvastatin daily among 12,000 heart attack\u000d\u000a      survivors. It showed that simvastatin 80mg produced further reductions in\u000d\u000a      major vascular events, but that the risk of myopathy was increased. In\u000d\u000a      tandem with this publication, the CTT published a meta-analysis of the\u000d\u000a      five major trials of intensive versus standard statin regimens (including\u000d\u000a      SEARCH), showing that more intensive regimens yield additional benefits,\u000d\u000a      and that this could be achieved safely with regimens other than\u000d\u000a      simvastatin 80mg. [4]\u000d\u000a    Recently, there has been controversy over whether statins are effective\u000d\u000a      for the prevention of first heart attacks and strokes in apparently\u000d\u000a      healthy people. In 2012, however, the CTT published a meta-analysis\u000d\u000a      showing definitively that the benefits of statin therapy clearly outweigh\u000d\u000a      the hazards in people at low risk of cardiovascular disease [5].\u000d\u000a    In addition to its work on the CTT collaboration, CTSU has also provided\u000d\u000a      the first reliable evidence that lowering cholesterol reduces the risk of\u000d\u000a      heart attacks and strokes among kidney patients. Its Study of Heart and\u000d\u000a      Renal Protection (SHARP) was the largest study of its kind, and included\u000d\u000a      over 9000 kidney patients in 380 hospitals from 18 countries. This study\u000d\u000a      showed that lowering cholesterol with the combination of a statin and a\u000d\u000a      drug that blocks cholesterol absorption, ezetimibe can reduce heart\u000d\u000a      attacks and strokes safely by about one quarter in kidney patients [6].\u000d\u000a    "},{"CaseStudyId":"9538","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    The key to being able to rapidly mount a study of pregnant women,\u000a      hospitalised with 2009\/H1N1 pandemic influenza, was the prior\u000a      establishment in 2005 of the novel UKOSS system, which allows for rapid\u000a      institution of research into pregnancy complications in the event of a\u000a      public health emergency such as this. For the influenza study, data were\u000a      analysed cumulatively on a monthly basis, enabling Professor Knight to\u000a      feedback results in real-time via weekly teleconferences and monthly\u000a      meetings at the Department of Health. In this way the UKOSS findings were\u000a      central to immediate policy development, for guidance on the management of\u000a      pregnant women infected the with 2009\/H1N1 virus, as the course of the\u000a      pandemic evolved [A, B, C]. The UKOSS results indicated that pregnant\u000a      women treated earlier with antiviral therapy had better maternal and\u000a      perinatal outcomes than those treated later in their clinical course or\u000a      not at all. National advice and the clinical algorithm was changed as a\u000a      result leading to the earlier initiation of antiviral therapy particularly\u000a      for pregnant women and action by the Department of Health to ensure the\u000a      availability of antiviral therapy to pregnant women through the National\u000a      Pandemic Flu Service and Antiviral Collection Points [C].\u000a    The extent of maternal morbidity, and maternal and perinatal deaths\u000a      quantified by the UKOSS study, contributed to the change in immunisation\u000a      policy in the UK during the course of the pandemic to actively offer\u000a      pregnant women immunisation. This policy change has now been adopted as an\u000a      on-going recommendation that annually all pregnant women should be\u000a      immunised against seasonal influenza [D, E]. The number of pregnant women\u000a      immunised against influenza in England has subsequently increased, from\u000a      118,000 in 2009\/10, to 124,000 in 2010\/11 and 196,000 in 2011\/12 [F].\u000a    The impact of the research was achieved by the direct input of real-time\u000a      research results by Professor Marian Knight into the decision making\u000a      systems at the Department of Health for England. Results were also shared\u000a      with the Influenza planning group at the Royal College of Obstetricians\u000a      and Gynaecologists during the course of the evolving pandemic. Later\u000a      impact is demonstrated by the subsequent recommendation, which\u000a      incorporated the study data, issued by the European Centre for Disease\u000a      Control and Prevention (ECDC). The recommendation states that universal\u000a      influenza immunisation for pregnant women should be offered throughout\u000a      Europe [G].\u000a    Once the pandemic had abated it became clear from data collected by UKOSS\u000a      and the National Confidential Enquiry into Maternal Deaths that 13\u000a      pregnant women in the UK had died as a direct result of 2009\/H1N1\u000a      influenza virus infection. These deaths could have been prevented by prior\u000a      immunisation. In addition, the study results suggested that early\u000a      treatment with antiviral medication led to a 90% reduction in the odds of\u000a      admission for critical care. The resulting substantial changes in\u000a      practice, which were instituted as a result of the UKOSS study findings,\u000a      were, and continue to be, instrumental in preventing the deaths and\u000a      serious morbidity for pregnant women and their babies in the UK and\u000a      elsewhere. The study is referenced in guidance for critical care\u000a      clinicians [H]. It is also referenced in current media campaigns to\u000a      highlight the importance of on-going immunisation to women [I], and in\u000a      policy documents recommending immunisation against influenza in pregnancy\u000a      in countries other than the UK [J].\u000a    ","ImpactSummary":"\u000a    Researchers at the University of Oxford instituted a rapid study of\u000a      pregnant women hospitalised across the UK with 2009\/H1N1 infection, which\u000a      demonstrated that early antiviral treatment improved maternal outcomes of\u000a      infection and led to actions by the Department of Health to ensure rapid\u000a      availability of antivirals specifically for pregnant women. The poor\u000a      maternal and perinatal outcomes identified by this study also led to an\u000a      on-going policy change, so that all pregnant women in the UK are now\u000a      recommended to receive annual immunisation against seasonal influenza.\u000a    ","ImpactType":"Political","Institution":"\u000a    The University of Oxford\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a[1]. Knight M, Kurinczuk JJ, Tuffnell D, Brocklehurst P. The UK Obstetric\u000a      Surveillance System for rare disorders of pregnancy. Br J Obstet Gynaecol\u000a      2005; 112: 263-5.\u000a      PubMed ID: 15713136. Paper describing the establishment of the UK\u000a          Obstetric Surveillance System.\u000a    \u000a\u000a[2]. Yates L, Pierce M, Stephens S, Mill AC, Spark P, Kurinczuk JJ,\u000a      Valappil M, Brocklehurst P, Thomas SH, Knight M. Influenza A\/H1N1v in\u000a      pregnancy: an investigation of the characteristics and management of\u000a      affected women and the relationship to pregnancy outcome for mother and\u000a      infant. Health Technol Assess 2010;14:109-82.\u000a      PubMed ID: 20630123. http:\/\/www.hta.ac.uk\/execsumm\/summ1434-02.shtml\u000a      [accessed 9\/10\/13]. Monograph describing the maternal outcomes of\u000a          2009\/H1N1 influenza. Oxford researchers led the secondary care study.\u000a    \u000a\u000a[3]. Knight M, Pierce M, Seppelt I, Kurinczuk JJ, Spark P, Brocklehurst\u000a      P, McLintock C, Sullivan E on behalf of the UK's Obstetric Surveillance\u000a      System, the ANZIC Influenza Investigators, and the Australasian Maternity\u000a      Outcomes Surveillance System. Critical illness with AH1N1v influenza in\u000a      pregnancy: a comparison of two population-based cohorts. Br J Obstet\u000a      Gynaecol 2011;118:232-9. doi: 10.1111\/j.1471-0528.2010.02736.x.\u000a      PubMed ID: 21040393. Paper showing better outcomes of 2009\/H1N1\u000a          influenza in the UK compared to Australasia, after public health\u000a          measures were introduced.\u000a    \u000a\u000a[4]. Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M on behalf\u000a      of UKOSS. Perinatal outcomes after maternal 2009\/H1N1 infection: a\u000a      national cohort study. Br Med J 2011 Jun 14;342:d3214. doi:\u000a      10.1136\/bmj.d3214. PubMed ID: 21672992. Paper detailing the\u000a          perinatal outcomes of 2009\/H1N1 influenza, after all on-going\u000a          pregnancies were completed.\u000a    \u000aThis research was funded by the UK National Institute for Health Research\u000a      Health Technology Assessment (HTA) programme.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [A]. Minutes and action logs available from the Influenza Clinical\u000a      Information Network (FLU-CIN) meetings\/teleconferences. These\u000a          documents demonstrate the use of the study data to inform policy\u000a          development during the H1N1 influenza pandemic.\u000a    [B]. Factual statement provided by the Department of Health Clinical\u000a      Advisor. Written statement describing the use made of the study\u000a          data to develop policy and clinical guidelines.\u000a    [C]. H1N1 (2009) winter flu: Updated guidance for providers of maternity\u000a      services. London: Department of Health 2011. http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1294740886540\u000a      [accessed 4\/11\/13]. This is the key Department of Health policy\u000a          document describing immunisation and antiviral prescription\u000a          recommendations.\u000a    [D]. http:\/\/www.nhs.uk\/news\/2011\/10October\/Pages\/swine-flu-H1N1-risk-pregnancy-still-birth.aspx\u000a      [accessed 9\/10\/13]. This immunisation campaign article references\u000a          the BMJ paper and advises women to get the vaccine.\u000a    [E]. http:\/\/www.hpa.org.uk\/web\/HPAweb&amp;HPAwebStandard\/HPAweb_C\/1195733756886\u000a      [accessed 9\/10\/13]. The Health Protection Agency link to vaccine\u000a          uptake information for 2009-2012.\u000a    [F]. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/147958\/Green-\u000a        Book-Chapter-19-v4_71.pdf [accessed 4\/11\/13]. Department of\u000a          Health guidance on immunisation for influenza in pregnancy (updated\u000a          for 2012\/13 winter influenza season). See page 202.\u000a    [G]. http:\/\/www.ecdc.europa.eu\/en\/publications\/publications\/seasonal%20influenza%20vaccination\u000a        %20of%20children%20and%20pregnant%20women.pdf [accessed 4\/10\/13]. This\u000a          is the ECDC European advice that all women should be immunised against\u000a          influenza in pregnancy. See pages 2, 3, 12, 14.\u000a    [H]. http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1287148502205\u000a      [accessed 4\/11\/13]. Guidance from the Health Protection Agency on\u000a          critical care management of adults with influenza with particular\u000a          reference to H1N1.\u000a    [I]. http:\/\/www.guardian.co.uk\/politics\/2010\/sep\/30\/pregnant-women-flu-jab-list\u000a      [accessed 9\/10\/13]. Guardian article citing the government campaign\u000a          to encourage women to have immunisation against seasonal influenza.\u000a    [J]. http:\/\/www.hpsc.ie\/hpsc\/A-Z\/Respiratory\/Influenza\/SeasonalInfluenza\/Guidance\/PregnancyGuidance\/File,13162,en.pdf\u000a      [accessed 4\/11\/13]. Guidance from the Republic of Ireland citing\u000a          the study and recommending immunisation against seasonal influenza for\u000a          pregnant women. \u000a    ","Title":"\u000a    UNDERPINNING EVIDENCE-BASED POLICY FOR MANAGEMENT OF INFLUENZA IN\u000a        PREGNANT WOMEN\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Following the outbreak of the 2009\/H1N1 influenza pandemic, pregnant\u000a      women were identified as a probable high-risk group. The existence of UK\u000a      Obstetric Surveillance System (UKOSS) [1] developed and led by Professor\u000a      Marian Knight and colleagues at the National Perinatal Epidemiology Unit,\u000a      University of Oxford, enabled the rapid initiation of a study of pregnant\u000a      women hospitalised across the UK with 2009\/H1N1 infection [2]. Data were\u000a      analysed on a monthly basis to inform the development of on-going policy\u000a      and guidance issued by the Department of Health. This allowed for\u000a      real-time changes to policy and guidelines as the data accumulated,\u000a      enabling a rapid response to the emerging pandemic.\u000a    The study findings demonstrated that early antiviral treatment for\u000a      pregnant women led to a 90% reduction in the odds of admission for\u000a      critical care. This resulted in actions by the Department of Health to\u000a      ensure rapid availability of antivirals specifically for pregnant women,\u000a      through the modification of the clinical algorithms in use, enabling\u000a      availability of antivirals for pregnant women through the National\u000a      Pandemic Flu Service. Guidance for obstetricians and other clinicians\u000a      involved in the care of pregnant women was also modified [2].\u000a    The poor maternal and perinatal outcomes identified by the study, showing\u000a      a five times increase in the risk of perinatal death and a more than three\u000a      times increase in the risk of premature birth amongst the infants of\u000a      infected women, also led to a change in immunisation policy in the UK\u000a      during the course of the pandemic. The updated policy classified pregnant\u000a      women as an \"at-risk group\" eligible for influenza vaccination [3,4].\u000a    These data have also led to an on-going policy change, so that all\u000a      pregnant women in the UK are now recommended to receive an annual\u000a      immunisation against seasonal influenza. The European Centre for Disease\u000a      Control and Prevention (ECDC) also issued a subsequent recommendation,\u000a      based on UKOSS data, that universal influenza immunisation for pregnant\u000a      women should be offered throughout Europe [see reference G in impact\u000a      section].\u000a    "},{"CaseStudyId":"9539","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2802361","Name":"Belgium"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Results from the University of Oxford's Million Women Study, have changed\u000d\u000a      attitudes towards HRT\u000d\u000a      dramatically, leading to significant changes in public policy and HRT use\u000d\u000a      around the world. This\u000d\u000a      research has also led to significant reductions in breast cancer incidence\u000d\u000a      amongst menopausal\u000d\u000a      women.\u000d\u000a    Public Policy\u000d\u000a      Results from the Million Women Study have influenced a number of European\u000d\u000a      health agency\u000d\u000a      guidelines, which now recommend that women at a high risk of breast cancer\u000d\u000a      consider alternative\u000d\u000a      options to HRT. These agencies include the Royal College of Obstetricians\u000d\u000a      and Gynaecologists\u000d\u000a      [A], the Medicines and Healthcare products Regulatory Agency [B], and the\u000d\u000a      European Medicines\u000d\u000a      Agency [C].\u000d\u000a    Culture and Behaviour\u000d\u000a      Since publication, the Million Women Study has been presented to the\u000d\u000a      public at length both in print\u000d\u000a      and online &#8212; from articles in the New York Times and Daily\u000d\u000a        Telegraph to women's health blogs and\u000d\u000a      cancer charity websites around the world.\u000d\u000a    This far-reaching public awareness of the study and its findings led to\u000d\u000a      significant behavioural\u000d\u000a      changes, predominately resulting in the swift decline of HRT prescriptions\u000d\u000a      throughout Europe and\u000d\u000a      the US from 2003. In stark contrast to the increase in HRT prescriptions\u000d\u000a      between 1991 and 1996,\u000d\u000a      which remained stable through to 2001, sales of HRT fell by 50% between\u000d\u000a      2002 and 2005\u000d\u000a      following the publication of the WHI trial and the Million Women Study\u000d\u000a      [D]. Recent studies\u000d\u000a      demonstrate the continuing impact of this research on behaviour in terms\u000d\u000a      of continued reduced\u000d\u000a      HRT use [E, F].\u000d\u000a    One such study published in 2010 in Belgium (a country known to have one\u000d\u000a      of the highest\u000d\u000a      incidences of breast cancer in Europe), shows that the proportion of women\u000d\u000a      aged 50-69 years\u000d\u000a      using HRT in Flanders went from a 20% peak in 2001, to just 8% in 2008.\u000d\u000a      The study also showed\u000d\u000a      a decrease in breast cancer incidence [G].\u000d\u000a    Health\u000d\u000a      Due to the substantial decline in the use of HRT in many countries, the\u000d\u000a      incidence of breast cancer\u000d\u000a      has markedly decreased in women between the ages of 45 and 64. Declines in\u000d\u000a      the rate of breast\u000d\u000a      cancer have been strongest for women between the age of 50 and 60 years,\u000d\u000a      with rates which were\u000d\u000a      previously on the incline dropping by 0.8% a year [H, I]. More recent data\u000d\u000a      [E, F, I], which were\u000d\u000a      published between 2010 and 2012, show that lower levels of HRT use and\u000d\u000a      breast cancer incidence\u000d\u000a      subsequent to the steep decline in HRT use, which followed the publication\u000d\u000a      of the Million Women\u000d\u000a      Study, have continued into the REF assessment period of 2008 - 2013.\u000d\u000a      Breast cancer incidence in\u000d\u000a      Great Britain among women aged 50 to 64 peaked in 2004 and then showed a\u000d\u000a      rapid decline over\u000d\u000a      three years, with the lower rates then persisting through to at least 2010\u000d\u000a      (the most recently\u000d\u000a      available incidence data) and being partly attributed to the reduction in\u000d\u000a      HRT use in this age group\u000d\u000a      [I]. Similarly, a report assessing breast cancer incidence in Belgium up\u000d\u000a      to the end of 2008 showed\u000d\u000a      a significant drop in breast cancer incidence, which was attributed to the\u000d\u000a      significant decrease in\u000d\u000a      HRT use in Belgium during and leading up 2008 [F].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The Million Women Study of 1.3 million UK women over the age of 50,\u000d\u000a      coordinated by the Cancer\u000d\u000a      Epidemiology Unit at Oxford, has established the relationship between\u000d\u000a      hormone replacement\u000d\u000a      therapy (HRT) and breast, endometrial, and ovarian cancer, and has had a\u000d\u000a      dramatic effect on HRT\u000d\u000a      prescription patterns and prescription guidelines worldwide. This has had\u000d\u000a      a major impact on\u000d\u000a      women's health. Prior to the study, one third of UK women aged 50-64 were\u000d\u000a      using HRT. The\u000d\u000a      marked decline in HRT use following publication of the study's findings\u000d\u000a      has led to a reduction in the\u000d\u000a      incidence of breast cancer among menopausal women.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    The University of Oxford\u000d\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1]. Million Women Study. cancerscreening.nhs.uk at\u000d\u000a      http:\/\/www.cancerscreening.nhs.uk\/breastscreen\/research-million-women-study.html.\u000d\u000a      [Accessed\u000d\u000a      6\/09\/13]. NHS website referring to the Million Women Study as the\u000d\u000a          largest study of its kind\u000d\u000a          in the world.\u000d\u000a    \u000a\u000a[2]. The Million Women Study: Million Women Study. millionwomenstudy.org\u000d\u000a      at\u000d\u000a      http:\/\/www.millionwomenstudy.org\/publications\/ [Accessed 6\/09\/13].The\u000d\u000a          Million Women Study\u000d\u000a          website showing the number of publications that have resulted from the\u000d\u000a          Million Women\u000d\u000a          Study.\u000d\u000a    \u000a\u000a[3]. Beral, V., Million Women Study Collaborators. Breast cancer and\u000d\u000a      hormone-replacement\u000d\u000a      therapy in the Million Women Study. Lancet 362, 419-427\u000d\u000a      (2003). PubMed ID: 12927427. Paper\u000d\u000a          on the relationship between breast cancer and HRT.\u000d\u000a    \u000a\u000a[4]. Beral, V., Million Women Study Collaborators. Breast cancer risk in\u000d\u000a      relation to the interval\u000d\u000a      between menopause and starting hormone therapy. J Natl Cancer Inst.\u000d\u000a      103, 296-305 (2011).\u000d\u000a      PubMed ID: 21278356. Paper on the relationship between breast\u000d\u000a          cancer and HRT by pattern\u000d\u000a          of use and tumour subtype.\u000d\u000a    \u000a\u000a[5]. Beral, V., Million Women Study Collaborators. Endometrial cancer\u000d\u000a      hormone &#8212; replacement\u000d\u000a      therapy in the Million Women Study. Lancet 365, 1543-1551\u000d\u000a      (2005). PubMed ID: 15866308.\u000d\u000a      Paper on the relationship between endometrial cancer and HRT.\u000d\u000a    [6]. Beral, V., Million Women Study Collaborators, Bull, D., Green, J. &amp;\u000d\u000a    Reeves, G. Ovarian cancer\u000d\u000a    and hormone replacement therapy in the Million Women Study. \u000aLancet 369,\u000d\u000a    1703-1710 (2007).\u000d\u000a    PubMed ID: 17512855. Paper on the relationship between ovarian cancer\u000d\u000a        and HRT.\u000d\u000a    This research was funded by Cancer Research UK, the NHS Breast Screening\u000d\u000a      Programme and\u000d\u000a      the UK Medical Research Council.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"12","Subject":"Oncology and Carcinogenesis"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    [A]. Whitehead, M. I. RCOG study group on menopause and HRT RCOG\u000d\u000a      recommendations on\u000d\u000a      hormone replacement therapy. Lancet 365, 749 (2005). PubMed ID:\u000d\u000a      15733708.\u000d\u000a      Paper making Royal College of Obstetricians and Gynaecologists\u000d\u000a          recommendations on\u000d\u000a          HRT use for menopausal women, which although published in 2005 has not\u000d\u000a          been\u000d\u000a          superseded.\u000d\u000a    [B]. Further advice on safety of hormone replacement therapy (HRT), at\u000d\u000a      http:\/\/www.mhra.gov.uk\/NewsCentre\/Pressreleases\/CON002044 [Accessed\u000d\u000a      6\/09\/13].\u000d\u000a      Recommendations from the Medicines and Healthcare products\u000d\u000a          Regulatory Agency (UK) on\u000d\u000a          HRT use, which refers directly to the Million Women Study.\u000d\u000a    [C]. European Medicines Agency. ema.europa.eu at\u000d\u000a      http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003348.pdf\u000a[Accessed\u000d\u000a      29\/09\/13]. Recommendations from the European Medicines Agency on\u000d\u000a          HRT use, published in 2005 but remaining in force and hence achieving\u000d\u000a          impact during the\u000d\u000a          assessment period. The Million Women Study is cited as one of the main\u000d\u000a          sources of\u000d\u000a          evidence (see page 9).\u000d\u000a    [D]. Watson, J., Wise, L. &amp; Green, J. Prescribing of hormone therapy\u000d\u000a      for menopause, tibolone, and\u000d\u000a      bisphosphonates in women in the UK between 1991 and 2005. Eur. J.\u000d\u000a        Clin. Pharmacol. 63, 843-849\u000d\u000a      (2007). PubMed ID: 17598097. Paper showing drop in HRT prescription\u000d\u000a          rates following\u000d\u000a          the publication of Million Women Studies.\u000d\u000a    [E]. Renard, F. et al. Decline in breast cancer incidence in the Flemish\u000d\u000a      region of Belgium after a\u000d\u000a      decline in hormonal replacement therapy. Ann. Oncol. 21, 2356-2360\u000d\u000a      (2010). PubMed ID:\u000d\u000a      20439342. Paper on the decline in breast cancer rates following the\u000d\u000a          drop in HRT use in\u000d\u000a          Belgium.\u000d\u000a    [F]. Antoine, C., Ameye, L., Paesmans, M. &amp; Rozenberg, S. Update of\u000d\u000a      the evolution of breast\u000d\u000a      cancer incidence in relation to hormone replacement therapy use in\u000d\u000a      Belgium. Maturitas 72, 317-323\u000d\u000a      (2012). PubMed ID: 22627077. Recent study on the decline in breast\u000d\u000a          cancer rates\u000d\u000a          following the drop in HRT use in Belgium.\u000d\u000a    [G]. Parkin, D. M. Is the recent fall in incidence of post-menopausal\u000d\u000a      breast cancer in UK related to\u000d\u000a      changes in use of hormone replacement therapy? Eur. J. Cancer 45,\u000d\u000a      1649-1653 (2009). PubMed\u000d\u000a      ID: 19217279. Paper showing the declines in the rate of breast\u000d\u000a          cancer since 1999.\u000d\u000a    [H]. Verkooijen, H. M., Bouchardy, C., Vinh-Hung, V., Rapiti, E. &amp;\u000d\u000a      Hartman, M. The incidence of\u000d\u000a      breast cancer and changes in the use of hormone replacement therapy: a\u000d\u000a      review of the evidence.\u000d\u000a      Maturitas 64, 80-85 (2009). PubMed ID: 19709827. Paper\u000d\u000a          reporting behavioral changes in HRT\u000d\u000a          use and the subsequent health outcomes.\u000d\u000a    [I]. Cancer Research UK Breast cancer statistics.\u000d\u000a      cancerresearchuk.org\/cancer-info\u000d\u000a      http:\/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/types\/breast\/incidence\/uk-breast-cancer-incidence-statistics\u000a[Accessed\u000d\u000a      6\/09\/13]. Cancer Research UK information sheet reporting\u000d\u000a          breast cancer incidence data and directly citing the Million Women\u000d\u000a          Study research on HRT\u000d\u000a          and breast cancer (see Figure 1.4 and subsequent text, citing\u000d\u000a          reference 11).\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    HORMONE REPLACEMENT THERAPY AND CANCER RISK: THE MILLION WOMEN STUDY\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Clinicians have questioned the health impacts of hormone replacement\u000d\u000a      therapy (HRT) for decades.\u000d\u000a      Although originally touted as a wonder drug benefiting health, vitality\u000d\u000a      and femininity, HRT has been\u000d\u000a      plagued by fears of its relationship to cancer since the 1950s. At the\u000d\u000a      turn of the 21st Century these\u000d\u000a      fears were supported by a number of studies showing the correlation\u000d\u000a      between HRT and cancer, in\u000d\u000a      particularly the Women's Health Initiative (WHI) study, which took place\u000d\u000a      in the United States.\u000d\u000a    Initially dismissed in the United Kingdom, due to the WHI study not being\u000d\u000a      based on European\u000d\u000a      women's health, the need for a similar epidemiological study to reflect\u000d\u000a      the risk factors of HRT\u000d\u000a      among women in Europe became a high priority.\u000d\u000a    Setting out to understand the health impacts of HRT from a European\u000d\u000a      perspective, a team\u000d\u000a      coordinated by Professor Dame Valerie Beral of the University of Oxford's,\u000d\u000a      Cancer Epidemiology\u000d\u000a      Unit, began recruiting a large number of UK women to investigate how\u000d\u000a      reproductive history can\u000d\u000a      affect women's health &#8212; focusing particularly on hormone replacement\u000d\u000a      therapy.\u000d\u000a    The Million Women Study, launched in 1997, has since recruited 1.3\u000d\u000a      million UK women over the\u000d\u000a      age of 50, through NHS breast screening centres. It is the largest study\u000d\u000a      of its kind in the world [1],\u000d\u000a      with one in four UK women in the target age group participating.\u000d\u000a    Results of the study have been published in more than 50 papers since\u000d\u000a      1998 [2], primarily\u000d\u000a      examining the effect of HRT on the development of breast, endometrial and\u000d\u000a      ovarian cancer.\u000d\u000a    Breast Cancer: In a landmark paper published in 2003, the Million\u000d\u000a      Women Study showed that\u000d\u000a      women taking HRT were at an increased risk of developing breast cancer,\u000d\u000a      with an estimated\u000d\u000a      20,000 UK women aged 50-64 having potentially developed the disease due to\u000d\u000a      HRT use [3]. The\u000d\u000a      study also showed that the risk of side effects increased the longer a\u000d\u000a      woman used HRT, but\u000d\u000a      dropped to a normal level five years after the use of HRT had ceased.\u000d\u000a      Analyses in the Million\u000d\u000a      Women Study have also demonstrated that the effects of HRT vary\u000d\u000a      considerably by pattern of use\u000d\u000a      and tumour subtype [4].\u000d\u000a    Endometrial Cancer: In 2005 the Million Women Study confirmed that\u000d\u000a      post-menopausal women\u000d\u000a      who have not had a hysterectomy (and are taking oestrogen-only HRT), are\u000d\u000a      at an increased risk of\u000d\u000a      endometrial cancer [5]. The study also showed that the risk of endometrial\u000d\u000a      cancer increases in\u000d\u000a      women who take the HRT drug tibolone, but may be reduced in women taking\u000d\u000a      combined\u000d\u000a      oestrogen-progestogen HRT. Interestingly, they also found that these\u000d\u000a      effects were dependent on a\u000d\u000a      woman's body mass index, with cancer risk being greater in thinner women\u000d\u000a      than in those who were\u000d\u000a      obese [5], as had been observed for breast cancer risk [3].\u000d\u000a    Ovarian Cancer: Results of the Million Women Study published in\u000d\u000a      2007 showed that women taking\u000d\u000a      HRT were at a slightly higher risk of ovarian cancer [6]. The study\u000d\u000a      analysing 948,576 post-menopausal\u000d\u000a      women over five years found that for every 1,000 women taking HRT, 2.6\u000d\u000a      developed\u000d\u000a      ovarian cancer, compared to 2.2 in those not taking HRT [6].\u000d\u000a    "},{"CaseStudyId":"9540","Continent":[{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":[],"ImpactDetails":"\u000a    Impact on International Policy\u000a      Work from UoA2 at Oxford University has provided a spectrum of studies\u000a      ranging from\u000a      epidemiological evidence of the hazards of smoking through to evidence of\u000a      the effectiveness of\u000a      quitting and the best available evidence of the success of interventions\u000a      that encourage quitting.\u000a      These studies have strongly influenced international policy on tobacco\u000a      control. In 2008 the WHO\u000a      adopted a set of 6 strategic recommendations for tobacco control, which\u000a      they refer to as\u000a      MPOWER: Monitor tobacco use and prevention policies, Protect people, Offer\u000a      help to quit, Warn,\u000a      Enforce bans, Raise taxes [A]. Many of the key epidemiological statistics\u000a      on tobacco hazards in the\u000a      report that defined the MPOWER strategy derive from NDPH work. The central\u000a      claim, that during\u000a      the 20th Century the tobacco epidemic killed 100 million\u000a      worldwide and that during the 21st Century\u000a      it will (on current smoking patterns) kill about one billion people, is\u000a      derived from NDPH work. The\u000a      MPOWER package has, since 2008, been the main vehicle by which WHO has\u000a      encouraged\u000a      tobacco control.\u000a    Similarly, the nicotine replacement therapy for smoking cessation review\u000a      (NRT) provided evidence\u000a      for a 2008 proposal for the inclusion of NRT in the World Health\u000a      Organization (WHO) list of\u000a      essential medicines. The WHO reports the review as \"the largest database\u000a      on the effectiveness of\u000a      NRT\" [B], approving the proposal in May 2009 supported by\u000a      CTARG's \"high-quality evidence of\u000a      effectiveness\" [C]. The WHO website predicts that inclusion of NRT on the\u000a      essential medicines list\u000a      will advance guideline development and improve access to NRT in developing\u000a      countries [C].\u000a    Impact on International Guidelines\u000a      The CTARG's NRT review has been cited in three key UK national guidelines\u000a      in recent years, and\u000a      continues to shape practice today. The evidence review [D] underpinning\u000a      NICE guidance on Brief\u000a      Interventions and Referral or Smoking Cessation recommends the use of NRT\u000a      based on the\u000a      Cochrane review. Guidelines published from the US and Australia also cite\u000a      the review, using it as\u000a      consistent evidence for use of NRT to aid smoking cessation and using it\u000a      to support the specific\u000a      recommendation that heavily dependent smokers use higher doses of oral NRT\u000a      [E, F].\u000a    Many physicians were initially reluctant to advise patients not to smoke,\u000a      as they doubted the\u000a      efficacy of the approach and were concerned it would affect the\u000a      doctor-patient relationship. The\u000a      Cochrane review of physician advice for smoking cessation has been used in\u000a      many guidelines as\u000a      evidence for the efficacy of this approach. The NICE Rapid Review of Brief\u000a      Interventions and\u000a      Referral for Smoking Cessation [D], the US Public Health Service\u000a      guidelines [E] and the Australian\u000a      Royal College of General Practitioner guidelines [F] all cite the review\u000a      as evidence that brief advice\u000a      from a physician is effective and should form part of routine clinical\u000a      care. The Australian guidelines\u000a      cite the Cochrane review as the key evidence against the belief that \"I am\u000a      not effective\", one of 7\u000a      barriers to engagement of health professionals with smoking cessation\u000a      identified by the guideline.\u000a    Impact on Smoking Prevalence and Subsequent Mortality\u000a      Though the direct relationship between research, subsequent guidelines,\u000a      practice, smoking\u000a      prevalence (and thereafter mortality) cannot be quantified, both smoking\u000a      prevalence and male\u000a      mortality have fallen in the UK and in many other European countries\u000a      during the REF reference\u000a      period. In the 1990's, the decline in UK smoking prevalence that began in\u000a      the 1970's had stalled. In\u000a      1996, 28% of the adult population smoked and there had been no decline in\u000a      prevalence from 1992,\u000a      In response, the UK government published its 1998 White Paper `Smoking\u000a      Kills' which set out a\u000a      range of interventions for reducing smoking prevalence in the UK,\u000a      including a substantial\u000a      investment in smoking cessation services. This White Paper was based on UK\u000a      national guidelines\u000a      [I] based on evidence from CTARG's reviews. In the subsequent 14 years,\u000a      the prevalence of adult\u000a      smoking in the UK has fallen to 20%, with over two million fewer adult\u000a      smokers in the UK [G].\u000a      Similarly, before the mid-1990s there was no material decrease in EU-wide\u000a      tobacco-attributed\u000a      mortality, but in recent years male tobacco-attributed mortality in the EU\u000a      has decreased by about\u000a      10% every 5 years [H].\u000a    There is substantial evidence of the impact of the Oxford's UoA2\u000a      researchers on the policies that\u000a      have been implemented during this period, and the above highlights the use\u000a      of selected research\u000a      outputs and Cochrane reviews in recent (and current) guidelines and\u000a      practice shaping documents.\u000a    ","ImpactSummary":"\u000a    Oxford's research has helped reduce smoking prevalence and\u000a      tobacco-related mortality worldwide.\u000a      Our epidemiological studies have documented the varied ways in which\u000a      smoking causes death in\u000a      many countries, as well as the large benefits of smoking cessation, and\u000a      have strongly influenced\u000a      the WHO\/Bloomberg 2008 MPOWER package, the key document guiding\u000a      governmental tobacco\u000a      policy worldwide. Oxford University researchers have also coordinated the\u000a      systematic reviews that\u000a      underpin effective evidence-based policies for encouraging smoking\u000a      cessation both in the UK and\u000a      worldwide, for example providing evidence supporting NICE guidance for\u000a      smoking cessation.\u000a    ","ImpactType":"Political","Institution":"\u000a    The University of Oxford\u000a    ","Institutions":[{"AlternativeName":"Oxford (University of)","InstitutionName":"University of Oxford","PeerGroup":"A","Region":"South East","UKPRN":10007774}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a[1]. Liu BQ, Peto R, Chen ZM, Boreham J, Wu YP, Li JY, Campbell TC, Chen\u000a      JS. Emerging\u000a      tobacco hazards in China: 1. Retrospective proportional mortality study of\u000a      one million deaths.\u000a      BMJ 1998; 317: 1411-1422. PubMed ID: 9822393. This paper quantifies\u000a          the effect of\u000a          smoking on mortality in China.\u000a    \u000a\u000a[2]. Jha P, Jacob B, Gajalakshmi V, Gupta PC, Dhingra N, Kumar R, Sinha\u000a      DN, Dikshit RP, Parida\u000a      DK, Kamadod R, Boreham J, Peto R for the RGI-CGHR Investigators. A\u000a      nationally\u000a      representative case-control study of smoking and death in India. New Engl\u000a      J Med 2008; 358:\u000a      1137-47. PubMed ID: 18272886. This shows that key causes of\u000a          mortality in India are\u000a          tuberculosis and heart attacks with smoking a key risk factor for\u000a          deaths from such\u000a          causes.\u000a    \u000a\u000a[3]. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking,\u000a      smoking cessation, and lung\u000a      cancer in the UK since 1950: combination of national statistics with two\u000a      case-control studies.\u000a      BMJ 2000; 321: 323-29. PubMed ID: 10926586. This study combines\u000a          data from hospital\u000a          patients with and without lung cancer to that from case control\u000a          studies from 1950 and\u000a          1990 and shows that people who stop smoking before middle age avoid\u000a          more than 90%\u000a          of the risk attributed to tobacco.\u000a    \u000a\u000a[4]. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to\u000a      smoking: 50 years'\u000a      observations on male British doctors. Br Med J 2004; 328:1519-28. PubMed\u000a      ID: 15213107.\u000a      This paper, with over 800 citations to date, shows that amongst men\u000a          born around 1920\u000a          prolonged cigarette smoking in adulthood tripled age specific\u000a          mortality rates but\u000a          cessation before age 50 halved the hazard.\u000a    \u000a\u000a[5]. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K,\u000a      Lancaster T. Nicotine\u000a      replacement therapy for smoking cessation. Cochrane Database of Systematic\u000a      Reviews 2012,\u000a      Issue 11. Art. No.: CD000146. DOI: 10.1002\/14651858.CD000146.pub4. PubMed\u000a      ID:\u000a      23152200. This systematic review demonstrated the efficacy of\u000a          nicotine replacement\u000a          therapy, a common treatment for smokers wishing to quit.\u000a    \u000a\u000a[6]. Stead LF, Bergson G, Lancaster T. Physician advice for smoking\u000a      cessation. Cochrane\u000a      Database of Systematic Reviews 2008, Issue 2. Art. No.: CD000165. DOI:\u000a      10.1002\/14651858.CD000165.pub3. PubMed ID: 18425860. This\u000a          systematic review\u000a          summarises the evidence for the efficacy of physician advice for\u000a          smoking cessation.\u000a    \u000aThis research was funded by Cancer Research UK and the UK Medical\u000a      Research Council.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [A]. WHO report on the global tobacco epidemic, 2008: The MPOWER package.\u000a      Geneva, WHO\u000a      http:\/\/whqlibdoc.who.int\/publications\/2008\/9789241596282_eng.pdf\u000a      Page 31 (NRT)\u000a      [Accessed 18\/09\/2013]. This WHO document describes 6 strategic\u000a          policies for tobacco\u000a          control.\u000a    [B]. 17th Expert Committee on the Selection and Use of Essential\u000a      Medicines, World Health\u000a      Organization. Proposal for Inclusion of Nicotine Replacement Therapy (NRT)\u000a      in the WHO Model\u000a      List of Essential Medicines. Geneva: 2008. Page 15 (NRT)\u000a      http:\/\/www.who.int\/selection_medicines\/committees\/expert\/17\/application\/NRT_inclusion.pdf\u000a      [Accessed 15\/09\/2013]. The proposal for inclusion of NRT on the WHO\u000a          Essential Medicines\u000a          list, which relies heavily on the CTARG's NRT review.\u000a    [C]. World Health Organization. Two forms of nicotine replacement therapy\u000a      chosen as WHO\u000a      \"Essential Medicines\".\u000a      http:\/\/www.who.int\/tobacco\/communications\/highlights\/note_nrt_therapy\/en\/index.html\u000a      [Accessed 18\/09\/2013]. A summary of the successful addition of NRT\u000a          to the WHO Essential\u000a          Medicines\u000a          list, including predictions about its impact.\u000a    [D]. Academic and Public Health Consortium, Rapid Review of Brief\u000a      Interventions and Referral for\u000a      Smoking Cessation, November 2005. Page 10 (physician advice) and page\u000a      15-16 (NRT)\u000a      http:\/\/www.nice.org.uk\/nicemedia\/pdf\/SmokingInterventionsReviewFINAL25-01-061.pdf\u000a      [Accessed\u000a      18\/09\/2013]. Evidence review for NICE guideline PH1, `Brief\u000a          interventions and referral for\u000a          smoking cessation in primary care'.\u000a    [E]. Tobacco Use and Dependence Guideline Panel. Treating Tobacco Use and\u000a      Dependence:\u000a      2008 Update. Rockville, MD: US Department of Health and Human Services,\u000a      2008. Page 14.\u000a      http:\/\/www.ahrq.gov\/professionals\/clinicians-providers\/guidelines-recommendations\/tobacco\/clinicians\/treating_tobacco_use08.pdf\u000a        [Accessed 15\/09\/2013].\u000a      US clinical practice guidelines for treating tobacco use.\u000a    [F]. Supporting smoking cessation: a guide for health professionals. The\u000a      Royal Australian College\u000a      of General Practitioners, 2012. Pages 21 (NRT) and 33 (physician advice)\u000a      http:\/\/www.racgp.org.au\/download\/documents\/Guidelines\/smoking-cessation.pdf\u000a      [Accessed\u000a      18\/09\/2013]. Australian clinical guideline for smoking cessation.\u000a    [G]. Office for National Statistics. General Lifestyle Survey, March 8\u000a      2012.\u000a      http:\/\/www.ons.gov.uk\/ons\/rel\/ghs\/general-lifestyle-survey\/2010\/index.html\u000a      [Accessed 18\/09\/2013]. Recent statistics on smoking prevalence in\u000a          the UK.\u000a    [H]. Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette\u000a      epidemic on entering its\u000a      second century. Tob Control 2012; 21: 96-101. PubMed ID: 22345230. Paper\u000a          assessed whether\u000a          qualitative predictions from the 4-stage model of the cigarette\u000a          epidemic matched recent\u000a          trends in smoking and smoking deaths across the world.\u000a    [I]. Raw M, McNeill A, West R. Smoking Cessation Guidelines for Health\u000a      Professionals. A Guide to\u000a      Effective Smoking Cessation Interventions for the Health Care System. Thorax,\u000a      December 1998,\u000a      53, Supplement 5. http:\/\/thorax.bmj.com\/content\/53\/suppl_5\/S1.full.pdf+html\u000a      [Accessed 4\/11\/2013]\u000a      The first British national guideline on smoking cessation. CTARG\u000a          reviews formed the main\u000a          evidence base. Page S3.\u000a    \u000a    ","Title":"\u000a    SHAPING INTERNATIONAL AND UK TOBACCO POLICY AND PRACTICE\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The underpinning research comes from two departments of UoA2 in Oxford\u000a      University. Following\u000a      major epidemiological studies of smoking in developed countries in the\u000a      1970s and 1980s, the\u000a      Nuffield Department of Population Health (NDPH, Peto, Co-Director CTSU)\u000a      developed its work\u000a      throughout China, showing that smoking was far more important than all\u000a      other known causes of\u000a      cancer combined. This affected UK, US and Chinese tobacco control\u000a      strategies. The families of\u000a      one million dead people across China were interviewed to determine the\u000a      decedent's smoking\u000a      habits and relate them to the disease that caused death, showing that\u000a      smoking was already\u000a      causing 12% of all deaths in Chinese men [1]. In collaboration with\u000a      others, this method of\u000a      interviewing families of large numbers of decedents was extended to Hong\u000a      Kong (showing that the\u000a      epidemic there was at a more advanced stage than in mainland China), to\u000a      South India (showing\u000a      that smoking was a major cause of death from TB), and then to a random\u000a      sample of all adult\u000a      deaths in India [2] (showing that the main diseases by which smoking kills\u000a      in rural and urban India\u000a      are, respectively, TB and heart attacks, and that smoking is causing\u000a      almost one million deaths per\u000a      year in India alone).\u000a    As well as assessing the full hazards of lifelong smoking among men and\u000a      among women in many\u000a      different populations, retrospective studies of lung cancer and the\u000a      50-year results of Richard Doll's\u000a      prospective study of smoking and death among male British doctors have\u000a      established the lifelong\u000a      benefits of cessation at various different ages [3, 4]. Both demonstrated\u000a      that stopping smoking\u000a      before age 40 avoided more than 90% of the excess risk among those who\u000a      continued to smoke.\u000a      This epidemiological research has been complemented by the work of the\u000a      Cochrane Tobacco\u000a      Addiction Review Group (Lancaster, CTARG Director) within the Department\u000a      of Primary Health\u000a      Care Sciences, Oxford University. Since 1995, CTARG has provided reliable,\u000a      regularly updated\u000a      summaries of the evidence for interventions designed to help tobacco users\u000a      to quit, and to prevent\u000a      people from taking up tobacco. The CTARG produces systematic reviews,\u000a      including meta-analyses\u000a      where appropriate, of individual and population-based interventions for\u000a      tobacco control. More than\u000a      60 reviews were completed within the reference period.\u000a    Examples of this work include:\u000a    \u000a      \u000aSystematic review of nicotine replacement therapy (NRT): The\u000a        first version of the Cochrane\u000a        review assessing the evidence for NRT was published in 1996 and has\u000a        grown from 72\u000a        studies at inception to over 150 studies now. This work has investigated\u000a        different forms,\u000a        delivery methods and settings, schedules, and dosages of NRT in a range\u000a        of subgroups,\u000a        and has shown definitively that all commercially available forms of NRT\u000a        increase the\u000a        proportion of people able to quit smoking (RR 1.60, 95% CI 1.53 to 1.68)\u000a        [5].\u000a      \u000aSystematic review of physician advice: Despite many doctors'\u000a        initial reluctance, physician\u000a        advice to quit has become part of everyday practice. The Physician\u000a        advice review was first\u000a        published in 1996, been updated eight times, and currently includes 41\u000a        trials. It shows that\u000a        brief clinical advice significantly increases the rate of quitting (RR\u000a        1.66, 95% CI 1.42 to\u000a        1.94). In addition, the effect was found to be stronger with more\u000a        intensive advice [6].\u000a    \u000a    "},{"CaseStudyId":"13835","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"2623032","Name":"Denmark"},{"GeoNamesId":"798544","Name":"Poland"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2264397","Name":"Portugal"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"458258","Name":"Latvia"}],"Funders":[],"ImpactDetails":"\u000d\u000a    The State of Men's Health in Europe report was launched at the European\u000d\u000a      Parliament by the European Commissioner, who has referred to the\u000d\u000a      importance of the report in several speeches1. There have been\u000d\u000a      two further meetings at the European Parliament based on the report\u000d\u000a      stimulating further debate on men's health and its implications for public\u000d\u000a      health policy. The findings of the report were widely covered by the press\u000d\u000a      both in the UK and abroad and included a BMJ podcast2. This\u000d\u000a      work has led to two awards for White:\u000d\u000a    Robert Tiffany International Award 2012, Nursing Standard, Royal College\u000d\u000a      of Nursing Outstanding Contribution Award 2011, Men's Health World\u000d\u000a      Congress, ISMH\u000d\u000a    White's work was also influential in the development of the EU Role of\u000d\u000a      Men in Gender Equality Report3.\u000d\u000a    The initial (unpublished) cancer data analysis undertaken by White in\u000d\u000a      2005 prompted the leading cancer charities and the national cancer\u000d\u000a      director to hold an expert symposium4, chaired by Mike\u000d\u000a      Richards, the then National Director of Cancer Services and subsequently\u000d\u000a      cited in the Cancer Reform Strategy5. White was a member of the\u000d\u000a      National Cancer Equalities Initiative Advisory Group; a Member of the\u000d\u000a      Cancer Reform Strategy &#8212; Awareness working group and a Member of the\u000d\u000a      National Cancer Equalities Initiative working group, where he has\u000d\u000a      contributed to the development of the UK Cancer Strategy. This led to a\u000d\u000a      report being undertaken with CRUK and NCIN based on new examination of\u000d\u000a      data relating to the relationship between sex, age and socio-economic\u000d\u000a      determinants and cancer susceptibility and survivorship6. This\u000d\u000a      work was widely reported in the press including a Radio 4 Today interview\u000d\u000a      with White and Mike Richards7 and was covered by the ITV news.\u000d\u000a    An up-date expert roundtable jointly run between the Men's Health Forum\u000d\u000a      and the National Cancer Equality Initiative has recently been held at the\u000d\u000a      King's Fund with White presenting the latest round of data on men and\u000d\u000a      cancer8.\u000d\u000a    Through his research with CRUK\/NCIN, his work is now influencing the\u000d\u000a      development of new cancer data at CRUK9. The data from the\u000d\u000a      Excess Burden report has been reported in a recent NCIN report (2013)\u000d\u000a      Cancer and Equality Groups: key metrics.\u000d\u000a    White's work has received wide coverage by the popular press including\u000d\u000a      BBC and ITV News; BBC News 24; BBC World Service; Sky News; a studio\u000d\u000a      interview for BBC Breakfast; Radio 4 PM programme; and the main\u000d\u000a      newspapers, both here and abroad (over 100 citations) along with a profile\u000d\u000a      of his work in the New Scientist10. He has also had a column in\u000d\u000a      the Men's Health Magazine and profiles of him and his work in national and\u000d\u000a      international magazines. White has presented his research at over 65\u000d\u000a      conferences since 2008, with over 30 of these international, with key note\u000d\u000a      addresses at the World Congress on Men's Health and papers and an invited\u000d\u000a      lecture tour to Australia in October 2013. White has been invited to key\u000d\u000a      policy meetings and workshops both in the UK and abroad including the\u000d\u000a      National Cancer Equalities Initiative Men and Cancer Gender Visioning\u000d\u000a      Event and a European Commission Health Information Workshop held at the\u000d\u000a      European Health Forum Gastein in 2010.\u000d\u000a    Key presentations that have influenced European thinking about men's\u000d\u000a      health include a key note presentation at the Gender and Health through\u000d\u000a      Life Conference with support and participation from the Danish EU\u000d\u000a      Presidency 2012; `Men's Health in Latvia' Young Peoples Conference, 2012,\u000d\u000a      Latvia; Gender differences: men's health in the EU. `Health Differences in\u000d\u000a      the Polish Population'. Warsaw, Poland 2011; `The State of Men's Health in\u000d\u000a      Europe'. Robert Koch Institute symposium at the Annual conference of the\u000d\u000a      German Society of Social Medicine and Prevention. Bremen, 2011; and The\u000d\u000a      state of men's health &#8212; a global perspective. Congresso Nacional De\u000d\u000a      Epidemiologia, Lisbon &#8212; Opening Ceremony (as part of Portugal's Presidency\u000d\u000a      of EU) Portugal 2008.\u000d\u000a    Part of the impact of White's work has been through his close association\u000d\u000a      with the Men's Health Forum and the European Men's Health Forum, who are\u000d\u000a      the leading men's health organisations in the UK and in Europe. The Men's\u000d\u000a      Health Forum run the national Men's Health Week and hold the secretariat\u000d\u000a      for the All Party Parliamentary Group on Men's Health, and are a strategic\u000d\u000a      partner of the Department of Health.\u000d\u000a    This media coverage and his work through the Charities in reaching out to\u000d\u000a      policy makers, practitioners and men on the street has been influential in\u000d\u000a      changing attitudes about the health risks men face from premature\u000d\u000a      mortality and the importance of preventative work with men, especially in\u000d\u000a      their early years.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The work of White has led to a re-appraisal of men's risk of premature\u000d\u000a      death, both in the UK and abroad. His analysis of morbidity and mortality\u000d\u000a      data has helped stimulate a worldwide debate on the health of men and the\u000d\u000a      risks they face with their health. In the UK, analysis of cancer data has\u000d\u000a      led the leading cancer charities to have a rethink on men's risk of\u000d\u000a      cancer. The EC State of Men's Health in Europe report has helped create a\u000d\u000a      new insight into the equality needs of men and stimulated the production\u000d\u000a      of similar reports globally.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    Leeds Metropolitan University\u000d\u000a    ","Institutions":[{"AlternativeName":"Leeds Metropolitan University","InstitutionName":"Leeds Metropolitan University","PeerGroup":"D","Region":"Yorkshire And Humberside","UKPRN":10003861}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2267057","Name":"Lisbon"},{"GeoNamesId":"2944388","Name":"Bremen"},{"GeoNamesId":"756135","Name":"Warsaw"}],"References":"\u000d\u000a    \u000a1. White, AK &amp; Cash, K (2003) The state of men's health\u000d\u000a      across 17 European Countries. Brussels, The European Men's Health Forum\u000d\u000a      ISBN 1-898883-94-7. Available at http:\/\/www.emhf.org\/resource_images\/EMHF_Report_part_1.pdf\u000d\u000a    \u000a\u000a2. White AK, Holmes M, (2006) Patterns of mortality across 44\u000d\u000a      Countries among men and women aged 15-44. Journal of Men's Health &amp;\u000d\u000a      Gender 3(2): 139-151. Available at http:\/\/www.sciencedirect.com\/science\/article\/pii\/S157189130600063X\u000d\u000a    \u000a\u000a3. EC (2011) The State of Men's Health in Europe: Extended Report.\u000d\u000a      Luxembourg, The European Commission, DG Sanco (authors: White A,\u000d\u000a      de Sousa B, de Visser R, Hogston R, Madsen SAa, Makara P, Richardson N,\u000d\u000a      Zato&#324;ski W doi: 10.2772\/61323. Available at http:\/\/ec.europa.eu\/health\/population_groups\/docs\/men_health_extended_en.pdf\u000d\u000a    \u000a\u000a4. White A, McKee M, de Sousa B, de Visser R, Hogston R, Madsen\u000d\u000a      SAa, Makara P, Richardson N, Zato&#324;ski W. (2013) An examination of the\u000d\u000a      association between premature mortality and life expectancy among men in\u000d\u000a      Europe. European Journal of Public Health doi: 10.1093\/eurpub\/ckt076.\u000d\u000a      Available at: http:\/\/eurpub.oxfordjournals.org\/content\/early\/2013\/06\/21\/eurpub.ckt076.abstract\u000d\u000a    \u000a\u000a5. White A, Thomson C, Howard T (2013) Excess Cancer burden in\u000d\u000a      men. 2nd Edition London, Cancer Research UK, National Cancer\u000d\u000a      Intelligence Network, Men's Health Forum, Leeds Metropolitan University\u000d\u000a      doi I:10.1016\/j.eursup.2010.03.003. Available at http:\/\/publications.cancerresearchuk.org\/downloads\/product\/CS_REPORT_EXCESSBURDEN.pdf\u000d\u000a    \u000a\u000a6. White AK, Thomson CS, Forman D, Meryn S (2010) Men's Health\u000d\u000a      and the Excess Burden of Cancer in Men. Eur Urol Suppl 9(3): 371-470\u000d\u000a      doi:10.1016\/j.eursup.2010.03.003. Available at http:\/\/www.cancerresearchuk.org\/cancer-help\/prod_consump\/groups\/cr_common\/@nre\/@sta\/documents\/generalcontent\/cr_042572.pdf\u000d\u000a    \u000aRelated Grants\u000d\u000a    2010 - 2011 The State of Men's Health in Europe Report. The European\u000d\u000a      Commission DG Sanco (Principal Investigator) (&#163;171,381)\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    \u000d\u000a      DG Sanco, European Commission. Personal contact details listed\u000d\u000a        separately\u000d\u000a      White A, McKee M, Richardson, N, Madsen SAa, de Sousa B, de Visser R,\u000d\u000a        Hogston R, Makara P, Zato&#324;ski W (2011) Europe's men need their own\u000d\u000a        health strategy. British Medical Journal 343:d7397 doi:\u000d\u000a        10.1136\/bmj.d7397. Available at:\u000d\u000a        http:\/\/www.bmj.com\/podcast\/2011\/12\/02\/aids-30\u000a\u000d\u000a      Study on the Role of Men in Gender Equality, prepared for European\u000d\u000a        Commission, edited by Elli Scambor, Katarzyna Wojnicka, Nadja Bergmann,\u000d\u000a        Consortium led by L&amp;R Social Research, with Dissens, abz*austria,\u000d\u000a        INBAS, Written by Belghiti-Mahut S, Bergmann N, G&#228;rtner M, Hearn J,\u000d\u000a        Gullv&#229;g Holter O, Hr&#382;enjak M, Puchert R, Scambor C, Scambor E, Schuck H,\u000d\u000a        Seidler V, White A &amp; Wojnicka K, 2013. Available at:\u000d\u000a        http:\/\/ec.europa.eu\/justice\/events\/role-of-men\/index_en.htm\u000a\u000d\u000a      Wilkins, D (2007) Tackling the excess incidence of cancer in men:\u000d\u000a        proceedings of the expert symposium health at Leeds Metropolitan\u000d\u000a        University on November 16th 2006. Men's Health Forum, Leeds Metropolitan\u000d\u000a        University, Macmillan, Cancer Backup. Available at:\u000d\u000a        http:\/\/www.menshealthforum.org.uk\/files\/images\/LeedsMen&amp;CancerProceedings.pdf\u000a\u000d\u000a      White AK, Thompson C and Forman D (2009) The Excess Burden of Cancer\u000d\u000a        in Men in the UK. London: NCIN, CRUK, MHF, Leeds Met &amp; White A,\u000d\u000a        Thomson C, Howard T (2013) Excess cancer burden in men. London, CRUK,\u000d\u000a        NCIN, MHF, Leeds Met. Available at:\u000d\u000a        http:\/\/publications.cancerresearchuk.org\/downloads\/product\/CS_REPORT_EXCESSBURDEN.pdf\u000a\u000d\u000a      Launch of Men and Cancer report 15th June BBC Radio 4 the Today\u000d\u000a        Programme with James Naughtie, ABC Radio Australia and 15+ UK regional\u000d\u000a        radio stations. Available on request\u000d\u000a      http:\/\/www.menshealthforum.org.uk\/22474-men-and-cancer-expert-round-table\u000d\u000a      Statistical Services, Cancer Research UK. Personal contact details\u000d\u000a        listed separately\u000d\u000a      Jessica Griggs One minute with... Alan White. New Scientist 18th June\u000d\u000a        2011. Available at\u000d\u000a        http:\/\/connection.ebscohost.com\/c\/interviews\/61969786\/one-minute-alan-white\u000a\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Reducing premature death in men\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    White's work in the area of men's health began in 1996; in 2001 he\u000d\u000a      conducted a funded `Scoping Study on Men's Health' for the then Public\u000d\u000a      Health Minister, which recognised the scarcity of research on men and the\u000d\u000a      need for more epidemiological data. Following this, a body of work\u000d\u000a      exploring health variations for men (gendered epidemiology) was commenced\u000d\u000a      by White, with Cash. This early work involved mapping sex and gender\u000d\u000a      differences in health across 17 countries1, this study revealed\u000d\u000a      for the first time the extent of men's risks of premature death across a\u000d\u000a      broad range of health disorders. Further research on the patterns of\u000d\u000a      mortality in men and women aged 15-44 years across 44 countries2\u000d\u000a      led by White built on this work and again highlighted high levels of\u000d\u000a      premature death in men.\u000d\u000a    In 2009 White was successful in tendering to complete the State of Men's\u000d\u000a      Health in Europe Report3 for the European Commission, covering\u000d\u000a      the 34 countries of the European Union, EFTA countries and accession\u000d\u000a      countries and involved 36 academic partners from across Europe, including\u000d\u000a      Hogston and Raine from Leeds Metropolitan University. Findings here\u000d\u000a      indicated that changes are occurring with the structure of the male\u000d\u000a      population that will result in a smaller working age population supporting\u000d\u000a      a burgeoning older population. In addition, the study gave further\u000d\u000a      evidence of high levels of premature deaths in men across the spectrum of\u000d\u000a      conditions that should affect men and women equally, with 630,000 male\u000d\u000a      deaths as compared to 300,000 female deaths across the EU27 within the age\u000d\u000a      range 15-64 years. The study also gave a much clearer picture of the\u000d\u000a      impact of major social change on men's health, with over 40% of male\u000d\u000a      deaths in the working age (15-64 years) being seen in Lithuania, Estonia\u000d\u000a      and Poland as opposed to less than 18% in Sweden. The study noted that\u000d\u000a      much of men's premature death is avoidable and as much a problem of\u000d\u000a      inequity as biological inevitability.\u000d\u000a    A follow on study, led by White, analysed trends in life expectancy at\u000d\u000a      birth in 19 EU member states between 1999 and 2008 using the Pollard\u000d\u000a      Decomposition method. The study, which explored the impact of changes in\u000d\u000a      health over the last ten years revealed that most improvements in life\u000d\u000a      expectancy are happening over the age of 65 years with little effect on\u000d\u000a      rates of premature death4.\u000d\u000a    In addition, analysis of cancer data in the UK highlighted a higher\u000d\u000a      incidence and rate of premature deaths from those cancers that should not\u000d\u000a      be seen as sex specific. Further examination of cancer deaths was\u000d\u000a      undertaken by White in collaboration with CRUK and the NCIN resulting in\u000d\u000a      two influential reports on the burden of cancer in men5,6. This\u000d\u000a      work highlighted that men had a 70% higher risk of dying prematurely from\u000d\u000a      those cancers that are not sex specific and a 60% higher risk of\u000d\u000a      developing these cancers. This work is on-going with further sex-specific\u000d\u000a      analysis of trends over time, routes to diagnosis and stages of cancer at\u000d\u000a      diagnosis currently underway.\u000d\u000a    "},{"CaseStudyId":"13837","Continent":[],"Country":[],"Funders":["Royal Society"],"ImpactDetails":"\u000d\u000a    The NIHR `People in Public Health' study provided a foundation to develop\u000d\u000a      understanding around lay health worker roles and related programme\u000d\u000a      support. This was a high profile study that involved extensive public\u000d\u000a      engagement and the production of outputs for practitioners and policy\u000d\u000a      makers. In 2007, the PIPH website was launched. A register of interest has\u000d\u000a      over 150 individuals who receive information about the study. In 2009, an\u000d\u000a      online searchable database was created on the website with the results of\u000d\u000a      224 reviewed publications [1]. A research briefing for practice (2010) was\u000d\u000a      published for commissioners, managers and practitioners. This carried\u000d\u000a      endorsements from Local Government Improvement and Development (LGID), the\u000d\u000a      Marmot Review team and from the Chair of Department of Health's 3rd Sector\u000d\u000a      and Social Enterprise sounding board [2].\u000d\u000a    A summary of the PIPH study was reported by the NHS Confederation's\u000d\u000a      Health Policy Digest reaching over 4,500 senior NHS managers [3].\u000d\u000a      Volunteering England highlighted the study in their January e-newsletter,\u000d\u000a      reaching 1200 people and a feature article was published in their on-line\u000d\u000a      newsletter in March 2011. The study findings also featured by LGID on\u000d\u000a      their website and a news item appeared in their Healthy Communities\u000d\u000a      bulletin in March 2011, reaching over 33,000 interested parties. The\u000d\u000a      article `Harnessing people power' was the lead article on cover of Primary\u000d\u000a      Health Care -the RCN community health nursing journal and the Editor wrote\u000d\u000a      \"it's time to take a look at what the government's talk of a Big Society\u000d\u000a      means for primary care nursing and public health... this article could not\u000d\u000a      have been more timely\" [4].\u000d\u000a    The CHPR have submitted evidence on lay health workers and volunteering\u000d\u000a      to various enquiries and consultations. For example, in 2010, J. South\u000d\u000a      took part in the Natural England and Local Government Information Unit\u000d\u000a      national inquiry on Walking for Health and findings from PIPH were given\u000d\u000a      prominence in the subsequent report [5:19]. A number of written\u000d\u000a      submissions based on the research findings were also made to parliamentary\u000d\u000a      groups and policy consultations, e.g. All Party Parliamentary Group on\u000d\u000a      Primary Care &amp; Public Health inquiry into NHS White Paper [6].\u000d\u000a      Meetings have been held with the Third Sector Partnership Team in the DH\u000d\u000a      Policy &amp; Strategy Directorate and with the Head of Patient Voice and\u000d\u000a      Information, NHS Commissioning Board.\u000d\u000a    Research on community health champions and health trainers has achieved\u000d\u000a      good reach into public health practice. Evidence reviews and thematic\u000d\u000a      evaluations on community champions have been disseminated nationally\u000d\u000a      through the champion network. Some indication of the reach is that the\u000d\u000a      Community Health Champion Evidence Review has been downloaded 3356 times\u000d\u000a      from Yorkshire &amp; Humber Health Intelligence [7]. The community health\u000d\u000a      champions approach was highlighted as a case study in the White Paper `\u000d\u000a      Healthy lives, healthy People' where it was noted that there was `a sound\u000d\u000a      practical evidence base for the approach' [p. 43]. J.White has led on the\u000d\u000a      development of a national web resource for health trainers: `Health\u000d\u000a      Trainers England' [8]. Oral evidence on health trainers was submitted to\u000d\u000a      House of Lords Science and Technology Sub-Committee on behaviour change\u000d\u000a      [9]. In October, 2011 J.White gave expert testimony to the NICE Programme\u000d\u000a      Development Group on `Obesity: working with local communities'.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The `People in Public Health' (PIPH) study and related research on health\u000d\u000a      trainers, health champions and volunteers has brought together evidence on\u000d\u000a      rationales for lay engagement, effectiveness and models of support.\u000d\u000a      Dissemination activities, supported by a Department of Health grant, have\u000d\u000a      achieved reach into various policy arenas and national networks. At the\u000d\u000a      same time there is evidence of research utilisation in public health\u000d\u000a      practice. One of the impacts has been the establishment of `Active\u000d\u000a      Citizens for Health', a national network of partner organisations to bring\u000d\u000a      together evidence and learning that has been hosted by Leeds Metropolitan\u000d\u000a      University.\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    Leeds Metropolitan University\u000d\u000a    ","Institutions":[{"AlternativeName":"Leeds Metropolitan University","InstitutionName":"Leeds Metropolitan University","PeerGroup":"D","Region":"Yorkshire And Humberside","UKPRN":10003861}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. South, J. Woodward, J., Lowcock, D. (2007) New beginnings: stakeholder\u000d\u000a      perspectives on the role of health trainers, Journal of the Royal Society\u000d\u000a      for the Promotion of Health, 127:224-230. Available at: http:\/\/rsh.sagepub.com\/content\/127\/5\/224.refs\u000d\u000a    \u000a\u000a2. South, J., Warwick-Booth, L. (2011) The Community health apprentices\u000d\u000a      project &#8212; the outcomes of an intermediate labour market project in the\u000d\u000a      community health sector. Community, Work &amp; Family 14: 1, 1-18.\u000d\u000a      Available at:\u000d\u000a      http:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/13668803.2010.506027#.UozY7hq-18E\u000d\u000a    \u000a\u000a3. South, J., Meah, A., Branney, P. (2011) \"Think differently and be\u000d\u000a      prepared to demonstrate trust\": findings from public hearings, England, on\u000d\u000a      supporting lay people in public health roles. Health Promotion\u000d\u000a      International, 27: 2: 284-294. Available at:\u000d\u000a      http:\/\/heapro.oxfordjournals.org\/content\/27\/2\/284.short\u000d\u000a    \u000a\u000a4. South, J. Meah, A., Bagnall, A-M., Jones, R. (2013) Dimensions of lay\u000d\u000a      health worker programmes: results of a scoping study and production of a\u000d\u000a      descriptive framework. Global Health Promotion, 20, 1: 5-15. Available at:\u000d\u000a      http:\/\/ped.sagepub.com\/content\/20\/1\/5.abstract\u000d\u000a    \u000a\u000a5. South, J. Kinsella, K. Meah, A. (2012) Lay perspectives on lay health\u000d\u000a      worker roles, boundaries and participation within three UK community-based\u000d\u000a      health promotion projects. Health Education Research, 27, 4: 656-670.\u000d\u000a      Available at:\u000d\u000a      http:\/\/her.oxfordjournals.org\/content\/27\/4\/656.abstract\u000d\u000a    \u000a\u000a6. Cattan, M and South, J. (2011). The use of knowledge translation in\u000d\u000a      developing evidence for public health policy and practice: a staged,\u000d\u000a      multi-methods study in England, 2007-2009. Moderated poster presentation\u000d\u000a      4th European Public Health Conference, Copenhagen, Denmark, 9 - 12\u000d\u000a      November 2011. European Journal of Public Health Conference supplement.\u000d\u000a      Available at: http:\/\/eurpub.oxfordjournals.org\/content\/21\/suppl_1.toc\u000d\u000a    \u000aRelevant grants awarded to J. South as Principal Investigator\u000d\u000a    1. A study of approaches to develop and support people in public health\u000d\u000a      roles, 2007-9, National Institute of Health Research Service Delivery and\u000d\u000a      Organisation programme, 08\/1716\/2006, &#163;244,142.\u000d\u000a    2. Dissemination of research-based information to support better\u000d\u000a      engagement with citizens, 2010-11. Department of Health, &#163;23,520.\u000d\u000a    3. Commission for Review and Evaluation work to Support the Altogether\u000d\u000a      Better Programme, 2009-2010. West Yorkshire Public Health Observatory,\u000d\u000a      &#163;52,892 [PI].\u000d\u000a    4. Health trainers &#8212; evaluation of health inequalities pilots, Yorkshire\u000d\u000a      &amp; Humber Region, 2010-11. NHS Wakefield, Teaching Public Health\u000d\u000a      Network, &#163;20,000\u000d\u000a    5. Sunderland Health Champions Evaluation. Sunderland teaching PCT,\u000d\u000a      2011-12, &#163;44,471.\u000d\u000a    6. A systematic review of the effectiveness and cost-effectiveness of\u000d\u000a      peer-based interventions to maintain and improve offender health in prison\u000d\u000a      settings. NIHR Health Services and Delivery Research programme, 2012.\u000d\u000a      [&#163;179, 791]. Co-applicants: Academic Centre of Health Economics,\u000d\u000a      University of Leeds; University of West of England: HMP Leeds; HMP\u000d\u000a      Bristol; HMP Eastwood and Wakefield District Community Health Care\u000d\u000a      Services.\u000d\u000a    7. A pilot study of the walking for wellness project and the befriender\u000d\u000a      role,2010-11. Natural England, &#163;5000.\u000d\u000a    8. Evaluation of the Department of Health's Health and Social Care\u000d\u000a      Volunteering Fund. Ecorys &amp; HSCV. 2012-13, &#163;76,532.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    \u000d\u000a       People in Public Health website and databases http:\/\/www.leedsmet.ac.uk\/health\/piph\/\u000a\u000d\u000a       South, J., Branney, P., White, J., Gamsu, M. (2010) Engaging the\u000d\u000a        public in delivering health improvement: Research Briefing. Centre for\u000d\u000a        Health Promotion research, Leeds Metropolitan University. A copy can be\u000d\u000a        found:\u000d\u000a        http:\/\/www.leedsmet.ac.uk\/health\/piph\/documents\/PIPH%20Research%20Briefing.pdf\/\u000a\u000d\u000a       Engaging the public in delivering health improvement. Health Policy\u000d\u000a        Digest 54. NHS Confederation. Issue 54, 19th October 2010. Available at:\u000d\u000a        http:\/\/www.nhsconfed.org\/Key-Health-Issues\/HPD-December2010\/Pages\/Research-Findings-summary2-191010.aspx\u000a\u000d\u000a       South, J., Sahota, P. (2010) Harnessing people power in health\u000d\u000a        promotion. Primary Health Care, 20, 8, 16-21. Available at:\u000d\u000a        http:\/\/rcnpublishing.com\/doi\/abs\/10.7748\/phc2010.10.20.8.16.c8036\u000a\u000d\u000a       Heron, C. and Bradshaw, G. (2010) Walk this way: recognising the\u000d\u000a        value in active health prevention. Local Government Information Unit,\u000d\u000a        Natural England (p.19) A copy can be found: http:\/\/www.leedsmet.ac.uk\/health\/piph\/documents\/Walk%20This%20Way.pdf\u000a\u000d\u000a       South, J and Woodward, J. (2010) A response to the inquiry: \"The NHS\u000d\u000a        White Paper &amp; Public Engagement\". From the People in Public Health\u000d\u000a        research team, Centre for Health Promotion Research. Submission to All\u000d\u000a        Party Parliamentary Group on Primary Care &amp; Public Health inquiry\u000d\u000a        into NHS White Paper. Available at http:\/\/www.nhsconfed.org\/Key-Health-Issues\/HPD-December2010\/Pages\/Research-Findings-summary2-191010.aspx\u000a\u000d\u000a       Community Health Champions &#8212; Evidence Review `Health Trainers\u000d\u000a        England': Yorkshire and Humber Health Intelligence. Available at:\u000d\u000a        http:\/\/www.yhpho.org.uk\/resource\/item.aspx?RID=87494\u000a\u000d\u000a       `Health Trainers England' Available at: http:\/\/www.healthtrainersengland.com\/\u000a\u000d\u000a       White, J. (January 2011). Evidence by oral presentation to the House\u000d\u000a        of Lords Science and Technology Sub-Committee on behaviour change, on\u000d\u000a        the evidence base for health trainers. House of Lords Science London.\u000d\u000a        Available at:\u000d\u000a        http:\/\/www.publications.parliament.uk\/pa\/ld201012\/ldselect\/ldsctech\/179\/179.pdf\u000a\u000d\u000a       South, J., Kinsella, K., Giuntoli, G. McKenna, J., Long, J., Carless,\u000d\u000a        D. (2011) Walking for Health: a qualitative study of the links between\u000d\u000a        community engagement, social capital and health outcomes within\u000d\u000a        volunteer-led health walks. Oral presentation at `Bridging the Gap\u000d\u000a        between science and practice' 3rd conference and 7th annual meeting of\u000d\u000a        HEPA Europe, 11-13 October 2011, Amsterdam. Available at: http:\/\/www.euro.who.int\/en\/health-topics\/disease-prevention\/physical-activity\/activities\/hepa-europe\/hepa-europe-membership-and-meetings\/meetings-of-hepa-europe\/7th-annual-meeting-and-3rd-conference-of-hepa-europe\u000d\u000a      \u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Developing evidence based practice on lay health roles\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Since its inception, the Centre for Health Promotion Research (CHPR) has\u000d\u000a      been a leading centre for the theory and practice of health promotion. A\u000d\u000a      focused programme of research on community participation and lay health\u000d\u000a      workers was developed within the CHPR, initially through the work of one\u000d\u000a      member of staff (J. South). Early work involved evaluations of innovative\u000d\u000a      public health programmes, which later led to further partnerships, new\u000d\u000a      research grants and transfer of knowledge to practice. Examples included:\u000d\u000a    \u000d\u000a       Development and evaluation of Bradford health trainers, one of the\u000d\u000a        first health trainer pilots in England (2005-7).\u000d\u000a       Evaluation of a community health apprentices project in Bradford\u000d\u000a        (2007)\u000d\u000a       Evaluation of a social prescribing pilot (2005).\u000d\u000a    \u000d\u000a    Publications resulting from this work explored various mechanisms to\u000d\u000a      strengthen community-state relationships [1 &amp; 2]. The strong links\u000d\u000a      with practice and the growing base of community research led to the award\u000d\u000a      of a NIHR SDO grant to examine lay roles in public health. The `People in\u000d\u000a      Public Health' study (2007-9) made a major contribution to understandings\u000d\u000a      of lay health worker roles and the support processes required to initiate\u000d\u000a      and sustain health programmes involving the public. The systematic scoping\u000d\u000a      review led to new categorisations of roles, including definitions of lay\u000d\u000a      status [4]. Three national expert hearings were held in June 2008, giving\u000d\u000a      the university a leading role in this field [3]. An accessible report was\u000d\u000a      later produced to highlight key issues for policy and practice and this\u000d\u000a      was disseminated throughout different practice networks. Overall results\u000d\u000a      identified key factors for the development of lay health worker programmes\u000d\u000a      and volunteering activity. Research findings have been published in\u000d\u000a      international journals and presented at various national and international\u000d\u000a      conferences [4-5]. In 2010, in recognition of the significance of the\u000d\u000a      research, the Department of Health (DH) awarded a grant for the\u000d\u000a      `Production and dissemination of accessible research-based information to\u000d\u000a      support better engagement with citizens to co-produce better health and\u000d\u000a      well-being outcomes'.\u000d\u000a    Lay engagement in public health and the wider issue of volunteering in\u000d\u000a      health feature prominently in UK policy. J. South was commissioned in\u000d\u000a      2009-10 to undertake a series of evidence reviews and thematic evaluations\u000d\u000a      on a new community health champion model and, in 2011, was awarded a NIHR\u000d\u000a      HS &amp;DR grant to undertake a systematic review of peer-based\u000d\u000a      interventions in prison settings. Further research includes an evaluation\u000d\u000a      of volunteer-led walking for health groups commissioned by Natural England\u000d\u000a      (2011) and an evaluation of the Department of Health's new volunteering\u000d\u000a      fund (2012-3). Staff at the CHPR (led by J.White) have made a major\u000d\u000a      contribution to the development of a national evidence base for health\u000d\u000a      trainers.\u000d\u000a    Over the past six years, public engagement activity has been strengthened\u000d\u000a      as part of this research programme. Staff, (led by J.South), have\u000d\u000a      pioneered new ways of public involvement, including use of deliberative\u000d\u000a      methods, participatory workshops, and informal consultation methods [6].\u000d\u000a      The CHPR maintains strong links with local community organisations and in\u000d\u000a      2013 established a Community Campus Partnerships initiative to promote\u000d\u000a      knowledge exchange between professionals, researchers and community\u000d\u000a      members.\u000d\u000a    "},{"CaseStudyId":"13838","Continent":[],"Country":[],"Funders":["Wellcome Trust"],"ImpactDetails":"\u000a    The applied nature of the research has led to improvement in the quality\u000a      of interventions that enhance nutrition, target childhood obesity and\u000a      influence practice and policy. The research has been viewed as relevant\u000a      and timely and has generated significant interest. The following summary\u000a      provides evidence of impact of the research undertaken.\u000a    The APPLES study was cited in NICE guidance on Obesity (1); WHO report on\u000a      Childhood Obesity (2) and included in numerous systematic reviews\u000a      including Cochrane (3) and the Centre for Reviews and Databases.\u000a    Dissemination and sharing of good practice in child weight management was\u000a      led by Professor Sahota through organisation at LeedsMet of 2 national\u000a      meetings (June 2006 and May 2009) that brought together leading academics\u000a      and practitioners involved in treatment programmes. This resulted in the\u000a      formation of the first ever group dedicated to childhood obesity\u000a      interventions, Childhood Obesity Research Group (CORG). The meetings\u000a      established a case for development of standard evaluation approaches for\u000a      child weight management programmes. Professor Sahota was subsequently\u000a      invited by the National Obesity Observatory to join a working group for\u000a      the development of the Standard Evaluation Framework (4) which is the\u000a      recommended evaluation framework across the UK, thereby facilitating\u000a      evidence from a wide range of programmes to contribute to the broader\u000a      evidence base. Additionally CORG provided a consultation base for e.g.\u000a      establishing the National Child Measurement Programme.\u000a    P. Sahota (PI) undertook a costing study of WATCH IT, a community-based\u000a      childhood obesity treatment programme which has been used by commissioners\u000a      of weight management services (5). The programme is on the list of 10\u000a      approved programmes by the DH and is currently being commissioned in Leeds\u000a      and other PCT's e.g. Birmingham and Coventry with the emerging data making\u000a      a major contribution to the understanding effectiveness of community-based\u000a      interventions (6.)\u000a    In March 2011, the HELP programme, an early intervention aimed at parents\u000a      of young children was submitted to the Centre for Excellence and Outcomes\u000a      in Children and Young People's Services (C4EO) (www.c4eo.org.uk)\u000a      of the National Foundation for Educational Research (NFER). The Centre\u000a      evaluates examples of effective local practice that provide demonstrable\u000a      evidence of improving outcomes for children, young people and\u000a      their families and aims to inform decision and policy making, and to share\u000a      and disseminate effective practice with others working across the\u000a      children's sector. HELP was judged as promising practice and is published\u000a      on the C4EO website under this category. This has resulted in the\u000a      programme and the accompanying resource manual being made available\u000a      practitioners (7), and thereby influencing practice by improving the\u000a      quality of advice and support offered to parents of young children.\u000a    The extensive experience in the development of child weight management\u000a      programmes and the access to a network of academics and practitioners in\u000a      obesity management led to the team being commissioned by NHS Health\u000a      Scotland to undertake an evidence-review of effective behavioural\u000a      strategies for childhood obesity programmes, (2010, NHS Health Scotland).\u000a      The aim of this review was to aid the development of effective weight\u000a      management programmes in Scotland. However there has been wider interest\u000a      in these findings and their application to practice and evidence was also\u000a      submitted to the House of Lords. Science and Technology Committee on\u000a      Behaviour Change (8).\u000a    The research on factors influencing uptake of free school meals in Dec\u000a      2010 has resulted in a new policy launched on 15 December 2010 for all\u000a      Leeds secondary schools which improves access to healthy food and makes\u000a      free school dinners more widely available. The research suggested many\u000a      children who are eligible for free school meals fail to take up their\u000a      entitlement and instead snack on unhealthy food during morning break time.\u000a      The new policy allows pupils to pre-order 'grab bags' &#8212; consisting of a\u000a      sandwich, dessert and drink which can be eaten at break-time when they are\u000a      hungry and thereby taking advantage of their entitlement.\u000a    In Jan 2012 research undertaken by the team resulted wide media coverage\u000a      on the role of family mealtimes in encouraging fruit and vegetable\u000a      consumption http:\/\/thefamilydinnerproject.org\/the-fruit-and-veggie-boosting-effects-of-family-dinner-2\/\u000a      (9)\u000a    As an acknowledgement of Professors Sahota's expertise in the field of\u000a      Childhood Obesity she was invited to:- join the International Scientific\u000a      Committee for the European Congress on Obesity (May 12-15 2013); join the\u000a      DH Expert Working Group in Nov 2012 to develop commissioning guidance for\u000a      Child Weight Management Programmes which are now available; in Feb 2013 to\u000a      present an Expert Testimony to the Programme Development Board on child\u000a      weight management programmes (10); the House of Commons to the launch of\u000a      the All Part Parliamentary Group on Obesity 16.4.13.\u000a    ","ImpactSummary":"\u000a    Research in the area of childhood obesity has focussed on the\u000a      development, implementation and evaluation of interventions. The APPLES\u000a      Study (1996-99), the first UK school-based RCT was key in contributing to\u000a      the evidence-base through wide dissemination including 3 BMJ (2001)\u000a      publications, cited in NICE (2006) and WHO guidance (2004). Collaborations\u000a      with academics, practitioners and the RCPCH led to the development of\u000a      further community-based obesity treatment and prevention interventions\u000a      including WATCH IT; early programmes e.g. EMPOWER, HELP and HAPPY and more\u000a      recently innovative school-based initiatives involving school gardening.\u000a      There is evidence of results being disseminated and influencing research,\u000a      practice and policy.\u000a    ","ImpactType":"Health","Institution":"\u000a    Leeds Metropolitan University\u000a    ","Institutions":[{"AlternativeName":"Leeds Metropolitan University","InstitutionName":"Leeds Metropolitan University","PeerGroup":"D","Region":"Yorkshire And Humberside","UKPRN":10003861}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2652221","Name":"Coventry"}],"References":"\u000a    References to the research\u000a    \u000a1. Sahota P, Rudolf MCJ, Cade J, Dixey R, Hill AJ. Barth JH. (2001)\u000a      APPLES: Process and Impact evaluation of a school-based obesity prevention\u000a      programme in the UK. BMJ, 323:1027 - 1029. DOI: http:\/\/dx.doi.org\/10.1136\/bmj.323.7320.1027\u000a    \u000a\u000a2. Sahota P, Rudolf MCJ, Cade J, Dixey R, Hill AJ. Barth JH. (2001)\u000a      APPLES: A group randomised trial of a school-based obesity prevention\u000a      programme in the UK. BMJ 323: 1029 - 1032. DOI: http:\/\/dx.doi.org\/10.1136\/bmj.323.7320.1029\u000a    \u000a\u000a3. Mary Rudolf, Pinki Sahota, Julian Barth, Jenny Walker.\u000a      (2001).Increasing prevalence of obesity in primary school children: cohort\u000a      study. BMJ 322: 1094-1095. DOI: http:\/\/dx.doi.org\/10.1136\/bmj.322.7294.1094\u000a    \u000a\u000a4. Rudolf MCJ, Christie D, McElhone S, Sahota P, Dixey R, Walker J,\u000a      Wellings C. (2006) WATCH IT: a community based programme for obese\u000a      children and adolescents. Archives of Disease in Childhood. Archives of\u000a      Disease in Childhood 2006;91;736-739. DOI: 10.1136\/adc.2005.089896\u000a      Available at: http:\/\/dx.doi.org\/10.1136%2Fadc.2005.089896\u000a    \u000a\u000a5. Pinki Sahota, Jenny Woodward, Rosemary Molinari and Jo Pike (2013)\u000a      Factors influencing take-up of free school meals in primary and\u000a      secondary-school children in England. Public Health Nutrition: page 1 of 9\u000a      doi:10.1017\/S136898001300092X Available at:\u000a      http:\/\/journals.cambridge.org\/download.php?file=%2FPHN%2FS136898001300092Xa.pdf&amp;code=da5b7ca31c8573bf67d2aaa56a4c8e16\u000a    \u000a\u000a6. Evans, CEL., Ransley, JK., Christian, MS Greenwood DC., Thomas, JD.,\u000a      &amp; Cade, JE (2013) A cluster-randomised controlled trial of a\u000a      school-based fruit and vegetable intervention: Project Tomato Public\u000a      Health Nutrition 14:1-9. DOI: http:\/\/dx.doi.org\/10.1017\/S1368980012005290\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    \u000a      The prevention, identification, assessment and management of\u000a        overweight and obesity in adults and children APPLES cited as best\u000a        practice on prevention. Full guideline &#8212; all of the evidence and\u000a        rationale (Dec 2006) available at www.nice.org.uk\/CG043fullguideline\u000a\u000a      Obesity in children and young people: A crisis in public health (2004)\u000a        Obesity Reviews, Vol 5. Supplement 1 May 2004. APPLES programme cited as\u000a        good practice in school-based obesity prevention available at http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15096099\u000a\u000a      T. Brown, S. Kelly and C. Summerbell (2007) Prevention of obesity: a\u000a        review of interventions obesity reviews (2007) 8 (Suppl. 1), 127-130.\u000a        APPLES Cited. Available at:\u000a        http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1467-789X.2007.00331.x\/abstract\u000a\u000a      Standard Evaluation Framework 2010. National Obesity Observatory\u000a        available at www.noo.org.uk\/SEF\u000a\u000a      C. Spoor1, P. Sahota1, C. Wellings2, M. C. J (2013) Costing a pilot\u000a        complex community-based childhood obesity intervention. Journal of Human\u000a        Nutrition and Dietetics; Volume 26, Issue 2, pages 126-131, April 2013.\u000a        Available at http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-277X.2012.01273.x\/full\u000a\u000a      The Foresight report, Tackling Obesities: Future Choices, was\u000a        published on 17 October 2007. Available at: www.foresight.gov.uk\/Obesity\/Obesity.html\u000a        WATCH IT cited as best practice programme.\u000a      Information on HELP intervention submitted to the Centre for\u000a        Excellence and Outcomes in Children and Young People's Services (C4EO).\u000a        Available at:\u000a        www.c4eo.org.uk\/themes\/general\/vlpdetails.aspx?lpeid=362\u000a\u000a      Sahota P, Wordley J, Woodward J (2010) Literature Review: Health\u000a        behaviour change models and approaches for families and young people to\u000a        support HEAT 3: Child Healthy Weight Programmes. NHS Health Scotland\u000a        30th Aug 2010. Available at:\u000a        http:\/\/www.healthscotland.com\/uploads\/documents\/14147-Child\u000a          Healthy Weight LiteratureReview.pdf\u000a\u000a      Available at http:\/\/thefamilydinnerproject.org\/the-fruit-and-veggie-boosting-effects-of-family-dinner-2\/\u000a\u000a       Available at http:\/\/www.nice.org.uk\/guidance\/index.jsp?action=download&amp;o=63653\u000a\u000a    \u000a    ","Title":"\u000a    Prevention of Childhood Obesity; Clinical and Public Health Approaches\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The work on nutrition and childhood obesity has its origins in the PhD\u000a      studies (Professor Pinki Sahota, Meaghan Christian), Dr Maria Maynard.\u000a      There is a strong history of collaborations with Leeds University and\u000a      practitioners resulting in acknowledgement of Leeds as a centre for\u000a      excellence in childhood obesity research. Pragmatic trials have been\u000a      designed and implemented within existing infrastructures with robust\u000a      evaluations to inform both practice and policy. The APPLES study (1, 2)\u000a      was one of the first to highlight the increasing prevalence of childhood\u000a      obesity within the UK in the late 1990's (3). Staff are recognised for\u000a      their expertise in generating evidence to inform better quality\u000a      interventions. Publications and conference presentations resulting from\u000a      this work have attempted to explore effective approaches in the prevention\u000a      and treatment of childhood obesity across a range of age groups and\u000a      settings. The applied nature of the research has focussed on improving the\u000a      quality of interventions and services through links with PCT\u000a      commissioning, other researchers and DH obesity policies resulting in a\u000a      number of grants being awarded. Building on this experience further\u000a      intervention studies have been undertaken which focus on the early\u000a      prevention of childhood obesity contributing to current evidence that the\u000a      early years are a critical period to address obesity risk factors. The\u000a      team has continued to collaborate with existing (Leeds University, NHS\u000a      Trust, PCT) and new partners (Universities of Bradford, Warwick,\u000a      Southampton, Cambridge, Royal College of Paediatrics and Child Health\u000a      (RCPCH)) in the development and evaluation of further interventions listed\u000a      below along with funding sources:-\u000a    2004 - 09 - WATCH IT, community-based treatment programme led by Health\u000a      Trainers (Wellcome Trust 650,000);(4)\u000a      2006 -11 - EMPOWER Project, health-visitor-led early intervention with\u000a      RCPCH (DH)\u000a      2006 - 11 HELP Programme targeting parents attending Children Centres,\u000a      LeedsMet Centenary PhD studentship\u000a    Further work is currently developing around this theme. P. Sahota is a\u000a      co-applicant on a NIHR programme grant (&#163;1.9m initially) with Professor\u000a      Wright (PI) from Bradford Institute of Health Research to assess health\u000a      determinants of 13,500 mothers and children in the Born in Bradford study.\u000a      Data from a subsample of 1700 has informed the development of an early\u000a      intervention for the multi-ethnic population of Bradford currently being\u000a      evaluated. P Sahota has secured funding from industry (Danone) for the\u000a      dietary analysis to increase understanding of dietary risk factors and\u000a      inform the targeted intervention.\u000a    School-based interventions remain as key research areas and novel\u000a      interventions are being evaluated and the impact of these studies is being\u000a      realised in practice and policy.\u000a      2008-11 Factors influencing uptake of free school meals (Education Leeds)\u000a      (5)\u000a      2008 - 2010 School-based fruit and vegetable intervention- (Project\u000a      Tomato) (NIHR)\u000a      2010-13 RHS School Gardening Project (NIHR)(6)\u000a      2012- 14 Evaluation of PhunkyFoods primary school-based nutrition and\u000a      physical activity programme.(NESTLE Global)\u000a    Child health and obesity remain key areas of public health policy in the\u000a      UK as referred to in the recent Public Health White Paper and Marmot\u000a      Review. The research undertaken includes interventions across childhood\u000a      and therefore compliments the life course approach proposed for impacting\u000a      on public health, practice and policy.\u000a    "},{"CaseStudyId":"14513","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"1605651","Name":"Thailand"},{"GeoNamesId":"3144096","Name":"Norway"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2802361","Name":"Belgium"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"6251999","Name":"Canada"}],"Funders":[],"ImpactDetails":"\u000d\u000a    The development of the SF-6D contributes to public policy and\u000d\u000a        services around the world and has\u000d\u000a      commercial benefits in the UK. The health system efficiency\u000d\u000a      improvement arises from the use of\u000d\u000a      SF-6D data in the assessment of the cost-effectiveness of health care\u000d\u000a      interventions by health\u000d\u000a      services and regulatory agencies around the world. Commercial benefits\u000d\u000a      come from the licensing\u000d\u000a      of the measure to pharmaceutical companies and others who need to\u000d\u000a      demonstrate the cost\u000d\u000a      effectiveness of their products to these agencies.\u000d\u000a    Achieving impact\u000d\u000a    Dissemination of the SF-6D was initially targeted at the funders\u000d\u000a      (GlaxoWelcome) and to key\u000d\u000a      decision makers (e.g. Department of Health). The work was presented at\u000d\u000a      conferences attended by\u000d\u000a      potential end users including: pharmaceutical companies (International\u000d\u000a      Society for\u000d\u000a      Pharmacoeconomics and Outcomes research), HTA agencies (International\u000d\u000a      Society of Technology\u000d\u000a      Assessment in Health Care, 1999), Australian policy makers (the Australian\u000d\u000a      Health Outcomes\u000d\u000a      Collaboration in 1999), and US policy advisors (Institute of Medicine, USA\u000d\u000a      in 2004). Information\u000d\u000a      about the SF-6D and other measures developed in ScHARR is advertised at\u000d\u000a      user conferences\u000d\u000a      (e.g. ISPOR, ISOQOL). The team has continued to promote the SD-6D through\u000d\u000a      publishing\u000d\u000a      research showing how well it performs compared to other instruments in\u000d\u000a      terms of psychometric\u000d\u000a      properties and across different conditions (R3).\u000d\u000a    To maximise access, the SF-6D is supplied in easy to use software\u000d\u000a      including excel, SPSS and\u000d\u000a      SAS programs accessible to a wide a range of users. These programs can be\u000d\u000a      run on SF-36\u000d\u000a      (version 1 or 2) and SF-12 datasets to estimate the SF-6D index on the\u000d\u000a      zero to one scale for\u000d\u000a      calculating QALYs. Guidance and instructions on how to use the programs\u000d\u000a      are provided at the sf-\u000d\u000a      6d website (see http:\/\/www.sheffield.ac.uk\/scharr\/sections\/heds\/mvh\/sf-6d).\u000d\u000a      Access to the SF-6D is\u000d\u000a      through either a license for commercial applications from the University's\u000d\u000a      commercialisation\u000d\u000a      partner in the UK, Fusion IP, or from Quality Metric in the US who supply\u000d\u000a      the software for a charge.\u000d\u000a      Non-commercial applications covering all public sector and charitable\u000d\u000a      applications are free of\u000d\u000a      charge and copies of the software can be obtained through ScHARR; 521\u000d\u000a      non-commercial\u000d\u000a      licenses have been distributed since 2008.\u000d\u000a    International public policy and services (HTA regulatory authorities)\u000d\u000a    An important impact of the SF-6D has been its use by HTA regulatory\u000d\u000a      bodies around the world for\u000d\u000a      assessing the cost-effectiveness of health technologies. The SF-6D is\u000d\u000a      recommended for use by\u000d\u000a      Health Technology Assessment (HTA) agencies in Ireland (S1) and\u000d\u000a      China (S2); it is explicitly\u000d\u000a      named as an accepted measure in Australia (S3), Belgium, Canada (S4),\u000d\u000a      Norway (S5), South\u000d\u000a      Korea and Thailand; it also meets the specific guideline requirements of\u000d\u000a      HTA agencies in 21 other\u000d\u000a      countries whose guidelines are available via the ISPOR\u000d\u000a      website(www.ispor.org\/PEguidelines\/index.asp)\u000d\u000a      and thus can be used for health care decision\u000d\u000a      making in those countries. It is also featured in the European Network for\u000d\u000a      Health Technology\u000d\u000a      Assessment (eunethat) Guideline on health-related quality of life and\u000d\u000a      utility measures (S6).\u000d\u000a    The SF-6D has been used in decision making in the UK by NICE, SMC and\u000d\u000a      AWMSG. It has been\u000d\u000a      used as the main health utility measure in important assessments such as\u000d\u000a      pharmacological\u000d\u000a      treatments for Alzheimer's (NICETA217), gout (NICESTA118301), low platelet\u000d\u000a      count\u000d\u000a      (NICESTA088101) and peripheral arterial disease (NICETA223), and has been\u000d\u000a      used alongside\u000d\u000a      other measures in many other appraisals.\u000d\u000a    Commercial benefits\u000d\u000a    The main commercial users of the SF-6D have been pharmaceutical companies\u000d\u000a      and consultancy\u000d\u000a      companies working on their behalf who wish to examine the\u000d\u000a      cost-effectiveness of new drugs and\u000d\u000a      make submissions to regulatory authorities. It is available through Fusion\u000d\u000a      IP, a company\u000d\u000a      specialising in marketing IP owned by the University. The selling of the\u000d\u000a      SF-6D has also been\u000d\u000a      subcontracted to Quality Metric (www.qualitymetric.com)\u000d\u000a      a US based company specialising in\u000d\u000a      measuring health outcomes who also distribute other SF products including\u000d\u000a      SF-36 and SF-12.\u000d\u000a      Since 2008 they have together sold over 460 licenses to pharmaceutical and\u000d\u000a      consultancy\u000d\u000a      companies including Novartis, Roche, Pfizer, Novo Nordisk, Astellas,\u000d\u000a      Merck, Sanofi and BMS.\u000d\u000a      Other important commercial users have been health care insurers and\u000d\u000a      providers in the USA.\u000d\u000a    The companies benefit because an accepted generic health measure\u000d\u000a      administered in their clinical\u000d\u000a      trial (the SF-36 or SF-12) can be directly, and easily, translated into a\u000d\u000a      preference based measure\u000d\u000a      that can be used in economic evaluation. The SF-6D enables them to\u000d\u000a      estimate the health related\u000d\u000a      quality of life benefits of their technology in terms of QALYs, which is a\u000d\u000a      requirement for a\u000d\u000a      submission to regulatory bodies around the world.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The decision about whether to fund new health care interventions is\u000d\u000a      increasingly being informed by\u000d\u000a      evidence of cost-effectiveness in terms of the cost per Quality Adjusted\u000d\u000a      Life Years (QALY). The\u000d\u000a      SF-6D health index is widely used internationally for calculating QALYs\u000d\u000a      from patient reported\u000d\u000a      health outcomes collected in clinical trials and other surveys. It\u000d\u000a      contributes to health system\u000d\u000a        efficiency from being used by health technology agencies around the\u000d\u000a      world (including Australia,\u000d\u000a      Canada, England, Scotland, Ireland and Norway) to calculate QALYs to\u000d\u000a      facilitate decisions about\u000d\u000a      the most efficient use of limited health care resources. The SF-6D is\u000d\u000a      freely available to non-commercial\u000d\u000a      bodies, including researchers and policy makers. Commercial benefits\u000d\u000a      come from the\u000d\u000a      licensing of the measure to pharmaceutical companies, health insurers and\u000d\u000a      others to assess the\u000d\u000a      cost-effectiveness of their products with 460 licenses being sold since\u000d\u000a      2008. A further 521 licenses\u000d\u000a      are distributed on a non-commercial basis to academic researchers, public\u000d\u000a      sector and charitable\u000d\u000a      organisations.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Sheffield\u000d\u000a    ","Institutions":[{"AlternativeName":"Sheffield (University of)","InstitutionName":"University of Sheffield","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007157}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    Main grant:\u000d\u000a    R1. Brazier J, Deverill M, Roberts J. Estimation of a utility based\u000d\u000a      algorithm for the SF-36, Glaxo-Welcome,\u000d\u000a      1997-99\u000d\u000a    Main journal paper\u000d\u000a    \u000aR2.Brazier J, Roberts J, Deverill M (2002) The Estimation of a\u000d\u000a      Preference-Based Measure of\u000d\u000a      Health from the SF-36 Journal of Health Economics, 21(2) 271-292.\u000d\u000a      doi: 10.1016\/S0167-6296(01)00130-8\u000d\u000a      [930] [Awarded the 2002 International Society for Quality of\u000d\u000a        Life Prize for\u000d\u000a      \"Outstanding contribution to the study of health related quality of\u000d\u000a      life''. Andrew Oswald (2009),\u000d\u000a      in his Warwick Economics Research Paper (No.887) \"World-leading\u000d\u000a        research and its measurement\", notes\u000d\u000a      this paper as among the top most cited economics papers in the world.\u000d\u000a    \u000aOther key papers arising from this research:\u000d\u000a    \u000aR3. Brazier J, Roberts J Tsuchiya A, Busschbach J. (2004) A comparison of\u000d\u000a      the EQ-5D and SF-6D\u000d\u000a      across seven patient groups Health Econ. 13(9) 873-884 doi: 10.1002\/hec.866\u000d\u000a      [247]\u000d\u000a    \u000a\u000aR4. Brazier J, Roberts J (2005) Estimation of a preference-based index\u000d\u000a      measure of health for the\u000d\u000a      SF-12 &amp; comparison to the SF-36 preference-based index Medical\u000d\u000a        Care, 42(9), 851-859 [271]\u000d\u000a    \u000a\u000aR5. Kharroubi SA, Brazier J, Roberts J, O'Hagan A. (2007) Modelling SF-6D\u000d\u000a      health state\u000d\u000a      preference data using a non-parametric Bayesian method. Journal Health\u000d\u000a        Econ. 26(3): 597-612\u000d\u000a      doi: 10.1016\/j.jhealeco.2006.09.002\u000d\u000a      [31]\u000d\u000a    \u000a\u000aR6. Brazier J, Fukuhara S, Kharroubi SA, Roberts J, (2009) Estimating a\u000d\u000a      preference-based index\u000d\u000a      from the Japanese SF-36 Journal Clinical Epidemiology 62(12):\u000d\u000a      1323-1331 doi:\u000d\u000a      10.1016\/j.jclinepi.2009.01.022\u000d\u000a      [11]\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"14","Level2":"2","Subject":"Applied Economics"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    Regulatory agencies around the world recommend and\/or accept use of the\u000d\u000a      SF6D as\u000d\u000a      demonstrated by the HTA guidelines. Examples include the following:\u000d\u000a    S1 Guidelines of the Health Information and Quality Authority in Ireland\u000d\u000a      state:\u000d\u000a    \"Use of an indirect preference-based measure, such as the EQ-5D or\u000d\u000a      SF-6D, is recommended for\u000d\u000a        the reference case as these measures have widespread availability, are\u000d\u000a        easy to use and interpret\u000d\u000a        and because they are based on preferences of the general public.\"\u000d\u000a      p31.\u000d\u000a    www.hiqa.ie\/publication\/guidelines-economic-evaluation-health-technologies-ireland\u000d\u000a    S2. The Chinese HTA guidelines states:\u000d\u000a    \"The recommended measuring instrument of health utility mainly\u000d\u000a        includes Standard Gamble (SG),\u000d\u000a        Time Trade-off (TTO), Visual Analogue Scale (VAS), EuroQol-5 Dimensions\u000d\u000a        (EQ-5D), Short-Form\u000d\u000a        Six-Dimensions (SF-6D), Health Utility Index (HUI)\u000d\u000a        and Quality Well Being (QWB)\" p8 (translated\u000d\u000a      from Chinese).\u000d\u000a    www.pe-cn.org\/en\/pe_guidelines\/index.asp\u000d\u000a    S3. The Australian HTA guidelines state:\u000d\u000a    \"Acceptable MAUIs are the Health Utilities Index (HUI2 or HUI3), the\u000d\u000a        EQ5D (`EuroQol'), the SF-6D\u000d\u000a      (a subset of the Short Form 36, or SF-36) or the Assessment of Quality\u000d\u000a        of Life (AQoL) instrument.\"\u000d\u000a        p78\u000d\u000a    http:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-guidelines\/PBAC4.3.2.pdf\u000d\u000a    S4. The Norwegian HTA guidelines state:\u000d\u000a    \"The main rule is that QALY-outcomes are to be calculated using\u000d\u000a        multi-attribute utility instruments\u000d\u000a        that evaluate both the physical and psychological condition of the\u000d\u000a        patient as well as his\/her social\u000d\u000a        functioning. Some examples of such instruments are EQ-5D, SF-6D\u000d\u000a        and 15D\". p16\u000d\u000a    www.ispor.org\/PEguidelines\/source\/Norwegian_guidelines2012.pdf\u000d\u000a    S5. The Canadian Agency for Drugs and Technologies in\u000d\u000a      Health states:\u000d\u000a    `Analysts are encouraged to use indirect measurement instruments,\u000d\u000a        because they are easy to\u000d\u000a        obtain, compare, and interpret. ... Some widely used instruments in this\u000d\u000a        category are the Health\u000d\u000a        Utilities Index (HUI), the EQ-5D, the SF-6D, and\u000d\u000a        the 15D.'\u000d\u000a    http:\/\/www.cadth.ca\/media\/pdf\/186_EconomicGuidelines_e.pdf\u000d\u000a    S6. EUNEHTA is an agency representing HTA bodies around Europe\u000d\u000a      that has produced a\u000d\u000a      guideline that includes the SF-6D and appends a list of country specific\u000d\u000a      guidelines.\u000d\u000a    Endpoints used for REA of pharmaceuticals: health related quality of life\u000d\u000a      and utility measures.\u000d\u000a      European Network for Health Technology Assessment. 2012\u000d\u000a    http:\/\/www.eunethta.eu\/sites\/5026.fedimbo.belgium.be\/files\/Health-related%20quality%20of%20life.pdf\"&gt;\u000d\u000a    ","Title":"\u000d\u000a    A new measure for assessing the cost-effectiveness of health care\u000d\u000a      interventions: the SF-6D\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The SF-6D health index is a measure used in assessing the\u000d\u000a      cost-effectiveness of health care\u000d\u000a      interventions. The main project was undertaken between 1999 and 2002 at\u000d\u000a      the University of\u000d\u000a      Sheffield's School of Health and Related Research (ScHARR) by John Brazier\u000d\u000a      (1989-), Jennifer\u000d\u000a      Roberts (1997-2003) and Mark Deverill (1995-2002), funded by a grant from\u000d\u000a      GlaxoWelcome (R1).\u000d\u000a    The SF-6D was derived from the SF36 (http:\/\/www.sf-36.org),\u000d\u000a      a widely used patient reported measure\u000d\u000a      that assesses health across 8 dimensions. The SF-36 does not enable\u000d\u000a      trade-offs between them\u000d\u000a      (e.g. pain vs. physical functioning), or between quality and length of\u000d\u000a      life and so could not be used\u000d\u000a      to assess cost-effectiveness. The SF-6D index was developed in order to\u000d\u000a      overcome these\u000d\u000a      limitations.\u000d\u000a    The main project (1999-2001) involved 3 stages:\u000d\u000a    1) Revising the SF-36 using psychometric methods to a 6 dimension\u000d\u000a      classification (physical\u000d\u000a      functioning, role limitation, social functioning, pain, mental health and\u000d\u000a      vitality) amenable to\u000d\u000a      valuation.\u000d\u000a    2) Obtaining population preferences for the 6 dimensions for a sample of\u000d\u000a      states via face-to-\u000d\u000a      face interviews with a representative sample of the UK general population\u000d\u000a      (n=836) using\u000d\u000a      standard gamble, a choice based method for measuring preferences under\u000d\u000a      uncertainty.\u000d\u000a    3) Estimating values for all 18,000 health states defined by the SF-6D\u000d\u000a      using econometric\u000d\u000a      modelling techniques.\u000d\u000a    The resulting algorithm generates an index for health anchored at 0\u000d\u000a      (equivalent to being dead),\u000d\u000a      and 1 (full-health), with negative values denoting states worse than being\u000d\u000a      dead. This algorithm\u000d\u000a      shows how much value people place on different health limitations and how\u000d\u000a      they trade-off between\u000d\u000a      them (e.g. how much vitality they will sacrifice for a reduction in pain).\u000d\u000a    The main research was published in 2002 (R2) and since then the SF-6D has\u000d\u000a      become widely used\u000d\u000a      around the world. The SF-6D has a number of advantages over the previously\u000d\u000a      used main health\u000d\u000a      valuation measure the EQ-5D: it has a richer descriptive system (with\u000d\u000a      18,000 states as opposed to\u000d\u000a      only 243 for the EQ-5D), it is more sensitive to health changes\u000d\u000a      particularly for milder states (R3)\u000d\u000a      and it covers a broader range of health dimensions by including role\u000d\u000a      limitations, social functioning\u000d\u000a      and vitality. The SF-36 is often used in clinical studies and so this\u000d\u000a      algorithm enables QALYs to be\u000d\u000a      estimated without the need for additional data collection.\u000d\u000a    There have been 4 main extensions to increase impact: 1) The development\u000d\u000a      of an algorithm for the\u000d\u000a      SF-12 (a reduced version of the SF-36), thus increasing the reach of the\u000d\u000a      work (R4). 2) The\u000d\u000a      development of an improved algorithm using Bayesian methods (R5), allowing\u000d\u000a      decision makers to\u000d\u000a      take better account of differences across patients. 3) The development of\u000d\u000a      valuation algorithms for\u000d\u000a      SF-6D in other countries including Japan (R6), Brazil, China (Hong Kong),\u000d\u000a      Australia, Portugal and\u000d\u000a      Spain. It has also been used to derive an index from the VR-12 for use in\u000d\u000a      Medicare data sets in the\u000d\u000a      USA. 4) The development of algorithms for condition specific measures of\u000d\u000a      health, extending the\u000d\u000a      reach to health problems and trials where generic measures have not been\u000d\u000a      used or are not\u000d\u000a      appropriate.\u000d\u000a    "},{"CaseStudyId":"14525","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"3175395","Name":"Italy"},{"GeoNamesId":"2750405","Name":"Netherlands"}],"Funders":[],"ImpactDetails":"\u000d\u000a    The impact of this research is on national policy and public services\u000d\u000a    Pathway to impact\u000d\u000a      A report was produced in April 2011 [R1] and this was presented to the DoH\u000d\u000a      Hospital Mortality committee chaired by Sir Bruce Keogh (Medical Director\u000d\u000a      of the NHS) in May 2011.The key insights were that a relatively simple\u000d\u000a      combination of age, sex, diagnosis on admission, method of admission\u000d\u000a      (emergency or elective) and comorbidity score produced a useful and stable\u000d\u000a      model which could be used to calculate how many deaths would have been\u000d\u000a      expected in a hospital, given its particular case-mix. Using random\u000d\u000a      effects model and funnel plots to identify unexplained variation, limits\u000d\u000a      were drawn for the ratio of the observed to expected number of deaths, and\u000d\u000a      above or below these limits a hospital was deemed to be an `outlier'. A\u000d\u000a      number of hospitals were thus identified.\u000d\u000a    We recommended that mortality indicators should not be used on their own\u000d\u000a      at one point in time, but rather over a period of time, and with due\u000d\u000a      consideration of the changes to both the observed mortality and the\u000d\u000a      expected mortality. We also advised that the index should be used in\u000d\u000a      conjunction with other indicators, and that avoidable mortality was only a\u000d\u000a      small proportion of the total deaths in a hospital.\u000d\u000a    The hospital morbidity indicator developed by Sheffield has been rolled\u000d\u000a      out across the NHS. Our SHMI enables robust and transparent monitoring of\u000d\u000a      hospital performance and enables early identification of possibly failing\u000d\u000a      hospitals so that investigations and remedial action can be taken. In the\u000d\u000a      long run patients will benefit from better hospital care.\u000d\u000a    ScHARR's contribution is highlighted by the following statement on the\u000d\u000a      NHS Information Centre website:\u000d\u000a    \"The Department of Health are committed to implementing the SHMI as\u000d\u000a        the single hospital-level indicator for the NHS in England and have\u000d\u000a        commissioned the Health and Social Care Information Centre to produce\u000d\u000a        it. This decision was based on the recommendations from the national\u000d\u000a        review of the Hospital Standardised Mortality Ratios (HSMR) with\u000d\u000a        independent statistical modelling work commissioned by the Department of\u000d\u000a        Health and carried out by the School of Health and Related Research\u000d\u000a        (ScHARR) at the University of Sheffield.\" (http:\/\/www.hscic.gov.uk\/SHMI\u000d\u000a      .)\u000d\u000a    Dissemination\u000d\u000a      The SHMI was disseminated via a major conference in London in May 2012:\u000d\u000a      http:\/\/www.healthcareconferencesuk.co.uk\/reducing-measuring-avoidable-mortality\u000d\u000a      attended by managers and clinicians from Hospital Trusts across England\u000d\u000a      and by the Department of Health.\u000d\u000a    Beneficiaries:\u000d\u000a      DoH &#8212; accurate and independent monitoring\u000d\u000a      The Francis Report on the Mid-Staffordshire Hospital Trust in Feb 2013\u000d\u000a      showed that excess mortality for the Trust was associated with poor care.\u000d\u000a      Subsequently 14 hospitals (many of which were also identified in our\u000d\u000a      report of 2011) have been identified by the Department of Health as having\u000d\u000a      unacceptably high mortality, over two years using the Sheffield SHMI,\u000d\u000a      amongst other measures. The consequence of this is that the Care Quality\u000d\u000a      Commission has sent teams in to investigate the care of patients at these\u000d\u000a      hospitals and this has been reported in the Keogh report (2013) which will\u000d\u000a      ultimately impact on staff, patients and hospital systems with the aim of\u000d\u000a      improving patient outcomes.\u000d\u000a    NHS Trusts &#8212; can verify their results from published weightings\u000d\u000a      Previous hospital mortality indicators have been strongly criticised\u000d\u000a      because of a lack of transparency as to how different case-mix variables\u000d\u000a      were weighted. This has been solved because the weights for the SHMI are\u000d\u000a      published on the NHS Information Centre's website and can be downloaded\u000d\u000a      and used by individual Trusts to verify their SHMI.\u000d\u000a    International beneficiaries &#8212; learning from our research\u000d\u000a      As authors of the SHMI we were in a unique position of being able to\u000d\u000a      advise on its use. In 2012 we gave a presentation on the use of the SHMI\u000d\u000a      to the Catalonian Department of Health in Barcelona. In April 2013 five\u000d\u000a      representatives from The Netherlands National Statistics Group came see us\u000d\u000a      to discuss comparisons with Dutch methods and we have also had a visitor\u000d\u000a      from Milan to discuss Italian methods. This may lead to attempts to\u000d\u000a      standardise these measure in parts of Europe.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    This case study describes a significant new index used to monitor death\u000d\u000a      rates in hospitals. The Summary Hospital Mortality Index (SHMI) was\u000d\u000a      developed as a direct result of research carried out at the School of\u000d\u000a      Health and Related Research (ScHARR). This was implemented nationally in\u000d\u000a      October 2011 and the SHMI is now the main mortality indicator used by the\u000d\u000a      NHS. Following publication of the high profile Francis Inquiry on Mid\u000d\u000a      Staffordshire in February 2013, set up to investigate excess mortality in\u000d\u000a      the Trust, the Government has used the SHMI to identify and target 8\u000d\u000a      further hospitals for investigation.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of Sheffield\u000d\u000a    ","Institutions":[{"AlternativeName":"Sheffield (University of)","InstitutionName":"University of Sheffield","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007157}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"3173435","Name":"Milan"},{"GeoNamesId":"3128760","Name":"Barcelona"},{"GeoNamesId":"3336901","Name":"Catalunya"}],"References":"\u000d\u000a    \u000aR1. Campbell MJ, Jacques RM, Fotheringham J, Pearson T, Maherswaran R,\u000d\u000a      Nicholl J (2011) An evaluation of the Summary Hospital Mortality Index.\u000d\u000a      Final Report\u000d\u000a      URL: http:\/\/sheffield.ac.uk\/scharr\/sections\/dts\/statistics\u000d\u000a    \u000d\u000a    \u000a\u000aR2. Campbell MJ, Jacques RM, Fotheringham J, Maheswaran R, Nicholl J\u000d\u000a      (2012) Developing a summary hospital mortality index: retrospective\u000d\u000a      analysis in English hospitals over five years. BMJ  British Medical\u000d\u000a        Journal;344:e101 doi: 10.1136\/bmj.e1001\u000d\u000a      Cited by 13 (google Scholar 21\/10\/2013)\u000d\u000a    \u000a\u000aR3.Campbell MJ (2012) Developing a summary hospital mortality index: how\u000d\u000a      do we compare hospitals? Invited talk, International Society for Clinical\u000d\u000a      Biostatistics Conference, Bergen, August.\u000d\u000a      http:\/\/kivik.no\/ISCB\/wordpress\/wp-content\/uploads\/2012\/08\/iscb33_2012_abstractbook_web.pdf\u000d\u000a    \u000d\u000a    \u000a\u000aR4. Jacques RM, Fotheringham J, Campbell MJ, Nichol J Did hospital\u000d\u000a      mortality in England change from 2005 to 2010? A retrospective cohort\u000d\u000a      analysis (2013) BMC Health Services Research, 13, 216,1-9. doi: 10.1186\/1472-6963-13-216\u000d\u000a    \u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    S1. The SHMI and the HSMR were used in the Keogh report, to identify 14\u000d\u000a      `at risk' hospitals\u000d\u000a      http:\/\/www.nhs.uk\/NHSEngland\/bruce-keogh-review\/Documents\/outcomes\/keogh-review-final-report.pdf\u000d\u000a      (p.3, 13, 16)\u000d\u000a    S2. The Francis Report into the mid Staffordhsire Hospital Trust states\u000d\u000a      (p.457) \"There is now a consensus that significantly high HSMR\/SHMI\u000d\u000a      results should trigger a serious consideration of whether poor care is an\u000d\u000a      explanation for them\"\u000d\u000a      http:\/\/www.midstaffspublicinquiry.com\/sites\/default\/files\/report\/Volume%201.pdf\u000d\u000a      (p.461)\u000d\u000a    S3. Its development was widely reported, for example News Medical `University\u000a          of Sheffield's ScHARR team develops new index to measure\u000d\u000a          hospital mortality rates'\u000d\u000a      http:\/\/www.news-medical.net\/news\/20110610\/University-of-Sheffields-ScHARR-team-develops-new-index-to-measure-hospital-mortality-rates.aspx\u000d\u000a    \u000d\u000a    S4. Medicalxpress `New hospital mortality rate index to be used across\u000d\u000a      UK'\u000d\u000a      http:\/\/medicalxpress.com\/news\/2011-06-hospital-mortality-index-uk.html\u000d\u000a    \u000d\u000a    S5. The fact that it has been used to identify failing hospitals was widely\u000d\u000a    reported for example by the Daily Telegraph, which named eight hospitals\u000d\u000a    identified by the SHMI as having high death rates.\u000d\u000a    http:\/\/www.telegraph.co.uk\/health\/healthnews\/9824260\/Persistently-high-death-rates-at-eight-large-hospitals.html\u000d\u000a    ","Title":"\u000d\u000a    Identifying failing hospitals : a new measure implemented by the NHS\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Around 60% of all deaths occur in hospital and preventing avoidable\u000d\u000a      deaths is an essential objective for health services. Since 2001, the\u000d\u000a      Department of Health (DoH) used the Hospital Standardised Mortality Ratio,\u000d\u000a      developed by commercial company Dr Foster. In 2010 the DoH decided it\u000d\u000a      needed its own index and after a competitive tendering round, the\u000d\u000a      University of Sheffield was commissioned to develop this. During the early\u000d\u000a      part of 2011 the ScHARR team had regular meetings with the DoH in London\u000d\u000a      and Sheffield as they worked on the project.\u000d\u000a    The research team was led by Mike Campbell (Professor of Medical\u000d\u000a      Statistics) and all the team were based in ScHARR.\u000d\u000a    The research question was this: When explainable factors such as the age\u000d\u000a      of the patient and method of admission are taken into account, is there\u000d\u000a      unexplainable variation remaining between hospitals in mortality in\u000d\u000a      hospital and 30 days after discharge?\u000d\u000a    The project was a major data processing and statistical exercise [R1]. It\u000d\u000a      led to two papers in mainstream journals [R2,R4] and an international\u000d\u000a      speaking invitation [R3]. It involved linking hospital and national\u000d\u000a      mortality data from 2005 to 2010 from the Office of National Statistics\u000d\u000a      (92 million records). There were considerable logistical problems to be\u000d\u000a      overcome in fitting statistical models to such large data sets. The\u000d\u000a      analysis used data from all deaths both in hospital and within 30 days of\u000d\u000a      discharge. The 30 day post discharge period is to try and discourage\u000d\u000a      hospitals from discharging patients who are likely to die within 30 days\u000d\u000a      so that the deaths no longer count in their mortality figures. The key\u000d\u000a      insight was that certain hospitals had mortality rates well above that\u000d\u000a      which could be accounted for by chance, even when known risk factors were\u000d\u000a      accounted for.\u000d\u000a    The key innovations are:\u000d\u000a    \u000d\u000a      The SHMI uses all deaths in hospital and deaths 30 days after\u000d\u000a        discharge rather than only 80% of in-hospital deaths used by the Dr\u000d\u000a        Foster model\u000d\u000a      It is robust to practices such as coding patients as `palliative care'\u000d\u000a      The limits are calculated using a `random effects' model\u000d\u000a      It is updated every three months, but with the weights calculated from\u000d\u000a        12 months of data, which means that seasonality is not a problem.\u000d\u000a      The weights are available on the NHS Information Centre Website and so\u000d\u000a        are open to scrutiny (unlike other competing models).\u000d\u000a    \u000d\u000a    Our report's specification was accepted by the DoH and was implemented\u000d\u000a    nationally in October 2011.\u000d\u000a    "},{"CaseStudyId":"14536","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"6251999","Name":"Canada"}],"Funders":[],"ImpactDetails":"\u000a    Our research directly informed changes to national and international\u000a      guidelines for the diagnosis of\u000a      DVT. Diagnostic assessment is undertaken in the UK using NICE guidelines\u000a      [S1] and\u000a      internationally using ACCP guidelines [S2].\u000a    Impact in the UK\u000a    NICE published its DVT guideline in 2012 (Clinical Guideline 144) [S1],\u000a      with the aim of reducing the\u000a      current high toll of long-term ill health or death caused by venous\u000a      thromboembolic diseases by\u000a      clarifying &#8212; for the first time &#8212; what combination of tests and treatments\u000a      results in the most cost-effective\u000a      diagnosis and management of these conditions. Specifically, the guidelines\u000a      provide an\u000a      algorithm to guide DVT diagnosis in the NHS and evidence-based guidance on\u000a      the use of clinical\u000a      probability scoring, D-dimer and ultrasound in the diagnosis of DVT.\u000a    The estimates of sensitivity and specificity, and the evidence statements\u000a      provided in the guidelines\u000a      are based upon our meta-analyses of these approaches\/methodologies. The\u000a      NICE DVT guidelines\u000a      recommend the algorithm identified in our analysis as being most likely to\u000a      be cost-effective and\u000a      feasible in the NHS.\u000a    Implementation of the NICE guidance will improve outcomes for patients\u000a      with suspected DVT by\u000a      reducing misdiagnosis and will result in more cost-effective care. NICE\u000a      claimed that the clinical\u000a      guideline would save lives by improving the diagnosis and management of\u000a      blood clots [S3]. This\u000a      will be achieved through NICE Quality Standard 29, Quality Statement 2\u000a      (Diagnosis of DVT), which\u000a      promotes implementation of NICE Clinical Guideline 144 [S4].\u000a    NICE Clinical Knowledge Summaries provide primary care practitioners with\u000a      a readily accessible\u000a      summary of the current evidence base and practical guidance on best\u000a      practice in respect of over\u000a      300 common and\/or significant primary care presentations. The NICE\u000a      Clinical Knowledge\u000a      Summary for predicting who is at risk for DVT [S5] cites data from our\u000a      meta-analysis [R1] and\u000a      economic analysis [R6] to guide practitioners.\u000a    Around 140,000 people are investigated for suspected DVT each year in the\u000a      UK. It is difficult to\u000a      estimate the impact of new guidance on health outcomes and costs since\u000a      practice varied\u000a      substantially prior to implementation of the guidance [S6]. However, on\u000a      the basis of our economic\u000a      model we estimate that adopting the NICE recommended algorithm instead of\u000a      using ultrasound for\u000a      all cases would result in a net benefit of &#163;42,919 per 1000 patients with\u000a      suspected DVT (i.e. per\u000a      year at a large hospital), assuming health outcomes are monetised with an\u000a      estimated value of\u000a      &#163;20,000 per QALY.\u000a    International impact\u000a    ACCP guidance is produced in the United States and Canada, and is used in\u000a      many other\u000a      countries. Updated ACCP guidelines for diagnosing DVT were published in\u000a      2012 [S2].\u000a      Recommendations in the guidance for the use of Wells score, D-dimer and\u000a      ultrasound all cited our\u000a      meta-analyses. Furthermore, as a direct result of our research the ACCP\u000a      Guideline Development\u000a      Group asked us to provide updated systematic reviews of CT and MR scanning\u000a      specifically for this\u000a      guideline. We were also asked to use our decision-analytic model to\u000a      estimate the probability of\u000a      adverse outcomes for commonly used diagnostic strategies. These estimates\u000a      were published in\u000a      the ACCP guidance.\u000a    The ACCP and NICE take different approaches to providing guidance, but\u000a      both based their\u000a      recommendations on our analyses. Whereas NICE recommends a specific\u000a      algorithm, the ACCP\u000a      guidance provides physicians with estimates of the likely consequences of\u000a      different diagnostic\u000a      approaches and leaves the choice of strategy to the physician. Our\u000a      approach to analysis allowed\u000a      us to adapt our outputs to the needs of both organisations. For NICE we\u000a      identified the strategy\u000a      most likely to be feasible and cost-effective in the NHS. For the ACCP we\u000a      estimated the likely\u000a      consequences of alternative diagnostic strategies. These mean that our\u000a      findings influenced\u000a      practice in different ways and in different settings.\u000a    Impact on the clinical community\u000a    To increase the use of our research throughout the clinical community,\u000a      the Chief Investigator for\u000a      the project published an educational article for Annals of Internal\u000a      Medicine in 2008 that provided\u000a      advice on DVT diagnosis based on our analysis [S7] and provided content\u000a      between 2007 and 2011\u000a      for the DVT module of the Physicians' Information and Education Resource\u000a      run by the American\u000a      College of Physicians, based on our analysis [S8]. We also presented our\u000a      findings at a specially\u000a      organised one-day conference for clinicians and at other conferences, such\u000a      as the Annual\u000a      Scientific Meetings of the College of Emergency Medicine and British\u000a      Society for Haematology.\u000a    ","ImpactSummary":"\u000a    Our research has led to the development of guidelines on the diagnosis of\u000a      deep vein thrombosis\u000a      (DVT), reducing the risk of death and saving resources by reducing\u000a      unnecessary tests and\u000a      treatments.\u000a    Meta-analysis and decision-analysis modelling studies undertaken at the\u000a      University of Sheffield\u000a      between 2005 and 2007 formed the basis of the National Institute for\u000a      Health and Clinical\u000a      Excellence (NICE) and the American College of Chest Physicians (ACCP)\u000a      guidelines for\u000a      diagnosing DVT. These guidelines determine the management of over 140,000\u000a      patients each year\u000a      in the United Kingdom with suspected DVT, and many more in other\u000a      countries.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Sheffield\u000a    ","Institutions":[{"AlternativeName":"Sheffield (University of)","InstitutionName":"University of Sheffield","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007157}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000aR1. Goodacre S, Sutton AJ and Sampson F. The value of\u000a      clinical assessment in the diagnosis of\u000a      deep vein thrombosis: a meta-analysis. Ann Intern Med 2005;143:129-139.\u000a      doi: 10.7326\/0003-4819-143-2-200507190-00012\u000a    \u000a\u000aR2.Goodacre S, Sampson FC, Sutton AJ, Mason S and Morris\u000a      F. Variation in the diagnostic\u000a      performance of D-dimer for suspected deep vein thrombosis: systematic\u000a      review, meta-analysis\u000a      and meta-regression. Q J Med 2005;98:513-517. doi: 10.1093\/qjmed\/hci085\u000a    \u000a\u000aR3. Goodacre S, Sampson F, Thomas S, van Beek E, Sutton AJ.\u000a      Systematic review and meta-\u000a      analysis of the diagnostic accuracy of ultrasonography for deep vein\u000a      thrombosis. BMC Medical\u000a      Imaging 2005;5:6. doi: 10.1186\/1471-2342-5-6\u000a    \u000a\u000aR4. Thomas SM, Goodacre SW, Sampson FC &amp; van Beek EJR.\u000a      Diagnostic value of CT for deep\u000a      vein thrombosis: results of a systematic review and meta-analysis.\u000a      Clinical Radiology \u000a      2008;63:299-304. doi: 10.1016\/j.crad.2007.09.010\u000a    \u000a\u000aR5.Sampson FC, Goodacre SW, Thomas SM &amp; VanBeek EJR. The\u000a      accuracy of MRI in\u000a      diagnosis of suspected deep vein thrombosis: systematic review and\u000a      meta-analysis. Eur Radiol\u000a      2007;17:175-181. doi: 10.1007\/s00330-006-0178-5\u000a    \u000a\u000aR6. Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton AJ, Thomas\u000a        S, Locker T &amp; Ryan\u000a        A. Measurement of the clinical and cost-effectiveness of\u000a      non-invasive diagnostic testing\u000a      strategies for deep vein thrombosis. Health Technol Assess 2006;15 (10).\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    S1. National Institute for Health and Clinical Excellence. Venous\u000a      thromboembolic diseases: the\u000a      management of venous thromboembolic diseases and the role of thrombophilia\u000a      testing. NICE\u000a      clinical guideline 144, June 2012, http:\/\/guidance.nice.org.uk\/CG144.\u000a      See Clinical Guideline\u000a      pages 42-52, reference 85, and Appendices pages 82, 102, 144, 474-476,\u000a      &amp; references 170-\u000a      173.\u000a    S2. Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD,\u000a      Kearon C,\u000a      Schunemann HJ, Crowther M, Pauker SG, Makdissi R, Guyatt GH. Diagnosis of\u000a      DVT:\u000a      Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American\u000a      College of Chest\u000a      Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012;\u000a      141(2)(Suppl)\u000a      http:\/\/journal.publications.chestnet.org\/article.aspx?articleid=1159488.\u000a      See pages e356S,\u000a      e383S, e384S, &amp; references 14,15,56,71,144.\u000a    S3. National Institute for Health and Clinical Excellence. NICE clinical\u000a      guideline set to save lives by\u000a      improving the diagnosis and management of blood clots (press release,\u000a      20\/6\/2012)\u000a      http:\/\/www.nice.org.uk\/newsroom\/pressreleases\/VTEDiseasesGuideline.jsp\u000a    S4. National Institute for Health and Clinical Excellence. QS29: Quality\u000a      standard for diagnosis and\u000a      management of venous thromboembolic diseases. Quality statement 2:\u000a      Diagnosis of deep vein\u000a      thrombosis. http:\/\/guidance.nice.org.uk\/QS29\u000a    S5. NICE Clinical Knowledge Summaries: Deep vein thrombosis (revised\u000a      April 2013).\u000a      http:\/\/cks.nice.org.uk\/deep-vein-thrombosis#!supportingevidence1\u000a    S6. Sampson F, Goodacre S, Kelly A-M and Kerr D. How is deep vein\u000a      thrombosis diagnosed and\u000a      managed in UK and Australian emergency departments? Emerg Med J\u000a      2005;22:780-2.\u000a    S7. Goodacre S. In the Clinic: Deep Vein Thrombosis. Ann Intern Med\u000a      2008;149:ITC3-1-16.\u000a    S8. American College of Physicians: Physicians' Information and Education\u000a      Resource website,\u000a      http:\/\/pier.acponline.org\/index.html\u000a    \u000a    ","Title":"\u000a    Changed clinical guidelines to improve the diagnosis of deep vein\u000a      thrombosis\u000a      (DVT)\u000a    ","UKLocation":[{"GeoNamesId":"2638077","Name":"Sheffield"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    DVT is a potentially life threatening condition with an annual incidence\u000a      of 124 per 100,000\u000a      population. Patients with DVT are at substantial risk of death if they are\u000a      not correctly diagnosed\u000a      and treated. The diagnostic assessment of DVT has changed dramatically\u000a      over the last 10-20\u000a      years, from being inpatient-based using contrast venography to becoming\u000a      outpatient-based using a\u000a      variety of non-invasive tests. The development of clinical prediction\u000a      scores, D-dimer blood testing,\u000a      ultrasonography, computed tomographic (CT) imaging and magnetic resonance\u000a      (MR) imaging,\u000a      alongside older tests such as plethysmography, had until 2005 led to\u000a      confusion over the best test\u000a      to use and different testing strategies being used in different hospitals.\u000a    Between 2005 and 2007, researchers from the School of Health and Related\u000a      Research (ScHARR)\u000a      at the University of Sheffield, led by Professor Steve Goodacre, undertook\u000a      an evidence synthesis\u000a      project funded by the National Institute for Health Research Health\u000a      Technology Assessment\u000a      programme. The project aimed to estimate the diagnostic accuracy of tests\u000a      for DVT and identify\u000a      the most cost-effective diagnostic strategy. It consisted of systematic\u000a      reviews, meta-analysis,\u000a      decision-analysis modelling of cost-effectiveness, and a national survey.\u000a    Goodacre and Fiona Sampson (ScHARR, University of Sheffield, since 1996)\u000a      undertook the\u000a      systematic reviews of the diagnostic accuracy of tests, and with\u000a      statistical support from Professor\u000a      Alex Sutton of the University of Leicester, conducted meta-analysis to\u000a      provide clinically useful\u000a      estimates of sensitivity, specificity and likelihood ratios. The\u000a      systematic reviews showed that\u000a      individual clinical features were of limited diagnostic value, while the\u000a      Wells clinical probability score\u000a      (a structured patient assessment that estimates the probability of DVT)\u000a      stratified proximal, but not\u000a      distal DVT [R1]. D-dimer had good sensitivity, but limited specificity for\u000a      DVT [R2]. Plethysmography\u000a      techniques had modest sensitivity and specificity. Ultrasound had good\u000a      sensitivity for proximal\u000a      DVT, modest sensitivity for distal DVT, and good specificity [R3]. CT and\u000a      MR imaging both had\u000a      similar diagnostic accuracy to ultrasound, but these estimates were based\u000a      upon limited data\u000a      [R4,R5].\u000a    Professor Matt Stevenson (ScHARR, University of Sheffield, since 1996)\u000a      developed the decision-\u000a      analysis model to estimate the cost-effectiveness of diagnostic strategies\u000a      for DVT. Goodacre and\u000a      Sampson undertook the national survey and a literature review in 2005 to\u000a      identify potential\u000a      diagnostic strategies. They then applied estimates of sensitivity and\u000a      specificity from the meta-\u000a      analysis to the strategies to estimate the outcomes in terms of overall\u000a      diagnostic accuracy.\u000a    Stevenson then used modelling to estimate the costs incurred and\u000a      quality-adjusted life years\u000a      (QALYs) gained by each strategy, along with the net benefit of each\u000a      strategy assuming willingness\u000a      to pay in accordance with NICE guidance. The analysis showed that the most\u000a      cost-effective and\u000a      feasible strategy involved a combination of Wells clinical probability\u000a      score, D-dimer and\u000a      compression ultrasound [R6].\u000a    In 2008-9, at the request of the ACCP Guideline Development Group,\u000a      Goodacre updated the\u000a      systematic reviews of CT and MR scanning and Stevenson used the\u000a      decision-analysis model to\u000a      estimate the risk of adverse outcome for various commonly used diagnostic\u000a      strategies for DVT.\u000a      The findings were published in 2012 in the ACCP Evidence-Based Clinical\u000a      Practice Guidelines for\u000a      the diagnosis of DVT.\u000a    "},{"CaseStudyId":"14543","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    Our research led to a substantial change in the treatment of acute\u000a      ST-elevation MI in the NHS. Primary angioplasty has replaced thrombolysis\u000a      as the standard treatment. This has resulted in improved outcomes for\u000a      people with ST-elevation MI.\u000a    Impact on policy\u000a    In 2008 the National Service Framework for Coronary Heart Disease (CHD)\u000a      was updated to set out the new national strategy using primary angioplasty\u000a      instead of thrombolysis [S1]. We reported our research directly to the\u000a      Department of Health CHD Policy Team and as a result the update cited our\u000a      independent research (pages 10-11) that concluded that national roll-out\u000a      of primary angioplasty was feasible and likely to be cost-effective. NHS\u000a      Improvement was then tasked with facilitating the national roll-out of\u000a      primary angioplasty for patients with ST-elevation MI [S2].\u000a    Impact on practice\u000a    \u000a      Treatments provided: National audit data show that following our\u000a        research, primary angioplasty replaced thrombolysis as the standard NHS\u000a        treatment for people with ST-elevation MI. The Myocardial Infarction\u000a        National Audit Project (MINAP) is a national audit of management of MI\u000a        in England, Wales and Northern Ireland [S3]. According to the Tenth\u000a        MINAP Public Report published in 2011 [S4], 82% of patients in England\u000a        who received any reperfusion treatment between April 2010 and March 2011\u000a        received primary angioplasty compared to 63% in 2009\/10. Increases were\u000a        also seen in Wales (22% to 30%) and Belfast (59% to 99%). An interim\u000a        report on the national roll-out of primary angioplasty published by NHS\u000a        Improvement in 2010 [S5] and based on MINAP data showed that between\u000a        2008 and 2010 the proportion of patients in England receiving any\u000a        reperfusion treatment who were treated with primary angioplasty\u000a        increased from 42% to 73%.\u000a      Patient management pathways: In accordance with findings from our\u000a        economic analysis the model for providing primary angioplasty proposed\u000a        by the National Service Framework and promoted by NHS Improvement\u000a        involved direct transfer of patients to the catheter laboratory of\u000a        specialist hospitals. This represents a substantial change from previous\u000a        practice of taking all patients with MI to the nearest hospital\u000a        emergency department. According to the MINAP report [S4] 75% of patients\u000a        that were treated with primary angioplasty in 2010-11 were admitted\u000a        directly to a specialist hospital with a catheter laboratory in England,\u000a        79% in Wales and 60% in Belfast.\u000a      Achieving time targets: In 2010-11 90% of eligible patients in\u000a        England, 68% in Wales and 87% in Belfast were treated with primary\u000a        angioplasty within the target of 90 minutes of arrival at the heart\u000a        attack centre [S4]. Furthermore, 81% of eligible patients in England,\u000a        75% in Wales and 90% in Belfast were treated with primary angioplasty\u000a        within 150 minutes of calling for professional help. The findings of the\u000a        organisational evaluation assisted the process of implementation and\u000a        helped to ensure that time targets for providing primary angioplasty\u000a        were achieved.\u000a    \u000a    Impact on patient outcomes\u000a    After our findings were reported and implemented through the National\u000a      Infarct Angioplasty Pilot in 2007, mortality from ST-elevation MI in the\u000a      NHS fell from 10.6% in 2006-2007 to 8.7% in 2010-11 [S4]. Randomised\u000a      trials have shown that primary angioplasty reduces mortality compared to\u000a      thrombolysis, so although other factors may have contributed to this\u000a      improvement, it is reasonable to attribute some of the improvement to\u000a      increased use of primary angioplasty.\u000a    Economic impact\u000a    An impact assessment based on our cost-effectiveness analysis was\u000a      undertaken by the Department of Health in 2008 [S7] and estimated that\u000a      over three years the policy would cost &#163;44.4 million and would yield\u000a      &#163;337.9 million in benefits, measured as discounted quality-adjusted life\u000a      years (QALYs) to patients and monetised on the basis of an estimate of\u000a      social value of a QALY at &#163;40,000.\u000a    Impact on older patients\u000a    Primary angioplasty has not been restricted on the basis of age and\u000a      reductions in mortality have been seen in older people with ST-elevation\u000a      MI. In-hospital mortality reduced from 30.1% in 2003 to 19.4% in 2010 in\u000a      those aged 85 or more (relative risk = 0.54, 95% CI: 0.38-0.75, P&lt;\u000a      0.001) [S6].\u000a    Impact on the wider clinical community\u000a    Although implementation of primary angioplasty is driven by national\u000a      policy, we believe that it is important to engage the clinical community.\u000a      Thus, in addition to publications in clinical journals outlined above, we\u000a      have produced an overview of our findings for ambulance paramedics [S8]\u000a      and have engaged directly with clinicians through presenting our findings\u000a      at clinical conferences, such as the College of Emergency Medicine Annual\u000a      Scientific Meeting [S9,S10].\u000a    ","ImpactSummary":"\u000a    Between 2006 and 2008 an evaluation carried out by the University of\u000a      Sheffield of the National Infarct Angioplasty Pilot showed that primary\u000a      angioplasty for ST-elevation myocardial infarction (heart attack) is\u000a      feasible, cost-effective and acceptable to patients and carers. As a\u000a      direct result, a new national strategy using primary angioplasty was\u000a      published in the National Service Framework for Coronary Heart Disease.\u000a      National audit data has since shown the proportion of patients receiving\u000a      primary angioplasty increasing from 42% to 73% and mortality falling from\u000a      10.6% to 8.7%. An impact assessment based on our economic analysis\u000a      estimated a &#163;294 million net benefit to the NHS.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Sheffield\u000a    ","Institutions":[{"AlternativeName":"Sheffield (University of)","InstitutionName":"University of Sheffield","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007157}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000aR1.Evaluation of the National Infarct Angioplasty project. HS&amp;DR\u000a      Project 08\/1604\/120. National Institute for Health Research, http:\/\/www.netscc.ac.uk\/hsdr\/projdetails.php?ref=08-1604-120\u000a    \u000a\u000aR2. Goodacre S, Sampson F, Carter A, Wailoo A, O'Cathain A, Wood S,\u000a      Capewell S, Campbell S. Evaluation of the National Infarct Angioplasty\u000a      Project: Report for the National Co-ordinating Centre for NHS Service\u000a      Delivery and Organisation R&amp;D (NCCSDO), 2008.\u000a    \u000a\u000aR3.Wailoo A, Goodacre S, Sampson F, Hernandez M, Asseburg C, Palmer SJ,\u000a      Sculpher M, Abrams K, de Belder MA, Gray H. Primary angioplasty versus\u000a      thrombolysis for acute ST- elevation myocardial infarction: an economic\u000a      analysis of the National Infarct Angioplasty Project. Heart\u000a      2010;96:668-672. doi: 10.1136\/hrt.2009.167130\u000a    \u000a\u000aR4.Sampson FC, O'Cathain A, Goodacre S. Is primary angioplasty an\u000a      acceptable alternative to thrombolysis? Quantitative and qualitative study\u000a      of patient and carer satisfaction. Health Expectations 2010;13:350-358.\u000a      doi: 10.1111\/j.1369-7625.2009.00589.x\u000a    \u000a\u000aR5.Sampson FC, O'Cathain A, Goodacre S. Feeling fixed and its\u000a      contribution to patient satisfaction with primary angioplasty: a\u000a      qualitative study. Eur J Cardiovasc Nurs 2009;8:85-90.\u000a      doi: 10.1016\/j.ejcnurse.2008.07.003\u000a    \u000a\u000aR6.Carter AJ, Wood S, Goodacre S, Sampson F, Stables RH. Evaluation of\u000a      the workforce and organisational issues in establishing primary\u000a      angioplasty in the National Infarct Angioplasty Project. J Health Serv Res\u000a      Policy 2010;15:6-13. doi: 10.1258\/jhsrp.2009.009019\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"10","Subject":"Nursing"}],"Sources":"\u000a    S1. Department of Health Coronary Heart Disease Policy Team. The Coronary\u000a      Heart Disease National Service Framework: Building on excellence,\u000a      maintaining progress. Progress report for 2008. Our independent evaluation\u000a      is cited on page 10 and our findings cited on page 11.\u000a    S2. NHS Improvement. A Guide to Implementing Primary Angioplasty (2008).\u000a    S3. The Myocardial Ischaemia National Audit Project (MINAP). Herrett E,\u000a      Smeeth L, Walker L, Weston C, on behalf of the MINAP Academic Group. Heart\u000a      2010;96:1264-1267 doi:10.1136\/hrt.2009.192328.\u000a    S4. How the NHS cares for patients with heart attack: The Myocardial\u000a      Ischaemia National Audit Project (MINAP) Tenth Annual Public Report.\u000a      University College London, 2011.\u000a      www.ucl.ac.uk\/nicor\/audits\/minap\u000a    S5. NHS Improvement. National roll-out of Primary PCI for patients with\u000a      ST segment elevation myocardial infarction: An interim report (2010).\u000a    S6. Gale CP, Cattle BA, Woolston A et al Resolving inequalities in care?\u000a      Reduced mortality in the elderly after acute coronary syndromes. The\u000a      Myocardial Ischaemia National Audit Project 2003-2010 Eur Heart J first\u000a      published online October 18, 2011 doi:10.1093\/eurheartj\/ehr381.\u000a    S7. Department of Health. Impact Assessment of Treatment of Heart Attacks\u000a      &#8212; National Guidance (2008).\u000a    S8. Sampson F, Goodacre S, Carter A, Wailoo A. Improving call-to-balloon\u000a      times for ST-elevation myocardial infarction. Journal of Paramedic\u000a      Practice 2011:3:625-631.\u000a    S9. Carter A, Wood S, Goodacre S, Sampson F. Emergency medicine and\u000a      primary angioplasty: Organisational analysis. Emerg Med J 2008;25:A19.\u000a    S10. Sampson F, O'Cathain A, Goodacre S. Is primary angioplasty an\u000a      acceptable treatment for patients with ST-elevation myocardial infarction?\u000a      Emerg Med J 2008;25:A19. \u000a    ","Title":"\u000a    Improving treatment for heart attack patients\u000a    ","UKLocation":[{"GeoNamesId":"2655984","Name":"Belfast"},{"GeoNamesId":"2638077","Name":"Sheffield"}],"UKRegion":[{"GeoNamesId":"2641364","Name":"Northern Ireland"},{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Prior to research carried out at the School of Health and Related\u000a      Research (ScHARR) at the University of Sheffield, the standard treatment\u000a      for acute ST-elevation myocardial infarction (MI) was intravenous\u000a      thrombolysis. Randomised controlled trials undertaken in a number of\u000a      international centres showed that primary angioplasty could produce better\u000a      outcomes than intravenous thrombolysis, provided reperfusion with\u000a      angioplasty was achieved within 90 minutes of when it could have been\u000a      achieved by thrombolysis. However, research was necessary to determine\u000a      whether primary angioplasty could be delivered in an acceptable, effective\u000a      and cost- effective manner.\u000a    The National Infarct Angioplasty Pilot was funded by the Department of\u000a      Health to test the feasibility of implementing primary angioplasty for\u000a      acute ST-elevation MI at ten pilot hospitals in the UK. The National\u000a      Institute for Health Research funded Professor Steve Goodacre (ScHARR\u000a      since 1999) and colleagues from ScHARR between 2006 and 2008 to undertake\u000a      [R1]:\u000a    \u000a      Descriptive analysis of the data from these pilot sites\u000a      Cost-effectiveness modelling using data from the ten pilot sites and\u000a        four control sites\u000a      Exploration of patient and carer perspectives.\u000a    \u000a    ScHARR researchers also collaborated with researchers from the Institute\u000a      of Work Psychology at the University of Sheffield to assess organisational\u000a      and workforce issues. Fiona Sampson (ScHARR, since 1996) undertook the\u000a      descriptive analysis and showed that primary angioplasty was provided in a\u000a      timely manner when patients were transported directly to the catheter\u000a      laboratory of a specialist hospital, but not when transported via other\u000a      hospitals or departments [R2].\u000a    Professor Allan Wailoo (ScHARR, since 2000) undertook the economic\u000a      analysis and showed that primary angioplasty-based care was more expensive\u000a      than thrombolysis-based care, but at &#163;4,520 per quality-adjusted life year\u000a      gained would be considered cost-effective by the NHS [R3]. Cost-\u000a      effectiveness of angioplasty was only assured if direct transport to a\u000a      specialist hospital catheter laboratory was used.\u000a    Fiona Sampson and Professor Alicia O'Cathain (ScHARR, since 1997)\u000a      undertook analysis of patient and carer satisfaction, and showed high\u000a      overall levels of satisfaction with primary angioplasty and\u000a      thromoblysis-based care [R4]. Patients at pilot sites reported higher\u000a      levels of satisfaction than control sites with the time waited (80% v 67%\u000a      rated excellent, p&lt;0.001) and the efficiency of treatment (83% v 74%,\u000a      p=0.009), whereas satisfaction with information given on how to manage the\u000a      condition in the future was lower in pilot sites than control sites (38% v\u000a      46%, p=0.049). Interviews undertaken by Sampson identified important\u000a      issues for patients and carers, and provided insights into their\u000a      perceptions of primary angioplasty [R5].\u000a    The organisational study undertaken in collaboration with Dr Angela\u000a      Carter from the Institute of Work Psychology [R6] showed that establishing\u000a      the full 24-hour primary angioplasty service from the start appeared to\u000a      work better than incremental expansion, identified requirements for staff\u000a      working patterns, training, pay and conditions, identified potential\u000a      knock-on effects and highlighted the importance of on-going audit.\u000a    Our studies showed that primary angioplasty could be implemented\u000a      successfully with acceptable time delays, was likely to be cost-effective\u000a      in most circumstances, was acceptable to patients and carers, and\u000a      identified key workforce and organisational issues that need to be\u000a      addressed during implementation.\u000a    "},{"CaseStudyId":"14565","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2963597","Name":"Ireland"}],"Funders":[],"ImpactDetails":"\u000a    The research study was used to inform a policy decision to implement a\u000a      national bowel cancer screening programme which in turn has led to\u000a      improvements in the prognosis of patients with diagnosed bowel cancer\u000a      (S6,S7). Whilst there is not yet direct evidence of patient benefit from\u000a      the programme itself, other evidence suggests that earlier diagnosis is\u000a      associated with improved survival (S7) and improved health-related quality\u000a      of life (S8). Analyses from RCTs and the English bowel cancer screening\u000a      programme indicate that screening results in earlier diagnosis, thus\u000a      patient benefit is fully expected.\u000a    This research study provided the key evidence which was reviewed by the\u000a      English Bowel Cancer Advisory Group in 2004 in formulating recommendations\u000a      to the Secretary of State for Health for colorectal cancer screening in\u000a      England (this can be corroborated by Professor Sir Mike Richards &#8212; See\u000a      coversheet).The commissioning of this options appraisal was cited in\u000a      Parliament in 2004 (S1) and its relationship to the policy decision is\u000a      cited in advice to the NHS on bowel cancer screening (S2).\u000a    The work was presented by Dr Tappenden to the English Bowel Cancer\u000a      Advisory Group in 2004. In 2005, the Secretary of State for Health\u000a      announced that a national screening programme involving FOBT for\u000a      individuals aged 60-69 would be launched in England. The NHS Bowel Cancer\u000a      Screening Programme launched an FOBT-based programme in 2006 and this is\u000a      now fully rolled out across England.\u000a    This policy decision resulted in a substantial service change for the NHS\u000a      requiring the establishment of whole new system infrastructures (screening\u000a      hubs, laboratory testing etc.) and their integration with existing\u000a      services for endoscopy. The screening programme is available to all men\u000a      and women in England from the date of their 60th or 61st,\u000a      birthday. An extension has recently been rolled out to include individuals\u000a      up to the age of 74 years of age. The government is also planning to\u000a      include an additional screening FSIG for individuals aged 55 years of age\u000a      (S3). This policy option was re-evaluated retrospectively in a Department\u000a      of Health funded project using the original ScHARR options appraisal\u000a      model.\u000a    The introduction of a national screening programme has also changed the\u000a      agenda for health intervention in this area, with a new focus on\u000a      increasing participation in screening and promoting the earlier diagnosis\u000a      of the disease.\u000a    At this time, it is difficult to assess the direct health impact of\u000a      introducing bowel cancer screening in England as cancer incidence and\u000a      mortality fluctuate year on year and other changes to the health system\u000a      may account for some additional benefits. There is also a time lag in the\u000a      availability of national mortality data from the Office for National\u000a      Statistics.\u000a    There is, however, an evident trend towards increased incidence (~13% in\u000a      the UK between 2006 and 2008) since the rollout of the programme; this\u000a      reflects additional cases of preclinical cancer that would otherwise have\u000a      been likely to have been diagnosed later, potentially at a more advanced\u000a      stage. Research evidence from randomised controlled trials has shown that\u000a      FOBT can reduce colorectal cancer mortality (approximately 16%) and that\u000a      FSIG can reduce both incidence and mortality (23% and 31% respectively).\u000a      Statistics from Cancer Research UK indicate that the mortality rate for\u000a      bowel cancer in the period 2008-2010 was 14% lower than the rate in the\u000a      period 1991-1999. It is likely that a proportion of this benefit is\u000a      attributable to the introduction of the screening programme (http:\/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/types\/bowel\/incidence\/uk-bowel-cancer-incidence-statistics).\u000a      The available evidence (see Section 5) indicates that the screening\u000a      programme has had a positive impact upon the prognosis of patients with\u000a      screen-detected colorectal cancer and a mortality reduction of\u000a      approximately 16% is estimated on the basis of this evidence; this\u000a      suggests around 2,500 colorectal cancer deaths are expected to be avoided\u000a      each year (S5).\u000a    ","ImpactSummary":"\u000a    Research undertaken at the University of Sheffield in 2005 to evaluate\u000a      the cost-effectiveness and resource implications of potential screening\u000a      programmes for colorectal cancer informed the decision to launch a\u000a      national colorectal cancer screening programme in England. Upon their\u000a      60th\/61st birthday, all individuals in England are now invited to\u000a      participate in biennial bowel cancer screening using faecal occult blood\u000a      testing (FOBT) until the age of 74. The programme identifies individuals\u000a      with less advanced colorectal cancer and there is emerging evidence that\u000a      it has led to an overall improvement in prognosis. Projections suggest\u000a      that the programme is on course to reduce colorectal cancer deaths by 16%.\u000a    Amongst others, follow-on research includes an options appraisal of\u000a      screening in Ireland that has informed national policy and a re-appraisal\u000a      of colorectal screening options following publication of a pivotal trial\u000a      of flexible sigmoidoscopy (FSIG) screening for NHS Cancer Screening\u000a      Programmes.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Sheffield\u000a    ","Institutions":[{"AlternativeName":"Sheffield (University of)","InstitutionName":"University of Sheffield","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007157}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000aR1.Tappenden P, Chilcott JB, Eggington S, Patnick J, Sakai H, Karnon J.\u000a      Option appraisal of population-based colorectal cancer screening\u000a      programmes in England. Gut 2007;56:677-684.\u000a    \u000a\u000aR2. Whyte S, Chilcott JB, Halloran S. Reappraisal of the options for\u000a      colorectal cancer screening in England. Colorectal Disease\u000a      2012;14:e547-3561 doi: 10.1111\/j.1463-1318.2012.03014.x\u000a    \u000a\u000aR3.Parkin DM, Tappenden P, Olsen AH, Patnick J, Sasieni P. Predicting the\u000a      impact of the screening programme for colorectal cancer in the UK. Journal\u000a      of Medical Screening 2008;15(4):163-74. doi: 10.1258\/jms.2008.008024\u000a    \u000a\u000aR4.Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C,\u000a      Tappenden P, Chilcott J, Staines A, Barry M, Comber H. Cost-effectiveness\u000a      of population-based screening for colorectal cancer: a comparison of\u000a      guaiac-based faecal occult blood testing, faecal immunochemical testing\u000a      and flexible sigmoidoscopy. British Journal of Cancer 2012;106(5):805-816.\u000a      (doi: 10.1038\/bjc.2011.580)\u000a    \u000a\u000aR5. Pilgrim H, Tappenden P, Chilcott JB, Bending M, Trueman P. The costs\u000a      and benefits of bowel cancer service developments using discrete event\u000a      simulation. Journal of the Operational Research Society 2009;60:1305-1314.\u000a      (doi: 10.1057\/jors.2008.109)\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    The benefits of colorectal cancer screening in reducing mortality have\u000a      been demonstrated in randomised controlled trials, meta-analyses and pilot\u000a      studies. There is now emerging evidence that the national bowel cancer\u000a      screening programme is having a positive impact upon patient prognosis.\u000a    References relating to policy decisions:\u000a    S1. Commissioning of ScHARR options appraisal discussed in Parliament May\u000a      20th 2004 &#8212; available from http:\/\/www.publications.parliament.uk\/pa\/cm200304\/cmhansrd\/vo040520\/text\/40520w01.htm\u000a    S2. Direct link between options appraisal and policy decision discussed\u000a      in NBCSP Bowel Cancer Advice to the NHS document &#8212; available from:\u000a      www.londonqarc.nhs.uk\/downloads.php?filename=313_DH_Advice_to_the_NHS.pdf\u000a    S3. Extension of screening programme to include flexible sigmoidoscopy.\u000a      Parliamentary minutes &#8212;\u000a      http:\/\/www.publications.parliament.uk\/pa\/cm201011\/cmhansrd\/cm111123\/debtext\/111123-0004.htm\u000a    Press releases relating to benefit impact for patients and predicted\u000a        economic benefits:\u000a    S4. National Cancer Research Institute. \"Bowel cancer screening reduces\u000a      cancer deaths by more than 25%.\" NCRI Conference 2011. Available from:\u000a      http:\/\/conference.ncri.org.uk\/archive\/2011\/press-releases\/2011_09Nov_BOWEL_SCREENING.pdf\u000a    S5. English Bowel Cancer Screening Programme. \"The NHSBCSP in England is\u000a      on track to cut bowel cancer deaths by 16 per cent.\" 2011. Available from:\u000a      www.cancerscreening.nhs.uk\/bowel\/news\/010.html\u000a    Peer reviewed publications relating to benefit impact &amp; prognosis\u000a        for patients:\u000a    S6. Logan R et al. Outcomes of the Bowel Cancer Screening Programme\u000a      (BCSP) in England after the first 1 million tests. Gut. 2012 October;\u000a      61(10): 1439-1446. Available from:\u000a      www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3437782\/\u000a    S7. Morris E et al. A retrospective observational study examining the\u000a      characteristics and outcomes of tumours diagnosed within and without of\u000a      the English NHS Bowel Cancer Screening Programme. British Journal of\u000a      Cancer (2012) 107, 757-764. Available from:\u000a      www.nature.com\/bjc\/journal\/v107\/n5\/abs\/bjc2012331a.html\u000a    S8. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome\u000a      states of colorectal cancer. American Journal of Gastroenterology\u000a      1999;94(6):1650-1657.\u000a    Other statistics relating to impact:\u000a    S9. Cancer Research UK lists sources of data: Between 2006 and 2008,\u000a      bowel cancer European age-standardised incidence rates for people aged\u000a      60-69 increased by more than 12% in the UK (http:\/\/www.ons.gov.uk\/ons\/search)\u000a    \u000a    ","Title":"\u000a    Introduction of a national colorectal cancer screening programme\u000a    ","UKLocation":[{"GeoNamesId":"2638077","Name":"Sheffield"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Colorectal (bowel) cancer is the third most common cancer with more than\u000a      41,000 people diagnosed with the disease each year in the UK.\u000a      Approximately 16,000 people die of colorectal cancer each year. Evidence\u000a      suggests that colorectal cancer screening may reduce incidence, morbidity\u000a      and mortality associated with the disease.\u000a    Between 2004 and 2005, the School of Health and Related Research (ScHARR)\u000a      at the University of Sheffield undertook a Colorectal Cancer Screening\u000a      Options Appraisal on behalf of NHS Cancer Screening Programmes and the\u000a      Department of Health. The work was undertaken by a team led by Dr Paul\u000a      Tappenden (Reader in Health Economic Modelling); other team members\u000a      included Hannah Sakai (Research Assistant, left 2004), Simon Eggington\u000a      (Research Associate, left 2006) and Jim Chilcott (Professor of Health\u000a      Economics and Decision Modelling).\u000a    The objective of the project was to evaluate the cost-effectiveness and\u000a      resource implications of potential screening programmes for colorectal\u000a      cancer to inform decisions about whether the NHS should adopt a bowel\u000a      cancer screening programme and, if so, which test modalities, population\u000a      and frequency should form the basis of the programme.\u000a    The research study included a review of existing randomised trials of\u000a      alternative screening modalities, a model-based health economic evaluation\u000a      and an analysis of resource implications for alternative options.\u000a    The team developed a health economic model to simulate the life\u000a      experience of a hypothetical cohort of individuals without polyps or\u000a      cancer through to the development of adenomas and malignant carcinoma and\u000a      subsequent death in the general population of England. The costs, health\u000a      effects and resource impact of five screening options were evaluated using\u000a      this model: (a) biennial FOBT for individuals aged 50-69; (b) biennial\u000a      FOBT for individuals aged 60-69; (c) once-only FSIG for individuals aged\u000a      55; (d) once-only FSIG for individuals aged 60; and (e) once-only FSIG for\u000a      individuals aged 60, followed by biennial FOBT for individuals aged 61-70.\u000a    Each option was compared in terms of expected health benefits\u000a      (survival\/quality-adjusted life years [QALYs] gained), costs and resource\u000a      implications. The economic analysis suggested that screening using FSIG\u000a      with or without FOBT was likely to produce cost-savings and additional\u000a      health benefits compared against no screening. However, the accompanying\u000a      resource use analysis suggested that the considerable endoscopy capacity\u000a      requirements associated with the FSIG screening options may make them\u000a      infeasible given capacity constraints.\u000a    The original work was presented by Dr Tappenden to the English Bowel\u000a      Cancer Working Party and was later discussed in Parliament. The study was\u000a      published as a peer-reviewed report which is hosted on the NHS Cancer\u000a      Screening Programmes website. A series of subsequent peer-reviewed\u000a      publications followed directly from this modelling work and from\u000a      subsequent research projects initiated by the original options appraisal.\u000a    Following the options appraisal, several further related research\u000a      projects have been undertaken by ScHARR using the bowel cancer screening\u000a      model including:\u000a    \u000a      Department of Health &#8212; an assessment of early awareness campaigns for\u000a        colorectal cancer\u000a      Department of Health &#8212; re-appraisal of colorectal screening options\u000a        following publication of the FSIG trial\u000a      HIQA &#8212; an appraisal of colorectal cancer screening options in Ireland.\u000a    \u000a    "},{"CaseStudyId":"14566","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    The research has had an impact on health and welfare, by informing NICE\u000a      guidance on treatment to prevent fractures due to osteoporosis in\u000a      post-menopausal women and thereby influencing treatment for this patient\u000a      group.\u000a    Process to impact:\u000a    The model, developed by the University of Sheffield researchers, was used\u000a      to draw up the NICE guidance TA87, released in 2005. Prior to this,\u000a      prescribing patterns and the use of bone mineral density tests were not\u000a      standardised across the country and had not been subjected to\u000a      cost-effectiveness analyses. In 2008, NICE released new guidance, TA160\u000a      and TA161 [S1 and S2], which used the same cost-effectiveness model\u000a      developed in Sheffield, updated by the Sheffield team to include the new\u000a      treatment, strontium ranelate.\u000a    In 2009, the guidance was taken to judicial review following complaints\u000a      by a number of stakeholders, and NICE was asked to review the model on\u000a      which their decisions had been based. NICE concluded that the model was\u000a      sound and so it remains the basis for their current guidance, updated in\u000a      2011.\u000a    Impact on health and welfare:\u000a    The research has had impact on health and welfare by informing the\u000a      decisions made by a regulatory authority, namely NICE.\u000a    The NICE guidance (TA160 and TA161) says: `The Committee concluded that\u000a      the Assessment Group [named as ScHARR in para 1.4.1 p14] had provided an\u000a      executable economic model ... The Committee confirmed that the model\u000a      provided a suitable framework to allow it to make recommendations on the\u000a      cost-effective use of treatment for women at risk of fracture... Therefore\u000a      the Committee concluded that the recommendations based on the Assessment\u000a      Group's model were appropriate, and that the recommendations should remain\u000a      unchanged.' (TA160, para 4.3.65 pp78-9; TA161, para 4.3.66 pp83-4) [S1,\u000a      S2].\u000a    NICE estimate that there are more than 2 million women with osteoporosis\u000a      in England and Wales (TA161 amended, p9). As NICE guidance is mandatory,\u000a      the research &#8212; through TA160 and TA161 &#8212; has influenced the treatment of\u000a      all post-menopausal women with osteoporosis in England and Wales since the\u000a      initial guidance was released in October 2008.\u000a    NICE guidance identifies which women should be offered a bone mineral\u000a      density scan, and based on the result of the scan, which women should be\u000a      offered treatment with alendronate. Where women are unable to take\u000a      alendronate, the guidance specifies whether alternative treatments can be\u000a      prescribed based on age, clinical risk factor and bone mineral density\u000a      characteristics (T-Score). Without the algorithm developed through the\u000a      Sheffield research, it would not be possible for NICE to issue guidance to\u000a      this level of granularity in terms of age, T-Score and clinical risk\u000a      factor combinations.\u000a    ","ImpactSummary":"\u000a    Research at the University of Sheffield to evaluate the\u000a      cost-effectiveness of different treatments for women with osteoporosis was\u000a      used by the National Institute of Health and Care Excellence (NICE) to\u000a      develop their guidance on the condition. The evaluation model was the\u000a      first to combine cost-effectiveness of both treatment and screening and to\u000a      include more detailed categorisation of patients. The model was used by\u000a      NICE in their 2005, 2008 and 2011 guidance, which is mandatory for the NHS\u000a      in England and Wales, and, therefore, since 2008 has influenced the\u000a      treatment of over two million women with osteoporosis.\u000a    ","ImpactType":"Political","Institution":"\u000a    University of Sheffield\u000a    ","Institutions":[{"AlternativeName":"Sheffield (University of)","InstitutionName":"University of Sheffield","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007157}],"Panel":"A         ","PlaceName":[],"References":"\u000a    Authors employed by the University of Sheffield during the period of the\u000a      research are highlighted in bold.\u000a    \u000aR1. Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S and\u000a        Oakley J. A systematic review and economic evaluation of\u000a      alendronate, etidronate, risedronate, raloxifene and teriparatide for the\u000a      prevention and treatment of postmenopausal osteoporosis. Health Technol\u000a      Assess 2005a; 9 (22) pp1-160\u000a    \u000a\u000aR2.Stevenson MD, Oakley J, Chilcott JB. Gaussian process\u000a      modelling in conjunction with individual patient simulation modelling. A\u000a      case study describing the calculation of cost-effectiveness ratios for the\u000a      treatment of osteoporosis. Med Decis Making 24 (2004) 89-100 doi: 10.1177\/0272989X03261561\u000a    \u000a\u000aR3. Stevenson MD, Brazier JE, Calvert NW, Lloyd-Jones M,\u000a        Oakley J, Kanis JA. Description of an individual patient methodology\u000a      for calculating the cost-effectiveness of treatments for osteoporosis in\u000a      women. Journal of Operational Research Society. 2005b; 56 (2):\u000a      214-221\u000a    \u000a\u000aR4.Stevenson M, Davis S, Lloyd Jones M, Beverley C. The\u000a      clinical and cost-effectiveness of strontium ranelate for the prevention\u000a      of osteoporotic fragility fractures in post-menopausal women. Health\u000a      Technol Assess 2007; 11 (4) pp1-134\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    S1. Alendronate, etidronate, risedronate, raloxifene and strontium\u000a      ranelate for the primary prevention of osteoporotic fragility fractures in\u000a      postmenopausal women (amended). NICE technology appraisal guidance Issued:\u000a      October 2008 (last modified: January 2011). http:\/\/guidance.nice.org.uk\/TA160\u000a      (primary prevention).\u000a    S2. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate\u000a      and teriparatide for the secondary prevention of osteoporotic fragility\u000a      fractures in postmenopausal women (amended). NICE technology appraisal\u000a      guidance Issued: October 2008 (last modified: January 2011). http:\/\/guidance.nice.org.uk\/TA161\u000a      (secondary prevention).\u000a    Relevant sections referencing the ScHARR reports are given in the text in\u000a      the section above. \u000a    ","Title":"\u000a    Informing guidance for treatment of women with osteoporosis\u000a    ","UKLocation":[{"GeoNamesId":"2638077","Name":"Sheffield"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The School of Health and Related Research (ScHARR) at the University of\u000a      Sheffield was contracted by NICE in 2003 to develop a model which could\u000a      assess the cost-effectiveness of available treatment options for\u000a      post-menopausal women with osteoporosis.\u000a    Between 2003 and 2004, a systematic review was carried out of all the\u000a      evidence on the then available treatments &#8212; alendronate, etidronate,\u000a      risedronate, raloxifene and teriparatide &#8212; to assess effectiveness in\u000a      terms of reduction in fractures and risk of side effects. (R1)\u000a    Professor Stevenson developed a new model, which was the first to combine\u000a      screening and treatment within one algorithm and provided a much more\u000a      granular categorisation of the population than had been attempted before,\u000a      incorporating: eight separate age bands (range 50-85 years); 13\u000a      classifications of a measure of bone fragility, (T-Score- ranging from 0\u000a      to &#8212;5 standard SD) and four classifications of number of risk factors\u000a      (range 0-3).\u000a    The aim was to develop a model which would not only identify which risk\u000a      factors made which treatments cost-effective, but to determine the\u000a      cost-effectiveness of screening for those risk factors. In order to create\u000a      a model which was able to deal with the complexity of so many different\u000a      factors, Professor Stevenson applied a Gaussian process technique which\u000a      had not been used previously in health economics. (R2, R3)\u000a    Prior to this research, there were few treatment algorithms and few\u000a      screening algorithms for people suspected of being osteoporotic. Where\u000a      algorithms did exist, they were simplistic, broad in nature and none had\u000a      been formulated explicitly within the context of a cost-effectiveness\u000a      framework.\u000a    For each combination of age, bone fragility measurements (T-Score) and\u000a      number of risk factors, Professor Stevenson's mathematical model was able\u000a      to assess the likelihood of hip, vertebral, wrist, and proximal humerus\u000a      fractures, nursing home admission and death. These data were combined with\u000a      cost and utility values derived from literature reviews to determine the\u000a      costs and benefits of treatment. From this, the model could estimate the\u000a      cost per quality adjusted life year in each of the age, T-Score and risk\u000a      factor combinations.\u000a    For each age and number of risk factor combination, the additional\u000a      expected costs of screening using a bone mineral density scan were\u000a      included to estimate if a combined policy of screening and treatment was\u000a      cost-effective. This step is required as it may be cost-effective to treat\u000a      a woman in isolation, but the costs of identifying the individual within a\u000a      group of seemingly homogeneous women may be prohibitive.\u000a    Between 2006 and 2007, Professor Stevenson updated his model to take into\u000a      account a new treatment, strontium ranelate whilst also updating, as\u000a      appropriate, the data within the model. (R4)\u000a    All of the research to develop the model was undertaken by the University\u000a      of Sheffield. The team are listed below, with the dates they joined and\u000a      left Sheffield, where applicable:\u000a    Professor Matt Stevenson, 1996- current; Professor John Brazier, 1989-\u000a      current; Professor John Kanis, 1979 &#8212; current (emeritus); Dr Myfanwy Lloyd\u000a      Jones 1996 - 2012; Sarah Davis, 2004-2006 \/ 2011 &#8212; current; Dr Jeremy\u000a      Oakley, 1999-current; and Enrico De Negris, 2002-2006.\u000a    "},{"CaseStudyId":"14567","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    Impacts on Health and Welfare\u000a    The ScHARR research report on statins was submitted to NICE in 2005 and\u000a      provided the key evidence which shaped new national guidance on statin\u000a      therapy for England and Wales, Statins for the prevention of\u000a        cardiovascular events. Technology Appraisal 96. (January 1996) [S1].\u000a      The guidance resulted in an increase in the number of people benefitting\u000a      from statin prescribing. Previously statins had been prescribed to people\u000a      with a history of a CVD event (secondary prevention), but the guidance led\u000a      to statin prescribing to include \"healthy\" populations at high risk of\u000a      future events (primary prevention) [S2], subsequently to diabetics [S3]\u000a      and to individuals at high genetic risk of coronary disease [S4].\u000a    The guidance resulted in an additional 3.3 million people in England and\u000a      Wales becoming eligible for statin treatment.[S2] In 2006 Professor David\u000a      Barnett, Chair of the independent NICE Appraisal Committee that developed\u000a      the TA94 guidance, predicted that \"In terms of potential impact this\u000a      guidance is arguably one of the most significant to have come out of NICE\u000a      since it started over six years ago.\"\u000a    The volume of statin prescriptions in England has increased year on year\u000a      since the guidance was issued in 2006, up by 44% between 2005 and 2008\u000a      (from 33,772,000 to 48,717,000) and up by 70% (to 57,454,000) between 2005\u000a      and 2011 (the latest year for which prescription data are available).[S5]\u000a      The Health Survey for England (HSE) 2006 reported that use of statins and\u000a      other lipid-lowering drugs was 73% in men and 65% in women with\u000a      self-reported doctor diagnosed ischaemic heart disease (IHD) or stroke.\u000a      [S5] This had increased to 79% of men and 72% of women over 35 with\u000a      self-reported doctor-diagnosed IHD or stroke, based on the HSE 2011. [S6]\u000a    Cardiovascular related mortality rates per 100,000 have reduced from\u000a      approximately 310 for males (approximately 180 for females) in 2004 to\u000a      approximately 250 for males (approximately 120 for females) in 2009.[S8]\u000a      Treatment with lipid lowering drugs, particularly statins, enables\u000a      effective reduction in LDL, and, therefore, total cholesterol levels, with\u000a      resulting reductions in CVD incidence and deaths, and overall\u000a      mortality.[S6] A gradual decrease in mean total cholesterol levels in both\u000a      sexes between 2006 and 2011 [S6] has occurred. Mean total cholesterol\u000a      levels have reduced by 4% (from 5.2 and 5.0 mmol\/l) in men and by 6% (from\u000a      5.4 and 5.1 mmol\/l) in women between 2008 and 2011.[S6] Every 1% fall in\u000a      mean population total cholesterol levels decreases CVD mortality by\u000a      approximately 2.5%. [S7]\u000a    Economic impact\u000a    Our research was the first research study to compare directly the five\u000a      statins available to the NHS in 2004 within the same systematic review and\u000a      economic model. The systematic review concluded that evidence from the\u000a      placebo-controlled trials did not indicate any difference between the\u000a      clinical efficacy of atorvastatin, fluvastatin, pravastatin and\u000a      simvastatin. The NICE guidance on statins, informed by this research, was,\u000a      therefore, able to recommend that \"when the decision has been made to\u000a        prescribe a statin, the therapy should usually be initiated with a drug\u000a        with a low acquisition cost (taking into account required daily dose and\u000a        product price per dose).\" [S1] A shift to prescribing the low cost\u000a      statin, simvastatin, has been seen in prescribing patterns since the\u000a      introduction of the guidance in 2006. [S9] Nationally, lower cost statins\u000a      have increased as a percentage of total statin prescriptions. The impact\u000a      of this has been to reduce the cost of statin prescribing per patient in\u000a      the NHS. The NAO reported savings of &#163;323 million achieved by cost\u000a      effective prescribing of statins in 2009 (relative to a 2005 baseline).\u000a      [S9]\u000a    CVD cost the health care system in the UK around &#163;8.6 billion in 2009.\u000a      [S10] The cost of hospital care for people who have CVD accounts for 50%\u000a      of these costs. [S10] Treating people with statins leads to large savings\u000a      in hospitalisation costs for all vascular events amongst a wide range of\u000a      high risk individuals. [S11]. For example, statins prescribing has\u000a      contributed to a fall in the incidence of hospitalised acute myocardial\u000a      infarction between 2008 and 2010 from 98 to 86 per 100,000 for men and\u000a      from 138 to 133 per 100,000 for women. [S10]\u000a    ","ImpactSummary":"\u000a    University of Sheffield research which evaluated the clinical and\u000a      cost-effectiveness of statins for the primary and secondary prevention of\u000a      cardiovascular events has directly led to an additional 3.3 million people\u000a      in England and Wales becoming eligible for this treatment. Statins have\u000a      been shown to reduce the risk of future cardiovascular events, such as\u000a      heart attacks and stroke.\u000a    Guidance on statin prescribing in England and Wales, issued by the\u000a      National Institute for Health and Care Excellence (NICE) Appraisal\u000a      Committee in January 2006 was informed by our research report. Following\u000a      this guidance the number of patients receiving statins has increased year\u000a      on year with the number of prescriptions increasing by 29% between 2007\u000a      and 2011, enabling these patients to benefit from reduced risk of heart\u000a      attacks and stroke and CVD related deaths.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Sheffield\u000a    ","Institutions":[{"AlternativeName":"Sheffield (University of)","InstitutionName":"University of Sheffield","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007157}],"Panel":"A         ","PlaceName":[],"References":"\u000a    The original work was published as a peer-reviewed Health Technology\u000a      Assessment monograph. A series of subsequent peer-reviewed publications,\u000a      and research projects followed directly from the modelling work undertaken\u000a      as part of the initial project.\u000a    \u000aR1. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo\u000a      W, Payne N. A systematic review and economic evaluation of statins\u000a      for the prevention of coronary events. Health Technol Assess\u000a      11(14):1-iv Apr 2007.\u000a    \u000a\u000aR2. NICE guidance. Statins for the prevention of cardiovascular events.\u000a      Technology Appraisal 96. January 1996\u000a    \u000a\u000aR3. Ara R, Pandor A, Stevens J, Rafia R, Ward S, Rees A, Durrington\u000a      P, Reynolds T, Wierzbicki A, Stevenson M. Prescribing high-dose\u000a      lipid-lowering therapy early to avoid subsequent cardiovascular events: is\u000a      this a cost-effective strategy? Eur J Cardiovasc Prev Rehabil\u000a      19(3) 01 Apr 2011 doi: 10.1177\/1741826711406616\u000a    \u000a\u000aR4. Ara R, Pandor A, Stevens J, Rees A, Rafia R. Early high-dose\u000a      lipid-lowering therapy to avoid cardiac events: a systematic review and\u000a      economic evaluation. Health Technol Assess 13(34):1-118 Jul 2009\u000a    \u000a\u000aR5. Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A,\u000a      Durrington PN, Chilcott J Ezetimibe monotherapy for cholesterol\u000a      lowering in 2,722 people: systematic review and meta-analysis of\u000a      randomized controlled trials. J Intern Med 265(5):568-580 May 2009\u000a      doi: 10.1111\/j.1365-2796.2008.02062.x\u000a    \u000a\u000aR6. Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A,\u000a        Paisley S, Chilcott J. Ezetimibe for the treatment of\u000a      hypercholesterolaemia: a systematic review and economic evaluation. Health\u000a      Technol Assess 12(21):iii-212 May 2008\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    S1. NICE guidance. Statins for the prevention of cardiovascular events.\u000a      Technology Appraisal 96. January 1996. http:\/\/www.nice.org.uk\/nicemedia\/pdf\/TA094guidance.pdf\u000a    S2. Millions more to get heart drugs. http:\/\/news.bbc.co.uk\/1\/hi\/health\/4644828.stm\u000a    S3. Statins for all diabetics urged. http:\/\/news.bbc.co.uk\/1\/hi\/health\/7180733.stm\u000a    S4. Genetic cholesterol test warning http:\/\/news.bbc.co.uk\/1\/hi\/health\/8118804.stm\u000a    S5. Health survey for England 2006:https:\/\/catalogue.ic.nhs.uk\/publications\/public-health\/surveys\/heal-surv-cvd-risk-obes-ad-ch-eng-2006\/heal-surv-cvd-risk-obes-ad-ch-eng-2006-rep-v1.pdf\u000a    S6. Health Survey for England 2011. Chapter 2 Cardiovascular Disease.\u000a      http:\/\/www.ic.nhs.uk\/catalogue\/PUB09300\u000a    S7. Capewell S and Ford E. Why have total cholesterol levels declined in\u000a      most developed countries? BMC Public Health. 2011; 11: 641\u000a    S8. Scarborough P, Wickramasinghe K, Bhatnagar P, Rayner M. BHF Trends in\u000a      Coronary heart disease 1961-2011 Available from: http:\/\/www.bhf.org.uk\/publications\/view-publication.aspx?ps=1001933\u000a    S9. Department of Health Cost-Effective Prescribing: Better Care Better\u000a      Value Indicator on Statins. April 2011\u000a    S10. Townsend N, Wickramasinghe K, Bhatnagar P, Smolina K, Nichols M,\u000a      Leal J, Luengo- Fernandez R, Rayner M (2012). Coronary heart disease\u000a        statistics 2012 edition. British Heart Foundation: London.\u000a    S11. Medical Research Council. Achievements and Impacts\u000a      http:\/\/www.mrc.ac.uk\/Achievementsimpact\/Storiesofimpact\/Statins\/index.htm\u000a    ","Title":"\u000a    Informing national policy to increase prescribing of statins for the\u000a      prevention of heart disease\u000a    ","UKLocation":[{"GeoNamesId":"2638077","Name":"Sheffield"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Researchers at the School of Health and Related Research (ScHARR) at the\u000a      University of Sheffield undertook a systematic review of the clinical and\u000a      cost-effectiveness of statins in the primary and secondary prevention of\u000a      coronary heart disease (CHD) and cardiovascular disease (CVD) in England\u000a      and Wales. In addition, they developed an economic model to explore the\u000a      cost-effectiveness of the five statins which were licensed for use in\u000a      England and Wales in April 2004. The research was undertaken in 2004 and\u000a      2005 and was funded by the Heath Technology Assessment (HTA) Programme,\u000a      part of the National Institute for Health Research (NIHR), on behalf of\u000a      the National Institute for Health and Care Excellence (NICE) in order to\u000a      compare directly the effectiveness and cost-effectiveness of different\u000a      statins for the first time and to assess the impact of statins in patients\u000a      who had not previously experienced a CVD event. The HTA programme\u000a      commissions research where there are uncertainties surrounding the\u000a      clinical and cost-effectiveness of interventions used in the NHS.\u000a    Statins help lower rates of low-density lipoprotein (LDL) cholesterol\u000a        in the blood, by reducing the production of LDL cholesterol inside\u000a      the liver. High levels of LDL cholesterol can lead to hardening and\u000a      narrowing of the arteries (atherosclerosis) which increase the risk of CVD\u000a      events such as heart attack and stroke. The systematic review on clinical\u000a      effectiveness, conducted at ScHARR by Myfanwy Lloyd Jones (at ScHARR\u000a      between 1996 and 2012) and Abdullar Pandor (at ScHARR since 1999),\u000a      identified and evaluated all literature relating to the effectiveness of\u000a      the five statins for the prevention of coronary events. This comprehensive\u000a      review was unique, looking at the efficacy and safety (including\u000a      post-market surveillance) of all RCTs (published and unpublished) of the\u000a      five statins in primary and secondary prevention of CVD. Previous reviews\u000a      had only focused on secondary prevention, had only considered large trials\u000a      and had undertaken only a limited review of adverse events.\u000a    The review concluded that there was robust evidence to suggest that\u000a      statin therapy is associated with a statistically significant reduction,\u000a      as high as 33%, for some events, in the risk of primary and secondary\u000a      cardiovascular events compared to placebo when assuming a class effect for\u000a      all statins and doses. The evidence from the placebo-controlled trials\u000a      indicated that the four statins with hard clinical endpoints of morbidity\u000a      and mortality (atorvastatin, fluvastatin, pravastatin and simvastatin)\u000a      demonstrated a very similar beneficial effect. The evidence base for\u000a      rosuvastatin was less well developed. Limited evidence from direct\u000a      comparisons between statins suggested that atorvastatin may be more\u000a      effective than pravastatin in patients with symptomatic CHD. The review\u000a        also concluded that statins were generally well tolerated, with a\u000a      good safety profile.\u000a    A new health economic model was developed by Sue Ward (Senior Operational\u000a      Research Analyst), Roberta Ara (Operational Research Analyst) and Mike\u000a      Holmes (Operational Research Analyst) at ScHARR to predict the\u000a      cost-effectiveness of statin therapy over a patient's lifetime. This was\u000a      the first economic analysis to compare the five different statins within\u000a      the same economic model. The model used clinical events to measure\u000a      effectiveness rather than the surrogate endpoint of cholesterol lowering\u000a      which had been used in previous models. (NICE guidance section 4.3.6) The\u000a      effect of statins on the reduction of events was based on relative risks\u000a      of coronary and cardiovascular outcomes estimated by a pioneering Bayesian\u000a      meta-analysis. Cost-effectiveness of statins within both secondary\u000a      prevention (for those who had already experienced a CHD event) and primary\u000a      prevention (for those at high risk of experiencing a first event) were\u000a      evaluated within the same model for the first time. For primary prevention\u000a      the cost-effectiveness was examined on the basis of decreasing risk in a\u000a      stepwise manner (for example, from a threshold of 3% annual risk to 2%\u000a      annual risk) to demonstrate the true incremental cost-effectiveness of\u000a      treating decreasing levels of absolute risk.\u000a    The economic modelling work showed that the incremental\u000a      cost-effectiveness ratios (ICERs) in secondary prevention of CVD increased\u000a      with age varying between &#163;8,000 and &#163;13,000 per quality adjusted life year\u000a      (QALY) for ages 45 and 85 respectively and, therefore, statin therapy was\u000a      likely to be considered cost-effective based on the accepted\u000a      cost-effectiveness threshold values of &#163;20,000 in England and Wales. In\u000a      primary prevention, the cost-effectiveness ratios were shown to be\u000a      dependent on the level of CVD risk and age. At 3% risk the ICERs remain\u000a      below &#163;17,000 for all ages whereas at 0.5% CHD risk the ICERs reach as\u000a      high as &#163;50,000. The analysis also suggested that that statin therapy was\u000a      cost effective in people with diabetes, who have a higher absolute risk of\u000a      CVD compared to those without diabetes.\u000a    This research was used by the NICE Appraisal Committee to inform their\u000a      guidance on statin prescribing in England and Wales. ([R2 Section 4.3.6\u000a      and Appendix B]. The research report was also cited in the subsequent\u000a      Lipid Modification Clinical Guideline CG67, issued in May 2008. This\u000a      research also led to two further high quality research projects in the UK,\u000a      led by Roberta Ara at ScHARR. Firstly, a Health Technology Assessment on\u000a      the clinical and cost-effectiveness of ezetimibe in patients with primary\u000a      hypercholesterolaemia (funded by the NIHR in 2007). This research was used\u000a      by the NICE Appraisal Committee to inform their national guidance on\u000a      ezetimibe prescribing in England and Wales. (NICE Technology Appraisal\u000a      TA132: Ezetimibe\u000a        for the treatment of primary (heterozygous-familial and non-familial)\u000a        hypercholesterolaemia Technology appraisals, November 2007).\u000a      Secondly, a Health Technology Assessment comparing the clinical and\u000a      cost-effectiveness of potent dose statins versus standard doses in\u000a      individuals with acute coronary syndrome (funded by the NIHR in\u000a      2008).[R3-R6]\u000a    "},{"CaseStudyId":"14568","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2186224","Name":"New Zealand"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2510769","Name":"Spain"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Economic and Social Research Council","Medical Research Council"],"ImpactDetails":"\u000d\u000a    The Sheffield Alcohol Research Group (SARG)'s strategy for impact is one\u000d\u000a      of on-going\u000d\u000a      engagement with policy stakeholders, from developing policy-relevant\u000d\u000a      research questions through\u000d\u000a      to responding rapidly and flexibly to the timescales of the policy debate.\u000d\u000a    SAPM has played a central role in informing the UK and Scottish\u000d\u000a      Governments' policy decisions to\u000d\u000a      introduce minimum unit pricing (MUP) as a central feature of their alcohol\u000d\u000a      strategies. The research\u000d\u000a      has also stimulated and advanced public debate in the UK and\u000d\u000a      internationally.\u000d\u000a    Our research has been central to policy decisions:\u000d\u000a    Scotland. 2009: The Scottish Government used\u000d\u000a      English SAPM results to support its decision to\u000d\u000a      pursue MUP policies and commissioned a Scottish model adaptation. Results\u000d\u000a      were presented to\u000d\u000a      the Scottish Ministerial Advisory Committee on Alcohol. 2010: We\u000d\u000a      served as expert witnesses in\u000d\u000a      the Alcohol Bill (Scotland) enquiry, Scottish Parliament Health and Sport\u000d\u000a      Committee. Also in 2010,\u000d\u000a      a first attempt at MUP legislation failed in Parliament. 2011: The\u000d\u000a      new majority SNP Government\u000d\u000a      introduced fresh MUP legislation. In the bill's explanatory notes [S1],\u000d\u000a      SAPM results feature on 13 of\u000d\u000a      24 pages. 2012: We appeared before the Scottish Parliament Health\u000d\u000a      and Sport Committee and\u000d\u000a      SAPM results were referenced in the Committee's report [S2]. The Alcohol\u000d\u000a      (Minimum Pricing)\u000d\u000a      (Scotland) Act 2012 was passed. A legal challenge by the Scotch Whisky\u000d\u000a      Association centred, in\u000d\u000a      part, on a critique of the evidence. A Scottish Government rebuttal used\u000d\u000a      SAPM results. 2013:\u000d\u000a      SARG submitted an expert witness report to the Court of Session, which\u000d\u000a      dismissed the legal\u000d\u000a      challenge. SAPM evidence was referred to by the judge to reject claims of\u000d\u000a      a poorly-targeted policy\u000d\u000a      [S3].\u000d\u000a    Our research has stimulated and informed policy debate:\u000d\u000a    England. 2008: Evidence briefings were invited by\u000d\u000a      policymakers in the Department of Health, by\u000d\u000a      the Prime Minister's Special Advisors at No 10, and by the Chief Medical\u000d\u000a      Officer (CMO). 2009: The\u000d\u000a      latter influenced the CMO's Annual Report, which cites SAPM findings and\u000d\u000a      lobbies strongly for a\u000d\u000a      MUP [S4]. SARG also gave oral evidence to the House of Commons Health\u000d\u000a      Select Committee,\u000d\u000a      and SAPM estimates are cited in the final report [S5]. 2010: SAPM\u000d\u000a      findings were used directly by\u000d\u000a      NICE in recommending MUP. SARG briefed senior Westminster civil servants\u000d\u000a      from the Cabinet\u000d\u000a      Office, Treasury, Department of Health, Home Office, DCMS, DCSF, and\u000d\u000a      DEFRA. 2011: SARG\u000d\u000a      was invited to a Government Engagement Workshop to discuss the draft\u000d\u000a      Alcohol Strategy. 2012:\u000d\u000a      The Alcohol Strategy 2012 included a commitment to introducing MUP, and\u000d\u000a      SAPM findings were\u000d\u000a      cited by the Prime Minister in his foreword [S6]. A 2012 House of Commons\u000d\u000a      Health Select\u000d\u000a      Committee report noted \"The debate so far is based almost entirely on the\u000d\u000a      work of the Sheffield\u000d\u000a      Alcohol Research Group\" [S7]. SAPM results have been cited prominently by\u000d\u000a      a range of bodies\u000d\u000a      engaging in public debate on alcohol policy, including the British Medical\u000d\u000a      Association, Alcohol\u000d\u000a      Concern [S8] and the Alcohol Health Alliance (which includes the Royal\u000d\u000a      Colleges of Physicians,\u000d\u000a      General Practitioners, Nursing and Psychiatrists, Cancer Research UK). 2013:\u000d\u000a      The Impact\u000d\u000a      Assessment accompanying the Government's consultation on the Alcohol\u000d\u000a      Strategy drew heavily on\u000d\u000a      SAPM results. In response to stakeholder engagement with the Home Office\u000d\u000a      and Department of\u000d\u000a      Health SARG published new evidence on the equality aspects of MUP. SARG\u000d\u000a      also published\u000d\u000a      rebuttals to several industry-funded reports critiquing SAPM. In July, the\u000d\u000a      UK Government replaced\u000d\u000a      the MUP commitment with an alternative floor price (level of alcohol duty\u000d\u000a      attracted by a product,\u000d\u000a      inclusive of VAT). According to ministers, MUP remains under consideration\u000d\u000a      as a future policy.\u000d\u000a    The research team have worked to advance public debate thorough regular\u000d\u000a      appearances across\u000d\u000a      all major UK print and broadcast media from 2009 to 2013. Examples of\u000d\u000a      public exposure to the\u000d\u000a      issues around alcohol MUP and its effects are evident from our engagement\u000d\u000a      with flagship radio\u000d\u000a      and television programmes, e.g. BBC 10 o'clock news (27\/09\/2009,\u000d\u000a      28\/09\/2009, 23\/03\/2012),\u000d\u000a      Question Time (26\/05\/2011), Panorama (28\/09\/2012), Daily Politics\u000d\u000a      (23\/03\/2012), BBC Radio 4\u000d\u000a      Today programme (18\/01\/2011) and You &amp; Yours (08\/06\/2010). There has\u000d\u000a      been extensive\u000d\u000a      newspaper coverage, e.g. Financial Times (28\/09\/2009), Guardian\u000d\u000a      (15\/05\/2009, 13\/10\/2009,\u000d\u000a      30\/04\/2013), Independent (03\/05\/2009), Scotsman (09\/09\/2009) and Daily\u000d\u000a      Telegraph (14\/05\/2009,\u000d\u000a      24\/03\/2010). An article on MUP was also invited by the New Scientist.\u000d\u000a    International. SARG have given invited briefings to the: EU\u000d\u000a      Commission Advisory Meeting on\u000d\u000a      Alcohol Cost Benefit Analysis, European Presidency Expert Meeting on\u000d\u000a      Alcohol and Health,\u000d\u000a      European Commission DG Health and Consumers, and to senior civil servants\u000d\u000a      of the National\u000d\u000a      Australian Government and the Western Australian Health Committee. SAPM\u000d\u000a      results are cited in\u000d\u000a      policy debate by, amongst others, the Australian National Preventive\u000d\u000a      Health Agency, Canadian\u000d\u000a      Public Health Association, Irish Department of Health, the New Zealand Law\u000d\u000a      Commission, and\u000d\u000a      World Health Organisation [S9].\u000d\u000a    Our research has informed national healthcare guidelines:\u000d\u000a    Our findings were used directly by NICE in making recommendations in June\u000d\u000a      2010 for minimum\u000d\u000a      pricing and also programmes of identification and brief advice. SAPM\u000d\u000a      modelling evidence\u000d\u000a      statements underpin five of the eleven recommendations in the NICE\u000d\u000a      guidance [S10].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The Sheffield Alcohol Policy Model (SAPM) has made a major contribution\u000d\u000a      to national and\u000d\u000a      international debate on public policy and services\u000d\u000a      focusing on reducing alcohol misuse in society.\u000d\u000a    SAPM provides the core evidence underpinning Scottish Government plans to\u000d\u000a      implement minimum\u000d\u000a      unit pricing (MUP) and is cited in the UK Prime Minister's foreword to the\u000d\u000a      2012 UK Alcohol\u000d\u000a      Strategy. Findings have influenced health policy debate in Australia,\u000d\u000a      Canada, Ireland, New\u000d\u000a      Zealand, Spain, Switzerland, and the European Commission.\u000d\u000a    SAPM estimates for the cost-effectiveness of brief intervention\u000d\u000a      programmes in primary care\u000d\u000a      underpin the National Institute for Health &amp; Clinical Excellence\u000d\u000a      guidance on this topic.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of Sheffield\u000d\u000a    ","Institutions":[{"AlternativeName":"Sheffield (University of)","InstitutionName":"University of Sheffield","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007157}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2058645","Name":"State of Western Australia"}],"References":"\u000d\u000a    \u000aR1. Purshouse RC, Meier PS, Brennan A, Taylor KB &amp; Rafia R. (2010).\u000d\u000a      `Estimated effect of alcohol\u000d\u000a      pricing policies on health and health economic outcomes in England: an\u000d\u000a      epidemiological\u000d\u000a      model', The Lancet, 375 (9723), pp.1355-64. doi: 10.1016\/S0140-6736(10)60058-X\u000d\u000a    \u000a\u000aR2. Brennan A, Meier P, Purshouse R, Rafia R, Meng Y &amp; Hill-MacManus\u000d\u000a      D. (2013) `Developing\u000d\u000a      policy analytics for public health strategy and decisions &#8212; the Sheffield\u000d\u000a      alcohol policy model\u000d\u000a      framework', Annals of Operational Research doi: 10.1007\/s10479-013-1451-z\u000d\u000a    \u000a\u000aR3.Meier PS, Brennan A, Purshouse R. (2010). `Policy options for alcohol\u000d\u000a      price regulation: the\u000d\u000a      importance of modelling population heterogeneity', Addiction, 105 (3),\u000d\u000a      pp.383-93. doi:\u000d\u000a      10.1111\/j.1360-0443.2009.02721.x\u000d\u000a    \u000a\u000aR4. Holmes J, Meier PS, Booth A, Guo Y, &amp; Brennan A (2012). The\u000d\u000a      temporal relationship between\u000d\u000a      per capita alcohol consumption and harm: A systematic review of time lag\u000d\u000a      specifications in\u000d\u000a      aggregate time series analyses. Drug and Alcohol Dependence, 123(1-3),\u000d\u000a      7-14. doi:\u000d\u000a      10.1016\/j.drugalcdep.2011.12.005\u000d\u000a    \u000a\u000aR5.Meng Y, Holmes J, Hill-McManus D, Brennan A &amp; Meier PS (2013).\u000d\u000a      Trend analysis and\u000d\u000a      modelling of gender-specific age, period and birth cohort effects on\u000d\u000a      alcohol abstention and\u000d\u000a      consumption level for drinkers in Great Britain using the General\u000d\u000a      Lifestyle Survey 1984-2009.\u000d\u000a      Addiction doi: 10.1111\/add.12330\u000d\u000a    \u000a\u000aR6. Purshouse RC, Brennan A, Rafia R, Latimer NR, Archer RJ, Angus CR,\u000d\u000a      Preston LR &amp; Meier\u000d\u000a      PS. (2012). `Modelling the cost-effectiveness of alcohol screening and\u000d\u000a      brief interventions in\u000d\u000a      primary care in England', Alcohol and Alcoholism, 48 (2), 180-8. doi: 10.1093\/alcalc\/ags103\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000d\u000a    S1. Alcohol (Minimum Pricing) (Scotland) Bill: Explanatory notes (2011)\u000d\u000a      (SP Bill 4-EN), Edinburgh:\u000d\u000a      OPQS. pp. 4, 6-9, 19. This corroborates that ScHARR\/SAPM evidence\u000d\u000a      is central to the SNP\u000d\u000a      Government's case for its MUP legislation.\u000d\u000a    S2. Health and Sport Committee (2012) `Stage 1 Report on the Alcohol\u000d\u000a      (Minimum Pricing)\u000d\u000a      (Scotland) Bill', (SP 2012, 83) shows that SAPM results are referenced in\u000d\u000a      the Committee's\u000d\u000a      report.\u000d\u000a    S3. The Scottish Court of Session Judgement 2013 (para 72) corroborates\u000d\u000a      that SAPM evidence\u000d\u000a      was referred to by the judge to reject claims of a poorly-targeted policy.\u000d\u000a    S4. Department of Health (2009) `Annual Report 2008 of the Chief Medical\u000d\u000a      Officer', London: DH\u000d\u000a      Publications, pp 21-22, shows that the CMO's report cited SAPM findings\u000d\u000a      and lobbied strongly\u000d\u000a      for a MUP.\u000d\u000a    S5. Health Select Committee (2009) `Alcohol', (HC 2009-10, 121-I), pp.\u000d\u000a      12, 39, 69, 77, 96-97, 105-113,\u000d\u000a      115; corroborates that the House of Commons Health Select Committee's\u000d\u000a      final report on\u000d\u000a      alcohol cites SAPM estimates.\u000d\u000a    S6. HM Government (2012) `The Government's Alcohol Strategy' (Cm 8336),\u000d\u000a      London: TSO, p. 2;\u000d\u000a      shows that SAPM evidence was referred to in the PM's foreword of the\u000d\u000a      Government's Alcohol\u000d\u000a      Strategy 2012.\u000d\u000a    S7. Health Select Committee (2012) `Government's Alcohol Strategy', (HC\u000d\u000a      2012-13, 132), pp. 20-\u000d\u000a      22. This report contains the statement that \"The debate so far is based\u000d\u000a      almost entirely on the\u000d\u000a      work of the Sheffield Alcohol Research Group\".\u000d\u000a    S8. Alcohol Concern (2012) `Alcohol Concern's response to the Health\u000d\u000a      Select Committee's inquiry\u000d\u000a      into the Government's Alcohol Strategy May 2012' (pp. 2-3) is indicative\u000d\u000a      of references to\u000d\u000a      SAPM estimates by a range of bodies engaging in public debate on alcohol\u000d\u000a      policy.\u000d\u000a    S9. World Health Organisation (2012) `Alcohol in the European Union:\u000d\u000a      Consumption, harm and\u000d\u000a      policy approaches', Copenhagen: WHO Regional Office for Europe (pp. 99,\u000d\u000a      108-9)\u000d\u000a      corroborates that SAPM results are of policy relevance beyond the UK\u000d\u000a    S10.National Institute for Health and Clinical Excellence (2010)\u000d\u000a      `Alcohol-use disorders: preventing\u000d\u000a      the development of hazardous and harmful drinking', NICE public health\u000d\u000a      guidance 24,\u000d\u000a      London: NICE. This corroborates the claim that SAPM modelling evidence\u000d\u000a      statements\u000d\u000a      underpin five of the eleven recommendations in the NICE guidance.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    The impact of the Sheffield Alcohol Policy Model on alcohol policy\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2638077","Name":"Sheffield"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Key researchers and periods of involvement: Prof Petra Meier\u000d\u000a      (ScHARR, 2008-, project lead\u000d\u000a      public health), Prof Alan Brennan (ScHARR, 2008-, project lead\u000d\u000a      modelling), Dr Andrew Booth\u000d\u000a      (ScHARR, 2008-10, systematic reviews), Dr John Holmes (ScHARR,\u000d\u000a      2010-, public health), Dr\u000d\u000a      Ravi Maheswaran (ScHARR, 2010-, geographical information systems),\u000d\u000a      Dr Yang Meng\u000d\u000a      (ScHARR, 2009-, modeller), Dr Robin Purshouse (ScHARR 2008-10,\u000d\u000a      Automatic Control and\u000d\u000a      Systems Engineering 2010-, modeller), Prof Karl Taylor (Economics,\u000d\u000a      2008, econometrics).\u000d\u000a    Funders: The programme of work has to date been funded by the UK\u000d\u000a      Department of Health (DH),\u000d\u000a      Home Office (HO), National Institute for Health and Care Excellence\u000d\u000a      (NICE), Medical Research\u000d\u000a      Council (MRC), Economic and Social Research Council (ESRC), the Scottish\u000d\u000a      Government (SG),\u000d\u000a      National Institute for Health Research (NIHR), the Canadian Institute for\u000d\u000a      Health Research (CIHR),\u000d\u000a      the Northern Ireland Department of Health, Social Services and Public\u000d\u000a      Safety and the EU\u000d\u000a      Framework 7 programme.\u000d\u000a    What was involved: SAPM is a mathematical model which estimates\u000d\u000a      the impact of a given alcohol\u000d\u000a      policy on levels of drinking and associated harm, giving detailed\u000d\u000a      information on the policy's effect\u000d\u000a      on health, crime and workplace harms and associated public sector costs\u000d\u000a      [R1]. The model first\u000d\u000a      uses econometric methods to link changes in alcohol price to changes in\u000d\u000a      consumption, and then\u000d\u000a      epidemiological modelling to link changes in consumption to changes in\u000d\u000a      harm [R2]. A strength of\u000d\u000a      SAPM is its capability to consider policy effects on population subgroups,\u000d\u000a      by drinking level, age,\u000d\u000a      gender and income [R3]. Key methodological work involved the integration\u000d\u000a      of disparate evidence\u000d\u000a      sources, including data from cohort studies, surveys, administrative data\u000d\u000a      and the published\u000d\u000a      literature, and accounting for underlying time trends in consumption and\u000d\u000a      harm [R4, R5]. Several\u000d\u000a      international adaptations were undertaken. The interdisciplinary team uses\u000d\u000a      methods from\u000d\u000a      epidemiology, systematic reviewing, systems engineering, econometrics, and\u000d\u000a      health economics.\u000d\u000a    Main findings: The model's most prominent use has been to estimate\u000d\u000a      the potential impact of\u000d\u000a      different minimum unit pricing policies (MUP) for alcohol which had not\u000d\u000a      previously been subject to\u000d\u000a      empirical analysis [R1]. These policies link alcoholic beverage prices to\u000d\u000a      their ethanol content by\u000d\u000a      setting a floor price below which a unit of alcohol cannot be sold.\u000d\u000a    1) Introducing a 50p minimum unit price in England would lead to 15,000\u000d\u000a      fewer alcohol-related\u000d\u000a      deaths and 480,000 fewer alcohol-related hospital admissions over the\u000d\u000a      first ten years of the\u000d\u000a      policy.\u000d\u000a    2) This is associated with a &#163;1.6bn saving over that period in direct\u000d\u000a      costs to the health service and\u000d\u000a      a &#163;9.7bn saving across all outcomes.\u000d\u000a    3) Minimum unit pricing is well-targeted: it reduces consumption and harm\u000d\u000a      by heavy drinkers, but\u000d\u000a      has only minor effects on those who drink within government guidelines.\u000d\u000a    4) Minimum unit pricing has difficult equity implications: the poorest\u000d\u000a      heavy drinkers reduce their\u000d\u000a      consumption more than more affluent heavy drinkers, but most of the health\u000d\u000a      gains are also\u000d\u000a      experienced by this group.\u000d\u000a    The model was also used to provide evidence for the cost-effectiveness of\u000d\u000a      screening and brief\u000d\u000a      intervention programmes for alcohol users in primary care [R6].\u000d\u000a    "},{"CaseStudyId":"18133","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"}],"Funders":[],"ImpactDetails":"\u000d\u000a4a. Informing public and professional debate on a sensitive issue\u000d\u000aThe findings emerged in the context of some high-profile deaths of Black men in UK psychiatric\u000d\u000ahospitals, and raised awareness of ethnic inequalities in mental health. Prior to this research, the\u000d\u000aprevailing paradigm for explaining these inequalities was `racism'. Not only was this an inaccurate\u000d\u000ainterpretation of the evidence; it also diverted policy attention into simplistic solutions (eg tick-lists\u000d\u000aof `cultural competencies' in which staff would need to be trained), and to undermine efforts of NHS\u000d\u000aorganisations and staff to provide effective and personalized care taking account of culture.\u000d\u000aResearch in Queen Mary has steadily shifted this paradigm towards more nuanced and socio-\u000d\u000aculturally informed perspectives. For example, the excess of compulsory detentions of Black men\u000d\u000afor psychosis may be due in small part to `racism' or `cultural stereotyping', but a full explanation\u000d\u000amust include other interacting variables, including poverty; educational background; stress and\u000d\u000adiscrimination in the workplace; cross-cultural differences in expressions of distress; differences in\u000d\u000afamily support and help-seeking behaviour; and medication adherence. The findings of this\u000d\u000aresearch and evaluation of the national programme [7] led to the recognition among policymakers\u000d\u000athat solutions must go beyond a behaviourist emphasis on `racial awareness' to embrace\u000d\u000aorganisational and systemic changes as well as personal culture and poor cultures of care.\u000d\u000a4b. Informing and developing national legislation and policy (includes):\u000d\u000a\u000d\u000aRevisions to the Mental Health Bill 2006. This research was reviewed and evidence taken\u000d\u000awhen the new bill was being developed. The findings, cited in the consultation documents [8],\u000d\u000ahelped halt legislation that was feared to risk greater ethnic inequalities in use of the Mental\u000d\u000aHealth Act. The final Bill was modified in a way that was unlikely to further increase inequalities\u000d\u000ain detention, and further research is investigating what explains increasing levels of compulsory\u000d\u000adetention in hospital in all groups, and the persistent excess among black patients.\u000d\u000aProf Bhui was invited to draft national policy in 1999-2004; this work produced a 5 year plan\u000d\u000a(`Delivering Race Equality 2005-2010' [9]) incorporating new service models, training and\u000d\u000afurther research. Many impacts resulted from this policy in 2008-13. In many localities,\u000d\u000acommunities had a greater say in local services and were more engaged with NHS services by\u000d\u000ainforming the implementation of the Race Relations Amendment Act and by promoting more\u000d\u000asophisticated models of workforce development to meet the needs of culturally diverse\u000d\u000apopulations. Most importantly, every trust was charged with improving their delivery of care to\u000d\u000aminority ethnic groups and to show this in inspections to the Regulator. Other impacts include:\u000d\u000aProf Bhui co-authored a report to the Department of Health on suicides in Black and Minority\u000d\u000aEthnic (BME) groups [10], contributing to the emphasis in the newly launched (Sept 2012)\u000d\u000aNational Suicide Prevention Strategy and to the work of the 2006 strategy as part of the\u000d\u000a`Delivering Race Equality' programme.\u000d\u000aA national Race Equality &amp; Cultural Competence programme (RECC) was mandated for all\u000d\u000amental health professionals, driven by strategic health authorities (SHAs) [11]. It led to\u000d\u000ainclusion of training by the Care Quality Commission in a race impact assessments of SHAs.\u000d\u000a\u000aFive hundred `race equality leads', a new workforce, were introduced nationally requiring\u000d\u000aeach Strategic Health Authority to develop an action plan [12].\u000d\u000aAs part of developing a competent and informed workforce to reduce inequalities, with pump-\u000d\u000apriming funds from Department of Health, Bhui set up an MSc in 2002 (plus Certificate and\u000d\u000aDiploma) in Transcultural Mental Health, delivered in an innovative online format to 80\u000d\u000astudents annually, now drawn from over 38 countries. This course has recently been extended\u000d\u000awith new pathways in Psychological Therapies, and Mental Health &amp; Law [13].\u000d\u000a\u000d\u000a4c. Informing and developing national and international guidelines\u000d\u000aThis work has been cited by, and strongly influenced, guidelines by the National Institute of Health\u000d\u000aand Clinical Excellence on schizophrenia, for which Bhui chaired the access and engagement\u000d\u000apanel [14]; the World Psychiatric Association Guidelines on Mental Health of Migrants [15];\u000d\u000aEuropean Union Guidelines on Healthcare of migrants: EU-COST action [16]; and European\u000d\u000aPsychiatric Association guidelines on Public Mental Health [17].\u000d\u000a4d: Implementing and evaluating new care pathways in the NHS\u000d\u000aThe action research project led by Queen Mary (2005-2007) `Enhancing Pathways Into Care'\u000d\u000a(EPIC) in four NHS trusts illustrated a range of ways of changing pathways into care and engaging\u000d\u000ahard-to-reach groups to improve access, often through partnerships between voluntary and\u000d\u000astatutory sector agencies [18]. For example, a Pakistani Muslim Centre developed a joint\u000d\u000aassessment protocol with an early intervention team in order to improve access to psychiatric care\u000d\u000afor women from this otherwise isolated population. In one site (Sheffield) local audits showed a\u000d\u000asmall reduction in the average duration of admissions among Black people. The evaluation showed\u000d\u000aclinical leadership, transformational leadership and cultural confidence were key ingredients to the\u000d\u000agenuine change in services. The graph below (from a peer-reviewed publication in Transcultural\u000d\u000aPsychiatry) shows one example of reduction in average length of stay in Black patients on\u000d\u000aadmissions on wards in Sheffield in a participating unit in the EPIC project in 2005-7.\u000d\u000a\u000d\u000a\u000d\u000a\u000d\u000a4e: Informing and influencing training and workforce development\u000d\u000aThe Queen Mary team were commissioned by NHS Tower Hamlets (&#163;450K) to provide the\u000d\u000aCultural Consultation Service to address intersectional inequalities arising in clinical practice.\u000d\u000aBhui set this up to provide individual staff training in holistic, socio-culturally informed care as well\u000d\u000aas organisational and system-level support and guidance to NHS organisations seeking to reduce\u000d\u000ainequalities in mental health service provision [19]. This is built on anthropological understandings\u000d\u000aof culture, which notes the significance of beliefs, arts, laws, morals and behaviours found in all\u000d\u000aethnic groups. The model uses patient and staff narratives of care as the basis for intervention\u000d\u000aalongside ethnographic research methods for evaluation. The team imported and adapted a\u000d\u000aCanadian model to provide a new service, including in-service workforce development by teaching\u000d\u000astaff how to use a cultural formulation, and addressing commissioning, management and team\u000d\u000ainfluences. This and the narrative approach permitted more negotiated care plans for patients who\u000d\u000awere disengaging or stuck in assertive outreach or other specialist psychiatric teams. The service\u000d\u000aalso included organizational analyses to assist the services and teams to adapt their ways of\u000d\u000aworking to reduce inequalities. Bhui led an audit of this service showing over 900 contacts, and\u000d\u000athat cultural competency of staff improved [20]. Among a small sample of complex patients (n=36)\u000d\u000aneeding specialist and in-depth work, there were significant cost savings (&#163;18K total) at three\u000d\u000amonth follow up. Patient functioning improved and trends showed fewer unmet needs.\u000d\u000a4f: Informing further research\u000d\u000aThe overall picture nationally from the Care Quality Commission is that despite an evidence-based\u000d\u000aintervention based on this research, there has been no overall reduction in ethnic inequalities in\u000d\u000adetentions, ie that dramatic improvements in some areas (see graph above) are counterbalanced\u000d\u000aby worsening inequalities in other areas. This has prompted new collaborative NIHR-funded\u000d\u000aresearch studies to explore variations in compulsory admissions across the country [21].\u000d\u000aHypotheses include various geographical factors and social determinants of health.\u000d\u000a4g: Oral and written evidence to Home Office and Government: Bhui's team undertook\u000d\u000aresearch on Khat (widely used in some minority ethnic groups and linked to mental health\u000d\u000aproblems) and presented the case for it being made illegal [22].\u000d\u000a","ImpactSummary":"\u000d\u000aResearch by Bhui 1996-2013 showed striking differences by ethnic group in diagnosis and\u000d\u000amanagement of mental health disorders due to a complex interplay of socio-cultural factors and\u000d\u000adifferent perspectives of patients and professionals. Impacts included: [a] the development and\u000d\u000aimplementation of a UK-wide mental health policy 'Delivering Race Equality'; [b] a national training\u000d\u000aand workforce development programme that shifted the conceptual paradigm from the cultural\u000d\u000acompetencies of individuals to system-wide intervention (called `cultural consultation'); [c] service\u000d\u000adevelopment research `Enhancing Pathways into Care' (EPIC) to implement findings and draw\u000d\u000alessons across four NHS Trusts; [d] incorporation of research findings into national and\u000d\u000ainternational guidelines, and influence on mental health legislation and policy; and [e] a new phase\u000d\u000aof research on implementing findings.\u000d\u000a","ImpactType":"Societal","Institution":"\u000d\u000aQueen Mary University of London (QMUL)\u000d\u000a","Institutions":[{"AlternativeName":"Queen Mary, University of London","InstitutionName":"Queen Mary, University of London","PeerGroup":"A","Region":"London","UKPRN":10007775}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000aSix papers listed of 40 relevant from this group (Queen Mary researchers in bold):\u000d\u000a\u000a1. Bhui K, Brown P, Hardie T, Watson JP, Parrott J. African-Caribbean men remanded to Brixton\u000d\u000aPrison. Psychiatric and forensic characteristics and outcome of final court appearance. British\u000d\u000aJournal of Psychiatry 1998; 172: 337-44.\u000d\u000a\u000a\u000a2. Bhui K, Bhugra D, Goldberg D, Dunn G, Desai M. Cultural influences on the prevalence of\u000d\u000acommon mental disorder, general practitioners' assessments and help-seeking among Punjabi\u000d\u000aand English people visiting their general practitioner. Psychological Medicine 2001; 31: 815-25.\u000d\u000a\u000a\u000a3. Bhui K, Stansfeld S, Hull S, Priebe S, Mole F, Feder G. Ethnic variations in pathways to and\u000d\u000ause of specialist mental health services in the UK. Systematic review. British Journal of\u000d\u000aPsychiatry 2003; 182: 105-16.\u000d\u000a\u000a\u000a4. Bhui K, Stansfeld S, McKenzie K, Karlsen S, Nazroo J, Weich S. Racial\/ethnic discrimination\u000d\u000aand common mental disorders among workers: findings from the EMPIRIC Study of Ethnic\u000d\u000aMinority Groups in the United Kingdom. American Journal of Public Health. 2005; 95: 496-501.\u000d\u000a\u000a\u000a5. Bhui K, R&#252;dell K, Priebe S. Assessing explanatory models for common mental disorders.\u000d\u000aJournal of Clinical Psychiatry 2006 67: 964-71.\u000d\u000a\u000a\u000a6. Bhui K, McKenzie K. Rates and risk factors by ethnic group for suicides within a year of\u000d\u000acontact with mental health services in England and Wales. Psychiatric Services 2008;59:414-6.\u000d\u000a\u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a\u000d\u000aNational Institute of Mental Health England 2003: `Inside Outside: Improving Mental Health\u000d\u000aServices for BME Communities in England' (includes 27 references to Queen Mary research)\u000d\u000aInside Outside: Improving mental health services for BME communities in England.\u000d\u000aMental Health Bill 2006. Hansard record of Queen Mary research being discussed in House of\u000d\u000aLords debate on this Bill: www.theyworkforyou.com\/lords\/?id=2006-11-\u000d\u000a28c.679.2&amp;s=Bhui#g704.0\u000a\u000d\u000aDepartment of Health and National Mental Health Development Unit. `Delivering Race Equality\u000d\u000ain Mental Health Care: A Review' 2009 (www.nmhdu.org.uk\/silo\/files\/delivering-race-equality-\u000d\u000ain-mental-health-care-a-review.pdf, see page 11) includes EPIC evaluation lead by Bhui:\u000d\u000awww.wolfson.qmul.ac.uk\/psychiatry\/epic\u000a\u000d\u000aNational Mental Health Development Unit: `Suicide Prevention for BME Groups in England'\u000d\u000a2006: www.nmhdu.org.uk\/silo\/files\/suicide-prevention-for-bme-groups-in-england.pdf\u000a\u000d\u000aRace Equality and Cultural Competence programme (RECC), see `Delivering Race Equality in\u000d\u000aMental Health Care: A Review' 2009: www.nmhdu.org.uk\/silo\/files\/delivering-race-equality-in-\u000d\u000amental-health-care-a-review.pdf\u000a\u000d\u000aMinisterial statement announcing 500 community development workers as race equality leads:\u000d\u000awww.publications.parliament.uk\/pa\/cm200405\/cmhansrd\/vo050111\/wmstext\/50111m01.htm\u000a\u000d\u000aTraining courses: www.wolfson.qmul.ac.uk\/psychiatry\/courses\/ and\u000d\u000awww.qmul.ac.uk\/events\/items\/2012\/83195.html\u000a\u000d\u000aNICE Guideline on Schizophrenia (updated 2010) www.nice.org.uk\/CG82 See pages 9,10,11\u000d\u000aand 30. Bhui et al, 2007 cited here has been accessed 28,648 times.\u000d\u000aWorld Psychiatric Association guidance on caring for migrants with mental health needs.\u000d\u000aBhugra, Gupta, Bhui et al, World Psychiatry 2011 10: 2-10.\u000d\u000awww.wpanet.org\/detail.php?section_id=7&amp;content_id=895\u000a\u000d\u000aEuropean Union Guidelines on Healthcare of migrants: EU-COST action:\u000d\u000awww.cost.eu\/domains_actions\/isch\/Actions\/IS0603?management\u000a\u000d\u000aCampion J, Bhui K, Bhugra D. European Psychiatric Association (EPA) guidance on\u000d\u000aprevention of mental disorders. European Psychiatry 2012; 27: 68-80.\u000d\u000aReports on EPIC project. All papers listed here:\u000d\u000awww.wolfson.qmul.ac.uk\/psychiatry\/epic\/epicppublications.html, published in: International\u000d\u000aReview of Psychiatry 2009; 21: 425-6, 450-9, 460-4, 465-471, 482-5. By Bhui, Moffatt,\u000d\u000aMcKenzie, Sass: www.wolfson.qmul.ac.uk\/psychiatry\/epic\/epicevaluation.html\u000a\u000d\u000aCultural Consultation website www.culturalconsultation.org\u000a\u000d\u000aAudit of Cultural Consultation Service. http:\/\/www.culturalconsultation.org.uk\/wp-\u000d\u000acontent\/uploads\/2013\/10\/CCS-Final-report.pdf [available in archive]\u000d\u000awww.netscc.ac.uk\/hsdr\/projdetails.php?ref=10-1011-70\u000d\u000aAdvisory Committee on Drug Misuse: Khat: A review of its potential harms to the individual and\u000d\u000acommunities in the UK. www.homeoffice.gov.uk\/publications\/agencies-public-\u000d\u000abodies\/acmd1\/ACMD-khat-report-2013\/report-2013?view=Binary\u000a\u000d\u000a\u000d\u000a\u000d\u000a","Title":"\u000d\u000aUnderstanding and addressing ethnic inequalities in mental health\u000d\u000a","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000aCommon mental disorders affect one in six adults in UK and cause significant morbidity. Psychotic\u000d\u000adisorders affect one in 100 but are more disabling and have greater risk of disability, social\u000d\u000aexclusion, self-harm, suicide and contact with specialist psychiatric services. Diagnosis and\u000d\u000amanagement of mental health conditions vary by ethnicity. Since the mid-1990s Professor\u000d\u000aKamaldeep Bhui's team have conducted research at Queen Mary on cross-cultural psychiatry\u000d\u000aaiming to identify and explore these ethnic differences and ensure that patients receive best care\u000d\u000aand achieve optimum outcome whatever their ethnic group, social class, language, culture or\u000d\u000areligion. The research can be divided into four broad groups:\u000d\u000a2a: Descriptive epidemiology (research conducted 1996-98). Prof Bhui showed that Black\u000d\u000aCaribbean people were more likely than Whites to enter care through forensic and psychiatric\u000d\u000aroutes, more likely to be detained under the Mental Health Act, and more likely to be diverted to\u000d\u000ahospital from prisons, suggesting that their illness was less likely to be noticed by police or courts\u000d\u000a[1]. His team also showed that South Asians are less likely to be referred to specialist psychiatric\u000d\u000acare, despite seeing their GPs more often than other ethnic groups for all health problems [2].\u000d\u000aThese findings were partly, but not fully, explained by differing expressions of distress as well as\u000d\u000adifferent thresholds (irrespective of GP ethnicity) for recognition of common mental disorders [2].\u000d\u000a2b: Systematic review of compulsory detention (2001-02). A systematic review of 38 papers\u000d\u000aand meta-analysis of 13 suitable studies quantified the excess detentions (odds ratio for being\u000d\u000acompulsorily detained under mental health legislation if Black vs White = 4.3) [3].\u000d\u000a2c: Quantitative surveys of socio-cultural determinants of mental health inequalities (2001-\u000d\u000a08). Bhui et al undertook a series of surveys of discrimination \/ work stress and common mental\u000d\u000adisorders, of which one secondary analysis showed that discrimination was an important risk factor\u000d\u000afor common mental disorders [4]. Other studies implicated explanatory models and coping; and\u000d\u000asocio-economic risk factors of common mental disorders [4]. This involved developing and\u000d\u000avalidating new survey instruments (eg the Barts Explanatory Model Interview) [5].\u000d\u000a2d. Analysis of national suicide statistics by ethnic group (2006-07). Bhui led a national\u000d\u000aevaluation of suicide and ethnicity [6] that documented a highly significant excess of suicide in\u000d\u000ayoung (13-24 year old) black Caribbean and African men compared to white British men of the\u000d\u000asame age. These findings were evident in both community and inpatient settings. The team also\u000d\u000ashowed that, in contrast to previous studies, South Asian women did not have significantly higher\u000d\u000arates of suicide. In a report to the Department of Health, the team demonstrated a near-absence of\u000d\u000acommunity-based suicide prevention initiatives, and notably none aimed at high-risk Black men.\u000d\u000aQueen Mary researchers included Professors Bhui, Stansfeld, Priebe, and Feder and Hull.\u000d\u000a"},{"CaseStudyId":"18134","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    QRisk had an impact in five areas: implementation and use of QRisk in UK\u000d\u000a      primary care (GP surgeries and pharmacies); direct uptake and use by the\u000d\u000a      public and patient organisations; informing policy on NHS Health Checks;\u000d\u000a      informing methodological work on risk score development and validation;\u000d\u000a      and inspiring further research on the use of QRisk-type scores for other\u000d\u000a      chronic conditions. We consider these in turn below.\u000d\u000a    4a: Implementation and routine use of QRisk in UK primary care\u000d\u000a      The success of QRisk has depended both on its robust scientific basis and\u000d\u000a      on intensive efforts on the implementation of the score in front-line\u000d\u000a      general practice. The effort included:\u000d\u000a    \u000d\u000a      Dr Robson worked with the GP system supplier EMIS to ensure that the\u000d\u000a        risk score was fully integrated in GP computer software to give a\u000d\u000a        `one-click' QRisk calculation covering 55% of the English population.\u000d\u000a      An accessible website (www.qrisk.org)\u000d\u000a        including a user-friendly risk calculator aimed at both health\u000d\u000a        professionals and the public. The website currently receives ~25,000\u000d\u000a        visits per month (around 2 million visits to date).\u000d\u000a      Dr Robson advised the DH and a London-wide team on QRisk\u000d\u000a        implementation. Locally in east London, he was a member of the North\u000d\u000a        East London Cardiac Network Board, CVD lead for Tower Hamlets PCT and\u000d\u000a        advisor to other local PCTs in east London.\u000d\u000a    \u000d\u000a    Using QRisk rather than Framingham as the risk score on GP computer\u000d\u000a      systems is more equitable for the needs of high risk ethnic minorities,\u000d\u000a      the socially disadvantaged and is estimated it will prevent 3,000 more CVD\u000d\u000a      events in five years in those at high risk in England because QRisk\u000d\u000a      identifies a risk group that is on average, at higher risk than that those\u000d\u000a      identified by Framingham. In people found to be at high CVD risk, events\u000d\u000a      will be further reduced by targeting treatment for high blood pressure and\u000d\u000a      earlier identification of diabetes.\u000d\u000a    Dr Robson collaborated with Prof Hippisley-Cox to design the QRisk\u000d\u000a      calculator and website and worked with EMIS, the largest UK computer\u000d\u000a      supplier to integrate QRisk in their electronic record using minimal\u000d\u000a      additional data and no duplicated entry. This was complex, requiring\u000d\u000a      automated on- line real-time connection to a remote `cloud' calculator,\u000d\u000a      which returns the score to the GP record within milliseconds in a seamless\u000d\u000a      electronic tool for busy clinicians and their patients in the consulting\u000d\u000a      room. An app is now available. The new QRisk-lifetime score was presented\u000d\u000a      by the Joint British Societies to replace the previous Framingham score as\u000d\u000a      their preferred risk engine [9].\u000d\u000a    QRisk has now been implemented by all GP system suppliers in England and\u000d\u000a      Wales. Other system suppliers use QRisk in community and pharmacy contexts\u000d\u000a      including Oskis, Wellpoint (kiosk\/pharmacies), Telehealth\u000d\u000a      (kiosk\/pharmacies), Cumbria Mental Health Trust, Informatica, Health\u000d\u000a      Diagnostics and Health Smart. These pharmacy and other community schemes\u000d\u000a      use QRisk as part of the NHS Health Checks programme (see below).\u000d\u000a    By 2011 the NHS Health Checks programme had identified 2.8 million people\u000d\u000a      at high CVD risk who have been started on statins &#8212; most of whom are\u000d\u000a      likely to have been identified with QRisk (as EMIS covers 60% of GP\u000d\u000a      practices and QRisk is implemented on all other major computer systems) &#8212;\u000d\u000a      though some will have been identified with Framingham. As statins reduce\u000d\u000a      CVD events by 25% and the average risk of those identified is around 10%,\u000d\u000a      it is estimated that this programme is preventing 9,000 CVD deaths or\u000d\u000a      events every year &#8212; about 50,000 since the programme started in 2009. This\u000d\u000a      is a major public health achievement [10].\u000d\u000a    4b: Uptake and use by the lay public and patient organisations\u000d\u000a      A key aspect of the QRisk website is that it can be used by an untrained\u000d\u000a      layperson to calculate their own cardiovascular risk, allowing\u000d\u000a      self-diagnosis and prompting people to attend their GP or pharmacist for\u000d\u000a      further investigation and advice. Public dissemination has been extensive\u000d\u000a      and QRisk is included on a number of websites including Patient UK,\u000d\u000a      National Prescribing Centre, NHS Health Check and NHS Improvement\u000d\u000a      websites. It was endorsed by the Director of the British Heart Foundation\u000d\u000a      and is included in their factsheets. The QRisk website is now being\u000d\u000a      accessed about 300,000 times a year, including 40,000 visits from outside\u000d\u000a      the UK.\u000d\u000a    4c: Informing policy on NHS health checks\u000d\u000a      Dr Robson has been an advisor to the Department of Health on NHS Health\u000d\u000a      Checks and a member of the London NHS Health Checks Implementation Group.\u000d\u000a      The NICE guideline [1 above], chaired by Dr Robson, provided the\u000d\u000a      scientific rationale and recommendation that underpinned the 2009 national\u000d\u000a      NHS Health Checks programme, which offers cardiovascular risk assessment\u000d\u000a      to all adults aged 40-74 years in England. On publication of NICE guidance\u000d\u000a      in 2007, the Department of Health endorsed QRisk for CVD risk estimation\u000d\u000a      in its NHS Checks programme [11,12] and used it to develop the economic\u000d\u000a      modelling underpinning the NHS Checks programme in 2008 [13]. This\u000d\u000a      demonstrated that QRisk potentially provided better value than Framingham\u000d\u000a      for the &#163;200m annual cost of NHS Health Checks [13]. In 2010, NICE revised\u000d\u000a      their original guidance to support the use of QRisk2 [14]. QRisk\u000d\u000a      technology integrated into the GP electronic record has been an essential\u000d\u000a      component of implementation and instrumental to widespread adoption.\u000d\u000a    4d: Informing methodological work on risk scores\u000d\u000a      QRisk development has contributed to the discussion on validation and\u000d\u000a      statistical comparison of models to predict risk, and to debates on\u000d\u000a      multiple imputation. For example, QRisk was a case study in a workshop\u000d\u000a      convened by the Foundation for Genomics and Population Health, Cambridge\u000d\u000a      [15,16]. The debate around the use of routine GP data for predictive\u000d\u000a      purposes has highlighted the potential of large primary care datasets for\u000d\u000a      research purposes (eHealth records research capacity and capability MRC\u000d\u000a      2011). The open source QRisk calculator has been downloaded from the QRisk\u000d\u000a      website by over 500 separate organisations in the last year and has been\u000d\u000a      used by a number of UK universities (including SCHARR for the health\u000d\u000a      economic modelling for NICE), Cambridge and Imperial. QRISK&#174; is\u000d\u000a      a registered trademark and IP is protected by GNU licences. QRisk has had\u000d\u000a      an international impact &#8212; for example, an American paper on health\u000d\u000a      economic assessment used QRisk in an Austrian population [17] and an\u000d\u000a      American review highlighted the importance of socio-economic data in\u000d\u000a      predicting individual and population CVD risk [18].\u000d\u000a    4e: Promoting development of further risk prediction scores\u000d\u000a      The principles behind the development of QRisk &#8212; using readily available\u000d\u000a      data items on GP systems to calculate real-time risk scores to inform\u000d\u000a      treatment decisions with patients and public health planning &#8212; have been\u000d\u000a      applied to other chronic conditions. These include diabetes risk scores\u000d\u000a      (with Dr Robson QDiabetes 2011 www.qdscore.org)\u000d\u000a      and cancer, osteoporotic fracture, renal disease and thrombosis risk tools\u000d\u000a      (Hippisely-Cox J www.QCancer.org).\u000d\u000a    Prizes, awards and grants\u000d\u000a      In 2011, Dr Robson received a NICE Shared Learning Award for his work\u000d\u000a      implementing NICE guidance on cardiovascular disease and the John Perry\u000d\u000a      Award of the British Computer Society for his work on this topic. In 2011,\u000d\u000a      he was awarded a two-year NIHR grant to evaluate the NHS Health Checks\u000d\u000a      programme, which will study the extent to which QRisk has been\u000d\u000a      implemented. The team is an important component of CHAPTER &#8212; the\u000d\u000a      successful &#163;5m MRC eHealth bid (PI Harry Hemmingway UCL) as the primary\u000d\u000a      care `arm' of this bid. The team are working to develop data linkage and\u000d\u000a      to demonstrate the success of a new paradigm in improvement science &#8212;\u000d\u000a      using networks of local practices that have produced a step change in\u000d\u000a      process and outcomes.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    QRisk is a statistical model \/ score derived from routine general\u000d\u000a      practice (GP) records to calculate an individual's risk of developing\u000d\u000a      cardiovascular disease (CVD). Queen Mary researchers formed the London arm\u000d\u000a      of a multi-centre study and were particularly instrumental in testing the\u000d\u000a      tool in general practice. QRisk targets treatment more effectively than\u000d\u000a      other scores; it is also more equitable for disadvantaged and minority\u000d\u000a      ethnic groups and cheaper per event prevented. QRisk is used in the NHS\u000d\u000a      Health Checks programme covering 20 million people in England and is\u000d\u000a      available at a keystroke in all GP computer systems in England. It has\u000d\u000a      contributed to the identification of an additional 2.8 million people in\u000d\u000a      England at high risk of CVD and their treatment with statins, reducing CVD\u000d\u000a      deaths and events by an estimated 9,000 per year &#8212; about 50,000 to date\u000d\u000a      since the NHS Checks programme started in 2009.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    Queen Mary University of London (QMUL)\u000d\u000a    ","Institutions":[{"AlternativeName":"Queen Mary, University of London","InstitutionName":"Queen Mary, University of London","PeerGroup":"A","Region":"London","UKPRN":10007775}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. NICE Guidance CG67. Cooper A, Nherera L, Calvert N, O'Flynn N,\u000d\u000a      Turnbull N, Robson J, et al. Clinical guidelines and evidence\u000d\u000a      review for lipid modification, cardiovascular risk assessment and the\u000d\u000a      primary and secondary prevention of cardiovascular disease. NCCP. London:\u000d\u000a      Royal College of General Practitioners; 2008.\u000d\u000a    \u000a\u000a2. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M,\u000d\u000a      Brindle P. Derivation and validation of QRISK, a new cardiovascular\u000d\u000a      disease risk score for the United Kingdom: prospective open cohort study.\u000d\u000a      BMJ 2007;335:136.\u000d\u000a    \u000a\u000a3. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle\u000d\u000a      P. Performance of the QRISK cardiovascular risk prediction algorithm in an\u000d\u000a      independent UK sample of patients from general practice: a validation\u000d\u000a      study. Heart 2008; 94: 34-9.\u000d\u000a    \u000a\u000a4. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas\u000d\u000a      R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales:\u000d\u000a      prospective derivation and validation of QRISK2. BMJ\u000d\u000a      2008;336:1475-82.\u000d\u000a    \u000a\u000a5. Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation,\u000d\u000a      validation, and evaluation of a new QRISK model to estimate lifetime risk\u000d\u000a      of cardiovascular disease: cohort study using QResearch database. BMJ\u000d\u000a      2010; 341: c6624.\u000d\u000a    \u000aIndependent validation studies on QRISK by external experts\u000d\u000a    \u000a6. Collins GS, Altman DG. An independent external validation and\u000d\u000a      evaluation of QRISK cardiovascular risk prediction: a prospective open\u000d\u000a      cohort study. BMJ 2009; 339: b2584.\u000d\u000a    \u000a\u000a7. Collins GS, Altman DG. An independent and external validation of\u000d\u000a      QRISK2 cardiovascular disease risk score: a prospective open cohort study.\u000d\u000a      BMJ 2010; 340: c2442.\u000d\u000a    \u000a\u000a8. Collins GS, Altman DG. Predicting the 10-year risk of cardiovascular\u000d\u000a      disease in the United Kingdom: independent and external validation of an\u000d\u000a      updated version of QRISK2. BMJ 2012; 344: e4181.\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000d\u000a    \u000d\u000a      Spiegelhalter D. JBS-3: The Joint British Societies' revised\u000d\u000a          guidelines for the prevention of cardiovascular disease. Lecture\u000d\u000a        given on 8th March 2013 at Royal Society of Medicine, in\u000d\u000a        which he announced that JBS will adopt QRisk in its new joint guideline.\u000d\u000a        www.rsm.ac.uk\/academ\/lic02.php.\u000d\u000a      van Staa TP. The efficiency of cardiovascular risk assessment: Do the\u000d\u000a        right patients get statins? Heart 2013; 0: 1-6. doi:\u000d\u000a        10.1136\/heartjnl-2013-303698.\u000d\u000a      Department of Health. Putting prevention first: Vascular checks: risk\u000d\u000a        assessment and management. 'Next steps' guidance for Primary Care\u000d\u000a        Trusts. London: 2008.\u000d\u000a      Department of Health. NHS Health Check: Vascular Risk Assessment and\u000d\u000a        Management Best Practice Guidance. London, Stationery Office, 2009.\u000d\u000a      Department of Health. Vascular Checks Programme. Economic modelling\u000d\u000a        for vascular checks. London, Stationery Office, 2008.\u000d\u000a      NICE. Change to lipid modification guidance CG67 2010: Available from:\u000d\u000a        www.nice.org.uk\/newsroom\/news\/ChangeToLipidModificationGuidelineCG67.jsp.\u000d\u000a      Dent TH. Predicting the risk of coronary heart disease. The use of\u000d\u000a        conventional risk markers. Atherosclerosis 2010; 213: 345-51.\u000d\u000a      Wright C, Dent TH. Quality standards in risk prediction. Cambridge:\u000d\u000a        PHG Foundation for genmomics and population health. ISBN\u000d\u000a          978-1-907198-05-2 2010.\u000d\u000a      Richter A, Thieda P, Thaler K, Gartlehner G. The impact of inclusion\u000d\u000a        criteria in health economic assessments. Applied Health Economics\u000d\u000a          and Health Policy 2011; 9: 139-48.\u000d\u000a      Franks P, Tancredi DJ, Winters P, Fiscella K. Including socioeconomic\u000d\u000a        status in coronary heart disease risk estimation. Annals of Family\u000d\u000a          Medicine 2010; 8: 447-53.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Implementation of QRisk tool for cardiovascular risk management\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The epidemic of premature CVD mortality (under 75 years old) peaked in\u000d\u000a      the 1970s, declining from 250 per 100,000 to 50 per 100,000 in 2010. But\u000d\u000a      ethnic and socio-economic differences in CVD risk have persisted. It has\u000d\u000a      been possible for many years to estimate a person's CVD risk, calculated\u000d\u000a      from paper look-up tables based on Framingham data. In 1997, Dr Robson\u000d\u000a      (based at Queen Mary throughout) implemented the first UK electronic\u000d\u000a      version of a CVD risk score (Framingham) on the leading GP computer system\u000d\u000a      (EMIS), which allowed GPs to use two keystrokes for an `automated' risk\u000d\u000a      score. However, the Framingham score was derived from research undertaken\u000d\u000a      in the 1970\/80s in one small, relatively affluent and largely white US\u000d\u000a      town. Framingham score substantially overestimates overall UK CVD risk and\u000d\u000a      underestimates this risk in South Asian and socially disadvantaged people.\u000d\u000a    Inaccurate estimates lead to poorly targeted interventions, including\u000d\u000a      lifetime statin treatment, and impact on equitable provision and outcomes.\u000d\u000a      The Framingham score targets 3 million people in England for preventive\u000d\u000a      therapy while QRisk targets 2 million more accurately. QRisk identifies\u000d\u000a      300,000 people who would miss out on treatment if CVD risk were calculated\u000d\u000a      with Framingham score, many of whom are South Asians and \/ or in\u000d\u000a      socio-economically disadvantaged groups.\u000d\u000a    QRisk: In 2004-08, the NICE guideline development group CG67,\u000d\u000a      chaired by Dr Robson, reviewed risk scores including Framingham, and\u000d\u000a      identified the need to develop more contemporary scores that included\u000d\u000a      minority ethnic groups, social disadvantage and family history of\u000d\u000a      premature CVD [1]. In 2007, Dr Robson worked with Prof Hippisley-Cox's\u000d\u000a      team in Nottingham to develop QRisk [2-4]. This was the first use of\u000d\u000a      routine GP records for risk prediction and the first to include socio-\u000d\u000a      economic status. The tool was validated in an internal subset and an\u000d\u000a      independent external dataset. QRisk reallocates treatment assignment in\u000d\u000a      1\/3 of those who would previously have been identified at high risk (1.3\u000d\u000a      million individuals), impacting significantly on individuals, equity and\u000d\u000a      resource use.\u000d\u000a    Validation: An international statistical and epidemiological panel\u000d\u000a      commissioned by NICE including Peto (Oxford) and Jackson (New Zealand)\u000d\u000a      recommended use of QRisk to the NICE guideline group. Despite this, the\u000d\u000a      group initially failed to reach agreement on QRisk. In 2008, a third\u000d\u000a      independent validation, carried out by Collins and Altman at DOH's\u000d\u000a      request, confirmed the methods, validation and superiority of QRisk\u000d\u000a      compared to the historically popular Framingham score [6,7]. In 2008, a\u000d\u000a      refined version of the score, QRisk2, was accepted as a major improvement\u000d\u000a      and the first independently validated score to include ethnic group. An\u000d\u000a      updated version was developed in 2010 [5] and externally validated in 2012\u000d\u000a      [8].\u000d\u000a    Updating: To avoid overestimation, the QRisk score equation is\u000d\u000a      regularly updated and modified using accessible real-time GP data &#8212;\u000d\u000a      important to maintain accurate prediction given continuing changes in\u000d\u000a      population behaviour (smoking\/diet) and falling trends in CVD risk. It\u000d\u000a      also allows periodic statistical refinements to the score (eg addition of\u000d\u000a      new components, revisions in the weightings assigned to each component).\u000d\u000a      In contrast, the Framingham score, based on an historical cohort, has led\u000d\u000a      to major inaccuracy in contemporary European populations.\u000d\u000a    The team that developed QRisk included the following academics:\u000d\u000a      Prof J Hippisley-Cox (U of Nottingham). Director QResearch clinical\u000d\u000a      database. QRisk team leader\u000d\u000a      Dr J Robson (QMUL). Academic GP and health services researcher\u000d\u000a      Dr P Brindle (Avon Primary Care Research Collaborative). General\u000d\u000a      Practitioner\u000d\u000a      C Coupland Y Vinogradova (U of Nottingham). Statisticians\u000d\u000a      Prof A Sheikh, University of Edinburgh. Academic GP and health services\u000d\u000a      researcher\u000d\u000a    Dr Robson [a] chaired the NICE guideline group that originally identified\u000d\u000a      the need to improve risk tools for general practice; [b] tested existing\u000d\u000a      tools in GP computer systems in east London as a preliminary phase to the\u000d\u000a      QRisk research; [c] helped develop and validate QRisk; [d] provided unique\u000d\u000a      input to the QRisk team as a GP academic with specific expertise in the\u000d\u000a      installation and implementation of computerised risk scores in the\u000d\u000a      community-based clinical setting across a socio- economically deprived\u000d\u000a      district; and [e] played an active role in implementing QRisk locally (to\u000d\u000a      demonstrate real-world feasibility) and nationally (through the EMIS user\u000d\u000a      group and otherwise). Funding was from local NHS trusts, Queen Mary, and\u000d\u000a      Universities of Nottingham and Edinburgh.\u000d\u000a    "},{"CaseStudyId":"18135","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"3144096","Name":"Norway"}],"Funders":[],"ImpactDetails":"\u000a    4a: Informed and affirmed NICE guidelines for CFS and ME\u000a    As a major recommendation within its guidelines, NICE recommends: \"Cognitive\u000a        behavioural therapy and\/or graded exercise therapy should be offered to\u000a        people with mild or moderate CFS\/ME and provided to those who choose\u000a        these approaches, because currently these are the interventions for\u000a        which there is the clearest research evidence of benefit.\" (page 30)\u000a      [7]. There have been no trials of GET in severe CFS\/ME. However, partly\u000a      because of an open study conducted at Queen Mary, showing that GET helps\u000a      severely disabled patients (Essame CS et al. Journal of\u000a        Chronic Fatigue Syndrome 1998; 4: 51-60), NICE recommend an activity\u000a      management programme for such patients that \"draws on the principles\u000a        of CBT and GET.\" Since publication of the PACE trial in 2011, NICE\u000a      have publicly affirmed their recommendation of GET (and CBT) [8].\u000a    4b: Graded exercise therapy has been adopted as a standard treatment\u000a        for CFS in the UK\u000a    The British Association for Chronic Fatigue Syndrome\/ME (BACME) \"champions\u000a        evidence-based approaches to the treatment of CFS\/ME\" and represents\u000a      clinicians of NHS specialist services in the UK [9]. BACME welcomed the\u000a      findings of the PACE trial saying: \"The PACE trial ... provides\u000a        convincing evidence that GET and CBT are safe and effective therapies\u000a        and should be widely available for patients with CFS\/ME.\"\u000a    BACME is supported by the National Outcomes Database [9], which holds\u000a      clinical assessment and outcome data on ~9,000 NHS patients, to allow\u000a      benchmarking of effectiveness. Crawley and colleagues compared patient\u000a      outcomes across six of the largest NHS services against outcomes after\u000a      both CBT and GET in the PACE trial. Three of the services used GET; three\u000a      used activity management incorporating the principles of GET. Symptomatic\u000a      improvement was similar to that achieved after GET provided within the\u000a      PACE trial [10]. However, the mean improvement in physical disability was\u000a      about a quarter of the size achieved by GET in the trial, which may be\u000a      partly explained by the fidelity of the intervention not always being\u000a      optimal when implemented outside a trial setting. One obvious difference\u000a      is that some services deliver interventions in a group setting, rather\u000a      than individually as in the trial [10].\u000a    4c: Graded exercise therapy has been adopted internationally as a\u000a        treatment of CFS\u000a    Permission has been granted for both translation into German and the use\u000a      of the PACE trial GET manuals for a trial in neuromuscular disease, and\u000a      for use in an Australian trial of rehabilitation for patients with\u000a      traumatic brain injuries. The PACE trial treatment manuals are free to\u000a      download from the trial website: www.pacetrial.org\/trialinfo.\u000a      The site was accessed by 6,672 people between June 2012 and 21 August\u000a      2013, particularly from the UK, USA, Australia, Germany, and Canada\u000a      (source &#8212; Google Analytics), this monitored period being more than a year\u000a      after the main results were published [11].\u000a    4d: Graded exercise therapy is included in guidelines for treatment of\u000a        CFS internationally\u000a    Guidelines published in other countries recommend GET. For example:\u000a    \u000a       In USA, the Mayo Clinic states: \"The most effective\u000a          treatment for chronic fatigue syndrome appears to be a two-pronged\u000a          approach that combines psychological counseling with a gentle exercise\u000a          program.\" [12]\u000a       Also in USA, the Centers for Disease Control recommend GET;\u000a        specifically White's clinical website: \"The GET Guide 2008 by Chronic\u000a          Fatigue Syndrome\/ME Service at St. Bartholomew's Hospital can be\u000a          helpful in structuring your graded exercise plan.\" [13]\u000a       Australian clinical guidelines for ME\/CFS recommend GET \"unless\u000a          severely affected\" [14]\u000a       The Norwegian Knowledge Centre for Health Services,\u000a        commissioned by their government, concluded: \"Cognitive behavioural\u000a          therapy and graded exercise therapy is likely to be effective for\u000a          people with chronic fatigue syndrome.\" [15]\u000a    \u000a    4c: Engagement with `lay epidemiology' and improving public\u000a        understanding of science\u000a    This research succeeded in spite of considerable opposition from\u000a      activists. Some people in the CFS\/ME community have developed a `lay\u000a      epidemiology' comprising purely organic explanations and hypotheses for\u000a      the condition, and view psychological hypotheses as dismissive of\u000a      patients' `real' experiences. A vocal minority has actively opposed any\u000a      research into this condition with a psychological component and has even\u000a      sought to sabotage such studies [16]. Pressure from such activists\u000a      (including threats of violence) has led some researchers to pull out of\u000a      researching CFS altogether. The approach taken at Queen Mary, as described\u000a      in Section 2, has been to seek dialogue with patients, carers and the lay\u000a      public, engage with their concerns, try to understand their explanations\u000a      and seek as far as possible to work with them rather than against them.\u000a    CFS is so controversial that the House of Lords held a debate about the\u000a      PACE trial in February 2013 [17]. One peer was critical, but seven others\u000a      supported the trial. Baroness Northover replied for the Government, and\u000a      later wrote to White: \"PACE was an example of a well conducted, robust\u000a        research study. It is with thanks to you and your team that we now have\u000a        some very good evidence that CBT and GET are moderately effective when\u000a        provided alongside specialist medical care.\" [18] As part of a\u000a      public relations policy to disseminate the PACE trial results, The Science\u000a      Media Centre hosted a press conference for the main paper [19]. This led\u000a      to positive, world-wide coverage, including almost all UK national\u000a      newspapers as well as the New York Times, Wall Street Journal,\u000a      Sky, BBC, and ITV, and radio stations in the UK, USA and Australia.\u000a    ","ImpactSummary":"\u000a    Chronic fatigue syndrome (CFS) is a disorder of unknown cause affecting\u000a      1% of people. Studies by Queen Mary researchers between 1993 and 2012\u000a      helped to characterise and demystify CFS and, in a series of randomised\u000a      trials, showed that graded exercise therapy (GET) was effective and\u000a      cost-effective, especially when costs to the patient and society were\u000a      included. For impacts, GET was [a] recommended in NICE guidance; [b]\u000a      offered as standard therapy in most UK centres managing CFS; [c]\u000a      recommended and used internationally. The lead researchers have worked\u000a      hard to build a dialogue with patient groups, including working with them\u000a      to co-design the most recent trial, thereby increasing the chance of\u000a      acceptance of findings by people affected by CFS.\u000a    ","ImpactType":"Health","Institution":"\u000a    Queen Mary University of London (QMUL)\u000a    ","Institutions":[{"AlternativeName":"Queen Mary, University of London","InstitutionName":"Queen Mary, University of London","PeerGroup":"A","Region":"London","UKPRN":10007775}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. White PD, Thomas JM, Kangro HO, Bruce-Jones WDA, Amess J,\u000a      Crawford DH, Grover SA, Clare AW. Predictions and associations of fatigue\u000a      syndromes and mood disorders that occur after infectious mononucleosis. Lancet\u000a      2001; 358: 1946-54. (Analysis of large Epstein-Barr virus infection\u000a      cohort, showing independent prediction of low physical fitness for later\u000a      development of CFS, but not depression. First papers from this cohort were\u000a      published in 1995.)\u000a    \u000a\u000a2. Fulcher KY, White PD. Randomised controlled trial of graded\u000a      exercise in patients with the chronic fatigue syndrome. BMJ 1997;\u000a      314: 1647-52. (The first randomised controlled trial of graded exercise\u000a      therapy for CFS, which also showed that increased fitness did not mediate\u000a      symptomatic relief; &gt;400 citations)\u000a    \u000a\u000a3. Fulcher KY, White PD. Strength and physiological response to\u000a      exercise in patients with the chronic fatigue syndrome. Journal of\u000a        Neurology Neurosurgery and Psychiatry 2000; 69: 302-7. (Case control\u000a      study showing that deconditioning was a problem in CFS, and graded\u000a      exercise therapy led to improved fitness, mediating improvement in objectively\u000a        measured disability.)\u000a    \u000a\u000a4. White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R,\u000a      DeCesare JC et al, and on behalf of the PACE trial management\u000a      group. Comparison of adaptive pacing therapy, cognitive behaviour therapy,\u000a      graded exercise therapy, and specialist medical care for chronic fatigue\u000a      syndrome (PACE): a randomised trial. Lancet 2011; 377: 823-36.\u000a      (The largest and definitive trial of GET for CFS, showing its efficacy and\u000a      safety, when compared to two other interventions, and its similar outcomes\u000a      to cognitive behaviour therapy, suggesting both interventions are\u000a      effective and safe.)\u000a    \u000a\u000a5. McCrone PM, Sharpe M, Chalder T, Knapp M, Johnson AJ, Goldsmith K, White\u000a        PD. Adaptive pacing therapy, cognitive behaviour therapy, graded\u000a      exercise therapy, and specialist medical care for chronic fatigue\u000a      syndrome: cost-effectiveness analysis. PLoS ONE 2012; 7 :e40808.\u000a      (GET is cost-effective, and pays for itself when costs of social care are\u000a      considered.)\u000a    \u000a\u000a6. White PD, Johnson AL, Goldsmith K, Chalder T, Sharpe MC.\u000a      Recovery from chronic fatigue syndrome after treatments given in the PACE\u000a      trial. Psychological Medicine, 2013, 1-9. (Three times more\u000a      patients recover their health after either GET or CBT than alternatives.)\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    \u000a       NICE Guideline 2007 (updated 2011) on Chronic Fatigue Syndrome \/\u000a        Myalgic Encephalomyelitis (CG053). http:\/\/guidance.nice.org.uk\/CG53\/Guidance\/pdf\/English\u000a\u000a       NICE affirming support of GET. www.nice.org.uk\/nicemedia\/live\/11824\/53532\/53532.pdf\u000a\u000a       British Association for Chronic fatigue syndrome\/ME BACME endorsement\u000a        of GET www.bacme.info\/aboutcfsme\/management\/get.html\u000a        and national outcomes database: http:\/\/www.bacme.info\/nod\/\u000a\u000a       Crawley E, Collin SM, White PD, Rimes K, Sterne JAC, May MT.\u000a        (Treatment outcome in adults with chronic fatigue syndrome: a\u000a        prospective study in England based on the CFS\/ME National Outcomes\u000a        Database. Quarterly Journal of Medicine 2013; 106: 555-565.\u000a        doi:10.1093\/qjmed\/hct061\u000a       PACE trial website: www.pacetrial.org\u000a\u000a       Mayo Clinic guideline on CFS www.mayoclinic.com\/health\/chronic-fatigue-syndrome\/DS00395\/DSECTION=treatments-and-drugs\u000a\u000a       US Center for Disease Control guideline on CFS www.cdc.gov\/cfs\/toolkit\/get.html\u000a\u000a       See for example Government of South Australia ME\/CFS guidelines\u000a        http:\/\/sacfs.asn.au\/download\/guidelines.pdf\u000a\u000a       Norwegian Knowledge Centre for Health Services rapid review on CFS\u000a        (English summary):\u000a        www.kunnskapssenteret.no\/Publikasjoner\/Behandling+av+kronisk+utmattelsessyndrom+CFSME.12742.cms?language=english&amp;threepage=1\u000a\u000a       Hawkes N. Dangers of research into chronic fatigue syndrome. BMJ\u000a        2011; 342: d3780\u000a       House of Lords debate on PACE, HANSARD 6 February 2013 (see column\u000a        GC65): www.publications.parliament.uk\/pa\/ld201213\/ldhansrd\/text\/130206-gc0001.htm\u000a\u000a       Letter from Baroness Northover. www.pacetrial.org\/docs\/Northover.pdf\u000a\u000a       Science Media Centre hosted a press conference on PACE.\u000a        www.sciencemediacentre.org\/cfsme-trial\/\u000a        &amp; www.sciencemediacentre.org\/expert-reaction-to-lancet-study-looking-at-treatments-for-chronic-fatigue-syndromeme-2-2\/\u000a\u000a    \u000a    ","Title":"\u000a    Chronic fatigue syndrome\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The research studies described here were undertaken from 1993 to 2012 and\u000a      published from 1995 to 2013. Back in 1993, CFS, sometimes called myalgic\u000a      encephalomyelitis (ME), was far from an established condition and those\u000a      who did believe in the condition thought it untreatable. In a series of\u000a      studies at Queen Mary, Prof White led work that established the separate\u000a      existence, incidence and prognosis of the syndrome after an infection, and\u000a      also showed that physical deconditioning predicted it [1]. On that basis,\u000a      White (with Fulcher, an exercise physiologist) designed graded exercise\u000a      therapy (GET), based on the existing literature (Richard Edwards had\u000a      already published an open study of exercise for \"effort syndrome\"). White\u000a      then led the first randomised controlled trial (RCT) of GET to show that\u000a      it was more effective than a non-specific therapy time-control\u000a      intervention for patients with CFS, whether or not this followed an\u000a      infection [2].\u000a    This work has been successfully replicated four times; systematic reviews\u000a      and meta-analyses of these studies have confirmed the efficacy of GET for\u000a      CFS. White went on to show (unexpectedly) that the effect of GET on global\u000a      improvement was not mediated by a physical training effect [2], a finding\u000a      since replicated by others. However, increased exercise tolerance,\u000a      measured objectively, was mediated by increased fitness after GET [3].\u000a      This suggested that GET works as much as a behavioural graded exposure\u000a      therapy as a physical training programme; something that was incorporated\u000a      into later designs of GET trials.\u000a    In spite of this scientific support, several surveys by patient\u000a      organisations claimed that GET was often damaging, and that \"pacing\"\u000a      (living within the limits of the illness) was most helpful. White\u000a      therefore approached a patient charity, Action for ME, who agreed\u000a      to help him design and implement an RCT to compare specialist medical care\u000a      (SMC) alone against such care supplemented by either adaptive pacing\u000a      therapy (APT), GET or cognitive behaviour therapy (CBT), the last of which\u000a      had also been shown to be effective and was recommended by NICE\u000a      (www.pacetrial.org) [4].\u000a    The PACE trial recruited 640 UK participants from secondary care [4].\u000a      Physiotherapists delivered GET, designed to increase exercise duration and\u000a      then intensity in a gradual and symptom-contingent manner, based on the\u000a      principles of behavioural graded exposure therapy (www.pacetrial.org). The\u000a      primary outcomes of fatigue and physical disability were significantly\u000a      improved in those who had received either GET or CBT, compared to those\u000a      who had received either APT or SMC; effect size was moderate (between 0.4\u000a      and 0.8) with similar effect sizes for both GET and CBT [4]. The pacing\u000a      approach of APT was no more effective than SMC. The patterns of results\u000a      were similar however CFS or ME were defined, as well as in those with a\u000a      comorbid depressive illness. Serious adverse events and reactions were\u000a      uncommon and equally distributed across the four treatment arms. CBT was\u000a      the most cost-effective, followed by GET [5]. At a societal level both GET\u000a      and CBT paid for themselves due to reductions in informal social care. 22%\u000a      of patients in the trial recovered their health after either of these\u000a      treatments, compared to 7% following SMC alone [6].\u000a    White et al concluded that individually delivered CBT and GET\u000a      were safe, effective and cost-effective when added to SMC, and should be\u000a      offered to all secondary care patients with CFS, however defined. In a\u000a      nutshell, gradually doing more is better for CFS than staying within\u000a      limits imposed by the illness. Consequent research includes an NIHR-funded\u000a      RCT of guided self-help using GET for patients with CFS (White is the PI).\u000a      The Cochrane Collaboration have a systematic review update of GET for CFS\u000a      in review, and an individual patient data meta-analysis is due for\u000a      submission this year (White is a co-author).\u000a    The trial was coordinated at Queen Mary and sponsored by them. White\u000a      (QMUL) was the lead principal investigator (PI), supported by co-PIs\u000a      Trudie Chalder (KCL) and Michael Sharpe (Oxford). Funding was from Medical\u000a      Research Council, Department of Health for England, Department for Work\u000a      and Pensions, and Scottish Chief Scientist's Office.\u000a    "},{"CaseStudyId":"18946","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000d\u000a    Treating and living with eczema has large cost and quality of life\u000d\u000a      implications for society and the\u000d\u000a      individual families affected. In 1995-6 the total annual UK cost of eczema\u000d\u000a      in children aged &#8804; 5\u000d\u000a      years was estimated to be &#163;47M (or &#163;79.59 per child), of which 64% was\u000d\u000a      accounted for by NHS\u000d\u000a      health-care costs. A further UK study looking at a broader age range\u000d\u000a      estimated the total annual\u000d\u000a      cost to be in the order of &#163;465M, of which &#163;125M was incurred by the NHS,\u000d\u000a      &#163;297M by the patients\u000d\u000a      and &#163;42M by society. Childhood eczema has been shown to have a similar\u000d\u000a      impact on health-related\u000d\u000a      quality of life as other common childhood conditions, such as asthma and\u000d\u000a      diabetes.\u000d\u000a    Current treatments consist predominantly of emollients, bath oils and\u000d\u000a      topical corticosteroid creams,\u000d\u000a      although some children may receive topical or oral antibiotics, or oral\u000d\u000a      antihistamines. Many\u000d\u000a      parents, however, worry about the side effects of conventional topical\u000d\u000a      medications, particularly in\u000d\u000a      relation to corticosteroids. Options that avoid the possible side effects\u000d\u000a      of conventional\u000d\u000a      pharmacological treatments, such as water softeners, wet wraps and special\u000d\u000a      dietary products,\u000d\u000a      have been be welcomed by many parents and medical professionals as an\u000d\u000a      additional way to\u000d\u000a      manage eczema. Indeed hard water is identified as an environmental trigger\u000d\u000a      in the NICE (2007)\u000d\u000a      guidelines on atopic eczema in children 12 years and under.\u000d\u000a    It is likely that a number of families of children with eczema have\u000d\u000a      purchased ion-exchange water\u000d\u000a      softeners in the belief that their use would provide relief from the\u000d\u000a      condition, although there was no\u000d\u000a      robust scientific evidence to support this. Indeed, up until 2010 the\u000d\u000a      National Eczema Society's\u000d\u000a      Factsheet on the use of water softeners for healthcare professionals and\u000d\u000a      eczema sufferers,\u000d\u000a      indicated that the use of water softeners may be beneficial. The results\u000d\u000a      of the SWET demonstrate\u000d\u000a      that the use of water softeners does not alleviate the symptoms of eczema.\u000d\u000a      The Chief Executive of\u000d\u000a      National Eczema Society now states (CS1): \"as a direct result of the\u000d\u000a      research conducted by\u000d\u000a      Professor Dean (University of Portsmouth) and Professor Williams and Dr\u000d\u000a      Thomas (University of\u000d\u000a      Nottingham) in their study, \"Effectiveness of water softeners in the\u000d\u000a      management of symptoms of\u000d\u000a      moderate to severe eczema\", which clearly demonstrated that water\u000d\u000a      softeners do not provide any\u000d\u000a      additional benefit compared to standard eczema treatments, we decided to\u000d\u000a      withdraw this Factsheet\u000d\u000a      from our range\".\u000d\u000a    In May 2011, Drinking Water Inspectorate (who provide independent\u000d\u000a      reassurance that public water\u000d\u000a      supplies in England and Wales are safe and drinking water quality is\u000d\u000a      acceptable to consumers)\u000d\u000a      issued a guidance document on `Water Hardness' which incorporated a\u000d\u000a      section on `Should I use\u000d\u000a      water softener?'. This document stated that our study `showed no objective\u000d\u000a      difference in outcomes\u000d\u000a      between the children whose homes were fitted with water softeners and\u000d\u000a      those without' (CS2),\u000d\u000a      citing our PLOS paper (reference 4 in section 3) as the only reference.\u000d\u000a    As a direct result of our work clinical practitioners and healthcare\u000d\u000a      professionals are now able to\u000d\u000a      provide evidence-based advice that the use of water softeners will not\u000d\u000a      alleviate the symptoms of\u000d\u000a      eczema, thus managing expectations in patients and their families. An\u000d\u000a      example of this is evidenced\u000d\u000a      by a letter from a General Practitioner CS3.\u000d\u000a    Our work has also resulted in significant cost savings for families, who\u000d\u000a      might otherwise have\u000d\u000a      purchased water softeners, and the selection of more appropriate\u000d\u000a      interventions for children with\u000d\u000a      moderate to severe eczema, The typical cost of a water softener unit is\u000d\u000a      &#163;600 (range: &#163;300-&#163;1800).\u000d\u000a      Our economic evaluation demonstrated that the additional mean total cost\u000d\u000a      of eczema treatment per\u000d\u000a      patient in the water-softener group compared with control group was &#163;198\u000d\u000a      for the 12 weeks trial\u000d\u000a      duration alone.. This significant cost difference was due to the cost of\u000d\u000a      the intervention; all other\u000d\u000a      resource categories (health professional visits, medications and other\u000d\u000a      medical items) were not\u000d\u000a      significantly different between groups. As our study conclusively\u000d\u000a      demonstrated that ion-exchange\u000d\u000a      water softeners were not found to be clinically effective or\u000d\u000a      cost-effective over the trial horizon, it\u000d\u000a      was not felt to be appropriate to model the longer term cost-effectiveness\u000d\u000a      of water softeners.\u000d\u000a    This study is generalisable with significant reach. It was designed as a\u000d\u000a      pragmatic study.\u000d\u000a      Participants were recruited from UK centres across the primary and\u000d\u000a      secondary care setting, and\u000d\u000a      included families of diverse socioeconomic backgrounds. The main impact\u000d\u000a      from this research is on\u000d\u000a      the health of the population, with associated impacts on clinicians who\u000d\u000a      can ensure that their\u000d\u000a      practice (with respect to use of water softeners in patients with eczema)\u000d\u000a      is based on robust high\u000d\u000a      quality evidence.\u000d\u000a      A further, indirect, impact of the research is the potential cost saving\u000d\u000a      offered to patients and their\u000d\u000a      families, or to the health services that might pay for purchase and\u000d\u000a      installation of a water softener.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Our research has shown that water softeners are not effective in reducing\u000d\u000a      the symptoms of\u000d\u000a      moderate to severe eczema in children, and that their use provides no\u000d\u000a      additional benefit over usual\u000d\u000a      care. This finding has had an impact on Healthcare practitioners ensuring\u000d\u000a      they are now able to\u000d\u000a      offer the evidence-based advice to patients that the use of water\u000d\u000a      softeners will not alleviate the\u000d\u000a      symptoms of eczema. This advice not only eliminates false hope in patient\u000d\u000a      groups but also results\u000d\u000a      in significant cost savings for families of children with moderate to\u000d\u000a      severe eczema who might\u000d\u000a      otherwise have purchased water softeners.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Portsmouth\u000d\u000a    ","Institutions":[{"AlternativeName":"Portsmouth (University of)","InstitutionName":"University of Portsmouth","PeerGroup":"D","Region":"South East","UKPRN":10007155}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a1) Williams H, Thomas K, Dean T, Brown N, Pollock I.\u000d\u000a      Randomised controlled trial of ion-exchange\u000d\u000a      water softeners for the treatment of atopic eczema in children, Department\u000d\u000a      of\u000d\u000a      Health Research &amp; Development, HTA Programme. Grant period: 2006-2009,\u000d\u000a      value:\u000d\u000a      &#163;980,000.\u000d\u000a    \u000a\u000a2) Thomas, K. and Sach, T.* on behalf of the SWET Trial Investigators\u000d\u000a        including Professor\u000d\u000a        Dean. (2008) A multicentre randomized controlled trial of\u000d\u000a        ion-exchange water softeners for\u000d\u000a        the treatment of eczema in children: protocol for the Softened Water\u000d\u000a        Eczema Trial (SWET)\u000d\u000a      (ISRCTN: 71423189). British Journal of Dermatology, 159: 561-566.\u000d\u000a      DOI: 10.1111\/j.1365-2133.2008.08704.x\u000d\u000a      Impact factor: 3.759\u000d\u000a    \u000a\u000a3) Thomas K., Koller K., Dean T., O'Leary C., Sach T., Frost A.,\u000d\u000a      et al. (2011) A multicentre\u000d\u000a        randomised controlled trial and economic evaluation of ion-exchange\u000d\u000a        water softeners for\u000d\u000a        the treatment of eczema in children: the Softened Water Eczema Trial\u000d\u000a        (SWET). Health\u000d\u000a      Technology Assessment, 15(8): 5-156.\u000d\u000a      DOI: 10.3310\/hta15080\u000d\u000a      Web: http:\/\/www.hta.ac.uk\/fullmono\/mon1508.pdf\u000d\u000a      Impact factor: 4.02\u000d\u000a    \u000a\u000a4) Thomas KS, Dean T, O'Leary C, Sach TH, Koller K, et al. (2011)\u000d\u000a      A Randomised Controlled\u000d\u000a        Trial of Ion-Exchange Water Softeners for the Treatment of Eczema in\u000d\u000a        Children. PLoS Med\u000d\u000a      8(2): e1000395.\u000d\u000a      DOI: 10.1371\/journal.pmed.1000395\u000d\u000a      Impact factor: 15.253\u000d\u000a      Output REF2 : 2-TD-003\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"7","Subject":"Immunology"}],"Sources":"\u000d\u000a    CS1. Letter from CEO of National Eczema Society re. withdrawal of water\u000d\u000a      softeners\u000d\u000a      Factsheet\u000d\u000a    CS2. Water Regulatory Authority Guidance Document &#8212;\u000d\u000a      http:\/\/dwi.defra.gov.uk\/consumers\/advice-leaflets\/hardness.pdf\u000d\u000a      Water Regulatory Authority\u000d\u000a      Guidance Document &#8212;\u000d\u000a    CS3. Letter from a General Practitioner with an interest in Eczema\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Demonstration of the ineffectiveness of water softeners in reducing\u000d\u000a      symptoms of eczema in\u000d\u000a      children\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2639996","Name":"Portsmouth"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Atopic eczema (AE), that has a varied clinical spectrum, is the most\u000d\u000a      common of the chronic\u000d\u000a      inflammatory skin diseases, with a life time prevalence of 15-30% in\u000d\u000a      children and 2-10% in adults\u000d\u000a      (WAO, White Book on Allergy, 2011). AE represents an important public\u000d\u000a      health issue due to its\u000d\u000a      impact on quality of life and its socio-economic burden. The economic\u000d\u000a      burden of AE in UK is high,\u000d\u000a      with an estimated total annual expenditure of &#163;465million in 1996.\u000d\u000a      Treatment options for childhood\u000d\u000a      eczema have focused on topical medications, with corticosteroids being the\u000d\u000a      mainstay of treatment,\u000d\u000a      along with the regular use of emollients. Many parents, however, worry\u000d\u000a      about the side effects of\u000d\u000a      the medications. Although side effects such as skin thinning and growth\u000d\u000a      retardation, have not been\u000d\u000a      supported by long-term studies, it is important to recognise these\u000d\u000a      concerns and to look for other\u000d\u000a      ways of treating eczema. Options that avoid these possible side effects\u000d\u000a      would be a welcome\u000d\u000a      addition to the management of eczema.\u000d\u000a    There have been widespread anecdotal reports of skin improvement of\u000d\u000a      people with eczema when\u000d\u000a      moving from a hard- to a soft-water area, but a previous systematic review\u000d\u000a      of eczema treatments\u000d\u000a      (Hoare et al HTA Systematic Review 2000) failed to identify any relevant\u000d\u000a      trials evaluating the\u000d\u000a      potential benefit of water softeners for eczema. In view of the limited\u000d\u000a      evidence, the high public\u000d\u000a      interest in their potential benefit, and low risk of adverse effects, the\u000d\u000a      UK NIHR Health Technology\u000d\u000a      Assessment programme prioritised and commissioned us(1) to\u000d\u000a      conduct the Softened Water\u000d\u000a      Eczema Trial (SWET). The study for which Professor Dean was a Principal\u000d\u000a      Investigator, took place\u000d\u000a      during 2007-2010, in collaboration with Professor Hywel Williams and Dr\u000d\u000a      Kim Thomas (Centre of\u000d\u000a      Evidence Based Dermatology, University of Nottingham). Professor Dean has\u000d\u000a      significant\u000d\u000a      experience of carrying out complex multi-centre clinical trials in the\u000d\u000a      area of asthma and allergy and\u000d\u000a      was pivotal in securing the funding needed to conduct the study.\u000d\u000a    The SWET had two main objectives: (1) to assess whether water softeners\u000d\u000a      reduce the severity of\u000d\u000a      eczema in children with moderate to severe eczema, and, if so, (2) to\u000d\u000a      establish the likely cost and\u000d\u000a      cost-effectiveness of the intervention. This was an observer-blind\u000d\u000a      randomised trial involving 336\u000d\u000a      children (aged 6 months-16 years) with moderate\/severe atopic eczema. This\u000d\u000a      sample size was\u000d\u000a      needed to provide 90% power, assuming a significance level of 5%.\u000d\u000a      Participants, living in hard\u000d\u000a      water areas, were randomly allocated into one of two groups: installation\u000d\u000a      of an ion-exchange water\u000d\u000a      softener plus usual eczema care, or usual eczema care alone2.\u000d\u000a      The primary assessment was\u000d\u000a      change in eczema severity (Six Area Six Sign Atopic Dermatitis Score,\u000d\u000a      SASSAD) at 12 weeks,\u000d\u000a      measured by research nurses (blinded to treatment allocation). The mean\u000d\u000a      change in SASSAD at\u000d\u000a      12 weeks was 25.0 (20% improvement) for the water softener group, and 25.7\u000d\u000a      (22% improvement)\u000d\u000a      for the usual care group (mean difference 0.66, 95% CI 21.37 to 2.69, p =\u000d\u000a      0.53). The research\u000d\u000a      provided conclusive evidence that the use of water softeners provides no\u000d\u000a      additional benefit to\u000d\u000a      usual care in this study population3,4.\u000d\u000a    "},{"CaseStudyId":"19667","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"3144096","Name":"Norway"},{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"660013","Name":"Finland"},{"GeoNamesId":"3175395","Name":"Italy"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2623032","Name":"Denmark"},{"GeoNamesId":"2186224","Name":"New Zealand"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    The initial clinical and cost-effectiveness results from the MASS trial\u000a      were presented to the UK National Screening Committee (NSC) in 2003-04 who\u000a      consequently recommended, in 2005, the introduction of a national AAA\u000a      screening programme for men aged 65 [impact ref 1]. Work was then\u000a      undertaken to raise the profile of AAA screening as a matter for public\u000a      debate, and in particular to increase awareness amongst policy makers and\u000a      politicians. Also during 2006-07 Thompson and Kim refined the estimates of\u000a      the long-term cost-effectiveness of an AAA screening programme in the UK,\u000a      made the NSC aware of this work, and worked with health economic modellers\u000a      at the Department of Health to answer questions about the health service\u000a      impacts of such a programme. In January 2008, the prime minister Gordon\u000a      Brown announced the introduction of a national AAA screening programme, in\u000a      line with the NSC's original recommendation [impact ref 2].\u000a    As a result, the NHS AAA Screening Programme (NAAASP) was initiated in\u000a      2009, in four geographical centres in England [impact ref 3]. On the basis\u000a      of the research findings, Thompson and colleagues provided advice on\u000a      issues including: training and quality control monitoring of\u000a      ultrasonographers; deployment of surgical services necessary to\u000a      accommodate the anticipated increased numbers of elective AAA repairs\u000a      undertaken; and content of the core data needed to audit and control the\u000a      programme as it rolled out. An issue crucial to the success of NAAASP in\u000a      terms of delivering the anticipated reduction in AAA-related mortality was\u000a      that the mortality from elective AAA operations was kept as low possible,\u000a      as had been achieved in the MASS trial. For this purpose, and after much\u000a      debate, it was decided that AAA surgery should be concentrated into larger\u000a      centres where surgical experience would be greater, excellence could be\u000a      more easily achieved, and monitoring could be more effective [impact ref\u000a      4].\u000a    NAAASP currently (August 2013) covers the whole of England [impact ref\u000a      3], with identical programmes being initiated in the devolved\u000a      jurisdictions of Wales, Scotland, and Northern Ireland [impact refs 5,6].\u000a      It is anticipated that full UK-wide coverage will be achieved in 2015. The\u000a      uptake of the screening invitation in NAAASP has been 75%, only slightly\u000a      lower than the 80% achieved in the MASS trial, and the elective surgical\u000a      mortality rate for large AAAs has been kept low (&lt;2%) [3]. Surveillance\u000a      for small AAAs follows the protocol and intervals developed for the\u000a      Cambridge-led MASS trial, but may be slightly relaxed in the future in\u000a      response to the publication [research ref 6] from the RESCAN Collaboration\u000a      on the effects and cost-effectiveness of alternative surveillance\u000a      intervals.\u000a    AAA screening leads to improved patient outcomes through the monitoring\u000a      of those at risk with a small AAA, and by offering elective surgery to\u000a      those with a large AAA. Based on the MASS trial and the three other\u000a      smaller randomised trials of AAA screening that are available\u000a      internationally, it is anticipated that mortality from AAA should be\u000a      reduced by about a half in men aged over 65 through the introduction of\u000a      NAAASP. Given current mortality rates, this corresponds to 1300 deaths\u000a      prevented per year in the UK [impact ref 3].\u000a    At international meetings in London (2012) and Budapest (2013),\u000a      representatives from 12 different countries worldwide compared their\u000a      prospects for initiating AAA screening programmes. Outside the UK,\u000a      screening programmes have started in Sweden [impact ref 7], New Zealand\u000a      and parts of Italy, while initiation is being actively discussed in\u000a      Denmark, Norway and Finland [impact refs 8,9]; in the USA, ultrasound AAA\u000a      screening is now recommended for all men aged over 65 who have ever smoked\u000a      [impact ref 10]. These changes in international policy have been driven by\u000a      the results from the MASS trial, as well as the early experience of NAAASP\u000a      in the UK.\u000a    ","ImpactSummary":"\u000a    Abdominal aortic aneurysm (AAA) is a major cause of death in older men,\u000a      in the UK and elsewhere. A large UK trial led by the University of\u000a      Cambridge evaluated the long-term benefits of ultrasound screening for AAA\u000a      in men aged 65-74 years. This provided the basis for the introduction of a\u000a      UK national AAA screening programme in men aged 65; this was announced in\u000a      2008, initiated in 2009, and achieved full coverage of England in 2013.\u000a      Similar screening has started in Sweden, New Zealand and in parts of\u000a      Italy, and is being actively discussed in Denmark, Norway and Finland.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Cambridge\u000a    ","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"3054643","Name":"Budapest"}],"References":"\u000a    \u000a1. Multicentre Aneurysm Screening Study Group (Scott RAP, Ashton HA,\u000a      Buxton MJ, Day NE, Kim LG, Marteau TM, Thompson SG, Walker NM). The\u000a      multicentre aneurysm screening study (MASS) into the effect of abdominal\u000a      aortic aneurysm screening on mortality in men: a randomised controlled\u000a      trial. Lancet 2002; 360: 1531-1539. 440 citations.\u000a    \u000a\u000a2. Thompson SG, Ashton HA, Gao L, Scott RAP. Screening men for abdominal\u000a      aortic aneurysm: 10 year mortality and cost effectiveness results from the\u000a      randomised Multicentre Aneurysm Screening Study. British Medical\u000a        Journal 2009; 338: b2307. 77 citations.\u000a    \u000a\u000a3. Kim LG, Thompson SG, Briggs AH, Buxton MJ, Campbell HE. How\u000a      cost-effective is screening for abdominal aortic aneurysms? Journal of\u000a        Medical Screening 2007; 14: 46-52. 18 citations\u000a    \u000a\u000a4. UK Small Aneurysm Trial Participants (Powell JT, Brady AR, Brown LC,\u000a      Fowkes FGR, Greenhalgh RM, Ruckley CV, Thompson SG). Long-term outcomes of\u000a      immediate repair compared with surveillance for small abdominal aortic\u000a      aneurysms. New England Journal of Medicine 2002; 346:\u000a      1445-1452. 249 citations\u000a    \u000a\u000a5. UK EVAR Trial Investigators (Greenhalgh RM, Brown LC, Powell JT,\u000a      Thompson SG, Epstein D). Endovascular versus open repair of abdominal\u000a      aortic aneurysm. New England Journal of Medicine 2010; 362;\u000a      1863-1871. 253 citations\u000a    \u000a\u000a6. RESCAN Collaborators (Bown MJ, Sweeting MJ, Brown LC, Powell JT,\u000a      Thompson SG). Surveillance intervals for small abdominal aortic aneurysms:\u000a      a meta-analysis. Journal of the American Medical Association 2013;\u000a      309: 806-813.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    \u000a      UK National Screening Committee statement on AAA screening: AAA policy\u000a        review summary, November 2005: http:\/\/www.screening.nhs.uk\/aaa\u000a        [accessed 2 Sept 2013] The screening committee's guidance (see \"Related\u000a        documents AAA policy review summary\" on this website cites the work\u000a        described above as the `major MRC sponsored trial of screening')\u000a      BBC News website: Men to get aneurysm screening, 5 January 2008:\u000a        http:\/\/news.bbc.co.uk\/1\/hi\/health\/7172094.stm\u000a        [accessed 14 Aug 2013]\u000a      NHS Abdominal Aortic Aneurysm Screening Programme (NAAASP) main\u000a        website:\u000a        http:\/\/www.aaa.screening.nhs.uk,\u000a        and most recent progress report for 2011-12 (Summary and Data): http:\/\/aaa.screening.nhs.uk\/annualreport\u000a        [accessed 14 Aug 2013]\u000a      Statement on NHS AAA Screening Programme's quality criteria for\u000a        elective surgery, June 2010.\u000a        http:\/\/aaa.screening.nhs.uk\/publications\u000a        [accessed 14 Aug 2013]\u000a      Wales Abdominal Aortic Aneurysm Screening Programme:\u000a        http:\/\/www.aaascreening.wales.nhs.uk\/home\u000a        [accessed 14 Aug 2013]\u000a      Scottish Abdominal Aortic Aneurysm Screening Programme:\u000a        http:\/\/www.scotland.gov.uk\/Topics\/Health\/Services\/Screening\/Abdominal-Aortic-Aneurysm\u000a        [accessed 14 Aug 2013]\u000a      Screening for Abdominal Aortic Aneurysm in Sweden, September 2008:\u000a        http:\/\/www.sbu.se\/en\/Published\/Alert\/Screening-for-Abdominal-Aortic-Aneurysm\u000a        [accessed 14 Aug 2013]\u000a      International progress on AAA screening: http:\/\/aaa.screening.nhs.uk\/international-research\u000a        [accessed 14 Aug 2013]\u000a      Stather PW, Dattani N, Bown MJ, Earnshaw JJ, Lees TA. International\u000a        variations in AAA screening. Eur J Vasc Endovasc Surg 2013; 45:\u000a        231-234.\u000a      US Preventive Services Task Force. Screening for abdominal aortic\u000a        aneurysm:\u000a        recommendation statement. Ann Intern Med 2005; 142:\u000a        198-202.\u000a    \u000a    ","Title":"\u000a    A major randomised trial of screening for abdominal aortic aneurysm, and\u000a      initiation of a UK national screening programme.\u000a    ","UKLocation":[{"GeoNamesId":"2653941","Name":"Cambridge"},{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"2641364","Name":"Northern Ireland"},{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Key researchers: Since the year 2000, Professor Simon Thompson\u000a      (Director, MRC Biostatistics Unit (2000-2011), Cambridge, and Professor of\u000a      Biostatistics, Department of Public Health and Primary Care, University of\u000a      Cambridge (2002-present) has been the lead statistician and co-principal\u000a      investigator of the Multicentre Aneurysm Screening Study randomised trial,\u000a      described below, and became the trial's principal investigator in 2005.\u000a      Under his supervision, Dr Lois Kim (early career researcher 2001-07)\u000a      undertook analyses of the accumulating data from the trial for its main\u000a      publications, developed a detailed health economic model so that long-term\u000a      cost-effectiveness could be estimated, and contributed to a variety of\u000a      related projects. Thompson was the lead applicant on grants (funded by\u000a      MRC) to extend the follow-up of the trial's participants from the initial\u000a      4 years to 13 years of follow-up. For the other studies mentioned below,\u000a      Thompson was the lead statistician and co-investigator in the national\u000a      trials of treatment of AAA (funded by MRC and NIHR HTA), and the principal\u000a      investigator of the international RESCAN Collaboration which aimed to\u000a      provide a better evidence-base for the choice of small AAA surveillance\u000a      intervals (funded by NIHR HTA). In Cambridge, Thompson supervised Lu Gao,\u000a      Anthony Brady and Dr Michael Sweeting for these studies.\u000a    Research undertaken: Uncertainty over the potential benefits of\u000a      screening for AAA in the 1990s led to the initiation of the UK Multicentre\u000a      Aneurysm Screening Study (MASS, started in 1997 with follow-up until\u000a      2013). This randomised trial recruited a population-based sample of 68,770\u000a      men aged 65-74, randomised to either invitation to ultrasound screening\u000a      (with surveillance follow-up for small AAAs detected, and surgical\u000a      intervention for large AAAs) or no invitation to screening. The University\u000a      of Cambridge led the trial's protocol development, its randomisation, data\u000a      management and patient recall systems, and supervision of statistical\u000a      analyses. MASS remains the largest trial that has been conducted to date,\u000a      and together with crucial long-term follow-up data has provided the\u000a      majority of the worldwide randomised evidence on the benefit of AAA\u000a      screening. Of the men invited, 80% attended screening, and 5% of these had\u000a      a latent AAA detected. The early results at 4 years of follow-up showed\u000a      that invitation to AAA screening led to a halving of AAA-related mortality\u000a      (relative risk reduction 42% amongst those invited, 53% amongst those\u000a      attending), as well as a halving of non-fatal AAA ruptures [research ref\u000a      1, Cambridge authors Day, Kim, Thompson, Walker]. This impressive\u000a      reduction resulting from invitation to once-only screening was maintained\u000a      in the longer term, despite some increase in the rate of AAA ruptures\u000a      during the later years in those originally screened as normal [research\u000a      ref 2, Cambridge authors Thompson, Gao]. In a linked health economic\u000a      assessment, it was shown that offering AAA screening to 65-year old men\u000a      was likely to be highly cost-effective in the long-term, with an estimated\u000a      cost of &#163;2970 per quality-adjusted year of life gained [research ref 3,\u000a      Cambridge authors Kim, Thompson].\u000a    Additional research to optimise impact: To underpin policy on\u000a      screening and treatment of AAA, Thompson and colleagues conducted large\u000a      nationally-based UK randomised trials to compare: (i) surveillance versus\u000a      early surgery for small AAAs based on 1090 patients recruited in 1991-95\u000a      and followed up until 2005 [research ref 4, Cambridge authors Brady,\u000a      Thompson], and (ii) open surgery versus endovascular aneurysm repair\u000a      (EVAR) for large AAAs amongst 1252 patients recruited in 1999-2004 and\u000a      followed up until 2009 [research ref 5, Cambridge author Thompson]. In the\u000a      RESCAN Collaboration, Thompson and colleagues also collated individual\u000a      longitudinal data on small AAA growth and rupture for 15,000 patients from\u000a      18 studies in different countries, with up to 8 years of follow-up, and\u000a      undertook a detailed individual patient data meta-analysis in order to\u000a      refine the choice of surveillance intervals [research ref 6, Cambridge\u000a      authors Sweeting, Thompson].\u000a    "},{"CaseStudyId":"19668","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Economic and Social Research Council","Medical Research Council"],"ImpactDetails":"\u000d    The impact of CFAS on policy, service and society can be seen widely,\u000d      e.g. through citations in policy documents, clinical guidance and the\u000d      quoting of findings in public discourse.\u000d    Epidemiology of dementia\u000d    \u000d       CFAS provided the core prevalence estimates for dementia in the UK\u000d        population in Dementia UK (2007), e.g. \"In terms both of sample size\u000d          and scope the evidence base is dominated by the Medical Research\u000d          Council Cognitive Function and Ageing Study\" (page 10, reference\u000d        1, section 5). These estimates remain those used nationally, though they\u000d        may in time be modified by Professor Brayne's most recent work which\u000d        includes a 20 year intergenerational comparison on prevalence in three\u000d        CFAS areas holding methods steady (Matthews et al Lancet. 2013 Jul 17)\u000d       The Dementia UK report for the Alzheimer's Society was instrumental\u000d        in bringing the weight of CFAS evidence into the 2009 National Dementia\u000d        Strategy, e.g. \"Key data for the UK as a whole include the following:\u000d          There are approximately 700,000 people with dementia; In just 30\u000d          years, the number of people with dementia is expected to double to 1.4\u000d          million; The national cost of dementia is about &#163;17 billion per year...\",\u000a        DoH (2009) Living well with Dementia: A National Dementia Strategy. p16.\u000d        (Figures from research ref 1). See section 5, nos 1 and 2.\u000d       The UK End of Life Care Strategy 2008 used our institutional data\u000d        which showed Dementia clearly to be a core business of care homes. See\u000d        section 5, no 3.\u000d       Increased investment in dementia research. The 2012 announcement of a\u000d        boost to funding for dementia research by the Secretary of State for\u000d        Health and the Prime Minister's progress report on his `dementia\u000d        challenge' November 2012, quoted the Dementia UK 2007 projected\u000d        prevalence figures, (research refs 1 and 3). See section 5 no 2.\u000d       Professional guidelines were influenced by baseline data on the\u000d        ageing population over 65, e.g. Good Practice Guidance for\u000d          Commissioning Interventions for people with dementia (DH 2011).\u000d        (research refs 1, 3, 4) See section 5, no 11.\u000d       Research findings also now underpin practical tools for strategic\u000d        planning and commissioning services. The CFAS prevalence data is the\u000d        driver of the 2012 Dementia Prevalence Calculator - a tool for\u000d        General Practices and Commissioners to better understand local dementia\u000d        prevalence in the community and care homes. (Research ref 1). See\u000d        section 5, no 10.\u000d       Modelling of long term care and costs has made a significant\u000d        contribution to the debate around the funding of long term care for the\u000d        ageing population (research ref 4). The clear economic case made for\u000d        better supporting dementia patients and carers was picked up by the\u000d        Wanless social care review in 2006, (\"The MRC CFAS data provides a\u000d          detailed breakdown of the level of demand that people with dementia\u000d          living outside institutions present to the social care system\"\u000d        p166. Section 5, no 4) which fed a debate that continued into the Dilnot\u000d        Commission review (2011) and the 2012 White Paper on Social Care.\u000d    \u000d    CFAS has also contributed additional knowledge (e.g. on risk factors,\u000d      disease progression, disability and recovery, depression, and\u000d      neuropathology), with the following impacts:\u000d    \u000d       New knowledge identifying the complexity of cognitive decline and\u000d        ageing (research refs 2 &amp; 5) raised awareness of the need to better\u000d        understand risk, cumulative risk, and vascular risk: e.g. \"mixed\u000d          pathology was the most common finding at autopsy in the brains of\u000d          older people\" (MRC\/CFAS) (section 5, no 8) This knowledge had an\u000d        important impact on the `pharma' view, influencing prevention work and\u000d        clinical trials that thereafter could no longer assume that any one drug\u000d        suits all dementia sufferers, and contributing to a new MRC call for a\u000d        Fresh Approach to Dementia.. (Section 5, no 8)\u000d       Professor Brayne's research has directly influenced a NICE guideline\u000d        on dementia. (CG42: Supporting people with dementia and their carers' in\u000d        health and social care) Estimates based on the improved understanding of\u000d        neuropathology and dementia drove work for the 2009 NICE Final Appraisal\u000d        Determination on donepezil, galantamine, rivastigmine and memantine for\u000d        the treatment of Alzheimer's disease, which led to the amended\u000d        guideline. (NICE technology appraisal guidance 217. See Section 5, no 9)\u000d       CFAS research outcomes are influencing policy beyond the UK, e.g.\u000d        findings on dementia sub-types have been incorporated into WHO policy\u000d        (Dementia: a public health priority. WHO and ADI, 2012. See section 5,\u000d        #6, p19), and a 2012 Research Review forming the foundation for\u000d        Ireland's developing National Dementia Strategy (see section 5, no 7,\u000d        p42).\u000d       Public awareness and involvement in research has increased in a very\u000d        real sense - in the numbers of `CFAS brains' donated to its Bioresource,\u000d        as well as dissemination efforts to increase awareness of brain banking.\u000d        BBC News and The Culture Show covered an innovative exhibition in\u000d        London, 2011: `Mind Over Matter' was based on portraits and life stories\u000d        of donors from the Cambridge longitudinal studies. The Science Museum's\u000d        Dana centre held a parallel debate, with Professor Brayne presenting\u000d        aspects of the neuropathological research, on the ethics and practice of\u000d        brain donation for research. (section 5, no12).\u000d    \u000d    ","ImpactSummary":"\u000d    Research by Professor Carol Brayne, has led to increased understanding\u000d      and awareness of dementia as a key public health issue of our time.\u000d      Outcomes of her DH\/MRC funded longitudinal Cognitive Function and Ageing\u000d      Studies (CFAS) have contributed to national and international health\u000d      policy on dementia as well as public debate.\u000d    Specifically, the CFAS study provided evidence that was used in the\u000d      highly influential report \"Dementia UK\" which led to the development of\u000d      the 2009 National Dementia Strategy. Results from CFAS have increased\u000d      healthcare workers' understanding of the condition, such as the complexity\u000d      of cognitive impairment and the relationship between illness and\u000d      disability.\u000d    ","ImpactType":"Health","Institution":"\u000d    University of Cambridge\u000d    ","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"A         ","PlaceName":[],"References":"\u000d    \u000a1. Cognitive function and dementia in six areas of England and\u000d      Wales: the distribution of MMSE and Prevalence of GMS organicity level in\u000d      the MRC CFA Study. MRC CFAS. Psychological Medicine 28(2):319-335\u000d      (1998).\u000d    \u000a\u000a2. Pathological correlates of late-onset dementia in a\u000d      multicentre, community-based population in England and Wales. Esiri M;\u000d      Matthews FE; Brayne C; Ince PG; Neuropathology Group. MRC\/CFAS. Lancet\u000d      357:169-175 (2001).\u000d    \u000a\u000a3. Dementia before death in ageing societies - The promise of\u000d      prevention and the reality. Brayne C; Gao L; Dewey M; Matthews FE; MRC\u000d      CFAS. PLoS Medicine 3(10):1922-1930 (2006).\u000d    \u000a\u000a4. Cognitive impairment in older people: future demand for\u000d      long-term care services and the associated costs. Comas-Herrera A,\u000d      Wittenberg R, Pickard L, and Knapp M. International Journal of\u000d        Geriatric Psychiatry 22(10):1037-1045 (2007)\u000d    \u000a\u000a5. Age, neuropathology and dementia. Savva G, Wharton S, Ince P,\u000d      Forser G, Matthews F, Brayne C. For the MRC CFAS. N Eng J Med\u000d      360(22):2302-2309 (2009)\u000d    \u000a\u000a6. Risk factors for incident dementia in England and Wales: The\u000d      Medical Research Council Cognitive Function and Ageing Study. A\u000d      population-based nested case-control study. Yip A; Brayne C; Matthews FE.\u000d      Age and Ageing 35: 154-160 (2006);\u000d    \u000aGrants which supported CFAS:\u000d    CFAS I: MRC G9901400 (ended 2012) CFAS renewal grant &#163;836,100 2005-2011\u000d    CFAS II: MRC G0601022 - &#163;2,014,172 (2008-2013)\u000d    Subcontract to Cambridge University to provide the administrative support\u000d      to Bangor University\u000d    (CFAS Wales) : ESRC 2010-2015 RG60916 - &#163;404,627.88\u000d    Sheffield (Neuropathology): RG57915 - &#163;256,237.00 (the Cambridge part of\u000d      the main grant) 01\/02\/2010 - 31\/01\/2014\u000d    In addition, the Brain Banking for MRC CFAS is supported in part by\u000d      grants for the Newcastle and Cambridge NIHR Biomedical Research Centres.\u000d    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000d    Policy\u000d    \u000d       Dementia UK: the full report. A report to the Alzheimer's Society by\u000d        Kings College London and the London School of Economics (2007). This\u000d        report was instrumental in bringing the weight of CFAS evidence into the\u000d        2009 National Dementia Strategy, and consequently, current\u000d        implementation of policies on dementia.\u000d        http:\/\/alzheimers.org.uk\/site\/scripts\/download_info.php?fileID=2\u000a\u000d       Living well with dementia: a National Dementia Strategy, DoH (2009).\u000d        Quotes both Dementia UK (pp16, 34, 77, 94) and analysis on long term\u000d        care costs which were grounded in CFAS data (p16).\u000d       The EOLC Strategy. Promoting high quality care for all adults at the\u000d        end of life, DoH (2008).\u000d       Wanless D et al (2006) Wanless social care review: securing good\u000d          care for older people, taking a long-term view. King's Fund,\u000d        London. CFAS data used in modelling predictions of disability, death and\u000d        need for long term care (p39, p165), prevalence of cognitive impairment\u000d        and combined disability in care homes, and in anticipating the level of\u000d        demand for social care and informal care (p166). This fed a debate on\u000d        provision of and funding for long term care that continued into the\u000d        Dilnot Commission review (2011) and the 2012 White Paper on Social Care.\u000d       Deaths from Alzheimer's disease, dementia and senility in England.\u000d        National end of life Intelligence Network, (2010)\u000d       Dementia: a public health priority. WHO and ADI 2012.\u000d        http:\/\/www.who.int\/mental_health\/publications\/dementia_report_2012\/en\/\u000a\u000d       Creating Excellence in dementia care: A research review for Ireland's\u000d        National Dementia Strategy, Cahill S, O'Shea O, Pierce M. (2012).\u000d        http:\/\/www.dohc.ie\/consultations\/closed\/dementiastrategy\/\u000a\u000d       http:\/\/www.mrc.ac.uk\/Fundingopportunities\/Calls\/dementia2013\/MRC008995\u000a\u000d    \u000d    Service \u000d    \u000d       NICE Final appraisal determination 2009. Donepezil, galantamine,\u000d        rivastigmine (review) and memantine for the treatment of Alzheimer's\u000d        disease (amended). (NICE technical report on the economic analyses\u000d        resulting from further analyses by the MRC Biostatistics Unit. Also the\u000d        mixed pathology findings (Research ref #2) were incorporated into NICE\u000d        Clinical Guidance (CG42) Dementia: Full Guideline.\u000d        http:\/\/guidance.nice.org.uk\/CG42\/NICEGuidance\/pdf\/English\u000a\u000d       The Dementia Prevalence Calculator 2012 (depends on CFAS data\u000d        (Dementia UK 2007)):\u000d        http:\/\/www.dementiapartnerships.org.uk\/diagnosis\/dementia-prevalence-calculator\/\u000d        (N.B. No data on usage of the tool currently exists).\u000d       www.bbc.co.uk\/news\/health-15200246\u000a\u000d       www.danacentre.org.uk\/events\/2011\/10\/06\/635Annotations\u000d    \u000d    ","Title":"\u000d    Dementia Research: The MRC Cognitive Functioning and Ageing Study (CFAS)\u000d    ","UKLocation":[{"GeoNamesId":"2653941","Name":"Cambridge"},{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d    Research setting: Since 1999, this multicentre longitudinal study\u000d      has been led by Professor Brayne in the Department of Public Health and\u000d      Primary Care (tenure since 1991).\u000d    Research group: Professor Brayne leads the CFAS research group\u000d      with national and international collaborators. The support of the MRC\u000d      Biostatistics Unit has been pivotal in providing rigorous statistical and\u000d      innovative methodology to support the diverse outputs from CFAS (&gt;220\u000d      peer reviewed publications to date).\u000d    Study rationale, and underpinning data and methodsM: Prior to\u000d      CFAS, there was limited representative evidence on the incidence and\u000d      prevalence of dementia in the UK population. In CFAS, survey methods have\u000d      measured prevalence and incidence of dementia in the UK population, and\u000d      have been applied to generate population representative findings for\u000d      detailed neuropathology and molecular analyses. CFAS is a longitudinal\u000d      study, with 18,000 subjects recruited at baseline in 1989\/1991, and new\u000d      generation studies (CFAS II) and CFAS Wales) which began in 2008 to test\u000d      differences in prevalence across the two decades. CFAS I subjects have\u000d      been surveyed at least three times since initial interview (in 1994, 1997\u000d      and 2001) and in CFAS II at two years, with continued follow up of those\u000d      from CFAS I consenting to brain donation. To date, 47,000 interviews have\u000d      taken place using standardised assessment for health, dementia, and\u000d      measures of health and social care services utilisation. There are\u000d      currently more than 560 brain donations from study participants.\u000d    Key findings and outcomes of the research include the following:\u000d    \u000d       Dementia prevalence. Before CFAS there were no population\u000d        figures which could be confidently applied nationally and to specific\u000d        geographical areas. CFAS showed that dementia is common, more prevalent\u000d        than previously thought (overall prevalence of dementia in the 65+\u000d        population, 6.6%), and increases as the population ages (prevalence in\u000d        the 85-89 population, 25.3%). Differences were tested across six sites,\u000d        enabling estimates to be made for different parts of the UK as well as\u000d        for the institutional care population. (Section 3. Research ref 1 and 3)\u000d       Care utilisation and cost. The study demonstrated the high\u000d        cost of informal care in supporting people with dementia, which was much\u000d        greater than previously estimated. The group was also able to predict\u000d        future demand for long term care and likely associated costs. Modelling\u000d        long term care needs and forecasting costs have been invaluable tools\u000d        for policy makers. (Research ref 4)\u000d       Better understanding of neuropathology of dementia\/demonstrating\u000d          complexity of cognitive decline (research refs 2 &amp; 5). CFAS\u000d        has been a major contributor (first brain donated in 1993) to a unique\u000d        population representative brain resource, available to deepen our\u000d        understanding of the neuropathological determinants of dementia.\u000d        Insights from a unique sample of donated brains show no clear thresholds\u000d        of Alzheimer-type and vascular pathology that predicted dementia status,\u000d        challenging conventional dementia diagnostic criteria.\u000d       Features associated with a higher or lower risk of developing\u000d          dementia. CFAS demonstrated a relationship between demographic and\u000d        lifestyle factors and risk of cognitive impairment, including age,\u000d        stroke and Parkinson's disease, and the protective effect of higher\u000d        education and of self-reported `good' or `excellent' health. (research\u000d        ref 5 and 6)\u000d    \u000d    "},{"CaseStudyId":"19671","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000d\u000a    PREDICT is implemented online as a national resource with the web\u000d\u000a      interface being hosted on a NHS web-server at www.predict.nhs.uk.\u000d\u000a      The ~4000 monthly hits on the website indicate clearly the impact of the\u000d\u000a      tool.\u000d\u000a    One of the key decisions in the management of women with early breast\u000d\u000a      cancer is whether or not to offer adjuvant chemotherapy in conjunction\u000d\u000a      with primary surgery and radiotherapy. The key output of PREDICT is the\u000d\u000a      expected absolute reduction in mortality at five and ten years associated\u000d\u000a      with adjuvant chemotherapy.\u000d\u000a    Cambridge Breast Unit (CBU)\u000d\u000a    Until 2010 the CBU estimated absolute benefits of chemotherapy were\u000d\u000a      estimated using Adjuvant! Online. During 2010 and 2011 both PREDICT and\u000d\u000a      Adjuvant! Online were used in parallel.\u000d\u000a    Clinical audit\u000d\u000a    The Cambridge Breast Unit carried out an audit of the first 200 patients\u000d\u000a      discussed when both Adjuvant! Online and PREDICT were used by the\u000d\u000a      multi-disciplinary team [6]. The chemotherapy recommendations that would\u000d\u000a      have been made based on the output from each model were then compared. In\u000d\u000a      163 patients (82 per cent) the chemotherapy decision would have been the\u000d\u000a      same whichever model was used, but a different recommendation would have\u000d\u000a      been made for 37 patients (18 per cent), clearly demonstrating the\u000d\u000a      potential for PREDICT to change clinical practice.\u000d\u000a    Change in practice\u000d\u000a    Since 2012 PREDICT has been the only model used routinely in Cambridge\u000d\u000a      for all patients being discussed at the weekly multi-disciplinary team\u000d\u000a      meeting. The absolute benefit of adjuvant chemotherapy estimated by\u000d\u000a      PREDICT is used to guide the use of adjuvant chemotherapy according to the\u000d\u000a      guideline described in section 2.\u000d\u000a    Other clinical departments in the UK\u000d\u000a    The impact of PREDICT on clinical practice is clearly demonstrated from\u000d\u000a      the extensive use of the web interface (see below). We have had multiple\u000d\u000a      requests from clinicians for the incorporation of additional features\u000d\u000a      indicating that the model is being widely used. Personal communication\u000d\u000a      indicates that PREDICT is used by the multi-disciplinary clinical teams in\u000d\u000a      Belfast, Brighton, Derby, Dundee, Oxford and Sheffield, but the web usage\u000d\u000a      statistics from 2012 suggest that PREDICT is being used widely across the\u000d\u000a      country.\u000d\u000a    Public, Patient Partnership\u000d\u000a    PREDICT has been widely reported in regional and national media including\u000d\u000a      ITV, The Times and The Daily Mail. We have clear evidence that women with\u000d\u000a      breast cancer are using the tool to develop a better understanding of\u000d\u000a      their own risk. This enables them to be fully informed in their discussion\u000d\u000a      with their oncologists about treatment options.\u000d\u000a    Web usage data\u000d\u000a    PREDICT was designed to have a user-friendly interface to help clinicians\u000d\u000a      in making clinical management decisions. Informal feedback from clinicians\u000d\u000a      from both Cambridge and elsewhere has indicated that the interface is easy\u000d\u000a      to use.\u000d\u000a    The number of visits to the web site each month has increased steadily\u000d\u000a      since its launch in January 2011, with 3,266 visits in April 2013.\u000d\u000a\u000d\u000aMonthly web usage statistics for the PREDICT website, Jan 2011-Jul 2013\u000d\u000a\u000d\u000a    There have been 54,600 visits to the web site with 68 per cent of the\u000d\u000a      visits (37,200) being accessed from UK and ten per cent (5,800) from USA.\u000d\u000a      The web site is visited from all over the UK, with London accounting for\u000d\u000a      17 per cent and Cambridge accounting for just 1 per cent of all traffic on\u000d\u000a      the web site.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    PREDICT is a prognostication and treatment benefit tool aimed at aiding\u000d\u000a      the breast cancer multi-disciplinary team in the management of women with\u000d\u000a      early breast cancer. The user-friendly, web-based tool was developed in\u000d\u000a      collaboration with the Cambridge Breast Unit multi-disciplinary team, the\u000d\u000a      Eastern Cancer Registration and Information Centre. Implemented online,\u000d\u000a      PREDICT is hosted on a NHS web-server at www.predict.nhs.uk.\u000d\u000a      Since 2010 PREDICT has been used widely by clinicians throughout the UK\u000d\u000a      and world-wide.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Cambridge\u000d\u000a    ","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence\u000d\u000a      G, Caldas C, Pharoah PD. PREDICT: a new UK prognostic model that predicts\u000d\u000a      survival following surgery for invasive breast cancer. Breast Cancer\u000d\u000a        Res. 2010;12(1):R1.\u000d\u000a    \u000a\u000a2. Wishart GC, Bajdik CD, Azzato EM, Dicks E, Greenberg DC, Rashbass J,\u000d\u000a      Caldas C, Pharoah PD. A population-based validation of the prognostic\u000d\u000a      model PREDICT for early breast cancer. Eur. J. Surg. Oncol.\u000d\u000a      2011;37(5):411-7.\u000d\u000a    \u000a\u000a3. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling\u000d\u000a      J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkila P, Heikkinen T,\u000d\u000a      Nevanlinna H, Akslen LA, Begin LR, Foulkes WD, Couch FJ, Wang X, Cafourek\u000d\u000a      V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha\u000d\u000a      E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross\u000d\u000a      SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF,\u000d\u000a      Garcia-Closas M, Caldas C, Pharoah PD, Huntsman D. Subtyping of breast\u000d\u000a      cancer by immunohistochemistry to investigate a relationship between\u000d\u000a      subtype and short and long term survival: a collaborative analysis of data\u000d\u000a      for 10,159 cases from 12 studies. PLoS Med 2010;7(5):e1000279.\u000d\u000a    \u000a\u000a4. Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M,\u000d\u000a      Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW,\u000d\u000a      Winqvist R, Cross SS, Severi G, Huntsman D, Pylkas K, Ellis I, Nielsen TO,\u000d\u000a      Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows\u000d\u000a      FM, Begin LR, Van't Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A,\u000d\u000a      Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PD. PREDICT\u000d\u000a      Plus: development and validation of a prognostic model for early breast\u000d\u000a      cancer that includes HER2. Br. J. Cancer 2012;107(5):800-7.\u000d\u000a    \u000a\u000a5. Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, Pharoah\u000d\u000a      PD, Caldas C. A Ki67\/BCL2 index based on immunohistochemistry is highly\u000d\u000a      prognostic in ER-positive breast cancer. J. Pathol.\u000d\u000a      2012;226(1):97-107.\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"12","Subject":"Oncology and Carcinogenesis"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    \u000d\u000a      Loh S-W, Rodriguez-Miguelez M, Pharoah P, Wishart G. A\u000d\u000a        comparison of chemotherapy recommendations using the Predict and\u000d\u000a        Adjuvant models. Eur. J. Surg. Oncol. 2011;37(5):S21-S22.\u000d\u000a    \u000d\u000a    Press coverage: see http:\/\/www.predict.nhs.uk\/press.shtml\u000d\u000a      for details.\u000d\u000a    Web usage statistics from Google Analytics at https:\/\/www.google.com\/analytics\u000d\u000a    ","Title":"\u000d\u000a    PREDICT: A prognostication and treatment benefit tool for early breast\u000d\u000a        cancer\u000d\u000a\u000d\u000a\u000d\u000a\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2654710","Name":"Brighton"},{"GeoNamesId":"2651347","Name":"Derby"},{"GeoNamesId":"2655984","Name":"Belfast"},{"GeoNamesId":"2650752","Name":"Dundee"},{"GeoNamesId":"2638077","Name":"Sheffield"},{"GeoNamesId":"2640729","Name":"Oxford"},{"GeoNamesId":"2653941","Name":"Cambridge"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2641364","Name":"Northern Ireland"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The PREDICT model was developed in 2010 jointly by Professor Carlos\u000d\u000a      Caldas (University Professor 2006-present), Professor Paul Pharoah (UOA 2:\u000d\u000a      CR-UK Senior Clinical Research Fellow 1999-2009, University Reader\u000d\u000a      2009-13, University Professor 2013-present) and Dr Elizabeth Azzato\u000d\u000a      (NIH\/Cambridge PhD student 2008-11) in collaboration with Gordon Wishart\u000d\u000a      and the Cambridge Breast Unit multi-disciplinary team.\u000d\u000a    Patients treated in the Cambridge Breast Unit are stratified for adjuvant\u000d\u000a      chemotherapy according to a guideline developed in 2004. This took into\u000d\u000a      account the serious adverse rate for chemotherapy and that \"many\u000d\u000a      physicians consider a cutoff of an additional 3% or more added benefit\u000d\u000a      sufficient to justify recommending treatment\". Thus, for an absolute\u000d\u000a      survival benefit of &lt; 3%, chemotherapy is not recommended, for an\u000d\u000a      absolute survival benefit of 3-5% the benefits and harms are considered\u000d\u000a      equivalent and discussed with the patient, for an absolute benefit of\u000d\u000a      &gt;5% chemotherapy is recommended.\u000d\u000a    Until 2010 the absolute benefits of chemotherapy were estimated using\u000d\u000a      Adjuvant! Online, an online prognostic model developed over a decade ago\u000d\u000a      by an American oncologist (Peter Ravdin). This is based on US data and has\u000d\u000a      not been validated with UK data. Furthermore, Adjuvant! Online does not\u000d\u000a      include several important prognostic variables including mode of detection\u000d\u000a      and molecular biomarkers such as tumour HER2 status. Thus there was a\u000d\u000a      clinical need for an equivalent model, based on and validated using UK\u000d\u000a      data that was flexible and able to incorporate additional prognostic\u000d\u000a      variables.\u000d\u000a    The PREDICT model was based on survival-time data on 5,700 women with\u000d\u000a      early breast cancer treated between 1999 and 2003. These data were\u000d\u000a      obtained through the Eastern Cancer Registration and Information Centre\u000d\u000a      and used to determine the influence of key prognostic variables on\u000d\u000a      survival [1]. The model was then validated using an independent data set\u000d\u000a      from the West Midlands Cancer Intelligence Unit [1]. The PREDICT web\u000d\u000a      interface was developed in 2010 and is hosted by the Eastern Cancer\u000d\u000a      Registration and Information Centre.\u000d\u000a    In order to compare directly the performance of Adjuvant! Online and\u000d\u000a      PREDICT, a second validation of PREDICT was carried out using the same\u000d\u000a      data set. While both models performed well, the breast cancer specific\u000d\u000a      survival calibration for PREDICT was better than that of Adjuvant! Online\u000d\u000a      with similar discrimination [2].\u000d\u000a    In parallel with the PREDICT model development work, Profs Caldas and\u000d\u000a      Pharoah have led a research programme investigating the molecular\u000d\u000a      pathology of breast cancer in collaboration with other groups from the\u000d\u000a      international Breast Cancer Association Consortium (BCAC). This research\u000d\u000a      has enabled further development of PREDICT in response to feedback from\u000d\u000a      clinicians and requests for additional features in the model. In\u000d\u000a      particular, there were many requests to incorporate tumour HER2 and KI67\u000d\u000a      status into the model. Results from one of the BCAC projects were used to\u000d\u000a      enable the incorporation of HER2 into the model [3], with the new PREDICT\u000d\u000a      model being further validated using the British Columbia data set used to\u000d\u000a      validate the original model [4]. More recently, the results from another\u000d\u000a      of our molecular pathology studies has informed the incorporation of\u000d\u000a      tumour KI67 status into the model [5].\u000d\u000a    "},{"CaseStudyId":"19672","Continent":[],"Country":[],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000aThe programme of research addressing strategies for the prevention of type 2 diabetes has had its\u000d\u000aimpact through the publication of NICE Public Health Guidance in 2011 and 2012. The NICE Public\u000d\u000aHealth programme produced two pieces of guidance. The first focussed on the prevention of\u000d\u000aprogression from high risk state to diabetes (NICE guidance. Preventing type 2 diabetes: risk\u000d\u000aidentification and intervention for individuals at high risk. NICE Public Health Guidance 38, 2012,\u000d\u000a(section 5, ref 1). The second guidance examined population and community-level interventions in\u000d\u000ahigh risk groups and the general population (NICE guidance. Preventing type 2 diabetes:\u000d\u000apopulation and community-level interventions in high risk groups and the general population. NICE\u000d\u000aPublic Health Guidance 35, 2011, (section 5, ref 2).\u000d\u000aThe research described in this impact statement is cited in both NICE reports. The guidance on\u000d\u000ainterventions in high risk individuals (section 5 ref 1) focused on two main activities: Identifying\u000d\u000apeople at risk of developing type 2 diabetes using a staged (or stepped) approach using a\u000d\u000avalidated risk-assessment score and a blood test (either the fasting blood glucose or the HbA1c\u000d\u000atest) to confirm high risk and the provision to those at high risk of a quality-assured, evidence-based, intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The\u000d\u000aNICE guidance cites evidence from the EPIC-Norfolk cohort in which the incidence of diabetes by\u000d\u000alevel of HbA1c is described, justifying the category of 6.0-&lt;6.5% as a high risk category in which\u000d\u000athe risk of progression to diabetes is 15 times greater than in those individuals with an HbA1c\u000d\u000a&lt;5.0% (research reference 6). In describing the range of possible validated risk-assessment tools,\u000d\u000athe NICE guidance cites the original paper on the Cambridge Risk Score (research reference 1)\u000d\u000awhich has subsequently been shown not only to predict prevalent undiagnosed diabetes but also\u000d\u000aincident diabetes (research reference 5).\u000d\u000aThe second piece of NICE Public Health Guidance examined strategies for prevention at the\u000d\u000apopulation level. Evidence of the incidence of diabetes in the UK is cited from the paper on the Ely\u000d\u000aStudy by Forouhi et al (research reference 4). The report cites the paper by Simmons et al\u000d\u000a(research reference 2) as the justification for recommending the focus of prevention at the\u000d\u000apopulation level on the same 5 behavioural targets that have been shown to be effective among\u000d\u000athe high risk population. It also cites the analysis in the EPIC-Norfolk study (research reference 3)\u000d\u000awhich demonstrates that although the high risk approach may be effective in the relatively small\u000d\u000agroup of individuals to whom it is targeted, greater public health potential comes from the\u000d\u000aapplication of strategies that attempt to address the same behaviours at the population level.\u000d\u000aThe guidance concludes that when developing national strategy to target non-communicable\u000d\u000adiseases with a major link to diet, physical activity and obesity (for example, type 2 diabetes,\u000d\u000acardiovascular disease, certain cancers), policy makers should consider integrating the strategy\u000d\u000awith other relevant national actions to prevent related non-communicable diseases addressing the\u000d\u000akey risk factors (for example, being overweight or obese, a sedentary lifestyle and an unhealthy\u000d\u000adiet) highlighting the contribution that partners in national and local government, industry,\u000d\u000ahealthcare and the voluntary sector can make by working together to reduce the risk of non-communicable diseases for the population as a whole taking account of variations in different\u000d\u000apopulation subgroups (for example, by ethnicity, age or gender) linking to targets and outcomes for\u000d\u000areducing the key risk factors for type 2 diabetes and other non-communicable diseases.\u000d\u000aThe work on the overall approach to prevention has contributed to strategic discussions beyond\u000d\u000aNICE through Wareham's contribution to the work of the International Diabetes Federation in\u000d\u000aformulating its Global Diabetes Plan 2011-2021 in the run up to the UN summit on non-communicable disease in 2011 (section 5, ref 3). The research into specific risk factors also has\u000d\u000aan impact through dissemination in the public media, with the findings from the large scale pan-European cohort study InterAct led by Wareham (research reference 7) on the association of\u000d\u000asugar-sweetened beverages and incident diabetes (research reference 8), for example, being\u000d\u000awidely discussed and informing public policy debates about actions that might limit consumption\u000d\u000a(section 5, ref 4).\u000d\u000a","ImpactSummary":"\u000d\u000aResearch founded on population-based cohort studies has directly informed NICE Public Health\u000d\u000aguidance on the prevention of diabetes. In prospective studies Wareham and Griffin demonstrated\u000d\u000athat diabetes can be predicted by a simple risk score using routinely available information and by\u000d\u000aHbA1c levels. Although people with a high HbA1c account for 36% of incidence, the majority of\u000d\u000afuture cases emerge from the larger population of people with moderately elevated levels, justifying\u000d\u000aa more population-wide perspective on the prevention of diabetes. The research also showed that\u000d\u000athe same behaviour targets that are effective in high risk individuals are strongly associated with\u000d\u000adiabetes in the wider population.\u000d\u000a","ImpactType":"Health","Institution":"\u000d\u000aUniversity of Cambridge\u000d\u000a","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a\u000a1. Griffin, S. J., P. S. Little, C. N. Hales, A. L. Kinmonth and N. J. Wareham (2000). \"Diabetes\u000d\u000arisk score: towards earlier detection of type 2 diabetes in general practice.\" Diabetes Metab\u000d\u000aRes Rev 16(3): 164-71. PMID: 10867715\u000d\u000a\u000a\u000a2. Simmons, R. K., A. H. Harding, R. W. Jakes, A. Welch, N. J. Wareham and S. J. Griffin\u000d\u000a(2006). \"How much might achievement of diabetes prevention behaviour goals reduce the\u000d\u000aincidence of diabetes if implemented at the population level?\" Diabetologia 49(5): 905-11.\u000d\u000aPMID: 16508778\u000d\u000a\u000a\u000a3. Harding, A. H., S. J. Griffin and N. J. Wareham (2006). \"Population impact of strategies for\u000d\u000aidentifying groups at high risk of type 2 diabetes.\" Prev Med 42(5): 364-8. PMID: 16504278\u000d\u000a\u000a\u000a4. Forouhi, N. G., J. Luan, S. Hennings and N. J. Wareham (2007). \"Incidence of Type 2\u000d\u000adiabetes in England and its association with baseline impaired fasting glucose: the Ely\u000d\u000astudy 1990-2000.\" Diabet Med 24(2): 200-7. PMID: 17257284\u000d\u000a\u000a\u000a5. Rahman, M., R. K. Simmons, A. H. Harding, N. J. Wareham and S. J. Griffin (2008). \"A\u000d\u000asimple risk score identifies individuals at high risk of developing Type 2 diabetes: a\u000d\u000aprospective cohort study.\" Fam Pract 25(3): 191-6. PMID: 18515811\u000d\u000a\u000a\u000a6. Chamnan, P., R. K. Simmons, N. G. Forouhi, R. N. Luben, K. T. Khaw, N. J. Wareham and\u000d\u000aS. J. Griffin (2011). \"Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria\u000d\u000ain the european prospective investigation of cancer-norfolk cohort: implications for\u000d\u000apreventive strategies.\" Diabetes Care 34(4): 950-6. PMID: 20622160\u000d\u000a\u000a\u000a7. Langenberg, C., S. Sharp, N. G. Forouhi, P. W. Franks, M. B. Schulze, N. Kerrison, et al\u000d\u000a(2011). \"Design and cohort description of the InterAct Project: an examination of the\u000d\u000ainteraction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC\u000d\u000aStudy.\" Diabetologia 54(9): 2272-82. PMID: 21717116\u000d\u000a\u000a\u000a8. Romaguera, D., T. Norat, P. Wark, A. Vergnaud, B. Schulze, G. van Woudenbergh et al\u000d\u000a(2013) \"Consumption of sweet beverages and type 2 diabetes incidence in European\u000d\u000aadults: results from EPIC-InterAct\". Diabetologia. 56:1520-30.PMID:23620057\u000d\u000a\u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"}],"Sources":"\u000d\u000a\u000d\u000aNICE guidance. Preventing type 2 diabetes: risk identification and intervention for\u000d\u000aindividuals at high risk. NICE Public Health Guidance 38, 2012.\u000d\u000awww.nice.org.uk\/nicemedia\/live\/13791\/59951\/59951.pdf Research paper 1 quoted on page\u000d\u000a72, Research paper 6 quoted on page 70.\u000d\u000aNICE guidance. Preventing type 2 diabetes: population and community-level interventions\u000d\u000ain high risk groups and the general population. NICE Public Health Guidance 35, 2011\u000d\u000awww.nice.org.uk\/nicemedia\/live\/13472\/54345\/54345.pdf Research reference 2 quoted on\u000d\u000apage 35, Research reference 3 quoted on page 31, Research reference 4 quoted on page\u000d\u000a48.\u000d\u000aThe IDF Global Plan for Diabetes 2011-2021.\u000d\u000ahttp:\/\/www.idf.org\/sites\/default\/files\/Global_Diabetes_Plan_Final.pdf\u000a\u000d\u000aPublic awareness of association of specific risk factors with diabetes incidence from large\u000d\u000ascale studies. E.g. http:\/\/www.dailymail.co.uk\/health\/article-2314353\/Diabetes-danger-just-ONE-sugary-drink-day-Chance-developing-Type-2-increases-fifth.html\u000d\u000a\u000a\u000d\u000a","Title":"\u000d\u000aStrategies for the prevention of type 2 diabetes\u000d\u000a","UKLocation":[{"GeoNamesId":"2653941","Name":"Cambridge"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000aProfessor Wareham (since 1993) and Professor Griffin (since 1999) of the MRC Epidemiology\u000d\u000aUnit, University of Cambridge have established a programme of research based on population-based cohort studies in which diabetes incidence has been ascertained (Forouhi et al,\u000d\u000a2007)(Chamnan et al, 2011)(Langenberg et al, 2011). These cohort studies have been used not\u000d\u000aonly to describe the relationship between aetiological factors and risk of diabetes (e.g. Romaguera\u000d\u000aet al, 2013) but also to address key questions that inform strategies for the prevention of diabetes.\u000d\u000aPrevious randomised controlled trials (RCT) have shown that lifestyle intervention can halve risk of\u000d\u000aprogression to diabetes among people at high risk. However, these explanatory trials are not easily\u000d\u000atranslated into everyday practice and our research has aimed at identifying barriers to successful\u000d\u000atranslation and at potential solutions.\u000d\u000aFirstly, the explanatory RCTs define individuals as being at high risk on the basis of demonstrable\u000d\u000anon-diabetic hyperglycaemia defined using the time consuming oral glucose tolerance test. In\u000d\u000aanalyses using the prospective EPIC-Norfolk cohort study commenced by the University of\u000d\u000aCambridge in 1990 (Principal Investigators Professors Khaw and Wareham), the MRC\u000d\u000aEpidemiology Unit has shown that easily measured risk factors such as family history and obesity\u000d\u000aare strongly predictive of risk and that information on them is readily available in General Practice\u000d\u000anotes. When combined together in a simple risk score, these factors not only predict prevalent\u000d\u000aundiagnosed diabetes (Griffin et al, 2000) but are also predictive of future diabetes (Rahman et al,\u000d\u000a2008). The advantage of this form of pragmatic risk score is that it can be deployed in primary care\u000d\u000awithout the necessity for acquisition of additional information. Thus it can be used as the initial step\u000d\u000ain a combined approach to detect previously undiagnosed diabetes and those at risk of future\u000d\u000adisease in whom additional testing and intervention would be warranted.\u000d\u000aSecondly the Unit has investigated the utility of simpler methods for defining diabetes than can be\u000d\u000aused in place of the time consuming oral glucose tolerance test. The measurement of HbA1c in the\u000d\u000aEPIC-Norfolk study has allowed investigation of its relationship to cardiovascular disease incidence\u000d\u000aand mortality which are part of the argument justifying the change in criteria to allow diabetes to be\u000d\u000adefined on the basis of HbA1c levels. In 2011 the Unit described the incidence of diabetes using\u000d\u000athe new diagnostic criteria showing that individuals with an HbA1c greater than 6.0% but less than\u000d\u000athe threshold for diabetes of 6.5% had a 3 year risk of progression to diabetes of 7 per 100 person\u000d\u000ayears of follow up. 36% of incident cases came from this category, justifying it as a target for\u000d\u000aindividualised preventive interventions (Chamnan et al, 2011).\u000d\u000aFinally the Unit has investigated alternative approaches to prevention. In the Finnish Diabetes\u000d\u000aPrevention program, the achievement of five key behavioural targets (reducing weight, increasing\u000d\u000aphysical activity, reducing total fat, reducing saturated fat and increasing dietary fibre) was strongly\u000d\u000aassociated with a reduction in the risk of developing diabetes. The Unit has shown that the same\u000d\u000atargets were strongly inversely associated with risk in the general population (Simmons et al, 2006)\u000d\u000aand that they should therefore be the main behavioural recommendations for the population as a\u000d\u000awhole, not just for high risk individuals. The Unit also demonstrated that focusing prevention efforts\u000d\u000aonly on individuals at high risk was a less effective strategy than a population-wide approach to\u000d\u000aprevention (Harding et al, 2006).\u000d\u000a"},{"CaseStudyId":"19676","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    The establishment of a suite of instruments by the MRC Epidemiology Unit\u000a      between 1993 and 2010 for measuring physical activity in different\u000a      population groups and settings and the production of an on-line DAPA\u000a      toolkit led by the Unit for the MRC Population Health Sciences Research\u000a      Network in 2011 to facilitate methodological knowledge exchange (1) has\u000a      promoted the use of measurement tools that are fit-for-purpose. For\u000a      example, in its report on Measuring diet and physical activity in weight\u000a      management programme, the National Obesity Observatory cites the DAPA\u000a      toolkit as a source of information on questionnaires (2). It also cites\u000a      validation work on the International Physical Activity Questionnaire\u000a      (IPAQ) (Ekelund et al, Public Health Nutrition 2006), a widely used\u000a      instrument for assessing the prevalence of inactivity which was used\u000a      recently in an analysis of global physical activity levels.\u000a    Although instruments such as IPAQ are useful for surveillance, there was\u000a      a need for a simple quick assessment tool that can be used in primary care\u000a      to identify inactive individuals as part of the assessment of risk. The\u000a      short version of the EPIC-Europe questionnaire that was validated by\u000a      comparison to repeated measures of objectively assessed energy expenditure\u000a      (Wareham et al, Public Health Nutrition 2003) has formed the basis of the\u000a      General Practice Physical Activity Questionnaire (GPPAQ) recommended by\u000a      the Department of Health (3) as a screening tool to be used in routine\u000a      general practice to provide a simple physical activity index. The validity\u000a      of the instrument provides one justification for its use, but the\u000a      Department of Health report also cites the evidence from the Unit's\u000a      research showing that this simple tool independently predicts events such\u000a      as cardiovascular incidence and mortality (Khaw et al, Int J Epidemiol\u000a      2006).\u000a    The MRC Epidemiology Unit's research on physical activity, sedentary\u000a      behaviour and different outcomes has contributed to the recent revision of\u000a      the UK Chief Medical Officers' recommendation on physical activity (4)\u000a      with the work in adults ( Ekelund et al, Am J Clin Nutr 2008) and children\u000a      (Steele et al, Am J Clin Nutr 2009) being cited in the review of the\u000a      current scientific evidence relating sedentary behaviour to obesity (5)\u000a      which was undertaken as part of the work leading to the formulation of the\u000a      new guidelines which place a greater emphasis on the avoidance of\u000a      prolonged periods of sedentary time.\u000a    A number of pieces of NICE Public Health guidance have emerged over the\u000a      past 5 years aimed at describing the effectiveness of different approaches\u000a      to promoting physical activity. The NICE Public Health Guidance (6) on\u000a      physical activity and the environment cites the Unit's analysis of\u000a      temporal trends in physical activity in the United Kingdom (Stamatakis et\u000a      al, 2007). The more recent guidance on promoting walking and cycling (7)\u000a      cites the Unit's systematic review of interventions to promote cycling\u000a      (Yang et al, BMJ 2010) in the supporting evidence for the guidance\u000a      including Expert Testimony Paper 5 &#8212;Programmes to promote cycling. The\u000a      recommendations for future research in this guidance draw heaving on\u000a      Expert Testimony Paper 3 which cites multiple publications from CEDAR to\u000a      demonstrate an approach to the evaluation of infrastructure developments\u000a      which have the potential to integrated walking and cycling into people's\u000a      daily routines. This includes the evaluation of interventions such as\u000a      CONNECT2, a SUSTRANS project funded by the Big Lottery Fund to transform\u000a      everyday travel for local people in communities across the UK, creating\u000a      new bridges and crossings to overcome busy roads, rivers and railways, and\u000a      linking these to networks of walking and cycling routes, making it easier\u000a      for millions of people to walk and cycle for everyday journeys (8).\u000a    Evaluations of this type are able to demonstrate impact of overall and\u000a      domain-specific physical activity levels but are unlikely to be able to\u000a      demonstrate an impact on health outcomes, which need to be modelled rather\u000a      than directly observed (Jarrett et al, Lancet 2012). The papers describing\u000a      the results of these models have contributed to analyses not only of the\u000a      benefits of promoting physical activity on health outcomes but are cited\u000a      in more extensive analyses of the health effects of climate change (9)\u000a      since physical activity, transportation, energy use, pollution and climate\u000a      change are closely linked issues.\u000a    ","ImpactSummary":"\u000a    Physical inactivity is strongly related to coronary heart disease, type 2\u000a      diabetes, osteoporosis and some cancers. Research at the University of\u000a      Cambridge has focused on the development and validation of methods for\u000a      assessing physical activity in population studies and on the application\u000a      of these methods to quantify the type and dose of physical activity that\u000a      is important for different health outcomes. This research has contributed\u000a      to development of public health guidelines. Research into the determinants\u000a      of activity levels in different population groups and the evaluation of\u000a      interventions aimed at individuals and the wider population has\u000a      contributed to NICE guidance on different forms of interventions to\u000a      increase physical activity.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Cambridge\u000a    ","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Ekelund, U., H. Sepp, S. Brage, W. Becker, R. Jakes, M. Hennings and\u000a      N. J. Wareham (2006). \"Criterion-related validity of the last 7-day, short\u000a      form of the International Physical Activity Questionnaire in Swedish\u000a      adults.\" Public Health Nutr 9(2): 258-65. PMID:\u000a      16571181\u000a    \u000a\u000a2. Wareham, N. J., R. W. Jakes, K. L. Rennie, J. Schuit, J. Mitchell, S.\u000a      Hennings and N. E. Day (2003). \"Validity and repeatability of a simple\u000a      index derived from the short physical activity questionnaire used in the\u000a      European Prospective Investigation into Cancer and Nutrition (EPIC)\u000a      study.\" Public Health Nutr 6(4): 407-13. PMID:\u000a      12795830\u000a    \u000a\u000a3. Stamatakis, E., U. Ekelund and N. J. Wareham (2007). \"Temporal trends\u000a      in physical activity in England: the Health Survey for England 1991 to\u000a      2004.\" Prev Med 45(6): 416-23. PMID: 17316777\u000a    \u000a\u000a4. Khaw, K. T., R. Jakes, S. Bingham, A. Welch, R. Luben, N. Day and N.\u000a      Wareham (2006). \"Work and leisure time physical activity assessed using a\u000a      simple, pragmatic, validated questionnaire and incident cardiovascular\u000a      disease and all-cause mortality in men and women: The European Prospective\u000a      Investigation into Cancer in Norfolk prospective population study.\" Int\u000a        J Epidemiol 35(4): 1034-43. PMID: 16709620\u000a    \u000a\u000a5. Ekelund, U., S. Brage, H. Besson, S. Sharp and N. J. Wareham (2008).\u000a      \"Time spent being sedentary and weight gain in healthy adults: reverse or\u000a      bidirectional causality?\" Am J Clin Nutr 88(3): 612-7. PMID:\u000a      18779275\u000a    \u000a\u000a6. Steele RM, van Sluijs EM, Cassidy A, Griffin SJ, Ekelund U\u000a      (2009).Targeting sedentary time or moderate- and vigorous-intensity\u000a      activity: independent relations with adiposity in a population-based\u000a      sample of 10-y-old British children. Am J Clin Nutr. 90 (5):\u000a      1185-92. PMID: 19776141\u000a    \u000a\u000a7. Yang L, Sahlqvist S, McMinn A, Griffin SJ, Ogilvie D (2010). BMJ. 341:c5293\u000a      PMID 20959282\u000a    \u000a\u000a8. Jarrett J, Woodcock J, Griffiths UK, Chalabi Z, Edwards P, Roberts I,\u000a      Haines A (2012). Effect of increasing active travel in urban England and\u000a      Wales on costs to the National Health Service. Lancet. 379(9832):2198-205.\u000a      PMID 22682466\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    \u000a      Diet and physical activity toolkit. The Medical Research Council. http:\/\/www.dapa-toolkit.mrc.ac.uk\/\u000a        (Last accessed 5th September 2013).\u000a      Measuring diet and physical activity in weight management programmes.\u000a        National Obesity Observatory.\u000a        http:\/\/www.noo.org.uk\/uploads\/doc\/vid_10414_Assessment%20Tools%20160311%20FINAL%20MG.pdf\u000a\u000a      General Practice Physical Activity Questionnaire. Department of\u000a        Health.\u000a        https:\/\/www.gov.uk\/government\/publications\/general-practice-physical-activity-questionnaire-gppaq\u000a\u000a      UK Physical Activity Guidelines. Department of Health. Sedentary\u000a        Behaviour and Obesity. Review of the current scientific evidence.\u000a        Department of Health.\u000a        https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/213745\/dh_128225.pdf\u000a\u000a      Physical activity and the Environment. NICE.\u000a        http:\/\/www.nice.org.uk\/nicemedia\/live\/11917\/38983\/38983.pdf\u000a\u000a      Walking and cycling: local measures to promote walking and cycling as\u000a        forms of travel or recreation. NICE. http:\/\/www.nice.org.uk\/nicemedia\/live\/13428\/58979\/58979.pdf\u000a        and http:\/\/www.nice.org.uk\/nicemedia\/live\/13428\/58977\/58977.pdf\u000a\u000a      Working with the research community. SUSTRANS. http:\/\/www.sustrans.org.uk\/our-services\/who-we-work\/researchers\u000a\u000a      Health effects of climate change in the UK 2012. Public Health\u000a        England. http:\/\/www.hpa.org.uk\/hecc2012\u000a\u000a    \u000a    ","Title":"\u000a    The epidemiology and promotion of physical activity\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The MRC Epidemiology Unit has a long standing programme in the\u000a      development and validation of methods for assessing physical activity in\u000a      population studies led by Professor Wareham (since 1993) and, Drs Ekelund\u000a      and Brage (since 2003). These methods include subjective and objective\u000a      approaches which can be used in different settings, different population\u000a      groups and for different purposes. These purposes include the descriptive\u000a      epidemiology of physical activity (1), aetiological investigation of the\u000a      association between activity and health outcomes, assessment of activity\u000a      as part of risk stratification (2) and measurement of activity change in\u000a      intervention studies. Between 1993 and 2010, the Unit has developed and\u000a      validated a suite of instruments that are fit for purpose, has published\u000a      validation studies (e.g. 1,2) and made the methods widely available by\u000a      leading the development in 2011 of an on-line Diet and Physical Activity\u000a      (DAPA) toolkit which enables researchers to identify the most suitable\u000a      instrument for their particular study and to access all the necessary\u000a      elements of the measurement instrument to allow them to use it\u000a      independently. The Unit has contributed to understanding temporal trends\u000a      in physical activity in the United Kingdom (3) and geographical variations\u000a      in prevalence of inactivity globally. It has assessed the association in\u000a      large-scale cohort studies between overall physical activity, different\u000a      domains and different intensities on chronic disease outcomes including\u000a      all-cause mortality, cardiovascular disease incidence (4), type 2 diabetes\u000a      and cancers. Research using objective measurement of physical activity in\u000a      cohort studies of adults and children has contributed to understanding of\u000a      the direction and quantification of the relationship between different\u000a      intensities of physical activity, sedentary behaviour and obesity and\u000a      metabolic disease (5,6).\u000a    These results have contributed to recommendations for physical activity\u000a      in the UK including recent refinements to focus not only on achieving 5 x\u000a      30 minute bouts of moderate to vigorous activity per week, but also to aim\u000a      to increase overall activity through whatever means and to diminish\u000a      sedentary behaviour. The studies have also informed the target of trials\u000a      to evaluate individualistic approaches to promoting physical activity. The\u000a      limited effectiveness of such individual approaches has led to investment\u000a      in research on understanding the wider population determinants of physical\u000a      activity, the effectiveness of planned and natural experimental\u000a      interventions that impact on physical activity levels (7) and the\u000a      estimation of the long term health benefits of changing activity (8). This\u000a      research has been led by the Cambridge UKCRC-funded Centre of Public\u000a      Health Research Excellence on Diet and Activity (CEDAR).\u000a    "},{"CaseStudyId":"19680","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Nature of impact Publications from the ERFC have been cited by 9\u000d\u000a      guideline statements:\u000d\u000a    2010: European Atherosclerosis Society (EAS) Consensus Panel on\u000d\u000a      lipoprotein(a) in cardiovascular disease.\u000d\u000a    2010: American College of Cardiology Foundation \/ American Heart\u000d\u000a      Association (ACCF \/ AHA) guideline for assessment of cardiovascular risk\u000d\u000a      in asymptomatic adults\u000d\u000a    2011: European Society of Cardiology and European Atherosclerosis Society\u000d\u000a      (ESC \/ EAS) Guidelines for the management of dyslipidaemias\u000d\u000a    2011: American Heart Association statement on Triglycerides and\u000d\u000a      cardiovascular disease\u000d\u000a    2011: American Association of Clinical Endocrinologists Medical\u000d\u000a      Guidelines for Clinical Practice for developing a diabetes mellitus\u000d\u000a      comprehensive care plan\u000d\u000a    2011: US National Lipid Association expert advice\u000d\u000a    2012: Canadian Cardiovascular Society Guidelines for the Diagnosis and\u000d\u000a      Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in\u000d\u000a      the Adult\u000d\u000a    2012: European Society of Cardiology (ESC) and Other Societies Guidelines\u000d\u000a      on cardiovascular disease prevention in clinical practice\u000d\u000a    2012: Evaluation and treatment of hypertriglyceridemia: an Endocrine\u000d\u000a      Society clinical practice guideline.\u000d\u000a      Specific impact\u000d\u000a    1. Major lipids [Research Refs #1 and #2]\u000d\u000a    Findings: The ERFC reported that lipid assessment can be greatly\u000d\u000a      simplified by measurement of HDL-cholesterol and total cholesterol without\u000d\u000a      the need to fast and without regard to triglyceride (Research Ref #1),\u000d\u000a      with major implications for screening millions of adults. The same report\u000d\u000a      demonstrated that measurement of apolipoproteins A and B provides similar\u000d\u000a      information about CVD risk as does assessment of conventional lipid\u000d\u000a      fractions. The ERFC reported that large-scale human biomarker and genetic\u000d\u000a      evidence is consistent with a causal association of triglyceride-related\u000d\u000a      pathways in CVD (Research Ref #2).\u000d\u000a      Impact on guidelines: The ERFC paper on major lipids has been cited\u000d\u000a      in the 2011 ESC \/ EAS Guidelines for the management of dyslipidaemias\u000d\u000a      [Impact Ref #1: footnote number 42], in the 2012 ESC Guidelines [Impact\u000d\u000a      Ref #2: footnote number 52], the 2011 American Association of Clinical\u000d\u000a      Endocrinologists Medical Guidelines [Impact Ref #4: footnote number 359],\u000d\u000a      and the 2011 AHA Statement on triglycerides and CVD [Impact Ref #5:\u000d\u000a      footnote number 17].\u000d\u000a      The ERFC publication on the causal relevance of triglyceride-related\u000d\u000a      pathways to CVD (Research Ref #2) has been cited in the following\u000d\u000a      guidelines to support diagnosis and treatment of hypertriglyceridaemia:\u000d\u000a      the 2012 Endocrine Society Clinical Practice Guideline [Impact Ref #3:\u000d\u000a      footnote number 9], the 2011 ESC \/ EAS Guidelines for the management of\u000d\u000a      dyslipidaemias [Impact Ref #1: footnote number 121], and the 2011 AHA\u000d\u000a      Statement on triglycerides and CVD [Impact Ref #5: footnote number 98].\u000d\u000a    2. Lipoproteins [Research Refs #3 and #4]\u000d\u000a    Findings: The ERFC reported that lipoprotein(a) is specifically,\u000d\u000a      continuously and independently associated with CVD in a manner consistent\u000d\u000a      with causality (Research Ref #3). The LpPLA2 Studies Collaboration\u000d\u000a      publication has reported that lipoprotein-associated phospholipase A2 is\u000d\u000a      log-linearly associated with risk of CVD (independent of established\u000d\u000a      lipids), with a similar magnitude of association as for LDL-cholesterol\u000d\u000a      (Research Ref #4).\u000d\u000a      Impact on guidelines: The ERFC paper on lipoprotein(a) has been\u000d\u000a      cited in the following four guidelines to support assessment of Lp(a) in\u000d\u000a      practice: the 2010 EAS Consensus Panel [Impact Ref #6: footnote number 3],\u000d\u000a      the 2011 ESC \/ EAS Guidelines for the management of dyslipidaemias [Impact\u000d\u000a      Ref #1: footnote number 49], the 2012 Canadian Cardiovascular Society\u000d\u000a      Guidelines [Impact Ref #7: footnote number 71], and the 2012 Endocrine\u000d\u000a      society [Impact Ref #3: footnote number 44], and the 2010 ACCF \/ AHA\u000d\u000a      Guidelines [Impact Ref #8: footnote number 102].\u000d\u000a      The Lp-PLA2 Studies Collaboration publication has been cited the 2011\u000d\u000a      National Lipid Association expert advice [Impact Ref #9: footnote number\u000d\u000a      78].\u000d\u000a    3. Inflammation biomarkers [Research Ref #5]\u000d\u000a    Findings: The ERFC reported that assessment of inflammation\u000d\u000a      biomarkers provides only modest improvement in CVD prediction (Research\u000d\u000a      Ref #5).\u000d\u000a      Impact on guidelines: The ERFC paper on inflammation biomarkers has\u000d\u000a      been cited in the following 2 guidelines: the 2011 ESC \/ EAS Guidelines\u000d\u000a      [Impact Ref #2: footnote number 126], the 2012 ESC Guidelines [Impact Ref\u000d\u000a      #2: footnote number 126], and the 2012 Canadian Cardiovascular Society\u000d\u000a      Guidelines [Impact Ref #7: footnote number 72].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The Cambridge-led Emerging Risk Factors Collaboration (ERFC) is a global\u000d\u000a      consortium involving individual-participant data on 2.5 million\u000d\u000a      participants from 130 cohort studies. The ERFC has helped optimise\u000d\u000a      approaches to cardiovascular disease (CVD) risk assessment by: 1)\u000d\u000a      quantifying the incremental predictive value provided by assessment of\u000d\u000a      risk factors 2) evaluating the independence of associations between risk\u000d\u000a      factors and CVD and 3) addressing uncertainties related to the\u000d\u000a      implementation of screening. ERFC publications on lipids, lipoproteins,\u000d\u000a      and inflammation biomarkers have been cited by 9 guidelines published\u000d\u000a      since 2010, including those of the European Society of Cardiology and the\u000d\u000a      American Heart Association.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Cambridge\u000d\u000a    ","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. ERFC: (writing committee: Di Angelantonio E, Sarwar N, Perry\u000d\u000a      P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S,\u000d\u000a      Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J).\u000d\u000a      Major lipids, apolipoproteins, and risk of vascular disease. JAMA\u000d\u000a      2009;302:1993-2000.\u000d\u000a    \u000a\u000a2. The Triglyceride Coronary Disease Genetics Consortium and ERFC:\u000d\u000a      (writing committee: Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di\u000d\u000a        Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ,\u000d\u000a      Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J).\u000a      Triglyceride-mediated pathways and coronary disease: collaborative\u000d\u000a      analysis of 101 studies. Lancet 2010;375:1634-9.\u000d\u000a    \u000a\u000a3. ERFC: (writing committee: Erqou S, Kaptoge S, Perry PL, Di\u000d\u000a        Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson\u000d\u000a        SG, Danesh J). Lipoprotein(a) concentration and the risk of\u000d\u000a      coronary heart disease, stroke, and nonvascular mortality. JAMA\u000d\u000a      2009;302:412-423.\u000d\u000a    \u000a\u000a4. The Lp-PLA2 Studies Collaboration: (writing committee: Thompson A, Gao\u000d\u000a      P*, Orfei L*, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne\u000d\u000a      C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG,\u000d\u000a      Collins R, Danesh J). Lipoprotein-associated phospholipase A2 and\u000d\u000a      risk of coronary disease, stroke and mortality: collaborative analysis of\u000d\u000a      32 prospective studies. Lancet 2010;375:1536-44.\u000d\u000a    \u000a\u000a5. ERFC: (writing committee: Kaptoge S, Di Angelantonio E,\u000d\u000a      Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J).\u000d\u000a      C-reactive protein concentration and risk of coronary heart disease,\u000d\u000a      stroke, and mortality: an individual participant meta-analysis. Lancet\u000d\u000a      2010;375:132-40.\u000d\u000a    \u000a\u000a6. ERFC: (writing committee: Thompson SG, Kaptoge S, White IR, Wood\u000a        AM, Perry PL, Danesh J) Statistical methods for the\u000d\u000a      time-to-event analysis of individual participant data from multiple\u000d\u000a      epidemiological studies. Int J Epidemiol 2010;39:1345-1359.\u000d\u000a    \u000aGrants Professor Danesh is the PI and holder of grants which have\u000d\u000a      supported the ERFC:\u000d\u000a    \u000d\u000a      \u000d\u000a        \u000d\u000a          Emerging risk factors in CVD\u000d\u000a          BHF\u000d\u000a          2003-2008\u000d\u000a          &#163;780K\u000d\u000a        \u000d\u000a        \u000d\u000a          Pooled analyses of CRP\u000d\u000a          BUPA\u000d\u000a          2005-2007\u000d\u000a          &#163;160K\u000d\u000a        \u000d\u000a        \u000d\u000a          Pooled analyses of triglycerides\u000d\u000a          MRC\u000d\u000a          2006-2009\u000d\u000a          &#163;440K\u000d\u000a        \u000d\u000a        \u000d\u000a          Statistical methods for risk prediction\u000d\u000a          MRC\u000d\u000a          2008-2013\u000d\u000a          &#163;440K\u000d\u000a        \u000d\u000a        \u000d\u000a          Emerging risk factors in CVD\u000d\u000a          BHF\u000d\u000a          2008-2013\u000d\u000a          &#163;1.9M\u000d\u000a        \u000d\u000a        \u000d\u000a          Risk factors in coronary heart disease\u000d\u000a          MRC\/BHF\u000d\u000a          2013-2018\u000d\u000a          &#163;4M\u000d\u000a        \u000d\u000a      \u000d\u000a    \u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"},{"Level1":"1","Level2":"4","Subject":"Statistics"}],"Sources":"\u000d\u000a    \u000d\u000a      Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O,\u000d\u000a        Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J,\u000d\u000a        Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, ESC\u000d\u000a        Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012\u000d\u000a        Committees. ESC\/EAS Guidelines for the management of dyslipidaemias: the\u000d\u000a        Task Force for the management of dyslipidaemias of the European Society\u000d\u000a        of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur.\u000d\u000a        Heart J. 2011; 32:1769-1818.\u000d\u000a      Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus\u000d\u000a        C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M,\u000d\u000a        Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L,\u000d\u000a        Scherer M, Syv&#228;nne M, Scholte op Reimer WJM, Vrints C, Wood D, Zamorano\u000d\u000a        JL, Zannad F, European Association for Cardiovascular Prevention &amp;\u000d\u000a        Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG).\u000d\u000a        European Guidelines on cardiovascular disease prevention in clinical\u000d\u000a        practice (version 2012). The Fifth Joint Task Force of the European\u000d\u000a        Society of Cardiology and Other Societies on Cardiovascular Disease\u000d\u000a        Prevention in Clinical Practice (constituted by representatives of nine\u000d\u000a        societies and by invited experts). Eur. Heart J. 2012; 33:1635-1701.\u000d\u000a      Evaluation and treatment of hypertriglyceridemia: an Endocrine Society\u000d\u000a        clinical practice guideline. Berglund L, Brunzell JD, Goldberg AC,\u000d\u000a        Goldberg IJ, Sacks F, Murad MH, Stalenhoef AFH, Endocrine society.\u000d\u000a        Evaluation and treatment of hypertriglyceridemia: an Endocrine Society\u000d\u000a        clinical practice guideline. J. Clin. Endocrinol. Metab. 2012;\u000d\u000a        97:2969-2989.\u000d\u000a      Task Force for Developing Diabetes Comprehensive Care Plan. Handelsman\u000d\u000a        Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA,\u000d\u000a        Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB,\u000d\u000a        Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovi&#269; L, Lebovitz\u000d\u000a        H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL, AACE Task Force\u000d\u000a        for Developing Diabetes Comprehensive Care Plan. American Association of\u000d\u000a        Clinical Endocrinologists Medical Guidelines for Clinical Practice for\u000d\u000a        developing a diabetes mellitus comprehensive care plan. Endocr Pract.\u000d\u000a        2011; 17 Suppl 2:1-53.\u000d\u000a      Triglycerides and cardiovascular disease a scientific statement from\u000d\u000a        the American Heart Association. Miller M, Stone NJ, Ballantyne C,\u000d\u000a        Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS,\u000d\u000a        Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American\u000d\u000a        Heart Association Clinical Lipidology, Thrombosis, and Prevention\u000d\u000a        Committee of the Council on Nutrition, Physical Activity, and\u000d\u000a        Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular\u000d\u000a        Biology, Council on Cardiovascular Nursing, Council on the Kidney in\u000d\u000a        Cardiovascular Disease. Triglycerides and cardiovascular disease: a\u000d\u000a        scientific statement from the American Heart Association. Circulation.\u000d\u000a        2011; 123:2292-2333.\u000d\u000a      Nordestgaard BG, Chapman MJ, Ray KK, Bor&#233;n J, Andreotti F, Watts GF,\u000d\u000a        Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT,\u000d\u000a        Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokg&#246;zoglu L,\u000d\u000a        Tybj&#230;rg-Hansen A, for the European Atherosclerosis Society Consensus\u000d\u000a        Panel. Lipoprotein(a) as a cardiovascular risk factor: Current status.\u000d\u000a        Eur Heart J 2010;31:2844-2853.\u000d\u000a      Anderson TJ, Gr&#233;goire J, Hegele RA, Couture P, Mancini GBJ, McPherson\u000d\u000a        R, Francis GA, Poirier P, Lau DC, Grover S, Genest J, Carpentier AC,\u000d\u000a        Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates\u000d\u000a        GM, Stone JA, Ur E. 2012 Update of the Canadian Cardiovascular Society\u000d\u000a        Guidelines for the Diagnosis and Treatment of Dyslipidemia for the\u000d\u000a        Prevention of Cardiovascular Disease in the Adult. Can J Cardiol 2013;29\u000d\u000a        :151-167.\u000d\u000a      Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA,\u000d\u000a        Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith Jr\u000d\u000a        SC, Taylor AJ, Weintraub WS, Wenger NK. ACCF\/AHA guideline for\u000d\u000a        assessment of cardiovascular risk in asymptomatic adults: A report of\u000d\u000a        the american college of cardiology foundation\/american heart association\u000d\u000a        task force on practice guidelines. Circulation 2010;122:e584-e636.\u000d\u000a      Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown\u000d\u000a        AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT,\u000d\u000a        Sniderman AD, Toth PP, Tsimikas S, Ziajka PE, Maki KC, Dicklin MR.\u000d\u000a        Clinical utility of inflammatory markers and advanced lipoprotein\u000d\u000a        testing: advice from an expert panel of lipid specialists. J Clin\u000d\u000a        Lipidol. 2011;5:338-67.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Optimising the management of cardiovascular disease\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    To help target scarce preventive resources, promote behavioural change,\u000d\u000a      and monitor risk, CVD risk is assessed in primary prevention settings in\u000d\u000a      most high-income countries. There is, however, substantial debate about\u000d\u000a      what constitutes an optimum approach to risk assessment.\u000d\u000a    Researchers and outputs The ERFC was conceived and established by\u000d\u000a      Professor John Danesh (Professor since 2001), together with colleagues at\u000d\u000a      the Department of Public Health and Primary Care, including Dr Emanuele Di\u000d\u000a      Angelantonio (UL since 2010) and Dr Stephen Kaptoge (SRA since 2007).\u000d\u000a      Under the direction of Professor Danesh, the Cambridge coordinating centre\u000d\u000a      has since 2003 led all aspects of this consortium, including: choice of\u000d\u000a      hypotheses to study, collation and harmonisation of data, statistical\u000d\u000a      analyses, interpretation of data, reporting and dissemination of findings.\u000d\u000a      The ERFC has also given rise to other closely-related consortia led by the\u000d\u000a      same Cambridge investigators, such as the LpPLA2 Studies Collaboration.\u000d\u000a      Research Refs #1-5 provide examples of substantive findings. Professor\u000d\u000a      Danesh has been the key senior scientific leader in all the substantive\u000d\u000a      reports, exemplified by his role as the senior author and\/or corresponding\u000d\u000a      author.\u000d\u000a    Underpinning data and methods About 130 long-term prospective\u000d\u000a      cohort studies based in 25 different countries have shared extensive\u000d\u000a      individual-level data with the Cambridge coordinating centre of the ERFC.\u000d\u000a      This effort has yielded one of the largest and most detailed central\u000d\u000a      databases in CVD epidemiology worldwide (i.e., up to ~500 covariates for\u000d\u000a      each of 2.5 million participants). More than 100,000 incident CVD outcomes\u000d\u000a      have been recorded during 15 million person-years at risk. More than\u000d\u000a      300,000 people have provided serial measurements of risk factors.\u000d\u000a    In addition to its size and detail, several additional features have\u000d\u000a      distinguished this consortium's approach that have enhanced its power,\u000d\u000a      generalisability, and validity. First, cohorts contributing data to the\u000d\u000a      consortium have typically shared more extensive individual-level data\u000d\u000a      (e.g., additional types of disease endpoints and extended follow-up) than\u000d\u000a      have been reported in their own cohort-specific publications, thereby\u000d\u000a      enhancing power and enabling comparison of different types of CVD\u000d\u000a      outcomes. Second, the coordinating centre has iteratively checked,\u000d\u000a      cleaned, re-coded, and harmonised all data shared in this consortium in\u000d\u000a      close liaison with the investigators of contributing studies, thereby\u000d\u000a      enhancing the validity of the underlying data analysed.\u000d\u000a    Third, analyses have focused on a uniform and appropriate subset of\u000d\u000a      participants (e.g., people without a history of CVD at the baseline\u000d\u000a      examination who have complete information on relevant risk factors), in\u000d\u000a      contrast with inconsistent inclusion\/exclusion criteria used in previous\u000d\u000a      studies. Fourth, the ERFC has used methods specifically appropriate for\u000d\u000a      the evaluation of incremental risk prediction, such as measures of\u000d\u000a      discrimination and reclassification that require time-to-event data.\u000d\u000a      Results have also been expressed in a manner to help enhance understanding\u000d\u000a      by clinicians and policy makers, such as the numbers needed to screen to\u000d\u000a      avoid 1 additional CVD outcome over 10 years of preventive treatment.\u000d\u000a    Fifth, under the leadership of Professor Simon Thompson (MRC\u000d\u000a      Biostatistics Unit Director until 2011 and Professor since 2002) and Dr\u000d\u000a      Angela Wood (University Lecturer in Biostatistics, Department of Public\u000d\u000a      Health and Primary Care since 2006), the coordinating centre has developed\u000d\u000a      methods to optimise such analyses, including measures of discrimination\u000d\u000a      and reclassification for the multi-study situation [Research Ref #6\u000d\u000a      provides an example].\u000d\u000a    "},{"CaseStudyId":"19880","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2186224","Name":"New Zealand"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    The UK Stroke Association used our work to inform development of their\u000a      nationally provided community support services. Specific changes based on\u000a      our work include a significant move away from input primarily from a\u000a      stroke liaison worker to a more focused patient-centred approach; and an\u000a      increased focus on identifying and addressing, on an individual basis, the\u000a      long-term problems faced by each stroke survivor and his\/her carers. This\u000a      impact has had wide reach: the Stroke Association currently provides 340\u000a      commissioned services with a contract income of &#163;12.3 million and many\u000a      thousands of clients: e.g. in 2011\/12 Stroke Association staff saw 35,940\u000a      new clients.\u000a\u0009  Our findings also have reach beyond the UK. Based on our\u000a      work, Clinical Guidelines for Stroke in several countries (including the\u000a      UK, Scotland, Canada, New Zealand and Australia) now provide guidance to\u000a      health and social care workers on the importance of providing information\u000a      combined with educational sessions, rather than information alone. Lack of\u000a      appropriate information is one of the commonest concerns of patients and\u000a      their families (up to 50% report lack of information) and can hinder\u000a      compliance with secondary prevention and access to relevant community\u000a      services. We reported that information combined with educational sessions\u000a      improved knowledge and patient mood and was more effective than providing\u000a      information only. Our findings are cited in all these Clinical Guidelines\u000a      for Stroke (A-D), among others. Provision of information about\u000a      diagnosis and prognosis is a component of the National Sentinel Audit for\u000a      Stroke, which assesses compliance with guidelines. The latest audit (G)\u000a      reported some improvement in communication with patients.\u000a    Clinical Guidelines for Stroke have significant influence on service\u000a      provision: for example, on development of services in London (E).\u000a      This development work, which references our underpinning research, is part\u000a      of a major initiative to redesign stroke services across London, where\u000a      6,000 people are left with impairments following stroke each year.\u000a    Assessment six months post stroke is a component of the National Stroke\u000a      Strategy, and the development of assessment procedures is informed by our\u000a      finding that outcomes following secondary care- based assessment\u000a      six months post-stroke were no different from those following usual care\u000a      (generally no formal assessment). Our trial on which this finding is based\u000a      (8) is highlighted by the UK Stroke Improvement Programme (F),\u000a      an NHS initiative set up to provide national support for local improvement\u000a      of stroke services and the implementation of the National Stroke Strategy.\u000a      and is informing UK stroke services as they develop methods to implement\u000a      the six month assessment component of the National Stroke Strategy.\u000a    Addressing psychological need is now included in the UK National Stroke\u000a      Strategy, and in the annual National Sentinel Audit for Stroke (G)\u000a      that underpins its implementation, as an important component of stroke\u000a      care, based on our work highlighting the importance of psychological\u000a      outcomes after stroke, which raised the profile of this previously\u000a      neglected area. House contributed to the development of the stepped care\u000a      model for psychological interventions after stroke (A) which has\u000a      been developed by the Stroke Improvement Programme for national\u000a      implementation.\u000a    Forster, House and Young are authors of five stroke-related reviews\u000a      within the Cochrane Library, the premier resource for the synthesis of\u000a      evidence-based health care, which are used across the world as the\u000a      foundation stone for clinical guidelines: these reviews provide the\u000a      evidence for and are cited in Clinical Guidelines for stroke in the UK,\u000a      Scotland, Australia and Canada (A-D) and elsewhere. These\u000a      guidelines are the national templates for stroke service provision.\u000a    Our research was supported by (among others) the NIHR HTA and SDO\u000a      programmes, MRC and The Stroke Association, further testifying to its\u000a      direct clinical relevance, and underpinned by the development of a\u000a      nationwide stroke research network and comprehensive research network.\u000a      Forster is founding clinical director of the regional stroke network and\u000a      House was founding clinical director of the regional comprehensive\u000a      research network - so that development and implementation of our research\u000a      has been intimately integrated with NIHR policy.\u000a    Research approach\u000a      In our leading roles in the stroke research network, we have directly\u000a      evidenced the potential of research networks for stroke rehabilitation\u000a      research. This potential has been realised in our TRACS trial in which 36\u000a      participating centres recruited 900 patient and caregiver dyads, making it\u000a      the world's largest completed stroke rehabilitation trial (5). This\u000a      approach, novel in stroke research, has been further strengthened by\u000a      tandem economic and process evaluations. TRACS has demonstrated that large\u000a      rehabilitation trials are feasible and provides a template for large\u000a      pragmatic trials in rehabilitation. The study acted as an important\u000a      vehicle to engage clinical teams from across the UK in implementation and\u000a      delivery of research. Enhancing research methodology is a policy of\u000a      charity funders, for example AgeUK and The Stroke Association. The\u000a      importance of TRACS in the stroke rehabilitation research landscape is\u000a      evidenced by a public statement made by a former National Clinical Lead\u000a      for the NHS Stroke Improvement Programme. \"TRACS has been a very\u000a      significant study for two reasons. Firstly, the results of TRACS should\u000a      help provide important clarity on how stroke carers can best be supported.\u000a      Secondly, the engagement of front-line clinical staff in the running of\u000a      the [TRACS] trial has been hugely successful. Both these factors will help\u000a      raise the quality of care and support for people who have had a stroke and\u000a      their carers.\" (H).\u000a    ","ImpactSummary":"\u000a    Forster, House and Young have played a leading role in establishing the\u000a      importance of long-term psychological and social distress after stroke,\u000a      shifting the clinical emphasis (and evidence base) in stroke care from a\u000a      limited focus on physical recovery to acceptance of the importance of\u000a      psychological and social factors. Evidence we have generated has informed\u000a      the stroke care pathway in national and international clinical guidelines\u000a      that influence stroke service delivery, by providing guidance to clinical\u000a      teams on psychological treatments after stroke and information provision.\u000a      In tandem we have developed the methodology of stroke rehabilitation\u000a      research, involving clinical staff in delivery of multi-site studies and\u000a      thereby enhancing evidenced-based stroke care.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Leeds\u000a    ","Institutions":[{"AlternativeName":"Leeds (University of)","InstitutionName":"University of Leeds","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007795}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2643743","Name":"London"}],"References":"\u000a    \u000a1. House A, Knapp P, Bamford J, Vail A. Mortality at 12 and 24\u000a      months after stroke may be associated with depressive symptoms at one\u000a      month. Stroke 2001;32:696-701. Showed early distress\u000a        predicts 12 month mortality independently of disability.\u000a    \u000a\u000a2. West R, Hill K, Hewison J, Knapp P, House A.\u000a      Psychological disorders after stroke are an important influence on\u000a      functional outcomes: A prospective cohort study. Stroke\u000a      2010;41:1723-7. Showed distress predicts rehabilitation outcomes\u000a        independently of disability\u000a    \u000a\u000a3. Forster A, Young J. Incidence and consequences of falls due to\u000a      stroke: a systematic inquiry. Brit Med J 1995;311:83-6. Demonstrated\u000a        high rate of falls and their social and emotional impact.\u000a    \u000a\u000a4. Smith J, Forster A, Young J. A randomised trial to evaluate an\u000a      education programme for patients and carers after stroke. Clinical\u000a        Rehabilitation 2004;18:726-736. Demonstrated education reduces\u000a        anxiety without increasing knowledge.\u000a    \u000a\u000a5. Forster A, Dickerson J, Young J, Patel A, Kalra L, Nixon\u000a        J, Smithard D, Knapp M, Holloway I, Anwar S, Farrin A. A\u000a      structured training programme for caregivers of inpatients after stroke\u000a      (TRACS): a cluster randomised controlled trial and cost-effectiveness\u000a      analysis. The Lancet. Online Sep 18, 2013: http:\/\/dx.doi.org\/10.1016\/S0140-6736(13)61603-7.\u000a      Showed early training of caregivers does not improve outcomes.\u000a    \u000a\u000a6. Green J, Forster A, Bogle S, Young J. Physiotherapy\u000a      for patients with mobility problems more than 1 year after stroke: a\u000a      randomised controlled trial. The Lancet 2002; 359: 199-203. Showed\u000a        late physiotherapy improves mobility but benefits are not sustained when\u000a        treatment stops.\u000a    \u000a\u000a7. Forster A, Young J. Specialist nurse support for patients with\u000a      stroke in the community: a randomised trial. BMJ 1996;312:1642-6.\u000a      Showed using specialist nurses did not improve outcomes\u000a    \u000a\u000a8. Forster A, Young J, Green J, Patterson C, Wanklyn P, Smith J,\u000a      Murray J, Wild H, Bogle S, Lowson K. Structured re-assessment system at\u000a      six months after a disabling stroke: a randomised controlled trial with\u000a      resource use and cost study. Age and Ageing 2009;38:576-83. Showed\u000a        that structured secondary care based 6 month assessment did not improve\u000a        12 month outcomes.\u000a    \u000aGrants:\u000a    \u000a      \u000aForster A, Young J, Bhakta B, Farrin A, Murray\u000a        J, Knapp M, Patel A, House A, Hewison J, Bhakta B,\u000a        Powell J, Steele V, Brady T. Improving patient and carer centred\u000a        outcomes in longer- term stroke care. &#163;1.9 million NIHR Programme\u000a          Grant October 2007 for 60 months.\u000a      \u000aForster A, Young J, Farrin A, Kalra L, Knapp M,\u000a        Nixon J, Patel A, Smithard D. A cluster randomised controlled\u000a        trial of a structured training programme for caregivers of in-patients\u000a        after stroke. &#163;2,029,049 MRC Clinical Trials Grant April 2007,\u000a        53 months. The first ever MRC funded trial in stroke rehabilitation.\u000a    \u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    A-D: national clinical guidelines\u000a    A. Royal College of Physicians, National Clinical Guidelines for Stroke,\u000a      Fourth edition, London 2012, ISBN 978-1-86016-493-4. http:\/\/www.rcplondon.ac.uk\/publications\/national-clinical-guidelines-stroke.\u000a      Five papers cited:\u000a    1) Long Term Management in respect of moderately disabled patients or\u000a      carers from a structured reassessment system at 6 months post-stroke (page\u000a      125)\u000a    2) Information provision for stroke patients and their carers (page 130)\u000a    3) Depression and anxiety which may be associated with mortality at 12\u000a      and 24 months after stroke (page 113)\u000a    4) Interventions for treating depression after stroke (page 114)\u000a    5) Pharmaceutical interventions for emotionalism after stroke (page 115)\u000a    B. Canadian Best Practice Recommendations for Stroke Care: Ottawa 2006.\u000a      The Canadian Stroke Strategy CMAJ JAMC, December 2 2008, Volume 179 (12) http:\/\/www.strokecenter.org\/wp-content\/uploads\/2011\/08\/CSSManualENG_WEB_Sept07.pdf.\u000a      Three papers cited:\u000a    1) Information provision for stroke patients and their caregivers (page\u000a      E14)\u000a    2) Reference to the Bradford Community stroke trial (page E60)\u000a    3) Interventions for treating depression after stroke (page E67)\u000a    C. Clinical Guidelines for Stroke Management (2010). National Stroke\u000a      Foundation Australia. http:\/\/strokefoundation.com.au\/site\/media\/Clinical_Guidelines_Acute_Management_Recommendations_2010.pdf.\u000a      13 papers cited, including:\u000a    1) Specialist nurse support for patients with stroke in the community\u000a      (page 42)\u000a    2) Structure re-assessment system at 6 months after a disabling stroke\u000a      (page 42)\u000a    3) Information provision for stroke patients and their caregivers (pages\u000a      46-7)\u000a    4) Carer support during the recovery process (page 117)\u000a    5) Review of longer-term problems after a disabling stroke - behavioural\u000a      change (p 108)\u000a    6) Physiotherapy for patients with mobility problems more than 1 year\u000a      after stroke - falls (p 110)\u000a    7) A comparative cost-effectiveness study - community rehabilitation\u000a      (page 122)\u000a    8) Mood disorders in the year after first stroke (page 107)\u000a    9) Interventions for preventing depression after stroke (pages 27 &amp;\u000a      107)\u000a    10) Pharmaceutical interventions for emotionalism after stroke (pages 27\u000a      &amp; 107)\u000a    D. Scottish Intercollegiate Guidelines Network. Management of patients\u000a      with stroke: rehabilitation, prevention and management of complications,\u000a      and discharge planning: a national clinical guideline. June 2010. http:\/\/www.sign.ac.uk\/pdf\/sign118.pdf.\u000a      Five papers cited:\u000a    (1) Reference to the Bradford Community stroke trial - results at 6\u000a      months (page 51)\u000a    (2) Information provision for stroke patients and their caregivers (page\u000a      64)\u000a    (3) Interventions for preventing depression after stroke (pages 43 &amp;\u000a      45)\u000a    (4) Management of depression after stroke - pharmacological therapies\u000a      (page 43)\u000a    (5) Pharmaceutical interventions for emotionalism after stroke &#8212;\u000a      emotional ability (pages 43-4)\u000a\u0009  E-F: impact on local service\u000a        developments\u000a    E. Stroke rehabilitation guide: supporting London commissioners to\u000a      commission quality services in 2010\/11 NHS Healthcare for London. November\u000a      2009. Three papers cited (pages 11, 27, 40, 45). http:\/\/www.londonprogrammes.nhs.uk\/wp-content\/uploads\/2011\/03\/Acute-Stroke-Rehabilitation-Guide.pdf\u000a    F. Department of Health Stroke Improvement Plan http:\/\/www.improvement.nhs.uk\/stroke\/Reviewsforstrokepatients\/Reviewsevidence\/tabid\/173\/Default.aspx\u000a      http:\/\/www.improvement.nhs.uk\/stroke\/Psychologicalcareafterstroke\/tabid\/177\/Default.aspx\u000a      http:\/\/www.improvement.nhs.uk\/stroke\/Psychologicalcareafterstroke\/Stepped.aspx\u000a    G. Intercollegiate Stroke Working Party. 2011. Public Report of National\u000a      Sentinel Stroke Audit 2010. Royal College of Physicians, London.\u000a    Impact of Research Methodology\u000a    H. Statement by a former National Clinical Lead for the NHS Stroke\u000a      Improvement confirming the importance of TRACS in the stroke\u000a      rehabilitation research landscape. Available at http:\/\/www.crncc.nihr.ac.uk\/NR\/rdonlyres\/F7881FF8-5E53-476D-83F9-FD8B3FB54811\/0\/SRNTRACSEBNFTNWFEB2011.pdf\u000a      which should be accessed via http:\/\/www.crncc.nihr.ac.uk\/about_us\/stroke_research_network\/health_professionals\/impact_on_clinical_practice\/index\u000a    ","Title":"\u000a    Transforming stroke rehabilitation research and care\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Every year approximately 110,000 people in England have a stroke - the\u000a      third largest cause of death and the commonest cause of severe disability\u000a      in the community. It is estimated that stroke costs the NHS over &#163;2.5\u000a      billion annually, accounting for 6% of total NHS and social services\u000a      expenditure. A particular focus of our research has been to explore and\u000a      address psychological and social recovery and their influences on the\u000a      longer-term quality of life of stroke survivors.\u000a    Improving stroke care\u000a      Work published by staff at the University of Leeds since 1995 has\u000a      highlighted the poor psycho- social outcome for stroke survivors and their\u000a      families. Since then we have explored the difficulties faced by stroke\u000a      survivors and their carers through a range of studies (all led by Forster,\u000a      Young and \/or House) including: systematic literature reviews; cohort\u000a      studies of the course and impact on physical outcomes of depressive\u000a      symptoms (1, 2) and the incidence of falls (an important cause of\u000a      anxiety) (3, cited &gt;190 times); qualitative work addressing\u000a      adjustment after stroke; and surveys of unmet need in stroke survivors.\u000a      Building on this research, which emphasises the need for stroke\u000a      rehabilitation to address psychological and social problems as well as\u000a      physical ones, we have developed interventions and led evaluations\u000a      (randomised trials) addressing pre-discharge preparation in stroke units\u000a      and post-discharge care. The following list gives such interventions (and\u000a      where available, their effects):\u000a    Pre-discharge:\u000a    \u000a      education and goal setting: gives significant reduction in patient\u000a        anxiety (4)\u000a      caregiver training immediately post stroke: has no benefit (5).\u000a    \u000a    Post-discharge:\u000a    \u000a      evaluation of home physiotherapy and day hospital care: the latter\u000a        showed no benefit\u000a      physical therapy later after stroke: improves mobility, but has no\u000a        long-term effect (6)\u000a      advice and guidance provided by a specialist nurse: showed there is no\u000a        proved strategy addressing the psychosocial difficulties of stroke\u000a        patients and their families (7, cited &gt;110 times)\u000a      UK national policy of routine re-assessment of disabled patients and\u000a        their carers at 6 months after stroke onset (the National Service\u000a        Framework for Older People): showed no benefit (8)\u000a      counselling and peer support: on-going work\u000a      continuity of care in stroke services: on-going work\u000a      structured assessment by a stroke care co-ordinator: on-going work.\u000a    \u000a    Our primary randomised trial work, specifically evaluation of input from\u000a      a specialist nurse, contributed to the Cochrane Review of `stroke liaison\u000a      workers'.\u000a    Development of research approach &#8212; randomised trials of complex\u000a        interventions.\u000a      In this work we have shown that it is possible to include mixed methods\u000a      (qualitative, process and realist evaluations) and health economic\u000a      analysis in trials of complex interventions even in the frail elderly\u000a      population that constitutes most stroke survivors. The trials have\u000a      progressed from small single-centre studies to two-centre studies\u000a      culminating recently with the implementation of two multicentre studies\u000a      (36 and 32 centres) recruiting 900 and 800 patients respectively, making\u000a      them the world's largest completed randomised trials in stroke\u000a      rehabilitation (Forster, Chief Investigator for both). The pioneering\u000a      nature of this work is evidenced by the former of these studies, the TRACS\u000a      trial, being the first stroke rehabilitation trial funded by the MRC (6).\u000a    Research presented here was led by: John Young Consultant Physician\/\u000a      Professor of Elderly Care 2005-present; Allan House, Professor of Liaison\u000a      Psychiatry, 1999-present; Anne Forster, Research Physiotherapist\/\u000a      Professor in Stroke Rehabilitation 1997-present\u000a    "},{"CaseStudyId":"20045","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000a    The AIRE study, which was conceived, designed and led by staff at Leeds,\u000a      showed for the first time the benefits of early initiation of ACEI\u000a      therapy for high-risk patients with clinical signs of heart failure after\u000a      AMI. This and subsequent research has led to the global introduction of a\u000a      simple and effective treatment, improving survival and quality of life for\u000a      many thousands of patients.\u000a    Impact on health and welfare\u000a    For patients surviving AMI, the debilitating syndrome of heart failure\u000a      secondary to left ventricular dysfunction is a common problem. The body's\u000a      production of angiotensin after AMI acts initially as a protective\u000a      mechanism to preserve blood pressure; however, prolonged angiotensin\u000a      production causes cell death. It had been proposed that ACEI therapy would\u000a      mitigate these effects but investigators were cautious about using the\u000a      drugs in these high-risk patients. The AIRE study was the first trial to\u000a      show survival benefits of the ACEI ramipril in these patients. A long-term\u000a      follow up study by Leeds of the trial's UK patients showed that these\u000a      beneficial effects persisted years later.\u000a    The international adoption of the strategy of early ACEI after AMI has\u000a      made it a fundamental part of routine treatment. In addition to\u000a      significantly changing clinical practice, the use of this simple and cost\u000a      effective treatment has contributed to the substantial decline in\u000a      mortality associated with AMI seen over the last two decades. For\u000a      instance, figures from the USA National Registry of Myocardial Infarction\u000a      Investigators indicates that in-hospital mortality after an AMI fell by\u000a      24% from 1990 to 2006 [A]. This trend due to improved care for AMI,\u000a      including the adoption of early secondary prevention such as ACEI\u000a      treatment, is reflected in data from other countries around the world. In\u000a      the UK, a study looking at trends in 3 year mortality in 3 month survivors\u000a      of AMI in the UK, demonstrated that between 1991 and 2002 the use of ACEI\u000a      increased from 11% to 71% and during the same period mortality fell by 28%\u000a      [B]. More recent data from the UK Myocardial Ischaemia National\u000a      Audit Project (covering England, Wales and Belfast) showed a continued\u000a      increase in the prescription of ACEI, from just over 80% of patients with\u000a      AMI in 2003 to 94% of patients with AMI in 2011\/12 [C, figure 15].\u000a      In 2011\/12 there were 79,433 individuals sustaining an AMI; in England,\u000a      95% of patients received ACEI treatment, Wales 90% and Belfast 98% [C;\u000a      table 7]. At a UK population level there has been a year-on-year fall in\u000a      the percentage of patients with AMI who die within 30 days of admission to\u000a      hospital [C; figures 19 and 20]. The observed improvements in\u000a      mortality are not solely attributable to use of ACEI; however, ACEI\u000a      therapy is a fundamental element of modern treatment strategies for AMI [D-F].\u000a      The AIRE study has had major reach and significance, as evidenced by its\u000a      recognition as one of the \"Landmark Heart Failure Treatment Trials\" [D]\u000a      which made \"a fundamental contribution to international clinical\u000a      guidelines, implementation of which has delayed or prevented morbidity and\u000a      death for millions of people worldwide.\" [E]. \"Two decades later\u000a      the results of this study still have a major impact on current guidelines\u000a      underscoring that this study significantly changed treatment of\u000a      cardiovascular high-risk patients.\" [F].\u000a    The importance of AIRE in contributing to the routine adoption of ACEI\u000a      therapy in patients sustaining an AMI is evidenced by the continuing\u000a      citation of this study in international clinical guidelines. The first\u000a      recommendation for the routine adoption of ACEI therapy in patients with\u000a      AMI who develop signs and symptoms of heart failure or who have reduced\u000a      left ventricular ejection fraction, the protocol used in the AIRE study,\u000a      was in the American College of Cardiology\/ American Heart Association\u000a      guidelines in 1996, which cited AIRE as supporting evidence. Since the\u000a      publication of AIRE, ACEI use after AMI has become standard practice\u000a      globally and is established as a class IA recommendation by, for instance,\u000a      the American College of Cardiology Foundation\/American Heart Association [G]\u000a      and the European Society of Cardiology [H] guidelines for\u000a      management of acute myocardial infarction. The AIRE Study is an\u000a      underpinning reference for this therapeutic strategy in both guidelines.\u000a      In the UK, the National Institute for Health and Care Excellence (NICE)\u000a      recommendation for secondary prevention following AMI, published in 2007,\u000a      has guided clinical practice during the current REF period and emphasised\u000a      the prescription of ACEI as a key priority [I, page 10]. This\u000a      guidance cites Leeds research on the efficacy of long term ACEI therapy as\u000a      supporting clinical evidence for the recommendation that: \"After an MI,\u000a      all patients with preserved left ventricular function or with left\u000a      ventricular systolic dysfunction should continue treatment with an ACE\u000a      inhibitor indefinitely, whether or not they have symptoms of heart\u000a      failure.\" [I, page 127]. Furthermore, cost effectiveness analysis\u000a      based on AIRE contributed to the conclusion that long-term ACEI was cost\u000a      effective in patients with and without left ventricular dysfunction [I,\u000a      pages 145-151]. A partial update of these guidelines released in June 2013\u000a      for consultation continues to emphasise ACEI as a key priority in\u000a      secondary prevention in patients with AMI and includes additional priority\u000a      recommendations on correct dosing of ACEI in acknowledgement of their\u000a      ongoing importance [J]. The updated guidance emphasises the\u000a      importance of rapidly achieving the target dose, based on relevant\u000a      clinical evidence, including AIRE, for specific ACEI (e.g. ramipril 10\u000a      mg\/day, as per AIRE): \"Titrate the ACE inhibitor dose upwards at short\u000a      intervals (for example, every 12-24 hours) before the person leaves\u000a      hospital until the maximum tolerated or target dose is reached. If this is\u000a      not possible, this should be completed within 4-6 weeks of hospital\u000a      discharge.\" [J].\u000a    ","ImpactSummary":"\u000a    Patients with evidence of heart failure following acute myocardial\u000a      infarction (AMI) have a particularly poor prognosis, with substantially\u000a      increased risk of death and subsequent cardiovascular events. The Acute\u000a      Infarct Ramipril Efficacy (AIRE) Randomised Controlled Trial (RCT) was an\u000a      international trial designed and led by the University of Leeds. AIRE\u000a      demonstrated, for the first time, that early treatment of patients with\u000a      clinical evidence of heart failure following AMI with the angiotensin\u000a      converting enzyme inhibitor (ACEI) ramipril significantly improved\u000a      survival and quality of life compared with placebo treated patients. The\u000a      strategy of early initiation of ACEI is now a cornerstone in the\u000a      management of patients suffering from AMI, leading to a global improvement\u000a      in post-AMI outcomes.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Leeds\u000a    ","Institutions":[{"AlternativeName":"Leeds (University of)","InstitutionName":"University of Leeds","PeerGroup":"A","Region":"Yorkshire And Humberside","UKPRN":10007795}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2655984","Name":"Belfast"}],"References":"\u000a    \u000a1. The Acute Infarction Ramipril Efficacy (AIRE) study investigators\u000a      (including Hall A). Effect on mortality and morbidity of survivors\u000a      of acute myocardial infarction with clinical evidence of heart failure. Lancet\u000a      1993; 342: 821-828. The first study to show the beneficial effect of\u000a        early ACEI treatment in patients sustaining an AMI with clinical\u000a        evidence of heart failure.\u000a    \u000a\u000a2. Hall AS, Murray GD, Ball SG. Follow-up study of patients\u000a      randomly allocated ramipril or placebo for heart failure after acute\u000a      myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997;\u000a      349:1493-97. Research showing long-term beneficial effect of ACEI in\u000a        patients sustaining an AMI with clinical evidence of heart failure.\u000a    \u000a\u000a3. Flather M, Yusuf S, Kober L, Pfeffer M, Hall AS, Murray G,\u000a      Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long term\u000a      ACE-inhibitor therapy in patients with heart failure or left ventricular\u000a      dysfunction: a systematic overview of data from individual patients. Lancet\u000a      2000; 355: 1575-81. A systematic review confirming the important role\u000a        of ACEI post AMI.\u000a    \u000a\u000a4. Cleland JGF, Erhardt L, Murray G, Hall AS, Ball SG. Effect of\u000a      ramipril on morbidity and mode of death among survivors of acute\u000a      myocardial infarction with clinical evidence of heart failure. A report\u000a      from the AIRE Study Investigators. European Heart Journal 1997;\u000a      18:41-51. Analysis of secondary and tertiary outcomes in AIRE\u000a        demonstrating that ACEI reduced sudden cardiac death and progression of\u000a        heart failure.\u000a    \u000a\u000a5. Cubbon RM, Gale CP, Rajwani A, Abbas A, Morrell C, Das R,\u000a      Barth JH, Grant PJ, Kearney MT, Hall AS. Aspirin and mortality in\u000a      patients with diabetes sustaining acute coronary syndrome. Diabetes\u000a        Care 2008; 31: 363-5. Data showing beneficial effect of ACEI in\u000a        patients with and without diabetes sustaining an AMI.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    [A] Rogers WJ, et al. Trends in presenting characteristics and hospital\u000a      mortality among patients with ST-elevation and non-ST elevation myocardial\u000a      infarction in the National Registry of Myocardial Infarction from 1990 to\u000a      2006. Am. Heart J 2008; 156: 1026-34.\u000a    [B] Hardoon et al. Trends in longer-term survival following an acute\u000a      myocardial infarction and prescribing of evidenced-based medications in\u000a      primary care in the UK from 1991: a longitudinal population-based study. J\u000a      Epidemiol Community Health. 2011 September; 65(9): 770-774.\u000a    [C] Myocardial Ischaemia National Audit Project (MINAP). How the NHS\u000a      cares for patients with heart attack. Annual public report 2011\/12.\u000ahttp:\/\/www.ucl.ac.uk\/nicor\/audits\/minap\/publicreports\/pdfs\/2012minappublicreportv2.pdf\u000a    [D] Letter of corroboration from Professor of Heart Failure and\u000a      Consultant Cardiologist, Heart Failure Unit, Kings College Hospital,\u000a      London, UK, confirming the AIRE study's fundamental contribution to\u000a      international clinical guidelines, implementation of which has delayed or\u000a      prevented morbidity and death for millions of people worldwide.\u000a    [E] Letter of corroboration from Professor of Vascular Medicine, Service\u000a      d'Hypertension et de M&#233;decine Vasculaire, Hopital Europ&#233;en Georges\u000a      Pompidou, Paris, France, confirming the AIRE study's fundamental\u000a      contribution to international clinical guidelines.\u000a    [F] Letter of corroboration from Professor of Medicine\/Cardiology,\u000a      Department of Internal Medicine I, University Hospital Aachen, Germany,\u000a      confirming the lasting impact of the AIRE study on current guidelines.\u000a    [G] O'Gara et al. 2013 ACCF\/AHA Guideline for the Management of\u000a      ST-Elevation Myocardial Infarction: A Report of the American College of\u000a      Cardiology Foundation\/American Heart Association Task Force on Practice\u000a      Guidelines. Circulation. 2013;127:e362-e425. Available from: http:\/\/circ.ahajournals.org\/content\/127\/4\/e362.full.pdf+html.\u000a      ACE inhibitor recommendations and reference to AIRE (table 12, p e389; p\u000a      e390; table 14, p e400; AIRE referenced p e412, references 421 and 430).\u000a    [H] Van de Werf F, et al. Management of acute myocardial infarction in\u000a      patients presenting with persistent ST-segment elevation: the Task Force\u000a      on the Management of ST-Segment Elevation Acute Myocardial Infarction of\u000a      the European Society of Cardiology. Eur Heart J 2008; 29: 2909-45.\u000a      Available from: http:\/\/eurheartj.oxfordjournals.org\/content\/29\/23\/2909.full.pdf+html.\u000a      ACE inhibitor recommendations (table 15, p 2924; table 22, p 2933; AIRE\u000a      referenced on p 2944, reference 213)\u000a    [I] The National Institute for Health and Clinical Excellence (NICE). MI:\u000a      secondary prevention. Secondary prevention in primary and secondary care\u000a      for patients following a myocardial infarction (CG48; 2007). Available\u000a      from: http:\/\/guidance.nice.org.uk\/CG48\/Guidance\/pdf\/English.\u000a      ACE inhibitor recommendations (p 10; p 127); Cost effectiveness of ACE\u000a      inhibitors in patients after MI with LV dysfunction including reference to\u000a      AIRE (pp 145-151).\u000a    [J] The National Institute for Health and Clinical Excellence (NICE).\u000a      Post myocardial infarction Secondary prevention in primary and secondary\u000a      care for patients following a myocardial infarction. Partial update of\u000a      NICE CG48: Methods, evidence and recommendations. June 2013 Available\u000a      from: http:\/\/www.nice.org.uk\/nicemedia\/live\/13502\/64153\/64153.pdf.\u000a      Updated guidance on ACEI in section 7.3 (pp 219-318). AIRE cited in: table\u000a      49 (p 228); table 61 (p 269) and references to AIRE (reference numbers 16,\u000a      24, 123, 169, 365).\u000a    ","Title":"\u000a    Reducing mortality following acute myocardial infarction (AMI)\u000a    ","UKLocation":[{"GeoNamesId":"2644688","Name":"Leeds"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Cardiovascular disease, in particular acute myocardial infarction (AMI)\u000a      and its complications, is the principal cause of premature mortality\u000a      worldwide (World Health Organisation September 2011, \u000a      http:\/\/www.who.int\/cardiovascular_diseases\/en). Whilst contemporary\u000a      mechanical reperfusion strategies significantly improve survival following\u000a      AMI, left ventricular dysfunction and heart failure develops in at least\u000a      40% of patients after AMI resulting in poorer outcomes, highlighting the\u000a      importance of effective management of heart failure in these patients.\u000a    The AIRE RCT (1) was conceived, designed and led by staff at the\u000a      University of Leeds (Professor SG Ball, British Heart Foundation Chair\u000a      (Leeds 1990-2010); Professor AS Hall (Leeds 1992-)), and built\u000a      upon evidence from earlier studies demonstrating the efficacy of\u000a      angiotensin converting enzyme inhibitors (ACEI) in reducing mortality in\u000a      patients with severe heart failure. A reduction in sympathetic activity\u000a      and decreased adverse cardiac remodelling were believed to contribute to\u000a      the beneficial effects of ACEI in heart failure, suggesting likely\u000a      benefits for patients with heart failure following AMI. The AIRE study\u000a      (named after the river running through the city of Leeds) evaluated the\u000a      effect of early initiation of ACEI (ramipril) therapy on subsequent\u000a      mortality in patients sustaining an AMI with clinical evidence of heart\u000a      failure in a large multicentre, international prospective RCT. AIRE was\u000a      the first RCT specifically designed to evaluate the efficacy of ACEI\u000a      therapy on mortality and morbidity in this high-risk group of patients\u000a      with AMI. Previously, investigators had been reluctant to adopt this\u000a      strategy because of fears over a negative effect of ACEI therapy in high\u000a      risk patients. The AIRE study demonstrated a significant reduction in\u000a      post-AMI mortality in patients randomised to ramipril, reported in a\u000a      series of high citation Lancet publications (1, 2, 3), providing\u000a      vital evidence that the use of early and prolonged ACEI therapy improved\u000a      outcomes; this has led to a global change in the clinical management of\u000a      AMI.\u000a    In patients suffering an AMI the study randomly allocated patients with\u000a      evidence of heart failure to placebo or ramipril. Two thousand and six\u000a      patients were recruited across 14 countries and on a background of optimal\u000a      therapy were prescribed placebo (982 patients), or 5 mg ramipril (1004\u000a      patients) twice per day. At an average follow-up of 15 months (minimum 6\u000a      months), there were 170 deaths (17%) in the ACEI group and 222 deaths\u000a      (23%) in the placebo group, representing a relative risk reduction for\u000a      all-cause mortality of 27% (95% CI 11-40%) (1). An evaluation of\u000a      secondary (time to death or re-infarction, severe resistant heart failure\u000a      or stroke) and tertiary (mode of death) outcomes, demonstrated that ACEI\u000a      reduced sudden cardiac death by approximately 30% (95% CI 8-47%), which\u000a      appeared to be largely attributable to a reduction in progressive heart\u000a      failure (4). In an analysis of longer-term mortality in the UK\u000a      cohort of AIRE, 3 years after cessation of study treatment (minimum\u000a      follow-up period of 42 months), the relative risk reduction for long-term\u000a      mortality in those randomised to ACEI was 34% [95% CI 11-51%],\u000a      corresponding to an extra 114 patients surviving at 5 years per 1000\u000a      patients treated with ACEI for an average of 1 year following AMI (2).\u000a      A subsequent meta-analysis, including data from AIRE, confirmed that ACEI\u000a      treatment in patients sustaining an AMI with LV dysfunction\/heart failure\u000a      reduced early and longer-term mortality, and reduced the composite\u000a      endpoint of mortality or subsequent cardiovascular events (including\u000a      recurrent AMI and readmission for heart failure), supporting the benefit\u000a      of long-term ACEI in high-risk patients (3).\u000a    More recent work from Leeds (Hall A and Gale (Leeds Senior\u000a      Lecturer 2007-, NIHR Clinician Scientist)) in the EMMACE-2 study\u000a      (Evaluation of Methods and Management of Acute Coronary Events-2) examined\u000a      outcomes in 2,499 unselected patients with acute coronary syndromes.\u000a      Results of this study demonstrated that ACEI treatment is equally\u000a      beneficial in patients with and without diabetes sustaining an AMI, which\u000a      was not found to be the case for aspirin (5).\u000a    "},{"CaseStudyId":"21201","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    Outcome of research: A web-based user-friendly interface was\u000a      developed for BOADICEA (Impact\u000a      reference 5.1) which allows users to obtain rapid estimates of BRCA1\u000a      and BRCA2 carrier\u000a      probabilities and risks of developing breast or ovarian cancer. This\u000a      web-tool was made available\u000a      for general use in January 2008.\u000a    Scope and reach of BOADICEA: The web-interface of BOADICEA\u000a      currently has more than 2500\u000a      registered users from the UK and 45 other countries (Europe, North America\u000a      and Australia and\u000a      other). Periodic monitoring of the web servers during 2012 revealed an\u000a      average of 50 concurrent\u000a      users at any given time during a working week. The chief beneficiaries of\u000a      BOADICEA have so far\u000a      been healthcare providers, notably organisers of genetic testing (clinical\u000a      geneticists and genetic\u000a      counsellors), breast cancer screening and chemoprevention programmes,\u000a      oncologists and general\u000a      practitioners, family members of women with breast cancer or otherwise at\u000a      high risk of the disease,\u000a      women with BRCA1 or BRCA2 mutations and their families who\u000a      could be counselled for their\u000a      breast or ovarian cancer risks, the general public and bodies involved in\u000a      the planning of screening\u000a      or intervention trials.\u000a    Indicators of extent of impact: BOADICEA is one of the risk\u000a      prediction algorithms currently\u000a      recommended by the UK National Institutes of Health and Clinical\u000a      Excellence (NICE, Impact\u000a      reference 5.2, since 2006). It was also recommended by equivalent bodies\u000a      in other countries (e.g.\u000a      American Cancer Society and Ontario Breast Screening program incorporated\u000a      in guidelines since\u000a      2011 for determining eligibility for screening of high risk patients\u000a      (Impact references 5.3-5.6).\u000a    Nature of impacts: BRCA1 and BRCA2 mutation\u000a      screening is expensive and is associated with\u000a      adverse psychosocial effects. Similarly, breast cancer screening is\u000a      expensive and has adverse\u000a      consequences including over-diagnosis. Chemoprevention is effective for\u000a      breast cancer prevention\u000a      but has adverse side effects. Thus, it is crucial that these interventions\u000a      are targeted at the\u000a      individuals most likely to benefit. Use of BOADICEA has had several\u000a      inter-related impacts in this\u000a      regard:\u000a    (1) To identify women eligible for screening by magnetic resonance\u000a        imaging (MRI) so that available\u000a        resources are targeted to those most likely to benefit most from early\u000a        cancer diagnosis, while\u000a        minimising the associated health service costs [Impact references\u000a      5.2, 5.5].\u000a      Under NICE current guidelines, women at raised risk of developing breast\u000a      cancer are offered\u000a      mammographic screening from age 40, and a subset of high risk women,\u000a      including BRCA1 and\u000a      BRCA2 mutation carriers, are offered screening by MRI. MRI screening is\u000a      more sensitive than\u000a      mammography but is approximately ten-fold more expensive. BOADICEA was\u000a      first adopted by\u000a      NICE in 2006 as a risk prediction algorithm for classifying women at risk\u000a      of familial cancer into\u000a      three risk categories: women at or near population risk, raised risk, or\u000a      high risk. BOADICEA\u000a      remains one of only two recommended breast cancer\/carrier risk assessment\u000a      tools by the revised\u000a      NICE guidelines (June 2013, Impact reference 5.2). Women predicted to be\u000a      at raised or high risk\u000a      are offered annual mammographic surveillance from age 40, compared to age\u000a      50 under the\u000a      standard NHS screening programme. Women at high risk are offered MRI\u000a      screening.\u000a    (2) Clinical genetics services are now using BOADICEA to refer women\u000a        for BRCA1 and BRCA2\u000a        mutation screening.\u000a      Predictions obtained by BOADICEA are being used to provide a consistent\u000a      way for referring\u000a      individuals for BRCA1 and BRCA2 mutation screening (NICE\u000a      guidelines currently recommend a\u000a      combined mutation carrier prediction of over 10% although the threshold\u000a      varies across countries,\u000a      Impact reference 5.2). This allows targeting mutation screening to those\u000a      individuals most likely to\u000a      carry BRCA1 and BRCA2 mutations, thus minimising the\u000a      psychosocial effects related to mutation\u000a      screening and the associated costs of mutation screening. Women found to\u000a      carry BRCA1 and\u000a      BRCA2 mutations could then be offered more intensive screening,\u000a      prophylactic surgery or other\u000a      risk reduction options.\u000a    (3) To guide chemoprevention and prophylactic surgery options for\u000a        women at high risk.\u000a      The predicted risks provided by BOADICEA are helping clinicians and\u000a      high-risk women take\u000a      informed decisions when faced with the options of risk reducing surgery,\u000a      regular screening or\u000a      chemoprevention. According to the revised NICE guidelines (Impact\u000a      reference 5.2) women\u000a      classified to be at high-risk of developing breast cancer may be offered\u000a      chemoprevention with\u000a      Tamoxifen or Raloxifene.\u000a    (4) To counsel women carrying BRCA1 and BRCA2 mutations\u000a      BRCA1 and BRCA2 cancer risk estimates based on BOADICEA are\u000a      being used to counsel women\u000a      carrying such mutations. These estimates have also been widely used by\u000a      various support groups\u000a      such as the patient support group FORCE (impact reference 5.7)\u000a    ","ImpactSummary":"\u000a    Basic and applied research at the University of Cambridge has culminated\u000a      in a widely-used risk\u000a      prediction algorithm (\"BOADICEA\") for familial breast and ovarian cancer.\u000a      This user-friendly\u000a      web-based tool predicts the likelihood of carrying mutations in breast and\u000a      ovarian cancer high-risk\u000a      genes (BRCA1 and BRCA2), and the risks of developing breast\u000a      or ovarian cancer.\u000a      BOADICEA has been adopted by several national bodies including NICE in the\u000a      UK (2006 until\u000a      present), the American Cancer Society and the Ontario Breast Screening\u000a      Program (both since\u000a      2011) for identifying women who would benefit from BRCA1\/2\u000a      mutation screening, intensified\u000a      breast cancer screening and chemoprevention.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Cambridge\u000a    ","Institutions":[{"AlternativeName":"Cambridge (University of)","InstitutionName":"University of Cambridge","PeerGroup":"A","Region":"East","UKPRN":10007788}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Antoniou A, Pharoah PD, Narod S, ..... Easton DF (2003). Average Risks\u000a      of Breast and Ovarian\u000a      Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series\u000a      Unselected for\u000a      Family History: A Combined Analysis of 22 Studies. Am J Human Genet 72:\u000a      1117-30 (&gt;1000\u000a      citations)\u000a    \u000a\u000a2. Antoniou AC, Cunningham AP.......... Easton DF (2008) The BOADICEA\u000a      model of genetic\u000a      susceptibility to breast and ovarian cancers: updates and extensions. Br J\u000a      Cancer 98:1457-66\u000a    \u000a\u000a3. Antoniou AC, ..., Easton DF, Pharoah PD (2008) Predicting the\u000a      likelihood of carrying a BRCA1\u000a      or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the\u000a      Manchester\u000a      scoring system using data from UK genetics clinics. J Med Genet 45:425-31\u000a    \u000a\u000a4. Easton DF, Pooley KA et al (2007) Genome-wide association study\u000a      identifies novel breast\u000a      cancer susceptibility loci. Nature 447: 1087-93 (&gt;1000 citations)\u000a    \u000a\u000a5. Antoniou AC, Beesley J, McGuffog L,...., Easton DF (2010) Common\u000a      breast cancer\u000a      susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2\u000a      mutation\u000a      carriers: implications for risk prediction. Cancer Res 70:9742-54\u000a    \u000a\u000a6. Pharoah PDP, Antoniou AC, Easton DF, Ponder BAJ (2008) Polygenes, Risk\u000a      Prediction, and\u000a      Targeted Prevention of Breast Cancer. New England Journal of Medicine 358:\u000a      2796-803\u000a    \u000aGrants:\u000a    &#8226; Four programme Grants from Cancer Research Campaign and CR-UK:\u000a        \"Genetic Epidemiology\u000a        of Cancer\", 1993-2013 (PI for all: D. Easton, funding from 1998 to 2013\u000a        &#163;4.5m).\u000a    &#8226; CR-UK Senior Cancer Research Fellowship (PI: A. Antoniou) \"Development\u000a        of risk prediction\u000a        algorithms for breast, ovarian and other cancers\" 2009-12. &#163;582,038\u000a    &#8226; CR-UK Project Grant (PI: D. Easton) \"Follow-up of Genome Wide\u000a        Association Studies in Breast\u000a        Cancer\". 2009-11. &#163;161,390\u000a    &#8226; EC Seventh Framework Programme (FP7) HEALTH-F2-2009-223175 (PI: P\u000a        Hall, co-PI: D\u000a        Easton) \"Collaborative Oncological Gene-environment Study (COGS)\"\u000a        2009-14 &#163;3,064,186\u000a    &#8226; Genome Canada\/CIHR (PI: J. Simard, Co-I D. Easton, Co-I A. Antoniou)\u000a        \"Personalised Risk\u000a        Stratification for Prevention and Early Detection of Breast Cancer\"\u000a        2013-17 Total Budget: $11\u000a        559 128 ($483,782 to D. Easton; $330,450 to A. Antoniou)\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"12","Subject":"Oncology and Carcinogenesis"},{"Level1":"6","Level2":"4","Subject":"Genetics"},{"Level1":"1","Level2":"4","Subject":"Statistics"}],"Sources":"\u000a    5.1 BOADICEA web application: http:\/\/ccge.medschl.cam.ac.uk\/boadicea\/\u000a    5.2 National Institutes of Health and Clinical Excellence, UK: CG41\u000a      Familial breast cancer: full\u000a      guideline. 2013: http:\/\/www.nice.org.uk\/nicemedia\/live\/14188\/64202\/64202.pdf\u000a      (paper 2 cited on\u000a      pages 8,13, 30).\u000a    5.3 American Cancer Society: Smith RA, et al. Cancer Screening in the\u000a      United States, 2012. A\u000a      Review of Current American Cancer Society Guidelines and Current Issues in\u000a      Cancer Screening\u000a      CA Cancer J Clin. 2012, 62:129-142 (paper 2 cited)\u000a    5.4 The U.S. National Society of Genetic Counselors. Riley BD, et al\u000a      (2012) Essential Elements of\u000a      Genetic Cancer Risk Assessment, Counseling, and Testing: Updated\u000a      Recommendations of the\u000a      National Society of Genetic Counselors. J Genet Counsel (2012) 21:151-161\u000a      (paper 2 cited)\u000a    5.5 Ontario Breast Screening Program (Canada):\u000a      https:\/\/www.cancercare.on.ca\/common\/pages\/UserFile.aspx?fileId=99492\u000a      [Paper 2 cited, pages 1,\u000a      3, 4]\u000a    5.6 Cancer Australia (Australian Government): Familial Risk Assessment -\u000a      Breast and Ovarian\u000a      Cancer: http:\/\/canceraustralia.gov.au\/clinical-best-practice\/gynaecological-cancers\/familial-risk-assessment-fra-boc.\u000a      (papers 1, 2 cited: http:\/\/canceraustralia.gov.au\/clinical-best-practice\/gynaecological-cancers\/familial-risk-assessment-fra-boc\/references.\u000a    5.7 FORCE (Facing Our Risk of Cancer Empowered) www.facingourrisk.org\/\u000a      cites research\u000a      references 1 and 4 in: http:\/\/www.facingourrisk.org\/info_research\/risk-factors\/breast-cancer-risks\/advanced.php,\u000a      specific page at\u000a      www.facingourrisk.org\/search\/index.php?query=easton&amp;type=and&amp;results=10&amp;search=1\u000a    \u000a    ","Title":"\u000a    Development of risk prediction algorithms for familial breast and ovarian\u000a      cancer and their use for\u000a      genetic counselling and screening purposes.\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Researchers: Department of Public Health and Primary Care: Prof\u000a      Easton (University Lecturer,\u000a      1995-1999; Reader, 1993-2003; Professor, since 2003) and Dr Antoniou\u000a      (post-doctoral fellow\u000a      2001-2009; CR-UK Senior Research Fellow 2009-13; Reader since 2013).\u000a    Research setting: BOADICEA was developed using primary research\u000a      findings from the Centre\u000a      for Genetic Epidemiology at the University of Cambridge since 1995. The\u000a      Centre is the host for\u000a      a number of large-scale epidemiological studies and has played a leading\u000a      role in the\u000a      identification and characterisation of breast (and other) cancer\u000a      susceptibility variants.\u000a    Underpinning data and methods: The models were developed using\u000a      data from local and national\u000a      studies collected from 1996, combined with data from large international\u000a      collaborative studies\u000a      coordinated at the Centre for Cancer Genetic Epidemiology [Research ref\u000a      2]. Using the largest\u000a      world-wide series of breast cancer patients screened for BRCA1 and\u000a      BRCA2 mutations, Dr\u000a      Antoniou and Prof Easton used advanced statistical methods in 2002-2003 to\u000a      estimate the\u000a      breast and ovarian cancer risks for BRCA1 and BRCA2\u000a      mutation carriers [Research ref 1]. In\u000a      parallel between 2001-2008, Dr Antoniou and Prof Easton developed novel\u000a      statistical techniques to\u000a      model susceptibility to disease within families [Research ref 2]. These\u000a      data and methods formed the\u000a      basis of developing the BOADICEA algorithm [Research ref 2]. This was the\u000a      first algorithm to\u000a      model comprehensively genetic susceptibility to breast cancer, based on\u000a      the largest available data\u000a      resources worldwide. Between 2006 and 2008, Dr Antoniou led the analysis\u000a      to evaluate risk\u000a      prediction algorithms for familial breast cancer which involved the large\u000a      majority of clinical\u000a      genetics centres in the UK [Research ref 3]. This was the largest study of\u000a      its kind, including\u000a      1934 families. It demonstrated that BOADICEA was well-calibrated and that\u000a      it provided the best\u000a      discrimination among available risk models. Thus, BOADICEA was shown to be\u000a      a valid tool that\u000a      could be used for genetic counselling of familial breast cancer.\u000a    Additional research to broaden applicability of BOADICEA: Since\u000a      2007 Prof Easton has been\u000a      leading world-wide efforts to identify common breast cancer susceptibility\u000a      alleles through\u000a      genome-wide association studies. Sixty of the 67 known breast cancer\u000a      alleles have been\u000a      identified through studies at the University of Cambridge [Research ref\u000a      4]. Prof Easton and Dr\u000a      Antoniou have been coordinating the analytical efforts for the Breast\u000a      Cancer Association\u000a      Consortium (BCAC) and Consortium of Investigators of Modifiers of BRCA1\/2\u000a      (CIMBA). These\u000a      consortia have played a key role in the characterisation of novel genetic\u000a      variants and of risks\u000a      for BRCA1 and BRCA2 mutation carriers [Research refs 4,5].\u000a      Recent risk modelling work, by\u000a      Dr Antoniou and Prof Easton, has also demonstrated that the research has\u000a      direct clinical\u000a      applicability for women who carry the BRCA1 and BRCA2 mutations who are\u000a      among the first\u000a      patients for whom the common breast cancer susceptibility variants can be\u000a      used for risk\u000a      prediction [Research ref 5]. Similarly, they have shown that common breast\u000a      cancer\u000a      susceptibility alleles identified from BCAC may have a role in targeted\u000a      prevention of breast\u000a      cancer [Research ref 6].\u000a    "},{"CaseStudyId":"21740","Continent":[],"Country":[],"Funders":["Economic and Social Research Council","Medical Research Council"],"ImpactDetails":"\u000d\u000aImpact of Newcastle research on informing prevalence rates\u000d\u000aA fundamental difficulty in tackling the challenges posed by dementia was the lack of knowledge of\u000d\u000athe scale of the problem, including prevalence rates and progression pathway. This was addressed\u000d\u000aby two reports that would prove influential in informing subsequent policy. The first, a report to the\u000d\u000aAlzheimer's Society entitled `Dementia UK' (EV a), contains prevalence and incidence data that\u000d\u000awere largely contributed by the CFAS (R 1-2): \"In terms both of sample size and scope the\u000d\u000aevidence base is dominated by the Medical Research Council Cognitive Function and Ageing\u000d\u000aStudy\" (EV a, pg. 10). Consequently, Dementia UK acted as the major source of information for the\u000d\u000asecond report, a 2007 National Audit Office document (EV b). These two reports formed the basis\u000d\u000afor the National Dementia Strategy (EV c), a high-level policy document published in 2009.\u000d\u000aImpact of Newcastle research on an improved care pathway\u000d\u000aNewcastle research has informed healthcare improvement programmes that highlight the\u000d\u000aimportance of early diagnosis, a well-performed disclosure and a well-planned care pathway.\u000d\u000aWhen preparing the National Dementia Strategy, the Early Diagnosis and Intervention working\u000d\u000agroup became aware of the lack of evidence to support opinions regarding earlier diagnosis and its\u000d\u000amore sensitive disclosure (EV d). This prompted research that resulted in the publication of R6,\u000d\u000awhich went on to inform the 2011 Health Foundation Improvement report. This cites R6 twice (EV\u000d\u000ae, pg 74), stating:\u000d\u000a\u000d\u000a\"patients are most likely to benefit from an early diagnosis if there is a coordinated team\u000d\u000awith representatives of different types of health and social care to plan the care of the\u000d\u000apatient\"\u000d\u000a\"Patients and carers prefer to be told the diagnosis early, as this ends their uncertainty\u000d\u000aabout the problem, allows them to learn more about the condition and how to cope with it. It\u000d\u000aalso gives them an opportunity to access support and allows them to achieve unfulfilled\u000d\u000aambitions in the short term.\"\u000d\u000a\u000d\u000aImpact of Newcastle research on policy implementation\u000d\u000aThe Department of Health appointed an expert group to develop \"commissioning packs\" which\u000d\u000aenable the implementation of recommendations, via enabling health and local authority\u000d\u000acommissioners to design cost-effective services that are suited to local needs. Professor Robinson\u000d\u000awas recruited to this expert group on the basis of her relevant research expertise. She was able to\u000d\u000abring to the group's deliberations both the results of her research on the beneficial effects of early\u000d\u000adiagnosis for patients and their families, and the findings from Newcastle-led research on best\u000d\u000apractice in disclosing a diagnosis of dementia. The National Clinical Director for Dementia stated:\u000d\u000a\"I ... confirm that the evidence and advice [Professor Robinson] provided in [her] role as a key\u000d\u000amember of the Department of Health [DH] Expert Group responsible for the development of the DH\u000d\u000aCommissioning Guidance packs for Dementia care, was crucial to determining key commissioning\u000d\u000atargets and outcomes of good quality care\" (EV f). These packs were also informed directly by\u000d\u000aNewcastle research (R5) and indirectly via the 2009 National Dementia Strategy (EV c, itself\u000d\u000aincluding Newcastle research).\u000d\u000aThe two Dementia Commissioning Packs (EV g, h), published in 2011, include the statement:\u000d\u000a\"Identifying people earlier in the disease pathway enables more people suffering from the disease\u000d\u000ato make choices rather than at a point when it is too late\" (EV g, pg. 15). Newcastle research (R5)\u000d\u000ais included in EV h (pg. 9) as evidence that a rapidly and sensitively communicated diagnosis of\u000d\u000adementia has several advantages to the patient over traditional diagnosis pathways, including \"a\u000d\u000abetter understanding of the situation\" and \"an end to uncertainty\". These packs also went on to\u000d\u000aform the basis of the Prime Minister's 2012 Challenge on Dementia.\u000d\u000aThe Prime Minister's Dementia Challenge\u000d\u000aIn the latest step in policy development, the Prime Minister established a \"Dementia Challenge\" in\u000d\u000a2012 (EV i) to increase implementation of recommendations. Professor Robinson was appointed to\u000d\u000aa senior role, as confirmed by the National Clinical Director for Dementia (EV d): \"[Professor\u000d\u000aRobinson's] expertise as a national researcher in dementia care contributed to [her] selection as\u000d\u000aPrimary care advisor to the Secretary of State for the Prime Minister's National Dementia\u000d\u000aChallenge\". The National Dementia Challenge identifies major improvement targets for dementia\u000d\u000acare by 2015. Its first interim report notes that those responsible for implementation believe they\u000d\u000aare on track for working with professionals to improve early diagnosis (EV j, pg. 38).\u000d\u000aSummary\u000d\u000aNewcastle contributed to a large, multi-centre cohort study that broke with the prevailing focus of\u000d\u000aresearch. The study showed that dementia was more common than previously thought, and that\u000d\u000aage was a significant risk factor, with implications for the ageing population. Subsequent Newcastle\u000d\u000aresearch that identified poor quality of the diagnosis and care pathway informed several high-level\u000d\u000apolicy documents, including the 2012 Prime Minister's Dementia Challenge, and guidance in the\u000d\u000aform of the Department of Health's 2011 commissioning packs.\u000d\u000a","ImpactSummary":"\u000d\u000aNewcastle research on dementia contributed two aspects that helped to shape high-level policy:\u000d\u000afirst that prevalence of the condition was higher than previously suspected, with implications for\u000d\u000acare of the ageing UK population. Secondly, that patients often experienced long delays before a\u000d\u000adiagnosis of dementia was given, leading to distress both for patients and their families. This\u000d\u000aresearch informed policy documents such as the Prime Minister's 2012 Challenge on dementia\u000d\u000aand national guidance in the form of commissioning packs. Patients benefit from more timely\u000d\u000adiagnosis with a better understanding of their needs and wishes and the NHS benefits through\u000d\u000apotential reductions in long term care costs.\u000d\u000a","ImpactType":"Political","Institution":"\u000d\u000aNewcastle University\u000d\u000a","Institutions":[{"AlternativeName":"Newcastle upon Tyne (University of)","InstitutionName":"Newcastle University","PeerGroup":"A","Region":"North East","UKPRN":10007799}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a(Newcastle authors in bold type, citation counts from Scopus, July 2013.)\u000d\u000a\u000aR1. MRC CFAS Medical Research Council Cognitive Function &amp; Ageing Study, including McKeith\u000d\u000aI, Hrisos S and Bond J. Cognitive function and dementia in six areas of England and Wales:\u000d\u000aThe distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study.\u000d\u000aPsychological Medicine 1998, 28(2), 319-35. DOI: 10.1017\/S0033291797006272. Cited by\u000d\u000a162\u000d\u000a\u000a\u000aR2. The Neuropathology Group of the Medical Research Council Cognitive Function and Ageing\u000d\u000aStudy, including Ince P and McKeith I. Pathological correlates of late-onset dementia in a\u000d\u000amulticentre, community-based population in England and Wales. Neuropathology Group of the\u000d\u000aMedical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001,\u000d\u000a357 (9251):169-75. DOI: 10.1016\/S0140-6736(00)03589-3. Cited by 673\u000d\u000a\u000a\u000aR3. Bamford C, Eccles M, Steen N, Robinson L. Can primary care record review facilitate\u000d\u000aearlier diagnosis of dementia? Family Practice, 2007; 24(2): 108-116. DOI:\u000d\u000a10.1093\/fampra\/cml068. Cited by 13\u000d\u000a\u000a\u000aR4. Manthorpe J, Samsi K, Campbell S, Abley C, Keady J, Bond J, Watts S, Robinson L,\u000d\u000aGemski A, Warner J, Goodman C, Drennan,V, Iliffe S. The transition from CI to dementia:\u000d\u000aolder people's experiences. 2011. NIHR Service Delivery and Organisation programme.\u000d\u000aSouthampton. HMSO Queens Printer and Controller. Available at\u000d\u000ahttp:\/\/www.kcl.ac.uk\/sspp\/kpi\/scwru\/pubs\/2011\/manthorpeetal2011transitionfinalreport.pdf\u000d\u000aCitation data unavailable in Scopus.\u000d\u000a\u000a\u000aR5. Bamford C, Lamont S, Eccles M, Robinson L, May C, Bond J. Disclosing a diagnosis of\u000d\u000adementia: a systematic review. International Journal of Geriatric Psychiatry. 2004; 19(2): 151-\u000d\u000a169. DOI: 10.1002\/gps.1050. Cited by 101\u000d\u000a\u000a\u000aR6. Iliffe S, Robinson L, Brayne C, Goodman C, Rait G, Manthorpe J, Ashley P. Primary care and\u000d\u000adementia: 1. diagnosis, screening and disclosure. International Journal of Geriatric Psychiatry.\u000d\u000a2009; 24(9): 895-901. DOI: 10.1002\/gps.2204. Cited by 40.\u000d\u000a\u000aRelevant funding awards, by funder:\u000d\u000a&#8226; The Economic and Social Research Council (ESRC). An award of &#163;155,286.\u000d\u000a&#8226; The Medical Research Council (MRC). Three awards totalling &#163;3,736,655\u000d\u000a&#8226; The National Institute for Health Research (NIHR). Three awards totalling &#163;1,429,563\u000d\u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000aEV a. Dementia UK 2007, produced for the Alzheimer's Society\u000d\u000ahttp:\/\/www.alzheimers.org.uk\/site\/scripts\/download_info.php?fileID=2\u000d\u000aEV b. National Audit Office report \"Improving services and support for people with dementia\" 2007\u000d\u000ahttp:\/\/www.nao.org.uk\/wp-content\/uploads\/2007\/07\/0607604.pdf\u000d\u000aEV c. Living Well With Dementia; A National Dementia Strategy. Produced by the Department of\u000d\u000aHealth 2009.\u000d\u000ahttps:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/168220\/dh_094051.pdf\u000d\u000aEV d. Letter from the Professor of Primary Care for Older people, University College London,\u000d\u000aavailable on request\u000d\u000aEV e. Health Foundation improvement report: Spotlight on dementia care, 2011:\u000d\u000ahttp:\/\/www.health.org.uk\/public\/cms\/75\/76\/4181\/2703\/Spotlight_Dementia%20Care.pdf?realName=1pWJno.pdf\u000d\u000aEV f. Letter from the National Clinical Director for Dementia, available on request\u000d\u000aEV g. Service specification for dementia: memory service for early diagnosis and intervention.\u000d\u000aJuly 2011.\u000d\u000ahttp:\/\/webarchive.nationalarchives.gov.uk\/20110907180004\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_128877.pdf\u000d\u000aEV h. Case for change &#8212; memory service for people with dementia. July 2011\u000d\u000ahttp:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_128580.pdf\u000d\u000aEV i. The Prime Minister's Challenge on Dementia. March 2012.\u000d\u000ahttps:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/215101\/dh_133176.pdf\u000d\u000aEV j. The first annual report on progress on the Prime Minister's Dementia Challenge. May 2013.\u000d\u000ahttps:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/200030\/9535-TSO-2900951-PM_Challenge_Dementia_ACCESSIBLE.PDF\u000d\u000a\u000d\u000a","Title":"\u000d\u000aShaping the UK's dementia care policy to reflect the importance of an early,\u000d\u000asensitively-communicated diagnosis of dementia\u000d\u000a","UKLocation":[{"GeoNamesId":"2641673","Name":"Newcastle-upon-Tyne"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000aNewcastle research staff All staff were employees at the University during the research period\u000d\u000aunless otherwise stated.\u000d\u000aProfessors John Bond, Ian McKeith and Louise Robinson were co-applicants and site leads of the\u000d\u000aMedical Research Council (MRC) Cognitive Function and Ageing Study (CFAS) study, with the\u000d\u000adata analysis performed by Dr Blossom Stephan (joined 2012). Professor Martin Eccles was\u000d\u000aPrincipal Investigator of the MRC Primary Care and Dementia study, with Ms Claire Bamford the\u000d\u000aSenior Research Associate and Dr Nicholas Steen the Senior Statistician. Professor Robinson was\u000d\u000athe co-applicant and site lead of the National Institute for Health Research (NIHR) Transitions\u000d\u000astudy and Dr Clare Abley (joined January 2009) was the Senior Researcher of the NIHR\u000d\u000aTransitions study.\u000d\u000aBackground: the challenge of dementia\u000d\u000aThe 2009 World Alzheimer Report estimated that 35.6 million people worldwide were living with\u000d\u000adementia, and ageing populations mean that this figure is likely to rise to 115 million by 2050. In\u000d\u000aterms of quality of life, dementia is the chronic illness that accounts for the greatest number of\u000d\u000ayears lived with disability in those aged over 60 years. The estimated global financial burden is\u000d\u000a$315 billion, with UK costs estimated at &#163;17 billion (EV a).\u000d\u000aDementia is characterised by impaired memory and communication, which inevitably lead to loss\u000d\u000aof independence and a need for long-term care. As people age, some loss of memory is natural;\u000d\u000athis is known as normal cognitive ageing. However, 1 in 14 people over 65 years, and 1 in 5 over\u000d\u000a80 years will develop dementia. There is no long-term cure, but Newcastle research has\u000d\u000acontributed to a deeper understanding of the quality of clinical care that people experience along\u000d\u000athe diagnostic pathway.\u000d\u000aUnderstanding the prevalence and risk factors for dementia\u000d\u000aPrior to the 1990s, the majority of research into dementia was targeted towards finding a cure or\u000d\u000aunderstanding the cause of this devastating illness. However, the focus of research shifted towards\u000d\u000aunderstanding the natural history of dementia during the early 1990s with the MRC-funded CFAS\u000d\u000astudy (R 1-2). Newcastle's contribution to this unique, primary care based cohort study was to\u000d\u000arecruit 20% of the 13,000 participants and perform data analysis. The two main findings of the\u000d\u000astudy were first that prevalence was higher than previously thought, and second that age was a\u000d\u000asignificant risk factor for dementia, implying that the prevalence would increase in the ageing UK\u000d\u000apopulation.\u000d\u000aPatient and family experiences of the diagnostic pathway\u000d\u000aFollowing this epidemiological research, Newcastle researchers, including Professor Robinson in\u000d\u000aher capacity as an academic GP, investigated the quality of care received by patients as they were\u000d\u000aassessed for dementia. An MRC-funded, Newcastle-based study (R3) analysed general practice\u000d\u000arecords of 300 people recently diagnosed with dementia, and found that average time to diagnosis\u000d\u000awas 18 months and the maximum was four years. In order to explore the reasons behind such\u000d\u000adelays, a qualitative study was conducted in 2009 to investigate the individual experiences of\u000d\u000apatients and their families during assessment in memory clinics. Results showed that despite\u000d\u000anational clinical guidance in this area (NICE CG42, 2006), people with memory problems continued\u000d\u000ato experience unnecessary delays and considerable distress during the diagnostic process (R4). In\u000d\u000aaddition, Newcastle-led research examined the way in which a diagnosis of dementia was\u000d\u000adisclosed to patients and their families. The findings demonstrated that the majority of patients\u000d\u000awished to be informed of a definitive diagnosis of dementia; however, the diagnosis was often\u000d\u000awithheld from the patients themselves, even though their families were told (R5).\u000d\u000aFindings from a review of how diagnosis is carried out in primary care (R6) showed three aspects\u000d\u000aof relevance: first, that diagnosis involves good co-operation between primary and secondary care\u000d\u000aproviders, secondly that patients with mild dementia wish to know their diagnosis, and thirdly that\u000d\u000athe benefits of a well-performed and early diagnosis include an end to uncertainty, allowing\u000d\u000apatients and their families to plan for the future and giving access to support.\u000d\u000a"},{"CaseStudyId":"21741","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    As a result of research led by Newcastle University, the UK National\u000a        Institute for Health and Care Excellence (NICE) has adopted: (i)\u000a      methods by which the world's leading valid clinical practice guidelines\u000a      are produced; and (ii) processes that offer the best opportunity for\u000a      implementation by those responsible. This maximises the opportunities for\u000a      health gains for patients and predictable costs for the NHS.\u000a    The National Institute for Health and Care Excellence\u000a    NICE was established in 1999, and over time it has expanded its remit to\u000a      provide guidance and advice to improve health and social care. NICE\u000a      guidance supports healthcare professionals and others in England to ensure\u000a      that the care they provide is of the highest quality, and that it offers\u000a      the best value for money. NICE is internationally recognised for the way\u000a      in which recommendations are developed, using the best available evidence\u000a      (Ev a).\u000a    NICE guidelines: the ongoing impact of Newcastle research\u000a    The first guideline adopted by NICE was one developed by Eccles' research\u000a      group concerning secondary prophylaxis following myocardial infarction (Ev\u000a      b). NICE also adopted the approach by which the guideline (and those on\u000a      asthma (R1) and another on angina) was produced. Six research publications\u000a      (led by the Newcastle group) on guideline development (including R3, R5\u000a      and R6 above) were later cited in the first edition of the NICE\u000a        Guideline Development Manual (2004). These publications continue to\u000a      underpin the method for preparing guidelines, as can be observed most\u000a      recently in the November 2012 edition of the NICE Guideline\u000a        Development Manual (Ev c).\u000a    A total of 174 NICE guidelines had been produced using the approved\u000a      methods as of July 2013, the majority of which were after 2007. In the\u000a      seven years 2001-7, a total of 65 guidelines were published. In the\u000a      following five years 109 guidelines were published (Ev d). Of all\u000a      guidelines produced, 169 remain in force: 142 of which are in their\u000a      original form and 27 have been updated.\u000a    A significant development has been the introduction of the requirement to\u000a      review guidelines and, if necessary, update them. This process has largely\u000a      taken place since 2008 (see Figure 1). NICE policy, which is based on\u000a      Newcastle-led work on the lifespan of guidelines, is: \"A formal review\u000a        of the need to update a guideline is usually undertaken by NICE 3 years\u000a        after its publication\" (Ev c, p189). This three-year recommendation\u000a      is based on advice presented in the 2001 Journal of the American\u000a        Medical Association paper (R4). Since 2008, 22 guidelines have been\u000a      re-written, and 67 other guidelines have been subjected to the review\u000a      process. Five guidelines have been withdrawn as a result of the review\u000a      process.\u000a\u000aFigure 1. The number of NICE guidelines (n) published and reviewed, by three-year periods.\u000a(Data obtained from www.nice.org.uk\/guidance, Ev d)\u000a\u000a    Advising on development and implementation\u000a    The Deputy Chief Executive of NICE has said of Professor Eccles and his\u000a      research that:\u000a    \"...your work on the effectiveness of strategies to implement evidence\u000a        based guidelines [... has] informed NICE's understanding of the\u000a        evidence base for implementation and led to the decision to form NICE's\u000a        Implementation Strategy Group.\" (Ev e)\u000a    Eccles chaired the Implementation Strategy Group from 2008 until retiring\u000a      from it in 2012 (Ev f). Consequently, Newcastle-led research on strategies\u000a      for promoting the uptake of research findings was incorporated into the\u000a      processes and activities of NICE.\u000a    Examples:\u000a    (i) Encouraging engagement in promoting implementation. Guidelines\u000a      are, and have always been, written and reviewed by external committees\u000a      convened for that purpose, rather than NICE staff. The Implementation\u000a      Strategy Group scrutinised the processes by which guideline development\u000a      committee members were recruited. As a result of Newcastle-led research on\u000a      behaviour change amongst professionals (R6), a recommendation was made\u000a      regarding the importance of appointing the appropriate people to promote\u000a      guideline implementation. As a result, since Autumn 2009, the NICE\u000a      Implementation Team has advised management on potential gaps in guideline\u000a      development committee membership in order to encourage the recruitment of\u000a      individuals who could be expected to champion the implementation of a\u000a      guideline.\u000a    (ii) Web-based practical advice on implementation. In 2009, the\u000a      Implementation Strategy Group gave advice (based on research such as that\u000a      described in R6) on promoting engagement with primary care services and\u000a      supported the production of web pages designed to aid general\u000a      practitioners with the implementation of guidelines. The Implementation\u000a      Programme Director of NICE has said:\u000a    \"This is still a well used part of the site. ... A cross Institute\u000a        group on general practice was formed and still active in 2013. [The\u000a      number of page] views within the first weeks of its launch were\u000a        equivalent to that of our most viewed guideline which is unusually high\u000a        for a support product, rather than a guidance product.\" (Ev g)\u000a    ","ImpactSummary":"\u000a    Clinical practice guidelines published in the UK by the National\u000a        Institute for Health and Care Excellence (NICE) are constructed\u000a      using an approach based on methodological research led by Professor Martin\u000a      Eccles of Newcastle University. This systematic approach includes the\u000a      incorporation of health economics considerations and review after three\u000a      years (and if found necessary, an update of the guidelines); both\u000a      important outcomes of Newcastle research. The implementation of guidelines\u000a      has long been an area of concern. Professor Eccles established and chaired\u000a      (2008-12) the NICE Implementation Strategy Group, which sought to improve\u000a      the assistance that NICE gives organisations in order to aid the\u000a      implementation of guideline recommendations. Valid clinical practice\u000a      guidelines, when implemented, lead to health gains and predictable care\u000a      costs, thus helping both patients and the NHS.\u000a    ","ImpactType":"Economic","Institution":"\u000a    Newcastle University\u000a    ","Institutions":[{"AlternativeName":"Newcastle upon Tyne (University of)","InstitutionName":"Newcastle University","PeerGroup":"A","Region":"North East","UKPRN":10007799}],"Panel":"A         ","PlaceName":[],"References":"\u000a    (Newcastle author in bold type, citation counts from Scopus, July 2013)\u000a    \u000aR1. Eccles MP and members of the guideline development and\u000a      technical advisory groups. North of England evidence based guidelines\u000a      development project: summary version of evidence based guideline for the\u000a      primary care management of asthma in adults. British Medical Journal\u000a      1996;312:762-6. doi: http:\/\/dx.doi.org\/10.1136\/bmj.312.7033.762\u000a      Cited by 43.\u000a    \u000a\u000aR2. Eccles MP, Clapp Z, Grimshaw JM, Adams PC, Higgins B, Purves\u000a      I, Russell IT. North of England evidence based guideline development\u000a      project: methods of guideline development. British Medical Journal\u000a      1996;312:760-2. doi:\u000a        http:\/\/dx.doi.org\/10.1136\/bmj.312.7033.760 Cited by 140.\u000a    \u000a\u000aR3. Eccles M, Mason J. How to develop cost-conscious guidelines. Health\u000a        Technology Assessment 2001;5(16). doi:10.3310\/hta5160 Cited by\u000a        96.\u000a    \u000a\u000aR4. Shekelle P, Ortiz E, Rhodes S, Morton S, Eccles M,\u000a      Grimshaw J, Woolf S. Validity of the agency for healthcare research and\u000a      quality clinical practice guidelines: how quickly do guidelines become\u000a      outdated? Journal of the American Medical Association\u000a      2001;286:1461-7. doi: 10.1001\/jama.286.12.1461 Cited by 238.\u000a      (Eccles contributed to the study concept and design, the analysis of data,\u000a      and the critical revision of the manuscript for important intellectual\u000a      content.)\u000a    \u000a\u000aR5. Eccles M, Rousseau N, Freemantle N. Updating evidence-based\u000a      clinical guidelines. Journal of Health Services Research and Policy\u000a      2002;7:98-103. doi:10.1258\/1355819021927746 Cited by 15.\u000a    \u000a\u000aR6. Eccles M, Grimshaw J, Walker A, Johnson M, Pitts N. Changing\u000a      the behavior of healthcare professionals: the use of theory in promoting\u000a      the uptake of research findings. Journal of Clinical Epidemiology\u000a      2005;58:107-12. doi: 10.1016\/j.jclinepi.2004.09.002 Cited by 213.\u000a    \u000aRelevant funding awards, by funder\u000a    Northern Regional Health Authority: Guidelines for management of\u000a        ischemic heart disease and asthma. 1993 for 18 months; &#163;51,000.\u000a    NHS R&amp;D Programme: Evaluating methods to promote the\u000a        implementation of research findings. 1997 for 42 months; &#163;798,682.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    Ev a. NICE website http:\/\/www.nice.org.uk\/aboutnice\/howwework\/how_we_work.jsp\u000a    Ev b. The first NICE guideline can be found at: http:\/\/guidance.nice.org.uk\/A\u000a    Ev c. NICE, `The guidelines manual' Published on 30\u000a      November 2012. The web version is available at http:\/\/publications.nice.org.uk\/pmg6\u000a      and a searchable pdf version (downloaded 17\/06\/13) is available on\u000a      request.\u000a    Ev d. The individual guidelines are available, beginning at http:\/\/www.nice.org.uk\/guidance\/index.jsp?action=byType&amp;type=2&amp;status=3\u000a      and continuing for several pages. Dates were gathered from webpages and\u000a      tabulated. This data can be made available on request.\u000a    Ev e. A letter from the Deputy Chief Executive of NICE (who has\u000a      agreed to be contacted to corroborate these claims if required) is\u000a      available on request.\u000a    Ev f. Notification of the vacancy, with a description of the role\u000a      of the Implementation Strategy Group is available at\u000a      http:\/\/www.nice.org.uk\/getinvolved\/joinnwc\/ChairAndMemberImplementationStrategyGroup.jsp\u000a    Ev g. A copy of e-mail communication with the Implementation\u000a      Programme Director of NICE (who has agreed to be contacted if required to\u000a      corroborate the claimed impacts) is available. \u000a    ","Title":"\u000a    NICE work: improving evidence-based clinical guideline development and\u000a      implementation\u000a    ","UKLocation":[{"GeoNamesId":"2641673","Name":"Newcastle-upon-Tyne"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Key Researcher\u000a    Professor Martin Eccles conceived and led the research in Newcastle and\u000a      contributed significantly to collaborative work, detailed where\u000a      appropriate.\u000a    Background \/ context\u000a    Clinical practice guidelines, defined as \"systematically developed\u000a        statements to assist practitioner and patient decisions about\u000a        appropriate health care for specific clinical circumstances\",\u000a      represent one of the foundations for efforts to improve healthcare (Field\u000a      &amp; Lohr, National Academy Press 1990). The development of clinical\u000a      practice guidelines (hereafter referred to as guidelines) began in the USA\u000a      in the early 1990s. However, legal challenges (a result of the largely\u000a      private nature of US healthcare) stopped progress soon afterwards leaving\u000a      significant methodological issues to be addressed, particularly\u000a      validation. Guidelines are considered valid only if: \"when followed,\u000a        they lead to the health gains and costs predicted for them\" (Field\u000a      &amp; Lohr, National Academy Press 1992). When appropriately disseminated\u000a      and implemented, valid guidelines can lead to changes in clinical practice\u000a      and improvements in patient outcome. Conversely, the dissemination and\u000a      implementation of invalid guidelines may lead to wasteful use of resources\u000a      on ineffective interventions or, worse still, deterioration in patients'\u000a      health. Research at Newcastle University sought to fill this gap in the\u000a      development of valid guidelines.\u000a    Research\u000a    The research undertaken at Newcastle first addressed the question of how\u000a      best to develop valid guidelines that help to improve the quality of\u000a      patient care. Building on the general method developed by the Agency for\u000a      Health Care Policy and Research in the USA, and refining it for\u000a      application to the NHS, in 1996 Professor Eccles led the development of\u000a      the first evidence-based guideline in the UK (R1). The following year,\u000a      further guidelines were published, along with a practical methodology for\u000a      the production of evidence-based guidelines (R2).\u000a    There had been little theoretical exploration, and a lack of a widely\u000a      accepted means, of incorporating economic considerations into guidelines.\u000a      The NHS Research and Development Health Technology Assessment Programme\u000a      document How to develop cost conscious guidelines (R3), authored\u000a      jointly by Eccles and Mason (York University) in 2001, was the first\u000a      published practical approach in which cost and cost-effectiveness concepts\u000a      were successfully incorporated into guideline development processes.\u000a    Between 2001 and 2005, Newcastle researchers played a leading role in an\u000a      international research effort that studied guidelines in use. This showed\u000a      that guidelines have an average lifespan of about six years and stated \"As\u000a        a general rule, guidelines should be reassessed for validity every 3\u000a        years.\" (R4, p1461) Further research led to a publication that\u000a      described approaches for updating clinical guidelines (R5).\u000a    In addition to this focus on guideline development, Newcastle researchers\u000a      developed an understanding of how new knowledge described in academic\u000a      medical literature was taken up by practising clinicians. This research\u000a      had implications for improving the implementation of guidelines in the\u000a      clinical setting (R6).\u000a    "},{"CaseStudyId":"21743","Continent":[],"Country":[],"Funders":["Economic and Social Research Council","Medical Research Council"],"ImpactDetails":"\u000d\u000a    Alcohol misuse presents a considerable problem in England, with over 10\u000d\u000a      million adults drinking more than Government-set lower-risk limits, and\u000d\u000a      2.6 million drinking more than higher-risk limits (EV b). Alcohol-linked\u000d\u000a      hospital admissions were 1.2 million during 2010-11 (EV c). In financial\u000d\u000a      terms, alcohol-related harm costs the UK economy up to &#163;25.1 billion\u000d\u000a      annually (EV b, d), and costs the health service &#163;2.7 billion (EV b, d).\u000d\u000a      Newcastle research on reducing alcohol-related risk has influenced\u000d\u000a      national policy, practice and patients themselves, specifically by\u000d\u000a      introducing and promoting methods of screening and brief intervention\u000d\u000a      (SBI). The first step involves screening, via a short questionnaire, to\u000d\u000a      identify which individuals would benefit from brief intervention, in the\u000d\u000a      form of specific advice or counselling to help a patient reduce their\u000d\u000a      drinking behaviour.\u000d\u000a    Impact of Newcastle research on policy\u000d\u000a      This has been demonstrated through specific citation of Newcastle-led work\u000d\u000a      in a wide range of national policy documents and reports.\u000d\u000a    A 2008 National Audit Office report (EV d) cites the Cochrane\u000d\u000a      Collaboration systematic review (R6), stating that: \"a meta-analysis of\u000d\u000a        22 randomised control trials concluded that, overall, brief\u000d\u000a        interventions lowered alcohol consumption.\" This Cochrane review was\u000d\u000a      also included in the March 2009 House of Commons Select Committee on\u000d\u000a      Alcohol (EV b), in which Kaner represented an expert source of evidence.\u000d\u000a      This report states: \"Since excessive drinking is responsive to even\u000d\u000a        brief intervention in community-based settings [the reference given\u000d\u000a      is R5], it is imperative that the public health community acts to\u000d\u000a        prevent alcohol-related risk and harm across the population.\"\u000d\u000a    Impact of Newcastle research on practice\u000d\u000a      Since 2008, the Newcastle-developed SBI programme `How Much is Too\u000d\u000a        Much' has been included in six annual Directed Enhanced Service\u000d\u000a      documents (EV e). These are commissioned by the Department of Health and\u000d\u000a      delivered to patients via their Primary Care Trust. Each refers to R7,\u000d\u000a      stating: \"The recommended brief advice is the basic five minutes of\u000d\u000a        advice used in the [World Health Organization] clinical trial ...\u000d\u000a        using a programme modified for the UK context by the University of\u000d\u000a        Newcastle: `How Much is Too Much?'.\" (R6).\u000d\u000a    The Department of Health's Alcohol Policy Team states: \"I can confirm\u000d\u000a        that your reports and the advice you provided for consideration by the\u000d\u000a        Quality Outcomes Framework Expert Group certainly made its way into the\u000d\u000a        thinking that informed the development of the Directed Enhanced Service.\u000d\u000a        In addition, the advice you produced in the reports and the material you\u000d\u000a        developed from the `How Much is Too Much?' programme went on to be the\u000d\u000a        basis of the Primary Care Service Framework that we use to support the\u000d\u000a        Directed Enhanced Service and local variations in the form of Local\u000d\u000a        Enhanced Services.\" (EV f)\u000d\u000a    Professor Kaner brought the results of Newcastle-led research on SBI to\u000d\u000a      the NICE Programme Development Group, which she chaired in 2009-10. In\u000d\u000a      June 2010, this group published an extensive set of evidence-based\u000d\u000a      recommendations (NICE guidance 24, EV g, page 34) to guide policy and\u000d\u000a      practice in this area. These guidelines specifically cite `How Much is\u000d\u000a        Too Much?', along with the Drink-Less pack, as \"coordinated\u000d\u000a        collections of evidence-based materials for use when screening and\u000d\u000a        carrying out a brief intervention\". The Government's 2012 Alcohol\u000d\u000a      Strategy (EV c, page 24) is informed by these NICE guidelines: \"[NICE]\u000d\u000a        recommends that NHS health professionals routinely carry out alcohol\u000d\u000a        screening as an integral part of their practice\".\u000d\u000a    In terms of reducing costs, the Department of Health estimates that\u000d\u000a      screening and brief advice can save a primary care trust &#163;650,000\u000d\u000a      annually. At the time of the document's publication in December 2009, this\u000d\u000a      figure applied to over 150 primary care trusts, representing annual saving\u000d\u000a      of nearly &#163;100 million across the UK (EV h).\u000d\u000a    Impact of Newcastle research on patients\u000d\u000a      Screening and brief intervention have already started to improve patient\u000d\u000a      health: a 2010 report commissioned by the Centre for Public Health\u000d\u000a      Excellence on behalf of NICE (EV i, page 17) included R5 as part of \"a\u000d\u000a        considerable body of evidence supportive of the effectiveness of brief\u000d\u000a        interventions for alcohol misuse in reducing alcohol consumption,\u000d\u000a        mortality, morbidity, alcohol-related injuries, alcohol-related social\u000d\u000a        consequences, healthcare resource use and laboratory indicators of\u000d\u000a        alcohol misuse\".\u000d\u000a    Using GP Read code data as a measure of delivery, recent Newcastle work\u000d\u000a      showed an increase in the use of formal screening tools, from 0.8% in 2008\u000d\u000a      to 7.5% in 2011 (EV j). Since screening and feedback may be sufficient to\u000d\u000a      reduce drinking, by alerting patients to their drinking levels, this\u000d\u000a      increase in screening indicates that a growing number of patients are\u000d\u000a      receiving targeted help to reduce alcohol consumption.\u000d\u000a    In summary, Newcastle work that developed a UK-specific screening\u000d\u000a      and brief intervention programme has influenced national policy, been\u000d\u000a      widely recommended and has seen increased use in general practice.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Newcastle research into practical methods to reduce alcohol-related risk\u000d\u000a      and harm has underpinned national policy, including the Government's\u000d\u000a      Alcohol Strategy and a National Audit Office report. This has shaped\u000d\u000a      public health practice concerning alcohol across England. A UK-specific\u000d\u000a      screening and brief intervention (SBI) programme was developed by\u000d\u000a      Newcastle University for use by GPs and nurses in primary care. This\u000d\u000a      programme, which was designed to reduce alcohol-related problems, has been\u000d\u000a      widely recommended and adopted. An evidence review commissioned by the\u000d\u000a      National Institute for Health and Care Excellence (NICE) found that the\u000d\u000a      use of SBI reduces alcohol consumption, mortality, morbidity and\u000d\u000a      alcohol-related injuries. Department of Health figures show that SBI\u000d\u000a      provides an estimated annual healthcare saving of around &#163;100 million.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    Newcastle University\u000d\u000a    ","Institutions":[{"AlternativeName":"Newcastle upon Tyne (University of)","InstitutionName":"Newcastle University","PeerGroup":"A","Region":"North East","UKPRN":10007799}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    (Newcastle authors in bold type, citation counts from Scopus, July 2013.)\u000d\u000a    \u000aR1. Kaner EFS, Heather, N, McAvoy BR, Lock CA,\u000d\u000a      Gilvarry E. Intervention for excessive alcohol consumption in primary\u000d\u000a      health care: attitudes and practices of English general practitioners. Alcohol\u000a        &amp; Alcoholism 1999; 34: 559-566. DOI: 10.1093\/alcalc\/34.4.559. Cited\u000a        by 122.\u000d\u000a    \u000a\u000aR2. Kaner E, Lock C, McAvoy B, Heather N, Gilvarry E. A\u000d\u000a      randomised controlled trial of three \u000d\u000a      training and support strategies to encourage implementation of screening\u000d\u000a      and brief alcohol intervention by general practitioners. British\u000d\u000a        Journal of General Practice 1999; 49: 699-703. DOI:\u000d\u000a      10.1186\/1471-2458-9-287. Cited by 67. \u000d\u000a    \u000a\u000aR3. Lock C, Kaner E, Heather N, Doughty J, Crawshaw\u000a        A, McNamee P, Purdy S, Pearson P. Effectiveness of\u000d\u000a      nurse-led brief alcohol intervention: A cluster randomised controlled\u000d\u000a      trial. Journal of Advanced Nursing 2006; 54: 426-439. DOI:\u000d\u000a      10.1111\/j.1365-2648.2006.03836.x. Cited by 30.\u000d\u000a    \u000a\u000aR4. Kaner E, Lock C, Heather N, McNamee P, Bond\u000a        S. Promoting brief alcohol intervention by nurses in primary care: a\u000d\u000a      cluster randomised controlled trial. Patient Education &amp;\u000d\u000a        Counselling 2003; 51: 277-284. DOI: 10.1186\/1471-2458-9-287. Cited\u000a        by 29.\u000d\u000a    \u000a\u000aR5. Kaner EFS, Dickinson HO, Beyer FR, Pienaar EDE\u000d\u000a      D, Campbell F, Schlesinger C, Heather N, Saunders JB, Burnand B.\u000d\u000a      Effectiveness of brief alcohol interventions in primary care populations.\u000d\u000a      Cochrane Database of Systematic Reviews 2007; 2: CD004148. DOI:\u000d\u000a      10.1002\/14651858.CD004148.pub3. Cited by 470.\u000d\u000a    \u000a\u000aR6. McCormick R, Docherty B, Segura L, Colom J, Gual A, Cassidy P,\u000d\u000a      Kaner E, Heather N. The research translation problem: Alcohol\u000d\u000a      screening and brief intervention in primary care. Real world evidence\u000d\u000a      supports theory. Drugs: Education, Prevention and Policy 2010; 17:\u000d\u000a      732-748. DOI: 10.3109\/09687630903286800. Cited by 9.\u000d\u000a    \u000aRelevant funding awards, by funder\u000d\u000a    &#8226; Alcohol Education Research Council. Four awards totalling &#163;314,124\u000d\u000a    &#8226; Department of Health. Three awards totalling &#163;5,322,083\u000d\u000a    &#8226; European Commission. Three awards totalling &#163;687,937 \u000d\u000a    &#8226; Economic and Social Research Council (ESRC). One award of &#163;17,430\u000d\u000a    &#8226; Medical Research Council (MRC). One award of &#163;98,001\u000d\u000a    &#8226; National Institute for Health Research (NIHR). Six awards totalling\u000d\u000a      &#163;2,247,899\u000d\u000a    &#8226; NHS Executive Regional Commissioned R&amp;D. Two awards totalling\u000d\u000a      &#163;464,978\u000d\u000a    &#8226; Primary Care Trusts. Three awards totalling &#163;162,364\u000d\u000a    &#8226; Tyne &amp; Wear Health Action Zone. One award of &#163;90,525\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    EV a. British Medical Association Board of Science, Alcohol\u000d\u000a        misuse: Tackling the UK epidemic 2008. http:\/\/www.dldocs.stir.ac.uk\/documents\/Alcoholmisuse.pdf\u000d\u000a    EV b. House of Commons Select Committee on Alcohol 2009. (Expert\u000d\u000a      27, pg 93-102)\u000d\u000a      http:\/\/www.publications.parliament.uk\/pa\/cm200809\/cmselect\/cmhealth\/368\/368ii.pdf\u000d\u000a    EV c. The Government's Alcohol Strategy, March 2012.\u000d\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/98121\/alcohol-strategy.pdf\u000d\u000a    EV d. National Audit Office Reducing alcohol harm: health services\u000d\u000a      in England 2008.\u000d\u000a      http:\/\/www.nao.org.uk\/wp-content\/uploads\/2008\/10\/07081049.pdf\u000d\u000a    EV e. Direct Enhanced Services, published by the British Medical\u000d\u000a      Association and NHS Employers April 2008:\u000d\u000a      www.alcoholpolicy.net\/files\/clinical_directed_enhanced_services.pdf.\u000d\u000a      Others (2009-2013) available on request.\u000d\u000a    EV f. Statement from the Alcohol Policy Team, Department of\u000d\u000a      Health, London. Contact details available on request.\u000d\u000a    EV g. NICE guidance 24, 2010. http:\/\/guidance.nice.org.uk\/PH24\/Guidance\/pdf\/English\u000d\u000a    EV h. NHS 2010-2015: from good to great. Preventative,\u000d\u000a      people-centred, productive. December 2009. http:\/\/www.official-documents.gov.uk\/document\/cm77\/7775\/7775.pdf\u000d\u000a    EV i. Screening and Brief Interventions for Prevention and Early\u000d\u000a      Identification of Alcohol Use Disorders in Adults and Young People,\u000d\u000a      http:\/\/www.nice.org.uk\/nicemedia\/live\/11828\/45665\/45665.pdf\u000d\u000a    EV j. Alcoholism: Clinical and Experimental Research Vol.\u000d\u000a      37 No. 6, June 2013 Supplement. Abstract number 554. \u000d\u000a    ","Title":"\u000d\u000a    Screening and brief interventions reduce alcohol consumption in England.\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2641673","Name":"Newcastle-upon-Tyne"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Key Newcastle research staff\u000d\u000a      (Where individuals left or joined the university in the period 1993-2013,\u000d\u000a      years are given in brackets)\u000d\u000a    Professors Eileen Kaner: MRC Research Fellow 1997-2000, Department of\u000d\u000a      Health Career Scientist 2000-2006, Senior Lecturer 2005-7, Professor of\u000d\u000a      Public Health Research 2007 onward, Brian McAvoy: Professor of Primary\u000d\u000a      Health Care (1994-2000), Dr Paul McNamee: Lecturer in Health Economics\u000d\u000a      (1997-2002), Amy O'Donnell, PhD student and Research Assistant 2012-date,\u000d\u000a      Dr Katie Haighton (n&#233;e Lock): Lecturer 2008-date.\u000d\u000a    Newcastle research into screening and brief intervention\u000d\u000a      Newcastle research has focused on identifying practical and evidence-based\u000d\u000a      methods of identifying and reducing alcohol-related risk and harm across\u000d\u000a      the population, for wider public health benefit. In 1995, Professor Kaner\u000d\u000a      coordinated the English arm of a World Health Organization (WHO)\u000d\u000a      Collaborative Study on Implementing and Supporting Early Intervention\u000d\u000a      Strategies in Primary Health Care. Newcastle led two aspects of the study:\u000d\u000a    (i) a postal survey of 430 general practitioners (GPs) in the Midlands,\u000d\u000a      which showed low GP involvement in screening and brief intervention (SBI)\u000d\u000a      activity and identified a range of barriers and incentives for such work\u000d\u000a      (R1)\u000d\u000a      (ii) a large randomised controlled trial that focused on evaluating social\u000d\u000a      marketing strategies to promote uptake of the Drink-Less SBI programme\u000d\u000a      (originally developed by the WHO), and training and support strategies to\u000d\u000a      encourage its use in general practice (R2).\u000d\u000a    The survey (R1) was included in an influential British Medical\u000d\u000a      Association Board of Science report from 2008 entitled \"Alcohol misuse:\u000d\u000a      Tackling the UK epidemic\" (EV a) as evidence demonstrating why there was\u000d\u000a        \"no system for routine screening and management of alcohol misuse in\u000d\u000a        primary or secondary care settings in the UK\" (pg 64).\u000d\u000a    The finding that GPs delegated much of this SBI work to practice\u000d\u000a      colleagues, to nurses in particular, led to national pioneering work with\u000d\u000a      primary care nurses between 1997 and 2000 (R3). This involved: (i)\u000d\u000a      qualitative interviews to identify opportunities for SBI use in nurses'\u000d\u000a      health promotion work; (ii) the development of new materials to support\u000d\u000a      nurse-led SBI delivery; and (iii) a randomised controlled trial of\u000d\u000a      strategies to promote SBI delivery by nurses (R4). The development of the\u000d\u000a      new UK specific SBI programme (called `How Much is Too Much') was\u000d\u000a      led by Kaner, in collaboration with Gateshead Primary Care Trust and\u000d\u000a      Northumbria University. The work was funded by Sunderland Teaching Primary\u000d\u000a      Care Trust, and Professor Nick Heather from Northumbria University was the\u000d\u000a      study Principal Investigator.\u000d\u000a    Kaner's subsequent five-year Department of Health funded primary care\u000d\u000a      career scientist award (2000-2006) enabled further development of this\u000d\u000a      research via: (i) a pragmatic randomised controlled trial to evaluate the\u000d\u000a      cost-effectiveness of `How Much is too Much' when delivered by\u000d\u000a      nurses in routine practice (R3), and (ii) a Cochrane Collaboration\u000d\u000a      systematic review of the wider evidence on SBI effectiveness in primary\u000d\u000a      care settings (R5).\u000d\u000a    In 2004, Kaner was part of a team that tested various aspects of alcohol\u000d\u000a      screening and brief intervention in 12 general practices (R6) to ensure\u000d\u000a      that `How Much is Too Much' could be readily integrated into\u000d\u000a      routine primary care, an essential requirement for wide scale and\u000d\u000a      sustainable adoption.\u000d\u000a    "},{"CaseStudyId":"21764","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    Adoption of FAST into national guidelines\u000a    In July 2008, FAST was included in NICE clinical guideline 68: \"In\u000a        people with sudden onset of neurological symptoms a validated tool, such\u000a        as FAST (Face Arm Speech Test [sic]), should be used outside\u000a        hospital to screen for a diagnosis of stroke or TIA [transient\u000a      ischemic attack: a mini-stroke]\" (EV b, pg. 8).\u000a    The 2012 National Clinical Guideline for stroke (EV c) addresses both of\u000a      the major barriers to rapid stroke care, recommending first that \"All\u000a        patients seen with an acute neurological syndrome suspected to be a\u000a        stroke should be transferred directly to a specialised hyperacute stroke\u000a        unit\". Secondly, R2 is included as the sole source of evidence for\u000a      the recommendation that \"People seen by ambulance staff outside\u000a        hospital, who have sudden onset of neurological symptoms, should be\u000a        screened using a validated tool (eg FAST) to diagnose stroke.\" The\u000a      guideline also states that \"The FAST is accepted as the tool of choice\u000a        for prehospital clinicians.\"\u000a    The effect of Newcastle work of re-organisation of stroke services\u000a    As a direct result of Newcastle research that demonstrated the\u000a      effectiveness of sending acute-stroke patients directly to a dedicated\u000a      unit, stroke services in two cites were reconfigured. In December 2008, a\u000a      new model was implemented to deliver acute stroke services in the Greater\u000a      Manchester region, which led to a substantial increase in thrombolysis\u000a      treatments given: from 10 eligible patients in 2006, 12 in 2007, to 20 in\u000a      2008 and 69 in 2009 (EV e, pg. 19). Between 2009 and 2010 a new model was\u000a      introduced in London that included eight hyper-acute stroke units (HASUs)\u000a      and in February 2010 stroke care in North Central London was merged into\u000a      one HASU to deliver a single standard of care. According to latest\u000a      available figures, thrombolysis rates increased in North Central London\u000a      from 3.5% in February 2009 to 12% by October 2010, and mortality rate\u000a      decreased from above 30% in 2006 to below 10% in 2011 (EV d, pg. 7).\u000a      Administration of thrombolytics within 4.5 hours has been found to be\u000a      significantly associated with a favourable outcome, in terms of measures\u000a      of disability such as the modified Rankin scale and functional scales such\u000a      as the Glasgow Outcome Scale (Hacke et al. 2008, DOI\u000a      10.1056\/NEJMoa0804656). However, this same study found no significant\u000a      difference in mortality rate between the group treated with thrombolytics\u000a      and placebo, a plausible explanation being that the decrease in mortality\u000a      rate seen in North Central London was due to more rapid transport to\u000a      hospital.\u000a    This reconfiguration of stroke care led to NHS London and the Greater\u000a      Manchester and Cheshire Cardiac and Stroke Network winning the 2009 and\u000a      2010 Health Service Journal (HSJ) award for Clinical Service Redesign,\u000a      respectively (EV d, e).\u000a    Adoption of FAST as a national campaign\u000a    The effectiveness of FAST in paramedic use led to its adoption as a\u000a      public recognition instrument. The first body to make use of the validated\u000a      FAST test was the Stroke Association, who state on their website that \"Professor\u000a        Gary Ford's team at Newcastle University showed that ambulance\u000a        paramedics can use the Face Arm Speech Time (FAST) test to recognise\u000a        when someone is having a stroke. The study, funded by The Stroke\u000a        Association, found that paramedics using the FAST test could identify a\u000a        stroke just as accurately as specially trained doctors.\" (EV f).\u000a    The work went on to inform the Department of Health's nationwide Act FAST\u000a      campaign, to help members of the public recognise the signs of stroke and\u000a      to act quickly to ensure that thrombolytics are administered within the\u000a      short window of opportunity. This campaign, originally launched in\u000a      February 2009, has seen several waves of activity, the latest in March\u000a      2013. The memorable imagery includes the use of a \"flaming head\" and has\u000a      appeared on national TV, posters and bus stops (EV g). The Director of\u000a      Research and Information at the Stroke Association states: \"I write to\u000a        confirm that the work you did in assessing the reliability of using FAST\u000a        by paramedics was key to the Stroke Association's decision to use FAST\u000a        in our bus stop campaign and then in the Department of Health using it\u000a        in the flaming head campaign.\" (EV h).\u000a    \u000aPoster from the Department of Health's national FAST campaign,launched in 2009 (EV g)\u000a\u000a    A National Audit Office report from February 2010 (EV i, pg 22-23) stated\u000a      that the Act FAST campaign had been seen by 92% of the 2000 people that\u000a      responded to a survey on its use. The same survey found that from before\u000a      to after the campaign, public awareness of the symptoms of stroke\u000a      increased from 15% to 82%. The report also states that an audit of one\u000a      hyper-acute stroke centre saw a 171% increase in the number of patients\u000a      presenting within three hours of a stroke between 2008 and 2009. Following\u000a      a renewal of the Act FAST campaign in 2012, there was a 25% rise in\u000a      stroke-related 999 calls and a 19% increase in stroke sufferers being seen\u000a      more quickly (EV g).\u000a    As a result of the re-organisation of stroke services and the\u000a      introduction of the Act FAST campaign, thrombolysis treatment for those\u000a      stroke patients who will benefit have increased nationwide fivefold\u000a      between 2006-7 and 2008-9 (EV i, pg. 24). The thrombolysis intervention\u000a      rate has continued to grow: from less than 1% in 20051, to 8%\u000a      by late 2011, according to the Stroke Improvement National Audit Programme\u000a      (SINAP, EV j).\u000a    ","ImpactSummary":"\u000a    Stroke is a major health burden to patients, carers and the NHS, with UK\u000a      costs estimated at &#163;15.5bn annually. Clot-busting agents (thrombolytics)\u000a      can substantially improve the consequences of ischaemic stroke, but only\u000a      if administered rapidly. Newcastle research that recognised the importance\u000a      of rapid referral to a stroke unit allowed reconfiguration of ambulance\u000a      services for direct transport of victims to a specialised centre.\u000a      Newcastle work also validated a test developed for paramedics to recognise\u000a      the signs of stroke, which was developed as the nationwide\u000a      Face-Arms-Speech-Time (Act FAST) campaign. Use of thrombolytics has\u000a      increased eightfold between 2005 and 2012, and there has been a\u000a      considerable increase in public awareness of FAST.\u000a    ","ImpactType":"Health","Institution":"\u000a    Newcastle University\u000a    ","Institutions":[{"AlternativeName":"Newcastle upon Tyne (University of)","InstitutionName":"Newcastle University","PeerGroup":"A","Region":"North East","UKPRN":10007799}],"Panel":"A         ","PlaceName":[],"References":"\u000a    (Newcastle researchers in bold type, citation counts from Scopus, July\u000a      2013)\u000a    \u000aR1. Harbison J, Massey A, Barnett L, Hodge D, Ford GA.\u000a      Rapid ambulance protocol for acute stroke. Lancet. 1999;353:1935.\u000a      DOI: 10.1016\/S0140-6736(99)00966-6. Cited by 46\u000a    \u000a\u000aR2. Harbison J, Hossain O, Jenkinson D, Davis J, Louw SJ, Ford\u000a        GA. Diagnostic accuracy of stroke referrals from primary care,\u000a      emergency room physicians, and ambulance staff using the face arm speech\u000a      test. Stroke. 2003;34:71-76. DOI:\u000a      10.1161\/01.STR.0000044170.46643.5E. Cited by 124\u000a    \u000a\u000aR3. Nor AM, McAllister C, Louw SJ, Dyker AG, Davis M, Jenkinson D,\u000a      Ford GA. Agreement between ambulance paramedic- and\u000a      physician-recorded neurological signs with face arm speech test (FAST) in\u000a      acute stroke patients. Stroke. 2004;35:1355-1359. DOI: 10.1161\/\u000a      01.STR.0000128529.63156.c5. Cited by 57\u000a    \u000aRelevant funding awards, by funder\u000a    &#8226; 2001-2003 Acute Stroke Admissions &#8212; Referral Patterns, Diagnostic\u000a        Accuracy and Development of Stroke Recognition Instruments for Accident.\u000a      The Stroke Association &#163;90,902.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000a    EV a. The Stroke Association, stroke statistics:\u000a      http:\/\/www.stroke.org.uk\/sites\/default\/files\/Stroke%20statistics.pdf\u000a    EV b. NICE clinical guideline 68, July 2008:\u000a      http:\/\/www.nice.org.uk\/nicemedia\/live\/12018\/41316\/41316.pdf\u000a    EV c. National Clinical Guidelines for stroke, September 2012:\u000a      http:\/\/www.rcplondon.ac.uk\/sites\/default\/files\/national-clinical-guidelines-for-stroke-fourth-edition.pdf\u000a    EV d. Harvard Business School Special Version report for UCL\u000a      Partners Value In Healthcare Delivery Program, June 2011:\u000a      http:\/\/islondon.files.wordpress.com\/2012\/06\/mountford-et-al-2010-reconfiguring-stroke-care-in-north-central-london_hbs-special-edition.pdf\u000a    EV e. National Audit Office report \"Progress in Improving Stroke\u000a      Care: A Good Practice Guide\", February 2010:\u000a      http:\/\/www.nao.org.uk\/wp-content\/uploads\/2010\/02\/0910291_good_practice.pdf\u000a    EV f. The Stroke Association: http:\/\/www.stroke.org.uk\/research\/achievements\/fast\u000a    EV g. Department of Health news story, March 2013:\u000a      https:\/\/www.gov.uk\/government\/news\/act-fast-shows-anyone-can-be-a-stroke-saver\u000a    EV h. Letter from the Director of Research and Information at the\u000a      Stroke Association, copy available on request.\u000a    EV i. National Audit Office report: Office \"Progress in improving\u000a      stroke care\", February 2010:\u000a      http:\/\/www.nao.org.uk\/wp-content\/uploads\/2010\/02\/0910291.pdf\u000a    EV j. Royal College of Physicians Stroke Improvement National\u000a      Audit Programme (SINAP) Comprehensive Report December 2011:\u000a      http:\/\/www.rcplondon.ac.uk\/sites\/default\/files\/documents\/sinap-generic-comprehensive-report-march_2012_0.pdf\u000a    ","Title":"\u000a    Re-organisation of ambulance services and increased public awareness of\u000a      stroke symptoms through the Act FAST campaign have improved outcomes for\u000a      stroke.\u000a    ","UKLocation":[{"GeoNamesId":"2641673","Name":"Newcastle-upon-Tyne"},{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2643123","Name":"Manchester"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Newcastle researchers\u000a    Professor Gary Ford CBE acted as Principal Investigator across all\u000a      underpinning studies, and was the only member of Newcastle academic staff\u000a      involved in the research. He left Newcastle University in October 2013.\u000a    The challenge of stroke and rapid diagnosis\u000a    In the UK alone, over 150,000 people have a stroke annually and 1.1\u000a      million people, of all ages, live with stroke (EV a). The annual costs of\u000a      stroke, which include health and informal care costs and loss of\u000a      productivity, are estimated to be up to &#163;15.5bn billion. Treatment exists\u000a      for ischaemic stroke in the form of clot-busting drugs, called\u000a      thrombolytics, but these are only effective if administered rapidly: each\u000a      hour over 714km of nerve fibre are lost. Translated into an example of\u000a      functional loss, every 10-minute delay results in a further 12 out of\u000a      every 1000 patients having impaired walking ability at discharge,\u000a      demonstrating the importance of rapid diagnosis and transfer to a\u000a      specialist centre (Saver et al. 2013, DOI:\u000a      10.1001\/jama.2013.6959). Thrombolytics are most effective if administered\u000a      within three hours (EV d), and beyond 4.5 hours the chances that the\u000a      treatment will help or harm the patients are approximately equal. This\u000a      highlights the importance of rapid diagnosis and transport to a\u000a      specialised unit.\u000a    A National Audit Office report from 2005 (\"Reducing Brain Damage:\u000a        Faster access to better stroke care\") stated that the rate of\u000a      thrombolytic treatment in England was below 1%, because of two major\u000a      contributing factors: firstly, \"the lack of public awareness of the\u000a        fact that stroke is a medical emergency, and that appropriate treatment\u000a        within the first few hours can make the difference between recovery and\u000a        serious disability\" and secondly \"Ambulance Trusts, Accident and\u000a        Emergency departments, Radiology departments and specialist stroke teams\u000a        do not routinely provide an effective, integrated emergency response to\u000a        stroke that includes rapid triage and access to scanning\".\u000a    Newcastle research addressed these two challenges by: 1) recognising that\u000a      paramedics could diagnose stroke with a high degree of accuracy; 2)\u000a      testing the theory that re-organising ambulance services would allow more\u000a      rapid admission of a patient directly to a stroke unit; and 3) developing\u000a      a protocol to increase public awareness of stroke as a medical emergency.\u000a    Re-organisation of stroke services\u000a    Until 1997, suspected stroke patients admitted to the Newcastle Hospitals\u000a      NHS Foundation Trust were first taken by ambulance to one of two Emergency\u000a      Departments before onward referral to the specialist acute stroke unit. To\u000a      improve the speed of access of acute-stroke patients to a dedicated acute\u000a      stroke unit, a protocol was established in Newcastle in 1997 and assessed\u000a      after 15 months (R1). The protocol required paramedics to assess patients\u000a      using the Face-Arm-Speech-Time (FAST) test (see below), with its outcome\u000a      determining whether patients were admitted directly by the acute stroke\u000a      unit, rather than by the Emergency Departments. During this time, 123\u000a      patients were admitted to the acute stroke unit. Admissions increased\u000a      during the first year from an average of three to 13 patients per month,\u000a      with diagnostic accuracy above 80%, showing that re-organisation of the\u000a      service allowed acute-stroke patients to be directed appropriately and\u000a      thus have a greater chance of rapid treatment.\u000a    Improving paramedic and public recognition of stroke\u000a    Research carried out by Professor Gary Ford CBE at Newcastle tested the\u000a      hypothesis that paramedics could recognise acute stroke using a simple,\u000a      quick protocol (R1, 2), and direct the patient to the appropriate unit for\u000a      prompt action. This protocol, named FAST for \"Face Arm Speech Time\" (or\u000a      sometimes \"Test\"), was developed from the Cincinnati Prehospital Stroke\u000a      Scale (CPSS). The FAST test contains three elements of the CPSS which were\u000a      modified to use assessment of spontaneous speech rather than repetition of\u000a      a sentence. This allows the test to be performed more quickly, reducing\u000a      assessment time and enabling a positively-identified stroke patient to be\u000a      transferred to a stroke unit without delay. The FAST test was also\u000a      developed to complement existing assessments that paramedics were familiar\u000a      with such as conscious level. Newcastle research found that paramedics\u000a      correctly diagnosed stroke in 79% of patients using FAST (R2), and that\u000a      there was good agreement between paramedic identification of stroke and\u000a      later confirmation by a specialist (R3).\u000a    "},{"CaseStudyId":"22020","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000d\u000a    Population ageing is a key social issue of our times. Not only do we need\u000d\u000a      to understand the factors which have contributed to increasing longevity\u000d\u000a      and how these may evolve; we also need to understand social differentials\u000d\u000a      in patterns and trends to inform policy making.\u000d\u000a    The immediate beneficiary of our research is the pensions provider Legal\u000d\u000a      &amp; General (L&amp;G). L&amp;G provides retirement income to some\u000d\u000a      250,000 customers and has recently received several high- profile\u000d\u000a      financial services industry awards, including: Best Life Assurance, Term\u000d\u000a      Assurance, Protection and Critical Illness Provider, 2011 &#8212; Financial\u000d\u000a      Advisor Life and Pension Awards; 4* winner in life and pensions category,\u000d\u000a      2011 - FT Adviser Service awards. The research has implications for the\u000d\u000a      valuation of pensions across social groups e.g. public sector final salary\u000d\u000a      schemes, occupational (defined contribution) schemes and privately funded\u000d\u000a      pensions.\u000d\u000a    One of the important ways we support L&amp;G is to translate published\u000d\u000a      epidemiological evidence to meet their specific information needs in a\u000d\u000a      practical way. Through engagement with UCL and DAHR seminars, L&amp;G have\u000d\u000a      also had the opportunity to hear `first-hand' discussions on the changing\u000d\u000a      needs, and matters relating to the provision of healthcare in the UK,\u000d\u000a      especially in relation to major chronic diseases now and in the future. We\u000d\u000a      also contribute to joint monthly seminars between UCL and L&amp;G analysts\u000d\u000a      to enable mutual knowledge transfer and capacity building. We have\u000d\u000a      disseminated findings in discipline-relevant media and in industry forums:\u000d\u000a      seminars, journals and magazines. A key outcome of the academic-industry\u000d\u000a      collaboration is to achieve a collective view on the future evolution of\u000d\u000a      health and longevity and to spur the development of a range of insurance\u000d\u000a      and annuity products that are fair, affordable and could improve the\u000d\u000a      quality of life of all in retirement\u000d\u000a    L&amp;G report that direct benefits to them include:\u000d\u000a    [text removed for publication] [a].\u000d\u000a    Reputational benefits of the research to L&amp;G are not easily\u000d\u000a      measureable. One measure of impact is that the lead UCL researcher\u000d\u000a      (Bajekal) is an invited member of the Institute and Faculty of Actuaries\u000d\u000a      Mortality Research Steering Committee and contributed a features article\u000d\u000a      to the profession's premier trade journal `The Actuary' (see below).\u000d\u000a    All of the UCL\/L&amp;G research outputs are in the public domain, so the\u000d\u000a      programme contributes indirect benefits to the pensions industry more\u000d\u000a      widely. By filling the gap in public availability of socially segmented\u000d\u000a      longevity risk analyses, including their epidemiological drivers via the\u000d\u000a      medium of peer-reviewed publications, the pension industry gains by having\u000d\u000a      an externally acknowledged benchmark against which to align company\u000d\u000a      specific client portfolios and to project future trajectories based on a\u000d\u000a      better understanding of the reasons for past differentials and the likely\u000d\u000a      direction of travel.\u000d\u000a    Bajekal was invited to serve on the Institute and Faculty of Actuaries\u000d\u000a      Mortality Research Steering Committee (MRSC) in Feb 2012. Since then, she\u000d\u000a      has organised a thought leadership seminar [b] and presented a\u000d\u000a      paper at the Institute's sessional research meeting [c]. She\u000d\u000a      continues to be active in the profession's research strand and is on the\u000d\u000a      scientific organising committee for the MRSC's bi-annual 2-day conference\u000d\u000a      in September 2014.\u000d\u000a    The research also has a wider impact on social and health policy &#8212; for\u000d\u000a      example, our research has been used by the ONS in their Statistical\u000d\u000a      Bulletin on Avoidable mortality in England and Wales, 2011 [d].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Our research has used epidemiological insights, data and methods to\u000d\u000a      enable Legal &amp; General (L&amp;G), a major pensions and annuity\u000d\u000a      provider, to understand the drivers of long-term trends in the annual\u000d\u000a      rates of improvement in mortality in older ages. Our first-ever analysis\u000d\u000a      of inequalities in mortality trends by cause of death over 25 years in\u000d\u000a      England, and future projections of these, has resulted in better informed\u000d\u000a      pricing and risk management (capital reserving) practices at L&amp;G. We\u000d\u000a      also modelled how much of the decline in coronary heart disease, the main\u000d\u000a      contributor to improving life expectancy, was due to improved healthcare\u000d\u000a      versus healthier lifestyles. Projections of these, based on plausible\u000d\u000a      scenarios of evolution of risk factors and disease management, helped\u000d\u000a      strengthen the evidence base for L&amp;G's assumptions of mortality\u000d\u000a      improvements for the UK financial regulators.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University College London\u000d\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Bajekal M, Scholes S, Love H, Hawkins N, O'Flaherty M, Raine R,\u000d\u000a      Capewell S. Analysing recent socioeconomic trends in coronary heart\u000d\u000a      disease mortality in England, 2000-2007: a population modelling study.\u000d\u000a      PLoS Med. 2012;9(6):e1001237.\u000d\u000a      http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001237\u000d\u000a    \u000a\u000a[2] Hawkins NM, Scholes S, Bajekal M, Love H, O'Flaherty M, Raine R,\u000d\u000a      Capewell S. Community care in England: reducing socioeconomic inequalities\u000d\u000a      in heart failure. Circulation. 2012 Aug 28;126(9):1050-7. http:\/\/dx.doi.org\/10.1161\/CIRCULATIONAHA.111.088047\u000d\u000a    \u000a\u000a[3] Scholes S, Bajekal M, Norman P, O'Flaherty M, Hawkins N, Kivim&#228;ki M,\u000d\u000a      Capewell S, Raine R. Quantifying policy options for reducing future\u000d\u000a      coronary heart disease mortality in England: a modelling study. PLoS One.\u000d\u000a      2013 Jul 25;8(7):e69935.\u000d\u000a      http:\/\/dx.doi.org\/10.1371\/journal.pone.0069935\u000d\u000a    \u000a\u000a[4] Lu J, Wong W, Bajekal M. Mortality improvement by socio-economic\u000d\u000a      circumstances in England (1982 to 2006). British Actuarial Journal,\u000d\u000a      FirstView Articles, pp 1-35. Published online: 17 December 2012 http:\/\/dx.doi.org\/10.1017\/S1357321712000359\u000d\u000a    \u000a\u000a[5] Bajekal M, Scholes S, Blane D, Lu J, Raine R: Trends in social\u000d\u000a      inequalities in old age life expectancy: decomposition by age and\u000d\u000a        cause of death (England, 1982 to 2006). &#8212; http:\/\/www.actuaries.org.uk\/research-and-resources\/documents\/c01-trends-inequalities-life-expectancy-age-65-england-socio-econom\u000d\u000a    \u000a\u000a[6] LSAP: Life expectancy: past and future variations by gender, England\u000d\u000a      and Wales. Available at: http:\/\/www.longevitypanel.co.uk\/docs\/life-expectancy-by-gender.pdf\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"},{"Level1":"1","Level2":"4","Subject":"Statistics"}],"Sources":"\u000d\u000a    [a] A letter from the Head of the Longevity Risk team at L&amp;G\u000d\u000a      corroborating all the impacts mentioned above is available on request.\u000d\u000a    [text removed for publication]\u000d\u000a    [b] Mortality Thought Leadership Seminar Series: `Socieconomic\u000d\u000a      inequalities in mortality and longevity', Staple Inn, 12th March 2013. http:\/\/www.actuaries.org.uk\/events\/one-day\/mortality-thought-leadership-seminar-series-socioeconomic-inequalities-mortality-and-\u000d\u000a      `Mortality improvements by socio-economic circumstances, discussion paper\"\u000d\u000a      Lu, J, Won W, Bajekal M. Staple Inn, 11th Sept 2012. http:\/\/www.actuaries.org.uk\/events\/one-day\/sessional-research-event-mortality-improvement-socio-economic-circumstances-england-1\u000d\u000a    [c] Bajekal, M. `Longevity modelling: signs of maturity', The Actuary,\u000d\u000a      1st Oct 2012. http:\/\/www.theactuary.com\/features\/2012\/10\/signs-of-maturity\/\u000d\u000a    [d] http:\/\/www.ons.gov.uk\/ons\/dcp171778_311826.pdf\u000d\u000a      See references section.\u000d\u000a    ","Title":"\u000d\u000a    Translating epidemiological evidence on social inequalities to support\u000d\u000a      the pensions industry.\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Since 2006, researchers at UCL's Department of Applied Health Research\u000d\u000a      (DAHR), have led a programme funded by Legal &amp; General, one of\u000d\u000a      Britain's top FTSE 100 companies and a major pension provider in the UK\u000d\u000a      insurance industry. The programme was set up to apply UCL's expertise in\u000d\u000a      the field of social epidemiology to key questions underpinning mortality\u000d\u000a      and longevity risk which are of interest to the UK actuarial profession.\u000d\u000a      The overarching aims are: to analyse social inequalities in health and\u000d\u000a      mortality risk in older age, between groups and over time; to identify the\u000d\u000a      underlying drivers of longevity change; and to project future trends.\u000d\u000a    The Principal Investigators for this collaboration are Mr Joseph Lu at\u000d\u000a      L&amp;G and at UCL Professor Rosalind Raine. Dr Madhavi Bajekal and Dr\u000d\u000a      Shaun Scholes (both L&amp;G employees and honorary staff at UCL, and based\u000d\u000a      at UCL) are the key researchers.\u000d\u000a    Over the four years to April 2013, we have focused on three streams of\u000d\u000a      work:\u000d\u000a    Firstly, we used a policy model developed by Professor Capewell\u000d\u000a      (Liverpool University) and extended in collaboration with him and his team\u000d\u000a      to examine whether the social gradient in the differential falls\u000d\u000a      in coronary heart disease (CHD) mortality in the UK were mostly due to\u000d\u000a      improved healthcare treatments or to healthier lifestyles. We quantified\u000d\u000a      the relative contributions of seven risk factors and approximately 50\u000d\u000a      medical therapies to the CHD mortality fall from 2000 to 2007 and the\u000d\u000a      variations between socio-economic groups. This research is now complete,\u000d\u000a      and key published papers are listed below [1, 2, 3]. To run this\u000d\u000a      model, we assembled a unique database from sources including population\u000d\u000a      health surveys, GP records, hospital admissions, specialist clinical\u000d\u000a      audits, and mortality statistics &#8212; all of which were uniformly coded at\u000d\u000a      the individual level to a deprivation index based on an individual's\u000d\u000a      postcode of residence. This dataset will continue to be vital in the next\u000d\u000a      phase of research from 2014.\u000d\u000a    Secondly, we compiled deprivation-coded mortality data from the Office of\u000d\u000a      National Statistics (ONS) for each year from 1981 onwards to address key\u000d\u000a      questions relating to long-term historical trends in rates of mortality\u000d\u000a      improvements among people over 50 years old, by age, gender and\u000d\u000a      socio-economic group. Such analyses had not previously been conducted for\u000d\u000a      the UK; the closest is the linked-mortality analysis of participants in\u000d\u000a      the ONS's Longitudinal Study &#8212; a one per cent sample of census records for\u000d\u000a      individuals in England and Wales, linked between successive censuses since\u000d\u000a      1971. However, results from the latter are available only once every\u000d\u000a      decade, and are indicative rather than conclusive due to the small sample\u000d\u000a      sizes at older ages, particularly when segmented by social position, age\u000d\u000a      and gender. Our mortality analyses included the following:\u000d\u000a    a) age, period and cohort effects in rates of mortality improvement for\u000d\u000a      different social groups. The results were presented at the Institute and\u000d\u000a      Faculty of Actuaries (IFoA) and published in the industry's leading\u000d\u000a      peer-reviewed journal, the British Actuarial Journal (BAJ) [4]\u000d\u000a    b) Cause of death decomposition of the differences in life expectancy at\u000d\u000a      age 50 between social groups and over time. Presentation at the IFoA\u000d\u000a      conference, Sept 2011 [5]\u000d\u000a    c) Gender differentials in life expectancy at older ages: are\u000d\u000a      differentials converging over time at the same pace across social groups?\u000d\u000a      What factors are contributing to the observed convergence over time? These\u000d\u000a      analyses are in support of the EU Gender Directive, adopted across the UK\u000d\u000a      in December 2012 [6].\u000d\u000a    Thirdly, we have provided epidemiological intelligence and support to\u000d\u000a      L&amp;G. Demographers, epidemiologists and actuaries often approach the\u000d\u000a      same question &#8212; e.g. longevity &#8212; in very different ways resulting in a gap\u000d\u000a      of integrated knowledge across the spectrum. For example: there are\u000d\u000a      numerous studies, replicated across several countries and cohorts, which\u000d\u000a      show that marital status in old age is a strong predictor of longevity.\u000d\u000a      But confusingly, the statistical methods used and effect sizes vary widely\u000d\u000a      between studies. In such instances where good evidence exists, rather than\u000d\u000a      carry out fresh analyses, we evaluated the evidence and converted these\u000d\u000a      into practical `best estimates' suitable for actuaries to use in longevity\u000d\u000a      models, e.g. as a rating factor.\u000d\u000a    To supplement our in-house expertise, we have actively built academic\u000d\u000a      collaborations across multi- disciplinary teams (e.g. with Liverpool\u000d\u000a      University for clinical epidemiology and policy modelling; Leeds\u000d\u000a      University and Max Planck Institute for demographic modelling; CASS for\u000d\u000a      actuarial forecasting).\u000d\u000a    "},{"CaseStudyId":"22418","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"226074","Name":"Uganda"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"895949","Name":"Zambia"},{"GeoNamesId":"927384","Name":"Malawi"}],"Funders":["Wellcome Trust","Medical Research Council"],"ImpactDetails":"\u000a    HIV-infected infants are at high risk of disease progression and death.\u000a      But initiating them on lifelong antiretroviral therapy (ART) is\u000a      problematic because:\u000a    \u000a      it is a lifelong commitment\u000a      it costs money\u000a      the drugs can have side effects\u000a      the earlier infants start treatment the more time there is for\u000a        resistance to develop.\u000a    \u000a    Until 2008, national and international guidelines recommended initiation\u000a      of antiretroviral therapy on the basis of a low CD4 percentage or count, a\u000a      high viral load, or the presence of clinical symptoms, whereas the\u000a      treatment of asymptomatic infants with high CD4 values was not mandated.\u000a    The early results of CHER were released at the 4th\u000a      International AIDS Society Conference on Pathogenesis, Treatment and\u000a      Prevention in July 2007. In response to these results, a number of key\u000a      national and international guidelines were changed.\u000a    In February 2008 US national guidelines were changed to recommend\u000a      immediate treatment of HIV-infected infants [a].\u000a    WHO held a meeting in April 2008 to look at the evidence from CHER in\u000a      relation to their guidelines, and launched new interim guidelines in June\u000a      2008, recommending immediate treatment of HIV- infected infants. These\u000a      were then incorporated into the full guidelines when they were revised in\u000a      2010 [b].\u000a    The Paediatric European Network for Treatment of AIDS (PENTA) changed\u000a      their guidelines to recommend immediate treatment of HIV-infected infants\u000a      in November 2008 [c].\u000a    WHO guidelines are very influential for national HIV policy, particularly\u000a      in African countries, where most HIV-positive infants live. A survey of\u000a      national HIV policymakers, carried out in 2008, found that WHO was an\u000a      important and frequent source of information to inform HIV policymaking in\u000a      Africa [d]. Therefore the incorporation of recommendations from\u000a      the CHER trial into WHO policy has had a knock-on effect on national\u000a      guidelines in Africa. Following the changes to WHO guidance, individual\u000a      countries began to follow suit by changing their national guidelines. For\u000a      example, in South Africa the Essential Drug List Committee approved the\u000a      recommendation in November 2008, and it was included in the national\u000a      guidelines issued in December 2010, following the costing study [e].\u000a      The Malawi Ministry of Health updated their guidelines in April 2008 [f],\u000a      and the Uganda Ministry of Health updated their guidelines in June 2009 on\u000a      when to start infants on treatment [g].\u000a    National guidelines are very important determinants of the treatments\u000a      given in practice in low- income settings. In many African settings most\u000a      children are treated by clinical officers rather than doctors. These\u000a      clinical officers have less training than doctors, and therefore use\u000a      national guidelines as the basis of how they treat patients to a much\u000a      greater extent than doctors in high- income countries.\u000a    One paediatrician working in Zambia describes the impact of the trial as\u000a      follows: \"These changes were quickly adapted by many African countries\u000a        including Zambia, a step that enabled many HIV infected children to be\u000a        started early on ART and not only have these children survived but they\u000a        have been able to lead a relatively normal childhood. Currently it is\u000a        estimated that about 43,000 children 0-14 years old are receiving ART in\u000a        Zambia, a 50% increase from the 21,120 in 2009 (WHO, UNAIDS, UNICEF\u000a        Progress Report 2010). The impact of the CHER trial has not only been on\u000a        outcome of children but the findings have also helped push for improved\u000a        laboratory diagnostic services in order to initiate early treatment in\u000a        as many infants and children as possible in Zambia...Deaths from\u000a        HIV\/AIDS have dramatically dropped in infants and children, as most of\u000a        the children are identified early and commenced on treatment. The CHER\u000a        trial results have had a great impact on treatment of HIV infected\u000a        infants and children, subsequently on survival, hospital admissions and\u000a        ultimately cost of treatment and care for HIV infected infants and\u000a        children\" [h].\u000a    As the results have led to changes in guidelines for HIV-infected infants\u000a      worldwide, the research has had a global impact on infants living with HIV\u000a      in both high and low-income settings. It is difficult to say exactly how\u000a      many children have benefited as a result of this research, as the routine\u000a      data collected by most countries does not disaggregate ART coverage\u000a      figures into small enough age- bands. We can, however, extrapolate how\u000a      many lives could potentially be saved based on global figures. Each year\u000a      around 390,000 children are infected with HIV [i]. The vast\u000a      majority of these children were vertically-infected infants. CHER found\u000a      that early ART reduced infant mortality from 16% to 4%. If we assume that\u000a      the WHO guidelines were fully implemented worldwide, the results of this\u000a      trial would lead to around 46,800 lives being saved each year (although\u000a      the number of infected infants will decline with the scale-up of\u000a      Prevention of Mother To Child Transmission programmes).\u000a    The costing study found that early ART for infants had lower costs per\u000a      child to the health system than deferred ART or the strategy that was\u000a      routine care at the time in South Africa ($1,387 vs $2,440 vs $3,008\u000a      respectively) [ref 3, above]. This means that the health system in\u000a      South Africa (and possibly other settings) will benefit through reduced\u000a      costs of treating HIV-infected infants, as they require less\u000a      hospitalisation. In 2011 there were approximately 29,000 new infections in\u000a      children in South Africa. If all these newly-infected infants had been\u000a      treated early, it could save the South African health system as much as 47\u000a      million USD.\u000a    ","ImpactSummary":"\u000a    HIV-infected infants are at high risk of disease progression and death.\u000a      Until 2008 guidelines recommended waiting until the infant displayed\u000a      symptoms, or had a weakened immune system before starting treatment. The\u000a      CHER trial found that starting infected infants on antiretroviral therapy\u000a      as early as possible substantially reduced mortality compared with waiting\u000a      until they developed symptoms or their immune system weakened. These\u000a      results led quickly to changes in guidelines for treating HIV-infected\u000a      infants issued by the US, World Health Organisation (WHO), Paediatric\u000a      European Network for Treatment of AIDS (PENTA) and South Africa. These\u000a      revised guidelines, if fully implemented along with early infant\u000a      diagnosis, would reduce the number of infant deaths because of HIV by 76%,\u000a      saving the lives of approximately 46,800 infants globally each year.\u000a    ","ImpactType":"Health","Institution":"\u000a    University College London\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a[1] Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA,\u000a      Jean-Philippe P, McIntyre JA; CHER Study Team. Early antiretroviral\u000a      therapy and mortality among HIV-infected infants. N Engl J Med. 2008 Nov\u000a      20;359(21):2233-44. http:\/\/dx.doi.org\/10.1056\/NEJMoa0800971\u000a    \u000a\u000a[2] Violari A, Cotton M, Gibb D, Babiker A, Steyn J, Jean-Phillip P,\u000a      McIntyre J, on behalf of the CHER Study Team. Antiretroviral therapy\u000a      initiated before 12 weeks of age reduces early mortality in young\u000a      HIV-infected infants: Evidence from the children with HIV early\u000a      antiretroviral therapy (CHER) study. Special session: 4th IAS Conference\u000a      on HIV Pathogenesis, Treatment and Prevention. 2007. Abstract no. WESS103.\u000a      http:\/\/www.iasociety.org\/Default.aspx?pageId=11&amp;abstractId=200705557\u000a    \u000a\u000a[3] Meyer-Rath Gesine, Violari A., Cotton M., Ndibongo B., Brennan A.,\u000a      Long L., Panchia R., Coovadia A., Gibb D.M., Rosen S., (2010). The cost of\u000a      early versus deferred paediatric antiretroviral treatment in South Africa:\u000a      A comparative economic analysis of the first year of the Children with HIV\u000a      Early Antiretroviral Therapy (CHER) trial. XVIII International AIDS\u000a      Conference, Vienna, Abstract no. THLBB103.\u000a      http:\/\/pag.aids2010.org\/Abstracts.aspx?AID=17823\u000a    \u000a\u000a[4] Cotton M, Violari A, Gibb D, Otwombe K, Josipovic D, Panchia R,\u000a      Jean-Philippe P, Handelsman E, McIntyre J, Babiker A. Early ART Followed\u000a      By Interruption is Safe &amp; Associated With Better Outcomes than\u000a      Deferred ART: Final Results From the 6-Year Randomized CHER (Children with\u000a      HIV Early antiRetroviral) Trial in South Africa. 19th\u000a      Conference on Retroviruses and Opportunistic Infections. 2012. Available\u000a      on request.\u000a    \u000a\u000a[5] Cotton M, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H,\u000a      Josipovic D, Liberty A, Lazarus E, Innes S, van Rensburg A, Pelser W,\u000a      Truter H, Madhi S, Handelsman E, Jean- Philippe P, McIntyre J, Gibb DM.\u000a      Early time-limited antiretroviral therapy versus deferred therapy in South\u000a      African infants infected with HIV: results from the children with HIV\u000a      early antiretroviral (CHER) randomised trial. Lancet 382. 2013. http:\/\/dx.doi.org\/10.1016\/S0140-\u000a        6736(13)61409-9\u000a    \u000aThe research was funded by a grant from the National Institute of Allergy\u000a      and Infectious Diseases of the National Institutes for Health through the\u000a      Comprehensive International Program of Research on AIDS network (U19\u000a      AI53217); the Departments of Health of the Western Cape and Gauteng, South\u000a      Africa; and GlaxoSmithKline. The NIAID grant was awarded after a\u000a      competitive process that included peer review.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000a    [a] US national guidelines: Working Group on Antiretroviral Therapy and\u000a      Medical Management of HIV-Infected Children. Guidelines for the Use of\u000a      Antiretroviral Agents in Pediatric HIV Infection. Rockville, MD: National\u000a      Institutes of Health, US, 2008.\u000a      http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/pediatricguidelines.pdf\u000a    [b] WHO guidelines: WHO (2010): ANTIRETROVIRAL THERAPY FOR HIV INFECTION\u000a      IN INFANTS AND CHILDREN: TOWARDS UNIVERSAL ACCESS Recommendations for a\u000a      public health approach 2010 revision.\u000a      http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241599801_eng.pdf\u000a    [c] PENTA guidelines: PENTA Steering Committee (2009): PENTA 2009\u000a      guidelines for the use of antiretroviral therapy in paediatric HIV-1\u000a      infection. HIV Medicine 10: 591-613 DOI:\u000a      10.1111\/j.1468-1293.2009.00759.x http:\/\/www.pentatrials.org\/HIV_759.pdf\u000a    [d] Parkhurst JO, Hyde A, South A, Brehmer L, Miller A, Newell JN.\u000a      Improving communication of research findings - identifying the sources of\u000a      information most important to national disease control officers in low and\u000a      middle income countries. Tropical Medicine and International Health\u000a      2010;15(10):1252-55. http:\/\/dx.doi.org\/10.1111\/j.1365-3156.2010.02599.x\u000a    [e] Department of Health, Republic of South Africa (2010): The South\u000a      African Antiretroviral Treatment Guidelines.\u000a      http:\/\/www.uj.ac.za\/EN\/CorporateServices\/ioha\/Documentation\/Documents\/ART%20Guideline.\u000a        pdf\u000a    [f] Malawi Ministry of Health (2008): Treatment of AIDS: Guidelines for\u000a      the use of antiretroviral therapy in Malawi. Third Edition, April 2008.\u000a      http:\/\/www.basics.org\/documents\/ART_Guidelines_Malawi.pdf\u000a      (page 29)\u000a    [g] Uganda Ministry of Health (2009): National Antiretroviral Treatment\u000a      Guidelines for Adults, Adolescents, and Children http:\/\/www.idi-makerere.com\/docs\/guidelines%202009.pdf\u000a      (page 22)\u000a    [h] Letter from Paediatrician, University Teaching Hospital, Lusaka,\u000a      Zambia. Copy available on request.\u000a    [i] http:\/\/www.unaids.org\/believeitdoit\/get-the-facts.html\u000a    ","Title":"\u000a    CHER trial leads to changes in international guidelines on when to start\u000a      HIV- infected infants on antiretroviral therapy\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The CHER trial aimed to see if giving a limited course of anti-retroviral\u000a      therapy (ART) to babies as soon as possible after their HIV status was\u000a      known would have a long-term health benefit, when compared with\u000a      HIV-infected babies who are treated after they develop symptoms of HIV, or\u000a      when their immune system has become weakened. Babies were randomised into\u000a      three groups:\u000a    \u000a      delayed ART until their immune system became weak (measured through a\u000a        CD4 count)\u000a      immediate ART, which was then stopped when the babies reached the age\u000a        of one year\u000a      immediate ART which was then stopped when they were two years old.\u000a    \u000a    The trial began in August 2005. In June 2007 the IDMC recommended\u000a      modifying the trial to stop enrolment into Arm 1, enrolled infants to be\u000a      urgently assessed for ART, immediate release of the results of Arm 1\u000a      versus Arms 2 &amp; 3, and trial follow-up to continue. This was because\u000a      the interim analysis showed that immediate ART reduced mortality by 76%,\u000a      and disease progression by 75% after a median follow-up of 32 weeks [1,2].\u000a    Follow-up continued until September 2011, and the final results were\u000a      presented at a conference in March 2012 [4].\u000a    This was the first large randomised trial looking at when infants should\u000a      start ART.\u000a    Based on the early results, we contributed to a costing study to look at\u000a      the costs of early versus deferred ART for infants in South Africa. This\u000a      found that early treatment was actually cheaper than deferred ART, mainly\u000a      because of the reduction in hospitalisation [3].\u000a    The trial was carried out in collaboration with the Perinatal HIV\u000a      Research Unit of the University of Witwatersrand, and the Children's\u000a      Infectious Disease Clinical Research Unit of Stellenbosch University, as\u000a      part of the CIPRA-SA programme. Professors Di Gibb and Abdel Babiker from\u000a      MRC Clinical Trials Unit (now part of UCL) played a major role in\u000a      designing the study, were part of the Trial Steering and Management\u000a      groups, advised on the execution of the trial, carried out and supervised\u000a      the statistical analyses, and wrote the papers with their South African\u000a      colleagues, Dr Avy Violari and Professor Mark Cotton.\u000a    A Wellcome Trust Fellowship has been awarded for Helen Payne to work with\u000a      the Cape Town Group, supervised by Nigel Klein and Robin Callard from the\u000a      UCL Institute of Child Health, Di Gibb and Abdel Babiker from MRC CTU, now\u000a      part of UCL, and Prof Mark Cotton from Cape Town. This work will provide\u000a      very important data on the immunology of early ART initiation in babies as\u000a      well as on stopping treatment. In addition following reports of the\u000a      `functional cure' of the Mississippi baby, further work is ongoing with\u000a      collaborators in US as part of the `cure' agenda.\u000a    "},{"CaseStudyId":"22421","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    Impact on NICE Guidelines:\u000a    Our evidence regarding CVD was used by NICE in the 2009 update of their\u000a      schizophrenia guideline (CG 082). This recommends that annual physical\u000a      review of these patients should focus on cardiovascular risk factors\u000a      including blood pressure, cholesterol, HDL cholesterol, smoking and\u000a      diabetes. The guideline cites five of our papers as the reason for\u000a      focussing on CVD risk factors in annual reviews for people with\u000a      schizophrenia in national mental health policy. Nazareth was on the expert\u000a      advisory panel of the NICE Schizophrenia guideline group [a].\u000a    Impact on European Guidelines:\u000a    Our work was cited as the research evidence justifying a position\u000a      statement by the European Psychiatric Association (EPA), supported by the\u000a      European Association for the Study of Diabetes (EASD) and the European\u000a      Society of Cardiology (ESC) in 2009. Their statement was designed to\u000a      improve the care of patients suffering from severe mental illness. They\u000a      cite two of our papers as the rationale for focusing on CVD risk screening\u000a      in people with SMI. The statement refers in detail to our systematic\u000a      review regarding the relative incidence of CVD risk factors in SMI, as\u000a      well as our research demonstrating excess CVD mortality in young people\u000a      with SMI [b].\u000a    The position statement from the EPA has had further impact both in the UK\u000a      and Australia. The EPA position document is referenced as the rationale\u000a      for specific algorithms to help mental health professionals to deal with\u000a      cardiovascular risk factors in people with SMI [c]. In turn the\u000a      Australian guidelines have recently been adapted and endorsed by the Royal\u000a      College of General Practitioners, Royal College of Psychiatrists, Royal\u000a      College of Nursing, Royal College of Physicians, HQIP, Rethink Mental\u000a      Illness and Diabetes UK to provide guidance in line with the SMI QoF (see\u000a      below) and NICE guidance, which largely originates from the research done\u000a      at UCL [d]. These guidelines have been sent to every GP and\u000a      psychiatrist in the UK.\u000a    Impact on Psychopharmacology guidance:\u000a    The British Association of Psychopharmacologists produces evidence-based\u000a      guidelines for international and national prescribing in mental health,\u000a      aimed at all psychiatrists and other clinicians who prescribe in mental\u000a      health. Their schizophrenia consensus guidelines cite two of our papers\u000a      (Osborn, 2006; Osborn 2008) in making their recommendations regarding\u000a      prescribing antipsychotics and screening for CVD risk factors for people\u000a      with SMI who have been prescribed antipsychotic medications [e].\u000a    Impact on Department of Health Policy:\u000a    The Department of Health published a new mental health strategy in 2011\u000a      titled \"No health without mental health\". It made a number of\u000a      recommendations regarding the interface between physical and mental\u000a      health. This included six main objectives, including \"that more people\u000a      with mental health problems will have good physical health\". Osborn was\u000a      invited to present our research findings to specific workshops run by the\u000a      DH to formulate this strategy [f].\u000a    Once published, the policy was developed into a guide for general\u000a      practitioners by the Centre for Mental Health, in alliance with seven key\u000a      national mental health organisations. These third sector organisations\u000a      (outside the NHS) such as RETHINK cite our mortality work as one of the\u000a      reasons why general practitioners should focus on CVD screening for people\u000a      with mental disorders [g].\u000a    Impact on the Quality Outcomes Framework:\u000a    In 2011, our influence on NICE guidelines led to changes in the national\u000a      GP contract, through the Quality Outcomes Framework (QoF) for people with\u000a      severe mental illnesses [h]. GPs are now remunerated for ensuring\u000a      that people with SMI have had specific cardiovascular risk factors\u000a      measured within the last 15 months. The QoF documents explicitly state\u000a      that their recommendations are in line with the NICE schizophrenia\u000a      guidelines regarding CVD screening and hence include screening for BMI,\u000a      cholesterol, blood pressure and diabetes screening in the outcomes\u000a      framework for SMI (see above). Our research has thus directly impacted on\u000a      the day to day care provided for people with severe mental illnesses in\u000a      general practices across England through NICE and into QoF.\u000a    Impact elsewhere in the UK\u000a    Further, the two most cited of our research papers on this topic were\u000a      used by the Scottish QoF in 2008, recommending that Scottish GPs included\u000a      these cardiovascular measurements in their annual assessments [i].\u000a    These important changes within the NHS are thus leading to a reduction in\u000a      the inequalities of care that occur in people with schizophrenia and\u000a      severe mental illnesses.\u000a    ","ImpactSummary":"\u000a    Our research has led to major changes in the management of people with\u000a      severe mental illness (SMI) in general practice. Our findings that people\u000a      with schizophrenia are at greater risk of cardiovascular diseases informed\u000a      NICE guidance in the UK and international guidelines. The Department of\u000a      Health's strategy on Mental Health was influenced by our work on the\u000a      interface between physical and mental health. Recommendations in the NICE\u000a      guidance have now been taken up by the NHS Quality Outcomes Framework\u000a      (QoF) in England and Scotland. General practitioners are specifically\u000a      required to monitor BMI (Body Mass Index), blood pressure, and glucose and\u000a      serum lipids levels in all registered patients with SMI.\u000a    ","ImpactType":"Health","Institution":"\u000a    University College London\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"294098","Name":"Nazareth"}],"References":"\u000a    \u000a[1] Nazareth I, King M, Davies S. Care of schizophrenia in general\u000a      practice: the general practitioner and the patient. British Journal of\u000a      General Practice. 1995 July; 45(396):343-347. http:\/\/europepmc.org\/articles\/PMC1239294\u000a    \u000a\u000a[2] Nazareth I, King M, See-Tai S. Monitoring psychosis in general\u000a      practice: a controlled trial. British Journal of Psychiatry. 1996\u000a      Oct;169(4):475-82. http:\/\/dx.doi.org\/10.1192\/bjp.169.4.475\u000a    \u000a\u000a[3] Osborn DPJ, King M, Nazareth I. Participation in screening for\u000a      cardiovascular risk by people with schizophrenia or similar mental\u000a      illnesses - a cross sectional study in general practice. BMJ. 2003 May\u000a      24;326(7399):1122-3. http:\/\/dx.doi.org\/10.1136\/bmj.326.7399.1122\u000a    \u000a\u000a[4] Osborn DPJ, Nazareth I, King M. Risk for coronary heart disease in\u000a      people with severe mental illness: a cross sectional comparative study in\u000a      primary care. British Journal of Psychiatry. 2006 Mar;188:271-7. http:\/\/dx.doi.org\/10.1192\/bjp.bp.104.008060\u000a    \u000a\u000a[5] Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A, King M. Relative\u000a      risk of cardiovascular and cancer mortality in people with severe mental\u000a      illness from the United Kingdom's general practice research database.\u000a      Archives of General Psychiatry. 2007 Feb;64(2):242-9. http:\/\/dx.doi.org\/10.1001\/archpsyc.64.2.242\u000a    \u000a\u000a[6] Osborn DPJ, King MB, Nazareth I. Physical activity, dietary habits\u000a      and coronary heart disease risk factor knowledge amongst people with\u000a      severe mental illness. A cross sectional comparative study in primary\u000a      care. Social Psychiatry and Psychiatric Epidemiology. 2007\u000a      Oct;42(10):787-93. http:\/\/dx.doi.org\/10.1007\/s00127-007-0247-3\u000a    \u000a\u000a[7] Osborn DPJ, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative\u000a      risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome\u000a      in people with severe mental illnesses. Systematic review and\u000a      metaanalysis. BMC Psychiatry. 2008 Sep 25;8:84. http:\/\/dx.doi.org\/10.1186\/1471-244X-8-84\u000a    \u000a\u000a[8] Osborn DPJ, Nazareth I, Wright CA, King MB. Impact of a nurse-led\u000a      intervention to improve screening for cardiovascular risk factors in\u000a      people with severe mental illnesses. Phase-two cluster randomised\u000a      feasibility trial of community mental health teams. BMC Health Services\u000a      Research. 2010 Mar 10;10:61. http:\/\/dx.doi.org\/10.1186\/1472-6963-10-61\u000a    \u000aPeer-reviewed funding\u000a    MRC Brain Sciences Initiative. Primary prevention of cardiovascular\u000a      diseases with Severe Mental Illnesses: development and feasibility of\u000a      complex intervention in primary and secondary care. &#163;228,000\u000a    NIHR Programme Grant - Prediction and management of cardiovascular risk\u000a      for people with severe mental illnesses. A research programme and trial in\u000a      primary care. PRIMROSE. &#163;2.03 million.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [a] National Institute for Health and Clinical Excellence (2009)\u000a      Schizophrenia: core interventions in the treatment and management of\u000a      schizophrenia in adults in primary and secondary care. NICE clinical\u000a      guideline 82. http:\/\/www.nice.org.uk\/CG082.\u000a      See pages 7, 15, 21, 22, 26.\u000a    [b] De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, M&#246;ller HJ.\u000a      Cardiovascular disease and diabetes in people with severe mental illness\u000a      position statement from the European Psychiatric Association (EPA),\u000a      supported by the European Association for the Study of Diabetes (EASD) and\u000a      the European Society of Cardiology (ESC). Eur Psychiatry. 2009\u000a      Sep;24(6):412-24. http:\/\/dx.doi.org\/10.1016\/j.eurpsy.2009.01.005.\u000a      See page 413.\u000a    [c] Australian guidelines: Curtis J, Newall H, Samaras K. HETI 2011.\u000a      Don't just screen. http:\/\/www.heti.nsw.gov.au\/cmalgorithm\u000a      See reference to [b] on page 2.\u000a    [d] Guidelines from the Royal Colleges:\u000a    \u000a      Royal College of Psychiatrists 2012. The Lester UK Adaptation. http:\/\/www.rcpsych.ac.uk\/quality\/nationalclinicalaudits\/schizophrenia\/nationalschizophrenia\u000a          audit\/nasresources.aspx Based on [c]\u000a\u000a    \u000a    [e] Barnes TR; Schizophrenia Consensus Group of British Association for\u000a      Psychopharmacology. Evidence-based guidelines for the pharmacological\u000a      treatment of schizophrenia: recommendations from the British Association\u000a      for Psychopharmacology. J Psychopharmacol. 2011 May;25(5):567-620. http:\/\/dx.doi.org\/10.1177\/0269881110391123.\u000a      See references to [5] and [7] on page 581.\u000a    [f] Department of Health (2011). No Health without Mental Health. http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_123766\"\u000a    [g] The Centre for Mental Health. No health without mental health. A\u000a      guide for general practitioners. http:\/\/www.centreformentalhealth.org.uk\/pdfs\/Web_Mental%20Health%20Strategic%20Partnership%20GPs.pdf\"\u000a      See reference to [5] on page 3.\u000a    [h] NHS Employers. (2011) The Quality and Outcomes Framework. 2011-12 http:\/\/www.nhsemployers.org\/SiteCollectionDocuments\/QOFguidanceGMScontract_2011_12_FL%2013042011.pdf\"\u000a      Based on [a]\u000a    [i] The Scottish Government (2008). Improving the physical health of\u000a      people experiencing Mental illness in Scotland. http:\/\/www.scotland.gov.uk\/Publications\/2008\/11\/28152218\/0\u000a      References to [4] and [5] on page 34\u000a    ","Title":"\u000a    Improving management of schizophrenia and severe mental illnesses in\u000a      general practice\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    UCL has led internationally on research on the care offered to people\u000a      with severe mental illnesses (i.e. schizophrenia and bipolar illnesses) in\u000a      general practice. Little was known about the primary care management of\u000a      this population prior to us initiating research work on this topic in the\u000a      1990s. Professor Irwin Nazareth and colleagues (Department of Primary Care\u000a      &amp; Population Health) found that although people with schizophrenia\u000a      were frequent attenders, their management was unstructured with little\u000a      attention given to their physical health, compared to the care offered to\u000a      people with other chronic diseases. We found that one in three people with\u000a      schizophrenia were exclusively managed by their general practitioners with\u000a      no contact with a psychiatrist. Moreover, most people with schizophrenia\u000a      were willing to have their physical and psychological health needs managed\u000a      by their general practitioners [1]. Early evidence from an\u000a      exploratory controlled evaluation suggested beneficial trends from\u000a      structured health care delivered in primary care [2]. Since then,\u000a      we have led on a programme of MRC-funded research to identify and reduce\u000a      cardiovascular disease (CVD) in NHS patients with severe mental disorders.\u000a    Our research demonstrated high relative rates of cardiovascular mortality\u000a      in people with severe mental illnesses when compared to people without\u000a      these disorders. There was a threefold risk of cardiovascular deaths in\u000a      people with schizophrenia between the age of 18-50, and twice the risk in\u000a      people aged 50-75 [5].\u000a    Further research on this topic found an excess rate of abnormal lipids\u000a      (especially low levels of HDL), smoking and diabetes in people with severe\u000a      mental illnesses in general practice compared with healthy controls [4].\u000a      The significantly lower level of HDL in people with schizophrenia was a\u000a      novel finding and had never been previously reported. This work also\u000a      revealed that poor diets and low levels of physical activity were common\u000a      in this group of people and were worthy targets for interventions [6].\u000a      Our research additionally demonstrated that people with mental disorders\u000a      were willing to participate in CVD screening in primary care [3]\u000a      and the importance of this finding was highlighted in a Lancet editorial\u000a      (vol 367; 1469-71).\u000a    We then published a systematic review regarding lipids, diabetes and\u000a      hypertension levels as well as qualitative and quantitative findings to\u000a      facilitate the design of a new nurse-led intervention for cardiovascular\u000a      screening in SMI [7]. This led to a successful phase II trial of\u000a      the intervention [8] subsequently highlighted as a promising\u000a      development for clinical services in a Lancet editorial in 2011 (Lancet\u000a      377; 611).\u000a    Our ongoing research, funded by the Department of Health and NIHR,\u000a      explores inequalities in cancer and CVD screening in people with mental\u000a      illnesses and intellectual disabilities. We are also investigating the\u000a      contribution of antipsychotic medication to cardiovascular risk in these\u000a      people. Furthermore, we are developing and testing CVD risk prediction\u000a      models for people with SMI, and refining and evaluating a an intervention\u000a      delivered over a period of one year within a cluster trial based in\u000a      primary care settings.\u000a    "},{"CaseStudyId":"22422","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"933860","Name":"Botswana"},{"GeoNamesId":"953987","Name":"South Africa"}],"Funders":[],"ImpactDetails":"\u000a    The research described above provided an evidence base to continue the\u000a      rollout of ART in sub-Saharan Africa without diverting resources for ART\u000a      to measures of viral load &#8212; a policy which had come under question in\u000a      previous years. It was seen as critical to understand whether the\u000a      consequences of roll out of ART without viral load monitoring were so\u000a      severe (due to concerns over transmission of HIV drug resistance) as to\u000a      mean that introduction of such testing should be prioritised over\u000a      continued ART expansion by ART programmes. Our findings provided support\u000a      for continued roll out in settings where viral load monitoring was not\u000a      available. A comment paper written by colleagues from the Global Fund for\u000a      HIV, TB and Malaria (the body which, along with U.S. President's Emergency\u000a      Plan for AIDS Relief (PEPFAR), provided most funds for the ART roll-out)\u000a      concluded that \"Phillips and colleagues' findings strengthen the policy\u000a        consensus and WHO recommendation &#8212; so far based on individual patient\u000a        outcomes and cost-effectiveness in the shorter term &#8212; that resource-poor\u000a        countries need not delay ART roll-out because of limitations in\u000a        laboratory capacity\" [a].\u000a    The Director\/Coordinator of Treatment and Prevention Scale-up at the WHO\u000a      HIV Department at that time reports that \"the work... adapting the HIV\u000a        synthesis to model the outcome of ART in low-income settings under\u000a        different monitoring practices helped shape global ART roll-out policy\u000a        and practice. Furthermore, because of its unique utility and approach,\u000a        the modelling work and synthesis adaptations continue to be used to\u000a        inform global policy development\" [b].\u000a    Since 2008, the trajectory of the number of people on ART has increased,\u000a      with 9.7 million people now on ART [c]. Almost all countries in\u000a      sub-Saharan Africa (with the exceptions of South Africa and Botswana) have\u000a      been providing ART without regular viral load monitoring. Point of care\u000a      tests for viral load are now close to coming to market and WHO has started\u000a      to encourage use of viral load testing in patient monitoring as resources\u000a      allow, so long as this does not inhibit roll-out.\u000a    Our publications in 2008 and 2011 were written jointly with colleagues at\u000a      WHO responsible for the public health approach [d], and influenced\u000a      their policy as described &#8212; i.e. to prioritise the continued expansion of\u000a      roll-out of ART over introduction of viral load monitoring, but to\u000a      encourage research and development of implementable viral load measurement\u000a      technology. The two publications are officially approved WHO publications\u000a      and our work has been cited in WHO guidelines. The 2008 WHO progress\u000a      report \"Towards Universal access: Scaling up priority HIV\/AIDS\u000a      interventions in the health sector\" cites our publication from the\u000a      previous year as providing support for WHO's recommendations on scaling up\u000a      ART provision [e]. Furthermore, there were 11 references in total\u000a      to the wider work of the HIV Epidemiology &amp; Biostatistics Group of the\u000a      Research Department of Infection &amp; Population Health in the key WHO\u000a      guideline \"Antiretroviral therapy for HIV infection in adults and\u000a      adolescents. Recommendations for a public health approach\" [f].\u000a    Our model has also been used by the Bill and Melinda Gates Foundation in\u000a      their assessment of CD4 investment options, and was influential in them\u000a      deciding to support development of a new point of care test. A program\u000a      officer at the Foundation writes that: \"I have used your modeling\u000a        analysis several times when we have been evaluating our options for CD4\u000a        investment. The impact of the Zyomyx test is a critical component of our\u000a        decision making and we are constantly re-evaluating our decisions as we\u000a        move forward, so your results have been considered again and again\"\u000a      [g].\u000a    ","ImpactSummary":"\u000a    Our work with the World Health Organisation (WHO) had a major impact on\u000a      global HIV treatment priorities at a critical time in the roll-out of\u000a      anti-retroviral treatment (ART) worldwide. Concern had been expressed that\u000a      if ART was provided without simultaneous monitoring of HIV viral load to\u000a      determine switch in treatment, this would lead to an epidemic of drug\u000a      resistant HIV. It was argued that viral load monitoring should be\u000a      introduced as a priority, despite the fact that this was expensive and\u000a      would inevitably divert resources from ART provision. We used a simulation\u000a      model to predict the impact of lack of viral load monitoring and showed\u000a      that while development of viral load assays was important, ART should be\u000a      prioritised. As a result, the roll out of ART continued despite continued\u000a      lack of viral load monitoring, and there are now over 9 million people on\u000a      ART.\u000a    ","ImpactType":"Health","Institution":"\u000a    University College London\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a[1] Phillips AN, Sabin C, Pillay D, Lundgren JD. HIV in the UK 1980-2006:\u000a      reconstruction using a model of HIV infection and the effect of\u000a      antiretroviral therapy. HIV Medicine. 2007 Nov;8(8):536-46. http:\/\/dx.doi.org\/10.1111\/j.1468-1293.2007.00507.x\u000a    \u000a\u000a[2] Phillips AN, Pillay D, Miners A, Bennett D, Gilks CF, Lundgren JD.\u000a      Outcomes from monitoring of patients on antiretroviral therapy in\u000a      resource-limited settings with viral load, CD4 cell count, or clinical\u000a      observation alone: a computer simulation model. Lancet. 2008 Apr\u000a      26;371(9622):1443-51. http:\/\/dx.doi.org\/10.1016\/S0140-6736(08)60624-8\u000a    \u000a\u000a[3] Phillips AN, Pillay D, Garnett G, Bennett D, Vitoria M, Cambiano V,\u000a      Lundgren JD. Effect on transmission of HIV-1 resistance of timing of\u000a      implementation of viral load monitoring to determine switches from first\u000a      to second line antiretroviral regimens in resource-limited settings. AIDS.\u000a      2011 Mar 27;25(6):843-50. http:\/\/dx.doi.org\/10.1097\/QAD.0b013e328344037a\u000a    \u000aThe research at this stage was directly funded by HEFCE (funding to\u000a      Andrew Phillips).\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"}],"Sources":"\u000a    [a] Korenromp EL, Fakoya A, Viisainen K. Scaling-up antiretroviral\u000a      treatment in resource-poor countries: prioritization and choices. AIDS.\u000a      2011 Mar 27;25(6):857-9.\u000a      http:\/\/dx.doi.org\/10.1097\/QAD.0b013e3283454401.\u000a    [b] Statement from Director of Treatment and Prevention Scale-up at the\u000a      WHO HIV Department. Copy available on request.\u000a    [c] WHO Global update on HIV treatment 2013: results, impact and\u000a      opportunities, June 2013.\u000a      www.who.int\/iris\/bitstream\/10665\/85326\/1\/9789241505734_eng.pdf\u000a    [d] Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y,\u000a      Sutherland D, Vitoria M, Guerma T, De Cock K. The WHO public-health\u000a      approach to antiretroviral treatment against HIV in resource-limited\u000a      settings. Lancet. 2006 Aug 5;368(9534):505-10.\u000a      http:\/\/dx.doi.org\/10.1016\/S0140-6736(06)69158-7\u000a    [e] World Health Organisation. Towards Universal access: Scaling up\u000a      priority HIV\/AIDS interventions in the health sector. 2008 Progress\u000a      Report.\u000a      http:\/\/www.who.int\/hiv\/pub\/2008progressreport\/en\/index.html\u000a      (See page 35)\u000a    [f] World Health Organisation. Antiretroviral therapy for HIV infection\u000a      in adults and adolescents. Recommendations for a public health approach.\u000a      2010 revision.\u000a      http:\/\/www.who.int\/hiv\/pub\/arv\/adult2010\/en\/index.html\u000a    [g] Statement from Senior Program Officer at the Bill and Melinda Gates\u000a      Foundation. Copy available on request.\u000a    ","Title":"\u000a    Influencing global policy on antiretroviral treatment priorities\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The underpinning research described below was carried out by the HIV\u000a      Epidemiology and Biostatistics Group at UCL led by Professor Andrew\u000a      Phillips, and was a collaboration with the WHO HIV\/AIDS Department.\u000a    In the early-2000s, global plans were being put in place to expand access\u000a      to ART as rapidly as possible to low resource settings (particularly\u000a      sub-Saharan Africa) where most people with HIV live. In order to make this\u000a      feasible, the WHO developed a public health approach, which involved use\u000a      of standard regimens with little requirement for the monitoring that was\u000a      being used at that time in developed country settings. Use of CD4 counts,\u000a      particularly to select who should start ART, was encouraged but measures\u000a      of viral load were very expensive in the context of low resource settings\u000a      (the current fully loaded cost of a viral load test is the cost of around\u000a      8 months of ART for one person) and could not be used in most settings. At\u000a      that time, however, increasing concerns were being expressed that\u000a      widespread delivery of ART without use of viral load monitoring to\u000a      identify people failing ART could lead to widespread development of drug\u000a      resistance, with consequences for both the treated individuals and for the\u000a      population, due to transmission of drug resistant HIV. There was no\u000a      research available to evaluate the likely consequences of the ongoing\u000a      roll-out strategy.\u000a    In previous work done by our group between 2003 and 2007, we had\u000a      developed a stochastic computer simulation model of HIV progression and\u000a      the effect of ART, based on our extensive work on studying HIV in cohort\u000a      studies. The first paper from this model, published in 2007, made\u000a      projections about the HIV population in the UK [1]. As a result of\u000a      concerns about the roll out of ART in low-resource settings, we adapted\u000a      our model to investigate the impact of lack of viral load monitoring on\u000a      outcomes of ART in low resource settings [2] and included a\u000a      transmission component to consider transmitted drug resistance [3].\u000a      This work helped us understand what the consequences of provision of ART\u000a      without viral load monitoring were likely to be, in terms of patient\u000a      survival and transmission of drug resistance. We showed that eventual use\u000a      of viral load monitoring is important, particularly to avoid future\u000a      widespread transmission of drug resistance, and that development of new\u000a      tests which are not dependent on substantial laboratory infrastructure or\u000a      highly trained staff should be a key research and development priority.\u000a      However, we also showed that the impact on mortality of lack of viral load\u000a      monitoring was likely to be modest in the short to medium term, relative\u000a      to the mortality impact of failing to provide more widespread ART. Thus\u000a      the message was to continue the roll-out without re-directing resources to\u000a      viral load measurement but to encourage the development of cheaper tests.\u000a    Continuing our research in this areas, we are currently working with WHO\u000a      on assessing the impact on transmission of HIV drug resistance of starting\u000a      more people on ART earlier, and defining threshold levels of transmitted\u000a      drug resistance beyond which a change in public health policy is required.\u000a      In further work using the model, we are collaborating with GSK Biologicals\u000a      to model potential effects of their vaccines. We collaborate on this\u000a      research with health economist colleagues at the London School of Hygiene\u000a      and Tropical Medicine (Alec Miners) and, more recently, the University of\u000a      York (Paul Revill).\u000a    "},{"CaseStudyId":"22423","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    a) Development and on-going review of the UK universal child vision\u000a        screening programme\u000a    Our research findings provided the first robust evidence base for the UK\u000a      National Screening Committee's policy on universal childhood vision\u000a      screening and surveillance. This has led to the revised programme status\u000a      and standards for the Newborn and Infant Physical Examination Programme\u000a      (NIPE) and discontinuation of 9-month and pre-school vision screening\u000a      examinations [a]. More recently we have completed a commissioned\u000a      systematic review for the National Screening Committee (NSC) which is\u000a      currently forming the basis of their policy review of the content and\u000a      timing of the 4-5 year\/school entry vision screening examination [b].\u000a    b) Improving the quality of paediatric ophthalmology services\u000a    Our work has underpinned the development of new quality standards for\u000a      paediatric ophthalmology services. A number of our publications are cited\u000a      in the Royal College of Ophthalmologists (RCOphth) standing report,\u000a      Ophthalmic Services for Children (Updated August 2012) for which Rahi\u000a      acted also acted as reviewer. Our work provides epidemiological background\u000a      and supports recommendations on the involvement of parents, on the early\u000a      detection of ophthalmic disorders and on certifying children as\u000a      sight-impaired [c]. Our study of the needs and experiences of\u000a      families of newly diagnosed visually impaired children informed the\u000a      successful implementation of a novel regional-level `key worker' service,\u000a      the Great Ormond Street Hospital (GOSH) Ophthalmology Community Link Team,\u000a      which provides information, support and liaison to families of our\u000a      patients [d]. This was taken as a model of key worker provision\u000a      and cited in the above document.\u000a    Following on from this, Rahi helped to develop Quality Standards for\u000a      Paediatric Ophthalmology on behalf of RCOphth [e]. These quality\u000a      standards are now in regular use in clinical practice. For example, this\u000a      can be seen on the GOSH website, which describes how it has measured its\u000a      services against the Quality Indicator Tool that we helped to develop [f].\u000a    In 2012, Rahi contributed to the first Atlas of Variation in Healthcare\u000a      for Children and Young people which was produced by the Department of\u000a      Health's QIPP (Quality, Innovation, Productivity and Prevention) programme.\u000a      This document presented variations across the breadth of child health\u000a      services provided by NHS England together for the first time to allow\u000a      clinicians, commissioners and service users to identify priority areas for\u000a      improving outcome, quality and productivity. Map 7 highlighted variation\u000a      in the proportion of eligible premature babies tested for retinopathy of\u000a      prematurity (ROP) within the recommended timeframe, and made\u000a      recommendations on improving services [g].\u000a    c) Improving the management of congenital cataract\u000a    Congenital cataract is the most common surgically treatable cause of\u000a      childhood visual impairment worldwide. Our studies on congenital cataract\u000a      have been conducted through the British Congenital Cataract Interest\u000a      Group, a network comprising over 150 ophthalmologists which we established\u000a      in 1995. This has led to timely implementation of findings to improve\u000a      clinical practices and provide improved outcomes information for parents\u000a      of affected infants [h]. For example, during our ongoing research\u000a      on intraocular lens implantation, we have used this network to spread use\u000a      of the data collection forms that we developed as part of the study. These\u000a      are now more widely used as routine clinical pro-formas for patient case\u000a      notes, leading to standardisation of key aspects of management nationally.\u000a      GOSH, for example, report that:\u000a    \"The per-operative data entry proforma currently used by our surgeons\u000a        at GOSH was developed as part of the IOLu2 [Intraocular lens under 2]\u000a        study by Dr Lola Solebo in 2009... Not only is [it] still used and can\u000a        be sampled for future studies it is now used by all the other surgeons\u000a        in the team... The team has found it promotes good record keeping when\u000a        performing childhood cataract surgery... It has also be shared with many\u000a        other centres through our lectures and when we have visiting\u000a        ophthalmologists. The proforma helps the department to enter clinical\u000a        data in an efficient, standardised and thorough manner\" [i].\u000a    d) Improving patient involvement in research\u000a    Our research over the years has directly involved service users and\u000a      patient groups. For example, our systematic review of Patient-reported\u000a      outcome measures (PROMs) in paediatric ophthalmology involved a service\u000a      user (visually impaired herself and parent of a visually impaired child)\u000a      as a co-investigator [j].\u000a    In the first stage of our work to develop our `quality of life'\u000a      instrument, we worked with the pupils in the Visual Impairment unit at\u000a      Exhall Grange, a specialist school in Coventry that caters for children\u000a      and young people with a range of disabilities. Specifically, we conducted\u000a      focus groups and interviews with these pupils to help us identify the\u000a      content for our instrument. In the focus groups we elicited the children's\u000a      thoughts and views about the impact of living with visual disability. The\u000a      mobility officer working with these children, who helped facilitate the\u000a      focus group discussion, was struck by how much the children opened up\u000a      about their lives and felt there was a broader benefit of this context.\u000a      Subsequently, he reported to us that as a result of this experience, the\u000a      Visual Impairment unit initiated a `forum for the visually impaired\u000a      pupils' where the pupils meet weekly or monthly for an `around the table'\u000a      discussion of any issues that they might have (modelled on their\u000a      participation in our research). Finally, the school was commended by\u000a      Ofsted for this initiative [k].\u000a    ","ImpactSummary":"\u000a    Our research into the epidemiology of childhood visual impairment has\u000a      transformed understanding of the epidemiology, outcomes and impact of\u000a      childhood visual impairment in the UK. As a result, changes have been made\u000a      to the Newborn and Infant Physical Examination Programme and the National\u000a      Vision Screening Programme. Our work has underpinned the development of\u000a      new quality standards for paediatric ophthalmology services issued by the\u000a      Royal College of Ophthalmologists. Our studies on congenital cataract have\u000a      improved the management of this condition nationally. We have involved\u000a      visually impaired service users and patient groups directly in our\u000a      research to improve quality of life measures and patient engagement.\u000a    ","ImpactType":"Health","Institution":"\u000a    University College London\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a[1] Rahi JS, Cable N; British Childhood Visual Impairment Study Group.\u000a      Severe visual impairment and blindness in children in the UK. Lancet. 2003\u000a      Oct 25;362(9393):1359-65. http:\/\/dx.doi.org\/10.1016\/S0140-6736(03)14631-4\u000a    \u000a\u000a[2] Rahi JS, Cumberland PM, Peckham CS; British Childhood Visual\u000a      Impairment Interest Group. Improving detection of blindness in childhood:\u000a      the British Childhood Vision Impairment study. Pediatrics. 2010\u000a      Oct;126(4):e895-903. http:\/\/dx.doi.org\/10.1542\/peds.2010-0498\u000a    \u000a\u000a[3] Rahi JS, Cumberland PM, Peckham CS. Does amblyopia affect\u000a      educational, health, and social outcomes? Findings from 1958 British birth\u000a      cohort. BMJ. 2006 Apr 8;332(7545):820-5. http:\/\/dx.doi.org\/10.1136\/bmj.38751.597963.AE\u000a    \u000a\u000a[4] Rahi J, Logan S, Timms C, Russell-Eggitt I, Taylor D. Risk, causes,\u000a      and outcomes of visual impairment after loss of vision in the\u000a      non-amblyopic eye: a population-based study. Lancet. 2002 Aug\u000a      24;360(9333):597-602. http:\/\/dx.doi.org\/10.1016\/S0140-6736(02)09782-9\u000a    \u000a\u000a[5] Chak M, Wade A, Rahi JS; British Congenital Cataract Interest Group.\u000a      Long-term visual acuity and its predictors after surgery for congenital\u000a      cataract: findings of the British congenital cataract study. Invest\u000a      Ophthalmol Vis Sci. 2006 Oct;47(10):4262-9. http:\/\/doi.org\/ddj6gh\u000a    \u000a\u000a[6] Rahi JS, Tadi&#263; V, Keeley S, Lewando-Hundt G; Vision-related Quality\u000a      of Life Group. Capturing children and young people's perspectives to\u000a      identify the content for a novel vision-related quality of life\u000a      instrument. Ophthalmology. 2011 May;118(5):819-24. http:\/\/doi.org\/ch4fxm\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"13","Subject":"Ophthalmology and Optometry"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [a] The Clinical Director of the NIPE screening programme states: \"Professor\u000a        Rahi has played a major role in relation to the Newborn and Infant\u000a        Physical Examination. On behalf of the National Screening Committee, she\u000a        and her team have reviewed the evidence relating to screening for vision\u000a        and ocular abnormalities in preschool children. The review and her other\u000a        contributions, have allowed us to strengthen and improve screening where\u000a        there is evidence to support it, while we have been able to cease\u000a        screening at ages when there is no benefit to be had.\" Copy\u000a      of email available on request.\u000a    [b] http:\/\/www.screening.nhs.uk\/vision-child\u000a      The Director of the National Screening Committee (Public Health England)\u000a      has confirmed in an email that \"The UKNSC commissioned a review of\u000a        vision screening in 4-5 years olds from Jugnoo Rahi. This work has been\u000a        developed in close collaboration with the UKNSC. It has been consulted\u000a        on through the UKNSC process and will form the basis of a policy\u000a        recommendation to be made by the UKNSC in November 2013.\" Copy of\u000a      email available on request.\u000a    [c] http:\/\/www.rcophth.ac.uk\/core\/core_picker\/download.asp?id=125\u000a      Guidance cites the following:\u000a    \u000a      Citing Rahi J et al. Meeting the needs of parents around the time of\u000a        diagnosis of disability in their children: evaluation of a novel scheme\u000a        for information, support and liaison by key workers. Pediatrics\u000a        2004;114:e477-82. Supports recommendation: \"Parental advocacy\u000a          should be supported and encouraged through provision of information\u000a          and social and emotional support, both in the context of the\u000a          management of individual children as well as more broadly in relation\u000a          to the planning of ophthalmic services for children with visual\u000a          impairment\"\u000a      Citing [1]. Supports the observation that: \"The\u000a          majority of children in the UK with severe visual\u000a          impairment\/blindness... have additional and often multiple serious\u000a          motor, sensory or learning impairments and\/or serious chronic\u000a          diseases\".\u000a      Citing Rahi J, Dezateux C. Epidemiology of Visual Impairment. In:\u000a        David T, ed. Recent Advances in Paediatrics 19. London: Churchill\u000a        Livingstone, 2001: 97-114. Research provides epidemiological basis:\u000a        \"Thus there are at least 4 newly visually impaired children each day\u000a          in the UK and around 2 per 1000 children in a given population are\u000a          visually impaired or blind.\"\u000a      Citing [2]. Supports the statement: \"The College\u000a          endorses the recommendations of the fourth edition of \"Health for all\u000a          children\" issued in 2003 and subsequently in the Child Health\u000a          Promotion Programme and the Healthy Child Programme regarding\u000a          screening, in order to promote early detection of ophthalmic disorders\u000a          or reduced vision.\"\u000a      Citing Cumberland PM, Peckham CS, Rahi JS. Blindness certification of\u000a        children 1 year after diagnosis: findings from the British Childhood\u000a        Vision Impairment Study. Br J Ophthalmology. 2010\u000a        Dec;94(12):1694-5. Supports recommendation: \"All eligible\u000a          children and young persons should be offered certification as\u000a          sight-impaired or severely sight impaired where indicated\"\u000a    \u000a    [d]http:\/\/www.gosh.nhs.uk\/medical-conditions\/clinical-specialties\/ophthalmology-information-for-parents-and-visitors\/clinics-and-wards\/\u000a    [e] http:\/\/www.rcophth.ac.uk\/page.asp?section=444&#167;ionTitle=Quality+Standards\u000a    [f] http:\/\/www.gosh.nhs.uk\/health-professionals\/clinical-outcomes\/ophthalmology-clinical-outcomes\/\u000a    [g] Atlas of Variation http:\/\/www.rightcare.nhs.uk\/index.php\/atlas\/children-and-young-adults\/\u000a      and for actual pdf see: https:\/\/docs.google.com\/file\/d\/0B8ePB71diJorM0ZMQzVqLWhFUjA\u000a      (Rahi is listed on p.84 as a contributor to Map 7).\u000a    [h]\u000ahttp:\/\/www.gosh.nhs.uk\/medical-conditions\/clinical-specialties\/ophthalmology-information-for-parents-and-visitors\/clinics-and-wards\/\u000a    [i] Impacts corroborated by Chris Lloyd, Chair of the Paediatric\u000a      Subcommittee of RCOPhth who says: \"the unit at ICH\/UCL has been hugely\u000a        influential in improving the care of children with congenital\u000a        cataracts(CC). You have enabled accurate biostatistical analysis of\u000a        children affected by CC &#8212; the most common surgically treatable cause of\u000a        childhood visual impairment. This has been facilitated by the\u000a        establishment of the British Congenital Cataract Interest Group - a\u000a        network comprising over 150 ophthalmologists in the UK and Ireland which\u000a        you set up in 1995.\" Copy of email available on request.\u000a    [j] Email from Consultant Ophthalmic Surgeon at GOSH. Available on\u000a      request.\u000a    [k] http:\/\/www.invo.org.uk\/resource-centre\/research-project-database\/research-project\/?id=750\u000a      http:\/\/www.invo.org.uk\/resource-centre\/research-project-database\/research-project\/?id=753\u000a    [l] Copies of correspondence with the Mobility Officer at Exhall Grange\u000a      School are available from Centre of Paediatric Epidemiology and\u000a      Biostatistics, UCL ICH. Contact details provided. \u000a    ","Title":"\u000a    Applying epidemiology to understand visual impairment in childhood:\u000a      burden, aetiology, diagnosis, management and outcomes.\u000a    ","UKLocation":[{"GeoNamesId":"2652221","Name":"Coventry"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    About two per 1,000 children in industrialised countries have bilateral\u000a      visual impairment, with up to a further five per cent having significant\u000a      sight impairment in one eye. Most are affected from birth and will\u000a      experience a significant lifelong burden of adverse impact on their\u000a      development, education, social and emotional wellbeing, and curtailed\u000a      occupational and social prospects, with high attendant economic costs for\u000a      affected individuals, their families and society. At the MRC Centre of\u000a      Epidemiology for Child Health, we have established an integrated and\u000a      innovative programme on childhood visual impairment that encompasses\u000a      classical, lifecourse, and genetic epidemiology and health services\u000a      research, led by Professor Jugnoo Rahi. Our research has transformed\u000a      understanding of the epidemiology, outcomes and impact of childhood visual\u000a      impairment in the UK and established a series of novel study-specific\u000a      clinical networks (most with 150+ consultant ophthalmologists) for rapid\u000a      implementation of findings into practice and policy.\u000a    We have undertaken a series of national studies of all-cause visual\u000a      impairment and of all of the most common (globally) treatable childhood\u000a      ophthalmic disorders i.e. amblyopia, congenital cataract, paediatric\u000a      glaucoma, ocular anomalies and hereditary retinal disorders. These have\u000a      provided the first population-based data on the frequency, distribution\u000a      and natural history of these individual disorders together with unbiased\u000a      assessment of effectiveness and safety of treatments.\u000a    We have shown for the first time that there are major variations in risk\u000a      of visual impairment\/eye disorders e.g. by socio-economic status,\u000a      ethnicity, birthweight and other early life factors and demonstrated a\u000a      growing and increasingly complex population at risk [1, 2].\u000a    Our longstanding programme on amblyopia, the most common paediatric eye\u000a      condition, has shown that contrary to long-held clinical opinion, there is\u000a      remarkably limited disutility per se [3] but that risk of\u000a      blindness and its attendant socio-economic consequences occurring through\u000a      loss of sight in the non-amblyopic eye is substantial [4].\u000a    Our series of studies on congenital cataract have provided for the first\u000a      time internationally accepted population based `benchmark' outcomes data\u000a      on visual function, quality of life, and complications [5] and\u000a      identified the risk factors associated with poor outcomes against a\u000a      backdrop of evolving surgical approaches. Most recently we have completed\u000a      the first national study of intra-ocular lens implantation in infants, the\u000a      key surgical innovation in this field, assessing early visual outcomes\u000a      with this new approach compared to established surgical treatment and\u000a      identifying the point of `equipoise' for clinicians in their choice of\u000a      surgical approach. This study established a unique national cohort which\u000a      is providing important early insights into the impact of this new\u000a      intervention on visual outcomes and iatrogenic complications. In due\u000a      course it will provide unique long-term outcomes data.\u000a    Our inter-disciplinary programme to understand the impact of visual\u000a      impairment has combined health services research and social sciences,\u000a      resulting in innovative child-centred methodology and a novel patient\/NHS\u000a      user research partnerships which have underpinned our development of the\u000a      first child-reported measures of quality of life and of functional vision\u000a      [6], which can also be used routinely in the NHS as a tool for\u000a      assessing quality and as outcome measures in clinical trials of novel\u000a      therapies.\u000a    "},{"CaseStudyId":"23145","Continent":[],"Country":[],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    The major impact of the research has been the implementation of Flexible\u000d\u000a      Sigmoidoscopy as a\u000d\u000a      single examination at age 55 as part of the National Bowel Cancer\u000d\u000a      Screening Programme.\u000d\u000a      Following the publication of the trial outcomes in the Lancet in April\u000d\u000a      2010, and the results of the\u000d\u000a      successful pilot programme in the Journal of Medical Screening in June\u000d\u000a      2010, the Prime Minister\u000d\u000a      David Cameron announced in October 2010 that once-only FS screening would\u000d\u000a      be included in the\u000d\u000a      NHS National Bowel Cancer Screening Programme. &#163;60m was pledged over the\u000d\u000a      next four years to\u000d\u000a      introduce this latest cancer screening technology, with estimates that\u000d\u000a      flexible sigmoidoscopy could\u000d\u000a      save 3,000 lives a year [a]. Then Health Secretary, Andrew Lansley\u000d\u000a      announced that pilot schemes\u000d\u000a      for the new screening programme would begin in spring 2011 [b],\u000d\u000a      subject to approval by the UK\u000d\u000a      National Screening Committee [c].\u000d\u000a    The existing NHS Bowel Cancer Screening Programme is based on biennial\u000d\u000a      faecal occult blood\u000d\u000a      testing using the guaiac-based test (gFOBT), with an immunochemical test\u000d\u000a      (iFOBT) being piloted\u000d\u000a      in 2014. An `options appraisal' of colorectal cancer (CRC) screening\u000d\u000a      modalities commissioned by\u000d\u000a      the NHS Cancer Screening Programme in 2004 from SCHARR (University of\u000d\u000a      Sheffield School of\u000d\u000a      Health and Related Research) had used the baseline data from the FS trial,\u000d\u000a      and concluded that FS\u000d\u000a      screening was likely to be highly cost-effective compared with other\u000d\u000a      methods because it reduced\u000d\u000a      incidence of CRC and therefore the costs of the programme would be likely\u000d\u000a      to be offset by a\u000d\u000a      substantial reduction in the costs of treatment. SCHARR repeated the\u000d\u000a      analysis in 2012 using the\u000d\u000a      full FS trial outcome data and concluded that: `For a strategy of\u000d\u000a        one-off FS screening, the optimal\u000d\u000a        effectiveness (QALYS) is achieved with a one-off FS screen in the age\u000d\u000a        range 55-60. The most\u000d\u000a        cost-effective strategy was FS at age 55 followed by biennial iFOBT\u000d\u000a        screening for ages 56-74,\u000d\u000a        irrespective of whether the comparator was the current screening\u000d\u000a        programme of biennial gFOBT\u000d\u000a        60-74 or no screening. This strategy was associated with the greatest\u000d\u000a        net monetary benefit and\u000d\u000a        also the greatest reduction in CRC incidence, CRC mortality and CRC\u000d\u000a        treatment costs'. The report\u000d\u000a      also concluded that `it may be cost-effective to spend considerable\u000d\u000a        resources on increasing\u000d\u000a        screening awareness' which has been a parallel focus of our\u000d\u000a      research, with a particular emphasis\u000d\u000a      on promoting awareness in order to reduce socioeconomic disparities in CRC\u000d\u000a      screening uptake\u000d\u000a      [d]. Professor Wardle now has programme grant funding from NIHR\u000d\u000a      trial for a trial (ASCEND) of\u000d\u000a      methods to reduce socioeconomic disparities in CRC screening uptake as\u000d\u000a      Co-PI with Professor\u000d\u000a      Rosalind Raine (also UCL).\u000d\u000a    In January 2011, the Department of Health's document Improving\u000d\u000a        Outcomes: A Strategy for\u000d\u000a        Cancer set out the plans for FS screening [e].\u000d\u000a      Implementation of the FS programme began in early\u000d\u000a      2011, with three `pathfinder' screening sites set up to finalise the\u000d\u000a      invitation and organisation\u000d\u000a      procedures [f]. One of the centres explored a novel method of\u000d\u000a      invitation, but the conclusion from\u000d\u000a      the 4,022 invitations across the three sites was that the invitation\u000d\u000a      system Wardle and her team had\u000d\u000a      developed in the FS Trial and applied in the Demonstration Pilot\u000d\u000a      (comprising a `flyer' giving brief\u000d\u000a      information about the programme, followed by a dated and timed invitation\u000d\u000a      that could be confirmed,\u000d\u000a      changed or cancelled, followed by a self-administered enema with detailed\u000d\u000a      information about the\u000d\u000a      test), was likely to be most successful.\u000d\u000a    Plans are now finalised for national implementation, and six sites began\u000d\u000a      screening between March\u000d\u000a      and July 2013 to finalise invitation procedures and patient information\u000d\u000a      materials [g]. Professor\u000d\u000a      Wardle's group has been commissioned to carry out real-time audits of\u000d\u000a      uptake, patient-reported\u000d\u000a      outcomes 24 hours after the test, and patient satisfaction at 12 weeks\u000d\u000a      when any follow-up\u000d\u000a      procedures should be completed, in the starter sites. This will allow\u000d\u000a      rapid identification of any\u000d\u000a      problems and make it possible to implement small modifications to optimise\u000d\u000a      procedures in advance\u000d\u000a      of the national rollout.\u000d\u000a    To the end of July, around 2,220 people had received FS screening between\u000d\u000a      the pathfinder and\u000d\u000a      starter sites. Data from the FS trial indicated that one colorectal cancer\u000d\u000a      diagnosis is prevented for\u000d\u000a      each 191 people screened. So even with the small number of people screened\u000d\u000a      so far, it is likely\u000d\u000a      that 11 of these terrible diagnoses have been prevented [h].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Our evidence that a single flexible sigmoidoscopy (FS) dramatically\u000d\u000a      reduced bowel cancer\u000d\u000a      mortality and incidence, combined with evidence of high public\u000d\u000a      acceptability in our pilot\u000d\u000a      programme, led the Prime Minister to announce in late 2010 that once-only\u000d\u000a      FS would be included\u000d\u000a      in the UK National Bowel Cancer Screening Programme. The new FS screening\u000d\u000a      programme\u000d\u000a      started in March 2013 in six pilot centres, and is being progressively\u000d\u000a      implemented nationally, with\u000d\u000a      full roll-out expected by 2016. All eligible adults will be invited for\u000d\u000a      screening around the time of\u000d\u000a      their 55th birthday using the invitation and bowel preparation\u000d\u000a      protocols developed for the trial. If\u000d\u000a      uptake rates similar to those in the pilot are achieved, bowel cancer\u000d\u000a      rates could be cut by a\u000d\u000a      quarter, and deaths by a third, giving the UK the best colorectal cancer\u000d\u000a      (CRC) outcomes in the\u000d\u000a      world.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University College London\u000d\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Atkin WS, Hart A, Edwards R, McIntyre P, Aubrey R, Wardle J, Sutton\u000d\u000a      S, Cuzick J, Northover\u000d\u000a      JM. Uptake, yield of neoplasia, and adverse effects of flexible\u000d\u000a      sigmoidoscopy screening. Gut.\u000d\u000a      1998 Apr;42(4):560-5. http:\/\/dx.doi.org\/10.1136\/gut.42.4.560\u000d\u000a    \u000a\u000a[2] Atkin WS, Edwards R, Wardle J, Northover JM, Sutton S, Hart AR,\u000d\u000a      Williams CB, Cuzick J.\u000d\u000a      Design of a multicentre randomised trial to evaluate flexible\u000d\u000a      sigmoidoscopy in colorectal cancer\u000d\u000a      screening. Journal of Medical Screening. 2001;8(3):137-44.\u000d\u000a      http:\/\/dx.doi.org\/10.1136\/jms.8.3.137\u000d\u000a    \u000a\u000a[3] Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JM, Wardle J; UK\u000d\u000a      Flexible Sigmoidoscopy\u000d\u000a      Screening Trial Investigators. Single flexible sigmoidoscopy screening to\u000d\u000a      prevent colorectal\u000d\u000a      cancer: baseline findings of a UK multicentre randomised trial. Lancet.\u000d\u000a      2002;359:1291-300.\u000d\u000a      http:\/\/dx.doi.org\/10.1016\/S0140-6736(02)08268-5\u000d\u000a    \u000a\u000a[4] Wardle J, Williamson S, Sutton S, Biran A, McCaffery K, Cuzick J,\u000d\u000a      Atkin W. Psychological\u000d\u000a      impact of colorectal cancer screening. Health Psychology. 2002 Apr\u000d\u000a      13;359(9314):1291-300.\u000d\u000a      http:\/\/dx.doi.org\/10.1037\/0278-6133.22.1.54\u000d\u000a    \u000a\u000a[5] Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover\u000d\u000a      JM, Parkin DM, Wardle\u000d\u000a      J, Duffy SW, Cuzick J; UK Flexible Sigmoidoscopy Trial Investigators.\u000d\u000a      Once-only flexible\u000d\u000a      sigmoidoscopy screening in prevention of colorectal cancer: a multicentre\u000d\u000a      randomised\u000d\u000a      controlled trial. Lancet. 2010 May 8;375(9726):1624-33. http:\/\/dx.doi.org\/10.1016\/S0140-6736(10)60551-X\u000d\u000a    \u000a\u000a[6] Robb K, Power E, Kralj-Hans I, Edwards R, Vance M, Atkin W, Wardle J.\u000d\u000a      Flexible\u000d\u000a      sigmoidoscopy screening for colorectal cancer: uptake in a\u000d\u000a      population-based pilot programme.\u000d\u000a      Journal of Medical Screening. 2010;17(2):75-8. http:\/\/dx.doi.org\/10.1258\/jms.2010.010055\u000d\u000a    \u000a\u000a[7] Robb K, Lo SH, Power E, Kralj-Hans I, Edwards R, Vance M, von Wagner\u000d\u000a      C, Atkin W, Wardle\u000d\u000a      J. Patient-reported outcomes following flexible sigmoidoscopy screening\u000d\u000a      for colorectal cancer\u000d\u000a      in a demonstration screening programme in the UK. Journal of Medical\u000d\u000a      Screening. 2013 Sep 2.\u000d\u000a      [Epub ahead of print] http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23417540\u000d\u000a    \u000aThis work was funded by the Medical Research Council, the National\u000d\u000a      Institute for Health Research,\u000d\u000a      and Cancer Research UK (http:\/\/www.mrc.ac.uk\/Newspublications\/News\/MRC006794)\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"12","Subject":"Oncology and Carcinogenesis"}],"Sources":"\u000d\u000a    [a] BBC report of David Cameron's announcement: \u000d\u000a        http:\/\/www.bbc.co.uk\/news\/uk-politics-11461495.\u000d\u000a    [b] BBC report of Lansley's interview about the outcomes of the\u000d\u000a      `Flexisig' trial and how cost-saving\u000d\u000a      and pioneering the FS programme will be: http:\/\/www.bbc.co.uk\/news\/health-11463005.\u000d\u000a    [c] Mayor, S., UK committee recommends flexible sigmoidoscopy to\u000d\u000a        screen for bowel cancer,\u000d\u000a      2011, which confirms that flexible sigmoidoscopy will be introduced to the\u000d\u000a      national screening\u000d\u000a      programme for bowel cancer. Available online: http:\/\/www.bmj.com\/content\/342\/bmj.d2325.\u000d\u000a    [d] School of Health and Related Research (ScHARR), Re-appraisal of\u000d\u000a        the options for colorectal\u000d\u000a        cancer screening, Feb 2011, which re-evaluates the options for CRC\u000d\u000a      screening in England\u000d\u000a      using new data sources. New data is available from the England Bowel\u000d\u000a      Cancer Screening\u000d\u000a      Programme and a large randomised UK trial of FS. Document available\u000d\u000a      online:\u000d\u000a      http:\/\/www.cancerscreening.nhs.uk\/bowel\/scharr-full-report-summary-201202.pdf.\u000d\u000a    [e] Department of Health report, Improving Outcomes: A Strategy for\u000d\u000a        Cancer, Jan 2011, which\u000d\u000a      announces funding for FS screening based on the results of our trial.\u000d\u000a      Document available\u000d\u000a      online:\u000d\u000a      \u000d\u000ahttp:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_123394.pdf\u000d\u000a    [f] Department of Health report, Bowel Cancer Screening\u000d\u000a        Specification, Apr 2013, which ensures\u000d\u000a      that there is a consistent and equitable approach to the provision and\u000d\u000a      monitoring of bowel\u000d\u000a      cancer screening across England. Document available online:\u000d\u000a      \u000d\u000ahttps:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/192977\/26_Bowel_Cancer_Screening_service_specification__VARIATION_130422_-_NA.pdf\u000d\u000a    [g] NHS Cancer Screening Programme's announcement of FS screening,\u000d\u000a      referring to our Lancet\u000d\u000a      paper as the basis of the decision: \u000d\u000ahttp:\/\/www.cancerscreening.nhs.uk\/bowel\/flexible-sigmoidoscopy-screening.html.\u000d\u000a      Document available online:\u000d\u000a      \u000d\u000ahttps:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/215205\/dh_132468.pdf.\u000d\u000a    [h] Numbers can be corroborated by audit lead, UCL. Contact details\u000d\u000a      provided.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Inclusion of flexible sigmoidoscopy in the UK Bowel Cancer Screening\u000d\u000a      Programme\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Colorectal cancer (CRC) is the second most common cause of cancer death,\u000d\u000a      and among the most\u000d\u000a      feared cancers because of the effects of surgical treatment. Professor\u000d\u000a      Jane Wardle from the\u000d\u000a      Department of Epidemiology and Public Health at UCL has a long-standing\u000d\u000a      collaboration with\u000d\u000a      Professor Wendy Atkin (Imperial) to evaluate the potential of flexible\u000d\u000a      sigmoidoscopy (FS) to\u000d\u000a      prevent CRC through finding and removing pre-cancerous adenomas.\u000d\u000a    The natural history of CRC suggested that a single FS examination in the\u000d\u000a      age range when\u000d\u000a      adenomas are likely to have developed, but before CRC incidence starts to\u000d\u000a      rise, could provide\u000d\u000a      protection for 10-25 years. With Professor Atkin and colleagues, Professor\u000d\u000a      Jane Wardle\u000d\u000a      developed and piloted screening and pathology protocols, quality control\u000d\u000a      procedures, patient\u000d\u000a      management systems, patient information materials, and invitation\u000d\u000a      protocols, which included\u000d\u000a      pioneering the use of a mailed, self-administered enema to be carried out\u000d\u000a      at home before the test.\u000d\u000a      The trial team then carried out pilot studies of FS screening in\u000d\u000a      asymptomatic 55-64 year olds in\u000d\u000a      Welwyn Garden City and Leicester. The results demonstrated that FS could\u000d\u000a      be safe and\u000d\u000a      acceptable, and the yield of neoplasia suggested there would be a\u000d\u000a      significant impact on CRC\u000d\u000a      incidence [1].\u000d\u000a    The success of the pilot studies led onto the main randomised controlled\u000d\u000a      trial in which almost\u000d\u000a      400,000 adults around the UK were randomised either to be invited for FS\u000d\u000a      screening at their local\u000d\u000a      hospital or to usual care, using a novel, two-stage invitation procedure\u000d\u000a      which allowed us to make a\u000d\u000a      robust estimate of efficacy [2]. Baseline findings revealed high\u000d\u000a      rates of pre-malignant adenomas,\u000d\u000a      most of which were low risk and could be safely removed during FS. Rates\u000d\u000a      of referral for\u000d\u000a      colonoscopy were manageable (around 5%), with evidence that the risk of\u000d\u000a      harm from the test was\u000d\u000a      low [3]. Professor Wardle was responsible for the psychosocial\u000d\u000a      elements of the trial and showed\u000d\u000a      that uptake and acceptability were high in both men and women, and the\u000d\u000a      psychological impact was\u000d\u000a      favourable [4]. After 11 years of follow-up for cancer\u000d\u000a      registrations and deaths, intention-to-treat\u000d\u000a      analyses showed a 23% reduction in incidence and a 31% reduction in\u000d\u000a      mortality, with per-protocol\u000d\u000a      analyses (attenders vs controls) showing a 33% reduction in incidence and\u000d\u000a      43% reduction in\u000d\u000a      mortality [5]. Incidence of distal colorectal cancer (rectum and\u000d\u000a      sigmoid colon), the secondary\u000d\u000a      outcome of the trial, was reduced by half. These were the best results\u000d\u000a      ever reported in a cancer\u000d\u000a      prevention trial, and the progressive divergence in incidence and\u000d\u000a      mortality curves between\u000d\u000a      screened and control groups indicates prolonged and continuing protection.\u000d\u000a    In the meantime, Professor Wardle had been commissioned by the National\u000d\u000a      Cancer Screening\u000d\u000a      Committee to set up a `demonstration' study of an FS screening programme\u000d\u000a      in a socio-economically\u000d\u000a      and ethnically diverse area of North London, with FS carried out by nurse\u000d\u000a      endoscopists. In collaboration with Professor Atkin, she modified the\u000d\u000a      trial procedures for a\u000d\u000a      population programme, and concurrently evaluated a range of methods for\u000d\u000a      promoting uptake. An\u000d\u000a      uptake rate of 55% was achieved in the pilot programme [6], and\u000d\u000a      patient-reported outcomes were\u000d\u000a      almost unanimously positive [7]. The Prime Minister announced in\u000d\u000a      2010 that FS screening would\u000d\u000a      be added to the National Bowel Cancer Screening Programme. Starting in\u000d\u000a      March 2013, a single\u000d\u000a      FS screening test will be offered to all adults aged 55. Professor\u000d\u000a      Wardle's group have been\u000d\u000a      commissioned to monitor uptake and patient-reported outcomes using methods\u000d\u000a      developed in the\u000d\u000a      trial. She is also collaborating in the continued follow-up of the FS\u000d\u000a      trial participants and they expect\u000d\u000a      to publish 15 year outcomes in 2014.\u000d\u000a    "},{"CaseStudyId":"23146","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Initial results were based on 2,688 patients, from ten randomised trials,\u000d\u000a      and updated to include 3,005 patients, from 11 trials, including the MRC\u000d\u000a      Clinical Trials Unit BA06 trial. This represents 98% of the available\u000d\u000a      randomised evidence. We showed that people with invasive bladder cancer\u000d\u000a      who had multi-drug, platinum-based chemotherapy before surgery and\/or\u000d\u000a      radiotherapy lived longer than those who had just surgery and\/or\u000d\u000a      radiotherapy. After five years, 50 out of every 100 people who received\u000d\u000a      additional chemotherapy were still alive compared with 45 out of every 100\u000d\u000a      who just had surgery and\/or radiotherapy. They were also less likely to\u000d\u000a      have their cancer recur or spread to other parts of the body. These\u000d\u000a      effects were independent of the whether neoadjuvant chemotherapy was added\u000d\u000a      to surgery or radiotherapy. There was no evidence to support the use of\u000d\u000a      neoadjuvant chemotherapy based on a single platinum-based drug.\u000d\u000a    The research has been cited as evidence in 19 national and international\u000d\u000a      guidelines from 2008 to 2013. In most cases, the guidelines citing this\u000d\u000a      review substantiate their clinical recommendations by directly quoting the\u000d\u000a      review:\u000d\u000a    European Association of Urology (2008\/2009\/2010\/2011\/2012\/2013)\u000d\u000a      \"Neoadjuvant cisplatin containing combination chemotherapy should be\u000d\u000a      considered in muscle invasive bladder cancer irrespective of definitive\u000d\u000a      treatment\" [a].\u000d\u000a    European Society for Medical Oncology (2008\/2009\/2010\/2011) \"A\u000d\u000a      meta-analysis supports the use of neoadjuvant chemotherapy before\u000d\u000a      cystectomy for T2 and T3 disease. The demonstrated survival benefit\u000d\u000a      encourages the use of platinum based combination chemotherapy for patients\u000d\u000a      with invasive bladder cancer before radical cystectomy or definitive\u000d\u000a      radiotherapy\" [b].\u000d\u000a    National Comprehensive Cancer Network (2010\/2011) \"In the most\u000d\u000a      recent meta-analysis, a statistically significant decrease in the death\u000d\u000a      rate was seen corresponding to an improvement in overall survival. The\u000d\u000a      NCCN Bladder Cancer panel members recommend considering cisplatin-based\u000d\u000a      neoadjuvant combination chemotherapy\" [c].\u000d\u000a    Japanese Urological Association (2010) \"At present, a definite\u000d\u000a      improvement in survival rates has been shown only for preoperative\u000d\u000a      cisplatin-based combination chemotherapy\" [d].\u000d\u000a    Associazione Urologi Italiani (2010) \"High-quality clinical\u000d\u000a      evidence shows that neoadjuvant cisplatin-based chemotherapy has\u000d\u000a      acceptable toxicity and increases the survival rate by 5-6.5%\" [e].\u000d\u000a    Saudi Oncology Society (2011) \"Neoadjuvant cisplatin-based\u000d\u000a      chemotherapy improved overall survival by 5-7% at 5 years and this option\u000d\u000a      should be offered to patients especially with locally advanced disease\u000d\u000a      (T3,T4)\" [f].\u000d\u000a    Our systematic review and meta-analysis of IPD was also cited as evidence\u000d\u000a      in these guidelines:\u000d\u000a    British Columbia Cancer Agency (2008) [g].\u000d\u000a    Association of Comprehensive Cancer Centres (2009) [h].\u000d\u000a    Alberta Health Services (2011) [i].\u000d\u000a    Spanish Society of Medical Oncology (2011) [j].\u000d\u000a    In addition, the routine use of neoadjuvant chemotherapy in the\u000d\u000a      management of locally advanced bladder cancer has been discussed in a\u000d\u000a      number of recent articles. Notably, it was the topic of a panel discussion\u000d\u000a      at the 11th Annual Meeting of the Society of Urologic Oncology,\u000d\u000a      where the international experts concluded that the current standard of\u000d\u000a      care for patients with muscle invasive bladder cancer is cisplatin-based\u000d\u000a      neoadjuvant chemotherapy followed by radical surgery [k]. Use of\u000d\u000a      neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer\u000d\u000a      has also increased. For example, a study published in 2011, which reviewed\u000d\u000a      treatment patterns across the USA using data from the National Cancer\u000d\u000a      Database, showed that the percentage of American patients receiving\u000d\u000a      neoadjuvant chemotherapy had more than doubled during the period from\u000d\u000a      2003-2007. The authors attributed this to the increase in data supporting\u000d\u000a      neoadjuvant treatment [l].\u000d\u000a    One of the recommendations of the IPD meta-analysis was that neoadjuvant\u000d\u000a      cisplatin-based chemotherapy should be used as the control arm in any\u000d\u000a      subsequent trials in this population. Whilst no recently initiated\u000d\u000a      randomised controlled trials could be identified, neoadjuvant chemotherapy\u000d\u000a      continues to be the subject of a number of ongoing and recently reported\u000d\u000a      trials. These studies have explored the use of novel therapeutic agents\u000d\u000a      (including bevacizumab, sunitinib and sorafenib) alongside standard\u000d\u000a      neoadjuvant, cisplatin-based chemotherapy; explored modifications to the\u000d\u000a      dose or duration of standard neoadjuvant chemotherapy regimens or used\u000d\u000a      novel drug combinations in attempts to further reduce side effects and\u000d\u000a      improve outcomes for patients with muscle invasive disease [m].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Researchers at the MRC Clinical Trials Unit conducted a systematic review\u000d\u000a      and meta-analysis of individual patient data on neoadjuvant chemotherapy\u000d\u000a      for invasive bladder cancer. This work has been cited as evidence in 19\u000d\u000a      national and international clinical practice guidelines from 2008 to 2013.\u000d\u000a      In most cases, the guidelines citing this review substantiate their\u000d\u000a      clinical recommendations by directly quoting the review content.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University College London\u000d\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    The results were published in the name of the Advanced Bladder Cancer\u000d\u000a      (ABC) Collaboration.\u000d\u000a    \u000a[1] Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.\u000d\u000a      Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review\u000d\u000a      and meta-analysis. Lancet. 2003 Jun 7;361(9373):1927-34. http:\/\/dx.doi.org\/10.1016\/S0140-6736(03)13580-5\u000d\u000a    \u000a\u000a[2] Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.\u000d\u000a      Neoadjuvant chemotherapy in invasive bladder cancer: update of a\u000d\u000a      systematic review and meta-analysis of individual patient data. European\u000d\u000a      Urology. 2005;48(2):202-6. http:\/\/dx.doi.org\/10.1016\/j.eururo.2005.04.006\u000d\u000a    \u000a\u000a[3] Advanced Bladder Cancer Overview Collaboration. Neoadjuvant\u000d\u000a      chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev. 2005\u000d\u000a      Apr 18;(2):CD005246.\u000d\u000a      http:\/\/dx.doi.org\/10.1002\/14651858.CD005246\u000d\u000a    \u000aThis research was initially funded as part of the MRC Clinical Trials\u000d\u000a      Unit Meta-analysis programme of research via two MRC programme Grants\u000d\u000a      (1997-1999: &#163;346,464; 2000-2002: &#163;429,826), and subsequently via core\u000d\u000a      support for the programme which was awarded following the Unit's 2003\u000d\u000a      Quinquennial Review.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"12","Subject":"Oncology and Carcinogenesis"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [a] European Association of Urology. The 2013 guidelines confirm\u000d\u000a      that the three meta-analyses conducted by the authors established that\u000d\u000a      neoadjuvant chemotherapy reduced mortality rate (p.30-1). There are no\u000d\u000a      other references in this source that confirm this result. See references\u000d\u000a      35 and 37 (p.33-4). http:\/\/www.uroweb.org\/gls\/pdf\/07_Bladder%20Cancer_LRV2.pdf.\u000d\u000a    [b] ESMO guidelines Working Group. Bladder cancer: ESMO\u000d\u000a        Clinical Practice Guidelines for diagnosis, treatment and follow-up\u000d\u000a      These guidelines confirm on p.vi46 that the use of neoadjuvant\u000d\u000a      chemotherapy was effective in reducing mortality rates. There are no other\u000d\u000a      references in this source that confirm this result. http:\/\/dx.doi.org\/10.1093\/annonc\/mdr376.\u000d\u000a      See references 7 and 8.\u000d\u000a    [c] National Comprehensive Cancer Network. The 2011 guidelines\u000d\u000a      confirm on p.MS-12 that the meta-analyses conducted by the authors\u000d\u000a      established that neoadjuvant chemotherapy caused a significant decrease in\u000d\u000a      death rate. There are no other references in this source that confirm this\u000d\u000a      result. Document is available on request (log in needed for online\u000d\u000a      access). See reference 46.\u000d\u000a      http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp\u000d\u000a    [d] Japanese Urological Association http:\/\/www.urol.or.jp\/en\/guideline.html\u000d\u000a      The 2010 guidelines confirm on p.114 that the meta-analyses conducted by\u000d\u000a      the authors established that neoadjuvant chemotherapy improves the overall\u000d\u000a      survival rate by 5%, and the recurrence-free rate by 9%. There are no\u000d\u000a      other references in this source that confirm this result.\u000d\u000a      http:\/\/dx.doi.org\/10.1111\/j.1442-2042.2010.02486.x.\u000d\u000a      See references 91 and 92.\u000d\u000a    [e] Associazione Urologi Italiani http:\/\/www.auro.it\/documenti-iniziative\/linee-guida\u000d\u000a      The 2010 guidelines confirm on p.172 that the meta-analyses conducted by\u000d\u000a      the authors established that neoadjuvant chemotherapy increases the\u000d\u000a      survival rate by 5-6%. There are no other references in this source that\u000d\u000a      confirm this result. http:\/\/dx.doi.org\/10.1111\/j.1464-410X.2010.09324.x\u000d\u000a      See references 151, 152 and 153.\u000d\u000a    [f] Saudi Oncology Society http:\/\/www.oncology.org.sa\/portal\u000d\u000a      The 2011 guidelines confirm on p.57 that the meta-analyses conducted by\u000d\u000a      the authors established that neoadjuvant chemotherapy improved overall\u000d\u000a      survival by 5-7%. There are no other references in this source that\u000d\u000a      confirm this result. http:\/\/dx.doi.org\/10.4103\/0974-7796.78549.\u000d\u000a      See references 22 and 23.\u000d\u000a    [g] British Columbia Cancer Agency: Cancer Management Guidelines.\u000d\u000a      The 2008 guidelines confirm on p.1 that the meta-analyses conducted by the\u000d\u000a      authors established that neoadjuvant chemotherapy caused a 5% improvement\u000d\u000a      in survival at 5 years. There are no other references in this source that\u000d\u000a      confirm this result. Document is available on request. See\u000d\u000a      references 18 and 20. http:\/\/www.bccancer.bc.ca\/HPI\/CancerManagementGuidelines\/default.htm\u000d\u000a    [h] Association of Comprehensive Cancer Centres http:\/\/www.oncoline.nl\/index.php\u000d\u000a      The 2009 guidelines confirm on p.37-39 that the meta-analyses conducted by\u000d\u000a      the authors established that neoadjuvant chemotherapy resulted in an\u000d\u000a      absolute improvement in the 5-year survival of 5%. There are no other\u000d\u000a      references in this source that confirm this result. Document is\u000d\u000a        available on request. See reference 45.\u000d\u000a    [i] Alberta Health Services. The 2011 guidelines confirm in the\u000d\u000a      section `Discussion &#8212; Advanced Stage Disease' that the meta-analyses\u000d\u000a      conducted by the authors established that neoadjuvant chemotherapy\u000d\u000a      resulted in a 14% reduction in the risk of death and 5% absolute increase\u000d\u000a      in overall survival at five years. There are no other references in this\u000d\u000a      source that confirm this result. http:\/\/www.albertahealthservices.ca\/hp\/if-hp-cancer-guide-gu002-bladder.pdf.\u000d\u000a      See references 23, 45 and 46.\u000d\u000a    [j] Spanish Society of Medical Oncology http:\/\/www.seom.org\/en\/publicaciones\/guias-clinicas\u000d\u000a      The 2011 guidelines confirm on p.554-555 that the meta-analyses conducted\u000d\u000a      by the authors established that neoadjuvant chemotherapy demonstrated an\u000d\u000a      improvement of 5-6.5% in 5 year survival. There are no other references in\u000d\u000a      this source that confirm this result. Document is available online: http:\/\/dx.doi.org\/10.1007\/s12094-011-0696-8.\u000d\u000a      See references 16 and 18.\u000d\u000a    [k] Apolo AB, Grossman HB, Bajorin D, Steinberg G, Kamat AM. Practical\u000d\u000a      use of perioperative chemotherapy for muscle-invasive bladder cancer:\u000d\u000a      summary of session at the Society of Urologic Oncology annual meeting.\u000d\u000a      Urol Oncol. 2012 Nov-Dec;30(6):772-80.\u000d\u000a      http:\/\/dx.doi.org\/10.1016\/j.urolonc.2012.01.012.\u000d\u000a    [l] Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder\u000d\u000a      cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol.\u000d\u000a      2011 Jan;185(1):72-8.\u000d\u000a      http:\/\/dx.doi.org\/10.1016\/j.juro.2010.09.015\u000d\u000a    [m] Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD,\u000d\u000a      Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN, Sonpavde G. A\u000d\u000a      systematic review of neoadjuvant and adjuvant chemotherapy for\u000d\u000a      muscle-invasive bladder cancer. Eur Urol. 2012 Sep;62(3):523-33.\u000d\u000a      http:\/\/dx.doi.org\/10.1016\/j.eururo.2012.05.048.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Neoadjuvant chemotherapy for invasive bladder cancer\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Bladder cancer is the second most common cancer of the genitourinary\u000d\u000a      system. Worldwide there are estimated to be about 336,000 new cases per\u000d\u000a      year, of which about one third are likely to be invasive or metastatic\u000d\u000a      disease.\u000d\u000a    Invasive bladder cancer, where the tumour has spread into (or invaded)\u000d\u000a      the muscle layer of the bladder, is likely to spread to other parts of the\u000d\u000a      body. At the time this project was initiated, standard treatment for\u000d\u000a      invasive bladder cancer was surgery to remove the tumour, and part or all\u000d\u000a      of the bladder and nearby lymph nodes and other tissues. Alternatively,\u000d\u000a      radiotherapy was also given instead of or in addition to surgery. However,\u000d\u000a      giving (neoadjuvant) chemotherapy before surgery and\/or radiotherapy\u000d\u000a      offered the potential to reduce tumour size and control cancer spread.\u000d\u000a      Furthermore, if chemotherapy is given before these potentially\u000d\u000a      debilitating treatments, it might be better tolerated than chemotherapy\u000d\u000a      given after them, so that patients are more likely to comply with their\u000d\u000a      chemotherapy treatment, allowing higher doses of drug to be administered.\u000d\u000a      However, most randomised trials investigating the use of neoadjuvant\u000d\u000a      chemotherapy were modestly sized and inconclusive about its effects,\u000d\u000a      although results of the largest trial, the MRC Clinical Trials Unit BA06\u000d\u000a      trial looked encouraging. Subsequent systematic reviews and meta-analyses\u000d\u000a      based on aggregate or summary data from publications of these trials were\u000d\u000a      limited by the availability and quality of data and were similarly\u000d\u000a      inconclusive.\u000d\u000a    We therefore initiated a systematic review and meta-analysis of\u000d\u000a      individual patient data (IPD). This international collaborative project\u000d\u000a      collected and analysed the original trial data from all patients included\u000d\u000a      in all the relevant trials, including BA06. This IPD approach can bring\u000d\u000a      about substantial improvements to the quality of the data and analysis,\u000d\u000a      leading to more reliable and robust results than a standard systematic\u000d\u000a      review of summary, and is considered the `gold standard'.\u000d\u000a    The research was carried out at the MRC Clinical Trials Unit by the\u000d\u000a      project management group on behalf of the Advanced Bladder Cancer (ABC)\u000d\u000a      Collaboration. This group was responsible for formulating the questions;\u000d\u000a      developing the protocol; collecting, checking and analysing data;\u000d\u000a      presenting and discussing the preliminary results and preparing the\u000d\u000a      manuscript. At the time their positions at the MRC Clinical Trials Unit\u000d\u000a      were:\u000d\u000a    \u000d\u000a      Claire Vale, Research Scientist (Now Senior Research Scientist)\u000d\u000a      Jayne Tierney, Senior Research Scientist (Now Meta-analysis Group\u000d\u000a        Lead)\u000d\u000a      Lesley Stewart, Meta-analysis Group Head (Now Centre for Reviews and\u000d\u000a        Dissemination Director)\u000d\u000a      Mahesh Parmar, Cancer Group Head (Now MRC Clinical Trials Unit\u000d\u000a        Director)\u000d\u000a    \u000d\u000a    An advisory group provided input and advice at all stages of the project\u000d\u000a      (NW Clarke, UK; JT Roberts, UK; R Sylvester, Belgium; D Raghavan, USA) and\u000d\u000a      the following supplied IPD and\/or contributed to discussion of the results\u000d\u000a      and commented on the drafts of the publication: H Abol-Enein, Egypt; P\u000d\u000a      Bassi, Italy; AV Bono, Italy; M Boyer, Australia; ML Coppin, Canada; E\u000d\u000a      Cortesi, Italy; PJ Goebell, Germany; S Groshen, USA; RR Hall, UK; A\u000d\u000a      Horwich, UK; P-U Malmstr&#246;m, Sweden; JT Roberts, UK; L Sengel&#248;v, Denmark; A\u000d\u000a      Sherif, Sweden; M Stockle, Germany; FM Torti, USA; DMA Wallace, UK).\u000d\u000a    "},{"CaseStudyId":"23147","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2750405","Name":"Netherlands"}],"Funders":[],"ImpactDetails":"\u000d\u000a    Our review of chlamydia control activities in Europe was commissioned by\u000d\u000a      the European Centre for Disease Control and Prevention (ECDC) to inform\u000d\u000a      development of its policy. The resulting policy document, ECDC Guidance on\u000d\u000a      Chlamydia Control in Europe 2009 [a], states that the guidance was\u000d\u000a      developed by a technical expert group using the evidence gathered in the\u000d\u000a      EU report \"Review of chlamydia control activities in EU countries\" [b]\u000d\u000a      and systematic review of the effectiveness of chlamydia screening [6,\u000d\u000a        above]. It provides guidance to health policy makers in the EU about\u000d\u000a      national strategies for chlamydia control.\u000d\u000a    The systematic review of chlamydia screening was commissioned by NICE to\u000d\u000a      inform its guidance [c]. Our findings indicated that there was a\u000d\u000a      lack of evidence from randomised trials to show the effectiveness of\u000d\u000a      chlamydia screening and the final NICE Guidance made no recommendations\u000d\u000a      about chlamydia screening except for more robust research to examine the\u000d\u000a      effectiveness of different screening approaches [d]. This\u000d\u000a      recommendation contributed to decisions to fund two large randomised\u000d\u000a      trials &#8212; one in the Netherlands of a register based screening programme\u000d\u000a      and one in Australia of an opportunistic screening programme. The research\u000d\u000a      in the Netherlands concluded \"There was no statistical evidence of an\u000d\u000a        impact on chlamydia positivity rates or estimated population prevalence\u000d\u000a        from the Chlamydia Screening Implementation programme after three years\u000d\u000a        at the participation levels obtained. The current evidence does not\u000d\u000a        support a national roll out of this register based chlamydia screening\u000d\u000a        programme\" [e]. The systematic review had a persistent\u000d\u000a      influence on development of chlamydia screening policy nationally and\u000d\u000a      internationally.\u000d\u000a    Our research into chlamydia screening had wide impact, as it contributed,\u000d\u000a      through informed and constructive criticism, to public debate about the\u000d\u000a      National Chlamydia Screening Programme (NCSP) in England and its future\u000d\u000a      direction. Stephenson presented insights gained from the research to the\u000d\u000a      annual NCSP meeting (2007) and to the Independent Advisory Group at the\u000d\u000a      House of Lords (2008) [f]. She was among the experts who gave\u000d\u000a      evidence at interview to the National Audit Office for their report on\u000d\u000a      value for money of the NCSP (NAO 2009). She highlighted that since the\u000d\u000a      NCSP did not use unique identifiers or collect any clinical outcome data,\u000d\u000a      it was not able to evaluate its aims. The NAO report cites both our review\u000d\u000a      of chlamydia control activities in EU countries and the subsequent ECDC\u000d\u000a      Guidance on chlamydia control in Europe [g]. It concluded that the\u000d\u000a      delivery of the NCSP had not demonstrated value for money. In accordance\u000d\u000a      with our research findings, it stated that \"due to uncertainties in the\u000d\u000a        scientific evidence on chlamydia, the Department does not know how often\u000d\u000a        infection leads to serious health problems and hence whether it is\u000d\u000a        cost-effective to invest so much public money in tackling this problem.\"\u000a      The NAO Report was swiftly followed by a highly critical report from the\u000d\u000a      Public Accounts Committee (2009-2010) [h]. In response to this\u000d\u000a      criticism, the NCSP focused on chlamydia testing in sexual health services\u000d\u000a      and primary care and has ceased screening in low risk groups that\u000d\u000a      identifies fewer positive cases [i]. These and other\u000d\u000a      organisational changes are expected to substantially improve value for\u000d\u000a      money. Between 2003 and 2009, c.&#163;100m was spent delivering the programme [h]\u000d\u000a      and cost savings on reconfiguration are expected to be considerable: \"The\u000a        average cost per chlamydia screening episode (including follow up of\u000d\u000a        positive clients, overheads and local coordination) was found to be\u000d\u000a        &#163;45... An estimated cost of &#163;33 per screening episode should be\u000d\u000a        achievable, as screening volumes increase, chlamydia screening is better\u000d\u000a        integrated in all community sexual health pathways, sexual health\u000d\u000a        networks develop and regions move to collaborative procurement\" [j].\u000d\u000a    While mathematical models tend to predict that screening will reduce the\u000d\u000a      prevalence of infection, there is currently no empirical evidence from the\u000d\u000a      NCSP to demonstrate a fall in prevalence. The latest (April 2013) update\u000d\u000a      on the National Chlamydia Screening Programme acknowledges the gaps in\u000d\u000a      current knowledge that our research highlighted and describes a new policy\u000d\u000a      of re-focusing chlamydia testing within health services, moving away from\u000d\u000a      population-based screening with coverage targets [k].\u000d\u000a    Reflecting on changes in chlamydia screening policy, Stephenson was\u000d\u000a      invited to present a plenary debate at the world congress of sexually\u000d\u000a      transmitted infections (Vienna, July 2013) on whether to abandon\u000d\u000a      population based chlamydia screening of asymptomatic young women [l].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research by Professor Judith Stephenson and colleagues at the UCL\u000d\u000a      Institute of Women's Health into the effectiveness of chlamydia screening\u000d\u000a      has led to guidance to health policy makers in the EU about national\u000d\u000a      strategies for chlamydia control, and has influenced NICE guidelines on\u000d\u000a      the subject. In particular, our work has informed debate on the value for\u000d\u000a      money of the National Chlamydia Screening Programme (NCSP). Stephenson\u000d\u000a      advised the National Audit Office on this topic, and a resulting report\u000d\u000a      led to the NCSP focusing on chlamydia testing in sexual health services\u000d\u000a      and primary care rather than screening in low risk groups. These changes\u000d\u000a      are expected to make considerable cost savings to the NHS.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University College London\u000d\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2761369","Name":"Vienna"}],"References":"\u000d\u000a    \u000a[1] Grun L, Tassano-Smith J, Carder C, Johnson AM, Robinson A, Murray E,\u000d\u000a      Stephenson J, Haines A, Copas A, Ridgway G. Comparison of two methods of\u000d\u000a      screening for genital chlamydial infection in women attending in general\u000d\u000a      practice: cross sectional survey. BMJ. 1997;315:226. http:\/\/dx.doi.org\/10.1136\/bmj.315.7102.226\u000d\u000a    \u000a\u000a[2] Carder C, Robinson AJ, Broughton C, Stephenson JM, Ridgway GL.\u000d\u000a      Evaluation of self-taken samples for the presence of genital Chlamydia\u000d\u000a      trachomatis infection in women using the ligase chain reaction assay.\u000d\u000a      International Journal of STD &amp; AIDS. 1999;10(12):776-9. http:\/\/dx.doi.org\/10.1258\/0956462991913538\u000d\u000a    \u000a\u000a[3] Stephenson J, Carder C, Copas A, Robinson A, Ridgway G, Haines A.\u000d\u000a      Home screening for chlamydial genital infection: is it acceptable to young\u000d\u000a      men and women? Sexually Transmitted Infections. 2000;76(1):25-7 http:\/\/dx.doi.org\/10.1136\/sti.76.1.25\u000d\u000a    \u000a\u000a[4] Stephenson JM. Screening for genital chlamydial infection. British\u000d\u000a      Medical Bulletin. 1998;54(4):891-902 http:\/\/bmb.oxfordjournals.org\/content\/54\/4\/891.long\u000d\u000a    \u000a\u000a[5] Low N, Cassell JA, Spencer B, Bender N, Hilber AM, van Bergen J,\u000d\u000a      Anderson B, Herrmann B, Dubois-Arber F, Hamers FF, van de Laar M,\u000d\u000a      Stephenson JM. Chlamydia control activities in Europe: cross-sectional\u000d\u000a      survey. European Journal of Public Health. 2012 Aug;22(4):556-61. http:\/\/dx.doi.org\/10.1093\/eurpub\/ckr046\u000d\u000a    \u000a[6] Low N, Bender N, Nartey L, Shang A and Stephenson JM. Effectiveness\u000d\u000a      of Chlamydia Screening: Systematic Review. International Journal of\u000d\u000a      Epidemiology. 2009;38(2):435-8. http:\/\/dx.doi.org\/10.1093\/ije\/dyn222\u000d\u000a    \u000a[7] Stephenson J. NICE guidance and the National Chlamydia Screening\u000d\u000a      Programme. Sexually Transmitted Infections. 2007;83:170. http:\/\/dx.doi.org\/10.1136\/sti.2007.025114\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    [a] European Centre for Disease Prevention and Control (ECDC) Guidance.\u000d\u000a      Chlamydia control in Europe (2009)\u000d\u000a      http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/0906_GUI_Chlamydia_Control_in_Europe.pdf\u000d\u000a    [b] European Centre for Disease Prevention and Control. Technical Report.\u000d\u000a      Review of Chlamydia Control Activities in EU Countries (2008).\u000d\u000a      http:\/\/ecdc.europa.eu\/en\/publications\/publications\/0805_ter_review_of_chlamydia_control_activities.pdf\u000d\u000a    [c] Review of evidence for the effectiveness of screening for genital\u000d\u000a      chlamydial infection in sexually active young women and men (2006)\u000d\u000a      http:\/\/www.nice.org.uk\/guidance\/index.jsp?action=download&amp;o=43876\u000d\u000a    [d] NICE public health intervention guidance 3 (2006). One to one\u000d\u000a      interventions to reduce the transmission of sexually transmitted\u000d\u000a      infections http:\/\/www.nice.org.uk\/PHI003\u000d\u000a    [e] van den Broek IV, van Bergen JE, Brouwers EE, Fennema JS, G&#246;tz HM,\u000d\u000a      Hoebe CJ, Koekenbier RH, Kretzschmar M, Over EA, Schmid BV, Pars LL, van\u000d\u000a      Ravesteijn SM, van der Sande MA, de Wit GA, Low N, Op de Coul EL.\u000d\u000a      Effectiveness of yearly, register based screening for chlamydia in the\u000d\u000a      Netherlands: controlled trial with randomised stepped wedge\u000d\u000a      implementation. BMJ. 2012 Jul 5;345:e4316. http:\/\/dx.doi.org\/10.1136\/bmj.e4316\u000d\u000a    [f] Independent Advisory Group on Sexual Health and HIV Seminar: The\u000d\u000a      Future of Chlamydia Testing, Thursday 24 July 2008.Transcript available on\u000d\u000a      request.\u000d\u000a    [g] National Audit Office Department of Health &#8212; Young people's sexual\u000d\u000a      health: the National Chlamydia Screening Programme.\u000d\u000a      http:\/\/www.nao.org.uk\/wp-content\/uploads\/2009\/11\/0809963.pdf\u000d\u000a      See reference 11, p.17.\u000d\u000a    [h] Public Accounts committee &#8212; seventh report &#8212; Young people's sexual\u000d\u000a      health: the National Chlamydia Screening Programme.\u000d\u000a      http:\/\/www.publications.parliament.uk\/pa\/cm200910\/cmselect\/cmpubacc\/283\/28302.htm\u000d\u000a    [i] National Chlamydia Screening Programme website\u000d\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/+\/www.dh.gov.uk\/en\/Aboutus\/Features\/DH_128779\u000d\u000a    [j] Guidance for the commissioners on the cost of providing chlamydia\u000d\u000a      screening in primary care and the community : a review of costs in\u000d\u000a      practice across England in 2009\u000d\u000a      http:\/\/www.chlamydiascreening.nhs.uk\/ps\/resources\/guidelines\/NCSP_costing_guidance_Dec09.pdf\u000d\u000a    [k] Presentation \"An update on the National Chlamydia Screening\u000d\u000a      Programme\" 13th March 2013; slides available from http:\/\/www.chlamydiascreening.nhs.uk\/ps\/resources.asp\u000d\u000a    [l] Debate programme available at\u000d\u000a      http:\/\/www.stivienna2013.com\/index.php?option=com_content&amp;view=article&amp;id=68&amp;Itemid=73\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Improving policy for sexual and reproductive health\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Our early research evaluated new molecular diagnostics for diagnosis of\u000d\u000a      genital chlamydia infection (nucleic acid amplification tests) which\u000d\u000a      compared favourably with the standard method (enzyme immunoassay) of the\u000d\u000a      day [1]. We then examined the feasibility of patients taking their\u000d\u000a      own samples (vaginal swabs) in a sexual health clinic compared with\u000d\u000a      clinicians taking cervical samples and showed that patient-taken samples\u000d\u000a      were acceptable to women and appropriately sensitive for the new molecular\u000d\u000a      diagnostics [2]. We went on to show the feasibility of women and\u000d\u000a      men taking their own samples outside the clinic setting in response to a\u000d\u000a      screening invitation sent to their home address and posting the samples to\u000d\u000a      a laboratory for chlamydia testing [3]. Together, these three\u000d\u000a      studies, in addition to baseline prevalence studies from Natsal [see\u000d\u000a        case study UCL02-JOH] were instrumental to the\u000d\u000a      rapid expansion and uptake of chlamydia testing in England. At the same\u000d\u000a      time, we made a strong case, based on review of the limited evidence base,\u000d\u000a      for the cost-effectiveness of chlamydia screening to be evaluated through\u000d\u000a      randomised trials before proceeding with implementation of a national\u000d\u000a      screening programme [4].\u000d\u000a    A systematic survey of chlamydia control activities in 29 European\u000d\u000a      countries was carried out 2006-2008, funded by the European Centre for\u000d\u000a      Disease Control and Prevention (ECDC). Stephenson collaborated with\u000d\u000a      Professor Nicola Low (PI, Bern University) on designing the survey and led\u000d\u000a      the work in the UK, including investigation of the National Chlamydia\u000d\u000a      Screening Programme (NCSP) as a case study. The survey showed wide\u000d\u000a      variation in the organisation of chlamydia control, with almost half of\u000d\u000a      the countries reporting no organised activity and national control\u000d\u000a      programmes in two countries. We outlined four levels for chlamydia control\u000d\u000a      programmes: Level A primary prevention, Level B case management, Level C\u000d\u000a      opportunistic testing, Level D screening programme and recommended a\u000d\u000a      step-by-step approach to ensure that accurate STI prevention and patient\u000d\u000a      management are in place before complex interventions such as screening are\u000d\u000a      considered, particularly as evidence for the impact of level C and D\u000d\u000a      programmes is lacking [5].\u000d\u000a    The early research described above sparked considerable debate and in\u000d\u000a      2006, Low's team and Stephenson were commissioned by NICE to carry out a\u000d\u000a      review of the effectiveness of chlamydia screening [6]. We\u000d\u000a      included 91 studies (5 systematic reviews or guidelines, 10 randomised\u000d\u000a      trials, 2 non-randomised trials, one time series and 73 prospective\u000d\u000a      studies) and produced multiple evidence statements to inform the NICE\u000d\u000a      guidance. We found a lack of evidence to support chlamydia screening in\u000d\u000a      the general population aged less than 25 and called for high-quality\u000d\u000a      trials of screening with clinical outcome measures to determine the\u000d\u000a      balance and harms of chlamydia screening [7].\u000d\u000a    "},{"CaseStudyId":"27326","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"2623032","Name":"Denmark"}],"Funders":[],"ImpactDetails":"\u000d\u000a    a) The FLU-CIN delivered its first report to SAGE, on time, less than 8\u000d\u000a      weeks after planning began. The Chairs of SAGE later wrote: \"We greatly\u000d\u000a      appreciated your work as the lead for the hub of the Flu Clinical\u000d\u000a      Information Network as well as your contribution to the sub-group on\u000d\u000a      clinical countermeasures and to research to inform the UK's response\". A\u000d\u000a      FLU-CIN report was submitted fortnightly to the UK Government (via SAGE)\u000d\u000a      from June 2009 until February 2010. This provided information on the\u000d\u000a      proportion of otherwise healthy individuals with pandemic influenza\u000d\u000a      requiring critical care, the burden of disease in children, and helped\u000d\u000a      towards the early identification of risk factors for severe outcomes. The\u000d\u000a      data we provided contributed towards UK government policy for the use of\u000d\u000a      antiviral drugs and vaccines to combat the pandemic. In addition, our data\u000d\u000a      fed directly into UK clinical management guidelines formulated by the\u000d\u000a      Pandemic Influenza Clinical and Operational group (PICO). As an example,\u000d\u000a      the minutes of the UK Scientific Advisory Group for Emergencies on 11th\u000d\u000a      January 2010 note: \"The FLU-CIN structure had proved a great success in\u000d\u000a      obtaining detailed clinical data about patients hospitalised with the\u000d\u000a      pandemic (H1N1) 2009 virus. Maintaining some sort of legacy structure,\u000d\u000a      that could be activated rapidly in the event of a new pandemic, should be\u000d\u000a      a priority\" (see reference 1 below).\u000d\u000a    b) Regarding the NIHR funded `emergency' influenza studies, these were\u000d\u000a      commissioned and awarded as part of the UK Government's R&amp;D response\u000d\u000a      to pandemic influenza, and all three were published rapidly in Health\u000d\u000a      Technology Assessment, in line with other NIHR funded work. The `MummyFlu'\u000d\u000a      project delivered critical data that demonstrated that 2009 pandemic\u000d\u000a      vaccines administered to pregnant women in the UK were highly likely to\u000d\u000a      protect newborns via transplacental transfer of passive immunity. This\u000d\u000a      work has contributed towards the UK's decision to adopt a policy of\u000d\u000a      influenza vaccination for pregnant women from Autumn 2010 onwards.\u000d\u000a      Similarly the work to evaluate the two pandemic vaccines used in adults in\u000d\u000a      the UK during 2009 provided rapid feedback to the UK Government that one\u000d\u000a      (adjuvanted with AS03) was in fact considerably more immunogenic than the\u000d\u000a      other. This work helped inform the UK's decision to target children with\u000d\u000a      the AS03 adjuvanted vaccine. (see reference 2)\u000d\u000a    c) The HPIRGs evaluation work for the WHO Regional Office for Europe was\u000d\u000a      the largest piece of post-pandemic evaluative work undertaken by WHO\u000d\u000a      Europe and led to a consultation workshop in Copenhagen in Autumn 2010,\u000d\u000a      and a formal WHO report (see Section 5). The Director of WHO Europe wrote\u000d\u000a      (Foreword): \"A principal value of this report is that it applies a\u000d\u000a      standard framework to highlight essential cross-cutting elements of\u000d\u000a      successful pandemic preparedness activities. Moreover, it takes an\u000d\u000a      objective approach to highlight not only the essential elements of\u000d\u000a      successful activities but also the areas on which the pandemic experience\u000d\u000a      suggests future planning must place greater emphasis...Member States, by\u000d\u000a      sharing the experiences gained and lessons learnt throughout the process,\u000d\u000a      have shaped the recommendations in this report, which we at WHO believe is\u000d\u000a      extremely useful for all countries and WHO alike, as we review our\u000d\u000a      pandemic plans\". The findings of our work have been incorporated into a\u000d\u000a      new draft Pandemic preparedness planning guide for Member States of the\u000d\u000a      WHO European Region and the European Union (affecting 900 million\u000d\u000a      citizens) which were published in late 2012. (see references 3 and 4)\u000d\u000a    d) The HPIRG's research work for WHO Headquarters in Geneva has comprised\u000d\u000a      of individual (unpaid) consultancy and expert advice as well as four major\u000d\u000a      systematic reviews and meta- analyses on the subject of influenza\u000d\u000a      vaccination in immunocompromised subjects and vaccination of healthcare\u000d\u000a      workers to protect patients. The WHO was so satisfied with the outputs of\u000d\u000a      this work, it wrote \"these reviews have been of fundamental importance in\u000d\u000a      supporting WHO's recommendations.....the impact of this work is\u000d\u000a      significant in terms of the change in policy, which has reduced the\u000d\u000a      economic impact on Member States for pandemic preparedness...\" (see\u000d\u000a      references 5, 6, 7 and 8).\u000d\u000a    e) The recently funded work on influenza transmission (awarded October\u000d\u000a      2011), results from sustained efforts to develop this area. In terms of\u000d\u000a      the lack of current understanding about modes of transmission of\u000d\u000a      influenza, this knowledge gap has been identified by the US CDC, the UK\u000d\u000a      Government, the European Centre for Disease Prevention and Control (ECDC),\u000d\u000a      the WHO Global Influenza Research Agenda and the Institutes of Medicine as\u000d\u000a      being a high priority unmet need for influenza. The findings will be\u000d\u000a      applicable in every nation of the world in the event of a future pandemic,\u000d\u000a      emphasising the global importance attached to this work. (see references 9\u000d\u000a      and 10)\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research carried out by the Health Protection and Influenza Research\u000d\u000a      Group (HPIRG), Division of Epidemiology and Public Health, impacted\u000d\u000a      directly on the UK Government's response to the 2009 influenza pandemic,\u000d\u000a      feeding directly into policy-making decisions. The group was appointed as\u000d\u000a      an official WHO Collaborating Centre for pandemic influenza in 2010 and\u000d\u000a      through its related research has \"reduced the economic impact on Member\u000d\u000a      States for pandemic preparedness\" (quote from reference 7, section 5). In\u000d\u000a      2011, it secured &#163;7M funding from the US Centers for Disease Control and\u000d\u000a      Prevention (CDC) to lead `once only' work to determine the modes of\u000d\u000a      influenza transmission using a human challenge model.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of Nottingham\u000d\u000a    ","Institutions":[{"AlternativeName":"Nottingham (University of)","InstitutionName":"University of Nottingham","PeerGroup":"A","Region":"East Midlands","UKPRN":10007154}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2618425","Name":"Copenhagen"},{"GeoNamesId":"2660646","Name":"Genve"}],"References":"\u000d\u000a    \u000a1. Nguyen-Van-Tam JS, Openshaw PJM, Hashim A, Gadd EM, Lim WS, Semple MG,\u000d\u000a      Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Armstrong C,\u000d\u000a      Nicholson KG. Risk factors for hospitalisation and poor outcome with\u000d\u000a      pandemic A\/H1N1 influenza: United Kingdom first wave (May-September 2009).\u000d\u000a      Thorax, 2010; 65: 645-651. doi:10.1136\/thx\/2010.135210 (most highly cited\u000d\u000a      paper in Thorax in 2012).\u000d\u000a    \u000a\u000a2. Puleston R, Bugg G, Hoschler K, Konje J, Thornton J, Stephenson I,\u000d\u000a      Myles P, Enstone J, Augustine G, Davis Y, Zambon M, Nicholson K,\u000d\u000a      Nguyen-Van-Tam J. Multi-centre observational study of transplacental\u000d\u000a      transmission of influenza antibodies following vaccination with AS03(A)-\u000d\u000a      adjuvanted H1N1 2009 vaccine. PLoS One. 2013;8(1):e47448.\u000d\u000a      doi:10.1371\/journal.pone.0047448. PubMed PMID: 23372640; PubMed Central\u000d\u000a      PMCID: PMC3553100.\u000d\u000a    \u000a\u000a3. Killingley B, Greatorex J, Cauchemez S, Enstone JE, Curran M, Read RC,\u000d\u000a      Lim WS, Hayward A, Nicholson KG, Nguyen-Van-Tam JS. Virus shedding and\u000d\u000a      environmental deposition of novel A (H1N1) pandemic influenza virus:\u000d\u000a      interim findings. Health Technol Assess. 2010 Oct;14(46):237-354. doi:\u000d\u000a      10.3310\/hta14460-04. PubMed PMID: 20923613 (pdf available on request).\u000d\u000a    \u000a\u000a4. Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS,\u000d\u000a      Medina MJ, Nguyen- Van-Tam JS, Read RC, Warren FC, Zambon M.\u000d\u000a      Immunogenicity and safety of a two-dose schedule of whole-virion and\u000d\u000a      AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised,\u000d\u000a      multicentre, age-stratified, head-to-head trial. Lancet Infect Dis. 2011\u000d\u000a      Feb;11(2):91-101. doi: 10.1016\/S1473-3099(10)70296-6. PubMed PMID:\u000d\u000a      21168369.\u000d\u000a    \u000a\u000a5. Hashim A, Jean-Gilles L, Hegermann-Lindencrone M, Shaw I, Brown C,\u000d\u000a      Nguyen-Van-Tam J. Did pandemic preparedness aid the response to pandemic\u000d\u000a      (H1N1) 2009? A qualitative analysis in seven countries within the WHO\u000d\u000a      European Region. J Infect Public Health. 2012 Aug;5(4):286-96. doi:\u000d\u000a      10.1016\/j.jiph.2012.04.001. PubMed PMID: 23021651.\u000d\u000a    \u000a\u000a6. Dolan GP, Harris RC, Clarkson M, Sokal R, Morgan G, Mukaigawara M,\u000d\u000a      Horiuchi H, Hale R, Stormont L, Bechard-Evans L, Chao YS, Eremin S,\u000d\u000a      Martins S, Tam JS, Penalver J, Zanuzadana A, Nguyen-Van-Tam JS.\u000d\u000a      Vaccination of health care workers to protect patients at increased risk\u000d\u000a      for acute respiratory disease. Emerg Infect Dis. 2012 Aug;18(8):1225-34.\u000d\u000a      doi: 10.3201\/eid1808.111355. PubMed PMID: 22840895; PubMed Central PMCID:\u000d\u000a      PMC3414018.\u000d\u000a    \u000aMajor Grants related to the activities in section 2 above:\u000d\u000a    1. Influenza Clinical Information Network. Awardee: Van-Tam. Sponsor:\u000d\u000a      University of Nottingham. Funder: Department of Health, England. Period of\u000d\u000a      the grant: 9 months (01 April 2010 to 31 Dec 2010). Value: &#163;181,360.50.\u000d\u000a    2. MummyFlu. Awardees: Van-Tam, Puleston. Sponsor: University of\u000d\u000a      Nottingham. Funder: NIHR. Period of the grant: 21 months (01 April 2009 to\u000d\u000a      31 Dec 2010). Value: &#163;82,851\u000d\u000a    3. Virus shedding study. Awardee: Van-Tam, Killingley. Sponsor:\u000d\u000a      University of Nottingham. Funder: NIHR. Period of the grant : 21 months\u000d\u000a      (21 August 2009 to 27 May 2011). Value: &#163;372,225.\u000d\u000a    4. WHO Evaluation of 2009 pandemic response. Awardee: Van-Tam, Hashim,\u000d\u000a      Shaw. Sponsor: University of Nottingham. Funder: World Health\u000d\u000a      Organization. Period of the grant: 22 months (01 December 2009 to 30\u000d\u000a      September 2012). Value: &#163;79,088\u000d\u000a    5. WHO systematic reviews and meta-analyses. Awardee: Van-Tam, Beck,\u000d\u000a      Dolan, Puleston. Sponsor: University of Nottingham. Funder: World Health\u000d\u000a      Organization. Period of the grant: 11 months (20 December 2010 to 30\u000d\u000a      November 2011). Value: &#163;12,293\u000d\u000a    6. EMIT: Evaluation of Modes of Influenza Transmission. Awardee: Van-Tam,\u000d\u000a      Enstone. Sponsor: University of Nottingham. Funder: CDC, Atlanta. Period\u000d\u000a      of the grant: 2 years; October 2011 to September 2013. Value: $10,800,000\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    Reports, reviews, web links or other documented sources of information in\u000d\u000a      the public domain:\u000d\u000a    \u000d\u000a      HM Government report on the function and value of FLU&#8212;CIN https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/215871\/dh_122754.pdf\u000d\u000a        (see Section on FLU-CIN)\u000d\u000a      Emergency pandemic research reports including two from Nottingham\u000d\u000a\u0009  http:\/\/www.journalslibrary.nihr.ac.uk\/collections\/h1n1-pandemic-flu-research\u000d\u000a        (see Volumes 2 &amp;3)\u000d\u000a      Pandemic assessment report produced by WHO, joint logo with University\u000d\u000a        of Nottingham\u000d\u000a\u0009\u0009http:\/\/www.euro.who.int\/en\/what-we-do\/health-topics\/communicable-diseases\/influenza\/publications\/2010\/recommendations-for-good-practice-in-pandemic-preparedness-identified-through-evaluation-of-the-response-to-pandemic-h1n1-2009\u000a\u000d\u000a      Changes to pandemic planning in WHO European Region arising from work\u000d\u000a        performed by Nottingham http:\/\/www.euro.who.int\/en\/what-we-do\/health-topics\/communicable-diseases\/influenza\/publications\/2012\/key-changes-to-pandemic-plans-by-member-states-of-the-who-european-region-based-on-lessons-learnt-from-the-2009-pandemic\u000a\u000d\u000a      Updated WHO global pandemic plan, including reference to supporting\u000d\u000a        work under taken in Nottingham\u000d\u000a\u0009\u0009http:\/\/www.who.int\/influenza\/preparedness\/pandemic\/GIP_PandemicInfluenzaRiskManagementInterimGuidance_Jun2013.pdf\u000d\u000a        (see reference 51, page 37)\u000d\u000a      Reference to work underway on a new clinical guideline driven by\u000d\u000a        expert reviews, two of which performed in Nottingham\u000d\u000a\u0009\u0009http:\/\/www.who.int\/influenza\/resources\/documents\/clinical_management_2012\/en\/\u000a\u000d\u000a      Statement\/letter from Dr Caroline S. Brown, Programme Manager,\u000d\u000a        Influenza &amp; other Respiratory Pathogens, Division of Communicable\u000d\u000a        Diseases, Health Security &amp; Environment, WHO Regional Office for\u000d\u000a        Europe\u000d\u000a      Contact: Nahoko Shindo MD PhD, Medical Officer, WHO Global Influenza\u000d\u000a        Programme\u000d\u000a      External BBC reporting of influenza transmission work http:\/\/www.bbc.co.uk\/news\/health-21773604\u000a\u000d\u000a      CDC report on status of influenza transmission and importance of\u000d\u000a        challenge experiments\u000d\u000a\u0009\u0009http:\/\/www.cdc.gov\/influenzatransmissionworkshop2010\/\u000a\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Responding to the threat of pandemic influenza\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    a) In late April 2009, as it became rapidly apparent that a pandemic had\u000d\u000a      started, the Department of Health (England) asked Prof Van-Tam, Head of\u000d\u000a      HPIRG, to design, establish and lead the Influenza Clinical Information\u000d\u000a      Network (FLU-CIN) to study the detailed clinical epidemiology of cases of\u000d\u000a      pandemic influenza in UK hospitals. The brief was to establish the network\u000d\u000a      within 4 weeks and begin reporting to the Scientific Advisory Group for\u000d\u000a      Emergencies (SAGE) within 8 weeks. These objectives were achieved by the\u000d\u000a      FLU-CIN coordinating team in Nottingham (Van-Tam &#8212; Head of Unit, Enstone &#8212;\u000d\u000a      Research Associate, Hashim &#8212; Research Associate, Myles &#8212; Associate\u000d\u000a      Professor) working in partnership with clinical groups across the length\u000d\u000a      and breadth of the UK to assemble the largest longitudinal cohort of\u000d\u000a      pandemic influenza patients in Europe, from which detailed clinical data\u000d\u000a      were extracted.\u000d\u000a    b) In May 2009, the NIHR began commissioning a series of `emergency'\u000d\u000a      research studies to address issues arising during the 2009 pandemic. The\u000d\u000a      HPIRG was awarded direct funding for two of these:\u000d\u000a    \u000d\u000a      `MummyFlu': an estimation of the degree of antibody protection\u000d\u000a        conferred to newborn babies by vaccination of their mothers during\u000d\u000a        pregnancy (2009-10: Puleston (Associate Professor), Van-Tam).\u000d\u000a      An estimation of influenza virus transmission parameters through the\u000d\u000a        sampling of patients with pandemic flu and the environment around them\u000d\u000a        (2009-11: Killingley &#8212; Clinical Research Fellow, Van-Tam, Enstone)\u000d\u000a    \u000d\u000a    The HPIRG was a major co-applicant (with Leicester University) on a\u000d\u000a      third:\u000d\u000a    \u000d\u000a      A comparative assessment of the serological response in adults to the\u000d\u000a        two pandemic vaccines chosen for deployment by the UK Government.\u000d\u000a        (2009-10: Van-Tam).\u000d\u000a    \u000d\u000a    c) In the aftermath of the 2009 pandemic, under its new WHO\u000d\u000a      responsibilities, HPIRG designed and led an evaluation to examine whether\u000d\u000a      preparedness activities put in place across Europe and central Asia prior\u000d\u000a      to 2009 aided the pandemic response, (2010-11:Hashim &#8212; PhD student, Shaw\u000d\u000a      (Prof Social Sciences), Van-Tam).\u000d\u000a    d) In addition, over the period 2011 to 2013, WHO Headquarters in Geneva\u000d\u000a      requested and funded HPIRG to undertake four commissioned systematic\u000d\u000a      reviews and meta-analyses on areas of international importance in relation\u000d\u000a      to influenza control:\u000d\u000a    \u000d\u000a      Effectiveness in immunocompromised patients (2011: Beck &#8212; Lecturer,\u000d\u000a        Hashim, Van-Tam, Enstone)\u000d\u000a      Effectiveness of vaccinating healthcare workers to prevent illness in\u000d\u000a        patients (2011: Dolan &#8212; seconded Public Health trainee, Van-Tam, Hale -\u000d\u000a        PhD student)\u000d\u000a      Effectiveness of antiviral drugs in reducing community transmission\u000d\u000a        (2013: Beck, Okoli &#8212; Research Associate, Van-Tam)\u000d\u000a      Effectiveness of movement restriction on disease containment (2013:\u000d\u000a        Beck, Mateus &#8212; seconded trainee, Van-Tam)\u000d\u000a    \u000d\u000a    e) It has long been recognised that the mode of influenza transmission is\u000d\u000a      poorly understood and is a significant international problem:\u000d\u000a      authoritative advice on prevention cannot be given to the public and\u000d\u000a      healthcare workers about protective countermeasures (e.g. hand hygiene,\u000d\u000a      face masks, respirators). Having undertaken pioneering pilot work to\u000d\u000a      develop a human challenge model for transmission of influenza, HPIRG\u000d\u000a      formed a major international consortium (EMIT) and was awarded &#163;7M from\u000d\u000a      CDC to continue this work (2011-13: Van-Tam, Enstone, Killingley), which\u000d\u000a      is regarded as globally important and absolutely unique.\u000d\u000a    "},{"CaseStudyId":"27327","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2963597","Name":"Ireland"}],"Funders":[],"ImpactDetails":"\u000a    The primary beneficiaries of our work are the millions of smokers in the\u000a      UK whose risks of death\u000a      and disease are dramatically reduced by stopping smoking; their families\u000a      and dependents, who\u000a      avoid the suffering and economic cost of loss of a family member;\u000a      employers, who enjoy higher\u000a      productivity from non-smokers; and wider society, which avoids the\u000a      estimated &#163;14 billion that\u000a      smoking costs society. The prevalence of adult smoking in the UK has\u000a      fallen by about 7\u000a      percentage points (&#8776;3 million smokers) in the last decade, and by about a\u000a      third in adolescents\u000a      aged &lt;16. Our work has contributed to these falls, thus helping to\u000a      prevent thousands of cases of\u000a      lifelong addiction to, and premature death from, smoking. Examples of\u000a      impact include:\u000a    Smoke-free policy and passive smoking: Our report on passive\u000a      smoking and children generated\u000a      widespread media coverage and calls by NGOs (including British Medical\u000a      Association, British Lung\u000a      Foundation, Action Cancer (Northern Ireland)) for wider restrictions on\u000a      smoking in the presence of\u000a      children, particularly in cars; a 2011 All Party Parliamentary Group\u000a      hearing on smoking in private\u000a      vehicles chaired by Steven Williams MP [5.1]); a private member's bill\u000a      calling for legislation to\u000a      prohibit smoking in cars in Northern Ireland (http:\/\/www.niassembly.gov.uk\/Assembly-Business\/Official-Report\/Reports-11-12\/14-November-2011\/#4)\u000a      and the Smoke-free Private\u000a      Vehicles Bill [HL] 2012-13 in the House of Lords. Britton briefed the\u000a      Secretary of State for Health\u000a      (Hunt) and Public Health Minister (Soubry) personally on passive smoking\u000a      and plain packaging on\u000a      21.11.12.\u000a    Point of sale legislation: McNeill's work on point of sale\u000a      legislation in Ireland, presented in the\u000a      House of Commons and followed by a personal telephone conversation with\u000a      the Secretary of State\u000a      for Health (Lansley), proved crucial to the retention of 2010 Health Act\u000a      point of sale legislation in\u000a      the 2011 Coalition Government's Tobacco Control Plan for England\u000a      [5.2].\u000a    Plain packaging: Our advocacy, with others, was crucial to the\u000a      inclusion of a commitment to\u000a      consider plain packaging in the Tobacco Control Plan for England\u000a      [5.2], and the systematic\u000a      evidence review (AM) a key driver of the formal consultation in 2012.\u000a    Smoking cessation and prevention: Our research in hospital\u000a      patients, adolescents, pregnant\u000a      women and people with mental disorders has fed directly into several NICE\u000a      guidelines over the\u000a      past decade. Britton was a member of the NICE PDG which produced guidance\u000a      on smoking\u000a      cessation in community settings in 2008 (www.nice.org.uk\/PH010).\u000a      Coleman provided expert\u000a      evidence reviews for 2010 NICE guidance on smoking cessation in pregnancy\u000a      and after childbirth\u000a      (http:\/\/guidance.nice.org.uk\/PH26).\u000a      Britton chaired the PDG (Ratschen and Murray members)\u000a      producing guidance on smoking cessation in all NHS acute, maternity and\u000a      mental health\u000a      secondary care settings (consultation draft published 5.4.13 [5.3]; final\u000a      guidance due 27.11.13),\u000a      with Ratschen, Murray, Leonardi-Bee and Szatkowski providing expert\u000a      reviews, and in which our\u000a      work in acute and mental health hospital cessation service models, and\u000a      clinical trials, were pivotal.\u000a      Szatkowski was part of the NICE Advisory Group which produced the 2013\u000a      Evidence Update on\u000a      school-based interventions to prevent the uptake of smoking among children\u000a      and young people\u000a      (http:\/\/guidance.nice.org.uk\/PH23).\u000a    Harm reduction: Our work, particularly the RCP harm reduction\u000a      report, has led to the inclusion of\u000a      harm reduction strategies in a number of government policies, including\u000a      the 2010 and 2011\u000a      Department of Health tobacco control strategies [5.2, 5.4], and encouraged\u000a      major industries to\u000a      enter the alternative nicotine market. Representations by Britton and\u000a      others to the Medicines and\u000a      Healthcare Products Regulatory Agency (MHRA) led to the establishment of\u000a      and our involvement\u000a      in an Expert Committee on Nicotine Containing Products [5.5], leading to a\u000a      substantive review of\u000a      MHRA licensing policy on nicotine products and an announcement of\u000a      permissive licensing for\u000a      nicotine-containing products in June 2013 [5.6]. The key change, a switch\u000a      from using placebo as\u000a      the safety comparator for nicotine products to the pragmatic likelihood of\u000a      continued smoking, has\u000a      opened the door to the development and use of alternative nicotine\u000a      products (e.g. electronic\u000a      cigarettes) as long-term substitutes for smoking. In 2008 Britton met with\u000a      the Director of NICE to\u000a      make the case for harm reduction as a public health strategy. This\u000a      initiated a NICE Citizens\u000a      Council on harm reduction in 2009 [5.7], and a NICE PDG on tobacco harm\u000a      reduction (Britton and\u000a      McNeill members) which produced guidance (June 2013) integrating harm\u000a      reduction into NHS\u000a      practice [5.8]. Britton also met with the Cabinet Office Behavioural\u000a      Insight Team (BIT) in 2011,\u000a      advocating harm reduction as a means to promote healthy choices, leading\u000a      to the inclusion of\u000a      harm reduction as a BIT policy [5.9]. Britton has since met twice with the\u000a      Prime Minister's senior\u000a      policy advisor on Health and Adult Care (Paul Bate) at 10 Downing St (in\u000a      2011 and 2012) to\u000a      discuss harm reduction and other prevention strategy. These policy changes\u000a      have established the\u000a      UK as world leader in harm reduction approaches to nicotine addiction. Our\u000a      influence and\u000a      leadership was directly acknowledged in a speech by the Secretary of State\u000a      for Health on 6.3.12\u000a      [5.10]. The RCP harm reduction report was also used by Britton to brief\u000a      (meeting 2.3.13) Linda\u000a      McAvan, rapporteur on the 2013 EU Tobacco Products Directive for the\u000a      Environment, Public\u000a      Health and Food Safety (ENVI) committee, to support permissive regulation\u000a      of nicotine-containing\u000a      products at EU level (and 75% health warnings on tobacco packs) in the EU\u000a      Directive:\u000a      http:\/\/www.europarl.europa.eu\/pdfs\/news\/expert\/infopress\/20130708IPR16824\/20130708IPR16824_en.pdf.\u000a    ","ImpactSummary":"\u000a    Research, policy development, evaluation and advocacy work at The\u000a      University of Nottingham has\u000a      achieved significant impact in helping to prevent the harm to health\u000a      caused by smoking, which is\u000a      the largest avoidable cause of death and disability, and of social\u000a      inequalities in health, in the UK.\u000a      This impact has been achieved through contributions in two areas of\u000a      prevention: (1) conventional\u000a      population- and individual-level interventions to prevent smoking uptake\u000a      and promote smoking\u000a      cessation; and (2) novel population-level measures to encourage\u000a      substitution of smoked tobacco\u000a      with alternative, low hazard nicotine products as a harm reduction\u000a      strategy.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Nottingham\u000a    ","Institutions":[{"AlternativeName":"Nottingham (University of)","InstitutionName":"University of Nottingham","PeerGroup":"A","Region":"East Midlands","UKPRN":10007154}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Royal College of Physicians. Passive smoking and children. A report by\u000a      the Tobacco Advisory\u000a      Group of the Royal College of Physicians. London: RCP; 2010. (Also\u000a      available on request)\u000a      http:\/\/www.rcplondon.ac.uk\/sites\/default\/files\/documents\/passive-smoking-and-children.pdf\u000a    \u000a\u000a2. Moodie C, Stead M, Bauld L, McNeill A, Angus K, Hinds K et al. Plain\u000a      Tobacco Packaging: A\u000a      Systematic Review. University of Stirling: 2012. (Also available on\u000a      request)\u000a      http:\/\/phrc.lshtm.ac.uk\/papers\/PHRC_006_Final_Report.pdf\u000a    \u000a\u000a3. McNeill A, Lewis S, Quinn C, Mulcahy M, Clancy L, Hastings G, Edwards\u000a      R. Evaluation of the\u000a      removal of point-of-sale tobacco displays in Ireland. Tobacco Control\u000a      2011;20:137-143\u000a      DOI:10.1136\/tc.2010.038141.\u000a    \u000a\u000a4. Quinn C, Lewis S, Edwards R, McNeill A. Economic evaluation of the\u000a      removal of tobacco\u000a      promotional displays in Ireland. Tobacco Control 2011;20:151-155 DOI:\u000a      10.1136\/tc.2010.039602.\u000a    \u000a\u000a5. Coleman T, Cooper S, Thornton J.G., Grainge MJ, Watts K, Britton J,\u000a      Lewis SA. A randomized\u000a      trial of nicotine replacement therapy patches in pregnancy. N Engl J Med\u000a      2012;366:808-818\u000a      DOI: 10.1056\/NEJMoa1109582.\u000a    \u000a\u000a6. Coleman T, Chamberlain C, Davey MA, Cooper S, Leonardi-Bee J.\u000a      Pharmacological\u000a      interventions for promoting smoking cessation during pregnancy. Cochrane\u000a      Library Cochrane\u000a      Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010078. DOI:\u000a      10.1002\/14651858.CD010078.\u000a      http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD010078\/pdf\u000a    \u000a\u000a7. Parker C, McNeill A, Ratschen E. Tailored tobacco dependence support\u000a      for mental health\u000a      patients: a model for inpatient and community services. Addiction\u000a      2012;107:18-25 DOI:\u000a      10.1111\/j.1360-0443.2012.04082.x.\u000a    \u000a\u000a8. Murray RL, Leonardi-Bee J, Marsh J, Jayes L, Li J, Parrott S, Britton\u000a      J. Systematic\u000a      identification and treatment of smokers by hospital based cessation\u000a      practitioners in a\u000a      secondary care setting: cluster randomised controlled trial. Br Med J\u000a      2013;347:f4004. DOI:\u000a      http:\/\/dx.doi.org\/10.1136\/bmj.f4004\u000a    \u000a\u000a9. Tobacco Advisory Group of the Royal College of Physicians. Harm\u000a      reduction in nicotine\u000a      addiction. London: RCP;2007. http:\/\/www.rcplondon.ac.uk\/sites\/default\/files\/documents\/harm-reduction-nicotine-addiction.pdf (Also available on request).\u000a    \u000aThe above work was supported by the UKCRC (Core UKCTCS funding as UK\u000a      Public Health\u000a      Research Centre of Excellence), along with the following peer-review\u000a      grants:\u000a    &#8226; Cancer Research UK. `Passive smoking and children: a report by the\u000a      Tobacco Advisory Group\u000a      of the Royal College of Physicians'. Principal applicant: J Britton. April\u000a      2009-March 2010.\u000a      &#163;39,943. [Reference 1 above]\u000a    &#8226; Department of Health. `Systematic review of plain packaging'.\u000a      Applicants: C Moodie, M Stead,\u000a      G Hastings, L Bauld, A McNeill. May-Sept 2011. &#163;126,613. [Reference 2]\u000a    &#8226; Cancer Research UK \/OTC Ireland\/ASH New Zealand\/Irish Cancer Society.\u000a      `Evaluation of the\u000a      impact of point of sale removal in Ireland'. Principal applicant: A\u000a      McNeill. 2009-2011. &#163;55,000.\u000a      [References 3 &amp; 4]\u000a    &#8226; NIHR Health Technology Assessment programme. `Smoking, Nicotine and\u000a      Pregnancy (SNAP)\u000a      Trial'. Principal applicant: T Coleman. 2006-2011. &#163;1,280,667. [Reference\u000a      5]\u000a    &#8226; Department of Health. `Tobacco Control Health Inequalities Pilots\u000a      programme'. Principal\u000a      applicant: A McNeill. April 2010-March 2012. &#163;1,837,775. [Reference 7]\u000a    &#8226; NIHR (Programme grant). `Smoking: new approaches to cessation service\u000a      delivery, prevention\u000a      of passive smoke exposure in children, and healthcare cost estimation'.\u000a      Principal applicant: J\u000a      Britton. March 2010-February 2015. &#163;2,002,012. [Reference 8].\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    \u000a       All Party Parliamentary Group on Smoking and Health Inquiry into\u000a        smoking in private vehicles\u000a        London: Action on Smoking and Health; 2011.\u000a        http:\/\/www.ash.org.uk\/files\/documents\/ASH_820.pdf (Call for consultation on options to protect\u000a          children from passive smoking in private vehicles; JB gave evidence\u000a          based on RCP 2010 report\u000a          and other UKCTCS research)\u000a\u000a       Department of Health. Healthy lives, healthy people. A tobacco\u000a        control plan for England.\u000a        London: Department of Health; 2011.\u000a        https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/213757\/dh_124960.pdf (Includes commitments to point of sale legislation, plain\u000a          packaging consultation, and\u000a          harm reduction; cites our work as source of evidence)\u000a\u000a       National Institute for Clinical Excellence. Smoking cessation in\u000a        secondary care: acute, maternity\u000a        and mental health services. NICE: 2013.\u000a        http:\/\/www.nice.org.uk\/nicemedia\/live\/13017\/63459\/63459.pdf (Programme group chaired by\u000a          Britton with input from multiple individuals from Division,\u000a          particularly on service designs for acute\u000a          and mental health services)\u000a\u000a       Department of Health. A Smokefree Future. A comprehensive tobacco\u000a        control strategy for\u000a        England. London: Department of Health; 2010.\u000a        http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@en\/@ps\/documents\/digitalasset\/dh_111789.pdf (Includes commitments to point of sale legislation and harm\u000a          reduction, and cites our work as\u000a          source of research evidence)\u000a\u000a       MHRA Public Assessment Report: The use of nicotine replacement\u000a        therapy to reduce harm in\u000a        smokers. London: MHRA; 2010\u000a        http:\/\/www.mhra.gov.uk\/home\/idcplg?IdcService=GET_FILE&amp;dDocName=CON068571&amp;RevisionSelectionMethod=LatestReleased (Addresses use of nicotine in harm reduction as a viable\u000a          strategy to provide a low hazard alternative to smoking for smokers\u000a          who cannot or will not quit)\u000a\u000a       Medicines and Healthcare products Regulatory Agency. The Regulation\u000a        of Nicotine Containing\u000a        Products (NCPs). London: MHRA; 2013\u000a        http:\/\/www.mhra.gov.uk\/home\/groups\/comms-ic\/documents\/websiteresources\/con286834.pdf\u000a\u000a       Report on NICE Citizens Council meeting: Smoking and harm reduction\u000a        London: National Institute for Health and Clinical Excellence; 2010\u000a        http:\/\/www.nice.org.uk\/media\/4EB\/13\/CCReportOnHarmReductionUpdated300410.pdf\u000a        (Citizens Council held as a consequence or our advocacy for adoption\u000a          of harm reduction as\u000a          health policy; driven by RCP report (above) and other work)\u000a\u000a       National Institute for Health and Care Excellence. Tobacco &#8212; harm\u000a        reduction. London: NICE;\u000a        2013 http:\/\/guidance.nice.org.uk\/PH45\/Guidance\/pdf\/English (Public health guidance on\u000a          adoption of tobacco harm reduction strategies into clinical practice\u000a          and policy. Britton and\u000a          McNeill members of programme development group)\u000a\u000a       Behavioural Insights Team. Annual Update 2010-11. London: Cabinet\u000a        Office;2011\u000a        http:\/\/www.cabinetoffice.gov.uk\/sites\/default\/files\/resources\/Behaviour-Change-Insight-Team-Annual-Update_acc.pdf (Includes harm reduction strategies, as direct consequence of\u000a          our\u000a          interactions with the BIT)\u000a\u000a       Speech: 6 March 2012, Andrew Lansley, Smoking and Health\u000a        http:\/\/mediacentre.dh.gov.uk\/2012\/03\/07\/speech-6-march-2012-andrew-lansley-smoking-and-health\/\u000a        (Speech by Secretary of State for Health at Royal College of\u000a          Physicians,\u000a          acknowledging RCP\/UKCTCS leadership of development of UK harm\u000a          reduction policy)\u000a\u000a    \u000a    ","Title":"\u000a    Development and implementation of UK tobacco control policy\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2641364","Name":"Northern Ireland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Original research, evidence synthesis and policy advocacy has been\u000a      carried out collaboratively\u000a      through the UK Centre for Tobacco Control Studies (UKCTCS), one of five UK\u000a      Clinical Research\u000a      Collaboration (UKCRC) Public Health Research Centres of Excellence\u000a      established in 2008 and led\u000a      by John Britton (Professor of Epidemiology since 2000, Director of UKCTCS\u000a      2008-present) with\u000a      Ann McNeill (Professor of Health Policy and Promotion 2005-12, now at\u000a      Kings College London),\u000a      Sarah Lewis (Professor of Medical Statistics), Tim Coleman (Professor of\u000a      Primary Care) and Jo\u000a      Leonardi-Bee (Associate Professor of Medical Statistics) and other\u000a      Nottingham staff, named below.\u000a      Centre funding was renewed for a further five years to 2018. The UKCTCS\u000a      works closely with the\u000a      Tobacco Advisory Group of the Royal College of Physicians (RCP), chaired\u000a      by Britton since 1996\u000a      with substantial input from McNeill, Coleman and Leonardi-Bee, and with\u000a      Action on Smoking and\u000a      Health (Britton a Board member) in advocacy. The team has played major\u000a      roles in producing\u000a      evidence to support legislation prohibiting point of sale tobacco displays\u000a      in England (now being\u000a      implemented in stages from April 2012), plain tobacco packaging,\u000a      development of more effective\u000a      models of cessation service provision, and most importantly by\u000a      establishing the UK as a world\u000a      leader in tobacco harm reduction. The work includes:\u000a    Passive smoking in children: 2010 RCP Report including systematic\u000a      reviews of health effects,\u000a      attributable fractions and economic consequences of passive smoking in\u000a      children, led and edited\u000a      by Britton with contributors including McNeill, Leonardi-Bee, Hubbard\u000a      (Professor of Respiratory\u000a      Epidemiology), Szatkowski (Lecturer in Statistics) and 11 other Nottingham\u000a      staff and students [1].\u000a    Plain tobacco packaging: While in Nottingham, McNeill developed\u000a      and co-authored the first UK\u000a      study of plain packaging and first international study involving children,\u000a      and co-authored the 2012\u000a      systematic review supporting the 2012 consultation on plain tobacco\u000a      packaging [2].\u000a    Point of sale legislation: McNeill and Lewis from Nottingham led\u000a      an evaluation of the impact of the\u000a      2010 point of sale legislation in Ireland on children's perceptions of\u000a      cigarette availability [3] and an\u000a      economic evaluation of the effect of the legislation on tobacco sales [4].\u000a    Smoking cessation: Our work includes a definitive trial of\u000a      nicotine therapy in pregnancy (led by\u000a      Coleman [5]) and Cochrane review of cessation pharmacotherapy in pregnancy\u000a      (Coleman and\u000a      Leonardi-Bee) [6], work on service delivery in mental health settings and\u000a      other hard-to-reach\u000a      groups (by Elena Ratschen, Lecturer in Epidemiology) [7] and hospital\u000a      inpatient settings (by\u000a      Rachael Murray, Lecturer Health Policy and Promotion) [8].\u000a    Harm reduction: Our harm reduction work was initiated by Britton\u000a      and driven through a range of\u000a      outputs including the evidence and policy reviews summarised in the 2007\u000a      RCP report Harm\u000a        reduction in Nicotine Addiction [9], which has fed into various\u000a      aspects of government policy\u000a      development and implementation, and resulted in a NICE Programme\u000a      Development Group (PDG)\u000a      on tobacco harm reduction (Britton and McNeill members; reported June\u000a      2013) and the MHRA\u000a      decision to introduce permissive nicotine licensing (June 2013).\u000a    Policy evaluation: Lewis, Szatkowski, Hubbard, Langley (Lecturer\u000a      in Economics) and Huang (Data\u000a      Manager) have pioneered the use of routine electronic health databases in\u000a      the evaluation of\u000a      impacts of policy on smoking behaviour, clinical practice and safety of\u000a      smoking cessation\u000a      interventions which underpin the above work. Examples of use of large\u000a      databases are available\u000a      through the Nottingham Tobacco Control Database\u000a      (http:\/\/www.ukctcs.org\/ukctcs\/research\/featuredprojects\/ntcd.aspx).\u000a    "},{"CaseStudyId":"27328","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000d\u000a    The assessment of individual patients is possible using a purpose\u000d\u000a      designed publically available website www.qrisk.org\u000a        which displays the patient's risk using approaches which the patient\u000d\u000a      is likely to understand (smiley faces to represent absolute risk). The\u000d\u000a      website is can be used by anyone to determine whether they are at high\u000d\u000a      risk or not. QRISK is also integrated into another website as a decision\u000d\u000a      aid (www.qintervention.org)\u000d\u000a      which can be used to help determine how interventions may lower the risk.\u000d\u000a      The QRISK web calculator is in constant use around the world with &gt;\u000d\u000a      500,000 hits since 2011[1]. www.qintervention.org website was\u000d\u000a        rated by the Times as one of the top five medical Websites in 2013[2]\u000d\u000a    Formation of ClinRisk Ltd\u000d\u000a    With the University's support, Julia Hippisley-Cox set up a company\u000d\u000a      (ClinRisk Ltd) in 2008 to develop software to ensure the reliable and\u000d\u000a      widespread implementation of the QRISK into clinical practice across the\u000d\u000a      UK. ClinRisk has since developed the public facing website (www.qrisk.org)\u000d\u000a      and software which integrates the algorithm into clinical computer\u000d\u000a      systems. The University provided legal support to enable licensing of the\u000d\u000a      algorithm, trademark and software to industry for use across the NHS.\u000d\u000a      Since 2008, QRISK software has been licensed by a number of companies\u000d\u000a      including the leading suppliers to primary and secondary care within the\u000d\u000a      NHS.\u000d\u000a    Clinical utility of QRISK at population level\u000d\u000a    QRISK is also used to risk-stratify entire populations. The software,\u000d\u000a      which is now embedded in &gt; 90% of UK GP clinical computer systems, runs\u000d\u000a      calculations every night which generate a rank-ordered list of those at\u000d\u000a      high risk of heart disease or stroke. The software is used daily by\u000d\u000a      clinicians during consultations with patients and as a risk stratification\u000d\u000a      tool to identify patients for recall for further assessment. Patients at\u000d\u000a      high risk of cardiovascular disease can therefore be identified and given\u000d\u000a      interventions to lower risk where appropriate. Interventions include\u000d\u000a      weight reduction, smoking cessation, blood pressure lowering treatment and\u000d\u000a      cholesterol lowering treatment.\u000d\u000a    The NHS Health Checks programme and Department of Health Policy\u000d\u000a    The NHS Health Checks Programme offers a cardiovascular risk assessment\u000d\u000a      to adults aged 40-74 years in England. The Department of Health endorsed\u000d\u000a      QRISK on publication and used it to develop the economic modelling\u000d\u000a      underpinning the NHS Checks programme in 2008, recommending its use for\u000d\u000a      the start of the programme in 2009[3].\u000d\u000a    Changes to NICE guidance and GP contract Quality and outcomes\u000d\u000a        framework\u000d\u000a    Use of QRISK was ratified by NICE guidance in 2010[4,9].\u000d\u000a      A favourable independent appraisal of QRISK2 [8] and other risk prediction\u000d\u000a      tools concluded that \"QRISK emerges with the greatest potential. It is\u000d\u000a      most likely to be sensitive to the equity issues of great current concern,\u000d\u000a      it reflects best the contemporary British population and its initial\u000d\u000a      results are encouraging. The uncertain approach of NICE's guideline\u000d\u000a      development group illustrates how difficult it can be to judge how much\u000d\u000a      evidence is needed before a change in practice can be recommended, but if\u000d\u000a      QRISK lives up to its promise, it will in time become established as the\u000d\u000a      risk assessment method of choice.\" Use of QRISK is also an integral part\u000d\u000a      of the UK GP contract since vascular screening is one of the quality\u000d\u000a      indicators for which GPs are paid. The new indicator for primary\u000d\u000a      prevention of cardiovascular disease was introduced in 2010\/11[5]\u000d\u000a    Implementation in NHS clinical computer systems\u000d\u000a    QRISK has now been implemented by all four major GP computer suppliers\u000d\u000a      covering in excess of 90% of all UK general practice: EMIS (5500 general\u000d\u000a      practices), InPractice Systems (1800 practices), The Phoenix Partnership\u000d\u000a      (2000 practices) and Microtest (~300 practices). Other suppliers use QRISK\u000d\u000a      in community and pharmacy contexts including Oskis, Wellpoint\u000d\u000a      (kiosk\/pharmacies), Telehealth (kiosk\/pharmacies). These pharmacy and\u000d\u000a      other community schemes use QRISK as part of the NHS Health Checks\u000d\u000a      programme. QRISK is also available as an app for the iphone.\u000d\u000a    Clinical Beneficiaries\u000d\u000a    The main beneficiaries of QRISK are the patients whose risk is assessed\u000d\u000a      more accurately, especially those high risk patients from ethnic\u000d\u000a      minorities or deprived areas who would otherwise have missed out on\u000d\u000a      effective treatments if the Framingham score had been used. Other\u000d\u000a      beneficiaries include clinicians using QRISK since it is better able to\u000d\u000a      identify high risk patients than Framingham. Health care professionals can\u000d\u000a      use the web interface to display an individual's risk of cardiovascular\u000d\u000a      disease in a way which the patient is likely to understand thereby\u000d\u000a      involving patients in decisions regarding their care. Clinical\u000d\u000a      Commissioning Groups also benefit from the integrated automated electronic\u000d\u000a      population tools which are efficient at identifying those at high risk and\u000d\u000a      summarise the number of patients at high risk and those with modifiable\u000d\u000a      risk factors.\u000d\u000a    Development of new technologies and approaches.\u000d\u000a    To our knowledge, QRISK is the first risk prediction tool to be developed\u000d\u000a      using routinely collected electronic data from primary care medical\u000d\u000a      records. It has stimulated development of a new research area resulting in\u000d\u000a      other similar tools to predict risks of other major clinical diseases.\u000d\u000a    Application of new technologies into clinical practice\u000d\u000a    The integration of QRISK software into multiple clinical computer systems\u000d\u000a      in a scalable, sustainable reliable way which can be regularly updated has\u000d\u000a      also provided a model which can be extended to other preventable clinical\u000d\u000a      conditions.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    QRISK is a new algorithm which predicts an individual's risk of\u000d\u000a      cardiovascular over 10 years. It was developed using the QResearch\u000d\u000a      database and is in routine use across the NHS. It is included in national\u000d\u000a      guidelines from NICE and the Department of Health and in the GP quality\u000d\u000a      and outcomes framework. It is incorporated into &gt; 90% of GP computer\u000d\u000a      systems as well as pharmacy and secondary care systems. The web calculator\u000d\u000a      has been used &gt;500,000 times worldwide. ClinRisk Ltd was incorporated\u000d\u000a      in 2008 to develop software to ensure the reliable widespread\u000d\u000a      implementation of the QRISK algorithm into clinical practice.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Nottingham\u000d\u000a    ","Institutions":[{"AlternativeName":"Nottingham (University of)","InstitutionName":"University of Nottingham","PeerGroup":"A","Region":"East Midlands","UKPRN":10007154}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    The underlying research was the development and validation of the QRISK\u000d\u000a      algorithm which was initiated and lead by Professor Julia Hippisley-Cox\u000d\u000a      and Dr Carol Coupland from the University Nottingham in collaboration with\u000d\u000a      colleagues from Bristol, Queen Mary's and Edinburgh University. The\u000d\u000a      publications listed below include four in the BMJ which is one of the\u000d\u000a      highest rated general medical journals internationally with an impact\u000d\u000a      factor of &gt; 14.\u000d\u000a    \u000a&#8226; Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P.\u000d\u000a      Derivation and validation of QRISK, a new cardiovascular disease risk\u000d\u000a      score for the United Kingdom: prospective open cohort study. BMJ\u000d\u000a      2007;335:136-41 doi:10.1136\/bmj.39261.471806.55\u000d\u000a    \u000a\u000a&#8226; Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting\u000d\u000a      cardiovascular risk in England and Wales: prospective derivation and\u000d\u000a      validation of QRISK2. BMJ 2008:bmj.39609.449676.25 doi:\u000d\u000a      10.1136\/bmj.39609.449676.25\u000d\u000a    \u000a\u000a&#8226; Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Performance of the\u000d\u000a      QRISK cardiovascular risk prediction algorithm in an independent UK sample\u000d\u000a      of patients from general practice: a validation study. Heart 2008;94:34-39\u000d\u000a      doi: 10.1136\/hrt.2007.134890\u000d\u000a    \u000a\u000a&#8226; Hippisley-Cox J, Coupland C, Robson J, et al. Derivation, validation,\u000d\u000a      and evaluation of a new QRISK model to estimate lifetime risk of\u000d\u000a      cardiovascular disease: cohort study using QResearch database. BMJ\u000d\u000a      2010;341:c6624 doi: http:\/\/dx.doi.org\/10.1136\/bmj.c6624\u000d\u000a    \u000a\u000a&#8226; Hippisley-Cox J, Coupland C. Unintended effects of statins in men and\u000d\u000a      women in England and Wales: population based cohort study using the\u000d\u000a      QResearch database. BMJ 2010;340:c2197 doi: 10.1136\/bmj.c2197[published\u000d\u000a      Online First: 21 May 2010]\u000d\u000a    \u000a\u000a&#8226; Hippisley-Cox J, Coupland C. Individualising the risks of statins in\u000d\u000a      men and women in England and Wales: population-based cohort study. Heart\u000d\u000a      2010;96(12):939-47 doi: 10.1136\/hrt.2010.199034 [published Online First:\u000d\u000a      20 May 2010]\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    \u000d\u000a      Google Analytics report, which gives uses of the web calculator over\u000d\u000a        the last 2 years, there have been 503,397 uses from 169 countries. A PDF\u000d\u000a        of the report is available, with a map indicating international usage\u000d\u000a        (PDF supplied).\u000d\u000a      The Times Newspaper &#8212; it was in the top 5 of the top '50 medical\u000d\u000a        websites you can't live without' http:\/\/www.thetimes.co.uk\/tto\/technology\/internet\/article3668490.ece\u000d\u000a\u0009\u0009(PDF supplied).\u000d\u000a      Department of Health. NHS Health Check: Vascular Risk Assessment and\u000d\u000a        Management Best Practice Guidance. In: Department of Health, ed. London,\u000d\u000a        2009 (Chapter 1, pgs 2 &amp; 4; Chapter 7, pgs 13-15; Chapter 11,\u000d\u000a          pgs 25-26)\u000d\u000a        http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_097489\u000d\u000a        (PDF supplied)\u000d\u000a      National Institute for Clinical Excellence (NICE). Change to lipid\u000d\u000a        modification guidance CG67. Secondary Change to lipid modification\u000d\u000a        guidance CG67 2010.\u000d\u000a        http:\/\/www.nice.org.uk\/newsroom\/news\/ChangeToLipidModificationGuidelineCG67.jsp\u000d\u000a        (Screenshot supplied)\u000d\u000a      National Institute for Clinical Excellence (NICE). Quality and\u000d\u000a        Outcomes Framework: QRISK is included in the GP contract (also known as\u000d\u000a        the \"Quality and Outcomes Framework\"). Quality and outcomes framework\u000d\u000a        (QOF) indicator guidance: primary prevention of cardiovascular disease.\u000d\u000a        Secondary Quality and outcomes framework (QOF) indicator guidance:\u000d\u000a        primary prevention of cardiovascular disease 2011.\u000d\u000a        http:\/\/bma.org.uk\/-\/media\/Files\/PDFs\/Practical%20advice%20at%20work\/Contracts\/gpqofguidance20132014.pdf\u000d\u000a        (PDF supplied)\u000d\u000a      External validation: Three studies undertaken by an independent team\u000d\u000a        of Oxford academics which have validated the performance of QRISK on\u000d\u000a        external datasets:\u000d\u000a\u0009\u0009\u000d\u000a      a. Collins GS, Altman A. Predicting the 10 year risk of cardiovascular\u000d\u000a        disease in the United Kingdom: independent and external validation of an\u000d\u000a        updated version of QRISK2. BMJ 2012;344: e4181 doi:10.1136\/bmj.e4181\u000d\u000a        http:\/\/www.bmj.com\/highwire\/filestream\/590813\/field_highwire_article_pdf\/0\/bmj.e4181.full.pdf\u000d\u000a        (PDF supplied)\u000d\u000a      b. Collins GS, Altman DG. An independent and external validation of\u000d\u000a        QRISK2 cardiovascular disease risk score: a prospective open cohort\u000d\u000a        study. BMJ 340: 340:c2442 doi:10.1136\/bmj.c2442\u000d\u000a        http:\/\/www.bmj.com\/highwire\/filestream\/362442\/field_highwire_article_pdf\/0\/bmj.c2442\u000d\u000a        (PDF supplied)\u000d\u000a      c. Collins GS, Altman DG. An independent external validation and\u000d\u000a        evaluation of QRISK cardiovascular risk prediction: a prospective open\u000d\u000a        cohort study. BMJ 2009;339:b2584 doi:10.1136\/bmj.b2584\u000d\u000a        http:\/\/www.bmj.com\/highwire\/filestream\/381004\/field_highwire_article_pdf\/0\/bmj.b2584.full.pdf\u000d\u000a        (PDF supplied)\u000d\u000a     \u000d\u000a      Independent editorial by international expert, Professor Rod Jackson,\u000d\u000a        New Zealand: Jackson R, Marshall R, Kerr A, et al. QRISK or Framingham\u000d\u000a        for predicting cardiovascular risk? BMJ 2009;339:b2673\u000d\u000a        doi:10.1136\/bmj.b2673 [published Online First: 7 July 2009]\u000d\u000a        http:\/\/www.bmj.com\/highwire\/section-pdf\/8958\/1\/1\u000a          (PDF supplied)\u000d\u000a      Independent appraisal of QRISK2 by PHG Foundation. Dent T.\u000d\u000a          Predicting the risk of Coronary Heart Disease with conventional\u000d\u000a          genetic &amp; novel molecular biomarkers. Cambridge: PHG Foundation\u000d\u000a          for Genomics and Population Health, January 2010 ISBN\u000d\u000a          978-1-907198-02-1\u000d\u000a        http:\/\/www.phgfoundation.org\/reports\/5160\/\u000a          (PDF supplied)\u000d\u000a      National Institute for Clinical Excellence (NICE). Lipid modification\u000d\u000a        &#8212; Cardiovascular risk assessment and the modification of blood lipids\u000d\u000a        for the primary and secondary prevention of cardiovascular disease. In:\u000d\u000a        NICE, ed. London: NICE, 2008 (Revised March 2010)\u000d\u000a        http:\/\/www.nice.org.uk\/nicemedia\/live\/11982\/40689\/40689.pdf\u000a          (PDF supplied)\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    QRISK &#8212; a new cardiovascular risk score to identify patients at high\u000d\u000a        risk of cardiovascular disease for prevention\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Cardiovascular disease is a leading cause of morbidity and mortality\u000d\u000a      worldwide. Clinicians need reliable information about an individual's risk\u000d\u000a      of developing cardiovascular disease since interventions exist which can\u000d\u000a      reduce risk of cardiovascular disease in individuals at high risk.\u000d\u000a      Historical methods for quantifying cardiovascular disease risk were based\u000d\u000a      on an American equation (Framingham) developed more than 20 years ago\u000d\u000a      based on a study of white people from a small American town. Consequently\u000d\u000a      the Framingham equation is not suitable for use in a contemporary\u000d\u000a      ethnically diverse UK population as it doesn't reliably identify those at\u000d\u000a      high risk and tends to over-predict risk in low risk individuals. New\u000d\u000a      approaches to cardiovascular risk estimation were needed to take account\u000d\u000a      of the characteristics of the population to which the tool should be\u000d\u000a      applied and which can be updated over time as the population changes and\u000d\u000a      national guidelines for prevention evolve. QRISK was therefore developed\u000d\u000a      as a new approach to cardiovascular risk estimation. The research was led\u000d\u000a      by Professor Julia Hippisley-Cox and Dr Carol Coupland and assisted by Ms\u000d\u000a      Vinogradova from the University of Nottingham with collaborators from\u000d\u000a      other institutions.\u000d\u000a    The new QRISK algorithm was developed using the QResearch database which\u000d\u000a      is a large anonymised repository of electronic health records for medical\u000d\u000a      research created as part of a not-for-profit partnership between the\u000d\u000a      University of Nottingham and EMIS &#8212; a leading supplier of GP clinical\u000d\u000a      computer systems in the UK (www.qresearch.org\u000a        ). The original QRISK algorithm was developed using health records\u000d\u000a      from a cohort of 1.3 million adults aged 35-74 years from 318 general\u000d\u000a      practices across the UK. A statistical model was developed to estimate\u000d\u000a      associations between occurrence of cardiovascular disease during follow-up\u000d\u000a      and a range of risk factors including age, sex, deprivation, smoking,\u000d\u000a      cholesterol, blood pressure, treated hypertension, body mass index and\u000d\u000a      family history. The model estimates were combined to give an algorithm for\u000d\u000a      predicting absolute risk of cardiovascular disease at 10 years. The\u000d\u000a      algorithm was validated in a separate validation cohort containing 610,000\u000d\u000a      people from 160 different practices. An updated algorithm QRISK2 was\u000d\u000a      derived from a cohort of 1.5 million adults and incorporated additional\u000d\u000a      terms for ethnicity, type 2 diabetes, rheumatoid arthritis, renal disease,\u000d\u000a      and atrial fibrillation. It is the largest cardiovascular risk prediction\u000d\u000a      study to date globally. Because it is derived from clinical information\u000d\u000a      collected in primary care, rather than on a specially assembled research\u000d\u000a      cohort, it is less likely to be affected by selection bias. It can be\u000d\u000a      updated to reflect changes in populations, data quality and improvements\u000d\u000a      in statistical methods.\u000d\u000a    Validation studies have shown that QRISK is more accurate than the\u000d\u000a      Framingham score at assessing risk for UK individuals. QRISK has\u000d\u000a      weightings for deprivation and ethnicity and so is less likely to\u000d\u000a      under-estimate cardiovascular risk in high-risk patients and can therefore\u000d\u000a      help avoid widening health inequalities. Unlike the Framingham score,\u000d\u000a      QRISK does not over estimate risk in low-risk UK patients thereby avoiding\u000d\u000a      unnecessary medication. Overall it is a more efficient tool for the\u000d\u000a      quantification of cardiovascular risk which is then used to guide\u000d\u000a      treatment decisions.\u000d\u000a    "},{"CaseStudyId":"27329","Continent":[],"Country":[],"Funders":["Wellcome Trust"],"ImpactDetails":"\u000d\u000a    The PRACtICe study has provided the best evidence to date on prevalence,\u000d\u000a      nature and causes of\u000d\u000a      prescribing errors in general practices whilst the PINCER trial has\u000d\u000a      identified a highly successful\u000d\u000a      intervention to reduce prescribing errors in primary care. The main\u000d\u000a      evidence of impact comes from\u000d\u000a      media coverage, changes to the RCGP curriculum, production of learning\u000d\u000a      materials for GPs,\u000d\u000a      developments to the TPP SystmOne GP computer system, and uptake from a\u000d\u000a      release of computer\u000d\u000a      queries used in the PINCER trial. These have all occurred in 2012-13. The\u000d\u000a      main beneficiaries are\u000d\u000a      patients and members of the public, GPs, pharmacists and the NHS.\u000d\u000a    Our report on the GMC-funded PRACtICe study was launched at a press\u000d\u000a      conference at the\u000d\u000a      Wellcome Trust in May 2012. The study findings received substantial media\u000d\u000a      interest [A] including\u000d\u000a      front-page headlines in The Daily Telegraph and The Daily\u000d\u000a        Express; articles in all major national\u000d\u000a      newspapers; Professor Avery being interviewed on the BBC Radio 4 Today\u000d\u000a      Programme and BBC\u000d\u000a        Radio 2 Jeremy Vine show; and coverage on several hundred radio\u000d\u000a      stations and several hundred\u000d\u000a      websites. This raised public awareness and debate around the problems of\u000d\u000a      prescribing errors in\u000d\u000a      general practice and interviews undertaken by Professors Avery helped\u000d\u000a      improve public\u000d\u000a      understanding of the issue. In an article for the Daily Mail,\u000d\u000a      Professor Avery explained how patients\u000d\u000a      can help reduce their chances of having a prescribing error. As a result\u000d\u000a      of this publicity, the BBC1\u000d\u000a        Inside-Out programme commissioned and produced a documentary on\u000d\u000a      prescribing errors in\u000d\u000a      primary care which included Professor Avery explaining the findings from\u000d\u000a      the PRACtICe study.\u000d\u000a      This was broadcast in three regions of England in October and November\u000d\u000a      2012.\u000d\u000a    As a result of the publication of the PRACtICE study report, Peter Rubin\u000d\u000a      (President of the GMC)\u000d\u000a      confirmed that in 2012\/13, \"We [the GMC] have met with relevant\u000d\u000a        organisations to ensure that the\u000d\u000a        findings [of the study] around a greater role for pharmacists in\u000d\u000a        supporting GPs, the better use of\u000d\u000a        computer systems and the extra emphasis on prescribing in GP training\u000d\u000a        are translated into actions\u000d\u000a        that help protect patients.\" [B] Professor Avery has worked closely\u000d\u000a      with the RCGP since the\u000d\u000a      publication of the report and presented findings and recommendations at an\u000d\u000a      RCGP Curriculum\u000d\u000a      Group meeting in June 2012, and the RCGP National Conference in October\u000d\u000a      2012. The following\u000d\u000a      impacts have resulted from this [C]: 1) Additional learning outcomes on\u000d\u000a      therapeutics and safe\u000d\u000a      prescribing skills, written by Professor Avery and ratified by the GMC,\u000d\u000a      were added to the 2013\u000d\u000a      RCGP curriculum [D]; 2) Following a meeting between Professor Avery and\u000d\u000a      RCGP examiners in\u000d\u000a      April 2013, assessment of therapeutics and safe prescribing has been\u000d\u000a      strengthened in the MRCGP\u000d\u000a      examination, e.g. new consultation skills assessments have been developed.\u000d\u000a    The PRACtICE study report suggested various ways in which the prescribing\u000d\u000a      safety features of\u000d\u000a      general practice computer systems could be improved. In August 2012, the\u000d\u000a      GP periodical Pulse\u000d\u000a      reported that TPP SystmOne, \"one of the country's biggest GP software\u000d\u000a      providers has\u000d\u000a      implemented a raft of changes to almost 2,000 practice systems in the wake\u000d\u000a      of a GMC-funded\u000d\u000a      study which estimated there are errors in 1 in 20 GP prescriptions\u000d\u000a      nationally\" [E]. This has included\u000d\u000a      computerised alerts aimed at ensuring that patients on high-risk drugs\u000d\u000a      receive necessary blood-tests.\u000d\u000a    As a result of the publication of the PINCER trial in The Lancet,\u000d\u000a      general practice organisations and\u000d\u000a      NHS leaders (including the Chief Pharmaceutical Officer) have expressed\u000d\u000a      considerable interest in\u000d\u000a      rolling out the intervention to general practices in England. Since 2012,\u000d\u000a      Professor Avery and\u000d\u000a      colleagues have worked with a University spin out company (PRIMIS) to\u000d\u000a      produce e-learning\u000d\u000a      materials [F] and develop new methods for general practices to download\u000d\u000a      computer queries used\u000d\u000a      in the PINCER trial [G] to identify prescribing errors and prevent patient\u000d\u000a      harm. By July 2013, over\u000d\u000a      800 general practices had downloaded these computer queries [H] with\u000d\u000a      potential benefits to\u000d\u000a      thousands of patients, and the NHS, from this cost-effective intervention.\u000d\u000a    Keith Ridge, the Chief Pharmaceutical Officer, stated in 2013 that the\u000d\u000a      PRACtICe Study, \"has\u000d\u000a        brought considerable, and much-needed, recognition of ... the problem of\u000d\u000a        prescribing errors ... in\u000d\u000a        general practice\" and that he \"and other senior Government and\u000d\u000a        NHS officials and professionals,\u000d\u000a        routinely use this study as justification for policy development and\u000d\u000a        initiatives designed to improve\u000d\u000a        quality and outcome for patients.\" [I] He also stated that PINCER is\u000d\u000a      \"an important step towards\u000d\u000a        improving patient safety and outcomes from medicines prescribing and\u000d\u000a        use, including the\u000d\u000a        development of IT to support clinical decisions.\" [I]\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Our research has: i) increased public and professional knowledge and\u000d\u000a      understanding of the\u000d\u000a      prevalence, nature and causes of prescribing errors in general practices;\u000d\u000a      ii) led the General\u000d\u000a      Medical Council to recommend improvements to GP education and training;\u000d\u000a      iii) led to the Royal\u000d\u000a      College of General Practitioners to revise its curriculum to increase the\u000d\u000a      emphasis on safe\u000d\u000a      prescribing; iv) led one of the major GP computer system suppliers to make\u000d\u000a      safety improvements;\u000d\u000a      v) identified an IT-based intervention that is effective at reducing\u000d\u000a      prescribing errors; vi) led to the\u000d\u000a      roll-out of the intervention in over 800 general practices.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Nottingham\u000d\u000a    ","Institutions":[{"AlternativeName":"Nottingham (University of)","InstitutionName":"University of Nottingham","PeerGroup":"A","Region":"East Midlands","UKPRN":10007154}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    This section should provide references to key outputs from the\u000d\u000a      research described in the previous\u000d\u000a      section, and evidence about the quality of the research.\u000d\u000a    \u000a1. Avery A, Barber N, Ghaleb M, Dean Franklin B, Sarah Armstrong S, Crowe\u000d\u000a      S, Dhillon S, Freyer\u000d\u000a      A, Howard R, Pezzolesi C, Serumaga B, Swanwick G, Talabi O. Investigating\u000d\u000a      the prevalence\u000d\u000a      and causes of prescribing errors in general practice: The PRACtICe Study\u000d\u000a      (PRevalence And\u000d\u000a      Causes of prescrIbing errors in general practiCe). London: General Medical\u000d\u000a      Council, 2012.\u000d\u000a      (259-page project report). Report available at: http:\/\/www.gmc-uk.org\/about\/research\/12996.asp\u000d\u000a      (PDF Supplied)\u000d\u000a    \u000a\u000a2. Avery A, Ghaleb M, Barber N, Dean Franklin B, Sarah Armstrong S,\u000d\u000a      Serumaga B, Dhillon S,\u000d\u000a      Freyer A, Howard R, Talabi O, Mehta RL. The prevalence and nature of\u000d\u000a      prescribing and\u000d\u000a      monitoring errors in English general practice &#8212; a retrospective case note\u000d\u000a      review. British Journal\u000d\u000a      of General Practice 2013; 63( 613):e543-e553 doi: 10.3399\/bjgp13X670679\u000d\u000a      (PDF Supplied)\u000d\u000a    \u000a\u000a3. Slight SP, Howard R, Ghaleb M, Barber N, Dean Franklin B, Avery AJ.\u000d\u000a      The causes of\u000d\u000a      prescribing errors in English general practices: a qualitative study.\u000d\u000a      British Journal of General\u000d\u000a      Practice 2013; Published online 30th September 2013: e713-e720\u000d\u000a      doi: 10.3399\/bjgp13X673739 (PDF Supplied)\u000d\u000a    \u000a\u000a4. Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M,\u000d\u000a      Elliott RA, Howard R,\u000d\u000a      Kendrick D, Morris CJ, Prescott RJ, Swanwick G, Franklin M, Putman K, Boyd\u000d\u000a      M, Sheikh A. A\u000d\u000a      pharmacist-led information technology intervention for medication errors\u000d\u000a      (PINCER): a\u000d\u000a      multicentre, cluster randomised, controlled trial and cost-effectiveness\u000d\u000a      analysis. The Lancet\u000d\u000a      2012; 379(9823): 1310-1319 doi:10.1016\/S0140-6736(11)61817-5 (PDF\u000d\u000a      Supplied)\u000d\u000a    \u000aDetails of grants:\u000d\u000a    The grant for the PINCER trial was awarded to Professor Avery, University\u000d\u000a      of Nottingham.\u000d\u000a    The grant title was: Cluster randomised trial evaluating the\u000d\u000a    effectiveness of a pharmacist-led\u000d\u000a      intervention vs. simple feedback in reducing rates of hazardous\u000d\u000a      prescribing in general practices\u000d\u000a      (The PINCER Trial).\u000d\u000a    The funder of the study was the Department of Health.\u000d\u000a    The period of the grant was 2006-2010.\u000d\u000a    The value of the grant was &#163;643,690.\u000d\u000a    The grant for the PRACtICE study was awarded to Professor Avery,\u000d\u000a      University of Nottingham.\u000d\u000a    The grant title was: Investigating the prevalence and causes of\u000d\u000a      prescribing errors in general\u000d\u000a      practice.\u000d\u000a    The funder of the study was the General Medical Council (GMC).\u000d\u000a    The period of the grant was January 2010-October 2011.\u000d\u000a    The value of the grant was &#163;101,380.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    Sources to corroborate the impact include:\u000d\u000a    A. An electronic file summarising the impact of the study in the media,\u000d\u000a      providing newspaper\u000d\u000a      clippings and details of the study being included in print media, online\u000d\u000a      and on the radio; and\u000d\u000a      audiofiles of Professor Avery being interviewed on BBC Radio 2 and Radio\u000d\u000a      4.\u000d\u000a    B. Letter from President of the GMC, on the impact of the PRACtICe study\u000d\u000a      on their policies*.\u000d\u000a    C. Letter from Chair of College Council, RCGP, on the impact of the\u000d\u000a      PRACtICe study on changes\u000d\u000a      to the RCGP curriculum, development of electronic learning materials, and\u000d\u000a      changes to MRCGP\u000d\u000a      examinations*.\u000d\u000a    D. Details of changes to the RCGP Curriculum specifically made as a\u000d\u000a      result of the\u000d\u000a      recommendations arising from our GMC-funded report.\u000d\u000a    E. Evidence presented in Pulse detailing the changes made to the\u000d\u000a      TPP SystmOne GP computer\u000d\u000a      systems specifically attributed to the findings of the GMC-funded report:\u000d\u000a      http:\/\/www.pulsetoday.co.uk\/tpp-upgrades-practice-systems-in-wake-of-gmc-prescribing-error-report\/14447023.article\u000d\u000a        (PDF supplied)\u000d\u000a    F. eLearning materials developed as a result of the PINCER study:\u000d\u000a      http:\/\/www.pulse-learning.co.uk\/commissioning-modules\/commissioning\/how-we-reduced-prescribing-errors-with-pharmacists-support\u000d\u000a       (PDF\/Screenshot provided)\u000d\u000a    G. Details showing how general practices can download the computer\u000d\u000a      queries used in the\u000d\u000a      PINCER trial:\u000d\u000a    a. Rodgers S. New PINCER Query Library Tool to support safer prescribing,\u000d\u000a      Prescriber\u000d\u000a      2013; 24(6): 11-14 (19 March 2013) DOI: 10.1002\/psb.1027\u000d\u000a      http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/psb.1027\/pdf\u000d\u000a        (PDF Supplied)\u000d\u000a    b. Rodgers S. Five steps to reducing prescribing errors using PINCER.\u000d\u000a      Pulse Today 12\u000d\u000a      February 2013 http:\/\/www.pulsetoday.co.uk\/your-practice\/practice-topics\/it\/-five-steps-to-reducing-prescribing-errors-using-pincer\/20001835.article\u000d\u000a        (PDF supplied)\u000d\u000a    H. Log from PRIMIS showing the number and distribution of general\u000d\u000a      practices downloading the\u000d\u000a      PINCER trial computer queries in the first 8 weeks plus cumulative data\u000d\u000a      showing the number of\u000d\u000a      downloads for February &#8212; July 2013.\u000d\u000a    I. Letter from Chief Pharmaceutical Officer, Department of Health,\u000d\u000a      England, on the impact of the\u000d\u000a      PRACtICe study and PINCER trial*. Minutes from RCGP Curriculum Group\u000d\u000a      meeting 15 June\u000d\u000a      2012 outlining actions to be taken as a result of the recommendations\u000d\u000a      arising from the\u000d\u000a      PRACtICe study report.\u000d\u000a    *Corroborative factual statements &#8212; letters are on file and available on\u000d\u000a      request.\u000d\u000a    ","Title":"\u000d\u000a    Implementing strategies for reducing prescribing errors in general\u000d\u000a        practices\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The PRACtICe study (2010-11)[1,2,3] has provided much-needed evidence on\u000d\u000a      the prevalence and\u000d\u000a      causes of prescribing errors in general practices, while the PINCER trial\u000d\u000a      (2006-10)[4] has\u000d\u000a      demonstrated an effective method for reducing the prevalence of errors.\u000d\u000a    The aim of the PRACtICE study was to determine the prevalence and nature\u000d\u000a      of prescribing errors\u000d\u000a      in general practice; to explore the causes, and to identify defences\u000d\u000a      against error. The methods\u000d\u000a      included: 1) Two systematic reviews; 2) Retrospective review of unique\u000d\u000a      medication items\u000d\u000a      prescribed over a 12 month period to a 2% random sample of patients from\u000d\u000a      15 general practices in\u000d\u000a      England; 3) Interviews with 34 prescribers and six focus groups involving\u000d\u000a      46 primary health care\u000d\u000a      team members.\u000d\u000a    The study involved examination of 6,048 unique prescription items for\u000d\u000a      1,767 patients. Prescribing\u000d\u000a      or monitoring errors were detected in one in twenty of all prescription\u000d\u000a      items. The following factors\u000d\u000a      were associated with increased risk of prescribing or monitoring errors:\u000d\u000a      male gender, age less than\u000d\u000a      15 years or greater than 64 years, number of unique medication items\u000d\u000a      prescribed, and being\u000d\u000a      prescribed preparations in certain therapeutic areas.\u000d\u000a      A wide range of underlying causes of error was identified. In particular,\u000d\u000a      a lack of focus on\u000d\u000a      therapeutics and safe prescribing skills was highlighted in GP training,\u000d\u000a      and deficiencies were found\u000d\u000a      with the design of computerised prescribing systems in general practices.\u000d\u000a      Also, general practices\u000d\u000a      did not have reliable systems for detecting and correcting errors once\u000d\u000a      they had occurred.\u000d\u000a    A number of strategies were identified for reducing prescribing errors in\u000d\u000a      general practices and\u000d\u000a      these include improvements to GP training, improvements to GP computer\u000d\u000a      systems, and the\u000d\u000a      introduction of better systems for detecting and correcting errors (as\u000d\u000a      demonstrated in the PINCER\u000d\u000a      trial [4]).\u000d\u000a    The aim of the PINCER trial was to determine the effectiveness,\u000d\u000a      costs\/benefits and acceptability of\u000d\u000a      a complex pharmacist-led IT-based intervention compared with simple\u000d\u000a      feedback in reducing rates\u000d\u000a      of prescribing and monitoring errors in general practice.\u000d\u000a      PINCER was a cluster randomised controlled trial which incorporated a\u000d\u000a      health economic analysis,\u000d\u000a      embedded longitudinal qualitative analysis, and process analysis of\u000d\u000a      pharmacists' interventions.\u000d\u000a      The control practices received computer-generated simple feedback for\u000d\u000a      patients at-risk of\u000d\u000a      hazardous prescribing. The intervention practices received feedback,\u000d\u000a      educational outreach and\u000d\u000a      dedicated support from a pharmacist.\u000d\u000a    Seventy-two practices were randomised. At 6 months follow-up, patients in\u000d\u000a      the intervention group\u000d\u000a      were up to 50% less likely to have one of a range of 10 prescribing or\u000d\u000a      monitoring errors. Economic\u000d\u000a      modelling showed that the PINCER intervention increased health gain at a\u000d\u000a      cost per QALY well\u000d\u000a      below the National Institute for Health and Care Excellence (NICE)\u000d\u000a      threshold.\u000d\u000a    University of Nottingham colleagues involved in the PINCER trial were\u000d\u000a      Tony Avery (chief\u000d\u000a      investigator) Sarah Rodgers (trial manager), Sarah Armstrong (trial\u000d\u000a      statistician), Denise Kendrick\u000d\u000a      and Rachel Elliott (health economist). Professor Avery also led the\u000d\u000a      PRACtICe study, and other\u000d\u000a      University of Nottingham colleagues involved were Sarah Armstrong and Raj\u000d\u000a      Mahta (statisticians).\u000d\u000a      The PINCER trial involved in the universities of Manchester and Edinburgh;\u000d\u000a      the PRACtICe study\u000d\u000a      involved University College London, and the universities of Hertfordshire\u000d\u000a      and Reading.\u000d\u000a    "},{"CaseStudyId":"28197","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    See numbered corroborating sources (S) in section 5.\u000a    Traditionally, assessment of quality of care in health services has been\u000a      limited to professional\u000a      perspectives, with little central collection of data and minimal\u000a      consideration of patient perspectives\u000a      on service delivery. We ensured that patients were at the heart of quality\u000a      improvement activities,\u000a      through the development, validation and implementation of measures of\u000a      patient experience, and\u000a      their adoption and collection on a national scale. Our impact has been to\u000a      raise the profile of patient\u000a      experience and link it to quality improvement activity across the UK.\u000a    Raising the profile of patient experience\u000a    Policy documents have highlighted the critical role of information on\u000a      patient experience. The White\u000a      Paper `Equity and excellence: Liberating the NHS' (S1) sought to\u000a      `encourage more widespread use\u000a      of patient experience surveys and real-time feedback' to inform choice and\u000a      drive quality\u000a      improvement.\u000a    The NHS centralised the use of standardised measures in the assessment of\u000a      patient experience in\u000a      2007-2008, sending our GPPS measure to samples of patients in a rolling\u000a      programme of quality\u000a      measurement. This has resulted in GPPS being completed by millions of\u000a      patients, with their views\u000a      assessed and analysed on a large scale and a sustained basis over time\u000a      (S2).\u000a    Collection of data on patient experience is not simply for the benefit of\u000a      managers and policy\u000a      makers. All NHS patients can now access information on GPPS scores of\u000a      their local general\u000a      practices from a website (www.gp-patient.co.uk\/faq\/accessing\/),\u000a      to help them assess the quality of\u000a      care and make choices about local services.\u000a    Linking patient experience to quality improvement\u000a    Much research has shown how simple provision of information is\u000a      insufficient for securing change.\u000a      To ensure appropriate impact from patient experience measures, in 2004,\u000a      use of one of our earlier\u000a      patient experience measures (GPAQ) was linked to payments in the early\u000a      version of the Quality\u000a      and Outcomes Framework (QOF).\u000a    The QOF represents a unique programme for quality improvement and the\u000a      results have been of\u000a      interest worldwide. Early in the development of the QOF, general\u000a      practitioners were incentivised to\u000a      conduct surveys on their practice population, and to respond to these\u000a      surveys with appropriate\u000a      quality improvement activities to enhance patient experience and ensure\u000a      that their services were\u000a      responsive to the needs of their local population. Between 2004 and 2009,\u000a      the vast majority of\u000a      practices (&gt;90%) undertook such activities.\u000a    To support this activity and enhance value for money, we disseminated\u000a      written guidance for\u000a      practitioners to interpret the GPAQ data and use it to target these\u000a      quality improvement activities at\u000a      a local level (S3). Twenty three thousand copies of the guidance were\u000a      disseminated, to stimulate\u000a      and guide quality improvement across the United Kingdom.\u000a    Although initial incentives linked to patient experience were largely for\u000a      the use of surveys, later\u000a      versions of the QOF significantly raised the level of achievement\u000a      required. In 2009, &#163;68 million\u000a      pounds worth of general practitioners' pay were linked to actual patient\u000a      reports of their ability to\u000a      gain ready access to care, such as getting an urgent appointment and being\u000a      able to book ahead\u000a      (S1). These targets were harder to meet, with around 70% of practices\u000a      achieving maximum\u000a      performance on these more stringent targets between 2010 and 2012.\u000a    The national regulator, the Care Quality Commission (CQC) used patient\u000a      experience scores as\u000a      part of their performance assessment of Primary Care Trusts undertaken by\u000a      the predecessor of the\u000a      CQC (the Health Care Commission). Current CQC documentation includes\u000a      patient experience\u000a      surveys as an indicator of standards to be expected of all GP practices\u000a      (S4,S5).\u000a    Department of Health reports list the other activities it has conducted\u000a      in response to the data\u000a      collected by patient surveys, including the GPPS (S6,S7). This has ranged\u000a      from public\u000a      dissemination to encourage responsiveness of patient experience among\u000a      Primary Care Trusts,\u000a      review of the needs of marginalised groups such as ethnic minorities, and\u000a      establishment of teams\u000a      to respond to practices and PCTs with the lowest scores.\u000a    ","ImpactSummary":"\u000a    Improving patient experience of health services is a policy priority\u000a      worldwide. The University of\u000a      Manchester (UoM) has conducted research on patient experience since 1995,\u000a      leading to the\u000a      development of a series of validated measures for assessing patient\u000a      experience of quality of care\u000a      in primary care, including access to care and the degree to which services\u000a      are patient-centred. Our\u000a      measures have been in routine use in the NHS since 2004, sent to samples\u000a      of several million\u000a      patients. The data have been used to provide incentives for the highest\u000a      quality practices, and to\u000a      inform policy makers about current care throughout the UK.\u000a    ","ImpactType":"Health","Institution":"\u000a    the University of Manchester\u000a    ","Institutions":[{"AlternativeName":"Manchester (University of)","InstitutionName":"University of Manchester","PeerGroup":"A","Region":"North West","UKPRN":10007798}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Mead N, Bower P (2000). Patient-centredness: a\u000a      conceptual framework and review of the\u000a      empirical literature. Social Science &amp; Medicine 51:1087-1110.\u000a      DOI: 10.1016\/S0277-9536(00)00098-8\u000a    \u000a\u000a2. Chapple A, Campbell S, Rogers A, Roland M (2002).\u000a      Users' understanding of medical\u000a      knowledge in general practice. Social Science &amp; Medicine\u000a      54:1215-1224. DOI:\u000a      10.1016\/S0277-9536(01)00091-0\u000a    \u000a\u000a3. Cheraghi-Sohi S, Hole A, Mead N, McDonald R, Whalley\u000a      D, Bower P, et al (2007). What\u000a      Patients want from Primary Care Consultations. A Discrete Choice\u000a      Experiment to Identify\u000a      Patients' Priorities. The Annals of Family Medicine 6:107-115.\u000a      DOI: 10.1370\/afm.816\u000a    \u000a\u000a4. Campbell J, Smith P, Nissen S, Bower P, Elliott M, Roland\u000a      M (2009). The GP Patient\u000a      Survey for use in primary care in the National Health Service in the UK -\u000a      development and\u000a      psychometric characteristics. BMC Family Practice 10: DOI:\u000a      10.1186\/1471-2296-10-57\u000a    \u000a\u000a5. Bower P, Roland M, Campbell J, Mead N (2003).\u000a      Setting standards based on patients'\u000a      views on access and continuity: secondary analysis of data from the\u000a      general practice\u000a      assessment survey. BMJ 326:258. DOI:\u000a      10.1136\/bmj.326.7383.258\u000a    \u000a\u000a6. Campbell S, Reeves D, Kontopantelis E, Sibbald B, Roland\u000a      M (2009). Effects of pay for\u000a      performance on the quality of primary care in England. The New England\u000a        Journal of\u000a        Medicine 361:368-378. DOI: 10.1056\/NEJMsa0807651\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000a    S1. Department of Health (2010). Equity and excellence: liberating\u000a        the NHS, The Stationery\u000a      Office, London\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/213823\/dh_117794.pdf\u000a    S2. Roland M, Elliott M, Lyratzopoulos G, Barbiere J, Parker R,\u000a      Smith, P, Bower P, Campbell J\u000a      (2009). Reliability of patient responses in pay for performance schemes:\u000a      analysis of national\u000a      General Practitioner Patient Survey data in England. BMJ. 339:b3851.\u000a      DOI: 10.1136\/bmj.b3851\u000a    S3. Carter M, Roland M, Bower P, Greco M, Jenner D\u000a      (2004). Improving your practice with\u000a      patient surveys. University of Manchester. NPCRDC\/CFEP.\u000a    S4. Care Quality Commission (2010). Essential standards of Quality and\u000a      Safety.\u000a      http:\/\/www.cqc.org.uk\/sites\/default\/files\/media\/documents\/gac_-_dec_2011_update.pdf\u000a    S5. Care Quality Commission (2013). What standards you have a right to\u000a      expect from the\u000a      regulation of your GP practice.\u000a      http:\/\/www.cqc.org.uk\/sites\/default\/files\/media\/documents\/standards_to_expect_gp.pdf\u000a    S6. Department of Health (2011). GP patient survey: guidance 2007\/08 for\u000a      strategic health\u000a      authorities, primary care trusts and GP practices.\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@en\/documents\/digitalasset\/dh_081109.pdf\u000a    S7. Data on the use of patient experience surveys by general practices\u000a      and associated\u000a      incentives within each year the Quality and Outcomes Framework can be\u000a      found\u000a      http:\/\/qof.hscic.gov.uk\/index.asp\u000a    \u000a    ","Title":"\u000a    Assessment of patient experience of NHS primary care services\u000a    ","UKLocation":[{"GeoNamesId":"2643123","Name":"Manchester"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    See numbered references in section 3.\u000a    The impact case is based on research that took place at the UoM from\u000a      2000-2011. The research\u000a      was conducted by the National Primary Care Research and Development Centre\u000a      (NPCRDC), a\u000a      Department of Health-funded policy research unit at the UoM. The key\u000a      researchers were:\u000a    \u000a      \u000aPeter Bower (Professor of Health Services Research, 1995-date)\u000a      \u000aStephen Campbell (Professor of Primary Care Research,\u000a        1993-date)\u000a      \u000aSudeh Cheraghi-Sohi (Research Fellow, 2004-date)\u000a      \u000aNicola Mead (Research Fellow, 1999-2010)\u000a      \u000aDavid Reeves (Reader in Statistics, 2001-date)\u000a      \u000aMartin Roland (Professor of General Practice, 1992-2009)\u000a    \u000a    A key aim of NPCRDC was to develop methods to assess and improve quality\u000a      of care for patients\u000a      in primary health care settings. Quality of health care for individual\u000a      patients can be judged in terms\u000a      of ready access to care, and the effectiveness of care once it is\u000a      accessed. Although scientific\u000a      evidence and clinical consensus are both important methods of determining\u000a      quality, there is\u000a      increasing agreement that a comprehensive assessment of quality needs\u000a      consideration of the\u000a      views and experience of patients.\u000a    However, reliable, valid and useable assessments of the patient\u000a      experience have not always been\u000a      available, which has meant that the patient voice has been largely missing\u000a      from the quality\u000a      improvement agenda.\u000a    Our work involved multidisciplinary research on theory, in-depth\u000a      qualitative work with patients, and\u000a      large-scale quantitative evaluations. Key contributions are detailed\u000a      below:\u000a    \u000a      We defined the core dimensions of patient-centredness (1).\u000a      We investigated how patients make judgments about quality of care,\u000a        assessing the\u000a        dimensions they can judge effectively, and those (such as clinical\u000a        quality of care) that may\u000a        be better assessed by other quality improvement methods (2). We also\u000a        considered the\u000a        relative priority that patients place on different aspects of care (3)\u000a        to help decision-makers\u000a        respond more effectively.\u000a      We designed a series of measures to provide reliable and valid\u000a        assessments of patient\u000a        experience of care. We progressively tested and refined these measures,\u000a        through ongoing\u000a        empirical and psychometric validation work, ending in the development of\u000a        the General\u000a        Practice Patient Survey (GPPS) (4).\u000a      We used our measures in a series of high impact research studies\u000a        exploring quality of care\u000a        in primary care and the determinants of quality. This approach enabled\u000a        us to better inform\u000a        policy makers about current deficits in care as experienced by patients.\u000a        For example, we\u000a        demonstrated the mismatch between the expectations of patients and\u000a        policy makers for\u000a        standards of service in general practice (5). Following the introduction\u000a        of a world-leading\u000a        pay-for-performance scheme in the UK (the Quality and Outcomes\u000a        Framework, or QoF),\u000a        and consequent improvements in the quality of clinical care, we also\u000a        demonstrated that\u000a        patient experience of continuity of care was worsening over time (6).\u000a      We worked closely with policy makers at the Department of Health to\u000a        develop methods to\u000a        use the products of this research programme within new incentive systems\u000a        for practitioners\u000a        to drive improvements in quality of care.\u000a    \u000a    "},{"CaseStudyId":"28198","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    See numbered references in section 3 with corroborating sources (S) in\u000a      section 5.\u000a    Context\u000a      The Department of Health allocates the National Health Service budget (&#163;85\u000a      billion in 2011\/12) to local commissioning organisations (Primary Care\u000a      Trusts, Clinical Commissioning Groups) on the basis of a funding formula,\u000a      which is designed to meet two objectives: (i) to secure equal opportunity\u000a      of access to healthcare for people at equal risk and (ii) to contribute to\u000a      the reduction of avoidable inequalities in health. There are separate\u000a      sub-formulae for different types of services (acute, maternity, mental\u000a      health, prescribing by GPs and primary medical services), each containing\u000a      elements to reflect variations in population size, population needs (age,\u000a      morbidity and socio-economic deprivation) and expected input prices. In\u000a      addition, there was a specific adjustment for health inequalities until\u000a      March 2013, which has now been passed to Local Government.\u000a    Pathways to Impact\u000a      A standing, independent expert body, the Advisory Committee on Resource\u000a      Allocation (ACRA), supported by a Technical Advisory Group (TAG), makes\u000a      recommendations to the Secretary of State for Health on changes to the\u000a      funding formula. Based on this formula, the Department of Health issues\u000a      annual allocations to local commissioning organisations (PCTs or CCGs).\u000a      The Department of Health commissions academic research on behalf of ACRA\u000a      to review the existing formulae and propose new needs-based estimates for\u000a      each local area. This approach ensures that the formula and the budget\u000a      shares for each area that result from it are independently produced and\u000a      based on cutting-edge research methods and evidence.\u000a    Reach and Significance of the Impact\u000a    In their report issued in December 2008, ACRA recommended changes to the\u000a    funding formula that included:\u000a    \u000a       adoption of the research team's recommendation to no longer apply the\u000a        Staff Market Forces Factor to expenditure on medical staff and the MFF\u000a        adjustments calculated by the research team (1);\u000a       adoption of needs estimates produced by the research team using\u000a        utilisation models for acute, maternity and GP prescribing rather than\u000a        prevalence-based estimates for the reasons described in publication (2).\u000a    \u000a    These recommendations were accepted and used by the Department of Health\u000a      when setting the 2009\/10 and 2010\/11 allocations to Primary Care Trusts.\u000a    For the 2011\/12 allocations, ACRA recommended:\u000a    \u000a       that there was currently no technical basis upon which to base the\u000a        weighting applied to the Health Inequalities Adjustment (3);\u000a       adoption of the needs estimates produced in the Report of the\u000a          Resource Allocation for Mental Health and Prescribing (RAMP) Project\u000a        for mental health services and for GP Prescribing (4).\u000a    \u000a    When setting the 2011\/12 allocations for Primary Care Trusts, the\u000a      Department of Health accepted ACRA's recommendation to adopt the RAMP\u000a      project estimates and reduced the weighting of the Health Inequalities\u000a      Adjustment from 15% to 10%.\u000a    The impact of this adoption of the research findings by the Department of\u000a      Health is for some PCTs to receive larger increases in their budget\u000a      compared to others. This approach contributes to the NHS objectives to\u000a      achieve equity in access to services and outcomes. Specifically, the\u000a      impact of adopting the mental health needs component from publication 4\u000a      was to change total PCTs budgets by an average of 1.2%, with the largest\u000a      increase of 4.0% for Islington PCT and the largest decrease of 3.1% for\u000a      Tower Hamlets PCT. The impact on total PCT budgets of adopting the changes\u000a      to the prescribing formula in publication 4 was smaller, with an average\u000a      change of 0.2% and range of changes between -0.7% (Isle of Wight PCT) and\u000a      +0.7% (Blackburn with Darwen Teaching Care Trust). The impact of the\u000a      changes to the weighting of the Health Inequalities Adjustment was larger,\u000a      with an average change in total budget of 1.5% and range of changes\u000a      between -3.9% (Tower Hamlets PCT) and +3.9% (Surrey PCT).\u000a    The needs-weighted population figures derived for the funding formula are\u000a      also used extensively by the Department of Health and NHS organisations\u000a      when benchmarking levels of activity and expenditure and setting other\u000a      budgets at PCT and general practice level (for example, the Programme\u000a      Budgeting Benchmarking Tool).\u000a    ","ImpactSummary":"\u000a    The Department of Health seeks to distribute the NHS budget to local\u000a      commissioning organisations to achieve equal access for equal need and\u000a      reduce health inequalities. The formula upon which it bases this\u000a      distribution must be evidence-based, robust and up-to-date. We summarise\u000a      four pieces of applied econometric research undertaken at the University\u000a      of Manchester (UoM) and commissioned by the Department of Health that have\u000a      developed the methodology for setting budgets fairly and determined the\u000a      content of the formula in use in England from 2008-date. Adoption of the\u000a      findings of this research by government has led to a substantial\u000a      redistribution of NHS funding between areas.\u000a    ","ImpactType":"Political","Institution":"\u000a    The University of Manchester\u000a    ","Institutions":[{"AlternativeName":"Manchester (University of)","InstitutionName":"University of Manchester","PeerGroup":"A","Region":"North West","UKPRN":10007798}],"Panel":"A         ","PlaceName":[],"References":"\u000a    The research was published in leading international peer-reviewed\u000a      journals. The project reports, once reviewed and approved by the Secretary\u000a      of State for Health's Advisory Committee on Resource Allocation\u000a      and its Technical Advisory Group, are published in the Department\u000a      of Health's online library of key Resource Allocation Research Papers.\u000a    Key publications\u000a    \u000a1. Elliott R, Ma A, Sutton M, Skatun D, Rice N, Morris S,\u000a      McConnachie A. The role of the staff MFF in distributing NHS funding:\u000a      taking account of differences in local labour market conditions. Health\u000a        Economics 2010;19(5):532-48. DOI: 10.1002\/hec.1489\u000a    \u000a\u000a2. Vallejo-Torres L, Morris S, Carr-Hill RA, Dixon P, Law MR, Rice N, Sutton\u000a        M. Can regional resource shares be based only on prevalence data? An\u000a      empirical investigation of the proportionality assumption. Social\u000a        Science &amp; Medicine 2009;69(11):1634-42. DOI:\u000a      10.1016\/j.socscimed.2009.09.020\u000a    \u000a\u000a3. Morris S, Sutton M, Dixon P, Wildman J, Birch S, Raine\u000a      R, Chandola T, Orr S, Jit M, Wolff J, Atkinson S, Marmot M. Research on\u000a      the health inequalities elements of the NHS weighted capitation formula.\u000a      Final Report. October 2010. Resource Allocation Research Paper 36\u000a      [accessed 8 Jul 2013]. Available\u000a      from:http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_122620.pdf\u000a    \u000a\u000a4. Sutton M, Whittaker W, Morris S, Glover G, Dusheiko M,\u000a      Wildman J, Gravelle H, Burrows S, Simpson J, F&#233;-Rodr03afguez E, Birch\u000a        S, Smith PCS. Report of the Resource Allocation for Mental health\u000a      and Prescribing (RAMP) Project. Report to the Department of Health.\u000a      December 2010. Resource Allocation Research Paper 35 [accessed 8 July\u000a      2013]. Available from: http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/\u000a      http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_\u000a        122619.pdf\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000a    The publication of the commissioned reports in the Department of Health's\u000a      online library of Resource Allocation Research Papers demonstrates that\u000a      these are key elements of the evidence-base on which decisions on the\u000a      funding formula have been made.\u000a    Publication 4 was explicitly cited in three places as the source for the\u000a      formulae for mental health services and prescribing by General\u000a      Practitioners in The Department of Health's publication explaining the\u000a      changes it had made to the formula for Primary Care Trust allocations in\u000a      the 2011\/12 financial year. See: Department of Health. Resource\u000a        Allocation: Weighted Capitation Formula. Seventh Edition. February\u000a      2011.\u000a      http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_124946\u000a    The same Department of Health publication explicitly confirms that the\u000a      Department of Health's decisions for the allocations since 2008\/9 to (i)\u000a      no longer apply the Staff Market Forces Factor adjustment to spend on\u000a      doctors and hospital dentists was based on the research that was published\u000a      in (1) and (ii) base the needs components on utilisation-models rather\u000a      than prevalence estimates was based on the research that was published as\u000a      publication 2. It also confirms that the relative weighting of the Health\u000a      Inequalities Adjustment could not be determined technically because of the\u000a      research published as publication 3.\u000a    ","Title":"\u000a    Needs-based formulae for distributing NHS resources\u000a    ","UKLocation":[{"GeoNamesId":"2655524","Name":"Blackburn"},{"GeoNamesId":"2646003","Name":"Islington"},{"GeoNamesId":"2651495","Name":"Darwen"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    See numbered references in section 3.\u000a    The impact is based on research that has been undertaken at the UoM with\u000a      national collaborators from 2008-date, with the key publications in 2010.\u000a      The key researchers are:\u000a    \u000a       Matthew Sutton (Professor of Health Economics, 2008-date)\u000a       Stephen Birch (Professor of Health Economics, 2004-date)\u000a       William Whittaker (Research Fellow, 2008-date)\u000a    \u000a    The aim of the research was (and continues to be) to develop the methods\u000a      used to estimate the formula for allocating the NHS budget to local health\u000a      care commissioning organisations. These econometric methods are applied to\u000a      national datasets to derive up-to-date shares of resources for each\u000a      organisation that reflect their population size, demographic composition,\u000a      morbidity and socio-economic deprivation, and expected input prices. The\u000a      main contributions since 2008 have been:\u000a    \u000a       To test the General Labour Market theory and method that underpins\u000a        the adjustment for variations in the expected costs of labour (called\u000a        the Staff Market Forces Factor), which has been used in the English NHS\u000a        funding formula for almost 30 years. The first publication (below)\u000a        derived from a commissioned report for the Department of Health,\u000a        involved analysis of spatial variations in vacancy rates, and found\u000a        empirical evidence to support the theory for nurses but not for medical\u000a        staff (1).\u000a       To review whether funding shares should be based on disease\u000a        prevalence rather than needs estimates derived from regression models of\u000a        variations in the utilisation of health care services to better reflect\u000a        unmet need. Publication 2 derived from a commissioned report for the\u000a        Department of Health, showed that there were methodological flaws as\u000a        well as data availability problems with the prevalence-based approach.\u000a        The proportionality assumption underpinning the prevalence-based\u000a        approach was shown not to hold and adoption of this approach would\u000a        under-allocate resources to rural areas, areas with younger populations,\u000a        and deprived areas (2).\u000a       To review the approach taken in the English formula to meet its\u000a        objective to contribute to the reduction of avoidable inequalities in\u000a        health. In a report to the Department of Health (3), we highlighted the\u000a        current lack of clarity in the distinction between the two objectives\u000a        for the English funding formula and the purpose of the current Health\u000a        Inequalities Adjustment, and the lack of a good evidence-base for making\u000a        such an adjustment.\u000a       To derive in a report to the Department of Health (4) improved\u000a        formulae for mental health services and prescribing by General\u000a        Practitioners using more robust econometric methods, a wider range of\u000a        variables, and more up-to-date data. We derived age-stratified models\u000a        for mental health and prescribing formulae that were robust to the\u000a        choice of population base.\u000a    \u000a    Collaboration and Sustained Contribution\u000a      Sutton has undertaken research to improve the funding formulae used\u000a      for the NHS in England and Scotland continuously since 1998. He has\u000a      first-authored or co-authored six of the 11 Resource Allocation Research\u000a      Papers published by the English Department of Health since 2002. All of\u000a      this work has been undertaken in collaboration with researchers from other\u000a      UK Universities, with Sutton taking the first or second project\u000a      leadership role.\u000a    The research programme is ongoing, with recent grants from the Department\u000a      of Health to develop formulae for setting budgets for Clinical\u000a      Commissioning Groups for hospital and community health services and mental\u000a      health services. These more local, non-geographically defined,\u000a      commissioning organisations have required development of a Person-Based\u000a      Resource Allocation approach.\u000a    "},{"CaseStudyId":"28199","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2921044","Name":"Germany"}],"Funders":[],"ImpactDetails":"\u000a    See numbered corroborating sources in section 5.\u000a    NPCRDC's research has had a substantial and ongoing impact on the\u000a      pay-for-performance\u000a      scheme in UK general practice, known as the QOF. This scheme covers all\u000a      general practices in\u000a      the UK, shaping the care they provide to all patients with one of the\u000a      common chronic illnesses\u000a      covered by the QOF (e.g. asthma, cardiovascular disease, diabetes).\u000a    1) Design and test new quality indicators\u000a    From 2009 NICE formally adopted the protocol developed by the NPCRDC to\u000a      test and validate\u000a      new indicators for inclusion in the national UK Quality and Outcomes\u000a      Framework (S1). Piloting\u000a      new indicators before roll out nationally has proved value for money as it\u000a      identifies potential\u000a      problems with reliability, feasibility, acceptability and unintended\u000a      consequences, and can also\u000a      identify indicators that should not be included because they may cause\u000a      harm to patients. The\u000a      cost of piloting a new indicator is &#163;150,000 which is only 0.0005% of the\u000a      overall cost of\u000a      &#163;1billion, which the government spends on the QOF each year.\u000a    2) Revise and retire existing indicators\u000a    From 2010 the framework developed by NPCRDC for revising and removing\u000a      indicators from\u000a      pay-for-performance schemes was adopted by NICE and NHS Employers to\u000a      inform their\u000a      annual reviews of the QOF. For example, our methodology led to the\u000a      retirement of 12 quality\u000a      indicators in April 2011 and 7 quality indicators in April 2012 (S1).\u000a    3) Structure pay-for-performance schemes to maximise quality and\u000a        minimise harm\u000a    NPCRDC research into exception reporting (i.e. allowing clinicians to\u000a      exempt patients from\u000a      quality indicator measurement where they believe the indicator is not\u000a      appropriate for the\u000a      individual patient) has demonstrated that it protects patients from\u000a      inappropriate care without\u000a      triggering widespread fraudulent behaviour by providers. This research\u000a      provided the evidence-base\u000a      supporting the case for retaining exception reporting within the QOF (S1)\u000a      in the face of\u000a      opposition to the provision, and has informed the international debate\u000a      about the need for an\u000a      exception reporting provision in physician incentive schemes (S2).\u000a    Methodologies developed by NPCRDC for designing and testing new quality\u000a      indicators have\u000a      influenced policy and practice in the USA, Germany and other countries. In\u000a      the USA, our\u000a      methodological work comparing different approaches for aggregating\u000a      indicators into composite\u000a      measures was recommended by the American Medical Association Physician\u000a      Consortium for\u000a      Performance Improvement (S3) and the USA Quality Forum (S4). In Germany,\u000a      our methodologies\u000a      for designing and testing new quality indicators have been adopted by the\u000a      Institute for Applied\u000a      Quality Improvement and Research in Health Care (AQUA-Institute), which\u000a      has been\u000a      commissioned by the German Federal Joint Committee to develop sets of\u000a      quality indicators and\u000a      instruments across both inpatient and outpatient healthcare sectors (S5).\u000a    The need we demonstrated for multilevel approaches to change as part of a\u000a      wider strategy for\u000a      quality improvement was cited in influential policy reviews conducted by\u000a      the World Health\u000a      Organisation (S6), the OECD (S7), and the Commonwealth Fund (S8).\u000a    ","ImpactSummary":"\u000a    Research conducted by the National Primary Care Research and Development\u000a      Centre (NPCRDC)\u000a      at the University of Manchester (UoM) has shaped the design of\u000a      pay-for-performance schemes in\u000a      primary health care in the UK and overseas. Specifically, the NPCRDC\u000a      developed methodologies\u000a      to: 1) design and test new indicators of care quality; 2) revise and\u000a      retire existing indicators; 3)\u000a      structure the financial incentives awarded for indicator achievement to\u000a      maximise quality\u000a      improvement and minimise harm. These methodologies have been implemented\u000a      by the National\u000a      Institute for Health and Care Excellence (NICE) in the UK, where they have\u000a      generated improved\u000a      clinical care and a reduction in inequalities in the quality of care for\u000a      people with common chronic\u000a      conditions (e.g. asthma, cardiovascular disease, diabetes) managed in\u000a      general practice. Findings\u000a      from the research have been disseminated internationally, where they have\u000a      influenced pay-for-performance\u000a      schemes in Germany and the United States of America.\u000a    ","ImpactType":"Health","Institution":"\u000a    The University of Manchester\u000a    ","Institutions":[{"AlternativeName":"Manchester (University of)","InstitutionName":"University of Manchester","PeerGroup":"A","Region":"North West","UKPRN":10007798}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000aThe research was published in high impact health services journals,\u000a      including: Social Science and\u000a      Medicine, Quality &amp; Safety in Health Care and the British Medical\u000a      Journal and is highly cited.\u000a    1. Campbell SM, Roland MO, Buetow SA. Defining quality of\u000a      care. Social Science &amp;\u000a        Medicine 2000;51(11):1611-25. DOI: 10.1016\/S0277-9536(00)00057-5\u000a    \u000a\u000a2. Campbell SM, Braspenning J, Hutchinson A, Marshall MN.\u000a      Research methods used in\u000a      developing and applying quality indicators in primary care. BMJ.\u000a      2003;326(7393):816-9.\u000a      DOI: 10.1136\/bmj.326.7393.816 \/ Campbell SM, Braspenning J,\u000a      Hutchinson A, Marshall\u000a        M. Research methods used in developing and applying quality\u000a      indicators in primary care.\u000a      Quality Safety Health Care. 2002;11(4):358-64. DOI:\u000a      10.1136\/qhc.11.4.358\u000a    \u000a\u000a3. Campbell SM, Kontopantelis E, Hannon K, Burke M,\u000a      Barber A, Lester HE. Framework\u000a      and indicator testing protocol for developing and piloting quality\u000a      indicators for the UK quality\u000a      and outcomes framework. BMC Family Practice. 2011;12:85. DOI:\u000a      10.1186\/1471-2296-12-85\u000a    \u000a\u000a4. Lester H, Schmittdiel J, Selby J, Fireman B, Campbell S,\u000a      Lee J, et al. The impact of\u000a      removing financial incentives from clinical quality indicators:\u000a      longitudinal analysis of four\u000a      Kaiser Permanente indicators. BMJ. 2010;340:c1898. DOI:\u000a      10.1136\/bmj.c1898\u000a    \u000a\u000a5. Reeves D, Doran T, Valderas JM, Kontopantelis E,\u000a      Trueman P, Sutton M, et al. How to\u000a      identify when a performance indicator has run its course. BMJ.\u000a      2010;340:c1717. DOI:\u000a      10.1136\/bmj.c1717\u000a    \u000a\u000a6. Doran T, Kontopantelis E, Fullwood C, Lester H, Valderas\u000a        JM, Campbell S. Exempting\u000a      dissenting patients from pay for performance schemes: retrospective\u000a      analysis of exception\u000a      reporting in the UK Quality and Outcomes Framework. BMJ.\u000a      2012;344:e2405. DOI:\u000a      10.1136\/bmj.e2405\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000a    S1. Letter from NICE (G Leng) attesting to NPCRDC role and influence in\u000a      QOF indicator\u000a      piloting and removal, and debates about exception reporting.\u000a    S2. Van Herck P, Annemans L, De Smedt D, Remmen R, Sermeus W.\u000a      Pay-for-performance\u000a      step-by-step: introduction to the MIMIQ model. Health Policy.\u000a      2011;102(1):8-17. DOI:\u000a      10.1016\/j.healthpol.2010.09.014\u000a    S3. Physician Consortium for Performance Improvement. Measures\u000a      Development,\u000a      Methodology, and Oversight Advisory Committee: Recommendations to PCPI\u000a      Work Groups\u000a      on Composite Measures, American Medical Association, 2010\u000a    S4. National Quality Forum, Composite Performance Measure Evaluation\u000a      Guidance, National\u000a      Quality Forum, April 8 2013.\u000a    S5. Letter from AQUA Institute in G&#246;ttingen (J Szecenyi) which used a\u000a      modified version of the\u000a      indicator development process as part of the Federal Government work.\u000a    S6. Elovainio E. (2010) Performance incentives for health in high-income\u000a      countries: key issues\u000a      and lessons learned, World health report 2010. Background Paper 32, World\u000a      Health\u000a      Organisation, 2010.\u000a      http:\/\/www.who.int\/healthsystems\/topics\/financing\/healthreport\/32PBF.pdf\u000a    S7. Cashin C et al. (2011) Major Developments in Results-Based Financing\u000a      in OECD\u000a      Countries: Country Summaries and Mapping of RBF Programs. OECD, March 29th\u000a      2011.\u000a    S8. Squires D, Incentivizing Quality Care Through Pay-for-Performance,\u000a      The Commonwealth\u000a      Fund, 2012\u000a    ","Title":"\u000a    Improving quality of care through pay-for-performance\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    See numbered references in section 3.\u000a    The impact is based on research that took place at the UoM from 1995 to\u000a      date, with the first major\u000a      publication in 1998. The key researchers are:\u000a    \u000a      \u000aDavid Reeves (Reader in Statistics, 2001-date)\u000a      \u000aStephen Campbell (Professor of Primary Care Research,\u000a        1993-date)\u000a      \u000aTim Doran (Reader in Health Inequalities, 2004-2013)\u000a      \u000aEvan Kontopantelis (Senior Research Fellow in Statistics,\u000a        2005-date)\u000a      \u000aHelen Lester (Professor of Primary Care, 2006 -2011)\u000a      \u000aMartin Marshall (Professor of General Practice, 2000-2006)\u000a      \u000aMartin Roland (Professor of General Practice, 1992-2009)\u000a      \u000aMatt Sutton (Professor of Health Economics, 2008-date)\u000a      \u000aJose Valderas (Clinical Lecturer in Primary Care, 2007-2010)\u000a    \u000a    The research programme initiated in 1995 has (1) developed measures of\u000a      quality of care in general\u000a      practice (2) described and explained variations in quality and (3)\u000a      developed and tested\u000a      interventions to improve the quality of care. The programme is underpinned\u000a      by a conceptual\u000a      definition of quality of care which showed that quality measurement must\u000a      address clinical\u000a      excellence (e.g. adherence to clinical care standards) as well as patient\u000a      experience, underpinned\u000a      by sound organisational systems and processes for driving quality\u000a      improvement (1).\u000a    Findings from the research informed the design of the Quality and\u000a      Outcomes Framework (QOF) for\u000a      primary care introduced in 2004 in which UK general practices are paid\u000a      according to their\u000a      performance against a range of quality of care indicators. NPCRDC\u000a      evaluated the impact of QOF\u000a      on the clinical quality of care and patient experience in general\u000a      practice, showing that pay-for-performance\u000a      improved clinical quality and reduced inequalities in care but also\u000a      adversely affected\u000a      some aspects of patient experience. The research was published in the\u000a      highest impact journals in\u000a      the field including the New England Journal of Medicine, Annals of Family\u000a      Medicine, British\u000a      Medical Journal, Health Affairs, Journal of the American Medical\u000a      Association and the Lancet.\u000a      This case study describes the impact of research designed to maximise\u000a      improvements in clinical\u000a      quality while minimising the adverse consequences of pay-for-performance\u000a      schemes in general\u000a      practice. Findings from the research shaped subsequent refinements to the\u000a      pay-for-performance\u000a      scheme in UK general practice from 2008 onwards. Specifically NPCRDC\u000a      developed innovative\u000a      methodologies to:\u000a    1) Design and test new quality indicators\u000a    NPCRDC developed a protocol to test and validate new indicators of care\u000a      quality in general\u000a      practice including identifying unintended consequences of their\u000a      implementation such as neglect\u000a      of patients with conditions, or aspects of care, not included in\u000a      pay-for-performance schemes\u000a      (2,3).\u000a    2) Revise and retire existing indicators\u000a    NPCRDC showed that removing quality indicators from a pay-for-performance\u000a      scheme can\u000a      lead to subsequent declines in the quality of care addressed by that\u000a      indicator (4). The\u000a      NPCRDC also developed a framework for assessing when to remove\/retire a\u000a      quality indicator\u000a      from pay-for-performance schemes so as to minimise any decrements in\u000a      quality (5).\u000a    3) Structure pay-for-performance to maximise quality and minimise harm\u000a    NPCRDC showed that, at relatively little financial cost, exception\u000a      reporting (excluding patients\u000a      for whom quality targets are deemed inappropriate or who actively decline\u000a      intervention)\u000a      provides some protection from inappropriate and coercive treatment for\u000a      patients whose\u000a      providers are subject to pay-for-performance schemes (6).\u000a    The research showed that physician incentives provide short-term gains\u000a      and are not a magic bullet\u000a      for quality improvement, nor are they entirely responsive to the complex\u000a      needs of individual\u000a      patients. Rather, it demonstrated the need for multilevel approaches to\u000a      change as part of a wider\u000a      strategy for quality improvement.\u000a    "},{"CaseStudyId":"28200","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"798549","Name":"Romania"},{"GeoNamesId":"3190538","Name":"Slovenia"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"2802361","Name":"Belgium"},{"GeoNamesId":"390903","Name":"Greece"},{"GeoNamesId":"2782113","Name":"Austria"}],"Funders":[],"ImpactDetails":"\u000d\u000a    See numbered corroborating sources (S) in section 5.\u000d\u000a    The European Practice Assessment (EPA) scheme has been used by 1,584\u000d\u000a      practices (1,170 primary care practices) across 7 countries: Germany,\u000d\u000a      Switzerland, Austria, Belgium, Greece, Romania, Slovenia. The scheme and\u000d\u000a      the indicators are available in the following languages: English, Dutch,\u000d\u000a      French, German, Romanian, Slovenian, Greek, Arab and Hebrew. Overall, 507\u000d\u000a      practices have used the EPA scheme (S1).\u000d\u000a    In 2005 the German federal government introduced a regulation which\u000d\u000a      stipulated that all healthcare providers, including general practices, are\u000d\u000a      obliged to implement an annual quality management programme in order to\u000d\u000a      demonstrate compliance with national systems for accountability in\u000d\u000a      healthcare provision. The European Practice Accreditation scheme, designed\u000d\u000a      by NPCRDC with its European partners is one federally approved option for\u000d\u000a      demonstrating compliance in general practice (S2). Implementation was\u000d\u000a      supported by our partners in the University of Heidelberg and the\u000d\u000a      Institute for Applied Quality Improvement and Research in Health Care\u000d\u000a      (AQUA-Institute) in Gottingen. In total 303 primary care practices have\u000d\u000a      used EPA in Germany. 103 of these German general practices used the\u000d\u000a      European Practice Accreditation scheme twice, to measure longitudinal\u000d\u000a      changes in quality improvement over the period 2008-date (S2). Practices\u000d\u000a      showed an overall 10% increase in scores across the domain \"Quality &amp;\u000d\u000a      safety\" including \"complaint management\" (30% increase), \"critical\u000d\u000a      incident analysis\" (10%) and \"quality procedures and policies\" (15%).\u000d\u000a    The methods used to develop the European Practice Assessment for general\u000d\u000a      practice have been applied by the AQUA-Institute to develop a European\u000d\u000a      Practice Assessment scheme for dental healthcare provision in Germany\u000d\u000a      (S3,S4). From 2008, 187 dental healthcare organisations have used the\u000d\u000a      EPA-Dental scheme to assess their quality of care (63 having used it\u000d\u000a      twice). Compared with the comparative group at first assessment, the\u000d\u000a      intervention group at second assessment had significantly better scores\u000d\u000a      for the domains \"infrastructure\" (Intervention group 94.2%, Comparative\u000d\u000a      group 84.0%) and \"quality and safety\" (Intervention group 88.7%,\u000d\u000a      Comparative group 78.1%).\u000d\u000a    In the UK, the General Practice Accreditation scheme developed by the\u000d\u000a      Royal College of General Practitioners in partnership with NPCRDC was\u000d\u000a      implemented in July 2011 and closed to new applicants in February 2013\u000d\u000a      (S5,S6). Upon successful completion, Practice Accreditation is valid for\u000d\u000a      three years. From 2011, 260 of the 8,088 general practices in England have\u000d\u000a      sought accreditation of which 4 have been successful with the remainder\u000d\u000a      ongoing. The scheme consists of six domains with the 78 standards, 42 of\u000d\u000a      which are mapped to processes, protocols and systems that specifically\u000d\u000a      support the requirements of CQC registration. The fulfilment of the RCGP\u000d\u000a      Practice Accreditation scheme will enable practices to demonstrate\u000d\u000a      compliance with the registration requirements of the Care Quality\u000d\u000a      Commission (CQC) which, from April 2013, is responsible for quality of\u000d\u000a      assurance of English primary care.\u000d\u000a    The Irish College of General Practitioners have built on the EPA and RCGP\u000d\u000a      accreditation schemes to develop their own national scheme, and informed\u000d\u000a      European-wide discussions on accreditation as led by EQUIP-WONCA (S7).\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research conducted at the University of Manchester (UoM) has shaped the\u000d\u000a      design of national systems of accreditation for general practice in the\u000d\u000a      UK, Europe and beyond. Accreditation systems set standards that reflect\u000d\u000a      key aspects of the organisational systems and processes in general\u000d\u000a      practice that are needed to ensure delivery of good quality care.\u000d\u000a      Accreditation systems also provide a kite mark of quality assurance and\u000d\u000a      act as a platform for supporting continuous quality improvement. UoM\u000d\u000a      developed indicators of quality in general practice structure and\u000d\u000a      organisation and demonstrated how they could be used effectively to\u000d\u000a      improve quality. Working in partnership with health professional\u000d\u000a      organisations, governmental organisations and other universities, UoM used\u000d\u000a      knowledge from the research to develop systems for general practice\u000d\u000a      accreditation now used in the UK and across Europe.\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    The University of Manchester\u000d\u000a    ","Institutions":[{"AlternativeName":"Manchester (University of)","InstitutionName":"University of Manchester","PeerGroup":"A","Region":"North West","UKPRN":10007798}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2907911","Name":"Heidelberg"}],"References":"\u000d\u000a    \u000aThe research was published in high impact health services journals,\u000d\u000a      including: Social Science and Medicine, the British Medical Journal and\u000d\u000a      the British Journal of General Practice and is highly cited.\u000d\u000a    1. Campbell SM, Roland MO, Buetow SA. Defining quality of care. Social\u000a        Science &amp; Medicine 2000;51(11):1611-25. DOI:\u000d\u000a      10.1016\/S0277-9536(00)00057-5\u000d\u000a    \u000a\u000a2. Campbell SM, Braspenning J, Hutchinson A, Marshall MN.\u000d\u000a      Research methods used in developing and applying quality indicators in\u000d\u000a      primary care. BMJ. 2003;326(7393):816-9. DOI: 10.1136\/bmj.326.7393.816 \/ Campbell\u000a        SM, Braspenning J, Hutchinson A, Marshall M. Research\u000d\u000a      methods used in developing and applying quality indicators in primary\u000d\u000a      care. Qual Saf Health Care. 2002;11(4):358-64. DOI: 10.1136\/qhc.11.4.358\u000d\u000a    \u000a\u000a3. Grol R, Dautzenberg M, Brinkmann H (Eds). Quality Management in\u000d\u000a      Primary Care. G&#252;tersloh: Verlag Bertelsmann Stiflung; 2004.\u000d\u000a      Available from: http:\/\/www.bertelsmann-stiftung.de\/cps\/rde\/xchg\/SID-AE04A872-887BDB39\/bst_engl\/hs.xsl\/publikationen_2725.htm\u000d\u000a    \u000a\u000a4. Engels Y, Campbell S, Dautzenberg M, van den Hombergh P,\u000d\u000a      Brinkmann H, Szecsenyi J, et al. Developing a framework of, and quality\u000d\u000a      indicators for, general practice management in Europe. Family Practice.\u000d\u000a      2005;22(2):215-22. DOI: 10.1093\/fampra\/cmi002\u000d\u000a    \u000a\u000a5. Goetz K, Campbell SM, Steinhaeuser J et al Does a\u000d\u000a      quality management system improve quality in primary care practices?\u000d\u000a      Canadian Medical Association Journal 2011.\u000d\u000a      DOI:10.1503\/cmaj.110412\u000d\u000a    \u000a\u000a6. Campbell SM, Chauhan U, Lester H. Primary Medical Care\u000d\u000a      Provider Accreditation (PMCPA): pilot evaluation. British Journal of\u000d\u000a        General Practice. 2010;60(576):295-304. DOI: 10.3399\/bjgp10X514800\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    S1. http:\/\/www.epa-qm.de\/epa\/front_content.php?idart=218\u000d\u000a    S2. Letter from AQUA Institute in G&#246;ttingen (J Szecenyi) which used a\u000d\u000a      modified version of the indicator development process as part of the\u000d\u000a      Federal Government work.\u000d\u000a    S3. G&#246;tz K, Szecsenyi J, Broge B, Willms S. Welche Wirkung hat\u000d\u000a        Qualit&#228;tsmanagement in Arztpraxen? Ergebnisse aus Entwicklung und\u000d\u000a        Evaluation des Europ&#228;ischen Praxisassessments (EPA). Aqua-Verlag,\u000d\u000a        G&#246;ttingen, 2011\u000d\u000a    S4. Qualit&#228;tsmanagement-Systeme f&#252;r die Zahnarztpraxis.\u000d\u000a      Informationsdienst des Instituts der Deutschen Zahn&#228;rzte (IDZ), K&#246;ln, 2005\u000d\u000a      (ISSN 0931-9816)\u000d\u000a    S5. http:\/\/www.rcgp-practiceaccreditation.org.uk\/CustomPages\/CustomPage.aspx?id=17\u000d\u000a    S6. Letter from RCGP detailing recruitment to practice accreditation\u000d\u000a      scheme.\u000d\u000a    S7. \u000d\u000a        http:\/\/www.topaseurope.eu\/?q=node\/3 for WONCA-EQUIP which notes role\u000d\u000a      of NPCRDC.\u000d\u000a    ","Title":"\u000d\u000a    Improving quality of care through general practice accreditation\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    See numbered references in section 3.\u000d\u000a    The impact is based on research that took place at UoM from 1995 to date,\u000d\u000a      with the first major publication in 1998. The key researchers were:\u000d\u000a    \u000d\u000a      \u000aStephen Campbell (Professor of Primary Care Research,\u000d\u000a        1993-date)\u000d\u000a      \u000aHelen Lester (Professor of Primary Care, 2006-2011)\u000d\u000a      \u000aMartin Marshall (Professor of General Practice, 2000-2006)\u000d\u000a      \u000aMartin Roland (Professor of General Practice, 1992-2009)\u000d\u000a    \u000d\u000a    The work was conducted by the National Primary Care Research and\u000d\u000a      Development Centre (NPCRDC), a Department of Health funded policy research\u000d\u000a      unit based in UoM. The programme of research initiated in 1995 (i)\u000d\u000a      developed measures of quality of care in general practice, (ii) described\u000d\u000a      and explained variations in quality and (iii) developed and tested\u000d\u000a      interventions to improve the quality of care. The programme is underpinned\u000d\u000a      by a conceptual definition of quality of care which showed that quality\u000d\u000a      measurement must address clinical excellence (e.g. adherence to clinical\u000d\u000a      care standards) as well as patient experience, underpinned by sound\u000d\u000a      organisational systems and processes for driving quality improvement (1).\u000d\u000a    This case study describes the impact of research relating to measures of\u000d\u000a      organisational quality. Separate case studies in this UoA describe the\u000d\u000a      impact of research relating to measures of patient experience and clinical\u000d\u000a      excellence.\u000d\u000a    Governments need to have accreditation systems in place to ensure that\u000d\u000a      healthcare provider organisations meet desired standards of care quality\u000d\u000a      and safety. This requires the development of care quality standards and\u000d\u000a      measures that can be applied efficiently to assess whether an organisation\u000d\u000a      has the necessary organisational systems and processes in place to deliver\u000d\u000a      safe and effective care. NPCRDC developed innovative methods to design and\u000d\u000a      test indicators of quality in the organisational systems and processes\u000d\u000a      within general practice that underpin care quality and safety (2).\u000d\u000a    In collaboration with the Universities of Nijmegen and Heidelberg, NPCRDC\u000d\u000a      applied these methods to the development of a European Practice Assessment\u000d\u000a      accreditation scheme suitable for use by general practices across Europe\u000d\u000a      (3,4). The research was funded by the Bertelsmann Foundation. The European\u000d\u000a      Practice Assessment accreditation scheme won the 2009 award of the\u000d\u000a      European Health Forum Gastein. This award, widely regarded as the\u000d\u000a      'European Oscar' for healthcare, is given for major innovations in\u000d\u000a      European healthcare. Subsequent research demonstrated the effectiveness of\u000d\u000a      practice accreditation as a method for driving quality improvement in\u000d\u000a      primary care (5).\u000d\u000a    In the UK, NPCRDC worked in partnership with the Royal College of General\u000d\u000a      Practitioners (RCGP), applying knowledge from the research to the\u000d\u000a      development of a British system of Practice Accreditation (6). The\u000d\u000a      development work was undertaken in close collaboration with the General\u000d\u000a      Medical Council, Royal College of Nursing, Care Quality Commission,\u000d\u000a      Department of Health, NHS Confederation Primary Care Trusts and patient\u000d\u000a      groups to ensure the Practice Accreditation scheme was aligned to the\u000d\u000a      priorities and concerns of other key stakeholders.\u000d\u000a    "},{"CaseStudyId":"29681","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2658434","Name":"Switzerland"}],"Funders":["Wellcome Trust","Medical Research Council"],"ImpactDetails":"\u000d\u000a    In 1993, the health, development and climate consequences of household\u000d\u000a      energy in Lower and\u000d\u000a      Middle Income Countries (LMICs) were barely recognised outside a small\u000d\u000a      number of specialist\u000d\u000a      agencies. The UoL's research has shown that HAP is the 4th most\u000d\u000a      important risk factor globally\u000d\u000a      leading to 4m premature deaths and 11m DALYs. The research has been\u000d\u000a      significant in generating\u000d\u000a      international awareness and mobilising action. The Liverpool WHO CC has\u000d\u000a      had a central advisory\u000d\u000a      role in many initiatives including the (i) United Nations Foundation\u000d\u000a      Global Alliance for Clean\u000d\u000a      Cookstoves (GACC) &#8212; a public-private partnership aiming to secure the\u000d\u000a      health, economic, climate\u000d\u000a      and related benefits of clean cooking, and (ii) the United Nations\u000d\u000a      initiative on Sustainable Energy\u000d\u000a      for All (SE4All). Bruce co-chaired the GACC health working group which\u000d\u000a      informed the strategic\u000d\u000a      plan (Igniting Change, 2011 [8]), Bruce and Pope led an NIH-sponsored\u000d\u000a      workshop (May 2011)\u000d\u000a      informing GACC research agenda, and have consulted on research funding\u000d\u000a      allocation for GACC.\u000d\u000a    The work is influencing global household air pollution initiatives. For\u000d\u000a      example, through secondment\u000d\u000a      with the WHO Public Health and Environment Department (PHE) from 2009 to\u000d\u000a      present, Bruce has\u000d\u000a      contributed to the UN SE4All strategy, including the recently published\u000d\u000a      tracking framework and\u000d\u000a      work to strengthen data collection on household energy use through\u000d\u000a      national surveys including the\u000d\u000a      Demographic and Health Survey. He has also contributed to health impact\u000d\u000a      assessment from\u000d\u000a      climate change mitigation strategies through recently-established\u000d\u000a      collaboration between WHO and\u000d\u000a      the United Nations Environment Programme-led Climate and Clean Air\u000d\u000a      Coalition (CCAC) which is\u000d\u000a      focused on securing climate and health co-benefits of action on\u000d\u000a      short-lived climate pollutants and\u000d\u000a      which builds on UoL's modelling approach. The Executive Director of UN\u000d\u000a      GACC, stated in 2013\u000d\u000a      that \"the University of Liverpool research led by Professor Bruce has\u000d\u000a        spurred global efforts over the\u000d\u000a        past 15 years to quantify and communicate the health burden from\u000d\u000a        household air pollution,\u000d\u000a        particularly in Sub-Saharan Africa and Latin America... it has certainly\u000d\u000a        helped gain commitment for\u000d\u000a        action at the highest levels and will support the development of the\u000d\u000a        clean cookstoves and fuels\u000d\u000a        markets\" [10]. These actions are also leading to health\u000d\u000a      improvements, lower costs for poor\u000d\u000a      families and reducing carbon emissions.\u000d\u000a    Liverpool WHO CC systematic reviews provided estimates of risk for the\u000d\u000a      GBD-2010 study, and\u000d\u000a      intervention effect estimates for several important preventive strategies\u000d\u000a      and tools. These include\u000d\u000a      (i) the Global Action Plan for the Prevention and Control of Pneumonia\u000d\u000a      &amp; Diarrhoea (GAPPD) &#8212; a\u000d\u000a      WHO\/UNICEF initiative integrating evidence-based prevention and treatment\u000d\u000a      measures for the two\u000d\u000a      largest causes of death of children under 5 years, and (ii) the\u000d\u000a      Lives-Saved Tool which is used to\u000d\u000a      prioritise interventions for child and maternal survival and which the UoL\u000d\u000a      has been working on with\u000d\u000a      the Child Health Epidemiology Reference Group (CHERG) since 2009. Bruce\u000d\u000a      served as a key\u000d\u000a      adviser on HAP for both GAPPD and CHERG, and recently served on the expert\u000d\u000a      committee\u000d\u000a      advising the Bill and Melinda Gates Foundation on financing strategy for\u000d\u000a      supporting work on HAP\u000d\u000a      and child pneumonia. The Director of Maternal and Child Health and\u000d\u000a      Development at WHO\u000d\u000a      Geneva, stated in 2013 that \"UoL-led research has been instrumental in\u000d\u000a        developing the\u000d\u000a        environmental component of our integrated strategy for the prevention\u000d\u000a        and control of pneumonia,\u000d\u000a        which remains the single largest global cause of under-5 mortality\"\u000d\u000a      [11].\u000d\u000a    Bruce was a WHO steering group member of WHO's indoor air quality\u000d\u000a      guidelines in 2010 [13]. The\u000d\u000a      Liverpool WHO CC is coordinating new WHO Guidelines on indoor air quality,\u000d\u000a      designed specifically\u000d\u000a      to address the scientific and implementation issues for household fuel\u000d\u000a      combustion with a focus on\u000d\u000a      LMICs. They are in an advanced state of development (publication expected\u000d\u000a      early 2014). Bruce,\u000d\u000a      Pope, Stanistreet and Dherani are on the expert Guidelines Development\u000d\u000a      Group (GDG). The GDG\u000d\u000a      is responsible for defining the guidelines scope, evidence review\u000d\u000a      including methodological quality,\u000d\u000a      and drafting recommendations. The guidelines incorporate much of the UoL's\u000d\u000a      systematic review\u000d\u000a      and primary research (including RESPIRE). The Director of the Department\u000d\u000a      of Public Health and\u000d\u000a      Environment, WHO stated in 2013 \"The University of Liverpool research\u000d\u000a        led by Professor Bruce\u000d\u000a        has, over a number of years, made an important and influential\u000d\u000a        contribution to WHO strategy on\u000d\u000a        energy, air pollution health and climate. This evidence, together with\u000d\u000a        direct technical inputs from\u000d\u000a        the Liverpool University team, have provided much of the core evidence\u000d\u000a        base for new indoor air\u000d\u000a        quality guidelines for household fuel combustion, reports and other\u000d\u000a        collaborative work which is\u000d\u000a        supporting WHO's contribution to implementing effective policy for this\u000d\u000a        issue.\" [12] These new\u000d\u000a      WHO guidelines will be used by governments and other implementing agencies\u000d\u000a      to develop policy,\u000d\u000a      standards and regulation affecting the lives and health of almost 3\u000d\u000a      billion people, and make an\u000d\u000a      important contribution to preventing up to 4 million premature deaths\u000d\u000a      annually.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The University of Liverpool (UoL) team at the WHO Collaborating Centre\u000d\u000a      for Policy Research on\u000d\u000a      Social Determinants of Health (Liverpool WHO CC) has made a leading,\u000d\u000a      internationally recognised\u000d\u000a      contribution to addressing the adverse health consequences of household\u000d\u000a      air pollution, a problem\u000d\u000a      responsible for an estimated 4 million premature deaths among 2.8 billion\u000d\u000a      of the world's poorest\u000d\u000a      people. Impacts include (i) generating global awareness of a hitherto\u000d\u000a      poorly recognised problem\u000d\u000a      through defining the disease burden, (ii) leading development of new WHO\u000d\u000a      Guidelines on the\u000d\u000a      issue, (iii) providing key evidence for intervention and policy studies in\u000d\u000a      low-income countries and\u000d\u000a      (iv) helping to formulate strategy for global initiatives to address the\u000d\u000a      problem.\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    UNIVERSITY OF LIVERPOOL\u000d\u000a    ","Institutions":[{"AlternativeName":"Liverpool (University of)","InstitutionName":"University of Liverpool","PeerGroup":"A","Region":"North West","UKPRN":10006842}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2660646","Name":"Genve"}],"References":"\u000d\u000a    Key publications\u000d\u000a    The following publications report research outputs of work that has been\u000d\u000a      on going throughout the\u000d\u000a      period of research. The work itself was used prior to publication to\u000d\u000a      underpin the outputs outlined in\u000d\u000a      section 4.\u000d\u000a    \u000a1. Bonjour S, Adair-Rohani H, Wolf J, Bruce N, Mehta S,\u000d\u000a      Pr&#252;ss-Ust&#252;n A, et al. Solid Fuel Use\u000d\u000a      for Household Cooking: Country and Regional Estimates for 1980-2010.\u000d\u000a      Environ Health\u000d\u000a      Perspect. 2013;121(7):784-90. Citations: 2 Impact Factor: 7.260\u000d\u000a    \u000a\u000a2. Lim S, Vos T, Flaxman A, et al, (Bruce N, Pope D, Dherani M).\u000d\u000a      A comparative risk\u000d\u000a      assessment of burden of disease and injury attributable to 67 risk factors\u000d\u000a      and risk factor\u000d\u000a      clusters in 21 regions, 1990-2010: a systematic analysis for the Global\u000d\u000a      Burden of Disease\u000d\u000a      Study 2010. Lancet. 2012;380(9859):2224-60. Citations: 203 Impact Factor:\u000d\u000a      39.060\u000d\u000a    \u000a\u000a3. Smith K, McCracken J, Weber M, Hubbard A, Jenny A, Thompson L, et al (Bruce\u000d\u000a        N). Effect\u000aof\u000d\u000a        reduction in household air pollution on childhood pneumonia in Guatemala\u000d\u000a        (RESPIRE): A\u000d\u000a        randomised controlled trial. Lancet. 2011;378:1717-26. Citations: 55\u000d\u000a      Impact Factor:\u000d\u000a      39.060\u000d\u000a    \u000a\u000a4. Bruce N, Dherani M, Das J, Balakrishnan K,\u000d\u000a      Adair-Rohani H, Bhutta Z, Pope D. Control of\u000d\u000a      household air pollution for child survival: estimates for intervention\u000d\u000a      impacts. . BMC Public\u000d\u000a      Health 2013; 13 (Suppl 3):S8 Citations: 0 Impact Factor: 2.076\u000d\u000a    \u000a\u000a5. Rehfuess E, Puzzolo E, Stanistreet D, Pope D, Bruce\u000d\u000a        N. Enablers and Barriers to Large-Scale\u000d\u000a      Uptake of Improved Solid Fuel Stoves: A Systematic Review. Environ Health\u000d\u000a      Perspect 2013 (in press). Impact Factor: 7.260\u000d\u000a    \u000a\u000a6. Wilkinson P, Smith K, Davies M, Adair H, Armstrong B, Barrett M, et al\u000d\u000a      (Bruce N). Public\u000d\u000a      health benefits of strategies to reduce greenhouse-gas emissions:\u000d\u000a      household energy. .\u000d\u000a      Lancet. 2009;374(9705):1917-29. Citations: 76 Impact Factor: 39.060\u000d\u000a    \u000aKey research grants\u000d\u000a    2001-2005. NIEHS (US). Indoor air pollution and child ARI: a\u000d\u000a      randomised trial,\u000d\u000a      US$1,734,457, PIs K Smith (UC Berkeley) and N Bruce.\u000d\u000a    2003-2006. World Health Organisation (Geneva), additional support\u000d\u000a      for Guatemala study\u000d\u000a      to include investigation of RSV infection in children, and respiratory\u000d\u000a      health of women,\u000d\u000a      US$71,000, PI N Bruce.\u000d\u000a    2003-2008. Department for International Development, Knowledge and\u000d\u000a        Research.\u000d\u000a      Smoke health and household energy &#8212; scaling up, &#163;250k. Jointly with ITDG\u000d\u000a      (International\u000d\u000a      NGO), 2003-2008, PIs N Bruce and D Pope.\u000d\u000a    2007-2010. World Health Organization. Global comparative review\u000d\u000a      of experiences with\u000d\u000a      household energy interventions. A systematic review of the impacts on\u000d\u000a      household air\u000d\u000a      pollution (and exposure and health outcomes if available), in context of\u000d\u000a      interventions that\u000d\u000a      being delivered in the context of development programs, US $45,000, PI N\u000d\u000a        Bruce.\u000d\u000a    2009-2010. The Wellcome Trust. Near-term health effects of\u000d\u000a      sectoral policies to reduce\u000d\u000a      greenhouse gas emissions in high and low-income settings, &#163; 21,000, Co-I N\u000d\u000a        Bruce.\u000d\u000a    2011-2012. Department for International Development. Systematic\u000d\u000a      review of enabling or\u000d\u000a      limiting factors influencing the large scale uptake by households of\u000d\u000a      cleaner and more\u000d\u000a      efficient household energy technologies, covering cleaner fuel and\u000d\u000a      improved solid fuel\u000d\u000a      cookstoves, &#163;40,150.\u000d\u000a    2012-2017. UK Medical Research Council. An advanced cookstove\u000d\u000a      intervention to\u000d\u000a      prevent pneumonia in children under 5 years old in Malawi: a cluster\u000d\u000a      randomised controlled\u000d\u000a      trial, &#163;2,678,588, PI Dr Kevin Mortimer (Liverpool School of Tropical\u000d\u000a      Medicine), Co-Is N\u000d\u000a        Bruce and D Pope.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    Each source listed below provides evidence for the corresponding numbered\u000d\u000a      claim made in section\u000d\u000a      4 (details of the impact).\u000d\u000a    \u000d\u000a    \u000d\u000a      End Preventable Deaths: Global Action Plan for Prevention and Control\u000d\u000a        of Pneumonia and\u000d\u000a        Diarrhoea. WHO and UNICEF (2013) Geneva.\u000d\u000a      Research evidence used as basis for inclusion of reducing household air\u000d\u000a        pollution as an\u000d\u000a        intervention for preventing pneumonia, and includes reports on global\u000d\u000a        solid fuel use and the\u000d\u000a        RESPIRE study.\u000d\u000a      Igniting change: a strategy for universal adoption of clean cookstoves\u000d\u000a        and fuels. UN\u000d\u000a        Foundation Global Alliance for Clean Cookstoves 2011, Washington DC.\u000d\u000a      The main strategy document for the UN Foundation Alliance, which\u000d\u000a        incorporates the\u000d\u000a        outputs of the working groups, including that for health informed by the\u000d\u000a        UoL research.\u000d\u000a      International Workshop Agreement (IWA) on international standards for\u000d\u000a        cookstoves and\u000d\u000a        fuels. International Organisation for Standardisation, March 2012.\u000d\u000a      The initial stage of development of international standards has been an\u000d\u000a        IWA. For health\u000d\u000a        risks, this uses emissions rate tiers based on exposure-response\u000d\u000a        evidence, derived mainly\u000d\u000a        from the RESPIRE study. An ISO technical committee has recently been\u000d\u000a        formed to\u000d\u000a        develop full ISO standards.\u000d\u000a      Letter: UN Foundation Global Alliance for Clean Cookstoves. Supporting\u000d\u000a        statement dated 8\u000d\u000a        October 2013.\u000d\u000a      Letter: Department of Maternal and Child Health and Development, WHO,\u000d\u000a        Geneva.\u000d\u000a        Supporting statement dated 30 October 2013.\u000d\u000a      Letter: Department of Public Health and Environment, WHO, Geneva.\u000d\u000a        Supporting\u000d\u000a        statement dated 8 October 2013.\u000d\u000a      Selected Pollutants: WHO Guidelines for Indoor Air Quality. WHO\u000d\u000a        (2010). ISBN 978 92 890\u000d\u000a        0213 4. http:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0009\/128169\/e94535.pdf\u000a\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Household Air Pollution from Global Inequalities in access to clean\u000d\u000a      energy: Improving Prevention\u000d\u000a      strategies to Maximise Health Gain\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The Liverpool WHO CC team has made a leading contribution to quantifying\u000d\u000a      the Global Burden of\u000d\u000a      Disease (GBD) from Household Air Pollution (HAP), with Nigel Bruce\u000d\u000a      (Professor in Public Health,\u000d\u000a      1993 &#8212; present) co-chairing the HAP expert group for the GBD 2010 study,\u000d\u000a      and Daniel Pope (Snr\u000d\u000a      Lecturer; 2003 &#8212; present) leading systematic reviews assisted by Debbi\u000d\u000a      Stanistreet (Snr Lecturer;\u000d\u000a      1997 &#8212; present) and Mukesh Dherani (Senior Research Fellow; 2006 &#8212;\u000d\u000a      present). They estimated\u000d\u000a      that 2.8 billion people globally rely on traditional solid fuels (wood,\u000d\u000a      dung, coal, etc) and simple\u000d\u000a      stoves for cooking [1] leading to levels of HAP (particulate matter &#8212; PM2.5)\u000d\u000a      in homes some 20 to 40\u000d\u000a      times the WHO `safe' air quality guideline level in 2010; this resulted in\u000d\u000a      4.3% of the GBD in 2010,\u000d\u000a      with 4 million premature deaths from childhood pneumonia and a range of\u000d\u000a      adult diseases [2].\u000d\u000a    Core to this work have been systematic reviews and the RESPIRE trial\u000d\u000a      co-led by Universities of\u000d\u000a      Liverpool and Berkeley [3]. RESPIRE is the first ever Randomised\u000d\u000a      Controlled Trial (RCT) of low-cost\u000d\u000a      technology to reduce air pollution in human populations. It tested the\u000d\u000a      impact of reducing HAP\u000d\u000a      exposure on child pneumonia, and showed that while a good quality chimney\u000d\u000a      stove could reduce\u000d\u000a      exposure (by about 50%) and achieve some reduction in pneumonia risk,\u000d\u000a      exposure reduction to\u000d\u000a      levels much closer to WHO guideline levels are needed to prevent most\u000d\u000a      pneumonia cases caused\u000d\u000a      by HAP. Building on the experience with RESPIRE, Liverpool WHO CC are\u000d\u000a      co-investigators on a\u000d\u000a      new RCT evaluating the impact of an improved combustion stove on childhood\u000d\u000a      pneumonia in\u000d\u000a      Malawi (CAPS &#8212; MRC JGHT grant).\u000d\u000a    The systematic reviews conducted by Liverpool WHO CC have provided\u000d\u000a      intervention effect\u000d\u000a      estimates for several important preventive strategies and tools, including\u000d\u000a      the Global Action Plan for\u000d\u000a      the Prevention and Control of Pneumonia &amp; Diarrhoea (GAPPD) and the\u000d\u000a      Lives-Saved Tool [4]\u000d\u000a      which is used to prioritise interventions for child and maternal survival,\u000d\u000a      work undertaken by UoL\u000d\u000a      jointly with the WHO, UNICEF and the Child Health Epidemiology Reference\u000d\u000a      Group (CHERG)\u000d\u000a      since 2009.\u000d\u000a    Liverpool WHO CC has led research on policy for securing effective and\u000d\u000a      lasting uptake of improved\u000d\u000a      household energy interventions at scale through a comprehensive\u000d\u000a      mixed-methods systematic\u000d\u000a      review [5]. Carried out under competitive tender for UK-DFID and\u000d\u000a      incorporated in the WHO\u000d\u000a      Guidelines (section 4), the review identified key factors across domains\u000d\u000a      spanning\u000d\u000a      household\/community characteristics and preferences, to national and\u000d\u000a      international policy on\u000d\u000a      energy supply, finance and regulation. The UoL is currently working with\u000d\u000a      DFID, WHO, UN Global\u000d\u000a      Alliance of Clean Cookstoves (GACC) and other partners to develop a tool\u000d\u000a      to support\u000d\u000a      implementation of these findings in LMICs.\u000d\u000a    Research by the Liverpool WHO CC modelling the benefits of a 10-year\u000d\u000a      programme to shift Indian\u000d\u000a      solid fuel-using homes to low-emission alternatives [6] found that\u000d\u000a      substantial health (deaths,\u000d\u000a      Disability Adjusted Life Years (DALYs) and climate change (CO2-equivalent)\u000d\u000a      co-benefits can be\u000d\u000a      obtained through household energy improvements.\u000d\u000a    "},{"CaseStudyId":"31380","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Wellcome Trust","Medical Research Council"],"ImpactDetails":"\u000d\u000a    Vaccination of healthcare workers\u000d\u000a    Hayward's DH Policy Research Programme research on vaccination of\u000d\u000a      healthcare workers against influenza in nursing homes and acute care\u000d\u000a      settings has led to national recommendations to immunise staff in nursing\u000d\u000a      homes and other social care settings [a] and is one of the main\u000d\u000a      streams of evidence supporting vaccination of healthcare workers against\u000d\u000a      influenza. Annual campaigns to increase uptake of the vaccination amongst\u000d\u000a      NHS staff have cited the publication for many years. (See, for example,\u000d\u000a      the current year's letter from the Chief Medical Officer [b].) The\u000d\u000a      evidence on low uptake contributed to DH decisions to set up mandatory\u000d\u000a      routine monitoring of influenza vaccine uptake in England and informs the\u000d\u000a      content of the DH \"Flu Fighters\" campaign (launched in 2010\/11) aimed at\u000d\u000a      increasing uptake amongst front line healthcare staff including protection\u000d\u000a      of patients, safety and effectiveness as key messages. This has led to a\u000d\u000a      range of local NHS trust campaigns [c]. Since the publication of\u000d\u000a      our research, healthcare worker vaccination in acute trusts in England has\u000d\u000a      increased from a steady low of around 15% to around 45% in the 2010\/11\u000d\u000a      season [d].\u000d\u000a    Internationally, the trial is cited in annual US guidance on healthcare\u000d\u000a      worker vaccination [e] and has also contributed to 27 States in\u000d\u000a      the US making healthcare worker influenza vaccination mandatory [f].\u000d\u000a      Our work was presented as key evidence in a 2013 test-case trial in Canada\u000d\u000a      on mandatory vaccination [g].\u000d\u000a    Informing US recommendations of prevention of stroke\u000d\u000a    Our systematic review and meta-analysis of the influence of influenza as\u000d\u000a      a trigger for acute vascular events was the first of its kind. It is now\u000d\u000a      cited in American Heart Association\/American Stroke Association guidance\u000d\u000a      for prevention of stroke, recommending influenza vaccine for all those at\u000d\u000a      raised risk of stroke [h].\u000d\u000a    Routine vaccination of children\u000d\u000a    Our work has also impacted on the recent recommendation by the Joint\u000d\u000a      Committee on Vaccination and Immunisation (JCVI) of routine vaccination of\u000d\u000a      all children against influenza every year and the decision not to\u000d\u000a      recommend extension of vaccination to all adults aged over 50 years. This\u000d\u000a      decision was largely based on the findings of a dynamic transmission\u000d\u000a      model, commissioned by the DH and conducted by LSHTM and HPA, to assess\u000d\u000a      the effectiveness and cost effectiveness of the national influenza\u000d\u000a      vaccination campaign and consider options for extending this to other\u000d\u000a      groups. The model predicted that 30% coverage in children would result in\u000d\u000a      net savings of around &#163;65m and prevent loss of around 17,000 Quality\u000d\u000a      Adjusted Life Years annually. The model also suggested that extending\u000d\u000a      vaccination to all those aged greater than 50 years would not be cost\u000d\u000a      effective [i].\u000d\u000a    In order to increase confidence in the findings of the economic model the\u000d\u000a      committee requested that the age specific baseline levels of infection and\u000d\u000a      disease inferred by the model be validated against Flu Watch data\u000d\u000a      (provided prior to publication) to check that the model provided an\u000d\u000a      accurate representation of the true community burden. The fact that model\u000d\u000a      output and the empirical measures from Flu Watch matched gave confidence\u000d\u000a      in the validity of the model and thus supported the recommendation to\u000d\u000a      extend routine influenza vaccination to children but not to all adults\u000d\u000a      aged over 50. In deliberating on the type of vaccine to be used the Flu\u000d\u000a      Watch finding that cellular immune responses provide protection against\u000d\u000a      both seasonal and pandemic disease was discussed and contributed to the\u000d\u000a      decision to use Live Attenuated Influenza Vaccine (which stimulates both\u000d\u000a      cellular and humoral immunity) rather than Trivalent Inactivated Vaccine\u000d\u000a      (which only stimulates humoral immunity) [j]. The childhood\u000d\u000a      vaccination campaign is being launched in test regions in 2013.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research undertaken at UCL's Centre for Infectious Disease Epidemiology\u000d\u000a      has provided evidence about vaccination of different groups against\u000d\u000a      influenza which have influenced policy and practice. In particular, our\u000d\u000a      work underpins the government's ongoing policy on vaccination of\u000d\u000a      healthcare workers, and is cited every year in the Chief Medical Officer's\u000d\u000a      letter to healthcare workers as well as international recommendations on\u000d\u000a      influenza vaccination of healthcare workers, including widespread\u000d\u000a      mandatory vaccination programmes in North America. Research on influenza\u000d\u000a      and acute cardiovascular events has informed US recommendations for\u000d\u000a      prevention of stroke through vaccination. Recent work also informed the\u000d\u000a      decision in the UK to extend regular influenza vaccination to children.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University College London\u000d\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Hayward AC, Harling R, Wetten S, Johnson AM, Munro S, Smedley J, et\u000d\u000a      al. Effectiveness of an influenza vaccine programme for care home staff to\u000d\u000a      prevent death, morbidity, and health service use among residents: cluster\u000d\u000a      randomised controlled trial. BMJ (Clinical Research Ed). 2006 Dec\u000d\u000a      16;333(7581):1241. http:\/\/dx.doi.org\/10.1136\/bmj.39010.581354.55\u000d\u000a    \u000a\u000a[2] Smedley J, Poole J, Waclawski E, Stevens A, Harrison J, Watson J, et\u000d\u000a      al. Influenza immunisation: attitudes and beliefs of UK healthcare\u000d\u000a      workers. Occupational and Environmental Medicine. 2007 Apr;64(4):223-7.\u000d\u000a\u0009  http:\/\/dx.doi.org\/10.1136\/oem.2005.023564\u000d\u000a    \u000a\u000a[3] Hayward AC, Watson J. Effectiveness of influenza vaccination of staff\u000d\u000a      on morbidity, and mortality of residents of long term care facilities for\u000d\u000a      the elderly. Vaccine. 2011 Mar 16;29(13):2357-8. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2011.01.020\u000d\u000a    \u000a\u000a[4] Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute\u000d\u000a      myocardial infarction or death from cardiovascular disease: a systematic\u000d\u000a      review. The Lancet Infectious Diseases. 2009 Oct;9(10):601-10. http:\/\/dx.doi.org\/10.1016\/S1473-3099(09)70233-6\u000d\u000a    \u000a[5] Summary results published online at:\u000d\u000a      http:\/\/www.fluwatch.co.uk\/Content.aspx?ContentName=ResultsSummary\u000d\u000a      (Publication currently under review by the Lancet)\u000d\u000a    Peer-reviewed funding\u000d\u000a    Influenza Vaccination of Health Care Workers. Jun 2003-Jun 2005.\u000d\u000a      Department of Health Policy Research Programme. &#163;139,829.\u000d\u000a    Flu Watch: Community study of behavioural &amp; biological determinants\u000d\u000a      of transmission to inform seasonal &amp; pandemic planning. Jul 2006-Dec\u000d\u000a      2008. Medical Research Council. &#163;1,094,090\u000d\u000a    Flu Watch 2008. Jul 2007-Jan 2009. Medical Research Council. &#163;1,143,819\u000d\u000a    Flu Watch Pandemic Extension. Sep 2009-Oct 2012. MRC Wellcome. &#163;2,319,272\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [a] Immunisation Against Infectious Disease &#8212; The Green Book\u000d\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/147958\/Green-\u000a        Book-Chapter-19-v4_71.pdf\u000d\u000a    [b] CMO letter detailing 2012-3 campaign to vaccinated NHS staff against\u000d\u000a      influenza:\u000d\u000a      https:\/\/www.gov.uk\/government\/publications\/the-flu-immunisation-programme-2012-13\u000d\u000a    [c] National NHS staff seasonal flu vaccination campaign 2013\/14 Flu\u000d\u000a      fighter communications toolkit &#8212; for use by communications teams in NHS\u000d\u000a      organisations.\u000d\u000a      http:\/\/www.nhsemployers.org\/SiteCollectionDocuments\/NHS%20Flu%20fighter%20communic\u000a        ations%20toolkit%20for%202013-14.pdf, Royal Free local campaign &#8212;\u000d\u000a      Flu Show &#8212; Flu Fighter Campaign Video. http:\/\/www.youtube.com\/watch?v=YoNyxceDMLg&amp;feature=related\u000d\u000a    [d] Seasonal influenza vaccine uptake amongst frontline healthcare\u000d\u000a      workers (HCWs) in England Winter season 2010\/11 (p 44)\u000d\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/216394\/dh_129\u000a        857.pdf\u000d\u000a    [e] MMWR &#8212; Prevention and Control of Influenza with Vaccines.\u000d\u000a      Recommendations of the Advisory Committee on Immunization Practices\u000d\u000a      (ACIP), 2010 Early Release, July 29, 2010\u000d\u000a      http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr59e0729a1.htm?s_c\u000d\u000a    [f] Stewart AM, Cox MA. State law and influenza vaccination of health\u000d\u000a      care personnel. Vaccine. 2013 Jan 21;31(5):827-32. http:\/\/dx.doi.org\/10.1016\/j.vaccine.2012.11.063\u000d\u000a    [g] Letter from Vice President Public Health Chief Medical Health\u000d\u000a      Officer, Fraser Health Authority highlighting role of our research on\u000d\u000a      Canada Test Case regarding mandatory health care worker vaccination. Copy\u000d\u000a      available on request.\u000d\u000a    [h] AHA\/ASA Guideline Guidelines for the Primary Prevention of Stroke. A\u000d\u000a      Guideline for Healthcare Professionals From the American Heart\u000d\u000a      Association\/American Stroke Association. Stroke. 2011; 42: 517-584 http:\/\/dx.doi.org\/10.1161\/STR.0b013e3181fcb238\u000d\u000a    [i] Baguelin M, Flasche S, Edmunds J. The cost-effectiveness of\u000d\u000a      vaccination against seasonal influenza in England. 2012. Copy available on\u000d\u000a      request.\u000d\u000a    [j] JCVI statement on the annual influenza vaccination programme &#8212;\u000d\u000a      extension of the programme to children. 25 July 2012. Copy available on\u000d\u000a      request.\u000d\u000a    ","Title":"\u000d\u000a    Informing national and international influenza vaccination policy\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Research led by Dr Andrew Hayward at UCL's Centre for Infectious Disease\u000d\u000a      Epidemiology, in collaboration with others at Southampton University, the\u000d\u000a      London School of Hygiene &amp; Tropical Medicine (LSHTM) and the Health\u000d\u000a      Protection Agency (HPA), has informed national influenza vaccination and\u000d\u000a      control policy.\u000d\u000a    Between 2003 and 2005, Hayward designed and led a seminal cluster\u000d\u000a      randomised controlled trial, funded by the Department of Health (DH) to\u000d\u000a      encourage influenza vaccination of staff in 44 nursing homes [1].\u000d\u000a      The study, which involved more than 1,700 healthcare workers and 2,600\u000d\u000a      residents, showed a significant decrease in patient mortality,\u000d\u000a      Influenza-like illness (ILI), consultations for ILI with general\u000d\u000a      practitioners, and ILI hospitalizations during a moderate influenza season\u000d\u000a      among residents of homes in the healthcare worker vaccination arm,\u000d\u000a      compared with those residing in control facilities. This provided clear\u000d\u000a      evidence in favour of vaccinating healthcare workers, which is continually\u000d\u000a      cited in key communications and international recommendations on this\u000d\u000a      topic.\u000d\u000a    Hayward was also part of the team that conducting the only national study\u000d\u000a      of influenza vaccine attitudes amongst NHS staff [2, 3]. This\u000d\u000a      DH-funded study among 6,302 NHS staff showed that 19% of responders had\u000d\u000a      taken up influenza immunisation during winter 2002\/3. Amongst those\u000d\u000a      vaccinated, the majority who accepted vaccination (66%) were most strongly\u000d\u000a      influenced by the personal benefits of protection against influenza.\u000d\u000a      Prevention of sickness absence and protection of patients were the prime\u000d\u000a      motivation for only 10% and 7% of subjects, respectively. Among 3,967 who\u000d\u000a      declined vaccination, the most common primary demotivators were concern\u000d\u000a      about safety (31%) and efficacy (29%). 22% were most strongly deterred by\u000d\u000a      lack of time to attend for vaccination. Free text answers indicated that\u000d\u000a      37% declined because of a perceived low ratio of personal benefits to\u000d\u000a      adverse effects. Subjects said they would be persuaded to take up\u000d\u000a      vaccination in future by easier access (36%), more information about\u000d\u000a      personal benefit and risk (34%) and more information about effects on\u000d\u000a      staff absence (24%).\u000d\u000a    Hayward is lead author in a systematic review and meta-analysis of the\u000d\u000a      impact of influenza on triggering acute cardiovascular events showing this\u000d\u000a      is an important preventable risk factor [4].\u000d\u000a    Since 2006, Hayward has led the MRC\/Wellcome Flu Watch study, the world's\u000d\u000a      largest community study of influenza transmission and immunity. This study\u000d\u000a      recruited households across England to monitor levels of illness over five\u000d\u000a      flu seasons, via serological testing of pre- and post-season blood\u000d\u000a      samples, weekly follow up to record any flu-like illness, and nasal swabs\u000d\u000a      for those who reported such illness. The main results, which are under\u000d\u000a      review by the Lancet, provide the most robust measures to date of\u000d\u000a      influenza burden across different age groups and highlight the\u000d\u000a      particularly high rates in children [5]. Further results showed\u000d\u000a      the importance of T-cell mediated immunity in protecting against seasonal\u000d\u000a      and pandemic influenza.\u000d\u000a    "},{"CaseStudyId":"31381","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"3144096","Name":"Norway"},{"GeoNamesId":"390903","Name":"Greece"},{"GeoNamesId":"2802361","Name":"Belgium"}],"Funders":[],"ImpactDetails":"\u000a    London is now the `TB capital' of Europe and has more cases annually than\u000a      the Netherlands,\u000a      Belgium, Greece and Norway combined. TB is curable in virtually all cases\u000a      and can be effectively\u000a      controlled provided cases are found early and patients can complete\u000a      treatment. The research\u000a      described above has resulted in new services to improve control of\u000a      tuberculosis in hard-to-reach\u000a      groups.\u000a    The Find&amp;Treat Project\u000a    The original TB profile study provided justification for London Region to\u000a      invest in a large\u000a      demonstration project of mobile X-ray screening in homeless people, drug\u000a      users and prisoners.\u000a      Our initial evaluation of the demonstration project led the Department of\u000a      Health (DH) to invest in\u000a      continued funding of mobile X-ray screening in homeless shelters and drug\u000a      services and the\u000a      expansion of the service to include workers to support patients through\u000a      diagnosis and treatment.\u000a      This has now become the Find&amp;Treat service &#8212; a specialist outreach\u000a      team that works alongside\u000a      over 200 NHS and third sector front-line services to tackle TB among\u000a      homeless people, drug or\u000a      alcohol users, vulnerable migrants and people who have been in prison. The\u000a      multidisciplinary\u000a      Find&amp;Treat team takes TB control into the community, finds cases of\u000a      active TB early and supports\u000a      patients to take a full course of treatment and get cured. The service\u000a      spans the TB pathway from\u000a      detection, to diagnosis and onward care. To `Find' TB cases early the team\u000a      raises awareness\u000a      among service users and frontline professionals and screen almost 10,000\u000a      high risk people every\u000a      year using a mobile digital X-ray unit (MXU) as recommended by the\u000a      National Institute of Health\u000a      and Clinical Excellence (NICE). The screening service covers every London\u000a      Borough and supports\u000a      Public Health England (PHE) to manage outbreaks of TB nationally. Our\u000a      subsequent evaluation of\u000a      the expanded service contributed to decisions for NHS to take over the\u000a      funding of the service\u000a      which is now hosted by UCLH on behalf of London [a].\u000a    Analysis of service data shows that between January 2008 and June 2013,\u000a      Find&amp;Treat undertook\u000a      45,385 X-rays leading to 385 referrals, 84 of which resulted in treatment\u000a      being commenced for\u000a      pulmonary tuberculosis (detection rate 247 per 100,000 individuals\u000a      screened). 84% successfully\u000a      completed treatment within 12 months (higher than the proportion of cases\u000a      who complete TB\u000a      treatment nationally). Since 2008 Find&amp;Treat have worked with 1,379\u000a      suspected and active TB\u000a      cases including 780 cases with active TB (696 referred from TB and allied\u000a      services in London and\u000a      Birmingham and 84 found on the MXU). Of the culture confirmed cases 33%\u000a      were drug resistant\u000a      including 59 multidrug-resistant (MDR) and 4 extensively drug-resistant\u000a      (XDR) cases. 371 of the\u000a      referrals to Find&amp;Treat were because of loss to follow up and deemed\u000a      un-contactable by local\u000a      services. The outreach team recontacted 74% (275) of whom 73% have\u000a      completed treatment (154)\u000a      or are well established and expected to complete treatment (46). The team\u000a      also support Directly\u000a      Observed Therapy (where a responsible adult watches every dose of\u000a      treatment being swallowed to\u000a      improve adherence) and have pioneered the use of Video Observed Therapy\u000a      (VOT) using laptops\u000a      and smartphones. VOT is now being evaluated as part of a randomised trial\u000a      funded within the\u000a      UCL-led TB Reach NIHR Programme grant [b].\u000a    Public Health England is now developing a project to expand the service\u000a      nationally, creating a\u000a      National Infection &amp; Inequality System (NIIS) to provide integrated\u000a      testing, treatment, health and\u000a      social care for vulnerable populations disproportionately affected by\u000a      serious public health\u000a      infections, in particular TB, Hepatitis C and HIV. This service will be\u000a      directly modelled on the\u000a      successful model of Find&amp;Treat [c].\u000a    Introduction of static screening in prisons\u000a    Our research demonstrated that turnover of prisoners was too high for a\u000a      mobile unit to provide\u000a      sufficient coverage to pick up cases and recommended the installation of\u000a      static digital X-ray units\u000a      (DXR) in key prisons. In March 2008, the Chief Medical Officer announced\u000a      the intention of DH to\u000a      fund the installation of static DXR machines in five London prisons at a\u000a      cost of &#163;10m. This decision\u000a      was explicitly linked by the CMO to our MXU evaluation project (ref 5\u000a      above) [d]. The X-ray units\u000a      were all installed and in operation by March 2012. PHE's Director of\u000a      Health and Justice reports that\u000a      \"I have no doubt that the MXU project has had a direct and positive\u000a        influence on policy and\u000a        programmes relating to active case finding for pulmonary TB among people\u000a        in prisons and other\u000a        places of detention.\" A new national partnership agreement just\u000a      signed between PHE, NHS\u000a      England and the National Offender Management Service (NOMS) has made\u000a      further commitments\u000a      to ensuring the service is fully utilised, and furthermore, following a\u000a      successful trial of the\u000a      Find&amp;Treat service at a large Immigration Removal Centre (IRC) near\u000a      London, proposals are now\u000a      being made to extend the service permanently for use in this setting [e].\u000a    Broader influence on control of tuberculosis in hard to reach groups\u000a    In July 2009 NICE received the following referral from DH: \"Produce\u000a        programme guidance on the\u000a        effectiveness and cost effectiveness of interventions based on active\u000a        case finding among hard-to-reach\u000a        groups (find and treat model) for reducing transmission of tuberculosis\u000a        and related mortality\u000a        and implications for service development.\" The guideline development\u000a      group was chaired by\u000a      Hayward and considered a wide range of evidence including the research\u000a      described above and\u000a      expert testimony from the Find&amp;Treat service. This resulted in the\u000a      publication of NICE Public\u000a        Health Guidance (37) on Identifying and managing tuberculosis among\u000a        hard-to-reach groups [f].\u000a      Key recommendations based on our findings included: mobile radiographic\u000a      screening to expand to\u000a      other higher incidence areas outside London; screening for TB in prisons;\u000a      screening for latent TB\u000a      in drug users; NHS to provide funds for housing of homeless TB patients\u000a      with no other recourse to\u000a      support; multidisciplinary teams to include social care workers to support\u000a      care; directly observed\u000a      therapy to become routine for homeless people, prisoners and drug users;\u000a      cohort review (a service\u000a      quality improvement model based on international experience and the London\u000a      TB profile) to\u000a      become routine across TB services nationally.\u000a    Simultaneously the Royal College of Nursing, British Thoracic Society,\u000a      Health Protection Agency,\u000a      National Treatment Agency for Substance Misuse produced detailed practical\u000a      guidance for\u000a      tuberculosis case management and cohort review. In addition to the above\u000a      this guidance includes\u000a      a risk assessment tool modelled on our original TB patient profile form.\u000a      This helps to systematically\u000a      identify patients in need of enhanced case management [g].\u000a    The approach of adding the support of allied health professionals to work\u000a      alongside TB services\u000a      which we pioneered in the TB Link project, is now in use in at least 18 TB\u000a      services across London\u000a      alone. A support workers' forum coordinated by Find&amp;Treat has recently\u000a      been established, and the\u000a      roles of those who attend vary considerably [h].\u000a    ","ImpactSummary":"\u000a    Research by led Dr Andrew Hayward and Dr Alistair Story (UCL Research\u000a      Department of Infection\u000a      and Population Health) on tuberculosis in hard-to-reach groups\u000a      (particularly homeless people,\u000a      problem drug users and prisoners) has led to the introduction of mobile\u000a      X-ray screening for\u000a      tuberculosis in London, screening 8-10,000 homeless people and drug users\u000a      annually. A pan-London\u000a      street outreach team has been developed to support hard-to-reach patients\u000a      with\u000a      tuberculosis, and social care workers are now a core part of\u000a      multidisciplinary TB teams. A static\u000a      digital teleradiology TB screening network has been established in key\u000a      prisons and, most recently,\u000a      the research has influenced NICE Public Health Programme Guidelines.\u000a    ","ImpactType":"Health","Institution":"\u000a    University College London\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a[1] Craig GM, Booth H, Hall J, Story A, Hayward A, Goodburn A, Zumla A.\u000a      Establishing a new\u000a      service role in tuberculosis care: the tuberculosis link worker. J Adv\u000a      Nurs. 2008\u000a      Feb;61(4):413-24. http:\/\/dx.doi.org\/10.1111\/j.1365-2648.2007.04498.x\u000a    \u000a\u000a[2] Story A, Murad S, Roberts W, Verheyen M, Hayward AC; London\u000a      Tuberculosis Nurses\u000a      Network. Tuberculosis in London: the importance of homelessness, problem\u000a      drug use and\u000a      prison. Thorax. 2007 Aug;62(8):667-71. http:\/\/dx.doi.org\/10.1136\/thx.2006.065409\u000a    \u000a\u000a[3] Story A, Bothamley G, Hayward A. Crack cocaine and infectious\u000a      tuberculosis. Emerg Infect\u000a      Dis. 2008 Sep;14(9):1466-9. http:\/\/dx.doi.org\/10.3201\/eid1409.070654\u000a    \u000a\u000a[4] Rodger AJ, Story A, Fox Z, Hayward A; London Tuberculosis Nurses\u000a      Network. HIV\u000a      prevalence and testing practices among tuberculosis cases in London: a\u000a      missed opportunity\u000a      for HIV diagnosis? Thorax. 2010 Jan;65(1):63-9. http:\/\/dx.doi.org\/10.1136\/thx.2009.122754\u000a    \u000a\u000a[5] Mobile targeted digital chest radiography in the control of\u000a      tuberculosis among hard to reach\u000a      groups &#8212; report to Department of Health 2007 (copy available on request)\u000a    \u000a\u000a[6] Jit M, Stagg HR, Aldridge RW, White PJ, Abubakar I; Find and Treat\u000a      Evaluation Team.\u000a      Dedicated outreach service for hard to reach patients with tuberculosis in\u000a      London:\u000a      observational study and economic evaluation. BMJ. 2011 Sep 14;343:d5376.\u000a      http:\/\/dx.doi.org\/10.1136\/bmj.d5376\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [a] Outline of Find&amp;Treat service on the UCLH website:\u000a      http:\/\/www.uclh.nhs.uk\/ourservices\/servicea-z\/htd\/pages\/mxu.aspx\u000a      BMJ video describing the service: http:\/\/www.bmj.com\/multimedia\/video\/2011\/07\/24\/find-and-treat\u000a    [b] Letter giving service data from Clinical Lead and Manager for\u000a      Find&amp;Treat. Copy available on\u000a      request.\u000a    [c] National Infections and Inequalities Service submission. See in\u000a      particular p. 2 \"The plan is to\u000a        model NIIS on the successful template of Find&amp;Treat\" and p. 5\u000a      for involvement of the UCL\u000a      team in planning the new service. Copy available on request.\u000a    [d] http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1207035533566\u000a      See p.3.\u000a    [e] Prison screening &#8212; letter of support from Director of Health and\u000a      Social Justice, Public Health\u000a      England. Copy available on request.\u000a    [f] PH37: Identifying and managing tuberculosis among hard-to-reach\u000a      groups. National Institute\u000a      of Health and Clinical Excellence http:\/\/publications.nice.org.uk\/identifying-and-managing-tuberculosis-among-hard-to-reach-groups-ph37\u000a    [g] Royal College of nursing, British Thoracic Society, Health Protection\u000a      Agency, National\u000a      Treatment Agency for Substance Misuse. Tuberculosis Case Management and\u000a      Cohort\u000a      Review. Guidance for Health Professionals. 2012\u000a      http:\/\/www.rcn.org.uk\/__data\/assets\/pdf_file\/0010\/439129\/004204.pdf\u000a    [h] Report on the forum provided by its co-ordinator. Copy available on\u000a      request, and the co-ordinator\u000a      can be contacted for corroboration. Contact details provided.\u000a    \u000a    ","Title":"\u000a    Improving control of tuberculosis in hard-to-reach groups\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2655603","Name":"Birmingham"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Research underpinning these impacts began in 2003 with the TB Link\u000a        Project which aimed to\u000a      improve patient outcomes by addressing social needs. Interventions mainly\u000a      involved supporting\u000a      access to housing (36%), income\/benefits (34%) and immigration entitlement\u000a      issues (7%). Over\u000a      80% of cases successfully completed treatment. The research was carried\u000a      out by Dr Andrew\u000a      Hayward in collaboration with Alistair Story (Health Protection Agency\u000a      (HPA) at that time, now\u000a      UCL\/UCLH) [1].\u000a    In 2003\/4 the London TB Patient Profile worked with all TB nurses\u000a      in 35 clinics across London to\u000a      look at social as well as clinical factors affecting patient outcomes. The\u000a      study included 1,941\u000a      patients (over 95% of London TB patients) and showed the importance of\u000a      three risk factors in\u000a      particular: homelessness, drug use and imprisonment. It demonstrated that\u000a      these groups had\u000a      extremely high prevalence of tuberculosis (higher than recent migrants\u000a      from high incidence\u000a      countries) and that these factors were strong independent predictors of\u000a      drug resistance, poor\u000a      adherence and loss to follow up [2]. Subsequent work based on this\u000a      data showed that Crack\u000a      Cocaine Users were substantially more likely than others to have smear\u000a      positive (infectious) forms\u000a      of tuberculosis than other cases, posing a great transmission risk [3].\u000a      The work also demonstrated\u000a      substantial missed opportunities for diagnosis and early treatment of HIV\u000a      (only 50.8% of TB\u000a      patients aged &gt; or =20 years without previous testing were offered HIV\u000a      testing) [4].\u000a    The first work to evaluate mobile X-ray screening started in\u000a      collaboration with colleagues in\u000a      Holland who were working on a similar project. In 2004 Story and Hayward\u000a      led a three-day\u000a        screening pilot across several of the larger homeless hostels in\u000a      London, and in a prison. One\u000a      case of TB was found in a prison, and one among the homeless. This\u000a      proof-of-concept study\u000a      demonstrated the potential of such a scheme, and prompted the Department\u000a      of Health to fund a\u000a      demonstration project entitled Evaluation of Targeted Mobile X Ray\u000a        Screening for tuberculosis\u000a        in high risk groups. Over 21 months the project undertook 23,881\u000a      chest X-rays and led to 43\u000a      patients starting treatment. Screening shortened delay to diagnosis\u000a      three-fold. Modelling\u000a      suggested this would prevent around 87 active cases and 389 infections per\u000a      year by 2013 and that\u000a      the intervention was cost-saving [5]. Nevertheless it highlighted\u000a      that because patients were being\u000a      lost between initial screening and diagnosis at a clinic, investment was\u000a      also needed to support\u000a      people through confirmation of diagnosis and treatment. The report also\u000a      noted that high turnover of\u000a      inmates in prisons prevented high screening coverage with a mobile unit.\u000a    A subsequent evaluation of an expanded Find &amp; Treat service\u000a      (Abubaker, then HPA now UCL and\u000a      Aldridge, UCL) showed the cost effectiveness of the service in identifying\u000a      hard to reach patients\u000a      and supporting their care [6].\u000a    "},{"CaseStudyId":"32321","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000d\u000a    In 2006, Scotland became the first country in the UK to introduce a ban\u000d\u000a      on smoking in public places. Prior to this, there was credible doubt that\u000d\u000a      a ban would be effective despite research to show that more than 13,000\u000d\u000a      people in Scotland were dying each year from the effects of smoking, with\u000d\u000a      an estimated 1,000 of those deaths caused by passive smoking. Researchers\u000d\u000a      from the University of Glasgow have presented the most robust evidence to\u000d\u000a      show that smoke-free laws have significant and wide-reaching health\u000d\u000a      benefits for smokers and non-smokers alike. The research has been widely\u000d\u000a      cited to further strengthen the public health case for smoking bans both\u000d\u000a      nationally and internationally, supporting the argument that smoke-free\u000d\u000a      laws protect non-smokers, including unborn children, from the effects of\u000d\u000a      second-hand smoke.\u000d\u000a    Informing advocacy and policy\u000d\u000a    In 2009, the European Union (EU) cited these findings in its `Q&amp;A\u000d\u000a      briefing memo' (published on 30 June 2009), which prepared ministers for\u000d\u000a      parliamentary questions on a European Commission proposal on smoke-free\u000d\u000a      environments.a In response to the question \"is there evidence\u000d\u000a      that smoke-free policies work?\", the author of the memo stated that\u000d\u000a      \"better air quality has been mirrored by substantial reductions in the\u000d\u000a      incidence of heart attacks, including... a 17% drop in Scotland \" citing\u000d\u000a      the Pell 2008, NEJM paper as the supporting reference. On 12\u000d\u000a      October 2010, the EU Health Commissioner John Dalli stated that \"a number\u000d\u000a      of studies indicate important health effects of smoke-free policies\" when\u000d\u000a      answering a question raised in the European Parliament regarding the\u000d\u000a      Commission's proposal, before referring to another memo that also\u000d\u000a      references the Pell findings.b\u000d\u000a    In 2011, the WHO released the document `Making Cities Smoke-free' to\u000d\u000a      support compliance with the WHO Framework Convention on Tobacco Control,\u000d\u000a      an international treaty signed by 174 countries.c Addressed to\u000d\u000a      mayors of cities across the world, this document drew on the experience of\u000d\u000a      many different jurisdictions and provided a practical framework for\u000d\u000a      implementing smoke-free laws in cities (effectively defining the\u000d\u000a      legislation, anticipating and countering opposition, ensuring civil\u000d\u000a      society involvement, and managing public communications). In the section\u000d\u000a      entitled `Key Resources', the 2008 study by Pell and colleagues (2008, NEJM\u000d\u000a      in section 3) was the sole reference provided for the UK to demonstrate\u000d\u000a      the benefit of measuring indicators of worker health pre- and post-ban,\u000d\u000a      specifically `the number of emergency admissions to hospital for acute\u000d\u000a      cardiovascular problems such as heart attacks'. Professor Pell was also\u000d\u000a      invited by the WHO to present at the 14th World Conference on\u000d\u000a      Tobacco and Health in 2009 in Mumbai, India. The World Heart Federation,\u000d\u000a      which supports \"reduction of the prevalence of risk factors associated\u000d\u000a      with cardiovascular deaths\" and includes tobacco control as one of its\u000d\u000a      advocacy strands has selected Pell's research as one of four international\u000d\u000a      case studies that exemplify \"the work of women who have played key roles\u000d\u000a      ensuring that women's needs are taken into account in the formation of\u000d\u000a      tobacco control policy and the provision of cessation services around the\u000d\u000a      world\".d\u000d\u000a    In the USA, the University of Glasgow findings have been covered widely\u000d\u000a      by the press. A White Paper produced in 2011 by the Health Care Foundation\u000d\u000a      for Greater Kansas City included a section entitled `Clean Indoor Air\u000d\u000a        Laws,e which cited Pell's research (2008, NEJM in\u000d\u000a      section 3), stating that \"after just one year in effect, Scotland's\u000d\u000a      comprehensive clean indoor air law resulted in a 17% reduction in hospital\u000d\u000a      admissions for heart attacks and other coronary problems.\" These data were\u000d\u000a      also referenced in a section of the Global Voices Status Report (2009)\u000d\u000a      that referred to the UK and Ireland as `Regional Leaders' for their\u000d\u000a      smoking legislation.f This report provides guidance for\u000d\u000a      clinicians and policy-makers on how to protect people from second-hand\u000d\u000a      smoke and was produced by the Global Smoke-free Partnership (GSP) &#8212; an\u000d\u000a      international umbrella organisation coordinated by the American Cancer\u000d\u000a      Society &#8212; which promotes effective smoke-free air policies worldwide. The\u000d\u000a      GSP has also disseminated the research of Pell's team in a number of the\u000d\u000a      smoking-related factsheets that are available on its website.\u000d\u000a    Evidence produced by the University of Glasgow has also been cited in the\u000d\u000a      Scottish Government's evaluation of the success of the smoking ban and\u000d\u000a      continues to support its tobacco control policies. ASH Scotland's\u000d\u000a      Information Service is funded by the British Heart Foundation and the\u000d\u000a      Scottish Government to provide reliable evidence-based information on\u000d\u000a      tobacco and its harmful effects on health, society, and the economy in\u000d\u000a      Scotland. In ASH's `National evaluation of Scotland's smoke-free\u000d\u000a      legislation' (2013), key findings of the University of Glasgow research\u000d\u000a      (2008, NEJM and 2010, NEJM in section 3) are presented as\u000d\u000a      headline items, including the positive impacts on childhood asthma and on\u000d\u000a      heart attack admissions to hospital.g The Scottish Government's\u000d\u000a      2013 strategy on tobacco control, entitled `Creating a tobacco-free\u000d\u000a      generation: A tobacco control strategy for Scotland', cites the \"clear\u000d\u000a      evidence that ... the smoking ban, has lead [sic] to a range of health\u000d\u000a      benefits including: reduced heart attack admissions to hospital; reduced\u000d\u000a      childhood asthma admissions to hospital; and fewer premature births\",\u000d\u000a      referencing the 2008 and 2010 NEJM papers (section 3),\u000d\u000a      demonstrating the continued influence of Glasgow research on the\u000d\u000a      government's current smoke-free policy.h\u000d\u000a    Leading public debate\u000d\u000a    Extensive coverage in UK and international newspapers, on the radio, and\u000d\u000a      on the internet mean that the findings of Pell and her team have played an\u000d\u000a      important role in the continuing and often vociferous public debate for\u000d\u000a      and against smoking legislation.i-p As an example, the Wall\u000d\u000a        Street Journal, with a daily circulation of 2.1 million readers,\u000d\u000a      cited the team's findings in its coverage of the smoking ban debate in the\u000d\u000a      USA in 2008, stating that \"a new study from Scotland provides what\u000d\u000a      public-health experts in the US say is the strongest evidence yet that\u000d\u000a      public bans on smoking being debated in several locales &#8212; improve health\u000d\u000a      by reducing exposure to secondhand smoke\".i\u000d\u000a    Despite research from the Scottish Government showing that 80% of people\u000d\u000a      supported the idea of a smoking ban, there were concerns expressed about\u000d\u000a      the potentially damaging effect it would have on businesses and vocal\u000d\u000a      opposition from pro-smoking groups is ongoing. The significance of the\u000d\u000a      Glasgow findings in supporting a smoking ban policy is evidenced by the\u000d\u000a      regularity with which they are targeted by ban opponents, e.g.\u000d\u000a      Freedom2Choose (F2C), a lobbying initiative seeking to `alleviate the\u000d\u000a      negative social and economic impacts of the ban' and to challenge\u000d\u000a      supposedly misleading claims over smoking issues, particularly in relation\u000d\u000a      to passive smoking.j Pell's research findings also feature\u000d\u000a      regularly in a blog entitled `Taking Liberties' written by Simon Clark,\u000d\u000a      the director of an anti-tobacco-legislation lobbying group called Forest\u000d\u000a      that is funded, in part, by British American Tobacco.k\u000d\u000a    On the other side of the debate, the Chief Executive of Action on Smoking\u000d\u000a      and Health (ASH) Scotland has contributed to a number of blogs in her\u000d\u000a      `Smoked out' series using the research by Pell's team to support the\u000d\u000a      argument in favour of smoking bansl. In 2011, on the 5-year\u000d\u000a      anniversary of the Scottish smoking ban, the Scotsman newspaper\u000d\u000a      published a feature covering the wide range of views on smoke-free\u000d\u000a      legislation. In addition to soliciting opinions from Simon Clark and\u000d\u000a      representatives from the ASH and the Scottish Licensed Trade Association,\u000d\u000a      they invited Jill Pell and Phil Hanlon to present the evidence base in\u000d\u000a      support of such laws.m In the BBC coverage of the 5th\u000d\u000a      anniversary of the ban, the legislation was described as one of the\u000d\u000a      country's \"big public health success stories\" &#8212; research by Pell and\u000d\u000a      colleagues (showing lower hospitalisation rates for children with asthma)\u000d\u000a      was used to support this statement.n\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Smoke-free laws are public policies that prohibit tobacco smoking in\u000d\u000a      workplaces and other public spaces. Since the end of March 2006, smoking\u000d\u000a      has been prohibited by law in all enclosed public spaces throughout\u000d\u000a      Scotland, with the specific aim of protecting non-smokers from the effects\u000d\u000a      of second-hand smoke. Studies led by the University of Glasgow have\u000d\u000a      provided the most robust available evidence that smoke-free laws have a\u000d\u000a      significant impact on rates of heart disease, childhood asthma,\u000d\u000a      complications in pregnancy, and stroke. This evidence has been used to\u000d\u000a      support policy debate and decision making in Scotland, the rest of the UK,\u000d\u000a      and around the world, providing guidance for other countries to implement\u000d\u000a      similar legislation. This research has also provided a focal point for an\u000d\u000a      extended and high profile global public debate over smoking legislation,\u000d\u000a      and underpins health advice and campaigns published by the World Health\u000d\u000a      Organization (WHO), World Heart Federation and other international bodies.\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    University of Glasgow\u000d\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"1275339","Name":"Mumbai"}],"References":"\u000d\u000a    \u000a1. Pell, J. P. et al. Smoke-free legislation and hospitalizations\u000d\u000a      for acute coronary syndrome. NEJM 2008; 359(5): 482-491; doi: 10.1056\/NEJMsa0706740.\u000d\u000a    \u000a\u000a2. Pell, J. P. et al. Secondhand smoke exposure and survival\u000d\u000a      following acute coronary syndrome: prospective cohort study of 1261\u000d\u000a      consecutive admissions among never-smokers. Heart 2009; 95(17):\u000d\u000a      1415-1418; doi: 10.1136\/hrt.2009.171702.\u000d\u000a    \u000a\u000a3. Mackay, D. F. et al. Smoke-free legislation and\u000d\u000a      hospitalizations for childhood asthma. NEJM 2010; 363: 1139-1145;\u000d\u000a      doi: 10.1056\/NEJMoa1002861.\u000d\u000a    \u000a\u000a4. Mackay, D. F. et al. Impact of Scotland's smoke-free\u000d\u000a      legislation on pregnancy complications: retrospective cohort study. PLOS\u000d\u000a        Med. 2012; 9(3): e1001175; doi: 10.1371\/journal.pmed.1001175.\u000d\u000a    \u000a\u000a5. Mackay, D. F. et al. Impact of Scotland's comprehensive,\u000d\u000a      smoke-free legislation on stroke. PLOS One 2013; 8(5): e62597;\u000d\u000a      doi: 10.1371\/journal.pone.0062597.\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    Contribution to advocacy and policy documents\u000d\u000a    a. European Commission. Questions\u000a          and answers on the Commission proposal on smoke-free environments;\u000d\u000a      a briefing memo on smoke-free laws released on 30 June 2009.\u000d\u000a    b. European Parliament. Parliamentary\u000a          questions; answers to a written question on smoke-free\u000d\u000a      environments published on the 12 October 2010.\u000d\u000a    c. Tobacco Free Initiative (TFI) and WHO Centre for Health Development. Making\u000a          Cities Smoke-free (2011); pg31.\u000d\u000a    d. World Heart Federation. Cardiovascular\u000a          harms from tobacco use and second-hand smoke (2012) pg4. World\u000a          No Tobacco Day: Case studies \/ women taking action (2011).\u000d\u000a    e. White Paper on Tobacco Policy for Kansas and Missouri. Clean\u000a          Indoor Air Laws (2011); pg3\u000d\u000a    f. Global Voices Status Report 2009. Rebutting\u000a          the tobacco industry winning smoke free air; pg33\u000d\u000a    g. Action on Smoking and Health (ASH). National\u000a          evaluation of Scotland's smoke-free legislation (2013).\u000d\u000a    h. Scottish Government. Creating\u000a          a tobacco-free generation: A tobacco control strategy for Scotland\u000d\u000a      (2013), pg6.\u000d\u000a    Contribution to public awareness and debate\u000d\u000a    i. The Wall Street Journal. Study\u000a          supports health benefits of smoking ban (2008).\u000d\u000a    j. Freedom2Choose. Lodging\u000a          motions on Pell in the Scottish Parliament (blog 2010)\u000d\u000a    k. Simon Clark, Taking\u000a        Liberties (blog 2011-13)\u000d\u000a    l. Chief Executive of ASH Scotland. Smoked\u000a          out: monthly musings on tackling tobacco (blog 2013).\u000d\u000a    m. The Scotsman. Five\u000a          years of the smoking ban (2011).\u000d\u000a    n. BBC News online: Scotland. Scotland's\u000a          smoking ban hailed as anniversary approaches (2011).\u000d\u000a    o. The Guardian. Smoking\u000a          ban 'has reduced asthma and heart attacks' (2012).\u000d\u000a    p. Netdoctor\u000a        news. Large fall in premature births following Scots smoking ban\u000d\u000a      (2012).\u000d\u000a    ","Title":"\u000d\u000a    Demonstrating and promoting the benefits of smoke-free policy in Scotland\u000d\u000a      and worldwide\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2648579","Name":"Glasgow"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Since the end of March 2006, smoking has been prohibited by law in all\u000d\u000a      enclosed public places throughout Scotland, the aim of which is to protect\u000d\u000a      non-smokers from second-hand smoke. The impact of smoke-free laws on\u000d\u000a      public health in Scotland has been evaluated in ongoing research by a\u000d\u000a      combined team of academics and health professionals at the University of\u000d\u000a      Glasgow that is led by Professor Jill Pell and funded by NHS\u000d\u000a      HealthScotland. This research has shown that smoke-free laws are\u000d\u000a      associated with a reduced incidence of key smoking-related disorders, such\u000d\u000a      as coronary heart disease, childhood asthma, complications in pregnancy,\u000d\u000a      and stroke.\u000d\u000a    Acute coronary syndrome (ACS) is a life-threatening form of heart\u000d\u000a      disease. Although eight previous studies in USA, Canada and Italy had\u000d\u000a      suggested that total admissions for ACS were reduced following the\u000d\u000a      introduction of smoke-free laws, Pell's team was the first to perform a\u000d\u000a      prospective study that linked reductions in admission rates to the smoking\u000d\u000a      status of patients.1 For 10 months before the enactment of the\u000d\u000a      smoking legislation in Scotland on the 26th March 2006 and the\u000d\u000a      same 10 months in the year following legislation, patients admitted with\u000d\u000a      ACS to nine Scottish hospitals (accounting for 64% of the total ACS\u000d\u000a      admissions in Scotland) were recruited to the study by Pell et al.1\u000d\u000a      The information collected from participating patients included\u000d\u000a      self-reported smoking status and exposure to second-hand smoke, which was\u000d\u000a      also measured objectively by a well-established biomarker for exposure to\u000d\u000a      tobacco smoke (cotinine &#8212; a breakdown product of nicotine). Over the\u000d\u000a      period studied, the number of hospital admissions for ACS in Scotland\u000d\u000a      decreased by 17% (from 3,235 in the 10 months prior to the introduction of\u000d\u000a      the law to 2,684 in the 10 months afterwards), with non-smokers accounting\u000d\u000a      for two-thirds of this reduction. By comparison, a 4% reduction was\u000d\u000a      reported during the same period in England, where no such legislation had\u000d\u000a      been introduced. The significance of this study was reflected by the fact\u000d\u000a      that the publication was voted the Top Paper of 2008 by the American Heart\u000d\u000a      Association.\u000d\u000a    In 2009, Pell's team used record linkage to conduct a follow-up study of\u000d\u000a      the 1,261 never smokers to establish the effect of exposure to second-hand\u000d\u000a      smoke on early outcomes of ACS. Never smokers who were exposed to\u000d\u000a      second-hand smoke had a higher risk of adverse events (such as death or\u000d\u000a      rehospitalisation) within 30 days of first admission to hospital.2\u000d\u000a      This finding further supported the argument for protecting non-smokers\u000d\u000a      from the harmful effects of second-hand smoke.\u000d\u000a    Pell's team also examined the effects of the smoke-free law on rates of\u000d\u000a      childhood asthma and pregnancy complications in Scotland. Research\u000d\u000a      published by this group showed that childhood asthma admissions had been\u000d\u000a      increasing by about 5% each year prior to the introduction of the\u000d\u000a      smoke-free law, but were reduced by 18% per year following introduction of\u000d\u000a      the legislation.3 Faculty of 1000 graded this article as 5*\u000d\u000a      stating it was \"an important study for health care providers, legislators\u000d\u000a      and public health care workers\". Pell and her team went on to examine data\u000d\u000a      on 717,000 women who conceived between August 1995 and February 2009, and\u000d\u000a      showed that, relative to the underlying trends, there was a significant\u000d\u000a      drop of more than &gt;10% in the overall number of preterm deliveries, and\u000d\u000a      significant drops of 5% and 8% in the number of infants born either small\u000d\u000a      or very small, respectively, for their gestational age.4 Following\u000d\u000a      the legislation, the number of expectant mothers who smoked fell from\u000d\u000a      25.4% to 18.8%. This dramatic decline was not observed in the general\u000d\u000a      population but was consistent with other Scottish studies that showed that\u000d\u000a      parents responded to the smoke-free legislation by implementing voluntary\u000d\u000a      home restrictions on smoking to protect their children.\u000d\u000a    More recently, Pell's team was the first to show a reduction in the\u000d\u000a      incidence of cerebral infarction as a result of the smoke-free law.\u000d\u000a      Cerebral infarction is a form of stroke caused by restriction of blood\u000d\u000a      flow to the brain, due to diseased or damaged cerebral arteries, and\u000d\u000a      accounts for 50% of all strokes. The incidence of cerebral infarction was\u000d\u000a      increasing at around 1% per year but, following introduction of the\u000d\u000a      smoke-free law, reduced by around 9%. This was sustained for 20 months,\u000d\u000a      before partially reverting to pre-legislation levels.5 This was\u000d\u000a      consistent with another study by Pell's team that showed an initial\u000d\u000a      increase in smoking quit rates, followed by some relapses.\u000d\u000a    Key researchers at the University of Glasgow: Jill Pell\u000d\u000a      (Henry Mechan Chair of Public Health, 2007-present); Daniel Mackay\u000d\u000a      (Research Associate, 1998-2011; Senior Lecturer of Public Health,\u000d\u000a      2012-present); Scott Nelson (Muirhead Chair of Reproductive and Maternal\u000d\u000a      Medicine, 2008-present); Peter Langhorne (Professor of Stroke Care,\u000d\u000a      1994-present); Alex McConnachie (Assistant Director of Biostatistics,\u000d\u000a      2010-present).\u000d\u000a    Key collaborator: Sally Haw &#8212; (NHS Health Scotland, moved\u000d\u000a      to University of Stirling, Department of Nursing Midwifery and Health in\u000d\u000a      2011). Professor Haw coordinated the whole portfolio of studies examining\u000d\u000a      the various impacts of the legislation.\u000d\u000a    "},{"CaseStudyId":"32322","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"6251999","Name":"Canada"}],"Funders":[],"ImpactDetails":"\u000a    Professor Williams has produced one of the most accessible and positively\u000a      evaluated CBT models for treating mild to moderate depression and anxiety\u000a      disorders. His core series of workbooks, `Overcoming depression and low\u000a      mood: a five areas approach' has sold 10,734 copies since 2008a\u000a      and his approach to guided self-help CBT has been shown in clinical\u000a      research and practice to effectively treat depression. Williams has\u000a      achieved significant local, national and international recognition for the\u000a      pioneering dissemination of his `five areas' model through two\u000a      complementary approaches &#8212; practitioner training and the provision of\u000a      online resources.\u000a    Practitioner training\u000a      Courses to train healthcare practitioners in using the `Overcoming\u000a      depression and low mood' materials with patients have been developed, and\u000a      then evaluated in the Glasgow team's research, facilitating the\u000a      implementation of self-help CBT treatments within existing clinical\u000a      settings.\u000a    The SPIRIT programme has operated since 2002, during which time it\u000a      has received (and continues to receive) NHS funding of around &#163;127,000 per\u000a      annum. The first accredited course of this kind, it delivers training to\u000a      teams operating within NHS Greater Glasgow &amp; Clyde (GG&amp;C).\u000a      Currently, all `adult' and `older adult' mental health teams in Glasgow\u000a      have been trained in SPIRIT, with 287 practitioners trained since 2008.b\u000a      This focus on team-based training has enhanced the assimilation of new\u000a      practice into wards and, since 2008, mental health clinical admissions in\u000a      GG&amp;C have undergone `five areas' assessment, with use of the SPIRIT\u000a      programme recorded in the electronic patient record\/PIMS system.\u000a    Widening access to Self-Help and Psychological Interventions\u000a      (WISH) is a programme funded by the Scottish Government to provide\u000a      short-course training to healthcare and community practitioners, carers\u000a      and physiotherapists, using a low-intensity application of the `five\u000a      areas' approach. In a pilot study performed from 2009 to 2010, WISH\u000a      provided training for 597 healthcare professionals practicing across three\u000a      Scottish NHS boards (Highland, Dumfries &amp; Galloway and Lanarkshire)\u000a      and employees of a national charity \"Action on Depression\" (AOD), in how\u000a      to support patients using the `five areas' resources. AOD staff and\u000a      volunteers lead small groups and provide telephone support for online\u000a      versions of the five areas approach. Since the beginning of April 2011, a\u000a      further 985 practitioners have been trained with WISH, including\u000a      clinicians from two additional NHS boards (Lothian and GG&amp;C)c\u000a      and funding has been extended a further year until March 2014.\u000a    Online resource\u000a      Williams' second approach was to develop a free-access CBT-related website\u000a      called \"Living Life to the Full\" (LLTTF). This was based upon the original\u000a      `Overcoming depression and low mood' book plus new resources to increase\u000a      accessibility. LLTTF was established in 2004 (and re-launched in 2011) to\u000a      widen and expedite the delivery of an adult life skills course; it can be\u000a      used alone or together with books, DVDs and face-to-face classes in both\u000a      clinical and non-clinical settings. Since 2008, 208,604 members have\u000a      registered with the website,d which receives an average of over\u000a      45,000 visits per monthd and has a Google page ranking of 5 (on\u000a      a 0-10 logarithmic scale that reflects both the number and quality of\u000a      other webpages referring to the site). Put into the context of other\u000a      popular websites, a ranking of 5 is considered to be a good score; for\u000a      example, the bbc.co.uk website has a ranking of 9 and the scot.nhs.uk\u000a      website has a ranking of 6. Since 2008, Williams has supported a number of\u000a      national and international projects that roll out local delivery of LLTTF,\u000a      which are outlined in the subsections below.\u000a    NHS Living Life is a telephone support line for people with low\u000a      mood or anxiety that is funded by the Scottish Health Department and\u000a      available in Scotland since 2011. Operated by GP referral or\u000a      self-referral, patients are directed towards the LLTTF website and the\u000a      \"Overcoming depression and low mood: a five areas approach\" workbook, and\u000a      receive support using these from SPIRIT-trained therapists. An independent\u000a      audit of the 2008-2010 pilot study of 224 patients who completed the\u000a      online treatment course found that 83% were either in remission or had\u000a      recovered upon completion of this course.e Feedback was\u000a      overwhelmingly positive, with responses including:\u000a    \u000a      \"The course is helping me think things through and I'm coping\u000a          better. I'm better able to catch and stop negative thoughts.\"\u000a        (Student, aged 22 years)\u000a      \"The online course with the follow-up phone calls is genius! It has\u000a          helped me so much and helped me get back to work.\" (Teacher, aged\u000a        40 years)\u000a      \"The anxiety session was a real eye-opener for me. Thanks for your\u000a          support. It has been a great resource.\" (Social worker, aged 46\u000a        years)\u000a    \u000a    NHS Choices is the online `front door' to the NHS, and is the\u000a      largest health website in the UK. The site hosts a webpage called the\u000a      `moodzone', which offers practical information and interactive tools for\u000a      people with subclinical mood-related issues. Williams was invited to\u000a      create a suite of eight CBT- based podcasts relating to low mood and\u000a      depression, which are based on the original `Overcoming depression and low\u000a      mood' series materials. The podcasts have been available online since\u000a      February 2013, and been collectively viewed 45,803 times by 31st\u000a      July 2013.f\u000a    AWARE Defeat Depression is a charity based in Northern Ireland and\u000a      the Republic of Ireland that delivers LLTTF life skills classes to groups.\u000a      In 2009 and 2010, the pilot course was delivered to 46 groups (with a\u000a      combined total of 356 people), including groups representing\u000a      ex-prison-officers, lesbian, gay, bisexual and transgender individuals,\u000a      carers and women. The proportion of participants identified as being\u000a      depressed (according to a standardised depression questionnaire) dropped\u000a      from 73% at the start of the course to 12% after completion of the course.f\u000a      All participants said they would recommend the course to friends. The\u000a      success of the pilot study led to the uptake of LLTTF classes in the\u000a      Republic of Ireland by the Irish charity AWARE, which, in partnership with\u000a      the Tesco supermarket chain, provides ongoing financial support for CBT\u000a      classes in both urban and rural areas. Since June 2012, 1,336 people have\u000a      completed the six-week programme of life- skills classes, the completion\u000a      of which was associated with a 50% improvement in low mood (based on a\u000a      validated clinical questionnaire to assess severity of depression) and\u000a      high levels of satisfaction with the course, as suggested by the following\u000a      comments:h\u000a    \u000a      \"It changed how I dealt with situations and I have stuck with the\u000a          information given and been using it.\"\u000a      \"Realising my thoughts cause my feelings means I can now control my\u000a          feelings and make myself feel better.\"\u000a      \"Beneficial in terms of improving my understanding and providing\u000a          practical steps to take.\"\u000a    \u000a    Highlighting the value of self-help CBT, and improved access to it by\u000a      practitioner training and online resources, the Canadian Mental Health\u000a      Association (CMHA) adapted the \"Overcoming depression and low mood: a five\u000a      areas approach\" workbook with support and training from Professor\u000a      Williams.i Bounce Back, a CAN $6 million initiative, employs 26\u000a      staff members in British Columbia who offer on-referral, low-intensity\u000a      self-help CBT telephone support for patients in primary care with mild or\u000a      moderate depression.\u000a    There have been 22,475 patient referrals since the launch of this\u000a      programme in June 2008.j In a survey of 2,903 patients who\u000a      completed at least one of the 3-5 sessions offered, only 56% were\u000a      considered to be depressed after completion of the LLTTF course (compared\u000a      with 91% prior to the course).j Bounce Back also offers a DVD\u000a      version of the LLTTF course and has distributed about 67,000 copies.j\u000a      The CMHA also run life skills classes modelled on those run by AWARE and\u000a      people can self-book onto the classes at http:\/\/www.llttf.ca.\u000a      In 2010 and 2011, the CMHA piloted the website and classes; of the 228\u000a      participants who were surveyed in the pilot study, 85% found the course to\u000a      be useful and 91% said that they would recommend it to their friends.i\u000a      The LLTTF Canadian website provides on-going certified training to a\u000a      nationwide network of facilitators who provide CBT coaching for the same\u000a      LLTTF classes described above that AWARE offer; so far, 120 facilitators\u000a      from five Canadian states have been trained.k\u000a    In recognition of his sustained outstanding contribution to CBT and its\u000a      dissemination in the UK and internationally, in 2013 Williams was awarded\u000a      an Honorary Fellowship by the British Association for Behavioural &amp;\u000a      Cognitive Psychotherapies (BABCP), the leading body for CBT provision in\u000a      the UK. He is one of only 16 other people to have received this highly\u000a      prestigious Fellowship since the founding of BABCP in 1972.l\u000a    ","ImpactSummary":"\u000a    An estimated one in four people in the UK will experience depression or\u000a      anxiety at some point in their lives. Cognitive behavioural therapy (CBT)\u000a      is the most widely recommended non-medication- based treatment for common\u000a      mental health problems, although access to this treatment is limited\u000a      because of low numbers of expert practitioners. Self-help CBT resources\u000a      developed by researchers at the University of Glasgow have been integrated\u000a      into routine clinical practice delivered by health services and the\u000a      voluntary sector in the UK, Ireland and Canada. Since 2008, these\u000a      practical user-friendly resources have provided support to over 200,000\u000a      users online and an estimated 250,000 people on a one-to-one basis or\u000a      within a class.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Glasgow\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Williams, C. Overcoming depression and low mood: a five areas\u000a        approach. Hodder Arnold, London, 2001 (2nd Ed. 2006; 3rd\u000a      Ed. 2009). ISBN-13: 978-1444167481.\u000a    \u000a\u000a2. Williams, C. et al. A cognitive-behavioural\u000a        therapy assessment model for use in everyday clinical practice. Adv.\u000a        Psychiatr. Treat. 8, 172-179 (2002); doi:\u000a      10.1192\/apt.8.3.172.\u000a    \u000a\u000a3. Martinez, R. et al. Can people read\u000a        self-help manuals for depression? A challenge for the stepped care model\u000a        and book prescription schemes. Behav. Cogn. Psychother. 36,\u000a      89-97 (2008); doi: 10.1017\/S1352465807004067.\u000a    \u000a\u000a4. Williams, C. et al. Guided self-help\u000a        cognitive behavioural therapy for depression in primary care: a\u000a        randomised controlled trial. PLoS ONE 8, e52735\u000a      (2013); doi: 10.1371\/journal.pone.0052735.\u000a    \u000a\u000a5. Williams, C. et al. Training\u000a        the wider workforce in cognitive behavioural self-help: The SPIRIT\u000a        (Structured Psychosocial InteRventions in Teams) training course. Behav.\u000a        Cogn. Psychother. 39, 139-149 (2011); doi:\u000a      10.1017\/S1352465810000445.\u000a    \u000aGrant funding:\u000a      An evaluation of the effectiveness of structured Cognitive Behaviour\u000a      Therapy self-help materials delivered by a self-help support worker within\u000a      Primary care. (Williams, Morrison, Wilson, Whitfield, Walker, McMahon,\u000a      Wallace). Chief Scientists Office CZH\/4\/61. April 2004 - June 2007. Local\u000a      PI &#163;144,850.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    a. Information from Taylor and Francis Group publishers; available on\u000a      request.\u000a    b. SPIRIT figures provided by Administrator, WISH and SPIRIT; available\u000a      on request.\u000a    c. WISH figures provided by the WISH programme manager; available on\u000a      request.\u000a    d. LLTTF website usage statistics;\u000a      available upon request or directly from the www.llttf.com\u000a      site.\u000a    e. NHS\u000a        Living Life\/NHS 24 CBT Telephone support service and a NHS Living\u000a      Life audit from NMAHP Research Unit, University of Stirling; available on\u000a      request.\u000a    f. Information on NHS Choices\u000a        Moodzone from NHS Choices; available on request.\u000a    g. Pilot evaluation presentation from AWARE (Northern Ireland); available\u000a      on request.\u000a    h. Training numbers from AWARE (Republic of\u000a      Ireland); available on request.\u000a    i. Canadian Mental\u000a        Health Association website.\u000a    j. Data on Bounce Back provided by British\u000a      Columbia Cognitive Behaviour Therapy Network; available on request.\u000a    k. `Become a facilitator', Living\u000a        life to the full, Canada\u000a    l. BABCP Honorary Fellows\u000a      webpage.\u000a    ","Title":"\u000a    Improving access to self-help therapies for mental health\u000a    ","UKLocation":[{"GeoNamesId":"2648579","Name":"Glasgow"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"2641364","Name":"Northern Ireland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    CBT is an evidence-based form of psychotherapy that aims to educate\u000a      patients with common mental health problems (such as depression and\u000a      anxiety) about their condition and to provide them with the skills to\u000a      manage it. Although CBT is recommended by clinical guidelines such as\u000a      those published by the National Institute of Health and Care Excellence\u000a      and the Scottish Intercollegiate Guidelines Network, access to treatment\u000a      has typically been limited by the low number of expert CBT practitioners,\u000a      resulting in long waiting times. Consequently, more recently published\u000a      clinical guidelines recommend new ways of delivering CBT, such as\u000a      self-help books, computerised training, classes and group sessions, as\u000a      well as a stepped-care delivery approach &#8212; a tiered system that directs\u000a      patients to the lowest intensity form of therapy requiring less\u000a      practitioner support time. Here, the self-help materials deliver some of\u000a      the work of therapy. Using this system, most people with mild or moderate\u000a      depression can undergo a brief period of self-help CBT as a first step,\u000a      before deciding on longer-term care options. The challenge with adopting\u000a      this approach is to determine how best to deliver such a service within\u000a      existing clinical settings.\u000a    Since 2000, Professor Chris Williams (Professor of Psychosocial\u000a      Psychiatry, 2000-present) and his team at the University of Glasgow have\u000a      focused on evaluating new ways of delivering evidence-based CBT in a\u000a      non-clinical setting. At the heart of this research is the `five areas'\u000a      model, a CBT assessment tool that Williams developed at the University of\u000a      Leeds between 1997-1999, which enables mental health practitioners to\u000a      offer focused interventions for individual patients. A series of workbooks\u000a      entitled `Overcoming depression and low mood: a five areas approach',\u000a      first published in 2001, explains this model and provides a structured and\u000a      educational guide to self-help CBT intervention that can be used by both\u000a      practitioners and patients.1\u000a    Briefly, this involves individuals using either written, DVD or computer\u000a      based formats, to work through a checklist identifying how low mood or\u000a      anxiety is affecting them in five key areas of life: people and events\u000a      around them, their thinking, feelings, physical symptoms and behaviour.\u000a      Users then choose which areas to work on first, addressing the most common\u000a      problems encountered in that area using the appropriate workbook module,\u000a      which cover, for example, practical problem solving, being assertive, and\u000a      identifying then changing upsetting thoughts.\u000a    Since 2001, Williams has refined and updated content in response to\u000a      feedback from clinical mental health teams in Glasgow and elsewhere, with\u000a      new editions and also new books addressing medically unexplained symptoms,\u000a      postnatal depression, and depression in young people. Development has\u000a      ensured that the content, structure and language of the model can be\u000a      easily understood by healthcare practitioners from a range of different\u000a      specialties and patients with a broad range of cognitive abilities. For\u000a      example, terms such as \"selective abstraction\" and \"negative automatic\u000a      thoughts\" were replaced with \"putting a negative slant on things\" and\u000a      \"unhelpful thinking\", respectively. The second edition of the book (which\u000a      was published in 2006) was subsequently shown to have an average reading\u000a      age of 12.6 years, which is lower than the reading ages of almost all\u000a      other widely recommended self-help books for depression (generally ranging\u000a      from age 13.1-15.4 years). This is an important consideration given that\u000a      16% of the adult UK population has a reading age of less than 11 years.2,3\u000a    In the largest randomised controlled trial of a book-based CBT resource\u000a      to date, Williams' team evaluated the efficacy of providing the\u000a      \"Overcoming depression and low mood: a five areas approach\" series of\u000a      workbooks to 203 adult patients in a primary-care setting from 2004 to\u000a      2007. With brief support from a person who was not a mental-health expert,\u000a      the approach was highly effective, with 43% of patients considered to have\u000a      recovered after 4 months, compared with 25% of those who received usual\u000a      care (such as antidepressant medication) only.4\u000a    The introduction of guided self-help CBT approaches into clinical\u000a      services requires specialised staff training, and Williams' research led\u000a      to the first accredited course to address this requirement. The Structured\u000a      Psychosocial InteRventions in Teams (SPIRIT) course was designed to train\u000a      mental health practitioners in Glasgow. It consists of nearly 40 hours of\u000a      workshops on the use of the five areas CBT self-help resources and 5 hours\u000a      of staff supervision to support their use of the Overcoming depression\u000a      series of workbooks in clinical practice. When given to community and\u000a      inpatient mental health teams in NHS Greater Glasgow, this course led to\u000a      both short-term and long-term improvements in the knowledge and skills of\u000a      trained staff, as well as high levels of practitioner satisfaction of the\u000a      usefulness of the approach in clinical practice.5\u000a    "},{"CaseStudyId":"32323","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2186224","Name":"New Zealand"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"6251999","Name":"Canada"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Context\u000d\u000a    By the late 1990s, concerns were growing about the global scale of the\u000d\u000a      obesity epidemic and high-profile health organisations sought to develop\u000d\u000a      public-health strategies to tackle the problem. The University of Glasgow\u000d\u000a      waist circumference Action Levels published 1995 were rapidly adopted by\u000d\u000a      the World Health Organisation (WHO) in its influential Technical Report\u000d\u000a      `Obesity: Preventing and Managing the Global Epidemic' released in 2000.a\u000d\u000a      Although the report did not include any citations to published research,\u000d\u000a      the WHO explicitly defined a waist circumference above 94 cm and 102 cm in\u000d\u000a      men, and above 80 cm and 88 cm for women, as corresponding to an increased\u000d\u000a      risk and a substantially increased risk, respectively, of obesity-related\u000d\u000a      illness within white populations. A statement from the Chairman of the WHO\u000d\u000a      committee confirms that University of Glasgow research (Lean et al.\u000d\u000a      1995a1) formed the evidence base for these cut-offs.b\u000d\u000a      Citation by the WHO gave the Glasgow Action Levels a global profile and\u000d\u000a      stimulated public-health impacts across the world. The WHO report is cited\u000d\u000a      by many of the campaigns that quote the University of Glasgow waist\u000d\u000a      circumference Action Levels. Indeed, since the exact values (94 cm in men\u000d\u000a      or 80 cm and 102 cm in men or 88 cm in women) stated by the waist\u000d\u000a      circumference Action Levels are entirely unique to the University of\u000d\u000a      Glasgow human nutrition research evidence-base, any publication or\u000d\u000a      guideline which cites these values can be considered an impact of this\u000d\u000a      research.\u000d\u000a    Incorporation in health promotion and disease risk screening\u000d\u000a          campaigns\u000d\u000a    The simplicity of measuring waist circumference and the ease of\u000d\u000a      interpretation of the Action Levels by the general public confer a\u000d\u000a      strategic advantage over previous BMI-focused messages and lend themselves\u000d\u000a      to inclusion in public-health initiatives. Since 2008, there has been a\u000d\u000a      flood of prominent public-health programmes targeting obesity and\u000d\u000a      obesity-related health risks. The waist circumference Action Levels\u000d\u000a      defined by the University of Glasgow have become the benchmarks in a broad\u000d\u000a      range of these campaigns internationally.c,d \u000d\u000a    For example, the charity Diabetes UK uses the University of Glasgow\u000d\u000a      Action Levels in their online materials to alert the public to the need\u000d\u000a      for weight loss to limit the risk of developing diabetes. Similarly, the\u000d\u000a      British Heart Foundation advocate the Glasgow Action Levels as a way to\u000d\u000a      determine if weight loss is required in order to `raise awareness of\u000d\u000a        shape as well as weight being important in relation to risk of coronary\u000d\u000a        heart disease'. To complement this, as part of their Heart Matters\u000d\u000a      campaign, the society offers a tape measure based on the `Waist Watcher'\u000d\u000a      in their welcome pack. The Waist Watcher tape is also available to buy\u000d\u000a      from online retail giant Amazon. Further UK campaigns that cite the\u000d\u000a      University of Glasgow Action Levels to promote weight loss and raise\u000d\u000a      awareness of the central obesity-related disease risks include the NHS\u000d\u000a      Choices `Why is my waist size important?' initiative, the British\u000d\u000a      Dietetic Association `Weight Wise' campaign and the Public Health\u000d\u000a      Agency, Northern Ireland information leaflet `Is your waistline\u000d\u000a        creeping up on you?'. Internationally, the University of Glasgow\u000d\u000a      Action Levels have been prolifically cited in health-promotion campaigns\u000d\u000a      from 2008 onwards, including `Healthy Weight &#8212; it's not a diet, it's a\u000d\u000a        lifestyle' (Centers for Disease Control and Prevention, USA.),\u000d\u000a      `Healthy Waist' (Heart and Stroke Foundation of Canada), `Measure\u000a        your waist' (National Heart Foundation of Australia), `Measure\u000d\u000a        Up' (Australian Government) and `Health@Work' (Hong Kong\u000d\u000a      Government).\u000d\u000a    Informing clinical guidelines and policies\u000d\u000a    The impact of the University of Glasgow Action Levels within clinical and\u000d\u000a      public-health medicine has been substantial. They are cited in numerous\u000d\u000a      national and international clinical guidelinese on obesity and\u000d\u000a      cardiovascular risk that recommend the use of the Action Levels for waist\u000d\u000a      circumference, in combination with BMI, for the diagnosis of obesity and\u000d\u000a      stratification of disease risk:\u000d\u000a    \u000d\u000a      The UK National Institute for Health and Clinical Excellence\u000d\u000a        (NICE) guideline CG43 on prevention, identification, assessment and\u000d\u000a        management of overweight and obesity in adults and children (originally\u000d\u000a        published in 2006, reviewed in 2011 with all recommendations upheld)\u000d\u000a      The Scottish Intercollegiate Guideline Network (SIGN)\u000d\u000a        guideline 115 on management of obesity (2010)\u000d\u000a      The Australian National Health and Medical Research Council\u000d\u000a        guideline on management of overweight and obesity in adults, adolescents\u000d\u000a        and children in Australia (2013)\u000d\u000a      The New Zealand Ministry of Health clinical guideline for\u000d\u000a        weight management in New Zealand adults (2009) as part of the clinical\u000d\u000a        weight management algorithm to raise patient awareness of\u000d\u000a        obesity-related disease risk\u000d\u000a      The joint European Society of Cardiology\/European Atherosclerosis\u000d\u000a          Society (ESC\/EAS) guidelines on the management of dyslipidaemias\u000d\u000a        (2011) included the Action Levels to categorise heightened\u000d\u000a        obesity-related cardiovascular risk and signal the need for blood\u000d\u000a        cholesterol testing\u000d\u000a      The International Atherosclerosis Society position paper on\u000d\u000a        global recommendations for the management of dyslipidemia (2013)\u000d\u000a      The World Gastroenterology Organisation (WGO) global guideline\u000d\u000a        on obesity (2011). The WGO is an umbrella organisation of over 100\u000d\u000a        national professional gastrointestinal societies. Their 2011 guideline\u000d\u000a        recommends a management scheme to stratify eligibility for surgery and\u000d\u000a        initial treatment options according to the Action Levels defined by the\u000d\u000a        University of Glasgow, in combination with BMI. Within this scheme,\u000d\u000a        individuals with a waist circumference above 94 cm (men) and 80 cm\u000d\u000a        (women) (Action Level 1) are recommended to receive diet and exercise\u000d\u000a        advice; above 102 cm (men) and 88 cm (women) (Action Level 2)\u000d\u000a        individuals should be considered for additional behavioural support and\u000d\u000a        weight-loss drugs. Patients should only be considered for surgery once\u000d\u000a        they have exceeded the upper Action Levels for waist circumference, with\u000d\u000a        a BMI greater than 35 and failed diet and lifestyle interventions.\u000d\u000a    \u000d\u000a    In addition, the University of Glasgow Action Levels have been highly\u000d\u000a      influential in government-commissioned population-based studies and are\u000d\u000a      routinely used to analyse the National Health Surveys (Scottish Health\u000d\u000a      Survey and Health Survey for England; most recently published in 2011).f\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Obesity is a global epidemic. Currently, more than half a billion adults\u000d\u000a      worldwide are estimated to be overweight or obese yet this problem is\u000d\u000a      entirely preventable. Excess weight costs the NHS over &#163;5 billion each\u000d\u000a      year and is associated with an increased risk of obesity-related disease\u000d\u000a      (e.g. type 2 diabetes and heart disease). University of Glasgow\u000d\u000a      researchers defined two `Action Levels' for waist circumference to\u000d\u000a      indicate the point when an individual needs to initiate weight loss to\u000d\u000a      reduce their risk of disease. These Action Levels have been incorporated\u000d\u000a      into national and international clinical guidelines for the diagnoses and\u000d\u000a      management of obesity-related disease, and have provided the foundation\u000d\u000a      for public-health campaigns and policies worldwide, designed to reduce the\u000d\u000a      burdens of chronic ill-health that follow obesity.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Glasgow\u000d\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"1819729","Name":"Hong Kong"}],"References":"\u000d\u000a    \u000a1. Lean ME et al. Waist\u000a        circumference as a measure for indicating weight management. BMJ\u000d\u000a      1995; 311: 158-116 doi 10.1136\/bmj.311.6998.158.\u000d\u000a    \u000a\u000a2. Han TS et al. Waist\u000a        circumference action levels in the identification of cardiovascular risk\u000d\u000a        factors: prevalence study in a random sample. BMJ 1995; 311:\u000d\u000a      1401-1405.\u000d\u000a    \u000a\u000a3. Lean ME et al. Predicting\u000a        body composition by densitometry from simple anthropometric measurements.\u000d\u000a      Am J Clin Nutr 1996; 63: 4-14 [doi not available]\u000d\u000a    \u000a\u000a4. Han TS et al. The\u000a        influence of height and age on waist circumference as an index of\u000d\u000a        adiposity in adults. Int J Obes 1997; 21: 83-89 [doi not\u000d\u000a      available]\u000d\u000a    \u000a\u000a5. Han TS &amp; Lean ME. Self-reported\u000a        waist circumference compared with the `Waist Watcher' tape-measure to\u000d\u000a        identify individuals at increased health risk through intra-abdominal\u000d\u000a        fat accumulation. Br J Nutr 1998, 80: 81-88\u000d\u000a      doi.\/10.1017\/S0007114598001809\u000d\u000a    \u000a\u000a6. Lean\u000a        ME et al. Impairment\u000a        of health and quality of life in people with large waist circumference.\u000d\u000a      Lancet 1998; 351: 853-856 doi: 10.1016\/S0140-736(97)10004-6\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    a. WHO report `Obesity:\u000a        Preventing and Managing the Global Epidemic' (see Chapter\u000a        2, page 11)\u000d\u000a    b. Statement from the Chairman of the WHO committee (available on\u000d\u000a      request)\u000d\u000a    c. Leading UK charities and professional bodies citing the University of\u000d\u000a      Glasgow waist circumference Action Levels as a means to monitor the need\u000d\u000a      for weight reduction\/disease risk:\u000d\u000a    \u000d\u000a      Diabetes UK: How\u000a          do I know if I need to lose weight?\u000a\u000d\u000a      British Heart Foundation: Your\u000a          weight; further information on this available on request\u000d\u000a      NHS Choices: Why\u000a          is my waist size important?\u000a\u000d\u000a      British Dietetic Association: Measure\u000a          your waist: are you an apple or a pear?\u000a\u000d\u000a      Public Health Agency, Northern Ireland information leaflet `Is\u000a          your waistline creeping up on you?'\u000a\u000d\u000a    \u000d\u000a    d. Leading international bodies citing waist circumference as a means to\u000d\u000a      monitor the need for weight reduction\/disease risk:\u000d\u000a    \u000d\u000a      US Centers for Disease Control and Prevention: Assessing\u000a          your weight\u000a\u000d\u000a      Heart and Stroke Foundation of Canada: Healthy\u000a          waists\u000a\u000d\u000a      National Heart Foundation of Australia: Measure\u000a          your waist\u000a\u000d\u000a    \u000d\u000a    e. Clinical guidelines on the management of obesity citing Glasgow waist\u000d\u000a      circumference Action Levels:\u000d\u000a    \u000d\u000a      \u000aSIGN guideline 115\u000d\u000a        (2011) (WHO report cited as ref 4; pg 10-11, Table 3)\u000d\u000a      \u000aNICE\u000a          guideline on obesity (2006, reviewed in 2011) (WHO report cited as\u000d\u000a        ref 44 and Lean et al. 1995a cited as ref 20; see pg 199 and\u000d\u000a        218-225; Tables 5.2, 5.6, 5.7, 5.9 and 5.10)\u000d\u000a      \u000aAustralian\u000a          National Health and Medical Research Council (2013) (WHO reported\u000d\u000a        cited [no ref number given]; section 4.3.1, pg 26)\u000d\u000a      World Gastroenterology Organisation Global\u000a          Guideline (2011) (Table 2, pg 15)\u000d\u000a      New Zealand Ministry of Health guideline\u000a          on weight management (2009) (Cites the WHO report; Table 1, pg 25)\u000d\u000a      ESC\/EAS guideline\u000a          on dyslipidaemia (2011) doi:10.1093\/eurheartj\/ehr158 (Table 4, pg\u000d\u000a        1780-1781)\u000d\u000a        International\u000a          Atherosclerosis Society Position Paper Global Recommendations for the\u000d\u000a          Management of Dyslipidemia (2013) (Cites WHO report; Table 2, pg\u000d\u000a        7)\u000d\u000a    \u000d\u000a    f. Health surveys:\u000d\u000a    \u000d\u000a      \u000aScottish\u000a          Health Survey (2011)\u000d\u000a      \u000aHealth\u000a          Survey for England (2011)\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Waist circumference defines the need to take action on disease risk\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2648579","Name":"Glasgow"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"2641364","Name":"Northern Ireland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Body mass index (BMI) has been traditionally applied to define overweight\u000d\u000a      and obesity for epidemiological purposes; this measure takes both a\u000d\u000a      person's weight and height into account. However, the general public\u000d\u000a      cannot easily calculate BMI, and errors are often compounded by\u000d\u000a      overestimating height and underestimating weight. Moreover, BMI can be\u000d\u000a      misleading when applied to individuals with variable muscle mass.\u000d\u000a      University of Glasgow research led by Professor Mike Lean aimed to\u000d\u000a      identify a simpler and more reliable measure than BMI to classify body fat\u000d\u000a      and consequent disease risk that could primarily be used in\u000d\u000a      health-promotion initiatives. Although waist circumference had been\u000d\u000a      measured in some previous epidemiological studies, University of Glasgow\u000d\u000a      research was the first to investigate the independent relation of this\u000d\u000a      parameter to total body fat, and to propose cut-off values of waist\u000d\u000a      circumference for practical use.\u000d\u000a    Waist circumference established as valid indicator of total body\u000d\u000a          fat (1995-1997)\u000d\u000a    A population-based study conducted by Lean's group in 1995 measured\u000d\u000a      height, weight, waist-to-hip ratio and waist circumference in almost 2,000\u000d\u000a      Scottish men and women.1 Through comparison with conventional\u000d\u000a      BMI categories (BMI &gt;25 and &gt;30 indicating excess weight and\u000d\u000a      obesity, respectively), this study demonstrated that waist circumference\u000d\u000a      alone could provide comparable classification.1 The accuracy of\u000d\u000a      waist circumference for estimating body fat was further established with\u000d\u000a      underwater weighing as the reference method for body composition and\u000d\u000a      predictive equations for body fat content were developed, using simple\u000d\u000a      body measurements.2 Between 1996 and 1997, while working in\u000d\u000a      collaboration with groups in the Netherlands (led by Jacob Seidell at the\u000d\u000a      National Institute of Public Health and the Environment, Bilthoven, and\u000d\u000a      Paul Deurenberg at the University of Wageningen), the University of\u000d\u000a      Glasgow researchers further validated the predictive ability of waist\u000d\u000a      circumference using data from two existing international survey databases.\u000d\u000a      Waist circumference was shown to be a better predictor of both total body\u000d\u000a      fat and its distribution than BMI,3 even without adjusting for\u000d\u000a      height.4\u000d\u000a    Development of `Action Levels' for waist circumference (1995-1998)\u000d\u000a    The above work culminated in the definition of two key `Action Levels'\u000d\u000a      for waist circumference,1 which identify the need for weight\u000d\u000a      management among white populations:\u000d\u000a    \u000d\u000a      \u000aAction Level 1: a waist circumference over 94 cm in men or 80\u000d\u000a        cm in women signals that personal action is required.\u000d\u000a      \u000aAction Level 2: a waist circumference over 102 cm in men or 88\u000d\u000a        cm in women signals that professional advice should be sought.\u000d\u000a    \u000d\u000a    To address the issue of self-assessed waist circumference being\u000d\u000a      under-estimated, Lean's team developed the `Waist Watcher' &#8212; a push-button\u000d\u000a      tension-controlled tape measure with three intuitively coloured bands:(i)\u000d\u000a      green: waist circumference below Action Level 1; (ii) amber: waist\u000d\u000a      circumference between Action Levels 1 and 2; and (iii) red: waist\u000d\u000a      circumference above Action Level 2. The University of Glasgow researchers\u000d\u000a      showed that individuals could self-assess waist circumference\u000d\u000a      significantly more accurately using the Waist Watcher than they could with\u000d\u000a      a conventional tape measure (sensitivity and specificity for Waist Watcher\u000d\u000a      both above 95%).5\u000d\u000a    Action Levels for waist circumference correlate with risk of\u000d\u000a          chronic disease\u000d\u000a    By the late 1990s, the association between increased accumulation of body\u000d\u000a      fat &#8212; particularly with an intra-abdominal or `central' distribution &#8212; and\u000d\u000a      obesity-related ill-health became widely accepted. To determine the\u000d\u000a      ability of waist circumference to predict such disease risk, the\u000d\u000a      University of Glasgow researchers performed statistical correlations of\u000d\u000a      data on cardiovascular risk factors (type 2 diabetes, blood pressure,\u000d\u000a      cholesterol levels and lifestyle factors) with waist circumference\u000d\u000a      measurements from over 5,000 men and women.2 Individuals with a\u000d\u000a      waist circumference between Action Levels 1 and 2 were 1.5-2.0 times more\u000d\u000a      likely to be at cardiovascular risk than were those with a waist\u000d\u000a      circumference below Action Level 1. At a waist circumference above Action\u000d\u000a      Level 2, individuals had a 2.5-4.0 times greater risk.2 In\u000d\u000a      addition, other obesity-related symptoms (shortness of breath, impaired\u000d\u000a      physical function and lower back pain), as well as the prevalence of type\u000d\u000a      2 diabetes, were significantly greater among individuals with a waist\u000d\u000a      circumference above Action Level 2, even following adjustment for age and\u000d\u000a      lifestyle.6 Higher waist circumference measurements were also\u000d\u000a      associated with impaired quality of life, including reduced capacity for\u000d\u000a      performing everyday activities and increased likelihood of becoming\u000d\u000a      unemployed.\u000d\u000a    Key University of Glasgow researchers: Mike Lean (Professor\u000d\u000a      of Human Nutrition [1990-present]); Caroline Morrison (Honorary Clinical\u000d\u000a      Lecturer [2007-2010]).\u000d\u000a    "},{"CaseStudyId":"32342","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    The Gay Men's Sexual Health (GMSH) Survey has provided robust evidence on\u000a      the sexual behaviours and prevention and testing activities of MSM in\u000a      Scotland since 1996. Since 2008, the findings have informed health\u000a      guidelines in Scotland, the UK and Europe and have been used in successful\u000a      NHS sexual health campaigns.\u000a    Health guidelines and practice\u000a    European level guidelines\u000a    The GMSH Survey findings &#8212; of rising infection levels and substantial\u000a      proportions of HIV-positive men undiagnosed at the time of survey &#8212; were\u000a      part of a wider body of similar findings from across the EU which formed\u000a      the evidence basea for guidance released in 2010 by the\u000a      European Centre for Disease Prevention &amp; Control (ECDC). The ECDC\u000a      states in its Guidance Report on HIV testing: increasing uptake and\u000a        effectiveness in the European Union that `the issue is the extent to\u000a      which people living with HIV who need treatment are unaware of their\u000a      infection' and identifies `low-risk perception' as an important barrier to\u000a      being tested.\u000a    UK level guidelines\u000a    National guidelines on safer sex were issued in 2012 by the British\u000a      Association for Sexual Health and HIV and the British HIV Association.b\u000a      These guidelines, provide guidance for practitioners in Level 3\u000a      Genitourinary medicine (GUM) services (Tier 5 in Scotland). The Glasgow\u000a      research is cited in the evidence-base for recommendations on repeat\u000a      testing for sexually transmitted infections (STIs, p12&#8212;13) which include\u000a      `HIV testing should be routinely recommended to all individuals attending\u000a      GUM or sexual health services. Pre- and post-test discussions and\u000a      counselling support should be available'.\u000a    Scottish guidelines\u000a    McDaid was invited to be part of the Scottish Government's HIV Action\u000a      Plan Groupc which produced the HIV Action Plan in Scotland:\u000a        March 2009 to March 2014.d As part of the Scottish\u000a      Government National Sexual Health &amp; HIV Advisory Committee, McDaid was\u000a      on the Project Groups tasked with the relevant actions in the HIV Action\u000a      Plan aimed at `Reducing levels of undiagnosed HIV and transmission in\u000a      Scotland' (specifically Action 7 and Action 9 Project Groups for the\u000a      periods May 2010&#8212;Dec 2011 and Mar 2011&#8212;Apr 2012 respectively). Action 7&#8212; `Systems\u000a        to monitor risk behaviours and new HIV infections among persons at\u000a        highest risk of acquiring infection will be reviewed and, if\u000a        appropriate, developed and implemented' &#8212; arose directly out of the\u000a      2005 GMSH survey findings and the recognised need to learn whether the\u000a      findings applied to broader geographical areas. Action 9 of the plan &#8212; `Existing\u000a        guidance on prevention of HIV transmission in MSM' &#8212; led to the\u000a      production of Health Protection Network Guidancee tailored to\u000a      national and\/or local circumstances. The survey findings (ref 5 and 6 in\u000a      section 3) contributed to the evidence base for the guidance and the\u000a      survey is given as an example of the behavioural outcome measures to use\u000a      in addressing research gaps and local needs assessments. The HIV Action\u000a      Plan was subsumed into the National Sexual Health &amp; Blood Borne\u000a      Viruses (BBV) Frameworkf published in 2011, which brought\u000a      together the two areas for the first time. The BBV Framework informs\u000a      practice across the Scottish NHS Boards and they are held accountable for\u000a      the delivery of the outcomes in the Framework.\u000a    Health practitioners and voluntary organisations\u000a    The insights gained through the GMSH survey were shared with health\u000a      practitioners and NGOs through informal channels, including local events\u000a      with voluntary organisations such as Gay Men's Health and Terence Higgins\u000a      Trust Scotland. Between 2008 and the present, McDaid has disseminated GMSH\u000a      survey findings to more than 150 healthcare practitioners and managers,\u000a      and voluntary sector workers. These events raised awareness on the current\u000a      risks, delivered Continuing Professional Development (CPD) training and\u000a      provided information to help inform the practice and delivery of services\u000a      to MSM in clinical settings.g,h McDaid was also twice invited\u000a      to present GMSH survey findings at Gaycon (in 2008 and 2012)i,\u000a      a biennial conference on gay and bisexual men's sexual health and\u000a      wellbeing attended by ~150 healthcare and public health practitioners, NGO\u000a      representatives and policy makers at local and national levels.\u000a    Public awareness and health campaigns in Scotland\u000a    Findings from the GMSH surveys have been covered extensively in the\u000a      mainstream media (e.g. BBC) and specialist press (e.g. NAM\/AidsMap article\u000a      warning of the `perfect storm' in HIV transmission, and a Nursing\u000a        Times article emphasising that `safer-sex' messages need to be\u000a      reinforced among gay men living with an HIV-positive diagnosis' and citing\u000a      University of Glasgow work4 in the article's first paragraph)j.\u000a      In the press coverage, attention was drawn to the high levels of\u000a      undiagnosed HIV-positive men and levels of HIV-positive men who were still\u000a      engaging in sexual risk behaviour. The GMSH survey findings have also\u000a      driven targeted HIV awareness campaigns in the Edinburgh, Lothian and\u000a      Glasgow areas, beginning in 2006 and continuing through 2009. Subsequent\u000a      GMSH surveys (2008 and 2011) have found consistently higher awareness of\u000a      HIV risk among respondents and a maintained increase of 23% more\u000a      respondents having been tested for HIV. In the 2008 survey, almost half\u000a      the men surveyed reported a recent HIV test; a substantial increase over\u000a      2005 findings. There had also been a decrease in undiagnosed HIV infection\u000a      (42% of men testing HIV positive were undiagnosed in 2005 compared with\u000a      26% in 2008).\u000a    `HIV: the comeback tour' was developed by a multi-agency group in Lothian\u000a      led by NHS Lothian. As a public information and social media campaign, it\u000a      aimed to increase HIV testing and condom use among gay and bisexual men\u000a      and was piloted in Edinburgh in 2007. The campaign materials and\u000a      information were created with direct input from the GMSH researchers, who\u000a      provided specific figures for the areas being targeted by the materials\u000a      and whose findings informed the general focus of the campaign.\u000a      Specifically, the GMSH finding that approximately 40% of HIV-positive men\u000a      in Scotland were undiagnosed was cited in campaign materials including\u000a      8,000 posters and postcards, which were distributed in clubs and bars\u000a      throughout Edinburgh's gay scene and more widely through primary care,\u000a      community (libraries and leisure centres) and local transport networks\u000a      (200 bus posters) in the city. External evaluation of the pilot phase\u000a      reflected increased awareness among MSM and a 23% increase in HIV testing\u000a      in Edinburgh. In 2008, in the lead-up to World Aids Day (1 December), NHS\u000a      Lothian announced the second phase of the campaign. This included a\u000a      roll-out to additional social venues, 126 GP surgeries, and 180 pharmacies\u000a      as well as libraries throughout the Lothian area; massive mobile\u000a      billboards carried on 20 regional buses in addition to the existing bus\u000a      posters; regular peer education sessions using trained volunteers;\u000a      internet outreach using specific websites such as Gaydar.com to promote\u000a      campaign messages, and further publicity in the media. For example, `ads'\u000a      for the `tour' featured in The List, and a series of `tour dates'\u000a      with `merchandise stalls' giving away postcards and leaflets on sexual\u000a      health, testing services etc.\u000a    The GMSH findings were instrumental in another high-profile campaign. Run\u000a      by NHS Greater Glasgow &amp; Clyde (NHSGG&amp;C), NHS Lanarkshire and NHS\u000a      Ayrshire &amp; Arran health boards, the `Make Your Position Clear' (MYPC)\u000a      campaigni was aimed at the estimated 50,000 gay and bisexual\u000a      men in the three health board regions.i This campaign resulted\u000a      in greater awareness of the risks of HIV and the need for prevention and\u000a      won a Silver Award in the 2010 Institute of Practitioners in Advertising\u000a      Effectiveness Awards, which judge healthcare-related communications. In a\u000a      presentation at Gaycon 2012, the NHSGG&amp;C delivered its evaluation of\u000a      MYPC (as part of a three-campaign social marketing programme which also\u000a      included HIV: the Comeback Tour). NHSGG&amp;C reports that in a survey on\u000a      Gaydar.com, one of the channels used by the campaigns, 72% of people\u000a      agreed that the campaign had made them think about the risks of HIV; 57%\u000a      said it had made them consider getting tested; and 41% said they had\u000a      gained new knowledge about HIV and testing. In the campaign evaluation,\u000a      which surveyed 822 MSM in Glasgow, those with mid-to- high exposure to\u000a      MYPC were more likely to have been tested for HIV (but not STIs) in the\u000a      previous 6 months. These findings informed the use of social marketing\u000a      interventions by NHSGG&amp;C.h\u000a    ","ImpactSummary":"\u000a    Men who have sex with men (MSM) are at highest risk of acquiring HIV in\u000a      the UK and an estimated one-quarter of HIV-infected MSM have not been\u000a      diagnosed. The Gay Men's Sexual Health (GMSH) Survey, conducted by\u000a      University of Glasgow researchers, has provided robust evidence of sexual\u000a      behaviours as well as prevention and testing activities of MSM in Scotland\u000a      since 1996. These findings have shaped health policies in Scotland, the UK\u000a      and Europe and have been used by health practitioners in the conduct of\u000a      successful NHS sexual health campaigns in Scotland. The campaigns have\u000a      been credited with increased testing rates and increased awareness of HIV\u000a      risks demonstrating the effectiveness of direct promotion of sexual health\u000a      awareness within the gay community.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Glasgow\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Flowers P et al. Does\u000a        bar-based, peer-led sexual health promotion have a community-leveleffect\u000a        amongst gay men in Scotland? Int. J.STD AIDS 2002;\u000a      13:102-108 doi: 10.1258\/0956462021924721. PDF available on request.\u000a    \u000a\u000a2. Hart GJ &amp; Williamson LM. Increase\u000a        in HIV sexual risk behaviour in homosexual men in Scotland,1996-2002:\u000a        Prevention Failure? Sex. Transm. Infect. 2005; 81:367-372\u000a      doi:10.1136\/sti.2004.013995.\u000a    \u000a\u000a3. Williamson LM &amp; Hart GJ. HIV\u000a        prevalence and undiagnosed infection among a communitysample of gay men\u000a        in Scotland. J. Acquir. Immune Defic. Syndr. 2007;\u000a      45:224-230 doi: 10.1097\/QAI.0b013e318058a01e.\u000a    \u000a\u000a4. Williamson LM et al. Sexual\u000a        risk behaviour and knowledge of HIV status among community samples of\u000a        gay men in the UK. AIDS 2008; 22(9):1063-1070. doi:\u000a      10.1097\/QAD.0b013e3282f8af9b.\u000a    \u000a\u000a5. McDaid LM &amp; Hart GJ. Increased\u000a        HIV testing and reduced undiagnosed infection among gay men in Scotland,\u000a        2005-2008: support for the opt-out testing policy? Sex. Transm.\u000a        Infect. 2011; 87:221-224. doi: 10.1136\/sti.2010.044560\u000a    \u000a\u000a6. Knussen C et al. HIV-related\u000a        sexual risk behaviour between 1996 and 2008, according to age,among men\u000a        who have sex with men (Scotland). Sex. Transm. Infect. 2011;\u000a      87:257-259. doi: 10.1136\/sti.2010.045047.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    Impact on policy and official guidelines:\u000a    a. \u000a        ECDC. HIV testing: increasing uptake and effectiveness in the\u000a          European Union: Evidence synthesis for Guidance on HIV Testing\u000a      Stockholm: ECDC; 2010. ISBN 978-92-9193-224-5 \/ doi:10.2900\/35250.\u000a      [Williamson &amp; Hart, 2007 is cited as ref 76 on pg8]\u000a    b. Clutterbuck, D. et al., The Clinical Effectiveness Group of\u000a      the British Association for Sexual Health and HIV (BASHH) and the British\u000a      HIV Association (BHIVA). UK\u000a          National Guidelines on Safer Sex Advice. London: BASHH\/BHIVA,\u000a      2012. [McDaid and Hart, 2011 is ref 88, pg12]\u000a    c. Confirming membership of HIV Action Plan working group [link]\u000a    d. HIV\u000a          Action Plan in Scotland December 2009 - March 2014. Edinburgh:\u000a      Scottish Government; 2009. [Includes ref to Williamson &amp; Hart, 2007]\u000a    e. Health Protection Network. Good\u000a        Practice Guidance on HIV Prevention in Men who have Sex with Men (MSM).\u000a      Scottish Guidance 8. Health Protection Scotland, Glasgow, 2012. [includes\u000a      ref 5\/pg49 Hart &amp; Williamson, 2005; ref 4\/pg49 Knussen et al.,\u000a      2011; ref 21\/pg50 Flowers, Hart, Williamson, 2002]\u000a    f. The\u000a          sexual health and blood borne virus framework: 2011-15.\u000a      Edinburgh: Scottish Government, 2011. [Government policy agenda; includes\u000a      findings on high level of sexual risk behaviour from 2008 survey as\u000a      evidence in Table 4.1, page 29 &#8212; not in reference list]\u000a    Impact on public and practitioner awareness and public health\u000a          campaigning:\u000a    g. `HIV: the Comeback Tour' &#8212; Gay Men's Health; Testing and Support\u000a      Manager\u000a    h. NHS Greater Glasgow &amp; Clyde; Principal Health Improvement Officer\u000a      &#8212; Sexual Health\u000a    i. Gaycon 2012 conference programme, Sessions 1 and 6 and Plenary 2 [link]\u000a    j. Selected media coverage: BBC\u000a        News 20 June 2008: coverage of survey results [Dr McDaid was also\u000a      interviewed on BBC 5 Live and BBC News on 21 June 2008]; Nursing\u000a        Times June 2008 [advising on the health messages required, based on\u000a      survey results]; and Nam:\u000a        AidsMap news article: Over 40% of gay men with HIV in UK are\u000a        undiagnosed, 60% believing they do not have HIV [reporting on\u000a      projected `perfect storm' in HIV transmission after the survey findings\u000a      about undiagnosed HIV among MSM]\u000a    k. Flowers et al., Exposure\u000a        and impact of a mass media campaign targeting sexual health amongst\u000a        Scottish men who have sex with men: an outcome evaluation. BMC\u000a        Public Health 2013;13:737 doi:10.1186\/1471-2458-13-737 \u000a    ","Title":"\u000a    Policy formulation and public health campaigns to target gay men's sexual\u000a      health\u000a    ","UKLocation":[{"GeoNamesId":"2648579","Name":"Glasgow"},{"GeoNamesId":"2650225","Name":"Edinburgh"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The Gay Men's Sexual Health Survey has been conducted by the\u000a      Glasgow-based Social and Public Health Sciences Unit (SPHSU), now part of\u000a      the University of Glasgow (see below) every three years since 1996. This\u000a      community-based questionnaire survey of gay, bisexual and other MSM is\u000a      conducted in exclusively gay commercial venues (bars and saunas) in\u000a      Glasgow and Edinburgh, Scotland's two largest cities and the main\u000a      commercial centres of the Scottish gay scene. Around 1500 men are surveyed\u000a      each year.\u000a    The survey was originally designed to evaluate a peer-led, sexual health\u000a      intervention set up by the Gay Men's Task Force (GMTF) and modelled on a\u000a      US intervention. GMTF was a bar-based, peer- led intervention designed to\u000a      increase sexual health service use and decrease sexual risk behaviours at\u000a      the community level.1 The initial findings of this survey\u000a      called into question the transferability of sexual health interventions\u000a      from one region to another, because the GMTF failed to replicate the\u000a      successful results of the US intervention.1 The survey,\u000a      repeated every 3 years, presented the opportunity to measure\u000a      community-level changes in sexual behaviour and sexual health service use\u000a      across time. The most notable finding was an increase in sexual risk\u000a      behaviour between 1996 and 2002.2 In 1996, 10.7% of men\u000a      surveyed (and 11.2% in 1999) reported unprotected anal intercourse (UAI)\u000a      with casual partners. This increased markedly to 18.6% in 2002. UAI with\u000a      more than one partner increased from 8.1% in 1996 to 13.7% in 2002. There\u000a      was also a significant increase in men reporting that they `knew' their\u000a      casual partners' HIV status, despite no increase in HIV testing among men\u000a      who reported UAI with casual partners.2 The Glasgow research\u000a      group argued that this finding could represent `prevention failure' on the\u000a      part of governments and health agencies.2\u000a    Between 2005 and 2011, the Glasgow group collected oral fluid samples\u000a      from the gay, bisexual and other MSM who took part in the survey for\u000a      anonymous HIV testing to improve the estimate of HIV prevalence and\u000a      undiagnosed infection in this population. These were the first data on HIV\u000a      prevalence and undiagnosed infection among a community-based sample of gay\u000a      men in Scotland; 4% of the men tested were HIV-positive, and of these, 42%\u000a      were undiagnosed.3 In collaboration with University College\u000a      London (UCL), data from surveys of gay men in London, Brighton, and\u000a      Manchester in 2003 and 2004 were combined with the Scottish data from 2005\u000a      to examine factors associated with undiagnosed HIV infection. The results,\u000a      published in 20084, revealed that most men with undiagnosed HIV\u000a      had previously tested HIV-negative, suggesting a need to promote frequent\u000a      repeat testing among high-risk men to reduce the levels of undiagnosed HIV\u000a      and ultimately the number of new infections in the UK.\u000a    The Glasgow group demonstrated that changes to HIV testing policy to\u000a      opt-out testing introduced in 2005, significantly increased recent testing\u000a      from 33.2% to 48.3% among gay men in Scotland between 2005 and 2008 and\u000a      potentially contributed to a substantial reduction in levels of\u000a      undiagnosed HIV from the 42% seen in 2005 to 26% in 2008.5\u000a      However, analysis of the survey findings between 1996 and 2008 also show\u000a      that HIV-related sexual risk behaviour is not diminishing, with the number\u000a      of men reporting UAI with more than one partner in 2008 remaining at the\u000a      level previously reported in 2002 (13.1%).6\u000a    Key researchers: Dr Lisa McDaid (n&#233;e Williamson; Research\u000a      Assistant [2000] then Senior Investigator Scientist [to 2010] then\u000a      Programme Leader Track [to 2012] then Programme Leader [to present]) and\u000a      Professor Graham Hart (Programme Leader and Associate Director, 1994&#8212;2005)\u000a      both McDaid and Hart are\/were members of the Medical Research\u000a      Council\/Chief Scientist Office (MRC\/CSO) SPHSU during the research period.\u000a      On 1 June 2013, the SPHSU was transferred to the Institute of Health and\u000a      Wellbeing at the University of Glasgow and SPHSU staff became employees of\u000a      the University. Permission has been granted from HEFCE to submit this case\u000a      study. Key collaborators: Paul Flowers (Professor of Sexual\u000a      Health Psychology, Glasgow Caledonian University); Danielle Mercey (Senior\u000a      Clinical Lecturer, University College London); Anne Johnson (Professor of\u000a      Infectious Disease Epidemiology, University College London).\u000a    "},{"CaseStudyId":"32380","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"1269750","Name":"India"}],"Funders":[],"ImpactDetails":"\u000a    Cardiovascular disease, resulting from damage to the heart, blood vessels\u000a      or both, is the leading cause of death worldwide. Current estimates\u000a      suggest that more than 7000 European and American adults die of\u000a      cardiovascular disease every day. Heart disease, a major form of\u000a      cardiovascular disease, is a broad term used to describe heart failure,\u000a      heart attack and angina, all of which present a substantial economic\u000a      burden to healthcare services. For example, in 2010-2011, it is estimated\u000a      that the NHS spent in excess of &#163;2 billion on patients with heart failure,\u000a      with around 70% of this expenditure reflecting hospitalisation. Medical\u000a      therapy limits heart disease progression and patients are typically\u000a      treated with a lifelong prescription of multiple classes of drugs. Since\u000a      2008, landmark clinical trials with leadership involvement of the RCB have\u000a      led to the expansion of therapeutic options for patients with heart\u000a      failure.\u000a    Regulatory approval\u000a    Conducting well-designed RCTs to determine whether medications are safe\u000a      and effective is the lynchpin of gaining regulatory approval for their use\u000a      in patients. Ivabradine (brand name, Procoralan) was originally approved\u000a      by the European Medicines Agency (EMA) in 2005 specifically for the\u000a      treatment of long-term angina among people with normal heart rhythm. The\u000a      findings of BEAUTIFUL prompted the manufacturer of this drug (leading\u000a      French pharmaceutical company Servier) to apply for an extension to the\u000a      original indication (angina).a In October 2009, the EMA\u000a      approved ivabradine as an add-on therapy (on top of beta blockers) for the\u000a      treatment of long-term angina in patients with coronary artery disease and\u000a      normal heart rhythm.b The BEAUTIFUL study (CL3-056) was\u000a      extensively cited as key supporting evidence for clinical benefit and\u000a      acceptable safety profile in this application (sections I.2.2 and I.2.3).\u000a      In March 2012, the EMA Committee for Medicinal Products for Human Use\u000a      (CHMP) granted a further request by Servier to extend the indications for\u000a      ivabradine to include patients with chronic heart failure.b The\u000a      SHIFT study (CL3-16257-063) was cited as the sole supporting evidence in\u000a      the CHMP assessment report (sections 1.1, 2.1, 2.3, 2.4 and 3).\u000a      Consequently, the CHMP recommendation for this novel use of ivabradine\u000a      (variation C.I.6.a; section 4) was based entirely on information made\u000a      available by the SHIFT investigators.\u000a    Commenting on the key role of the RCB in this approval process, Servier's\u000a      Director of the Division for Medical Affairs stated that `The\u000a        internationally recognised combination of outstanding biostatistical\u000a        skill, knowledge of the disease area and experience in large\u000a        cardiovascular clinical outcome trials...highlighted the synergy between\u000a        the [RCBs] expertise and our own research aims in developing treatments\u000a        for heart disease...[the] findings of BEAUTIFUL and particularly SHIFT\u000a        were pivotal in Servier's successful application to the EMA in 2012 to\u000a        extend the original licence for ivabradine in stable angina to include\u000a        heart failure'.a\u000a    The Scottish Medicines Consortium (SMC) is responsible for assessing new\u000a      treatments for use within NHS Scotland. The SMC approved the restricted\u000a      use of ivabradine for chronic heart failure in September 2012, citing\u000a      SHIFT as the sole evidence base for this decision.c In November\u000a      2012, the UK National Institute for Health and Care Excellence (NICE)\u000a      approved ivabradine for this application throughout the NHS.d\u000a      The NICE technical appraisal document (TA 267) cites SHIFT in the evidence\u000a      as the \"only randomised controlled trial that assessed the effect of\u000a        ivabradine in people with heart failure\" (section 3.1). Regulatory\u000a      approval of ivabradine in 2012 was widely reported by major UK media\u000a      outlets, including the Telegraph, Guardian, Mail\u000a        Online and Daily Mirror, reaching a potential audience of\u000a      approximately 9 million.e Specialist coverage included NHS\u000a      Choices, theheart.org, and the British Heart Foundation.\u000a    Generic drug formulations can significantly lower health costs and\u000a      improve access to treatment once brand-name drugs come off patent. Data\u000a      from IONA was cited in the evidence base supporting the marketing of\u000a      generic nicorandil in the UK. This application was approved by the\u000a      Medicines and Healthcare Products Regulatory Agency (MHRA) in November\u000a      2010.f\u000a    Clinical guidelines\u000a    RCB research has underpinned high-level recommendations in the leading\u000a      international and national guidelines on the management of patients with\u000a      heart disease.\u000a    The joint American College of Cardiology Foundation and American Heart\u000a      Association (ACCF\/AHA, estimated professional membership of 73,000)\u000a      guideline on the management of heart failure was published in June 2013.g\u000a      The CAPRICORN study of carvedilol is cited in this guideline and underpins\u000a      the following highest level (Level I) recommendations:\u000a    \u000a      \u000aIn patients with heart attack (myocardial infarction; MI) and\u000a          reduced heart output (ejection fraction; EF), evidence-based beta\u000a          blockers should be used to prevent heart\u000a          failure.\u000a\u000a      \u000aUse of 1 of the 3 beta blockers proven to reduce mortality is recommended\u000a          for all stable patients.\u000a\u000a    \u000a    Similarly, the DOT-HF results have been included in the evidence base to\u000a      form guideline recommendations on device therapy for management of chronic\u000a      (Stage C) heart failure.\u000a    In May 2012, the European Society of Cardiology (ESC; estimated\u000a      professional membership of 80,000) published guidelines on the diagnosis\u000a      and treatment of heart failure.h These guidelines cite SHIFT,\u000a      BEAUTIFUL and CAPRICORN. Data from SHIFT and BEAUTIFUL underpin the\u000a      following recommendations on the use of ivabradine:\u000a    \u000a      \u000aShould be considered to reduce the risk of heart\u000a          failure hospitalisation in patients in sinus rhythm with an EF &#8804;35%, a\u000a          heart rate remaining &#8805;70 bpm, and persisting symptoms (NYHA class\u000a          II-IV) despite treatment with an evidence-based dose of beta-blocker\u000a          (or maximum tolerated dose below that), ACE inhibitor (or ARB), and an\u000a          MRA (or ARB). SHIFT is cited as the sole underpinning evidence.\u000a      \u000aShould be considered in patients in sinus rhythm who\u000a          cannot tolerate a beta-blocker, to relieve angina (effective\u000a          antianginal treatment and safe in HF). SHIFT and BEAUTIFUL are the\u000a        only studies cited.\u000a      \u000aThe addition of ivabradine is recommended\u000a          when angina persists despite treatment with a beta-blocker (or\u000a          alternative), to relieve angina (effective antianginal treatment and\u000a          safe in HF). SHIFT and BEAUTIFUL are the only studies cited.\u000a    \u000a    Data from CAPRICORN underpins the following recommendation for carvedilol:\u000a    \u000a      \u000aA beta-blocker is recommended in patients\u000a          with an EF &#8804;40%, after stabilization, to reduce the risk of death and\u000a          recurrent myocardial infarction. CAPRICORN is the only study\u000a        cited.\u000a    \u000a    More than 158,000 copies of this guideline have been downloaded from the\u000a      ESC website, making it the leading downloaded guideline in the ESC series\u000a      in 2012.i These data are complemented by a further 28,500\u000a      downloads of the ESC pocket guideline version, with a worldwide readership\u000a      including South America, India and China.\u000a    The Scottish Intercollegiate Guidelines Network (SIGN) develops\u000a      evidence-based clinical guidelines for NHS Scotland. In February 2013,\u000a      SIGN published a guideline on acute coronary syndromes.j\u000a      CAPRICORN is cited as the sole evidence in support of the following\u000a      highest level recommendation:\u000a    \u000a      \u000aPatients with clinical myocardial infarction should be maintained\u000a          on long term beta blocker therapy.\u000a    \u000a    In summary, these landmark clinical trials with leadership involvement of\u000a      the RCB (described in section 2) have widened therapeutic options for\u000a      patients with heart failure worldwide.\u000a    ","ImpactSummary":"\u000a    Randomised placebo-controlled trials (RCTs) are the most robust way to\u000a      demonstrate the effectiveness of medical therapies. The University of\u000a      Glasgow's Robertson Centre for Biostatistics (RCB) is internationally\u000a      renowned for its biostatistical input and leading roles on landmark RCTs\u000a      of cardiovascular therapies. The findings of the BEAUTIFUL and SHIFT\u000a      studies underpinned European and UK regulatory approval for a novel use of\u000a      the heart-rate-lowering drug ivabradine, potentially preventing thousands\u000a      of hospital admissions for heart failure every year. The IONA trial\u000a      supported UK approval of generic versions of another heart drug\u000a      (nicorandil), thereby enhancing cost-effectiveness for the NHS. The\u000a      BEAUTIFUL, SHIFT, DOT-HF and CAPRICORN trials provided the evidence base\u000a      for US, European and UK guideline recommendations, steering best practice\u000a      for treatment of patients with heart disease worldwide.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Glasgow\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. The CAPRICORN Investigators. Effect\u000a        of carvedilol on outcome after myocardial infarction in patients with\u000a        left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet,\u000a      2001; 357: 1385-1390. doi:10.1016\/S0140-6736(00)04560-8\u000a    \u000a\u000a2. The IONA Study Group. Effect\u000a        of nicorandil on coronary events in patients with stable angina: the\u000a        Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet,\u000a      2002; 359: 1269-1275. doi:10.1016\/S0140-6736(02)08265-X\u000a    \u000a\u000a3. Fox K, et al. on behalf of the BEAUTIFUL Investigators. Ivabradine\u000a        for patients with stable coronary artery disease and left-ventricular\u000a        systolic dysfunction (BEAUTIFUL): a randomised,double-blind,\u000a        placebo-controlled trial. Lancet, 2008; 372: 807-816.\u000a      doi:10.1016\/S0140-6736(08)61170-8\u000a    \u000a\u000a4. Swedberg K, et al. on behalf of the SHIFT Investigators. Ivabradine\u000a        and outcomes in chronic heart failure (SHIFT): a randomised\u000a        placebo-controlled study. Lancet, 2010; 376: 875-885.\u000a      doi:10.1016\/S0140-6736(10)61198-1\u000a    \u000a\u000a5. The DOT-HF invesitgators. Intrathoracic\u000a        impedance monitoring, audible patient alerts, and outcome in patients with heart failure.\u000a      Circulation,\u000a      2011; 124:1719-26. doi: 10.1161\/CIRCULATIONAHA.111.043042\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    a. Statement from Servier Director of the Division for Medical Affairs\u000a    b. EMA approval of licence extension for ivabradine, 2009\u000a      and 2012\u000a    c. SMC\u000a        No. 805\/12, 2012\u000a    d. NICE\u000a        TA267, 2012\u000a    e. Media coverage of regulatory approval of ivabradine, 2012: Telegraph,\u000a      Guardian,\u000a      Mail\u000a        Online and Daily\u000a        Mirror\u000a    f. MHRA\u000a        approval of generic nicorandil, 2010\u000a    g. ACCF\/AHA\u000a        guideline on heart failure, 2013 Recommendations for treatment of\u000a      stage B HF; CAPRICORN (ref 346), Table 12, p261 and Table 19, p275; DOT-HF\u000a      (table 28, p109 data supplement) referenced on p277\u000a    h. ESC\u000a        guideline on heart failure, 2012 Other treatments for systolic HF,\u000a      p1808, SHIFT (ref 112); Alternatives to beta-blockers, p1822, SHIFT and\u000a      BEAUTIFUL (ref 122); Recommendations for acute HF, p1829, CAPRICORN (ref\u000a      223).\u000a    i. ESC 2012 guideline download data up to June 2013 &#8212; were obtained\u000a      directly through correspondence with the ESC, copies of the data are\u000a      available on request\u000a    j. SIGN guideline 93 on\u000a        acute coronary syndromes, 2013 Beta blocker therapy, p24, CAPRICORN\u000a      (ref 169) \u000a    ","Title":"\u000a    ractice-changing clinical trials expand the treatment options for heart\u000a      disease\u000a    ","UKLocation":[{"GeoNamesId":"2648579","Name":"Glasgow"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The University of Glasgow RCB is a world-renowned centre of excellence in\u000a      the collaborative conduct of national and international multicentre\u000a      clinical trials, particularly those involving cardiovascular\u000a      therapies\/devices. The RCB comprises statisticians, trial managers and IT\u000a      staff who make key contributions to the design and protocols of RCTs. In\u000a      addition, they co-ordinate trial implementation, conduct interim and final\u000a      analyses, and interpret the clinical outcome data. To complement this, RCB\u000a      investigators have extensive experience of the clinical context and\u000a      epidemiology of cardiovascular disease. Such robust methodologies have\u000a      contributed to the RCB's position as a leading UK Clinical Research\u000a      Collaboration registered Clinical Trials Unit (since 2007) and formed the\u000a      foundation of its role in the highly successful National Institute for\u000a      Health Research Stroke Research Network. RCTs performed by the RCB that\u000a      underpin this case study include CAPRICORN (2001),1 IONA\u000a      (2002),2 BEAUTIFUL (2008),3 SHIFT (2010)4\u000a      and DOT-HF (2011).5\u000a    Carvedilol improves survival in patients with a history of heart\u000a       attack\u000a    In the mid-1990s, it was unclear whether beta-blockers were beneficial\u000a      when given in addition to angiotensin-converting-enzyme (ACE) inhibitors\u000a      to patients with severe cardiac disease (e.g. patients such as those who\u000a      had just experienced a heart attack and were at high risk of subsequent\u000a      cardiovascular events). Professor Ian Ford was on the Steering Committee\u000a      of CAPRICORN, which was designed and analysed in collaboration with the\u000a      RCB. This RCT examined the effect of the beta-blocker carvedilol in 1,959\u000a      patients from 17 countries worldwide with abnormal heart function (left\u000a      ventricular dysfunction) following a heart attack. Treatment with\u000a      carvedilol (on top of background ACE inhibitor therapy) led to a 23%\u000a      reduction in mortality during follow-up (average 1.3 years), supporting\u000a      the use of beta-blockers in this patient population.1\u000a    Nicorandil is cardioprotective in patients with stable angina\u000a    Stable angina is a form of chest pain or discomfort that occurs upon\u000a      exertion and results from poor blood flow through the arteries of the\u000a      heart. The pioneering IONA study was designed, conducted and analysed by\u000a      the RCB, with Ford serving on the Steering Committee. This RCT assessed\u000a      the effects of nicorandil (a drug that maintains blood flow to the heart)\u000a      on morbidity and mortality among 5,126 patients, recruited from across the\u000a      UK, with stable angina pectoris. The findings of IONA (2002) showed a 17%\u000a      reduction in the risk of coronary events and deaths in patients being\u000a      treated with nicorandil compared with placebo.2\u000a    Ivabradine reduces cardiovascular events in heart failure patients\u000a          with elevated heart rate\u000a    Elevated heart rate is an established risk factor for cardiovascular\u000a      events. BEAUTIFUL was the first RCT to examine the effect of ivabradine (a\u000a      drug that lowers heart rate) on cardiovascular events. This study involved\u000a      10,917 patients with coronary disease and left ventricular dysfunction who\u000a      were recruited internationally. Whilst ivabradine did not affect the\u000a      composite primary endpoint in the general trial population, the results\u000a      established the importance of a heart rate over 70 beats per minute (bpm)\u000a      in identifying high-risk patients and those who might benefit from\u000a      heart-rate-lowering therapy.3 The ground-breaking SHIFT study\u000a      of 6,558 patients demonstrated the ability of ivabradine to reduce\u000a      cardiovascular death or hospital admission for heart failure by 18% among\u000a      individuals with a heart rate above 70bpm.4 SHIFT was the first\u000a      RCT to provide robust evidence that lowering heart rate can specifically\u000a      reduce the incidence of cardiovascular events, and provide an additional\u000a      therapy on top of the maximally tolerated beta-blocker dose to further\u000a      improve outcomes for patients with heart failure. Ford had key roles on\u000a      the Executive Committees of BEAUTIFUL and SHIFT, which were designed and\u000a      analysed with considerable involvement of the RCB.\u000a    Implantable devices to enable early detection of fluid accumulation\u000a          in heart failure patients\u000a    Progressive worsening of heart failure results in fluid accumulation in\u000a      the lungs and peripheral tissues, which requires emergency hospitalisation\u000a      and urgent in-patient intensification of therapy to relieve fluid\u000a      overload. Contrary to expectations, the DOT-HF trial determined that\u000a      implantation of expensive devices to detect fluid accumulation at an early\u000a      stage and intensify treatment as an out-patient resulted in higher rather\u000a      than lower rate of heart failure hospitalisation (and no improvement in\u000a      any other outcome). This negative result was important as it challenged\u000a      the rationale that the use of expensive technology to detect and manage\u000a      fluid overload could improve patient outcomes in patients with heart\u000a      failure.5\u000a    In summary, the RCB held leading roles in these four major projects\u000a      providing vital, independent analysis in all of these practice-changing\u000a      trials &#8212; an important point given that the individual members of steering\u000a      committees and trial management groups differed across all four trials.\u000a    Key University of Glasgow researchers: Ian Ford (Professor of\u000a      Statistics\/Biostatistics [1992-present] all trials above); Michele\u000a      Robertson (Consultant statistician [1994-2008], Senior statistician,\u000a      [2008-2010], Assistant Director Commercial Biostatistics [2010-present];\u000a      CAPRICORN, BEAUTIFUL and SHIFT); Henry Dargie (Professor of Cardiology\u000a      [1994-1999], Honorary Senior Research Fellow [1999-present]; Steering\u000a      committee CAPRICORN, IONA); William Hillis (Professor of Cardiovascular\u000a      and Exercise Medicine [1997-2008]; Steering committee IONA). External\u000a        collaborators: Members of the Executive Committees (SHIFT,\u000a      BEAUTIFUL) and Steering Committees (IONA, CAPRICORN, DOT-HF); see original\u000a      articles for details.\u000a    "},{"CaseStudyId":"32388","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    Practitioner empathy involves an ability to understand the patient's\u000a      situation, perspective and feelings, the capability to communicate and\u000a      confirm this with the patient, and subsequently apply this understanding\u000a      in a therapeutic manner. Before 2000 there were no validated measures to\u000a      assess empathy that were suitable for use in routine healthcare across a\u000a      range of settings. Research at University of Glasgow has developed the\u000a      first validated patient-rated questionnaire in a primary care setting that\u000a      measures patient perceptions of healthcare professionals' empathy and\u000a      quality of care for general practice.\u000a    The CARE Measure is freely available to download from the University of\u000a      Glasgow website.a The image to the right illustrates the\u000a      questions involved in the measure. Since 2004, the CARE Measure has formed\u000a      an integral component of professional bodies and government initiatives\u000a      (details of which are provided below):\u000a    \u000a      RCGP professional training standards, to facilitate assessment,\u000a        appraisal and revalidation\u000a      Scottish Government policy on Healthcare Quality\u000a      Chartered Society of Physiotherapy patient experience reporting\u000a    \u000a\u0009  \u000a\u0009  \u000a\u0009  \u000a    In addition, funding was provided by the Scottish Government to establish\u000a      a website in 2012 as part of the validation work in Allied Health\u000a      Professionals, led by Duncan in collaboration with Mercer.b\u000a      This website facilitates the collection and use of CARE Measure data from\u000a      medical, Nursing and Allied Health Professional practitioners, allowing\u000a      registered users to compare their data with that of their peers, to\u000a      identify any potential areas of improvement. Between going live in\u000a      September 2012 and 31st July 2013, there were 1180 registered\u000a      users, primarily doctors.c\u000a    Incorporation of the CARE Measure in RCGP professional training\u000a          standards to facilitate assessment, appraisal and revalidation\u000a    The MRCGP exam is a compulsory assessment system that complies with the\u000a      standards set by the UK's GMC. It confirms a doctor's competence in the\u000a      speciality of General Practice and ability to practice independently in\u000a      the UK. Completion of the MRCGP is a pre-requisite for the certificate of\u000a      completion of training (CCT) and full RCGP membership. Since August 2007,\u000a      the CARE Measure (renamed Patient Satisfaction Questionnaire (PSQ) by the\u000a      RCGPd) has been used as a compulsory evidence-based tool in the\u000a      Workplace-Based Assessment component of the MRCGP Exame. In\u000a      this capacity, the PSQ allows patient feedback to be gathered on empathy\u000a      and relationship-building with each GP trainee. Two cycles of the PSQ are\u000a      used during the training period: once in GP placement in Speciality\u000a      Training year 1 or year 2 and once in Speciality Training year 3.e\u000a      The RCGP estimates that with approximately 3,000 GP trainees each year, an\u000a      average of 33,000 cycles of PSQ were completed by trainees between 1st\u000a      Jan 2008 and 31st July 2013.e The decision by RCGP\u000a      to adopt the CARE Measure was based on its proven ability to effectively\u000a      discriminate between doctors [references 3 and 4, above].\u000a    iMAP is the process whereby independent practitioners on the GP register\u000a      may become members of the RCGP. Assessment for membership on this basis\u000a      requires the completion of fifteen compulsory modules, one of which\u000a      specifically addresses the PSQ. The PSQ was initially the only tool to\u000a      facilitate this when iMAP was launched in 2007.f It is now one\u000a      of seven tools approved; encouraging its uptake, it is the only tool\u000a      available free of charge.g The RCGP estimates that since 2007,\u000a      approximately 30% of applicants to iMAP used the PSQ.f The\u000a      decision by RCGP to adopt the CARE Measure was based on its proven ability\u000a      to effectively discriminate between doctors [references 3 and 4, above].\u000a    Revalidation is the process by which all 60,000 licensed doctors must\u000a      demonstrate to the GMC that they are up to date and fit to practice; this\u000a      ensures compliance with the relevant professional standards, and is thus\u000a      compulsory to maintain a license to practice. To determine its suitability\u000a      for use in revalidation, the CARE Measure has twice been comprehensively\u000a      reviewed by the RCGP; in 2009 it was one of nine patient feedback tools\u000a      reviewed,h and in 2010 it was one of ten reviewed.h\u000a      Subsequently, the CARE Measure has been fully endorsed by RCGP as a `fit\u000a      for purpose' patient survey for use in the revalidation process.h,i\u000a      The CARE Measure is used by GPs in Scotland as both a patient satisfaction\u000a      survey and for appraisal and revalidation; it is listed in the Scottish\u000a      Online Appraisal Resource (the key online information point for GP\u000a      Appraisal).j,k Since 2004, it has been accredited for use in\u000a      appraisal of all GPs in Scotland.l The decision by the GMC to\u000a      adopt the CARE Measure was based on its proven ability to effectively\u000a      discriminate between doctors [references 3-6, above].\u000a    Implementation of the CARE Measure into government policy\u000a    In Scotland, the CARE Measure is detailed in the Government's Quality\u000a      Strategy (2010).m The Quality Strategy aims to allow those\u000a      involved in Scotland's healthcare &#8212; namely all healthcare professionals\u000a      (numbering 100,000), partners and the public &#8212; to work towards achieving\u000a      three Quality Ambitions of Safe, Person-Centred and Effective healthcare.\u000a      The Quality Strategy specifies the use of the CARE Measure as a tool to\u000a      capture patients' assessments of their relationships with healthcare\u000a      professionals, allowing an understanding of health outcomes and patient\u000a      experience to be determined, and for improvement to be informed where\u000a      required.m Inclusion of the CARE Measure has made Scotland the\u000a      first country in the world to include staff empathy as a component of\u000a      healthcare quality. The decision by the Government to adopt the CARE\u000a      Measure was based on its proven ability to effectively discriminate\u000a      between practitioners [references 3-6, above], and by a series of\u000a      high-level meetings and discussion between Mercer and the Scottish\u000a      Government between 2009-2010, including the Chief Executive of NHS\u000a      Scotland at the time (Dr Derek Feeley) and the then Cabinet Secretary and\u000a      Minister for Health, Nicola Sturgeon.\u000a    Implementation of the CARE Measure as a validated Patient\u000a          Reported Experience Measure\u000a    Since 2012, the Chartered Society of Physiotherapy has recommended the\u000a      CARE Measure to their 52,000 members (98% of UK physiotherapists).n\u000a      In this context, the CARE Measure is being used by the Chartered Society\u000a      of Physiotherapy as the primary validated Patient Reported Experience\u000a      Measure, to assess and improve Physiotherapy services along with the\u000a      overall patient journey.n The CARE Measure became a\u000a      recommendation after a 2009 Scottish pilot study (collaboration between\u000a      University of Glasgow and University of Stirling) associated with\u000a      Physiotherapy training and person centred care, which subsequently led to\u000a      involvement in validation work in Allied Health Professionals.\u000a    ","ImpactSummary":"\u000a    The ability of healthcare professionals to empathise with patients has\u000a      been shown to enhance patient satisfaction, improve symptoms and promote\u000a      well-being. Research at University of Glasgow has developed the\u000a      Consultation and Relational Empathy (CARE) Measure &#8212; the first validated,\u000a      patient-rated questionnaire developed in a primary care setting that\u000a      measures patient perceptions of healthcare professionals' empathy and\u000a      quality of care. The CARE Measure is formally embedded into healthcare\u000a      professional training standards through its inclusion in Scottish General\u000a      Practitioner (GP) appraisals and the Royal College of General\u000a      Practitioners Membership (MRCGP) and Interim Membership by Assessment of\u000a      Performance (iMAP) processes; through these means more than 8,000 GPs are\u000a      using the CARE Measure. It has also been incorporated into the Scottish\u000a      Government's policy on Healthcare Quality and adopted by the General\u000a      Medical Council and the Chartered Society of Physiotherapy.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Glasgow\u000a    ","Institutions":[{"AlternativeName":"Glasgow (University of)","InstitutionName":"University of Glasgow","PeerGroup":"A","Region":"Scotland","UKPRN":10007794}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Mercer, S. W. &amp; Reynolds, W. Empathy\u000a        and quality of care. BJGP 2002, 52 (Supplement), S9-S12. [no\u000a      doi available]\u000a    \u000a\u000a2. Mercer, S. W. et al. The\u000a        consultation and relational empathy (CARE) measure: development and\u000a        preliminary validation and reliability of an empathy-based consultation\u000a        process measure. Fam. Pract. 2004, 21 (6), 699-705.\u000a      doi:10.1093\/fampra\/cmh621.\u000a    \u000a\u000a3. Mercer, S. W. et al. Relevance\u000a        and practical use of the Consultation and Relational Empathy (CARE)\u000a        Measure in general practice. Fam. Pract. 2005, 22 (3),\u000a      328-334. doi:10.1093\/fampra\/cmh730\u000a    \u000a\u000a4. Murphy, D. J. et al. The\u000a        reliability of workplace-based assessment in postgraduate medical\u000a        education and training: a national evaluation in general practice in the\u000a        United Kingdom. Adv. Health Sci. Educ. Theory Pract. 2009,\u000a      14: 219-232. doi: 10.1007\/s10459-008-9104-8\u000a    \u000a\u000a5. Mercer, S. W. et al. Capturing\u000a        patients' views on communication with anaesthetists: the CARE Measure.\u000a      Clin. Govern. Intl J. 2008, 13 (2): 128-137. doi:\u000a      10.1108\/14777270810867320.\u000a    \u000a\u000a6. Mercer, S.W. &amp; Murphy, D. J. Validity\u000a        and reliability of the CARE Measure in secondary care. Clin.\u000a        Govern. Intl J. 2008, 13; 269-283. doi:10.1108\/14777270810912969.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    a. CARE\u000a        Measure, University of Glasgow webpage\u000a    b. CARE Measure Website\u000a    c. Evidence to substantiate available on request (Organisation: CARE\u000a      Measure.org)\u000a    d. PSQ\u000a        Form, RCGP\u000a    e. Evidence to substantiate available on request (Organisation: RCGP)\u000a    f. Evidence to substantiate available on request (Organisation: RCGP)\u000a    g. iMAP\u000a        Handbook, RCGP, April 2013\u000a    h. Evidence to substantiate available on request (Organisation: RCGP)\u000a    i. Patient\u000a        feedback tools `fit for purpose', RCGP\u000a    j. Scottish\u000a        Online Appraisal Resource Guidance (p18), RCGP Scotland\u000a    k. Guidance\u000a        on revalidation, RCGP Scotland\u000a    l. Evidence to substantiate available on request (Organisation: RCGP\u000a      Scotland)\u000a    m. \u000a        The Healthcare Quality Strategy for NHS Scotland (May 2010)\u000a    n. Evidence to substantiate available on request (Organisation: Chartered\u000a      Society of Physiotherapy) \u000a    ","Title":"\u000a    Incorporating empathy in training standards for healthcare professionals\u000a    ","UKLocation":[{"GeoNamesId":"2636910","Name":"Stirling"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Empathy is recognised as a vital interpersonal skill that enables\u000a      healthcare professionals to provide optimal care for patients.1\u000a      Between 2000 and 2003, Mercer led the development and validation of a\u000a      novel and suitable tool to assess clinician empathy; the Consultation and\u000a      Relational Empathy (CARE) Measure. The research steps undertaken between\u000a      2000-2003 were:\u000a    Firstly, following an extensive literature review, Mercer highlighted the\u000a      importance of empathy in healthcare, whilst confirming a lack of validated\u000a      measures suitable for use in primary care1. Secondly, Mercer\u000a      led the initial development and preliminary validation of the CARE Measure\u000a      in primary care.2 An important aspect of this was the\u000a      collaborative approach taken to the measure's development and testing,\u000a      which involved patients and practitioners from both high and low\u000a      socioeconomic deprivation areas.2 The aim of developing the\u000a      measure in this manner was to ensure it was meaningful to all patients,\u000a      irrespective of their deprivation level, which was deemed to be important\u000a      given the wide health inequalities that exist in Scotland and indeed the\u000a      UK. Thirdly, Mercer led a major study on more than 3,000 patients (again\u000a      in areas of high and low deprivation) which confirmed the validity and\u000a      reliability of the CARE Measure in General Practice, and its ability to\u000a      effectively discriminate between qualified GPs; thus establishing\u000a      its utility in GP assessment.3 This research, carried out at\u000a      the University of between 2000-2003 and published in international\u000a      peer-reviewed journals, laid the academic foundation for the subsequent\u000a      adoption of the measure `by RCGP Scotland for use in GP Appraisal. The\u000a      utility of the CARE Measure in assessment of GPs in training was\u000a      then established in research led by Murphy and colleagues at NHS Education\u000a      for Scotland, (NES) in collaboration with Mercer.4 On the basis\u000a      of this cumulative research, the CARE Measure was subsequently adopted as\u000a      part of work-based assessment of GPs in training in the UK.\u000a    The utility of the CARE Measure in secondary care was established between\u000a      2003-2008 in work led by Mercer in collaboration with Murphy and others.5,6\u000a      This established validity of the measure in both primary and secondary\u000a      care.\u000a    Since 2008, the CARE Measure has been validated in other professional\u000a      groups, including Nurses and a wide range of Allied Health professionals.\u000a      The work is funded by the Scottish Government and led by Dr Edward Duncan\u000a      at Stirling University, in collaboration with Mercer. Publications are in\u000a      preparation.\u000a    Key University of Glasgow Researchers\u000a    Stewart Mercer (Clinical Fellow, [2000-2003]; Senior Clinical Fellow\u000a      [2003-2008], now Chair in Primary Care Research) led the development of\u000a      the CARE Measure; Professor Graham Watt Professor of General Practice\u000a      [1994-present]) provided mentoring input, but did not have specific\u000a      expertise in questionnaire design or validation. He was a co-author on two\u000a      publications.2,3  Alex McConnachie (Consultant Statistician\u000a      [1996-2008]) provided statistical expertise in one publication.3\u000a    Key External Collaborators\u000a    Dr Margaret Maxwell and Dr David Heaney (both University of Edinburgh),\u000a      gave advice on the methodology of validation of the CARE Measure between\u000a      2000-2003. They were co-authors on two of the CARE Measure publications.2,3\u000a        Douglas Murphy (University of Dundee) was involved in work on GPs\u000a      in training.4 Mercer led the validation work in secondary care,\u000a      with input from Murphy on the statistical analysis.5,6 Dr\u000a      Edward Duncan (The Nursing, Midwifery and Allied Health Professions\u000a      Research Unit, University of Stirling) was the Principal Investigator on a\u000a      Scottish Government funded project, involving University of Glasgow, to\u000a      validate the CARE Measure in other professional groups. Publications are\u000a      in preparation.\u000a    "},{"CaseStudyId":"35209","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2264397","Name":"Portugal"}],"Funders":[],"ImpactDetails":"\u000a    Around 300,000 people have completed the self-assessment tools through\u000a      the Diabetes UK website, general practices, road shows, faith centres,\u000a      Boots and Tesco pharmacies and PCT-organised screening events. If T2DM\u000a      could be prevented in just 3% of these people as a result, this could\u000a      produce a gross saving for the NHS of &#163;40m a year over four years.\u000a    Impact on policy\u000a    Both tools are now specifically recommended by NICE for identifying those\u000a      at high risk of T2DM (Khunti is Chair and Davies is a member of the NICE\u000a      guidance group; A,B).\u000a    The impact of the work around diabetes prevention led to Khunti and\u000a      Davies being invited, by the UK National Screening Committee, to lead on\u000a      developing the content and structure of The Handbook of Vascular Risk\u000a      Assessment, Risk Reduction and Risk Management (both the original 2008\u000a      version and updated 2012 version; C). Gray authored the section on\u000a      risk scores. The handbook is widely used within the Department of Health\u000a      and across the NHS and was also a major contributor to the development of\u000a      the Department of Health Best Practice Guidance (2009; D).\u000a    Impact on public expenditure\u000a    Modelling work by NICE showed that utilising risk scores in a screening\u000a      programme is cost-effective and is likely to be cost-saving in those from\u000a      black and minority ethnic backgrounds. Work carried out by the Centre\u000a      shows that the cost per case detected is lowered significantly, from &#163;350\u000a      to around &#163;200, by incorporating risk scores (E).\u000a    Impact on public health in the UK\u000a    Clinical commissioning groups: The self-assessment tool is being\u000a      used by clinical commissioning groups around the country at screening\u000a      events. It is also used to target people for the NHS Health Check, a\u000a      programme to prevent heart disease, stroke, diabetes and kidney disease.\u000a      Here it identifies those at high risk, who can then be given support and\u000a      lifestyle interventions to reduce their risk and prevent onset of these\u000a      conditions.\u000a    Healthy Lifestyle roadshows: Diabetes UK has used the\u000a      self-assessment tool at local road shows since 2011. In 2012 (latest\u000a      available figures) they carried out 20,911 risk assessments and referred\u000a      10,945 visitors, 3,700 of whom were at high risk of having or developing\u000a      T2DM in the next 10 years. In a survey conducted in 2011, of those who\u000a      were in these higher risk categories, 69% had been to their general\u000a      practice or intend to go. Recall of the risk factors for T2DM and how to\u000a      reduce risk was high among visitors two months after attending the road\u000a      show (F).\u000a    Evaluation of the use of the self-assessment score within Diabetes UK\u000a      activities showed that after being risk assessed: 41% had started to eat\u000a      more healthily and a further 44% intended to; 33% had increased their\u000a      physical activity levels and a further 43% intended to; and 44% of those\u000a      referred to their GP had been to their GP to seek a test. Bridget Turner\u000a      of Diabetes UK says: \"The diabetes risk score plays an important part in\u000a      encouraging more people to take greater notice of their health and their\u000a      lifestyles &#8212; helping to tackle the growing public health challenge of Type\u000a      2 diabetes and working towards earlier diagnosis and prevention.\" (G).\u000a    Community Champions: Diabetes UK has embarked on a programme of\u000a      awareness-raising within black and minority ethnic communities by\u000a      recruiting 'Community Champions' &#8212; volunteers who are trained to deliver\u000a      healthy lifestyle and diabetes awareness messages, through information\u000a      stands and talks at community centres, places of worship and at festivals\u000a      and events. Over 100 champions have been trained in London, and the\u000a      programme is being rolled out in four other towns across England. Some\u000a      champions have been trained to undertake the risk assessments.\u000a    Faith centres: The test has been used with 200 people in three\u000a      faith centres in Leicester, by interpreters using iPads. It is being\u000a      adapted for use by non-English speaking Guajarati speakers.\u000a    Pharmacies: In conjunction with Diabetes UK the self-assessment\u000a      test is available in Boots and Tesco pharmacies: the latter is advertising\u000a      the service on buses, taxis, and London Underground carriages; on radio\u000a      stations and online; and in shopping centres and on high streets across\u000a      the UK In Northern Ireland during Diabetes Week 2011, Diabetes UK ran a\u000a      risk assessment event in 11 Boots stores: 140 risk assessments were\u000a      carried out, with 25 people referred to their GP. The Regional Pharmacy\u000a      Manager, Boots, said: \"We were delighted with the success of our recent\u000a      work with Diabetes UK Northern Ireland. In helping to identify patients\u000a      who are at high risk of diabetes, we can work with other healthcare\u000a      professionals to ensure an early diagnosis is made and help people reduce\u000a      their risk.\" (H).\u000a    In Wales, the self-assessment score was used in 700 pharmacies as part of\u000a      a free health check initiative; the 10-day Diabetes UK Cymru\/Community\u000a      Pharmacy Wales project 2011. This project involved an extensive media\u000a      campaign. More than 17,500 people visited their local pharmacy for the\u000a      assessment with 1,478 (8.4%) being referred to their GP for a diabetes\u000a      test after being found to be at high risk of developing the condition (I).\u000a    Online and TV: The test has been available on the Diabetes UK\u000a      website since 2011 and is now on the Boots and Tesco websites, free of\u000a      charge. It has been used by over 260,000 people since July 2011. It was\u000a      featured in the Embarrassing Bodies programme (Channel 4, 6 June 2011),\u000a      reaching around 2 million viewers. The automated tool allows for targeted\u000a      population-based screening within primary care and is available on the\u000a      University's website. It will soon be available through the Royal College\u000a      of General Practitioners website.\u000a    International impact\u000a    Khunti and Gray are part of the International Diabetes Federation's\u000a      PREDICT 2 project which is developing a global risk score to be used in\u000a      developing countries. Gray is currently developing risk scores for use in\u000a      Portugal and Spain.\u000a    Awards\u000a    Davies was awarded a prestigious NIHR Senior Investigator status in 2009\u000a      and this was renewed to the maximum term in 2012. The risk scores were\u000a      awarded gold at the national Quality in Care (QIC) Diabetes Awards 2011\u000a      for the best early detection\/screening initiative, and Gray won the Best\u000a      Presentation Prize at the World Congress for the Prevention of Diabetes\u000a      2011.\u000a    ","ImpactSummary":"\u000a    Around 2.5 million people in the UK have Type 2 diabetes, with many more\u000a      in a pre-diabetic state, Both conditions are hard to detect and frequently\u000a      remain undiagnosed and untreated for years. The cost burden to the NHS of\u000a      eventual treatment is estimated at &#163;10 billion; 80% of which is spent on\u000a      complications that are, with good care, avoidable. Targeted diabetes\u000a      prevention programmes could aid in prevalence reduction and associated\u000a      costs. Leicester's Diabetes Research Centre has developed two risk scores,\u000a      both suitable for use with an ethnically diverse UK population, to detect\u000a      these conditions: a self-assessment questionnaire and a general practice\u000a      database tool. Recommended by NICE, they have been used successfully in\u000a      varied settings. Since July 2011, around 260,000 people have completed the\u000a      self-assessment score online and more than 40,000 through other means.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Leicester\u000a    ","Institutions":[{"AlternativeName":"Leicester (University of)","InstitutionName":"University of Leicester","PeerGroup":"A","Region":"East Midlands","UKPRN":10007796}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"1266622","Name":"Khunti"}],"References":"\u000a    \u000a1 Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu\u000a      RT, Khunti K. Pharmacological and lifestyle interventions to\u000a      prevent or delay type 2 diabetes in people with impaired glucose\u000a      tolerance: systematic review and meta-analysis. BMJ. 2007 Feb\u000a      10;334(7588):299. Epub 2007 Jan 19. Review.\u000a    \u000a\u000a2 Eborall HC, Stone MA, Aujla N, Taub N, Davies MJ, Khunti K:\u000a      Influences on the uptake of diabetes screening in primary care. Br J Gen\u000a      Pract 2012, 62(596):e204-11.\u000a    \u000a\u000a3 Webb DR, Gray L.J, Khunti K, Srinivasan B, Taub N,\u000a      Campbell S, Barnett J, Farooqi A, Echouffo-Tcheugui JB, Griffin SJ,\u000a      Wareham NJ, Davies MJ. Screening for diabetes using an oral\u000a      glucose tolerance test within a western multi-ethnic population identifies\u000a      modifiable cardiovascular risk: the ADDITION-Leicester study.\u000a      Diabetologia. 2011 Sep;54(9):2237-46\u000a    \u000a\u000a4 Gray L.J, Taub NA, Khunti K, Gardiner E, Hiles S, Webb\u000a      DR, Srinivasan BT, Davies MJ. The Leicester Risk Assessment score\u000a      for detecting undiagnosed Type 2 diabetes and impaired glucose regulation\u000a      for use in a multi-ethnic UK setting. Diabet Med. 2010 Aug;27(8):887-95.\u000a    \u000a\u000a5 Gray L.J, Davies MJ, Hiles S, Taub N, Webb DR,\u000a      Srinivasan BT, Khunti K. Detection of Impaired Glucose Regulation\u000a      and\/or Type 2 Diabetes Mellitus, using primary care electronic data, in a\u000a      multi-ethnic UK community setting. Diabetologia. 2012 Apr;55(4):959-66.\u000a    \u000a\u000a6. Gray L.J., Tringham J.R., Davies M.J., Webb D.R.,\u000a      Jarvis, J.,Skinner T.C., Farooqi A.M., Khunti K. (2010). Screening\u000a      for type 2 diabetes in a multi-ethnic setting using known risk factors to\u000a      identify those at high risk: a cross-sectional study. Vascular Health and\u000a      Risk Management, 6:837- 42.\u000a    \u000a\u000a7 Gray L.J, Khunti K, Edwardson C, Goldby S, Henson J, Morris DH,\u000a      Sheppard D, Webb D, Williams S, Yates T, Davies MJ. Implementation\u000a      of the automated Leicester Practice Risk Score in two diabetes prevention\u000a      trials provides a high yield of people with abnormal glucose tolerance.\u000a      Diabetologia. 2012 Dec;55(12):3238-44.\u000a    \u000aGrants\u000a    NIHR. A community based primary prevention programme for Type 2 Diabetes\u000a      integrating identification, lifestyle intervention and community services\u000a      for prevention &#8212; the Let's Prevent Study. (June 2007-June 2014).\u000a      &#163;1,993,371\u000a    CLAHRC LNR. The Walking Away from Diabetes Study, The Leicester-self\u000a      assessment score, PRISM, ATTEND. (June 2008-June 2013). &#163;10,234,278\u000a    NIHR: Development of a structured screening and lifestyle intervention\u000a      for prevention of Type 2 Diabetes Mellitus in a population with Learning\u000a      Disabilities. (Oct 2011-Oct 2016). &#163;1,894,340\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    A. Chatterton H, Younger T, Fischer A, Khunti K; Programme\u000a      Development Group (2012) Risk identification and interventions to prevent\u000a      type 2 diabetes in adults at high risk: summary of NICE guidance. BMJ.\u000a      2012 Jul 12; 345:e4624. doi: 10.1136\/bmj.e4624.\u000a    B. National Institute for Health and Clinical Excellence (2012) Preventing\u000a        type 2 diabetes: risk identification and interventions for individuals\u000a        at high risk. Public health guidance, PH38. http:\/\/www.nice.org.uk\/PH38.\u000a    C. UK National Screening Committee. The Handbook of Vascular Risk\u000a      Assessment, Risk Reduction and Risk Management (2012). www.screening.nhs.uk\/getdata.php?id=14338\u000a    D. National Operations Manager, UK National Screening Committee\/NHS\u000a      Screening Programmes. 10 July 2013\u000a    E. Khunti K, Gillies CL, Taub NA, Mostafa SA, Hiles SL, Abrams\u000a      KR, Davies MJ. A\u000a        comparison of cost per case detected of screening strategies for Type 2\u000a        diabetes and impaired glucose regulation: modelling study. Diabetes\u000a      Res Clin Pract. 2012 97(3):505-13. doi: 10.1016\/j.diabres.2012.03.009.\u000a      Epub 2012 May 2.\u000a    F. Healthy Lifestyle road shows: http:\/\/www.diabetes.org.uk\/Documents\/Reports\/nhs-health-\u000a        check-lets-get-it-right-0912.pdf\u000a    G. Director of Policy &amp; Care Improvement, Diabetes UK. 14 June 2013\u000a    H. Diabetes UK Northern Ireland campaign: http:\/\/www.lurganmail.co.uk\/news\/boots-staff-help-identify-people-with-diabetes-risk-1-2911076.\u000a    I. Diabetes UK Wales campaign:\u000a      http:\/\/www.diabetes.org.uk\/In_Your_Area\/Wales\/Campaigning\/Pharmacy-campaign\/,\u000a      http:\/\/www.cpwales.org.uk\/News\/September-2011\/Diabetes-Risk-Campaign-(Nualu)-Final-Version--(2).aspx\u000a    ","Title":"\u000a    Pre-diabetes and Type 2 diabetes: Risk-assessment tools for early\u000a      detection and prevention\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2644668","Name":"Leicester"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2641364","Name":"Northern Ireland"},{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Benefits of early detection\u000a    Type 2 diabetes (T2DM) is one of the most common long-term conditions\u000a      globally; it is also non-communicable and potentially preventable. In the\u000a      UK around 10% of the adult population over 45 has T2DM, and diabetes\u000a      prevalence is increasing steadily due to an ageing population, high\u000a      obesity levels and a more ethnically diverse make-up. T2DM is preceded by\u000a      a pre-diabetic state called impaired glucose regulation (IGR).\u000a      Population-based screening studies have shown that around 20% of the adult\u000a      population over 45 has an undiagnosed glucose disorder and this prevalence\u000a      is significantly higher (up to six times) in those from black and minority\u000a      ethnic groups.\u000a    Need for novel screening strategies\u000a    Leicester's Diabetes Research Centre, one of the largest of its kind in\u000a      Europe, focuses on finding new ways of identifying people at high risk of\u000a      diabetes as well as developing effective interventions to stop, slow and\u000a      treat the condition.\u000a    In 2007, a study reported in the BMJ showed that timely treatment with\u000a      medication or modifications to lifestyle can delay or prevent progression\u000a      to T2DM in people with IGR, as well as the development of complications\u000a      such as heart and renal disease in people with T2DM (1). Despite\u000a      the evidence for these benefits, uptake in screening programmes is\u000a      generally low, and lower still in black and minority ethnic populations. A\u000a      qualitative study identified a number of barriers to uptake of screening:\u000a      the time commitment involved in attending a long appointment during\u000a      working hours, low self-perception of risk, difficulties with arranging\u000a      general practice appointments, and dislike of oral glucose tolerance tests\u000a      (2). The findings highlighted the need for novel screening\u000a      strategies.\u000a    Two self-assessment scores for an ethnically diverse population\u000a    In 2008, the Centre offered screening within 20 general practices to\u000a      30,950 randomly selected people from Leicestershire, who had not been\u000a      previously diagnosed with T2DM (3). Of these, 6,390 took up the\u000a      offer, and a fifth were identified as either having undiagnosed T2DM or at\u000a      high-risk of developing the disease. A comprehensive set of data &#8212; sex,\u000a      BMI, waist circumference, family history of diabetes, history of high\u000a      blood pressure and ethnicity &#8212; as well as oral glucose tolerance tests,\u000a      was collected from all those attending.\u000a    This data was used to develop two scores to detect undiagnosed IGR or\u000a      T2DM in an ethnically diverse population; the results were published in\u000a      leading journals Diabetic Medicine and Diabetologia (4,5). The\u000a      Leicester Self-Assessment (LSA) score is based on factors known to the\u000a      patient and the Leicester Practice Risk (LPR) score is designed to enable\u000a      general practices to identify those at highest risk in their populations,\u000a      using routinely stored data (minus waist circumference). These are the\u000a      first scores that have been specifically developed or validated in a UK\u000a      multi-ethnic population. Both scores were externally validated using data\u000a      from a second screening study (6).\u000a    Clinical trials\u000a    The tools have been successfully used to identify those at risk in\u000a      clinical studies led by the Centre: the Let's Prevent Diabetes trial used\u000a      the LPR score to rank people by risk of IGR\/T2DM within general practices,\u000a      and those with the highest 10% of scores were then invited for\u000a      second-stage screening and a quarter of those screened were found to have\u000a      either IGR or T2DM (7). Similar results were seen for a study into\u000a      the Walking Away from Diabetes programme, a 3-hour course which offers\u000a      participants the opportunity to explore their risk of developing diabetes\u000a      and to identify the changes they need to make to remain healthy. The\u000a      self-assessment score is being used in two CLAHRC (Collaboration for\u000a      Leadership in Applied Health Research and Care) early detection studies,\u000a      ATTEND and PRISM, which have screened over 3,000 participants to date.\u000a    Key Leicester researchers: Melanie Davies, Professor of Diabetes\u000a      Medicine, 2006-present; Kamlesh Khunti, Professor of Primary Care Diabetes\u000a      and Vascular Medicine, 2007-present; Dr Laura Gray, Lecturer of Population\u000a      and Public Health Sciences, 2008-present\u000a    Other Leicester researchers: Dr Clare Gillies, Lecturer in Medical\u000a      Statistics, 2000-present; Dr Helen Eborall, Lecturer in Social Sciences,\u000a      2008-present; Dr Margaret Stone, Sen. Res. Fellow, 1999-present.\u000a    "},{"CaseStudyId":"35582","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    The NICE appraisal process depends on evaluations of efficacy and\u000a      cost-effectiveness in various\u000a      circumstances, and these appraisals are always based in the multiple\u000a      technology appraisal\u000a      process on the work of independent academic centres such as PenTAG 1,2.\u000a      The reports are HTAs\u000a      which generally consist of systematic reviews, meta-analyses and health\u000a      economic models\u000a      combined. The impact NICE has made since its inauguration is acknowledged\u000a      to be partly\u000a      attributable to the high quality of the independent academic reports\u000a      delivered in tight timescales.\u000a      NICE guidelines are now recognised to be of importance throughout the\u000a      developed world 3 The\u000a      Exeter based PenTAG group has contributed greatly to this process through\u000a      its many reports for\u000a      NICE and its methodological research.\u000a    The specific project (HTA 09\/87\/01) was commissioned by the NETSCC HTA\u000a      programme on\u000a      behalf of NICE in November 2009 with the title `The effectiveness and\u000a      cost-effectiveness of\u000a      donepezil, galantamine, rivastigmine and memantine for the treatment of\u000a      Alzheimer's disease\u000a      (Review of TA111)'. The project was to review and update the evidence\u000a      presented to NICE in 2004\u000a      of how good a number of drugs were for treating Alzheimer's disease. The\u000a      assessment would also\u000a      assess whether the reviewed drugs were likely to be considered good value\u000a      for money for the\u000a      NHS. The final technology appraisal report, consisting of systematic\u000a      reviews, meta-analyses and\u000a      mixed treatment comparisons of RCTs (both the new evidence alone and\u000a      cumulatively with\u000a      previous evidence), systematic reviews of cost-effectiveness evaluations,\u000a      critical appraisals of\u000a      three manufacturer submissions and a de novo cost-effectiveness model was\u000a      submitted in June\u000a      2010 and considered by the NICE Appraisal Committee in August 2010 3.\u000a    In the previous guidance NICE in 2004 had recommended that donepezil,\u000a      galantamine and\u000a      rivastigmine could be used for people with moderate Alzheimer's disease\u000a      but memantine could\u000a      only be used in clinical trials.\u000a    The report from PenTAG 4was the key piece of evidence that\u000a      informed the decision by NICE's\u000a      Appraisal Committee to provide its 2011 guidance, which extended the\u000a      availability of donepezil,\u000a      galantamine and rivastigmine to people with mild Alzheimer's disease, and\u000a      allowed memantine to\u000a      be used with those with severe forms of the disease for the first time5.\u000a      This guidance was released\u000a      in March 2011. It is mandatory for NHS commissioners to adhere to any\u000a      technology appraisal\u000a      guidance released. Data for prescribing in England published on the NHS\u000a      Health and Social Care\u000a      website indicates that there has been a massive increase in use of these\u000a      drugs between 2010, the\u000a      year before the 2011 NICE guidance was released, and 2012, the first\u000a      complete year after\u000a      (although arguably the full extent of the effect on prescribing may not be\u000a      seen until the 2013, the\u000a      data for which are not yet available). Between 2010 and 2012 donepezil use\u000a      increased by 41%,\u000a      rivastigmine by 51% and memantine by 278%, with 3% decrease in use of\u000a      galantamine6,7. Based\u000a      on the results of the economic model in our HTA we estimate that there\u000a      were 110,000 persons with\u000a      \"untreated\" mild Alzheimer's disease in England and Wales at the time of\u000a      the change in guidance\u000a      and if these individuals are now prescribed either donepezil or\u000a      galantamine or rivastigmine we can\u000a      expect on average cognition to be improved by 4% (absolute increase) in\u000a      this population and there\u000a      to be a cumulative delay in time to admission to long term care of 13,000\u000a      person\/years. Similarly\u000a      we estimate that there were 103,000 persons with \"untreated\" severe\u000a      Alzheimer's disease in\u000a      England and Wales at the time of the change in guidance and if these\u000a      individuals are now\u000a      prescribed memantine we can expect on average cognition to be improved by\u000a      3% (absolute\u000a      increase) in this population and there to be a cumulative delay in time to\u000a      admission to long term\u000a      care of 8,000 person\/years, with consequential large financial savings.\u000a    The change in decision about recommended drugs was directly attributed by\u000a      NICE to change in\u000a      the evidence, the key source of which was PenTAG's independent academic\u000a      report8,9,10. The NICE\u000a      decision on drugs for Alzheimer's disease thus provides a clear example of\u000a      how PenTAG's\u000a      research makes an impact on national policy making, and the important\u000a      influence of the\u000a      independent academic report is always reflected in the NICE appraisal\u000a      process. In addition, NICE\u000a      does have great worldwide influence3, so we expect that this\u000a      work has had beneficial impacts on\u000a      the treatment on patients with Alzheimer's disease throughout the world.\u000a    ","ImpactSummary":"\u000a    About 800,000 people are living with Alzheimer's disease in the UK today,\u000a      at a cost of about &#163;23\u000a      Billion\/annum. Researchers in Exeter produced a report in 2010 about the\u000a      effectiveness and cost-\u000a      effectiveness of available drugs, which formed the basis for revised NICE\u000a      guidelines (2011),\u000a      recommending more widespread drug usage. 2012 NHS data showed a big\u000a      increase in drug\u000a      prescribing since 2010. We estimate that if the 110,000 people with\u000a      untreated mild disease at the\u000a      time of the report are now being treated, there would be an average delay\u000a      in time to admission to\u000a      care of 13,000 person years.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Exeter\u000a    ","Institutions":[{"AlternativeName":"Exeter (University of)","InstitutionName":"University of Exeter","PeerGroup":"B","Region":"South West","UKPRN":10007792}],"Panel":"A         ","PlaceName":[],"References":"\u000a    Evidence of the quality of the research is clear from the following four\u000a      publications in high quality\u000a      peer-review journals:\u000a    \u000a1. Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T,\u000a      Davis S, Thokala\u000a      P, Wailoo A, Jeffreys M, Hyde, C.. The effectiveness and\u000a      cost-effectiveness of donepezil,\u000a      galantamine, rivastigmine and memantine for the treatment of Alzheimer's\u000a      disease (review\u000a      of NICE technology appraisal guidance 111): a systematic review and\u000a      economic model.\u000a      Health Technol Assess 2012;16(21):1-470.\u000a    \u000a\u000a2. Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M,\u000a      Davis S, Thokala\u000a      P, Moxham T. Evolution of the evidence on the effectiveness and\u000a      cost-effectiveness of\u000a      acetylcholinesterase inhibitors and memantine for Alzheimer's disease:\u000a      systematic review\u000a      and economic model. Age and Ageing 2013;42(1):14-20.\u000a    \u000a\u000a3. Peters J, Anderson R, Hoyle M, Hyde C. Evolution of a cost utility\u000a      model of donepezil for\u000a      Alzheimer's disease. Int J Technol Assess Health Care\u000a      2013;29:147-154.\u000a      doi:10.1017\/S026646231300007X.\u000a    \u000a\u000a4. Pitt M, Stahl-Timmins W, Anderson R, Stein K. Using information\u000a      graphics in health\u000a      technology assessment. Toward a structured approach. Int J Technol\u000a        Assess Heath Care\u000a      2009;25(4):555-563. DOI: 10.1017\/S0266462309990286\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    To support the central role of independent academic reports in the NICE\u000a      appraisal process:\u000a    \u000a      \u000a1.\u000a          http:\/\/www.nice.org.uk\/aboutnice\/howwework\/devnicetech\/developing_nice_multiple_technology_appraisals.jsp\u000a        and\u000a      \u000ahttp:\/\/www.nice.org.uk\/media\/B52\/A7\/TAMethodsGuideUpdatedJune2008.pdf\u000a        To support the worldwide importance of NICE:\u000a      http:\/\/www.nytimes.com\/2008\/12\/03\/health\/03nice.html?pagewanted=all\u000a    \u000a    PenTAG report to NICE:\u000a    \u000a      http:\/\/www.nice.org.uk\/nicemedia\/live\/12248\/49789\/49789.pdf\u000a    \u000a    NICE's guidance on drugs for Alzheimer's disease:\u000a    \u000a      http:\/\/www.nice.org.uk\/guidance\/index.jsp?action=byID&amp;o=13419\u000a    \u000a    To support changes in drug prescribing:\u000a    \u000a      \u000ahttps:\/\/catalogue.ic.nhs.uk\/publications\/prescribing\/primary\/pres-cost-anal-eng-2012\/pres-\u000a          cost-anal-eng-2012a-rep.pdf\u000a        and\u000a      https:\/\/catalogue.ic.nhs.uk\/publications\/prescribing\/primary\/pres-cost-anal-eng-2010\/pres-\u000a          cost-anal-eng-2010-rep.pdf\u000a    \u000a    To support NICE attributing change in guidance to change in evidence:\u000a    \u000a      \u000ahttp:\/\/www.bbc.co.uk\/news\/health-11486367\u000a        and\u000a      \u000a9.\u000a          http:\/\/www.telegraph.co.uk\/health\/healthnews\/8045775\/Alzheimers-u-turn-by-Nice-to-allow-drugs-for-mild-cases.html\u000a        and\u000a      http:\/\/www.channel4.com\/news\/alzheimers-drug-u-turn-welcomed\u000a    \u000a    ","Title":"\u000a    Supporting national policy making &#8212; \"Extending the availability of\u000a        drugs\u000a        to combat Alzheimer's disease\"\u000a    ","UKLocation":[{"GeoNamesId":"2649808","Name":"Exeter"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    In 2010, as part of its contract to support NICE, the University of\u000a      Exeter's Peninsula Technology\u000a      Group (PenTAG), led by Professor Hyde (appointed 2009) produced a health\u000a      technology\u000a      assessment (HTA) about the treatment of Alzheimer's disease with\u000a      anticholinesterase (AChE)\u000a      inhibitors. This HTA considered new evidence on the effectiveness and\u000a      cost-effectiveness of\u000a      donepezil, rivastigmine, galantamine and memantine in the treatment of\u000a      Alzheimer's disease,\u000a      superseding the 2004 HTA report that had informed the previous NICE\u000a      guidance. Although not\u000a      formally published in the HTA Monograph series until 2012 (Bond et al)1,\u000a      the report was completed\u000a      in June 2010 and considered by the Appraisal Committee of NICE in August\u000a      2010, who then\u000a      issued their new guidance in March 2011. The report by PenTAG included\u000a      systematic reviews,\u000a      meta-analyses and mixed treatment comparisons of RCTs (both the new\u000a      evidence alone and\u000a      cumulatively with previous evidence), systematic reviews of\u000a      cost-effectiveness evaluations, critical\u000a      appraisals of three manufacturer submissions and a new cost-effectiveness\u000a      model, subsequently\u000a      published in peer review journals (Hyde et al, Peters et al) 2,3.\u000a      The findings showed a consolidation\u000a      of evidence on the effectiveness of donepezil, rivastigmine, galantamine\u000a      and slightly enhanced\u000a      evidence on the effectiveness of memantine. For instance a statistically\u000a      significant beneficial effect\u000a      on measures of patient function and global impact emerged when randomised\u000a      controlled trials\u000a      comparing memantine with best-supportive care were formally meta-analysed\u000a      in our report. This\u000a      was not apparent previously. The most marked change was on the evidence on\u000a      cost-effectiveness,\u000a      which was greatly improved for donepezil, rivastigmine and galantamine and\u000a      slightly improved for\u000a      memantine relative to the assessment in 2004. The PenTAG model\u000a      demonstrated that each of the\u000a      AChE inhibitors was cost saving compared with best supportive care, and\u000a      that for memantine the\u000a      incremental cost-effectiveness ratio was &#163;32,100\/QALY gained. As well as\u000a      including cutting edge\u000a      analytical methods the report also included novel methods of presenting\u000a      large volumes of research\u000a      data of a complex nature (Pitt et al)4.\u000a    Each piece of NICE guidance in the technology appraisal programme is\u000a      supported by an\u000a      independent academic report. In the multiple technology appraisal process\u000a      a health technology\u000a      assessment (HTA), generally comprising systematic reviews, meta-analyses\u000a      and health economic\u000a      modelling, is prepared by an academic group. The Exeter based Peninsula\u000a      Technology\u000a      Assessment Group (PenTAG) has been performing this role for 12 years and\u000a      has conducted over\u000a      30 HTAs, all published in peer reviewed journals. The work is funded by DH\u000a      through the NIHR HTA\u000a      Programme. This is currently in its fourth period of renewal, which will\u000a      run until 2016. The work was\u000a      led by Professor Ken Stein until 2009 and subsequently by Professor Chris\u000a      Hyde. The PenTAG\u000a      group working on the Alzheimer's drug appraisal, while led by Hyde, was\u000a      multidisciplinary,\u000a      including economists (Anderson and Hoyle) as well as experts in systematic\u000a      reviews (Hyde, Bond,\u000a      Peters and others), and used new methodological approaches developed\u000a      within the group (Pitt et\u000a      al 2009)4.\u000a    Grant:\u000a      Stein K. Technology Appraisal Reports (TARs). Dept of Health. April 2005\u000a      to March 2011.\u000a      &#163;2,430,000\u000a    "},{"CaseStudyId":"35583","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"1861060","Name":"Japan"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    1) Public involvement in suicide prevention\u000a    This research is highlighted in the new national suicide prevention\u000a      strategy for England1 (p.41). It\u000a      took centre stage at a National Experts' Consensus Meeting on Suicide\u000a      Prevention in 2011,\u000a      where Owens was invited to deliver the opening presentation.\u000a      Recommendations from the\u000a      meeting fed into a Call to Action, spearheaded jointly by Samaritans and\u000a      the Department of\u000a      Health, which is driving forward implementation of the national strategy.\u000a    This has resulted in a strategic partnership with The Alliance of Suicide\u000a      Prevention Charities\u000a      (TASC), which appointed Owens as its scientific advisor in 2012 with a\u000a      view to collaborating on a\u000a      public education programme. In 2013, agreement was reached with IPC Media\u000a      to run a series of\u000a      articles in leading magazines to raise awareness and break the taboo\u000a      surrounding suicide. The\u000a      first of these appeared in the September 2013 issue of Marie Claire,\u000a      using scientific content\u000a      provided by the Exeter group. The Exeter\/TASC partnership is now\u000a      developing a range of multi-media\u000a      materials (including booklets, videos and an interactive web resource)\u000a      designed to equip\u000a      members of the public with the confidence to talk openly about suicide and\u000a      to intervene in a\u000a      crisis.\u000a    2) Preventing suicides in public places\u000a    This work has achieved international reach and made an important\u000a      contribution to public safety at\u000a      high-risk locations.\u000a    England: The Guidance on action to be taken at suicide\u000a        hotspots is highlighted in the new\u000a      national suicide prevention strategy 1(p.37), and cited in\u000a      local strategies nationwide. There is\u000a      good evidence that the processes for identifying and managing high-risk\u000a      locations have been\u000a      implemented. For example, in 2009 the NW Public Health Observatory\u000a      identified 49 locations that\u000a      had been used for two or more suicidal acts. Signs encouraging suicidal\u000a      individuals to call\u000a      Samaritans were installed at several of these locations; at one of them,\u000a      an average of 2 suicides\u000a      per year has been reduced to only 2 suicides in the last 3 years2.\u000a      Placing of Samaritans signs\u000a      on the Tyne Bridge in December 2007 led to a reduction in the number of\u000a      call-outs by police\u000a      negotiators to deal with individuals threatening suicide, from 131 in 2007\u000a      to 47 in 2008, and 30 in\u000a      2009. Further benefits have been reported there, including improved\u000a      information sharing\u000a      between police and mental health trusts about high-risk individuals3.\u000a      In 2011, an NHS Trust\u000a      agreed to increase the height of the parapets around the top floor of a\u000a      new multi-storey hospital\u000a      car park, after the Guidance was brought to its attention by a\u000a      member of the public4. These\u000a      impacts have been acknowledged by NIHR5 (p.16).\u000a    Scotland: In 2010 NHS Health Scotland requested permission to\u000a      adapt the Guidance for use in\u000a      the Scottish context. It was subsequently instrumental in persuading\u000a      Transport Scotland to install\u000a      fencing to prevent jumping from the Erskine Bridge. In the two years prior\u000a      to installation (Aug\u000a      2011) there were 16 suicides from the bridge; in the two years after\u000a      installation this reduced to\u000a      only 36.\u000a    Northern Ireland: The Guidance was cited in support of\u000a      recommendations to improve public\u000a      safety at the Langan Weir Bridge in 20127.\u000a    Japan: The Guidance was translated into Japanese in 2007.\u000a      Two thousand copies were\u000a      disseminated to prefectural governments, mental health and welfare centres\u000a      and other agencies,\u000a      and are believed to have contributed to local suicide prevention\u000a      initiatives.\u000a    Australia: In 2011 the Government of Australia sought consent to\u000a      use the Guidance as the\u000a      model for the development of their own, and the authors of the Australian\u000a      guidance worked\u000a      closely with the Exeter team8a. The Australian Government has\u000a      subsequently committed $12\u000a      million funding to capital works to improve safety at identified hotspots8b.\u000a    The USA is home to the world's number one suicide site, the Golden\u000a      Gate Bridge, estimated to\u000a      be responsible for around 24 deaths per year. Installation of barriers to\u000a      prevent individuals from\u000a      jumping had been strenuously resisted for many years, but a Physical\u000a      Suicide Deterrent System\u000a      has now been given the go-ahead. The English Guidance is cited in\u000a      support of the scheme9. The\u000a      $5m design stage is due for completion in 2013. Safety nets are also being\u000a      installed on seven\u000a      bridges across Fall Creek Gorge, following the deaths of Cornell\u000a      University students. Again, the\u000a      Guidance is cited as a key resource10.\u000a    There is strong evidence to suggest that an individual who is prevented\u000a      from carrying out a\u000a      suicidal plan at one location, e.g. by the erection of a physical barrier,\u000a      is unlikely to seek out\u000a      another location or another method of suicide.\u000a    ","ImpactSummary":"\u000a    Our work on suicide prevention, led by Christabel Owens of the University\u000a      of Exeter in\u000a      conjunction with Devon Partnership NHS Trust, has led to environmental\u000a      changes to improve\u000a      safety at public locations worldwide. The work has been recognised by\u000a      ministries of health and\u000a      cited in national suicide prevention strategies and guidance documents\u000a      worldwide, and is\u000a      associated with demonstrable benefits at specific high-risk sites.\u000a      Ground-breaking research into\u000a      the role of family members and friends in suicide prevention has led to a\u000a      strategic partnership\u000a      with all the major suicide prevention charities that are leading the way\u000a      in public education in\u000a      England.\u000a    ","ImpactType":"Societal","Institution":"\u000a    University of Exeter\u000a    ","Institutions":[{"AlternativeName":"Exeter (University of)","InstitutionName":"University of Exeter","PeerGroup":"B","Region":"South West","UKPRN":10007792}],"Panel":"A         ","PlaceName":[],"References":"\u000a    Evidence for the quality of the research is apparent from the fact that\u000a      the first five of the six listed\u000a      references are to articles published in high impact peer review journals,\u000a      and the sixth to the\u000a      resultant guidance:\u000a    \u000a1. Owens C, Lambert H, Lloyd K, Donovan J. Tales of biographical\u000a      disintegration: how\u000a      parents make sense of their sons' suicides. Sociology of Health &amp;\u000a        Illness 2008;30(2):237-\u000a      54.\u000a    \u000a\u000a2. Owens C, Owen G, Belam J, Rapport F, Lloyd K, Donovan J, et al.\u000a      Recognising and\u000a      responding to a suicidal crisis in the family and social network:\u000a      qualitative study. BMJ\u000a      2011;343:d5801. doi: 10.1136\/bmj.d5801.\u000a    \u000a\u000a3. Owen G, Belam J, Lambert H, Donovan J, Rapport F, Owens C. Suicide\u000a      Communication\u000a      Events: Lay interpretation of the communication of suicidal ideation and\u000a      intent. Social\u000a        Science &amp; Medicine 2012;75(2):419-28.\u000a    \u000a\u000a4. Owens C, Lloyd-Tomlins S, Emmens T, Aitken P. Suicides in public\u000a      places: findings from\u000a      one English county. European Journal of Public Health\u000a      2009;19(6):580-2.\u000a    \u000a\u000a5. Cox G, Owens C, Robinson J, Nicholas A, Lockley A, Williamson M,\u000a      Cheung YTD, Pirkis J.\u000a      Interventions to reduce suicides at suicide hotspots: A systematic review.\u000a      BMC Public\u000a        Health 2013. 9;13:214. doi: 10.1186\/1471-2458-13-214.\u000a    \u000a\u000a6. National Institute for Mental Health in England (Authors: Aitken P,\u000a      Owens C, Lloyd-Tomlins\u000a      S et al). Guidance on action to be taken at suicide hotspots.\u000a      Leeds: National Institute for\u000a      Mental Health in England, 2006.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [S1] Department of Health. Preventing suicide in England: A\u000a        cross-government outcomes strategy\u000a        to save lives. London: Department of Health; 2012.\u000a      http:\/\/www.dh.gov.uk\/health\/files\/2012\/09\/Preventing-Suicide-in-England-A-cross-government-outcomes-strategy-to-save-lives.pdf\u000a    [S2] Hannon K, Giles S, Deacon L, Tocque K. Suicide in the North\u000a        West: A review of non-residential\u000a        and outdoor suicide locations. Liverpool: North West Public Health\u000a      Observatory;\u000a      2009. http:\/\/www.nwph.net\/nwpho\/publications\/SuicideintheNW.pdf.\u000a      Contact details and\u000a      personal correspondence available.\u000a    [S3] Taylor S, Napier J, Turkington D, Gray A, Hume K. Hotspot signage\u000a      reduces calls to police\u000a      negotiators. BMJ 2010;340:c3054, doi:10.1136\/bmjc3054. http:\/\/www.bmj.com\/rapid-response\/2011\/11\/03\/hotspot-signage-reduces-calls-police-negotiators.\u000a      Contact details and\u000a      personal correspondence available.\u000a    [S4] http:\/\/www.thisisgloucestershire.co.uk\/Suicide-prevention-fences-hospital-car-park\/story-12859923-detail\/story.html.\u000a      Contact details and personal correspondence available.\u000a    [S5] National Institute for Health Research. Embedding Health\u000a        Research: National Institute for\u000a        Health Research Annual Report 2009\/10. London: Department of Health;\u000a      2010.\u000a      http:\/\/www.selcrn.nhs.uk\/wp-content\/themes\/selcrn\/uploads\/2012\/03\/149_NIHR_Annual_Report_2009-2010.pdf\u000a    [S6] http:\/\/www.healthscotland.com\/documents\/4880.aspx.\u000a      http:\/\/www.transportscotland.gov.uk\/news\/Erskine-Bridge-parapet-work-moves-forward\u000a      Contact details and personal correspondence available.\u000a    [S7] Department for Social Development. Lagan Weir Footbridge:\u000a        Assessment of Existing Safety\u000a        Arrangements. Ireland: RPS Group; 2012. http:\/\/www.dsdni.gov.uk\/lagan-weir-footbridge-march12.pdf.\u000a      Contact details and personal correspondence available.\u000a    [S8a] University of Melbourne. Preventing suicide at suicide hotspots.\u000a      Canberra: Government of\u000a      Australia Department of Health and Ageing; 2012.\u000a      http:\/\/livingisforeveryone.com.au\/Uploads\/docs\/Hotspots%20Prevention.pdf\u000a    [S8b] Government of Australia. Funding Available to Improve Safety at\u000a        Suicide `Hotspots'. Media\u000a      Release. 2012;\u000a      http:\/\/www.health.gov.au\/internet\/ministers\/publishing.nsf\/Content\/93160F90537CE78ACA2579D700101207\/$File\/MB025.pdf\u000a    [S9] http:\/\/www.ggbsuicidebarrier.org;\u000a      http:\/\/www.ggbsuicidebarrier.org\/documents\/feir_chapter7.pdf\u000a    [S10] http:\/\/meansrestrictionstudy.fs.cornell.edu;\u000a      http:\/\/meansrestrictionstudy.fs.cornell.edu\/resources.cfm\u000a    \u000a    ","Title":"\u000a    Preventing suicides in non-clinical populations and settings\u000a    ","UKLocation":[{"GeoNamesId":"2649808","Name":"Exeter"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2641364","Name":"Northern Ireland"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Around one million people take their own lives each year, approximately\u000a      4,500 of them in\u000a      England, where three-quarters are not in contact with mental health\u000a      services, and half have not\u000a      had recent contact with a general practitioner, so opportunities for\u000a      clinical intervention are limited.\u000a      Our research programme has concentrated on non-clinical approaches, with\u000a      two aims: to\u000a      promote public involvement in suicide prevention, and to prevent suicides\u000a      in public places.\u000a    1) Public involvement in suicide prevention\u000a    Christabel Owens and her team have been studying suicide among those who\u000a      are outside the\u000a      care of mental health services since the Medical School was established in\u000a      2000, beginning with\u000a      a psychological autopsy study. They went on to pioneer the use of\u000a      qualitative methods to gain\u000a      insight into lay perspectives 1. This led in 2006 to an MRC\u000a      grant to learn more about the role that\u000a      lay people can play in preventing suicides and the resources they need in\u000a      order to do so. They\u000a      found that:\u000a    \u000a      signs of suicidal despair can be oblique, ambiguous and difficult to\u000a        interpret; individuals\u000a        who are intent on suicide employ a range of face-saving strategies when\u000a        communicating\u000a        with those around them, which make it difficult for listeners to judge\u000a        the intention behind\u000a        their words2,3;\u000a      family members and friends are predisposed to disregard warning signs\u000a        and focus instead\u000a        on positive `countersigns';\u000a      even when relatives and friends are aware that something is seriously\u000a        wrong, taking any\u000a        action at all involves considerable personal risk;\u000a      proximity to the suicidal person and emotional investment in the\u000a        relationship make it difficult\u000a        for them to see, say or do anything at all2.\u000a    \u000a    The team concluded that efforts to strengthen the capacity of lay people\u000a      to play a role in\u000a      preventing suicide should focus on helping people to recognise\u000a      communications of suicidal intent\u000a      for what they are and to acknowledge and overcome their fears about\u000a      intervening.\u000a    2) Preventing suicides in public places\u000a    Restricting access to lethal means is one of the most effective\u000a      approaches to suicide prevention.\u000a      In pursuit of this goal, the first National Suicide Prevention\u000a        Strategy for England (2002) pledged to\u000a      produce guidance on action to be taken at suicide `hotspots', i.e. bridges\u000a      and other public\u000a      locations that offer means and opportunity for suicide. In 2006,\u000a      Christabel Owens' team were\u000a      awarded a grant to develop the guidance.\u000a    The team collected data on locations of suicidal acts and found that\u000a      nearly a third (31%) were\u000a      carried out in public places4. They then:\u000a    \u000a      reviewed the evidence for interventions to prevent suicides at\u000a        high-risk locations5;\u000a      outlined a process for identifying high-risk locations at local level\u000a        and piloted it;\u000a      outlined a multi-agency approach to managing high-risk locations and\u000a        piloted it.\u000a    \u000a    They produced a simple practical handbook with guidance to support local\u000a      efforts to prevent\u000a      suicides in public places6.\u000a    Grants: 1) Owens C and Aitken P &#8212; Development of national guidance\u000a      on action to be taken at\u000a      suicide hotspots &#8212; NIMHE, 2006, &#163;9,916. 2) Owens C et al &#8212; Public\u000a      involvement in suicide\u000a      prevention &#8212; MRC, 2006, &#163;280,200.\u000a    "},{"CaseStudyId":"35584","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    This research has had a far-reaching and significant impact on the lives\u000d\u000a      of patients with depression. Other beneficiaries include health service\u000d\u000a      commissioners and providers, mental health workers, and the wider populace\u000d\u000a      through the economic benefits of increased productivity and reduced\u000d\u000a      welfare costs (in 2007, depression's total annual costs in England were\u000d\u000a      &#163;7.5 billion, &#163;1.7 billion health service costs, &#163;5.8 billion lost\u000d\u000a      earnings). Reflecting his expertise, Richards was a national advisor to\u000d\u000a      the Department of Health (2008-2011) on the design and implementation of\u000d\u000a      the nationwide IAPT initiative and the underpinning informatics systems.\u000d\u000a    The results of Richards' research are currently being implemented\u000d\u000a      nationally and internationally, providing more treatment options for\u000d\u000a      patients, and informing service and training provision. The research\u000d\u000a      results provide the empirical bedrock for the low-intensity, high-volume\u000d\u000a      component of the &#163;700m implementation of IAPT services throughout England1.\u000d\u000a    The IAPT programme has been described in a Nature editorial2\u000d\u000a      on 27th September 2012 as \"a world-beating standard thanks\u000d\u000a        to the scale of its implementation and the validation of its treatments\u000d\u000a        by the UK National Institute for Health and Clinical Excellence\"\u000d\u000a      (pp473-474). It continues to receive unanimous cross-parliamentary support\u000d\u000a      in both houses of parliament, for example House of Lords Early Day Motion\u000d\u000a      1433; 09.02.2011 \"...welcomes the news that 3,660 new psychological\u000d\u000a        therapists, trained under the Improving Access to Psychological\u000d\u000a        Therapies programme, are in place as of January 2011; commends the\u000d\u000a        current Government for its on-going commitment to invest in the IAPT\u000d\u000a        programme; also commends the previous Government for starting the IAPT\u000d\u000a        programme...\". The programme underpins the current coalition\u000d\u000a      government's mental health `No Health without Mental Health' and\u000d\u000a      talking therapies strategies.\u000d\u000a    Key successes of the programme in the first three full financial years\u000d\u000a      from 2008 onwards, as documented by the Department of Health3,\u000d\u000a      include:\u000d\u000a    \u000d\u000a      Over 1 million people entering treatment\u000d\u000a      680,000 people completing treatment\u000d\u000a      Recovery rates consistently in excess of 45%; 65% of people\u000d\u000a        significantly improved\u000d\u000a      Over 45,000 people moving off sick pay and benefits\u000d\u000a      Nearly 4,000 new practitioners trained\u000d\u000a    \u000d\u000a    The vast majority of these patients receive treatments established and\u000d\u000a      delivered through Richards' research programme. These impressive\u000d\u000a      implementation results have been underpinned by Richards' team in Exeter,\u000d\u000a      and their academic and professional publications. They have created the\u000d\u000a      IAPT para-professional `Psychological Wellbeing Practitioner' (PWP) role\u000d\u000a      and established it as a core component of the stepped care IAPT treatment\u000d\u000a      delivery method. In addition to trial results, Richards et al's\u000d\u000a      publications include the first major international edited textbook on\u000d\u000a      low-intensity CBT (Bennett-Levy, Richards, Farrand, et al, 20104);\u000d\u000a      the national curriculum for IAPT low-intensity workers (Richards, Farrand\u000d\u000a      and Chellingsworth, 20115), and three sets of educational\u000d\u000a      guidebooks for HEIs, low-intensity Psychological Wellbeing Practitioner\u000d\u000a      (PWP) students and their supervisors (Richards and White 2010; 2009a;\u000d\u000a      2009b 6,7,8). These materials are in use throughout the HEI\u000d\u000a      sector and the NHS in England. Richards also worked closely with public\u000d\u000a      and patient involvement representatives in his IAPT national advisor role\u000d\u000a      and advised RETHINK, the national mental health charity, on their\u000d\u000a      ultimately successful tenders for a number of IAPT services in England.\u000d\u000a    In addition, the recent (2009) NICE guidelines on depression9\u000d\u000a      references the work of Richards' group, and particularly notes that the\u000d\u000a      results of the recently published CADET trail (2013) \"should inform\u000d\u000a        further updates of this guideline\"\u000d\u000a    Richards' research has prompted interventions to be implemented\u000d\u000a      internationally: For example, he is an advisor to the `Mindspot'\u000d\u000a      Australian Federal Government service commission won by Macquarie\u000d\u000a      University, Sydney, to implement low-intensity CBT throughout all states\u000d\u000a      in Australia; he is also advisor to `Beyond Blue' the national Australian\u000d\u000a      Depression Initiative10. (Letters of engagement available for\u000d\u000a      both examples).\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Depression is a major public health problem, producing substantial\u000d\u000a      deterioration in health and well- being and costing the UK &#163;billions\u000d\u000a      annually. A programme of research at Exeter, led by Professor Richards,\u000d\u000a      (trials and Phase IV implementation studies) has changed national policy\u000d\u000a      on the treatment of depression (NICE guidelines). It has also underpinned\u000d\u000a      the UK's Improving Access to Psychological Therapies (IAPT) programme\u000d\u000a      which has been widely implemented, leading to new treatment for over 1\u000d\u000a      million people, with a recovery rate in excess of 45%, and over 45,000\u000d\u000a      people coming off sick pay and benefits. The research has also achieved\u000d\u000a      International impact.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of Exeter\u000d\u000a    ","Institutions":[{"AlternativeName":"Exeter (University of)","InstitutionName":"University of Exeter","PeerGroup":"B","Region":"South West","UKPRN":10007792}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2147714","Name":"Sydney"}],"References":"\u000d\u000a    Evidence for the quality of the research is apparent from the fact that\u000d\u000a      each of the six references that follow is published is a high quality\u000d\u000a      peer-review journal:\u000d\u000a    \u000a1. Clark, D.M., Layard, R., Smithies, R., Richards, D.A., Suckling, R.,\u000d\u000a      and Wright, B. (2009). Improving access to psychological therapy: initial\u000d\u000a      evaluation of two UK demonstration sites. Behaviour Research and\u000d\u000a        Therapy, 47, 910-920.\u000d\u000a    \u000a\u000a2. Richards, D.A. and Suckling, R. (2009) Improving Access to\u000d\u000a      Psychological Therapies (IAPT): Phase IV Prospective Cohort Study. British\u000d\u000a        Journal of Clinical Psychology, 48, 377-396\u000d\u000a    \u000a\u000a3. Richards, D.A., &amp; Borglin, G. (2011). Implementation\u000a        of psychological therapies for anxiety and depression in routine\u000d\u000a        practice: Two year prospective cohort study. Journal of Affective\u000d\u000a        Disorders, 133, 51-60.\u000d\u000a    \u000a\u000a4. Richards D et al (2013). Clinical effectiveness of collaborative care\u000d\u000a      for depression in UK primary care (CADET): cluster-randomised controlled\u000d\u000a      trial; BMJ, 347:f4913\u000d\u000a    \u000a\u000a5. Ekers, D., Richards, D.A., McMillan, D., Bland, J.M. &amp; Gilbody, S.\u000d\u000a      (2011). Behavioural Activation delivered by the non specialist: phase II\u000d\u000a      randomised controlled trial. British Journal of Psychiatry, 198:\u000d\u000a      66-72.\u000d\u000a    \u000a\u000a6. Gask, L., Bower, P., Lovell, K., Escott, D., Archer, J., Gilbody, S.,\u000d\u000a      Lankshear, A., Simpson, A. &amp; Richards, D.A. (2010). What work has to\u000d\u000a      be done to implement collaborative care for depression? Process evaluation\u000d\u000a      of a trial utilizing the Normalization Process Model. Implementation Science, 5, 15.\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    \u000d\u000a      Department of Health (2011). Talking Therapies: a four year plan\u000d\u000a          of action. London: Department of Health.\u000d\u000a      Editorial (2012). Therapy deficit: studies to enhance psychological\u000d\u000a        treatments are scandalously under-supported. Nature, 489,\u000d\u000a        473-474 (27 September 2012)\u000d\u000a      Department of Health (2012). IAPT three-year report. The\u000d\u000a          first million patients. London, Department of Health.\u000d\u000a      Bennett-Levy, J., Richards, D.A., Farrand, P., Christensen, H.,\u000d\u000a        Griffiths, K., Kavanagh, D., Klein, B., Lau, M., Proudfoot, J., White,\u000d\u000a        J. and Williams, C. eds. (2010). The Oxford Guide to Low Intensity\u000d\u000a          CBT Interventions. Oxford, Oxford University Press.\u000d\u000a      Richards, DA, Farrand, P, Chellingsworth, M (2011). National\u000d\u000a          curriculum for the education of psychological wellbeing practitioners\u000d\u000a          (PWPs) (second edition, updated and revised, March 2011).\u000d\u000a        Department of Health, London\u000d\u000a      Richards, D. and Whyte, M. (2010a). Reach Out: National Programme\u000d\u000a          Supervisor Materials to Support the Delivery of Training for\u000d\u000a          Practitioners Delivering Low Intensity Interventions. London:\u000d\u000a        Rethink\u000d\u000a      Richards, D. and Whyte, M. (2009a). Reach Out: National Programme\u000d\u000a          Student Materials to Support the Delivery of Training for\u000d\u000a          Practitioners Delivering Low Intensity Interventions 2nd\u000d\u000a        Edition. London: Rethink\u000d\u000a      Richards, D. and Whyte, M. (2009b). Reach Out: National Programme\u000d\u000a          Educator Materials to Support the Delivery of Training for\u000d\u000a          Practitioners Delivering Low Intensity Interventions 2nd\u000d\u000a          Edition. London: Rethink\u000d\u000a      NICE Depression Guideline Group (2007-9) [CG90 Depression in adults:\u000d\u000a        full guidance: http:\/\/www.nice.org.uk\/nicemedia\/live\/12329\/45896\/45896.pdf]\u000d\u000a      \"Beyond Blue\", Melbourne Australia. Letter of Engagement, June 2013.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Improving Treatment Delivery for Depression\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    As a frequent, recurrent condition, depression is a major public health\u000d\u000a      problem causing reduced health and well-being and significant disability\u000d\u000a      (and described by the WHO as a leading cause of disability in 2000), with\u000d\u000a      large economic costs through lost productivity and health and welfare\u000d\u000a      costs. A priority for the NHS and health systems internationally is\u000d\u000a      maximizing the accessibility of evidence-based therapies and developing\u000d\u000a      more effective treatment delivery models. Because of the limited\u000d\u000a      availability of treatment for many depressed patients Richards' work\u000d\u000a      (Professor of Health Services Research, Exeter, appointed 2008) has been\u000d\u000a      to improve the evidence for and the accessibility of low-cost,\u000d\u000a      evidence-based treatments. He and his team have also provided leadership\u000d\u000a      in translational implementation programmes from this research, to train\u000d\u000a      the next generation of NHS clinicians.\u000d\u000a    His studies have provided one crucial element of the empirical rationale\u000d\u000a      for the &#163;700m expansion of Improving Access to Psychological Therapies\u000d\u000a      (IAPT) services throughout England. He developed the `low-intensity'\u000d\u000a      clinical methods and collaborative care organisational structures in a\u000d\u000a      trial of collaborative care (Richards et al, 20081) and then\u000d\u000a      implemented these clinical and organisational procedures in one of the\u000d\u000a      IAPT pilot sites (Clark et al, 2009; Richards and Suckling, 2009; Richards\u000d\u000a      and Borglin, 2011 2,3,4). Data from 7859 consecutive patients\u000d\u000a      treated by this service over two years demonstrated that combining low-\u000d\u000a      and high-intensity treatments maximised treatment volumes whilst\u000d\u000a      maintaining good clinical outcomes (Richards and Borglin, 20114).\u000d\u000a      Subsequently, he has led one of the largest trials (MRC\/NIHR-EME) of\u000d\u000a      collaborative care internationally (CADET), to directly address a NICE\u000d\u000a      2009 Depression Guideline research priority to improve depression\u000d\u000a      treatment (Richards et al, 20135). Results have removed the\u000d\u000a      uncertainty about the effectiveness of Collaborative Care for depression\u000d\u000a      in the UK, in that collaborative care had persistent positive effects, was\u000d\u000a      cost effective within the NICE affordability threshold, and patients were\u000d\u000a      more satisfied than in usual care.\u000d\u000a    Addressing a further NICE research recommendation, Richards is leading an\u000d\u000a      on-going large-scale NIHR-HTA trial (COBRA) which is examining whether a\u000d\u000a      simpler treatment &#8212; behavioural activation (Ekers et al, 20116)\u000d\u000a      &#8212; is as efficacious as CBT but potentially cheaper and more accessible\u000d\u000a      through delivery by less expensive health-care professionals.\u000d\u000a    Externally funded grant support related to reported research\u000d\u000a    A Trial Platform of Enhanced Care for Depression in Primary Care.\u000d\u000a      MRC &#163;164,849. Chief Investigator Richards. With Bower, Gilbody, Lovell,\u000d\u000a      Gask, Torgersen, Barkham and Rogers. ID: TP139 G0300677; start date 1st\u000d\u000a      July 2004.\u000d\u000a    CADET: Multi-centre Randomised Controlled Trial of Collaborative\u000d\u000a      Care for Depression. Medical Research Council. &#163;2,287,916. Chief\u000d\u000a      Investigator Richards. With Chew-Graham, Manning, Kessler, Cape, Bower,\u000d\u000a      Gilbody, Pilling, Lewis, Bland, Lovell, Gask, Barkham, Araya. Start date 1st\u000d\u000a      September 2008.\u000d\u000a    COBRA: Cost and Outcome of BehaviouRal Activation: a Randomised\u000d\u000a      Controlled Trial of Behavioural Activation versus Cognitive Behaviour\u000d\u000a      Therapy for Depression. &#163;1.9m. Chief Investigator Richards. With Gilbody,\u000d\u000a      Kuyken, Taylor, O'Neill, Byford, Watkins, Wright, Ekers, McMillan,\u000d\u000a      O'Mahen, Farrand. Four years. Start date: April 2012\u000d\u000a    "},{"CaseStudyId":"35828","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"3190538","Name":"Slovenia"},{"GeoNamesId":"1668284","Name":"Taiwan"},{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"3202326","Name":"Croatia"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    This work produced by Steele and the Colorectal Screening\u000a      Research Unit has contributed centrally to a complex programme that is\u000a      currently having a major impact on cancer mortality rates. Their matched\u000a      cohort study utilising the pilot data convincingly demonstrated a\u000a      reduction of 27% in deaths from colorectal cancer among those\u000a      participating in screening [1], vindicating the assumptions that had been\u000a      made at the planning stage. National screening was developed from the\u000a      pilot work and subsequent research led by Steele. It commenced in\u000a      England in 2006, was followed by Scotland and Wales in 2007 and Northern\u000a      Ireland in 2010 [2], and is already impacting on national mortality rates.\u000a    The impact of the group's research on repeated invitations [3] and on\u000a      pre-notification [4] is reflected in demonstrated increases in the overall\u000a      uptake of screening and of colonoscopy. For example, uptake of a first\u000a      invitation for prevalence screening was 53%, and for a second and third\u000a      invitation was 15% and 12% respectively, with a significant number\u000a      proceeding to colonoscopy [3]; pre- notification with a letter (with or\u000a      without an accompanying booklet) increased the uptake of screening from\u000a      54% to 59% [4]. Mortality figures are expected to continue to improve as\u000a      this research, which has been incorporated into the national screening\u000a      algorithm, leads to increased uptake and participation. As a result of the\u000a      research into faecal occult blood testing methodology [vi], the screening\u000a      algorithm in Scotland has also been changed to incorporate immunological\u000a      testing. However, a study of interval cancers has demonstrated that the\u000a      sensitivity of the screening Faecal Occult Blood test is only about 50%\u000a      for cancer and that it is less sensitive in women than in men [5]. This\u000a      set in train a piece of work funded by the Scottish Government (&#163;130,241)\u000a      that demonstrated the utility (improved efficiency, and age- and\u000a      gender-specificity) and potential impact of improved faecal testing using\u000a      quantitative faecal immunochemical testing as the first line test [6]. A\u000a      business case for the introduction of this technology is currently being\u000a      developed.\u000a    The demonstration pilot achieved similar short term outcomes to previous\u000a      randomised trials, indicating that 30 colorectal cancer deaths per million\u000a      of the total population per year will be avoided in the first instance.\u000a      These figures will certainly continue to improve (a) as the proportion of\u000a      the population participating in the screening programme increases; (b)\u000a      with the implementation of more accurate testing methodologies such as\u000a      immunological faecal occult blood testing (already partially implemented\u000a      in Scotland) and the novel proteomics approaches that are currently under\u000a      development in Dundee; and (c) as the uptake and impact of lifestyle\u000a      interventions identified by the BeWEL study reduces the incidence of\u000a      malignant tumours among those participating in screening. This work\u000a      therefore demonstrates that the screening programme prevents around 2,000\u000a      UK colorectal cancer deaths each year, and will inevitably prevent many\u000a      more in the future.\u000a    In addition to informing the decision to introduce a national colorectal\u000a      cancer screening programme, the research described here has had a\u000a      significant impact on the testing modalities used in the screening\u000a      programme and on the method of invitation. Furthermore, extremely valuable\u000a      information has been gathered on the significance of interval cancers. In\u000a      addition, &#163;2m funding has also been made available from the Scottish\u000a      Government in order to explore the introduction of flexible sigmoidoscopy\u000a      as a primary screening modality, and a randomised evaluation is under\u000a      development. Professor Steele chairs the Steering Group for this\u000a      study.\u000a    The Screening Programme has attracted major national and international\u000a      media attention [7], and has served as a model for the implementation of\u000a      similar programmes in a number of other countries (most recently Ireland\u000a      [8], with others under development in the Netherlands, Sweden, Croatia,\u000a      Slovenia and Taiwan). The recently published European Guidelines for\u000a      Quality Assurance in Colorectal Cancer Screening [9], to which Professor Steele\u000a      made a major contribution [10], drew heavily on the experience gained in\u000a      Scotland and the rest of the United Kingdom, and is a major influence on\u000a      these programmes.\u000a    ","ImpactSummary":"\u000a    The UK Faecal Occult Blood Test Screening Programme, based on Dundee-led\u000a      research (Steele), offers bowel cancer screening through mailed\u000a      test kits followed up with colonoscopy when faecal blood is detected. It\u000a      is estimated to prevent about 2,000 UK deaths annually. Steele's\u000a      Screening Research Unit also trialled immunological faecal occult blood\u000a      testing, which was subsequently incorporated into the Scottish screening\u000a      algorithm. In addition to demonstrating a 27% reduction in bowel cancer\u000a      deaths through participation in Faecal Occult Blood screening, the Unit\u000a      has researched the incidence of interval cancers and the impact of\u000a      repeated invitations, development of new tests, and strategies for\u000a      increasing participation. All of these drive the National Screening\u000a      Programme, and will further reduce mortality.\u000a    ","ImpactType":"Technological","Institution":"\u000a    University of Dundee\u000a    ","Institutions":[{"AlternativeName":"Dundee (University of)","InstitutionName":"University of Dundee","PeerGroup":"B","Region":"Scotland","UKPRN":10007852}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000ai. Steele RJC for the UK Colorectal Cancer Screening Pilot Group\u000a      (2004) Results of the first round of a demonstration pilot of screening\u000a      for colorectal cancer in the United Kingdom. Brit. Med. J. 329,\u000a      133-5 (DOI: 10.1136\/bmj.38153.491887.7C).\u000a    \u000a\u000aii. The UK CRC Screening Pilot Evaluation Team (2003) Evaluation of the\u000a      UK Colorectal Cancer Screening Pilot Final Report; http:\/\/www.cancerscreening.nhs.uk\/bowel\/finalreport.pdf.\u000a    \u000a\u000aiii. Steele RJC, McClements PL, Libby G, Black R, Morton C,\u000a      Birrell J, Mowat NAG, Wilson JA, Kenicer M, Carey FA, Fraser CG (2009)\u000a      Results from the first three rounds of the Scottish Demonstration Pilot of\u000a      FOBT Screening for Colorectal Cancer. Gut 58, 530-5 (DOI:\u000a      10.1136\/gut.2008.162883).\u000a    \u000a\u000aiv. Steele RJC, Kostourou I, McClements P, Watling C, Libby G,\u000a      Weller D, Brewster DH, Black R, Carey FA, Fraser C (2010) Effect of\u000a      repeated invitations on uptake of colorectal cancer screening using faecal\u000a      occult blood testing; analysis of prevalence and incidence screening. Brit.\u000a        Med. J. 341:c5531 (DOI:10.1136\/bmj.c5531).\u000a    \u000a\u000av. Libby G, Bray J, Champion J, Colford L, Birrell J, Gorman D, Crighton\u000a      E, Fraser C, Steele RJC (2011) Pre-notification increases uptake\u000a      of colorectal cancer screening in all demographic groups; a randomised\u000a      controlled trial. J. Med. Screening; 18: 24-29 (DOI:\u000a      10.1258\/jms.2011.011002)\u000a    \u000a\u000avi. Fraser CG, Matthew CM, Mowat NAG, Wilson J, Carey FA, Steele\u000a      RJC (2006) Immunochemical testing of individuals positive for guaiac\u000a      faecal occult blood test in a screening programme for colorectal cancer:\u000a      an observational study. Lancet Oncol. 7, 127-131\u000a      (DOI:10.1016\/S1470-2045(05)70473-3).\u000a    \u000aFunding\u000a    &#8226; Steele R (PI), Brewster D, Carey F, Kenicer M and Fraser C:\u000a      Establishing a Bowel Screening Research Unit; Chief Scientist Office,\u000a      Scotland (September 2007-August 2012) &#163;546,227.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"12","Subject":"Oncology and Carcinogenesis"}],"Sources":"\u000a    \u000a      Libby G, Brewster DH, McClements PL, Carey FA, Black RJ, Birrell J\u000a        Fraser CG, Steele RJC (2012) The impact of population based\u000a        faecal occult blood test screening on colorectal cancer mortality: a\u000a        matched cohort study. Br. J. Cancer 107, 255-259 (DOI:\u000a        10.1038\/bjc.2012.277).\u000a      NHS websites that describe the introduction and current status of the\u000a        national bowel screening programmes in the UK: http:\/\/www.bowelscreening.scot.nhs.uk\/\u000a        http:\/\/www.cancerscreening.nhs.uk\/bowel\/\u000a        http:\/\/www.wales.nhs.uk\/sites3\/home.cfm?orgid=747\u000a        http:\/\/www.screening.nhs.uk\/bowelcancer-northernireland\u000a\u000a      \u000aSteele RJC, Kostourou I, McClements P, Watling C, Libby G,\u000a        Weller D, Brewster DH, Black R, Carey FA, Fraser C (2010) Effect of\u000a        repeated invitations on uptake of colorectal cancer screening using\u000a        faecal occult blood testing; analysis of prevalence and incidence\u000a        screening. Brit. Med. J. 341:c5531\u000a        (DOI:10.1136\/bmj.c5531).\u000a      Libby G, Bray J, Champion J, Colford L, Birrell J, Gorman D, Crighton\u000a        E, Fraser C, Steele RJC (2011) Pre-notification increases uptake\u000a        of colorectal cancer screening in all demographic groups; a randomised\u000a        controlled trial. J. Med. Screening 18, 24-29 (DOI:\u000a        10.1258\/jms.2011.011002).\u000a      \u000aSteele RJC, McClements P, Watling C, Libby G, Weller D,\u000a        Brewster DH, Black R, Carey FA, Fraser CG (2012) Interval cancers in a\u000a        FOBT-based colorectal cancer population screening programme:\u000a        implications for stage, gender and tumour site. Gut 61,\u000a        576-581 (DOI: 10.1136\/gutjnl-2011-300535).\u000a      \u000aSteele RJC, McDonald PJ, Digby J, Brownlee L, Strachan JA,\u000a        Libby G, McClements PL, Birrell J, Carey FA, Diament RH, Balsitis M,\u000a        Fraser CG (2013) Clinical outcomes using a faecal immunochemical test\u000a        for haemoglobin in a national colorectal cancer screening programme\u000a        constrained by colonoscopy capacity. UEG Journal 1,\u000a        198-205 (DOI: 10.1177\/2050640613489281).\u000a      Examples of media reports (November 2011) of reduction in cancer\u000a        deaths due to screening programme: Cancer Research UK press release: http:\/\/www.cancerresearchuk.org\/cancer-\u000ainfo\/news\/archive\/pressrelease\/2011-10-09-Bowel-screening-reduces-cancer-deaths-by-\u000a          more-than-25-per-cent.\u000a      STV news report: http:\/\/news.stv.tv\/scotland\/278230-screening-cuts-bowel-cancer-deaths-\u000a          by-a-quarter\/.\u000a      National Cancer Screening Service (Ireland). Implementing Ireland's\u000a        First National Population-based Colorectal Cancer Screening Programme\u000a        (2009) www.cancerscreening.ie\/publications\/ImplementingColorectalProgramme.pdf,\u000a        based on Steele`s Scottish, UK and European models, and to which\u000a        Professor Steele contributed directly (page 9)\u000a      Segnan N, Patnick J and von Karsa L (eds) (2011) European Guidelines\u000a        for Quality Assurance in Colorectal Cancer Screening and Diagnosis.\u000a        First Edition. European Commission (DOI:10.2772\/15379; electronic\u000a        version) http:\/\/www.pathologie-\u000aguetersloh.de\/informationen\/leitlinien-empfehlungen-und\/prostata-leitlinien-und-\u000a          emp\/crc_guidelines_publication.pdf.\u000a      Corroborating statement from the Director, NHS Cancer Screening\u000a        Programmes, Directorate of Health and Wellbeing, Public Health England\u000a        (impact on UK screening programmes and European guidelines).\u000a    \u000a    ","Title":"\u000a    Faecal Occult Blood screening and the prevention of deaths from\u000a        colorectal cancer\u000a    ","UKLocation":[{"GeoNamesId":"2650752","Name":"Dundee"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Colorectal cancer is the third commonest cancer in the UK, with a\u000a      lifetime incidence of ~5%, and is the second leading cause of cancer\u000a      deaths; it caused over 16,000 deaths per year before routine screening was\u000a      introduced. Cases often present clinically at an advanced stage of\u000a      disease, with consequently poor outcome.\u000a    Single cohort randomised controlled trials carried out in Nottingham,\u000a      England and Funen, Denmark and published in 1993 demonstrated that\u000a      screening for colorectal cancer using Faecal Occult Blood testing reduced\u000a      disease-specific mortality by up to 18%. On the advice of the National\u000a      Screening Committee, the UK Departments of Health commissioned a\u000a      demonstration pilot of faecal occult blood test screening to be carried\u000a      out in two geographical areas, one in England and one in Scotland. The\u000a      areas chosen, on the basis of competitive bids, were Tayside, Grampian and\u000a      Fife in Scotland and Coventry and Warwick in England. The executive group\u000a      established to oversee this exercise was chaired by Steele\u000a      (Professor of Surgical Oncology, Ninewells Hospital and Medical School,\u000a      Dundee). This group developed the pilot methodology and subsequently\u000a      carried out the major piece of underpinning research, a demonstration\u000a      pilot exercise in the two sites to test the effectiveness of the first\u000a      round of a biennial screening programme. This ran between March 2000 and\u000a      May 2003 and proved to be extremely successful, inviting 478,250\u000a      individuals aged 50-69 for faecal occult blood test screening over a\u000a      two-year period and assessing key performance indicators against\u000a      benchmarks set by the previous randomised controlled trials [i]. The\u000a      results of this research were evaluated by an independent team and\u000a      reported to the UK Departments of Health who acted on them by developing\u000a      and introducing National Colorectal Screening Programmes [ii]. In\u000a      Scotland, the demonstration pilot continued for two further biennial\u000a      screening rounds. This provided information on the performance of both\u000a      prevalence and incidence screening, allowing for more precise planning by\u000a      the screening centres and NHS Boards [iii]. Subsequent research\u000a      demonstrated that telephone communication with screen positive individuals\u000a      increased the uptake of colonoscopy and that repeated invitations\u000a      increased the overall uptake of screening [iv]. A further randomised\u000a      controlled trial [v] to assess the impact of pre-notification for\u000a      screening demonstrated a further significant increase in uptake.\u000a      Additionally, research carried out at the Screening Centre and the\u000a      Research Unit established that the use of a sensitive immunological faecal\u000a      occult blood test in those with a weak positive guaiac faecal occult blood\u000a      test provided a more accurate method of selecting screen-positive\u000a      individuals for colonoscopy [vi].\u000a    Both the research work and the implementation of the screening programme\u000a      involved close collaborations between the University of Dundee, NHS Boards\u000a      and Government Health Departments. In order to analyse the data generated\u000a      by the Scottish arm of the demonstration pilot and to support new\u000a      developments, a Colorectal Screening Research Unit was established at the\u000a      Scottish Bowel Screening Centre in Dundee. This was funded by a programme\u000a      grant awarded to the University of Dundee by the Chief Scientist Office of\u000a      the Scottish Government Health Department, and led by Professor Steele.\u000a      Other local researchers were Callum Fraser (Director, Scottish Bowel\u000a      Screening Laboratory and Honorary Professor in Molecular and Cellular\u000a      Pathology); Frank Carey (Pathology Lead for Colorectal Cancer Screening in\u000a      Scotland and Honorary Professor of Pathology); and Gillian Libby (Research\u000a      Statistician).\u000a    Finally, the Screening Research Unit obtained funding of &#163;262,000 from\u000a      TENOVUS to work with the College of Life Sciences, University of Dundee on\u000a      the utilisation of advanced proteomics for the development of more\u000a      sensitive and specific screening tests, and &#163;1.55M from the MRC (through\u000a      the National Prevention Research Initiative) with Anderson to\u000a      study lifestyle interventions in individuals diagnosed with adenomas\u000a      through the screening programme (the BeWEL study, which ran from January\u000a      2010 to July 2013).\u000a    "},{"CaseStudyId":"35829","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000d    Our research has been central to the development of methods for\u000d      evaluating the impact of antibiotic policy and the relationship between\u000d      hospital prescribing and resistance in Europe; Davey has, for example,\u000d      participated in Europe-wide reviews of the issue [1,2]. In Scotland our\u000d      work on prescribing indicators and quality improvement has enabled\u000d      sustainable evaluation of hospital antibiotic prescribing by hospitals in\u000d      all 14 Health Boards; this was accompanied by a demonstrated 43% reduction\u000d      in C. difficile infection in Scotland between 2008 and 2011 [3,p7\u000d      and 4]\u000d    In addition to multiple citations of the main report of the Cochrane\u000d      review [iii], its impact is evidenced by the ORION guidelines [iv] arising\u000d      from subsequent collaboration with researchers from University College\u000d      London and the University of Bristol. These have been endorsed by\u000d      professional societies in the UK, Europe and USA and disseminated at their\u000d      meetings [4]. The Cochrane review was quoted in the Scottish Management of\u000d      Antimicrobial Resistance Action Plan (http:\/\/www.scotland.gov.uk\/Publications\/2008\/03\/12153030\/0)\u000d      and influenced the recommendation for a national organisation to integrate\u000d      improvement in antibiotic prescribing with control of healthcare\u000d      associated infection. This resulted in establishment of the Scottish\u000d      Antimicrobial Prescribing Group (SAPG) as part of the Scottish Medicines\u000d      Consortium (2007) [5].\u000d    Research outputs [i-iv] led to Davey being invited to lead the Hospital\u000d      Subproject of ESAC from 2003-2010. From 2006-2010 Davey led the\u000d      development and testing in 20 European hospitals of a web based method for\u000d      reporting on point prevalence studies of antibiotic use [v]. The ESAC\u000d      project continued until 2010 and the ESAC website documents wide\u000d      dissemination across Europe. The 2009 point prevalence survey included 172\u000d      hospitals from 25 European countries [6]. In Scotland, hospitals from all\u000d      14 Health Boards participated in the 2009 ESAC point prevalence survey,\u000d      and this is specifically cited by NHS Boards when discussing the impact\u000d      SAPG has had in their area, in the SAPG 2009 Annual Report [7].\u000d    As the Representative with Responsibility for International Liaison and\u000d      Research for SAPG Davey recommended that the ESAC quality\u000d      indicators should be adopted as national targets. This SAPG recommendation\u000d      was included by Scottish Government in 2009 as part of their HEAT (Health,\u000d      Efficiency and Access to Treatment) target to reduce the rate of C.\u000d        difficile Associated Disease among patients aged 65 and over by at\u000d      least 30% by 31 March 2011 [8]. SAPG adapted the ESAC Point Prevalence\u000d      Survey method for continuous measurement of compliance with the national\u000d      targets for hospital antibiotic use. A secure, web based system was\u000d      created for all acute hospitals in Scotland to report their compliance\u000d      with antibiotic policy with monthly prevalence surveys in acute medical\u000d      and surgical admission units. The recommended restrictive antibiotic\u000d      policy for reducing C. difficile Associated Disease was based on Davey's\u000d      study to identify high risk antibiotics [vi] as well as the Cochrane\u000d      review [iii]. The SAPG Report on Progress from 2008-11 cites the\u000d      development and measurement of hospital prescribing indicators as being\u000d      critical to SAPG's contribution to the 43% reduction in C. difficile\u000d      infection seen throughout NHS Scotland by national restriction of\u000d      antimicrobials associated with a high risk of C. difficile\u000d      infection [3,p7]. SAPG continues to use the hospital antibiotic\u000d      prescribing indicators for measurement of antibiotic use and compliance\u000d      with policy and produces annual reports [9,10]. The C. difficile\u000d      infection HEAT target for 2009-11 has been reviewed by the Healthcare\u000d      Acquired Infection Task Force and a new C. difficile infection\u000d      target from April 2011 has been set using a `best in class' approach so\u000d      that by March 2013 the rate of C. difficile infection in patients\u000d      aged 65 and over is 0.39 cases or less per 1000 total occupied bed days in\u000d      all NHS boards. As a result of the impact of this work the University of\u000d      Dundee is being funded by Scottish Government's Healthcare Associated\u000d      Infection Task Force to work with National Services Scotland on the\u000d      development of further quality indicators of hospital antibiotic\u000d      prescribing. Internationally, the Clinical Excellence Commission in\u000d      Sydney, Australia invited Davey to be a consultant in February\u000d      2013, and has subsequently adapted the ESAC quality indicators for\u000d      implementation across New South Wales [11].\u000d    ","ImpactSummary":"\u000d    The need to measure and improve hospital antibiotic prescribing was\u000d      identified as a priority in European and UK policy documents about\u000d      antibiotic resistance in the late 1990s. Our research developed\u000d      sustainable methods for evaluating interventions to improve hospital\u000d      antibiotic prescribing, and led to Davey collaborating with the\u000d      European Surveillance of Antimicrobial Consumption (ESAC) project and\u000d      becoming the Scottish Antimicrobial Prescribing Group's Representative\u000d      with Responsibility for International Liaison and Research. Implementation\u000d      of ESAC quality indicators and measurement methods has been associated\u000d      with progressive improvement in antibiotic policy compliance and reduction\u000d      in Clostridium difficile infection in all 14 Health Boards in\u000d      Scotland since 2008.\u000d    ","ImpactType":"Health","Institution":"\u000d    ","Institutions":[{"AlternativeName":"Dundee (University of)","InstitutionName":"University of Dundee","PeerGroup":"B","Region":"Scotland","UKPRN":10007852}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2147714","Name":"Sydney"},{"GeoNamesId":"2654675","Name":"Bristol"}],"References":"\u000d    \u000ai. Ramsay C, Brown E, Hartman G and Davey P (2003) Room for\u000d      improvement: a systematic review of the quality of evaluations of\u000d      interventions to improve hospital antibiotic prescribing. J.\u000d        Antimicrob. Chemother. 52, 764-771 (DOI:\u000d      10.1093\/jac\/dkg460).\u000d    \u000a\u000aii. Ansari F, Gray K, Nathwani D, Phillips G, Ogston S, Ramsay C, and Davey\u000a        P (2003) Outcomes of an intervention to improve hospital antibiotic\u000d      prescribing: interrupted time series with segmented regression analysis. J.\u000a        Antimicrob. Chemother. 52, 842-848 (DOI:\u000d      10.1093\/jac\/dkg459).\u000d    \u000a\u000aiii. Davey P, Brown E, Fenelon L, Finch R, Gould I, Hartman G,\u000d      Holmes A, Ramsay C, Taylor E, Wilcox M and Wiffen P (2005) Interventions\u000d      to improve antibiotic prescribing practices for hospital inpatients. Cochrane\u000a        Database of Systematic Reviews 2013 Issue 4: CD003543 (DOI:\u000d      10.1002\/14651858.CD003543.pub2).\u000d    \u000a\u000aiv. Stone SP, Cooper BS, Kibbler CC, Cookson BD, Roberts JA, Medley GF,\u000d      Duckworth G, Lai R, Ebrahim S, Brown EM, Wiffen PJ and Davey, PG\u000d      (2007) The ORION statement: guidelines for transparent reporting of\u000d      outbreak reports and intervention studies of nosocomial infection. Lancet\u000a        Infect. Dis. 7, 282-288 (DOI:10.1016\/S1473-3099(07)70082-8).\u000d    \u000a\u000av. Ansari F, Erntell M, Goossens H and Davey P (2009) The\u000d      European surveillance of antimicrobial consumption (ESAC) point-prevalence\u000d      survey of antibacterial use in 20 European hospitals in 2006. Clin.\u000d        Infect. Dis. 49, 1496-1504 (DOI: 10.1086\/644617).\u000d    \u000a\u000avi. Vernaz N, Hill K, Leggeat S, Nathwani D, Philips G, Bonnabry P and Davey,\u000a        P (2009) Temporal effects of antibiotic use and Clostridium\u000d        difficile infections. J. Antimicrob. Chemother. 63,\u000d      1272-1275 (DOI: 10.1093\/jac\/dkp128).\u000d    \u000aFunding\u000d    &#8226; Davey P (lead for Hospital Prescribing Sub-project) with\u000d      Goossens (University of Antwerp): European Surveillance of Antimicrobial\u000d      Consumption; DG Sanco of the European Union (01\/10\/2005 to 01\/10\/2007)\u000d      Value to University of Dundee &#163;16,562 (Total grant &#8364;3.5M).\u000d    &#8226; Davey P (lead for Work Packages 4 and 5) with Frank, Schumacher\u000d      (University of Freiburg), Grundman (RIVM, Netherlands), Suetens (Institute\u000d      of Public Health, Brussels): Burden of Resistance and Disease in European\u000d      Nations; DG Sanco of the European Union. (01\/07\/2007 to 31\/07\/2009). Value\u000d      to University of Dundee &#163;185,256 (Total grant &#8364;1.32M).\u000d    &#8226; Davey P (with Donnan P, University of Dundee):\u000d      Monitoring consequences of changes in antibiotic regime for surgical\u000d      prophylaxis; Healthcare Associated Infection Task Force, Scottish\u000d      Government (01\/10\/ 2011 to 30\/06\/2013) &#163;60,227.\u000d    &#8226; Davey P, (with Marwick C, University of Dundee, Charani\u000d      E, Imperial College Gould I, Ramsay C, University of Aberdeen): Systematic\u000d      review and meta-analysis of interventions to improve antibiotic\u000d      prescribing practices for hospital inpatients; Chief Scientist Office,\u000d      Scotland (01\/06\/2013 to 31\/03\/2015) &#163;174,906.\u000d    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"}],"Sources":"\u000d    \u000d      Adriaenssens N and Coenen S, for European Surveillance of Antibiotic\u000d        Prescribing Management Team (2010) Disease-specific antibiotic\u000d        prescribing quality indicators report. http:\/\/ecdc.europa.eu\/en\/activities\/surveillance\/esac-net\/publications\/documents\/report_disease_specific_antibiotic_prescribing_quality_indicators.pdf\u000a\u000d      Corroboration statement from the Co-ordinator, European Surveillance\u000d        of Antibiotic Consumption, Belgium.\u000d      Scottish Antimicrobial Prescribing Group (2011) Scottish Antimicrobial\u000d        Prescribing Group Progress Report for 2008-2011; available at http:\/\/www.scottishmedicines.org.uk\/files\/sapg\/SAPG_Progress_Report_2008-11.pdf.\u000d      Infectious Diseases Research Network. ORION Statement Website. http:\/\/www.idrn.org\/orion.php.\u000d      Corroboration statement from Project Lead, Scottish Antimicrobial\u000d        Prescribing Group, Scottish Medicines Consortium, Scottish Medicines\u000d        Consortium.\u000d      \u000aZarb\u000d          P, Amadeo\u000d          B, Muller\u000d          A, Drapier\u000d          N, Vankerckhoven\u000d          V, Davey\u000d          P, Goossens\u000d          H; ESAC-3\u000d          Hospital Care Subproject Group (2011) Identification of targets\u000d        for quality improvement in antimicrobial prescribing: the web-based ESAC\u000d        Point Prevalence Survey 2009. J. Antimicrob. Chemother. 66,\u000d        443-49 (DOI: 10.1093\/jac\/dkq430).\u000d      Andrea Patton on behalf of Scottish Antimicrobial Prescribing Group\u000d        (2010) CDI HEAT Target (CEL April 2009) Hospital-based Empirical\u000d        Prescribing National Report May 2010. http:\/\/www.scottishmedicines.org.uk\/files\/SAPG_Antimicrobial_Supporting_Indicators_Report_Final_National_Report_May_2010.pdf\u000a\u000d      McGuire M, Keel A and Scott B (Chief Nursing Officer Directorate)\u000d        (2009) A revised framework for national surveillance of Healthcare\u000d        Associated Infection and the introduction of a new Health Efficiency and\u000d        Access to Treatment (HEAT) target for Clostridium difficile-associated\u000a        disease (CDAD) for NHS Scotland. Scottish Government, Edinburgh. http:\/\/www.sehd.scot.nhs.uk\/mels\/CEL2009_11.pdf\u000a\u000d      Scottish Antimicrobial Prescribing Group (2010) Scottish Antimicrobial\u000d        Prescribing Group Annual Report 2008-2009. http:\/\/www.scottishmedicines.org.uk\/files\/sapg\/SAPG_AR_Lo-Res.pdf.\u000d      Scottish Antimicrobial Prescribing Group (2012) Empirical Prescribing\u000d        Indicator Report April 2011 - December 2011\u000d        http:\/\/www.scottishmedicines.org.uk\/files\/sapg\/Empirical_Prescribing_Report_February_2012.pdf.\u000d      Corroboration statement from Acting Deputy Chief Executive Officer,\u000d        Clinical Excellence Commission of New South Wales, Australia.\u000d    \u000d    ","Title":"\u000d    Improving antibiotic prescribing to hospital inpatients\u000d    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d    Following the House of Lords reports on Antimicrobial Resistance in 1998\u000d      and 2001 and the European Union's Microbial Threat in 1998, which\u000d      expressed extreme concern with the lack of progress in measurement of\u000d      antibiotic use and compliance with policies in hospitals (http:\/\/www.publications.parliament.uk\/pa\/ld199798\/ldselect\/ldsctech\/081vii\/st0701.htm,\u000d      http:\/\/www.publications.parliament.uk\/pa\/ld200001\/ldselect\/ldsctech\/56\/5601.htm\u000d      and http:\/\/soapimg.icecube.snowfall.se\/strama\/Kopenhamnsmotet_1998.pdf),\u000a      Davey (Lead for Clinical Quality Improvement, Division of\u000d      Population Health Sciences, Dundee) collaborated with Ramsay (University\u000d      of Aberdeen) and the British Society for Antimicrobial Chemotherapy on a\u000d      systematic review [i]. This confirmed significant gaps in the evidence\u000d      base on interventions to improve hospital antibiotic prescribing. They\u000d      tested a novel approach to measurement of effect size with segmented\u000d      regression analysis of an intervention to change antibiotic policy in NHS\u000d      Tayside [ii] and used the method in the systematic review to demonstrate a\u000d      significant association between reduction in use of broad spectrum\u000d      antibiotics and infections with drug resistant bacteria and with C.\u000d        difficile [iii]. Collaboration with authors of another systematic\u000d      review about infection control produced the ORION guidelines for good\u000d      practice in reporting interventions [iv].\u000d    Most hospital data systems only record supply of antibiotics to hospital\u000d      wards. This information can be used to analyse the impact of interventions\u000d      on use of antibiotics targeted by policy change [ii]. However, hospitals\u000d      also need a sustainable method for measurement of prescribing to\u000d      individual patients in order to assess compliance with antibiotic policy\u000d      for treatment of specific infections. Davey was the UK\u000d      representative for the 2000-2003 ESAC project and from 2003-10 was funded\u000d      by ESAC II and III to lead work on surveillance of hospital consumption.\u000d      This led to the development and testing in 20 European hospitals of a\u000d      method for point prevalence surveying of the treatment of individual\u000d      patients. The participating hospitals conducted the point prevalence\u000d      survey without any additional resources for data collection [v]. Analysis\u000d      and comparison between hospitals was enabled by a web based reporting\u000d      system. The output from this work included identification of three quality\u000d      indicators:\u000d    \u000d      Documentation of indication for antibiotics in the hospital case notes\u000d      Compliance with the hospital antibiotic policy\u000d      Duration of all antibiotic prophylaxis for surgery no greater than 24h\u000d    \u000d    Following on from the ESAC project Davey collaborated with\u000d      colleagues in Geneva on time series analysis of pharmacy data to identify\u000d      targets for reduction in C difficile infections. The model for\u000d      hospital-acquired C. difficile infections suggested that variation\u000d      in four antibiotics explained 61% of the variance in C. difficile\u000d      infections in hospitals in NHS Tayside [vi] and led to an intervention to\u000d      change antibiotic policy in hospitals in Scotland.\u000d    "},{"CaseStudyId":"37276","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"3017382","Name":"France"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"2750405","Name":"Netherlands"}],"Funders":[],"ImpactDetails":"\u000a    The trial has had a number of important outcomes: not only did it lead to\u000a      the establishment of a\u000a      centrally funded national ECMO service and an international centre for\u000a      research and training in\u000a      Leicester, but it also served as an early template for evidence-based\u000a      research still relevant in 2013.\u000a    Setting up of a national ECMO service\u000a    The findings of the UK Collaborative trial informed the National\u000a      Specialised Commissioning Team's\u000a      (NSCT) Service Standards for the Neonatal Respiratory ECMO Service\u000a      (designated in 1997,\u000a      extended in 2005 to include children up to age 18) and the centrally\u000a      ring-fenced funding of a\u000a      national neonatal ECMO service based in Leicester, Newcastle, London\u000a      (Great Ormond Street\u000a      Hospital) and Glasgow. Service standards and funding are reviewed annually\u000a      by commissioners\u000a      and providers. The latest standards refer to 2012\/13 (A), and the\u000a      budget for Leicester for this\u000a      period is just over &#163;4.3 million.\u000a    NSCT and providers have a commitment to working together to continually\u000a      improve the service\u000a      and react to innovative and dynamic ideas, such as developing a mobile\u000a      ECMO service for\u000a      neonatals and children in 2011\/12. This is now offered by Glenfield\u000a      Hospital (B).\u000a    The response to the CESAR trial has been to commission an adult ECMO\u000a      service: since 2011 this\u000a      has operated in five centres, with transport of patients on ECMO as part\u000a      of the contract (C).\u000a      Glenfield is the only one offering a neonatal, paediatric and adult\u000a      service.\u000a    Quality of life\u000a    The neonatal trial provided clear data of improved survival, reduced risk\u000a      of disability and cost\u000a      effectiveness. These data remain unchallenged in 2013.\u000a    Survival rates: The most immediate impact has been on survival of\u000a      babies entered into the ECMO\u000a      programme. Statistically, for every three babies with breathing problems\u000a      and lung failure treated\u000a      with ECMO rather than conventional ventilation, one more survived. The\u000a      number of additional\u000a      survivors to 2013 can be estimated, based on 100 suitable cases per year\u000a      in the UK, at 340.\u000a      Paediatric and adult patients are also being successfully treated in\u000a      increasing numbers.\u000a    Reduced risk of disability: In the neonatal trial, overall rates\u000a      of impairment and disability were\u000a      approximately half that seen in survivors treated conventionally. An\u000a      important feature of both\u000a      neonatal and adult trials was that the end-point was not survival; it was\u000a        intact survival after an\u000a      interval. In the case of the neonatal trial it was 1-, 4- and 7-year\u000a      intact survival based on\u000a      neurological assessments. In the case of CESAR it was functional\u000a      independence six months after\u000a      treatment. An often unrecognised aspect of ECMO support is that the\u000a      quality of both neonatal and\u000a      adult survivors is excellent and there is limited long-term functional\u000a      disability. Provided they are\u000a      otherwise healthy before needing ECMO, they go on to have long and\u000a      productive lives in society\u000a      (D).\u000a    Cost-effectiveness: In the period from discharge from initial\u000a      hospitalisation until 7-year follow-up,\u000a      there was consistently higher use of health care resources in the ECMO\u000a      arm, but this is largely\u000a      because of increased survival in this group. Economic evaluations of ECMO\u000a      after 4 and 7 years\u000a      provided rigorous evidence of the cost-effectiveness of ECMO. The measures\u000a      of benefit used were\u000a      the life-years gained and the disability-free life-years gained (E).\u000a    International renown\u000a    Since 2009, Leicester has been the largest centre in the world in terms\u000a      of the combined number of\u000a      neonatal, paediatric and adult cases annually. The trial data have\u000a      influenced practice in Europe\u000a      (Sweden, the Netherlands, France and Germany) and further afield (US and\u000a      Australia), and many\u000a      practitioners have come to Leicester to train in the use of ECMO.\u000a      Glenfield has a reciprocal\u000a      agreement with European centres, particularly the Karolinska Institute in\u000a      Stockholm. During the\u000a      H1N1 influenza A pandemic (swine flu) in 2009\/10, which produced a number\u000a      of young adults\u000a      whose respiratory function was severely compromised, Glenfield treated 62\u000a      additional patients,\u000a      some from abroad, who showed significant benefit from being able to access\u000a      ECMO.\u000a    When Glenfield's ECMO unit for children was threatened with closure in\u000a      2012, the Director of the\u000a      ECMO unit at Karolinska, warned that 20 years' experience would be thrown\u000a      away, and that about\u000a      50 babies would die over five years if the unit was moved. \"Leicester\u000a        has one of the highest\u000a        survival rates for patients who need ECMO in the world,\" he is\u000a      quoted as saying. Leicester and\u000a      Karolinska both have survival rates 10 to 20% higher than in other parts\u000a      of the world (F).\u000a    Beginnings of evidence-based approach\u000a    The novel neonatal trial recruited babies with a predicted mortality of\u000a      80%: it also incorporated a\u000a      prospective health economic evaluation, a follow-up programme and a review\u000a      of parent opinions of\u000a      the procedure and the trial. Sir Iain Chalmers of the Cochrane Collection\u000a      says: \"The trial provided\u000a        the opportunity to do some important social scientific studies exploring\u000a        the challenges of explaining\u000a        controlled trials to parents in the fraught circumstances of the birth\u000a        of a severely ill child.\" (G).\u000a    It set an important precedent for how research trials should be designed\u000a      to reduce uncertainty and\u000a      provide better evidence to inform future decisions in clinical practice\u000a      and policy implementation. It\u000a      is one of the earliest examples of direct engagement between NHS\u000a      Commissioners and academics\u000a      to assess a new technology prior to any `creep' into general practice.\u000a      Chalmers says: \"The\u000a        example set by British neonatologists when they decided that ECMO should\u000a        only be offered within\u000a        the context of a multicentre trial until its effects were clearer\u000a        remains today a beacon showing the\u000a        way that clinicians should behave when there is uncertainty about the\u000a        effects of their practices.\"\u000a      (G).\u000a    ","ImpactSummary":"\u000a    Neonatal extracorporeal membrane oxygenation (ECMO) is a complex\u000a      procedure of life support\u000a      used in severe but potentially reversible respiratory failure in newborn\u000a      infants. In 1993 researchers\u000a      in Leicester carried out the first and, to date, only large-scale\u000a      randomised trial comparing the value\u000a      of ECMO with other means of life support. The trial, with follow-up\u000a      research at 4 and 7-year\u000a      intervals, has shown ECMO to be a life-saving and cost-effective\u000a      treatment, and has led to the\u000a      establishment of a centrally funded neonatal programme that is estimated\u000a      to have saved around\u000a      340 lives in the UK alone. In 2013 the University remains internationally\u000a      renowned in the field of\u000a      ECMO research, and since 2009 Glenfield Hospital has been home to the\u000a      world's largest ECMO\u000a      centre for the treatment of newborns, older babies and adults. The trial\u000a      is still held up by advocates\u000a      of fair clinical trials as an example of how evidence should translate\u000a      into practice and policy.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Leicester\u000a    ","Institutions":[{"AlternativeName":"Leicester (University of)","InstitutionName":"University of Leicester","PeerGroup":"A","Region":"East Midlands","UKPRN":10007796}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2673730","Name":"Stockholm"}],"References":"\u000a    \u000a1 UK collaborative randomised trial of neonatal extracorporeal membrane\u000a      oxygenation. Lancet\u000a      1996; 348:75-82. (Published on behalf of the UK Collaborative ECMO Trial.\u000a      Corr. author Field)\u000a    \u000a\u000a2 UK collaborative randomised trial of neonatal extracorporeal membrane\u000a      oxygenation: Follow up\u000a      to one year.Pediatrics 1998;101:http\/\/www.pediatrics.org.e1\u000a    \u000a\u000a3 Bennett CC. Johnson A. Field DJ. Elbourne D. UK Collaborative\u000a      ECMO Trial Group. UK\u000a      collaborative randomised trial of neonatal extracorporeal membrane\u000a      oxygenation: follow-up to age\u000a      4 years. Lancet. 357(9262):1094-6, 2001 Apr 7.\u000a    \u000a\u000a4 Helena McNally, Charlotte C. Bennett, Diana Elbourne, David J.\u000a        Field, for the UK Collaborative\u000a      ECMO Trial Group United Kingdom Collaborative Randomized Trial of Neonatal\u000a      Extracorporeal\u000a      Membrane Oxygenation: Follow-up to Age 7 Years. Pediatrics\u000a      2006;117: e845-e854\u000a      (doi:10.1542\/peds.2005-1167).\u000a    \u000a\u000a5 Horan M, Ichiba S, Firmin R, Killer H, Edwards D, Azzopardi D\u000a      Hodge R, Kotecha S, Field D. A\u000a      pilot investigation of mild hypothermia in neonates receiving\u000a      extracorporeal membrane oxygenation\u000a      (ECMO). Journal of Pediatrics 2004;144:301-308.\u000a    \u000a\u000a6 Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E,\u000a      Thalanany MM, Hibbert, CL, Truesdale\u000a      A, Clemens F, Cooper N, Firmin RK, Elbourne D; CESAR trial collaboration.\u000a      Efficacy and\u000a      economic assessment of conventional ventilatory support versus\u000a      extracorporeal membrane\u000a      oxygenation for severe adult respiratory failure (CESAR): a multicentre\u000a      randomised controlled trial.\u000a      Lancet. 2009 Oct 17;374(9698):1351-63.\u000a    \u000aGrants\u000a    1992-97 UK Collaborative ECMO Trial &#163;1,400,000.Department of Health\u000a      Research &amp; Development\u000a    2004 Randomised trial of mild hypothermia during newborn ECMO. British\u000a      Heart Foundation\u000a      &#163;383,000. (Plus pilot investigation &#163;77,000 and 2008 supplementary award\u000a      &#163;41,613)\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"14","Subject":"Paediatrics and Reproductive Medicine"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    A. Specialised Services. Service specification and standard document &#8212;\u000a      Respiratory\u000a      extracorporeal membrane oxygenation (ECMO) for children and neonates\u000a      (2012\/13)\u000a      http:\/\/www.specialisedservices.nhs.uk\/document\/10348\u000a    B. Daily Mail: Seriously ill newborn baby given tiny ear defenders so he\u000a      can be flown by helicopter\u000a      to be closer to his family. 20 July 2013. http:\/\/www.dailymail.co.uk\/news\/article-2371316\u000a    C. NHS Specialised Services. Service specification and standard document\u000a      &#8212; Respiratory\u000a      extracorporeal NHS membrane oxygenation (ECMO) for adults (2012\/13)\u000a      http:\/\/www.specialisedservices.nhs.uk\/document\/service-specification-standards-respiratory-extracorporeal-membrane-oxygenation-ecmo-adults\u000a    D. Mugford, M, Elbourne, D., Field D. Cochrane review: Extracorporeal\u000a      membrane oxygenation for\u000a      severe respiratory failure in newborn infants.16 Jul 2008.\u000a    E. Petrou, S., Bischof, M., Bennett, C., Elbourne, D., Field, D.,\u000a      McNally, H.. Cost-Effectiveness of\u000a      Neonatal Extracorporeal Membrane Oxygenation Based on 7-Year Results From\u000a      the United\u000a      Kingdom Collaborative ECMO Trial. Pediatrics 2006; 117:1640-1649\u000a    F. BBC News: Expert's warning over Glenfield's loss of ECMO. 10 July 2012\u000a      http:\/\/www.bbc.co.uk\/news\/uk-england-leicestershire-18783972\u000a    G. Statement from founder of the Cochrane Collection and an advocate of\u000a      non-commercialised\u000a      controlled trials.\u000a    ","Title":"\u000a    Extracorporeal membrane oxygenation (ECMO) in newborn babies: from\u000a      pioneering technique to accepted practice\u000a    ","UKLocation":[{"GeoNamesId":"2644668","Name":"Leicester"},{"GeoNamesId":"2648579","Name":"Glasgow"},{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2641673","Name":"Newcastle-upon-Tyne"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Background\u000a    ECMO uses an artificial lung to oxygenate the blood outside the body when\u000a      a patient has a serious\u000a      condition which prevents the lungs or heart from working normally. ECMO\u000a      provides time for the\u000a      heart to rest and recover, while maintaining a good blood supply to the\u000a      brain and other organs.\u000a      First used in the US in the late 1970s, it was still a pioneering\u000a      technique when Richard Firmin, a\u000a      paediatric surgeon at Glenfield Hospital in Leicester and an honorary\u000a      senior lecturer at the\u000a      University, convinced that the treatment was effective (unlike many other\u000a      surgeons), approached\u000a      the children's charity Heart Link for funds to support the introduction of\u000a      an ECMO programme in\u000a      Leicester. After a successful series of cases, Firmin and colleagues,\u000a      buoyed by huge public\u000a      support and the backing of Leicester MP Greville Janner, persuaded the\u000a      Department of Health to\u000a      fund a grant proposal; that was followed by &#163;1.4 million to conduct a\u000a      randomised controlled trial to\u000a      assess the effectiveness of ECMO against conventional ventilation.\u000a    The randomised controlled trial\u000a    The trial was not an easy undertaking. It was complex and expensive. It\u000a      was ethically and\u000a      practically difficult to design, given the type of patient being studied:\u000a      babies with only a 20%\u000a      chance of survival were assigned randomly to the ECMO group or control\u000a      group within hours of\u000a      their birth. At the time ECMO was a highly controversial procedure and the\u000a      long-term outcomes\u000a      were completely unknown: there was a very real possibility that reduced\u000a      mortality might be\u000a      achieved only with an increase in severe disability among survivors.\u000a    Between January 1993 and November 1995, 185 infants with severe\u000a      respiratory failure were\u000a      recruited for the study: 93 infants were randomly allocated to the ECMO\u000a      group and 92 to the\u000a      conventional treatment group. The trial was led by Professor David Field,\u000a      who set up the trial,\u000a      established a protocol and trained staff from five regional centres that\u000a      formed the UK Collaborative\u000a      &#8212; Leicester, Glasgow, Newcastle, Kings College London and Great Ormond\u000a      Street Hospital. All\u000a      five centres recruited babies to the trial. Analysis of results was\u000a      carried out by the National\u000a      Perinatal Epidemiology Unit (NPEU) in Oxford.\u000a    Recruitment to the trial was stopped two months early by the independent\u000a      Data Monitoring\u000a      Committee when the results showed that ECMO had a clear advantage: 63 of\u000a      93 infants allocated\u000a      ECMO survived compared with 38 of 92 allocated conventional care. The\u000a      conclusion was that\u000a      ECMO support should be actively considered for neonates with severe but\u000a      potentially reversible\u000a      respiratory failure. The results were published in The Lancet by the UK\u000a      Collaborative ECMO trial\u000a      Group, with Field listed as corresponding author. Despite the highly\u000a      specialised nature of the\u000a      subject matter, the article has been cited 337 times (1).\u000a    Follow-up research\u000a    The UK Collaborative carried out three follow-up studies. Initial\u000a      assessment at one year showed\u000a      that the results were in accord with earlier preliminary findings: that\u000a      ECMO support reduces the risk\u000a      of death without a concomitant rise in severe disability (2).\u000a    A fuller assessment at 4 years of age, using six clinical areas\u000a      (cognitive ability, neuromotor skills,\u000a      general health, behaviour, hearing and vision) demonstrated both an\u000a      increased number of\u000a      survivors (62 versus 38) and an increased number of survivors who were\u000a      free of disability (30\u000a      versus 13) in the ECMO group, compared with the conventional treatment\u000a      group. The results were\u000a      published in The Lancet and Field was one of the authors (3).\u000a    Further research at 7 years, when the children were old enough for\u000a      educational and other longer-term\u000a      impacts to be assessed, showed that the ECMO technique resulted in 34\u000a      (37%) cases of\u000a      death and severe disability v. 54 (59%) cases in the conventional\u000a      treatment group. Although both\u000a      groups had problems, the ECMO group consistently performed better and the\u000a      authors concluded\u000a      that the beneficial influence of an ECMO policy is still present at the\u000a      age of 7 years, and likely to be\u000a      at age 18. The results were published in Paediatrics and Field was the\u000a      corresponding author (4).\u000a    Other research\u000a    The establishment of an ECMO centre in Leicester has enabled a series of\u000a      studies with global\u000a      significance. In 2004 a multi-centre trial, again led by Field, and\u000a      assisted by Marie Horan (MD\u000a      student) focused on the use of hypothermia as a means of protecting brain\u000a      function in this group of\u000a      babies. The results made clear that this intervention, used widely in\u000a      neonatal ECMO centres\u000a      around the world, was potentially harmful (5).\u000a    Research has also been conducted on older babies (12 to 15 months) and\u000a      adults. The 2001-2006\u000a      CESAR (Conventional Ventilation or ECMO for Severe Adult Respiratory\u000a      Failure) trial involving\u000a      seriously ill adult patients led by Dr Giles Peek (Hon Senior Lecturer,\u000a      Cardiac Surgery) and\u000a      Professor Andrew Wilson (Primary Care) with colleagues from the London\u000a      School of Hygiene &amp;\u000a      Tropical Medicine, showed that 63% of patients given ECMO survived to 6\u000a      months without\u000a      disability compared to 47% of those assigned to conventional treatment\u000a      with a ventilator (6).\u000a    Key personnel\u000a    Leicester: Professor David Field, Neonatal Medicine (1985 &#8212;\u000a      present)\u000a    Other institutions: Prof Diana Elbourne; Prof Miranda Mugford; Dr\u000a      Stavros Petrou (NPEU, Oxford).\u000a    Clinical leads: Mr Richard Firmin (Leicester); Dr Duncan McCrae\u000a      (Great Ormond Street Hospital);\u000a    Mr Carl Davies and Dr Charlie Skeoch (Glasgow &#8212; Royal Hospital for Sick\u000a      Children); Prof Anne\u000a      Greenough (Kings College Hospital); and Mr Leslie Hamilton (Newcastle\u000a      Royal Victoria Infirmary).\u000a    "},{"CaseStudyId":"38353","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"3175395","Name":"Italy"},{"GeoNamesId":"294640","Name":"Israel"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"1861060","Name":"Japan"},{"GeoNamesId":"2186224","Name":"New Zealand"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":[],"ImpactDetails":"\u000a    The HAPO study identified for the first time, on a global basis, the\u000a      adverse impact on both\u000a      mother and baby of mildly elevated levels of glucose below those\u000a      traditionally used to make a\u000a      diagnosis of diabetes in pregnancy. The traditionally used criteria for\u000a      diabetes in pregnancy\u000a      were based on the principle of identifying women at risk of diabetes after\u000a      the pregnancy, rather\u000a      than the principle of identifying pregnancies where there was significant\u000a      risk to mother and\/or\u000a      baby as a consequence of elevated glucose. HAPO aimed to determine the\u000a      level of maternal\u000a      glucose associated with abnormal pregnancy outcomes for mother and baby,\u000a      and hence to\u000a      allow the development of new criteria for the diagnosis of diabetes in\u000a      pregnancy.\u000a    Following the publication of the major HAPO results in 2008, the\u000a      International Association of\u000a      Diabetes and Pregnancy Study Groups (IADPSG) convened a consensus panel,\u000a      which\u000a      published new recommended criteria for the diagnosis of diabetes in\u000a      pregnancy based on the\u000a      HAPO study findings, in Diabetes Care in 20101,2. Queen's\u000a      researchers were members of the\u000a      Consensus Panel which published the recommendations and are amongst its\u000a      authors. The\u000a      new criteria are based on identification of average glucose values at\u000a      which odds for increased\u000a      birth weight, levels of insulin in cord blood and percentage body fat of\u000a      the baby in the top 10%\u000a      reached 1.75 times the estimated odds of these outcomes at average glucose\u000a      values.\u000a      Therefore, the whole basis on which the diagnosis of diabetes in pregnancy\u000a      is made has been\u000a      changed from risk of subsequent diabetes in the mother, to risk to the\u000a      baby at birth.\u000a    The new criteria have already begun to have far reaching consequences at\u000a      an international\u000a      level1,3. A completely new two phase screening strategy for\u000a      diabetes in pregnancy is\u000a      recommended. This consists of an initial measurement of fasting plasma\u000a      glucose, random\u000a      glucose or HbA1c (a test that indicates average blood glucose levels over\u000a      the past three\u000a      months) in all women at the first prenatal visit. If the results are\u000a      abnormal, the woman is\u000a      managed as if she had diabetes preceding pregnancy. In all women with\u000a      normal results at this\u000a      initial visit, it is proposed that a 2 hour 75 g oral glucose tolerance\u000a      test is carried out at between\u000a      24 and 28 weeks gestation, and new criteria are provided for the diagnosis\u000a      of gestational\u000a      diabetes. In a typical developed population, use of the new criteria\u000a      approximately doubles the\u000a      percentage of women who will be diagnosed as suffering from gestational\u000a      diabetes, from 8% to\u000a      16%. Appropriate management of women with this condition improves outcomes\u000a      both for\u000a      mother and baby.\u000a    The new criteria for diabetes in pregnancy were endorsed by the American\u000a      Diabetes\u000a      Association in January 2011 and are currently under review by many other\u000a      national guideline\u000a      bodies. There is widespread acceptance that the HAPO results indicate the\u000a      need for change in\u000a      glycaemic management during pregnancy. The problem is addressed in a very\u000a      large number\u000a      of papers, reflecting on how to implement the changes in management in\u000a      many countries, This\u000a      is the case for example in China, Japan, Australia, New Zealand, India,\u000a      Israel, Germany,\u000a      Switzerland, UK, USA and Canada. The IADPSG guidelines have been accepted\u000a      or endorsed\u000a      in part or whole by many bodies including the American Diabetes\u000a      Association, the Japanese\u000a      Diabetes Pregnancy Society, the Australasian Diabetes in Pregnancy Society\u000a      (Australia and\u000a      New Zealand)4, and the Italian Diabetes Pregnancy Society5.\u000a    ","ImpactSummary":"\u000a    New criteria for the diagnosis of diabetes in pregnancy have been\u000a      developed by the\u000a      International Association of Diabetes in Pregnancy Study Groups and\u000a      adopted by the\u000a      American Diabetes Association on the basis of the Hyperglycaemia and\u000a      Pregnancy Outcomes\u000a      (HAPO) study. These new criteria double the percentage of women diagnosed\u000a      with diabetes\u000a      in pregnancy from approximately 8.5% to 17%. Appropriate management\u000a      improves outcomes\u000a      for them and their new born children. The results, which proved valid for\u000a      all ethnic groups and\u000a      countries, have led to a worldwide re-appraisal of glycaemic risk in\u000a      pregnancy and the\u000a      introduction of new guidelines to manage this.\u000a    ","ImpactType":"Political","Institution":"\u000a    Queen's University Belfast\u000a    ","Institutions":[{"AlternativeName":"Queen's University Belfast","InstitutionName":"Queen's University Belfast","PeerGroup":"A","Region":"Northern Ireland","UKPRN":10005343}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Roberts RN, Moohan JM, Foo RL, Harley JM, Traub AI, Hadden DR. Fetal\u000a      outcome in\u000a      mothers with impaired glucose tolerance in pregnancy. Diabet Med.\u000a      1993; 10 (5): 438-43.\u000a      DOI: 10.1111\/j.1464-5491.1993.tb00095.x (article cited 31 times).\u000a      This publication\u000a      is available on request.\u000a    \u000a\u000a2. McCance DR, Hanson RL, Pettitt DJ, Bennett PH, Hadden DR, Knowler WC.\u000a      Diagnosing diabetes mellitus--do we need new criteria? Diabetologia.\u000a      1997; 40 (3):\u000a      247-55. DOI: 10.1007\/s001250050671 (article cited 65 times).\u000a    \u000a\u000a3. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR,\u000a      Trimble\u000a      ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD,\u000a      Oats JJ, Persson B, Rogers MS, Sacks DA. Hyperglycemia and adverse\u000a      pregnancy\u000a      outcomes. N Engl J Med. 2008; 8; 358 (19): 1991-2002.\u000a      DOI: 10.1056\/NEJMoa0707943 (Article cited 586 times).\u000a    \u000a\u000a4. Metzger BE, Persson B, Lowe LP, Dyer AR, Cruickshank JK,\u000a      Deerochanawong C,\u000a      Halliday HL, Hennis AJ, Liley H, Ng PC, Coustan DR, Hadden DR, Hod M, Oats\u000a      JJ,\u000a      Trimble ER; HAPO Study Cooperative Research Group. Hyperglycemia and\u000a      adverse\u000a      pregnancy outcome study: neonatal glycemia. Pediatrics. 2010; 126\u000a      (6): e1545-52.\u000a      DOI: 10.1542\/peds.2009-2257 (article cited 9 times).\u000a    \u000a\u000a5. Yogev, Chen, Hod, Coustan, Oats, McIntyre, Metzger, Lowe, Dyer,\u000a      Dooley, Trimble,\u000a      McCance, Hadden, Persson, Rogers; Hyperglycemia and Adverse Pregnancy\u000a      Outcome\u000a      (HAPO) Study Cooperative Research Group. Hyperglycemia and Adverse\u000a      Pregnancy\u000a      Outcome (HAPO) study: preeclampsia. Am J Obstet Gynecol. 2010; 202\u000a      (3): 255.e1-7.\u000a      DOI: 10.1016\/j.ajog.2010.01.024.\u000a    \u000a\u000a6. HAPO Study Cooperative Research Group. Hyperglycemia and Adverse\u000a      Pregnancy\u000a      Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes.\u000a      2009;\u000a      58 (2): 453-9. DOI: 10.2337\/db08-1112 (article cited 94 times).\u000a    \u000aFunding\u000a    Central Laboratory of HAPO Study. Principal Investigator: Professor\u000a        Elisabeth Trimble\u000a      Sponsor: North Western University (USA); duration: 08\/08\/2000 -\u000a      28\/07\/2009\u000a      From NIH: total $18.0 million: of which $2.36 million to Central\u000a      Lab at Queen's\u000a      From American Diabetes Association total $1.37 million: of which $\u000a      0.5 million to Central Lab\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"14","Subject":"Paediatrics and Reproductive Medicine"}],"Sources":"\u000a    \u000a      International Association of Diabetes and Pregnancy Study Groups\u000a        Consensus Panel.\u000a        International association of diabetes and pregnancy study groups\u000a        recommendations on\u000a        the diagnosis and classification of hyperglycemia in pregnancy. Diabetes\u000a          Care, 2010;\u000a        33 (3):676-682. DOI: 10.2337\/dc09-1848.\u000a        The proposed new international criteria for diagnosis of diabetes in\u000a          pregnancy based\u000a          on the HAPO study.\u000a\u000a      Waugh N, Royle P, Clar C, Henderson R, Cummins E, Hadden D, Lindsay R,\u000a        Pearson\u000a        D. Screening for hyperglycaemia in pregnancy: a rapid update for the\u000a        National\u000a        Screening Committee. Health\u000a              Technol Assess. 2010, 14 (45):1-183. DOI:\u000a        10.3310\/hta14450.\u000a        A rapid assessment of the relevance of HAPO for the UK National\u000a          Screening\u000a          Committee\u000a\u000a      Holt RI, Coleman MA, McCance DR. The implications of the new\u000a        International\u000a        Association of Diabetes and Pregnancy Study Groups (IADPSG) diagnostic\u000a        criteria for\u000a        gestational diabetes. Diabet Med. 2011, 28 (4):382-5. DOI:\u000a        10.1111\/j.1464-5491.2011.03236.x.\u000a      Flack JR, Ross GP, Ho S, McElduff A. Recommended changes to\u000a        diagnostic criteria\u000a        for gestational diabetes: impact on workload. Aust N Z J Obstet\u000a          Gynaecol. 2010, (5):\u000a        439-43. DOI:10.1111\/j.1479-828X.2010.01218.x\u000a      Paglia MJ, Coustan DR. Gestational diabetes: evolving diagnostic\u000a        criteria. Curr Opin\u000a        Obstet Gynecol. 2011, 23 (2):72-5. DOI:\u000a        10.1097\/GCO.0b013e328342d21e.\u000a    \u000a    ","Title":"\u000a    Changing the International Criteria for the diagnosis of Diabetes\u000a      in Pregnancy\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Researchers in Belfast had a long-standing interest in the impact of high\u000a      glucose in pregnancy,\u000a      which led to a series of papers from the late 1980s describing the harmful\u000a      effects of elevated\u000a      maternal glucose on both mother and baby, and suggesting that new criteria\u000a      for the diagnosis\u000a      of diabetes in pregnancy might be required1,2. Elizabeth\u000a      Trimble (Professor of Clinical\u000a      Biochemistry) and David Hadden (Honorary Professor of Diabetic Medicine)\u000a      were key to this.\u000a      As a consequence, researchers at Queen's University Belfast were lead\u000a      participants in\u000a      discussions with other leading international research groups that led to\u000a      the development of the\u000a      protocol for the Hyperglycaemia and Pregnancy Outcome (HAPO) study. This\u000a      major\u000a      international study involved a total of 25,505 pregnant women at 15\u000a      centres in nine countries,\u000a      who underwent 75-g oral glucose-tolerance testing at 24 to 32 weeks of a\u000a      pregnancy. The\u000a      study was led by Dr. Boyd Metzger from North-Western University in the USA\u000a      and funded by a\u000a      grant from the US National Institute of Health (NIH). Queen's\u000a      investigators were co-applicants\u000a      on the successful proposal, which was led from Chicago, and were members\u000a      of the study\u000a      Steering Committee, Head of the Central laboratory (Professor Elisabeth\u000a      Trimble), Head of the\u000a      European Clinical Area (with 3 separate clinical centres) (Professor David\u000a      Hadden) and Co-chair\u000a      of the Publications Committee (Professor Elisabeth Trimble). Belfast\u000a      provided the Central\u000a      laboratory for the study, because of its long and wide experience in\u000a      measuring peptides in\u000a      clinical samples developed under the leadership of the late Professor\u000a      Keith Buchanan. This\u000a      laboratory performed the analysis of samples from all countries for the\u000a      key parameters of\u000a      glucose, insulin and C-peptide. In addition, Belfast was one of the key\u000a      recruitment centres for\u000a      the study.\u000a    The main results of the HAPO study were published in the New England\u000a      Journal of Medicine in\u000a      2008 with three Queen's staff among the 14 authors3, and\u000a      subsequently, a number of\u000a      secondary publications appeared in other journals4-6. The main\u000a      findings of the HAPO study\u000a      were as follows: maternal glucose levels, even though these were below\u000a      those diagnostic for\u000a      diabetes, strongly correlated with the main outcomes of (i) increased\u000a      birth weight of the baby,\u000a      (ii) an increased need for primary Caesarean section, (iii) clinically\u000a      evident low blood glucose in\u000a      the newborn child and (iv) increased cord-blood insulin levels. In\u000a      addition, maternal obesity\u000a      also affected the main outcomes independent of the mother's elevated blood\u000a      glucose levels.\u000a      Obesity together with elevated blood glucose increased the risk for\u000a      undesirable outcomes\u000a      round the birth of the baby. The results proved to be valid for all\u000a      ethnicities and geographical\u000a      regions tested.\u000a    In summary, the global relevance of the risk revealed by the HAPO study\u000a      combined with\u000a      emerging evidence that intervention at lower plasma glucose levels leads\u000a      to improved\u000a      outcomes, has lent great urgency to re-evaluation of risk levels in\u000a      `gestational diabetes' and the\u000a      development of new guidelines for risk management.\u000a    "},{"CaseStudyId":"38354","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2963597","Name":"Ireland"}],"Funders":[],"ImpactDetails":"\u000d\u000a    Of the 3,800 individuals who are suspected to suffer from FH in Northern\u000d\u000a      Ireland, less than 200 had been identified at the start of this programme\u000d\u000a      of research. A clinical register of families that appeared to have an\u000d\u000a      inherited problem with levels of lipids in the blood was established in\u000d\u000a      Belfast from the early 1970s, and research into the causes of these\u000d\u000a      disorders began in Queen's in the late 1980's. As a result of the\u000d\u000a      programme of work, which has been outlined here, the number of identified\u000d\u000a      individuals is now approximately 1,100. Having initially been funded as a\u000d\u000a      research project, a fully funded laboratory and clinical service covering\u000d\u000a      the entire Northern Ireland population has now been established with the\u000d\u000a      support of the Department of Health and Social Care.\u000d\u000a    The service offers testing in individual and families with suspected FH\u000d\u000a      after the identification of index cases which are referred from primary or\u000d\u000a      secondary care to the specialist clinics according to agreed local\u000d\u000a      guidelines. The service is now embedded within the Northern Ireland\u000d\u000a      Cardiovascular Care Framework. The Service Framework for Cardiovascular\u000d\u000a      Health and Wellbeing [DHSSPS June 2009] recognises the importance of\u000d\u000a      familial hypercholesterolaemia in Overarching standard 12, which states1:\u000d\u000a    \"All people with genetically linked high cholesterol (FH) should be\u000d\u000a        identified and treated and their names entered on a regional register so\u000d\u000a        that other family members can be identified in order that measures can\u000d\u000a        be introduced to prevent the development of cardiovascular disease\".\u000d\u000a    Patients are offered lipid lowering therapy aimed at achieving a 50%\u000d\u000a      reduction in pre- diagnosis LDL cholesterol, in line with NICE guidance.\u000d\u000a      Audit has shown that this standard is met in over 70% of cases.\u000d\u000a    The expertise of the genetic testing laboratory is widely recognised:\u000d\u000a      samples are routinely received and tested from a number of regions in\u000d\u000a      England and Scotland, as well as the Republic of Ireland. In addition, the\u000d\u000a      world's leading laboratory medicine organisation The International\u000d\u000a      Federation for Clinical Chemistry and Laboratory Medicine has recognised\u000d\u000a      the Belfast laboratory as an expert laboratory in this area, one of only\u000d\u000a      two global laboratories so recognised. As a result of this, the laboratory\u000d\u000a      provides advice and guidance on genetic diagnosis of inherited lipid\u000d\u000a      disorders to clinical laboratories throughout the world.\u000d\u000a    The NICE guidance on FH (CG71: Identification and management of familial\u000d\u000a      hypercholesterolaemia, August 2008) was significantly informed by the\u000d\u000a      Northern Ireland experience (references 54 and 55; cited on pages 59, 71\u000d\u000a      and 104; table 6 extracted from these papers), and the recommendations in\u000d\u000a      the NICE guidance for England and Wales are very similar to established\u000d\u000a      practice in Northern Ireland2.\u000d\u000a    Currently, around 700 samples for genetic testing for FH are received by\u000d\u000a      the genetics laboratory each year5. A Northern Ireland target\u000d\u000a      has been agreed for the identification of 200 new cases of familial\u000d\u000a      hypercholesterolaemia per year. Furthermore, recent research work in\u000d\u000a      collaboration with the local biotechnology company Randox has developed a\u000d\u000a      test for common polymorphisms on a chip which has been commercially\u000d\u000a      launched on the international market this year6.\u000d\u000a    Thus the development of the diagnostic service based on the\u000d\u000a      identification of specific mutations in FH has led to the identification\u000d\u000a      of 900 more people in Northern Ireland who carry a high risk of\u000d\u000a      cardiovascular disease. A pro rata number in England would be 32,000\u000d\u000a      people who could be offered behaviour modification or treatment with\u000d\u000a      statins or other drugs to reduce their risk of serious morbidity and\u000d\u000a      mortality.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    A routine service for genetic diagnosis of familial hypercholesterolaemia\u000d\u000a      (FH) was developed and commissioned by the Northern Ireland Department of\u000d\u000a      Health, based on the identification by the Queen's team of a series of\u000d\u000a      mutations causing this condition. The team then developed novel diagnostic\u000d\u000a      strategies that led to over 900 affected individuals being identified so\u000d\u000a      that treatment could be delivered to them. Samples are received for\u000d\u000a      diagnosis from the UK and Ireland and the work of the Centre helped to\u000d\u000a      inform recent NICE guidance. The laboratory is recognised as an expert\u000d\u000a      laboratory for the diagnosis of inherited lipid disorders by the\u000d\u000a      International Federation for Clinical Chemistry and Laboratory Medicine.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Queen's University Belfast\u000d\u000a    ","Institutions":[{"AlternativeName":"Queen's University Belfast","InstitutionName":"Queen's University Belfast","PeerGroup":"A","Region":"Northern Ireland","UKPRN":10005343}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. Graham CA, Wright WT, McIlhatton BP, Young IS, Nicholls DP.\u000d\u000a      The LDLR variant T705I does not cause the typical phenotype of familial\u000d\u000a      hypercholesterolaemia. Atherosclerosis. 2006 Sep; 188(1):218-9.\u000d\u000a      Doi: 10.1016\/j.atherosclerosis.2006.04.014 (cited 2 times)\u000d\u000a    \u000a\u000a2. Ward AJ, O'Kane M, Nicholls DP, Young IS, Nevin NC,\u000d\u000a      Graham CA. A novel single base deletion in the LDLR gene (211delG): Effect\u000d\u000a      on serum lipid profiles and the influence of other genetic polymorphisms\u000d\u000a      in the ACE, APOE and APOB genes. Atherosclerosis. 1996 Feb;\u000d\u000a      120(1-2):83-91. Doi: 10.1016\/0021-9150(95)05685-8 (cited 31 times)\u000d\u000a    \u000a\u000a3. Graham CA, McIlhatton BP, Kirk CW, Beattie ED, Lyttle K, Hart P, Neely\u000d\u000a      RD, Young IS, Nicholls DP. Genetic screening protocol for familial\u000d\u000a      hypercholesterolemia which includes splicing defects gives an improved\u000d\u000a      mutation detection rate. Atherosclerosis. 2005 Oct; 182(2):331-40.\u000d\u000a      Doi: 10.1016\/j.atherosclerosis.2005.02.016 ( cited 3 times)\u000d\u000a    \u000a\u000a4. Graham CA, McClean E, Ward AJ, Beattie ED, Martin S, O'Kane M, Young\u000a        IS, Nicholls DP. Mutation screening and genotype: phenotype\u000d\u000a      correlation in familial hypercholesterolaemia. Atherosclerosis.\u000d\u000a      1999 Dec; 147(2):309-16. Doi: 10.1016\/S0021-9150(99)00201-4 (cited 43\u000d\u000a      times)\u000d\u000a    \u000a\u000a5. Nicholls P, Young IS, Graham CA. Genotype\/phenotype\u000d\u000a      correlations in familial hypercholesterolaemia. Curr\u000a          Opin Lipidol. 1998 Aug; 9(4):313-7. Doi:\u000d\u000a      10.1097\/00041433-199808000-00005 (cited 12 times)\u000d\u000a    \u000a\u000a6. Wright WT, Heggarty SV, Young IS, Nicholls DP, Whittall R,\u000d\u000a      Humphries SE, Graham CA. Multiplex MassARRAY spectrometry (iPLEX) produces\u000d\u000a      a fast and economical test for 56 familial hypercholesterolaemia-causing\u000d\u000a      mutations. Clin Genet. 2008 Nov; 74(5):463-8. Doi:\u000d\u000a      10.1111\/j.1399-0004.2008.01071.x (cited 14 times)\u000d\u000a    \u000aFunding:\u000d\u000a      1992 - 1995 Graham, Nicholls, Young. NI Chest Heart &amp;\u000d\u000a        Stroke Association \"Molecular genetics of familial\u000d\u000a      hypercholesterolaemia &#8212; in depth family studies and evaluation of a\u000d\u000a      screening program to improve detection of FH in NI.\" &#163;81,236.\u000d\u000a    1995 - 1998 Graham, Nicholls, Young. NI Chest Heart &amp;\u000d\u000a        Stroke Association \"LDL receptor mutations and other genetic lipid\u000d\u000a      markers in FH: genotype &#8212; phenotype study\" &#163;33,244.\u000d\u000a    1999 - 2002 Graham, Nicholls, Young. British Heart Foundation\u000d\u000a      \"Genetic basis of Familial Hypercholesterolaemia: Families without\u000d\u000a      LDLR\/FDB point mutations\" &#163; 87,000.\u000d\u000a    2002 - 2008 Graham, Nicholls, Young. NI Health and Social\u000d\u000a        Care R&amp;D office RRG 7.8 [5.28] \"The genetic basis of\u000d\u000a      hyperlipidaemia and vascular disease in Northern Ireland\" &#163; 545,000.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"},{"Level1":"6","Level2":"4","Subject":"Genetics"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    1) The Northern Ireland Department of Health, Social Services and Public\u000d\u000a      Safety. Service framework for cardiovascular health and well-being, 2009.\u000d\u000a      http:\/\/www.dhsspsni.gov.uk\/service_framework_for_cardiovascular\u000a        health_and_wellbeing.pdf\u000d\u000a    2) NICE clinical guideline 71. 2008. Identification and management of\u000d\u000a      familial hypercholesterolaemia. http:\/\/www.nice.org.uk\/nicemedia\/live\/12048\/41700\/41700.pdf.\u000d\u000a    3) International Federation for Clinical Chemistry and Laboratory\u000d\u000a      Medicine molecular diagnostics centres. www.ifcc.org.\u000d\u000a    4) Royal College of Physicians of London familial hypercholesterolaemia\u000d\u000a      audit, 2010. http:\/\/www.rcplondon.ac.uk\/resources\/audits\/FH.\u000d\u000a    5) Genetic Testing for Familial Hypercholesterolaemia. Leaflet from\u000d\u000a      genetic laboratory indicating testing approach and current price list.\u000d\u000a      Northern Ireland Regional Genetics Centre, Belfast Health and Social Care\u000d\u000a      Trust, Belfast City Hospital. This leaflet can be supplied on request.\u000d\u000a    6) Randox website : (http:\/\/www.randox.com\/fh-genetic-molecular-test.php)\u000d\u000a    ","Title":"\u000d\u000a    Identifying patients and families at risk of inherited high cholesterol\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2655984","Name":"Belfast"}],"UKRegion":[{"GeoNamesId":"2641364","Name":"Northern Ireland"},{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Resulting from research by Professor Young and his colleagues at Queen's\u000d\u000a      University Belfast, a service has been set up to test patients and their\u000d\u000a      families for inherited high cholesterol (familial hypercholesterolaemia &#8212;\u000d\u000a      FH). FH is the most common significant inherited clinical disorder in the\u000d\u000a      UK. It affects somewhere between 1 in 200 and 1 in 500 of the population,\u000d\u000a      meaning that there are over 110,000 affected individuals in the UK, and\u000d\u000a      approximately 3,800 in Northern Ireland. Traditional diagnosis of the\u000d\u000a      condition relies on measuring serum cholesterol, but this is unreliable,\u000d\u000a      especially in children and adolescents. If FH is not identified and\u000d\u000a      treated, 50% of men will have a heart attack before the age of 50, and 50%\u000d\u000a      of women before the age of 60. The majority of individuals suffering from\u000d\u000a      FH currently remain unidentified.\u000d\u000a    The key pathways of importance to the regulation of serum cholesterol and\u000d\u000a      the relevant genes controlling them were identified by Brown and Goldstein\u000d\u000a      in the USA in work originating in the 1970s. FH usually arises as a result\u000d\u000a      of a defect in one of three genes1,2. In a programme of work\u000d\u000a      originating in the early 1990s, researchers from Queen's (Young and\u000d\u000a      Nicholls) published a series of papers describing the identification of\u000d\u000a      genetic defects causing FH in the Northern Ireland population, and a\u000d\u000a      number of methodology papers describing improved methods for testing for\u000d\u000a      the condition2. Young is Professor of Medicine and the Director\u000d\u000a      of the Centre for Public Health, Queen's University Belfast, while\u000d\u000a      Nicholls is an Honorary Professor of Medicine.\u000d\u000a    The impact reported derives from ten papers published between 1995 and\u000d\u000a      2008. Initial research was funded by the Northern Ireland Chest Heart and\u000d\u000a      Stroke Association and subsequently by the British Heart Foundation. This\u000d\u000a      involved the clinical identification of families with suspected FH. In\u000d\u000a      these families cholesterol levels were measured and this was correlated\u000d\u000a      with assessments of heart disease in family members3,4,5. Once\u000d\u000a      a potential family had been identified, DNA was collected from them to\u000d\u000a      start a screening process. The majority of cases of FH result from a\u000d\u000a      defect in the low density lipoprotein receptor gene. A relatively small\u000d\u000a      number of cases result from defects in two other genes (known as ApoB and\u000d\u000a      PCSK9). Young and his colleagues identified over 20 novel genetic defects\u000d\u000a      in the Northern Ireland population as well as a number of mutations which\u000d\u000a      had been previously described in other populations, and the relationship\u000d\u000a      between these defects, gene expression and clinical presentation was\u000d\u000a      established. In parallel with the clinical work, a laboratory-based\u000d\u000a      program developed increasingly sophisticated methods of genetic diagnosis.\u000d\u000a      The most recent evolution of the laboratory methodology was published in Clinical\u000a        Genetics in 2008 and now provides the basis of the routinely offered\u000d\u000a      genetic approach6. This is followed by sequencing of the\u000d\u000a      relevant genes if a defect is not identified in a family with a high\u000d\u000a      degree of clinical suspicion.\u000d\u000a    In summary, the research led to the identification of new mutations\u000d\u000a      involved in FH and these were incorporated into a diagnostic screening\u000d\u000a      programme.\u000d\u000a    "},{"CaseStudyId":"38355","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000d\u000a    The effect of the NIBR research has been an increased recognition of the\u000d\u000a      lower cancer risk in\u000d\u000a      BO than previously thought, the importance of using clinicopathological\u000d\u000a      characteristics (and\u000d\u000a      potentially biomarkers) to stratify BO patients according to cancer risk\u000d\u000a      and tailoring endoscopic\u000d\u000a      surveillance of BO patients accordingly. The principal aim of the register\u000d\u000a      was to determine the\u000d\u000a      true clinical and public health importance of BO and to influence clinical\u000d\u000a      practice in the UK and\u000d\u000a      internationally by providing unbiased estimates of cancer incidence and\u000d\u000a      mortality in patients\u000d\u000a      diagnosed with this condition. The research has informed changes in\u000d\u000a      influential clinical\u000d\u000a      gastroenterology guidelines. An important additional aim was to identify\u000d\u000a      clinico-pathological\u000d\u000a      characteristics and tissue biomarkers associated with a high risk of\u000d\u000a      progression to cancer to\u000d\u000a      enable effective targeting of endoscopic surveillance or other clinical\u000d\u000a      interventions to high risk\u000d\u000a      patients.\u000d\u000a    The central findings of this research is that cancer incidence in BO\u000d\u000a      patients, although raised\u000d\u000a      compared to the general population, is lower than has been previously\u000d\u000a      believed and is at a level\u000d\u000a      where routine surveillance of all BO patients is very unlikely to be a\u000d\u000a      cost-effective use of health\u000d\u000a      care resources. This work has resulted in a paradigm shift in the thinking\u000d\u000a      of clinicians and health\u000d\u000a      service providers involved in the management of BO. It is now recognised\u000d\u000a      that BO patients\u000d\u000a      should be stratified according to cancer risk and endoscopic surveillance\u000d\u000a      and associated\u000d\u000a      interventions targeted at those with higher cancer risk. Work in NIBR\u000d\u000a      based on clinico-pathological\u000d\u000a      factors has identified some groups at higher cancer risk3 and\u000d\u000a      seminal publications\u000d\u000a      have also identified tissue biomarkers that may be applied within routine\u000d\u000a      clinical settings to aid\u000d\u000a      targeting of surveillance practice.\u000d\u000a    The importance of the research undertaken within the register to the\u000d\u000a      shaping of scientific and\u000d\u000a      clinical thinking with respect to BO is evidenced by the fact that the\u000d\u000a      main publications have been\u000d\u000a      accompanied by editorials from leading practitioners in the field.1,2,4.\u000d\u000a      These editorials have, for\u000d\u000a      example, pointed out that the finding that cancer mortality in BO patients\u000d\u000a      is low `has direct\u000d\u000a        clinical relevance as well as public health significance'. The `population\u000d\u000a        based epidemiology'\u000d\u000a      approach used was recognised as `the only way the much needed\u000d\u000a        quantitative information about\u000d\u000a        the condition (BO) and its natural history can be gained'.\u000d\u000a    The work has also drawn much attention from the scientific media3,4,6.\u000d\u000a      For example the main\u000d\u000a      cancer incidence paper was heralded as a `Game Changer in\u000d\u000a        Gastroenterology 2011' by\u000d\u000a      Medscape International, the influential and widely read web resource for\u000d\u000a      physicians and other\u000d\u000a      health professionals.3\u000d\u000a    Most importantly with respect to impact on clinical practice, NIBR\u000d\u000a      research has been among key\u000d\u000a      publications referenced in recent guidelines for the diagnosis and\u000d\u000a      management of BO issued by\u000d\u000a      the two most influential gastroenterological societies worldwide, the\u000d\u000a      American\u000d\u000a      Gastroenterological Association7 and the British Society for\u000d\u000a      Gastroenterology (BSG). The most\u000d\u000a      recent BSG guidelines `Diagnosis and Management of Barrett's oesophagus'\u000d\u000a      (Gut, In Press)8\u000d\u000a      reference six papers from the NIBR research group, with NIBR research\u000d\u000a      providing key evidence\u000d\u000a      underpinning six of the practice recommendations made, especially the\u000d\u000a      following three:\u000d\u000a    \u000d\u000a      Surveillance regimens should take into account the presence of IM\u000d\u000a          and length of the\u000d\u000a          Barrett's oesophagus segment\u000d\u000a      For patients with segments &lt;3cm without intestinal metaplasia or\u000d\u000a          dysplasia a repeat\u000d\u000a          endoscopy with quadrantic biopsies is recommended to confirm the\u000d\u000a          diagnosis. If repeat\u000d\u000a          endoscopy confirms the absence of intestinal metaplasia consideration\u000d\u000a          should be given\u000d\u000a          to discharge from surveillance as the risks for endoscopy likely\u000d\u000a          outweigh the benefits\u000d\u000a      The addition of a p53 immunostaining to the histopathological\u000d\u000a          assessment may improve\u000d\u000a          the diagnostic reproducibility of a diagnosis of dysplasia in\u000d\u000a          Barrett's oesophagus and\u000d\u000a          should be considered as an adjunct to routine clinical diagnosis\u000d\u000a    \u000d\u000a    Furthermore, The National Clinical Lead for Endoscopy, Department of\u000d\u000a      Health, England stated9.\u000d\u000a      \"It (the register) provides one of the few unbiased samples of the\u000d\u000a        natural history of Barrett's and\u000d\u000a        factors that predict the development of malignancy. As such, it is of\u000d\u000a        huge importance to the\u000d\u000a        ongoing controversies surrounding the management of Barrett's. It has\u000d\u000a        been uncomfortable\u000d\u000a        reading for the advocates of surveillance of Barrett's and it has\u000d\u000a        undoubtedly influenced recent\u000d\u000a        guidelines in the UK and North America\".\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research within the Northern Ireland Barrett's oesophagus Register\u000d\u000a      demonstrated that cancer\u000d\u000a      risk in this disease was substantially lower than previously thought. It\u000d\u000a      identified clinico-pathological\u000d\u000a      characteristics and potential biomarkers that allow Barrett's patients to\u000d\u000a      be stratified\u000d\u000a      into those with higher and lower cancer risk. This research has influenced\u000d\u000a      recommendations\u000d\u000a      from Gastroenterological Associations in the UK and USA and resulted in\u000d\u000a      altered clinical\u000d\u000a      practice nationally and internationally, in which costly routine\u000d\u000a      endoscopic surveillance is now\u000d\u000a      targeted to Barrett's oesophagus patients with the highest cancer risk.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    Queen's University Belfast\u000d\u000a    ","Institutions":[{"AlternativeName":"Queen's University Belfast","InstitutionName":"Queen's University Belfast","PeerGroup":"A","Region":"Northern Ireland","UKPRN":10005343}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. Yousef F, Cardwell CC, Cantwell MM, Galway K, Johnston BT, Murray\u000d\u000a        LJ. The incidence of\u000d\u000a      oesophageal cancer in Barrett's oesophagus. A systematic review and\u000d\u000a      meta-analysis. American\u000d\u000a        Journal of Epidemiology 2008;168(3):237-49. Doi: 10.1093\/aje\/kwn121.\u000d\u000a      Main findings: Very substantial variation in the reported incidence of\u000d\u000a        OAC in BO. Available\u000d\u000a        estimates of incidence are generally from small studies of biased high\u000d\u000a        risk populations. 113\u000d\u000a        citations:\u000d\u000a    \u000a\u000a2. Anderson LA, Murray LJ, Murphy SJ, Fitzpatrick DA, Johnston\u000d\u000a        BT, Watson RG, Gavin A.\u000d\u000a      Mortality in Barrett's Oesophagus: results of a population-based study. Gut\u000d\u000a      2003;52:1081-4.\u000d\u000a      Doi:10.1136\/gut.52.8.1081.\u000d\u000a      Main findings: Low mortality from OAC in BO patients and overall\u000d\u000a        mortality not different from the\u000d\u000a        general population. 108 citations\u000d\u000a    \u000a\u000a3. Bhat S, Mulholland H, Yousef F, Johnston B, McManus D, Gavin A,\u000d\u000a        Murray L. Risk of\u000d\u000a      Malignant Progression in Barrett's Esophagus Patients: Results from a\u000d\u000a      Large Population-Based\u000d\u000a      Study. Journal of the National Cancer Institute\u000d\u000a      2011;103(13):1049-57. Doi: 10.1093\/jnci\/djr203.\u000d\u000a      Main findings: Cancer risk in BO lower than previously reported.\u000d\u000a        Clinico-pathological\u000d\u000a        characteristics including male gender, aged 60-79 at BO diagnosis,\u000d\u000a        presence of Specialised\u000d\u000a        Intestinal Metaplasia, long segment length were associated with higher\u000d\u000a        cancer risk. 71 citations\u000d\u000a    \u000a\u000a4. Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie\u000d\u000a      LJ, Forman D, Wild CP. TP53\u000d\u000a      and progression from Barrett's metaplasia to oesophageal adenocarcinoma in\u000d\u000a      a UK population\u000d\u000a      cohort. Gut 2006;55(10):1390-7. Doi: 10.1136\/gut.2005.083295.\u000d\u000a      Main findings: Expression of TP53, measured by immunohistochemistry,\u000d\u000a        identified as a\u000d\u000a        biomarker of progression from BO to OAC. 54 citations\u000d\u000a    \u000a\u000a5. Bird-Lieberman EL, Dunn JM, Coleman HG, Lao-Sirieix P, Oukrif D, Moore\u000d\u000a      CM, Varghese S,\u000d\u000a      Johnston BT, Arthur K, McManus DT, Novelli MR, O'Donovan M, Cardwell CR,\u000d\u000a      Lovat LB,\u000d\u000a      Murray LJ and Fitzgerald RC. Phase 3 population-based\u000d\u000a      study reveals new risk-stratification\u000d\u000a      biomarker panel for Barrett's esophagus. Gastroenterology\u000d\u000a      2012;143(4):927-35. Doi:\u000d\u000a      10.1053\/j.gastro.2012.06.041.\u000d\u000a      Main findings: A biomarker panel comprising low grade dysplasia as\u000d\u000a        defined by expert\u000d\u000a        pathologists, abnormal DNA ploidy measured using image cytometry, and\u000d\u000a        immunohistochemical\u000d\u000a        staining for Aspergillus oryzae lectin expression predicted cancer risk\u000d\u000a        in BO patients. 11\u000d\u000a        citations\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    1) Heading\u000d\u000a        RC. Barrett's oesophagus: epidemiology comes up with a surprise. Gut\u000d\u000a      2003;52(8):1079-80\u000d\u000a      This editorial emphasises the importance of the population based\u000d\u000a        epidemiological studies such\u000d\u000a        as NIBR in understanding the natural history and clinical and public\u000d\u000a        health relevance of BO.\u000d\u000a    2) Corley\u000d\u000a        DA. Understanding cancer incidence in Barrett's esophagus: light at\u000d\u000a      the end of the\u000d\u000a      tunnel. Journal\u000d\u000a          of the National Cancer Institute 2011;103(13):994-5\u000d\u000a      This editorial emphasises the importance of NIBR research as the first\u000d\u000a        work to provide robust\u000d\u000a        population based evidence addressing crucial issues related to the\u000d\u000a        clinical management of\u000d\u000a        Barrett's e.g. cancer risk according to presence of intestinal\u000d\u000a        metaplasia, age and sex and time\u000d\u000a        since diagnosis.\u000d\u000a    3) Medscape. Game Changer in Gastroenterology 2011.\u000d\u000a      http:\/\/www.medscape.com\/viewarticle\/753828_8\u000d\u000a      This commentary on the NIBR paper published in Journal of the National\u000d\u000a        Cancer Institute in\u000d\u000a        2011 (Reference 3) states that the paper is a game changer in the\u000d\u000a        Gastroenterology field\u000d\u000a        because it identifies extremely low cancer rates in the BO patients\u000d\u000a        without intestinal metaplasia\u000d\u000a        and raises questions about the value and cost-effectiveness of\u000d\u000a        endoscopic surveillance in BO\u000d\u000a        patients.\u000d\u000a    4) http:\/\/www.cancerresearchuk.org\/cancer-info\/news\/archive\/cancernews\/2011-06-20-Current-UK-system-of-Barretts-oesophagus-monitoring-not-cost-effective\u000d\u000a      This comment on Reference 3 concludes that the NIBR data calls into\u000d\u000a        question the cost\u000d\u000a        effectiveness of current BO surveillance practice in the UK.\u000d\u000a    5) Preston\u000d\u000a        SL, Jankowski\u000d\u000a        JA. Gut\u000d\u000a      2006 Oct;55(10):1377-9. Drinking from the fountain of\u000d\u000a      promise: biomarkers in the surveillance of Barrett's oesophagus--the glass\u000d\u000a      is half full!\u000d\u000a      This editorial emphasises the importance of exploring biomarkers of\u000d\u000a        cancer risk in BO patients,\u000d\u000a        as undertaken within NIBR, to assist the identification of patients at\u000d\u000a        high risk that will benefit\u000d\u000a        most from surveillance or interventions to reduce cancer risk.\u000d\u000a    6) http:\/\/www.gastrohep.com\/news\/news.asp?id=109128\u000d\u000a      This scientific news piece drew the attention of the Clinical\u000d\u000a        Gastroenterology community to the\u000d\u000a        biomarker work undertaken by the NIBR group in collaboration with the\u000d\u000a        University of Cambridge\u000d\u000a        and University College London, which identified an increased cancer risk\u000d\u000a        in biomarker defined\u000d\u000a        subgroups of BO patients.\u000d\u000a    7) American Gastroenterological Association Technical Review on the\u000d\u000a      Management of Barrett's\u000d\u000a      Esophagus. Gastroenterology 2011;140:e18-e52\u000d\u000a      These guidelines on the management of BO quote NIBR research (Reference\u000d\u000a        2) as key work\u000d\u000a        examining the impact of BO on life expectancy.\u000d\u000a    8) British Society of Gastroenterology guidelines. Diagnosis and\u000d\u000a      Management of Barrett's\u000d\u000a      oesophagus. In Press, Gut, August 2013. (Discussed in Section 4)\u000d\u000a    9) Letter from National Clinical Lead for Endoscopy, Department of\u000d\u000a      Health, England. (Discussed\u000d\u000a      in Section 4).\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Re-assessment of Cancer risk in Barrett's oesophagus\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2641364","Name":"Northern Ireland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Barrett's oesophagus (BO) is the precursor of a lethal cancer of the\u000d\u000a      oesophagus called\u000d\u000a      oesophageal adenocarcinoma (OAC). Rapid increases in the last 30 years in\u000d\u000a      OAC incidence\u000d\u000a      led to the widespread practice of routine endoscopic surveillance in the\u000d\u000a      UK, Europe and USA in\u000d\u000a      patients diagnosed with BO. It has been a widely held premise that the\u000d\u000a      cancer risk in BO\u000d\u000a      patients is high and that regular endoscopy would lead to detection of\u000d\u000a      cancer at an early or pre-invasive\u000d\u000a      stage and thereby provide a cost-effective opportunity for surgery or\u000d\u000a      other\u000d\u000a      interventions; to improve outcomes for BO patients and reduce the public\u000d\u000a      health burden\u000d\u000a      associated with OAC.\u000d\u000a    A systematic review of the published literature in this field undertaken\u000d\u000a      by Professor Liam Murra\u000d\u000a      (Cancer Epidemiologist, Centre for Public Health, Queen's) identified that\u000d\u000a      the case for\u000d\u000a      surveillance of BO patients was primarily based on flawed evidence from\u000d\u000a      small studies of biased\u000d\u000a      high-risk BO populations, which provided inflated estimates of cancer\u000d\u000a      risk.1 The review identified\u000d\u000a      that no unbiased population-based studies of cancer incidence in BO had\u000d\u000a      been performed.\u000d\u000a      Therefore, Professor Murray, Professor Brian Johnston (Gastroenterologist,\u000d\u000a      Belfast Health and\u000d\u000a      Social Care Trust (BHSCT), Honorary Clinical Professor, Queen's), Dr\u000d\u000a      Damian McManus\u000d\u000a      (Pathologist, BHSCT, Honorary Clinical Senior Lecturer, Queen's) and Dr\u000d\u000a      Anna Gavin (Director,\u000d\u000a      Northern Ireland Cancer Registry, Queen's) established the Northern\u000d\u000a      Ireland Barrett's\u000d\u000a      oesophagus Register (NIBR). The NIBR is a unique, population based\u000d\u000a      register of every case of\u000d\u000a      BO diagnosed in NI since 1993. NIBR reflects everyday practice within the\u000d\u000a      NHS and avoids\u000d\u000a      referral biases (e.g. to specialist centres), which afflict other studies\u000d\u000a      in the field. The NIBR was\u000d\u000a      followed up with minimal loss of follow-up (until 2010) for cancer\u000d\u000a      incidence and death. Uniquely,\u000d\u000a      it was possible to access diagnostic BO tissue and link to detailed\u000d\u000a      clinical data.\u000d\u000a    The first NIBR publication was reported in Gut in 2003.2\u000d\u000a      This study showed that, although the\u000d\u000a      death rate from OAC was elevated, OAC accounted for only a small\u000d\u000a      proportion of deaths and\u000d\u000a      the overall mortality in BO patients was the same as in the general\u000d\u000a      population. This was one of\u000d\u000a      the first and most influential reports to query the prevailing view within\u000d\u000a      the scientific and clinical\u000d\u000a      community that BO carried a very high OAC incidence and mortality risk. In\u000d\u000a      2011, the group\u000d\u000a      published the cancer incidence within NIBR.3 The study\u000d\u000a      confirmed that the cancer risk in BO\u000d\u000a      was substantially lower than previously believed and was at a level where\u000d\u000a      the cost-effectiveness\u000d\u000a      of endoscopic surveillance of BO patients was questionable. The study\u000d\u000a      underlined the\u000d\u000a      importance of strategies to identify BO patients who are at the highest\u000d\u000a      risk of developing cancer\u000d\u000a      and in whom surveillance may be beneficial and cost-effective. Such\u000d\u000a      strategies include the use\u000d\u000a      of clinico-pathological characteristics and tissue biomarkers for cancer\u000d\u000a      progression. Using NIBR\u000d\u000a      resources, the research group and collaborators in the Universities of\u000d\u000a      Cambridge (Dr Rebecca\u000d\u000a      Fitzgerald) and Leeds (Professor Chris Wild, now Director of the\u000d\u000a      International Agency for\u000d\u000a      Research on Cancer (IARC) and Professor David Forman, now Head of\u000d\u000a      Information at IARC)\u000d\u000a      and University College London (Dr Laurence Lovat) have published the first\u000d\u000a      population-based\u000d\u000a      biomarker studies in BO.4,5 These studies identified several\u000d\u000a      promising biomarkers of the cancer\u000d\u000a      risk in BO that, once validated in other studies, can be applied in\u000d\u000a      routine clinical settings.\u000d\u000a    "},{"CaseStudyId":"38356","Continent":[],"Country":[],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    The impact of the MONICA studies was in the 2008 production of a European\u000d\u000a      Health Examination Survey Manual. Under Evans's leadership the MONICA\u000d\u000a      Manual established the necessary quality assurance procedures and collated\u000d\u000a      the information with which to judge the reliability and comparability of\u000d\u000a      data on risk factors and outcomes of coronary heart disease. This enabled\u000d\u000a      unbiased international comparisons, which allowed policymakers in many\u000d\u000a      countries to make informed decisions about the balance between primary and\u000d\u000a      secondary prevention strategies for cardiovascular disease.\u000d\u000a    Evans was a member of the MONICA Steering Committee from 1990 and was its\u000d\u000a      Publication Coordinator from 1992. He subsequently assumed responsibility\u000d\u000a      for the revision of the MONICA Survey Manual, re-designing several\u000d\u000a      elements to remove ambiguities. In 1994 he became Chairman of the MONICA\u000d\u000a      Steering Committee and he led the MONICA EU Biomed Concerted Action from\u000d\u000a      1996-1999, during which the success of the standardization process was\u000d\u000a      thoroughly assessed and published in a series of reports1. As\u000d\u000a      Chairman and with senior colleagues from other participating centres, he\u000d\u000a      also set the direction for the subsequent MONICA research outputs.\u000d\u000a    The insights gained from the research led to the promotion of uniform\u000d\u000a      methods for cardiovascular surveys (collated as manuals and e-publications\u000d\u000a      on the MONICA website1) and their adoption by initially 38\u000d\u000a      population centres of coronary heart disease registration. Based on the\u000d\u000a      MONICA Manuals, the European Commission supported the development of the\u000a        European Health Examination Survey (EHES). This standardized\u000d\u000a      national health examination surveys in the European countries. The\u000d\u000a      Feasibility of the European Health Examination Survey (FEHES) programme\u000d\u000a      assessed the capacity to conduct uniform national health examination\u000d\u000a      surveys in all EU countries. This feasibility project2\u000d\u000a      (2006-2008) led directly to the EHES Pilot. The pilot in 12 countries\u000d\u000a      between 2009 and 2012supported by the EU Joint Action programme set up the\u000d\u000a      EHES Reference Centre (EU Service Contract) led directly to the production\u000d\u000a      of a European Health Examination Survey Manual2.\u000d\u000a    MONICA's survey manual and consistency of approach has also permitted\u000d\u000a      policy makers to draw robust inferences about trends in CHD and the\u000d\u000a      impacts of prevention and healthcare policies on them. For example,\u000d\u000a      research based on MONICA survey data demonstrated that approximately 60%\u000d\u000a      of the substantial CHD mortality decline in Northern Ireland between 1987\u000d\u000a      and 2007 was attributable to major cardiovascular risk factor changes and\u000d\u000a      approximately 35% was attributable to treatments. These findings were\u000d\u000a      launched by the Chief Medical Officer for Northern Ireland and the\u000d\u000a      Minister for Employment and Learning in April 20123. Similar\u000d\u000a      conclusions have been replicated in many countries4 and would\u000d\u000a      not have been possible but for the adoption of MONICA's harmonised survey\u000d\u000a      methods. Editorials in major journals have long testified to the need for\u000d\u000a      data, such as are available in MONICA, for policy making5,6.\u000d\u000a    Other direct beneficiaries of the research include commissioners of\u000d\u000a      health services. A careful analysis of MONICA data from Belfast and\u000d\u000a      Glasgow7 showed little additional benefit in Belfast of having\u000d\u000a      more expensive medically staffed coronary care ambulances. As a result,\u000d\u000a      local commissioners moved away from supporting a medically manned mobile\u000d\u000a      coronary care ambulance service and supported more paramedic-led coronary\u000d\u000a      care models, appropriate to local geography and service needs.\u000d\u000a    The adoption of the MONICA survey methods also paved the way for a\u000d\u000a      further important commissioning decision at EU level, namely to support\u000d\u000a      the MORGAM programme8, which has already successfully\u000d\u000a      provided follow-up for cardiovascular disease of the cohorts defined by\u000d\u000a      the MONICA risk factor surveys and other similar European population\u000d\u000a      surveys. This has formed an important data harmonization infrastructure\u000d\u000a      for the epidemiology, genetics and biomarkers of CHD in Europe which is\u000d\u000a      now impacting on CHD service research and delivery in Europe. The Deputy\u000d\u000a      Head of Unit for Research and Innovation for Advanced Therapies and\u000d\u000a      Systems Medicine at the EU stated that \"under Professor Alun Evans's\u000d\u000a      careful chairmanship and planning, the outputs from MONICA laid the\u000d\u000a      foundation for many subsequent decisions that the EU took concerning our\u000d\u000a      investment in the dissemination of uniform methods for population health\u000d\u000a      surveys\" and that he felt it \"a privilege to see the legacy of MONICA\u000d\u000a      mature in the genomic age.\"9\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research in the MONICA project set the standards for national\u000d\u000a      cardiovascular health surveys in Europe, by establishing quality\u000d\u000a      assessment benchmarks for how cardiovascular health should be monitored in\u000d\u000a      populations. These standards were subsequently adopted by the European\u000d\u000a      Union, and by local health bodies, to improve their commissioning\u000d\u000a      decisions. This research has had an important impact on public health\u000d\u000a      monitoring, enabling robust epidemiological comparisons across countries\u000d\u000a      and the sort of analysis that policy makers need to inform the balance\u000d\u000a      between primary and secondary prevention for cardiovascular health.\u000d\u000a    ","ImpactType":"Technological","Institution":"\u000d\u000a    Queen's University Belfast\u000d\u000a    ","Institutions":[{"AlternativeName":"Queen's University Belfast","InstitutionName":"Queen's University Belfast","PeerGroup":"A","Region":"Northern Ireland","UKPRN":10005343}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    Research outputs from MONICA (&gt;120 papers) relied on contributions\u000d\u000a      from many partners. Evans led MONICA's dissemination efforts as the\u000d\u000a      publication coordinator from 1990 and was the overall Steering Committee\u000d\u000a      Chairman from 1994-1999, it's most productive period.\u000d\u000a    \u000a1. Evans A, Dobson A, Ferrario M, Kuulasmaa K, Moltchanov\u000d\u000a      V, Sans S, Tunstall-Pedoe H, Tuomilehto J, Wedel H, Yarnell J, for the WHO\u000d\u000a      MONICA Project. The WHO MONICA Project: changes in coronary risk in the\u000d\u000a      1980s. Proceedings of the XIth International Symposium on\u000d\u000a        Atherosclerosis; 5-9 October 1997, Paris, France. Elsevier Science,\u000d\u000a        Atherosclerosis XI, 1998; 49-55. This output can be supplied on\u000d\u000a        request. In this early output, an aggregate \"risk factor score\"\u000d\u000a        in the MONICA populations, showed a secular downward trend, predicting a\u000d\u000a        subsequent downward trend in mortality, the latter borne out by later\u000d\u000a        analyses.\u000d\u000a    \u000a\u000a2. Tunstall-Pedoe H, Kuulasmaa K, M&#228;h&#246;nen M, Tolonen H, Ruokokoski\u000d\u000a      E, Amouyel P, for the WHO MONICA (monitoring trends and\u000d\u000a      determinants in cardiovascular disease) Project. Contribution of trends in\u000d\u000a      survival and coronary-event rates to changes in coronary heart disease\u000d\u000a      mortality: 10-year results from 37 WHO MONICA Project populations. Lancet\u000d\u000a      1999; 353:1547-57. Doi: 10.1016\/S0140-6736(99)04021-0. This output can\u000d\u000a        be supplied on request. Analyses in this highly cited paper\u000d\u000a        showed that the factors driving the incidence of new coronary events\u000d\u000a        helped explain the trends in overall mortality better than those\u000d\u000a        affecting survival from heart attack.\u000d\u000a    \u000a\u000a3. Moore W, Kee F, Evans AE, McCrum-Gardner EE,\u000d\u000a      Morrison C, Tunstall-Pedoe H. Pre-hospital coronary care and coronary\u000d\u000a      fatality in the Belfast and Glasgow MONICA populations. Int J\u000d\u000a        Epidemiol 2005; 34 (2): 422-30. Doi: 10.1093\/ije\/dyh377\u000d\u000a      Analyses in this paper capitalised on having access to a detailed\u000d\u000a        \"MONICA\" dataset, including the place of occurrence of all heart attacks\u000d\u000a        in Belfast and Glasgow and the timing and adequacy of resuscitation and\u000d\u000a        coronary care provided, demonstrating that any differences in coronary\u000d\u000a        mortality between the cities could not easily be attributed to the\u000d\u000a        provision of a medically manned out-of-hospital ambulance service in\u000d\u000a        Belfast.\u000d\u000a    \u000a\u000a4. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S,\u000d\u000a      Tolonen H, Evans A, Ferrario M, Tuomilehto J, for the WHO MONICA\u000d\u000a      Project. Estimation of contribution of changes in classic risk factors to\u000d\u000a      trends in coronary-event rates across the WHO MONICA Project populations.\u000d\u000a      Lancet 2000; 355:675-87. http:\/\/www.scopus.com\/record\/display.url?eid=2-s2.0-0034716468&amp;origin=inward&amp;txGid=AE4E357CE735F20F9C6A52A9C808D38B.Vdktg6RVtMfaQJ4pNTCQ%3a13.\u000d\u000a      This paper showed that changes in the classic risk factors across the\u000d\u000a        38\u000d\u000a        MONICA populations partly explained the variation in population trends\u000d\u000a        in CHD. Residual variance was attributable to difficulties in\u000d\u000a        measurement and analysis, including assumptions about the time lag for\u000d\u000a        risk factor effects, and to factors that were not included, such as\u000d\u000a        medical interventions. The results supported prevention policies based\u000d\u000a        on the classic risk factors but suggested potential for prevention\u000d\u000a        beyond these.\u000d\u000a    \u000a\u000a5. Evans A, Tolonen H, Hense HW, Ferrario M, Sans S, Kuulasmaa K,\u000d\u000a      for the WHO MONICA Project. Trends in coronary risk factors in the WHO\u000d\u000a        MONICA Project. Int J Epidemiol 2001; 30 (Suppl 1):S35-S40.\u000d\u000a      http:\/\/ije.oxfordjournals.org\/content\/30\/suppl_1\/S35.full.pdf.\u000d\u000a      This paper used repeated cross sectional surveys in the MONICA\u000d\u000a        populations to analyse trends in classic risk factors and revealed\u000d\u000a        worrying trends in smoking in women and obesity among men that had\u000d\u000a        significant public health implications.\u000d\u000a    \u000aRelated grants:\u000d\u000a    &#8226; EC QLG2-CT-2002-01254 (GENOMEUTWIN). Studies of European\u000d\u000a        volunteer twins to identify genes underlying common diseases,\u000d\u000a      2002-2006, Alun Evans &#8212; &#163;338,798.\u000d\u000a    &#8226; EC FP6 LSHM-CT-2004-005268 EUROCLOT Genetic regulation of\u000d\u000a        the end-stage clotting process that leads to thrombotic stroke,\u000d\u000a        2005-2008, Alun Evans &#8212; &#163;34,780.67.\u000d\u000a    &#8226; EU FP6 037593 CARDIOGENICS. The Cardiogenics project,\u000d\u000a      2006-2011, Alun Evans &#8212; &#163;3,140.90.\u000d\u000a    &#8226; MRC G0601463 ID NO 80983 BIOMARKER. Serum biomarkers in the\u000d\u000a        MORGAM Project, 2007-2010, Alun Evans and Frank Kee &#8212;\u000d\u000a      &#163;507,840.\u000d\u000a    &#8226; EU FP7 201413. European network of genetic and genomic\u000d\u000a        epidemiology (ENGAGE), 2008-2012, Alun Evans &#8212; &#163;316,560.\u000d\u000a    &#8226; EC FP7 HEALTH-F2-2011-278913. BiomarcaRE Biomarkers for\u000d\u000a        cardiovascular risk assessment in Europe, 2011-2015, Frank Kee\u000d\u000a      &#8212; &#163;44,728.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    Several editorials and commentaries in leading journals testified to the\u000d\u000a      impact of the MONICA project including:\u000d\u000a    \u000d\u000a      (http:\/\/www.ktl.fi\/publications\/monica\/).\u000a        This source documents the MONICA quality assessment procedures\u000d\u000a          themselves.\u000a\u000d\u000a      (http:\/\/www.julkari.fi\/bitstream\/handle\/10024\/78265\/2008b21.pdf?sequence=1).\u000a        This source shows how the CHD aspects of EHES have been informed by\u000d\u000a          previous MONICA quality assessment procedures.\u000a\u000d\u000a      (http:\/\/www.northernireland.gov.uk\/index\/media-centre\/news-departments\/news-del\/news-del-march-archive-2011\/news-del-030311-obesity-costing-economy.htm).\u000a        This source highlights the NI Minister of Health's role in helping\u000d\u000a          launch the findings of a policy analysis which was conducted for\u000d\u000a          Northern Ireland based on MONICA data, available in: Heart\u000d\u000a        2013;99:1179-1184 Doi:10.1136\/heartjnl-2013-303921\u000d\u000a      Capewell S et al. Cardiovascular risk factor rends and potential for\u000d\u000a        reducing coronary heart disease mortality in the United States of\u000d\u000a        America. Bulletin of the World Health Organization 2010;\u000d\u000a        88:120-130. Doi: 10.2471\/BLT.08.057885. This source is one of many,\u000d\u000a          internationally, demonstrating how analysing MONICA data can inform\u000d\u000a          policy on CHD prevention.\u000a\u000d\u000a      Grover S. Role of WHO-MONICA Project in unravelling of the\u000d\u000a        cardiovascular puzzle (Editorial) Lancet 2000; 355: 668-9. Doi:\u000d\u000a        10.1016\/S0140-6736(00)00016-7. This source testifies to the\u000d\u000a          relevance of MONICA for prevention policy analysis.\u000a\u000d\u000a      Alpert JS. Coronary heart disease: where have we been and where are we\u000d\u000a        going? (Editorial) Lancet 1999; 353: 1540. Doi:\u000d\u000a        10.1016\/S0140-6736(99)00154-3. This source testifies to the\u000d\u000a          relevance of MONICA for prevention policy analysis.\u000a\u000d\u000a      Wayne R, Johnson A-M. Commentary: Modern day `flying ambulances' for\u000d\u000a        coronary care: a tale of two cities. Int. J. Epidemiol. (April\u000d\u000a        2005) 34(2): 431-432. Doi: 10.1093\/ije\/dyi018. This editorial\u000d\u000a          testifies to how use of carefully quality assured MONICA data informed\u000d\u000a          the policy debate on models of out of hospital coronary care.\u000a\u000d\u000a      Evans A, Salomaa V, Kulathinal S et al. MORGAM (an international\u000d\u000a        pooling of cardiovascular cohorts. Int. J. Epidemiol. 2005 Feb;\u000d\u000a        34(1):21-7. Doi:10.1093\/ije\/dyh327. This source demonstrates how\u000d\u000a          MONICA gave birth to the MORGAM study.\u000a\u000d\u000a      Key decision makers have offered personal written testimonies to the\u000d\u000a        impact claimed including: The Deputy Head of Unit European Commission DG\u000d\u000a        Research &amp; Innovation, and The Medical Director Northern Ireland\u000d\u000a        Ambulance Service Health and Social Care Trust.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    The Global Monitoring of Cardiovascular Disease\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2655984","Name":"Belfast"}],"UKRegion":[{"GeoNamesId":"2641364","Name":"Northern Ireland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    By the 1970s coronary heart disease (CHD) mortality had fallen in western\u000d\u000a      countries, but there were divergent trends in eastern Europe. The correct\u000d\u000a      policy response to these trends was uncertain because both the incidence\u000d\u000a      of and mortality from CHD is affected by the nature of the presentation,\u000d\u000a      the location of the event and the speed and rigour of the diagnosis and\u000d\u000a      medical intervention. To understand which of these factors could explain\u000d\u000a      international differences in coronary mortality, the World Health\u000d\u000a      Organisation sponsored the MONICA Project (Multinational MONItoring\u000a      of trends and determinants in CArdiovascular disease). Queen's\u000d\u000a      University investigators led by Evans (Professor of Epidemiology, QUB from\u000d\u000a      1988-2010) were the first to join MONICA. Evans attracted the initial\u000d\u000a      grant from the MRC, recruited and trained the staff and was responsible\u000d\u000a      for the project's overall conduct in Northern Ireland. He recruited Kee\u000d\u000a      (Professor of Public Health Medicine) who worked with him from 1994\u000d\u000a      onwards.\u000d\u000a    MONICA was a global epidemiological study on a scale never before matched\u000d\u000a      covering 38 populations, 21 countries in 4 continents over 23 years. Under\u000d\u000a      Evans' leadership, the project was responsible for the detailed assessment\u000d\u000a      of the quality of reporting of populations-at-risk, risk factor and case\u000d\u000a      definitions, and survivorship, all of which were subsequently collated as\u000d\u000a      manuals and e-publications on the MONICA website http:\/\/www.thl.fi\/publications\/monica\/.\u000d\u000a      This huge effort pre-dated the current capability of digital\u000d\u000a      communications and electronic data-capture.\u000d\u000a\u0009  The number of people who die\u000d\u000a      of a heart attack each year comprise those having a heart attack and who\u000d\u000a      die immediately, and the \"early\" survivors who reach hospital but die soon\u000d\u000a      afterwards (within 28 days). The case fatality rate is this number divided\u000d\u000a      by the total number of heart attack patients per year i.e. the incidence\u000d\u000a      of heart attack. The key insights that Evans and the MONICA team made(1,2)\u000d\u000a      were that among countries experiencing a decline in mortality, changes in\u000d\u000a      case fatality (the proportion who die within 28 days) contributed only\u000d\u000a      about a third of the overall improvement and that a major factor was\u000d\u000a      variation in the measurement of incidence. Variability in the suspicion,\u000d\u000a      recognition, and confirmation of non-fatal versus fatal events can create\u000d\u000a      error in the mortality rates if these are not defined accurately.\u000d\u000a      International standards are needed for fair population comparisons and for\u000d\u000a      comparisons of coronary care, so that spurious drivers of overall\u000d\u000a      mortality can be distinguished from real ones. For example, in some low\u000d\u000a      incidence countries where case fatality in women was high, the application\u000d\u000a      of MONICA criteria suggested that non-fatal events in women were less\u000d\u000a      consistently recognised. Less complete recording of non-fatal events\u000d\u000a      artefactually inflates case fatality rates, making the latter a poor proxy\u000d\u000a      for the quality of coronary care. Using consistent case definitions and a\u000d\u000a      uniform measurement of acute coronary care allowed the first comparisons\u000d\u000a      of the pathways of care and mortality in different counties that had\u000d\u000a      differing models of acute out-of-hospital care(3).\u000d\u000a    In summary, MONICA resulted in 120 publications, many confirming that\u000d\u000a      classic risk factors (such as high blood pressure, cholesterol and\u000d\u000a      smoking) only partly explained the trends in heart disease. Residual\u000d\u000a      variance across counties was attributable to difficulties in measurement\u000d\u000a      and analysis(4,5).\u000d\u000a    "},{"CaseStudyId":"38795","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2186224","Name":"New Zealand"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"2782113","Name":"Austria"},{"GeoNamesId":"285570","Name":"Kuwait"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"286963","Name":"Oman"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Shifting delivery of anticoagulation services\u000d\u000a    Impact on Clinical Practice and Patient Health\u000d\u000a    Primary care research within UoB UoA2 has led to the transfer of oral\u000d\u000a      anticoagulation services from secondary to primary care, and latterly\u000d\u000a      patient self-management resulting in improved clinical outcomes for\u000d\u000a      patients throughout the 2008-13 REF impact period. The Birmingham Model\u000d\u000a      for oral anticoagulation management (a primary care based service\u000d\u000a      utilising near patient testing and computerised decision support software)\u000d\u000a      was adopted within the NHS through the inclusion of anticoagulation\u000d\u000a      services as a Nationally Enhanced Service (NES) within the GP contract in\u000d\u000a      2004 (GSM Contract for Anticoagulation in Primary Care). The research also\u000d\u000a      informed the 2006 recommendations of the NHS National Patient Safety\u000d\u000a      Agency on making anticoagulation therapy safer, recommendations that are\u000d\u000a      still current [1] and that have, together with the contract changes,\u000d\u000a      enabled transfer of oral anticoagulation management from secondary to\u000d\u000a      primary care, leading to significant improvements in both patient\u000d\u000a      experience and clinical outcome.\u000d\u000a    Changes in the management of AF\u000d\u000a    Impact on Public Policy\u000d\u000a    SAFE demonstrated the effectiveness of opportunistic screening for AF in\u000d\u000a      UK primary care, whilst BAFTA established superior efficacy and safety of\u000d\u000a      warfarin as compared to aspirin in patients aged 75 and over. These\u000d\u000a      studies have influenced the UK policy framework during the 2008-13 REF\u000d\u000a      impact period, both through clinical guidelines and NHS GP contracting.\u000d\u000a      Clinical guidelines published in 2011 by The British Committee for\u000d\u000a      Standards in Haematology `Guidelines on oral anticoagulation' 2011 [2]\u000d\u000a      recommend computer assisted dosing, referencing the Computerised Decision\u000d\u000a      Support research. The work has also informed the increasing awareness of\u000d\u000a      AF as a serious cause of morbidity and has directly influenced indicators\u000d\u000a      within the NHS Quality and Outcomes Framework throughout the REF period,\u000d\u000a      with indicators to directly influence, through funding arrangements,\u000d\u000a      provision of anti-coagulation drug therapy for AF patients [3, 4].\u000d\u000a    Impact on UK Clinical Practice and Patient Health\u000d\u000a    There has been impact on patient management throughout the 2008-2013 REF\u000d\u000a      impact period resulting from the policy changes described above, but also\u000d\u000a      from important NICE guidelines that were produced prior to this, but were\u000d\u000a      still current during this time. The 2006 NICE National Atrial Fibrillation\u000d\u000a      Clinical Guideline for Management in Primary and Secondary Care [5]\u000d\u000a      references the SAFE study. This guidance remained current throughout the\u000d\u000a      period 2008-2013.\u000d\u000a    Impact on International Policy and Clinical Practice\u000d\u000a    As well as influencing UK clinical practice, the work of the Birmingham\u000d\u000a      team has also influenced guidelines in Europe and the USA: These include:\u000d\u000a      the European Society of Cardiology guidelines, produced in 2010 and\u000d\u000a      updated in 2012 [6] &#8212; the updated guidelines, referencing the work of the\u000d\u000a      Birmingham group, indicated that \"We therefore recommend that, in\u000d\u000a        patients aged 65 years or over, opportunistic screening for AF by pulse\u000d\u000a        palpation, followed by recording of an ECG to verify diagnosis, should\u000d\u000a        be considered for the early detection of AF\"; the European Stroke\u000d\u000a      Organisation Guidelines for the Management of Ischaemic Stroke and\u000d\u000a      Transient Ischaemic Attack, 2008 [7]; the American College of Chest\u000d\u000a      Physicians guidelines, June 2008 [8].\u000d\u000a    Impact on Education and CPD\u000d\u000a    Research in this area has led to the establishment of the National Centre\u000d\u000a      for Anticoagulation Training within UoB, which provides accredited\u000d\u000a      training for health care professionals involved in the management of\u000d\u000a      patients receiving anticoagulation treatment [9]. 42 CPD courses were run\u000d\u000a      between January 2008 and June 2013, with 1,234 participants.\u000d\u000a    Following publication of the research on anticoagulation Fitzmaurice\u000d\u000a      and Murray have provided two in-depth learning modules for the BMJ\u000d\u000a      available from 2008 (Fitzmaurice, Cousins, Clark) and updated (Fitzmaurice,\u000d\u000a        Murray) during the 2008-13 period [10]. BMJ Learning offers\u000d\u000a      high-quality (peer reviewed, up-to-date, and evidence-based) continuing\u000d\u000a      medical education in an economical and time efficient manner, for general\u000d\u000a      practitioners, hospital doctors and other healthcare professionals. The\u000d\u000a      anticoagulation modules are accredited by a number of associations,\u000d\u000a      including Australian Practice Nurses Association, Austrian Academy of\u000d\u000a      Physicians, The Royal New Zealand College of General Practitioners, The\u000d\u000a      Colleges of Medicine of South Africa, Oman Medical Specialty Board, and\u000d\u000a      Kuwait Institute for Medical Specialization. Comments on BMJ Learning\u000d\u000a      suggest the modules are received positively.\u000d\u000a    Screening for AF\u000d\u000a    This work has informed the increasing awareness of AF as a serious cause\u000d\u000a      of morbidity and there is on-going work within the NHS Health Improvement\u000d\u000a      Service to improve detection of AF with parallel efforts being undertaken\u000d\u000a      to ensure optimum treatment of those patients with appropriate therapy\u000d\u000a      [11]. The SAFE &amp; BAFTA trials have resulted in a debate (2012) amongst\u000d\u000a      the Royal College of Physicians around developing a national screening\u000d\u000a      programme for AF [12].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Atrial fibrillation (AF) is the commonest heart rhythm abnormality,\u000d\u000a      affecting around 8.8 million people in the European Union, and conferring\u000d\u000a      a substantial risk of stroke and death. Up to 2% of the UK population,\u000d\u000a      some 1.2 million individuals, take oral anticoagulation medication.\u000d\u000a    The University of Birmingham is an internationally-respected centre of\u000d\u000a      excellence for research in AF, and has made crucial impacts in\u000d\u000a      international clinical practice guidelines and improvements in patient\u000d\u000a      care. Primary care research at the University of Birmingham has led to the\u000d\u000a      transfer of oral anticoagulation services from secondary to primary care,\u000d\u000a      and latterly patient self-management, resulting in improved clinical\u000d\u000a      outcomes. In addition, the BAFTA trial has provided evidence to support\u000d\u000a      the use of anticoagulation therapy (warfarin) for people aged over 75 who\u000d\u000a      have atrial fibrillation, resulting in changes in clinical management of\u000d\u000a      these patients.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Birmingham\u000d\u000a    ","Institutions":[{"AlternativeName":"Birmingham (University of)","InstitutionName":"University of Birmingham","PeerGroup":"A","Region":"West Midlands","UKPRN":10006840}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. Fitzmaurice DA, Hobbs FDR, Murray ET, Holder RL, Allan TF, Rose PE.\u000d\u000a      Oral Anticoagulation Management in Primary Care With the Use of\u000d\u000a      Computerized Decision Support and Near-Patient Testing. Randomized,\u000d\u000a      Controlled Trial. Arch Intern Med. 2000;160:2343-2348.\u000d\u000a      http:\/\/archinte.jamanetwork.com\/article.aspx?articleid=746624#qundefined\u000d\u000a    \u000a\u000a2. Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S.\u000d\u000a      Self-management of oral anticoagulation: randomised trial. BMJ.\u000d\u000a      2005;331(7524):1057.\u000d\u000a      http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1283185\/\u000d\u000a    \u000a\u000a3. Mant J, Fitzmaurice DA, Hobbs FDR, Jowett S, Murray ET, Holder R,\u000d\u000a      Davies M, Lip GHY. Accuracy of diagnosing atrial fibrillation on\u000d\u000a      electrocardiogram by primary care practitioners and interpretative\u000d\u000a      diagnostic software: analysis of data from screening for atrial\u000d\u000a      fibrillation in the elderly (SAFE) trial. BMJ 2007;335(7616):380 http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1952490\/\u000d\u000a    \u000a\u000a4. Fitzmaurice DA, Hobbs FDR, Jowett S, Mant J, Murray ET, Holder R, et\u000d\u000a      al. Screening versus routine practice in detection of atrial fibrillation\u000d\u000a      in patients aged 65 or over: cluster randomised controlled trial. BMJ\u000d\u000a      2007;335(7616):383 http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1952508\/\u000d\u000a    \u000a\u000a5. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice DA, Lip GYH,\u000d\u000a      Murray ET. BAFTA investigators, Midland Research Practices Network\u000d\u000a      (MidReC). Warfarin versus aspirin for stroke prevention in an elderly\u000d\u000a      population with atrial fibrillation (the Birmingham Atrial Fibrillation\u000d\u000a      treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet\u000d\u000a      2007;370(9586):493-503 .\u000d\u000a      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17693178\u000d\u000a    \u000a\u000a6. Connock MJ, Stevens C, Fry-Smith AS, Jowett SM, Fitzmaurice DA, Moore\u000d\u000a      DJ et al. Clinical effectiveness and cost-effectiveness of different\u000d\u000a      models of managing long-term oral anticoagulation therapy: a systematic\u000d\u000a      review and economic modelling. Health Technology Assessment.\u000d\u000a      2007;11(38). http:\/\/www.hta.ac.uk\/execsumm\/summ1138.htm\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    \u000d\u000a      National Patient Safety Agency. Risk assessment of anticoagulant\u000d\u000a          therapy. January 2006. Accessed through: http:\/\/www.improvement.nhs.uk\/heart\/AnticoagulationResources.aspx\u000a\u000d\u000a      Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C et al.\u000d\u000a        British Committee for Standards in Haematology Guidelines on oral\u000d\u000a        anticoagulation with warfarin. Fourth edition. British Journal of\u000d\u000a          Haematology 2011; 154(3): 311-324 http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08753.x\/full\u000a\u000d\u000a      BMA\/NHS Employers. Quality and Outcomes Framework guidance for GMS\u000d\u000a          contract 2009\/10. Delivering investment in general practice. March\u000d\u000a        2009 (AF Indicator 3, pp.107-109). Accessed through:http:\/\/www.nhsemployers.org\/PayAndContracts\/GeneralMedicalServicesContract\/QOF\/Pages\/ChangesToQOF200910.aspx\u000a\u000d\u000a      2013\/14 general medical services (GMS) contract quality and outcomes\u000d\u000a        framework (QOF) Guidance for GMS contract 2013\/14. (Indicators\u000d\u000a        AF003-004, pp.33-38).\u000d\u000a        http:\/\/www.nhsemployers.org\/Aboutus\/Publications\/Pages\/qof-2013-14.aspx\u000a\u000d\u000a      National Collaborating Centre for Chronic Conditions. Atrial\u000d\u000a          fibrillation. National Clinical Guideline for management in\u000d\u000a        primary and secondary care. London: Royal College of Physicians; 2006. http:\/\/www.nice.org.uk\/nicemedia\/live\/10982\/30055\/30055.pdf\u000d\u000a        ; NICE. Atrial fibrillation. The management of atrial fibrillation.\u000d\u000a        NICE Clinical Guideline 36. London: NICE; 2006.\u000d\u000a        http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG036niceguideline.pdf;\u000d\u000a        NICE. Anticoagulation therapy service. Commissioning Guide.\u000d\u000a          Implementing NICE guidance NICE Clinical Guideline 36. London:\u000d\u000a        NICE; 2007. http:\/\/www.nice.org.uk\/media\/4A1\/D5\/Anticoagulation_commissioning_guide.pdf\u000a\u000d\u000a      Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH,\u000d\u000a        Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for\u000d\u000a        the management of atrial fibrillation. European Heart Journal.\u000d\u000a        2012;33:2719-2747.\u000d\u000a        http:\/\/eurheartj.oxfordjournals.org\/content\/33\/21\/2719.full?sid=52c01292-182c-4e76-9289-e7b156335d78\u000a\u000d\u000a      European Stroke Organisation. Guidelines for the management of\u000d\u000a        ischaemic stroke and transient ischaemic attack. Cerebrovascular\u000d\u000a          Diseases 2008; 25(5): 457-507.\u000d\u000a        http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18477843\u000a\u000d\u000a      Antithrombotic therapy in atrial fibrillation: American College of\u000d\u000a        Chest Physicians evidence- based clinical practice guidelines (8th\u000d\u000a        edition). Chest 2008; 133 (6 supp) : 546s-592s\u000d\u000a        http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18574273\u000a\u000d\u000a      National Centre for Anticoagulation Training. http:\/\/www.anticoagulation.org.uk\/courses.php\u000a\u000d\u000a      BMJ Learning. Starting patients on anticoagulants: how to do it.\u000d\u000a        http:\/\/learning.bmj.com\/learning\/module-intro\/starting-patients-anticoagulants.html?moduleId=5004325&amp;searchTerm=\"fitzmaurice\"&amp;page=1&amp;locale=en_GB\u000d\u000a        ; Maintaining patients on anticoagulants: how to do it http:\/\/learning.bmj.com\/learning\/module-intro\/maintaining-patients-anticoagulants.html?locale=en_GB&amp;moduleId=5004429\u000a\u000d\u000a      NHS Improvement &#8212; Heart. Anticoagulation for atrial fibrillation.\u000d\u000a          A simple overview to support the commissioning of quality services.\u000d\u000a        2011.\u000d\u000a        http:\/\/www.improvement.nhs.uk\/heart\/HeartImprovementHome\/AtrialFibrillation\/AtrialFibrillationAnticoagulation\/tabid\/129\/Default.aspx\u000a\u000d\u000a      RCPE UK Consensus Conference on \"Approaching the comprehensive\u000d\u000a        management of Atrial Fibrillation: Evolution or revolution?\", March\u000d\u000a        2012.RCP Edinburgh press release March 2012\u000d\u000a        http:\/\/www.rcpe.ac.uk\/press-releases\/2012\/medical-experts-call-on-scottish-and-uk-governments.php)\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Atrial fibrillation: Developing anticoagulation management and therapy\u000d\u000a        for atrial fibrillation through primary care\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Around 2% of the UK population take oral anticoagulation (mainly warfarin\u000d\u000a      in the UK) with around 75% of these having atrial fibrillation (AF) as the\u000d\u000a      main indication. AF increases in prevalence with age and presents in 12%\u000d\u000a      of people aged over 75 years; 56% of patients with this arrhythmia are\u000d\u000a      over the age of 75. AF is a major risk factor for stroke, leading to a\u000d\u000a      five-fold increase in risk. As risk of stroke increases with age, stroke\u000d\u000a      prevention in elderly people with atrial fibrillation is a key aspect of\u000d\u000a      management for this group. Anticoagulation therapy with warfarin is highly\u000d\u000a      effective in reducing stroke risk but is associated with monitoring costs\u000d\u000a      and higher risk of haemorrhage compared with other treatments. Work on\u000d\u000a      this area has focused on service re- design, screening and treatment for\u000d\u000a      AF and has included generation of robust primary evidence through RCTs\u000d\u000a      [1-5], economic evaluation [4,6] and systematic review [6].\u000d\u000a    Shifting service delivery into primary care\u000d\u000a    Until a decade ago, patients in the UK who received oral anticoagulation\u000d\u000a      management were managed in secondary care because of the need for\u000d\u000a      monitoring via a laboratory blood test, the international normalised ratio\u000d\u000a      (INR). UoB UoA2 has undertaken an extensive primary care research\u000d\u000a      programme within the area of service delivery for oral anticoagulation\u000d\u000a      management (Professor David Fitzmaurice, Professor of Primary\u000d\u000a      Care, UoB; Dr Kate Fletcher, Stroke Prevention Programme Manager\u000d\u000a      UoB; Professor Richard Hobbs, Professor of Primary Care,\u000d\u000a      UoB until April 2011; Mr Roger Holder, Medical Statistician, UoB;\u000d\u000a      Dr Susan Jowett, Senior Lecturer in Health Economics, UoB;\u000d\u000a      Professor Gregory Lip, Consultant Cardiologist and Professor of\u000d\u000a      Cardiovascular Medicine, UoB [UoA1]; Professor Jonathan Mant,\u000d\u000a      Professor of Primary Care, UoB until September 2008; Dr Ellen Murray,\u000d\u000a      Senior Lecturer in Primary Care, UoB; Mrs Andrea Roalfe, Senior\u000d\u000a      Lecturer in Primary Care, UoB) led by Fitzmaurice (NHS national\u000d\u000a      R&amp;D Primary Care Career Scientist Award (CSA99\/025)) to investigate\u000d\u000a      the integration and evaluation of new technologies &amp; the Birmingham\u000d\u000a      model, comprising computerised decision support dosing software, and point\u000d\u000a      of care INR testing within primary care, to facilitate oral\u000d\u000a      anticoagulation management [1].\u000d\u000a    Self-monitoring of oral anticoagulation\u000d\u000a    In 1999, UoB's primary care grouping within UoA2 began the SMART\u000d\u000a      (Self-Management of Anticoagulation: a Randomised Trial) study (PI: Fitzmaurice,\u000d\u000a      &#163;285K, MRC, 1999-2002). SMART demonstrated the effectiveness of\u000d\u000a      self-management for approximately 25% of patients receiving warfarin,\u000d\u000a      compared with routine care whether provided through primary or secondary\u000d\u000a      care [2]. These data were the first UK RCT data and the first in the world\u000d\u000a      from primary care and have underpinned subsequent meta-analyses\u000d\u000a      demonstrating the clinical and cost-effectiveness of this model of care\u000d\u000a      (Garcia-Alamino et al Cochrane review 2010). Different models of managing\u000d\u000a      long- term oral anticoagulation therapy have also been assessed [6]. More\u000d\u000a      recently the Patient Self- Management registry (PI: Fitzmaurice\u000d\u000a      &#163;50k, NIHR National School for Primary Care Research 2011-2014) has been\u000d\u000a      developed. As more people undertake self-monitoring or self- management of\u000d\u000a      their oral anticoagulation it is important to ensure that therapeutic\u000d\u000a      control is maintained. This electronic central register provides a\u000d\u000a      valuable tool for studying the safety and effectiveness of this method of\u000d\u000a      service delivery. This study is evaluating the feasibility of patients\u000d\u000a      with AF who self- monitor or self-manage their conditions entering their\u000d\u000a      data onto a website to produce a register.\u000d\u000a    Screening for AF\u000d\u000a    The Screening for Atrial Fibrillation in the Elderly (SAFE) study (Fitzmaurice\u000d\u000a      (PI), Hobbs, Mant, &#163;485k HTA funded 1999-2003) was\u000d\u000a      a trial of systematic screening (targeted and total population screening)\u000d\u000a      versus routine practice for the detection of AF in 15,000 patients aged\u000d\u000a      over 65 [3,4]. SAFE determined the optimal method of AF diagnosis &amp;\u000d\u000a      ECG interpretation [3] and established the incremental cost-effectiveness\u000d\u000a      (Jowett) of different screening options compared with routine\u000d\u000a      clinical practice, determining that opportunistic screening was most\u000d\u000a      cost-effective [4].\u000d\u000a    Management of AF\u000d\u000a    Meta-analysis has demonstrated that anticoagulants are significantly more\u000d\u000a      effective than aspirin at preventing stroke, but that this benefit is at\u000d\u000a      the cost of higher risk of major bleeding (van Walraven C, Hart RG, Singer\u000d\u000a      DE, Laupacis A, Connolly S, Petersen P et al. Oral anticoagulants vs\u000d\u000a      aspirin in nonvalvular atrial fibrillation: an individual patient\u000d\u000a      meta-analysis. JAMA 2002 ; 288(19) : 2441-8.). However, there were\u000d\u000a      concerns as to the applicability of this research to elderly patients with\u000d\u000a      AF, particularly in primary care settings.\u000d\u000a    In view of these uncertainties, the primary care grouping within UoB's\u000d\u000a      UoA2 conducted the BAFTA (Birmingham Atrial Fibrillation Treatment of the\u000d\u000a      Aged) study (PIs: Fitzmaurice, Hobbs, &#163;740k MRC,\u000d\u000a      1999-2004). This compared the efficacy of warfarin with that of aspirin\u000d\u000a      for the prevention of stroke in a primary care population of 973 patients\u000d\u000a      with AF aged 75 years or over.\u000d\u000a    The effect on stroke prevention reported in the BAFTA study [5] was\u000d\u000a      similar to that reported in the 2002 meta-analysis. However, the key\u000d\u000a      difference between the two results is that the meta-analysis showed a\u000d\u000a      doubling of risk of major haemorrhage in people on oral anticoagulants\u000d\u000a      compared with those on aspirin, whereas the BAFTA study found no such\u000d\u000a      difference. The BAFTA study provided accurate data on the risk of\u000d\u000a      haemorrhage, which appears to be an important factor in physicians'\u000d\u000a      decisions whether to prescribe warfarin. In addition, the study\u000d\u000a      demonstrated the actual benefits of warfarin compared to aspirin and\u000d\u000a      reported data showing improved efficacy and equivalent safety of warfarin\u000d\u000a      versus aspirin in stroke prevention in the very elderly. The study\u000d\u000a      provided evidence to support the use of anticoagulation therapy (warfarin)\u000d\u000a      for people aged over 75 with AF unless there are contraindications or the\u000d\u000a      patient chooses otherwise [5].\u000d\u000a    "},{"CaseStudyId":"38796","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"953987","Name":"South Africa"}],"Funders":[],"ImpactDetails":"\u000a    The key impacts are as follows:\u000a    Impact on public policy\u000a      NICE guidelines are the accepted standard for determining the management\u000a      of hypertension in UK\u000a      primary care. As a result of this research, the National Institute for\u000a      Health and Clinical Excellence\u000a      (NICE) has published a new guideline for the Clinical Management of\u000a      Primary Hypertension in\u000a      Adults (CG 127; 24 August 2011). The guideline reported the inaccuracy of\u000a      CBPM using this\u000a      research: \"these findings suggest that the current practice of using a\u000a        series of CBPM alone for the\u000a        diagnosis of hypertension can lead to inaccurate diagnosis\" and that\u000a      \"this detailed analysis\u000a        suggested that the current practice of using CBPM to define hypertension\u000a        will lead to drug\u000a        treatment being offered to a substantial number of people who are\u000a        normotensive according to\u000a        ABPM\". The Guideline Development Group \"thus recommended that\u000a        ABPM should be\u000a        implemented for the routine diagnosis of hypertension in primary care\"\u000a      [1]\u000a    Impact on clinical practice and health\u000a      The key to the success of implementing the recommendations of the review\u000a      is buy-in from\u000a      clinicians. The original research was widely reported in the national\u000a      press, including the Daily\u000a      Telegraph, the Guardian and the GP publication Pulse [2]. At the time of\u000a      the full publication of the\u000a      NICE guidelines, it was again widely reported, including on BBC national\u000a      news and on the BBC\u000a      website [3]. To encourage adoption, the British Hypertension Society has\u000a      made a series of videos\u000a      covering key aspects of the guidance [4]. These, along with the NICE\u000a      implementation materials\u000a      (http:\/\/www.nice.org.uk\/CG127),\u000a      are helping to facilitate dissemination and implementation of this\u000a      evidence-based evolution of the NICE hypertension guidelines.\u000a    As the NICE guidelines are relatively new (2011) it is not possible at\u000a      this stage to specify impact in\u000a      terms of changes in patient outcome, however the NICE Primary Care Quality\u000a      and Outcomes\u000a      Framework Indicator Advisory Committee recommended that an indicator be\u000a      piloted to ensure\u000a      practices use ABPM for all new diagnoses of hypertension; the proposed\u000a      wording of the indicator\u000a      is: `The percentage of patients with a new diagnosis of hypertension after\u000a      1 April 2012 whose\u000a      diagnosis was confirmed following ABPM.'[Pulse http:\/\/www.pulsetoday.co.uk\/nice-to-pilot-ambulatory-blood-pressure-monitoring-qof-indicator\/14101039.article].\u000a    Economic impact\u000a      The cost-effectiveness analysis of ABPM conducted by the University of\u000a      Birmingham was reported\u000a      by the full NICE clinical guidelines \"This analysis suggests that ABPM\u000a        is the most cost-effective\u000a        method of confirming a diagnosis of hypertension in a population\u000a        suspected of having hypertension\u000a        based on a Clinical BPM screening measurement &gt;140\/90 mmHg, compared\u000a        with further CBPM or\u000a        HBPM. This conclusion was consistent across a range of age\/gender\u000a        stratified subgroups.\" and\u000a      impacted on the NICE guideline [1].\u000a    The research has also influenced the South African Hypertension guideline\u000a      of 2011 which\u000a      recommends that ABPM should be encouraged for clear indications, quoting\u000a      the economic\u000a      evidence generated in this research as evidence for this guidance [5]: \"In\u000a        patients with a raised\u000a        clinic BP, ABPM was shown to reduce misdiagnosis and save costs\u000a        (reference, Lovibond et al)\".\u000a    Impact on education and CPD\u000a      The research is influencing medical education. Members of the research\u000a      team (Hodgkinson,&#160;\u000a      McManus,&#160; Martin, Wood) have\u000a      completed the setting of a Continuing Medical Education version\u000a      of the BMJ article [6] to support practitioner learning in:\u000a    1) Appraising the relative effectiveness of different indirect methods of\u000a      monitoring blood\u000a      pressure in diagnosing hypertension;\u000a    2) Evaluating the strength of evidence for these findings; and\u000a    3) Recognising the potential implications of the study's findings for\u000a      clinical practice.\u000a    Following the publication of the main research study, they have also been\u000a      commissioned and will\u000a      provide a further in-depth learning module for the BMJ, to be published\u000a      shortly [7]. BMJ Learning\u000a      offers high-quality (peer reviewed, up-to-date, and evidence-based)\u000a      continuing medical education\u000a      in an economical and time efficient manner, for general practitioners,\u000a      hospital doctors and other\u000a      healthcare professionals such as practice nurses and practice managers.\u000a      The modules are\u000a      accredited by colleges, associations, and authorities from around the\u000a      world.\u000a    Other educational impacts have included the commissioning of an article\u000a      for The Practitioner (a\u000a      monthly peer review clinical journal for GPs) on diagnosing and managing\u000a      hypertension in primary\u000a      care [8] and an international commentary [9].\u000a    ","ImpactSummary":"\u000a    High blood pressure (or hypertension) is the major cause of stroke and\u000a      other cardiovascular\u000a      disease, and is one of the most important preventable causes of morbidity\u000a      and mortality in\u000a      developed and developing countries. In the UK it affects half the\u000a      population over 60 and costs the\u000a      NHS &#163;1Bn per year in drugs alone.\u000a    A University of Birmingham primary care-led study has provided definitive\u000a      evidence of the\u000a      superiority of ambulatory blood pressure measurement (ABPM) over clinic\u000a      and home blood\u000a      pressure monitoring as a means of diagnosing hypertension. The associated\u000a      cost-effectiveness\u000a      study showed that this approach will save the NHS over &#163;10.5M per year. As\u000a      a result of this\u000a      research, NICE guidelines have been amended and ABPM has become the\u000a      reference standard.\u000a      The research has also influenced public and policy debate in the UK and\u000a      internationally.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Birmingham\u000a    ","Institutions":[{"AlternativeName":"Birmingham (University of)","InstitutionName":"University of Birmingham","PeerGroup":"A","Region":"West Midlands","UKPRN":10006840}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FDR, Deeks\u000a        JJ, Heneghan C, Roberts N,\u000a      McManus RJ. Relative effectiveness of clinic and home\u000a      blood pressure monitoring compared\u000a      to ambulatory blood pressure monitoring in the diagnosis of hypertension:\u000a      a systematic review. BMJ 2011; 342: d3621 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21705406\u000a    \u000a\u000a2. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs\u000a        FDR, Hodgkinson J,\u000a      Mant J, Martin U, Williams B, Wonderling D, McManus RJ.\u000a      Cost-effectiveness of options for\u000a      the diagnosis of high blood pressure in primary care: a modelling study. The\u000a        Lancet 2011;\u000a      378(9798); 1219-1230 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21868086\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"}],"Sources":"\u000a    \u000a      National Clinical Guideline Centre. Hypertension: management of\u000a        hypertension in adults in\u000a        primary care. Clinical Guideline 127. London : National Institute for\u000a        Clinical Excellence ; 2011.\u000a        http:\/\/www.nice.org.uk\/guidance\/CG127\/NICEGuidance\u000a\u000a      Media links for reporting of original research:\u000a    \u000a    \u000a      The Telegraph. Millions of high blood pressure patients are wrongly\u000a        diagnosed. 22\u000a        February 2011http:\/\/www.telegraph.co.uk\/health\/healthnews\/8339545\/Millions-of-high-blood-pressure-patients-are-wrongly-diagnosed.html\u000a\u000a      The Guardian. Blood pressure testing faces overhaul to reduce\u000a        misdiagnosis. 22 February\u000a        2011. http:\/\/www.guardian.co.uk\/society\/2011\/feb\/22\/blood-pressure-testing-overhaul?INTCMP=ILCNETTXT3487\u000a\u000a      Pulse. NICE rewrites rules on hypertension diagnosis. 22 February\u000a        2011.\u000a        http:\/\/www.pulsetoday.co.uk\/nice-rewrites-rules-on-hypertension-diagnosis\/11053584.article\u000a\u000a    \u000a    \u000a      Media links for alterations to NICE guidance:\u000a    \u000a    \u000a      Pulse. NICE rips up hypertension guidance. 24 August 2011\u000a        http:\/\/www.pulsetoday.co.uk\/nice-rips-up-hypertension-guidance\/12588147.article\u000a\u000a      BBC. Blood pressure guidelines revised in England and Wales. 24 August\u000a        2011.\u000a        http:\/\/www.bbc.co.uk\/news\/health-14629425\u000a        also national news broadcast\u000a    \u000a    \u000a      British Hypertension Society, September 2011\u000a        http:\/\/www.bhsoc.org\/index.php\/download_file\/view\/404\/139\/\u000a\u000a      Seedat YK, Rayner BL. South African Hypertension guideline 2011. South\u000a          African Medical\u000a          Journal 2012; 102(1): 57-83. http:\/\/www.samj.org.za\/index.php\/samj\/article\/view\/5373\/3798\u000a\u000a      Continuing Medical Education, June 2011 http:\/\/learning.bmj.com\/learning\/module-intro\/.html?moduleId=10023906&amp;searchTerm=\"blood_pressure\"&amp;page=0&amp;locale=en_GB\u000a\u000a      Letter from BMJ Learning regarding November 2013 publication of\u000a        module: BP Measurement\u000a        Module \"Blood pressure: an evidence-based approach to measuring it\"\u000a      Hodgkinson J, Wood S, Martin U, McManus R. ABPM is best for diagnosing\u000a        hypertension in\u000a        primary care. Practitioner 2011; 255 (1744):21-23\u000a        http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23251987\u000a\u000a      Feldman RD. Review: Home and clinic BP have limited accuracy compared\u000a        with ambulatory\u000a        BP for diagnosing hypertension Ann Intern Med 2011 155(12)\u000a        :JC6-10;\u000a        http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22184711\u000a\u000a    \u000a    ","Title":"\u000a    Hypertension: Improving routine diagnosis of hypertension in primary\u000a        care\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Effective diagnosis of hypertension is critically important. High blood\u000a      pressure (or hypertension) is\u000a      the major cause of stroke and other cardiovascular disease and is one of\u000a      the most important\u000a      preventable causes of morbidity and mortality in developed and developing\u000a      countries. At least a\u000a      quarter of the adult population of the UK has hypertension, and this\u000a      figure rises to more than 50%\u000a      in people over the age of 60 years. Hypertension is the commonest chronic\u000a      disorder seen in\u000a      primary care with around 1:8 receiving antihypertensive treatment in the\u000a      UK. Moreover, as the\u000a      demographics shift towards an older, more sedentary and obese population,\u000a      the prevalence of\u000a      hypertension and the requirement for effective treatment will continue to\u000a      rise.\u000a    High blood pressure is currently diagnosed in primary care and in\u000a      hospital clinics using the\u000a      traditional technique of measurement by a GP or nurse with either a\u000a      mercury sphygmomanometer\u000a      and stethoscope or with an automated device. In terms of patient outcomes,\u000a      these methods\u000a      compare poorly with ABPM where a cuff connected to a portable monitor is\u000a      worn continuously by\u000a      the patient for a period of 24 hours. However, no previous study had\u000a      attempted to bring together\u000a      and synthesise the literature on the accuracy of diagnosis of hypertension\u000a      using different methods\u000a      of measurement.\u000a    This research, which forms part of the Birmingham\/ Oxford Universities\u000a      Collaborative BP\u000a      Monitoring Programme Group, has provided robust evidence of the\u000a      superiority of ABPM over clinic\u000a      (CBPM) and home (HBPM) blood pressure monitoring in diagnosing\u000a      hypertension. In 2009, a\u000a      group led from Primary Care within the University of Birmingham (Professor\u000a      Richard McManus,\u000a      Professor of Primary Care, UoB up to 31 August 2011; Professor Richard Hobbs,\u000a      Professor of\u000a      Primary Care, UoB up to 30 April 2011; Dr Pelham Barton, Reader in\u000a      Economic Modelling, UoB;\u000a      Dr James Hodgkinson, Research Fellow, UoB; Dr Boliang Guo,\u000a      Research Fellow, UoB) and\u000a      working with others in the University of Birmingham (Professor Jon Deeks,\u000a      Professor of Health\u000a      Statistics, UoB; Dr Una Martin, Reader in Clinical Pharmacology,\u000a      UoB [UoA1]) and in the\u000a      University of Oxford (Mant, Heneghan, Roberts) conducted a systematic\u000a      review of the worldwide\u000a      literature and a meta-analysis using hierarchical summary\u000a      receiver-operating characteristic\u000a      models. The study was funded by an NIHR Programme Grant for Applied\u000a      Research (RP-PG-0407-10347,\u000a      Mant et al, including McManus, Hobbs); Hodgkinson,\u000a      McManus and Martin extracted the\u000a      data in conjunction with Mant; Guo, Hodgkinson and Deeks\u000a      undertook the analysis.\u000a    The objective of the systematic review was to determine the relative\u000a      accuracy of clinic\u000a      measurements and home blood pressure monitoring compared with ambulatory\u000a      blood pressure\u000a      monitoring as a reference standard for the diagnosis of hypertension. The\u000a      research identified that,\u000a      compared with ambulatory monitoring, neither clinic nor home blood\u000a      pressure measurements have\u000a      sufficient sensitivity or specificity to be recommended as a single\u000a      diagnostic test. If ambulatory\u000a      monitoring is taken as the reference standard, then treatment decisions\u000a      based on clinic or home\u000a      blood pressure alone may result in substantial over-diagnosis (and\u000a      subsequent over-medication\u000a      and unnecessary cost). For example, if the prevalence of hypertension in a\u000a      screened population\u000a      was 30%, there would only be a 56% chance that the clinic measurement\u000a      would be correct\u000a      compared with using the ABPM methods. These results suggest that\u000a      ambulatory monitoring prior\u000a      to commencement of life-long drug treatment would lead to more appropriate\u000a      targeting of\u000a      treatment, particularly around the diagnostic threshold [1]. The review\u000a      was published in BMJ in\u000a      2011 and has been cited 45 times.\u000a    The research findings had profound implications for the diagnosis of\u000a      hypertension, particularly as\u000a      ambulatory monitors are considerably more expensive than clinic BP\u000a      monitors so, as part of the\u000a      programme grant, health economists at the University of Birmingham (Dr Sue\u000a      Jowett, Senior\u000a      Lecturer in Health Economics; Dr Pelham Barton, Reader in Economic\u000a      Modelling) and the\u000a      National Clinical Guideline Centre (Lovibond, Wonderling) in conjunction\u000a      with the Birmingham team\u000a      described above and members of the relevant clinical guidelines group\u000a      undertook the most\u000a      detailed cost-benefit analysis ever conducted for ABPM. The UoB health\u000a      economists supervised\u000a      the modelling, which was conducted by Lovibond at NICE.\u000a    This Markov model-based probabilistic cost-effectiveness analysis of the\u000a      three different diagnostic\u000a      strategies for hypertension included a hypothetical primary care\u000a      population aged &#8805;40 years with a\u000a      screening blood pressure measurement above 140\/90 mmHg and risk factor\u000a      prevalence reflecting\u000a      the general population. Ambulatory monitoring was identified as the most\u000a      cost effective strategy for\u000a      the diagnosis of hypertension for men and women of all ages, and resulted\u000a      in more quality-adjusted\u000a      life years (QALYs) for male and female groups aged over 50. Implementation\u000a      of a\u000a      diagnostic strategy for hypertension using ambulatory monitoring following\u000a      an initial raised clinic\u000a      reading would reduce misdiagnosis and reduce unnecessary treatment costs.\u000a      Whilst ABP monitors\u000a      are expensive, the additional costs of ambulatory monitoring are more than\u000a      offset by cost savings\u000a      from better targeting of treatment and the study estimated that it use\u000a      would save the NHS &#163;10.5M\u000a      per annum. The study indicated that service commissioners should recommend\u000a      ambulatory\u000a      monitoring prior to the commencement of anti-hypertensives for the\u000a      majority of patients. The\u000a      results showed clearly that the use of ABPM would result in substantial\u000a      savings to the NHS.\u000a    These findings were published in the Lancet in 2011 and have been cited\u000a      more than 30 times [2].\u000a      Media coverage included television (ITV central; reach 655,000), print\u000a      newspapers (Daily Mail,\u000a      Daily Express; reach 2,434,00) and online (BBC, Forbes; reach 8,352,000).\u000a    "},{"CaseStudyId":"38797","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"2963597","Name":"Ireland"}],"Funders":[],"ImpactDetails":"\u000a    This work has had major impacts on international policy and practice &#8212;\u000a      including patient groups\u000a      who wish to campaign on this topic &#8212; as well as directly for children and\u000a      their parents where the\u000a      test has been implemented as a result. The research was described as `a\u000a      new milestone in the\u000a      history of congenital heart disease' in a Lancet editorial [1].\u000a    Impact on international policy\u000a    The Lancet paper (2011), HTA report (2012) and subsequent international\u000a      media attention led to a\u000a      demand from policy makers internationally for advice on implementation of\u000a      pulse oximetry. In the\u000a      USA, where CCHD affects about 4,800 babies born every year, Dr Ewer was\u000a      invited in 2011 to\u000a      advise a working group of the Secretary's Advisory Committee on Heritable\u000a      Diseases in Newborns'\u000a      and Children (SACHDNC) in Washington, USA with his data described as\u000a      `instrumental in creating\u000a      recommendations for the screening algorithm' [2] . Following this meeting,\u000a      the group issued a\u000a      statement advocating the introduction of pulse oximetry screening endorsed\u000a      by the American\u000a      Academy of Pediatrics [3] and the American Heart Association [4]. As a\u000a      direct result, in 2011 the\u000a      US Secretary for Health and Human Services recommended the addition of\u000a      pulse oximetry\u000a      screening for CCHD across the US [5,6], with the chosen strategy [7]\u000a      referencing just the work of\u000a      the Birmingham team (reference 14) and one Swedish study. Seven US states\u000a      (including New\u000a      Jersey, Michigan) currently perform routine screening; 27 others have\u000a      passed legislation towards\u000a      this goal, with 3 having active legislation in process. Current\u000a      information on progress towards\u000a      legislation can be obtained at [8] and an example of guidance on screening\u000a      referencing the\u000a      Birmingham team's work for the state of Alabama at [9].\u000a    The research has also impacted on provision in Ireland, where the Royal\u000a      College of Physicians in\u000a      2011 recommended that pulse oximetry `should be undertaken in all Units\u000a      across the country',\u000a      citing the `seminal research' of the Birmingham team as the basis for the\u000a      decision, and indicating\u000a      that screening would identify 99 babies per year with the condition [10].\u000a    Impact on UK policy\u000a    The UK National Screening Committee (NSC) assesses evidence for\u000a      programmes against a set of\u000a      internationally recognised screening criteria, advises ministers\/the NHS\u000a      on all aspects of screening\u000a      and supports implementation of screening programmes. The UK NSC will\u000a      shortly conduct a public\u000a      consultation over whether to add pulse oximetry to the assessment of\u000a      newborn babies. The\u000a      consultation highlights the `...considerable research evidence to\u000a        demonstrate that pulse oximetry,\u000a        as an adjunct to clinical examination, increases the detection rate of\u000a        critical or life-threatening\u000a        CHDs at the newborn screening opportunity' and that `routine\u000a        pulse oximetry is probably the most\u000a        promising additional newborn screening modality' under\u000a      consideration, for which the University of\u000a      Birmingham's work provides the bulk of the underpinning rationale and\u000a      evidence [11].\u000a    Impact on UK clinical practice and patient health\u000a    Although the UK policy situation is still developing, changes in clinical\u000a      practice are already\u000a      occurring. A 2010 national survey found that only 7% of UK neonatal units\u000a      were undertaking\u000a      routine pulse oximetry screening. A survey of 204 units in 2012 indicated\u000a      a rise in these figures,\u000a      with 18% of units utilising pulse oximetry routinely and 4% in the process\u000a      of introducing it [12]. Of\u000a      non-screening units, 70% were considering its introduction. This survey\u000a      and associated\u000a      correspondence clearly indicates a shift of opinion among UK\u000a      neonatologists about pulse oximetry\u000a      screening, with a substantial majority now in favour, albeit with\u000a      reservations about cost.\u000a    One centre adopting pulse oximetry screening is Birmingham Women's\u000a      Hospital, with 8000 live\u000a      births per year. With screening, over a three year period (2010-13) there\u000a      were 187 admissions as\u000a      a result of an abnormal screening test. This equates to approximately\u000a      60\/year, 0.8% of all live\u000a      births. Of the 187 babies admitted, seven had a critical congenital heart\u000a      defect unsuspected prior\u000a      to screening. Five further babies had an unsuspected non-critical\u000a      congenital heart defect. Further,\u000a      for those 180 babies who did not have critical congenital heart defects,\u000a      many other serious health\u000a      conditions (including congenital pneumonia, sepsis and pulmonary\u000a      hypertension) were identified\u000a      through the positive pulse oximetry screening, and only 36\/180 (20%)\u000a      admitted babies had no\u000a      health issues. This indicates the additional benefits obtained through\u000a      incorporating this screening\u000a      into routine practice. If it is assumed that the 18% of units currently\u000a      applying pulse oximetry\u000a      screening look after 18% of the 700,000 babies born annually in the UK and\u000a      that the rates for\u000a      Birmingham Women's Hospital are typical, then an additional 63 babies with\u000a      congenital heart\u000a      defects were detected by pulse oximetry screening in 2012, including 37\u000a      babies with critical defects\u000a    International campaign groups\u000a    A significant impact of the work has been its use by lobbying groups, who\u000a      were quick to recognise\u000a      the potential benefits of pulse oximetry for screening newborns and have\u000a      actively campaigned for\u000a      its routine use nationally. These UK groups all cite the Birmingham Pulse\u000a      Ox study as the most\u000a      important piece of evidence for their campaigns, and letters of support\u000a      have been provided by:[13]\u000a    \u000a      \u000aChildren's Heart Federation (\"The extensive and compelling\u000a          research... has been crucial to\u000a          our understanding and work around the issue. It has allowed us to\u000a          strongly make the case that\u000a          this test should be introduced for newborns in the UK.\");\u000a      \u000aLittle Hearts Matter (\"Little Hearts Matter has been able to\u000a          use the findings to add credence to\u000a          our call for better diagnosis of congenital heart disease with NIPE\");\u000a      \u000aTiny Tickers (\"This research highlights the possibility of a\u000a          timely and cost-effective neonatal\u000a          solution and has resulted in Tiny Tickers lobbying of NIPE... it is\u000a          likely to be enormously\u000a          important to babies with undetected heart disease and their families\u000a          and community\").\u000a    \u000a    Internationally, campaign groups also commonly recognise the value of\u000a      Birmingham's work. A US\u000a      website exists for parents to lobby for the use of pulse oximetry and\u000a      cites the PulseOx study as one of\u000a      \"the most compelling pieces of evidence\", which \"should be part of any\u000a      advocacy work\" [14].\u000a    ","ImpactSummary":"\u000a    Congenital heart defects are a leading cause of infant death, accounting\u000a      for more deaths than any\u000a      other type of malformation and up to 7.5% of all infant deaths. Timely\u000a      diagnosis is crucial for the\u000a      best possible outcome for these children. However, the accuracy of current\u000a      methods for screening\u000a      newborn babies for critical congenital heart defects (CCHD) is variable\u000a      and currently only detects\u000a      these issues in between 35-50% of babies before birth. Although some cases\u000a      are picked up after\u000a      birth, up to a third of children with these problems are sent home\u000a      undiagnosed, where they may\u000a      become unwell or die. Research at the University of Birmingham has\u000a      demonstrated that pulse\u000a      oximetry is a rapid, safe, non-invasive, painless method of detecting the\u000a      low blood oxygen levels\u000a      associated with CCHD, and is also a cost-effective approach. As a result\u000a      of our research, pulse\u000a      oximetry was recommended for adoption across the US in 2011 by the\u000a      Secretary for Health and\u000a      Human Services. In the UK, our research is prompting a national review of\u000a      screening for these\u000a      conditions and some units are already using the approach, meaning that\u000a      some patients are already\u000a      benefitting.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Birmingham\u000a    ","Institutions":[{"AlternativeName":"Birmingham (University of)","InstitutionName":"University of Birmingham","PeerGroup":"A","Region":"West Midlands","UKPRN":10006840}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"4829764","Name":"Alabama"}],"References":"\u000a    \u000a1. Thangaratinam S, Daniels J, Ewer AK, Zamora J, Khan KS.\u000a      Accuracy of pulse oximetry in\u000a      screening for congenital heart disease in asymptomatic newborns: A\u000a      systematic review. Arch Dis\u000a        Child Fetal Neonatal Ed 2007;92(3):F176-F180. http:\/\/fn.bmj.com\/content\/92\/3\/F176.long\u000a    \u000a\u000a2. Ewer AK, Furmston AT, Middleton LJ, Deeks JJ,\u000a      Daniels JP, Pattison HM, Powell R,\u000a      Roberts TE, Barton P, Auguste A et al. Pulse\u000a      oximetry as a screening test for congenital heart\u000a      defects in newborn infants: a test accuracy study with evaluation of\u000a      acceptability and cost-effectiveness.\u000a      Health Technol Assess 2012;16(2):1-184.\u000a      http:\/\/www.hta.ac.uk\/execsumm\/summ1602.htm\u000a    \u000a\u000a3. Ewer AK, Middleton LJ, Furmston AT, Bhoyar A, Daniels\u000a      JP, Thangaratinam S, Deeks\u000a      JJ, Khan KS. Pulse oximetry as a screening test for congenital heart\u000a      defects in newborn infants\u000a      (PulseOx): a test accuracy study. Lancet 2011;378:785-94.\u000a      http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(11)60753-8\/abstract#aff3\u000a    \u000a\u000a4. Roberts TE, Barton P, Auguste P, Middleton\u000a      LJ, Furmston AT, Ewer AK. Pulse oximetry\u000a      as a screening test for congenital heart disease in newborn infants: a\u000a      cost effectiveness analysis.\u000a      Arch Dis Child 2012;97(3):221-226. http:\/\/adc.bmj.com\/content\/early\/2012\/01\/13\/archdischild-2011-300564.full\u000a    \u000a\u000a5. Powell R, Pattison HM, Bhoyar A, Furmston AT, Middleton\u000a      LJ, Daniels JP, Ewer AK.\u000a      Pulse oximetry as a screening test for congenital heart defects in newborn\u000a      infants: An evaluation of\u000a      acceptability to mothers. Arch Dis Child Fetal Neonatal Ed\u000a      2013;58:F59-63.\u000a      http:\/\/fn.bmj.com\/content\/98\/1\/F59.long\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"14","Subject":"Paediatrics and Reproductive Medicine"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"}],"Sources":"\u000a    \u000a      A new milestone in the history of congenital heart disease. Lancet.\u000a        2012;379:2401.\u000a        http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(12)61045-9\/fulltext\u000a\u000a      Martin GR, Bradshaw EA. Sensitivity of pulse oximetry for detection of\u000a        critical congenital heart\u000a        defects in newborn infants higher than that of antenatal ultrasound with\u000a        few false positives.\u000a        Evid Based Med. 2012 Apr;17(2):57-8. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22127340\u000a\u000a      From the American Academy of Pediatrics: Policy Statement. Endorsement\u000a        of Health and\u000a        Human Services Recommendation for Pulse Oximetry Screening for Critical\u000a        Congenital Heart\u000a        Disease 2012;129:190 -192 http:\/\/pediatrics.aappublications.org\/content\/129\/1\/190.full\u000a\u000a      Mahle WT, Sable CA, Matherne PG, Gaynor JW, Gewitz MH. Key concepts in\u000a        the evaluation of\u000a        screening approaches for heart disease in children and adolescents: A\u000a        science advisory from\u000a        the American Heart Association. Circulation\u000a        2012;125(22):2796-801.\u000a        http:\/\/circ.ahajournals.org\/content\/early\/2012\/04\/30\/CIR.0b013e3182579f25.full.pdf\u000a\u000a      US Secretary of Health and Human Services. Decision to adopt the\u000a        SACHDNC's first\u000a        recommendation pertaining to the addition of Critical Congenital Heart\u000a        Disease (CCHD)\u000a        screening to the Recommended Uniform Screening Panel (RUSP). Letter to\u000a        RR Howell.\u000a        Washington, DC: Department of Health and Human Services , 21 September\u000a        2011\u000a        http:\/\/www.hrsa.gov\/advisorycommittees\/mchbadvisory\/heritabledisorders\/recommendations\/correspondence\/cyanoticheartsecre09212011.pdf\u000a\u000a      U.S. Health &amp; Human Services Makes Critical Congenital Heart\u000a        Defect Screening Using\u000a        Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard.\u000a        PR Newswire 23\u000a        September 2011. http:\/\/www.prnewswire.com\/news-releases\/us-health--human-services-makes-critical-congenital-heart-defect-screening-using-motion-tolerant-pulse-oximetry-a-nationwide-newborn-screening-standard-130473518.html\u000a\u000a      Kemper AR, et al. Strategies for Implementing Screening for Critical\u000a        Congenital Heart Disease\u000a        Pediatrics 2011:128:e1259-e1267 http:\/\/pediatrics.aappublications.org\/content\/128\/5\/e1259.full\u000a\u000a      Alabama Department of Public Health. Hospital guidelines for\u000a        implementing pulse oximetry\u000a        screening for critical congenital heart disease. Montgomery, Al : ADPH;\u000a        March 2012.\u000a        http:\/\/www.adph.org\/newbornscreening\/assets\/FHS.NBS.CCHDGuidelines.0312.na.pdf\u000a\u000a      CCHD Screening Map: http:\/\/cchdscreeningmap.org\/\u000a\u000a      Health Services Executive, Royal College of Physicians in Ireland.\u000a        Pulse oximietry testing for\u000a        newborn congenital heart disease. 2011. http:\/\/www.docstoc.com\/docs\/147405914\/Pulse-Oximetry-Screening-for-Newborn-Congenital-Heart-Disease-FINAL\u000a\u000a      Screening for Congenital Heart Defects, External review against\u000a        programme appraisal criteria\u000a        for the UK NSC. September 2013. http:\/\/www.screening.nhs.uk\/congenitalheartdisease\u000a\u000a      Singh A, Ewer AK. Pulse oximetry screening for critical congenital\u000a        heart defects: a UK national\u000a        survey The Lancet, 2013;381:535http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(13)60278-0\/fulltext\u000a\u000a      Letters from Children's Heart Foundation, Little Hearts Matter, Tiny\u000a        Tickers.\u000a      Pulse Oximetry Advocacy. http:\/\/pulseoxadvocacy.com\/research\/\u000a\u000a    \u000a    ","Title":"\u000a    PulseOx: Detecting heart disease in newborn babies through pulse\u000a        oximetry screening\u000a    ","UKLocation":[{"GeoNamesId":"2655603","Name":"Birmingham"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Congenital heart defects (i.e. issues existing at birth or during\u000a      pregnancy) are the most common\u000a      group of congenital malformations, affecting up to 9\/1000 live born\u000a      babies, and accounting for 40%\u000a      of all deaths from congenital malformations. They are a leading cause of\u000a      infant deaths in the\u000a      developed world, with most deaths occurring in the first year of life.\u000a      Critical congenital heart defects\u000a      (CCHD) are a key subset; affecting around 2\/1000 babies, they are have\u000a      significant implications for\u000a      the child's survival. If they are not detected early, risks for\u000a      circulatory collapse increase. Although\u000a      surgery can greatly improve survival, if diagnosis is not timely, the risk\u000a      of surgical mortality also\u000a      increases. Screening for congenital heart defects at the time of the\u000a      research relied on antenatal\u000a      ultrasonography and postnatal clinical examination. However, these methods\u000a      are not very accurate\u000a      for detecting CCHD, identifying before birth only 35-50% of babies for\u000a      whom it is a problem. For\u000a      the remaining babies, these defects are then either identified after birth\u000a      or remain undetected when\u000a      children are sent home. Overall, around one third of children with these\u000a      potentially life-threatening\u000a      heart defects are discharged from hospital without being diagnosed.\u000a    A team from the University of Birmingham UoA2 (Professor Jon Deeks,\u000a      Professor of Health\u000a      Statistics, UoB; Professor Tracy Roberts, Professor of Health\u000a      Economics, UoB; Dr Pelham\u000a      Barton, Reader in Mathematical Modelling, UoB; Dr Jane Daniels,\u000a      Senior Research Fellow, UoB,\u000a      Alexandra Furmston; Trial Co-ordinator, UoB, Lee Middleton,\u000a      Statistician, UoB; Peter Auguste,\u000a      Research Associate, UoB until December 2012) with clinical colleagues in\u000a      UoB UoA1 (Bhoyar,\u000a      Ewer, Khan, Thangaratinam) and others (Edwards, Birmingham Women's\u000a      Hospital; Pattison,\u000a      Aston; University, Wright, Birmingham Children's Hospital) has worked\u000a      since 2007 to conduct a\u000a      programme of research around the use of pulse oximetry to better identify\u000a      babies with these\u000a      problems.\u000a    It is well established that blood oxygen levels are often low in CCHD and\u000a      so one way of identifying\u000a      these defects might be to identify those babies with low blood oxygen\u000a      levels. Pulse oximetry is a\u000a      method of measuring blood oxygen levels by placing a sensor on part of the\u000a      patient's body (such\u000a      as a fingertip or earlobe), not requiring any invasive techniques. The\u000a      sensor can detect the baby's\u000a      oxygenation levels during labour. The technique was developed in the 1970s\u000a      and explored for\u000a      monitoring fetal oxygenation, but results had been inconclusive. The\u000a      University of Birmingham\u000a      team conducted a systematic review in 2007 which showed encouraging\u000a      results but drew attention\u000a      to various difficulties in assessing the accuracy of pulse oximetry\u000a      including variations in patient\u000a      selection, timing of measurement, cut-offs for a positive result, types of\u000a      congenital heart defects\u000a      screened for, rigour of follow-up, and type of oximeters used [1]. The\u000a      systematic review\u000a      demonstrated a clear need for a larger, robust, well-conducted study to\u000a      confirm the value,\u000a      acceptability and cost effectiveness of such a screening programme.\u000a    In 2007, the National Institute of Health Research funded the PulseOx\u000a      study (Ewer, Daniels,\u000a        Roberts, Thangaratinam, Khan, Deeks, Pattison, Wright, NIHR\u000a      HTA; &#163;947k 2007-10). This large,\u000a      multi-centre study assessed the accuracy of pulse oximetry for screening\u000a      major congenital heart\u000a      defects in newborn babies. It was the largest UK study in this field,\u000a      screening 20,055 newborn\u000a      babies between February 2008 and January 2009, and the first to assess the\u000a      added value of pulse\u000a      oximetry screening in modern healthcare systems where antenatal ultrasound\u000a      screening was\u000a      widely available. The study used robust methods to generate precise\u000a      estimates of the accuracy\u000a      [2,3], cost-effectiveness [2,4] and acceptability [2,5] of pulse oximetry.\u000a      The test accuracy paper\u000a      [2,3] demonstrated that the addition of pulse oximetry screening to the\u000a      routine anomaly scan and\u000a      newborn physical examination resulted in 92% of babies with critical\u000a      congenital heart defects being\u000a      detected prior to discharge; no baby died with unidentified congenital\u000a      heart defects. The study\u000a      found that pulse oximetry is a safe, feasible (i.e. easy to undertake and\u000a      simple to adopt into routine\u000a      practice) test that complements and adds value to existing screening by\u000a      identifying more issues at\u000a      birth, including cases of CCHD that would go undetected with antenatal\u000a      ultrasonography. The\u000a      team also demonstrated that pulse oximetry screening in combination with\u000a      clinical examination\u000a      identified almost 30 additional CCHD cases per 100,000 live births with a\u000a      timely diagnosis\u000a      compared with routine clinical examination alone, with a very high\u000a      likelihood (over 90%) that this\u000a      would be regarded as `cost-effective', i.e. worth the extra investment\u000a      needed to identify these\u000a      cases [2,4]. The acceptability research undertaken clearly showed that\u000a      both parents and health\u000a      professionals felt the test was not painful, difficult to perform or\u000a      inconvenient [2,5]. False-positive\u000a      results did not significantly increase anxiety. Overall, the results\u000a      substantially enhanced the\u000a      evidence that indicates the potential benefits of the introduction of\u000a      pre-discharge pulse oximetry\u000a      screening as a routine procedure.\u000a    Media coverage of the work has included print newspapers (Guardian,\u000a      Independent, Scotsman,\u000a      Express, Star; reach 319,300), Radio (Heart FM, Classic FM, BBC Radio WM;\u000a      reach 97,300) and\u000a      online (Mail, Guardian, Telegraph, Independent; reach 4,888,400).\u000a    "},{"CaseStudyId":"38798","Continent":[{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"3077311","Name":"Czech Republic"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"2186224","Name":"New Zealand"}],"Funders":[],"ImpactDetails":"\u000a    Impact on Public Policy\u000a    CARE-HF has been used as key evidence supporting the use of cardiac\u000a      resynchronization therapy in a series of international guidelines at both\u000a      regional (Europe [1]) and national level, in countries as diverse as\u000a      Australia [2], Brazil [3], Canada [4], Czech Republic [5], New Zealand\u000a      [2,6], and USA [7,8,9]. Examples include:\u000a    1) European Society of Cardiology Guidelines for the Diagnosis and\u000a      Treatment of Heart Failure, were initially published in 2005 and later\u000a      revised during the 2008-13 impact period, in both 2008 and 2012 [1]. These\u000a      guidelines all cite CARE-HF as a source of key evidence for recommending\u000a      the use of cardiac resynchronization therapy in patients with moderate to\u000a      severely symptomatic heart failure (Section 9.2.1, reference 157 in 2012\u000a      revision)\u000a    2) American College of Cardiology Foundation\/American Heart Association\u000a      Guidelines for the Diagnosis and Management of Heart Failure in Adults\u000a      2005 and 2009 [9]. CARE-HF is cited as one of the trials providing strong\u000a      evidence supporting the use of CRT in selected patients (Section\u000a      4.3.1.3.4., reference 101).\u000a    3) Guidelines for the prevention, detection and management of chronic\u000a      heart failure in Australia published in 2011 [2] (Section 8.1; pg 36,\u000a      reference 204). These guidelines cite CARE-HF (reference 204) as\u000a      supporting use of biventricular pacing for patients with: NYHA symptoms\u000a      Class III\/IV despite optimal medical therapy; dilated heart failure with\u000a      an ejection fraction less than or equal to 35%; QRS duration greater than\u000a      or equal to 120 ms; sinus rhythm.\u000a    The 2012 expert consensus statement on cardiac resynchronization therapy\u000a      in heart failure from EHRA\/HRS cites evidence from the CARE-HF trial as\u000a      influencing a number of recommendations including around use of biomarkers\u000a      in assessing heart failure (Section 1.2.2, reference 8), around\u000a      considerations for patients with CRT and concomitant atrial fibrillation\u000a      (Section 6.2, reference 264), and concerning the cost-effectiveness of CRT\u000a      (Section 6.8, references 348, 350) [10]. This consensus statement is\u000a      endorsed by the governing bodies of European Association of\u000a        Cardiovascular Imaging, American Heart Association, American Society of\u000a        Echocardiography, Heart Failure Society of America, Heart Failure\u000a        Association of the European Society of Cardiology, European Heart Rhythm\u000a        Association, and Heart Rhythm Society.\u000a    Impact on Clinical Practice and Patient Health\u000a    There has been impact on UK patients throughout the 2008-2013 impact\u000a      period, resulting from both the UK guidelines included above and also the\u000a      incorporation of the research into NICE guidance just prior to the impact\u000a      period. In the UK, CARE-HF provided evidence that underpins the NICE\u000a      Technology Appraisal Guidance: Cardiac resynchronisation therapy for the\u000a      treatment of heart failure, 2007 [11] and which recommended the use of CRT\u000a      in selected patients with left ventricular dysfunction. CARE-HF was one of\u000a      4 RCTs considered by the NICE Appraisal Committee on CRT-P versus optimal\u000a      pharmacological therapy alone (see p7-15). In addition the strict clinical\u000a      inclusion criteria was adopted by the committee as a requirement in\u000a      clinical practice (see pages 14\/15):\u000a    \"The Committee noted that in one of the large studies (CARE-HF)\u000a        additional evidence of mechanical dyssynchrony from echocardiography was\u000a        required in patients with a QRS duration of between 120 ms and 150 ms,\u000a        and was therefore persuaded that such a requirement would be appropriate\u000a        to use in clinical practice.\" (p14)\u000a    \"The Committee also understood from the clinical specialists that\u000a        confirmation of the presence of mechanical dyssynchrony by\u000a        echocardiography was considered appropriate in patients with electrical\u000a        dyssynchrony as indicated by a QRS duration of between 120 ms and 149\u000a        ms. The Committee noted that this approach was the same as the inclusion\u000a        criteria for the CARE-HF trial.\" (p15)\u000a    The publication of the CARE-HF Trial was a substantial contribution\u000a      within the overall portfolio of evidence which has seen the use of CRT\u000a      substantially increased throughout Europe. Eucomed data, based on reports\u000a      from major device manufacturers, suggest an increase in CRT (+\/-ICD) use\u000a      across Europe rising from 86 units per million inhabitants in 2008 to 141\u000a      units per million inhabitants in 2012 [12]. In the UK new CRT implants\u000a      have increased significantly following the publication of the CARE-HF\u000a      trial in 2005 [12] and are now over 100\/million population [13].\u000a    ","ImpactSummary":"\u000a    Heart failure affects more than 22 million people worldwide, including 6\u000a      million in Europe and 5 million in the United States, with approximately\u000a      500,000 new patients diagnosed each year.\u000a    The cardiac resynchronisation in heart failure trial (CARE-HF)\u000a      demonstrated that, in patients with heart failure and cardiac\u000a      dyssynchrony, use of an implantable pacemaker to improve heart contraction\u000a      led to a 37% reduction in the risk of death and hospitalisations and\u000a      significant improvements in patient quality of life. The benefits are in\u000a      addition to those of standard pharmacologic therapy. As a result of the\u000a      CARE-HF trial, international and NICE guidelines have recommended the use\u000a      of cardiac resynchronization therapy in patients with heart failure and\u000a      dyssynchrony resulting in an increased use of cardiac resynchronisation\u000a      throughout the world and significant improvements in quality of life and\u000a      survival for heart failure patients.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Birmingham\u000a    ","Institutions":[{"AlternativeName":"Birmingham (University of)","InstitutionName":"University of Birmingham","PeerGroup":"A","Region":"West Midlands","UKPRN":10006840}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a1. Cleland J, Daubert J-C, Erdmann E, Freemantle N, Gras\u000a      D, Kappenberger L et al . CARE-HF Study Investigators (inc. Calvert M).\u000a      The effect of cardiac resynchronization on morbidity and mortality in\u000a      heart failure N Engl J Med 2005; 352(15) :1539-1549.\u000a      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15753115\u000a    \u000a\u000a2. Cleland JG, Calvert MJ, Verboven Y, Freemantle N.\u000a      Effects of cardiac resynchronization therapy on long-term quality of life:\u000a      an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF)\u000a      study. Am Heart J. 2009 ;157(3):457-66. Epub 2009 Jan 20.\u000a      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19249415\u000a    \u000a\u000a3. Calvert MJ, Freemantle N, Yao G, Cleland JG, Billingham\u000a        L, Daubert JC et al. CARE-HF investigators. FASTTRACK.\u000a      Cost-effectiveness of cardiac resynchronization therapy: results from the\u000a      CARE-HF trial. Eur Heart J. 2005;26(24) : 2681-8. Epub 2005 Nov\u000a      11.\u000a      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16284203\u000a    \u000a\u000a4. Yao G, Freemantle N, Calvert MJ, Bryan S,\u000a      Daubert JC, Cleland JG. The long-term cost-effectiveness of cardiac\u000a      resynchronization therapy with or without an implantable\u000a      cardioverter-defibrillator. Eur Heart J. 2007;28(1): 42-51. Epub\u000a      2006 Nov 16.\u000a      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17110403\u000a    \u000a\u000a5. Calvert MJ, Freemantle N, Cleland JGF. The impact of\u000a      chronic heart failure on health-related quality of life data acquired in\u000a      the baseline phase of the CARE-HF study. Eur J Heart Fail. 2005;\u000a      7(2) : 243-51. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15701474\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    \u000a      European Society of Cardiology. ESC guidelines for the diagnosis and\u000a        treatment of acute and chronic heart failure. ESC Task Force for the\u000a        Diagnosis and Treatment of Acute and Chronic Heart Failure. European\u000a          Heart Journal 2012; 33: 1787-1847\u000a        http:\/\/www.escardio.org\/guidelines-surveys\/esc-guidelines\/GuidelinesDocuments\/Guidelines-\u000a          Acute%20and%20Chronic-HF-FT.pdf\u000a\u000a      National Heart Foundation of Australia and the Cardiac Society of\u000a        Australia and New Zealand. Guidelines for the prevention, detection\u000a          and management of chronic heart failure in Australia.\u000a        Revised July 2011. http:\/\/www.csanz.edu.au\/LinkClick.aspx?fileticket=TGB_bO-\u000a          yI1k%3D&amp;tabid=148\u000a\u000a      Bocchi EA, Braga FG, Ferreira SM, Rohde LE, Oliveira WA, Almeida DR,\u000a        et al. [III Brazilian Guidelines on Chronic Heart Failure]. Arq Bras\u000a          Cardiol 2009;93(1 Suppl 1):3-70.\u000a        http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20963312\u000a\u000a      Howlett JG et al . Canadian Cardiovascular Society Consensus\u000a        Conference Guidelines on heart failure, update 2009: Diagnosis and\u000a        management of right-sided heart failure, myocarditis, device therapy and\u000a        recent important clinical trials. Can J Cardiol\u000a        2009;25(2):85-105.\u000a        http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19214293\u000a\u000a      Spinar J, Vitovec J, Hradec J, Malek I, Meluzin J, Spinarova L, et al.\u000a        Czech Society of Cardiology guidelines for the diagnosis and treatment\u000a        of chronic heart failure 2011. Cor et vasa 54[2], e113-e134.\u000a        1-3-2012.\u000a        http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0010865012000355\u000a\u000a      Smith W. New Zealand primary implantable cardioverter defibrillator\u000a        implantation and biventricular pacing guidelines. New Zealand Med J\u000a        2010 Feb 19;123(1309):86-96.\u000a        http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20186245\u000a\u000a      Heart Failure Society of America. Comprehensive Heart Failure Practice\u000a        Guideline. Journal of Cardiac Failure: 2010; 475-506:16(6).\u000a        http:\/\/www.heartfailureguideline.org\/_assets\/document\/Guidelines.pdf\u000a\u000a      Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA, III, Freedman RA,\u000a        Gettes LS, et al. ACC\/AHA\/HRS 2008 Guidelines for device-based therapy\u000a        of cardiac rhythm abnormalities. Heart Rhythm 2008\u000a        Jun;5(6):e1-62. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18534360\u000a\u000a      Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et\u000a        al. 2009 Focused Update: ACCF\/AHA Guidelines for the Diagnosis and\u000a        Management of Heart Failure in Adults. Circulation 2009 Apr\u000a        14;119(14):1977-2016.\u000a        http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19324967\u000a\u000a      2012 EHRA\/HRS expert consensus statement on cardiac resynchronization\u000a        therapy in heart failure: implant and follow-up recommendations and\u000a        management. Heart Rhythm. 2012;9(9),1524-1576. http:\/\/dx.doi.org\/10.1016\/j.hrthm.2012.07.025\u000a\u000a      National Institute for Health and Clinical Excellence . Heart\u000a          failure &#8212; cardiac resynchronisation: guidance. NICE TA120 .\u000a        London: National Institute for Health and Clinical Excellence; 2007\u000a        (proposed for review July 2010). http:\/\/guidance.nice.org.uk\/TA120\/Guidance\/pdf\/English.\u000a        National Institute for Health and Clinical Excellence. Chronic heart\u000a          failure: Management of chronic heart failure in adults in primary and\u000a          secondary care. NICE Clinical Guideline CG108; August 2010. http:\/\/guidance.nice.org.uk\/CG108\/NICEGuidance\/pdf\/English\u000a\u000a      Eucomed, 2013.\u000a        http:\/\/www.eucomed.org\/uploads\/_medical_technology\/facts_figures\/Graphs_CRM_2013.pdf\u000a\u000a      Cunningham D, Charles R, Cunningham M, Whittaker T. Cardiac Rhythm\u000a        Management. NICOR, 2013.\u000a        https:\/\/nicor5.nicor.org.uk\/CRM\/device.nsf\/65153b7e3756850e80256aff003a2c78\/$FILE\/CRM\u000a         %20National%20Annual%20Report%202011%20final%20release%20revised.pdf\u000a\u000a    \u000a    ","Title":"\u000a    Heart failure: Improving the quality of life and survival of heart\u000a        failure patients through Cardiac Resynchronisation Therapy\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Heart failure affects more than 22 million people worldwide, including 6\u000a      million in Europe and 5 million in the United States, with approximately\u000a      500,000 new patients diagnosed each year (http:\/\/www.medtronic.com\/physician\/care_hf\/faqs.html).\u000a      Despite improvements in pharmacological treatment, many patients with\u000a      heart failure have severe and persistent symptoms and their prognosis\u000a      remains poor. Early studies of an implantable pacemaker &#8212; cardiac\u000a      resynchronization therapy (CRT) suggested that it was a promising new\u000a      intervention for patients with heart failure, left ventricular systolic\u000a      dysfunction and ventricular dyssynchrony with evidence that CRT decreased\u000a      symptoms, improved exercise capacity, quality of life, and ventricular\u000a      function. The COMPANION trial (2004) showed that CRT alone or combined\u000a      with an implantable defibrillator reduced the composite end point of death\u000a      from any cause or hospitalization during a mean follow-up of 16 months;\u000a      however, the decrease in the risk of death was not significant with CRT\u000a      alone (P=0.06). Meta-analyses left lingering uncertainty about the effects\u000a      of cardiac resynchronization on the risk of complications and death.\u000a    From 2001 to 2005, a team from the University of Birmingham (Professor\u000a      Nick Freemantle, Professor of Clinical Epidemiology and\u000a      Biostatistics, UoB up to April 2011; Dr Melanie Calvert, Reader in\u000a      Epidemiology, UoB) led the design and analysis of the landmark Cardiac\u000a      Resychronisation in Heart Failure Trial (CARE-HF) and its extension study.\u000a      The CARE-HF trial (PI Cleland, University of Hull; funded by Medtronic\u000a      Ltd; design &amp; analysis Freemantle, Calvert) was a\u000a      multi-centre, international, randomised controlled trial to evaluate\u000a      long-term effects of CRT on the mortality and morbidity of patients with\u000a      heart failure due to left ventricular systolic dysfunction and cardiac\u000a      dyssynchrony who were receiving standard pharmacologic therapy. A total of\u000a      813 patients were recruited between January 2001 and March 2003 at 82\u000a      centres across 12 European countries. Patients were randomly assigned to\u000a      receive medical therapy alone or with CRT and followed for a mean of 29.4\u000a      months.\u000a    The primary end point was the time to death from any cause or unplanned\u000a      hospitalisation for a major cardiovascular event. The principal secondary\u000a      end point was death from any cause. The primary end point was reached by\u000a      159 patients in the cardiac-resynchronization group, as compared with 224\u000a      patients in the medical-therapy group (39 percent vs. 55 percent; hazard\u000a      ratio, 0.63; 95 percent confidence interval, 0.51 to 0.77; P&lt;0.001).\u000a      There were 82 deaths in the CRT group, as compared with 120 in the\u000a      medical-therapy group (20 percent vs. 30 percent; hazard ratio 0.64; 95\u000a      percent confidence interval, 0.48 to 0.85; P&lt;0.002). As compared with\u000a      medical therapy, CRT reduced the interventricular mechanical delay, the\u000a      end-systolic volume index, and the area of the mitral regurgitant jet;\u000a      increased the left ventricular ejection fraction; and improved symptoms\u000a      and the quality of life (P&lt;0.01 for all comparisons). This landmark\u000a      trial thus demonstrated significant improvements in survival and quality\u000a      of life in patients randomised to CRT. These benefits are in addition to\u000a      those afforded by standard pharmacologic therapy and it was recommended\u000a      that the implantation of a cardiac-resynchronization device should\u000a      routinely be considered in such patients. The results were published in\u000a      the New England journal of Medicine [1] and have been cited 2715 times accessed\u000a        via Scopus online 30th July 2013. The\u000a      observed benefits in survival and quality of life were sustained over time\u000a      [2].\u000a    Whilst the CARE-HF trial demonstrated reduced morbidity and mortality,\u000a      CRT is relatively costly thus it was essential to establish the\u000a      incremental cost-effectiveness of using the device compared to standard\u000a      care. Within trial and life-time simulation model based cost-effectiveness\u000a      analyses were led from the University of Birmingham (Freemantle;\u000a        Calvert; Professor Stirling Bryan, Professor of\u000a      Health Economics, UoB, up to August 2008; Dr Lily Yao,\u000a      Senior Lecturer in Health Economics, UoB, up to February 2013; Professor\u000a      Lucinda Billingham, Professor of Biostatistics, UoB) in\u000a      conjunction with CARE-HF investigators from elsewhere (Cleland, Daubert).\u000a      The aim of the within trial cost-effectiveness analysis was to evaluate\u000a      the incremental cost per QALY gained and incremental cost per life year\u000a      gained of CRT plus medical therapy compared to medical therapy alone. It.\u000a      CRT was associated with increased costs (&#8364;4316, 95% CI: 1327 to 7485),\u000a      survival (0.10 years, 95% CI: &#8212; 0.01 to 0.21), and QALYs (0.22, 95% CI:\u000a      0.13 to 0.32). The incremental cost-effectiveness ratio was &#8364;19 319 per\u000a      QALY gained (95% CI: 5482 to 45 402) and &#8364;43 596 per life-year gained (95%\u000a      CI: &#8212; 146 236 to 223 849) [3]. A further long term cost-effectiveness\u000a      analysis used a lifetime simulation model developed based upon individual\u000a      patient data from the CARE-HF trial to examine the additional effect of\u000a      CRT with an implantable cardioverter-defibrilator (ICD) function, which\u000a      further reduces risk of death. Both CRT + medical therapy and CRT-ICD +\u000a      medical therapy were cost-effective at a notional willingness to pay\u000a      threshold of &#8364;29 400 (&#163;20,000) but the latter to a lesser extent [4].\u000a      There were also contributions to cost-effectiveness analyses for the\u000a      Nordic region and Greece (Freemantle, Calvert).\u000a    The CARE-HF trial has resulted in a further 24 publications (including\u000a      Birmingham authors Freemantle; Calvert; Dr Puvanendran Tharmanathan,\u000a      doctoral student, UoB up to December 2008; Matthew Richardson,\u000a      research fellow, UoB up to April 2012; Aparna Shankar,\u000a      research associate, UoB up to August 2008) on topics including quality of\u000a      life [5], neurohormonal effects, procedure success rate and predictors of\u000a      outcome.\u000a    "},{"CaseStudyId":"38799","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2963597","Name":"Ireland"}],"Funders":[],"ImpactDetails":"\u000a    Impact on Public Policy\u000a    This research on the effects of epidurals at the University of Birmingham\u000a      has directly influenced and changed clinical practice in the UK and\u000a      internationally. The COMET trial is the definitive (and only) trial in the\u000a      review of traditional versus modern regimens of epidural infusion in the\u000a      UK NICE Intrapartum Care guideline updated in 2008 and still current, and\u000a      led to the recommendation stating that: `traditional high\u000a        concentration local anaesthetic solutions (0.25% or above of bupivacaine\u000a        or equivalent) should not be used routinely for either establishing or\u000a        maintaining epidural analgesia' [1]. It had previously been\u000a      calculated by others that such changes would result in 10,000 fewer\u000a      instrumental deliveries year on year in the UK (Thornton JG, Capogna G.\u000a      Reducing likelihood of instrumental delivery with epidural anaesthesia.\u000a      The Lancet 2001; 358: 2001). Forceps births are known to be associated\u000a      with increased problems for women, such as faecal incontinence, perineal\u000a      pain and pain on intercourse (dyspareunia).\u000a    These changes to UK policy are reinforced by Royal College of\u000a      Anaesthetists Guidelines (2009, 2013) on the provision of Obstetric\u000a      Anaesthesia Services, which recommends that units should be able to\u000a      provide low dose regional analgesia, citing COMET as the sole reference\u000a      [2]. Internationally, the COMET trial has influenced clinical policy in\u000a      Canada and Australia. The Canadian Agency for Drugs and Technologies in\u000a      Health (2010) clinical guidelines on effectiveness and safety of\u000a      ambulatory epidural analgesia in obstetrics [3] includes references to the\u000a      main Lancet paper and several of the subsequent COMET papers. These\u000a      subsequent papers have provided evidence on safety and leg strength in\u000a      relation to ambulation, urinary catheterisation and anaesthetic outcomes\u000a      such as speed of analgesia, drug utilisation and requirement for\u000a      anaesthetist re-attendance. In Western Australia, the research was\u000a      referenced in 2010 in the Department of Health's Women and Newborn Health\u000a      Service, obstetrics and midwifery clinical guidelines [4].\u000a    Impact on Clinical Practice and Patient Care\u000a    There has been impact on patients throughout the 2008-2013 impact period\u000a      resulting both from these policy changes as well as earlier guidelines\u000a      that were still current during this time. The Obstetric Anaesthetists'\u000a      Association (OAA) \/ The Association of Anaesthetists of Great Britain and\u000a      Ireland (AAGBI) Guidelines for Obstetric Anaesthetic Services [5]\u000a      had recommended in 2005 (with COMET as the sole reference) that units\u000a      should have guidelines for management of epidural blocks and should be\u000a      able to provide low-dose regional analgesia. Together, the original\u000a      research and the subsequent guidelines and policy changes, have moved the\u000a      UK from a situation just before the COMET trial in which only 24% of units\u000a      offered low dose techniques in 1996\/7 (Burnstein R, Buckland R, Pickett\u000a      JA, A survey of epidural analgesia for labour in the United Kingdom.\u000a      Anaesthesia 1999; 54(7): 634-640) to one in which UK units rarely use the\u000a      traditional high dose technique for standard labour analgesia. This change\u000a      in approach can be directly linked to the COMET study through these\u000a      changes in policy and guidance. This work has also been incorporated into\u000a      local unit guidelines e.g. cited in Guidelines for the Practice of\u000a      Obstetric Anaesthesia in Nottingham University Hospitals [6]. The COMET\u000a      trial has also influenced clinical care through its incorporation in\u000a      textbooks on pain management: an example is the Oxford Handbook on pain\u000a      management [7], which references the COMET trial.\u000a    Economic Impact\u000a    The impact of a reduction in the instrumental delivery rate has had a\u000a      corresponding effect on reducing the costs of deliveries. This is because,\u000a      if a woman has an instrumental rather than a spontaneous delivery, the\u000a      costs rise due to an obstetrician being required for instrumental\u000a      deliveries, the costs of the instruments and the cost of an associated\u000a      increase in the length of the hospital stay. The cost-effectiveness study\u000a      that formed part of the COMET trial demonstrated reduced obstetrician\u000a      attendance and duration of stay. At the time the overall cost saving in\u000a      clinical time and hospital stay was offset by the greater cost of the use\u000a      of the newer drug, but these drugs are now less costly. In addition,\u000a      several studies have shown that forceps deliveries are associated with an\u000a      increase in faecal incontinence, haemorrhoids, constipation, perineal pain\u000a      and dyspareunia occurring after birth, such problems incurring greater\u000a      costs to both the NHS and women themselves. Little is known about these\u000a      symptoms in the longer term following instrumental births, except for\u000a      faecal incontinence which has been shown to persist for many years even in\u000a      women who have had only one forceps delivery thus continuing additional\u000a      costs (evidenced in other research by MacArthur [8]). The\u000a      prevalence of persistent faecal incontinence (including less severe\u000a      symptoms) at 12 years postpartum in the largest postpartum cohort study\u000a      was 4.6% in women who had only had spontaneous vaginal deliveries, whereas\u000a      it was 9.3% in women whose delivery history included a forceps birth [8].\u000a    ","ImpactSummary":"\u000a    Instrumental births can cause problems and are needed more often with\u000a      epidurals. The Comparative Obstetric Mobile Epidural Trial (COMET) was the\u000a      definitive trial that led to the NICE Intrapartum Care guideline\u000a      recommendation to discontinue traditional epidurals using high\u000a      concentration local anaesthetic solutions in favour of low dose epidural\u000a      techniques which allow women to be mobile during labour. It is estimated\u000a      that these changes have resulted in about 10,000 fewer instrumental\u000a      deliveries annually in the UK. Correspondingly, numbers of women\u000a      experiencing effects of instrumental births such as faecal incontinence\u000a      will have been substantially reduced. This research has also influenced\u000a      clinical guidelines and led to changes in practice on the type of\u000a      epidurals used during labour elsewhere, including Australia and Canada.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Birmingham\u000a    ","Institutions":[{"AlternativeName":"Birmingham (University of)","InstitutionName":"University of Birmingham","PeerGroup":"A","Region":"West Midlands","UKPRN":10006840}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2058645","Name":"State of Western Australia"}],"References":"\u000a    \u000a1. Comparative Obstetric Mobile Epidural Trial (COMET) study group UK\u000a      Effect of low-dose mobile versus traditional epidural techniques on mode\u000a      of delivery: a randomised controlled trial. The Lancet 2001;\u000a      358(9275): 19-23. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11454372\u000a    \u000a\u000a2. Comparative Obstetric Mobile Epidural Trial (COMET) study group UK.\u000a      Randomised controlled trial comparing traditional with two \"mobile\"\u000a      epidural techniques: anaesthetic and analgesic efficacy. Anesthesiology\u000a      2002; 97(6):1567-75. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12459686\u000a    \u000a\u000a3. Cooper GM, MacArthur C, Wilson M, Moore P, Shennan A. Satisfaction,\u000a      control and pain relief: short and long term assessments in a randomised\u000a      controlled trial of low-dose and traditional epidurals and a non-epidural\u000a      comparison group. International Journal of Obstetric Anaesthesia\u000a      2010; 19(1): 31-37. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19945274\u000a    \u000a\u000a4. Wilson MJ, Moore PA, Shennan A, Lancashire RJ, MacArthur C. Long term\u000a      effects of epidural analgesia in labor: a randomized controlled trial\u000a      comparing high dose with two mobile techniques. Birth. 2011;\u000a      38(2):105-110.\u000a        http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21599732\u000a    \u000a\u000a5. Wilson M, MacArthur C, Cooper GM, Bick D, Moore PA, Shennan A.\u000a      Epidural analgesia and breastfeeding: a randomised controlled trial of\u000a      epidural techniques with and without fentanyl and a non-epidural\u000a      comparison group. Anaesthesia 2010; 65(2): 145-153 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19912160\u000a    \u000a\u000a6. Wilson M, MacArthur C, Cooper GM, Shennan A. Ambulation in labour and\u000a      delivery mode: a randomised controlled trial of high-dose versus mobile\u000a      epidural analgesia. Anaesthesia 2009; 64(3):266-272. http:\/\/ncbi.nlm.nih.gov\/pubmed\/19302638\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"14","Subject":"Paediatrics and Reproductive Medicine"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    \u000a      National Institute for Health and Clinical Excellence. Intrapartum\u000a        Care. Care of healthy women and their babies during childbirth. NICE\u000a        Guidance,CG55 London: NICE: September 2007. http:\/\/guidance.nice.org.uk\/CG55\u000a        Revised print 2008,\u000a        http:\/\/guidance.nice.org.uk\/CG55\/Guidance\/pdf\/English\u000a\u000a      Royal College of Anaesthetists. Guidelines for the provision of\u000a        anaesthetic services. Chapter 9. Obstetric Anaesthesia Services. London:\u000a        RCOA; 2013.\u000a        http:\/\/wwhttps:\/\/www.rcoa.ac.uk\/system\/files\/GPAS-2013-09-OBSTETRICS_1.pdf\u000a\u000a      Canadian Agency for Drugs and Technologies in Health. Ambulatory\u000a        Epidural Analgesia in Obstetrics: Clinical Effectiveness, Safety, and\u000a        Guidelines. Ottawa: CADTH; November 2010.http:\/\/cadth.ca\/media\/pdf\/K0271_Ambulatory_Epidurals_Obstetrics_abs.pdf\u000a\u000a      Government of Western Australia, Department of Health, Women and\u000a        Newborn Health Service. Clinical Guidelines. Section B. Obstetrics and\u000a        Midwifery Guidelines. 4. Pain management in labour. 4.8. Neuraxial\u000a        blockade. Perth: Government of Western Australia; revised 2010. http:\/\/www.kemh.health.wa.gov.au\/development\/manuals\/O&amp;G_guidelines\/sectionb\/2\/b2.10.2.1.pdf\u000a\u000a      The Association of Anaesthetists of Great Britain and Ireland\/\u000a        Obstetric Anaesthetists' Association. OAA\/AAGBI Guidelines for Obstetric\u000a        Anaesthetic Services. Revised edition 2005. AAGBI\/OAA; 2005. http:\/\/www.aagbi.org\/sites\/default\/files\/obstetric05.pdf\u000a\u000a      Nottingham University NHS Trust. Guidelines for the Practice of\u000a        Obstetric Anaesthesia, ninth revision. Nottingham: Nottingham University\u000a        Hospitals NHS Trust; January 2008. http:\/\/www.docstoc.com\/docs\/38608919\/Obstetric-guidelines---NEMSAnet\u000a\u000a      Brook P, Connell J, Pickering T (eds). Oxford Handbook of pain\u000a        management. First edition. Oxford; OUP; 2011. ISBN13: 9780199298143\u000a        ISBN10: 0199298149\u000a      MacArthur C, Wilson D, Herbison P, Lancashire R, Hagen S, Toozs-Hobson\u000a        P et al. Faecal incontinence persisting after childbirth: a 12 year\u000a        longitudinal study, BJOG2013; 120(2): 169-179. DOI:\u000a        10.1111\/1471-0528.12039 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23190303\u000a\u000a    \u000a    ","Title":"\u000a    Epidural analgesia: Reducing instrumental delivery and side-effects of\u000a        epidural analgesia during childbirth\u000a    ","UKLocation":[{"GeoNamesId":"2655603","Name":"Birmingham"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Epidural analgesia is the most effective pain relief during childbirth\u000a      and in the mid-1990s was used by more than 150,000 women in the UK alone\u000a      and substantially more in North America, Europe, Australia and New\u000a      Zealand. However, it is associated with increased rates of instrumental\u000a      vaginal delivery and other effects, which may be related to the dense\u000a      motor block produced by traditional high dose epidurals. Professor MacArthur\u000a      (Professor of Maternal and Child Epidemiology, University of Birmingham)\u000a      and colleagues considered that new low dose or \"mobile\" epidural\u000a      techniques that preserve motor function might reduce rates of obstetric\u000a      intervention.\u000a    Professor MacArthur with anaesthetists at Birmingham Women's NHS\u000a      Foundation Trust began studying the effects of epidurals in 1988 as part\u000a      of their Department of Health funded study of health problems following\u000a      childbirth. This observational study of almost 12,000 women linked women's\u000a      responses to a questionnaire to data from their obstetric case notes and\u000a      showed an association between increased reporting of backache and other\u000a      symptoms in those who had used epidurals for pain relief. Three papers\u000a      were published in BMJ between 1991 and 1993. Prompted by this work, a\u000a      group in Harvard also investigated effects of epidurals but failed to find\u000a      the same associations. Discussions between Professor MacArthur and\u000a      the Harvard team highlighted that they used a new low dose `mobile'\u000a      infusion (LDI) epidural in their centre because women liked mobility,\u000a      rather than the high dose epidurals formerly used. This led Professor MacArthur\u000a      to develop the COMET study. The Birmingham team applied to NHS R&amp;D for\u000a      funding and formed a collaboration with an obstetrician (Professor Andrew\u000a      Shennan) in London where a Combined Spinal Epidural (CSE) mobile technique\u000a      had been developed. Both groups were funded jointly by NHS R&amp;D to\u000a      undertake a randomised controlled trial to test the effects of mobile\u000a      techniques relative to traditional epidurals: the Comparative Obstetric\u000a      Mobile Epidural Trial (COMET, ISRCTN49349244) commenced 1997 and completed\u000a      2001 (http:\/\/www.controlled-trials.com\/ISRCTN49349244\/).\u000a    COMET was a three-arm, two-centre randomised controlled trial, which\u000a      compared the effects of two `mobile' low-dose epidural techniques (LDI and\u000a      CSE) with high-dose traditional epidural. Between February 1999 and April\u000a      2000, 1054 nulliparous women requesting epidural analgesia were randomly\u000a      assigned to traditional (n=353), LDI (n=350), or CSE (n=351) groups. The\u000a      primary short term outcome was mode of delivery (spontaneous vaginal\u000a      birth) and secondary outcomes included labour progress, efficacy of\u000a      procedure, effect on newborns and women's satisfaction and control. Data\u000a      were collected during labour and women were interviewed postnatally, then\u000a      completed a postal questionnaire12 months after birth, to assess long-term\u000a      symptoms.\u000a    The COMET trial demonstrated that both of the low-dose `mobile' epidural\u000a      techniques resulted in significantly fewer instrumental deliveries and\u000a      authors concluded that continued routine use of traditional epidurals\u000a      might not be justified [1]. There were no differences in pain relief\u000a      ratings and satisfaction with mobile techniques, whilst feelings of\u000a      control in labour were superior [1,2,3]. Follow-up at 12 months showed no\u000a      long-term disadvantages of using mobile techniques and significantly less\u000a      faecal and stress incontinence reported by the LDI group and less headache\u000a      by the CSE group, than the traditional epidural group [3,4]. The main\u000a      findings were published in the Lancet in 2001 [1] accompanied by a\u000a      commentary summarising the impact of the research in terms of avoidance of\u000a      large numbers of instrumental deliveries if mobile rather than traditional\u000a      techniques were to be used. Numerous subsequent papers have been published\u000a      in specialist journals [4,5,6,] and the main COMET study paper [1] has\u000a      been cited over 130 times.\u000a    "},{"CaseStudyId":"39367","Continent":[{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"3895114","Name":"Chile"},{"GeoNamesId":"2510769","Name":"Spain"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    The direct clinical impact this trial had on Bell's Palsy management in\u000a      UK General Practice was\u000a      measured by analysing trends in prescribing behaviour (with significance\u000a      confirmed by interrupted\u000a      times series regression analysis) between 2001 and 2012 [1]. This analysis\u000a      used 14,460 Bell's\u000a      Palsy cases identified from the Clinical Practice Research Datalink\u000a      database (5.25 million active\u000a      UK electronic medical records), and clearly demonstrated that the trial\u000a      was associated with a\u000a      significant increase in treatment with prednisolone and reduction in\u000a      combination treatment with\u000a      antivirals, the maximum relative increases and decreases being 70% and 41%\u000a      respectively. These\u000a      significant changes in clinical behaviour began very soon after\u000a      publication of the clinical trial in\u000a      October 2007 and were in line with trial recommendations. The use of more\u000a      effective early therapy\u000a      was associated with a reduction in referrals to hospital by 36% (from 9.2%\u000a      to 5.9% of incident\u000a      cases).\u000a    The wider impact of the study is on management of Bell's Palsy with\u000a      clinical guideline\u000a      recommendations to avoid unnecessary medication, and the establishment of\u000a      a strong clinical\u000a      research network able to undertake methodologically rigorous work in\u000a      Primary Care in Scotland.\u000a    As soon as the results of the main study were published in the New\u000a        England Journal of Medicine\u000a      there was considerable press interest internationally involving print,\u000a      radio and television (BBC).\u000a      This paper has been cited by many other groups studying Bell's Palsy and\u000a      related conditions with\u000a      commentaries in major journals such as the Lancet. To date (16.10.13), the\u000a      paper has been cited\u000a      270 times.\u000a    As a result of the findings, the Cochrane Collaboration recognized the\u000a      need to update the previous\u000a      reviews of antivirals and steroids in Bell's Palsy. Our group was given\u000a      responsibility for keeping the\u000a      former up to date [2] and collaborates with colleagues in Chile on the\u000a      latter [3]. This is being\u000a      updated again in 2013 and an individual patient meta-analysis is being\u000a      prepared studying the\u000a      experience of the most severely affected patients. This will involve a\u000a      reanalysis of patients in this\u000a      study and severely affected cases in Scandinavia and South Korea, and may\u000a      lead to further trials\u000a      of candidate interventions for severe disease. We have also been\u000a      commissioned by the Cochrane\u000a      Neuromuscular Review Group at King's College London to prepare an overview\u000a      of all interventions\u000a      in Bell's Palsy. The Royal College of General Practitioners, Academy of\u000a      Medical Royal Colleges\u000a      and Sense About Science used this study in Evidence Based Medicine\u000a        Matters as one of 15 case\u000a      studies of the \"game changers in evidence based medicine\", highlighting it\u000a      as an example of an\u000a      evidence-based approach to general practice [4].\u000a    We disseminated the results of our study to patients and clinicians in\u000a      Scotland who had been\u000a      directly involved and sent briefing notes to policy makers in the UK. We\u000a      also presented the\u000a      findings at a number of primary care and specialist conferences and were\u000a      invited to present the\u000a      results in prestigious lectures in the UK and overseas. Professional\u000a      recognition of the quality and\u000a      impact of the research included awards from the RCGP (UK) Medical\u000a      Association\u000a      (http:\/\/thebmjawards.bmj.com\/previous-winners\/2009\/research-paper-of-the-year)\u000a      for the best\u000a      research published in the year of award [4].\u000a    The findings have been incorporated into NHS and international guidelines\u000a      (e.g. in India, Spain,\u000a      Ireland) [5-8] providing advice to clinicians and patients in a range of\u000a      formats (BMJ Point of Care\u000a      series, BMJ Best Practice Series, BMJ Clinical Evidence, RCP Map of\u000a      Medicine Project) and the\u000a      study has been selected by the National Institute for Health Research as\u000a      an exemplar project.\u000a    This clinical trial has contributed to the reputation of the NHS-funded\u000a      Scottish Primary Care\u000a      Research Network and Tayside Academic Health Science Collaboration. These\u000a      facilitate\u000a      collaboration between front-line clinicians and academics, which is often\u000a      difficult; in fact half of all\u000a      clinical trials fail to recruit adequate numbers of study subjects [9].\u000a    In summary, we led a complex and collaborative randomised controlled\u000a      trial that enrolled acute\u000a      cases of Bell's Palsy through a nationwide research network, providing and\u000a      disseminating clear\u000a      results, both to clinicians and the general public [10]. This project had\u000a      a beneficial impact on the\u000a      evidence base for primary care internationally. It has led directly to\u000a      cost effective changes in\u000a      prescribing practice which produce clear patient benefit.\u000a    ","ImpactSummary":"\u000a    This multicentre research study, led by Sullivan (University of\u000a      Dundee), demonstrated that in\u000a      patients with Bell's Palsy (where no best treatment had been defined),\u000a      early treatment with\u000a      prednisolone significantly improved the chances of complete recovery at\u000a      three and nine months.\u000a      Furthermore, this complex randomised controlled trial, recruiting 551\u000a      incident cases from primary\u000a      care, demonstrated no evidence of benefit from aciclovir alone, or in\u000a      combination with\u000a      prednisolone. The findings led to revisions in the Cochrane reviews on the\u000a      subject and have been\u000a      incorporated into national and international guidelines. Substantial\u000a      changes in prescribing practice\u000a      for Bell's Palsy and reduced hospital referrals in the UK have been\u000a      demonstrated as a direct result\u000a      of publication of this study.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Dundee\u000a    ","Institutions":[{"AlternativeName":"Dundee (University of)","InstitutionName":"University of Dundee","PeerGroup":"B","Region":"Scotland","UKPRN":10007852}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000ai. Sullivan FM, Swan IRC, Donnan PT, Morrison JMM, Smith\u000a        BH, McKinstry B, Davenport\u000a      RJ, Vale LD, Clarkson JE, Hammersley V, Hayavi S, Daly FD (2007)\u000a      Early treatment with\u000a      prednisolone or acyclovir in Bell's palsy. N. Engl. J. Med. 357,\u000a      1598-607 (DOI:\u000a      10.1056\/NEJMoa072006).\u000a    \u000a\u000aii. Salinas RA, Alvarez G, Daly F, Ferreira J (2004)\u000a      Corticosteroids for Bell's palsy (idiopathic\u000a      facial paralysis). Cochrane Database of Systematic Reviews 2004\u000a      Issue 2:CD001942.\u000a      (DOI: 10.1002\/14651858.CD001942.pub2).\u000a    \u000a\u000aiii. Allen D, Dunn L (2004) Aciclovir or valaciclovir for Bell's palsy\u000a      (idiopathic facial paralysis).\u000a      Cochrane Database of Systematic Reviews 2004 Issue 1:CD001869.\u000a      (DOI:\u000a      10.1002\/14651858.CD001869.pub2).\u000a    \u000a\u000aiv. Sullivan F, Swan I, Donnan P, Morrison J, Smith B,\u000a      McKinstry B, Davenport R, Vale L,\u000a      Clarkson J, Hern&#225;ndez R, Stewart K, Hammersley V, Hayavi S, McAteer A,\u000a      Gray D, Daly F\u000a      (2009) A randomised controlled trial of the use of aciclovir and\/or\u000a      prednisolone for the early\u000a      treatment of Bell's palsy: the BELLS study. Health Technol. Assess.\u000a      13 No.47 (DOI:\u000a      10.3310\/hta13470).\u000a    \u000a\u000av. Hern&#225;ndez R, Sullivan F, Donnan P, Swan I, Vale L for\u000a      the BELLS Trial Group (2009)\u000a      Economic evaluation of early administration of prednisolone and\/or\u000a      aciclovir for the\u000a      treatment of Bell's palsy. Fam. Pract. 26,137-44 (DOI:\u000a      10.1093\/fampra\/cmn107).\u000a    \u000aFunding\u000a    &#8226; Sullivan, F., Morrison, J., Swan, I., Cairns, J., Donnan, P.,\u000a      Smith, B., McKinstry, B. and\u000a      Davenport, R: A national multicentre, factorial trial of the early\u000a      administration of steroids\u000a      and\/or antivirals for Bell's Palsy Health Technology Assessment Board;\u000a      (2003-2007)\u000a      &#163;658,347.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000a    \u000a      Morales D, Donnan PT, Daly F, Staa TV, Sullivan FM\u000a        (2013) Impact of clinical trial\u000a        findings on Bell's palsy management in general practice in the UK\u000a        2001-2012: interrupted\u000a        time series regression analysis. BMJ Open 16, 3:e003121\u000a        (DOI:10.1136\/bmjopen-2013-003121).\u000a      Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan\u000a        F (2009) Antiviral treatment for\u000a        Bell's palsy (idiopathic facial paralysis). Cochrane Database of\u000a          Systematic Reviews 2009\u000a        Issue 4: CD001869 (DOI: 10.1002\/14651858.CD001869.pub4).\u000a      Salinas RA, Alvarez G, Daly F, Ferreira J (2010)\u000a        Corticosteroids for Bell's palsy (idiopathic\u000a        facial paralysis). Cochrane Database of Systematic Reviews 2010\u000a        Issue 3:CD001942.\u000a        (DOI: 10.1002\/14651858.CD001942.pub4).\u000a      Sense About Science, Academy of Medical Royal Colleges. Evidence Based\u000a        Medicine\u000a        Matters. London: Sense About Science, April 2013.\u000a        http:\/\/www.aomrc.org.uk\/about-us\/news\/item\/evidence-based-medicine.html;\u000a        http:\/\/www.senseaboutscience.org\/data\/files\/resources\/124\/Evidence-Based-Medicine-Matters.pdf.\u000a      \u000ahttp:\/\/www.patient.co.uk\/doctor\/facial-nerve-palsy;\u000a        http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3152161\/;\u000a        http:\/\/emedicine.medscape.com\/article\/1146903-treatment;\u000a        http:\/\/www.eguidelines.co.uk\/eguidelinesmain\/gip\/vol_10\/may_07\/jaunoo_bells_may07.php#.UkmXvYYqiSo.\u000a      National Institute for Health and Care Excellence (NICE):\u000a        http:\/\/cks.nice.org.uk\/bells-palsy#!scenariobasis:1\u000a        http:\/\/cks.nice.org.uk\/bells-palsy#!references;\u000a        NHS Choices (for patients):\u000a        http:\/\/www.nhs.uk\/Conditions\/Bells-palsy\/Pages\/Treatment.aspx.\u000a      GPNotebook: http:\/\/www.gpnotebook.co.uk\/simplepage.cfm?ID=x20101006114225162451.\u000a      5Minute Clinical Consult: http:\/\/www.unboundmedicine.com\/5minute\/ub\/view\/5-Minute-Clinical-Consult\/116074\/6\/bell_palsy.\u000a      Treweek S, Mitchell E, Pitkethly M, Cook J, Kjeldstr&#248;m M, Taskila T,\u000a        Johansen M, Sullivan\u000a        F, Wilson S, Jackson C, Jones R (2010) Strategies to improve recruitment\u000a        to randomised\u000a        controlled trials. Cochrane Database of Systematic Reviews 2010\u000a        Issue 1:MR000013.\u000a        (DOI: 10.1002\/14651858.MR000013.pub4) (Colloquium presentation).\u000a      Further examples of lay press reporting impact of the study:\u000a        http:\/\/www.facialpalsy.org.uk\/about-us\/media-centre\/press-releases\/150813-facing-facts-44-of-bells-palsy-patients-do-\/440;\u000a        http:\/\/medicalxpress.com\/news\/2013-07-bell-palsy-treatment.html\u000a\u000a    \u000a    ","Title":"\u000a    Changing clinical practice in Bell's Palsy: the impact of a clinical\u000a        trial\u000a        highlighting the impact of evidence for primary care\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The annual incidence of Bell's Palsy is approximately 38\/100,000; one\u000a      person in sixty will develop\u000a      this condition during their lifetime. Although many cases resolve\u000a      spontaneously around 25% have\u000a      a poor outcome with persistent facial nerve malfunction and deformity. Its\u000a      aetiology is unknown but\u000a      the dominant hypothesis before our study was that viral reactivation\u000a      caused oedematous swelling\u000a      of the facial nerve within the temporal bone. This was assumed to cause\u000a      distal denervation of\u000a      motor (and sometimes sensory) fibres. Prior to publication of our Scottish\u000a      Bell's Palsy Study paper\u000a      in the New England Journal of Medicine [i] in 2007, two Cochrane\u000a      reviews, published in 2002 and\u000a      updated in 2004 [ii, iii], found an insufficiency of high quality evidence\u000a      and concluded that more\u000a      data were needed to determine whether early treatment with steroids and\/or\u000a      antivirals for Bell's\u000a      Palsy was effective in reducing poor outcomes. In the face of this\u000a      uncertainty increasing amounts\u000a      of expensive antiviral drugs were being prescribed.\u000a    We undertook pilot work in the emergent Primary Care Research Networks of\u000a      Tayside and the\u000a      West of Scotland to scope the feasibility of a study to examine the effect\u000a      of different treatments on\u000a      outcomes in Bell's Palsy.\u000a    The Scottish Bell's Palsy study was led by the University of Dundee; the\u000a      lead researcher was\u000a      Sullivan and other key researchers in Dundee were Smith\u000a      (local Principal Investigator in\u000a      Grampian), Donnan (Study Statistician), Clarkson (UoA3,\u000a      co-ordinated dental participation) and\u000a      Daly (Trial Manager)). It was a collaboration built around the\u000a      Scottish School of Primary Care, with\u000a      other University partners including Swan and Morrison (Glasgow), McKinstry\u000a      and Davenport\u000a      (Edinburgh) and Vale (Aberdeen).\u000a    The key features of the underpinning science developed through this work\u000a      were that:\u000a    a) There was genuine uncertainty about how to manage this acute,\u000a      distressing condition;\u000a    b) It was a national, acute, primary care trial involving GPs in half of\u000a      all practices in Scotland;\u000a    c) It had a primary outcome measure that was highly relevant to patients,\u000a      clinicians and\u000a      policymakers: complete recovery at three and nine months;\u000a    d) It recorded and reported adverse events;\u000a    e) It used an intention-to-treat analysis;\u000a    f) The results were presented in a variety of ways to aid understanding.\u000a      In addition to odds\u000a      ratios, we also provided Absolute Risk Reduction and Numbers Needed to\u000a      Treat and an\u000a      economic analysis;\u000a    g) The conclusion was clear: early treatment with prednisolone\u000a      significantly increased\u000a      chances of complete recovery at three and nine months. In contrast,\u000a      aciclovir had little or\u000a      no effect [iv];\u000a    h) Implementing the result is cost-effective and does not require the\u000a      health service to be\u000a      reorganised; a GP simply prescribes a single, relatively inexpensive drug\u000a      instead of a\u000a      relatively expensive drug or a combination [v].\u000a    We therefore rejected the hypothesis that the aetiology of Bell's Palsy\u000a      is reactivation of the Herpes\u000a      Simplex Virus affecting the facial nerve. The specific contribution of\u000a      this study is that prednisolone\u000a      (50mg\/day for 10 days) significantly improves outcomes (83.0% recovery to\u000a      a House Brackmann\u000a      Grade of I at 3 months for prednisolone compared with 63.6% for no\u000a      prednisolone) and antivirals\u000a      confer no additional advantage. The Numbers Needed to Treat for treatment\u000a      with oral\u000a      corticosteroids were six (95% Confidence Interval 4 to 9) at three months\u000a      and eight (95% CI 6 to\u000a      14) at nine months.\u000a    "},{"CaseStudyId":"40165","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000a    Prostate cancer screening is one of the most controversial healthcare\u000a      topics globally. Prostate cancer kills over 11,000 men per annum in the\u000a      UK. Many prostate cancers can be identified when potentially curable\u000a      following screening with a PSA blood test and prostate biopsy, but it is\u000a      not possible to identify which tumours will become aggressive or\u000a      life-threatening (the vast majority will not). Screening leads to large\u000a      numbers of men being diagnosed and suffering harms related to the\u000a      diagnosis and treatment of prostate cancer in the context of small and\u000a      uncertain benefits &#8212; hence the current UK policy not to recommend\u000a      screening. Our research has provided the evidence-base for this policy and\u000a      has had the following specific impacts:\u000a    The establishment of UK policy and origin of the impact\u000a    UK policy was established in a letter from the DH to all UK health\u000a      authorities and clinicians in 1997, stating that: \"Population screening\u000a      for prostate cancer, including the use of prostate specific antigen (PSA)\u000a      as a screening test, should not be provided by the NHS or offered to the\u000a      public until there is new evidence of an effective screening technology\u000a      for prostate cancer\".[a] This was based directly on two cited systematic\u000a      literature reviews, one led from UoB.[1] The policy has remained unchanged\u000a      throughout the REF impact reporting period, based on this original policy\u000a      statement.\u000a    Implementing UK policy\u000a    A National Screening Committee (NSC) Scientific Reference Group\u000a      (including UoB Donovan and Lane as members) launched the Prostate Cancer\u000a      Risk Management Programme (PCRMP) in 2002. PCRMP issued on-line and paper\u000a      documents containing information about PSA testing, prostate cancer\u000a      diagnosis, and treatment, based on evidence from the UoB systematic\u000a      review[1] to enable patients to make informed decisions about\u000a      screening.[b] PCRMP documents were revised in 2009[c] with UoB Donovan\u000a      given first acknowledgement (p.2) for contributing evidence from the\u000a      review[1] and ProtecT feasibility study.[2] The PCRMP remains the primary\u000a      source of information for UK GPs and men.\u000a    Low levels of UK PSA-testing have been corroborated by independent\u000a      research in 2004 showing the rate of PSA-testing in primary care of 6% of\u000a      eligible men;[d] UoB research confirmed this rate (6.2%) in 2008.[8]\u000a    Evaluating the benefits and harms of screening\u000a    UK policy has led to much lower levels of incidence and treatment of\u000a      localised prostate cancer compared with countries where PSA testing has\u000a      been widespread since the 1980s: for example in the USA (as shown by our\u000a      research[7]), and Canada, Australasia, Northern and Western Europe.[e]\u000a      Evidence for a potential prostate cancer-specific mortality benefit from\u000a      screening comes from a relatively robust European RCT,[f] published\u000a      alongside a USA RCT showing no benefit from screening.[g] Our research has\u000a      provided evidence about the harms of screening. A cohort study of men\u000a      undergoing prostate biopsy in the ProtecT study showed that 1.3% required\u000a      hospital admission and 10.4% consultation with a doctor because of\u000a      post-biopsy symptoms including pain, fever, and blood in urine, faeces and\u000a      ejaculate.[4] Among the two-thirds of men who received a negative or\u000a      inconclusive biopsy result, around 20% reported high distress persisting\u000a      up to 12 weeks.[5] Concerns about the harms caused by prostate cancer\u000a      diagnosis and treatment in the context of uncertain benefit, and\u000a      increasing realisation that high levels of PSA-testing did not reflect\u000a      clinical need, led to a policy review in the USA in 2011. The review\u000a      focussed on the harms and uncertain benefits[h] and so in 2011, USA policy\u000a      changed explicitly not to recommend prostate cancer screening &#8212; 14 years\u000a      after the 1997 UK policy decision.\u000a    Formal review of UK policy in 2010\u000a    The UK NSC formally reviewed policy for prostate cancer screening in 2010\u000a      using evidence from an independent option appraisal analysis based on\u000a      ProtecT trial data (acknowledged, p.xi).[i] The appraisal analysis\u000a      estimated rates of diagnosis, potential benefits and harms of treatment,\u000a      as well as impact on survival and costs to the UK economy of introducing\u000a      prostate cancer screening at age 50 years, annually, or every two or four\u000a      years, using statistical modelling. The harms of treatment always\u000a      outweighed any possible benefit of screening in each potential\u000a      scenario.[i] The clinical costs alone, without administrative costs, were\u000a      estimated to be &#163;0.6 to &#163;1.7 billion per year.[i] The 2010 review\u000a      concluded that UK policy should remain as established in 1997, and\u000a      re-iterated that any change needed to await evidence from this research\u000a      team's ProtecT[3] and CAP[6] RCTs.[j]\u000a    Health Technology Assessment in the UK, review 2013\u000a    This review, written by an independent team, specifically identified the\u000a      ProtecT study as \"The outstanding example of 143 projects for screening\u000a      and diagnostics funded by the HTA programme,\" and noted ProtecT had\u000a      \"affected clinical practice ... by allowing the UK to reaffirm its policy\u000a      of no routine screening\" and through its qualitative research that\u000a      \"pioneered ways to involve patients\" in recruitment, and research on the\u000a      psychosocial effect of screening.[k, page 1280]\u000a    In summary, UoB-led research established UK policy in 1997, and UoB-led\u000a      and collaborative research has supported policy implementation since then,\u000a      including providing evidence for the formal confirmation of UK policy in\u000a      2010. UK policy, underpinned by this research, has ensured that knowledge\u000a      about prostate cancer screening has increased, very many men have avoided\u000a      known harms of testing, and the UK economy has saved billions of &#163;s every\u000a      year.\u000a    ","ImpactSummary":"\u000a    Research at the University of Bristol (UoB) led to the Department of\u000a      Health (DH) decision in 1997 that screening for prostate cancer would not\u000a      be introduced in the UK until there was evidence that benefits outweighed\u000a      harms. UoB-led and collaborative research subsequently provided evidence\u000a      to support informed decision-making in the NHS. A formal review by the DH\u000a      in 2010 endorsed the policy and confirmed that any change would be based\u000a      on evidence from the team's randomised trials. This research has ensured\u000a      UK men have avoided known harms of prostate cancer screening in the\u000a      context of uncertain benefits, and saved the UK economy &#163; billions.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Bristol\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"A         ","PlaceName":[],"References":"\u000a    [1] Donovan JL (PI), Faulkner A, Coast J et al. Prostate cancer: a\u000a      systematic review. NHS R&amp;D HTA Programme. 1\/1\/95 - 31\/12\/95. &#163;52,052.\u000a      (Peer-reviewed research grant.)\u000a    \u000aSelley S, Donovan JL, Faulkner A et al. Diagnosis, management and\u000a      screening of early localised prostate cancer. Health Technology\u000a        Assessment 1997; 1 (2). Doi: 10.3310\/hta1020\u000a    \u000a[2] Donovan JL (PI), Peters TJ, Hamdy FC et al. The feasibility of\u000a      conducting a multicentre randomised controlled trial of treatment for\u000a      localised prostate cancer: early detection, recruitment strategies and a\u000a      pilot (ProtecT) trial. NHS R&amp;D HTA Programme. 1\/5\/99 &#8212; 30\/4\/01. &#163;1.03\u000a      million. (Peer-reviewed research grant.)\u000a    \u000aDonovan JL, Hamdy FC, Neal DE et al. Prostate Testing for Cancer and\u000a      Treatment (ProtecT) feasibility study. Health Technol Assess 2003;\u000a      7(14) pp.1-42. DOI : 10.3310\/hta7140\u000a        http:\/\/www.hta.nhs.uk\/fullmono\/mon714.pdf\u000a    \u000a[3] Donovan JL, Hamdy FC, Neal DE (PIs) et al. The ProtecT study: a\u000a      multi-centre RCT of treatments for localised prostate cancer, NHS\/NIHR HTA\u000a      Programme:1\/5\/01- 31\/5\/08 (&#163;20 million); 1\/6\/08-31\/12\/13 (&#163;14 million);\u000a      1\/1\/2014-31\/12\/2016 (&#163;5.4 million). (Peer-reviewed research grant.)\u000a    \u000a[4] Rosario DJ, Lane AJ, Metcalfe C et al. Short term outcomes of\u000a      prostate biopsy in men tested for cancer by prostate specific antigen:\u000a      prospective evaluation within ProtecT study. BMJ 2012;344:d7894. http:\/\/dx.doi.org\/10.1136\/bmj.d7894.\u000a      (Included in REF2.)\u000a    \u000a\u000a[5] Wade J, Rosario DJ et al, Donovan JL. Psychological impact of\u000a      prostate biopsy: physical symptoms, anxiety, and depression. Journal of\u000a      Clinical Oncology, 2013: published ahead of print, 21st October\u000a      2013 as 10.1200\/JCO.2012.45.4801. (Included in REF2.)\u000a    \u000a[6] Martin RM, Donovan JL, Hamdy FC, Neal DE (PIs) et al. Evaluating\u000a      population-based screening for localised prostate cancer in the UK: an\u000a      extension to ProtecT &#8212; the CAP trial. Cancer Research-UK\/DoH.\u000a      1\/3\/02-31\/12\/06 (&#163;1.19 million); 1\/1\/07-31\/12\/09 (&#163;931,232);\u000a      1\/1\/10-31\/12\/12 (&#163;1.3 million); 1\/1\/13-31\/12\/16 (&#163;1.2 million).\u000a      (Peer-reviewed research grant.)\u000a    \u000a[7] Collin SM, Martin RM, Metcalfe C et al. Prostate-cancer mortality in\u000a      the USA and UK in 1975-2004: an ecological study. Lancet Oncology\u000a      2008; 9: 445-52. Doi: 10.1016\/S1470-2045(08)70104-9. Listed in REF2.\u000a    \u000a\u000a[8] Williams\u000a        N, Hughes\u000a        LJ, Turner\u000a        EL et al. Prostate-specific antigen testing rates remain low in UK\u000a      general practice: a cross-sectional study in six English cities. BJU Int.\u000a      2011, 108(9):1402-8. Doi: 10.1111\/j.1464-410X.2011.10163.x.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"12","Subject":"Oncology and Carcinogenesis"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    [a] Letter EL(97)12 from Graham Winyard, DoH Medical Director (Room 3N12,\u000a      Quarry House, Leeds LS2 7UE), June, 1997, to Health Authority and NHS\u000a      Trust Chief Executives and all UK health practitioners. It stated that\u000a      \"systematic reviews commissioned by the NHS R&amp;D HTA Programme have\u000a      concluded that current evidence does not support a national screening\u000a      programme for prostate cancer in the United Kingdom. Current screening\u000a      technologies (including the PSA test) have a limited accuracy that could\u000a      lead to a positive result for those without the disease. Follow up\u000a      procedures could thus cause unnecessary harm to healthy individuals.\" One\u000a      of the cited reviews was UoB[1].\u000a    [b] UK Prostate Cancer Risk Management Programme (PCRMP). This webpage\u000a      links to PCRMP documents providing information for GPs and patients to\u000a      make informed decisions. http:\/\/www.cancerscreening.nhs.uk\/prostate\/about-pcrm.html\u000a      cites the UoB systematic review[1] in paragraph eight, after bullet\u000a      points.\u000a    [c] http:\/\/www.cancerscreening.nhs.uk\/prostate\/prostate-booklet-text.pdf\u000a      is the 2009 revised booklet with UoB Donovan given first acknowledgement\u000a      on p.2 for contributing evidence from the UoB review.[1]\u000a    [d] Melia J, Moss S, Johns L. Rates of PSA-testing in general practice in\u000a      England and Wales. BJU International, 2004: 94: 51-56. Doi:\u000a      10.1111\/j.1464-4096.2004.04832.x. Paper from independent group\u000a      corroborating policy implementation leading to low rates of PSA testing in\u000a      the UK.\u000a    [e] Center MM, Jemal A, Lortet-Tieulent et al. International variation in\u000a      prostate cancer incidence and mortality rates. European Urology. 2012, 6:\u000a      1079-1092. Doi: 10.1016\/j.eururo.2012.02.054. Paper from independent group\u000a      corroborating higher levels of diagnosis and treatment of prostate cancer\u000a      in the absence of UK-like policy.\u000a    [f] Schr&#337;der FH, Hugosson J, Roobol MJ et al. Screening and prostate\u000a      cancer mortality in a randomized European study. NEJM 2009, 360 (13):\u000a      1320-1328. Doi: 10.1056\/NEJMoa0810084. Paper from independent group\u000a      indicating small mortality benefit from screening with considerable\u000a      over-diagnosis and over-treatment.\u000a    [g] Andriole GL, Crawford ED, Grubb RL et al. Mortality results from a\u000a      randomized prostate-cancer screening trial. NEJM 2009; 360 (13): 1310-19.\u000a      Doi: 10.1056\/NEJMoa0810696. Paper from independent group showing no\u000a      mortality benefit from screening and considerable harms.\u000a    [h] Chou R, Croswell JM et al. Screening\u000a        for prostate cancer: a review of the evidence for the U.S.Preventive\u000a        Services Task Force. Ann Intern Med. 2011. 155(11):762-71.\u000a      Doi: 10.7326\/0003-4819-155-11-201112060-00375. Most recent systematic\u000a      review to inform USA policy review decision.\u000a    [i] Chilcott J, Hummel S, Mildred M. Report to the UK National Screening\u000a      Committee, May 2010 Option\u000a        appraisal: screening for prostate cancer [ScHARR] (PDF document, 1.11MB,\u000a        02\/08\/10). Report from the independent option appraisal analysis\u000a      commissioned by the NSC from the University of Sheffield for the policy\u000a      review. Potential benefits and harms of screening, and costs to the\u000a      economy were estimated using ProtecT data (directly acknowledged on\u000a      p.xi.).\u000a    [j] This web-link: http:\/\/www.screening.nhs.uk\/prostatecancer\u000a      confirms the 2010 National Screening Committee review decision that UK\u000a      policy should remain as established in 1997, and directly cites documents\u000a      produced by PCRMP ([b] above), UoB systematic review[1] and ProtecT study\u000a      data.\u000a    [k] Raftery J, Powell J. Health Technology Assessment in the UK. Lancet\u000a      2013; 38:1278-85; doi: 10.1016\/S0140-6736(13)61724-9. Report from an\u000a      independent group specifically citing the impact of ProtecT study on\u000a      prostate cancer screening policy and identifying other health impacts,\u000a      p.1280.\u000a    ","Title":"\u000a    Avoiding harm and evaluating benefit: establishing and implementing an\u000a      evidence-based policy for prostate cancer screening in the UK\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The research was initiated at UoB with a comprehensive systematic review\u000a      of prostate cancer diagnosis, treatment and screening literature, funded\u000a      by NHS R&amp;D and led by Donovan (UoB).[1] Published in 1997, the review\u000a      concluded \"current evidence does not support a national screening\u000a      programme for prostate cancer in the UK\".[1] A major research programme\u000a      was then designed and undertaken by UoB researchers in collaboration with\u000a      Hamdy (Oxford) and Neal (Cambridge) to provide the required evidence,\u000a      including:\u000a    \u000a      The ProtecT (Prostate testing for cancer and Treatment) feasibility\u000a        study led by Donovan (UoB) investigated barriers inhibiting an RCT\u000a        (randomised controlled trial) of treatment.[2] Over 8,500 men aged 50-69\u000a        years were recruited from general practices, and 224 men diagnosed with\u000a        localised prostate cancer participated in the pilot RCT of\u000a        treatments.[2] Integrated qualitative research supported clinicians and\u000a        men in accepting randomisation between surgery, radiotherapy and `active\u000a        monitoring' (a management option developed with patients consisting of\u000a        regular review and avoiding radical treatment).[2]\u000a      The main ProtecT RCT (joint Principal Investigators (PIs): Donovan\u000a        (UoB), Hamdy and Neal) was launched in 2001 to evaluate the comparative\u000a        effectiveness of radical surgery, radical conformal radiotherapy and\u000a        active monitoring for men with localised prostate cancer.[3] Recruitment\u000a        of 111,000 men with a PSA (prostate specific antigen) blood test was\u000a        completed in 2009, over 8,500 received biopsies, and 1,650 with prostate\u000a        cancer were randomised between the treatment arms. The primary outcome\u000a        (prostate cancer mortality) will be analysed in 2015 (with 10 years'\u000a        median follow up). A nested cohort study of 1,100 men undergoing\u000a        prostate biopsy investigated side-effects of prostate biopsy, including\u000a        symptoms, health-care use,[4] and psychological impact.[5].\u000a      The CAP (Cluster RCT of testing for Prostate Cancer) (joint PIs:\u000a        Martin and Donovan (UoB), Hamdy, Neal) randomised 573 general practices\u000a        to enable a comparison between PSA testing and treatment in ProtecT\u000a        (screening) and usual NHS care (control) in 415,000 UK men.[6] An\u000a        ecological study confirmed a much lower incidence of prostate cancer in\u000a        the UK compared with the USA,[7] and a cohort study confirmed low rates\u000a        of PSA testing in UK primary care[8] &#8212; reflecting much higher rates of\u000a        screening in the USA compared with the UK.\u000a    \u000a    The research programme began by exposing the lack of evidence for\u000a      prostate cancer screening,[1] and then carried out a study to investigate\u000a      the feasibility of mounting an RCT to provide robust evidence.[2] The\u000a      success of the feasibility study,[2] led to the launch of the ProtecT RCT\u000a      to evaluate the effectiveness of treatment[3] and the CAP RCT to evaluate\u000a      the population impact of screening.[6] Studies embedded in these RCTs have\u000a      produced policy-relevant evidence about the impacts on men of undergoing\u000a      prostate biopsy,[4,5] and levels of PSA testing and cancer diagnosis\u000a      compared with the USA,[7] and in UK primary care.[8]\u000a    Research team (positions held at UoB or dates of leaving; and\u000a      researchers outside UoB)\u000a    Principal investigators: at UoB &#8212; Donovan (Professor), Martin\u000a      (Professor); outside UoB &#8212; Hamdy (Professor, Oxford), Neal (Professor,\u000a      Cambridge).\u000a    Key researchers at UoB: Collin (Research Fellow &#8212; RF), Metcalfe (Reader),\u000a      Turner (Research Associate &#8212; RA), Lane (Senior RF), Peters (Professor),\u000a      Wade (RA); outside UoB: Williams (RA Sheffield), Rosario (CSL Sheffield),\u000a      Hughes (RA Cambridge).\u000a    Left UoB: Selley (RA, 1998), Faulkner (RF, 1999), Coast (Reader, 2005).\u000a    "},{"CaseStudyId":"40166","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2186224","Name":"New Zealand"},{"GeoNamesId":"2921044","Name":"Germany"}],"Funders":[],"ImpactDetails":"\u000d\u000a    Implementation in the UK of SIDS risk reduction programmes based on UoB\u000d\u000a      research findings was followed by a 67% fall in SIDS rates by 1992; the\u000d\u000a      number of SIDS deaths in England and Wales fell from 1597 in 1988 (2.3\u000d\u000a      deaths per 1000 live births) to 531 in 1992 (0.77 per 1000 live births).\u000d\u000a      As the Figure below shows, the number of deaths fell by a further 54% to\u000d\u000a      244 by 2011 (0.34 per 1000 live births), the last year for which national\u000d\u000a      data is available.\u000d\u000a    \u000d\u000aPublication dates (number of studies): &#8216;CESDI&#8217; study - 1995(1), 1996(2), 1999(3), 2000(3), 2001(1), 2002(2), 2003(2), 2004(2), 2006(3) and 2007(1). &#8216;SWISS&#8217; study - 2009(1) and 2010(1).\u000d\u000a\u000d\u000a    This further fall was not due to any change in prone positioning in\u000d\u000a      England but concomitant with changes in other identified risk factors (see\u000d\u000a      Table in Section 2).\u000d\u000a    If death rates had remained the same as 1992 over 10,000 infants would\u000d\u000a      have died in England and Wales between 1993 and 2011 rather than the 6434\u000d\u000a      SIDS deaths that did occur. Over 2,100 would have died from 2008 to 2011\u000d\u000a      rather than the 1075 deaths that did occur. The persistent year on year\u000d\u000a      fall in SIDS rates over the last two decades has been instrumental in the\u000d\u000a      halving of the post-neonatal infant mortality rate in England and Wales\u000d\u000a      over the same time period (from 2.2 deaths to 1.2 deaths per 1000 live\u000d\u000a      births).\u000d\u000a    At every stage of this process the UoB researchers have been closely\u000d\u000a      involved: generating the findings; developing the risk-reduction messages;\u000d\u000a      changing statutory law in 2008 on how child deaths are investigated (see\u000d\u000a      below); and collaborating with national and international organisations to\u000d\u000a      ensure families are given accurate information to care for their infants\u000d\u000a      in ways that lead to the lowest possible risk of SIDS. In the last 5 years\u000d\u000a      they have been particularly involved in the translational work of getting\u000d\u000a      their evidence-based findings implemented into public health policy.\u000d\u000a    In UK [a] and Australian [b] parent information leaflets, every\u000d\u000a      recommendation to reduce the risk of SIDS is based partly or fully on the\u000d\u000a      results of the UoB studies. Collaborative work with other groups in\u000d\u000a      Germany, New Zealand, and Scandinavia has led to the development of\u000d\u000a      standardised protocols for data collection in the investigation of\u000d\u000a      unexpected infant deaths, which in turn have allowed more rapid\u000d\u000a      identification and evaluation of significant changes in parenting\u000d\u000a      practices and their effects.\u000d\u000a    UoB studies on infant thermal balance have produced charts of optimal\u000d\u000a      thermal conditions adopted by both manufacturers and parents in many\u000d\u000a      countries, and sequential studies show a clear reduction in covering\u000d\u000a      (infant clothes and bedding combined) from an average of 8 tog (unit of\u000d\u000a      thermal resistance) 20 years ago to just 2.4 tog more recently.[4 &#8212; page\u000d\u000a      8]\u000d\u000a    Fleming and Blair recognise that findings from their studies need to fit\u000d\u000a      with current evidence of infant care practices outside the field of SIDS\u000d\u000a      so that consistent public health messages can be given to parents and\u000d\u000a      health professionals. They have worked closely in the last five years with\u000d\u000a      UNICEF UK [c, d], who are currently promoting breastfeeding in Baby\u000d\u000a      Friendly Hospitals, to produce a leaflet `Caring for your baby at night'\u000d\u000a      which encourages breastfeeding, acknowledges some parents may want to\u000d\u000a      bed-share but outlines the circumstances in which bed-sharing may be\u000d\u000a      unsafe. An evidence-based guideline for health professionals [e, f]\u000d\u000a      accompanies the leaflet (lead author Blair). The leaflets and guidelines,\u000d\u000a      printed in January 2012, have proved popular &#8212; over 210,000 have so far\u000d\u000a      been distributed, mainly to NHS hospitals, trusts and health visiting\u000d\u000a      teams. Blair is a regular invited speaker at health care professional\u000d\u000a      conferences and seminars (see a selection of UK and International lectures\u000d\u000a      since 2008 [g, h, i]) to promote the UoB-based findings.\u000d\u000a    The UoB approach to the investigation of unexpected infant deaths and the\u000d\u000a      care of families was adopted by the Kennedy Committee which was set up by\u000d\u000a      the Royal College of Pathologists and Royal College of Paediatrics and\u000d\u000a      Child Health to improve the quality of such investigations after a series\u000d\u000a      of miscarriages of justice in 2003, and was subsequently incorporated into\u000d\u000a      the Children Act 2004, becoming a statutory requirement throughout England\u000d\u000a      from 2008. This process of child death reviews (in which Fleming was\u000d\u000a      centrally involved) has led to a major change in the way medico-legal\u000d\u000a      agencies involved in providing services to children interact, with a\u000d\u000a      resultant improvement in the quality of such investigations and services\u000d\u000a      to bereaved families.[j, k]\u000d\u000a    Fleming was elected as Vice Chair of the International Society for the\u000d\u000a      Study and prevention of Perinatal and Infant Deaths (ISPID) in 2008,\u000d\u000a      succeeded in that role in 2010 by Blair. The Society is instrumental in\u000d\u000a      the delivery of SIDS public health campaigns in different countries. Both\u000d\u000a      have been involved in developing risk reduction messages on the ISPID\u000d\u000a      website (http:\/\/www.ispid.org\/) which\u000d\u000a      receives around 300 visits a day. Blair currently helps co-ordinate the\u000d\u000a      website activities and chairs the epidemiology group working towards\u000d\u000a      consensus positional statements on safe infant care practices. Both\u000d\u000a      researchers have worked extensively on the development of internationally\u000d\u000a      agreed policies for parent education and support, and on advice about\u000d\u000a      parenting practices, which have been adopted in many countries.\u000d\u000a    In 2006 Fleming was included in the \"Eureka UK\" publication celebrating\u000d\u000a      the 100 most important research achievements of British Universities. In\u000d\u000a      2009 Blair was awarded an Honorary Fellowship by UNICEF for work in the\u000d\u000a      SIDS field and in 2012 both Fleming and Blair were awarded the UoB\u000d\u000a      Vice-Chancellor Impact award for their translational research in this\u000d\u000a      field. This work has also been instrumental in the UoB receiving the\u000d\u000a      Queen's anniversary prize for Higher and Further Education in the field of\u000d\u000a      Obstetrics and Neonatal practice in 2012-14.[l]\u000d\u000a    ","ImpactSummary":"\u000d\u000a    University of Bristol research has led to a marked and persisting\u000d\u000a      reduction in the number of cot deaths (sudden infant death syndrome or\u000d\u000a      SIDS). The dramatic 67% fall from 1988 to 1992 in England and Wales\u000d\u000a      resulted from the identification of risks associated with putting babies\u000d\u000a      to sleep face-down (prone). Nationally, death rates have more than halved\u000d\u000a      again (54% fall) between from 1992 and 2011, with an estimated additional\u000d\u000a      1025 lives saved between 2008 and 2011, after two studies conducted in\u000d\u000a      1993-6 and 2003-6 identified further contributory risk factors. Tens of\u000d\u000a      thousands of SIDS deaths worldwide have been prevented thanks to the\u000d\u000a      team's research, international collaboration and development of\u000d\u000a      risk-reduction recommendations.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Bristol\u000d\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Fleming PJ, Blair PS, Bacon C et al. Environment of infants during\u000d\u000a      sleep and risk of the sudden infant death syndrome: results from 1993-5\u000d\u000a      case-control study for confidential inquiry into stillbirths and deaths in\u000d\u000a      infancy. BMJ 1996; 313:191-5 (Document can be supplied upon\u000d\u000a      request)\u000d\u000a    \u000a\u000a[2] Blair PS, Fleming PJ et al. Smoking and the sudden infant death\u000d\u000a      syndrome: results from 1993-5 case-control study for confidential inquiry\u000d\u000a      into stillbirths and deaths in infancy. BMJ 1996; 313:195-8.\u000d\u000a      (Document can be supplied upon request)\u000d\u000a    \u000a\u000a[3] Blair PS, Fleming PJ, Smith IJ et al. Babies sleeping with parents:\u000d\u000a      case-control study of factors influencing the risk of sudden infant death\u000d\u000a      syndrome. BMJ 1999;319:1457-61. (Document can be supplied upon\u000d\u000a      request)\u000d\u000a    \u000a\u000a[4] Blair PS, Sidebotham P, Evason-Coombe C, Edmonds M, Heckstall-Smith\u000d\u000a      EM, Fleming P. Hazardous cosleeping environments and risk factors amenable\u000d\u000a      to change: case-control study of SIDS in south west England. BMJ\u000d\u000a      2009;339:b3666. DOI:10.1136\/bmj.b3666\u000d\u000a    \u000a\u000a[5] Blair PS, Sidebotham P, Berry PJ, et al. Major epidemiological\u000d\u000a      changes in sudden infant death syndrome: a 20-year population-based study\u000d\u000a      in the UK. Lancet 2006;367:314-9. DOI:\u000d\u000a      10.1016\/SO140-6736(06)67968-3\u000d\u000a    \u000a\u000a[6] Blair\u000a        PS, Heron\u000a        J, Fleming\u000a        PJ. Relationship between bed sharing and breastfeeding:\u000d\u000a      longitudinal, population-based analysis. Pediatrics\u000d\u000a      2010; 126(5):e1119-26.\u000d\u000a      DOI:10.1542\/peds.2010-1277\u000d\u000a    \u000aPeer reviewed grants: UK Department of Health &#163;620,000 (1993-8); FSID\u000d\u000a      Charity &#163;80,580 (1995-6); Babes in Arms Charity &#163;109,500 (2000-6) and\u000d\u000a      Charitable Trusts for UoB &#163;54,000 (2006-7).\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"14","Subject":"Paediatrics and Reproductive Medicine"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [a] http:\/\/www.lullabytrust.org.uk\/document.doc?id=300\u000d\u000a      UK (FSID now Lullaby Trust). Evidence base for risk reduction messages,\u000d\u000a      PJF and PSB work cited 15 times\u000d\u000a    [b] http:\/\/www.sidsandkids.org\/wp-content\/uploads\/SidsSafeSleeping14ppa1.pdf\u000d\u000a      Australian SIDS and Kids leaflet. PSB and PJF acknowledged for their work\u000d\u000a      on the last page\u000d\u000a    [c] Letter of support from Sue Ashmore, Programme Director, UNICEF UK\u000d\u000a      Baby Friendly Initiative\u000d\u000a    [d] http:\/\/www.unicef.org.uk\/BabyFriendly\/News-and-Research\/Research\/Cot-death\/Study-draws-link-between-increased-risk-of-SIDS-and-alcohol-or-drug-use-when-co-sleeping\/\u000d\u000a      and\u000d\u000a      http:\/\/www.unicef.org.uk\/BabyFriendly\/News-and-Research\/Research\/Cot-death\/Research-concludes-no-increase-in-risk-of-cot-death-from-bed-sharing-for-infants-over-14-weeks-with-non-smoking-parents\/\u000d\u000a      Exemplars of involvement with UNICEF UK including website reporting\u000d\u000a      research conducted by PJF and PSB regarding both the hazards of\u000d\u000a      bed-sharing and when bed-sharing is safe.\u000d\u000a    [e] http:\/\/www.unicef.org.uk\/BabyFriendly\/Resources\/Resources-for-parents\/Caring-for-your-baby-at-night\/\u000d\u000a      Caring for your baby at night leaflet: (UNICEF 2012) both PJF and PSB were\u000d\u000a      instrumental in advising on the contents of this leaflet.\u000d\u000a    [f]http:\/\/www.unicef.org.uk\/Documents\/Baby_Friendly\/Leaflets\/HPs_Guide_to_Coping_At_Night_Final.pdf\u000d\u000a      Health profession guidelines to the UNICEF leaflet. PSB is the lead\u000d\u000a      author.\u000d\u000a    [g] http:\/\/www.unicef.org.uk\/Documents\/Baby_Friendly\/Programmes\/3\/08programme.pdf\u000d\u000a      PSB gives talk to 500 health professionals in Glasgow 2008, Page 3,\u000d\u000a      abstract page 8 of programme.\u000d\u000a    [h] https:\/\/www.dur.ac.uk\/sleep.lab\/sim\/\u000d\u000a      PSB gives talk in Durham, 2012, similar talks given in Bristol 2012 and\u000d\u000a      2013.\u000d\u000a    [i] Flyer listing a series of seminars delivered to health professionals\u000d\u000a      in Australia (program 2: Sydney, Adelaide and Perth) in 2012 by PSB\u000d\u000a    [j] http:\/\/www.rcpath.org\/publications-media\/publications\/sudden-unexpected-death-in-infancy\u000d\u000a      The Kennedy Report. PJF was a member of the committee that wrote this\u000d\u000a      report and helped write chapter 7, on investigating childhood deaths.\u000d\u000a    [k]http:\/\/www.education.gov.uk\/childrenandyoungpeople\/safeguardingchildren\/childdeathreview\/a0068831\/why-jason-died-a-dvd-familiarisation-resource\u000d\u000a      A DVD: \"Working together to safeguard children\" 2010. PJF is featured\u000d\u000a      extensively in the accompanying DVD.\u000d\u000a    [l] Letter of award to UoB for the Queen's Anniversary Prizes for Higher\u000d\u000a      and Further Education for 2012-14 (Obstetrics and Neonatal Practice-Saving\u000d\u000a\u0009  Babies lives around the world).\u000d\u000a    ","Title":"\u000d\u000a    Bristol research leads to a worldwide fall in the number of cot deaths.\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    University of Bristol (UoB) led studies, published in the early 1990s\u000d\u000a      were the first population-based investigations to document the importance\u000d\u000a      of a number of factors (prone sleeping position, wrapping infants too\u000d\u000a      warmly and pre-natal smoking) that contribute to SIDS. Subsequently, two\u000d\u000a      case-control studies were conducted by Peter Fleming (Professor of Infant\u000d\u000a      Health and Developmental Physiology, UoB since 1982) and Peter Blair\u000d\u000a      (Senior Research Fellow, UoB since 1992). Data from the Confidential\u000d\u000a      Enquiry into Stillbirths and Deaths in Infancy (CESDI) in 1993-6 [1-3] and\u000d\u000a      the South West Infant Sleep Scene (SWISS) study in 2003-6 [4] identified a\u000d\u000a      number of further contributory factors to deaths. These included\u000d\u000a      post-natal smoking, parental drug and alcohol use when bed-sharing,\u000d\u000a      co-sleeping on a sofa, putting the baby to sleep on their side and loose\u000d\u000a      covering found over the infant's head. The team also identified factors\u000d\u000a      not contributory to the risk of SIDS (e.g. immunisation and toxic gas\u000d\u000a      emanating from mattresses) and some that were beneficial (e.g. infants\u000d\u000a      sleeping in the same room as parents, dummy use and breastfeeding). Advice\u000d\u000a      against the prone sleeping position had already been widely adopted prior\u000d\u000a      to CESDI in 1993-6. In the ten years between CESDI and SWISS, prone\u000d\u000a      sleeping position rates did not change, but rates of infants being placed\u000d\u000a      on their side to sleep, infants exposed to tobacco smoke after the birth\u000d\u000a      and infants found with bedding over their heads decreased while rates of\u000d\u000a      infants being placed `feet to foot' (with their feet at the foot of the\u000d\u000a      cot to avoid wriggling under the covers) and infants being breastfed\u000d\u000a      increased suggesting that the subsequent 54% fall in SIDS rates was\u000d\u000a      related to the further contributory factors identified by the UoB team\u000d\u000a      (see table below). [4]\u000d\u000a        \u000d\u000a      \u000d\u000a        \u000d\u000a          Impact\u000d\u000a              of risk reduction advice in the 10 years between CESDI and SWISS\u000d\u000a              studies\u000d\u000a        \u000d\u000a        \u000d\u000a          Risk(R) or Protective(P) Factor\u000d\u000a          CESDI\u000d\u000a            Study\u000d\u000a            Fleming &amp; Blair 1993-6[1]\u000d\u000a          SWISS\u000d\u000a            study\u000d\u000a            Blair &amp; Fleming 2003-6[3]\u000d\u000a        \u000d\u000a        \u000d\u000a          \u000d\u000a          SIDS%\u000d\u000a          Controls%\u000d\u000a          SIDS%\u000d\u000a          Controls%\u000d\u000a        \u000d\u000a        \u000d\u000a          R-Placed prone to sleep\u000d\u000a          15%\u000d\u000a          3%\u000d\u000a          14%\u000d\u000a          6%\u000d\u000a        \u000d\u000a        \u000d\u000a          R-Placed on side to sleep\u000d\u000a          41%\u000d\u000a          28%\u000d\u000a          18%\u000d\u000a          10%\u000d\u000a        \u000d\u000a        \u000d\u000a          R-Postnatal exposure to smoke\u000d\u000a          54%\u000d\u000a          23%\u000d\u000a          16%\u000d\u000a          6%\u000d\u000a        \u000d\u000a        \u000d\u000a          R-Head covered by bedding\u000d\u000a          16%\u000d\u000a          3%\u000d\u000a          5%\u000d\u000a          0%\u000d\u000a        \u000d\u000a        \u000d\u000a          P-Feet placed at foot of cot\u000d\u000a          3%\u000d\u000a          4%\u000d\u000a          50%\u000d\u000a          60%\u000d\u000a        \u000d\u000a        \u000d\u000a          P-Mother attempted to breastfeed\u000d\u000a          44%\u000d\u000a          60%\u000d\u000a          70%\u000d\u000a          79%\u000d\u000a        \u000d\u000a      \u000d\u000a    \u000d\u000a    Evidence from these two population-based, case-control studies ten years\u000d\u000a      apart suggests that the messages from the UoB team have changed parental\u000d\u000a      behaviour. Laboratory and community studies of thermal balance (solely\u000d\u000a      conducted in Bristol) have led to detailed recommendations in current\u000d\u000a      safety guidelines regarding how much bedding infants should have,\u000d\u000a      according to bedroom temperature.[4, 5] In the last five years the team\u000d\u000a      has identified potential risks to the baby if they share the same sleep\u000d\u000a      surface and have been working with UNICEF to provide a more evidence-based\u000d\u000a      approach that acknowledges the importance of breastfeeding while outlining\u000d\u000a      specific hazards when bed-sharing deaths occur.\u000d\u000a    UoB-led studies in the Avon Longitudinal Study of Parents and Children\u000d\u000a      (ALSPAC) study showed no adverse effects from changes in sleeping position\u000d\u000a      advice and findings published in 2010 suggest an interdependent effect\u000d\u000a      with bed-sharing and breastfeeding.[6]\u000d\u000a    The UoB team also includes PJ Berry (Pathologist 1983-2001), P Sidebotham\u000d\u000a      (Sen Clinical Lecturer 1997-2005) and J Golding (Prof of Paediatric &amp;\u000d\u000a      Perinatal Epidemiology 1985-present).\u000d\u000a    "},{"CaseStudyId":"40167","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Wellcome Trust"],"ImpactDetails":"\u000d\u000a    During the 1990s rationing of surgery for visually impairing cataract was\u000d\u000a      common with contract limits placed on secondary care providers. 2nd\u000d\u000a      eye surgery was particularly targeted for access restrictions and NHS\u000d\u000a      waiting times for surgery were typically a year or more. For older people,\u000d\u000a      for example, the implications of long waits and poor vision were\u000d\u000a      substantial, leading to potentially reduced confidence and higher\u000d\u000a      functional dependence. Following publication of our Randomised Controlled\u000d\u000a      Trial of 2nd eye cataract surgery in the Lancet in 1998[2], the\u000d\u000a      DH `Action on Cataracts' policy document released in 2000 recommended 2nd\u000d\u000a      eye surgery as uncontroversially good practice[a]. Our Lancet paper was\u000d\u000a      referred to as 1 of just 7 references in the policy document. The clear\u000d\u000a      benefits, both in terms of visual function and self reported symptoms\u000d\u000a      which our research demonstrated, informed a firm and strong policy\u000d\u000a      recommendation in favour of 2nd eye surgery across the NHS.\u000d\u000a      During the early and mid 1990s, prior to the publication of our research\u000d\u000a      report, 2nd eye surgery comprised around 25% of operations[b].\u000d\u000a      Data from the National Ophthalmology Database (NOD &#8212; 30 contributing NHS\u000d\u000a      trusts) for the years 2004-2010 show a steady increase each year of 2nd\u000d\u000a      eye surgery from 24.2% in 2004 to 34.9% in 2010 based on around 232,000\u000d\u000a      operations[c], with our own published analysis of over 55,000 operations\u000d\u000a      (12 trusts) in the mid to late 2000s indicating 41.5% of operations being\u000d\u000a      on 2nd eyes[d] reflecting widespread acceptance within the NHS\u000d\u000a      of the benefits gained from 2nd eye surgery for bilateral\u000d\u000a      cataract. Similarly the European Registry of Quality Outcomes for Cataract\u000d\u000a      and Refractive Surgery (EUREQUO) reported that based on 318,000 operations\u000d\u000a      from 2009 to August 2011, 40.6% of cataract surgery was for 2nd\u000d\u000a      eyes [e].\u000d\u000a    The findings of our RCT have since been corroborated through studies in\u000d\u000a      which the benefits of 1st and 2nd eye surgery have\u000d\u000a      been found to be either similar or, as in the Swedish National Cataract\u000d\u000a      Register data, greater from 2nd eye surgery for certain\u000d\u000a      subgroups compared with 1st eyes[f].\u000d\u000a    Our research report on the population requirements for both 1st\u000d\u000a      and 2nd eye cataract surgery[7] provided a robust estimate of\u000d\u000a      the cataract surgical backlog facing the NHS. Our estimate of around half\u000d\u000a      a million additional operations needed to clear the backlog was based on\u000d\u000a      sound applied epidemiological and ophthalmological methodology and\u000d\u000a      provided an empirically evidenced and considerably more accurate estimate\u000d\u000a      of unmet need for surgery than earlier inflated estimates. During the\u000d\u000a      decade following publication of our research an uplift of just over half a\u000d\u000a      million operations cleared the backlog (HES data), confirming the accuracy\u000d\u000a      of our estimate.\u000d\u000a    The 2000 DH `Action on Cataracts' document referred to our randomised\u000d\u000a      trial and recommended 2nd eye cataract surgery along with\u000d\u000a      process and commissioning changes to increase efficiency, delivery and\u000d\u000a      access for cataract surgery [a]. This document was reinforced by the\u000d\u000a      subsequent NHS Institute for Innovation and Improvement publication,\u000d\u000a      `Focus on Cataracts' [g], and sequential updates of the Royal College of\u000d\u000a      Ophthalmologists Cataract Surgery Guidelines in 2010[h] which directly\u000d\u000a      cited our research. Internationally our RCT on 2nd eye cataract\u000d\u000a      surgery has been referred to in the previous and the current American\u000d\u000a      Academy of Ophthalmology Preferred Practice Pattern: Cataract in the Adult\u000d\u000a      Eye, 2011 [i] and in Guidelines based on data in the European Registry of\u000d\u000a      Quality Outcomes for Cataract[e], with the International Centre for Eye\u000d\u000a      Health [j] having recommend the Royal College 2010 Guidelines which\u000d\u000a      directly cite our research.\u000d\u000a    In the NHS, with achievable numbers [7] and the strong policy impetus\u000d\u000a      provided by the DH significant inroads were made into the unmet need for\u000d\u000a      cataract surgery. A 65% increase in the frequency of cataract surgery\u000d\u000a      resulted across England, from 201,682 operations in 1998-1999 to 332,625\u000d\u000a      in 2009-2010. During the 1990s long waiting times for cataract surgery\u000d\u000a      patients were routine, typically around a year. As a consequence of the\u000d\u000a      policy adjustments informed by our research, this increase in cataract\u000d\u000a      surgery reduced waiting times in England to below 18 weeks from referral\u000d\u000a      to surgery for well over 90% of NHS patients.\u000d\u000a    In addition to the direct benefits to vision [d] and QoL [f] provided by\u000d\u000a      cataract surgery, there are downstream benefits to health such as a\u000d\u000a      reduction in falls for people with improved vision. These benefits are\u000d\u000a      difficult to quantify but include prevention of falls and associated\u000d\u000a      mortality and morbidity among elderly people. Recent austerity-driven\u000d\u000a      reductions in numbers of cataract operations has attracted professional\u000d\u000a      and media interest. Giving evidence to a hearing of the public accounts\u000d\u000a      committee in January 2013 the Medical Director of the NHS, Sir Bruce Keogh\u000d\u000a      said: \"We do know that about 50 per cent of PCTs have restricted access to\u000d\u000a      cataract surgery, and we do know that the bulk of policies used by PCTs\u000d\u000a      actually haven't used the best evidence that's available in order to\u000d\u000a      ration that care.\"\u000d\u000a    The Royal National Institute for Blind people (RNIB) has cited our RCT[2]\u000d\u000a      in its collaborative report with the RCOphth `Don't turn back the clock:\u000d\u000a      Cataract surgery- the need for patient-centred care', June 2011[k]. The\u000d\u000a      RNIB is investigating the variation in cataract surgery across England and\u000d\u000a      has done a FOI request to each PCT with regards to their commissioning\u000d\u000a      policies on 2nd eye surgery. The RNIB Assistant Policy and\u000d\u000a      Campaigns Officer (Eye Health) has indicated that the UoB research\u000d\u000a      evidence would be used to `interact with commissioners and highlight\u000d\u000a      evidence as to why their restrictive 2nd eye policy is harmful\u000d\u000a      to patients' and that `some PCTs have decided to review their policies in\u000d\u000a      light of our [RNIB] concerns'. NHS Atlas of Variation in Healthcare (Nov\u000d\u000a      2010) discusses standardising cataract surgery. It mentions `added value\u000d\u000a      of 2nd eye surgery' and cites our RCT. Our RCT is cited first\u000d\u000a      in The European Registry of Quality Outcomes for Cataract and Refractive\u000d\u000a      Surgery (EUREQUO) project publication `Evidence-based guidelines for\u000d\u000a      cataract surgery: Guidelines based on data in the European Registry of\u000d\u000a      Quality Outcomes for Cataract and Refractive Surgery database', 2012 [e].\u000d\u000a      The Technology Scoping Report No.8 from Healthcare Improvement Scotland\u000d\u000a      (August 2012) cites our RCT.\u000d\u000a    In summary, UoB research has been instrumental in informing and changing\u000d\u000a      cataract surgical policy to the visual and quality of life benefit of\u000d\u000a      hundreds of thousands of older people with cataract in the UK and beyond.\u000d\u000a      We demonstrated the visual and QoL benefits of 2nd eye cataract\u000d\u000a      surgery following successful 1st eye surgery, corroborated by\u000d\u000a      subsequent observational research, and we quantified the population\u000d\u000a      requirements for 1st and 2nd eye cataract surgery\u000d\u000a      and the unmet need for NHS surgery, our estimates being borne out by the\u000d\u000a      numbers of operations subsequently required to bring down the surgical\u000d\u000a      backlog. In the current climate of austerity our research is again of\u000d\u000a      direct relevant to policy decisions as illustrated by the recent RNIB FOI\u000d\u000a      survey of PCTs and the ongoing citations of UoB cataract research in both\u000d\u000a      academic and the policy setting arenas.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The most frequent surgical procedure undertaken in the NHS is cataract\u000d\u000a      surgery and it improves vision and quality of life (QoL). In the 1990's\u000d\u000a      there were long waiting times for cataract surgery with rationing most\u000d\u000a      frequently restricting surgery on the 2nd eye. A randomised\u000d\u000a      controlled trial undertaken at the University of Bristol (UoB)\u000d\u000a      demonstrated clear QoL benefits from 2nd eye cataract surgery,\u000d\u000a      followed by a population study quantifying population requirements for 1st\u000d\u000a      and 2nd eye surgery and the surgical backlog. Government\u000d\u000a      policy, announced in `Action on Cataracts &#8212; Good Practice Guidance, 2000',\u000d\u000a      advised that the volume cataract surgery, including on the 2nd\u000d\u000a      eye, should be increased. This policy ensured timely access to surgery\u000d\u000a      becoming routine practice in the NHS, thus improving the lives of\u000d\u000a      thousands of people. Second-eye surgery rates rose from ~25% of operations\u000d\u000a      to 35-40%, with overall increases in operations for patients needing\u000d\u000a      surgery (e.g. in England up from 201,682 operations in 1998-1999 to\u000d\u000a      332,625 in 2009-2010) and reduced waiting times. These improvements were\u000d\u000a      sustained through to the end of the 2000's. The research has become highly\u000d\u000a      relevant again as the NHS enters another period of constrained\u000d\u000a      expenditure.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Bristol\u000d\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    [1] The Wellcome Trust. Project: Is there a benefit from second eye\u000d\u000a      cataract extraction? Wellcome Trust Grant Code: 039254\/Z\/93\/Z\/1.5\/DG\/SRD.\u000d\u000a      Holders: Harrad, Frankel, Sparrow, Williams, Laidlaw. Period:\u000d\u000a      1\/101993-30\/9\/1995. &#163;92,079 (peer reviewed).\u000d\u000a    \u000a[2] Laidlaw DA, Harrad RA, Hopper CD, Whitaker A, Donovan JL, Brookes ST,\u000d\u000a      Marsh GW, Peters TJ, Sparrow JM, Frankel SJ. Randomised trial of\u000d\u000a      effectiveness of second eye cataract surgery. Lancet 1998;352:925-9.\u000d\u000a      (Document can be supplied upon request)\u000d\u000a    \u000a\u000a[3] Donovan JL, Brookes ST, Laidlaw DA, Hopper CD, Sparrow JM, Peters TJ.\u000d\u000a      The development and validation of a questionnaire to assess visual\u000d\u000a      symptoms\/dysfunction and impact on quality of life in cataract patients:\u000d\u000a      the Visual Symptoms and Quality of life (VSQ) Questionnaire. Ophthalmic\u000d\u000a      Epidemiology 2003;10:49-65. DOI: 10.1076\/opep.10.1.49.13775\u000d\u000a    \u000a[4] DH: Population requirements for elective surgery: Cataract Surgery.\u000d\u000a      DH Grant Code: 121\/6022. Holders: Frankel, Williams. Period:\u000d\u000a      1\/4\/1995-30\/9\/1997. &#163;99,873 (peer reviewed).\u000d\u000a    [5] SW Regional Research &amp; Development Project Grant: The\u000d\u000a      identification of the Population Requirements for Cataract Surgery.\u000d\u000a      R&amp;D Grant code: C\/COM\/01\/15-08-94\/Sparrow\/D. Sparrow, Frankel,\u000d\u000a      Williams. Period: 1\/5\/1995-31\/\/8\/1998. &#163;162,262 (peer reviewed).\u000d\u000a    [6] SW Regional Health Authority R&amp;D Directorate: Research training\u000d\u000a      fellowship &#8212; Frost NA, Supervisors: Sparrow, Williams, Frankel. Period:\u000d\u000a      1\/10\/1994-30\/9\/1997. &#163;86,229 (peer reviewed).\u000d\u000a    \u000a[7] Frost NA, Hopper C, Frankel S, Peters TJ, Durant J, Sparrow J. The\u000d\u000a      population requirement for cataract extraction: a cross-sectional study.\u000d\u000a      Eye 2001;15:745-52. (Document can be supplied upon request)\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"13","Subject":"Ophthalmology and Optometry"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [a] DH. Action on Cataracts: Good practice guidance, NHS Executive.\u000d\u000a      http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_4005637 2000. 2nd eye cataract surgery should uncontroversially be\u000d\u000a        provided by the NHS with streamlined patient pathways to facilitate and\u000d\u000a        support increased surgical throughput.\u000d\u000a    [b] Claridge KG, Francis PJ, Bates AK. Should second eye cataract surgery\u000d\u000a      be rationed? Eye (Lond) 1995;9:47-9. In early to mid 1990s ~26% NHS\u000d\u000a        cataract operations were for 2nd eyes.\u000d\u000a    [c] Donachie P. National Ophthalmology Database tabulation of rates of 2nd\u000d\u000a      eye cataract surgery between 2004 and 2010 derived from data contributed\u000d\u000a      by 30 NHS cataract surgery units. June 2013. Increasing proportion of\u000d\u000a        2nd eye NHS cataract operations through mid to\u000d\u000a        late 2000's.\u000d\u000a    [d] Jaycock P, Johnston RL, Taylor H, Adams M, Tole DM, Galloway P,\u000d\u000a      Canning C, Sparrow JM. The Cataract National Dataset electronic\u000d\u000a      multi-centre audit of 55,567 operations: updating benchmark standards of\u000d\u000a      care in the United Kingdom and internationally. Eye 2009;23:38-49. In\u000d\u000a        mid to late 2000s ~42% of NHS cataract operations were for 2nd eye\u000d\u000a        cataracts (P40). This sample indicates a significant increase in the\u000d\u000a        proportion of 2nd eyes in comparison to 1990s.\u000d\u000a    [e] Lundstrom M, Barry P, Henry Y, Rosen P, Stenevi U. Evidence-based\u000d\u000a      guidelines for cataract surgery: guidelines based on data in the European\u000d\u000a      Registry of Quality Outcomes for Cataract and Refractive Surgery database.\u000d\u000a      J Cataract Refract Surg 2012;38:1086-93. European guidelines\u000d\u000a        illustrate international recognition of UoB RCT evidence for the benefit\u000d\u000a        of 2nd eye surgery and recommend surgery for symptomatic 2nd &amp; 1st\u000d\u000a        eye cataracts. The document confirms the current rate of 2nd eye\u000d\u000a        cataract surgery in Europe is just over 40% (P1087).\u000d\u000a    [f] Lundstrom M, Stenevi U, Thorburn W. Quality of life after first- and\u000d\u000a      second-eye cataract surgery: five-year data collected by the Swedish\u000d\u000a      National Cataract Register. J Cataract Refract Surg 2001;27:1553-9. Self\u000d\u000a        reported benefits from 2nd eye cataract surgery are similar or greater\u000d\u000a        than 1st eye surgery (P1555, T4&amp;5). Observational evidence supports\u000d\u000a        our RCT result.\u000d\u000a    [g] DH. Focus on Cataracts. NHS Institute for Innovation and Improvement\u000d\u000a      publication 2006;\u000d\u000a      http:\/\/www.institute.nhs.uk\/quality_and_value\/high_volume_care\/cataracts.html\u000d\u000a      . Policy encouraged high volume cataract surgery to meet population\u000d\u000a        requirements for surgery and confirmed that 2nd eye surgery should be\u000d\u000a        uncontroversially routine care when indicated.\u000d\u000a    [h] The Royal College of Ophthalmologists Cataract Surgery Guidelines\u000d\u000a      (current). 2010;\u000d\u000a      http:\/\/www.rcophth.ac.uk\/core\/core_picker\/download.asp?id=544&amp;filetitle=Cataract+Surgery+Guidelines+2010.\u000d\u000a      Royal College guideline comments on population requirements (P6)\u000d\u000a        recommended that people with symptomatic 1st and 2nd eye cataracts\u000d\u000a        should be considered for surgery (P10,14,17,60) and cites UoB research\u000d\u000a        (P8,15,65).\u000d\u000a    [i] American Academy of Ophthalmology's Preferred Practice Pattern:\u000d\u000a      Cataract in the Adult Eye. 2011; http:\/\/one.aao.org\/CE\/PracticeGuidelines\/PPP.aspx?sid=a3043761-ec14-40a0-bb84-d353240d211e.\u000d\u000a      US guideline recommended that people with symptomatic 1st and 2nd eye\u000d\u000a        cataracts should be considered for surgery (P40) and cites UoB research\u000d\u000a        (Ref 769).\u000d\u000a    [j] International Centre for Eye Health 2013;\u000d\u000a      https:\/\/www.iceh.org.uk\/display\/WEB\/Cataract+Surgery+Guidelines+2010.\u000d\u000a      Endorsement of [h] recommendation that people with symptomatic 1st and\u000d\u000a        2nd eye cataracts should be considered for surgery internationally.\u000d\u000a    [k] Royal National Institute for Blind people and Royal College of\u000d\u000a      Ophthalmologists Joint report: Don't turn back the clock. Cataract surgery\u000d\u000a      &#8212; the need for patient-centred care.\u000d\u000a      http:\/\/www.rnib.org.uk\/getinvolved\/campaign\/policy\/eyehealth\/reports\/Pages\/cataract-2011.aspx.\u000d\u000a      Draws attention to cost driven and inappropriate restrictions on access\u000d\u000a        to NHS cataract surgery and the targeting of 2nd eye\u000a        surgery, and cites UoB research (Ref 3). \u000d\u000a    ","Title":"\u000d\u000a    Cataract Surgery &#8212; Quality of Life Benefits and Improved Access to\u000d\u000a      Treatment in the UK and beyond\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Prior to and during the 1990s there was uncertainty and disagreement\u000d\u000a      regarding the indications for and benefits from cataract surgery, in\u000d\u000a      particular 2nd eye surgery. There were widespread limits to the\u000d\u000a      number of NHS procedures permitted, with more stringent restrictions\u000d\u000a      applied to 2nd eye surgery on the assumption that good vision\u000d\u000a      in one eye was sufficient for the needs of most people. Demand for surgery\u000d\u000a      outstripped supply resulting in the build up of long waiting times. These\u000d\u000a      NHS delivery and clinical issues provided the rationale for the UoB\u000d\u000a      research, which aimed to address two key questions:\u000d\u000a    Q1. What are the benefits of a 2nd eye\u000d\u000a        cataract operation following a successful 1st eye\u000a        operation?\u000d\u000a    A Wellcome Trust funded[1] randomised controlled trial of 2nd\u000d\u000a      eye cataract surgery, published in 1998 in the Lancet[2] was undertaken\u000d\u000a      collaboratively between the University of Bristol and the Bristol Eye\u000d\u000a      Hospital from 1993 to 1998. People who had undergone a successful 1st\u000d\u000a      eye cataract operation and who were awaiting surgery for their 2nd\u000d\u000a      cataract were eligible for recruitment. The intervention group underwent\u000d\u000a      expedited surgery and were compared at 6 months following randomisation\u000d\u000a      with the control group (who were still awaiting 2nd eye\u000d\u000a      surgery). Outcomes included visual function and patient reported benefits\u000d\u000a      which were assessed with a valid cataract specific instrument, the Visual\u000d\u000a      Symptoms and Quality of life (VSQ) questionnaire[3] developed by the\u000d\u000a      research group for the trial. 208 patients were recruited into the study\u000d\u000a      which showed significant visual function and vision related QoL benefits\u000d\u000a      from 2nd eye surgery. Distance acuity, near acuity, contrast\u000d\u000a      sensitivity and particularly stereo-acuity and self reported vision\u000d\u000a      problems (such as reading and seeing faces) improved when assessed with\u000d\u000a      both eyes open[1]. Our RCT remains the only randomised trial of 2nd\u000d\u000a      eye cataract surgery to date which directly addresses the visual function\u000d\u000a      and quality of life benefits of 2nd eye surgery following a\u000d\u000a      successful 1st eye operation.\u000d\u000a    Q2. What are the population requirements for cataract surgery?\u000d\u000a    A further University of Bristol and Bristol Eye Hospital collaboration\u000d\u000a      funded by DH[4] and Regional R&amp;D research[5,6] funding streams from\u000d\u000a      1995 to 2001 undertook a cross sectional geographically based population\u000d\u000a      study of chronic potentially blinding eye disease on over 1000\u000d\u000a      participants aged 65 years and older. Eligibility for cataract surgery in\u000d\u000a      this representative sample was assessed using an applied epidemiological\u000d\u000a      approach in which indications for surgery were modelled from detailed\u000d\u000a      clinical and quality of life data. From this work it was estimated that\u000d\u000a      the backlog of cataract surgery for visually significant cataract in\u000d\u000a      England was of the order of half a million operations [7].\u000d\u000a    Key researchers with UoB positions from 1992 forward:\u000d\u000a    \u000d\u000a      Sparrow, J. M. Senior Lecturer UoB 1992-2000, subsequently Honorary\u000d\u000a        Senior Lecturer and Honorary Professor\u000d\u000a      Donovan, J. L. Lecturer, subsequently Professor and Head of School of\u000d\u000a        Social and Community Medicine, UoB\u000d\u000a      Frankel, S. J. Professor, Head of Department of Social Medicine, UoB,\u000d\u000a        now retired\u000d\u000a      Laidlaw, D. A. Lecturer UoB 1993-1995, subsequently left Bristol for\u000d\u000a        promotion to Consultant\u000d\u000a      Harrad, R. A. Honorary Senior Lecturer UoB, subsequently Honorary\u000d\u000a        Reader\u000d\u000a      Peters, T. J. Senior Lecturer, subsequently Professor of Primary Care\u000d\u000a        Health Services Research and Head of School of Clinical Sciences, UoB\u000d\u000a      Frost, N. A. Research Fellow and Honorary Lecturer UoB, 1994-2001,\u000d\u000a        subsequently left Bristol for promotion to Consultant.\u000d\u000a    \u000d\u000a    "},{"CaseStudyId":"40168","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"3017382","Name":"France"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    Impact on Policy\u000a    The research associated with the development and evaluation of ASSIST has\u000a      had a substantial impact on policy.\u000a    \u000a      In February 2010, the UK government published `A Smokefree Future',\u000a        its White Paper on tobacco control. It outlines future policy and\u000a        focuses on the use of evidence-based policies in three areas, the first\u000a        of which is `To stop the inflow of young people recruited as smokers'\u000a        [a]. The review of evidence into smoking and young people which informed\u000a        this White Paper identified ASSIST as a `potentially important\u000a        intervention' [b].\u000a      ASSIST has been cited as an example of good practice in another\u000a        Government White Paper, Healthy Lives, Brighter Futures: The\u000a          Strategy for Children and Young People's Health [c].\u000a      It was also flagged as an example of an effective preventative\u000a        strategy aimed at young people in the NHS Stop Smoking Services:\u000a          Service and Monitoring Guidance [d].\u000a      Guidance published by NICE, `School-based Interventions to Prevent\u000a          Smoking',[e] which was informed by four separate reviews [f, g],\u000a        has a specific recommendation on peer-led initiatives. It states that\u000a        those commissioning health care should `consider offering\u000a        evidence-based, peer-led interventions aimed at preventing the uptake of\u000a        smoking such as the ASSIST (A Stop Smoking in School Trial) programme'\u000a        and refers the reader to the main trial results published in The\u000a          Lancet.\u000a      The Tobacco Action Plan for Wales, published in February 2012,\u000a        has, as one of four strategic action areas, `reducing the uptake of\u000a        tobacco use, especially amongst children and young people.' It restates\u000a        the Welsh Government's continuing commitment to providing the ASSIST\u000a        programme to 40 to 50 schools per year, focussing on areas of\u000a        deprivation.[h]\u000a    \u000a    Implementation of ASSIST\u000a    The research intervention was faithfully translated into a practical\u000a      model that can be implemented by national, regional and local bodies with\u000a      health and education responsibilities. The major vehicle for dissemination\u000a      has been DECIPHer (the Centre for the Development and Evaluation of\u000a      Complex Interventions for Public Health Improvement), the UKCRC (UK\u000a      Clinical Research Collaboration) Public Health Research Centre of\u000a      Excellence jointly established by the universities of Bristol, Cardiff and\u000a      Swansea.\u000a    In order to ensure effective support for the implementation of ASSIST and\u000a      to maintain its integrity, the universities of Bristol and Cardiff created\u000a      DECIPHer Impact Ltd, a `not for profit' company, limited by guarantee\u000a      which aims to maximise the translation and impact of evidence-based public\u000a      health improvement research and expertise. Its first product is ASSIST,\u000a      which is trade-marked as the DECIPHer-ASSIST smoking prevention programme.\u000a      Licences are sold by the company and purchasers receive DECIPHer-ASSIST\u000a      materials, training, support and ongoing quality assurance. This ensures\u000a      that DECIPHer-ASSIST is implemented in a high quality way and maximises\u000a      the likelihood that the effects found in the RCT are reproduced in real\u000a      world implementation.\u000a    There has been substantial demand for DECIPHer-ASSIST from local\u000a      healthcare purchasers [i]. To date 25 health bodies in England and the\u000a      Channel Islands have been issued with licences costing up to &#163;34K each. A\u000a      more substantial licence has also been issued covering the whole of Wales,\u000a      where ASSIST is being implemented at a rate of 40-50 schools per annum.\u000a      Company turnover in the year ending July 2013 was &#163;240K [i]. In its recent\u000a      tobacco control policy the Scottish government committed to pilot ASSIST\u000a      and discussions are ongoing with state and educational institutions in\u000a      France and Germany about implementing ASSIST.[i] To date over 350 UK\u000a      schools have been involved in the programme and over 150 staff from former\u000a      primary care trusts and local authorities have been trained to deliver the\u000a      programme.\u000a    Impact on teenagers\u000a    The use of ASSIST is growing every year. In the academic year 2012\/2013\u000a      over 25,000 Year 8 students (via more than 4,500 peer supporters)\u000a      were involved in DECIPHer-ASSIST. By summer 2013 more than 60,000 Year 8\u000a      students and over 11,000 peer supporters were involved in DECIPHer-ASSIST,\u000a      resulting in 1674 fewer teenagers taking up smoking.[i]\u000a    Recognition of the impact on health\u000a    In 2011 DECIPHer-IMPACT was the overall winner of the Bristol Health\u000a      Partners Health Innovation Award [j] which recognises outstanding health\u000a      innovation achievements. In 2013 DECIPHer- IMPACT won the Innovation in\u000a      Healthcare Award as part of Cardiff University's Innovation and Impact\u000a      Awards 2013[j].\u000a    ","ImpactSummary":"\u000a    ASSIST (A Stop Smoking in School Trial) is reducing smoking rates among\u000a      teenagers by 22%. `DECIPHer' Impact Ltd was set up to rollout the ASSIST\u000a      programme which has been adopted widely in England and Wales with 26\u000a      licences being commissioned. The company has achieved &#163;240K annual\u000a      turnover. As a result, an estimated 1674 young people have not taken up\u000a      smoking. The Lancet estimates that if ASSIST were implemented\u000a      across the UK, 40,000 teenagers a year would not start smoking.\u000a    ASSIST has been commended by the English and Welsh Governments and\u000a      recommended in National Institute for Health and Care Excellence (NICE)\u000a      guidelines.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Bristol\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a[1] Audrey S, Cordall K, Moore L, Cohen D, Campbell R on behalf of ASSIST\u000a      (A Stop Smoking In Schools Trial). The development and implementation of a\u000a      peer-led intervention to prevent smoking among secondary school students\u000a      using their established social networks. Health Education Journal\u000a      2004. 63(3) 266-284. http:\/\/dx.doi.org\/10.1177\/001789690406300307\u000a    \u000a\u000a[2] Starkey F, Moore L, Campbell R, Sidaway M, Bloor M. and ASSIST (A\u000a      Stop Smoking in Schools Trial) Rationale, design and conduct of a\u000a      comprehensive evaluation of a school-based peer-led anti-smoking\u000a      intervention in the UK: the ASSIST cluster randomised trial\u000a      [ISRCTN55572965]. BMC Public Health 2005, 5:43 http:\/\/dx.doi.org\/10.1186\/1471-2458-5-43.\u000a    \u000a\u000a[3] Campbell R, Starkey F, Holliday J, Audrey S, Bloor M, Parry-Langdon\u000a      N, Hughes R, Moore L. An informal school-based peer-led intervention for\u000a      smoking prevention in adolescence (ASSIST): a cluster randomised trial\u000a        Lancet 2008; 371: 1595-1602. http:\/\/dx.doi.org\/10.1016\/S0140-6736(08)60692-3\u000a    \u000a\u000a[4] Audrey, S. Holliday J. Campbell R. It's good to talk: Adolescent\u000a      perspectives of an informal, peer-led intervention to reduce smoking. Social\u000a        Science &amp; Medicine 2006:63:320-334. http:\/\/dx.doi.org\/10.1016\/j.socscimed.2005.12.010\u000a    \u000a\u000a[5] Audrey S, Holliday J, Campbell R. Commitment and compatibility:\u000a      Teacher perspectives on the implementation of a school-based, peer-led\u000a      smoking intervention. Health Education Journal. 2008;67: 74-90.\u000a      doi: 10.1177\/0017896908089387\u000a    \u000a\u000a[6] Hollingworth W, Cohen D, Hawkins J, Hughes R, Moore L, Holliday J,\u000a      Audrey S, Starkey F, Campbell R. Reducing smoking in adolescents:\u000a      cost-effectiveness results from the cluster randomised ASSIST (A Stop\u000a      Smoking In Schools Trial). Nicotine and Tobacco Research 2012,\u000a      14:161-168. http:\/\/dx.doi.org\/10.1093\/ntr\/ntr155\u000a    \u000aGrant (peer reviewed)\u000a    Moore L. Campbell R, (Co PIs), Bloor M, Parry Langdon N, Williams G.\u000a      Randomised controlled trial of a schools based, per led, smoking\u000a      intervention. Medical Research Council. 2001-2005, &#163;1,428,087\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [a] Department of Health (2010) A smokefree future: A comprehensive\u000a      tobacco control strategy for England. White Paper (p 31).This\u000a      substantiates that the research associated with ASSIST has had an impact\u000a      on policy.\u000a    [b] Amos A and Hastings G, Angus K, Bostock Y, Fidler J. (2009). A review\u000a      of young people and smoking in England. Public Health Research Consortium.\u000a      (p97) This is a review cited in [a] which further substantiates the impact\u000a      on policy.\u000a    [c] Department of Health (2009) Healthy lives, brighter futures: The\u000a      strategy for children and young people's health (p 59). Substantiates the\u000a      impact on policy.\u000a    [d] Melanie Chambers (2009) NHS Stop Smoking Services: Service and\u000a      monitoring guidance (p 69). Substantiates the impact on policy.\u000a    [e] National Institute for Health and Clinical Excellence (2010) NICE\u000a      public health guidance 23: School-based interventions to prevent smoking\u000a      (p10). Available at:\u000a      http:\/\/www.nice.org.uk\/nicemedia\/live\/12827\/47582\/47582.pdf\u000a      . Substantiates the impact on policy.\u000a    [f] Bauld L, Brandling J, Templeton J (2009) Facilitators and barriers to\u000a      the delivery of school- based interventions to prevent the uptake of\u000a      smoking among children: A systematic review of qualitative research\u000a      Available at:\u000a      http:\/\/www.nice.org.uk\/nicemedia\/live\/12827\/47627\/47627.pdf\u000a      . Substantiates the impact on policy.\u000a    [g] Uthman O, Yahaya I, Pennant M, Bayliss S, Aveyard P, Jit M, Barton P,\u000a      Meads C, Chen Y. (2009) School-based interventions to prevent the uptake\u000a      of smoking among children and young people: effectiveness review Available\u000a      at:\u000a      http:\/\/www.nice.org.uk\/nicemedia\/live\/12827\/47624\/47624.pdf\u000a      Substantiates the impact on policy.\u000a    [h] Welsh Government (2012) Welsh Government: Tobacco Control Action Plan\u000a      for Wales (pp 7,15-16). Available at:\u000a      http:\/\/wales.gov.uk\/topics\/health\/improvement\/index\/tobaccoplan\/?lang=en.\u000a      Substantiates the impact on policy.\u000a    [i] Michael Day, Chief Executive Officer, DECIPHer Impact Ltd, (2013)\u000a      Personal communication. For verification of the impact on teenagers\u000a      including details regarding DECIPHer Impact Ltd, licence sales and the\u000a      reach of the intervention.\u000a    [j] DECIPHer IMPACT- Winners of the BRIG-H 2011 award for Innovation!\u000a      Available at:\u000a      http:\/\/www.decipher-impact.com\/?p=121\u000a      and Cardiff University's Innovation in Health Care Award 2013 available\u000a      at:\u000a      http:\/\/www.innovation-network.org.uk\/innovation-awards\/innovation-in-healthcare-award-1.aspx Evidence of recognition\u000a      of the impact on health and commerce. \u000a    ","Title":"\u000a    DECIPHer-ASSIST: Reducing teenage smoking through a cost-effective\u000a      prevention programme\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Smoking kills nearly six million people a year and is forecast to kill\u000a      one billion people in the 21st century. Tobacco users who die\u000a      prematurely leave their families without income, increase the cost of\u000a      healthcare, and impede economic development. In the UK, smoking accounts\u000a      for nearly 20% of deaths and costs the NHS around &#163;2.7 billion every year.\u000a      Children who start smoking before the age of 16 are twice as likely to\u000a      continue as adults (compared to those who start later). They are also more\u000a      likely to have respiratory illnesses, use alcohol and drugs, and be absent\u000a      from school compared to those who do not smoke.\u000a    Preventing young people from starting to smoke is a key element of\u000a      tobacco-control strategies. ASSIST is based on an American model where\u000a      opinion leaders in the gay community train others to promote better sexual\u000a      health choices. ASSIST adapted this model and trained and supported\u000a      influential Year 8 school students (aged 12-13) to support their friends\u000a      and classmates [1]. These `peer supporters' have informal conversations\u000a      with other Year 8 students about the risks of smoking and the benefits of\u000a      being smoke-free.\u000a    ASSIST was a joint initiative of the Universities of Bristol and Cardiff.\u000a      In the major part of the research the intervention was further developed\u000a      and evaluated by a randomised controlled trial (RCT) funded by the Medical\u000a      Research Council [2]. Rona Campbell from the University of Bristol led\u000a      this research jointly with Laurence Moore of Cardiff University. The RCT\u000a      followed young people for two years and found ASSIST was effective in\u000a      reducing smoking uptake by 22% over this period [3]. The trial results\u000a      were published in The Lancet and estimated that if implemented\u000a      throughout the UK, the programme would prevent 40,000 young people taking\u000a      up smoking each year. The research also evaluated the delivery process to\u000a      help understand what made the programme successful. It found that ASSIST\u000a      was implemented with a high degree of fidelity and was acceptable to\u000a      schools and teachers, and to the young people who received it [4,5].\u000a      Further analysis also indicated that the ASSIST intervention was cost\u000a      effective [6].\u000a    More detailed follow-on research on the peer supporters found that those\u000a      who were asked to work informally, rather than under the supervision of\u000a      teaching staff, took the responsibility seriously and were effective at\u000a      passing on messages about not smoking to their peers [5]. This is a\u000a      research finding of considerable significance that can be applied to other\u000a      health areas.\u000a    The RCT fieldwork was carried out equally by Bristol and Cardiff\u000a      universities. The data analysis for the RCT was conducted in Bristol and\u000a      Bristol took the lead in publishing research from the RCT: eight of the\u000a      nine journal papers produced have a Bristol-based first author (Campbell,\u000a      Audrey, Starkey and Hollingworth) and in six of the nine papers Rona\u000a      Campbell is the senior (last-named) author. Jo Holliday was seconded to\u000a      Bristol from Cardiff for 9 months to work on the dissemination of ASSIST.\u000a    Bristol Research Team\u000a      Professor Rona Campbell\u000a      Dr Susanne Audrey-Research Associate\u000a      Dr Fenella Starkey-Trial-cordinator-Left 15th Sept 2007\u000a      Mrs Kathleen Cordall-Health Promotion Specialist-30th Sept 2002\u000a      Dr Rachel Hughes -Statistician\u000a      Professor William Hollingworth-Health Economist\u000a      Mr James Hawkins-Health Economist-11th April 2012\u000a      Dr Jo Holliday-Research Associate-8th Sept 2008-31st May 2010.\u000a    "},{"CaseStudyId":"40169","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"1227603","Name":"Sri Lanka"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000d\u000a    UoB research findings have influenced local, national and international\u000d\u000a      policymakers and health organisations, including the WHO, and have\u000d\u000a      resulted in the implementation of public health measures to restrict\u000d\u000a      access to specific suicide methods, as well as in curtailing news\u000d\u000a      reporting of these methods. Implementation of these approaches has\u000d\u000a      resulted in significant reductions in suicides.\u000d\u000a    Local research and its wider impact\u000d\u000a      UoB research led to the construction of effective barriers on the Clifton\u000d\u000a      Suspension Bridge, Bristol. Evaluation of the impact of these barriers on\u000d\u000a      suicide in Bristol indicates that they have prevented over 60 suicides by\u000d\u000a      jumping (1998-2012): deaths from the bridge declined from eight per year\u000d\u000a      (1994-98) to four per year (1998-2003) [6], with further reductions to\u000d\u000a      three per year in (2008-11). An estimated 30 fewer suicides occurred in\u000d\u000a      2008-13 as a result of the barriers [a]. This research has been used to\u000d\u000a      inform the planned introduction of prevention barriers at the Golden Gate\u000d\u000a      Bridge, USA (a process that has included consultation with Gunnell in 2006\u000d\u000a      during the planning of the barriers), and at other sites [b,c]. The\u000d\u000a      Department of Health (England) used the research findings in their Impact\u000d\u000a      assessment of the National Suicide Prevention Strategy [d]. The Bristol\u000d\u000a      research on preventing suicides by jumping has also been used to inform\u000d\u000a      position statements from important NGOs on this issue, e.g. the National\u000d\u000a      Suicide Prevention Lifeline (USA) statement on preventing suicide from\u000d\u000a      bridges.\u000d\u000a    Paracetamol and Co-proxamol in the UK\u000d\u000a      The pain killers paracetamol and co-proxamol accounted for almost half of\u000d\u000a      all the UK's overdose suicide deaths in the 1990s. UoB work on method\u000d\u000a      restriction [1] and the relationship between paracetamol availability,\u000d\u000a      pack size and mortality following paracetamol overdose [4] has contributed\u000d\u000a      to policies to restrict paracetamol pack size. Subsequent evaluative\u000d\u000a      research (with Oxford (lead) and Manchester) showed that restrictions in\u000d\u000a      the UK led to reductions in paracetamol deaths and liver transplantation\u000d\u000a      (estimated 765 fewer deaths in 1999-2009; this equated to 400 fewer in\u000d\u000a      2008-13[e]). Similarly, UoB's collaborative work with Oxford (lead) and\u000d\u000a      Manchester on the impact of co-proxamol withdrawal [7] demonstrated that\u000d\u000a      there have been 600 fewer co-proxamol suicides since its withdrawal\u000d\u000a      (2005-10).\u000d\u000a    Impact on countries' national policies\u000d\u000a      UoB research has materially influenced recommendations in national policy\u000d\u000a      documents. For example: The 2012 National Suicide Prevention Strategy for\u000d\u000a      England Preventing Suicide in England: a cross-government outcomes\u000d\u000a        strategy to save lives includes citations concerning prevention of\u000d\u000a      suicide by hanging and bridge jumping [f]; Ireland's 2000 Strategy Reach\u000d\u000a        Out (hanging), the 2012 USA National Strategy for Suicide\u000d\u000a        Prevention (pesticide poisoning) [g]; and the Canadian Institute of\u000d\u000a      Health Economics report Means Restriction for Suicide Prevention\u000d\u000a      (pesticides, paracetamol and coproxamol).\u000d\u000a    Global impact\u000d\u000a      UoB-led research on pesticide poisoning has been used widely by the WHO to\u000d\u000a      inform priorities for prevention in both global and regional (Western\u000d\u000a      Pacific) suicide prevention documents [h,i]. The research, including that\u000d\u000a      carried out in collaboration with colleagues in the South Asian Clinical\u000d\u000a      Toxicology Research Collaboration (SACTRC), encouraged the WHO to respond\u000d\u000a      to the global problem of pesticide suicides. Gunnell was a member of the\u000d\u000a      WHO advisory group and wrote an editorial to disseminate the work jointly\u000d\u000a      with the WHO leads for the strategy. Since the publication of these\u000d\u000a      documents, the Registrar of Pesticides in Sri Lanka has banned paraquat,\u000d\u000a      one of the most toxic pesticides ingested by humans; and China, where\u000d\u000a      pesticides account for two thirds of all suicides in rural areas, has\u000d\u000a      banned over 20 highly toxic pesticides (see: http:\/\/www.reach24h.com\/en\/news-a-events\/item\/439-production-ban-on-22-highly-toxic-pesticides.html).\u000a      Bans have also been introduced in Korea, Europe and India. Bristol researchers'\u000d\u000a      evaluation of bans on the most toxic pesticides in Sri Lanka indicated\u000d\u000a      that they resulted in 19,769 fewer suicides in 1996-2005 as compared with\u000d\u000a      1986-95 [2]. Based on these estimates, recent bans will have resulted in\u000d\u000a      many thousands of fewer suicides globally, as there are an estimated\u000d\u000a      370,000 pesticide suicides worldwide every year [3]. UoB researchers\u000d\u000a      worked with the company Syngenta to evaluate the impact of an improved\u000d\u000a      formulation of paraquat on case-fatality. It was shown that such new\u000d\u000a      formulations failed to substantially reduce case-fatality and imports of\u000d\u000a      paraquat were subsequently restricted in Sri Lanka [8].\u000d\u000a    Working with the mass media\u000d\u000a      UoB's work on suicide has informed the revised media guidelines produced\u000d\u000a      by the Samaritans (2013) and was used in briefings given to major national\u000d\u000a      news and media organisations (including ITV and the BBC). Gunnell met with\u000d\u000a      national newspaper editors in Parliament (organised by Madeleine Moon MP,\u000d\u000a      30 Jun 2009), the Press Complaints Commission (London, 20 Jan 2011), the\u000d\u000a      Evening Post (Bristol, 21 Dec 2011) and BBC, S4C and ITV and other news\u000d\u000a      agencies in Wales (Cardiff, 4 Dec 2012) to discuss their reporting of\u000d\u000a      suicide methods and to urge caution in describing suicide methods,\u000d\u000a      particularly those that are novel, highly lethal and readily accessible\u000d\u000a      such as those that have led to rises in suicide in some countries in East\u000d\u000a      Asia. The Samaritans used our research on the impact of their proactive\u000d\u000a      approach to advise the press on how to report (and when not to report)\u000d\u000a      novel methods of suicide in their submission to the Leveson Inquiry [j]\u000d\u000a    Additional benefits to society, the economy, and the police and health\u000d\u000a        services\u000d\u000a      It is estimated that for every suicide, six people are seriously affected,\u000d\u000a      so the overall fall in suicide rates reduces the emotional toll on friends\u000d\u000a      and family, who may require bereavement and counseling services and time\u000d\u000a      off work due to the bereavement (which also carries a cost to the\u000d\u000a      economy). The reduced toxicity of drugs \/ poisons taken in overdose will\u000d\u000a      also result in cost savings through reduced use of intensive care beds and\u000d\u000a      shortened hospital admissions. These are real and substantial benefits but\u000d\u000a      the actual cost saving is difficult to quantify.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    University of Bristol research has played an important role in shaping\u000d\u000a      local, national and global suicide prevention initiatives. The consequent\u000d\u000a      reductions in suicide rates have been substantial and many hundreds of\u000d\u000a      lives have been saved thanks to this research.\u000d\u000a    The scope and scale of the impact has ranged from shaping World Health\u000d\u000a      Organisation (WHO) strategy on preventing suicides by pesticide poisoning,\u000d\u000a      informing national legislation on limiting access to the means of suicide\u000d\u000a      in several countries (e.g. analgesics in the UK &#8212; 1000 fewer suicides\u000d\u000a      between 2008 and 2013), informing guidelines on the responsible reporting\u000d\u000a      of suicide for the UK media, and developing highly successful prevention\u000d\u000a      measures at the Clifton Suspension Bridge, a suicide site in Bristol (30\u000d\u000a      fewer suicides between 2008 and 2013).\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    University of Bristol\u000d\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Gunnell D, Frankel S. Prevention of suicide: aspirations and\u000d\u000a      evidence. BMJ 1994,308:1227-33. (Document can be supplied upon request)\u000d\u000a    \u000a\u000a[2] Biddle L, Donovan J, et al. A qualitative study of factors\u000d\u000a      influencing the decision to use hanging as a method of suicide. BJPsych\u000d\u000a      2010; 197, 320-325. DOI: 10.1192\/bjp.bp.109.076349\u000d\u000a    \u000a\u000a[3] Gunnell D, Eddleston M, Phillips M, et al The global burden of fatal\u000d\u000a      pesticide self-poisoning: Systematic review. BMC Public Health\u000d\u000a      2007, 7:357. DOI:10.1186\/1471-2458-7-357\u000d\u000a    \u000a\u000a[4] Gunnell D, Hawton K, Murray V, et al. Use of paracetamol\u000d\u000a      for suicide and non-fatal self-poisoning in the UK and France: are\u000d\u000a      restrictions on availability justified? JECH. 1997;51:175-179 DOI:\u000d\u000a      10.1136\/jech.51.2.175 (document can be supplied upon request)\u000d\u000a    \u000a\u000a[5] Gunnell D, Fernando R, Hewagama M et al. The impact of pesticide\u000d\u000a      regulations on suicide in Sri Lanka. Int J Epid 2007;36:1235-42.\u000d\u000a      DOI: 10.1093\/ije\/dym164\u000d\u000a    \u000a\u000a[6] Bennewith O, Nowers M, Gunnell D. The effect of the barriers on the\u000d\u000a      Clifton Suspension Bridge, England on local patterns of suicide. BJPsych\u000d\u000a        2007;190:266-7 DOI: 10.1192\/bjp.bp.106.027136\u000d\u000a    \u000a\u000a[7] Hawton K, Bergen H, Simkin S, Wells C, Kapur N, Gunnell D. Six-Year\u000d\u000a      Follow-Up of Impact of Co-proxamol Withdrawal in England and Wales on\u000d\u000a      Prescribing and Deaths. PLoS Med 2012; 9: e1001213 DOI:\u000d\u000a      10.1371\/journal.pmed.1001213\u000d\u000a    \u000a\u000a[8] Wilks MF, Fernando R, Ariyananda PL, Eddleston M, Berry DJ, Tomeson\u000d\u000a      JA, Buckley NA, Jayamanne S, Gunnell D, Dawson A. Improvement in survival\u000d\u000a      after paraquat following introduction of a new formulation in Sri Lanka. PloS\u000d\u000a        Med. 2008;5(2): e49. DOI: 10.1371\/journal.pmed.0050049\u000d\u000a    \u000aKey Grants (all peer reviewed)\u000d\u000a    [9] Gunnell (co-investigator) (2003-4) Coroner Based Investigation of\u000d\u000a        Suicide Methods. Department of Health. &#163;122,000\u000d\u000a    [10] Gunnell (PI), Bennewith (co-investigator) (2005-6) The effect of\u000d\u000a        barriers on the Clifton Suspension Bridge, England on local patterns of\u000d\u000a        suicide: implications for prevention. American Foundation for\u000d\u000a      Suicide Prevention $45,000.\u000d\u000a    [11] Gunnell (PI), Donovan, Biddle (co-investigators). (2006-9) What\u000d\u000a        influences the decision to use hanging as a means of suicide? A\u000d\u000a        qualitative study of people who have survived a nearly lethal suicide\u000d\u000a        attempt. Department of Health &#163;111,319.\u000d\u000a    [12] Gunnell (PI), Donovan (co-investigator) (2007-11) A multi-centre\u000d\u000a        programme of clinical and public health research in support of the\u000d\u000a        National Suicide Prevention Strategy for England. Department of\u000d\u000a      Health (NIHR) &#163;1,012,247.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [a] Sources to corroborate impact of research on suicide by\u000d\u000a      jumping\/suicide from the Clifton Suspension Bridge: Data from Mr Dave\u000d\u000a      Anderson, Bridgemaster, Clifton Suspension Bridge Suicide showing\u000d\u000a      reduction in suicide; [reference [6], page 2 includes data on deaths\u000d\u000a      before the installation of the barrier].\u000d\u000a    [b] The use of barriers on the Clifton Suspension Bridge has used to\u000d\u000a      inform construction of a bridge barrier for the Archway Bridge, London\u000d\u000a      (email seeking advice)\u000d\u000a    [c] The use of barriers on the Clifton Suspension Bridge has used to\u000d\u000a      inform construction of a bridge barrier for the Archway Bridge: online\u000d\u000a      news article citing suspension bridge barrier halving suicides): http:\/\/hollowayexpress.co.uk\/large-anti-suicide-barriers-to-be-installed-at-archway-bridge\u000d\u000a    [d] Source to corroborate use of research on suicide by jumping on\u000d\u000a      national strategy Impact assessment - used in UK Government Impact\u000d\u000a      Assessment \/ Consultation on New Government Suicide Prevention Strategy\u000d\u000a      2011 http:\/\/www.thecalmzone.net\/wp-content\/uploads\/2013\/05\/government-suicide-strategy-impact-assessment.pdf\u000d\u000a      (page 2);\u000d\u000a    [e] Evidence of the impact of co-proxamol and paracetamol restrictions on\u000d\u000a      reducing suicides. Reference [7] and Hawton et al Long term effect of\u000d\u000a      reduced pack sizes of paracetamol on poisoning deaths and liver transplant\u000d\u000a      activity in England and Wales: interrupted time series analyses BMJ2013;346:f403\u000d\u000a      doi: 10.1136\/bmj.f403\u000d\u000a    [f] Examples of impact of work on National Suicide Prevention Strategy\u000d\u000a      for England: National Suicide Prevention Strategy for England (DoH 2012):\u000d\u000a      Preventing Suicide in England: a cross-government outcomes strategy to\u000d\u000a      save lives (DoH, 2012) http:\/\/www.dh.gov.uk\/health\/files\/2012\/09\/Preventing-Suicide-in-England-A-cross-government-outcomes-strategy-to-save-lives.pdf,\u000d\u000a      (UoB research cited on pages 54-56)\u000d\u000a    [g] Evidence of reach of research into other country's national\u000d\u000a      prevention strategies: Research cited to support method restriction on\u000d\u000a      page 44 of the 2012 National Strategy for Suicide Prevention document\u000d\u000a      (USA): http:\/\/www.surgeongeneral.gov\/library\/reports\/national-strategy-suicide-prevention\/full_report-rev.pdf;\u000d\u000a    [h] Evidence of reach of research into WHO strategies to prevent suicide,\u000d\u000a      particularly pesticide suicide - research findings cited in Violence\u000d\u000a        prevention, the evidence: Guns, knives and pesticides: reducing access\u000d\u000a        to lethal means WHO 2009 ISBN 978 92 4 159773 9 (see pages 63, 71\u000d\u000a      and 72 references: 6,94,111);\u000d\u000a    [i] Towards Evidence Based Suicide Prevention Programmes WHO Western\u000d\u000a      Pacific Region: WHO, 2010 ISBN 978 92 9061 462 3 (see pages 9,12,14,17);\u000d\u000a    [j] Evidence of impact of research on media reporting of suicide methods:\u000d\u000a      Research on novel methods of suicide cites Samaritans evidence to the\u000d\u000a      Leveson Inquiry: http:\/\/www.levesoninquiry.org.uk\/witness\/samaritans\/.\u000d\u000a    [k] Further evidence of impact of research on media reporting of suicide\u000d\u000a      methods: Letter from The Samaritans summarising the contribution made in\u000d\u000a      relation to working with the media to improve reporting of suicide.\u000d\u000a    ","Title":"\u000d\u000a    Fewer suicides worldwide following changes in policy and practice\u000d\u000a      influenced by University of Bristol research\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2653822","Name":"Cardiff"},{"GeoNamesId":"2643123","Name":"Manchester"},{"GeoNamesId":"2640729","Name":"Oxford"},{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Each year, suicide accounts for 5,000 deaths in the UK and one million\u000d\u000a      deaths worldwide. In 1994 University of Bristol (UoB) researchers carried\u000d\u000a      out the first systematic review of suicide prevention strategies [1]; they\u000d\u000a      identified that restricting access to commonly used, highly lethal methods\u000d\u000a      of suicide is one of the few effective approaches to suicide prevention\u000d\u000a      strategies. This is because the risk of death varies enormously depending\u000d\u000a      on the method used in a suicide attempt. Following an overdose of\u000d\u000a      paracetamol and most antidepressants it is under 1%; after taking as\u000d\u000a      little as a tablespoonful of the toxic weed-killer paraquat it is over\u000d\u000a      70%. The risk rises to over 95% in people who jump from high structures\u000d\u000a      such as the Clifton Suspension Bridge in Bristol. Most people who survive\u000d\u000a      a suicide attempt, even one using a high-lethality method, do not make a\u000d\u000a      repeat attempt.\u000d\u000a    The researchers' seminal review led to a series of studies, many led by\u000d\u000a      the UoB, to clarify the factors that influence people's choice of suicide\u000d\u000a      method [2], the key methods of suicide used in the UK and internationally\u000d\u000a      [3,9], which methods were likely to respond to being restricted [4,5,9],\u000d\u000a      and evidence of the effectiveness of such approaches [5,6,7].\u000d\u000a    Research underpinning this impact included: (i) qualitative interviews\u000d\u000a      (led by Biddle, Donovan and Gunnell, in collaboration with University of\u000d\u000a      Taipei) with people who have survived high lethality suicide attempts in\u000d\u000a      order to better understand their choice of suicide method [2,11]; (ii)\u000d\u000a      evaluations (using natural experimental designs) of specific approaches\u000d\u000a      aimed at reducing suicide by restricting access to methods such as\u000d\u000a      pesticides and analgesics (UoB, Oxford and Edinburgh leads) [5-7,9,12];\u000d\u000a      (iii) systematic reviews [1,3,9] and (iv) collaboration with industry\u000d\u000a      (Syngenta, the manufacturer of paraquat and other pesticides) to evaluate\u000d\u000a      how a new formulation of paraquat affected death rates following\u000d\u000a      self-poisoning with paraquat (Gunnell, epidemiology lead) [8].\u000d\u000a    This research has been complemented by systematic reviews of the evidence\u000d\u000a      concerning use of specific methods of suicide (pesticides, hanging,\u000d\u000a      firearms, paracetamol and the painkiller co-proxamol) &#8212; how common they\u000d\u000a      are, how preventable they are and death rates [3,9].\u000d\u000a    Key findings of the research:\u000d\u000a    \u000d\u000a      Pesticide self-poisoning accounts for approximately one third of\u000d\u000a        global suicides [3].\u000d\u000a      Bans on toxic pesticides can have a profound impact on method-specific\u000d\u000a        and overall suicide rates. A natural experimental evaluation of bans on\u000d\u000a        toxic pesticides in Sri Lanka identified a halving of suicides following\u000d\u000a        the bans [5].\u000d\u000a      In-depth qualitative studies with survivors of near-lethal suicide\u000d\u000a        methods in the UK and Taiwan reveal that news media reporting informed\u000d\u000a        their choice of suicide method [2,11].\u000d\u000a      Preventive barriers on the Clifton Suspension Bridge led to a halving\u000d\u000a        of jumping suicides, with no substitution to other sites in Bristol\u000d\u000a        [6,10].\u000d\u000a      Bans on co-proxamol have resulted in a reduction in its use for\u000d\u000a        suicide with no evidence of major substitution to other pain killers\u000d\u000a        [7,12].\u000d\u000a    \u000d\u000a    Names of key University of Bristol researchers:\u000d\u000a      Professor David Gunnell (Professor of Epidemiology), University of\u000d\u000a      Bristol, 1993-present.\u000d\u000a      Professor Jenny Donovan (Professor of Social Medicine), University of\u000d\u000a      Bristol 1990-present.\u000d\u000a      Dr Lucy Biddle (Lecturer in Medical Sociology), University of Bristol\u000d\u000a      1999-present.\u000d\u000a      Ms Olive Bennewith (Research Associate) University of Bristol 1998-2012.\u000d\u000a    "},{"CaseStudyId":"40170","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"3017382","Name":"France"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    4.1 Updated treatment guidelines resulted in earlier treatment\u000d\u000a    Earlier ART leads to better treatment outcomes for people with HIV\u000d\u000a      throughout the world with fewer deaths and hospitalisations. ART-CC's\u000d\u000a      research on prognosis [1-3] has been extensively cited by treatment\u000d\u000a      guidelines between 2008 and 2013. Our 2009 paper on timing of ART [3],\u000d\u000a      which clarified that the CD4 threshold for starting ART should be at least\u000d\u000a      350 cells\/mm3, was particularly influential and informed\u000d\u000a      changes during 2009-11 to World Health Organization (WHO) [a], British\u000d\u000a      [b], European, US [c], and other national [d] guidelines to recommend\u000d\u000a      starting treatment earlier.\u000d\u000a    \u000d\u000a\u000d\u000a\u000d\u000a    High income countries: ART-CC research suggests that increasing\u000d\u000a      the CD4 count at start of ART from 200 to 350 cells\/mm3 will\u000d\u000a      increase life expectancy of a 20-year-old by between 8 [6] and 12 years\u000d\u000a      [5]. The bar chart on page 2 (based on unpublished ART-CC data) shows that\u000d\u000a      patients started treatment earlier in the UK, Europe and North America\u000d\u000a      after guidelines were changed in 2009-10. The Health Protection Agency\u000d\u000a      (HPA) 2012 report stated that between 2010 and 2011 AIDS diagnoses in the\u000d\u000a      UK decreased by 33% and mortality by 18% [e].\u000d\u000a    Low income countries: UNAIDS reported that the number of people in\u000d\u000a      Africa receiving ART increased from less than a million in 2005 to 7.1\u000d\u000a      million in 2012, with nearly 1 million added in 2012 alone. During 2009-11\u000d\u000a      the recommended threshold for treatment in at least 29 low and middle\u000d\u000a      income countries changed (based in part on ART-CC's work) from 200 to 350\u000d\u000a      cells\/mm3 [d]. This has led to more and earlier treatment,\u000d\u000a      particularly in Africa. Data from Western Cape, South Africa, show the\u000d\u000a      steep increase in numbers of people treated and their increased CD4 count\u000d\u000a      at start of ART as a consequence of the adoption of the new guidelines\u000d\u000a      (graph &#8212; personal communication, Cape Town University, South Africa).\u000d\u000a      During this period, AIDS-related deaths in Africa fell by 32% from\u000d\u000a      approximately 1.75 to 1.19 million (calculated from UNAIDS 2012 global\u000d\u000a      report). The massive scale-up in treatment due to increasing the threshold\u000d\u000a      from 200 to 350 cells\/mm3 has been replicated across the globe.\u000d\u000a    \u000d\u000a\u000d\u000a\u000d\u000a    4.3 Raised public awareness of consequences of starting treatment late\u000d\u000a    May worked with the UK Collaborative HIV Cohort (UK CHIC) Study to raise\u000d\u000a      awareness of the loss in life expectancy due to starting HIV treatment\u000d\u000a      later than guidelines recommend [6]. This work was extensively reported in\u000d\u000a      the UK and worldwide, for example in a two-page feature in The\u000d\u000a        Independent in October 2011 [f] and in The China Daily [f]\u000d\u000a      and was also discussed by professional publications such as Nursing\u000d\u000a        Times, on 8 November 2011 [f]. The same research was presented in a\u000d\u000a      poster [f] displayed in hospital waiting rooms across the UK, to\u000d\u000a      communicate the findings to patients as part of a wider effort by UKCHIC\u000d\u000a      to disseminate information to key patient communities. According to the\u000d\u000a      2012 HPA UK HIV report, the proportion of HIV positive people diagnosed\u000d\u000a      late (with CD4 count below 350 cells\/mm3) fell by 3% during\u000d\u000a      2011 [e].\u000d\u000a    The ART-CC paper on life expectancy [4] influenced a campaign to halve\u000d\u000a      the proportion of people diagnosed late with HIV [g]. The UK CHIC life\u000d\u000a      expectancy paper [5] contributed evidence to \"Standard 1: HIV Testing and\u000d\u000a      Diagnosis\" in the policy document from BHIVA on \"Standards of Care for\u000d\u000a      People Living with HIV\" [h]. Earlier diagnosis and prompt treatment\u000d\u000a      reduces onward transmission since successfully treated people with\u000d\u000a      suppressed virus replication do not transmit HIV [h]. This not only avoids\u000d\u000a      illnesses and early deaths, but also has the potential to deliver huge\u000d\u000a      financial savings. The HPA 2011 report estimated that the prevention of\u000d\u000a      one new HIV infection saves the public purse between &#163;280,000 and &#163;360,000\u000d\u000a      in direct lifetime healthcare costs [e]. This research therefore impacts\u000d\u000a      not only the 22,600 people the HPA estimated were living with undiagnosed\u000d\u000a      HIV in the UK in 2011 (2012 report) [e] but also uninfected individuals,\u000d\u000a      who are less likely to be exposed to HIV if those infected with HIV are\u000d\u000a      diagnosed and treated [e].\u000d\u000a    4.4 Improved access to insurance.\u000d\u000a    The opportunity to obtain life insurance has a major impact on quality of\u000d\u000a      life, particularly since a term of 20 years is required for a mortgage.\u000d\u000a      ART-CC research [1,6] had a commercial impact by providing data to\u000d\u000a      insurance companies that led them to improve the provision of life\u000d\u000a      insurance and open up the insurance market to HIV positive people. Swiss\u000d\u000a      Re [i], Hannover Re (UK) and AERAS (France) [i] based their assessment of\u000d\u000a      insurability of HIV positive people on ART-CC's publications [1,6] and\u000d\u000a      web-based mortality risk calculator. Based on our 2002 data [1], SwissRe\u000d\u000a      recommended that certain patient groups should be offered up to 10 years'\u000d\u000a      insurance. During 2010-12, ART-CC worked with SwissRe to extend this to 20\u000d\u000a      years and estimate the excess premium that HIV positive individuals would\u000d\u000a      need to pay [6]. This had an impact prior to publication: ART-CC tables\u000d\u000a      were presented at a national meeting of insurers in Paris [i], and New\u000d\u000a      York [i] by Swiss Re, and to the French AIDS research agency (Agence\u000d\u000a      Nationale de Recherche sur la Sida et les hepatites virales, ANRS) by\u000d\u000a      May[i]. Based on this research, Swiss Re updated its underwriting\u000d\u000a      guidelines for western Europe resulting in cheaper insurance costs and\u000d\u000a      broader coverage with policies offered up to 25 years [j]. The Head of\u000d\u000a      Research Innovation and Product Development, Swiss Re, stated that there\u000d\u000a      would be \"greater access to home ownership and to business loans for HIV\u000d\u000a      positive persons\" and the research \"has led to increased normalisation of\u000d\u000a      HIV compared to other chronic diseases... The study has also influenced\u000d\u000a      Swiss Re's ratings for HIV+ lives in South Africa and the ratings of\u000d\u000a      direct insurers\" and \"has influenced debate on HIV ratings in India and\u000d\u000a      Australia\" [j].\u000d\u000a    ART-CC research on insurability [6] has impacted awareness of insurance\u000d\u000a      products among HIV positive people through the work of advocacy groups\u000d\u000a      such as HIV i-base [i] and the European AIDS Treatment Group, which in\u000d\u000a      discussing our paper [6] wrote \"People doing well on HIV therapy should be\u000d\u000a      eligible for life insurance\" [i]. The proportion of UK insurers that\u000d\u000a      provide services to HIV positive people increased from 33% to 66% between\u000d\u000a      2010 and 2012 [i]. A 2012 UK survey found that the percentage of HIV\u000d\u000a      positive people who knew of the existence of life insurance products\u000d\u000a      increased from only 20% in 2012 to 78% in 2013 [i].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    In 2011, 34 million people worldwide were living with, and 1.7 million\u000d\u000a      died from, HIV\/AIDS. Since 2002, HIV-positive people have benefited from\u000d\u000a      research by the Antiretroviral Therapy Cohort Collaboration (ART-CC) based\u000d\u000a      at University of Bristol (UoB). Research on the timing of ART led to\u000d\u000a      updated international HIV treatment guidelines that recommended starting\u000d\u000a      treatment earlier. Research on life expectancy highlighted the benefits to\u000d\u000a      patients of earlier ART, and was used by policy makers, clinicians and\u000d\u000a      patient groups to promote earlier treatment. Patients are now starting\u000d\u000a      treatment earlier resulting in increased life expectancy. Insurance\u000d\u000a      companies changed their criteria for providing life insurance, influenced\u000d\u000a      by ART-CC.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Bristol\u000d\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"1085599","Name":"Province of the Western Cape"},{"GeoNamesId":"2988507","Name":"Paris"}],"References":"\u000d\u000a    \u000a[1] Egger M, May M, Sterne JAC. et al. Prognosis of\u000d\u000a      HIV-1-infected patients starting highly active antiretroviral therapy: a\u000d\u000a      collaborative analysis of prospective studies. The Lancet. 2002 Jul;360\u000d\u000a      (9327):119 - 129. doi:10.1016\/S0140-6736(02)09411-4\u000d\u000a    \u000a\u000a[2] Braitstein, P, et al (including May, Sterne, Egger).\u000d\u000a      Mortality of HIV-1-infected patients in the first year of antiretroviral\u000d\u000a      therapy: Comparison between low-income and high-income countries. Lancet,\u000d\u000a      2006. 367 (9513): p. 817-24. PMID: 16530575\u000d\u000a      doi:10.1016\/S0140-6736(06)68337-2\u000d\u000a    \u000a\u000a[3] Sterne JA, May M, Costagliola D, Egger M et al.\u000d\u000a      Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected\u000d\u000a      patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;\u000d\u000a      373 (9672): 1352-1363. PMID: 19361855 doi:10.1016\/S0140-6736(09)60612-7\u000d\u000a    \u000a\u000a[4] ART-CC (including May, Sterne). Life expectancy of\u000d\u000a      individuals on combination antiretroviral therapy in high-income\u000d\u000a      countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;\u000d\u000a      372 (9635): 293-299. PMID: 18657708 doi:10.1016\/S0140-6736(08)61113-7\u000d\u000a    \u000a\u000a[5] May M, Gompels M, Delpech V et al. Impact of late diagnosis\u000d\u000a      and treatment on life expectancy in people with HIV-1: UK Collaborative\u000d\u000a      HIV Cohort (UK CHIC) Study. BMJ 2011, 343:d6016 doi: http:\/\/dx.doi.org\/10.1136\/bmj.d6016\u000d\u000a    \u000a\u000a[6] Kaulich-Bartz J, Dam W, May MT, Lederberger B et al. Sterne\u000a        JAC.Insurability of HIV-positive people treated with antiretroviral\u000d\u000a      therapy in Europe: collaborative analysis of HIV cohort studies. AIDS\u000d\u000a      2013; 27:1641-1655 PMID: 3678894 doi: 10.1097\/QAD.0b013e3283601199\u000d\u000a    \u000aMedical Research Council (MRC) Peer Reviewed Grants\u000d\u000a    Sterne JAC (PI), Ingle SM, May M, Egger M, et al. Prognosis of\u000d\u000a      HIV-positive patients treated with antiretroviral therapy: comparative\u000d\u000a      analyses and treatment strategies. MR\/J002380\/1 &#163;589,409 2012-15.\u000d\u000a    Sterne JAC (PI), May M, Egger M. et al. Monitoring and modelling\u000d\u000a      prognosis in the era of HAART. G0100221 &#163;171,227, 2005-8 and G0700820\u000d\u000a      &#163;627,188 2008-11.\u000d\u000a    Egger M (PI), Sterne JAC, et al. The impact of highly active\u000d\u000a      antiretroviral therapy: Monitoring and modelling benefit and potential\u000d\u000a      harm. G0100221, &#163;218,046, 2002-5.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [a-d] corroborate influence of ART-CC research on changes in treatment\u000d\u000a      guidelines worldwide, [e-g] on earlier treatment, decreased AIDS and\u000d\u000a      deaths in UK, and [i-j] document increased provision of insurance based on\u000d\u000a      ART-CC analyses.\u000d\u000a    [a] WHO ART for HIV infection in adults and adolescents: recommendations\u000d\u000a      for a public health approach 2010 revision [cites 2 P65 &amp; 3 P26] http:\/\/www.who.int\/hiv\/pub\/arv\/adult2010\/en\/index.html\u000d\u000a    [b] British HIV Association guidelines for the treatment of\u000d\u000a      HIV-1-positive adults with ART 2012 [cites 3 P22 and 5 P8] http:\/\/www.bhiva.org\/documents\/Guidelines\/Treatment\/2012\/hiv1029_2.pdf\u000d\u000a    [c] US 2011: Guidelines for the use of antiretroviral agents in\u000d\u000a      HIV-1-infected adults and adolescents. 1\/2011; 1-166. [cites 1 P7 &amp;\u000d\u000a      extensively discusses 3 P28-9], revision 10\/2011 [cites 4 P25] http:\/\/aidsinfo.nih.gov\/guidelines\u000d\u000a    [d] Table of low and middle income countries that have changed guidelines\u000d\u000a      to start ART at CD4 count threshold of 350 derived from http:\/\/www.aidstar-one.com\/\u000d\u000a    [e] HPA: HIV in the United Kingdom: 2011 [cites 5 P4] and 2012 Annual\u000d\u000a      Reports\u000d\u000a      http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1317131685847\u000d\u000a      and C\/1317137200016\u000d\u000a    [f] Media, NHS and charities awareness reports after publication of paper\u000d\u000a      on life expectancy [5].\u000d\u000a    [g] Early testing saves lives: HIV is a public health priority. 2nd\u000d\u000a      edition Halve It Coalition.\u000d\u000a      http:\/\/www.bhiva.org\/documents\/Publications\/Halve_it_Position_Paper.pdf\u000d\u000a      [cites 4 P7]\u000d\u000a    [h] BHIVA Standards of Care for People Living with HIV in 2013 - Standard\u000d\u000a      1: HIV Testing and Diagnosis [cites 5 P12] http:\/\/www.bhiva.org\/standards-of-care-2012.aspx\u000d\u000a    [i] PDF Evidence of impact of ART-CC on insurability and awareness of\u000d\u000a      life insurance for HIV+.\u000d\u000a    [j] Personal statement: Director, Swiss Re.\u000d\u000a    ","Title":"\u000d\u000a    Improving treatment guidelines, life expectancy and access to life\u000d\u000a      insurance for HIV positive people\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    2.1 The Antiretroviral Therapy (ART) Cohort Collaboration\u000d\u000a    ART-CC is a large collaboration set up in 2000 to study the survival of\u000d\u000a      HIV positive individuals starting treatment with ART. Funded by four\u000d\u000a      successive grants from the Medical Research Council, it includes nineteen\u000d\u000a      cohorts from Europe and North America and is coordinated by a team based\u000d\u000a      in the SSCM, UoB, led by Professor Jonathan Sterne and Dr Margaret May.\u000d\u000a    2.2 Informing treatment strategies\u000d\u000a    Analyses published in The Lancet in 2002, based on over 12000\u000d\u000a      patients, identified that the most important predictor of mortality was\u000d\u000a      the CD4 count, a measure of immune deficiency, at which patients started\u000d\u000a      ART [1]. Estimates of cumulative mortality for 80 risk groups were made\u000d\u000a      available via a web-based calculator (www.art-cohort-collaboration.org).\u000a      Scale-up of treatment in low-income countries started in 2002, and in 2006\u000d\u000a      ART-CC published the first comparison of mortality of patients starting\u000d\u000a      ART between low and high-income countries [2]. When patients and\u000d\u000a      physicians consider starting ART, they must balance its beneficial effects\u000d\u000a      in preventing AIDS and death with harmful side-effects and the\u000d\u000a      inconvenience of taking lifelong medication. Before 2009 the CD4 count at\u000d\u000a      which ART should be started was a central, unresolved issue in the care of\u000d\u000a      HIV positive people. ART-CC provided evidence that 350 cells\/mm3\u000d\u000a      should be the minimum CD4 count below which ART should be started [3].\u000d\u000a    2.3 Life expectancy and the consequences of late treatment\u000d\u000a    ART-CC found that improvements in treatment for HIV decreased mortality\u000d\u000a      by nearly 40% and increased life expectancy by 13 years in high-income\u000d\u000a      countries between 1996-2005 [4], but that starting treatment too late\u000d\u000a      resulted in poorer survival [1,4]. May worked with the UK Collaborative\u000d\u000a      HIV Cohort (UK CHIC) Study to raise awareness amongst the general public\u000d\u000a      that starting treatment later than guidelines recommended resulted in up\u000d\u000a      to 15 years' loss of life [5]. For patients treated in the UK between 1996\u000d\u000a      and 2008, life expectancy was 13 years less than that of the UK general\u000d\u000a      population, and lower the later in the course of HIV disease that patients\u000d\u000a      started treatment. Life expectancy at age 20 was 38 years in those who\u000d\u000a      started ART with CD4 count &lt;100, but &gt;53 years in those who started\u000d\u000a      with CD4 between 200 and 350 cells\/mm3.\u000d\u000a    2.4 Insurability of people living with HIV\u000d\u000a    In 2009, access to life insurance was very limited for people living with\u000d\u000a      HIV. Swiss Re (a reinsurance company based in Zurich, Switzerland)\u000d\u000a      collaborated with ART-CC to analyse data in the manner most useful for\u000d\u000a      promoting insurance by estimating excess mortality in HIV positive people\u000d\u000a      compared with expected mortality in the insured populations in 6 European\u000d\u000a      countries based on actuarial tables. This research showed that up to 50%\u000d\u000a      of HIV patients in lower risk groups could be eligible for life insurance\u000d\u000a      with terms up to 25 years [6].\u000d\u000a    ART-CC Co-ordinating Centre, University of Bristol team members\u000d\u000a    Prof Matthias Egger (2000-4 (Visiting Prof from 2004)); Prof Jonathan\u000d\u000a      Sterne (2000-present); Dr Margaret May (2000-present); Ross Harris\u000d\u000a      (2004-8); Dr Suzanne Ingle (2010-present).\u000d\u000a    "},{"CaseStudyId":"40171","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    The UoB MPES group contributed to the 2008 and 2013 Revisions of the NICE\u000d\u000a      Methods Guide, which define the role for MTC methods in submissions to\u000d\u000a      NICE [a,b]. The Technical Support Documents developed by the MPES group,\u000d\u000a      available on the NICE Decision Support Unit website [5], are cited in the\u000d\u000a      NICE 2012 Guidelines Manual [c,d], which define the methods to be used in\u000d\u000a      NICE Clinical Guidelines. The same methods and WinBUGS code are\u000d\u000a      recommended by the International Society for Pharmacoeconomics and\u000d\u000a      Outcomes Research, the leading society for Health Technology Assessment\u000d\u000a      methods [e].\u000d\u000a    Impact of MTC methods via NICE Technology Appraisals\u000d\u000a    Mixed Treatment Comparisons have been presented in submissions underlying\u000d\u000a      59 (46%)[f] of the 129 NICE Technical Appraisals (TA) since January 2009,\u000d\u000a      covering a wide range of clinical areas[f]. Of these, 24 (41%) directly\u000d\u000a      cite papers by the MPES group and\/or clearly use WinBUGS code written by\u000d\u000a      the MPES group [f]. NICE Technology Appraisals determine whether new\u000d\u000a      technologies are cost-effective for the UK National Health Service (NHS),\u000d\u000a      and if they are then they must be adopted by law (i.e. provided to\u000d\u000a      patients by the NHS) within three months of the guidance being issued.\u000d\u000a      NICE Technology Appraisals therefore impact directly on healthcare policy\u000d\u000a      governing which new treatment options are available to health\u000d\u000a      professionals to treat patients. Because NICE guidance is primarily based\u000d\u000a      on cost-effectiveness, it secures more health-related quality of life per\u000d\u000a      pound spent by the NHS.\u000d\u000a    For example, TA199 [f] cites MTC methods (p.213), the research of the\u000d\u000a      MPES group (references 204, 205, 230), and uses WinBUGS code derived from\u000d\u000a      the MPES groups code (p.224). Based on MTC methods TA199 recommends that\u000d\u000a      Etanercept, infliximab or adalimumab may be used for the treatment of\u000d\u000a      active and progressive psoriatic arthritis, but that the least expensive\u000d\u000a      should be used based on locally available prices. This was based on the\u000d\u000a      view that these products were equally effective, a conclusion that could\u000d\u000a      not be reached without MTC methods.\u000d\u000a    Impact of MTC methods via NICE Clinical Guidelines\u000d\u000a    The UoB MPES group has provided consultancy work to assist the\u000d\u000a      incorporation of MTC methods into several NICE Clinical Guidelines (CG) in\u000d\u000a      a range of clinical areas[d]. For example, research by the MPES group is\u000d\u000a      cited in CG153 Psoriasis (Oct 2012). The research methods that were\u000d\u000a      developed during this consultancy work, and which were used in these\u000d\u000a      guidelines, have since been published [d]. Although NICE Clinical\u000d\u000a      Guidelines are not mandatory, there is evidence that uptake is generally\u000d\u000a      good for those guidelines evaluated in the ERNIE Uptake Database,\u000d\u000a      available on the NICE web-pages. NICE Clinical Guidelines are based on\u000d\u000a      cost-effectiveness, and so uptake of the guidelines implies impact in\u000d\u000a      terms of maximising the health-related quality of life obtained from NHS\u000d\u000a      resources.\u000d\u000a    Impact of MTC methods in Canada\u000d\u000a    The Canadian Agency for Drugs and Technologies in Health (CADTH) has used\u000d\u000a      MTC methods in its reports and recommendations on second and third line\u000d\u000a      therapies for Type 2 Diabetes inadequately controlled on metformin, and\u000d\u000a      for their Therapeutic Review on Biologics in Rheumatoid Arthritis [g]. The\u000d\u000a      various biologic drugs have not been compared directly in head-to-head in\u000d\u000a      trials, and so MTC methods are essential to compare their effectiveness\u000d\u000a      and cost-effectiveness. As in the UK, the impact was to make the biologic\u000d\u000a      drugs available in Canada as the most cost-effective use of resources.\u000d\u000a    Impact of MTC methods in other countries\u000d\u000a    MTC methods are being used in other countries. In Germany the Institut\u000d\u000a      fur Qualitat und Wirtschaftlichkeit in Gesundheitswesen (IQWiG) approved\u000d\u000a      the use of MTC methods in 2009, and used them in the Final Report on\u000d\u000a      treatments for essential hypertension (A05-09). The National\u000d\u000a      Evidence-based healthcare Collaborating Agency (NECA) in South Korea has\u000d\u000a      used MTC methods since 2009 [h].\u000d\u000a    Commercial Impact\u000d\u000a    The use of MTC by pharmaceutical firms in 46% of all submissions to NICE\u000d\u000a      represents a substantial commercial activity in itself, with several\u000d\u000a      consultancy firms now specialising in conducting MTC analyses on behalf of\u000d\u000a      pharmaceutical company clients, and marketing this specialism. These\u000d\u000a      consultancy firms send staff on courses taught by the MPES group, and use\u000d\u000a      WinBUGS code developed by the group, with resulting impact in terms of\u000d\u000a      commercial economic activity [i, j].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Patients are more likely to get the most effective healthcare, at\u000d\u000a      affordable cost to the NHS, as a result of research methodology, developed\u000d\u000a      by researchers at the University of Bristol, that allows the efficacy and\u000d\u000a      cost-effectiveness of multiple treatment options to be compared, based on\u000d\u000a      all the available evidence, much more efficiently than in the past. Since\u000d\u000a      2008, these methods have been used to inform Clinical Guidelines issued by\u000d\u000a      the National Institute for Health and Care Excellence (NICE) and in\u000d\u000a      submissions to NICE's Technology Appraisals. Guidance in NICE's Technology\u000d\u000a      Appraisals is mandatory and therefore impacts directly on clinical\u000d\u000a      practice. The methodology is used in decision making by NICE's equivalents\u000d\u000a      in other countries including Canada, Germany, and South Korea, and by\u000d\u000a      consultancy firms that conduct analyses for pharmaceutical companies.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University of Bristol\u000d\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Lu G, Ades AE Combination of direct and indirect evidence in\u000d\u000a      mixed treatment comparisons. Statistics in Medicine 2004; 23:3105-3124.\u000a      doi: 10.1002\/sim.1875\u000d\u000a    \u000a\u000a[2] Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of\u000d\u000a      multiple treatments: combining direct and indirect evidence. BMJ\u000d\u000a      2005; 331:897-900. doi: http:\/\/dx.doi.org\/10.1136\/bmj.331.7521.897\u000d\u000a    \u000a\u000a[3] Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton\u000d\u000a        N, Lu G. Bayesian Methods for Evidence Synthesis in\u000d\u000a      Cost-Effectiveness Analysis. Pharmacoeconomics 2006; 24:\u000d\u000a      1-19. doi: 10.2165\/00019053-200624010-00001\u000d\u000a    \u000a\u000a[4] Sutton A, Ades A, Cooper N, Abrams KR. Use of indirect and\u000d\u000a      mixed treatment comparisons for technology assessment. Pharmacoeconomics\u000a        2008; 26:753-767. doi: 10.2165\/00019053-200826090-00006\u000d\u000a      (Document can be supplied upon request)\u000d\u000a    \u000a\u000a[5] NICE Decision Support Unit Evidence Synthesis Technical Support\u000d\u000a      Documents:\u000d\u000a      http:\/\/www.nicedsu.org.uk\/Evidence-Synthesis-TSD-series(2391675).htm\u000d\u000a      (Accessed 3rd October 2013)\u000d\u000a    \u000a\u000a[6] Lu G, Ades AE. Assessing evidence consistency in mixed\u000d\u000a      treatment comparisons. Journal of the American Statistical Association\u000d\u000a        2006; 101: 447-459. doi:10.1198\/016214505000001302\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000d\u000a    [a] Letter from NICE, Centre of Technology Evaluation: \"[a]\u000d\u000a      CTE_NICE_Letter.doc\" Letter from the Director of Health Technology\u000d\u000a      Evaluation at NICE confirming the role of the MPES group in the\u000d\u000a      development of the section on \"indirect comparisons and network\u000d\u000a      meta-analyses\" of the NICE Guide to the Methods of Technology Appraisals\u000d\u000a      (2013).\u000d\u000a    [b] Guide to the methods of technology appraisal 2013 Working Party\u000d\u000a      http:\/\/publications.nice.org.uk\/guide-to-the-methods-of-technology-appraisal-2013-pmg9\/further-information#nice-methodology-working-party\u000d\u000a\u0009  (accessed 3rd\u000d\u000a      Oct 2013)\u000d\u000a    Prof. Ades and Dr. Dias are listed as special advisors to the working\u000d\u000a        group for the development of the NICE Guide to the Methods of Technology\u000d\u000a        Appraisals (2013).\u000d\u000a    [c] Letter from NICE, Centre for Clinical Practice: \"[c]\u000d\u000a      CCP_NICE_Letter.pdf\"\u000d\u000a    Letter from NICE Centre for Clinical Practice, confirming the role of\u000d\u000a        the research and staff of the MPES group in supporting the development\u000d\u000a        of NICE clinical guidelines, and the citation to the research of the\u000d\u000a        MPES group in the NICE 2012 Guidelines Manual (2012).\u000d\u000a    [d] List of NICE Clinical Guidelines where the MPES groups research was\u000d\u000a      involved: \"[d] NICE CGs using MTC.doc\"\u000d\u000a    In 6 published and 1 forthcoming NICE Clinical Guidelines, the MPES\u000d\u000a        group were directly involved advising on and\/or conducting MTC analyses,\u000d\u000a        and in the development of new methods specifically for the guideline\u000d\u000a        (subsequently published in peer-reviewed journals). The research of the\u000d\u000a        MPES is cited in the NICE Guidelines Manual (2012).\u000d\u000a    [e] Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC,\u000d\u000a      Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A. Conducting\u000d\u000a      Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of\u000d\u000a      the ISPOR Task Force on Indirect Treatment Comparisons Good Research\u000d\u000a      Practices: Part 2. Value in Health 2011; 14:429-437. \"[e]\u000d\u000a      Hoaglin ViH 2011.pdf\"\u000d\u000a    The methods and code of the MPES group are recommended by the\u000d\u000a        International Society for Pharmacoeconomics and Outcomes Research, the\u000d\u000a        leading society for Health Technology Assessment methods.\u000d\u000a    [f] Details of the 59 NICE Technology Appraisals (TAs) since 2009 that\u000d\u000a      have used Indirect or Mixed Treatment Comparisons: \"[f] NICE TAs using\u000d\u000a      MTC.doc\"\u000d\u000a    The methods of the MPES group are used in 46% of NICE Technology\u000d\u000a        Appraisals since 2009, and the MPES group research is directly cited in\u000d\u000a        41% of those. Decisions made in NICE Technology Appraisals are\u000d\u000a        mandatory, and so directly impact on which treatments are available to\u000d\u000a        patients via the NHS.\u000d\u000a    [g] Letter from Chief Scientist and Vice President Strategic Initiatives,\u000d\u000a      Canadian Agency for Drugs and Technology in Health (CADTH): \"[g]\u000d\u000a      CADTH_Letter.pdf\"\u000d\u000a    The methods of the MPES group have been used and cited in health\u000d\u000a        technology assessments in Canada for treatments for patients with type-2\u000d\u000a        diabetes, biologics for the treatment of rheumatoid arthritis, and\u000d\u000a        treatment for atrial fibrillation. This has impacted on coverage\u000d\u000a        decisions and clinical practice in Canada.\u000d\u000a    [h] Letter from Senior Director, National Evidence-based healthcare\u000d\u000a      Collaborating Agency (NECA), Seoul, South Korea: \"[h] NECA_Letter.pdf\"\u000d\u000a    The methods of the MPES group are being used in other countries in\u000d\u000a        health technology assessments for organisations similar to NICE,\u000d\u000a        including South Korea.\u000d\u000a    [i] Letter from Vice President Health Economics, Oxford Outcomes: \"[i]\u000d\u000a      VicePresident_OO_Letter.pdf\"\u000d\u000a    The research of the MPES group is contributing to the commercial\u000d\u000a        success for Oxford Outcomes. A review by Oxford Outcomes identified 8\u000d\u000a        countries with guidelines on the use of MTC methods which cite the work\u000d\u000a        of the MPES group.\u000d\u000a    [j] Letter from Managing Director, Global HEOR &amp; Strategic Market\u000d\u000a      Access, Mapi Consultancy: \"GlobalDirector_Mapi_Letter.pdf\"\u000d\u000a    The research of the MPES group and the training the MPES group has\u000d\u000a        provided is acknowledged as contributing to commercial success for Mapi\u000d\u000a        Consultancy.\u000d\u000a    ","Title":"\u000d\u000a    Patients, organisations providing clinical guidelines, and commercial\u000d\u000a      companies benefit from new approach to comparing multiple healthcare\u000d\u000a      options\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The University of Bristol's (UoB) Multi-Parameter Evidence Synthesis\u000d\u000a      (MPES) research group, led by Professor Ades (2002-present), has been\u000d\u000a      funded by Medical Research Council programme grants, fellowships, and\u000d\u000a      research grants from July 2001-present. Other group members contributing\u000d\u000a      to the impact are Drs Lu (2002-12, Senior Research Fellow), Welton\u000d\u000a      (2002-present, Senior Lecturer), Caldwell (2002-present, Research Fellow),\u000d\u000a      and Dias (2007-present, Research Fellow). All research outputs were\u000d\u000a      published in peer reviewed journals.\u000d\u000a    MPES methods statistically combine evidence from multiple sources. The\u000d\u000a      research underpinning the impact was the development (2002-present) of\u000d\u000a      Mixed Treatment Comparison (MTC) methods (also known as Network\u000d\u000a      Meta-Analysis). Standard meta-analysis combines estimates of the relative\u000d\u000a      effects of two treatments (e.g. drug A versus drug B, or drug C versus\u000d\u000a      placebo) from all available randomized trials. However there are often\u000d\u000a      many competing health technologies for a given condition\/patient group\u000d\u000a      (e.g. drugs A, B, C, D and placebo). MTC methods allow information from all\u000d\u000a      the trials of all the treatments of interest to be compared\u000d\u000a      simultaneously (A versus B versus C versus D, etc). The simplest example\u000d\u000a      of an MTC is an \"indirect comparison\", where in the absence of trials\u000d\u000a      comparing A versus B, the effect of A versus B is inferred from trials\u000d\u000a      comparing A versus C and trials comparing B versus C.\u000d\u000a    Because MTC methods allow more evidence to be combined, relative\u000d\u000a      treatment effects can be estimated more precisely than with standard\u000d\u000a      meta-analysis methods. Treatments can also be ranked according to both\u000d\u000a      efficacy and cost-effectiveness, allowing policymakers and guideline\u000d\u000a      development groups, whether in insurance- or state-funded health systems,\u000d\u000a      to make better-informed decisions, supporting equitable and optimum\u000d\u000a      resource allocation by health service purchasers.\u000d\u000a    The UoB MPES group firstly set out the theoretical framework for MTC\u000d\u000a      methods, showing them to be natural extensions of standard meta-analysis,\u000d\u000a      and developing robust software for estimating them, published in peer\u000d\u000a      review journals 2004-2008[1,2,3,4]. The scope of the methods was further\u000d\u000a      extended and generalised, so that it could be applied to trials reporting\u000d\u000a      a variety of different types of outcomes (probabilities; rates;\u000d\u000a      continuous; ordinal; competing risks)[5]. The group has also developed\u000d\u000a      theory on the robustness and reliability of MTC, and developed methods to\u000d\u000a      check consistency of the different evidence sources[5,6].\u000d\u000a    These methodology developments were led and conducted by the MPES group,\u000d\u000a      which also developed general computer code (written for the freely\u000d\u000a      available WinBUGS software) to conduct MTC and made this code freely\u000d\u000a      available through its website. These methods are now widely accepted, and\u000d\u000a      were adopted in the 2008 and 2013 updates of the NICE Guide to the Methods\u000d\u000a      of Technology Appraisal. NICE, through its Decision Support Unit,\u000d\u000a      commissioned the MPES group to write a series of Technical Support\u000d\u000a      Documents, including general code for a range of different types of\u000d\u000a      outcomes and evidence structures [5] to guide those making submissions to\u000d\u000a      NICE. These were first published on the NICE Decision Support Unit website\u000d\u000a      in 2011 following peer-review, and have subsequently all been published in\u000d\u000a      the journal Medical Decision Making (July 2013, Vol 33 No.5), following\u000d\u000a      further peer review. All other references [1,2,3,4,5,6] are published in\u000d\u000a      peer-reviewed journals.\u000d\u000a    "},{"CaseStudyId":"40172","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    Background\u000a    IRIS is a landmark trial [4] in the field of domestic violence research,\u000a      testing a training and support programme, including a referral pathway,\u000a      designed to improve the response of general practice to women experiencing\u000a      domestic violence.\u000a    Dissemination\u000a    The findings were disseminated via presentation at 28 non-academic\u000a      conferences or meetings to July 2013 (total audience ~ 1200), 9\u000a      non-academic publications, and provision of information to national health\u000a      policy fora, notably the 2009\/10 taskforce on health aspects of violence\u000a      against women and children. The trial findings and cost effectiveness\u000a      analysis [5], supported through a case study [a] and web-based publicity\u000a      [b] were presented to meetings of local health care commissioners in\u000a      conjunction with local third sector organisations\u000a    Programme Implementation\u000a    Maximising impact was an integral part of the IRIS research programme.\u000a      Following the success of this trial, `IRIS &#8212; strengthening impact'\u000a      (IRISimp), an implementation vehicle to mainstream the IRIS model into\u000a      practices across the country, was created. This two-year programme of work\u000a      was undertaken in conjunction with and, funded by, the Health Foundation.\u000a      Beginning in June 2010, it facilitates the commissioning of the IRIS model\u000a      by primary care trusts and provides advocate educator training. UoB\u000a      researchers then secured a Department of Health Innovation, Excellence and\u000a      Strategic Development Grant to fund further implementation of IRIS in\u000a      England. A key part of the implementation programme was the translation of\u000a      the findings of the trial into a commissioning document designed to enable\u000a      and support the commissioning of the programme by CCGs and local\u000a      authorities in England [c].\u000a    Up to July 2013, 12 localities have commissioned the programme, and 122\u000a      practices in 7 localities have received training and started to use the\u000a      IRIS referral pathway. [d]\u000a    Benefits to women\u000a    Currently 683 women are being referred annually to IRIS domestic violence\u000a      advocates in the areas that have implemented the programme. [c] This is\u000a      estimated to be at least six times the number of referrals occurring in\u000a      the absence of IRIS. We know from our previous systematic reviews of\u000a      advocacy interventions [1] [3] that this will result in a reduction of\u000a      recurrence of domestic violence, improved quality of life and probably\u000a      improved mental health of these women. The other benefit for patients is a\u000a      safer and more appropriate response of clinicians to disclosure of\u000a      domestic violence, a core feature of the IRIS intervention. We have\u000a      evidence for this impact from interviews with patients who disclosed abuse\u000a      to their GPs and were referred to an IRIS advocate educator.\u000a    For example, here is the account of a woman who spoke to her GP about\u000a      abuse after seeing an IRIS poster in the waiting room: \"I had been\u000a      experiencing verbal, emotional and financial abuse from my husband for\u000a      over 26 years. I felt sad, low and unable to cope. The doctor referred me\u000a      to someone who could help... I don't need to go to the doctor's as much\u000a      now and have cut down on the tablets I take for depression and\u000a      sleeplessness. I have slowly got my freedom back and am so happy to be\u000a      making my own decisions and planning my own way in life. This is not just\u000a      for me, it's for my children and women like me out there. I feel\u000a      empowered. I feel proud of me.\" The patient narratives, as referenced in\u000a      the corroborative sources, provide further evidence. [e]\u000a    Benefits to NHS staff\u000a    Intermediate beneficiaries from the widespread implementation of IRIS\u000a      have been the doctors, nurses and other members of the practice teams in\u000a      the 122 IRIS practices nationally (Bristol, Hackney, Lambeth, Manchester,\u000a      Nottingham, Portsmouth, Southampton). IRIS has been commissioned in an\u000a      additional four areas (South Gloucestershire, Berkshire West, Enfield and\u000a      Nottingham) and practice training will be delivered in Autumn 2013. From\u000a      our nested qualitative study [6] we know that the participating clinicians\u000a      think that the training and support from IRIS allows them to engage with\u000a      the difficult challenge of domestic violence. The clinician narratives, as\u000a      referenced in the corroborative sources, provide further evidence. [e]\u000a    Impact on national policy\u000a    The trial findings were made available pre-publication to the Department\u000a      of Health taskforce on the health aspects of violence against women and\u000a      children [f] and they were a key source of evidence on training of health\u000a      care professionals. The IRIS model was cited as an exemplar alongside the\u000a      recommendation about training of staff (recommendation 3, p. 31) and was\u000a      highlighted as a case example in the commissioning guidance, [g] (p.58)\u000a      based on the report. Draft NICE guidelines have a specific training and\u000a      support recommendation for primary care based explicitly on IRIS (p.21).\u000a      [h] The 2012 Welsh Assembly Government White Paper [i] specifies IRIS as\u000a      an effective primary care training model (pp.48-49) and this will be the\u000a      basis of implementation of IRIS in Wales. Twelve IRIS advocate educators\u000a      have been trained in Scotland. They are delivering the IRIS practice\u000a      training and referral pathway in three Health Boards.[j] IRIS\u000a      implementation has been part of the recommendations of Home Office\u000a      Domestic Homicide Reviews [k].\u000a    Impact on international policy\u000a    The landmark 2013 WHO publication `Responding to intimate partner\u000a      violence and sexual violence against women: WHO clinical and policy\u000a      guidelines' drew heavily on the research of the UoB team in framing their\u000a      approach and in making recommendations about the training of healthcare\u000a      providers with specific citation of the IRIS model (p.33). [l]\u000a    Economic impact\u000a    With the current number of IRIS practices, the annual societal cost\u000a      saving is estimated to be greater than &#163;1m annually. This estimate is\u000a      based upon the results of the cost-effectiveness model developed from the\u000a      trial outcomes [5]. This modelling indicated that implementation of the\u000a      IRIS programme is cost-effective as judged by NICE criteria, generates\u000a      societal cost savings and is likely to reduce NHS costs.\u000a    Impact on national DV screening policy\u000a    Broader UK government policy on domestic violence has been deeply\u000a      influenced by the outputs of the UoB domestic violence research programme.\u000a      In particular the systematic reviews that underpinned the IRIS study\u000a      helped forestall the implementation of ineffective domestic violence\u000a      screening\/routine enquiry in health care settings in England, as reflected\u000a      in the DH taskforce report [d] and in the UK national screening committee\u000a      recommendations. [m] The National Screening Committee has adopted the\u000a      definition of domestic violence developed by Feder.\u000a    ","ImpactSummary":"\u000a    Domestic violence (DV) has a devastating public health, clinical and\u000a      economic impact on women. It is also a major breach of human rights. IRIS\u000a      (Identification and Referral to Improve Safety), a University of Bristol\u000a      led randomised controlled trial of a training and support programme to\u000a      improve the general practice response to DV, demonstrated a substantial\u000a      increase in identification of victims and their referral to specialist DV\u000a      services resulting in a subsequent reduction in recurrent abuse and\u000a      improved quality of life. The programme has now been commissioned by\u000a      clinical commissioning groups (CCGs) and local authorities in 12 English\u000a      localities and the training delivered to 122 general practices. The\u000a      current annual rate of referral of victims of domestic violence from IRIS\u000a      practices in England to specialist domestic violence agencies is 683 per\u000a      year, with trial data indicating that at least 600 of these would not have\u000a      taken place without the IRIS programme. The programme started\u000a      implementation in Scotland in June 2013.\u000a    ","ImpactType":"Societal","Institution":"\u000a    University of Bristol\u000a    ","Institutions":[{"AlternativeName":"Bristol (University of)","InstitutionName":"University of Bristol","PeerGroup":"A","Region":"South West","UKPRN":10007786}],"Panel":"A         ","PlaceName":[],"References":"\u000a    Grant awarded &#8212; Gene Feder; title &#8212; Primary care domestic violence trial;\u000a      sponsor &#8212; UoB &amp; QMUL; period of grant: April 2007 to March 2010; value\u000a      of grant - &#163;428,434; peer reviewed\u000a    \u000a[1] Ramsay J, Rutterford C, Gregory A, Dunne D, Eldridge S, Sharp D et\u000a      al. Domestic violence: knowledge, attitudes, and clinical practice of\u000a      selected UK primary healthcare clinicians. Br J Gen Pract 2012;\u000a      62(602):647-655 doi: 10.3399\/bjgp12X654623\u000a    \u000a\u000a[2] Ramsay J, Carter Y, Davidson L, Dunne D, Eldridge S, Feder G et al.\u000a      Advocacy interventions to reduce or eliminate violence and promote the\u000a      physical and psychosocial well-being of women who experience intimate\u000a      partner abuse. Cochrane Database Syst Rev 2009;(3):CD005043. doi:\u000a      10.1002\/14651858.CD005043.pub2\u000a    \u000a\u000a[3] Feder G, Ramsay J, Dunne D, Rose M, Arsene C, Norman R et al. How far\u000a      does screening women for domestic (partner) violence in different\u000a      health-care settings meet criteria for a screening programme? Systematic\u000a      reviews of nine UK National Screening Committee criteria. Health\u000a        Technol Assess 2009; 13(16):iii-xiii, 1. doi: 10.3310\/hta13160\u000a    \u000a\u000a[4] Feder G, Davies RA, Baird K, Dunne D, Eldridge S, Griffiths C et al.\u000a      Identification and Referral to Improve Safety (IRIS) of women experiencing\u000a      domestic violence with a primary care training and support programme: a\u000a      cluster randomised controlled trial. Lancet 2011;\u000a      378(9805):1788-1795. doi: 10.1016\/S0140-6736(11)61179-3\u000a    \u000a\u000a[5] Devine A, Spencer A, Eldridge S, Norman R, Feder G.\u000a      Cost-effectiveness of Identification and Referral to Improve Safety\u000a      (IRIS), a domestic violence training and support programme for primary\u000a      care: a modelling study based on a randomised controlled trial. BMJ\u000a        Open 2012; 2(3):e001008. doi: 10.1136\/bmjopen-2012-001008\u000a    \u000a\u000a[6] Yeung H, Choudry N, Malpass A, Feder GS. Responding to domestic\u000a      violence in general practice: a qualitative study on perceptions and\u000a      experiences. Int J Fam Med 2012:960523. doi: 10.1155\/2012\/ 960523.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"16","Level2":"7","Subject":"Social Work"}],"Sources":"\u000a    [a] Case study from the Health Foundation website\u000a      http:\/\/www.health.org.uk\/publications\/identification-and-referral-to-improve-safety\/\u000a    [b] Web pages on the Health Foundation website developed to disseminate\u000a      findings of the trial, including interviews with intervention and trial\u000a      team members\u000a      http:\/\/www.health.org.uk\/areas-of-work\/programmes\/engaging-with-quality-in-primary-care\/related-projects\/primary-care-domestic-violence-programme-iris\/\u000a    [c] This document describes the components of the IRIS programme in the\u000a      format of a commissioning specification, including a budget and\u000a      deliverables. It is used both by domestic violence service providers to\u000a      pitch to commissioners and by commissioning groups http:\/\/www.irisdomesticviolence.org.uk\/holding\/IRIS_Commissioning_Guidance.pdf\u000a    [d] Report on localities that have commissioned IRIS: number of\u000a      practices, clinicians and administrative staff trained, referrals made to\u000a      IRIS advocate educators\u000a    [e] IRIS website that includes narrative evidence from patients and\u000a      clinicians\u000a      http:\/\/www.irisdomesticviolence.org.uk\/iris\/patient-quotes\/\u000a    [f] Main report of DH taskforce on health aspects of violence against\u000a      women and children that includes IRIS as exemplar http:\/\/www.health.org.uk\/media_manager\/public\/75\/external-\u000apublications\/Responding-to-violence-against-women-and-children%E2%80%93the-role-of-the-NHS.pdf\u000a    [g] DH Commissioning guide on domestic violence that cites IRIS as model\u000a      programme\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/215635\/dh_125938.pdf\u000a    [h] NICE public health draft guidance: Domestic violence and abuse: how\u000a      social care, health services and those they work with can identify,\u000a      prevent and reduce domestic violence and abuse &#8212; makes recommendation\u000a      about integrated training and referral programme for primary care based on\u000a      IRIS model\u000a      http:\/\/www.nice.org.uk\/nicemedia\/live\/12116\/64783\/64783.pdf\u000a    [i] Welsh Government white paper Consultation on legislation to end\u000a      violence against women, domestic abuse and sexual violence that cites IRIS\u000a      model\u000a      http:\/\/wales.gov.uk\/docs\/dsjlg\/consultation\/121126taskfingrouprepen.pdf\u000a    [j] Statement from Katie Cosgrove, Gender-based Violence Programme\u000a      Manager, NHS Health Scotland that evidences implementation of IRIS in\u000a      Scotland\u000a    [k] Home Office Domestic Homicide Review recommending IRIS implementation\u000a      (pages 4&amp;5) https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/259547\/Domestic_homicide_review_-_lessons_learned.pdf\u000a    [l] WHO guidelines on health care response to intimate partner violence\u000a      that make recommendations on training of health care professionals partly\u000a      based on IRIS http:\/\/apps.who.int\/iris\/bitstream\/10665\/85240\/1\/9789241548595_eng.pdf\u000a    [m] Draft expert review informing National Screening Committee decision\u000a      on domestic violence screening that is largely based on Feder's HTA review\u000a      http:\/\/www.screening.nhs.uk\/domesticviolence\u000a      DRAFT_Domestic_Violence_Adults_17_05_13.pdf \u000a    ","Title":"\u000a    Reducing domestic violence through `IRIS', a training and support\u000a      programme that improves the response of general practice\u000a    ","UKLocation":[{"GeoNamesId":"2654675","Name":"Bristol"},{"GeoNamesId":"2637487","Name":"Southampton"},{"GeoNamesId":"2639996","Name":"Portsmouth"},{"GeoNamesId":"2641170","Name":"Nottingham"},{"GeoNamesId":"2643123","Name":"Manchester"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Contextual information\u000a    Domestic violence (DV) against women, a major public health and clinical\u000a      problem, requires a healthcare response. Historically clinicians in\u000a      general and GPs in particular have not responded effectively to the needs\u000a      of patients experiencing DV. Most clinicians have little or no training,\u000a      fail to identify patients experiencing abuse and are uncertain about\u000a      further management after disclosure.[1] Women accessing specialist DV\u000a      advocacy have a reduced recurrence of physical abuse [2], on which rests\u000a      the claim that increased referral to advocacy can reduce domestic violence\u000a      and its detrimental effects on health.\u000a    Research undertaken\u000a    University of Bristol (UoB) research conducted Cochrane [2] and Health\u000a      Technology Assessment [3] reviews on individual and system (health care\u000a      setting) level interventions to improve the response to DV. These were the\u000a      foundation for a cluster randomised controlled trial [4] testing a\u000a      training and support programme delivered by \"advocate-educators\" based in\u000a      third sector DV agencies. Eligible general practices in Bristol and\u000a      Hackney (London) were randomised to intervention and control groups each\u000a      of 24 practices. The intervention programme included practice-based\u000a      training sessions for clinicians and administrative teams, a prompt within\u000a      the medical record to ask about abuse and a referral pathway to a named DV\u000a      advocate, who delivered the training and further consultancy.\u000a    Key findings\u000a    One year after the second training session, advocacy agencies recorded\u000a      278 self and direct referrals of patients from intervention practices and\u000a      40 from control practices, (adjusted intervention incident rate ratio of\u000a      6&#183;6 (95% confidence interval 4&#183;1 to 10&#183;7). Intervention practices recorded\u000a      641 disclosures of DV and control practices recorded 236 (intervention\u000a      rate ratio 3&#183;1, 95% confidence interval 2&#183;2 to 4&#183;3). The trial proved that\u000a      a training and support programme targeted at primary care staff improves\u000a      recorded identification of women experiencing domestic violence and\u000a      referral to specialist DV agencies.\u000a    When\u000a    The intervention study took place between September 2007 and September\u000a      2008 with follow up to September 2009.\u000a    Who\u000a    UoB researchers led the trial, which was carried out in full\u000a      collaboration with Queen Mary, University of London (QMUL). A distinctive\u000a      and pioneering aspect of the trial, which has amplified its impact, was\u000a      the close collaboration with third sector domestic violence organisations\u000a      (the `nia project' and `Next Link'). These organisations were directly\u000a      involved in the design of the trial, delivery of the intervention and\u000a      national implementation of the IRIS model.\u000a    Gene Feder (UoB): professor of primary health care &#8212; principal\u000a      investigator\u000a      Debbie Sharp (UoB): professor of primary health care &#8212; co-investigator\u000a      Alison Gregory (UoB): research associate,\u000a      Roxane Agnew Davies (Domestic Violence Training Ltd &amp; UoB honorary\u000a      contract) &#8212; co-investigator\u000a      Annie Howell (nia and UoB honorary contract): IRIS advocate educator\u000a      Medina Johnson (Next Link and UoB honorary contract): IRIS advocate\u000a      educator\u000a      Kim Sales: domestic violence survivor and service user\u000a      QMUL co-investigators: Danielle Dunne, Sandra Eldridge, Chris Griffiths,\u000a      Jean Ramsay\u000a    "},{"CaseStudyId":"40405","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000d\u000a    Worldwide, obesity represents one of the most challenging health\u000d\u000a      problems, with the UK having among the highest rates in Europe. The\u000d\u000a      associations between obesity and health problems such as type 2 diabetes\u000d\u000a      are set to add substantially to health service costs in the future.\u000d\u000a    Measurements taken as part of the Health Survey for England (HSE) have\u000d\u000a      been used extensively at every stage of obesity policy making and\u000d\u000a      monitoring. Public Health England describes HSE as \"currently the most\u000d\u000a        robust data source to monitor trends in adult obesity in England\" [a].\u000d\u000a      HSE data are used extensively by the Department of Health, NHS and local\u000d\u000a      authority staff, the media, and the public. In one year alone (1 April\u000d\u000a      2012-1 April 2013) there were 36,803 page views (26,928 unique) of HSE\u000d\u000a      pages on the Health and Social Care Information Centre (HSCIC)'s website.\u000d\u000a      The three months April-June 2013 saw 7,796 downloads [b]. The UK\u000d\u000a      Data Service reported that the HSE was the second most frequently\u000d\u000a      downloaded dataset in the UK in 2011 [c]. Here we present key\u000d\u000a      evidence for how, during the period 2008-13, HSE has informed the\u000d\u000a      quantification of the obesity problem, the development of Government\u000d\u000a      policy and strategy, the development of clinical guidelines, and the\u000d\u000a      monitoring of progress.\u000d\u000a    Measuring the obesity problem\u000d\u000a    HSE data have enabled the extent and escalation of obesity within the\u000d\u000a      population to be quantified, drawing the attention of Government and\u000d\u000a      policymakers to the issue. Importantly, HSE data enabled the\u000d\u000a      quantification of the obesity problem within sub-groups of the population,\u000d\u000a      highlighting the high rates in children and among adults from lower\u000d\u000a      socioeconomic positions. The Foresight Report, funded by the Government\u000d\u000a      Office for Science, used HSE 1994-2004 data to project population trends\u000d\u000a      to 2050 and examine future impacts on life expectancy and economic costs\u000d\u000a      of overweight and obesity [d]. The 2010 adult update [e]\u000d\u000a      used HSE data from 1993 to 2007. The adult obesity projections varied\u000d\u000a      little: future health problems were predicted to soar, with\u000d\u000a      obesity-related diabetes rising by 98%, strokes by 23%, and heart disease\u000d\u000a      by 44% by 2050.\u000d\u000a    Influencing Government policy and strategy\u000d\u000a    HSE measurement data are used by Government to produce evidence-based\u000d\u000a      strategies to combat obesity. The Chief Medical Officer (CMO), the\u000d\u000a      Government's most senior medical advisor, publishes an annual report to\u000d\u000a      identify priorities in health and recommend action to improve public\u000d\u000a      health. The CMO's 2011 report used a range of HSE data, including on\u000d\u000a      obesity [f]. The UCL team were responsible for the analyses which\u000d\u000a      identified obesity as one of the main risk factors behind the differences\u000d\u000a      in prevalence of multiple lifestyle risk factors by age and by\u000d\u000a      socio-economic position.\u000d\u000a    The research on the HSE that was cited in the Foresight report was used\u000d\u000a      to justify investment of money and Government focus on obesity. For\u000d\u000a      example, in the 2008 Healthy Weight, Healthy Lives: A Cross-Government\u000d\u000a        Strategy for England, a range of commitments for reducing obesity\u000d\u000a      were identified [g]. It states: \"the Government will make\u000d\u000a        available an additional &#163;372 million for promoting the achievement and\u000d\u000a        maintenance of healthy weight over the period 2008-11.\" The 2011\u000d\u000a      document Healthy Lives, Healthy People: A call to action on obesity in\u000d\u000a        England set out specific plans for dealing with the obesity problem\u000d\u000a      [h]. One specific area in which our data influenced this report was\u000d\u000a      in relation to the Change4Life campaign, an extensive public\u000d\u000a      health programme run by the Department of Health which started in 2009.\u000d\u000a      HSE data were used to choose the appropriate adult age group to target for\u000d\u000a      a new phase of the health promotion campaign entitled Change4Life: One\u000d\u000a        Year On [i]. In addition, a calorie reduction target set out\u000d\u000a      in this document was derived from HSE weight gain data, to estimate that a\u000d\u000a      mean reduction in daily energy intake of 100 calories (kcal) per person\u000d\u000a      would correct the energy imbalance nationally. This was also set out\u000d\u000a      within in Responsibility Deal &#8212; a series of pledges that food\u000d\u000a      manufacturers, retailers, caterers, suppliers and service organisations\u000d\u000a      such as restaurants signed up to with the goal of providing \"a mechanism\u000d\u000a      for the food and drink industry to make and record its contribution to\u000d\u000a      helping the population meet the calorie reduction challenge\" [j].\u000d\u000a    Informing clinical guidance\u000d\u000a    The National Institute of Health and Care Excellence (NICE) clinical\u000d\u000a      guidelines on the prevention, identification, assessment and management of\u000d\u000a      overweight and obesity in adults and children, currently being reviewed\u000d\u000a      and updated, used HSE data to justify the document's creation, quantifying\u000d\u000a      the issue of obesity, attaching economic costs to this, and assessing\u000d\u000a      cost-effectiveness of clinical treatments. NICE 2012 guidance Obesity:\u000d\u000a        working with local communities also used HSE obesity data to\u000d\u000a      quantify the extent of the problem [k]. Mean measured height by\u000d\u000a      age and sex from the Health Survey for England were used by the Standing\u000d\u000a      Advisory Committee on Nutrition (SACN) in the SACN Dietary Recommendations\u000d\u000a      for Energy to calculate energy requirements [l].\u000d\u000a    Monitoring and evaluating the success of obesity strategies.\u000d\u000a    HSE data have been used to monitor targets and evaluate the success of\u000d\u000a      obesity strategies. HSE data showed early indications that the focus on\u000d\u000a      childhood obesity was paying off, with wider evaluation shifting further\u000d\u000a      strategy work to adults. One area of particular importance has been the\u000d\u000a      monitoring of equality considerations. For example, equality impact\u000d\u000a      assessments for the two Government reports Healthy Weight, Healthy\u000d\u000a        Lives and Healthy Lives, Healthy People used HSE BMI data\u000d\u000a      related to age, sex and ethnicity to show that the strategies met their\u000d\u000a      legal requirements and could be implemented [m, n]. HSE is one of\u000d\u000a      the Department of Health's main data sources for Parliamentary Questions\u000d\u000a      on obesity (for example, PQ48492 in 2011) and Parliamentary debates (for\u000d\u000a      example, House of Lords, 7 Jan 2010).\u000d\u000a    ","ImpactSummary":"\u000d\u000a    UCL research, from the Department of Epidemiology &amp; Public Health,\u000d\u000a      has underpinned the Health Survey for England's (HSE) role in informing\u000d\u000a      obesity policy in England. HSE data quantified the extent and escalation\u000d\u000a      of obesity within the population as a whole as well as specific\u000d\u000a      sub-groups, resulting in this issue being given significant attention in\u000d\u000a      government. HSE data has underpinned strategy development, the modelling\u000d\u000a      of future scenarios, the identification of inequalities, and the creation\u000d\u000a      of clinical guidance. HSE data has showed early indications that the focus\u000d\u000a      on childhood obesity is paying off, with wider evaluation shifting further\u000d\u000a      strategy work to adults. HSE data has also played a role in this area,\u000d\u000a      defining the adult target group for the Change4Life programme.\u000d\u000a      Furthermore, HSE data are underpinning new agreements with the food\u000d\u000a      industry through the Responsibility Deal.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University College London\u000d\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    [1] Details about each report can be found here: http:\/\/www.natcen.ac.uk\/series\/health-survey-for-england\u000d\u000a    \u000a[2] Mindell J, Becares L, Aresu M, Tolonen H. The right time for a\u000d\u000a      survey? Socio-demographic variation in survey responses by time of day and\u000d\u000a      day of week. Eur J Public Health.\u000d\u000a      http:\/\/dx.doi.org\/10.1093\/eurpub\/ckr093\u000d\u000a    \u000a\u000a[3] Stamatakis E, Zaninotto P, Falaschetti E, Mindell J, Head J. Time\u000d\u000a      trends in childhood and adolescent obesity in England from 1995 to 2007\u000d\u000a      and projections of prevalence to 2015. J Epidemiol Community Health.\u000d\u000a      2010;64:167-74. http:\/\/dx.doi.org\/10.1136\/jech.2009.098723\u000d\u000a    \u000a\u000a[4] HSE annual report chapters on obesity, e.g.: Tabassum F. `Adult\u000d\u000a      anthropometric measures, overweight and obesity.' Chapter 7 in Craig R,\u000d\u000a      Hirani V (eds). The Health Survey for England 2009. Leeds: NHS Information\u000d\u000a      Centre, 2010. (Copy available on request.)\u000d\u000a    \u000a\u000a[5] Zaninotto P, Head J, Stamatakis E, Wardle H, Mindell J. Trends in\u000d\u000a      obesity among adults in England from 1993 to 2004 by age and social class\u000d\u000a      and projections of prevalence to 2012. J Epidemiol Community Health.\u000d\u000a      2009;63:140-6. http:\/\/dx.doi.org\/10.1136\/jech.2008.077305\u000d\u000a    \u000a\u000a[6] Annual report of the Chief Medical Officer 2011. London: Department\u000d\u000a      of Health, 2012.\u000d\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/142164\/CMO_Annual_Report_Vol_1.pdf\u000d\u000a    \u000a\u000a[7] Mindell JS, Dinsdale H, Ridler C, Rutter HR. Changes in waist\u000d\u000a      circumference among adolescents in England from 1977-1987 to 2005-2007.\u000d\u000a      Public Health. 2012 Aug;126(8):695-701.\u000d\u000a      http:\/\/dx.doi.org\/10.1016\/j.puhe.2012.05.004\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000d\u000a    [a] http:\/\/www.noo.org.uk\/data_sources\/adult\u000d\u000a    [b] HSE Web Analytics, 1 April 2012 to 1 April 2013 and April to June\u000d\u000a      2013. Provided the Health and Social Care Information Centre, 12 August\u000d\u000a      2013. Copies of the email and the Excel sheets available on request.\u000d\u000a    [c] Economic and Social Data Service webpage `ESDS facts and figures:\u000d\u000a      Most used data for 2011'\u000d\u000a      http:\/\/www.esds.ac.uk\/about\/facts.asp\u000d\u000a    [d] Foresight, Tackling Obesities: Future Choices &#8212; Project Report, 2nd\u000d\u000a      Edition, Government Office for Science http:\/\/www.bis.gov.uk\/assets\/foresight\/docs\/obesity\/17.pdf\u000d\u000a    [e] Brown M, Byatt T, Marsh T, McPherson K (2010) Obesity Trends for\u000d\u000a      Adults. Analysis from the Health Survey for England 1993 - 2007. London:\u000d\u000a      National Heart Forum.\u000d\u000a      http:\/\/nhfshare.heartforum.org.uk\/RMAssets\/NHFreports\/NHF_adultobese_long_170210.pdf\u000d\u000a    [f] Annual report of the Chief Medical Officer 2011. London: Department\u000d\u000a      of Health, 2012.\u000d\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/142164\/CMO_Annual_Report_Vol_1.pdf\u000d\u000a      See chapter 3 for obesity, and p222-3 for the section on risk factors.\u000d\u000a    [g] Cross-Government Obesity Unit (2008) Healthy Weight, Healthy Lives: A\u000d\u000a      Cross-Government Strategy for England. Equality Impact Assessment\u000d\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_082408.pdf\u000d\u000a    [h] Healthy Lives, Healthy People: A call to action on obesity in England.\u000d\u000a      See page 18 for reference to the foresight report, and HSE annual report;\u000d\u000a      see page 6 and 8 for initiatives quoted.\u000d\u000a      www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_130487.pdf\u000d\u000a    [i] Department of Health (2010) Change for Life: One Year On. See\u000d\u000a      p78 and ref 39 to HSE 2007.\u000d\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@en\/documents\/digitalasset\/dh_115511.pdf\u000d\u000a    [j] Department of Health (2012) Calorie Reduction. https:\/\/responsibilitydeal.dh.gov.uk\/f4-factsheet\u000d\u000a      \/\u000d\u000a    [k] National Institute for Health and Clinical Excellence (2012) Obesity:\u000d\u000a      working with local communities. NICE public health guidance 42. http:\/\/guidance.nice.org.uk\/ph42\/\u000d\u000a    [l] Scientific Advisory Committee on Nutrition (2011) Dietary\u000d\u000a        Reference Values for Energy.\u000d\u000a      www.sacn.gov.uk\/pdfs\/sacn_dietary_reference_values_for_energy.pdf\u000d\u000a    [m] Cross-Government Obesity Unit (2008) Healthy Weight, Healthy Lives: A\u000d\u000a      Cross-Government Strategy for England. Equality Impact Assessment\u000d\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_082408.pdf\u000d\u000a    [n] Department of Health (2011) A call to action on obesity in England\u000d\u000a      Equality Analysis.\u000d\u000a      www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_130511.pdf\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Health Survey for England informs public policy on obesity\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The Health Survey for England (HSE) is an annual, cross-sectional health\u000d\u000a      examination survey of the general population in England. It combines\u000d\u000a      self-reported data (including demographic, socio-economic, health, and\u000d\u000a      lifestyle data) with objective measures of health (such as measured\u000d\u000a      height, weight, and waist circumference) [1]. It has been run by\u000d\u000a      the Joint Health Surveys Unit of UCL and NatCen Social Research since\u000d\u000a      1994; the 23rd survey is currently in the field. HSE provides\u000d\u000a      data from nationally representative samples to monitor trends in the\u000d\u000a      nation's health; identifies the prevalence of specified health conditions\u000d\u000a      in the general population; measures the rates of certain risk factors and\u000d\u000a      combinations of risk factors; examines differences between subgroups of\u000d\u000a      the population; and monitors progress towards selected health targets. The\u000d\u000a      UCL contribution to the HSE falls into three categories: providing the\u000d\u000a      clinical and methodological expertise for the survey; jointly writing and\u000d\u000a      editing the annual HSE reports; and leading the work on secondary data\u000d\u000a      analysis and policy evaluation. The fieldwork and operational side of the\u000d\u000a      HSE are conducted by NatCen, with UCL providing clinical oversight.\u000d\u000a    UCL has developed internationally acclaimed expertise in survey\u000d\u000a      methodology. For example, we have compared the effect of mode and context\u000d\u000a      of survey on response rates, non-response bias, and responses; and of\u000d\u000a      demographic and socio-economic variation in survey participants by time\u000d\u000a      and day interviewed [2].\u000d\u000a    HSE is one of the few health surveys in Europe to obtain objectively\u000d\u000a      measured anthropometric data, rather than relying on self-reporting which\u000d\u000a      consistently under-reports obesity. HSE provides objective, national,\u000d\u000a      general population data on prevalence of general and abdominal obesity [3,\u000a        4]. Extensive demographic and socio-economic data also permit\u000d\u000a      assessment of inequalities in obesity by age, sex, geography, and several\u000d\u000a      markers of socio-economic position.\u000d\u000a    The HSE team at UCL have conducted a considerable amount of secondary\u000d\u000a      analysis work using the HSE data. In 2009, for example, we used HSE data\u000d\u000a      to analyse trends in obesity, and to make projections into the future [5].\u000d\u000a      In 2011 we conducted the analyses and wrote the commentary for the section\u000d\u000a      of the Chief Medical Officer's 2011 report on co-occurrence of multiple\u000d\u000a      risk factors, which could be determined in the general population only\u000d\u000a      through use of HSE data. We identified obesity as one of the main risk\u000d\u000a      factors behind the differences in prevalence of multiple lifestyle risk\u000d\u000a      factors by age and by socio-economic position, and for which the trend was\u000d\u000a      upwards, unlike most other lifestyle risk factors [6]. Our 2012\u000d\u000a      paper used HSE data to demonstrate that waist circumference (a marker for\u000d\u000a      central\/abdominal obesity) had increased in adolescents at a greater rate\u000d\u000a      than generalised obesity (as shown by measuring BMI) [7].\u000d\u000a    Since 2005, the UCL team has been led by Dr Jennifer Mindell in the\u000d\u000a      Health and Social Surveys Research Group of the Research Department of\u000d\u000a      Epidemiology &amp; Public Health, with substantial contributions from Dr\u000d\u000a      Nicola Shelton and a number of post-doctoral and junior researchers.\u000d\u000a    "},{"CaseStudyId":"40406","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"878675","Name":"Zimbabwe"},{"GeoNamesId":"337996","Name":"Ethiopia"},{"GeoNamesId":"953987","Name":"South Africa"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    TB is a major health problem, with 9.4 million new cases and 1.7 million\u000d\u000a      deaths in 2009 [a]. WHO guidelines issued in 2003 [b]\u000d\u000a      recommended a regimen of daily ethambutol, isoniazid, rifampicin and\u000d\u000a      pyrazinamide for 2 months, followed by ethambutol and isoniazid for 6\u000d\u000a      months (2EHRZ\/6HE) as one of the category 1 regimens for the treatment of\u000d\u000a      drug sensitive M Tuberculosis. However, that regimen had not been\u000d\u000a      evaluated in a randomised controlled trial. Study A found that this\u000d\u000a      regimen was clearly inferior to a regimen with the same 2-month intensive\u000d\u000a      phase, followed by 4 months of isoniazid and rifampicin.\u000d\u000a    The results of Study A were published in 2004. It took several years for\u000d\u000a      the results of the research to change international guidelines, perhaps\u000d\u000a      partly because the results were disappointing to international agencies,\u000d\u000a      who would have preferred not to use rifampicin after the initial intensive\u000d\u000a      phase of treatment because of the risk of acquired resistance to this drug\u000d\u000a      in patients who failed treatment. However, eventually the results did\u000d\u000a      begin to influence international policy, as they provided evidence that\u000d\u000a      filled an important gap in knowledge of how to treat TB.\u000d\u000a    In 2006 the International Standards for Tuberculosis Care cited the Study\u000d\u000a      A results [c], and recommended 2EHRZ\/4HR as the preferred\u000d\u000a      treatment regimen, but that 2EHRZ\/6HE could be used where adherence\u000d\u000a      through the continuation phase cannot be assessed. It was considered to be\u000d\u000a      of particular relevance for the developing world, where the majority of\u000d\u000a      people with active TB live.\u000d\u000a    Study A was included in an influential 2009 meta analysis, which said \"The\u000a        most important finding of this review is that all three treatment\u000d\u000a        outcomes were significantly worse with regimens that used rifampin for\u000d\u000a        the first 1-2 mo rather than throughout therapy. This finding adds\u000d\u000a        considerable weight to similar findings by Jindani and colleagues, who\u000d\u000a        compared regimens containing 2 mo versus 6 mo of rifampin\" [d].\u000d\u000a    Eventually, in 2010, the WHO guidelines were updated in a periodic review\u000d\u000a      [e]. This involved carrying out a systematic review of the\u000d\u000a      evidence, which included the results from Study A, which were graded as\u000d\u000a      the most convincing of the available evidence. One of the principal\u000d\u000a      investigators of the trial (Professor Andrew Nunn) was a member of the\u000d\u000a      expert advisory group which helped to develop the new guidelines. The new\u000d\u000a      WHO guidelines included the recommendation that \"New patients with\u000d\u000a        pulmonary TB should receive a regimen containing 6 months of rifampicin:\u000d\u000a        2EHRZ\/4HR\". Indeed, the foreword states the importance of this\u000d\u000a      change: \"The World Health Organization's Stop TB Department has\u000d\u000a        prepared this fourth edition of Treatment of tuberculosis: guidelines,\u000d\u000a        adhering fully to the new WHO process for evidence-based guidelines.\u000d\u000a        Several important recommendations are being promoted in this new\u000d\u000a        edition.\u000d\u000a    First, the recommendation to discontinue the regimen based on just 2\u000d\u000a        months of rifampicin (2HRZE\/6HE) and change to the regimen based on a\u000d\u000a        full 6 months of rifampicin (2HRZE\/4HR) will reduce the number of\u000d\u000a        relapses and failures. This will alleviate patient suffering resulting\u000d\u000a        from a second episode of tuberculosis (TB) and conserve patient and\u000d\u000a        programme resources.\"\u000d\u000a    WHO guidelines are very influential for national TB policy, particularly\u000d\u000a      in African countries, which face a high burden of TB. A survey of national\u000d\u000a      tuberculosis policymakers found that WHO was an important and frequent\u000d\u000a      source of information to inform TB policymaking in Africa. This means that\u000d\u000a      the WHO recommendation, based on Study A, has influenced which TB\u000d\u000a      treatment regimens are used in many countries. National guidelines for TB\u000d\u000a      have been updated to refect the new treatment regimes including Ethiopia,\u000d\u000a      South Africa, and Zimbabwe [f]. Routine data collected by WHO\u000d\u000a      shows that in 2011, 196 out of 206 countries reported using the 6 month\u000d\u000a      regimen with rifampicin throughout for new TB patients. The number of new\u000d\u000a      TB cases (excluding multi-drug resistant TB) in these 196 countries\u000d\u000a      totalled 7,883,245 in 2011, so the results of Study A have had a\u000d\u000a      wide-reaching impact (although it should be noted that not all of these\u000d\u000a      countries were previously using the 8 month regimen) [g].\u000d\u000a    From the perspective of these eight million patients, the 2EHRZ\/4HR has\u000d\u000a      several benefits over the previous 8-month regimen. As well as reducing\u000d\u000a      the number of people who have unfavourable outcomes and require\u000d\u000a      retreatment, it also reduces the inconvenience of attending for treatment\u000d\u000a      (whether fully supervised or not) and reduced the time in which they were\u000d\u000a      exposed to toxic drugs.\u000d\u000a    National Ministries of Health have benefited from the research, as the\u000d\u000a      2EHRZ\/4HR patient kit is US$ 4-10 less expensive than the 2EHRZ\/6HE\u000d\u000a      patient kit [d]. Reducing the number of people requiring\u000d\u000a      retreatment also reduces costs. This allows more people to be treated with\u000d\u000a      the available (limited) resources.\u000d\u000a    It is difficult to determine the exact impact Study A's finding have had\u000d\u000a      in reducing unfavourable outcomes. However if we assume that the reduction\u000d\u000a      of relapses and treatment failures is the same in real life as in the\u000d\u000a      trial, and that around 7.9 million people were treated with the 2EHRZ\/4HR\u000d\u000a      regimen in 2011, then the impact of Study A in that year alone was to\u000d\u000a      prevent over 400,000 relapses and failures, compared to if those people\u000d\u000a      had been treated with the eight month regimen. However, the actual number\u000d\u000a      of relapses prevented directly due to Study A is likely to be lower than\u000d\u000a      this, as not all countries were previously using the 8 month regimen, and\u000d\u000a      some of those countries that did change may have done so for other\u000d\u000a      reasons.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Prior to the change in WHO recommendations which occurred following this\u000d\u000a      study many patients in Africa and other developing countries were\u000d\u000a      receiving an inferior regimen for the management of tuberculosis, a\u000d\u000a      consequence of which meant that many had to be retreated. Since the\u000d\u000a      implementation of the revised WHO Guidelines in 2010 almost all countries\u000d\u000a      have now switched to the gold standard tuberculosis treatment regimen\u000d\u000a      based on 6 months of isoniazid and rifampicin\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University College London\u000d\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy\u000d\u000a      for treatment of newly diagnosed pulmonary tuberculosis: international\u000d\u000a      multicentre randomised trial. The Lancet. 2004 364:1244-51. http:\/\/dx.doi.org\/10.1016\/S0140-6736(04)17141-9\u000d\u000a    \u000a\u000a[2] Nunn AJ, Jindani A, Enarson DA. Results at 30 months of a randomised\u000d\u000a      trial of two 8-month regimens for the treatment of tuberculosis.\u000d\u000a      International Journal of Tuberculosis and Lung Disease. 2011 15(6):\u000a      741-745. http:\/\/dx.doi.org\/10.5588\/ijtld.10.0392\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"12","Subject":"Oncology and Carcinogenesis"}],"Sources":"\u000d\u000a    [a] Figure for TB incidence and deaths in 2011 taken from WHO Global\u000d\u000a      Tuberculosis Report 2012, available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/75938\/1\/9789241564502_eng.pdf\u000d\u000a    [b] World Health Organization. Treatment of Tuberculosis: Guidelines for\u000d\u000a      National Programmes. 3rd edition. Geneva: World Health Organization; 2003.\u000d\u000a      http:\/\/whqlibdoc.who.int\/hq\/2003\/WHO_CDS_TB_2003.313_eng.pdf\u000d\u000a      See section 4.8, which contains the discussion of the two regimens.\u000d\u000a    [c] Tuberculosis Coalition for Technical Assistance. International\u000d\u000a      Standards for Tuberculosis Care (ISTC). The Hague: Tuberculosis Coalition\u000d\u000a      for Technical Assistance; 2006.\u000d\u000a      http:\/\/www.who.int\/tb\/publications\/2006\/istc_report.pdf\u000d\u000a      See standard 8, page 9. Research [1] is reference 73 therein.\u000d\u000a    [d] Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A,\u000d\u000a      Lienhardt C, Burman W. Effect of duration and intermittency of rifampin on\u000d\u000a      tuberculosis treatment outcomes: a systematic review and meta-analysis.\u000d\u000a      PLoS Med. 2009 Sep;6(9):e1000146.\u000d\u000a      http:\/\/dx.doi.org\/10.1371\/journal.pmed.1000146.\u000d\u000a      See reference 26.\u000d\u000a    [e] World Health Organization. Treatment of Tuberculosis Guidelines. 4th\u000d\u000a      edition. Geneva: World Health Organization; 2010. http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241547833_eng.pdf\u000d\u000a      See section 3.5 for references to [d] above. See page 117 the quoted for\u000d\u000a      cost saving.\u000d\u000a    [f] Updated National guidelines:\u000d\u000a    \u000d\u000a      South Africa, National Tuberculosis Management Guidelines 2009\u000d\u000a        http:\/\/familymedicine.ukzn.ac.za\/Libraries\/Guidelines_Protocols\/TB_Guidelines_2009.sflb.ashx\u000a\u000d\u000a      Zimbabwe, National TB Guidelines, Fourth Edition, October 2010\u000d\u000a        http:\/\/www.who.int\/hiv\/pub\/guidelines\/zimbabwe_tb.pdf\u000d\u000a        See page 37\u000d\u000a      Ethiopia, Guidelines for Clinical and Programmatic Management of TB,\u000d\u000a        TB\/HIV and Leprosy In Ethiopia, Fifth Edition, March, 2013\u000d\u000a        http:\/\/www.moh.gov.et\/English\/Resources\/Documents\/FMOH_Guidelines%20for%20TBL_T\u000a          B_HIV%20March_2013_Final%20Version.pdf See page 28\u000d\u000a    \u000d\u000a    [g] World Health Organization 2012: Data provided by countries and\u000d\u000a      territories: case notifications &amp; implementing the Stop TB strategy in\u000d\u000a      2011\u000d\u000a      http:\/\/www.who.int\/tb\/country\/data\/download\/en\/index.htm\u000d\u000a      [accessed 14\/06\/13]. Analysed spreadsheet available on request.\u000d\u000a    ","Title":"\u000d\u000a    Study A leads to changes in Tuberculosis treatment guidelines\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Study A was a multi-centre randomised controlled trial testing two\u000d\u000a      8-month regimens (one of which was recommended in international guidelines\u000d\u000a      at the time) against the gold standard 6-month regimen for treatment of\u000d\u000a      newly diagnosed pulmonary tuberculosis. The trial was sponsored by the\u000d\u000a      International Union Against Tuberculosis and Lung Disease (IUATLD) and\u000d\u000a      involved 1,355 patients from eight centres in Africa and Asia. This was\u000d\u000a      the first TB trial to utilise a non-inferiority trial design.\u000d\u000a    From 1993 onwards WHO recommended an 8-month regimen without rifampicin\u000d\u000a      in the maintenance phase, in preference to a 6-month regimen with\u000d\u000a      rifampicin throughout. WHO guidelines (issued in 2003) recommended a\u000d\u000a      regimen of daily ethambutol, isoniazid, rifampicin and pyrazinamide for 2\u000d\u000a      months, followed by ethambutol and isoniazid for 6 months (2EHRZ\/6HE).\u000d\u000a      However, that regimen had not been evaluated in a randomised controlled\u000d\u000a      trial. Study A compared that regimen with a 6-month regimen with the same\u000d\u000a      initial intensive phase as the first regimen, followed by four months of\u000d\u000a      daily rifampicin and isoniazid (2EHRZ\/4HR).\u000d\u000a    Study A demonstrated that the WHO-recommended 2EHRZ\/6HE regimen was\u000d\u000a      clearly inferior to the 2EHRZ\/4HR regimen [1]. 12 months after the\u000d\u000a      end of chemotherapy 10.4% treated with 2EHRZ\/6HE had unfavourable\u000d\u000a      outcomes, compared to only 4.9% of those treated with 2EHRZ\/4HR. At 30\u000d\u000a      months the failure\/relapse rates were 11.7% of those treated with\u000d\u000a      2EHRZ\/6HE and 6.0% of those treated with 2EHRZ\/4HR [2]. The study\u000d\u000a      was carried out between March 1998 and June 2004 and the results 12 months\u000d\u000a      after stopping treatment were presented at the IUATLD meeting in Montreal\u000d\u000a      in October 2002, and were published in 2004 [1]; the 30 month\u000d\u000a      follow-up results were published in 2011 [2].\u000d\u000a    Key researchers and the positions they held at the time of the\u000d\u000a        research\u000d\u000a    The International Union Against Tuberculosis and Lung Disease is a long\u000d\u000a      established NGO working to support national tuberculosis programmes\u000d\u000a      world-wide. Its mission is to bring innovation, expertise, solutions and\u000d\u000a      support to address health challenges in low- and middle-income\u000d\u000a      populations. The IUATLD conceived the trial and invited Andrew Nunn at the\u000d\u000a      MRC Clinical Trials Unit (MRC CTU) to be an investigator because of his\u000d\u000a      long-standing involvement in TB clinical trials, as he had been\u000d\u000a      statistician for previous practice-changing trials. The MRC CTU took the\u000d\u000a      lead in statistics, in the non-inferiority design of the study, in the\u000d\u000a      interim analyses for the Data Monitoring Committee and analyses for the\u000d\u000a      published findings. Andrew Nunn was also closely involved in the writing\u000d\u000a      of the papers for publication. IUALTD chose to work with MRC CTU because\u000d\u000a      of the Unit's expertise in trial design and statistical analysis.\u000d\u000a    Dr Amina Jindani and Professor Donald Enarson were both employed by the\u000d\u000a      IUATLD, Professor Enarson as the Scientific director, Dr Jindani was the\u000d\u000a      chief investigator on the study; Professor Andrew Nunn who was at that\u000d\u000a      time Head of Division Without Portfolio, MRC Clinical Trials Unit, was the\u000d\u000a      senior statistician.\u000d\u000a    "},{"CaseStudyId":"40408","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Wellcome Trust","Medical Research Council"],"ImpactDetails":"\u000a    The research of Hemingway's group has directly informed national and\u000a      international public health\u000a      policy, clinical guidelines and the development of underpinning methods\u000a      which have subsequently\u000a      been implemented and have had an important impact on the healthcare and\u000a      health of the UK and\u000a      international populations, and our capacity for carrying out research for\u000a      patient benefit.\u000a    Clinical investigation of patients with suspected or confirmed\u000a        coronary disease\u000a    Since the early post-war period the exercise electrocardiogram (ECG) has\u000a      been the most widely\u000a      performed diagnostic test for stable angina. In March 2010, however, NICE\u000a      guidelines on Chest\u000a        pain of recent onset (CG95) recommended the following: \"Do not\u000a        use exercise ECG to diagnose or\u000a        exclude stable angina for people without known CAD\". Hemingway was a\u000a      member of the Guideline\u000a      Development Group and his research is cited 16 times in the guideline [a].\u000a      This has led to one of\u000a      the most significant changes in the diagnostic pathway of patients with\u000a      suspected stable angina for\u000a      decades. In the light of recent evidence showing the modest incremental\u000a      value for exercise ECG &#8212;\u000a      the strongest contemporary UK evidence coming from our research &#8212; NICE\u000a      made this bold\u000a      recommendation, which has subsequently been implemented.\u000a    This recommendation has since gone on to change clinical practice. For\u000a      example, an analysis of\u000a      diagnostic testing at the Newcastle Rapid Access Chest Pain Clinic in 2011\u000a      reported that: \"The\u000a        proportion of the study population before and after the guidelines\u000a        undergoing exercise testing was\u000a        50.1% vs 0.0%; for calcium score\/CT coronary angiography 0.0% vs 14.7%;\u000a        for functional imaging\u000a        25.6% vs 13.4%; and for invasive coronary angiography 15.3% vs 25.8%.\u000a        The proportion not\u000a        requiring further testing was unchanged (30.0% vs 31.0%)\" [b].\u000a      An analysis from the Royal Derby\u000a      Hospital in 2013 reported that \"implementation of the 2010 NICE\u000a        guidance...resulted in a greater\u000a        proportion of initial discharge to primary care with less frequent\u000a        outpatient review and similar rates\u000a        of referral for coronary angiography\" [c].\u000a    CG95 also made recommendations based on our research on sex and ethnicity\u000a      in angina pain.\u000a      The guideline recommended: \"Do not define typical and atypical features\u000a        of anginal chest pain and\u000a        non-anginal chest pain differently in men and women\" (recommendation\u000a      1.3.3.2) and \"Do not\u000a        define typical and atypical features of anginal chest pain and\u000a        non-anginal chest pain differently in\u000a        ethnic groups\" (recommendation 1.3.3.3). These two recommendations\u000a      (arising from ref. 5 above)\u000a      for the first time make an unequivocal statement to clinicians that\u000a      typical anginal pain does not\u000a      differ by sex and ethnicity. This is important because it has previously\u000a      been used as a post-hoc\u000a      justification of why rates of procedure use might differ between these\u000a      groups.\u000a    Treatment of patients with angina\u000a    From the perspective of the patient, or the health system payer, one of\u000a      the most significant\u000a      decisions taken among patients with angina relates to the mode of\u000a      revascularisation (coronary\u000a      artery bypass graft [CABG] or percutaneous coronary intervention [PCI]).\u000a      Our work was cited ten\u000a      times in the NICE guidelines on Management of stable angina\u000a      (CH126) issued in July 2011 and\u000a      directly influenced recommendations, all of which were `Key priorities for\u000a      implementation' [d].\u000a    First, `When either procedure would be appropriate, explain to the\u000a        person the risks and benefits of\u000a        PCI and CABG for people with anatomically less complex disease whose\u000a        symptoms are not\u000a        satisfactorily controlled with optimal medical treatment. If the person\u000a        does not express a\u000a        preference, take account of the evidence that suggests that PCI may be\u000a        the more cost-effective\u000a        procedure in selecting the course of treatment.'\u000a    Second, `When either procedure would be appropriate, take into account\u000a        the potential survival\u000a        advantage of CABG over PCI for people with multivessel disease whose\u000a        symptoms are not\u000a        satisfactorily controlled with optimal medical treatment and who have\u000a        diabetes or are over 65 years\u000a        or have anatomically complex three-vessel disease, with or without\u000a        involvement of the left main\u000a        stem.'\u000a    Our published unique `real world' cost and outcome data highlighted the\u000a      prevalence of patients\u000a      who are judged appropriate for both forms of revascularisation (refs [1]\u000a      and [3] above) and\u000a      underpinned to specification of these recommendations. Our UK evidence\u000a      base added to that\u000a      internationally has led to a slowing in the rate of increase of PCI for\u000a      stable coronary disease.\u000a    Co-existing depression among people with myocardial infarction\u000a    Our systematic reviews and meta-analyses of the role of depression in the\u000a      prognosis of coronary\u000a      disease have contributed in part to recommendations in European guidance\u000a      on the need to assess\u000a      psychosocial factors in these patients. Hemingway contributed to the 2007\u000a      guidelines on\u000a      cardiovascular disease prevention in clinical practice from European\u000a      Society of Cardiology, and the\u000a      most recent (2012) guidelines directly cite our work in support of the\u000a      identification of depression as\u000a      a specific risk factor in CVD [e]. These are the strongest\u000a      recommendations to date that clinicians\u000a      might consider psychosocial factors in addition to the better recognised\u000a      behavioural and biological\u000a      factors.\u000a    ","ImpactSummary":"\u000a    Research led by Professor Harry Hemingway at UCL on the quality and\u000a      outcomes of care of\u000a      people with, or at risk of, cardiovascular diseases has informed\u000a      guidelines and clinical\u000a      management in a number of areas. The work influenced NICE guidelines on Chest\u000a        pain of recent\u000a        onset (CG95) with regard to the use of exercise electrocardiography\u000a      (ECG) in the diagnosis of\u000a      stable angina and approaches to sex and ethnicity in diagnosis. Our\u000a      research also underpinned\u000a      recommendations on revascularisation in the NICE guidelines on Management\u000a        of stable angina\u000a      (CH126). Additionally, the research has led to recommendations about the\u000a      need to assess\u000a      psychosocial factors including depression in people with myocardial\u000a      infarction.\u000a    ","ImpactType":"Health","Institution":"\u000a    University College London\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a[1] Hemingway H, Crook AM, Feder G, Banerjee S, Dawson JR, Magee P,\u000a      Philpott S, Sanders J,\u000a      Wood A, Timmis AD. Underuse of coronary revascularization procedures in\u000a      patients\u000a      considered appropriate candidates for revascularization. N Engl J Med.\u000a      2001 Mar\u000a      1;344(9):645-54. http:\/\/dx.doi.org\/10.1056\/NEJM200103013440906\u000a    \u000a\u000a[2] Feder G, Crook AM, Magee P, Banerjee S, Timmis AD, Banerjee S,\u000a      Hemingway H. Ethnic\u000a      differences in the invasive management of coronary disease: prospective\u000a      cohort study of\u000a      patients undergoing angiography. BMJ 2002;324: 511-516.\u000a      http:\/\/dx.doi.org\/10.1136\/bmj.324.7336.511\u000a    \u000a\u000a[3] Griffin SC, Barber JA, Manca A, Sculpher MJ, Thompson SG, Buxton M,\u000a      Hemingway H. Cost\u000a      effectiveness of clinically appropriate decisions on alternative\u000a      treatments for angina pectoris:\u000a      prospective observational study. BMJ 2007;334(7594):624.\u000a      http:\/\/dx.doi.org\/10.1136\/bmj.39129.442164.55\u000a    \u000a\u000a[4] Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P,\u000a      Keskim&#228;ki I. Incidence\u000a      and Prognostic Implications of Stable Angina Pectoris Among Women and Men\u000a      in a Large\u000a      Ambulatory Population; JAMA 2006; 295:1404-1411.\u000a      http:\/\/dx.doi.org\/10.1001\/jama.295.12.1404\u000a    \u000a\u000a[5] Zaman MJ, Junghans C, Sekhri N, Chen R, Feder GS, Timmis AD,\u000a      Hemingway H.\u000a      Presentation of stable angina pectoris among women and South Asian people.\u000a      CMAJ 2008\u000a      Sep 23; 179(7): 659-67. http:\/\/dx.doi.org\/10.1503\/cmaj.071763\u000a    \u000a\u000a[6] Nicholson A, Kuper H, Hemingway H. Depression as an etiologic and\u000a      prognostic factor in\u000a      coronary heart disease: a meta-analysis of 6496 events among 147416\u000a      participants in 61\u000a      observational studies. Eur Heart J 2006; 27(23): 2763-74.\u000a      http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehl338\u000a    \u000aMajor grant funding\u000a    This work was funded by the Department of Health (&#163;742,000), NHS R&amp;D\u000a      (&#163;480,000), and British\u000a      Heart Foundation (&#163;380,000).\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"2","Subject":"Cardiorespiratory Medicine and Haematology"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    [a] Chest pain of recent onset: Assessment and diagnosis of recent\u000a        onset chest pain or discomfort\u000a        of suspected cardiac origin. NICE Clinical Guidelines, CG95 &#8212;\u000a      Issued: March 2010\u000a      http:\/\/guidance.nice.org.uk\/CG95\/Guidance.\u000a      Cites ref 5 (above) and two other publications from\u000a        our group not listed above.\u000a    [b] Haq IU, Skinner JS, Adams PC. Implications of a likelihood based\u000a      approach to diagnostic\u000a      testing in coronary artery disease: impact of the new nice guidelines.\u000a      Heart 2011;97:Suppl 1\u000a      A39. http:\/\/dx.doi.org\/10.1136\/heartjnl-2011-300198.63\u000a    [c] Sheppard C, Edmund J, Frawley K, Dubey G, Baron J, Burn S, Azeem T,\u000a      Bhandari M, Chitkara\u000a      K, Tukan A, McCance A, Kelly D. More discharges, less follow-up and\u000a      similar rates of coronary\u000a      angiography: initial `real-world' experience of NICE guidance on\u000a      assessment of chest pain of\u000a      recent onset in the Rapid access chest pain clinic. Heart 2013 99: A76.\u000a      http:\/\/dx.doi.org\/10.1136\/heartjnl-2013-304019.128\u000a    [d] The management of stable angina. NICE Clinical guidelines,\u000a      CG126 &#8212; Issued: July 2011.\u000a      http:\/\/guidance.nice.org.uk\/CG126\/Guidance\/pdf\/English.\u000a      Cites ref. 3 (above) and another\u000a        publication from our group not listed above.\u000a    [e] Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M,\u000a      Albus C, Benlian P,\u000a      Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R,\u000a      Hoes A,\u000a      Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syv&#228;nne M, Scholte\u000a      op Reimer WJ,\u000a      Vrints C, Wood D, Zamorano JL, Zannad F; European Association for\u000a      Cardiovascular\u000a      Prevention &amp; Rehabilitation (EACPR); ESC Committee for Practice\u000a      Guidelines (CPG).\u000a      European Guidelines on cardiovascular disease prevention in clinical\u000a        practice (version\u000a      2012). The Fifth Joint Task Force of the European Society of Cardiology\u000a      and Other Societies\u000a      on Cardiovascular Disease Prevention in Clinical Practice (constituted by\u000a      representatives of\u000a      nine societies and by invited experts). Eur Heart J. 2012\u000a      Jul;33(13):1635-701.\u000a      http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehs092.\u000a      Cites ref 6 (above) in support of its identification of\u000a        depression as a risk factor in CVD.\u000a    \u000a    ","Title":"\u000a    Improving the quality of care of people with and at risk of\u000a      cardiovascular\u000a      diseases\u000a    ","UKLocation":[{"GeoNamesId":"2641673","Name":"Newcastle-upon-Tyne"},{"GeoNamesId":"2651347","Name":"Derby"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Clinical practice in cardiovascular medicine does not necessarily keep\u000a      pace with evidence-based\u000a      recommendations. Beginning in 1994, Hemingway led a prospective study of\u000a      consecutive patients\u000a      undergoing coronary angiography at three London hospitals. Previous\u000a      studies had suggested that\u000a      `appropriateness' might offer a missing link in optimising clinical\u000a      practice with evidence-based care,\u000a      for several inter-related reasons. However, it was unknown whether these\u000a      ratings of\u000a      appropriateness for coronary revascularisation or coronary angiography\u000a      were valid in terms of\u000a      clinical outcomes. Among consecutive `real world patients' we hypothesised\u000a      that people who were\u000a      appropriate for a procedure but who did not receive it (underuse) would go\u000a      on to experience worse\u000a      outcomes. Ours was the first (and still among the few) studies to\u000a      prospectively test, and confirm,\u000a      this hypothesis [1].\u000a    Our appropriateness studies allowed us to go beyond clinically na&#239;ve but\u000a      widely published crude\u000a      differences in rates of procedures e.g. between ethnic minorities, women\u000a      and men (which are to be\u000a      expected based on well known differences in the epidemiology of coronary\u000a      disease) to assess\u000a      whether procedure rates are clinically fair. What we demonstrated was that\u000a      there was little\u000a      evidence that South Asians had clinically important (in terms of death and\u000a      heart attack risk)\u000a      differences from the rest of the population in appropriateness for\u000a      revascularisation [2].\u000a    We used a novel method to address the clinically important decision\u000a      arising when revascularisation\u000a      with both coronary artery bypass grafting (CABG) and percutaneous coronary\u000a      intervention (PCI)\u000a      are considered clinically appropriate. Based on our formally-defined\u000a      appropriateness criteria, and\u000a      long-term follow up (five years) we demonstrated the cost-effectiveness of\u000a      revascularisation with\u000a      CABG, but showed that revascularisation with PCI was not cost effective [3].\u000a      These results were\u000a      subsequently demonstrated (among selected patients) in randomised trials.\u000a    We exploited linked electronic health records in primary care in Finland\u000a      to provide the first large-scale\u000a      evidence that stable angina has a considerably higher incidence than\u000a      myocardial infarction\u000a      and affects women and men with similar incidence risks. Furthermore,\u000a      stable angina in women,\u000a      among easily identifiable clinical subgroups, has similarly high absolute\u000a      rates of prognostic\u000a      outcomes compared with men [4].\u000a    Between 1996 and 2002 we investigated the role of exercise\u000a      electrocardiography in the initial\u000a      evaluation of people with suspected stable angina and found that it\u000a      contributed little new prognostic\u000a      information beyond simpler clinical measures [5].\u000a    Our systematic reviews and meta-analyses since the late 1990s have tested\u000a      the long-held clinical\u000a      impression that social and psychological factors might influence outcome\u000a      in coronary disease.\u000a      Most recently, in a systematic review looking at depression in particular,\u000a      we found some evidence\u000a      that depression may be important but also identified the need for\u000a      methodological improvements in\u000a      the research [6].\u000a    Our research has led to the establishment of the Farr Institute of Health\u000a      Informatics Research,\u000a      funded to a total of &#163;9.3m from 10 UK funders (including MRC, Wellcome\u000a      Trust, NIHR, British\u000a      Heart Foundation.) We have also established the National Institute of\u000a      Cardiovascular Outcomes\u000a      Research, with &#163;5.3m funding to curate and exploit quality registries for\u000a      acute coronary syndromes\u000a      and other cardiac conditions.\u000a    Key academic co-investigators involved in the research include: Professor\u000a      Gene Feder (initially\u000a      QMUL, Bristol since 2009), Professor Adam Timmis (QMUL), Professor Douglas\u000a      Altman (Oxford).\u000a    "},{"CaseStudyId":"41172","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1227603","Name":"Sri Lanka"},{"GeoNamesId":"2300660","Name":"Ghana"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"2328926","Name":"Nigeria"}],"Funders":[],"ImpactDetails":"\u000a    King's research has achieved impact in the field of sickle cell disease\u000a      through its contribution to the roll-out of an antenatal and newborn\u000a      screening programme, linked to designated NHS specialist treatment\u000a      services for haemoglobin disorders. The principal beneficiaries are people\u000a      with sickle cell disease and their families whose management has moved\u000a      from the margins of the NHS to the mainstream. Individuals with sickle\u000a      cell disease have benefited from earlier diagnosis and better treatment.\u000a      Carriers of the sickle cell trait have benefited through being enabled to\u000a      make informed reproductive choices when a pregnancy may be affected.\u000a    King's hosts the national Screening Programme Centre\u000a    Following up the research on newborn bloodspot coverage, King's was\u000a      commissioned by the Department of Health to implement a National Audit of\u000a      the Newborn Bloodspot Programme. As a result of a 1999 workshop convened\u000a      by the National Screening Committee (NSC), at which the King's research on\u000a      bloodspot programme coverage was presented alongside the results of two\u000a      Health Technology Assessment reviews, universal newborn screening for\u000a      sickle cell disease was recommended. In 2000, the Department of Health\u000a      committed to introduce newborn and antenatal screening for\u000a      haemoglobinopathies including sickle cell disease and thalassaemia. The\u000a      National Programme Centre for the NHS screening programme was established\u000a      at King's College London from 2000 to 2013 through a contract between the\u000a      Department of Health and King's, which had a value of &#163;7.75 million in the\u000a      period 2008-2013. The Programme was directed by Dr Streetly (2000- 2013),\u000a      reporting to Dr Anne Mackie as Director of Programmes, for the National\u000a      Screening Committee. The Programme Centre transferred to Public Health\u000a      England in 2013. The aim of the NHS Haemoglobinopathy Screening Programme\u000a      is to support people to make informed choices during pregnancy and before\u000a      conception, to improve infant health through prompt identification of\u000a      affected babies, to provide high quality and accessible care for these\u000a      conditions throughout England and promote greater understanding and\u000a      awareness of the disorders (NHS\u000a        Sickle Cell and Thalassaemia Screening Programme, 2013).\u000a    King's leads implementation of the National Screening Programme\u000a    With national leadership based at King's, universal newborn and antenatal\u000a      screening for sickle cell disease was introduced in England while\u000a      implementation in Scotland and Northern Ireland was also supported. This\u000a      was achieved through setting standards (Ryan\u000a        et al. 2010); designing pathways for screening and care; education\u000a      and training; establishing communications and preparing materials for\u000a      professionals and the public; establishing data collection systems for\u000a      surveillance and monitoring; and quality assurance and evaluation. The\u000a      main impacts of the screening programme roll-out in England are summarised\u000a      in the Table including results from the Screening\u000a        Programme Data Reports from 2008\/9 to 2011\/12 (NHS Sickle Cell and\u000a      Thalassaemia Screening Programme 2013).\u000a    \u000a      \u000a        \u000a          Programme\u000a              Impacts for England \u000a          2008\/09 \u000a          2009\/10 \u000a          2010\/11 \u000a          2011\/12 \u000a        \u000a        \u000a          Newborn infants screened\u000a          669,427\u000a          648,317\u000a          688,314\u000a          693,278\u000a        \u000a        \u000a          Significant clinical condition identified\u000a          360\u000a          361\u000a          358\u000a          320\u000a        \u000a        \u000a          Carriers identified\u000a          9,624 \u000a          9,732 \u000a          9,830 \u000a          9,718 \u000a        \u000a        \u000a          \u000aAntenatal women screened \u000a          657,160\u000a          643,671\u000a          723,768\u000a          733,610\u000a        \u000a        \u000a          Screen positive sickle or thalassaemia \u000a          22,305\u000a          16,135\u000a          17,354\u000a          16,556\u000a        \u000a        \u000a          Fathers offered test\u000a          18,500\u000a          16,670\u000a          15,908\u000a          15,681\u000a        \u000a        \u000a          Partners tested\u000a          10,279\u000a          9,554\u000a          9,028\u000a          9,465\u000a        \u000a        \u000a          &#8216;At risk&#8217; pregnancy\u000a          938\u000a          1,006\u000a          940\u000a          918\u000a        \u000a        \u000a          Prenatal diagnosis procedures\u000a          388\u000a          396\u000a          420\u000a          418\u000a        \u000a        \u000a          Affected foetus identified\u000a          88\u000a          102\u000a          95\u000a          101\u000a        \u000a      \u000a    \u000a    Newborn screening has increased the number of children being identified\u000a      with sickle cell disease, in many areas almost doubling the service\u000a      workload (Streetly\u000a        et al., 2009). The King's group proposed that under-ascertainment of\u000a      the condition may have allowed a downplaying of the scale of need and\u000a      contributed to infant mortality rates in urban areas as babies died\u000a      without a diagnosis or treatment (Streetly\u000a        et al., 2009).\u000a    Influenced by the results of King's SHIFT Trial (whose Trial Manager,\u000a      Dormandy, became Screening Programme Deputy Director), the national NHS\u000a      Screening Programme has set a minimum standard of requiring 50% of\u000a      prenatal diagnosis procedures to be implemented by 12 weeks and 6 days\u000a      gestation. The Data\u000a        Report for 2011\/12 (NHS Sickle Cell and Thalassaemia Screening\u000a      Programme, 2013) (Table AN-4) shows that 61% of all initial antenatal\u000a      screening tests in England are now performed by 12 weeks gestation. This\u000a      has been accompanied by an increase in the number of pre-natal diagnosis\u000a      procedures being performed from 307 in 2004\/5 to 418 in 2011\/12, with 52%\u000a      of these now being performed within 12 weeks 6 days of gestation (Table\u000a      PND- 6).\u000a    King's provides international advice on haemoglobinopathy screening\u000a    During the assessment period, the Screening Programme has benefitted from\u000a      strong stakeholder involvement, with the Archbishop of York chairing the\u000a      Programme Steering Group. There has been international interest in the\u000a      screening programme, which is recognised to be the best developed in\u000a      Europe, and arguably the world, providing a model for many other\u000a      countries. Dr Streetly has given invited presentations at the Centres for\u000a      Disease Control, Atlanta, USA, Ghana, and in Europe in Rome, Lisbon,\u000a      Barcelona, Paris and Berlin. The Programme has also hosted visits from, or\u000a      provided advice to, public health advisers to the Netherlands government,\u000a      US Centres for Disease Control, Sri Lanka and Nigeria among others. The\u000a      Programme website is regularly accessed and materials downloaded by\u000a      interested parties from across the world.\u000a    King's research stimulates action to improve patient care and\u000a        specialist treatment services\u000a    King's research drew attention to the difficulties that patients with\u000a      sickle cell disease experience in their interactions with hospital\u000a      services. Following on from the research, a National Confidential Enquiry\u000a      into Patient Outcomes and Death (NCEPOD,\u000a        2008) into sickle cell disease was launched. King's contributed to\u000a      the authorship of the NCEPOD report (Professor Sebastian Lucas, Dr Allison\u000a      Streetly). The NCEPOD findings confirmed and extended the results of the\u000a      King's research. Of 35 sickle cell disease patients who died in hospital,\u000a      19 had pain as an admitting complaint. In nine patients excessive doses of\u000a      opioids were judged to have been administered, contributing to the\u000a      patient's death in five cases. The NCEPOD report made 28 specific\u000a      recommendations for the improvement of clinical treatment and service\u000a      delivery for sickle cell disease including better management of acute pain\u000a      and improved care of the long-term illness by clinicians with specialist\u000a      expertise and training. The recommendations were circulated to Medical\u000a      Directors of all Trusts for action. Recognising the need for action to\u000a      improve the quality of care highlighted by this report, the Department of\u000a      Health commissioned a National Haemoglobinopathies project that produced\u000a      guidance for commissioners on effectively commissioning high quality\u000a      sickle cell and thalassaemia services. The guidance included designated\u000a      standards that Trusts must deliver to secure specialist status for\u000a      haemoglobinopathy care as well as model service specifications and a\u000a      commissioning framework. The final NHS guideline document (NHS\u000a        East Midlands 2011) included an endorsement written by Dr Streetly\u000a      from King's in her capacity as Programme Director of the National NHS\u000a      Haemoglobinopathy Screening Programme. The Department of Health also\u000a      prioritised this as an area for National Institute for Health and Care\u000a      Excellence (NICE) guidance leading to sickle cell crises being defined as\u000a      an emergency condition (NICE,\u000a        2012).\u000a    ","ImpactSummary":"\u000a    King's College London research identified the feasibility of implementing\u000a      newborn screening for sickle cell disease, which was advocated. King's\u000a      research also demonstrated the feasibility of antenatal screening for\u000a      sickle cell disease early in pregnancy. A new national NHS Programme for\u000a      antenatal and newborn screening for haemoglobin disorders was rolled out,\u000a      with the national Programme Centre based at King's, resulting in\u000a      increasing numbers of women and newborn infants being tested for sickle\u000a      cell disease and trait. The screening programme enables informed choices\u000a      for carrier individuals, and contributed to earlier diagnosis and better\u000a      care for those with disease. King's research identified important problems\u000a      in the delivery of treatment services for patients with sickle cell\u000a      disease. The research informed the decision to designate specialist NHS\u000a      services in order to address deficiencies in care.\u000a    ","ImpactType":"Health","Institution":"\u000a    King's College London\u000a    ","Institutions":[{"AlternativeName":"King's College London","InstitutionName":"King's College London","PeerGroup":"A","Region":"London","UKPRN":10003645}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2950159","Name":"Berlin"},{"GeoNamesId":"2988507","Name":"Paris"},{"GeoNamesId":"2267057","Name":"Lisbon"},{"GeoNamesId":"4180439","Name":"Atlanta"},{"GeoNamesId":"3128760","Name":"Barcelona"}],"References":"\u000a    \u000aDormandy E,\u000a      Gulliford MC, Reid EP, Brown K, Marteau TM; SHIFT Research Team (2008).\u000a      Delay between pregnancy confirmation and sickle cell and thalassaemia\u000a      screening: a population-based cohort study. Br J Gen Pract 58:154-9.\u000a      doi: 10.3399\/bjgp08X277267.\u000a    \u000a\u000aDormandy E,\u000a      Bryan S, Gulliford MC et al. (2010a) Antenatal screening for\u000a      haemoglobinopathies in primary care: a cohort study and cluster randomised\u000a      trial to inform a simulation model. The Screening for Haemoglobinopathies\u000a      in First Trimester (SHIFT) trial. Health Technol Assess 14:1- 160.\u000a      doi: 10.3310\/hta14200.\u000a    \u000a\u000aDormandy E,\u000a      Gulliford M, Bryan S, Roberts TE, Calnan M, Atkin K, Karnon J, Logan J,\u000a      Kavalier F, Harris HJ, Johnston TA, Anionwu EN, Tsianakas V, Jones P,\u000a      Marteau TM. (2010b) Effectiveness of earlier antenatal screening for\u000a      sickle cell disease and thalassaemia in primary care: cluster randomised\u000a      trial. BMJ 341:c5132. doi: 10.1136\/bmj.c5132.\u000a    \u000a\u000aMaxwell K,\u000a      Streetly A, Bevan D (1999). Experiences of hospital care and treatment\u000a      seeking for pain from sickle cell disease: qualitative study. BMJ.\u000a      318:1585-90.\u000a    \u000a\u000aStreetly A,\u000a      Grant C, Bickler G, Eldridge P, Bird S, Griffiths W (1994). Variation in\u000a      coverage by ethnic group of neonatal (Guthrie) screening programme in\u000a      south London. BMJ. 309:372-4.\u000a    \u000aResearch Grants\u000a    Evaluation of neonatal screening programme in Camberwell and West\u000a      Lambeth. A Streetly. South East Thames Regional Health Authority, Locally\u000a      Organised Research Scheme. 1992-1993.\u000a    A qualitative comparative investigation of sickle cell patients'\u000a      experiences of pain management. A Streetly. King's Fund, Marks and\u000a      Spencer, South Thames Region, Roald Dahl Foundation. &#163;45,000. 1996-1998.\u000a    Antenatal screening for hemoglobinopathy: a cluster randomised trial.\u000a      SHIFT Trial. T Marteau and 16 others. NHS R&amp;D Health Technology\u000a      Assessment Programme. 2004-2007. &#163;599,000.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"14","Subject":"Paediatrics and Reproductive Medicine"}],"Sources":"\u000a    National Institute for Health and Care Excellence (NICE) (2012) Sickle\u000a        cell acute painful episode (CG143) Appendix E. London: NICE: page\u000a      101, Table 82.\u000a    NCEPOD (2008). A\u000a        sickle crisis? A report of the National Confidential Enquiry into\u000a      Patient Outcome and Death. London: NCEPOD:\u000a    NHS East Midlands Specialist Commissioning Group (2011). The\u000a        National Haemoglobinopathies Project.\u000a        A guide to effectively commissioning high quality sickle cell and\u000a        thalassaemia services. (page 7)\u000a    NHS Sickle Cell and Thalassaemia Screening Programme (2013): Website\u000a    \u000a      \u000a        \u000a        Data report 2011\/12\u000a\u0009\u0009Programme Review 2011\/12\u000a        \u000a\u0009    \u000a\u0009\u0009Data report 2010\/11\u000a\u0009\u0009Annual Report 2010\/11\u000a        \u000a\u0009\u0009\u000a\u0009    Data report 2009\/10\u000a\u0009\u0009Annual Report 2009\/10\u000a        \u000a\u0009\u0009\u000a\u0009\u0009Data report 2008\/09\u000a\u0009\u0009Annual report 2008\/09\u000a\u0009\u0009\u000a\u0009 \u000a    \u0009\u000a    Ryan K et\u000a      al. (2010). British Committee for Standards in Haematology. Significant\u000a      haemoglobinopathies: guidelines for screening and diagnosis. Br J\u000a        Haematol. 149:35-49. doi: 10.1111\/j.1365-2141.2009.08054.x.\u000a    Streetly A,\u000a      Latinovic R, Hall K, Henthorn J (2009). Implementation of universal\u000a      newborn bloodspot screening for sickle cell disease and other clinically\u000a      significant haemoglobinopathies in England: screening results for 2005-7.\u000a      J Clin Pathol 62:26-30. doi: 10.1136\/jcp.2008.058859 \u000a    ","Title":"\u000a    Sickle Cell Disease: Introduction of Population Screening Linked to\u000a          Improved Treatment Services\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"2641364","Name":"Northern Ireland"},{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Sickle Cell Disease and Thalassaemia\u000a    Haemoglobin disorders, including sickle cell disease and thalassaemia,\u000a      are the most common genetic disorders worldwide, primarily affect black\u000a      and minority ethnic populations and contributing to inequalities in\u000a      health. King's research led by Dr Allison Streetly (Senior Lecturer in\u000a      Public Health, 1994-7; Honorary Senior Research Fellow, 1997-2013),\u000a      Professor Theresa Marteau (Professor of Health Psychology, King's 1993 to\u000a      2012) and Dr Elizabeth Dormandy (SHIFT Trial Manager, later Deputy\u000a      Director, Sickle Cell and Thalassaemia Screening Programme, King's 1999 to\u000a      2013); explored the feasibility of introducing a newborn screening\u000a      programme for the condition; demonstrated the effectiveness of screening\u000a      for haemoglobin disorders early in pregnancy; and evaluated the delivery\u000a      of care for patients with sickle cell disease.\u000a    King's research identifies the potential to screen newborns for Sickle\u000a        Cell Disease\u000a    King's research investigated the coverage of newborn bloodspot screening,\u000a      as a potential means of screening infants for sickle cell disease (Streetly\u000a        et al., 1994). This research found that overall coverage of\u000a      bloodspot screening was 96% but there were important inequalities in\u000a      coverage with lower screening coverage in infants of African ethnicity\u000a      than in white infants. The research pointed out that the newborn bloodspot\u000a      test could be used to screen for sickle cell disease but poorer coverage\u000a      of infants of African origins might result in cases of sickle cell disease\u000a      going undetected. The report authors advocated using the newborn bloodspot\u000a      in screening for sickle cell disease in subsequent\u000a        publications. The research showed that arrangements for monitoring\u000a      the existing screening programme were inadequate and the research report\u000a      recommended that an improved system for managing and monitoring the blood\u000a      spot programme should be established.\u000a    King's research shows Sickle Cell carriers may be identified very\u000a        early in pregnancy\u000a    King's research evaluated the potential for screening for sickle cell\u000a      disease early in pregnancy. Dormandy\u000a        et al. (2008) reported a study of 1,441 eligible women attending 25\u000a      general practitioner clinics offering universal antenatal screening. The\u000a      median time interval between pregnancy confirmation in primary care and a\u000a      screening test for sickle cell or thalassaemia being performed was 6.9\u000a      weeks, with only 4.4% of women being screened before 10 weeks gestation (Dormandy et al., 2008).\u000a      The King's SHIFT cluster randomised trial provided evidence of the\u000a      effectiveness, and impact on informed choice, of offering antenatal\u000a      screening at the earliest stage of pregnancy in primary care (Dormandy\u000a        et al., 2010a; Dormandy\u000a        et al., 2010b). The SHIFT trial showed that in a conventional\u000a      midwife-led model of care only 2% of women are screened for haemoglobin\u000a      disorders before 10 weeks' gestation, compared with over 25% of women\u000a      receiving general practitioner-led care with either parallel or sequential\u000a      partner testing. These results showed that offering antenatal screening\u000a      for haemoglobin disorders as part of consultations for pregnancy\u000a      confirmation in primary care substantially increases the proportion of\u000a      women offered screening before 10 weeks' gestation. This is important in\u000a      enabling carrier couples to choose their preferred option in early\u000a      pregnancy with less time pressure. Options may include prenatal diagnosis,\u000a      with amniocentesis or chorionic villus sampling, leading to possible\u000a      termination of pregnancy.\u000a    King's research identifies problems experienced in seeking care for\u000a        Sickle Cell Disease\u000a    King's research (Maxwell\u000a        et al., 1999) showed that patients with sickle cell disease\u000a      experienced substantial difficulties in hospital care. These were\u000a      characterised by health professionals' mistrust of patients with sickle\u000a      cell disease; their stigmatisation of sickle cell disease patients as\u000a      potential drug addicts; professionals' control of treatment plans,\u000a      diminishing opportunities for self-care; neglect of patients' personal\u000a      care needs and monitoring of vital signs; and failure to offer\u000a      psychological support. The research found that individuals who usually\u000a      manage their pain at home showed different attitudes and strategies\u000a      towards hospital services from those who are frequently admitted to\u000a      hospital. The study recommended that models of care should be developed\u000a      that acknowledge the diversity of the population with sickle cell\u000a      disorders and prioritise the involvement and empowerment of patients in\u000a      their care (Maxwell\u000a        et al., 1999).\u000a    "},{"CaseStudyId":"41173","Continent":[],"Country":[],"Funders":["Medical Research Council","Natural Environment Research Council"],"ImpactDetails":"\u000d\u000a    Impacts of King's air quality research include: evidence linking poor air\u000d\u000a      quality in urban environments to traffic; evidence to inform the policies\u000d\u000a      to improve air quality; contributing to the design and implementation and\u000d\u000a      evaluation of traffic control schemes in the UK; informing the development\u000d\u000a      of schemes in other countries; evidence of measurable improvements in air\u000d\u000a      quality; evidence of improvements in health outcomes. Beneficiaries from\u000d\u000a      the research include the populations of urban centres that have benefited\u000d\u000a      from control measures directed at traffic related air pollution.\u000d\u000a    King's research influences air quality strategy in London\u000d\u000a    In 2000, London's air quality was the worst in the UK and there was\u000d\u000a      evidence to show that these pollution levels caused serious health\u000d\u000a      impacts. Ken Livingstone, as Mayor of London published the `The Mayor's\u000d\u000a        Air Quality Strategy: Cleaning London's Air,' in 2001 (updated in\u000d\u000a      2002) which drew heavily on information from King's London Air Quality\u000d\u000a      Network (LAQN). The strategy put forward a range of policies and proposals\u000d\u000a      designed to move London toward the point where air pollution no longer\u000d\u000a      poses a significant risk to human health. The underpinning research from\u000d\u000a      King's, constituted an extensive programme that has delivered innovative\u000d\u000a      modelling and monitoring methodologies, guiding the design of the\u000d\u000a      Congestion Charging Scheme and subsequently the world's largest low\u000d\u000a      emission zone (LEZ). London's LEZ was proposed in order to \"accelerate the\u000d\u000a      introduction of cleaner vehicles and reduce the numbers of older, more\u000d\u000a      polluting vehicles\" into the capital. King's researchers engaged in the\u000d\u000a      LEZ feasibility study and, in 2005, King's was chosen to partner Transport\u000d\u000a      for London (TfL) in delivering the London LEZ, which became a key\u000d\u000a      component of The Mayor's Air Quality Strategy. In the assessment period,\u000d\u000a      results from King's monitoring and modelling were used extensively by the\u000d\u000a      Mayor's office. `The Mayor's Air Quality Strategy' (2010) details current pollution\u000d\u000a      levels and highlights measures which `will result in significant\u000d\u000a      reductions in pollution concentrations across Greater London.' King's LAQN\u000d\u000a      is specifically identified for the contribution to monitoring of air\u000d\u000a      quality and emissions. The LAQN index, developed by King's, is used\u000d\u000a      throughout the report to `provide a useful picture of the overall\u000d\u000a      improvements in London's air quality'. The London Air Quality Network not only informs Transport for London, but can\u000d\u000a      be used by the public to find, for instance, street-level, interactive\u000d\u000a      current pollution maps; incidences of high pollution episodes; news,\u000d\u000a      videos and podcasts pertaining to air quality; interactive graphs by\u000d\u000a      London borough and yearly reports.\u000d\u000a    The LEZ was established in 2008 and has continued to the present. It\u000d\u000a      operates 24 hours a day, 365 days a year. It applies to diesel-engine,\u000d\u000a      heavy goods vehicles (HGVs), buses and coaches, larger vans and minibuses,\u000d\u000a      using cameras to identify the registration numbers of vehicles and the\u000d\u000a      Driver and Vehicle Licensing Agency (DVLA) database to identify a\u000d\u000a      vehicle's emissions. The impact of the research undertaken by King's in\u000d\u000a      partnership with TfL, not only encompasses the evaluation the\u000d\u000a      effectiveness of the LEZ on an ongoing basis, but also ensured that key\u000d\u000a      projected impacts of the scheme were understood and characterised well in\u000d\u000a      advance of the implementation date, as part of the monitoring network\u000d\u000a      design process. The 2008 TfL report `London Low Emission Zone &#8212; Impacts Monitoring' details the collaboration\u000d\u000a      with the King's LAQN saying that measurements provided by them \"will be\u000d\u000a      the first point of reference for stakeholders assessing the air quality\u000d\u000a      impacts of the scheme and are the legal basis for assessing compliance\u000d\u000a      with UK and European air quality objectives.\" This report also discusses\u000d\u000a      the health impacts of the LEZ, utilising data that contributed to the Tonne et al, (2008)\u000d\u000a      and Kelly et al, (2011b) research reports.\u000d\u000a    King's scientists provide expert advice and advocacy to UK\u000d\u000a        policy-makers\u000d\u000a    Prof Frank Kelly from King's has actively advocated the merits of LEZs\u000d\u000a      when giving expert advice to Environmental Audit Committee enquiries into\u000d\u000a      air quality in the UK. Prof Kelly gave detailed verbal evidence to the House of Commons Environmental Audit Committee to\u000d\u000a      aid in the compilation of their Air Quality Report. This report detailed the government's response to a\u000d\u000a      previous meeting of the committee that found that \"air quality was not\u000d\u000a      seen as a priority across Government\" and as such the UK was \"failing to\u000d\u000a      meet a range of domestic and European targets.\" Failure to meet standards\u000d\u000a      could incur millions of pounds of fines. The single most important\u000d\u000a      exposure to harmful air pollutants was known to be caused by transport. It\u000d\u000a      was decided local authorities must be involved in tackling poor air\u000d\u000a      quality. The government undertook this current enquiry to \"assess the\u000d\u000a      extent to which the Government had implemented the processes outlined in\u000d\u000a      its response and to assess their results.\" Prof Kelly was one of the key\u000d\u000a      people giving evidence and a reference was also made to LAQN documents\u000d\u000a      when discussing how, in London, PM10 daily limit values were\u000d\u000a      being exceeded. King's researchers have also compiled several reports for\u000d\u000a      the Department for Environment Food and Rural Affairs (DEFRA). For\u000d\u000a      instance, in 2009 they produced a report on `Air pollution and emissions trends in London' that \"summarises detailed\u000d\u000a      and comprehensive assessment of trends in emissions and concentrations of\u000d\u000a      NOX and PM in London\". They also produced a review of air quality modelling that \"identifies specific policy needs for\u000d\u000a      the use of models and evaluates each model in turn in terms of the\u000d\u000a      scientific content and credibility of the models, their ease of use and\u000d\u000a      transparency and their fitness for purpose in delivering DEFRA's needs. Many UK cities are now investigating LEZs with 15 local authorities being\u000d\u000a      allocated central government funds to develop schemes similar to the\u000d\u000a      London LEZ. King's researchers are members of the Committee on the Medical\u000d\u000a      Effects of Air Pollutants, the expert advisory group of the Department of\u000d\u000a      Health in the UK for which Kelly is Chair; Quantification of air pollution\u000d\u000a      health effects, a sub-group of COMEAP; and the Air Quality Expert Group,\u000d\u000a      the DEFRA advisory group.\u000d\u000a    King's scientists provide expert advice to international agencies\u000d\u000a    Professor Kelly and colleagues played significant roles in the air\u000d\u000a      quality review process initiated by the WHO in 2005, 2010 and again in\u000d\u000a      2012. Members of King's staff are also members of influential national and\u000d\u000a      international scientific panels including: UN Economic Commission for\u000d\u000a      Europe Convention on Long Range Transboundary Air Pollution; and the US\u000d\u000a      Health Effects Institute investigation into the Health Effects of Traffic\u000d\u000a      pollution.\u000d\u000a    King's research informs similar interventions throughout Europe\u000d\u000a    Since the inception of the LEZ, King's has contributed innovative\u000d\u000a      analysis of pollution concentrations as part of our ongoing assessment of\u000d\u000a      the impacts of the LEZ on air quality. This work has been of benefit to\u000d\u000a      the UK, and other Governments around the globe, as they contemplate\u000d\u000a      measures to reduce traffic pollution in increasingly congested urban\u000d\u000a      areas. The LEZ was designed to move London closer to achieving national\u000d\u000a      and EU air quality objectives. The use of traffic intervention schemes to\u000d\u000a      achieve an improvement in air quality is now widespread. More than 200\u000d\u000a      cities in 13 European countries have introduced LEZ's and international teams are\u000d\u000a      following King's lead in assessing their potential health benefit.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Poor air quality is an important public health issue especially in cities\u000d\u000a      where traffic is the major source of pollution. It is estimated that\u000d\u000a      29,000 people die prematurely in the UK each year, and 310,000 in Europe,\u000d\u000a      because of air pollution. King's research, based on the London Air Quality\u000d\u000a      Network (LAQN), including emissions modelling and vehicle profiling,\u000d\u000a      indicated that improvements in air quality could be achieved by\u000d\u000a      restricting the entrance of specific vehicle classes into urban areas.\u000d\u000a      These research outputs were utilised by the Mayor of London to introduce\u000d\u000a      the Congestion Charging Scheme (CCS), from 2003 to the present, and the\u000d\u000a      London Low Emission Zone (LEZ), from 2008 to the present. This research,\u000d\u000a      together with King's ongoing evaluation of air quality and the impact of\u000d\u000a      traffic control schemes in London, has created increasing international\u000d\u000a      interest in this method of pollution control resulting in the adoption of\u000d\u000a      similar interventions across Europe.\u000d\u000a    ","ImpactType":"Environmental","Institution":"\u000d\u000a    King's College London\u000d\u000a    ","Institutions":[{"AlternativeName":"King's College London","InstitutionName":"King's College London","PeerGroup":"A","Region":"London","UKPRN":10003645}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000aBeevers, S.D. and Carslaw, D.C. (2005). The impact of congestion charging on\u000d\u000a      vehicle emissions in London. Atmospheric Environment 39,\u000d\u000a      1-5. http:\/\/dx.doi.org\/10.1016\/j.atmosenv.2004.10.001\u000d\u000a    \u000a\u000aKelly, F.J.\u000d\u000a      (2003). Oxidative stress: its role in air pollution and adverse health\u000d\u000a      effects. Occup Envir Med 60, 612-616.\u000d\u000a      doi:10.1136\/oem.60.8.612\u000d\u000a    \u000a\u000aKelly F,\u000d\u000a      Anderson HR, Armstrong B, Atkinson R, Barratt B, Beevers S, Derwent D,\u000d\u000a      Green D, Mudway I, Wilkinson P; HEI Health Review Committee. (2011a) The\u000d\u000a      impact of the congestion charging scheme on air quality in London. Part 1.\u000d\u000a      Emissions modeling and analysis of air pollution measurements. Res Rep\u000d\u000a        Health Eff Inst 155, 5-71. http:\/\/pubs.healtheffects.org\/getfile.php?u=638\u000d\u000a    \u000a\u000aKelly F,\u000d\u000a      Armstrong B, Atkinson R, Anderson HR, Barratt B, Beevers S, Cook D, Green\u000d\u000a      D, Derwent D, Mudway I, Wilkinson P.(2011b) The London low emission zone\u000d\u000a      baseline study. Res Rep Health Eff Inst. 163, 3-79. http:\/\/pubs.healtheffects.org\/getfile.php?u=669\u000d\u000a    \u000a\u000aMudway, I.S. and Kelly, F.J. (2004). An investigation of inhaled ozone dose and the\u000d\u000a      magnitude of airway inflammation in health adults. Am J Resp Crit Care\u000d\u000a        Med 169, 1089-95. doi: 10.1164\/rccm.200309-1325PP\u000d\u000a    \u000a\u000aTonne C,\u000d\u000a      Beevers S, Armstrong B, Kelly F J, Wilkinson P. (2008). Air pollution and\u000d\u000a      mortality benefits of the London Congestion Charge: spatial and\u000d\u000a      socioeconomic inequalities. Occup Environ Med 65, 620-627.\u000d\u000a      doi: 10.1136\/oem.2007.036533\u000d\u000a    \u000aResearch Grants\u000d\u000a    PI: Prof Frank Kelly with Prof Steven Belcher. Title: Clean Air for\u000d\u000a      London (ClearfLo). Sponsor: NERC. Period: 2010 - 2012. Total Awarded:\u000d\u000a      &#163;2.8M.\u000d\u000a    PI: Prof Frank Kelly. Title: Traffic Pollution and Health in London.\u000d\u000a      Sponsor: NERC. Period: 2011 - 2014. Total Awarded: &#163;2.0M.\u000d\u000a    PI: Prof Frank Kelly. Oxidative Potential of Particulate Matter and Risk\u000d\u000a      of Cardiovascular Disease: A Hybrid Toxico-Epidemiological Study. Sponsor:\u000d\u000a      Department of Health Period: 2009-2010. &#163;150K.\u000d\u000a    PI: Prof Frank Kelly. Title: London Congestion Charging Scheme: its\u000d\u000a      impact on air quality &amp; health. Sponsor: Health Effects Institute\u000d\u000a      (US). Period: 2005-2007. Total Awarded: $700K.\u000d\u000a    PI: Prof Frank Kelly. Title: London Low Emission zone: its impact on air\u000d\u000a      quality &amp; health. Sponsor: Health Effects Institute (US). Period:\u000d\u000a      2006-2007. Total Awarded: $800K.\u000d\u000a    PI: Prof Frank Kelly. Title: London Low Emission. Transport for London.\u000d\u000a      2005-2007. &#163;330K.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    Mayor's Air Quality Strategy. London: Greater London Authority, 2010.\u000d\u000a    Main report: Clearing the Air. The Mayor's Air Quality Strategy.\u000d\u000a    Appendix C &#8212; Further Technical Information. How we model air quality in London:\u000d\u000a    London Air Quality Network.\u000d\u000a    \u000d\u000a      \u000d\u000a        \u000d\u000a          Website\u000d\u000a          Interactive pollution maps\u000d\u000a        \u000d\u000a        \u000d\u000a          Pollution episodes\u000d\u000a          &#160;Interactive graphs\u000a\u000d\u000a        \u000d\u000a      \u000d\u000a    \u000d\u000a    Transport for London (2008): London Low Emission Zone. Impacts\u000d\u000a      Monitoring.\u000d\u000a    London Low Emission Zone. Impacts Monitoring Baseline Report, July 2008.\u000d\u000a    Appendix 5: Air quality monitoring networks.\u000d\u000a    House of Commons Environmental Audit Committee.\u000d\u000a    Air Quality Report. Ninth Report of Session 2010-12. (LAQN reference,\u000d\u000a      page 9; Prof Kelly\u000d\u000a\u0009  Oral Evidence from page 30): Evidence given by Professor Kelly 8th June 2011.\u000d\u000a    Department for Environment, Food and Rural Affairs\u000d\u000a    April 2009 report. Air pollution and emissions trends in London. Beevers S, Carslaw D et\u000d\u000a      al.\u000d\u000a    April 2011 report: Review of air quality modelling in DEFRA\u000d\u000a    British Vehicle Rental and Leasing Association (BVRLA) LEZ implementation in England\u000d\u000a    World Health Organisation\u000d\u000a    \u000d\u000a      \u000d\u000a        \u000d\u000a          WHO\u000a              Air Quality Guidelines 2005\u000d\u000a          &#160;WHO\u000a              Indoor Air Quality Guidelines 2010\u000a\u000d\u000a        \u000d\u000a      \u000d\u000a    \u000d\u000a    US Health Effects Institute Traffic-Related Air Pollution: A\u000d\u000a      Critical Review of the Literature on Emissions, Exposure, and Health\u000d\u000a      Effects\u000d\u000a    Examples of international media coverage\u000d\u000a    \u000d\u000a      \u000d\u000a        \u000d\u000a          China Radio International\u000d\u000a          Portuguese media\u000d\u000a        \u000d\u000a        \u000d\u000a          Bloomberg TV\u000d\u000a          Spanish media\u000d\u000a        \u000d\u000a      \u000d\u000a    \u000d\u000a    Implementation of Low Emission Zones in Europe.\u000d\u000a    International teams following King's research into the benefit of LEZ's\u000d\u000a    \u000d\u000a      \u000d\u000a        \u000d\u000a          Lisbon Low Emission Zone\u000d\u000a          Australian Evaluation of London LEZ\u000d\u000a        \u000d\u000a        \u000d\u000a          Low Emission Zones in Europe\u000d\u000a          \u000d\u000a        \u000d\u000a      \u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Improving Air Quality and Health through Design and Evaluation of\u000d\u000a          Traffic Control Schemes\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    King's scientists quantify the impacts of air pollutants on health\u000d\u000a    King's College London's Medical Research Council (MRC)-Public Health\u000d\u000a      England (PHE) Centre for Environment and Health is a leading centre for research on air\u000d\u000a      quality and health. The Centre is led by Professor Frank Kelly (King's\u000d\u000a      1992-date). In 1995, King's established the London Air Quality Network, which has evolved into the largest urban air\u000d\u000a      quality network in Europe, consisting of over 120 fixed measurement sites\u000d\u000a      for a range of pollutants including oxides of nitrogen (NOx),\u000d\u000a      notably nitrogen dioxide (NO2), ozone (O3) and\u000d\u000a      particulate matter (PM). King's research used information from the LAQN to\u000d\u000a      understand the sources of atmospheric pollution and to estimate the health\u000d\u000a      impacts of these pollutants in a major urban environment. In cities,\u000d\u000a      vehicles are the main contributors to air pollution; transport-related\u000d\u000a      pollutants are strong oxidants which, when in contact with the delicate\u000d\u000a      respiratory airways, lead to damage (Kelly, 2003). When these finding were linked to experimental chamber\u000d\u000a      studies in human volunteers demonstrating decreased airway function and\u000d\u000a      inflammation (Mudway and Kelly, 2004), this work contributed to the growing literature\u000d\u000a      that identified exposure to transport-related pollutants as a cause of ill\u000d\u000a      health.\u000d\u000a    King's scientists design and evaluate interventions to reduce harmful\u000d\u000a        exposures\u000d\u000a    The King's team began research to inform the design and evaluation of\u000d\u000a      traffic control schemes to improve air quality and hence health. Working\u000d\u000a      in partnership with Transport for London, King's researchers utilised\u000d\u000a      automatic number plate recognition (ANPR) data in combination with the\u000d\u000a      King's urban dispersion model to predict the air quality impact of the\u000d\u000a      introduction of a congestion charging scheme (CCS). A temporal-spatial\u000d\u000a      design was employed in which modelled and measured air quality data from\u000d\u000a      LAQN monitoring stations were used to compare time periods before\u000d\u000a      (2001-2002) and after (2003-2004) the CCS was introduced. Using a range of\u000d\u000a      approaches, King's researchers found evidence of only small changes in air\u000d\u000a      quality from the CCS (Beevers and Carslaw, 2005). However, attributing changes to the introduction\u000d\u000a      of the CCS alone is difficult because the scheme was introduced at a time\u000d\u000a      when other traffic and emissions interventions were also being implemented\u000d\u000a      (Kelly et al., 2011a).\u000a      King's research suggested that the health benefits of the CCS introduction\u000d\u000a      might be small (Tonne et al., 2008) and so began to determine the benefit of a London-wide\u000d\u000a      low emission zone (LEZ). Prior to activation of the first phase of the LEZ\u000d\u000a      in 2008, King's research showed that a LEZ could provide improvements in\u000d\u000a      urban air quality, crucially predicting that the emissions controls\u000d\u000a      enforced by the scheme were expected to have the greatest effect close to\u000d\u000a      major roads with high volumes of heavy-goods-vehicle traffic. This\u000d\u000a      research was instrumental in guiding the design of a carefully considered\u000d\u000a      and extensive environmental impacts monitoring network, directed from\u000d\u000a      King's, that generates robust air quality data from baseline to the\u000d\u000a      present as part of our ongoing evaluation of the effectiveness of the LEZ\u000d\u000a      (Kelly et al., 2011b).\u000d\u000a    "},{"CaseStudyId":"41174","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    King's stroke research has had substantial impact through translation\u000a      into national and local\u000a      policies for stroke care, leading to improved commissioning and delivery\u000a      of stroke services. This\u000a      has contributed to reductions in mortality and cost savings for health\u000a      services, mainly through\u000a      transformation of services in cities and the implementation of Early\u000a      Supported Discharge, the latter\u000a      also being rolled out internationally. The ultimate beneficiaries of these\u000a      impacts are patients with\u000a      stroke, as well as their family members, who benefit from better health,\u000a      less disability and longer\u000a      lives. Other stakeholders benefit from our research through high quality\u000a      evidence to inform policy.\u000a      Such beneficiaries include the government and non-governmental\u000a      policy-makers, commissioners\u000a      and providers of health and social care, and the voluntary sector\u000a      including the Stroke Association\u000a      and aphasia charities.\u000a    King's research influences national policy for stroke\u000a      South London Stroke Register data informed the Department of Health National\u000a          Stroke Strategy on\u000a      the need for acute and longer term stroke care. King's data informed and\u000a      were embedded into\u000a      `Action\u000a        on Stroke Services: An Evaluation Toolkit (ASSET) for providers and for\u000a        commissioners'\u000a      which is cited as a `key resource' in Annex B of the National Stroke\u000a      Strategy. King's was also\u000a      commissioned by the Department of Health to develop recommendations for\u000a      the top\u000a        ten priorities in stroke service research.\u000a      The South London Stroke Register team was commissioned by the\u000a      National Audit Office (NAO) to write an annex to the report on\u000a      stroke care (NAO, 2010: `Progress\u000a        in improving stroke care').\u000a      This utilised King's estimates for risk of stroke, long term outcomes and\u000a      survival to inform recommendations for stroke care. King's data were used\u000a      to model cost-effective\u000a      options for stroke care (NAO, 2010: `Report\u000a        on the findings from our modelling of stroke care provision',\u000a      pages 15-16), informing the Parliamentary\u000a        Public Accounts Committee (2010) report on\u000a      the need for a step change in stroke care.\u000a    King's research informs major service reconfiguration in London\u000a      In response to Lord Darzi's 2007 report `Healthcare for London: A\u000a      Framework for Action', South\u000a      London Stroke Register data on incidence and patient outcomes were used by\u000a      Healthcare for\u000a        London to develop a Stroke\u000a        Strategy for London (2008). King's data were specifically employed\u000a      to estimate the number of people who can be expected to have a stroke and\u000a      thereby the number of\u000a      Hyper Acute Stroke Unit (HASU) and Acute Stroke Unit (ASU) beds required\u000a      in the city, and to\u000a      develop models of cost effective configurations of services (page 7).\u000a      Wolfe and Rudd led work\u000a      streams for the strategy development. The reconfiguration, implemented in\u000a      2010, consisted of 8\u000a      HASUs and 24 Stroke Units. An evaluation (Hunter\u000a        et al., 2013) found an estimated 12% reduction\u000a      in deaths at 90 days, as well as a reduction in the median length of stay,\u000a      with an estimated cost\u000a      saving of &#163;811 per patient (2011) in London after the reconfiguration.\u000a    King's provides professional leadership and research evidence to\u000a        inform clinical guidelines\u000a      The South London Stroke Register leadership has also been instrumental in\u000a      improving stroke care\u000a      nationally. Professor\u000a        Anthony Rudd from King's has chaired the Royal College of\u000a        Physicians'\u000a        (RCP) Intercollegiate Stroke Working Party (ISWP) since its\u000a      inception in 1995. The fourth edition of\u000a      the Working Party's National\u000a        Clinical Guideline for Stroke (2012) recommends that Early\u000a      Supported Discharge should be a component of stroke care. The Guidelines\u000a      also discuss the\u000a      unmet needs of stroke patients (following McKevitt et al., 2011 cited\u000a      above). The RCP's National\u000a        Sentinel Stroke Audit 2010\u000a      recommended that Early Supported Discharge should be made\u000a      available in all districts.' (page 11). Early Supported Discharge is now\u000a      provided by 66% of English\u000a      hospitals. (RCP Sentinel Audit 2012) and has been implemented\u000a      internationally (Fisher\u000a        et al.2011).\u000a      Earlier editions of the ICSWP National Stroke Guidelines, which also cite\u000a      King's stroke\u000a      research, have been used to inform the 2008 National Institute of\u000a        Health and Care Excellence\u000a      (NICE) guidelines\u000a        on stroke and the 2010 Stroke\u000a        Quality Standard, the latter recommending Early\u000a      Supported Discharge as a component of the rehabilitation pathway. In a\u000a      report authored by King's\u000a      stroke researchers, and using methods developed by King's researchers to\u000a      estimate the quality of\u000a      stroke care, data from the RCP National Stroke Audit data for the first 72\u000a      hours of stroke care in\u000a      NHS facilities, demonstrated reduced mortality in hospitals with better\u000a      organised stroke care (Bray\u000a        et al., 2013).\u000a      The work of King's is also influential in the NHS Improvement\u000a      initiative for stroke care.\u000a      For instance, the ISWP documents are referenced throughout their website\u000a      and publications,\u000a      especially in terms of calling for pathways that include Early Supported\u000a      Discharge.\u000a    King's works with voluntary sector and patients to articulate needs\u000a      The Stroke Association (SA) recently published `Saving\u000a          Lives. 20 years of investment in vital stroke research'\u000a      that identifies how the research it has funded has led to patient benefit.\u000a      This report\u000a      highlights King's research in developing and evaluating Early Supported\u000a      Discharge. The results of\u000a      the Stroke Association 2010 Stroke\u000a        Survivor Needs survey have informed Stroke Association\u000a      policy, and identified stroke survivor priorities, for areas of research\u000a      and service development\u000a      which have not previously been addressed, for example high prevalence of\u000a      stroke-related fatigue.\u000a    ","ImpactSummary":"\u000a    The King's South London Stroke Register is the world's longest running,\u000a      population-based stroke\u000a      research register, assessing the incidence of stroke; the acute and\u000a      long-term needs of stroke\u000a      patients; and quality of stroke care. The South London Stroke Register\u000a      provided data and analyses\u000a      that informed the Parliamentary Public Accounts Committee report on\u000a      stroke, the National Strategy\u000a      for Stroke, and contributed to two National Audit Office reports on acute\u000a      and longer-term stroke\u000a      care. The latter contributed to a major service reconfiguration in London,\u000a      which has led to lower\u000a      mortality and more efficient use of health care resources for stroke. The\u000a      King's South London\u000a      Stroke Register provides a platform for designing and evaluating new\u000a      models of stroke care,\u000a      including the largest trial of Early Supported Discharge, a cost-effective\u000a      intervention which is now\u000a      provided in 66% of hospitals in England, as well as being rolled out\u000a      internationally.\u000a    ","ImpactType":"Health","Institution":"\u000a    King's College London\u000a    ","Institutions":[{"AlternativeName":"King's College London","InstitutionName":"King's College London","PeerGroup":"A","Region":"London","UKPRN":10003645}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000aGrieve, R.,\u000a      et al. (2001) A comparison of the costs and survival of hospital-admitted\u000a      stroke patients\u000a      across Europe. Stroke 32:1684-91. doi:\u000a      10.1161\/01.STR.32.7.1684\u000a    \u000a\u000aHeuschmann,\u000a        P.U., et al. (2008) Ethnic group disparities in ten-year trends in\u000a      stroke incidence and\u000a      vascular risk factors: the South London Stroke Register (SLSR). Stroke\u000a      39 (8):2204-210. doi:\u000a      10.1161\/STROKEAHA.107.507285\u000a    \u000a\u000aHeuschmann PU\u000a      et al. (2009) Incidence of stroke in Europe at the beginning of the 21st\u000a      century.\u000a      Stroke. 2009 May;40(5):1557-63. doi: 10.1161\/STROKEAHA.108.535088.\u000a    \u000a\u000aHeuschmann PU\u000a      et al. (2011) Three-month stroke outcome: the European Registers of Stroke\u000a      (EROS) investigators. Neurology 76:159-65. doi:\u000a      10.1212\/WNL.0b013e318206ca1e\u000a    \u000a\u000aLanghorne, P.,\u000a      et al. (2005) Early supported discharge services for stroke patients: a\u000a      meta-analysis\u000a      of individual patients' data. Lancet 365 (9458):501-6.\u000a      (doi:10.1016\/S0140-6736(05)17868-4)\u000a    \u000a\u000aMcKevitt, C.,\u000a      et al. (2011) Self-reported long term needs after stroke. Stroke 42:1398-1403.\u000a      doi:\u000a      10.1161\/STROKEAHA.110.598839\u000a    \u000a\u000aRudd, A.G.,\u000a      Wolfe, C.D., et al. (1997) Randomised controlled trial to evaluate early\u000a      discharge\u000a      scheme for patients with stroke. BMJ 315 (7115):1039-44.\u000a    \u000a\u000aSaka, O., et\u000a      al. (2009) Cost-Effectiveness of Stroke Unit Care Followed by Early\u000a      Supported\u000a      Discharge. Stroke 40:24-29. doi: 10.1161\/STROKEAHA.108.518043\u000a    \u000a\u000aStewart, J.,\u000a      et al. (1999) Ethnic differences in stroke incidence. The South London\u000a      Stroke Register.\u000a      BMJ 318:967-971.\u000a    \u000a\u000aWolfe, C.D., et\u000a      al. (2011) Estimates of outcomes up to ten years after stroke: analysis\u000a      from the\u000a      prospective South London Stroke Register. PLoS Med. 8(5):e1001033.\u000a      doi:\u000a      10.1371\/journal.pmed.1001033\u000a    \u000aResearch Grants\u000a      UK Stroke Survivor Needs Survey. Redfern, J., et al. The Stroke\u000a      Association, 2009: &#163;81K.\u000a    Modelling, evaluation and implementing cost effective services to reduce\u000a      the impact of stroke.\u000a      Wolfe, C et al. NIHR Programme Grant for Applied Research, 2008-2013:\u000a      &#163;1.134m.\u000a    Identifying the long-term needs of stroke survivors and modelling\u000a      implications for innovative\u000a      services. McKevitt et al. NIHR, Research for Patient Benefit, 2008-2010:\u000a      &#163;226k.\u000a    The South London Stroke Register. Wolfe, C. Department of Health,\u000a      2003-2007: &#163;300k.\u000a    European variation in stroke interventions from patients, carers,\u000a      primary, ambulatory, community,\u000a      and hospital services: its impact on outcomes and costs. Wolfe, C.\u000a      European Community BIOMED\u000a      2 Programme, 1996-1998: &#163;574k.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000a    Department of Health: National\u000a        Stroke Strategy\u000a      `Action\u000a        on Stroke Services: An Evaluation Toolkit (ASSET) for providers and for\u000a        commissioners'\u000a      Top\u000a        ten priorities in stroke services research\u000a    House of Commons Committee of Public Accounts. Progress\u000a        in improving stroke care. Twenty-sixth\u000a      report of Session 2009-10.\u000a    NHS Improvement. Stroke\u000a        Improvement: Early Supported Discharge\u000a      NHS London. Healthcare\u000a        for London: A framework for action. London: NHS, 2009:\u000a      National Audit Office (2010). Progress\u000a        in improving stroke care. Second report. London: National\u000a      Audit Office. Report\u000a        on the findings from our modelling of stroke care provision\u000a    National Institute for Health and Care Excellence:\u000a      National\u000a        clinical guideline for diagnosis and initial management of acute stroke\u000a        and transient ischaemic attack (TIA)\u000a      Stroke\u000a        quality standard (stroke rehabilitation pathway recommends Early\u000a      Supported Discharge)\u000a    Royal College of Physicians Intercollegiate Stroke Working Party\u000a      National\u000a        Clinical Guideline for Stroke. Fourth Edition. 2012.\u000a      National\u000a        Sentinel Stroke Audit 2010\u000a      Stroke\u000a        Improvement National Audit Programme:\u000a    Published Evidence on Implementation\u000a      Bray BD et al.\u000a      (2013) Associations between the organisation of stroke services, process\u000a      of care,\u000a      and mortality in England: prospective cohort study. BMJ 346:f2827.\u000a      doi: 10.1136\/bmj.f2827.\u000a      Fisher RJ et\u000a        al. (2011) A consensus on stroke: early supported discharge. Stroke\u000a      42:1392-7. doi:\u000a      10.1161\/STROKEAHA.110.606285\u000a      Hunter\u000a        RM et al. (2013) Impact on clinical and cost outcomes of a\u000a      centralized approach to acute\u000a      stroke care in London: a comparative effectiveness before and after model.\u000a      PLoS One. 8:e70420.\u000a      doi: 10.1371\/journal.pone.0070420.\u000a    The Stroke Association\u000a      Stroke Association (2012) Saving\u000a        Lives. 20 years of investment in vital stroke research (page 33)\u000a      Stroke Association (2010) UK\u000a        Stroke Survivor Needs Survey\u000a    ","Title":"\u000a    King's South London Stroke Register: Informing Innovation in Stroke\u000a          Care\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The South London Stroke Register at King's collects data for stroke\u000a      incidence and stroke\u000a      outcomes (including mortality, morbidity and quality of life) in a\u000a      well-defined multi-ethnic population.\u000a      The South London Stroke Register is led by Professor Charles Wolfe\u000a      (King's, 1988 to present),\u000a      Professor Anthony Rudd (King's, 1990 to present), and Dr Christopher\u000a      McKevitt (King's, 1994 to\u000a      present). To date we have collected detailed information from almost 5,000\u000a      stroke patients in the\u000a      Register area, with each patient followed up at 3 months and annually\u000a      after stroke, for life.\u000a    King's stroke research has: 1) measured the incidence of stroke and its\u000a      immediate and long-term\u000a      consequences for patients, contributing to understanding needs for\u000a      services; 2) provided evidence\u000a      of the effectiveness of Early Supported Discharge and other models of\u000a      post-stroke care;\u000a      3) measured the quality and cost-effectiveness of care; and 4) explored\u000a      patient and carer\u000a      perspectives of need and outcome and developed a framework for\u000a      patient\/carer engagement in\u000a      stroke research and service development in the UK and Europe.\u000a    King's research provided epidemiological estimates of the needs for\u000a        stroke care\u000a      From its first key study (Stewart\u000a        et al., 1999), the South London Stroke Register has continued to\u000a      report changing patterns in stroke incidence since 1995, with a focus on\u000a      ethnic variations in risk\u000a      (Heuschmann et al.,\u000a        2008). Our research showed that stroke risk and stroke sub-types\u000a      vary\u000a      substantially between ethnic groups, with a large proportion of strokes\u000a      occurring in people with\u000a      untreated risk factors including hypertension with limited\u000a      improvement in detecting these risk\u000a      factors over time (Heuschmann\u000a        et al., 2008). We have used Register data to show that 20-30% of\u000a      survivors have a poor range of functional outcomes (e.g. walking\u000a      ability) up to ten years after\u000a      stroke (Wolfe et al.\u000a        2011), over half of all stroke patients have depression (Ayerbe et al., 2011),\u000aand stroke has a substantial long-term impact through cognitive impairment\u000a      (Douiri et al., 2013).\u000aWe and other research groups have used our epidemiological data to quantify\u000a      risk of stroke and\u000a      needs for long term care, as well as to develop interventions to reduce\u000a      the significantly poor\u000a      outcomes of stroke survivors.\u000a    King's research provided evidence of the effectiveness of Early\u000a        Supported Discharge\u000a      The South London Stroke Register team conducted the first and largest\u000a      randomised trial to assess\u000a      the clinical effectiveness of an Early Supported Discharge (ESD) policy (Rudd et al., 1997).\u000a      This\u000a      study provided evidence that outcomes following ESD were comparable to\u000a      conventional hospital\u000a      and community care, while the length of hospital stay was substantially\u000a      reduced. King's contributed\u000a      data and co-authored a meta-analysis that pooled data on the effectiveness\u000a      of ESD internationally\u000a      (Langhorne et al.,\u000a        2005), showing that appropriately resourced ESD services, provided\u000a      for selected\u000a      groups of stroke patients, can reduce long-term dependency and admission\u000a      to institutional care as\u000a      well as shortening hospital stays. Subsequently, the King's group has\u000a      reported on the cost-\u000a      effectiveness of ESD (Saka\u000a        et al., 2009).\u000a    King's researchers led and co-ordinated Europe-wide research on stroke\u000a      The team has co-ordinated a programme of collaborative research across the\u000a      European Union with\u000a      a focus on explaining variations in incidence (Heuchmann\u000a        et al. 2009), quality and costs of stroke\u000a      care in Europe (Grieve\u000a        et al, 2001) and outcomes (Heuschmann\u000a        et al., 2011). These studies\u000a      highlighted the high costs and poor outcomes associated with acute stroke\u000a      care in the UK,\u000a      contributing to making the case for more efficient service models that\u000a      provide higher quality care.\u000a      They also showed wide variations in quality of stroke care and\u000a      implementation of evidence-based\u000a      practice. The studies were the catalyst for research registers being\u000a      established in other European\u000a      centres which have enabled on-going comparative research to improve the\u000a      quality of stoke care.\u000a    King's researchers engaged with patients and families to inform stroke\u000a        research\u000a      The King's stroke research programme is informed by an active Stroke\u000a      Patient and Family Group,\u000a      established since 2005, with over 20 people participating in 6 research\u000a      meetings a year, at which\u000a      research priorities are identified and research methods refined. The group\u000a      contributed to the\u000a      development of a national survey of long term need that has informed the\u000a      Stroke Association's\u000a      policy on longer term care (McKevitt\u000a        et al., 2011). The group also produces a research newsletter\u000a      sent to 1,600 Stroke Register patients twice a year. It has contributed to\u000a      the national Stroke\u000a      Research Network strategy for public and patient involvement (PPI) in\u000a      research and service\u000a      development and to the European developments in PPI. The group is linked\u000a      to a social science\u000a      programme embedded within the Stroke Register; our European Programme has\u000a      also focused on\u000a      patient and public engagement well as facilitating patients and carers\u000a      involvement in designing\u000a      studies and tools for research and the dissemination of results.\u000a    "},{"CaseStudyId":"41451","Continent":[{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"3562981","Name":"Cuba"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"3932488","Name":"Peru"},{"GeoNamesId":"3703430","Name":"Panama"},{"GeoNamesId":"3686110","Name":"Colombia"},{"GeoNamesId":"3895114","Name":"Chile"},{"GeoNamesId":"1562822","Name":"Vietnam"},{"GeoNamesId":"2921044","Name":"Germany"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"3617476","Name":"Nicaragua"},{"GeoNamesId":"3489940","Name":"Jamaica"},{"GeoNamesId":"1168579","Name":"Pakistan"},{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"3996063","Name":"Mexico"},{"GeoNamesId":"3865483","Name":"Argentina"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"3585968","Name":"El Salvador"},{"GeoNamesId":"3625428","Name":"Venezuela"},{"GeoNamesId":"2077456","Name":"Australia"}],"Funders":[],"ImpactDetails":"\u000a    Since Gilbert joined LSHTM in 2002 she has presented research findings\u000a      extensively which has led to greater awareness of the public health\u000a      problem of ROP. Dissemination has been through workshops attended by\u000a      ophthalmologists, neonatologists and neonatal nurses: 19 workshops in\u000a      Latin America (Brazil, Mexico, Colombia, Cuba, Venezuela, Panama and\u000a      Peru), and 3 in Eastern Europe. Other facilitators are now taking over\u000a      this role to increase the reach. Presentations have been made since 2008\u000a      to Ministries of Health (Peru, Brazil, Jamaica), at two World ROP\u000a      Congresses (India 2009; China 2012), to NGOs who support prevention of\u000a      blindness (Sightsavers; ORBIS International; Standard Chartered Bank's\u000a      Seeing is Believing programme) and at numerous international, regional and\u000a      national meetings, conferences and seminars. Research findings have been\u000a      summarised in five textbooks (13 chapters, including updates in new\u000a      editions), one of which, The Epidemiology of Eye Disease, is the\u000a      standard textbook for several postgraduate training courses.5.1\u000a    The educational package developed for the Rio study was made available in\u000a      2013 as an online course (at http:\/\/neonatal.estacaodigitalsaude.org.br\/aia\/)\u000a      and over 4,500 professionals have registered.\u000a    Greater awareness that ROP is a major avoidable cause of blindness in\u000a      children has had the following impact:\u000a    \u000a      ROP continues to be recognised as a major cause of avoidable blindness\u000a        by VISION 2020: The Right to Sight, which is the 20-year global\u000a        initiative of WHO and the International Agency for the Prevention of\u000a        Blindness (IAPB). The latter is an umbrella organisation of all the\u000a        organisations involved in prevention of blindness including NGOs,\u000a        professional bodies, service providers, the corporate sector and\u000a        university departments. IAPB currently has 155 members.\u000a      In 2009 the control of blindness due to ROP was prioritised within the\u000a        Pan American Health Organization's prevention of blindness policy for\u000a        Latin America5.2 and the Caribbean in 2010.5.3,5.4,5.5\u000a\u000a      ROP is a priority in the Chinese National Plan for the Prevention and\u000a        Treatment of Blindness (2012-2015).\u000a      In 2008, neonatologists from 8 countries, ophthalmologists from 12\u000a        countries and neonatal nurses from 6 countries in Latin America met in\u000a        Panama to develop regional guidelines for ROP programmes, which have\u000a        since been published, referencing the applicant's research.5.6\u000a        These guidelines are being updated and modified by many other countries\u000a        in the region (e.g. Venezuela, Nicaragua). Guidelines are being drawn up\u000a        in India.\u000a      In Peru (2010),5.7 Mexico (2013),5.8 Argentina,\u000a        Chile, Colombia and El Salvador, legislation has been passed making eye\u000a        examination of preterm infants mandatory.\u000a      Ministries of Health in Argentina, Chile, Colombia, El Salvador,\u000a        Mexico and Peru have issued resolutions recommending eye examination of\u000a        all preterm births, and in Rio de Janeiro programmes are fully\u000a        integrated within state and municipal health systems.\u000a      The Pan American Ophthalmology Society has established an ROP Society.\u000a      There has been increased support for the control of ROP in Latin\u000a        America and other countries (e.g. Pakistan, India, China, Vietnam) from\u000a        NGOs: ORBIS international (USA),5.9 CBM, (Germany), Seeing is\u000a        Believing (UK), the Queen Elizabeth Diamond Jubilee Trust (UK), Fred\u000a        Hollows Foundation (Australia). UNICEF has supported initiatives for\u000a        prevention in Argentina and is supporting initiatives in India.\u000a    \u000a    All these factors have led to rapid expansion of ROP programmes in many\u000a      countries in Latin and Central America, and in Asia. For example, in Rio\u000a      de Janeiro, Brazil, only 40% of preterm infants were admitted to neonatal\u000a      units with a screening programme in 2002, but this has increased so that\u000a      most government units now have programmes. Similar expansion has occurred\u000a      in other major cities in Brazil. Legislation in Peru has had a dramatic\u000a      impact, building consensus and leading to expansion of programmes in Lima\u000a      and many other cities across the country.\u000a    Treatment at a critical stage in the natural history of ROP is highly\u000a      effective at preventing blindness. In the screening programme in Rio de\u000a      Janeiro 1,444 infants most at risk of ROP were examined and 118 were\u000a      treated. The disease regressed completely in all but 5 infants. Without\u000a      treatment at least a quarter would have become blind. Data from Argentina\u000a      suggests that there has been a dramatic reduction in blindness from ROP,\u000a      with far fewer children being admitted to schools for the blind than 10\u000a      years ago, when almost 40% of blindness was due to ROP.5.10\u000a      Extrapolating these findings across Latin America and other low- and\u000a      middle-income countries means that many thousands of infants are having\u000a      their sight preserved.\u000a    ","ImpactSummary":"\u000a    Professor Gilbert's research identified retinopathy of prematurity (ROP)\u000a      to be a major cause of blindness in children in middle-income countries\u000a      and cities in Asia, and delineated those infants most at risk. Since\u000a      Gilbert joined LSHTM in 2002, her research and advocacy have led to ROP\u000a      being prioritised for control by the Pan American Health Organization,\u000a      with regional guidelines developed for Latin America, and national\u000a      guidelines in many middle-income counties. Programmes for control are\u000a      expanding and improving. Six Latin American countries have made eye\u000a      examination mandatory. Although difficult to quantify, these initiatives\u000a      are preserving the sight of many thousands of infants.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"3936456","Name":"Lima"},{"GeoNamesId":"3936456","Name":"Lima Peru"},{"GeoNamesId":"3451190","Name":"Rio de Janeiro"}],"References":"\u000a    \u000a3.1 Gilbert, C, Fielder, A, Gordillo, L, Quinn, G, Semiglia, R, Visintin,\u000a      P and Zin, A, on behalf of the International NO-ROP Group (2005)\u000a      Characteristics of infants with severe retinopathy of prematurity in\u000a      countries with low, moderate, and high levels of development: implications\u000a      for screening programs, Pediatrics, 115(5): e518-e525, doi:\u000a      10.1542\/peds.2004-1180. Citation count: 137\u000a    \u000a\u000a3.2 Gilbert, C (2008) Retinopathy of prematurity: a global perspective of\u000a      the epidemics, population of babies at risk and implications for control,\u000a      Early Human Development, 84(2): 77-82,\u000a      doi:10.1016\/j.earlhumdev.2007.11.009. Citation count: 106.\u000a    \u000a\u000a3.3 Varughese, S, Gilbert, C, Pieper, C and Cook, C (2008) Retinopathy of\u000a      prematurity in South Africa: an assessment of needs, resources and\u000a      requirements for screening programmes, British Journal of\u000a        Ophthalmology, 92(7): 879-882, doi:10.1136\/bjo.2008.137588. Citation\u000a      count: 5\u000a    \u000a\u000a3.4 Zin, AA, Moreira, MEL, Bunce, C, Darlow, B and Gilbert, C (2010)\u000a      Retinopathy of prematurity in 7 neonatal units in Rio de Janeiro:\u000a      screening criteria and workload implications, Pediatrics, 126(2):\u000a      e410-e417, doi:10.1542\/peds.2010-0090. Citation count: 14\u000a    \u000a\u000a3.5 Darlow, BA, Zin, AA, Beecroft, G, Moreira, MEL and Gilbert, C (2012)\u000a      Capacity building of nurses providing neonatal care in Rio de Janeiro,\u000a      Brazil: methods for the POINTS of care project to enhance nursing\u000a      education and reduce adverse neonatal outcomes, BMC Nursing,\u000a      11(3), doi:10.1186\/1472-6955-11-3. Citation count: 1\u000a    \u000a\u000a3.6 Urrets-Zavalia, JA, Crim, N, Knoll, EG, Esposito, FA, Collino, E,\u000a      Urrets-Zavalia ME, Saenz-de- Tejada, G, Torrealday, JI, Serra, HM and\u000a      Gilbert C (2012) Impact of changing oxygenation policies on retinopathy of\u000a      prematurity in a neonatal unit in Argentina, British Journal of\u000a        Ophthalmology, 96(12): 1456-1461,\u000a      doi:10.1136\/bjophthalmol-2011-301394. Citation count: 0.\u000a    \u000aKey grants\u000a    The Thrasher Medical Research Trust (USA); Christofel Blind Mission (CBM)\u000a      (Germany). The other large donor wishes to remain anonymous.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    5.1 Editor, The Epidemiology of Eye Disease. (Johnson, GJ,\u000a      Minassian, DC, Wheale, RA and West, SK (2012) The Epidemiology of Eye\u000a        Disease, 3rd edn. London: Imperial College Press).\u000a    5.2 Pan American Health Organization (2009) 144th Session\u000a        of the Executive Committee: Plan of Action on the Prevention of\u000a        Avoidable Blindness and Visual Impairment, CE144\/20 (English).\u000a      Washington, DC: WHO, http:\/\/www2.paho.org\/hq\/dmdocuments\/2009\/CE144-20-e.pdf\u000a      (accessed 11 September 2013). Gilbert's work is referred to in paragraph 8\u000a      and reference 9.\u000a    5.3 Pan American Health Organization (2010) Strategic Framework for\u000a        VISION 2020: The Right to Sight, Caribbean Region, OPS\/PBL\/2010.1\u000a      PAHO\/ECC. Barbados: WHO, http:\/\/www.eyecarecaribbean.com\/ecc\/research\/VISION%202020%20Strategic%20Framework-\u000a        Caribbean%202010.pdf (accessed 11 September 2013). ROP covered in\u000a      para 2.1.1, and Gilbert's work referenced in Bibliography ref 6.\u000a    5.4 Regional Adviser on Eye Care, Pan American Health Organization, WHO.\u000a    5.5 Regional Coordinator, VISION 2020 Latin America.\u000a    5.6 Grupo de Trabajo Colaborativo Multic&#233;ntrico para la Prevenci&#243;n de la\u000a      Ceguera en la Infancia por Retinopat&#237;a del Prematuro (Lomuto C, Ben&#237;tez A,\u000a      Bouzas L, Galina, L, Sep&#250;lveda, T, Goldsmit, G, Visint&#237;n, P, Hauviller, V,\u000a      Brussa, M, Luj&#225;n, S, Alda, E, Bauer, G, Dinerstein, A, Santos, N,\u000a      Marinaro, S, Falbo, J, Quiroga, A, Erpen, N, Sola, A, Gilbert C and Vohr,\u000a      B) (2008) Recomendaci&#243;n para la pesquisa de Retinopat&#237;a del Prematuro en\u000a      poblaciones de riesgo [Recommendations for retinopathy of prematurity\u000a      screening in at-risk populations] (Spanish), Archivos Argentinos de\u000a        Pediatr&#237;a, 106(1): 71-76,\u000a      http:\/\/www.scielo.org.ar\/scielo.php?script=sci_arttext&amp;pid=S0325-\u000a        00752008000100016&amp;lng=en&amp;nrm=iso&amp;tlng=en (accessed 23\u000a      September 2013).\u000a    5.7 Ministro de Salud (2010) Aprueban Norma T&#233;cnica de Salud de\u000a        Atenci&#243;n del Recien Nacido pre t&#233;rmino con riesgo de Retinopatia del\u000a        Prematuro (Spanish), Resulition Ministerial no 707- 2010\/MINDSA.\u000a      Lima: Ministro de Salud, Peru,13 September.\u000a    5.8 Secretaria de Salud (2013) Decreto por el que se reforma el articulo\u000a      61 de la Ley General de Salud (Spanish), Diaro Oficial de la\u000a        Federaci&#243;n: Organo del Gobierno Constitucional de los Estados Unidos\u000a        Mexicanos, 712(19), 25 January,\u000a      http:\/\/www.dof.gob.mx\/nota_detalle.php?codigo=5285817&amp;fecha=25\/01\/2013\u000a      (accessed 23 September 2013).\u000a    5.9 Director LAC Regional Program, Monitoring &amp; Evaluation, &amp;\u000a      Senior Technical Adviser, ORBIS International.\u000a    5.10 Director, Valentin Hauy, Centre for the Rehabilitation of the\u000a      Visually Impaired, Corrientes, Argentina. \u000a    ","Title":"\u000a    Improving the control of blindness in children in low- and middle-income\u000a      countries through programmes, policy and legislation\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    In 1993, while at the Institute of Ophthalmology, Clare Gilbert worked\u000a      with WHO to develop the first classification system for blindness in\u000a      children, which has become the standard methodology. Initial research\u000a      entailed examining children in schools for the blind in Latin America,\u000a      Eastern Europe, Africa and Asia. Research published in 1997 demonstrated\u000a      for the first time that ROP was as an important cause of avoidable\u000a      blindness in children in middle-income countries.\u000a    In June 2002, Gilbert moved to LSHTM as Senior Lecturer in International\u000a      Eye Health. Population- based studies undertaken in a number of countries\u000a      (e.g. Vietnam and Bangladesh) showed the situation to be dynamic, with\u000a      some causes of blindness declining in importance while ROP was increasing\u000a      in the middle-income countries of Latin America and Eastern Europe, and in\u000a      the emerging economics of China, India and Vietnam.3.1\u000a    A multi-country study led by Gilbert clearly demonstrated that the\u000a      population of infants at risk of severe ROP varies by level of\u000a      development,3.2 and more detailed studies in South Africa3.3\u000a      and Brazil3.4 identified weaknesses in neonatal service\u000a      delivery. The large, prospective study in seven neonatal units in Rio de\u000a      Janeiro, Brazil3.4 had several purposes. An initial situation\u000a      analysis of the health system highlighted limitations in human resources,\u000a      technology and equipment, leadership and governance, and information\u000a      management. Most of the nursing was provided by nurse assistants who had\u000a      received no formal training. A further purpose was to determine which\u000a      babies were at risk of ROP, to inform screening criteria. Findings\u000a      supported the earlier work by Gilbert that bigger, more mature infants\u000a      develop severe ROP, which has important implications for screening\u000a      criteria. Researchers also explored the additional workload if wider\u000a      screening criteria were used. A case control study was nested within this\u000a      study, showing for the first time that neonatal units were an independent\u000a      risk factor. This supported the notion that ROP is a reflection of the\u000a      overall level of neonatal care and that improvement in many aspects of the\u000a      health system are needed to prevent ROP.\u000a    A further study in Rio,3.5 with a before and after design,\u000a      assessed whether an educational package for nurses, strengthening\u000a      information systems and building the capacity of nurse tutors would reduce\u000a      mortality and ROP. The results showed that `healthy survival' (i.e.\u000a      without ROP) was declining in the pre-intervention year, and that the\u000a      downward trend reversed in the post- intervention year. Unfortunately, the\u000a      change in trend was not statistically significant. However, a study in\u000a      Argentina in 20123.6 showed that better control of oxygen\u000a      reduced the risk of severe ROP.\u000a    A situation analysis of 32 neonatal units in five states in Mexico\u000a      highlighted limitations in service delivery, lack of awareness among\u000a      nurses of risk factors for ROP and poor nursing practices. Only 25% of\u000a      infants at risk of ROP were in units with an ROP programme of adequate\u000a      quality.\u000a    "},{"CaseStudyId":"41452","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"2434508","Name":"Chad"},{"GeoNamesId":"2363686","Name":"Togo"},{"GeoNamesId":"2453866","Name":"Mali"},{"GeoNamesId":"2245662","Name":"Senegal"}],"Funders":[],"ImpactDetails":"\u000a    Following encouraging results of early trials of SMC, a meeting was held\u000a      in Dakar, Senegal, in October 2008 to discuss what further research\u000a      questions needed to be addressed before SMC could be considered as a\u000a      potential control tool. An important feature of this meeting was the\u000a      attendance of malaria control managers and policy-makers as well as\u000a      researchers. Areas identified for further research included drug safety,\u000a      delivery of SMC to older children and the added benefit of SMC to children\u000a      using an ITN. These were addressed subsequently in studies described\u000a      above.\u000a    In July 2010, WHO's Global Malaria Programme convened an informal\u000a      consultation to determine if there was sufficient evidence for a formal\u000a      review of SMC. The committee agreed but requested more information on cost\u000a      effectiveness, and on the geographical areas where SMC would be most\u000a      appropriate. Following provision of this information, the SMC dossier\u000a      compiled by LSHTM staff,5.1,5.2 was reviewed by WHO's Technical\u000a      Expert Group (TEG) on malaria treatment and prophylaxis.5.3\u000a      Professor D Schellenberg (LSHTM since 2003) was a co-opted member of the\u000a      TEG. On the basis of the dossier, the TEG recommended implementation of\u000a      SMC with SP+AQ in areas of the Sahel with seasonal transmission of malaria\u000a      but requested further information on the duration of protection provided\u000a      by each cycle, on the optimal dosing by age and on the level of malaria\u000a      transmission at which SMC would no longer be cost effective. This\u000a      information was generated by an SMC working group (including LSHTM staff\u000a      Cairns, Greenwood, Milligan) and provided to WHO. A GRADES assessment was\u000a      prepared.5.4 In March 2012, the report of the TEG was presented\u000a      to the recently established WHO Malaria Policy Advisory Committee (MPAC);\u000a      Greenwood is a member. The committee endorsed the TEG recommendations and\u000a      made a formal recommendation, endorsed by the Director General, that\u000a      children living in areas of the Sahel and sub-Sahel with highly seasonal\u000a      malaria transmission should receive SMC with SP+AQ for up to four months\u000a      of the year.5.5\u000a    The areas currently targeted for SMC have about 22m children under 5\u000a      among whom there are approximately 20m cases and 90,000 deaths annually\u000a      from malaria. Thus, there is a potential for SMC to prevent millions of\u000a      cases of malaria and tens of thousands of unnecessary deaths each year.\u000a      The speed at which SMC is implemented in the target areas, and hence its\u000a      impact, will depend upon local political commitment and the availability\u000a      of funds to purchase and distribute antimalarials, but the process has\u000a      already commenced. SMC implementation started in two countries in July\u000a      2012, and by December an implementation guide on SMC had been published by\u000a      WHO, and a total of 10 countries had plans for SMC.5.6 In 2012,\u000a      SMC was implemented by MSF in Koutiala district in southern Mali and in\u000a      two areas of Mo&#239;ssala district, in Chad. In Mali, malaria cases fell by\u000a      65% in the week following the first monthly cycle of SMC treatment and\u000a      malaria- associated hospitalisations by 70%.5.7 The Senegalese\u000a      Ministry of Health has secured finance to implement SMC in five regions\u000a      starting in 2013 and SMC will be implemented in Northern Togo starting in\u000a      2013. With support from the Medicines from Malaria Venture (MMV), steps\u000a      are being taken to obtain SP+AQ packages for SMC as cheaply as possible\u000a      from a manufacturer in China.\u000a    Several factors have contributed to the rapid adoption of SMC. Firstly,\u000a      LSHTM research has been conducted in close partnership with scientists in\u000a      the endemic countries where SMC might be implemented. Secondly, LSHTM\u000a      researchers and their partners kept in close contact with policy-makers in\u000a      WHO and with national Ministries of Health from early in the development\u000a      process. Thirdly, the implementation guide, based on experience in Senegal\u000a      (co-authors included LSHTM staff Milligan, Ciss&#233;, Diallo), was published\u000a      by WHO quickly,5.8 and meetings coordinated jointly by LSHTM\u000a      (Milligan) and the Universite Chiekh Anta Diop (Senegal), and subsequently\u000a      by WHO, were held5.6 with national malaria control programme\u000a      managers to help develop implementation plans.\u000a    The way in which SMC has progressed rapidly from pilot research studies\u000a      to early implementation is widely regarded as a model of how this process\u000a      should be conducted. Staff from LSHTM, working together with their\u000a      partners in Africa, have played a key role in all stages of this process.5.9,5.10\u000a    ","ImpactSummary":"\u000a    Research in West Africa by LSHTM and partners has shown that monthly\u000a      treatment with effective antimalarial drugs during the rainy season\u000a      provides children with a very high degree of personal protection against\u000a      malaria, can be delivered on a large scale by community health workers at\u000a      moderate cost, and with no serious side-effects. Based on this research,\u000a      WHO now recommends that children living in Sahel areas where malaria is a\u000a      major problem should receive such `seasonal malaria chemoprevention' (SMC)\u000a      with sulfadoxine-pyrimethamine plus amodiaquine. Ten countries have\u000a      incorporated SMC into their strategic plans for malaria control.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2253354","Name":"Dakar"},{"GeoNamesId":"2172797","Name":"Cairns"},{"GeoNamesId":"2454268","Name":"Koutiala"}],"References":"\u000a    \u000a3.1 Ciss&#233;, B, Sokhna, C, Boulanger, D, Milet, J, B&#226;, elH, Richardson, K,\u000a      Hallett, R, Sutherland, C, Simondon, K, Simondon, F, Alexander, N, Gaye,\u000a      O, Targett, G, Lines, J, Greenwood, B and Trape, JF (2006) Seasonal\u000a      intermittent preventive treatment with artesunate and sulfadoxine-\u000a      pyrimethamine for prevention of malaria in Senegalese children: a\u000a      randomised, placebo-controlled, double-blind trial, Lancet,\u000a      367(9511): 659-667, doi:10.1016\/S0140-6736(06)68264-0. Citation count: 107\u000a    \u000a\u000a3.2 Dicko, A, Diallo, AI, Tembine, I, Dicko, Y, Dara, N, Sidibe, Y,\u000a      Santara, G, Diawara, H, Conar&#233;, T, Djimde, A, Chandramohan, D, Cousens, S,\u000a      Milligan, PJ, Diallo, DA, Doumbo, OK and Greenwood, B (2011) Intermittent\u000a      preventive treatment of malaria provides substantial protection against\u000a      malaria in children already protected by an insecticide-treated bednet in\u000a      Mali: a randomised, double-blind, placebo-controlled trial, PLoS\u000a        Medicine, 8(2): e1000407, doi:10.1371\/journal.pmed.1000407. Citation\u000a      count: 21\u000a    \u000a\u000a3.3 Konat&#233;, AT, Yaro, JB, Ou&#233;draogo, AZ, Diarra, A, Gansan&#233;, A, Soulama,\u000a      I, Kangoy&#233;, DT, Kabor&#233;, Y, Ou&#233;draogo, E, Ou&#233;draogo, A, Tiono, AB,\u000a      Ou&#233;draogo, IN, Chandramohan, D, Cousens, S, Milligan, PJ, Sirima, SB,\u000a      Greenwood, B and Diallo, DA (2011) Intermittent preventive treatment of\u000a      malaria provides substantial protection against malaria in children\u000a      already protected by an insecticide-treated bednet in Burkina Faso: a\u000a      randomised, double-blind, placebo-controlled trial', PLoS Medicine,\u000a      8(2): e1000408, doi:10.1371\/journal.pmed.1000408. Citation count: 18\u000a    \u000a\u000a3.4 Cairns, M, Roca-Feltrer, A, Garske, T, Wilson, AL, Diallo, D,\u000a      Milligan, PJ, Ghani, AC and Greenwood, BM (2012) Estimating the potential\u000a      public health impact of seasonal malaria chemoprevention in African\u000a      children, Nature Communications, 3(881), doi: 10.1038\/ncomms1879.\u000a      Citation count: 6\u000a    \u000aKey grants\u000a    &#8226; Greenwood, Gates Malaria Partnership (GMP), Bill &amp; Melinda Gates\u000a      Foundation, 2001-2010, $40M.\u000a    &#8226; Ciss&#233;, GMP Studentship (LSHTM), October 2001-2005, $176,961.\u000a    &#8226; Greenwood, A Trial of the Combined Impact of Intermittent Preventive\u000a      Treatment and Insecticide Treated Bednets on Morbidity from Malaria in\u000a      African Children, Bill &amp; Melinda Gates Foundation, 2007-2010,\u000a      $2,991,720.\u000a    &#8226; Gaye, Large Scale Implementation of Intermittent Preventive Treatment\u000a      through the Health Service in Senegal, Bill &amp; Melinda Gates\u000a      Foundation, 2007-2011, $4,464,546, including LSHTM award (Milligan)\u000a      $986,000 for coordination.\u000a    &#8226; Greenwood, Defining the Role of Seasonal Intermittent Preventive\u000a      Treatment in Children in Malaria Control, Bill &amp; Melinda Gates\u000a      Foundation, 2007-2010, $309,487.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"}],"Sources":"\u000a    5.1 Seasonal Malaria Chemoprevention Bibliography: Publications on IPTc\u000a      in children in the community under five years of age,\u000a      http:\/\/www.who.int\/malaria\/mpac\/feb2012\/smc_bibliography.pdf\u000a      (accessed 13 September 2013).\u000a    5.2 NDiaye, JL, Ciss&#233;, B, Ba, EH, Gomis, JF, Molez, JF, Fall, FB, Sokhna,\u000a      C, Faye B, Kouevijdin, E, Niane, FK, Cairns, M, Trape, JF, Gaye, O,\u000a      Greenwood, BM and Milligan, PJM (2011, unpublished) Safety of seasonal\u000a        Intermittent Preventive Treatment against malaria with Sulfadoxine\u000a        Pyrimethamine +Amodiaquine when delivered to children under 10 years of\u000a        age by district health staff in Senegal. Unpublished report\u000a      submitted to WHO TEG in April 2011.\u000a    5.3 WHO (2011) Report of the Technical Consultation on Seasonal\u000a        Malaria Chemoprevention (SMC), 4-6 May. Geneva: WHO,\u000a      http:\/\/www.who.int\/malaria\/publications\/atoz\/smc_report_teg_meetingmay2011\/en\/index.html\u000a      (accessed 11 September 2013).\u000a    5.4 Sinclair, D, Meremikwu, MM and Garner, P (2012) Seasonal Malaria\u000a        Chemoprevention for Preventing Malaria Morbidity in Children Aged Less\u000a        than 5 years Living in Areas of Marked Seasonal Transmission: GRADE\u000a        tables to assist guideline development and recommendations, MPAC\u000a      Inaugural Meeting, 31 January-2 February,\u000a      http:\/\/www.who.int\/malaria\/mpac\/feb2012\/smc_grade_tables.pdf\u000a      (accessed 11 September 2013).\u000a    5.5 WHO (2012) WHO Policy Recommendation: Seasonal Malaria\u000a        Chemoprevention (SMC) for Plasmodium falciparum Malaria Control in\u000a        Highly Seasonal Transmission Areas of the Sahel Sub- region in Africa.\u000a      Geneva: WHO,\u000a      http:\/\/www.who.int\/malaria\/publications\/atoz\/who_smc_policy_recommendation\/en\/index.html\u000a      (accessed 11 September 2013).\u000a    5.6 Milligan, P, et al. (2013, unpublished) Implementation of\u000a        Seasonal Malaria Chemoprevention. Report of Two Meetings.\u000a    5.7 http:\/\/www.msf-me.org\/en\/news\/news-media\/news-press-releases\/novel-program-shows-strong-promise-in-malaria-prevention-1.html.\u000a    5.8 WHO (2013) Seasonal Malaria Chemoprevention with\u000a        Sulfadoxine-pyrimethamine Plus Amodiaquine in Children: A Field Guide.\u000a      (July 2013) Geneva: WHO,\u000a      http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241504737\/en\/index.html\u000a      (accessed 11 September 2013).\u000a    5.9 Director, Global Malaria Programme, WHO.\u000a    5.10 Director of National Malaria Control Programme, Ministry of Health,\u000a      Senegal [French].\u000a    ","Title":"\u000a    Developing a new approach to malaria prevention in children: seasonal\u000a      malaria chemoprevention in West Africa\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Studies pre-1993 undertaken in the Gambia by Greenwood and colleagues\u000a      showed that administration of Maloprim&#174; (pyrimethamine plus\u000a      dapsone) fortnightly to children under 5 during the malaria transmission\u000a      season was highly effective in preventing malaria and reduced overall\u000a      child mortality by about 35%. However, this approach to malaria control\u000a      was not pursued due to increasing use of insecticide treated bednets\u000a      (ITNs) and concerns over safety and costs.\u000a    Interest in chemoprevention of malaria in children revived when, in 2002,\u000a      a LSHTM study with partners in Senegal, planned by Greenwood (Professor of\u000a      Clinical Tropical Medicine at LSHTM since 1996) and coordinated by Ciss&#233;\u000a      (then LSHTM PhD student), showed that administration of\u000a      sulphadoxine-pyrimethamine (SP) plus one dose of artesunate monthly for\u000a      three months to children under 5 reduced the incidence of malaria over\u000a      three months by 86%.3.1 The proportion of parasites with\u000a      genotypes associated with resistance to SP at the end of the malaria\u000a      transmission season was higher in children who had received the\u000a      intervention than in the controls, but the number of children carrying\u000a      resistant parasites was less in the intervention group.3.2\u000a      Several drug regimens for SMC were then considered.3.3 Two\u000a      long-acting drug combinations (SP combined with amodiaquine (AQ) or\u000a      piperaquine) were more effective than artemisinin-containing combinations,\u000a      giving a high degree of protection for about four weeks. Because both SP\u000a      and AQ retain efficacy in areas of the Sahel where SMC has a role, the\u000a      SP+AQ combination was chosen for further studies. Initial trials of SMC\u000a      had been conducted in communities with low use of ITNs. To determine\u000a      whether SMC would give any added benefit in populations with high ITN\u000a      coverage, trials planned by Greenwood and coordinated by Diallo (then\u000a      Research Fellow at LSHTM) were conducted simultaneously with partners in\u000a      Burkina Faso and Mali in 2009, in children who were all provided with an\u000a      ITN. A 77% reduction in the incidence of uncomplicated malaria was\u000a      observed in children who received SMC with the SP+AQ combination, with\u000a      similar protection being seen against severe malaria. There was no\u000a      evidence of substantial increase in risk of malaria in the first year\u000a      after the intervention in children who received SMC with SP+AQ.3.2,3.3\u000a    Important policy questions that remained following these trials concerned\u000a      the safety of SMC and the practicality and cost of administering SMC to\u000a      children in rural areas. These issues have been investigated with partners\u000a      in Senegal by Milligan (Reader in Epidemiology and Medical Statistics,\u000a      LSHTM staff since 2004 as Reader), Ciss&#233; (LSHTM staff since 2008 as\u000a      Clinical Lecturer) and colleagues. Their studies have shown that SMC with\u000a      SP+AQ delivered by community health workers coordinated by the district\u000a      health team is safe, acceptable to the community, can achieve high\u000a      coverage and is highly cost effective (papers in preparation). To\u000a      determine the geographical regions where SMC might be an appropriate\u000a      malaria intervention, research conducted by Cairns (Research Fellow, now\u000a      Lecturer, LSHTM staff since 2010) and colleagues defined the areas of\u000a      Africa where malaria is highly seasonal and where incidence is high enough\u000a      to warrant implementation of SMC.3.4\u000a    "},{"CaseStudyId":"41454","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"226074","Name":"Uganda"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000a    LSHTM's research into the effects of male circumcision as a strategy for\u000a      HIV prevention, as well as the prevention of other STIs, has been widely\u000a      used to underpin international policy recommendations on male\u000a      circumcision, in particular for sub-Saharan Africa. Its key contribution\u000a      was to use systematic reviews, meta-analyses and modelling to draw clear\u000a      conclusions from a wide body of research.\u000a    In March 2007, WHO\/UNAIDS convened a pivotal meeting bringing together\u000a      stakeholders, policy- makers and researchers. Weiss and Hayes presented a\u000a      meta-analysis of the three trials, providing a point estimate that\u000a      underscored the strength of the evidence and underpinned the document\u000a      issued by the meeting recommending male circumcision as an HIV prevention\u000a      strategy in combination with other methods like condom promotion.5.1\u000a      This key document laid the foundations for subsequent guidelines and\u000a      policy statements published after January 2008 and may be found\u000a      at www.malecircumcision.org.\u000a    In 2008, WHO\/UNAIDS' operational guidance for countries wishing to scale\u000a      up male circumcision for HIV prevention cited the research conducted by\u000a      Weiss and colleagues as evidence of a strong link between male\u000a      circumcision and reduced HIV prevalence, as well as evidence of male\u000a      circumcision providing protection against ulcerative STIs and penile\u000a      cancer.5.2 In the same year, the US Centers for Disease Control\u000a      and Prevention (CDC) made reference to the research in a paper laying out\u000a      the implications of the findings on male circumcision for the USA.5.3\u000a      In August 2012, the American Academy of Pediatrics published new\u000a      guidelines for infant male circumcision in the US (see http:\/\/pediatrics.aappublications.org\/content\/early\/2012\/08\/22\/peds.2012-1990),\u000a      which also cited the underpinning research.\u000a    In June 2009, Weiss chaired the first session of an international\u000a      consultation convened by WHO and UNAIDS on male circumcision and HIV\u000a      prevention, which focused on how to scale up male circumcision services in\u000a      sub-Saharan Africa following the March 2007 WHO\/UNAIDS recommendation.5.4\u000a    The UNAIDS\/WHO\/SACEMA expert group (including White and Weiss) on\u000a      modelling the impact and cost of male circumcision for HIV prevention\u000a      published a consensus statement aimed at policy-makers in September 2009,\u000a      building on earlier research including that by White and colleagues.3.5\u000a      This work helped estimate the number of circumcisions needed for maximum\u000a      impact, and the costs of scale-up.5.5 The paper cites our work,3.2,\u000a        3,3. 3.4, 3.5 and Hankins and colleagues show that an investment\u000a      of US$1.5bn between 2011 and 2015 could achieve 80% coverage in 13\u000a      priority countries in southern and eastern Africa and would avert 3.4m new\u000a      HIV infections, resulting in net savings of US$16.5bn. In November 2011,\u000a      WHO\/UNAIDS published a joint strategic five- year action framework to\u000a      accelerate the scale-up of voluntary medical male circumcision for HIV\u000a      prevention in eastern and southern Africa.5.6 Intended for use\u000a      by country, regional and global stakeholders, this highlights the\u000a      consensus modelling paper3.5 demonstrating the cost\u000a      effectiveness of medical male circumcision. The Framework set a goal of\u000a      circumcising 80% of males (20m circumcisions) in 14 priority countries by\u000a      2015, and an additional 8.4m circumcisions between 2016 and 2025.5.6\u000a      The most recent data available from WHO is to the end of 2011, by which\u000a      time an estimated 1.4m male circumcisions had been conducted since the\u000a      beginning of 2008 in the priority countries.5.7\u000a    As a direct result of her research expertise, Weiss serves on the WHO\u000a      Technical Advisory Group on Innovations In Male Circumcision. Following a\u000a      meeting in January 2012, in which Weiss participated, the Group\u000a      recommended the use of an elastic ring-controlled radial compression\u000a      device for adult male circumcision in preference to traditional surgery\u000a      (March 2012).5.8\u000a    Also as a direct result of her research, Weiss has frequently attended\u000a      other WHO\/UNAIDS meetings to present research findings and discuss policy\u000a      issues. She and members of LSHTM were commissioned by WHO to conduct\u000a      several further systematic reviews as input to their policy deliberations\u000a      (e.g. on male circumcision and the risk of HIV infection in women, 2009),5.9\u000a      presented at a meeting on implications of the research findings for women\u000a      in Nairobi in June 2008; and provided model projections on combining\u000a      microbiocide and male circumcision interventions in rural Uganda (2011).5.10\u000a    Weiss has raised the profile of male circumcision for HIV prevention in\u000a      public discourse in the UK through appearances in the media. In August\u000a      2008, she discussed the impact of male circumcision on their female\u000a      partners on Woman's Hour on BBC Radio 4. In July 2011, she\u000a      appeared on The Health Show on BBC World News to discuss the new\u000a      device for bloodless circumcision mentioned above.\u000a    ","ImpactSummary":"\u000a    Research carried out by LSHTM into the effects of male circumcision on\u000a      HIV prevention has led to important policy recommendations by WHO and\u000a      UNAIDS, the joint UN Programme on HIV\/AIDS. The research showed a strongly\u000a      reduced risk of HIV infection among circumcised men, and modelling studies\u000a      estimated that male circumcision programmes in 13 priority countries in\u000a      Africa could avert 4m HIV infections by 2025. Members of the research team\u000a      serve on key international advisory groups, and these results have been\u000a      widely used to underpin international policy guidelines.\u000a    ","ImpactType":"Political","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"184745","Name":"Nairobi"}],"References":"\u000a    \u000a3.1 Buv&#233;,\u000a        A, Cara&#235;l,\u000a        M, Hayes,\u000a        RJ, Auvert,\u000a        B, Ferry,\u000a        B, Robinson,\u000a        NJ, Anagonou,\u000a        S, Kanhonou,\u000a        L,\u000a      Laourou,\u000a        M, Abega,\u000a        S, Akam,\u000a        E, Zekeng,\u000a        L, Chege,\u000a        J, Kahindo,\u000a        M, Rutenberg,\u000a        N, Kaona,\u000a        F,\u000a      Musonda,\u000a        R, Sukwa,\u000a        T, Morison,\u000a        L, Weiss,\u000a        HA and Laga,\u000a        M for the Study Group on Heterogeneity of HIV Epidemics in African\u000a      Cities (2001) The multicentre\u000a        study on factors determining the differential spread of HIV in four\u000a        African cities: summary and conclusions, AIDS, 15(Suppl. 4):\u000a      s127-S131, doi: 10.1097\/00002030-200108004-00014.\u000a      Citation count: 84\u000a    \u000a\u000a3.2. Weiss, HA, Quigley, MA and Hayes RJ (2000) Male circumcision and\u000a      risk of HIV infection in sub-Saharan Africa: a systematic review and\u000a      meta-analysis, AIDS, 14(15): 2361-2370, doi:\u000a      10.1097\/00002030-200010200-00018.\u000a      Citation count: 293\u000a    \u000a\u000a3.3 Weiss, HA, Halperin, D, Bailey, RC, Hayes, RJ, Schmid, G and Hankins\u000a      CA (2008) Male circumcision for HIV prevention: from evidence to action?',\u000a      AIDS, 22(5): 567-574, doi: 10.1097\/QAD.0b013e3282f3f406. Citation\u000a      count: 89\u000a    \u000a\u000a3.4 Weiss, HA, Thomas, SL, Munabi, SK and Hayes RJ (2006) Male\u000a      circumcision and risk of syphilis, chancroid, and genital herpes: a\u000a      systematic review and meta-analysis, Sexually Transmitted Infections,\u000a      82(2): 101-110, doi: 10.1136\/sti.2005.017442. Citation count: 161\u000a    \u000a\u000a3.5 UNAIDS\/WHO\/SACEMA Expert Group on Modelling the Impact and Cost of\u000a      Male Circumcision for HIV Prevention (2009) Male circumcision for HIV\u000a      prevention in high HIV prevalence settings: what can mathematical\u000a      modelling contribute to informed decision making?, PLoS Medicine,\u000a      6(9), e1000109, doi: 10.1371\/journal.pmed.1000109. Citation count: 5\u000a    \u000a\u000a3.6 White, RG, Glynn, JR, Orroth, KK, Freeman, EE, Bakker, R, Weiss, HA,\u000a      Kumaranayake, L, Habbema, JDF, Buv&#233;, A and Hayes RJ (2008) Male\u000a      circumcision for HIV prevention in sub- Saharan Africa: who, what and\u000a      when?, AIDS, 22(14): 1841-1850, doi: 10.1097\/QAD.0b013e32830e0137.\u000a      Citation count: 33\u000a    \u000aKey grants\u000a      Weiss, A Systematic Review and Meta-analysis of the Association Between\u000a      Male Circumcision and HIV Infection in sub-Saharan Africa, UNAIDS,\u000a      4\/1999-6\/1999, &#163;3,100.\u000a    Weiss, Neonatal Circumcision Landscaping, Bill &amp; Melinda Gates\u000a      Foundation, 11\/2007-4\/2008, $132,585.\u000a    Weiss, Health Risks and Benefits of Male Circumcision for Women and HIV\u000a      Infected Men: Summary of Evidence to Date, WHO, 10\/2008-2\/2009, &#163;26,324.\u000a    Weiss and Larke, Systematic Reviews of the Associations of Male\u000a      Circumcision with Infectious Diseases in Males, Other than HIV, WHO,\u000a      3\/2009-9\/2009, &#163;36,256.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"}],"Sources":"\u000a    5.1 WHO\/UNAIDS (2007) New Data on Male Circumcision and HIV\u000a        Prevention: Policy and Programme Implications: Conclusions &amp;\u000a        Recommendations (WHO\/UNAIDS Technical Consultation on Male\u000a      Circumcision and HIV Prevention: Research Implications for Policy &amp;\u000a      Programming, 6-8 March. Montreux: WHO\/UNAIDS,\u000a      http:\/\/whqlibdoc.who.int\/publications\/2007\/9789241595988_eng.pdf\u000a      (accessed 16 October 2013) (although published in 2007, this document\u000a      continues to underpin the ongoing expansion and scale-up of male\u000a      circumcision in southern and eastern Africa).\u000a    5.2 WHO\/UNAIDS (2008) Operational Guidance for Scaling Up Male\u000a        Circumcision Services for HIV Prevention. Geneva: WHO,\u000a      http:\/\/www.malecircumcision.org\/programs\/documents\/MC_OpGuideFINAL_web.pdf\u000a      (accessed 16 October 2013) (see refs 7, 11).\u000a    5.3 Centers for Disease Control and Prevention (2013) Male\u000a        Circumcision,\u000a      http:\/\/www.cdc.gov\/hiv\/prevention\/research\/malecircumcision\/index.html\u000a      (accessed 16 October 2013) (see refs 6, 12, 21, 44, original guidance\u000a      published 2008).\u000a    5.4 WHO\/UNAIDS (2009) Male Circumcision and HIV Prevention:\u000a        Operations Research Priorities, An International Consultation (1-2\u000a      June). Nairobi: WHO\/UNAIDS,\u000a      http:\/\/www.malecircumcision.org\/resources\/documents\/MeetingObjectivesandAgendaNairobiJune20093Junefinal.pdf\u000a      (accessed 16 October 2013).\u000a    5.5 Hankins, CA, Forsythe S and Njeuhmeli E (2011) Voluntary male\u000a      circumcision: an introduction to the cost, impact and challenges of\u000a      accelerated scaling up, PLoS Medicine, 8(11), e1001127,\u000a      doi:10.1371\/journal.pmed.1001127.\u000a    5.6 WHO\/UNAIDS (2011) Joint Strategic Action Framework to Accelerate\u000a        the Scale-up of Voluntary Medical Male Circumcision for HIV Prevention\u000a        in Eastern and Southern Africa: 2012- 2016. UNAIDS,\u000a      http:\/\/www.unaids.org\/en\/media\/unaids\/contentassets\/documents\/unaidspublication\/2011\/JC2251_Action_Framework_circumcision_en.pdf\u000a      (accessed 16 October 2013).\u000a    5.7 WHO (2011) Progress in Scaling Up Voluntary Medical Male\u000a        Circumcision for HIV Prevention in Eastern and Southern Africa: January\u000a        &#8212; December 2011. Geneva: WHO,\u000a      http:\/\/www.malecircumcision.org\/country_updates\/documents\/FINAL%20VMMC%20Progress%20Report%20Jan-Dec%202011%20WHO.pdf\u000a      (accessed 16 October 2013).\u000a    5.8 WHO (2012) Use of Devices for Adult Male Circumcision in Public\u000a        Health HIV Prevention Programmes: Conclusions of the Technical Advisory\u000a        Group on Innovations in Male Circumcision. Geneva: WHO, http:\/\/www.malecircumcision.org\/documents\/Use_of_MC_devices_conclusions.pdf\u000a      (accessed 16 October 2013).\u000a    5.9 Weiss, HA, Hankins, CA and Dickson, K (2009) Male circumcision and\u000a      risk of HIV infection in women: a systematic review and meta-analysis, Lancet\u000a        Infectious Diseases, 9(11): 669-677, doi:\u000a      10.1016\/S1473-3099(09)70235-X.\u000a    5.10 Cox, AP, Foss, AM, Shafer, LA, Nsubuga, RN, Vickerman, P, Hayes, RJ,\u000a      Watts, C and White, RG (2011) `Attaining realistic and significant\u000a      reductions in HIV incidence: model projections of combining microbiocide\u000a      and male circumcision interventions in rural Uganda, Sexually\u000a        Transmitted Infections, 87(7): 635-639, doi:\u000a      10.1136\/sti.2010.046227.\u000a    ","Title":"\u000a    Male circumcision as an HIV prevention strategy\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    An estimated 34m people live with HIV, of whom two-thirds live in\u000a      sub-Saharan Africa. Approximately 2.7m people are newly infected with HIV\u000a      every year, and despite advances in scaling up antiretroviral treatment,\u000a      1.8m per year die of HIV-related causes. Discovering ways to prevent HIV\u000a      acquisition and transmission therefore remains a primary concern\u000a      worldwide.\u000a    In 1997, researchers from LSHTM &#8212; including Helen Weiss, Reader in\u000a      Epidemiology and International Health (joined LSHTM in 1997, then\u000a      Lecturer), and Richard Hayes, Professor of Epidemiology and International\u000a      Health (joined LSHTM in 1978, then Research Fellow) &#8212; joined the Study\u000a      Group on Heterogeneity of HIV Epidemics in African Cities. The group\u000a      carried out a series of large, population-based cross-sectional surveys in\u000a      four African cities, investigating why HIV had spread at very different\u000a      rates in East and West Africa and reached very different prevalence in the\u000a      two regions. The results showed that two biological variables &#8212; herpes\u000a      simplex virus type 2 (HSV- 2) and male circumcision &#8212; were independent\u000a      individual-level risk factors for HIV and differed between low and high\u000a      HIV prevalence areas.3.1\u000a    Weiss and Hayes subsequently carried out a systematic literature review\u000a      of studies published up to April 1999 that included circumcision as a risk\u000a      factor for HIV-1 infection in males in sub-Saharan Africa, and found\u000a      strong consistent evidence that circumcised men were at lower risk of HIV.3.2\u000a      Weiss presented the findings at an informal WHO consultation in 2000 in\u000a      Durban, and an updated meta-analysis at USAID in 2002, and helped provide\u000a      the justification for three subsequent randomised controlled trials (RCTs)\u000a      started in 2002\/2003 by French and US research teams. These trials showed\u000a      conclusively that male circumcision reduces the risk of HIV acquisition by\u000a      between 48 and 60%.3.3\u000a    LSHTM researchers then went on to examine whether this protective effect\u000a      of circumcision could be partly due to its protective effect against other\u000a      STIs, especially those causing ulcers. They conducted the first systematic\u000a      review and meta-analysis of circumcision and ulcerative STIs,3.4\u000a      quantifying the effect of male circumcision on syphilis, chancroid and\u000a      HSV-2. Published in 2006, the findings strongly indicated that circumcised\u000a      men are at lower risk of chancroid and syphilis. In other studies, Weiss\u000a      and colleagues reviewed the evidence of an association between male\u000a      circumcision and penile cancer (2011), and circumcision and human\u000a      papillomavirus (HPV) infection (2011), showing that both conditions could\u000a      be reduced by the expansion of circumcision services.\u000a    In 2008, Weiss and Richard White (Reader in Infectious Disease Modelling,\u000a      joined LSHTM 1998, then Research Assistant) participated in an Expert\u000a      Group formed by UNAIDS, the WHO and the South African Centre for\u000a      Epidemiological Modelling and Analysis (SACEMA), to model the likely\u000a      population-level impact of male circumcision on the HIV epidemic.3.5\u000a      The resulting modelling statement (2009), itself building on earlier\u000a      research by White and colleagues,3.6 predicted that\u000a      circumcision is capable of yielding large benefits among heterosexual men\u000a      in low-circumcision, high-HIV prevalence settings, with one HIV infection\u000a      being averted for every 5 to 15 male circumcisions performed.\u000a    "},{"CaseStudyId":"41455","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2434508","Name":"Chad"},{"GeoNamesId":"3355338","Name":"Namibia"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2275384","Name":"Liberia"},{"GeoNamesId":"239880","Name":"Central African Republic"},{"GeoNamesId":"2413451","Name":"Gambia"},{"GeoNamesId":"2440476","Name":"Niger"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    Research carried out by LSHTM's Andrew Hall in collaboration with the\u000a      GHIS team has been\u000a      central to informing WHO's current recommendations on controlling the\u000a      hepatitis B virus, a disease\u000a      estimated to have infected 2bn people worldwide, through an infant\u000a      vaccination programme.\u000a      Crucially WHO guidelines explicitly state that there is no evidence to\u000a      support the need for a booster\u000a      dose following three doses of hepatitis B vaccine in infancy, a\u000a      recommendation drawn directly from\u000a      the conclusions of Hall's body of research that the vaccine confers\u000a      adequate protection up to 15\u000a      years of age - since extended to 22 years.\u000a    The WHO position paper on hepatitis B vaccine,5.1 published in\u000a      2009 and replacing previous\u000a      guidelines issued in 2004, cites six papers co-authored by Hall between\u000a      1995 and 2008. The\u000a      position paper recommends that all infants in highly endemic areas like\u000a      Africa should receive their\u000a      first dose of hepatitis B vaccine as soon as possible after birth, ideally\u000a      within 24 hours. It advises\u000a      governments that delivery of the vaccine within this 24-hour time period,\u000a      as advocated by the GHIS\u000a      research study, should be a `performance measure for all immunisation\u000a      programmes'. Unless\u000a      vaccinated at birth, the majority of children born to contagious mothers\u000a      become chronically\u000a      infected. The WHO paper noted that 2006 data showed the first dose was\u000a      administered within 24\u000a      hours of birth in only 27 per cent of cases.\u000a    As of 2008, 177 countries had incorporated a hepatitis B vaccine into\u000a      their routine national EPI\u000a      programmes as a result of the success of the Gambia study.5.2\u000a      During the impact period, at least\u000a      five further countries in the African WHO region have added infant\u000a      hepatitis B vaccination to their\u000a      EPI, providing virtually universal coverage in the African region. These\u000a      countries are Liberia, Niger,\u000a      Central African Republic, Chad and Namibia. In 2012, given numbers of\u000a      babies born in these\u000a      countries and hepatitis B third dose coverage from the most recent\u000a      coverage surveys (for Liberia,\u000a      Central African Republic, Chad), and from official reports (for Niger and\u000a      Namibia),5.3 this means\u000a      that approximately an additional 1.2m infants per year are being protected\u000a      against developing liver\u000a      cancer later in life in these predominantly highly disadvantaged countries\u000a      which introduced the\u000a      vaccine during the impact period. The majority of remaining countries\u000a      globally not to have\u000a      introduced universal vaccination are in north-west Europe.\u000a    A series of follow-up studies by Hall into vaccine efficacy provided the\u000a      evidence underlying the\u000a      WHO 2009 recommendation that no booster programme for the hepatitis B\u000a      vaccine is required if\u000a      the vaccine is correctly administered at birth. The consequences of adding\u000a      a booster programme\u000a      on the budget of Ministries of Health in the less developed world would\u000a      have been significant. In\u000a      order to formulate the 2009 position paper, WHO's Strategic Advisory Group\u000a      of Experts (SAGE) on\u000a      immunisation, the principal advisory group to WHO for vaccines and\u000a      immunisation, assessed the\u000a      available scientific evidence to review the need for booster doses of the\u000a      vaccine.5.4,5.5 Hall was a\u000a      member of the SAGE sub-committee that used the GRADE system of assessing\u000a      evidence.5.6 The\u000a      Gambia study was judged the only `high-quality' study and therefore played\u000a      a critical role in the\u000a      final formulation of the booster policy recommendation.\u000a    Professor Hall was knighted in the Queen's Birthday Honours for 2013 for\u000a      services to public health.\u000a      His citation notes his seminal contribution to hepatitis B vaccination:\u000a      `He is leading the single most\u000a      important validation of the hepatitis B vaccine outside the Far East, in\u000a      which over 125,000 infants\u000a      in The Gambia have been enrolled. A world authority on hepatitis vaccines\u000a      and viruses, he is in\u000a      international demand for his knowledge of infectious disease control'.5.7\u000a    ","ImpactSummary":"\u000a    Research conducted by LSHTM has informed the delivery of a 30-year WHO\u000a      strategy aimed at\u000a      reducing the devastating burden of liver cancer in Africa and least\u000a      developed countries in other\u000a      regions. Studies evaluating the effectiveness of the Gambia Hepatitis\u000a      Intervention Study (GHIS) - the\u000a      only randomised trial of a hepatitis B vaccine with a disease endpoint in\u000a      Africa - have shaped\u000a      current WHO policy recommendations for vaccinations against the virus,\u000a      enabling WHO to advise\u000a      against the need for a booster programme, and protecting governments in\u000a      the less developed\u000a      world from significant additional expenditure.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1 Fortuin, M, Chotard, J, Jack, AD, Maine, NP, Mendy, M, Hall, AJ,\u000a      Inskip, HM, George,\u000a      MO and Whittle HC (1993) Efficacy of hepatitis B vaccine in the Gambian\u000a      Expanded\u000a      Programme of Immunisation, Lancet, 341(8853): 1129-1131,\u000a      doi:10.1016\/0140-6736(93)93137-P.\u000a      Citation count: 55\u000a    \u000a\u000a3.2 Hall, AJ, Robertson, RL, Crivelli, PE, Lowe, Y, Inskip, HM, Snow, SK\u000a      and Whittle, H\u000a      (1993) Cost-effectiveness of hepatitis B vaccine in The Gambia, Transactions\u000a        of the Royal\u000a        Society of Tropical Medicine and Hygiene, 87(3): 333-336, doi:\u000a      10.1016\/0035-9203(93)90154-I.\u000a      Citation count: 39\u000a    \u000a\u000a3.3 Jack, AD, Hall, AJ, Maine, N, Mendy, M and Whittle HC (1999) What\u000a      level of hepatitis B\u000a      antibody is protective?, Journal of Infectious Diseases, 179(2):\u000a      489-492, doi:10.1086\/314578.\u000a      Citation count: 85\u000a    \u000a\u000a3.4 Viviani, S, Jack, A, Hall, AJ, Maine, N, Mendy, M, Montesano, R and\u000a      Whittle, HC (1999)\u000a      Hepatitis B vaccination in infancy in The Gambia: protection against\u000a      carriage at 9 years of age,\u000a      Vaccine, 17(23-24): 2946-2950, doi:10.1016\/S0264-410X(99)00178-4.\u000a      Citation count: 92\u000a    \u000a\u000a3.5. van der Sande, MAB, Waight, PA, Mendy, M, Zaman, S, Kaye, S, Sam, O,\u000a      Kahn, A, Jeffries,\u000a      D, Akum, AA, Hall, AJ, Bah, E, McConkey, SJ, Hainaut, P and Whittle, HC\u000a      (2007) Long-term\u000a      protection against HBV chronic carriage of Gambian adolescents vaccinated\u000a      in infancy and\u000a      immune response in HBV booster trial in adolescence, PLoS One,\u000a      2(8): e753,\u000a      doi:10.1371\/journal.pone.0000753.\u000a      Citation count: 6\u000a    \u000a\u000a3.6. Mendy, M, Peterson, I, Hossin, S, Peto, T, Jobarteh, ML, Jeng-Barry,\u000a      A, Sidibeh, M, Jatta, A,\u000a      Moore, SE, Hall, AJ and Whittle, H (2013) Observational study of vaccine\u000a      efficacy 24 years after\u000a      the start of hepatitis B vaccination in two Gambian villages: no need for\u000a      a booster dose, PLoS\u000a        One, 8(3): e58029, doi:10.1371\/journal.pone.0058029.\u000a      Citation count: 0\u000a    \u000aKey grants\u000a    This work was funded from core funding of the IARC (WHO) and the Medical\u000a      Research Council\u000a      Unit The Gambia. Professor Hall was employed by IARC from 1986 to 1990 and\u000a      subsequently has\u000a      been a consultant to IARC to maintain the project.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"}],"Sources":"\u000a    5.1 WHO (2009) Hepatitis B vaccines: WHO position paper, WHO Weekly\u000a        Epidemiological Record,\u000a      84(40): 405-420, http:\/\/www.who.int\/entity\/wer\/2009\/wer8440.pdf\u000a      (accessed 7 November 2013).\u000a    5.2 Fran&#231;ois, G, Dochez, C, Jeffrey M, Burnett, R, Van Hal, G and Meheus,\u000a      A (2008) Hepatitis B\u000a      vaccination in Africa: mission accomplished? The Southern African\u000a        Journal of Epidemiology and\u000a        Infection, 23(1): 24-28.\u000a    5.3 WHO vaccine-preventable diseases: monitoring system, 2013 global\u000a      summary\u000a      http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\u000a      (accessed 7 November 2013).\u000a    5.4 The role of the evidence in the SAGE process of policy formulation\u000a      can be verified by the\u000a      Executive Secretary to the SAGE committee, WHO.\u000a    5.5 The role of the evidence in the SAGE process of policy formulation\u000a      can be verified by the\u000a      former head of the WHO Hepatitis Section, WHO.\u000a    5.6 The Grade document of the SAGE committee can be found at\u000a      http:\/\/www.who.int\/immunization\/hepb_grad_duration.pdf\u000a      (accessed 7 November 2013).\u000a    5.7 Knighthood: https:\/\/www.gov.uk\/government\/publications\/birthday-honours-lists-2013\u000a      (accessed 7 November 2013).\u000a    \u000a    ","Title":"\u000a    Controlling the hepatitis B virus in Africa and preventing unnecessary\u000a      expenditure\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Around 600,000 people die each year from the acute or chronic\u000a      consequences of hepatitis B with\u000a      25% of adults chronically infected during childhood later dying from liver\u000a      cancer or cirrhosis.\u000a      The GHIS, beginning in 1986, was designed to evaluate the effectiveness of\u000a      administering a\u000a      hepatitis B vaccine to infants in one of the worst affected countries in\u000a      sub-Saharan Africa - an\u000a      estimated 10% of adults in West Africa die prematurely from the virus. The\u000a      GHIS is a collaboration\u000a      between WHO's International Agency for Research on Cancer (IARC), the\u000a      Gambian government\u000a      and the Medical Research Council Unit The Gambia.\u000a    As an IARC employee, Andrew Hall, Professor of Epidemiology, was\u000a      principal investigator on the\u000a      project at its inception before moving to LSHTM in 1990 (then Senior\u000a      Lecturer). Since 1993, Hall\u000a      has published more than 20 papers in leading journals, analysing the\u000a      efficacy of the vaccination\u000a      programme as the trial cohorts grow older.\u000a    Around 126,000 children were recruited to the study and, in the first\u000a      phase from 1986 to 1990, half\u000a      were randomised to receive hepatitis vaccination at birth, 2, 4 and 9\u000a      months of age in addition to\u000a      vaccines delivered under the Gambian Expanded Programme on Immunisation\u000a      (EPI). In Phase II\u000a      (1991-1997), the efficacy of the vaccine was evaluated and Phase III\u000a      (1998-present) continues to\u000a      follow up the children in the trial. A national cancer register was set up\u000a      in 1986 and continues to be\u000a      updated, enabling linkages to be drawn between cancer cases and\u000a      vaccination.\u000a    Hall was co-author of a paper published in The Lancet in 19933.1\u000a      that demonstrated the protection\u000a      conferred by the hepatitis B vaccine. Through examining 3- and 4-year-old\u000a      children who had\u000a      received the vaccine in infancy, the paper showed it to be 84% effective\u000a      against infection and 94%\u000a      effective against chronic carriage. Hall was lead author on a paper that\u000a      showed universal hepatitis\u000a      B immunisation was cost effective,3.2 offering a replicable\u000a      model for other African countries.\u000a    Hall was subsequently involved in a number of subgroup studies to\u000a      measure, at regular intervals in\u000a      childhood and adolescence, immune response and infections, generating data\u000a      on antibody decay\u000a      and vaccine efficacy against hepatitis B infection.3.3 Funded\u000a      by the IARC and the Italian and\u000a      Swedish governments, the ultimate aim was to determine whether there was a\u000a      need to implement\u000a      a hepatitis B booster programme. A paper in Vaccine in 1999\u000a      demonstrated vaccine efficacy at the\u000a      age of 9,3.4 supporting WHO recommendations to introduce\u000a      hepatitis B vaccination into the EPI\u000a      across Africa.\u000a    Research published in 2007 demonstrated, through serological assessments\u000a      of vaccines aged up\u000a      to 15, that hepatitis B vaccination early in life confers long-lasting\u000a      protection against carriage of the\u000a      virus despite decreasing antibody levels, highlighting the need for\u000a      further research to evaluate the\u000a      necessity of a booster.3.5 Subsequent studies found that good\u000a      levels of protection existed in 18-and\u000a      22-year-olds following vaccination in infancy, leading to the conclusion\u000a      that a costly booster\u000a      programme was not required.3.6\u000a    "},{"CaseStudyId":"41456","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2328926","Name":"Nigeria"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"2275384","Name":"Liberia"},{"GeoNamesId":"163843","Name":"Syria"},{"GeoNamesId":"2309096","Name":"Equatorial Guinea"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"337996","Name":"Ethiopia"},{"GeoNamesId":"248816","Name":"Jordan"},{"GeoNamesId":"1210997","Name":"Bangladesh"},{"GeoNamesId":"3703430","Name":"Panama"},{"GeoNamesId":"272103","Name":"Lebanon"}],"Funders":["Wellcome Trust"],"ImpactDetails":"\u000d\u000a    LSHTM's research has played a key role in promoting new approaches to\u000d\u000a      mental health care and\u000d\u000a      influencing policy-makers and donors, in the following ways.\u000d\u000a    \u000d\u000a      Informing global and national policies for improving access to mental\u000d\u000a        disorders. In 2008, WHO\u000d\u000a        launched a flagship action plan to scale-up services for mental\u000d\u000a        disorders (mhGAP). This\u000d\u000a        referenced The Lancet mental health series in which Patel played\u000d\u000a        a leading role.5.1 This\u000d\u000a        subsequently led to a WHO resolution for a Comprehensive Mental Health\u000d\u000a        Action Plan approved\u000d\u000a        by the World Health Assembly in 2013. In 2011, the Ministry of Health in\u000d\u000a        India set up a mental\u000d\u000a        health policy group, including Patel, to write India's first mental\u000d\u000a        health policy and make\u000d\u000a        recommendations for the scaling-up of mental health care. For example,\u000d\u000a        Patel's research was\u000d\u000a        extensively cited in the XIIth Plan District Mental Health Programme\u000d\u000a        which is now being rolled\u000d\u000a        out throughout the country.5.2\u000a\u000d\u000a      Enabling the launch of global civil society partnerships to advocate\u000d\u000a        for mental health. In October\u000d\u000a        2008, the Movement for Global Mental Health was launched in direct\u000d\u000a        response to LSHTM's\u000d\u000a        research and Patel's call to action.5.3 The Movement, a\u000d\u000a        coalition of individuals and institutions\u000d\u000a        aiming to improve services for people with mental disorders worldwide,\u000d\u000a        now has over 3,000\u000d\u000a        individual and 150 institutional members from over 100 countries.\u000d\u000a      Increased resources for global mental health. Grand Challenges Canada5.4\u000d\u000a        has committed\u000d\u000a        C$30m for innovations which address the Grand Challenges in Global\u000d\u000a        Mental Health and the\u000d\u000a        funding of a Global Mental Health Platform (led by LSHTM) to disseminate\u000d\u000a        innovations to the\u000d\u000a        wider communities of policy-makers, practitioners and civil society\u000d\u000a        stakeholders. The US\u000d\u000a        National Institute of Mental Health (NIMH) has also committed over\u000d\u000a        US$15m to fund five hubs in\u000d\u000a        developing countries involving partnerships between researchers, policy\u000d\u000a        makers and civil society\u000d\u000a        to implement these Challenges (LSHTM is the lead institution for one of\u000d\u000a        the hubs). Both\u000d\u000a        reference papers co-authored by Patel.\u000d\u000a      Informing the mental health programmes of development agencies and\u000d\u000a        NGOs. Various\u000d\u000a        international agencies have cited the research of LSHTM as justification\u000d\u000a        to initiate and expand\u000d\u000a        their own mental health care programmes. For example, the World\u000d\u000a        Federation for Mental Health\u000d\u000a        (the world's largest mental health NGO) has aligned its global programme\u000d\u000a        to be consistent with\u000d\u000a        the research evidence generated by LSHTM and the call to action.5.5\u000a\u000d\u000a      Providing practical tools for mental health care in the field: (i)\u000d\u000a        Patel's manual, Where There is No\u000d\u000a          Psychiatrist, published in 2003 and providing practical guidance,\u000d\u000a        has been translated into more\u000d\u000a        than a dozen languages. Since 2010, the manual has been core reading for\u000d\u000a        a new mental health\u000d\u000a        nursing training programme in Liberia, and has been used by over 4,000\u000d\u000a        village doctors in\u000d\u000a        Bangladesh since 2008. It is the core mental health manual for MSF\u000d\u000a        programme staff.5.6 In 2008\u000d\u000a        permission was given to reproduce the manual as 25,000 CD-ROMs, produced\u000d\u000a        by WHO and the\u000d\u000a        Inter-Agency Standing Committee (IASC) and disseminated to agencies\u000d\u000a        working in emergency\u000d\u000a        situations. The message of the value of lay health workers in mental\u000d\u000a        illness care has been taken\u000d\u000a        to a wide public audience, for example through a TED talk by Patel5.7\u000d\u000a        which by end July 2013\u000d\u000a        has had 353,047 hits. (ii) A specially appointed WHO guideline\u000d\u000a        development group, including\u000d\u000a        Patel, developed guidelines5.8 based in part on LSHTM's\u000d\u000a        research for the management of mental\u000d\u000a        disorders. Since its launch in October 2010, the resulting mhGAP Intervention\u000d\u000a          Guide has been\u000d\u000a        rolled out in Ethiopia, Jordan, Nigeria and Panama, and used in\u000d\u000a        humanitarian settings in Haiti,\u000d\u000a        Equatorial Guinea, Palestine, Syria and Lebanon.\u000d\u000a      Establishing global mental health as a discipline for study and\u000d\u000a        practice. The research has\u000d\u000a        prompted several leading international universities to set up teaching\u000d\u000a        programmes in global\u000d\u000a        mental health (e.g. Duke, Harvard, New York University). Patel has led\u000d\u000a        or been actively involved\u000d\u000a        in the establishment of Centres for Public Mental Health in South Africa\u000d\u000a        (at the Universities of\u000d\u000a        Cape Town\/Stellenbosch) and India (at the Public Health Foundation of\u000d\u000a        India where he directs\u000d\u000a        the new Centre for Mental Health).5.9 Patel's work has been\u000d\u000a        specifically cited by Arthur Kleinman,\u000d\u000a        one of the most influential thinkers in global mental health: `Medical\u000d\u000a        students who seem largely\u000d\u000a        uninterested in academic psychiatric research are flocking to ...\u000d\u000a        projects inspired by other\u000d\u000a        models of community care such as those initiated by Vikram Patel and\u000d\u000a        colleagues [see\u000d\u000a        www.sangath.com; www.centreforglobalmentalhealth.org].\u000d\u000a        Among many others, these\u000d\u000a        approaches appeal to those health professionals and students for whom\u000d\u000a        social justice and care\u000d\u000a        for the suffering of the poor are central, and have moral force.'5.10\u000a\u000d\u000a    \u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research carried out by LSHTM into mental disorders in low- and\u000d\u000a      middle-income countries has\u000d\u000a      promoted new approaches to mental health care and influenced donors,\u000d\u000a      practitioners and policy-makers,\u000d\u000a      contributing to changing global priorities in this area. WHO launched a\u000d\u000a      flagship action plan\u000d\u000a      based on the research, governments and NGOs made substantial financial\u000d\u000a      allocations for\u000d\u000a      implementing the research innovations, and the findings have been\u000d\u000a      translated into treatment\u000d\u000a      guidelines used to train health workers in managing mental illness in many\u000d\u000a      countries.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000d\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a3.1 Patel, V, Chatterji, S, Chisholm, D, Ebrahim, S, Gururaj, G, Mathers,\u000d\u000a      C, Mohan, V,\u000d\u000a      Prabhakaran, D, Ravindran, RD and Reddy, KS (2011) Chronic diseases and\u000d\u000a      injuries in India,\u000d\u000a      Lancet, 377(9763): 413-428, doi:10.1016\/S0140-6736(10)61188-9.\u000d\u000a      Citation count: 28\u000d\u000a    \u000a\u000a3.2 Patel, V, Ramasundarahettige, C, Vijayakumar, L, Thakur, JS,\u000d\u000a      Gajalakshmi, V, Gururaj, G,\u000d\u000a      Suraweera, W and Jha, P for the Million Death Study Collaborators (2012)\u000d\u000a      Suicide mortality in\u000d\u000a      India: a nationally representative survey, Lancet, 379(9834):\u000d\u000a      2343-2351, doi:10.1016\/S0140-6736(12)60606-0.\u000d\u000a      Citation count: 10\u000d\u000a    \u000a\u000a3.3 Patel, V, Chisholm, D, Rabe-Hesketh, S, Dias-Saxena, F, Andrew, G and\u000d\u000a      Mann, A (2003)\u000d\u000a      Efficacy and cost-effectiveness of drug and psychological treatments for\u000d\u000a      common mental disorders\u000d\u000a      in general health care in Goa, India: a randomised, controlled trial, Lancet,\u000d\u000a      361(9351): 33-39,\u000d\u000a      doi:10.1016\/S0140-6736(03)12119-8. Citation count: 90.\u000d\u000a    \u000a\u000a3.4 Patel, V, Weiss, HA, Chowdhary, N, Naik, S, Pednekar, S, Chatterjee,\u000d\u000a      S, De Silva, MJ, Bhat,\u000d\u000a      B, Araya, R, King, M, Simon, G, Verdeli, H and Kirkwood, BR (2010)\u000d\u000a      Effectiveness of an\u000d\u000a      intervention led by lay health counsellors for depressive and anxiety\u000d\u000a      disorders in primary care in\u000d\u000a      Goa, India (MANAS): a cluster randomised controlled trial, Lancet,\u000d\u000a      376(9758): 2086-2095,\u000d\u000a      doi:10.1016\/S0140-6736(10)61508-5. Citation count: 60\u000d\u000a    \u000a\u000a3.5 Collins, PY, Patel, V, Joestl, SS, March, D, Insel, TR, Darr, AS,\u000d\u000a      Bordin, IA, Costello, EJ, Durkin,\u000d\u000a      M, Fairburn, C, Glass, RI, Hall, W, Huang, Y, Hyman, SE, Jamison, K,\u000d\u000a      Kaaya, S, Kapur, S,\u000d\u000a      Kleinman, A, Ogunniyi, A, Otero-Ojeda, A, Poo, MM, Ravindranath, V,\u000d\u000a      Sahakian, BJ, Saxena, S,\u000d\u000a      Singer, PA, Stein, DJ, Anderson, W, Dhansay, MA, Ewart, W, Phillips, A,\u000d\u000a      Shurin, S and Walport, M\u000d\u000a      (2011) Grand challenges in global mental health, Nature,\u000d\u000a      475(7354): 27-30, doi:10.1038\/475027a.\u000d\u000a      Citation count: 133\u000d\u000a    \u000a\u000a3.6 Lancet Global Mental Health Group (2007) Scale up services\u000d\u000a      for mental disorders: a call for\u000d\u000a      action, Lancet, 370(9594): 1241-1252,\u000d\u000a      doi:10.1016\/S0140-6736(07)61242-2 (corresponding\u000d\u000a      author and leader of the writing group: Patel, V). Citation count: 156\u000d\u000a    \u000aKey grants\u000d\u000a    &#8226; Patel, A Community Cohort Study of the Relationship Between\u000d\u000a      Gynaecological Morbidity and\u000d\u000a      Common Mental Disorders in Goa, India, Wellcome Trust Career Development\u000d\u000a      Fellowship in\u000d\u000a      Clinical Tropical Medicine (UK), 10\/2000-9\/2005, &#163;760,190.\u000d\u000a    &#8226; Patel, A Cluster Randomised Trial of a Primary Care Intervention for\u000d\u000a      Common Mental Disorders\u000d\u000a      in Goa, India, Wellcome Trust Senior Clinical Fellowship in Clinical\u000d\u000a      Tropical Medicine, 10\/2005-9\/2010,\u000d\u000a      &#163;1.1m.\u000d\u000a    &#8226; Patel, The Development and Dissemination of the Lancet Series\u000d\u000a      on Global Mental Health,\u000d\u000a      MacArthur Foundation, 2006-2008, US$50,000.\u000d\u000a    &#8226; Wellcome Trust Strategic Award, to Ebrahim, Patel and others,\u000d\u000a      10\/2008-2014, The South Asia\u000d\u000a      Centre for Chronic Diseases, &#163;4.5 million\u000d\u000a    &#8226; Patel, Cohen and De Silva, Evaluating Packages of Care for People with\u000d\u000a      Severe Mental\u000d\u000a      Disorders for Scaling-up in Low and Middle Income Countries, CBM,\u000d\u000a      10\/2008-3\/2011,\u000d\u000a      &#8364;192,373.\u000d\u000a    &#8226; Patel, PREMIUM: A Program for Effective Mental Health Interventions in\u000d\u000a      Under-resourced\u000d\u000a      Health Systems, Wellcome Trust Senior Research Fellowship in Clinical\u000d\u000a      Science, 10\/2010-9\/2015,\u000d\u000a      &#163;1.6m.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    5.1 WHO (2008) mhGAP: Mental Health Gap Action Programme: Scaling Up\u000d\u000a        Care for Mental,\u000d\u000a        Neurological, and Substance Use Disorders. Geneva: WHO, pp. 9, 36\u000d\u000a      (citation 6),\u000d\u000a      http:\/\/www.who.int\/mental_health\/mhgap_final_english.pdf\u000d\u000a      (accessed 11 September 2013).\u000d\u000a    5.2 Mental Health Policy Group (2012) XIIth Plan District Mental\u000d\u000a        Health Programme. India: Mental\u000d\u000a      Health Policy Group, p. 67 (citations 1, 2, 3, 5, 11, 12, 13), p. 68\u000d\u000a      (citations 3, 9, 10, 11)\u000d\u000a      http:\/\/mhpolicy.files.wordpress.com\/2012\/07\/final-dmhp-design-xii-plan2.pdf\u000d\u000a      (accessed 20\u000d\u000a      September 2013).\u000d\u000a    5.3 The Movement for Global Mental Health cites the 2007 Lancet\u000d\u000a      series and LSHTM research as\u000d\u000a      the rationale for its launch\u000d\u000a      (http:\/\/www.globalmentalhealth.org\/about\/history).\u000d\u000a    5.4 Grand Challenges Canada (2012) Global Mental Health: Integrated\u000d\u000a        Innovations to Improve\u000d\u000a        Treatments and Expand Access to Care &#8212; Round 2. Canada: Grand\u000d\u000a      Challenges Canada, p. 2 (ref.\u000d\u000a      5), p. 3 (ref. 6), http:\/\/www.grandchallenges.ca\/wordpress\/wp-content\/uploads\/globalmentalhealth-round2-requestforproposals-2012Nov05-EN.pdf\u000d\u000a      (accessed 11 September 2013).\u000d\u000a    5.5 Former President, The World Federation for Mental Health.\u000d\u000a    5.6 Former mental health referent, Medicins sans Frontieres.\u000d\u000a    5.7 Patel, V (2012) Vikram Patel: Mental Health for All by Involving\u000d\u000a        All. Edinburgh: TEDGlobal,\u000d\u000a      June 2012 http:\/\/www.ted.com\/talks\/vikram_patel_mental_health_for_all_by_involving_all.html\u000d\u000a      (accessed 11 September 2013). Over 353,000 hits since it was launched on\u000d\u000a      the internet in\u000d\u000a      September 2012.\u000d\u000a    5.8 WHO (2010) mhGAP Intervention Guide for Mental, Neurological and\u000d\u000a        Substance Use\u000d\u000a        Disorders in Non-Specialized Health Settings: Mental Health Gap Action\u000d\u000a        Programme (mhGAP).\u000d\u000a      Geneva: WHO, http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241548069_eng.pdf\u000d\u000a      (accessed 11\u000d\u000a      September 2013). Patel was a member of the WHO mhGAP Guideline Development\u000d\u000a      Group (p iv).\u000d\u000a    5.9 Launch of a new Centre of Excellence on Mental Health by the Public\u000d\u000a      Health Foundation of\u000d\u000a      India, India's leading public health training institution and appointment\u000d\u000a      of Vikram Patel as its\u000d\u000a      Director (http:\/\/www.phfi.org\/our-activities\/research-a-centres\/centres-of-excellence\/869-centre-for-mental-health).\u000d\u000a    5.10 Kleinman, A (2012) Rebalancing academic psychiatry: why it needs to\u000d\u000a      happen &#8212; and soon,\u000d\u000a      British Journal of Psychiatry, 201(421-422),\u000d\u000a      doi:10.1192\/bjp.bp.112.118695.\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Improving access to mental health care in low- and middle-income\u000d\u000a      countries\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Mental health problems make a substantial contribution to the global\u000d\u000a      burden of disease. In low-and\u000d\u000a      middle-income countries, more than 20% of all disability related to health\u000d\u000a      conditions is caused\u000d\u000a      by mental health problems. It is on these pressing issues that Professor\u000d\u000a      Vikram Patel, who joined\u000d\u000a      the LSHTM in 2000 (then Senior Lecturer), has focused his research. The\u000d\u000a      research was carried out\u000d\u000a      between 2000 and 2012 in collaboration with many LSHTM colleagues who have\u000d\u000a      mental health\u000d\u000a      expertise, and especially Alex Cohen (LSHTM from 2008 as Senior Lecturer),\u000d\u000a      Mary De Silva\u000d\u000a      (LSHTM from 2005, then Research Fellow, now Senior Lecturer) and Professor\u000d\u000a      Betty Kirkwood\u000d\u000a      (LSHTM from 1979, then Lecturer). Since 2009, they have been functioning\u000d\u000a      under the umbrella of\u000d\u000a      the Centre for Global Mental Health (CGMH) in partnership with King's\u000d\u000a      College London.\u000d\u000a    The research fell into three areas:\u000d\u000a    \u000d\u000a      Evidence of the burden of mental health problems in low- and\u000d\u000a        middle-income countries.\u000d\u000a        Projects included the first systematic review of the burden of, and cost\u000d\u000a        effective treatments for,\u000d\u000a        mental disorders (along with other noncommunicable diseases &#8212; NCDs)3.1\u000d\u000a        and the first\u000d\u000a        nationally representative survey of suicide mortality in India in 2010.3.2\u000d\u000a        Other research included\u000d\u000a        population-based surveys carried out in 60 countries in 2006, examining\u000d\u000a        the association of\u000d\u000a        depression with other chronic conditions; identification of close\u000d\u000a        association of mental health\u000d\u000a        issues with maternal and child health and chronic physical health\u000d\u000a        conditions (e.g. a cohort\u000d\u000a        study demonstrating the impact of maternal depression on infant growth\u000d\u000a        in India 1998-2000);\u000d\u000a        and examination of the vicious cycle of disadvantage, social exclusion\u000d\u000a        and mental health\u000d\u000a        problems (e.g. a study of young women in five Indian states, 2002-2003).\u000d\u000a      Demonstrating that evidence-based treatments can be delivered in\u000d\u000a        low-resource settings by\u000d\u000a        non-specialist health care workers.3.3 Research projects\u000d\u000a        included the Manas cluster\u000d\u000a        randomised controlled trial, the largest trial in psychiatry in the\u000d\u000a        developing world, in India\u000d\u000a        (2007-2009),3.4 which tested the effectiveness of an\u000d\u000a        intervention led by lay health counsellors\u000d\u000a        for people with depression and anxiety disorders, and the first trial\u000d\u000a        for supporting caregivers of\u000d\u000a        people with dementia in the developing world, also in India (2003).\u000d\u000a      Demonstrating the great paucity and inequitable distribution of global\u000d\u000a        mental health research\u000d\u000a        resources and outputs (e.g. via a survey of researchers from 52\u000d\u000a        countries in the developing\u000d\u000a        world, 2004-2005). This led to efforts to set the priority agenda for\u000d\u000a        mental health research,\u000d\u000a        policy and practice in the global context (e.g. through a global Delphi\u000d\u000a        priority-setting research\u000d\u000a        initiative involving 422 mental health stakeholders around the world,\u000d\u000a        2010-2011).3.5 This body\u000d\u000a        of evidence also formed the basis of a pivotal six-article Lancet\u000d\u000a        series and a call to action led\u000d\u000a        by Patel on global mental health.3.6 Its publication was a\u000d\u000a        key event in the emerging field of\u000d\u000a        global mental health and was followed by several other high-profile\u000d\u000a        series, including two in\u000d\u000a        PLoS Medicine (2009, 2012) and another in The Lancet\u000d\u000a        (2011), both led by Patel.\u000d\u000a    \u000d\u000a    "},{"CaseStudyId":"41458","Continent":[{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"2017370","Name":"Russia"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Wellcome Trust"],"ImpactDetails":"\u000d\u000a    A sustained advocacy campaign following the 2010 publication of the\u000d\u000a      CRASH-2 trial results has ensured TXA is being used to treat trauma\u000d\u000a      patients in hospitals all over the world.\u000d\u000a    In 2010 the CRASH-2 team applied for the inclusion of TXA on WHO's List\u000d\u000a      of Essential Medicines, which guides purchasing decisions by Ministries of\u000d\u000a      Health in developing countries. It was accepted in March 20115.1\u000d\u000a      `on the basis of the results of a very large trial of the use of\u000d\u000a      tranexamic acid specifically for trauma patients'.\u000d\u000a    The CRASH-2 findings received blanket coverage across the global media in\u000d\u000a      several languages, helped by a coordinated media campaign by all 40\u000d\u000a      centres involved in the clinical trial. A BBC News report5.2\u000d\u000a      quoted WHO's Dr Etienne Krug as saying that doctors needed to be aware of\u000d\u000a      the trial results to `strengthen trauma response'. He said: `The problem\u000d\u000a      affects hundreds of millions every year worldwide.' The UK Health Minister\u000d\u000a      Earl Howe said: `This is a great example of how important research can\u000d\u000a      help the NHS save more lives and spread best practice around the world.'\u000d\u000a    The CRASH-2 trial has changed the practices of the UK Ministry of Defence\u000d\u000a      (MOD) and the US Department of Defense. Roberts began communications with\u000d\u000a      the MOD in 2006 after discovering that British soldiers in Afghanistan and\u000d\u000a      Iraq were being treated with an experimental blood-clotting drug &#8212;\u000d\u000a      NovoSeven &#8212; that had not been fully tested. After the story broke in the\u000d\u000a      UK, Roberts alerted MOD officials to the potential of TXA. In March 2010,\u000d\u000a      the British Army incorporated TXA into combat care treatment protocols on\u000d\u000a      the basis of the results of the CRASH-2 trial. A subsequent news report on\u000d\u000a      British Forces News5.3 quoted the Surgeon-General as\u000d\u000a      saying that within weeks of the CRASH-2 trial results, they were using TXA\u000d\u000a      to treat wounded troops &#8212; the first time the drug had been used routinely\u000d\u000a      in trauma patients.\u000d\u000a    The US Army carried out its own analysis of the efficacy of TXA,5.4\u000d\u000a      reaching the same conclusions. US Army officials invited Roberts to\u000d\u000a      Washington in June 2011 to discuss the CRASH-2 trial and in the same month\u000d\u000a      announced TXA's inclusion in its treatment protocols.\u000d\u000a    In May 2011, the CRASH-2 trial won the Research Paper of the Year5.5\u000d\u000a      at the 2011 BMJ awards, raising the profile of TXA among doctors.\u000d\u000a      Two months later the Directors of Clinical Care for the UK ambulance\u000d\u000a      service agreed that TXA would be given to all adults and teenagers who\u000d\u000a      suffer major injury in the UK. At the same time, the Joint Royal Colleges\u000d\u000a      Ambulance Liaison Committee approved a pre-hospital guideline on the\u000d\u000a      administration of TXA and the Royal College of Paediatrics and Child\u000d\u000a      Health agreed to convene a meeting of its Medicines Committee to consider\u000d\u000a      TXA dosing requirements in paediatric trauma, with advice released in\u000d\u000a      November 2012.5.6\u000d\u000a    In January 2012, The Independent reported that TXA was to be\u000d\u000a      fast-tracked for use in the NHS, making it the first drug to be approved\u000d\u000a      under the UK government's new `medicines innovation scheme', designed to\u000d\u000a      speed up the adoption of promising medication. Ambulance crews in south-\u000d\u000a      west England had already been given access to TXA but the decision by the\u000d\u000a      Department of Health (DH) led to it being rolled out across the UK. Health\u000d\u000a      Secretary Andrew Lansley commented: `The successful use of this drug to\u000d\u000a      help some of our most seriously wounded troops in Afghanistan really shows\u000d\u000a      the wide potential it has for our civilian emergency services.'5.7\u000d\u000a    As TXA is a low-profit drug it misses out on large advertising budgets\u000d\u000a      but Roberts has led innovative campaigns to ensure more clinicians use\u000d\u000a      TXA. In 2011 he oversaw the production of an animated video featuring\u000d\u000a      cartoon character `Tranman'. Recorded in several languages, the cartoon is\u000d\u000a      designed to reach doctors in China, India, Brazil, Russia and Africa. The\u000d\u000a      video was published on YouTube and The Lancet websites, and the New\u000d\u000a        York Times5.8 covered the making of the cartoon as an\u000d\u000a      example of creative science communication.\u000d\u000a    The findings from the CRASH-2 trial resulted in follow-on funding\u000d\u000a      (announced in 2010; reported by BBC News)5.9 from the\u000d\u000a      DH and the Wellcome Trust to investigate whether TXA can help to save some\u000d\u000a      of the 100,000 lives lost every year when women bleed to death after\u000d\u000a      giving birth. The ongoing WOMAN trial, coordinated by LSHTM and involving\u000d\u000a      13 partners, attracted &#163;3.7m in funding. CRASH-3, to investigate TXA for\u000d\u000a      treatment of significant traumatic brain injury, has received &#163;400,000 for\u000d\u000a      the pilot phase.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research by LSHTM has alerted international health bodies, the UK and US\u000d\u000a      militaries, politicians and doctors around the world to a new trauma\u000d\u000a      treatment that could save over 100,000 lives each year. A proactive\u000d\u000a      advocacy campaign following the publication of the CRASH-2 trial in The\u000d\u000a        Lancet has secured media coverage in major global news outlets, the\u000d\u000a      inclusion of the drug tranexamic acid (TXA) on the WHO List of Essential\u000d\u000a      Medicines and direct endorsements from WHO officials, UK ministers and\u000d\u000a      army figures. TXA was the first drug to be approved under the UK\u000d\u000a      government's Medicines Innovation Scheme.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000d\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a3.1 CRASH-2 Collaborators (2010) Effects of tranexamic acid on death,\u000d\u000a      vascular occlusive events, and blood transfusion in trauma patients with\u000d\u000a      significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial,\u000d\u000a      Lancet, 376(9734): 23-32, doi:10.1016\/S0140-6736(10)60835-5.\u000d\u000a      Citation count: 262\u000d\u000a    \u000a\u000a3.2 Ker, K, Kiriya, J, Perel, P, Edwards, P, Shakur, H and Roberts, I\u000d\u000a      (2012) Avoidable mortality from giving tranexamic acid to bleeding trauma\u000d\u000a      patients: an estimation based on WHO mortality data, a systematic\u000d\u000a      literature review and data from the CRASH-2 trial, BMC Emergency\u000d\u000a        Medicine, 12(3), doi:10.1186\/1471-227X-12-3. Citation count: 12\u000d\u000a    \u000a\u000a3.3 CRASH-2 collaborators (2011) The importance of early treatment with\u000d\u000a      tranexamic acid in bleeding trauma patients: an exploratory analysis of\u000d\u000a      the CRASH-2 randomised controlled trial, Lancet, 377(9771):\u000d\u000a      1096-1101, doi:10.1016\/S0140-6736(11)60278-X. Citation count: 97\u000d\u000a    \u000a\u000a3.4 Roberts, I, Perel, P, Prieto-Merino, D, Shakur, H, Coats, T, Hunt,\u000d\u000a      BJ, Lecky, F, Brohi K and Willett, K, on behalf of the CRASH-2\u000d\u000a      Collaborators (2012) Effect of tranexamic acid on mortality in patients\u000d\u000a      with traumatic bleeding: prespecified analysis of data from randomised\u000d\u000a      controlled trial, BMJ, 345(e5839), doi:10.1136\/bmj.e5839. Citation\u000d\u000a      count: 6\u000d\u000a    \u000a\u000a3.5 Guerriero, C, Cairns, J, Perel, P, Shakur, H and Roberts I, on behalf\u000d\u000a      of the CRASH-2 trial collaborators (2011) Cost-effectiveness analysis of\u000d\u000a      administering tranexamic acid to bleeding trauma patients using evidence\u000d\u000a      from the CRASH-2 trial, PLoS One, 6(5): e18987,\u000d\u000a      doi:10.1371\/journal.pone.0018987. Citation count: 20\u000d\u000a    \u000a\u000a3.6 CRASH-2 Collaborators (Intracranial Bleeding Study) (2011) Effect of\u000d\u000a      tranexamic acid in traumatic brain injury: a nested randomised, placebo\u000d\u000a      controlled trial (CRASH-2 Intracranial Bleeding Study), BMJ,\u000d\u000a      343(d3795), doi:10.1136\/bmj.d3795. Citation count: 0\u000d\u000a    \u000aKey funding\u000d\u000a    Roberts, Shakur, Coats, Hunt, The CRASH-2 Trial, NIHR, 2007-2010, &#163;2.5m.\u000d\u000a      Additional funding from Pfizer, Novo Nordisk, The BUPA Foundation, The\u000d\u000a      Moulton Charitable Trust.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000d\u000a    5.1 Inclusion of tranexamic acid on WHO List of Essential Medicines, http:\/\/www.who.int\/selection_medicines\/committees\/expert\/18\/en\/index.html\u000d\u000a      (accessed 20 September 2013).\u000d\u000a    5.2 BBC News report and UK Health Minister endorsement http:\/\/www.bbc.co.uk\/news\/10311371\u000d\u000a      (accessed 20 September 2013).\u000d\u000a    5.3 British Army starts using tranexamic acid (quotes Surgeon-General) http:\/\/www.youtube.com\/watch?v=oj6P2cwwRYw\u000d\u000a      (accessed 20 September 2013).\u000d\u000a    5.4 US Army starts using tranexamic acid: Morrison, JJ, Dubose, JJ,\u000d\u000a      Rasmussen, TE and Midwinter, MJ (2012) Military Application of Tranexamic\u000d\u000a      Acid in Trauma Emergency Resuscitation (MATTERs) study, JAMA Surgery,\u000d\u000a      147(2): 113-119, doi:10.1001\/archsurg.2011.287.\u000d\u000a    5.5 The BMJ Awards: Research paper of the year winner 2011, http:\/\/thebmjawards.bmj.com\/previous-winners\/2011\/research-paper-of-the-year\u000d\u000a      (accessed 21 November 2013).\u000d\u000a    5.6 Royal College of Paediatrics and Child Health guidelines (2012) Evidence\u000a        Statement: Major Trauma and the Use of Tranexamic Acid in Children,\u000d\u000a      November. London: Royal College of Paediatrics and Child Health, http:\/\/www.rcpch.ac.uk\/system\/files\/protected\/page\/121112_TXA%20evidence%20statement_final\u000a        %20v2.pdf (accessed 11 September 2013).\u000d\u000a    5.7 Independent newspaper article, http:\/\/www.independent.co.uk\/life-style\/health-and-\u000afamilies\/health-news\/from-afghanistan-to-the-ambulance-the-warzone-drug-that-will-save-\u000a        hundreds-of-lives-6285560.html (accessed 20 September 2013).\u000d\u000a    5.8 New York Times article on Tranman plus Youtube clip, http:\/\/www.nytimes.com\/2011\/11\/22\/health\/trauma-to-highlight-benefits-of-a-clotting-drug-a-\u000a        cartoon-figure-dies-a-messy-death.html (accessed 20 September 2013).\u000d\u000a    5.9 WOMAN trial http:\/\/www.bbc.co.uk\/news\/health-11177856\u000d\u000a      (accessed 20 September 2013). \u000d\u000a    ","Title":"\u000d\u000a    Identifying and promoting a new trauma treatment which could save over\u000d\u000a      100,000 lives a year\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Traumatic bleeding, mostly from road traffic accidents or violent crime,\u000d\u000a      kills around 2m people worldwide each year, with over 90% of deaths in\u000d\u000a      low- and middle-income countries.\u000d\u000a    Shosuke and Utako Okamoto discovered in 1962 that TXA is a potent\u000d\u000a      inhibitor of fibrinolysis. Since then it has been used to treat heavy\u000d\u000a      menstrual periods, for dental extraction in people with bleeding\u000d\u000a      disorders, and to reduce blood transfusion in surgical patients. Because\u000d\u000a      similar haemostatic mechanisms are activated in surgery and trauma,\u000d\u000a      researchers from LSHTM hypothesised that TXA might also reduce bleeding in\u000d\u000a      trauma patients, up to one third of whom die from acute haemorrhage.\u000d\u000a    A group of academics and doctors, led by Professor Ian Roberts (LSHTM\u000d\u000a      since 2001) and Senior Lecturer Haleema Shakur (LSHTM since 2002 then\u000d\u000a      Trial Manager), secured &#163;2.5m in funding from the National Institute of\u000d\u000a      Health Research in 2007 to carry out the CRASH-2 trial &#8212; a randomised\u000d\u000a      controlled trial of the effects of the early administration of TXA on\u000d\u000a      death, vascular occlusive events and blood transfusion. Other\u000d\u000a      collaborators were Professor Tim Coats, University of Leicester, and\u000d\u000a      Professor Beverley Hunt, Guy's and St Thomas' Trust. The team also secured\u000d\u000a      around &#163;850,000 in additional funding.\u000d\u000a    The CRASH-2 trial was designed and coordinated by LSHTM and carried out\u000d\u000a      within a global network of trauma hospitals. A total of 20,211 adult\u000d\u000a      patients with significant traumatic bleeding were recruited from 274\u000d\u000a      hospitals in 40 countries. They were injected with 1g of TXA or placebo\u000d\u000a      within a few hours of being injured followed by another 1g in a drip over\u000d\u000a      the next eight hours, or a matching placebo. The researchers found that\u000d\u000a      TXA reduced the chances of death from severe blood loss by one third, with\u000d\u000a      no side effects. The results were published in The Lancet3.1\u000d\u000a      in March 2010 (and subsequently republished in many languages), and the\u000d\u000a      academics recommended the inclusion of TXA on the WHO List of Essential\u000d\u000a      Medicines. They subsequently estimated that TXA could prevent over 100,000\u000d\u000a      deaths every year across the world3.2 and in countries like\u000d\u000a      India and China it could save tens of thousands of lives each year.\u000d\u000a    A subsequent analysis of the CRASH-2 trial published in The Lancet3.3\u000d\u000a      in 2011 showed strong evidence that the effect of TXA on death due to\u000d\u000a      bleeding varied according to the time from injury to treatment, with early\u000d\u000a      treatment (within an hour from injury) significantly more effective. A\u000d\u000a      second pre-specified analysis, published in the BMJ, showed that\u000d\u000a      TXA can be administered safely to a wide spectrum of patients with\u000d\u000a      traumatic bleeding and should not be restricted to the most severely\u000d\u000a      injured.3.4 A cost effectiveness analysis3.5 showed\u000d\u000a      that TXA administration is highly cost effective in high-, middle- and\u000d\u000a      low-income countries. A study3.6 of the effect of TXA in\u000d\u000a      traumatic brain injury &#8212; CRASH-2 Intracranial Bleeding Study &#8212; concluded\u000d\u000a      that neither moderate benefits nor moderate harmful effects of TXA in\u000d\u000a      patients with traumatic brain injury could be excluded; further clinical\u000d\u000a      trials are needed for this type of patient.\u000d\u000a    "},{"CaseStudyId":"41459","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    Zimmerman's findings have put the issue of human trafficking and health\u000a      on the international\u000a      agenda, and important changes have been made in how trafficked women are\u000a      treated by\u000a      government departments and law enforcement agencies overseas and in the\u000a      UK.\u000a    Zimmerman's work on health, psychological trauma and trafficking was the\u000a      only research cited in a\u000a      text box in the introduction to the US State Department's Trafficking\u000a        in Persons Report, the US\u000a      government's principal diplomatic tool to engage other countries on human\u000a      trafficking5.1 and the\u000a      most recognised annual, global report on trafficking. The text states (p.\u000a      41): `Research has shown\u000a      a clear link between sex trafficking and both pre-trafficking domestic\u000a      violence and trafficking-related\u000a      gender-based violence. Cathy Zimmerman, a noted authority on victim\u000a      trauma, identified\u000a      domestic and sexual violence as a key \"push\" factor that makes a woman\u000a      vulnerable to trafficking.'\u000a    The anti-human trafficking manual for criminal justice practitioners\u000a      produced by the UN Office of\u000a      Drugs and Crime (UNODC) drew directly from Zimmerman's work in the module\u000a      on the\u000a      psychological reactions of victims.5.2 Similarly, the\u000a      Organisation for Security and Co-operation in\u000a      Europe (OSCE) highlighted Zimmerman's findings in its report, Combating\u000a        Trafficking as Modern-Day\u000a        Slavery.5.3 Former OSCE Special Representative on\u000a      Combating Trafficking in Human Beings\u000a      stated to Zimmerman in 2012: `The fact that more and more countries are\u000a      providing health services\u000a      - not just emergency care &#8212; free of charge to victims of trafficking, and\u000a      that victims of trafficking are\u000a      no longer being forced to return to states where their needs cannot be\u000a      met, has its roots &#8212; to a\u000a      large extent &#8212; in Cathy Zimmerman's work. She has been able to provide\u000a      sustainable insight and\u000a      inspiration for stakeholders, activists, and policy-makers &#8212; including\u000a      myself.'5.4\u000a    In the UK, Department of Health (DH) staff have consulted regularly with\u000a      Zimmerman and her\u000a      colleagues, and she contributed significantly to the report for the\u000a      Taskforce on the Health Aspects\u000a      of Violence Against Women and Children through membership of the Harmful\u000a      Traditional Practices\u000a      and Human Trafficking subgroup.5.5\u000a    Zimmerman translated her findings into an International Organization for\u000a      Migration (IOM) handbook\u000a      to guide health providers treating trafficked people.5.6 This\u000a      has been translated into at least five\u000a      languages and was viewed 29,643 times (downloaded 4,199) between July 2009\u000a      and June 2012\u000a      on IOM's website. In 2011, training materials complementing the\u000a      handbook were translated into\u000a      Spanish and Arabic and pilot-tested by Zimmerman, IOM and local health\u000a      authorities in the Middle\u000a      East, Caribbean and Central America, with 200 health providers receiving\u000a      training.\u000a    Zimmerman co-authored the Ethical and Safety Recommendations for\u000a        Interviewing Trafficked\u000a        Women for WHO5.7 which was translated into eight\u000a      languages. Although originally produced in\u000a      2003, this remains the main WHO document on trafficking in women.\u000a      Zimmerman also authored\u000a      WHO's fact sheet on human trafficking (downloaded 2,533 times between\u000a      November 2012 and\u000a      February 2013) and the human trafficking page for Public Health England.\u000a    Many law enforcement training materials in the UK, Europe and other\u000a      regions have incorporated\u000a      Zimmerman's findings and their potential implications for investigations,\u000a      including the UK's Central\u000a      Police Training and Development Authority (Centrex, internal police\u000a      documents), UNODC and\u000a      OSCE.\u000a    Zimmerman's research has contributed to policy changes resulting in\u000a      significant practical benefits\u000a      for trafficked women. Amnesty UK and other advocacy groups used\u000a      Zimmerman's evidence to\u000a      persuade the Home Office to extend the victim `recovery and reflection'\u000a      period. Amnesty's former\u000a      Women's Division Director states: `LSHTM's evidence enabled Amnesty to\u000a      promote support for\u000a      victims as primarily a health rather than an immigration issue and thus\u000a      was central to the UK\u000a      government agreeing to sign the Council of Europe Convention on Action\u000a      Against Trafficking and\u000a      extend the minimum reflection period.'5.8 Although legislators\u000a      stopped short of extending the period\u000a      to a full 90 days, it was extended to 45, going beyond the minimum 30 days\u000a      required in the\u000a      European Convention Against Trafficking. Ratified in December 2008,\u000a      the new regulations allow for\u000a      the period to be prolonged further if the victim's health and other\u000a      circumstances require it. A former\u000a      Minister of State (Home Office) (Policing, Crime &amp; Security) commented\u000a      that evidence from\u000a      Zimmerman's research `indeed contributed to action both at the UK and EU\u000a      level'.5.9\u000a    Zimmerman has regularly conducted police training on victim health and\u000a      care for police personnel\u000a      associated with the UK Human Trafficking Centre (UKHTC), influencing the\u000a      `victim-centred'\u000a      approach, including delayed timing of full interviews with trafficking\u000a      victims to foster recovery time\u000a      and more consistent testimony. Based on her research, Dr Zimmerman has\u000a      offered training\u000a      sessions over a number of years for police personnel dealing with cases of\u000a      trafficking, contributing\u000a      to our understanding of a victim's needs and a victim-centred approach.5.10\u000a    ","ImpactSummary":"\u000a    Research conducted by LSHTM put the physical and mental health of women\u000a      trafficked for sexual\u000a      exploitation firmly on the international agenda. The research generated\u000a      the first-ever guidance for\u000a      health providers caring for trafficking victims and internationally\u000a      recognised ethical and safety\u000a      recommendations from WHO. The research resulted in the UK giving\u000a      trafficked women a longer\u000a      period to decide whether to cooperate with any criminal investigation\u000a      against their traffickers, and\u000a      police training on victim symptoms and interview timing to support\u000a      recovery. Findings and health\u000a      care recommendations have been incorporated into guidance materials\u000a      globally.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1 Zimmerman, C, Hossain, M, Yun, K, Gajdadziev, V, Guzun, N,\u000a      Tchomarova, M, Ciarrocchi, RA,\u000a      Johansson, A, Kefurtova, A, Scodanibbio, S, Motus, MN, Roche, B, Morrison,\u000a      L and Watts, C\u000a      (2008) The health of trafficked women: a survey of women entering\u000a      posttrafficking services in\u000a      Europe, American Journal of Public Health, 98(1): 55-59,\u000a      doi:10.2105\/AJPH.2006.108357.\u000a    \u000a\u000a3.2 Hossain, M, Zimmerman, C, Abas, M, Light, M and Watts, C (2010) The\u000a      Relationship of trauma\u000a      to mental disorders among trafficked and sexually exploited girls and\u000a      women, American Journal of\u000a        Public Health, 100(12): 2442-2449, doi:10.2105\/AJPH.2009.173229.\u000a    \u000a\u000a3.3 Zimmerman, C, Hossain, M and Watts, C (2011) Human trafficking and\u000a      health: a conceptual\u000a      model to inform policy, intervention and research, Social Science\u000a        &amp; Medicine, 73(2): 327-335,\u000a      doi:10.1016\/j.socscimed.2011.05.028.\u000a    \u000a\u000a3.4 Oram, S, St&#246;ckl, H, Busza, B, Howard, LM and Zimmerman, C (2012)\u000a      Prevalence and risk of\u000a      violence and the physical, mental, and sexual health problems associated\u000a      with human trafficking:\u000a      systematic review, PLoS Medicine, 9(5): e1001224,\u000a      doi:10.1371\/journal.pmed.1001224.\u000a    \u000aKey grants\u000a    &#8226; Zimmerman and Watts, Prospective, Multi-site Survey on Health Risks and\u000a      Consequences of\u000a      Women Trafficked for Forced Sex Work, European Commission, Daphne\u000a      Programme, 11\/2005-12\/2007,\u000a      &#8364;250,000.\u000a    &#8226; Zimmerman and Watts, Qualitative Study on Health Risks and Consequences\u000a      of Trafficking in\u000a      Women, European Commission, Daphne Programme, 8\/2002-9\/2005, &#8364;150,000.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    5.1 US Department of State (2009) Trafficking in Persons Report 2009.\u000a      Washington, DC: US\u000a      Department of State, http:\/\/www.state.gov\/j\/tip\/rls\/tiprpt\/2009\/\u000a      (accessed 12 September 2013)\u000a      (Zimmerman's work cited pp. 15, 41).\u000a    5.2 UNODC (2009) Anti-human Trafficking Manual for Criminal Justice\u000a        Practitioners: Module 3:\u000a        Psychological Reactions of Victims of Trafficking in Persons.\u000a      Vienna: UNODC,\u000a      http:\/\/www.unodc.org\/documents\/human-trafficking\/TIP_module3_Ebook.pdf\u000a      (accessed 12\u000a      September 2013).\u000a    5.3 Office of the Special Representative and Co-ordinator for Combating\u000a      Trafficking in Human\u000a      Beings (2010) Combating Trafficking as Modern-Day Slavery: A Matter of\u000a        Rights, Freedoms and\u000a        Security. Vienna: OSCE, http:\/\/www.osce.org\/cthb\/74730\u000a      (accessed 12 September 2013)\u000a      (Zimmerman's work cited pp. 22, 27, 63).\u000a    5.4 Former OSCE Special Representative on Combating Trafficking in Human\u000a      Beings.\u000a    5.5. Taskforce on the Health Aspects of Violence Against Women and\u000a      Children (2010) Report from\u000a        the Harmful Traditional Practices and Human Trafficking Sub-group:\u000a        Responding to Violence\u000a        against Women and Children &#8212; The role of the NHS,\u000a      http:\/\/fflm.ac.uk\/upload\/documents\/1268670730.pdf\u000a      (accessed 12 September 2013) (Zimmerman's\u000a      work cited pp. 11, 17, membership of subgroup p. 43).\u000a    5.6. International Organization for Migration, UN Global Initiative to\u000a      Fight Human Trafficking &amp;\u000a      LSHTM (2009) Caring for Trafficked Persons: Guidance for Health\u000a        Providers,\u000a      http:\/\/www.unodc.org\/documents\/hiv-aids\/publications\/Caring_for_Trafficked_Persons_Guidance_for_Health_Providers_2009.pdf\u000a      (accessed 12 September 2013).\u000a    5.7 Zimmerman, C and Watts, C (2003) WHO Ethical and Safety\u000a        Recommendations for\u000a        Interviewing Trafficked Women. London: WHO, LSHTM &amp; Daphne\u000a      Programme of the European\u000a      Commission,\u000a      http:\/\/www.who.int\/gender\/documents\/en\/final%20recommendations%2023%20oct.pdf\u000a      (accessed\u000a      12 September 2013).\u000a    5.8 Former Women's Division Director, Amnesty.\u000a    5.9 Former Minister of State (Home Office) (Policing, Crime &amp;\u000a      Security).\u000a    5.10 Former Tactical Adviser to the United Kingdom Human Trafficking\u000a      Centre.\u000a    ","Title":"\u000a    Securing action to address the health needs of trafficked women\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Millions of women and girls are thought to be trafficked globally,\u000a      including within the EU, and the\u000a      UK is no exception. Violence, deprivation and exploitation are key\u000a      features of human trafficking.\u000a      The resulting damage to women's health and wellbeing is often profound and\u000a      enduring.\u000a    Prior to research led by Dr Cathy Zimmerman, Senior Lecturer working with\u000a      Charlotte Watts\u000a      (LSHTM since 2000, then Research Fellow), the health of trafficked persons\u000a      and their particular\u000a      medical needs were widely neglected within policy discussions and guidance\u000a      documents. Pre-2006\u000a      editions of the US State Department Trafficking in Persons Report,\u000a      the most comprehensive global\u000a      trafficking report, are a case in point: the focus of anti-trafficking\u000a      initiatives was immigration and law\u000a      enforcement.\u000a    As Zimmerman showed in the research on which this case study is based,\u000a      the trafficking of women\u000a      into forced sex work has serious implications for their physical, sexual\u000a      and, above all, mental\u000a      health.\u000a    Zimmerman initially led a two-year qualitative study on women's health\u000a      and trafficking in the EU in\u000a      2000-2003 with the aim of highlighting the health risks and consequences\u000a      of trafficking in women\u000a      and providing information on their health needs for service providers, law\u000a      enforcement officials and\u000a      policy-makers.\u000a    A second study, Stolen Smiles, carried out in 2003-2005, surveyed\u000a      207 women in seven European\u000a      cities who had either been trafficked into sex work or sexually abused as\u000a      domestic labourers.\u000a      Results of this study, the first quantitative survey of the physical and\u000a      mental health of trafficked\u000a      persons, were produced as a report by LSHTM and highlighted in a Lancet\u000a      editorial in 2006.The\u000a      study, funded by the European Commission and the International\u000a      Organization for Migration, was\u000a      the first to employ rigorous epidemiological methods to investigate the\u000a      physical, sexual and mental\u000a      health of trafficked women and adolescents.\u000a    The Stolen Smiles survey found that trafficked women's physical\u000a      and sexual health problems\u000a      include high levels of injury and sexually transmitted infections, for\u000a      which the women are often\u000a      unable to seek treatment.3.1 However, the most persistent\u000a      problems are related to mental health.3.2\u000a      Up to 14 days after entry into post-trafficking care, 58% of women showed\u000a      symptoms associated\u000a      with post-traumatic stress disorder (PTSD). Symptoms of depression and\u000a      anxiety were in the 90th\u000a      percentile compared to a general population of adult women who had not\u000a      been trafficked. For over\u000a      50% of trafficked women, these symptoms did not decrease significantly\u000a      even 90 days after\u000a      entering an assistance programme.\u000a    Based on this research, Zimmerman, collaborating with Amnesty UK,\u000a      recommended that the\u000a      `recovery and reflection' period &#8212; the period trafficked people are given\u000a      to decide on whether to\u000a      cooperate with any criminal investigation &#8212; should be extended to at least\u000a      90 days to ensure that\u000a      the women's health had improved sufficiently for them to be able to make\u000a      informed and thoughtful\u000a      choices.\u000a    Follow-on research, designed to strengthen the knowledge base related to\u000a      human trafficking and\u000a      health and further raise awareness, has provided a basis for conceptual\u000a      thinking about policy,\u000a      implementation and research,3.3 and undertaken a systematic\u000a      review of the prevalence and risk of\u000a      violence and the physical, mental, and sexual health problems associated\u000a      with human trafficking.3.4\u000a    "},{"CaseStudyId":"41460","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1668284","Name":"Taiwan"},{"GeoNamesId":"1643084","Name":"Indonesia"}],"Funders":[],"ImpactDetails":"\u000a    The research described above has influenced both individual countries and\u000a      international organisations to modify their influenza preparedness\u000a      policies and plans. The following aspects are key.\u000a    Improving national pandemic planning and response capacities\u000a    Since 2008, research findings on existing plans for an influenza\u000a      pandemic, together with further capacity evaluations, have led some\u000a      governments in Europe and Southeast Asia to significantly alter their\u000a      influenza pandemic plans.\u000a    In the UK, for example, the published results on pandemic planning in\u000a      Europe led the government, through the Cabinet Office, to commission Coker\u000a      and Mounier-Jack to help develop cross-government strategy on human\u000a      pandemic and avian influenza.5.1 In addition, Mounier-Jack\u000a      became specialist adviser to the House of Lords inquiry into pandemic\u000a      preparedness in the UK in 2008, which stated: `we are enormously grateful\u000a      for her assistance'.5.2 During this inquiry she provided\u000a      insight and advice to scrutinise whether the response to the 2009 H1N1\u000a      pandemic was adequate.5.2 In 2011, she was also appointed\u000a      specialist adviser to a House of Commons inquiry reviewing scientific\u000a      advice and evidence in emergencies,5.3 and she contributed to\u000a      Dame Deirdre Hine's report on the H1N1 pandemic response.5.4\u000a      Specific recommendations to which she contributed included clarifying the\u000a      function and operation of the national flu line service and the need to\u000a      ensure adequate capacity for critical care, which was responded to by the\u000a      government.\u000a    An evaluation led by collaborators in the AsiaFluCap project revealed a\u000a      number of impacts in several Asian countries.5.5 Some of these\u000a      impacts occurred even before the outputs detailed in Section 3 had been\u000a      published, due to strong and ongoing engagement with policy-makers\u000a      throughout the programme of work. In Taiwan, supplies of the anti-viral\u000a      drug, Osetamivir, were redistributed to ensure more equitable coverage\u000a      across administrative areas.5.6 Policies in Taiwan were also\u000a      revised to improve strategies for risk communication,5.6 after\u000a      these were identified as a weakness by AsiaFluCap. In Indonesia, the\u000a      research led to a countrywide `Health Facility Framework Survey'\u000a      (`RIFASKES') by the National Institute for Health Research and Development\u000a      (NIHRD). This, modelled on work conducted through AsiaFluCap, was carried\u000a      out in 2011 to enumerate and map health care resources across the country\u000a      and is informing policy on the allocation of health care resources across\u000a      Indonesia.5.7 In Cambodia, policy-makers are drawing upon the\u000a      research to support decisions around investments for preparedness.5.8\u000a    Based on responses of policy-makers, the AsiaFluCap evaluation also\u000a      concluded that the project had `strengthened cooperation and information\u000a      exchange between national ministries and government institutions, national\u000a      communicable disease control institutions, policy-makers, district health\u000a      care administrations and hospital administrations'.5.5 This is\u000a      echoed by the former Director of the Taiwan CDC who writes: `I applaud\u000a      Professor Coker's coordination skills to bring so many countries with\u000a      various cultures together, which in fact has also resulted in an informal\u000a      yet useful network to fight future infectious diseases in the region.'5.6\u000a    An innovative software tool for influenza-related resource allocation\u000a      developed by Coker and colleagues on the basis of the research was\u000a      launched online in 2012 and allows policy-makers and other stakeholders to\u000a      estimate and display the availability, needs and gaps of 28 key health\u000a      care resources for a selected pandemic scenario in a country or region\u000a\u0009  (http:\/\/www.biomedcentral.com\/1471-2458\/12\/870).\u000a      The tool was considered among project partners, including several\u000a      policy-makers, to be very useful for informing policy decisions for\u000a      resource allocation, particularly at the national level and for major\u000a      hospitals.\u000a    Shaping global policy on influenza control\u000a    At the invitation of the UN System Coordinator for Influenza, Coker and\u000a      his team have contributed time and personnel to feed research findings\u000a      into the annual UN\/World Bank reports 2006-2010. The 2010 report\u000a      acknowledges the contribution of Coker's research, noting its usefulness\u000a      to `address priority setting for strengthening public health systems' and\u000a      calling upon the greater use of approaches such as those of his team to\u000a      `strengthen allocation of funding ... for countries with scarce\u000a      resources.'5.9\u000a    ","ImpactSummary":"\u000a    Research conducted by LSHTM into how governments and international\u000a      organisations are preparing for an influenza pandemic has made an\u000a      important contribution towards efforts to avoid the risks of up to 150m\u000a      deaths anticipated by WHO in the event of such a pandemic. Governments,\u000a      including the UK, and global institutions, have made policy changes and\u000a      resource allocation decisions directly as a result of this research and\u000a      technical advice.\u000a    ","ImpactType":"Political","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1 Mounier-Jack, S and Coker RJ (2006) How prepared is Europe for\u000a      pandemic influenza? Analysis of national plans, Lancet, 367(9520):\u000a      1405-1411, doi:10.1016\/S0140-6736(06)68511-5.\u000a    \u000a\u000a3.2 Coker R and Mounier-Jack S (2006) Pandemic influenza preparedness in\u000a      the Asia-Pacific region, Lancet, 368(9538): 886-889,\u000a      doi:10.1016\/S0140-6736(06)69209-X.\u000a    \u000a\u000a3.3 Putthasri, W, Lertiendumrong, J, Chompook, P, Tangcharoensathien, V\u000a      and Coker R (2009) Capacity of Thailand to contain an emerging influenza\u000a      pandemic, Emerging Infectious Diseases, 15(3): 423-432,\u000a      doi:10.3201\/eid1503.080872.\u000a    \u000a\u000a3.4 Rudge, JW, Hanvoravongchai, P, Krumkamp, R, Chavez, I, Adisasmito, W,\u000a      Ngoc Chau, P, Phommasak, B, Putthasri, W, Chin-Shui S, Stein, M, Timen, A,\u000a      Touch, S, Reintjes, R and Coker, R, on behalf of the AsiaFluCap Project\u000a      Consortium (2012) Health system resource gaps and associated mortality\u000a      from pandemic influenza across six Asian territories, PLoS One,\u000a      7(2): e31800, doi:10.1371\/journal.pone.0031800.\u000a    \u000a\u000a3.5 Drake, TL, Chalabi, Z and Coker R (2012) Cost-effectiveness analysis\u000a      of pandemic influenza preparedness: what's missing?, Bulletin of the\u000a        World Health Organization, 90(12): 940-941,\u000a      doi:10.2471\/BLT.12.109025.\u000a    \u000a\u000a3.6 Watson, SK, Rudge JW and Coker R (2013) Health systems' `surge\u000a      capacity': state of the art and priorities for future research, Milbank\u000a        Quarterly, 91(1): 78-122, doi:10.1111\/milq.12003.\u000a    \u000aKey grants\u000a    &#8226; Coker, Heath System Analysis to Support Capacity Development in\u000a      Response to the Threat of Pandemic Influenza in Cambodia and Laos,\u000a      Rockefeller Foundation, 2008-2011, $619,270.\u000a    &#8226; Coker, Health System Analysis to Support Capacity Development to\u000a      Respond to Pandemic Influenza in Asia, European Commission, 2008-2011,\u000a      &#8364;3,896,000.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"99","Subject":"Other Medical and Health Sciences"}],"Sources":"\u000a    5.1 Mounier-Jack, S and Coker, RJ (2008) UK Cross-government\u000a        International Strategy on Human Pandemic and Avian Influenza,\u000a      Cabinet Office briefing paper, April. London: Cabinet Office.\u000a    5.2 House of Lords, Science and Technology Committee (2009) 3rd\u000a        Report of Session 2008\/2009: Pandemic Influenza &#8212; Follow-up (see p.\u000a      7, para 14, p. 15, p. 49, Q51),\u000a      http:\/\/www.publications.parliament.uk\/pa\/ld200809\/ldselect\/ldsctech\/155\/155.pdf.\u000a    5.3 House of Commons Science and Technology Committee (2011) Third\u000a        Report: Scientific Advice and Evidence in Emergencies. London: House\u000a      of Commons Science and Technology Committee (see p. 6, para 6),\u000a      http:\/\/www.publications.parliament.uk\/pa\/cm201011\/cmselect\/cmsctech\/498\/498.pdf).\u000a    5.4 Hine, D. and Pandemic Flu Response Review Team (2010) The 2009\u000a        Influenza Pandemic: An Independent Review of the UK Response to the 2009\u000a        Influenza Pandemic. London: Cabinet Office, p. 151, http:\/\/www.dhsspsni.gov.uk\/the2009influenzapandemic_acc.pdf\u000a      (accessed 12 September 2013).\u000a    5.5 Ahmad, A, Krumkamp, R, Hanvoravongchai, P, Coker, R and Reintjes R\u000a      (2011) The AsiaFluCap Project: Evaluation. Hamburg: http:\/\/www.cdprg.org\/resources\/AsiaFluCap%20-\u000a        %20Final%20Evaluation%20Report%20-%2010.04.pdf (accessed 12\u000a      September 2013).\u000a    5.6 Former Director, Taiwan Center for Disease Control.\u000a    5.7 Director of Partnership and Business Incubator, Universitas\u000a      Indonesia.\u000a    5.8 Director of Communicable Disease Control Department, Ministry of\u000a      Health, Cambodia.\u000a    5.9 UN System Influenza Coordination and World Bank (2010) Animal and\u000a      Pandemic Influenza: A Framework for Sustaining Momentum, 5th Global\u000a      Progress Report. Bangkok: UN\/World Bank, http:\/\/siteresources.worldbank.org\/EXTAVIANFLU\/Resources\/3124440-\u000a      1172616490974\/Fifth_Global_Progress_Report_July_2010.pdf\u000a      (accessed 24 October 2013) (see p. 158, refs 86, 88, 91 and\u000a      acknowledgements, xiii).\u000a    ","Title":"\u000a    Supporting influenza pandemic preparedness\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    WHO estimates that a pandemic could cause up to 150m deaths worldwide.\u000a      Unsurprisingly, therefore, governments have spent billions preparing for\u000a      such a pandemic. Professor Richard Coker (LSHTM since 2001, then Senior\u000a      Lecturer) has focused his research on preparedness for influenza\u000a      pandemics.\u000a    In 2005\/2006, Coker and Mounier-Jack (Lecturer, LSHTM since 2005, then\u000a      Research Fellow) developed an innovative framework to analyse national\u000a      strategic preparedness for an influenza pandemic, which was used to\u000a      evaluate plans produced by countries in regions across the world &#8212; for\u000a      example, Europe3.1 and Asia-Pacific.3.2 In 21\u000a      European countries they found that, although preparation was good in some\u000a      areas, maintenance of essential services, putting plans into action and\u000a      public health interventions were inadequate. Plans for the timely\u000a      distribution of available medical supplies were notably absent, and\u000a      substantial variations existed between countries.\u000a    The evaluations in other parts of the world showed that low-and\u000a      middle-income countries were much less well prepared than European\u000a      countries. It was clear that, in addition to evaluating national plans,\u000a      novel frameworks were needed to evaluate systematically, and identify\u000a      strategies for improving, the capacity of countries to implement their\u000a      plans. This was (and still is) of particular importance in Southeast Asia,\u000a      where conditions are fertile for the emergence of novel (and possibly\u000a      highly lethal) influenza viruses with pandemic potential, not least due to\u000a      the continued circulation of the highly pathogenic avian influenza H5N1.\u000a    In 2007, Coker and country partners conducted a pilot project in Thailand\u000a      using three pandemic scenarios to determine resource needs, availability\u000a      and gaps.3.3 Building on this, the EU and the Rockefeller\u000a      Foundation funded the AsiaFluCap project which developed a framework to\u000a      assess pandemic response capacity, including analyses of governance\u000a      arrangements, modelling pandemic scenarios and mapping the availability\u000a      and shortages of key health care resources. Working directly with\u000a      policy-makers, Coker and colleagues applied the framework across six\u000a      Southeast Asian countries. They found marked inequities in the\u000a      distribution of resources within and between countries, and showed how\u000a      such inequities and resource gaps could greatly increase the number of\u000a      pandemic deaths, and how resolving resource mismatches and cross-border\u000a      sharing of resources might pay dividends.3.4\u000a    In 2011, Coker and colleagues built on the results of AsiaFluCap with two\u000a      detailed country case studies extending their analyses of pandemic\u000a      preparedness in Cambodia and Indonesia in collaboration with country\u000a      academics and government officials. In Cambodia, research focused on\u000a      prioritising pandemic mitigation investment options. Analysis of\u000a      stakeholder perspectives, H5N1 case outcomes and cost of illness, and\u000a      social contact patterns fed into a cost effectiveness mathematical model\u000a      characterising epidemiological, clinical and economic aspects of pandemic\u000a      influenza events and potential interventions. Methodological development\u000a      in the pandemic cost effectiveness models included a critical appraisal of\u000a      previous studies;3.5 inclusion of health system capacity within\u000a      the model; and an analysis of parameter uncertainty identifying\u000a      time-to-pandemic as a key driver of uncertainty in cost effectiveness\u000a      results.\u000a    The Indonesian study integrated influenza pandemic preparedness into a\u000a      multi-hazards framework to inform policy to enhance the health system's\u000a      ability to cope with other types of surges in demand.3.6\u000a    "},{"CaseStudyId":"41461","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000a    The research into PROMs carried out at LSHTM has led directly to their\u000a      introduction across the\u000a      NHS in England for four elective surgical procedures. It is the first time\u000a      that such measures have\u000a      been introduced on a nationwide scale with the aim of comparing the\u000a      performance of hospitals.\u000a    After Black and colleagues reported their research findings to the\u000a      Department of Health (DH) in\u000a      July 2007 and recommended the use of PROMs, the NHS Management Board\u000a      decided in\u000a      December 2007 that from April 2009 it would be mandatory for all NHS\u000a      patients undergoing the\u000a      designated operations to be invited to complete pre- and postoperative\u000a      PROMs questionnaires\u000a      (2009\/2010 NHS Operating Framework).5.1 The Chair of the DH\u000a      PROMs Stakeholder Reference\u000a      Group, Dr Andrew Vallance-Owen,5.2 recognised that `Nick Black\u000a      and his colleagues were pivotal in\u000a      giving the DH the confidence to start the National PROMs Programme', and\u000a      Lord Darzi, then\u000a      Minister of Health, addressing the Health Select Committee, stated: `I\u000a      think the best investment we\u000a      have made was actually in this report ... It is good reading actually. It\u000a      has come from LSHTM, and\u000a      was done jointly with the Royal College of Surgeons.'5.3 In\u000a      June 2008, High Quality Care for All (a\u000a      key policy document for the DH under the Labour government) provided a\u000a      strong endorsement:\u000a      `Just as important [as clinical measures] is the effectiveness of care\u000a      from the patient's own\u000a      perspective which will be measured through patient-reported outcome\u000a      measures.'5.4\u000a    During 2008-2009, Black and colleagues briefed Conservative shadow\u000a      ministers several times on\u000a      the opportunities that PROMs presented. Despite the change of government\u000a      in 2010, there has\u000a      been seamless political support for the use of PROMs; in July 2010 the\u000a      coalition government in its\u000a      White Paper, Equity and Excellence &#8212; Liberating the NHS stated:\u000a      `Information generated by\u000a      patients themselves will be critical ... and will include much wider use\u000a      of effective tools like\u000a      PROMs.' Ministers' positive views on PROMs were reflected in the NHS\u000a      Operating Framework\u000a      2011\/2012 (pp. 25-26)5.5 and by the inclusion of PROMs in the\u000a      NHS Outcomes Framework\u000a      2011\/2012 (p20).5.6\u000a    The value of PROMs for more sophisticated estimates of NHS productivity\u000a      has been recognised by\u000a      the Office of National Statistics5.7 and the National Audit\u000a      Office.5.8 The latter stated that, `When\u000a      producing productivity measures, new data on quality such as PROMs should\u000a      be considered' (p.\u000a      10).\u000a    The historical importance for surgeons was recognised in 2012 by\u000a      Professor Norman Williams,\u000a      President of the Royal College of Surgeons, when he stated that `the\u000a      introduction of PROMs has\u000a      been a major development in the history of surgery'.5.9 \u000a    Since April 2010, PROMs data have been published online (http:\/\/www.ic.nhs.uk\/proms)\u000a      for the\u000a      use of clinicians, managers, commissioners and the public. The huge scale\u000a      of the programme is\u000a      indicated by the 515,000 patients who participated over the first three\u000a      years (over 70% of those\u000a      eligible). In 2012, the DH's Branch Head of Strategy, Finance and NHS\u000a      Directorate, David Nuttall,\u000a      commended Black and colleagues' continued research after the introduction\u000a      of PROMs as having\u000a      `informed decisions on how data should best be analysed, presented and\u000a      used'.5.10\u000a    Another indication of success is that coronary revascularisation will be\u000a      included from 2014 using a\u000a      PROM (CROQ) developed at LSHTM. The University of Oxford has undertaken\u000a      preliminary work\u000a      on the use of PROMs in long-term conditions, but the impact described in\u000a      this case study is a\u000a      direct result of the work of LSHTM alone.\u000a    Black has raised awareness and understanding of PROMs among clinicians,\u000a      NHS managers and\u000a      patient organisations by chairing many national conferences and giving 11\u000a      keynote talks since\u000a      2009, including at the Royal College of Nursing (March 2010); the\u000a      Pre-Operative Assessment\u000a      Association (September 2010); the NHS Medical Directors Conference\u000a      (October 2010); the\u000a      National PROMs Summit (December 2012, 2013); and the International Society\u000a      for Quality in\u000a      Healthcare (October 2013) at which his contribution internationally was\u000a      recognised by the award of\u000a      the first Career Achievement Prize in PROMs, funded by the Medical\u000a      Outcomes Trust in the USA.\u000a      He is advising the US National Institute of Medicine and the American\u000a      Medical Association.\u000a    The introduction of PROMs was widely reported in the press, raising\u000a      awareness and understanding\u000a      among the general public. In a Financial Times report on 19 August\u000a      2011, Professor Sir Bruce\u000a      Keogh, Medical Director of the NHS, was quoted as saying he hoped PROMS\u000a      `would shift the\u000a      focus among doctors [away] from technocratic results, where an operation\u000a      was deemed a success\u000a      regardless of whether the patient remained in pain'.\u000a    ","ImpactSummary":"\u000a    Research carried out by LSHTM to develop and test patient reported\u000a      outcome measures (PROMs),\u000a      which measure health outcomes from the patient perspective, has\u000a      demonstrated the feasibility of\u000a      routinely collecting such measures before and after elective operations.\u000a      In 2009, the Labour\u000a      government mandated that PROMs should be collected on all NHS patients in\u000a      England undergoing\u000a      one of four surgical operations, a policy endorsed by the coalition\u000a      following the 2010 election. This\u000a      remains the only nationwide programme of its kind worldwide, providing\u000a      essential data for\u000a      comparing providers' performance, patient choice and other quality\u000a      improvement approaches.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    Development of PROMs\u000a    \u000a3.1 Lamping, DL, Rowe, P, Clarke, A, Black, N and Lessof, L (1998)\u000a      Development and validation of\u000a      the menorrhagia outcomes questionnaire, British Journal of Obstetrics\u000a        and Gynaecology, 105(7): 66-\u000a      779, doi: 10.1111\/j.1471-0528.1998.tb10209.x.\u000a    \u000a\u000a3.2 Schroter, S and Lamping, DL (2004) Coronary revascularisation outcome\u000a      questionnaire\u000a      (CROQ): development and validation of a new, patient based measure of\u000a      outcome in coronary\u000a      bypass surgery and angioplasty, Heart, 90(12): 1460-1466, doi:\u000a      10.1136\/hrt.2003.021899.\u000a    \u000aMethodological research\u000a    \u000a3.3 Hutchings, A, Grosse Frie, K, Neuburger, J, van der Meulen, J and\u000a      Black, N (2013) Late\u000a      response to patient-reported outcome questionnaires after surgery was\u000a      associated with worse\u000a      outcome, Journal of Clinical Epidemiology, 66(2): 218-225, doi:\u000a      10.1016\/j.jclinepi.2012.09.001.\u000a    \u000a\u000a3.4 Browne, JP, van der Meulen, JH, Lewsey, JD, Lamping, DL and Black, N\u000a      (2010) Mathematical\u000a      coupling may account for the association between baseline severity and\u000a      minimally important\u000a      difference values, Journal of Clinical Epidemiology, 63(8):\u000a      865-874,\u000a      doi:10.1016\/j.jclinepi.2009.10.004.\u000a    \u000aApplied research\u000a    \u000a3.5 Neuburger, J, Hutchings, A, van der Meulen, J and Black, N (2013)\u000a      Using patient-reported\u000a      outcomes (PROs) to compare the providers of surgery: does the choice of\u000a      measure matter?,\u000a      Medical Care, 51(6): 517-523, doi: 10.1097\/MLR.0b013e31828d4cde.\u000a    \u000a\u000a3.6 Hildon, Z, Allwood, D and Black, N (2012) Making data more\u000a      meaningful. Patients' views of the\u000a      format and content of quality indicators comparing health care providers,\u000a      Patient Education &amp;\u000a        Counselling, 88(2): 298-304, doi: 10.1016\/j.pec.2012.02.006.\u000a    \u000aKey grants\u000a    Lamping, Development and Validation of Disease-specific Patient-based\u000a      Measures of Outcome in\u000a      Plastic Surgery, British Association of Plastic Surgeons, Stoke Mandeville\u000a      Burns and Reconstructive\u000a      Surgery Research Trust, NHSE Anglia &amp; Oxford Regional Office R&amp;D,\u000a      1996-1998, &#163;47,890.\u000a    Black, Patient Reported Outcome Measures for Evaluating Elective Surgery:\u000a      Systematic Review of\u000a      Instruments and Development Study, Department of Health Policy Research\u000a      Programme, 2004-\u000a      2006, &#163;299,000.\u000a    Black, Patient Reported Outcome Measures: Methodological Development for\u000a      National PROMs\u000a      Programme, Department of Health, 2008-2012, &#163;817,000.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    5.1 Department of Health (2008) The Operating Framework for the NHS\u000a        in England 2009\/10: High\u000a        Quality Care for All. London: DH,\u000a      http:\/\/www.connectingforhealth.nhs.uk\/systemsandservices\/infogov\/links\/opframework20092010.pdf\u000a      (accessed 16 October 2013).\u000a    5.2 Chair, Department of Health PROMs Stakeholder Review Group.\u000a    5.3 Health Select Committee (2008) NHS Next Stage Review (HC 937-ii),\u000a      17 July, uncorrected\u000a      transcript of oral evidence,\u000a      http:\/\/www.publications.parliament.uk\/pa\/cm200708\/cmselect\/cmhealth\/uc937-ii\/uc93702.htm\u000a      (accessed 16 October 2013) (q.154).\u000a    5.4 Darzi, A (2008) High Quality Care for All: NHS Next Stage Review\u000a        Final Report, Cm 7432.\u000a      London: The Stationery Office, http:\/\/www.official-documents.gov.uk\/document\/cm74\/7432\/7432.pdf\u000a      (accessed 16 October 2013).\u000a    5.5 Department of Health (2010) The Operating Framework for the NHS\u000a        in England 2011\/12.\u000a      London: DH,\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/216187\/dh_122736.pdf\u000a      (accessed 16 October 2013).\u000a    5.6 Department of Health (2010) The NHS Outcomes Framework 2011\/12.\u000a      London: DH,\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/213789\/dh_123138.pdf\u000a      (accessed 16 October 2013).\u000a    5.7 Hardie, M, Cheers, J, Pinder, C and Qaiser, U (eds) (2011) Public\u000a        Service Output, Inputs and\u000a        Productivity: Healthcare. Newport: ONS, http:\/\/www.ons.gov.uk\/ons\/rel\/psa\/public-service-productivity\/healthcare-2011\/public-service-output--input-and-productivity.pdf\u000a      (accessed 16 October 2013).\u000a    5.8 National Audit Office (2010) Department of Health: Management of\u000a        NHS Hospital Productivity,\u000a      report by the Comptroller and Auditor General, HC 491, Session 2010-2011.\u000a      London: The\u000a      Stationery Office, http:\/\/www.nao.org.uk\/wp-content\/uploads\/2010\/12\/1011491.pdf\u000a      (accessed 16\u000a      October 2013).\u000a    5.9 President, Royal College of Surgeons.\u000a    5.10 Deputy Branch Head, Choice and PROMs, Commissioning Development,\u000a      Department of\u000a      Health.\u000a    \u000a    ","Title":"\u000a    Introducing patient reported outcome measures (PROMs) into the NHS\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Patients' views are essential to achieving high quality care. Their\u000a      perspective complements that of\u000a      clinicians, providing unique insights into their own perceptions of health\u000a      status and health-related\u000a      quality of life. It is therefore important to find ways of involving\u000a      patients in reporting on their own\u000a      health outcomes.\u000a    The goal of research carried out by LSHTM since 1996 has been to create\u000a      PROMs &#8212; measures of\u000a      patients' health and health-related quality of life collected before and\u000a      after surgery. Involving\u000a      patient interviews and the development and testing of questionnaires, the\u000a      research has been led\u000a      by Nick Black, Professor of Health Services Research at LSHTM since 1995.\u000a    The research fell into three phases: the development and psychometric\u000a      testing of PROMs (1996-\u000a      2004); methodological research to ensure accurate analysis and\u000a      interpretation of these measures\u000a      (1993-2012); and applied research into the feasibility of the routine use\u000a      of PROMs to assess the\u000a      quality of care of providers (since 2005). While many universities around\u000a      the world have\u000a      contributed to the first of these areas and some have focused on the\u000a      second, Black and colleagues\u000a      have been unique in researching the third.\u000a    In terms of developing and psychometrically testing patient\u000a      questionnaires, under the leadership of\u000a      Donna Lamping (Professor of Health Psychology, LSHTM from 1992, until her\u000a      death in 2011,\u000a      initially Senior Lecturer), major contributions have been made to the\u000a      development of new PROMs\u000a      for a wide range of surgical procedures: stress incontinence (1996);\u000a      benign prostatic hypertrophy\u000a      (1998); menorrhagia (1998);3.1 venous disorders (2003); plastic\u000a      surgery on hands\/arms and on\u000a      head \/neck procedures (2004); and coronary revascularisation (2004).3.2\u000a      Rigorous qualitative and\u000a      quantitative methods were used by LSHTM experts in sociology, psychology,\u000a      epidemiology and\u000a      statistics.\u000a    Work in the second area was undertaken on a range of methodological\u000a      aspects of the use of\u000a      PROMs, including: the influence of patients' preoperative expectations;\u000a      the impact of late response\u000a      and non-response to follow-up; 3.3 the use of minimally\u000a      important differences;3.4 and many others.\u000a    Finally, Black, Jan van der Meulen (Professor of Clinical Epidemiology,\u000a      LSHTM since 2000, then\u000a      Senior Lecturer) and other colleagues have made a unique contribution to\u000a      the routine\u000a      implementation of PROMs in the NHS. In 2005 they undertook a systematic\u000a      review of instruments\u000a      for the routine assessment of outcomes following five common elective\u000a      operations (hip and knee\u000a      replacement, varicose vein surgery, hernia repair and cataract surgery).\u000a      This led directly to a study\u000a      to develop pre- and postoperative questionnaires for four procedures and\u000a      to test the feasibility of\u000a      using them routinely in the NHS. Findings reported in 2007 confirmed that\u000a      it was possible to recruit\u000a      patients, follow them up and make risk-adjusted comparisons of providers,\u000a      all at reasonable cost.\u000a      To confirm these findings on a larger scale, in 2008 Black established a\u000a      much larger study with\u000a      about 35,000 patients. In parallel, since 2009, studies have included\u000a      equity of use and outcomes,\u000a      the impact of choice of metric3.5 and clinicians' and\u000a      patients' views of how best to feed back\u000a      comparisons of health care providers' performance to maximise the\u000a      likelihood that the data will\u000a      stimulate improvements in the quality of care.3.6\u000a    "},{"CaseStudyId":"41463","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2300660","Name":"Ghana"},{"GeoNamesId":"3723988","Name":"Haiti"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"1210997","Name":"Bangladesh"},{"GeoNamesId":"1282988","Name":"Nepal"},{"GeoNamesId":"2328926","Name":"Nigeria"}],"Funders":[],"ImpactDetails":"\u000d\u000a    As a direct result of Curtis' research, HWWS is now a key strategy in the\u000d\u000a      international fight against\u000d\u000a      diarrhoeal disease, attracting both public and &#8212; increasingly &#8212; private\u000d\u000a      investment. As a result of the\u000d\u000a      innovative public-private collaborative approach to public health\u000d\u000a      campaigning, designed and\u000d\u000a      evaluated in the course of her work, Curtis has spearheaded an effective\u000d\u000a      alliance of industry with\u000d\u000a      organisations like the World Bank, USAID and UNICEF to promote good\u000d\u000a      hygiene. This means that\u000d\u000a      millions of people around the world have now been exposed to HWWS\u000d\u000a      promotion programmes. In\u000d\u000a      the last decade, diarrhoea deaths in under 5s have steadily fallen from\u000d\u000a      1.2m to 0.85m per year,5.1\u000d\u000a      and while some of the credit must go to economic development and improved\u000d\u000a      clinical treatment,\u000d\u000a      some is undoubtedly due to the promotion of better hand hygiene based on\u000d\u000a      Curtis' research.\u000d\u000a    Global awareness\u000d\u000a    Curtis' Ghanaian research demonstrated the potential benefits of\u000d\u000a      private-public collaboration in\u000d\u000a      promoting good hygiene. It was following the dissemination of this\u000d\u000a      research at a series of\u000d\u000a      presentations organised by the PPPHW and WHO (2006-2008) that Curtis'\u000d\u000a      proposal of an annual\u000d\u000a      GHD was adopted, and on 15 October 2008 the first ever GHD was celebrated.5.2\u000d\u000a      It has steadily\u000d\u000a      gained momentum since.\u000d\u000a    In 2012, 200m people participated in GHD in over 100 countries. GHD\u000d\u000a      events included special TV\u000d\u000a      shows, school competitions, nationwide poster campaigns and media outreach\u000d\u000a      &#8212; a combination of\u000d\u000a      public and private strategies. As part of GHD 2012, 6 million Nepalese\u000d\u000a      noodle packs carried the\u000d\u000a      GHD logo; 160,000 Haitian schoolchildren saw handwashing demonstrations;\u000d\u000a      98,000 people\u000d\u000a      participated in community events and rallies in Bangladesh; 16 million\u000d\u000a      Keralans received\u000d\u000a      handwashing messages alongside a mass de-worming programme; and in the UK,\u000d\u000a      LSHTM worked\u000d\u000a      with Radox, a Unilever brand, to put GHD stands in every Sainsbury's\u000d\u000a      supermarket.\u000d\u000a    In 2012 there were 40,000 visitors to www.globalhandwashingday.org,\u000d\u000a      48,000 hits on World Wash\u000d\u000a      Up Twitter game, and GHD had 96,000 fans on Facebook. On 15 October,\u000d\u000a      #iwashmyhands\u000d\u000a      trended globally on Twitter. The most recent estimate is that GHD has now\u000d\u000a      reached 1 billion\u000d\u000a      people.5.3 Google trends in searches for `handwashing' show a\u000d\u000a      peak in October every year after\u000d\u000a      GHD.\u000d\u000a    Secondary reach through media\u000d\u000a    GHD has grabbed media headlines since it began in 2008, and Curtis has\u000d\u000a      been extensively and\u000d\u000a      regularly interviewed about her research in association with the event\u000d\u000a      ever since. Among her many\u000d\u000a      media appearances have been interviews in the New York Times\u000d\u000a      (13\/7\/2008); Radio 4's Woman's\u000d\u000a        Hour (28\/2\/2012); BBC World Service's Health Check, which\u000d\u000a      has tens of millions of listeners,\u000d\u000a      especially in Africa (19\/10\/2011); BBC News and News Online\u000d\u000a      (13\/10\/11 and again on 15\/10\/12);\u000d\u000a      Sky News (6\/3\/12); and NPR Radio's Science Friday\u000d\u000a      (23\/10\/09).\u000d\u000a    In 2012 Curtis was nominated and highly commended by The Society of\u000d\u000a      Biology's Science\u000d\u000a      Communication Awards for her work to raise awareness of HWWS.5.4\u000d\u000a    Policy change and private sector campaigns\u000d\u000a    Curtis' research demonstrated conclusively that HWWS is both an effective\u000d\u000a      and cost-effective way\u000d\u000a      for governments to promote health. As a result, an increasing number of\u000d\u000a      countries have been\u000d\u000a      developing their own national policies since 2008.5.5\u000d\u000a    Curtis' research into behaviour change for handwashing also galvanised\u000d\u000a      industry to invest in its\u000d\u000a      own HWWS public health campaigns. Chief among these is Unilever's\u000d\u000a      `Lifebuoy Way of Life' (LWL)\u000d\u000a      launched in 2008. LWL targets mothers and schoolchildren across Asia and\u000d\u000a      much of Africa, aiming\u000d\u000a      at getting hands washed at five key times to reduce diarrhoeal illness.\u000d\u000a      LSHTM is now included\u000d\u000a      among Lifebuoy's global partners, and Curtis is listed as one of\u000d\u000a      Lifebuoy's experts. In this capacity\u000d\u000a      she and her research continue to contribute to the evolution of the\u000d\u000a      company's strategy.5.6 Lifebuoy\u000d\u000a      says its campaign has already reached 48 million people in eight countries\u000d\u000a      in Asia and Africa. The\u000d\u000a      goal is to reach a billion by 2015.5.7 LWL has given good\u000d\u000a      results for Unilever and as a result other\u000d\u000a      manufacturers have started investing in their own HWWS campaigns. Examples\u000d\u000a      include Procter &amp;\u000d\u000a      Gamble's 2012 launch of the Safeguard `Doctors on Wheels' programme to\u000d\u000a      promote handwashing\u000d\u000a      in Nigeria,5.8 and GoJo Industries' sponsorship of Canada's\u000d\u000a      STOP! Clean Your Hands Day in\u000d\u000a      2012.5.9\u000d\u000a    Partly as a result of Curtis' work over 300 organisations from civil\u000d\u000a      society, government and the\u000d\u000a      private sector espouse handwashing with soap.5.10\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research by LSHTM has put handwashing with soap (HWWS) at the heart of\u000d\u000a      international efforts\u000d\u000a      towards diarrhoeal disease prevention, changing the way good hygiene\u000d\u000a      practices are\u000d\u000a      communicated globally. The research led to the global Public-Private\u000d\u000a      Partnership for Handwashing\u000d\u000a      with Soap (PPPHW), a coalition of stakeholders interested in child health\u000d\u000a      and handwashing, and a\u000d\u000a      billion people have been reached through initiatives such as Global\u000d\u000a      Handwashing Day (GHD).\u000d\u000a      Millions more have benefited from the research through hygiene programmes\u000d\u000a      set up by industry.\u000d\u000a      The risk of death from diarrhoeal disease for those reached by these\u000d\u000a      campaigns has been\u000d\u000a      substantially reduced.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000d\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a3.1 Curtis, V and Cairncross, S (2003) Effect of washing hands with soap\u000d\u000a      on diarrhoea risk in the\u000d\u000a      community: a systematic review, Lancet Infectious Diseases, 3(5):\u000d\u000a      275-281, doi:10.1016\/S1473-3099(03)00606-6.\u000d\u000a      Citation count: 258.\u000d\u000a    \u000a\u000a3.2 Cairncross, S and Valdemanis, V (2006) Water supply, sanitation and\u000d\u000a      hygiene promotion, in DT\u000d\u000a      Jamison, JG Breman, AR Measham, G Alleyne, M Claeson, DB Evans, P Jha, A\u000d\u000a      Mills and P\u000d\u000a      Musgrove (eds) Disease Control Priorities in Developing Countries.\u000d\u000a      Washington DC: World Bank\u000d\u000a      (peer reviewed). Citation count: 34\u000d\u000a    \u000a\u000a3.3 Curtis, VA, Danquah, LO and Aunger, RV (2009) Planned, motivated and\u000d\u000a      habitual hygiene\u000d\u000a      behaviour: an eleven country review, Health Education Research,\u000d\u000a      24(4): 655-673,\u000d\u000a      doi:10.1093\/her\/cyp002. Citation count 40\u000d\u000a    \u000a\u000a3.4 Scott, BE, Schmidt, WP, Aunger, R, Garbrah-Aidoo, N and Animashaun, R\u000d\u000a      (2008) Marketing\u000d\u000a      hygiene behaviours: the impact of different communication channels on\u000d\u000a      reported handwashing\u000d\u000a      behaviour of women in Ghana, Health Education Research, 23(3):\u000d\u000a      392-401,\u000d\u000a      doi:10.1093\/her\/cym056. Citation count: 15\u000d\u000a    \u000a\u000a3.5 Curtis, VA, Garbrah-Aidoo, N and Scott, B (2007) Ethics in public\u000d\u000a      health research: masters of\u000d\u000a      marketing: bringing private sector skills to public health partnerships, American\u000d\u000a        Journal of Public\u000d\u000a        Health, 97(4): 634-641, doi 10.2105\/AJPH.2006.090589. Citation count\u000d\u000a      27.\u000d\u000a    \u000a\u000a3.6 Dodrill, L, Schmidt, WP, Cobb, E, Donachie, P, Curtis, V and de\u000d\u000a      Barra, M (2011) Male\u000d\u000a      commuters in north and south England: risk factors for the presence of\u000d\u000a      faecal bacteria on hands,\u000d\u000a      BMC Public Health, 11(31), doi:10.1186\/1471-2458-11-31. Citation\u000d\u000a      count: 0\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000d\u000a    5.1 Liu, L, Johnson, HL, Cousens, C, Perin, J, Scott, S, Lawn, JE, Rudan,\u000d\u000a      I, Campbell, H,\u000d\u000a      Cibulskis, R, Li, M, Mathers, C and Black, RE (2012) Global, regional, and\u000d\u000a      national causes of child\u000d\u000a      mortality: an updated systematic analysis for 2010 with time trends since\u000d\u000a      2000, Lancet, 379(9832):\u000d\u000a      2151-2161, doi:10.1016\/S0140-6736(12)60560-1.\u000d\u000a    5.2 Global Handwashing Day, Coordinator, Global PPPHW at FHI360.\u000d\u000a    5.3 Global Public-Private Partnership for Handwashing (PPPHW) (2012), Global\u000d\u000a        Handwashing Day\u000d\u000a        2012 Celebrating 5 Years! (unpublished).\u000d\u000a    5.4 Society of Biology's Science Communication Awards &#8212; Certificate.\u000d\u000a    5.5 Global Public-Private Partnership for Handwashing (PPPHW) (2011) Making\u000d\u000a        Global\u000d\u000a        Handwashing Day More Than Just a Day: Governments Take Action.\u000d\u000a      Washington, DC: PPPHW,\u000d\u000a      http:\/\/globalhandwashing.org\/sites\/default\/files\/Governments-Handwashing-Report.pdf\u000d\u000a      (accessed\u000d\u000a      11 September 2013).\u000d\u000a    5.6 Lifebuoy Social Mission Manager, Unilever.\u000d\u000a    5.7 Unilever (2013) Reaching 1 billion people, viewed 20 September 2013,\u000d\u000a      http:\/\/www.unilever.com\/sustainable-living\/healthandhygiene\/handwashing\/reaching1billionpeople\/.\u000d\u000a    5.8 Procter &amp; Gamble (2012) Press release: Safeguard celebrates\u000d\u000a      Global Handwashing Day with\u000d\u000a      launch of Doctors on Wheels program,\u000d\u000a      http:\/\/www.pg.com\/en_NG\/downloads\/media\/safeguard_celebrates_global_handwashing.pdf\u000d\u000a      (accessed 20 September 2013).\u000d\u000a    5.9 GOJO Industries (2012) GOJO CANADA: Healthcare: Canadian\u000d\u000a      Patient Safety Institute &#8212; Stop!\u000d\u000a      Clean your Hands Day!, viewed 20 September 2013,\u000d\u000a      http:\/\/www.gojo.com\/canada\/markets\/healthcare\/healthcare\/resources\/healthcare-resources\/canadian-patient-safety-hc.aspx.\u000d\u000a    5.10 List of organisations available upon request.\u000d\u000a    ","Title":"\u000d\u000a    Preventing disease through promotion of handwashing with soap\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Globally, there are over 2bn cases of diarrhoeal disease every year,\u000d\u000a      resulting in the deaths of\u000d\u000a      0.85m children. Diarrhoea is the second leading cause of death in children\u000d\u000a      under 5.\u000d\u000a    Research by Val Curtis, Reader in Hygiene at LSHTM (joined 1989, then\u000d\u000a      Research Fellow) has\u000d\u000a      shown that HWWS can save up to 1m lives a year, and is one of the most\u000d\u000a      cost effective means of\u000d\u000a      preventing disease globally. Through developing and testing innovative\u000d\u000a      approaches to promote\u000d\u000a      safe hygiene, Curtis' research has shown the benefits of joint\u000d\u000a      public\/private sector collaboration,\u000d\u000a      engaging industry and using marketing approaches to implement effective\u000d\u000a      large-scale public health\u000d\u000a      promotion programmes.\u000d\u000a    In 2003, Curtis and Sandy Cairncross (LSHTM Professor of Environmental\u000d\u000a      Health; joined 1984\u000d\u000a      then Senior Lecturer) carried out a systematic review of the literature on\u000d\u000a      hand hygiene. They came\u000d\u000a      to the surprising conclusion that HWWS could reduce the risk of diarrhoeal\u000d\u000a      disease by 42-47%\u000d\u000a      and might save a million lives per year.3.1 Cost-effectiveness\u000d\u000a      studies calculated that hygiene\u000d\u000a      promotion costs around US$3.35 per Disability Adjusted Life Year (DALY)\u000d\u000a      averted,3.2 putting\u000d\u000a      HWWS at the top of the list for the most cost-effective interventions to\u000d\u000a      prevent disease in\u000d\u000a      developing countries.\u000d\u000a    Between 2000 and 2007, Curtis and her team (including Aunger, joined\u000d\u000a      2003) conducted extensive\u000d\u000a      field research into handwashing behaviour in 11 countries, using a\u000d\u000a      combination of focus groups,\u000d\u000a      behaviour trials and structured observations. They identified key drivers\u000d\u000a      of handwashing behaviour:\u000d\u000a      disgust, nurture and the desire to conform to social norms &#8212; not simply a\u000d\u000a      desire for better health.3.3\u000d\u000a      Using these insights, novel handwashing promotion programmes were rolled\u000d\u000a      out in Africa and\u000d\u000a      India. These proved to be effective in improving HWWS behaviour among\u000d\u000a      those reached.3.4\u000d\u000a    In 2002 at Curtis' instigation a coalition of international stakeholders,\u000d\u000a      including the World Bank,\u000d\u000a      Colgate-Palmolive, USAID, UNICEF and Unilever among others, founded the\u000d\u000a      global PPPHW. Built\u000d\u000a      on their understanding of handwashing behaviour and on the process used by\u000d\u000a      industry to market\u000d\u000a      soap, Curtis worked with the Ghanaian Ministry of Water and the PPPHW to\u000d\u000a      roll out an innovative\u000d\u000a      nationwide handwashing campaign in 2003. Subsequent evaluation found that\u000d\u000a      71% of Ghanaian\u000d\u000a      mothers knew the TV ad and the reported rates of HWWS increased\u000d\u000a      substantially. Overall the\u000d\u000a      initiative proved that there are many economic and public health benefits\u000d\u000a      to be gained from public-private\u000d\u000a      collaboration. For example, the public sector can employ the marketing\u000d\u000a      skills of the private\u000d\u000a      sector and both can benefit from academia's insights into behaviour\u000d\u000a      change.3.5\u000d\u000a    Realising that the private sector often commissions studies explicitly to\u000d\u000a      generate media attention,\u000d\u000a      Curtis and LSHTM's Hygiene Centre team have carried out a series of\u000d\u000a      studies for release annually\u000d\u000a      on Global Handwashing Day (2009-2012). The findings that 25% of male\u000d\u000a      commuter's hands and\u000d\u000a      12% of mobile phones in Britain are contaminated with faecal bacteria,3.6\u000d\u000a      achieved over 200 media\u000d\u000a      mentions in 2011.\u000d\u000a    "},{"CaseStudyId":"41488","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2413451","Name":"Gambia"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"49518","Name":"Rwanda"},{"GeoNamesId":"953987","Name":"South Africa"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    The Gambia\u000a      The Gambian phase 3 PCV trial was conducted in close collaboration with\u000a      the Ministry of Health.\u000a      The results of the trial were immediately available to the Ministry (2005)\u000a      and it took a decision to\u000a      introduce a PCV into the routine infant immunisation programme of The\u000a      Gambia as soon as\u000a      vaccine became available. Wyeth Lederle stopped production of the 9-valent\u000a      vaccine shortly after\u000a      completion of the Gambian and South African trials but made a donation of\u000a      the 7-valent vaccine\u000a      (Prevenar&#174;) used in the USA to the Gambian Ministry of Health\u000a      in 2009. This allowed introduction\u000a      of this vaccine into the routine immunisation programme of The Gambia,\u000a      only the second country\u000a      in sub-Saharan Africa (after Rwanda) to take this step. In 2011, with\u000a      financial support from GAVI,\u000a      the seven-valent vaccine, which lacks some of the key serotypes needed for\u000a      a maximally effective\u000a      pneumococcal conjugate vaccine in Africa, was replaced by a 13-valent\u000a      vaccine. The impact on\u000a      mortality and morbidity of introducing PCVs into a national infant\u000a      immunisation programme in\u000a      Africa is currently being studied in detail in Upper River Region, The\u000a      Gambia, with support from the\u000a      Bill and Melinda Gates Foundation. It is too early to determine the extent\u000a      of the impact on mortality\u000a      and morbidity of this vaccine, which has now been received by nearly\u000a      100,000 Gambian infants,\u000a      but it is likely that many lives have already been saved.\u000a    Internationally\u000a      The results of the Gambian phase 3 trial, together with those of the\u000a      parallel study undertaken in\u000a      South Africa, provided key information which led the WHO Strategic\u000a      Advisory Group of Experts\u000a      (SAGE) committee to recommend to WHO that pneumococcal conjugate vaccines\u000a      should be\u000a      introduced into the routine infant immunisation programmes of all\u000a      countries with a high child\u000a      mortality. This recommendation was accepted by WHO in 2007, with the\u000a      findings of the Gambian\u000a      trial being influential in this decision.5.1,5.2 The unique\u000a      evidence provided from The Gambia of an\u000a      effect on mortality proved especially influential. Economic data collected\u000a      during the Gambian trial\u000a      allowed demonstration that deployment of the vaccine in developing\u000a      countries would be highly cost\u000a      effective5.3 and this information also contributed to the\u000a      positive recommendation by SAGE.\u000a    Because of their complex nature, PCVs are relatively expensive and so\u000a      there were concerns\u000a      whether it would be possible to implement the WHO recommendation in some\u000a      of the poorest\u000a      countries of the world where PCVs would be most effective. However,\u000a      substantial progress has\u000a      been made in achieving this goal through the financial support obtained\u000a      for the introduction of new\u000a      vaccines in poor countries provided through GAVI and the Advanced Market\u000a      Commitment5.4 (an\u000a      innovative financing method which guarantees a market if a vaccine or\u000a      medicine is successfully\u000a      developed). By 31 March 2013, 24 GAVI-eligible countries had introduced a\u000a      PCV into their routine\u000a      immunisation programme (8 of these were supported by the Advanced Market\u000a      Commitment), and\u000a      a further 27 countries were approved by GAVI for introduction, including\u000a      nearly all countries in sub-Saharan\u000a      Africa,5.5 a dramatic uptake over a period of only three years.5.6\u000a    PCVs would have been introduced into most developing counties eventually,\u000a      but experience with\u000a      hepatitis B and Haemophilus influenzae type B vaccines indicates\u000a      that the lag between uptake in\u000a      industrialised and developing countries may be up to 15 years. PCVs are\u000a      being introduced more\u000a      rapidly than this as the international community has found better ways of\u000a      accelerating the uptake of\u000a      new vaccines. A strong case can be made that the Gambian PCV trial has\u000a      played an important\u000a      part in achieving this success and thus helped in saving many thousands of\u000a      young lives in poor\u000a      countries which would otherwise have been lost to pneumococcal infection.5.7\u000a    ","ImpactSummary":"\u000a    A trial of a pneumococcal conjugate vaccine (PCV) coordinated by\u000a      Greenwood (LSHTM) and\u000a      conducted in Gambian infants, showed a significant reduction in invasive\u000a      pneumococcal disease,\u000a      severe pneumonia, hospital admissions and deaths in vaccinated children.\u000a      These results played an\u000a      important role in encouraging WHO to recommend the introduction of a PCV\u000a      into the routine\u000a      immunisation programme of all countries with a high child mortality.\u000a      Fifty-one GAVI eligible\u000a      countries have now introduced, or made a commitment to introduce, a PCV\u000a      into their routine infant\u000a      immunisation programme with the consequent saving of many young lives.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1 Cutts, FT, Zaman, SMA, Enwere, G, Jaffar, S, Levine, OS, Okoko, JB,\u000a      Oluwalana, C, Vaughan, A,\u000a      Obaro, SK, Leach, A, McAdam, KP, Biney, E, Saaka, M, Onwuchekwa, U,\u000a      Yallop, F, Pierce, NF,\u000a      Greenwood, BM &amp; Adegbola, RA 2005, `Efficacy of nine-valent\u000a      pneumococcal conjugate vaccine\u000a      against pneumonia and invasive pneumococcal disease in The Gambia:\u000a      randomised, double-blind,\u000a      placebo-controlled trial', Lancet; vol. 365, no. 9465,\u000a      pp.1139-1146, doi:10.1016\/S0140-6736(05)71876-6.\u000a      Citation count:432\u000a    \u000a\u000a3.2 Leach, A, Ceesay, SJ, Banya WAS and Greenwood, BM (1996) Pilot trial\u000a      of a pentavalent\u000a      pneumococcal polysaccharide\/protein conjugate vaccine in Gambian infants,\u000a      Pediatric Infectious\u000a        Disease Journal, 15(4): 333-339,\u000a      doi:10.1097\/00006454-199604000-00010. Citation count: 71\u000a    \u000a\u000a3.3 Obaro, SK, Adegbola, RA, Banya, WAS and Greenwood, BM (1996) Carriage\u000a      of pneumococci\u000a      after pneumococcal vaccination, Lancet, 348(9022): 271-272,\u000a      doi:10.1016\/S0140-6736(05)65585-7.\u000a      Citation count: 218\u000a    \u000a\u000a3.4 Obaro, SK, Adegbola, RA, Chang, I, Banya, WAS, Jaffar S, McAdam KWJP\u000a      and Greenwood, BM\u000a      (2000) Safety and immunogenicity of a nonavalent pneumococcal vaccine\u000a      conjugated to CRM197\u000a      administered simultaneously but in a separate syringe with diphtheria,\u000a      tetanus and pertussis vaccines\u000a      in Gambian infants, Pediatric Infectious Disease Journal, 19(5):\u000a      463-469,\u000a      http:\/\/journals.lww.com\/pidj\/pages\/articleviewer.aspx?year=2000&amp;issue=05000&amp;article=00014&amp;type=abstract\u000a      (accessed 23 September 2013). Citation count: 55\u000a    \u000a\u000a3.5 Saaka, M, Okoko, BJ, Kohberger, RC, Jaffar, S, Enwere, G, Biney, EE,\u000a      Oluwalana, C,\u000a      Vaughan, A, Zaman, SMA, Asthon, L, Goldblatt, D, Greenwood, BM, Cutts, FT\u000a      and Adegbola RA\u000a      (2008) Immunogenicity and serotype-specific efficacy of a 9-valent\u000a      pneumococcal conjugate\u000a      vaccine (PCV-9) determined during an efficacy trial in The Gambia, Vaccine,\u000a      26(29-30): 3719-3726,\u000a      doi:10.1016\/j.vaccine.2008.04.066. Citation count: 24\u000a    \u000a\u000a3.6 Cheung, YB, Zaman, SMA, Nsekpong, ED, Van Beneden, CA, Adegbola, RA,\u000a      Greenwood, B\u000a      and Cutts, FT (2009) Nasopharyngeal carriage of Streptococcus\u000a        pneumoniae in Gambian children\u000a      who participated in a 9-valent pneumococcal conjugate vaccine trial and in\u000a      their younger siblings,\u000a      Pediatric Infectious Disease Journal, 28(11): 990-995,\u000a      doi:10.1097\/INF.0b013e3181a78185.\u000a      Citation count: 23\u000a    \u000aKey grants\u000a      The project was funded through a consortium supported by NIAID, WHO, the\u000a      Children's Vaccine\u000a      Programme at PATH, USAID and the UK MRC. Vaccines were donated by Wyeth\u000a      Vaccines. The\u000a      grant ran from 2000-2005. The total value of the grant made to the MRC\u000a      unit The Gambia was\u000a      approximately US$10,000,000 with a subcontract of $557,000 to LSHTM.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    5.1 Coordinator, Programme and Impact Monitoring, Immunisation, Vaccines\u000a      and Biologicals,\u000a      WHO.\u000a    5.2 Former chair, WHO SAGE committee.\u000a    5.3 Sinha, A, Levine, O, Knoll, MD, Muhib, F and Lieu, TA (2007)\u000a      Cost-effectiveness of\u000a      pneumococcal conjugate vaccination in the prevention of child mortality:\u000a      an international economic\u000a      analysis, Lancet, 369(9559): 389-396,\u000a      doi:10.1016\/S0140-6736(07)60195-0 (see p. 391).\u000a    5.4 Director, Vaccine Delivery, Bill &amp; Melinda Gates Foundation.\u000a    5.5 GAVI Alliance Secretariat (2013) Advance Market Commitment for\u000a        Pneumococcal Vaccines:\u000a        Annual Report 1 April 2012 -31 March 2013 (sections 2.3-2.4),\u000a      http:\/\/www.gavialliance.org\/funding\/pneumococcal-amc\/.\u000a    5.6 http:\/\/www.gavialliance.org\/support\/nvs\/pneumococcal\/\u000a      &#8212; see pneumococcal factsheet and\/or\u000a      http:\/\/www.gavialliance.org\/results\/goal-level-indicators\/vaccine-goal-indicators\/.\u000a    5.7 Levine, OS, Bloom, DE, Cherian, T, de Quadros, C, Sow, S, Wecker, J,\u000a      Duclos, P and\u000a      Greenwood, B (2011) The future of immunisation policy, implementation, and\u000a      financing, Lancet,\u000a      378(9789): 439-448, doi:10.1016\/S0140-6736(11)60406-6 (see p. 442).\u000a    \u000a    ","Title":"\u000a    Influencing the widespread adoption of pneumococcal conjugate vaccines in\u000a      low-and middle-income countries\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Pneumonia causes over 1m deaths each year in children, with nearly all\u000a      occurring in the\u000a      developing world. Streptococcus pneumoniae (the pneumococcus) is\u000a      the most important cause of\u000a      severe pneumonia in children. Developing a vaccine that could prevent\u000a      pneumococcal infections in\u000a      young children is, therefore, a high public health priority. Initial\u000a      vaccines based on the capsular\u000a      polysaccharide of the pneumococcus were not effective as they induced only\u000a      a poor immune\u000a      response in young children. Coupling of capsular polysaccharides to a\u000a      protein to produce a PCV\u000a      overcame this problem. Initial trials of a 7-valent PCV (Prevenar&#174;)\u000a      in the USA showed that this\u000a      vaccine was highly effective in protecting vaccinated infants and\u000a      unvaccinated members of their\u000a      family by preventing nasopharyngeal carriage and thus interrupting\u000a      transmission. Whether a PCV\u000a      would be equally effective in developing countries was unknown. To\u000a      investigate this, a trial of a 9-valent\u000a      PCV was undertaken in The Gambia, West Africa,3.1 the first\u000a      large-scale trial of a PCV to be\u000a      undertaken in a low-income country (a parallel study was undertaken in\u000a      Soweto, South Africa).\u000a    The Gambian phase 3 trial built on many years of background work,\u000a      including a series of phase 2\u000a      trials of prototype PCVs conducted during the period 1994-1999. These\u000a      trials, funded largely by\u000a      NIH, were coordinated by Brian Greenwood who was director of the MRC Unit,\u000a      The Gambia until\u000a      1996 when he took up a chair at LSHTM. These pilot trials demonstrated the\u000a      safety and\u000a      immunogenicity of PCVs in African infants for the first time.3.2,3.3,3.4\u000a      They also showed that PCVs\u000a      reduced nasopharyngeal carriage of pneumococci of vaccine serotype but\u000a      that these bacteria were\u000a      replaced in the nasopharynx by pneumococci of serotypes not represented in\u000a      the vaccine,3.3 the\u000a      first description of a phenomenon known as `serotype replacement' which\u000a      has subsequently posed\u000a      a major challenge to the effectiveness of PCVs in many countries,\u000a      including the UK.\u000a    The Gambian phase 3 PCV trial undertaken in Upper River Region during\u000a      2000-2004 was a\u000a      partnership between the MRC Laboratories, The Gambia and LSHTM. It was\u000a      designed and\u000a      planned by Greenwood. The study was led by Felicity Cutts (honorary LSHTM\u000a      staff). Professor\u000a      Shabbar Jaffar (joined LSHTM 1996, then Lecturer) provided statistical\u000a      support on study design\u000a      and undertook the trial analysis. During the trial, 17,437 infants were\u000a      given either three doses of a\u000a      9-valent PCV or placebo at the ages of approximately 6, 10 and 14 weeks.3.1\u000a      The vaccine was safe\u000a      and immunogenic.3.5 During 30 months of follow-up, the vaccine\u000a      reduced invasive pneumococcal\u000a      disease of vaccine serotype by 77%, severe pneumonia by 37%, hospital\u000a      admissions by 15% and\u000a      mortality by 16%. The vaccine reduced nasopharyngeal carriage of\u000a      pneumococci of vaccine\u000a      serotype with an increase in carriage of pneumococci of non-vaccine\u000a      serotype.3.6 The trial provided\u000a      data that allowed the cost effectiveness of introducing PCVs to be\u000a      evaluated.\u000a    "},{"CaseStudyId":"41490","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"2300660","Name":"Ghana"}],"Funders":[],"ImpactDetails":"\u000a    The Ghana trials have substantially influenced global policy on VAS as\u000a      well as having a major influence on the development and content of the\u000a      national vitamin A programme in Ghana.\u000a    In 2011 WHO published four revised VAS guidelines relating to VAS in:\u000a      infants and children 6-59 months of age;5.1 infants 1-5 months\u000a      of age;5.3 postpartum women;5.5 and pregnant women.5.7\u000a      These were based on updated Cochrane reviews5.2, 5.4, 5.6. 5.8\u000a      commissioned by WHO and, in some cases, additional analyses carried out by\u000a      WHO. They replaced the previous recommendations published by WHO, UNICEF\u000a      and IVACG Task Force in 1997. Evidence from the trials in Ghana made\u000a      substantial contributions to all the new guidelines:\u000a    \u000a      The Ghana VAST trials constituted 28.9% of the total evidence\u000a        concerning the impact of VAS on all-cause mortality in children aged\u000a        6-59 months and the continued recommendation that this is a key child\u000a        survival intervention.5.1, 5.2\u000a\u000a      The latest Countdown to 2015 (maternal, newborn and child survival)\u000a        report5.9 estimated a median coverage of 80% for children\u000a        aged 6-59 months receiving VAS in low- and middle-income countries; the\u000a        2013 Lancet nutrition review series highlights the importance of\u000a        continuing to improve this coverage, estimating that this could prevent\u000a        an additional 145,000 deaths each year at a cost of $159 per life saved.\u000a        This estimate was derived using the Lives Saved Tool (LiST) which models\u000a        the number of child deaths that could be saved with different\u000a        interventions. The cause-specific findings from the Ghana VAST trials\u000a        make a major contribution to the evidence base on effect sizes for VAS\u000a        used in LiST.\u000a      The EPI-Plus trial provided 11.3% of the mortality evidence behind the\u000a        recommendation not to recommend VAS in infants 1-5 months of age.5.3,\u000a          5.4 This is a reversal of the previous policy recommending\u000a        supplementation in this age group and which was not evidence based.\u000a      Both the EPI-Plus trial and the ObaapaVitA trial contributed evidence\u000a        behind the recommendation not to recommend VAS in postpartum women.5.5,\u000a          5.6 This is also a reversal of previous policy which recommended\u000a        postpartum supplementation.\u000a      The ObaapaVitA trial contributed 61.9% of the evidence concerning no\u000a        overall impact of VAS to pregnant women on maternal mortality and 61.9%\u000a        of the evidence concerning no overall impact on neonatal mortality.5.7,\u000a          5.8 Supplementation of pregnant women is not recommended.\u000a    \u000a    The VAS trial findings have also had a major influence within Ghana. The\u000a      establishment of the National Vitamin A Programme was in direct response\u000a      to the Ghana VAST trials, and the content of the programme has been\u000a      influenced and informed by the subsequent trials in Ghana. The 2012\u000a      Countdown report5.9 gives 93% coverage of two doses per year of\u000a      VAS to children aged 6-59 months. The national vitamin A programme no\u000a      longer supports VAS given with vaccines in the first six months of life or\u000a      supplementation of postpartum women, saving the programme considerable\u000a      money and opportunity costs each year, and, following the ObaapaVitA\u000a      trial, VAS for women of reproductive age will not be introduced. The\u000a      definitive no impact findings of the ObaapaVitA trial emphasize that good\u000a      research can make important contributions by showing that something\u000a      doesn't work; Esi Amoaful, the National Vitamin A Programme Manager, Ghana\u000a      Health Service5.10 commented: `Research does not just tell us\u000a      what new things to do, it also tells us what not to do. The remarkable\u000a      finding has made the case that had the Ghana Health Sector implemented\u000a      this policy all over the country to women without the requisite\u000a      information about its benefits, we might have spent millions of dollars\u000a      each year to no avail.\"\u000a    Finally, the vitamin A trials in Ghana have made a major contribution to\u000a      research capacity, building the initial infrastructures for the Navrongo\u000a      and Kintampo Health Research Centres which are making substantial research\u000a      contributions to global health. For example, the Kintampo Health Research\u000a      Centre has a widespread malaria programme and was one of the seven African\u000a      sites carrying out trials to assess the GlaxoSmithKline RTS,S malaria\u000a      vaccine which has just been reported to almost halve the number of malaria\u000a      cases in young children. The vitamin A trials have also trained staff who\u000a      have gone on to senior research and policy positions in Ghana including\u000a      two current university Vice-chancellors and Directors of two health\u000a      research centres.\u000a    ","ImpactSummary":"\u000a    Vitamin A deficiency (VAD) is a major public health problem in low- and\u000a      middle-income countries with young children and pregnant women\u000a      particularly at risk. Over the last 20+ years LSHTM researchers have\u000a      carried out a series of definitive trials in collaboration with the Ghana\u000a      Health Service to evaluate the impact of different vitamin A\u000a      supplementation (VAS) strategies on maternal and\/or child survival.\u000a      Findings have had major impacts on national and global VAS programmes and\u000a      influenced WHO guidelines on VAS in: infants and children 6-59 months of\u000a      age; infants 1-5 months of age; postpartum women; and pregnant women.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2297505","Name":"Navrongo"}],"References":"\u000a    \u000a3.1 Ghana VAST Study Team (Ross, DA, Dollimore, N, Smith, PG, Kirkwood,\u000a      BR, Arthur, PR, Morris, SS, Addy, HA, Binka FN, Arthur P, Gyapong, JO and\u000a      Tomkins, AM) (1993) Vitamin A supplementation in northern Ghana: effects\u000a      on clinic attendances, hospital admissions, and child mortality, Lancet,\u000a      342(8862): 7-12, doi: 10.1016\/0140-6736(93)91879-Q. Citation count: 83\u000a    \u000a\u000a3.2 Binka, FN, Ross, DA, Morris, SS, Kirkwood, BR, Arthur, P, Dollimore,\u000a      N, Gyapong, JO and Smith PG (1995) Vitamin A supplementation and childhood\u000a      malaria in northern Ghana, American Journal of Clinical Nutrition,\u000a      61(4): 853-859, http:\/\/ajcn.nutrition.org\/content\/61\/4\/853.abstract\u000a      (accessed 16 October 2013). Citation count: 55\u000a    \u000a\u000a3.3 Kirkwood, BR, Ross, DA, Arthur, P, Morris, SS, Dollimore, N, Binka,\u000a      FN, Shier, RP, Gyapong, JO, Addy, HA and Smith, PG (1996) Effect of\u000a      vitamin A supplementation on the growth of young children in Northern\u000a      Ghana, American Journal of Clinical Nutrition, 63(5): 773-781, http:\/\/ajcn.nutrition.org\/content\/63\/5\/773.abstract\u000a      (accessed 16 October 2013). Citation count: 32\u000a    \u000a\u000a3.4 WHO\/CHD Immunisation-Linked Vitamin A Supplementation Study Group\u000a      (Martines, J, Underwood, B, Bahl, R, Bhan, MK, Kirkwood, BR, Moulton, LH,\u000a      Panny, ME, Ram, M, Kjolhede, CL, Propper, L, Arthur, P, Morris, S, Etego,\u000a      SA, Zandoh, C, Boahen, O, Wahed, MA, Lanata, CF, Butr&#243;n, B, Huapaya, AR\u000a      and Rivera, KB (1998) Randomised trial to assess benefits and safety of\u000a      vitamin A supplementation linked to immunisation in early infancy, Lancet,\u000a      352(9136):1257-1263, doi:10.1016\/S0140-6736(98)02487-8. Citation count:\u000a      112\u000a    \u000a\u000a3.5 Bahl, R, Bhandari, N, Wahed, MA, Kumar, GT, Bhan, MK and the WHO\/CHD\u000a      Immunisation- Linked Vitamin A Group (Arthur, P, Kirkwood, BR, Morris, S,\u000a      Etego, SA, Zandoh C, Boahen O, Penny, ME, Lanata, CF, Butron, B, Huapaya,\u000a      AR, Rivera, KB, Bhandari, N, Bahl, R, Bhan, MK, Wahed, MA, Moulton, LH,\u000a      Ram, M, Kjolhede, CL, Propper, L, Martines J and Underwood B) (2002)\u000a      Vitamin A supplementation of women postpartum and of their infants at\u000a      immunisation alters breast milk retinol and infant vitamin A status, Journal\u000a        of Nutrition, 132(11): 3243-3248, http:\/\/jn.nutrition.org\/content\/132\/11\/3243.abstract\u000a      (accessed 16 October 2013). Citation count: 35\u000a    \u000a\u000a3.6 Kirkwood, BR, Hurt, L, Amenga-Etego, S, Tawiah, C, Zandoh, C, Danso,\u000a      S, Hurt, C, Edmond, K, Hill, Z, ten Asbroek, G, Fenty, J, Owusu-Agyei, S,\u000a      Campbell, O and Arthur P, for the ObaapaVitA Trial Team (2010) Effect of\u000a      vitamin A supplementation in women of reproductive age on maternal\u000a      survival in Ghana (ObaapaVitA): a cluster-randomised, placebo-controlled\u000a      trial, Lancet, 375(9726):1640-1649, doi:\u000a      10.1016\/S0140-6736(10)60311-X. Citation count: 35\u000a    \u000aKey grants\u000a    Kirkwood, Evaluating the Impact of Vitamin A Supplementation on Maternal\u000a      Mortality in Ghana, DFID, 1999-2009, &#163;6,493,282.\u000a    Kirkwood, NEOVITA: Efficacy of Newborn Vitamin A Supplementation in\u000a      Improving Child Survival in\u000a    Rural Ghana: Generation of Evidence Necessary for Informing Global\u000a      policy, WHO (through a grant from the Bill &amp; Melinda Gates\u000a      Foundation), 2009-2013, &#163;3,146,510.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"14","Subject":"Paediatrics and Reproductive Medicine"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    WHO VAS guideline &amp; related systematic review: Children 6-59\u000a        months\u000a    5.1 WHO (2011) Guideline: Vitamin A Supplementation in Infants and\u000a        Children 6-59 Months of Age. Geneva: WHO, http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241501767_eng.pdf\u000a      (accessed 16 October 2013).\u000a    5.2 Imdad, A, Herzer, K, Mayo-Wilson, E, Yakoob, MY and Bhutta, ZA (2010)\u000a      Vitamin A supplementation for preventing morbidity and mortality in\u000a      children from 6 months to 5 years of age, Cochrane Database of\u000a        Systematic Reviews, 12, doi:10.1002\/14651858.CD008524.pub2.\u000a    WHO VAS guideline &amp; related systematic review: Infants 1-5 months\u000a    5.3 WHO (2011) Guideline: Vitamin A Supplementation in Infants 1-5\u000a        Months of Age. Geneva: WHO, http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241501811_eng.pdf\u000a      (accessed 16 October 2013).\u000a    5.4 Gogia, S and Sachdev, HS (2011) Vitamin A supplementation for the\u000a      prevention of morbidity and mortality in infants six months of age or\u000a      less, Cochrane Database of Systematic Reviews, 10, doi:\u000a      10.1002\/14651858.CD007480.pub2.\u000a    WHO VAS guideline &amp; related systematic review: postpartum women\u000a    5.5 WHO (2011) Guideline: Vitamin A Supplementation in Postpartum\u000a        Women. Geneva: WHO, http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241501774_eng.pdf\u000a      (accessed 16 October 2013).\u000a    5.6 Oliveira-Menegozzo, JM, Bergamaschi, DP, Middleton, P and East, CE\u000a      (2010) Vitamin A supplementation for postpartum women, Cochrane\u000a        Database of Systematic Reviews, 10, doi:\u000a      10.1002\/14651858.CD005944.pub2.\u000a    WHO VAS guideline &amp; related systematic review: pregnant women\u000a    5.7 WHO (2011) Guideline: Vitamin A Supplementation in Pregnant Women.\u000a      Geneva: WHO, http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241501781_eng.pdf\u000a      (accessed 16 October 2013).\u000a    5.8 van den Broek, N, Dou, L, Othman, M, Neilson, JP, Gates, S and\u000a      G&#252;lmezoglu, AM (2010) Vitamin A supplementation during pregnancy for\u000a      maternal and newborn outcomes, Cochrane Database of Systematic Reviews,\u000a      11, doi:10.1002\/14651858.CD008666.pub2.\u000a    Coverage of VAS for children 6-59 months: 2012\u000a    5.9 Countdown to 2015: Maternal, Newborn &amp; Child Survival (2012) Building\u000a        a Future for Women and Children: the 2012 Report. Geneva:\u000a      WHO\/UNICEF,\u000a      http:\/\/www.countdown2015mnch.org\/documents\/2012Report\/2012-Complete.pdf\u000a      (accessed 16 October 2013).\u000a    LSHTM contribution to policy in Ghana\u000a    5.10 Deputy Chief Nutrition Officer &amp; National Vitamin A Programme\u000a      Manager, Ghana Health Service.\u000a    ","Title":"\u000a    Informing policy and decision-making on vitamin A supplementation for\u000a      mothers and children\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    VAD is a widespread public health problem in low- and middle-income\u000a      countries; it is the most common cause of blindness and in the 1980s was\u000a      also shown to be associated with increased child mortality. LSHTM has been\u000a      at the forefront of research since then, leading a series of definitive\u000a      randomised controlled trials in collaboration with the Ghana Health\u000a      Service to evaluate the impact of different VAS strategies on child\u000a      survival.\u000a    The Ghana VAST Survival and Health trials3.1 in the early\u000a      1990s were led by Professors David Ross (LSHTM since 1983, then Research\u000a      Fellow) and Betty Kirkwood (LSHTM since 1979, then Lecturer) respectively.\u000a      The survival trial was cluster randomised and involved 21,906 children\u000a      aged 6 to 59 months, while the health study was individually randomised\u000a      and involved 1,455 children followed weekly for one year. The trials were\u000a      unique in including a detailed assessment of VAS on morbidity alongside\u000a      mortality. They demonstrated that VAS reduces occurrence of severe (but\u000a      not mild) episodes of illness, clinic attendances and hospitalisations, as\u000a      well as reducing mortality by 19% (95% CI 2-32%, P = 0.03), suggesting\u000a      that VAS protects children by reducing the severity of illness, rather\u000a      than by increasing resistance to initial infection. The trials also\u000a      allowed examination of impacts on the main causes of death (diarrhoea,\u000a      pneumonia, measles, malaria)3.2 and on growth.3.3\u000a      They confirmed that four- to six-monthly VAS of children aged 6 to 59\u000a      months could save lives in a malaria-endemic sub-Saharan setting.\u000a    Three other large-scale trials followed under the leadership of Betty\u000a      Kirkwood. The EPI-Plus trial was a multi-centre individually randomised\u000a      trial in Ghana, India and Peru involving a total of 9,424 mother-infant\u000a      pairs. It tackled VAD in the first six months of life and tested the\u000a      safety and benefits of giving a postpartum dose to the mother together\u000a      with VAS to the infant alongside the polio and DPT\u000a      (diphtheria-pertussis-tetanus) vaccines at 6, 10 and 14 weeks of age,\u000a      since combining VAS with the successful expanded programme of immunisation\u000a      (EPI) would achieve coverage at scale. It confirmed the safety of this\u000a      approach, but showed no impact on infant mortality up to nine months of\u000a      age3.4 (RR 0&#183;96; 95% Cl 0&#183;73-1&#183;27) and no sustained benefits in\u000a      terms of vitamin A status beyond six months.3.5\u000a    The ObaapaVitA trial3.6 was cluster randomised, evaluating the\u000a      effect of weekly VAS to women of reproductive age (including during\u000a      pregnancy and the postpartum period) on their survival and that of their\u000a      babies. Analyses based on a total 207,781 women, 581,870 woman-years,\u000a      78,835 pregnancies and 73,752 livebirths yielded the following relative\u000a      risks\/rates (95% CIs) comparing weekly VAS with placebo: 0.92 (0.73, 1.17)\u000a      for pregnancy-related mortality; 0.98 (0.89, 1.09) for severe\u000a      pregnancy-related morbidity; 1.01 (0.93, 1.09) for all cause adult female\u000a      mortality; 1.04 (0.96, 1.13) for stillbirths; and 0.98 (0.91, 1.05) for\u000a      infant mortality. This body of evidence does not support inclusion of VAS\u000a      for women in either safe motherhood or child survival strategies.\u000a    "},{"CaseStudyId":"41517","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"878675","Name":"Zimbabwe"},{"GeoNamesId":"895949","Name":"Zambia"},{"GeoNamesId":"149590","Name":"Tanzania"},{"GeoNamesId":"192950","Name":"Kenya"},{"GeoNamesId":"226074","Name":"Uganda"},{"GeoNamesId":"2245662","Name":"Senegal"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    The research described has had a direct impact on the HIV-related\u000d\u000a      policies of both international organisations and national governments in\u000d\u000a      Africa. Findings on knowledge and attitude change through education in\u000d\u000a      particular have been widely implemented.\u000d\u000a    UNESCO's 2009 International Technical Guidance on Sexuality Education\u000d\u000a      drew heavily on the evidence from the Tanzanian and Zimbabwean trials and\u000d\u000a      the Steady.., Ready..., Go! reviews, highlighting the MEMA kwa Vijana\u000d\u000a      results as `particularly interesting' while picking up on its caveat that\u000d\u000a      education and community-based programmes alone are not sufficient to bring\u000d\u000a      HIV incidence down.5.1 In 2010, comprehensive HIV knowledge\u000d\u000a      among 80% of young people was agreed as the first `bold result' of the\u000d\u000a      UNAIDS Business Case on Empowerment of Young People for HIV Prevention.\u000d\u000a      To help countries achieve this result, the UNAIDS Inter-Agency Task Team\u000d\u000a      on HIV and Young People agreed in 2011 to focus their efforts on sexuality\u000d\u000a      education in schools. The two trials were influential in these global\u000d\u000a      policy moves.5.2 The new UNAIDS Strategy for 2011-2015 points\u000d\u000a      to the need for expanded provision of effective school-based sexuality\u000d\u000a      education.5.3\u000d\u000a    The MEMA kwa Vijana intervention materials were introduced into schools\u000d\u000a      in Tanzania, Zambia and Zimbabwe in the early 2000s, and roll-out\u000d\u000a      continued between 2008-2013.5.3 The materials are approved for\u000d\u000a      use in primary schools in Tanzania, where they are published in Swahili,\u000d\u000a      and are freely available in both English and Swahili on the MEMA kwa\u000d\u000a      Vijana website.5.4 They were also the first HIV prevention\u000d\u000a      educational materials to be featured in the Global HIV Archive in 2012.5.5\u000d\u000a      Two reviews for UNESCO stressed the importance of these two trials and\u000d\u000a      specifically highlighted the MEMA kwa Vijana trial. SIECUS (Sexuality\u000d\u000a      Information and Education Council of the United States), in its Global\u000d\u000a        Vision: Promising Resources From Around the World (2008) describes\u000d\u000a      MEMA kwa Vijana as `innovative' and highlights the features of its\u000d\u000a      training package.5.6 MEMA kwa Vijana's results were also\u000d\u000a      important evidence used for the WHO guidelines on preventing early\u000d\u000a      pregnancy and poor reproductive outcomes among adolescents in developing\u000d\u000a      countries (2011),5.7 and the key UNICEF Opportunity in\u000d\u000a        Crisis document (2011) endorsed MEMA kwa Vijana and Regai Dzive\u000d\u000a      Shiri as `successful in changing attitudes'.5.8\u000d\u000a    Ministries of Health in Tanzania, Uganda and Kenya have accepted the two\u000d\u000a      programmes' joint policy recommendations that educational interventions\u000d\u000a      will need to be combined with both biomedical and structural measures to\u000d\u000a      change social and sexual norms. Global health-related agencies such as\u000d\u000a      UNESCO, WHO, UNICEF and UNAIDS have also used the recommendations, with\u000d\u000a      UNICEF's Fourth Stocktaking Report on Children and HIV citing the\u000d\u000a      policy brief based on these projects.5.9\u000d\u000a    The results of the Steady.., Ready..., Go! reviews have been used\u000d\u000a      extensively by policy-makers and programme implementers in international\u000d\u000a      agencies and governments to focus their priorities on `Go!' and `Ready'\u000d\u000a      interventions &#8212; those that should be implemented forthwith without needing\u000d\u000a      further evidence, and those that should be implemented with careful\u000d\u000a      evaluation.5.2, 5.10 Senior UNICEF staff have quoted the\u000d\u000a      reviews to justify their priorities, including Geeta Rao Gupta, Deputy\u000d\u000a      Executive Director at the International AIDS Conference in July 2012.5.10\u000d\u000a      A 2012 LSHTM-UNICEF review of the national response to prevent HIV among\u000d\u000a      young people in 20 high-prevalence countries found that the programme with\u000d\u000a      the strongest evidence and thus designated as `Go!' in the review &#8212;\u000d\u000a      in-school interventions that are adult-led and curriculum-based &#8212; was the\u000d\u000a      most widely-implemented youth prevention strategy across countries.5.10\u000d\u000a    Presentations of the research to policy-makers and health practitioners\u000d\u000a      have helped raise awareness and understanding of the research findings.\u000d\u000a      Ross presented findings from the MEMA kwa Vijana trial and the systematic\u000d\u000a      reviews at numerous UN and other meetings, including the Annual Meeting of\u000d\u000a      HIV Program Focal Points from Ministries of Education in Sub-Saharan\u000d\u000a      Africa, Dakar, Senegal, December 2008 (over 50 participants from 30\u000d\u000a      countries); and an expert consultation at the International Centre for\u000d\u000a      Research on Women, Washington DC, May 2011 (over 50 participants from\u000d\u000a      international organisations, funding agencies and governments).\u000d\u000a    Ross has also been influential as the Chair of the Technical Steering\u000d\u000a      Committee of the WHO's Department of Maternal, Newborn, Child and\u000d\u000a      Adolescent Health,5.2 on the UNAIDS Monitoring and Evaluation\u000d\u000a      Reference Group, and as an academic lead on the new Lancet\u000d\u000a      Commission on Adolescent Health and Wellbeing.5.2\u000d\u000a    In July 2013, Ross and colleagues presented their latest review of global\u000d\u000a      evidence on the effectiveness of interventions for HIV prevention,\u000d\u000a      treatment and care to UNICEF (48 participants, including UNICEF staff,\u000d\u000a      government adolescent health focal persons, etc.) and these have been used\u000d\u000a      as a central piece in UNICEF's new operational guidance on adolescents and\u000d\u000a      HIV.5.10\u000d\u000a    ","ImpactSummary":"\u000d\u000a    During the 1990s, LSHTM researchers documented a steep rise in HIV\u000d\u000a      prevalence among young people between the ages of 15 and 24 in eastern and\u000d\u000a      southern Africa. Subsequent trials in Tanzania and Zimbabwe examined the\u000d\u000a      effectiveness of interventions to reduce HIV incidence among this age\u000d\u000a      group. The results, and subsequent reviews, have substantially influenced\u000d\u000a      the HIV policies of international organisations such as UNICEF, UNESCO and\u000d\u000a      WHO, and HIV programmes in individual African countries. In particular,\u000d\u000a      findings on knowledge and attitude change through sexual health education\u000d\u000a      have been widely implemented.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000d\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2253354","Name":"Dakar"}],"References":"\u000d\u000a    \u000a3.1 Ross, DA, Changalucha, J, Obasi, AIN, Todd, J, Plummer, ML,\u000d\u000a      Cleophas-Mazige, B, Anemona, A, Everett, D, Weiss, HA, Mabey, DC,\u000d\u000a      Grosskurth, H and Hayes RJ (2007) Biological and behavioural impact of an\u000d\u000a      adolescent sexual health intervention in Tanzania: a community-randomized\u000d\u000a      trial, AIDS, 21(14): 1943-1955, doi: 10.1097\/QAD.0b013e3282ed3cf5.\u000d\u000a      Citation count: 95\u000d\u000a    \u000a\u000a3.2 Doyle, AM, Ross, DA, Maganja, K, Baisley, K, Masesa, C, Andreasen, A,\u000d\u000a      Plummer, ML, Obasi AIN, Weiss, HA, Kapiga, S, Watson-Jones, D,\u000d\u000a      Changalucha, J and Hayes RJ for the MEMA kwa Vijana Trial Study Group\u000d\u000a      (2010) Long-term biological and behavioural impact of an adolescent sexual\u000d\u000a      health intervention in Tanzania: follow-up survey of the community-based\u000d\u000a      MEMA kwa Vijana Trial, PLoS Medicine, 7(6): e1000287, doi:\u000d\u000a      10.1371\/journal.pmed.1000287. Citation count: 23\u000d\u000a    \u000a\u000a3.3 Cowan, FM, Pascoe, SJ, Langhaug, LF, Mavhu, W, Chidiya, S, Jaffar, S,\u000d\u000a      Mbizvo, MT, Stephenson, JM, Johnson, AM, Power, RM, Woelk, G and Hayes, RJ\u000d\u000a      on behalf of the Regai Dzive Shiri trial team (2010) The Regai Dzive Shiri\u000d\u000a      project: results of a randomized trial of an HIV prevention intervention\u000d\u000a      for youth, AIDS, 24(16): 2541-2552, doi:\u000d\u000a      10.1097\/QAD.0b013e32833e77c9. Citation count: 13\u000d\u000a    \u000a\u000a3.4 Wamoyi, JM, Wight, D, Plummer, M, Mshana, GH and Ross, D (2010)\u000d\u000a      Transactional sex amongst young people in rural northern Tanzania: an\u000d\u000a      ethnography of young women's motivations and negotiation, Reproductive\u000d\u000a        Health, 7(2), doi:10.1186\/1742-4755-7-2. Citation count: 19\u000d\u000a    \u000a\u000a3.5 Chapman, R, White, RG, Shafer, LA, Pettifor, A, Mugurungi, O, Ross,\u000d\u000a      D, Pascoe, S, Cowan, FM, Grosskurth, H, Buve, A and Hayes, RJ (2010) Do\u000d\u000a      behavioural differences help to explain variations in HIV prevalence in\u000d\u000a      adolescents in sub-Saharan Africa?, Tropical Medicine and\u000d\u000a        International Health, 15(5): 554-566, doi:\u000d\u000a      10.1111\/j.1365-3156.2010.02483.x. Citation count: 10\u000d\u000a    \u000a\u000a3.6 Napierala Mavedzenge, SM, Doyle, AM and Ross, DA (2011) HIV\u000d\u000a      prevention in young people in sub-Saharan Africa: a systematic review, Journal\u000d\u000a        of Adolescent Health, 49(6): 568-586, doi:\u000d\u000a      10.1016\/j.jadohealth.2011.02.007. Citation count: 8\u000d\u000a    \u000aKey grants\u000d\u000a    Hayes, MEMA kwa Vijana Trial, European Commission, 1997-2002, &#8364;3m and\u000d\u000a      Irish Aid, 2001-2002, &#8364;948,000.\u000d\u000a    Ross, Wight and Changalucha, HALIRA Programme, MRC, 1999-2004, &#163;844,000.\u000d\u000a    Ross, MEMA kwa Vijana Trial Further Survey, DFID and Irish Aid,\u000d\u000a      2006-2009, &#163;1.85m.\u000d\u000a    Ross, Review of Effectiveness of Interventions for HIV Prevention,\u000d\u000a      Treatment and Support. UNICEF, 2013, US$137,000.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    5.1 UNESCO (2009) International Technical Guidance on Sexuality\u000d\u000a        Education: An Evidence-informed Approach for Schools, Teachers and\u000d\u000a        Health Educators. Paris: UNESCO, http:\/\/hivaidsclearinghouse.unesco.org\/fileadmin\/user_upload\/pdf\/2009\/20091210_international_guidance_sexuality_education_vol_1_en.pdf\u000d\u000a      (accessed 16 October 2013) (this review highlighted the MEMA kwa Vijana\u000d\u000a      Trial in Box 4 on p. 16).\u000d\u000a    5.2 Scientist, Maternal, Newborn, Child &amp; Adolescent Health Dept\u000d\u000a      (MCA), WHO.\u000d\u000a    5.3 UNAIDS (2010) Getting to Zero: 2011-2015 Strategy,\u000d\u000a      http:\/\/www.unaids.org\/en\/media\/unaids\/contentassets\/documents\/unaidspublication\/2010\/JC2034_UNAIDS_Strategy_en.pdf\u000d\u000a      (accessed 16 October 2013) (see particularly p. 32).\u000d\u000a    5.4 MEMA kwa Vijana (2008) Teacher's Guides, http:\/\/memakwavijana.org\/materials-and-resources\/teachers-guides.html\u000d\u000a      (accessed 16 October 2013) (this web page had been accessed 457 times as\u000d\u000a      of June 2013).\u000d\u000a    5.5 MEMA kwa Vijana Program: Good Things for Young People, Global\u000d\u000a      HIV Archive, http:\/\/www.socio.com\/globalhivarchive\/GHA07.php.\u000d\u000a      (accessed 17 October 2013) (featured in Archive from 2012, this website\u000d\u000a      selects and then archives the most important and best evaluated\u000d\u000a      interventions for HIV prevention globally).\u000d\u000a    5.6 Sexuality Information and Education Council of the United States\u000d\u000a      (SIECUS) (2008) Global Vision: Promising Resources from Around the\u000d\u000a        World, http:\/\/www.siecus.org\/index.cfm?fuseaction=Feature.showFeature&amp;featureID=1154&amp;noheader=1\u000d\u000a      (accessed 16 October 2013) (this initiative provides `an online resource\u000d\u000a      that connects educators and program planners with the latest, most\u000d\u000a      compelling, international sexuality education, HIV and AIDS prevention,\u000d\u000a      and sexual and reproductive health interventions and practices').\u000d\u000a    5.7 WHO (2011) WHO Guidelines on Preventing Early Pregnancy and Poor\u000d\u000a        Reproductive Outcomes Among Adolescents in Developing Countries.\u000d\u000a      Geneva: WHO, http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241502214_eng.pdf\u000d\u000a      (accessed 16 October 2013) (specifically see refs #13 and 15 for Outcome\u000d\u000a      3, `Increase use of contraception by adolescents at risk of unintended\u000d\u000a      pregnancy', p. 68).\u000d\u000a    5.8 UNICEF, UNAIDS, UNESCO, UNFPA, ILO, WHO and World Bank (2011) Opportunity\u000a        in Crisis: Preventing HIV from Early Adolescence to Young Adulthood,\u000d\u000a      UNICEF, http:\/\/www.unicef.org\/publications\/index_58708.html\u000d\u000a      (accessed 16 October 2013) (see particularly pp. 17\/18 and their ref.\u000d\u000a      #81).\u000d\u000a    5.9 UNICEF, UNAIDS, WHO and UNFPA (2009) Children and AIDS: Fourth\u000d\u000a        Stocktaking Report. New York: UNICEF,\u000d\u000a      http:\/\/www.unicef.org\/publications\/files\/Children_and_AIDS_Fourth_Stocktaking_Report_EN_110609.pdf\u000d\u000a      (accessed 16 October 2013) (see particularly ref. #54, p. 17).\u000d\u000a    5.10 Senior Specialist\/Team Leader, HIV (Adolescents), UNICEF HQ.\u000d\u000a    ","Title":"\u000d\u000a    Preventing HIV in African adolescents\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Young people remain at the centre of the global HIV\/AIDS epidemic, with\u000d\u000a      15-24-year-olds accounting for 50% of new cases in developing countries.\u000d\u000a      There is increasing recognition that for anti-HIV interventions to work,\u000d\u000a      they must be tailored to meet the local circumstances of young people.\u000d\u000a    LSHTM has been at the forefront of global research on approaches to\u000d\u000a      improve sexual and reproductive health, and prevent HIV, among youth\u000d\u000a      (15-24 years) in Africa. In the 1990s, population-based HIV prevalence\u000d\u000a      surveys in sub-Saharan African countries, led by Richard Hayes (Professor\u000d\u000a      of Epidemiology &amp; International Health, LSHTM since 1978, then\u000d\u000a      Research Fellow) and others, highlighted a relatively low prevalence of\u000d\u000a      HIV and other STIs in 15-19-year-olds but a dramatic increase in\u000d\u000a      prevalence in 20-24-year-olds. There was a clear need for sexual and\u000d\u000a      reproductive health (SRH) interventions targeted specifically at youth.\u000d\u000a    Two major collaborative intervention programmes were subsequently\u000d\u000a      conducted by Hayes, David Ross (Professor of Epidemiology and Public\u000d\u000a      Health, LSHTM since 1983, then Research Fellow) and others, with\u000d\u000a      collaborators from University College London, Tanzania and Zimbabwe. These\u000d\u000a      included randomised controlled trials conducted between 1997 and 2008,\u000d\u000a      named MEMA kwa Vijana in Tanzania and Regai Dzive Shiri in Zimbabwe. They\u000d\u000a      showed that it was feasible to implement high-quality interventions in\u000d\u000a      schools, health facilities and the community using government employees\u000d\u000a      and\/or youth volunteers, and to scale these up. The trials also showed\u000d\u000a      that these interventions had a substantial and sustained impact on young\u000d\u000a      people's SRH knowledge and self-reported attitudes to sexual risks, and on\u000d\u000a      key self-reported sexual risk behaviours. However, there was no consistent\u000d\u000a      impact on pregnancy or HIV rates, which highlighted the importance of\u000d\u000a      including biomedical evidence in trials.3.1, 3.2, 3.3\u000d\u000a    HALIRA, a comprehensive qualitative study carried out in 1999-2002\u000d\u000a      alongside the Tanzanian trial (in collaboration with the Medical Research\u000d\u000a      Council's Social and Public Health Sciences Unit and the National\u000d\u000a      Institute for Medical Research, Tanzania) highlighted key societal and\u000d\u000a      social barriers to sexual behaviour change among young people. The\u000d\u000a      findings showed that societal norms predispose against young people\u000d\u000a      avoiding risky sex, for example by condoning and even encouraging\u000d\u000a      transactional sex; for young women, exchanging sex for gifts or support is\u000d\u000a      seen as normal and acceptable.3.4\u000d\u000a    Hayes, Ross and colleagues subsequently used data from the Tanzanian and\u000d\u000a      Zimbabwean trials, along with other data from South Africa, Zimbabwe and\u000d\u000a      Uganda, to show a lack of association between reported adolescent risk\u000d\u000a      behaviours and adolescent HIV prevalence. These findings suggest that it\u000d\u000a      is primarily sex with adults rather than each other that puts adolescents\u000d\u000a      at risk, and so future interventions should include adults.3.5\u000d\u000a    Meanwhile, Ross and colleagues (in collaboration with WHO) led the\u000d\u000a      `Steady..., Ready..., Go!' reviews published in 2006 for the UN\u000d\u000a      Inter-Agency Task Team for Young People. These examined what kinds of\u000d\u000a      interventions work to prevent HIV infection among youth in low- and\u000d\u000a      middle-income countries. Among the interventions graded as Go! (i.e. to be\u000d\u000a      implemented widely) were curriculum-based programmes in schools and\u000d\u000a      interventions run through existing community structures. LSHTM updated\u000d\u000a      three of the key reviews for sub-Saharan Africa in 2011.3.6\u000d\u000a    "},{"CaseStudyId":"41532","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"3144096","Name":"Norway"},{"GeoNamesId":"927384","Name":"Malawi"},{"GeoNamesId":"2361809","Name":"Burkina Faso"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"337996","Name":"Ethiopia"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"2328926","Name":"Nigeria"},{"GeoNamesId":"226074","Name":"Uganda"},{"GeoNamesId":"1269750","Name":"India"}],"Funders":[],"ImpactDetails":"\u000d\u000a    Since its launch in 2008 on the Futures Institute website,5.1\u000d\u000a      LiST has been adopted as a policy and decision-making tool by a wide range\u000d\u000a      of international agencies and organisations, governments, NGOs and others.5.2\u000d\u000a    The Global Action Plan for the Prevention and Control of Pneumonia\u000d\u000a      (GAPP), published by WHO and UNICEF in 2009, called for the increased use\u000d\u000a      of interventions of proven benefit and provided guidance on how this could\u000d\u000a      be done, using LiST to estimate the deaths due to pneumonia that could be\u000d\u000a      prevented by scaling-up different interventions.5.3\u000d\u000a    In November 2009, the science academies of seven sub-Saharan African\u000d\u000a      countries launched a seminal report, Science in Action: Saving the\u000d\u000a        Lives of Africa's Mothers, Newborns, and Children. A call to action\u000d\u000a      for African policy-makers, the report encouraged them to work with\u000d\u000a      scientists to make the most efficient changes to their health care\u000d\u000a      systems. The report makes extensive reference to LiST and its use in\u000d\u000a      preparing its findings.5.4\u000d\u000a    The Bill and Melinda Gates Foundation used LiST to underpin their\u000d\u000a      Impatient Optimist scheme (November 2009) and their Vaccine Delivery\u000d\u000a      Strategy (January 2010). Save the Children employed the tool in the\u000d\u000a      preparation of their Missing Midwives report (2011) to show that\u000d\u000a      1.3 million newborns annually could be saved using eight key\u000d\u000a      interventions.5.5\u000d\u000a    Born Too Soon: The Global Action Report on Preterm Birth, produced\u000d\u000a      in May 2012 by WHO, Save the Children, March of Dimes (an NGO that works\u000d\u000a      to improve the health of mothers and babies) and The Partnership for\u000d\u000a      Maternal, Neonatal and Child Health, with 50 partner organisations, used\u000d\u000a      LiST to identify priority packages and interventions for preterm babies.5.6\u000d\u000a      This initiative achieved wide media coverage, including reports in The\u000d\u000a        Guardian, Reuters and on the BBC in the UK, and in the New York\u000d\u000a        Times, USA Today and The Wall Street Journal in the USA. A\u000d\u000a      global relay on Twitter reached nearly 6.5 million users.\u000d\u000a    The UN Commission on Life Saving Commodities for Women and Children used\u000d\u000a      LiST in 2012 to estimate how many maternal and child lives could be saved\u000d\u000a      by different commodities.5.7\u000d\u000a    Other international users of LiST include the Pan-American Health\u000d\u000a      Organisation (PAHO), the GAVI Alliance, which exists to bring life-saving\u000d\u000a      vaccines to children in developing countries, and the Global Fund to Fight\u000d\u000a      AIDS, Tuberculosis and Malaria; bilateral agencies including DFID, USAID,\u000d\u000a      the Canadian International Development Agency (CIDA) and the Norwegian\u000d\u000a      Agency for Development Cooperation; as well as large NGOs and foundations\u000d\u000a      including PSI, World Vision, the Clinton Foundation, and the Children's\u000d\u000a      Investment Fund Foundation.\u000d\u000a    At national and regional level, LiST has been used in the following ways.\u000d\u000a    \u000d\u000a      The 2010 Evaluation of Malawi's Emergency Human Resources Programme\u000d\u000a        used LiST to analyse four indicators against which to measure increases\u000d\u000a        in utilisation in priority health services; as the report states, the\u000d\u000a        result was over 13,000 lives saved due to increased coverage of these\u000d\u000a        indicators.5.8\u000a\u000d\u000a      Two editions of Nigeria's national government report, Saving\u000d\u000a          Newborn Lives in Nigeria (2009 and 2011) used LiST analyses.5.9\u000d\u000a        The second report was linked to the addition of a line in the national\u000d\u000a        health budget for newborn health care.\u000d\u000a      Other individual countries that have used LiST to devise strategies to\u000d\u000a        save the lives of newborns have included Burkina Faso, Ethiopia, Uganda,\u000d\u000a        India (several states) and China.\u000d\u000a      \u000aThe Lancet Stillbirth series used LiST in 2011 to estimate\u000d\u000a        stillbirths averted with various packages of care, and the linked\u000d\u000a        maternal and newborn lives saved.\u000d\u000a    \u000d\u000a    In many of the examples mentioned, decisions based on LiST have\u000d\u000a      ultimately benefited newborns and children of families in low- and\u000d\u000a      middle-income countries by giving them increased access to life-saving\u000d\u000a      interventions.\u000d\u000a    Jeremy Shiffman, Associate Professor of Public Administration and Policy\u000d\u000a      at American University, examined the increased attention being paid to\u000d\u000a      newborn survival in his paper in The Lancet in 2010.5.10\u000d\u000a      He categorised this increase as `surprising: there was no sudden increase\u000d\u000a      in the number of babies dying or swift spread of a virus that alarmed\u000d\u000a      citizens of rich countries'. He concluded that The Lancet Neonatal\u000d\u000a      Survival series 2005, to which Cousens and colleagues had contributed\u000d\u000a      vital research, was important in solidifying links between key individuals\u000d\u000a      in the field and became `a point of reference on the severity, causes,\u000d\u000a      costing, and solutions to the problem of newborn mortality and had\u000d\u000a      substantial influence in agenda setting'.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    LSHTM research led to the development of a computer-based tool known as\u000d\u000a      the Lives Saved Tool (LiST), which has been made available to\u000d\u000a      international organisations, governments and NGOs free of charge. It\u000d\u000a      allows policy-makers and programme managers in the 75 countries with the\u000d\u000a      highest number of child deaths to identify which policy and programme\u000d\u000a      choices are likely to have the greatest impact in cutting neonatal and\u000d\u000a      child mortality. Since its 2008 launch, LiST has been used widely by\u000d\u000a      international agencies, foundations, bilateral agencies, large NGOs and\u000d\u000a      individual countries to determine investment priorities and programme\u000d\u000a      choices.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000d\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"5128638","Name":"New York"}],"References":"\u000d\u000a    \u000a3.1 Lawn, JE, Wilczynska-Ketende, K and Cousens SN (2006) Estimating the\u000d\u000a      causes of 4 million neonatal deaths in the year 2000, International\u000d\u000a        Journal of Epidemiology, 35(3): 706-718, doi:10.1093\/ije\/dyl043.\u000d\u000a      Citation count: 130\u000d\u000a    \u000a\u000a3.2 Darmstadt, GL, Bhutta, ZA, Cousens, S, Adam, T, Walker, N and de\u000d\u000a      Bernis, L (2005) Evidence-based, cost-effective interventions: how many\u000d\u000a      newborns can we save?, Lancet, 365(9463): 977-988, doi:\u000d\u000a      10.1016\/S0140-6736(05)71088-6. Citation count: 426\u000d\u000a    \u000a\u000a3.3 Bhutta, ZA, Ahmed, T, Black, RE, Cousens, S, Dewey, K, Giugliani, E,\u000d\u000a      Haider, BA, Kirkwood, B, Morris, SS, Sachdev, HP and Shekar, M, for the\u000d\u000a      Maternal and Child Undernutrition Study Group (2008) What works?\u000d\u000a      Interventions for maternal and child undernutrition and survival, Lancet,\u000d\u000a      371(9610): 417-440, doi:10.1016\/S0140-6736(07)61693-6. Citation count: 386\u000d\u000a    \u000a\u000a3.4 Walker, N, Fischer-Walker, C, Bryce, J, Bahl, R and Cousens, S,\u000d\u000a      writing for the CHERG Review Groups on Intervention Effects (2010)\u000d\u000a      Standards for CHERG reviews of intervention effects on child survival, International\u000a        Journal of Epidemiology, 39(Suppl. 1): i21-i31,\u000d\u000a      doi:10.1093\/ije\/dyq036. Citation count: 60\u000d\u000a    \u000a\u000a3.5 Cousens, S, Blencowe, H, Gravett, M and Lawn JE (2010) Antibiotics\u000d\u000a      for pre-term pre-labour rupture of membranes: prevention of neonatal\u000d\u000a      deaths due to complications of pre-term birth and infection, International\u000a        Journal of Epidemiology, 39(Suppl 1): i134-i143,\u000d\u000a      doi:10.1093\/ije\/dyq030. Citation count: 12\u000d\u000a    \u000a\u000a3.6 Blencowe, H, Lawn, J, Vandelaer, J, Roper, M and Cousens, S (2010)\u000d\u000a      `Tetanus toxoid immunization to reduce mortality from neonatal tetanus, International\u000a        Journal of Epidemiology, 39 (Suppl. 1): i102-i109,\u000d\u000a      doi:10.1093\/ije\/dyq027. Citation count: 24\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    5.1 Website of the Futures Institute with download facility for LiST,\u000d\u000a      http:\/\/www.futuresinstitute.org\/spectrum.aspx.\u000d\u000a    5.2 Selected list of applications of LiST and articles referencing the\u000d\u000a      tool,\u000d\u000a      http:\/\/www.jhsph.edu\/departments\/international-health\/IIP\/list\/applications.html.\u000d\u000a    5.3 WHO\/UNICEF (2009) Global Action Plan for Prevention and Control\u000d\u000a        of Pneumonia (GAPP), WHO\/FCH\/CAH\/NCH\/09.04, WHO\/UNICEF, http:\/\/www.unicef.org\/media\/files\/GAPP3_web.pdf\u000d\u000a      (accessed 20 September 2013). Developed using LiST (see e.g. footnote to\u000d\u000a      Figure 3, p. 2 and footnote 2, p. 8).\u000d\u000a    5.4 Kinney, MV, Lawn, JE and Kerber, KJ (eds) (2009) Science in\u000d\u000a        Action: Saving the Lives of Africa's Mothers, Newborns, and Children,\u000d\u000a      report for the African Academy Science Development Initiative. Cape Town,\u000d\u000a      South Africa,\u000d\u000a      http:\/\/www.nationalacademies.org\/asadi\/2009_Conference\/PDFs\/ScienceInActionFullReport.pdf\u000d\u000a      (accessed 11 September 2013) (see e.g. p. 3 `Saving 4 million lives each\u000d\u000a      year').\u000d\u000a    5.5 Rawe, K, Williams, S, Kerber, K and Lawn, J (2011) Missing\u000d\u000a        Midwives. London: Save the Children, http:\/\/www.savethechildren.org.uk\/sites\/default\/files\/docs\/Missing_Midwives_1.pdf\u000d\u000a      (accessed 11 September 2013) (see e.g. p. 3).\u000d\u000a    5.6 WHO, March of Dimes, The Partnership for Maternal, Newborn and Child\u000d\u000a      Health and Save the Children (2012) Born Too Soon: The Global Action\u000d\u000a        Report on Preterm Birth. Geneva: WHO,\u000d\u000a      http:\/\/www.who.int\/pmnch\/media\/news\/2012\/preterm_birth_report\/en\/index1.html\u000d\u000a      (accessed 20 September 2013) (use of LiST, see e.g. Table 5.2, p. 65 and\u000d\u000a      p. 87).\u000d\u000a    5.7 UN (2012) UN Commission on Life-Saving Commodities for Women and\u000d\u000a        Children:\u000d\u000a        Commissioner's Report September 2012. New York: UN,\u000d\u000a      http:\/\/www.everywomaneverychild.org\/images\/UN_Commission_Report_September_2012_Final.pdf\u000d\u000a      (accessed 11 September 2013). Used LiST to estimate the potential of\u000d\u000a      different commodities to save maternal and child lives (see Annex, Page\u000d\u000a      19).\u000d\u000a    5.8 O'Neil, M, Jarrah, Z, Nkosi, L, Collins, D, Perry, C, Jackson, J,\u000d\u000a      Kuchande, H and Mlambala, A (2010) Evaluation of Malawi's Emergency\u000d\u000a        Human Resources Programme: EHRP Final Report.\u000d\u000a      Management Sciences for Health (MSH), Management Solutions Consulting\u000d\u000a      (MSC) Ltd., Department for International Development,\u000d\u000a      http:\/\/www.who.int\/workforcealliance\/media\/news\/2010\/Malawi_MSH_MSC_EHRP_Final.pdf\u000d\u000a      (accessed 11 September 2013) (used LiST to estimate the lives saved by the\u000d\u000a      Emergency Human Resources Programme in Malawi &#8212; see e.g. p. 4).\u000d\u000a    5.9 Federal Ministry of Health (2011) Saving Newborn lives in\u000d\u000a        Nigeria: Newborn Health in the Context of the Integrated Maternal,\u000d\u000a        Newborn and Child Health Strategy, 2nd edn. Abuja: Federal Ministry\u000d\u000a      of Health, Save the Children &amp; Jhpiego,\u000d\u000a      http:\/\/www.healthynewbornnetwork.org\/sites\/default\/files\/resources\/Nigeria%20Sit%20An%20final\u000a        %20lowres_FINAL.pdf (accessed 11 September 2013) (the report used\u000d\u000a      LiST to estimate the lives that could be saved by increasing coverage of\u000d\u000a      key interventions &#8212; see p. 76).\u000d\u000a    5.10 Shiffman, J (2010) Issue attention in global health: the case of\u000d\u000a      newborn survival, Lancet, 375(9730): 2045-2049, doi:\u000d\u000a      10.1016\/S0140-6736(10)60710-6. Article which discusses the importance of The\u000a        Lancet Neonatal Survival series.\u000d\u000a    ","Title":"\u000d\u000a    Enhancing evidence-based policy decisions for neonatal and child survival\u000d\u000a      in the highest mortality countries\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Every year 7m children worldwide die before their fifth birthday, with\u000d\u000a      98% occurring in low- and middle-income countries, and 43% taking place\u000d\u000a      during the first 28 days of life. Reducing child mortality by two thirds\u000d\u000a      between 1990 and 2015 is one of the UN Millennium Development Goals.\u000d\u000a    Research conducted by Simon Cousens, Professor of Epidemiology and\u000d\u000a      Medical Statistics (LSHTM since 1985), has contributed important work\u000d\u000a      towards this goal through the development of the LiST. LSHTM research has\u000d\u000a      contributed in three main areas: developing methods to estimate\u000d\u000a      country-specific cause of death distributions; defining the structure of\u000d\u000a      the model underpinning LiST; and providing key inputs to the neonatal\u000d\u000a      component of LiST (estimates of neonatal deaths by cause and by country,\u000d\u000a      and estimates of the effectiveness of interventions to prevent neonatal\u000d\u000a      deaths).\u000d\u000a    Cousens is a member of the Child Health Epidemiology Reference Group\u000d\u000a      (CHERG), which provides independent technical expertise to WHO and UNICEF\u000d\u000a      on child morbidity and mortality estimates. Along with Joy Lawn, formerly\u000d\u000a      Director Global Evidence and Policy, Saving Newborn Lives, Save the\u000d\u000a      Children, and Professor of Maternal Reproductive and Child Health\u000d\u000a      Epidemiology at LSHTM since 2013, he developed a statistical model using a\u000d\u000a      multinomial modelling approach applied to vital registration data and\u000d\u000a      datasets identified from a review of the literature. This produced\u000d\u000a      national estimates of neonatal deaths by cause,3.1 an approach\u000d\u000a      now also used for post-neonatal child deaths.\u000d\u000a    These estimates were key inputs into the 2005 Lancet Neonatal\u000d\u000a      Survival series (co-led with Lawn). As part of the series, Cousens\u000d\u000a      developed a computer model, building on that developed previously for the\u000d\u000a      2003 Lancet Child Survival Series, using the estimates of neonatal\u000d\u000a      deaths by cause, to estimate the number of neonatal deaths that could be\u000d\u000a      prevented with different interventions.3.2 Subsequently Cousens\u000d\u000a      developed a cohort model for child mortality which formed part of the Lancet\u000d\u000a      Maternal and Child Undernutrition series and provided estimates of the\u000d\u000a      number of deaths and cases of stunting that could be averted by providing\u000d\u000a      nutrition.3.3 These models were the predecessors of LiST.\u000d\u000a    In 2008, the Bill and Melinda Gates Foundation provided funding through\u000d\u000a      the Johns Hopkins School of Public Health to enable the Futures Institute\u000d\u000a      to integrate the models mentioned above into Spectrum, a pre-existing\u000d\u000a      suite of policy models which provide policy-makers with `analytical tools\u000d\u000a      to support the decision-making process'. This process directly led to the\u000d\u000a      launch of LiST as a publicly available tool later that year.\u000d\u000a    A key input for LiST are estimates of the effectiveness of different\u000d\u000a      interventions in terms of the proportion of deaths due to specific causes\u000d\u000a      that an intervention can prevent. Cousens played a key role in setting the\u000d\u000a      standards for the literature reviews from which these effect estimates\u000d\u000a      were derived, and in establishing rules for deriving effect estimates.3.4\u000d\u000a      He and Hannah Blencowe, Research Fellow at LSHTM since 2010, also\u000d\u000a      contributed to or led many of the reviews of interventions to prevent\u000d\u000a      neonatal deaths that were coordinated by Lawn and published in a\u000d\u000a      supplement to the International Journal of Epidemiology in 2010.3.5,3.6\u000d\u000a    "},{"CaseStudyId":"41548","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"2328926","Name":"Nigeria"},{"GeoNamesId":"1512440","Name":"Uzbekistan"},{"GeoNamesId":"1210997","Name":"Bangladesh"},{"GeoNamesId":"2413451","Name":"Gambia"},{"GeoNamesId":"1036973","Name":"Mozambique"},{"GeoNamesId":"1562822","Name":"Vietnam"},{"GeoNamesId":"630336","Name":"Belarus"},{"GeoNamesId":"2029969","Name":"Mongolia"},{"GeoNamesId":"1168579","Name":"Pakistan"}],"Funders":[],"ImpactDetails":"\u000a    The research carried out by the LSHTM team as part of the Hib Initiative\u000a      directly contributed to a\u000a      large number of low- and middle-income countries deciding to introduce the\u000a      vaccine, reducing their\u000a      paediatric death and disease burden very significantly.\u000a    The research LSHTM did within the Hib Initiative allowed health\u000a      ministries in developing countries\u000a      to establish the disease burden of Hib and make evidence-based arguments\u000a      in favour of\u000a      introducing a suitable vaccine. The resulting figures show the very\u000a      significant rise in Hib vaccine\u000a      take-up. While in 2005, only 91 out of 193 WHO member states (47%) were\u000a      using Hib vaccine, this\u000a      number had risen to 163 out of 193 (84%) by 2010.5.1 The\u000a      greatest increase occurred in GAVI-\u000a      eligible countries, with an increase from 24 (33%) in 2007 to 71 (97%) out\u000a      of 73 countries by June\u000a      2013. In India and Nigeria, Hib vaccine is used only regionally.\u000a    According to the 2013 WHO report on GAVI progress, 153m children were\u000a      vaccinated with Hib\u000a      through GAVI support during 2000-2012, which has prevented approximately\u000a      658,000 deaths.5.2\u000a      Deaths prevented in GAVI countries during the period 2008-2013 are\u000a      estimated as 509,000.5.2 In\u000a      2011, the GAVI Alliance committed to vaccinating a further 224m children\u000a      with Hib vaccine by\u000a      2015.\u000a    The example of Mozambique (which introduced the vaccine in 2009 following\u000a      a country-specific\u000a      study supported by the LSHTM team to aid decision-making) impressively\u000a      illustrates the impact of\u000a      Hib vaccine adoption on a country's death and disease burden in a rural\u000a      high-HIV epidemic area.\u000a      Among children under 1 and under 5, significant reductions occurred in\u000a      rates of invasive Hib\u000a      disease (91% and 85%, respectively) and very severe pneumonia (29% and\u000a      34%, respectively).5.3\u000a      Radiologically-confirmed pneumonia incidence fell by 33% in children under\u000a      2.\u000a    Another pertinent example is Bangladesh, which also introduced the Hib\u000a      vaccine in 2009, citing\u000a      advocacy by the Hib Initiative as a catalyst for action for its adoption.5.4\u000a      The measure is expected to\u000a      save 20,000 lives in Bangladesh per year.5.5\u000a    A number of other countries specifically studied by the LSHTM team to aid\u000a      decision-making also\u000a      introduced the Hib vaccine within the impact assessment period. These\u000a      included Pakistan (2008),\u000a      Uzbekistan (2009) and Vietnam (2010). Work in India is ongoing as the\u000a      country slowly moves\u000a      towards full implementation, with implementation strongly recommended by\u000a      local authorities.5.6\u000a    Apart from their direct research input into the Hib Initiative, the LSHTM\u000a      team also actively helped\u000a      promote awareness and understanding of their findings among\u000a      decision-makers at country and\u000a      international organisation level. They actively sought to change country\u000a      policy,5.7 with Griffiths\u000a      presenting the findings at no fewer than nine high-level international\u000a      gatherings between 2008 and\u000a      2012. These included, among others:\u000a    \u000a      a meeting involving the Indian Ministry of Health and WHO in 2008,\u000a        which discussed proposed\u000a        plans for estimating the cost-effectiveness of Hib vaccine in India\u000a      a meeting with officials from the Belarus Ministry of Health in Minsk\u000a        in 2009, where Griffiths\u000a        again reported on cost-effectiveness\u000a      a presentation at WHO in Geneva in 2012, where Griffiths highlighted\u000a        that the vaccine has\u000a        been shown to be cost-effective for all countries, and is likely to be\u000a        cost-saving in Africa.5.8\u000a\u000a    \u000a    Since 2008, other team members have been engaged in similar advocacy work\u000a      based on the\u000a      research. Mulholland has spoken at 15 international meetings in major\u000a      plenaries as well as at\u000a      smaller regional and country meetings, and Edmond built a trusting\u000a      relationship with decision-\u000a      makers in Mongolia (2007-2010).\u000a    The GAVI Alliance calls the Hib Initiative a `success story', stating\u000a      that `By pooling the knowledge\u000a      and expertise of the Johns Hopkins Bloomberg School of Public Health,\u000a      LSHTM, and the CDC, the\u000a      Hib Initiative used a combination of collecting and disseminating existing\u000a      data, research and\u000a      advocacy to help countries build a case for adopting the Hib vaccine.'5.9\u000a      The Deputy Chief\u000a      Executive Officer of the GAVI Alliance has affirmed that `the success of\u000a      the Hib Initiative program\u000a      can be seen by the excellent uptake of Hib vaccine by GAVI eligible\u000a      countries during the relatively\u000a      short period of the project. LSHTM played a major role in this project,\u000a      particularly in the areas of\u000a      gathering, synthesizing and generating the epidemiology and economic\u000a      evidence'.5.10\u000a    ","ImpactSummary":"\u000a    Research at LSHTM has been central to the introduction of the Hib vaccine\u000a      in developing\u000a      countries. School staff were involved in the 1990s Gambia Hib vaccine\u000a      trial, which demonstrated\u000a      the impact of Hib vaccine on pneumonia. Through their work on the\u000a      subsequent Hib Initiative, their\u000a      research was instrumental in speeding up evidence-based decision-making\u000a      for Hib vaccine\u000a      introduction in a number of countries, mainly in Asia and Africa. The\u000a      project has been an\u000a      outstanding success, with Hib vaccine now introduced into 71 of the 73\u000a      countries eligible for GAVI\u000a      Alliance support.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2660646","Name":"Genve"},{"GeoNamesId":"625144","Name":"Minsk"}],"References":"\u000a    \u000a3.1 Mulholland, K, Hilton, S, Adegbola, R, Usen, S, Oparaugo, A,\u000a      Omosigho, C, Weber, M,\u000a      Palmer, A, Schneider, G, Jobe, K, Lahai, G, Jaffar, S, Secka, O, Lin, K,\u000a      Ethevenaux, C and\u000a      Greenwood, B (1997) Randomised trial of Haemophilus influenzae\u000a      type-b tetanus protein\u000a      conjugate vaccine for prevention of pneumonia and meningitis in Gambian\u000a      infants, Lancet,\u000a      349(9060): 1191-1197, doi:10.1016\/S0140-6736(96)09267-7. Citation count:\u000a      281\u000a    \u000a\u000a3.2 O'Loughlin, RE, Edmond, K, Mangtani, P, Cohen, AL, Shetty, S, Hajjeh,\u000a      R and Mulholland, K\u000a      (2010) Methodology and measurement of the effectiveness of Haemophilus\u000a        influenzae type b\u000a      vaccine: systematic review, Vaccine, 28(38): 6128-6136,\u000a      doi:10.1016\/j.vaccine.2010.06.107.\u000a      Citation count: 9\u000a    \u000a\u000a3.3 Watt, JP, Wolfson, LJ, O'Brien, KL, Henkle, E, Deloria-Knoll, M,\u000a      McCall, N, Lee, E, Levine, OS,\u000a      Hajjeh, R, Mulholland, K and Cherian, T for the Hib and Pneumococcal\u000a      Global Burden of Disease\u000a      Study Team (2009) Burden of disease caused by Haemophilus influenzae\u000a      type b in children\u000a      younger than 5 years: global estimates, Lancet, 374(9693):\u000a      903-911, doi:10.1016\/S0140-\u000a      6736(09)61203-4. Citation count: 121\u000a    \u000a\u000a3.4 Edmond, K, Clark, A, Korczak, VS, Sanderson, C, Griffiths, UK and\u000a      Rudan, I (2010) Global and\u000a      regional risk of disabling sequelae from bacterial meningitis: a\u000a      systematic review and meta-\u000a      analysis, Lancet Infectious Diseases, 10(5): 317-328,\u000a      doi:10.1016\/S1473-3099(10)70048-7.\u000a      Citation count: 57\u000a    \u000a\u000a3.5 Griffiths, UK , Clark, A and Hajjeh, R (2013) Cost-effectiveness of Haemophilus\u000a        influenzae type\u000a      b conjugate vaccine in low- and middle-income countries: regional analysis\u000a      and assessment of\u000a      major determinants, Journal of Paediatrics, 163(1) (Suppl.):\u000a      S50-S59.e9,\u000a      doi:10.1016\/j.jpeds.2013.03.031. Citation count: 0\u000a    \u000a\u000a3.6 Griffiths, UK, Clark, A, Shimanovich, V, Glinskaya, I, Tursunova, D,\u000a      Kim, L, Mosina, L, Hajjeh,\u000a      R and Edmond, K (2011) Comparative economic evaluation of Haemophilus\u000a        influenzae type b\u000a      vaccination in Belarus and Uzbekistan, PLoS One, 6(6): e21472,\u000a      doi:10.1371\/journal.pone.0021472. Citation count: 2\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    5.1 International Vaccine Access Center (IVAC) (2013) Vaccine\u000a        Information Management System\u000a        (VIMS) Report: Global Vaccine Introduction. Baltimore, MD: Johns\u000a      Hopkins Bloomberg School of\u000a      Public Health, http:\/\/www.jhsph.edu\/research\/centers-and-institutes\/ivac\/vims\/IVAC-VIMS-Report-2013-03.pdf\u000a      (accessed 12 September 2013).\u000a    5.2 WHO (2012) WHO Report on GAVI Progress 2000-2011 &amp; Projected\u000a      Achievements 2012, rev.\u000a      March 2013, [unpublished].\u000a    5.3 Siga&#250;que, B, Vubil, D, Sozinho, A, Quint&#243;, L, Morais, L, Sacoor, C,\u000a      Carvalho, MG, Verani, JR,\u000a      Alonso, PL and Roca A (2013) Haemophilus influenzae type b disease\u000a      among children in rural\u000a      Mozambique: impact of vaccine introduction, Journal of Pediatrics,\u000a      163(1) (Suppl.): S19-S24,\u000a      doi:10.1016\/j.jpeds.2013.03.026.\u000a    5.4 Burchett, HED, Mounier-Jack, S, Griffiths, UK, Biellik, R,\u000a      Ongolo-Zogo, P, Chavez, E, Sarma,\u000a      H, Uddin, J, Konate, M, Kitaw, Y, Molla, M, Wakasiaka, S, Gilson, L and\u000a      Mills A (2012) New\u000a      vaccine adoption: qualitative study of national decision-making processes\u000a      in seven low- and\u000a      middle-income countries, Health Policy and Planning, 27(2)\u000a      (Suppl.): ii5-ii16,\u000a      doi:10.1093\/heapol\/czs035 (reference to Hib Initiative p. 11).\u000a    5.5 http:\/\/www.icddrb.org\/media-centre\/news\/2016-hib-vaccine-introduced-into-routine-immunization-in-bangladesh.\u000a    5.6 Subcommittee on Introduction of Hib Vaccine in Universal Immunization\u000a      Program, National\u000a      Technical Advisory Group on Immunization, India (2009) NTAGI subcommittee\u000a      recommendations\u000a      on Haemophilus influenzae type B (Hib) vaccine introduction in\u000a      India, Indian Pediatrics, 46(11):\u000a      945-954.\u000a    5.7 Hajjeh, RA, Privor-Dumm, L, Edmond, K, O'Loughlin, R, Shetty, S,\u000a      Griffiths, UK, Bear, AP,\u000a      Cohen, AL, Chandran, A, Schuchat, A, Mulholland, EK and Santosham M (2010)\u000a      Supporting new\u000a      vaccine introduction decisions: lessons learned from the Hib Initiative\u000a      experience, Vaccine, 28(43):\u000a      7123-7129, doi:10.1016\/j.vaccine.2010.07.028.\u000a    5.8 http:\/\/www.who.int\/immunization\/sage\/meetings\/2012\/november\/9._Cost_effectiveness_of_Hib_vaccine_review_of_literature_Griffiths_U_2012.pdf\u000a    5.9 Hib Initiative: a GAVI success story, http:\/\/www.gavialliance.org\/library\/news\/roi\/2010\/hib-initiative--a-gavi-success-story\/.\u000a    5.10 Deputy Chief Executive Officer, GAVI Alliance.\u000a    ","Title":"\u000a    Supporting decision-making on the introduction of Haemophilus\u000a        influenzae\u000a      type b (Hib) vaccine in low- and middle-income countries\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    In 2008 Hib was the third biggest cause of vaccine-preventable deaths in\u000a      children under 5 years.\u000a      Hib vaccine, first licensed in the US in 1990, was introduced into routine\u000a      vaccination schedules in\u000a      most high-income countries within a few years, leading to the elimination\u000a      of invasive Hib disease in\u000a      those countries. However, the use of Hib vaccine in developing countries\u000a      remained low due to high\u000a      cost and uncertain disease burden.\u000a    A team at LSHTM has focused a substantial programme of research on\u000a      supporting decision-\u000a      making for Hib vaccine introduction. Between 1993 and 1996, a large trial\u000a      in The Gambia\u000a      demonstrated the efficacy of the vaccine for the prevention of Hib\u000a      invasive disease and pneumonia\u000a      in Africa for the first time.3.1 LSHTM staff members at that\u000a      time (Peter Smith, Professor of Tropical\u000a      Epidemiology, at LSHTM since 1979, and Shabbar Jaffar, now Professor of\u000a      Epidemiology, at\u000a      LSHTM since 1996, then Lecturer ) were involved in the design, oversight\u000a      and analysis of the trial,\u000a      which was led by Professors Kim Mulholland and Sir Brian Greenwood, both\u000a      of whom later joined\u000a      LSHTM (in 2005 and 1996, respectively). However, by 2000, only one\u000a      sub-Saharan African country\u000a      (The Gambia) had introduced Hib vaccine.\u000a    The GAVI Alliance, a private-public global health partnership, was set up\u000a      in 2000 to increase\u000a      access to immunisation in poor countries. Initially, it offered Hib\u000a      vaccine free of charge to eligible\u000a      countries for five years. However, by early 2005, only 14 countries had\u000a      made use of this offer due\u000a      to lack of awareness and concerns about financial sustainability. In\u000a      response, the GAVI Alliance\u000a      invited proposals for a project aiming to accelerate the use of\u000a      evidence-informed decision-making\u000a      about Hib vaccine. In late 2005, Kim Mulholland (by then Professor of\u000a      Child Health and\u000a      Vaccinology at LSHTM) secured the US$37m project in partnership with Johns\u000a      Hopkins University,\u000a      with WHO and US Centers for Disease Control (CDC) as collaborators.\u000a    Within the Hib Initiative consortium, LSHTM was responsible for\u000a      epidemiological studies (lead, Kim\u000a      Mulholland; also Karen Edmond, LSHTM 2002-12, initially Research Fellow),\u000a      health economics\u000a      (lead, Ulla Griffiths, LSHTM Lecturer since 2006) and mathematical\u000a      modelling (Andrew Clark,\u000a      LSHTM Research Fellow since 2002). The group developed epidemiological\u000a      methods for\u000a      determining the effectiveness of Hib vaccine.3.2 It contributed\u000a      to estimating the global burden of Hib\u000a      disease,3.3,3.4 showing that Hib caused 371,000 deaths in\u000a      children under 5 each year, and that the\u000a      substantial disease burden caused by Hib is almost entirely\u000a      vaccine-preventable.3.3 The group also\u000a      showed that Hib conjugate vaccine is cost saving or highly cost effective\u000a      in low- and middle-income\u000a      countries.3.5 In addition, starting in 2007, a number of\u000a      country-specific studies were undertaken in\u000a      Mozambique, Ethiopia, Pakistan, Bangladesh, Vietnam, Belarus and\u000a      Uzbekistan, all with a view to\u000a      aiding decision-making on introducing the vaccine.3.6 The\u000a      project supported countries through the\u000a      various stages of decision-making and vaccine introduction. The Hib\u000a      Initiative Project will wind up\u000a      at the end of 2013.\u000a    "},{"CaseStudyId":"41565","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"149590","Name":"Tanzania"},{"GeoNamesId":"192950","Name":"Kenya"}],"Funders":["Wellcome Trust"],"ImpactDetails":"\u000a    LSHTM research was pivotal both in shaping the design of the AMFm, an\u000a      initiative launched in\u000a      2009 seeking to enable countries to increase the provision of affordable,\u000a      quality-assured ACTs\u000a      through the public, private not-for-profit and private for-profit sectors;\u000a      and subsequently influencing\u000a      the 2012 decision to integrate the AMFm into the core funding mechanism of\u000a      the Global Fund to\u000a      fight AIDS, Tuberculosis and Malaria.\u000a    In 2004, the US IOM committee suggested a subsidy of ACT administered at\u000a      the top of the supply\u000a      chain, and available through public and private sectors, to increase\u000a      access to effective\u000a      antimalarials and reduce the risk of artemisinin resistance. LSHTM\u000a      research on the size of the\u000a      private market and on private sector antimalarial prices was one of the\u000a      few pieces of empirical\u000a      evidence available. This evidence underlined the need to include the\u000a      private sector in the subsidy\u000a      mechanism, and was used to estimate the magnitude of price reduction\u000a      needed to crowd out non-\u000a      artemisinin therapies.5.1, 5.2 Hosted and managed by the Global\u000a      Fund, the AMFm was implemented\u000a      in 2009 at national scale in eight African countries as a result of the\u000a      IOM proposals, which were\u000a      championed by the Roll Back Malaria partnership (which implements\u000a      coordinated action against\u000a      malaria).\u000a    The hypotheses that a subsidy programme would increase access to ACT and\u000a      reduce the\u000a      availability of artemisinin monotherapies which can encourage the spread\u000a      of artemisinin-resistant\u000a      strains of malaria, were tested in pilot antimalarial subsidy programmes\u000a      in Kenya and Tanzania in\u000a      2008-2010, for which LSHTM researchers provided key methodological\u000a      guidance5.3 and which\u000a      also informed the design of the AMFm.\u000a    The working groups designing the AMFm made direct reference to LSHTM work\u000a      and LSHTM\u000a      researchers were consulted on aspects of the design.5.4 LSHTM\u000a      research was also included\u000a      among the evidence used to establish the success metrics against which\u000a      AMFm would be\u000a      assessed in the 2010-2012 independent evaluation5.5 which would\u000a      guide future board decisions.\u000a    LSHTM researchers (Hanson, Goodman and Tougher) were key members of the\u000a      (competitively\u000a      selected) AMFm independent evaluation team, and led the design and\u000a      analysis of the outlet survey\u000a      in the eight AMFm countries in Africa. LSHTM researchers also designed the\u000a      qualitative case\u000a      studies which generated data used to interpret and attribute programme\u000a      impact. AMFm countries\u000a      started ordering subsidised ACT in mid-2010, and by the end of 2012 over\u000a      292m doses of\u000a      subsidised ACT had been ordered, of which 56% were paediatric.5.6,\u000a        5.7 The independent evaluation\u000a      showed that purchases of quality-assured ACT increased substantially in\u000a      all but two countries, with\u000a      ACT market share increasing from 16 to 40%. Subsidised antimalarials were\u000a      reaching rural and\u000a      remote areas and drug affordability was substantially improved, with price\u000a      reductions observed in\u000a      rural as well as urban areas.5.7\u000a    The research methods developed by LSHTM for studying retail antimalarial\u000a      medicine supply have\u000a      subsequently been adapted and used on a much larger scale by ACTwatch, a\u000a      consortium including\u000a      LSHTM and funded by Gates to monitor programme implementation in 2008-2013\u000a      and provide\u000a      evidence on how to improve ACT availability and reduce private sector\u000a      prices. ACTwatch adapted\u000a      the tools of Goodman et al. for more than 30 nationwide surveys of retail\u000a      outlets in 10 developing\u000a      countries across Africa and Southeast Asia. Methodological innovations\u000a      included sampling outlets\u000a      where no sampling frame exists; ways to question informal medicine\u000a      suppliers; metrics for\u000a      comparing volumes across different antimalarial classes and formulations;\u000a      methods for measuring\u000a      sales volumes; and approaches for documenting the distribution chain.\u000a      ACTwatch helped stimulate\u000a      funding for new research and policy advocacy. The data have also been used\u000a      for policy advocacy\u000a      at country level, contributing, for instance, to the decision in Zanzibar\u000a      to strengthen regulation to\u000a      remove oral artemisinin monotherapies from drug selling outlets.5.8\u000a    The independent evaluation ultimately led to the integration of AMFm into\u000a      core Global Fund\u000a      processes in 2012. The note of the Global Fund board decision explicitly\u000a      recognised the\u000a      independent evaluation.5.9, 5.10 In future, countries will be\u000a      responsible for allocating resources to\u000a      expand access to malaria diagnosis and treatment through the private\u000a      sector from their overall\u000a      Global Fund grants.\u000a    Research team members Hanson and Tougher were cited in a range of media,\u000a      including US\u000a      National Public Radio, Nature, the Irish Journal, BBC\u000a        News, Science, The New York Times and\u000a      News Medical, helping to increase understanding of AMFm and the\u000a      underpinning research among\u000a      the general public.\u000a    ","ImpactSummary":"\u000a    Research carried out by LSHTM made a fundamental contribution to the\u000a      creation of the Affordable\u000a      Medicines Facility &#8212; malaria (AMFm), a financing mechanism initiated to\u000a      improve access to\u000a      effective antimalarials through subsidies and price negotiations with drug\u000a      manufacturers. Drawing\u000a      on LSHTM research showing the importance of the private sector in\u000a      supplying antimalarial\u000a      medicines, the scheme was proposed by the US Institute of Medicine (IOM)\u000a      and piloted in Kenya\u000a      and Tanzania. After its 2009 launch, a subsequent evaluation by LSHTM and\u000a      others using LSHTM\u000a      methodological innovations led to AMFm's integration into ongoing funding\u000a      streams.\u000a    ","ImpactType":"Economic","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1 Goodman, C, Kachur, SP, Abdulla, S, Mwageni, E, Nyoni, J,\u000a      Schellenberg, JA, Mills, A and\u000a      Bloland, P (2004) Retail supply of malaria-related drugs in rural\u000a      Tanzania: risks and opportunities,\u000a      Tropical Medicine and International Health, 9(6): 655-663, doi:\u000a      10.1111\/j.1365-3156.2004.01245.x.\u000a      Citation count: 46\u000a    \u000a\u000a3.2 Goodman, C, Kachur, SP, Abdulla, S, Bloland, P and Mills, A (2009)\u000a      Concentration and drug\u000a      prices in the retail market for malaria treatment in rural Tanzania, Health\u000a        Economics, 18(6): 727&#8212;742,\u000a      doi: 10.1002\/hec.1473. Citation count: 6\u000a    \u000a\u000a3.3 O'Connell, KA, Gatakaa, H, Poyer, S, Njogu, J, Evance, I, Munroe, E,\u000a      Solomon, T, Goodman,\u000a      C, Hanson, K, Zinsou, C, Akulayi, L, Raharinjatovo, J, Arogundade, E,\u000a      Buyungo, P, Mpasela, F,\u000a      Adjibabi, CB, Agbango, JA, Ramarosandratana, BF, Coker, B, Rubahika, D,\u000a      Hamainza, B,\u000a      Chapman, S, Shewchuk, T and Chavesse, D (2011) Got ACTs? Availability,\u000a      price, market share\u000a      and provider knowledge of anti-malarial medicines in public and private\u000a      sector outlets in six\u000a      malaria-endemic countries, Malaria Journal, 10(326), doi:\u000a      10.1186\/1475-2875-10-326. Citation\u000a      count: 16\u000a    \u000a\u000a3.4 O'Connell, KA, Poyer, S, Solomon, T, Munroe, E, Patouillard, E,\u000a      Njogu, J, Evance, I, Hanson,\u000a      K, Shewchuk, T and Goodman, C (2013) Methods for implementing a medicine\u000a      outlet survey:\u000a      lessons from the anti-malarial market, Malaria Journal, 12(52),\u000a      doi: 10.1186\/1475-2875-12-52.\u000a      Citation count: 0\u000a    \u000a\u000a3.5 Kangwana, BP, Kedenge, SV, Noor, AM, Alegana, VA, Nyandigisi, AJ,\u000a      Pandit, J, Fegan, GW,\u000a      Todd, JE, Brooker, S, Snow, RW and Goodman, C (2011) The impact of\u000a      retail-sector delivery of\u000a      artemether-lumefantrine on malaria treatment of children under five in\u000a      Kenya: a cluster randomized\u000a      controlled trial, PLoS Medicine, 8(5): e1000437,\u000a      doi:10.1371\/journal.pmed.1000437. Citation count:\u000a      13\u000a    \u000a\u000a3.6 Tougher, S, ACTwatch Group, Ye, Y, Amuasi, JH, Kourgueni, IA,\u000a      Thomson, R, Goodman, C,\u000a      Mann, AG, Ren, R, Willey, BA, Adegoke, CA, Amin, A, Ansong, D, Bruxvoort,\u000a      K, Diallo, DA, Diap,\u000a      G, Festo, C, Johanes, B, Juma, E, Kalolella, A, Malam, O, Mberu, B,\u000a      Ndiaye, S, Nguah, SB,\u000a      Seydou, M, Taylor, M, Rueda, ST, Wamukoya, M, Arnold, F and Hanson, K\u000a      (2012) Effect of the\u000a      Affordable Medicines Facility &#8212; malaria (AMFm) on the availability, price,\u000a      and market share of\u000a      quality-assured artemisinin-based combination therapies in seven\u000a      countries: a before-and-after\u000a      analysis of outlet survey data, Lancet, 380(9857): 1916-1926, doi:\u000a      10.1016\/S0140-6736(12)61732-2. Citation count: 10\u000a    \u000aKey grants\u000a      Goodman, Economic Analysis of the Markets for Antimalarials in Rural\u000a      Africa, Wellcome Trust,\u000a      1\/10\/2000&#8212;31\/12\/2004, &#163;174,011.\u000a    Hanson, Antimalarial Drugs: Market and Supply Chain Research and Policy\u000a      Recommendations\u000a      (ACTwatch), Bill &amp; Melinda Gates Foundation (LSHTM contracted by PSI),\u000a      1\/9\/2007&#8212;28\/2\/2013,\u000a      $987,024.\u000a    Hanson, Independent Evaluation of the Affordable Medicines Facility &#8212;\u000a      Malaria (AMFm), The\u000a      Global Fund to Fight AIDS, Tuberculosis and Malaria (LSHTM subcontracted\u000a      by ICF\u000a      International), 15\/2\/2010-31\/12\/2012, $890,000.\u000a    Goodman, Evaluation of the Impact of Retail Sector Delivery of ACT on\u000a      Effective Malaria\u000a      Treatment of Children Under Five in Kenya, DFID, through a grant to\u000a      Population Services\u000a      International, 1\/4\/2008&#8212;30\/6\/2010, $411,783.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"}],"Sources":"\u000a    5.1 University of Washington School of Public Health, Professor of Global\u000a      Health.\u000a    5.2 Arrow, KJ, Panosian, CB and Gelband, H (eds) (2004) Saving Lives,\u000a        Buying Time: Economics\u000a        of Malaria Drugs in an Age of Resistance. Washington, DC: National\u000a      Academies Press,\u000a      http:\/\/www.nap.edu\/openbook.php?isbn=0309092183\u000a      (accessed 8 October 2013) (Box 3-1\u000a      summarises work by Goodman et al. on retail antimalarial markets in\u000a      Tanzania; the AMFm,\u000a      implemented in 2009, was proposed by this report; hence it is cited here\u000a      although it predates the\u000a      impact period; note also that the report cites Goodman et al. and Coleman\u000a      et al. on evidence of\u000a      cost effectiveness of ACT, reflecting earlier research).\u000a    5.3 Clinton Health Access Initiative former Executive Vice President.\u000a    5.4 AMFm Task Force, Roll Back Malaria Partnership (2007) Affordable\u000a        Medicines Facility &#8212; Malaria\u000a        (AMFm): Technical Design,\u000a      http:\/\/www.rbm.who.int\/partnership\/tf\/globalsubsidy\/AMFmTechProposal.pdf\u000a      (accessed 10 October\u000a      2013) (references to LSHTM work on pp. 32, 45 [ref. 54], 46 [refs 75,\u000a      99]).\u000a    5.5 Sch&#228;ferhoff, M and Yamey G (2011) Estimating Benchmarks of\u000a        Success in the Affordable\u000a        Medicines Facility &#8212; Malaria (AMFm) Phase 1. Report submitted to the\u000a      Global Fund to Fight AIDS,\u000a      Tuberculosis and Malaria by the Evidence to Policy Initiative (E2Pi),\u000a      Global Health Group, San\u000a      Franciso, CA,\u000a      http:\/\/www.theglobalfund.org\/Documents\/amfm\/E2PI_EstimatingBenchmarksInAMFm_Report_en\/\u000a      (accessed 8 October 2013) (LSHTM research referred to pp. 14, 15, 48 [x\u000a      2], 63 [note 1], 64 [note\u000a      51].\u000a    5.6 Global Fund to Fight AIDS, Tuberculosis and Malaria (2013) Affordable\u000a        Medicines Facility &#8212; Malaria\u000a        (AMFm): Summary Report on Co-paid ACTs (AMFm orders database),\u000a      http:\/\/portfolio.theglobalfund.org\/ReportLibrary\/AMFm\/Summary\u000a      (accessed 8 October 2013).\u000a    5.7 Tougher, S et al. (2012) (see 3.6 above).\u000a    5.8 Zanzibar Malaria Control Programme, AMFm Coordinator.\u000a    5.9 Global Fund to Fight AIDS, Tuberculosis and Malaria (2012) Board\u000a      approves integration of\u000a      AMFm into core global fund grant processes, press release, 15 November,\u000a      http:\/\/www.theglobalfund.org\/en\/mediacenter\/newsreleases\/2012-11-15_Board_Approves_Integration_of_AMFm_into_Core_Global_Fund_Grant_Processes\/\u000a      (accessed 10 October 2013) (Global Fund minute refers to the Independent\u000a      Evaluation report as\u000a      guiding the decision, and the evaluation report was co-authored by LSHTM:\u000a      see\u000a      http:\/\/www.theglobalfund.org\/en\/amfm\/independentevaluation\/,\u000a      accessed 10 October 2013).\u000a    5.10 Specialist, Monitoring, Evaluation and Implementation Research,\u000a      Global Fund to Fight AIDS,\u000a      Tuberculosis and Malaria.\u000a    ","Title":"\u000a    Expanding access to effective antimalarial treatment through the private\u000a      sector\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Effective medicines to treat malaria exist, but access to them remains\u000a      low. As recently as 2008,\u000a      only about 16% of febrile children under 5 (the population group most at\u000a      risk of dying from malaria\u000a      in high transmission settings) received an artemisinin-based combination\u000a      therapy (ACT), the\u000a      recommended drug for malaria case management. Research by LSHTM\u000a      established the\u000a      importance of the private sector in treating malaria, in many settings\u000a      exceeding 50% of care-seeking\u000a      for fever.\u000a    Catherine Goodman (then Research Fellow, now Senior Lecturer) started her\u000a      PhD in 2000,\u000a      supervised by Anne Mills (Professor of Health Economics and Policy), on\u000a      the nature of the private\u000a      retail market for antimalarial medicines in rural Tanzania. Kara Hanson\u000a      (then Lecturer, now\u000a      Professor of Health System Economics) joined them in leading research on\u000a      the role of the private\u000a      sector in delivering malaria medicines, supported by Research\u000a      Fellows\/Lecturers Benjamin\u000a      Palafox, Edith Patouillard, Sarah Tougher (from 2008), and Sergio Torres\u000a      Rueda, Barbara Willey\u000a      and Andrea Mann (from 2011). All were based at LSHTM throughout their\u000a      research involvement.\u000a    The research fell into three main areas. First, an investigation into the\u000a      use of the private sector for\u000a      malaria case management and the conditions under which medicines are\u000a      supplied.3.1 Research in\u000a      2000-2002 explored the retail market for antimalarials from both a supply\u000a      and demand\u000a      perspective, using qualitative and quantitative methods. The results\u000a      showed that antimalarial\u000a      medicines were widely available from retail outlets, which provided easier\u000a      access to the drugs than\u000a      health facilities, and were widely used by the population. The research\u000a      highlighted the importance\u000a      of these private retail providers, but also the weaknesses of drug sales\u000a      regulation. The same\u000a      research examined competition in the antimalarial medicine market,3.2\u000a      identifying the effects of\u000a      market concentration in rural Tanzania as having a significant impact on\u000a      the price of antimalarials.\u000a      LSHTM also contributed to research in 2009&#8212;2010 showing the widespread\u000a      market penetration of\u000a      artemisinin monotherapies in some countries3.3 via surveys of\u000a      outlets in Benin, the Democratic\u000a      Republic of the Congo (DRC), Madagascar, Uganda and Zambia.\u000a    Second, the development and strengthening of methods for collecting data\u000a      on the characteristics\u000a      and practices of private sector drug retailers. For example, a\u000a      standardised metric was developed\u000a      for comparing quantities of antimalarials - the Adult Equivalent Treatment\u000a      Dose &#8212; and retail audit\u000a      methods were developed to capture the range of antimalarials available in\u000a      an outlet, their prices\u000a      and mark-ups, and volumes sold. Many of these methods were subsequently\u000a      extended and\u000a      adapted through the multi-country ACTwatch project.3.4\u000a    Third, research studies which evaluated the impact of subsidies and\u000a      interventions. These were\u000a      carried out at sub-national (pilot) scale, using a cluster randomised\u000a      controlled trial in Kenya (2008&#8212;2009)3.5\u000a      and a controlled before-and-after study design in Tanzania (2007-2008).\u000a      Finally, a mixed-\u000a      method, multi-country study was conducted in 2010-2012 to evaluate ACT\u000a      subsidies at a national\u000a      scale in Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda and Tanzania\u000a      (including Zanzibar).\u000a      Subsidies and supporting interventions were shown to have been effective\u000a      in improving availability,\u000a      affordability and market share in the majority of settings.3.6\u000a    "},{"CaseStudyId":"41586","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"798544","Name":"Poland"},{"GeoNamesId":"2017370","Name":"Russia"},{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2658434","Name":"Switzerland"}],"Funders":[],"ImpactDetails":"\u000a    The trial results were first published in the New England Journal of\u000a        Medicine in 2008, with an\u000a      accompanying editorial stating `HYVET puts the question of the usefulness\u000a      of treating hypertension\u000a      in the very old to rest and provides important guidance to physicians and\u000a      writers of such\u000a      guidelines'.5.1\u000a    As a result, updated national and international guidelines started to\u000a      appear from 2009 onwards, all\u000a      of which cited HYVET as their main source of evidence to support change.\u000a      While no guideline is\u000a      binding, in each case these are strong recommendations intended to improve\u000a      standards, assist in\u000a      the knowledge and training of health care professionals and help patients\u000a      make informed decisions\u000a      about their care.\u000a    The 2009 Canadian Hypertension Education Program recommendations for the\u000a      management of\u000a      hypertension stated `HYVET clearly demonstrates the beneficial effects of\u000a      antihypertensive therapy\u000a      in reducing the risk of stroke and death in very elderly patients; these\u000a      results form the basis of the\u000a      new recommendation to prescribe antihypertensive therapy regardless of\u000a      age'.5.2\u000a    The 2011 American College of Cardiology and American Hypertension\u000a      Association published a\u000a      joint consensus report with the European Society of Hypertension, and a\u000a      number of American\u000a      societies for various patient groups and clinical conditions. Emphasising\u000a      the shift brought about by\u000a      HYVET, the report was divided into two sections &#8212; evidence before the\u000a      trial and evidence after.\u000a      The report stated `The HYVET results provide clear evidence that BP\u000a      lowering by drugs is\u000a      associated with definite CV benefits in patients &#8805;80 years of age'.5.3\u000a    In the UK the most influential guidelines are those from NICE. The\u000a      revised guidelines prepared in\u000a      consultation with the British Hypertension Society were published in 2011\u000a      based on a meta-analysis\u000a      of HYVET data &#8212; used both in its entirety and divided into patient\u000a      subgroups. The\u000a      guidelines provided a firm recommendation to offer treatment to people\u000a      aged 80 and over with\u000a      hypertension.5.4\u000a    Updated guidelines were also published in a number of other countries\u000a      including Poland (2012)\u000a      and Russia (2012).5.5 Outside Europe, organisations including\u000a      the Brazilian Society of\u000a      Hypertension (2010)5.6 and the South African Hypertension\u000a      Society (2011) also published reviewed\u000a      clinical guidance as a direct result of research findings.\u000a    A further influential guideline update was anticipated in mid-2013 in the\u000a      USA but has been delayed.\u000a      The eighth report of the Joint National Committee on Prevention,\u000a      Detection, Evaluation, and\u000a      Treatment of High Blood Pressure (JNC 8) will be published by the National\u000a      Heart, Lung and Blood\u000a      Institute, part of the US Department of Health and Human Services, and\u000a      will replace the current\u000a      2003 guidelines. The reach of these recommendations extends beyond the USA\u000a      and they will be\u000a      seen and adopted by practitioners throughout the developed world.\u000a    The HYVET trial has been widely reported by the media, with both the\u000a      national and medical press\u000a      picking up on the story and highlighting the positive findings of the\u000a      trial. In 2008 HYVET was the\u000a      subject of articles in the New York Times, the Guardian\u000a      and the BBC and British Heart Foundation\u000a      websites, all of which praised the HYVET researchers for addressing the\u000a      needs of a frequently\u000a      neglected age group. The Guardian article quoted James Goodwin,\u000a      Head of Research at Help the\u000a      Aged, as saying the findings had `serious implications for the treatment\u000a      of hypertensive people\u000a      over 80'.5.7\u000a    Mentions of HYVET in online clinical resources are too numerous to list\u000a      but include the Primary\u000a        Care Cardiovascular Journal (2008), American Medical News\u000a      (2009) and Swiss Medical Weekly\u000a      (2012) as well as the influential F1000 (2008), which highlights\u000a      recent research of clinical\u000a      importance.\u000a    The HYVET trial has been recognised for its outstanding contribution to\u000a      research by a number of\u000a      awards including the Society for Clinical Trials Trial of the Year Award\u000a      2009.5.8 HYVET was\u000a      nominated as one of the most important clinical trials of the year in 2009\u000a      by Medscape, an online\u000a      resource for clinicians5.9 and recognised in the F1000\u000a      Medicine All time Top 10 in 2009. The\u000a      American Heart Association voted HYVET among the top 10 major advances in\u000a      heart and stroke\u000a      research.5.10\u000a    ","ImpactSummary":"\u000a    Hypertension is well known to increase the risk of stroke and other\u000a      cardiovascular diseases, but up\u000a      until recently few very elderly people received treatment for it. The\u000a      first large randomised trial of the\u000a      pharmacological treatment of hypertension in people aged 80 and over &#8212; the\u000a      Hypertension in the\u000a      Very Elderly Trial (HYVET) &#8212; demonstrated clear benefits of such treatment\u000a      for this age group. As\u000a      a direct result of HYVET, changes were made to a number of influential\u000a      national and international\u000a      guidelines on the treatment of hypertension, including those published by\u000a      the UK's National\u000a      Institute for Health and Clinical Excellence (NICE).\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1 Beckett, NS, Peters, R, Fletcher, AE, Staessen, JA, Liu, L,\u000a      Dumitrascu, D, Stoyanovsky, V,\u000a      Antikainen, RL, Nikitin, Y, Anderson, C, Belhani, A, Forette, F, Rajkumar,\u000a      C, Thijs, L, Banya, W\u000a      and Bulpitt, CJ for the HYVET Study Group (2008) Treatment of hypertension\u000a      in patients 80 years\u000a      of age or older, New England Journal of Medicine, 358(18):\u000a      1887-1898, doi:\u000a      10.1056\/NEJMoa0801369. Citation count: 709\u000a    \u000a\u000a3.2 Peters, R, Beckett, N, Forette, F, Tuomilehto, J, Clarke, R, Ritchie,\u000a      C, Waldman, A, Walton, I,\u000a      Poulter, R, Ma, S, Comsa, M, Burch, L, Fletcher, A and Bulpitt, C for the\u000a      HYVET investigators\u000a      (2008) Incident dementia and blood pressure lowering in the Hypertension\u000a      in the Very Elderly Trial\u000a      cognitive function assessment (HYVET-COG): a double-blind, placebo\u000a      controlled trial, Lancet\u000a        Neurology, 7(8): 683-689, doi: 10.1016\/S1474-4422(08)70143-1.\u000a      Citation count: 191\u000a    \u000a\u000a3.3 Peters, R, Beckett, N, Burch, L, de Vernejoul, M-C, Liu, L, Duggan,\u000a      J, Swift, C, Gil-Extremera,\u000a      B, Fletcher, A and Bulpitt C (2010) The effect of treatment based on a\u000a      diuretic (indapamide) +\/-\u000a      ACE inhibitor (perindopril) on fractures in the Hypertension in the Very\u000a      Elderly Trial (HYVET), Age\u000a        and Ageing, 39(5): 609-616, doi: 10.1093\/ageing\/afq071. Citation\u000a      count: 9\u000a    \u000aResearch funding\u000a    Bulpitt (Imperial College), Fletcher (LSHTM), Pilot study for\u000a      Hypertension in the Very Elderly Trial\u000a      (HYVET), British Heart Foundation, 1994-1996, &#163;150,000.\u000a    Bulpitt (Imperial College), Fletcher (LSHTM), Hypertension in the Very\u000a      Elderly Trial (HYVET),\u000a      British Heart Foundation 1997-2004, &#163;741,649 and Institut de Recherches\u000a      Internationales Servier,\u000a      2000-2009, &#163;1m+.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000a    5.1 Kostis, JB (2008) Treating hypertension in the very old, New\u000a        England Journal of Medicine,\u000a      358(18): 1958-1960, doi: 10.1056\/NEJMe0801709.\u000a    5.2 Khan, NA, Hemmelgarn, B, Herman, RJ, Bell, CM, Mahon, JL, Leiter, LA,\u000a      Rabkin, SW, Hill,\u000a      MD, Padwal, R, Touyz, RM, Larochelle, P, Feldman, RD, Schriffin, EL,\u000a      Campbell, NRC, Moe, G,\u000a      Prasad, R, Arnold, MO, Campbell, TS, Milot, A, Stone, JA, Jones, C,\u000a      Ogilvie, R, Hamet, P, Fodor,\u000a      G, Carruthers, G, Burns, KD, Ruzicka, M, deChamplain, J, Pylypchuk, G,\u000a      Petrella, R, Boulanger, J-M,\u000a      Trudeau, L, Hegele, RA, Woo, V, McFarlane, P, Vall&#233;e, M, Howlett, J,\u000a      Bacon, SL, Lindsay, P,\u000a      Gilbert, RE, Lewanczuk, RZ and Tobe, S for the Canadian Hypertension\u000a      Education Program\u000a      (2009) The 2009 Canadian Hypertension Education Program recommendations\u000a      for the\u000a      management of hypertension: part 2 &#8212; therapy, Canadian Journal of\u000a        Cardiology, 25(5): 287-298,\u000a      doi: 10.1016\/S0828-282X(09)70492-1.\u000a    5.3 Aronow, WS, Fleg, JL, Pepine, CJ, Artinian, NT, Bakris, G, Brown, AS,\u000a      Ferdinand, KC,\u000a      Forciea, MA, Frishman, WH, Jaigobin, C, Kostis, JB, Mancia, G, Oparil, S,\u000a      Ortiz, E, Reisin, E, Rich,\u000a      MW, Schocken, DD, Weber, MA and Wesley DJ (2011) ACCF\/AHA 2011 expert\u000a      consensus\u000a      document on hypertension in the elderly: a report of the American College\u000a      of Cardiology\u000a      Foundation Task Force on clinical expert consensus documents, developed in\u000a      collaboration with\u000a      the American Academy of Neurology, American Geriatrics Society, American\u000a      Society for\u000a      Preventive Cardiology, American Society of Hypertension, American Society\u000a      of Nephrology,\u000a      Association of Black Cardiologists, and European Society of Hypertension,\u000a      Journal of the American\u000a        College of Cardiology, 57(20): 2037-2114, doi:\u000a      10.1016\/j.jacc.2011.01.008.\u000a    5.4 National Clinical Guideline Centre (2011) Hypertension: The\u000a        Clinical Management of Primary\u000a        Hypertension in Adults; Update of Clinical Guidelines 18 and 34\u000a      (Clinical Guideline 127). London:\u000a      NCGC, Royal College of Physicians, http:\/\/www.nice.org.uk\/nicemedia\/live\/13561\/56007\/56007.pdf\u000a      (accessed 30 September 2013) (p. 275, ref. 63).\u000a    5.5 Karpov, IuA (2012) [New guidelines for hypertension in Russia &#8212; a\u000a      priority of combined\u000a      treatment], Terapevticheski012d arkhiv, 84(1): 61-64 (Russian)\u000a      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22616534\u000a      (accessed 28 October 2013) (refers in the abstract\u000a      to new data from foreign and Russian trials using the antihypertensive\u000a      drug that was used in\u000a      HYVET and HYVET included a Russian centre).\u000a    5.6 Sociedade Brasileira de Cardiologia, Sociedade Brasileira de\u000a      Hipertens&#227;o &amp; Sociedade\u000a      Brasileira de Nefrologia (2010) [VI Brazilian guidelines on hypertension],\u000a      Arquivos Brasileiros de\u000a        Cardiologia, 95(1) (Suppl. 1): 1-51 (Portuguese),\u000a      http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&amp;pid=S0066-\u000a        782X2010001700001&amp;lng=en&amp;nrm=iso&amp;tlng=pt (accessed 17\u000a      October 2013) (section 8 ref. 21).\u000a    5.7 Jha, A (2008) Over-80s benefit from blood pressure drugs, Guardian,\u000a      1 April,\u000a      http:\/\/www.theguardian.com\/science\/2008\/apr\/01\/medicalresearch.longtermcare\u000a      (accessed 30\u000a      September 2013).\u000a    5.8 Society for Clinical Trials (2013) SCT Trial of the Year Award,\u000a      http:\/\/www.sctweb.org\/public\/about\/toty.cfm\u000a      (accessed 30 September 2013) (see 2009 Awards).\u000a    5.9 Black, HR (2009) This year's awards for the most important trials go\u000a      to ... HYVET and\u000a        ACCOMPLISH, Medscape Cardiology, 2 March, http:\/\/www.medscape.com\/viewarticle\/588818\u000a      (accessed 30 September 2013).\u000a    5.10 American Heart Association (2009) News releases: Top research\u000a      advances include studies\u000a      that influence medical care, apply science to 'real world' communities,\u000a      press release, 21 January,\u000a      http:\/\/web.archive.org\/web\/20090531023544\/http:\/americanheart.mediaroom.com\/index.php?s=43\u000a        &amp;item=648 (accessed 17 October 2013) (ref. 10).\u000a    \u000a    ","Title":"\u000a    Improving treatment of hypertension in the very elderly\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Hypertension (high blood pressure) is a major health problem worldwide.\u000a      The condition is just as\u000a      prevalent in the developing world as in high-income countries and affects\u000a      an estimated one in four\u000a      adults. The incidence of hypertension increases dramatically with age,\u000a      affecting around 30% of the\u000a      population aged 40-49 and 75% of those aged over 70. Estimates suggest\u000a      that about 54% of\u000a      stroke, 47% of ischaemic heart disease and 25% of other cardiovascular\u000a      diseases worldwide are\u000a      attributable to hypertension. Given that heart disease and stroke rank in\u000a      the top three causes of\u000a      mortality and disability in the Global Burden of Disease Study, strategies\u000a      to address hypertension\u000a      are an urgent priority.\u000a    While prevention of hypertension through weight control, exercise and\u000a      diet is desirable, it is difficult\u000a      to achieve, leaving control by pharmacological treatment as the most\u000a      effective intervention. Trials\u000a      have demonstrated the benefit of drug treatment on stroke mortality and\u000a      morbidity. However these\u000a      trials included very few people aged 80 years and over and there was\u000a      concern that treatment for\u000a      this age group might be harmful.\u000a    The HYVET was designed to fill the gap in this knowledge and provide\u000a      evidence for this neglected\u000a      age group. The trial was particularly important in view of ethical\u000a      concerns that elderly people were\u000a      being denied the opportunity to benefit. Conversely, if treatment was\u000a      harmful this would have major\u000a      implications for those already on treatment.\u000a    The HYVET trial was conceived and designed by Professor Chris Bulpitt\u000a      (Hammersmith Hospital,\u000a      Imperial College) and Astrid Fletcher (Professor of Epidemiology of Ageing\u000a      at LSHTM, joined in\u000a      1992 as Senior Lecturer) and led on from previous collaborative research\u000a      in trials of hypertension\u000a      treatment. HYVET was coordinated from the Hammersmith Hospital. Astrid\u000a      Fletcher was\u000a      responsible for the statistical aspects of the trial (including the sample\u000a      size, trial stopping\u000a      boundaries and plan of analysis) and of the design of add-on studies\u000a      (dementia, fracture risk,\u000a      quality of life). She participated in regular trial monitoring meetings\u000a      and contributed to the\u000a      preparation of manuscripts.\u000a    HYVET was the first large trial of hypertension treatment in the over\u000a      80s. Nearly 4,000 patients\u000a      took part in 195 centres across 13 countries in Western and Eastern\u000a      Europe, China, Australasia\u000a      and North Africa. The results showed that pharmacological treatment\u000a      reduced overall mortality and\u000a      stroke mortality and the incidence of heart failure.3.1 The\u000a      results also suggested that treatment\u000a      reduced dementia, although the evidence here &#8212; as with three other\u000a      hypertension trials that had\u000a      assessed dementia &#8212; was inconclusive.3.2 When the four trials\u000a      including HYVET were pooled in a\u000a      meta-analysis, a significant reduction in dementia from treatment was\u000a      found, although the size of\u000a      the reduction was small at 13%. The trial provided reassurance that the\u000a      trial interventions (a\u000a      thiazide diuretic and indapamide) had no adverse effects on fracture risk,\u000a      an important result in the\u000a      elderly.3.3\u000a    "},{"CaseStudyId":"41605","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"3595528","Name":"Guatemala"},{"GeoNamesId":"3202326","Name":"Croatia"},{"GeoNamesId":"3923057","Name":"Bolivia"},{"GeoNamesId":"3658394","Name":"Ecuador"},{"GeoNamesId":"783754","Name":"Albania"},{"GeoNamesId":"357994","Name":"Egypt"},{"GeoNamesId":"3585968","Name":"El Salvador"},{"GeoNamesId":"3865483","Name":"Argentina"},{"GeoNamesId":"3437598","Name":"Paraguay"},{"GeoNamesId":"3595528","Name":"Guatemala"},{"GeoNamesId":"3932488","Name":"Peru"},{"GeoNamesId":"1168579","Name":"Pakistan"},{"GeoNamesId":"3617476","Name":"Nicaragua"},{"GeoNamesId":"3489940","Name":"Jamaica"},{"GeoNamesId":"587116","Name":"Azerbaijan"}],"Funders":[],"ImpactDetails":"\u000a    LSHTM models measuring the cost effectiveness and impact of new vaccines\u000a      are now being used by key stakeholders and vaccine policy-makers at\u000a      national and international levels to provide evidence for and support\u000a      health initiative decisions. The models have been used by country teams\u000a      including experts from Ministries of Health and Finance, and national\u000a      vaccination programme managers. In 10 of these countries the new vaccine\u000a      in question has been introduced, benefiting many thousands of children.\u000a      Sanderson and Clark have also been regularly called upon to provide\u000a      analysis and advice for policy-makers, donors and stakeholders at the\u000a      highest level.\u000a    TRIVAC and CERVIVAC\u000a    Launched in 2010, TRIVAC is now an integral part of international efforts\u000a      to collect and disseminate data and research to help countries build or\u000a      scrutinise the case for adopting vaccines. TRIVAC has been used to\u000a      expedite national decision-making around Hib vaccination in the developing\u000a      world (through GAVI's `Hib Initiative') 5.1 and to support\u000a      country-level evidence-based decisions about adopting new vaccines in\u000a      countries who are members of the PAHO through its ProVac Initiative.5.2\u000a      It has also been used by the GAVI Alliance (a public-private health\u000a      partnership aimed at increasing international access to immunisation).\u000a    Between 2010 and July 2013, TRIVAC and\/or CERVIVAC were used in 14\u000a      vaccine cost effectiveness studies in the PAHO region. Typically, this has\u000a      followed an invitation from national policy-makers to conduct workshops\u000a      for teams made up of local Ministry of Health and immunisation officials,\u000a      during which an LSHTM researcher (usually Clark) uses the model(s) to\u000a      scrutinise data, consider plausible scenarios and carry out sensitivity\u000a      analyses.\u000a    Following these studies, a pneumococcal conjugate vaccine (PCV) has been\u000a      introduced in Argentina, Bolivia, Costa Rica, Ecuador, El Salvador,\u000a      Nicaragua, Paraguay, Peru and Guatemala. Guatemala has also introduced a\u000a      rotavirus vaccine. CERVIVAC was launched in 2011, and a study using this\u000a      model was reviewed prior to HPV vaccination being introduced in Argentina.\u000a      Decisions are pending following studies in Bolivia, Ecuador and Jamaica.5.3\u000a    In October 2012, a TRIVAC analysis by the Costa Rican Department of\u000a      Social Security restored public confidence in PCV for children under the\u000a      age of 2, after a controversially expensive universal vaccination\u000a      programme was introduced.5.4\u000a    In 2009\/2010 TRIVAC was used by Sanderson in a World Bank\/GAVI study of\u000a      cost-effectiveness and financial consequences of new vaccine introduction\u000a      in Pakistan.5.5 Since 2010 TRIVAC has also been used by WHO to\u000a      generate annual immunisation progress reports for GAVI.5.5\u000a      These reports include estimates of deaths prevented by new vaccines in the\u000a      world's 70 poorest countries, and estimates of the health benefits\u000a      attributable to GAVI-financed vaccines.\u000a    Seven further TRIVAC cost-effectiveness analyses are currently (7\/2013)\u000a      in progress in Albania, Azerbaijan, Croatia, Egypt, Georgia, Iran and\u000a      Senegal.\u000a    The rotavirus risk\/benefit model\u000a    In April 2012 Sanderson presented the results of the LSHTM rotavirus\u000a      study at a meeting of WHO's Strategic Advisory Group of Experts (SAGE) on\u000a      immunisation. LSHTM evidence regarding the additional lives saved by\u000a      changing the age restrictions for initiation of the rotavirus vaccination\u000a      resulted in their review. Further LSHTM findings were presented in a\u000a      follow-up meeting which resulted in SAGE issuing that same year a new\u000a      recommendation to relax age restrictions for rotavirus vaccination. LSHTM\u000a      findings are quoted as evidence in related WHO documents.5.6, 5.7\u000a    The schedules model\u000a    Results for Hib from the schedules model were presented by Clark and\u000a      Sanderson to SAGE at meetings in October and November 2012 and April 2013.\u000a      Drawing on this evidence, at the April meeting SAGE recommended two\u000a      possible schedules countries should choose between dependent on local\u000a      epidemiology and health system considerations. SAGE also recommended use\u000a      of the schedules model to help countries with this task,5.8 and\u000a      Clark and Sanderson have developed a website for WHO that carries relevant\u000a      country-level data and analyses (www.vaccine-schedules.com).\u000a    Making research findings available to policy-makers and other users\u000a    In 2012, supported by PAHO and WHO, LSHTM launched a new website `OLIVES'\u000a      (On-line International Vaccine Economics and Statistics) which provides\u000a      access to new analyses of data from LSHTM, new data and literature reviews\u000a      from universities in the PAHO region, including details and quality\u000a      assessments of studies reviewed, and relevant extracts from international\u000a      databases.5.9 Designed to be used by policy-makers and analysts\u000a      to provide financial and health benefit evidence and support for vaccine\u000a      decisions, the site is regularly updated and provides an accessible\u000a      reference source for information on vaccine economics and statistics, for\u000a      use in conjunction with LSHTM models or otherwise.\u000a    ","ImpactSummary":"\u000a    LSHTM researchers have developed four computer models to help\u000a      decision-makers make evidence-based choices about new vaccines and vaccine\u000a      schedules. These models analyse the public health impact and\u000a      cost-effectiveness of different options under different assumptions and\u000a      scenarios on a country-by-country basis. They are used by national\u000a      immunisation managers and key decision-makers, international committees\u000a      and partner organisations (e.g. the Global Alliance for Vaccines and\u000a      Immunisation and the Bill &amp; Melinda Gates Foundation). LSHTM's\u000a      researchers have built on this research for WHO, informing global\u000a      recommendations on vaccine timing and schedules.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1 Clark, A, Jauregui, B, Griffiths, U, Janusz, C, Bola&#241;os-Sierra, B,\u000a      Hajjeh, R, Andrus, JK and Sanderson C (2013) TRIVAC decision-support model\u000a      for evaluating the cost-effectiveness of Haemophilus influenzae\u000a      type b, pneumococcal and rotavirus vaccination, Vaccine, 31(Suppl.\u000a      3): C19-C29, doi:10.1016\/j.vaccine.2013.05.045.\u000a    \u000a\u000a3.2 Patel, MM, Clark, AD, Sanderson, CFB, Tate, J and Parashar, UD\u000a      (2012) Removing the age restrictions for rotavirus vaccination: a\u000a      benefit-risk modeling analysis, PloS Medicine, 9(10): e1001330,\u000a      doi:10.1371\/journal.pmed.1001330.\u000a    \u000a\u000a3.3 Edmond, K, Clark, A, Korczak, VS, Sanderson, C,\u000a      Griffiths, UK and Rudan I (2010) Global and regional risk of disabling\u000a      sequelae from bacterial meningitis: a systematic review and meta-analysis,\u000a      Lancet Infectious Diseases, 10(5): 317-328,\u000a      doi:10.1016\/S1473-3099(10)70048-7.\u000a    \u000a\u000a3.4 Clark, A and Sanderson, C (2009) Timing of children's vaccinations in\u000a      45 low-income and middle-income countries: an analysis of survey data, Lancet,\u000a      373(9674): 1543-1549, doi: 10.1016\/S0140-6736(09)60317-2.\u000a    \u000a\u000a3.5 Griffiths, UK, Clark, A, Gessner, B, Miners, A, Sanderson, C,\u000a      Sedyaningsih, ER and Mulholland, KE (2012) Dose-specific efficacy of Haemophilus\u000a        influenzae type b conjugate vaccines: a systematic review and\u000a      meta-analysis of controlled clinical trials, Epidemiology &amp;\u000a        Infection, 140(8): 1343-1355, doi:10.1017\/S0950268812000957.\u000a    \u000aKey grants\u000a    Clark, Evaluation of introducing Rotovirus &amp; Pneumococcal Vaccines,\u000a      PAHO, 1\/10\/2012-31\/12\/2014, &#163;113,207.\u000a    Sanderson, OLIVES (Extension), PAHO\/WHO, 1\/07\/2009-31\/12\/2014, &#163;328,722.\u000a    Sanderson and Clark, Project Proposal to Transfer Tools, Methods and\u000a      Lessons (ProVac), Bill &amp; Melinda Gates Foundation,\u000a      4\/07\/2012-31\/12\/2013, &#163;115,714.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"}],"Sources":"\u000a    5.1 Director, Division of Bacterial Diseases, Center for Disease Control,\u000a      Atlanta Georgia, USA.\u000a    5.2 Jauregui, B, Sinha, A, Clark, AD, Bolanos, BM, Resch, S, Toscano, CM,\u000a      Matus, CR and Andrus JK (2011) Strengthening the technical capacity at\u000a      country-level to make informed policy decisions on new vaccine\u000a      introduction: lessons learned by PAHO's ProVac Initiative, Vaccine,\u000a      29(5): 1099-1106, doi:10.1016\/j.vaccine.2010.11.075, http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X10017196\u000a      (accessed 12 September 2013) (see p. 1101 panel 1 and section 3.1, for\u000a      example).\u000a    5.3 Project Manager, ProVac Initiative, PAHO.\u000a    5.4 Fallas, CV (2012) Vacuna contra neumococo ahorrar&#225; casi $24 millones\u000a      al Seguro Social, Al Dia (Costa Rica) (Spanish), 13 October\u000a      2012, http:\/\/wvw.aldia.cr\/ad_ee\/2012\/octubre\/13\/nacionales3352605.html\u000a      (accessed 3 October 2013).\u000a    5.5 Manager, Strategic Information Team, Expanded Programme on\u000a      Immunization (EPI), Initiative for Vaccine Research, WHO.\u000a    5.6 Team Leader, Implementation Research and Economic Analysis,\u000a      Initiative for Vaccine Research, Department of Immunisation Vaccines and\u000a      Biologicals, WHO.\u000a    5.7 WHO (2013) Rotavirus vaccines: WHO position paper January 2013', WHO\u000a        Weekly Epidemiological Record, 88(5): 49-64, http:\/\/www.who.int\/wer\/2013\/wer8805.pdf\u000a      (accessed 12 September 2013) (references to LSHTM work in footnotes 2 and\u000a      23).\u000a    5.8 WHO (2013) Meeting of the Strategic Advisory Group of Experts on\u000a      immunization, April 2013: conclusions and recommendations, WHO Weekly\u000a        Epidemiological Record, 88(20): 201-216, http:\/\/www.who.int\/wer\/2013\/wer8820.pdf\u000a      (accessed 12 September 2013) (LSHTM mentioned on p. 14).\u000a    5.9 http:\/\/provac-olives.com\/\u000a      OLIVES website. (accessed 21 November 2013)\u000a    ","Title":"\u000a    Encouraging adoption of new children's vaccines through the development\u000a      of methods for decision support modelling\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    An estimated 1.5m children in low\/middle income countries die every year\u000a      from vaccine-preventable diseases such as diarrhoea and pneumonia. New\u000a      vaccines are among the most effective health interventions ever developed,\u000a      but can also be costly. The development of tools to assist policy-makers\u000a      in weighing the impact of a vaccine against cost and other related factors\u000a      has been the focus of research led by Colin Sanderson, Professor of\u000a      Operational Research in Health Care (at LSHTM since 1981, then Lecturer)\u000a      and Andrew Clark, Research Fellow (LSHTM, 2002-).\u000a    In 2007, Sanderson and Clark began developing TRIVAC, a decision-support\u000a      model that calculates the impact and cost effectiveness ratios for\u000a      childhood vaccines against Haemophilus influenzae type b (Hib),\u000a      pneumococcus and rotavirus (RV).3.1 Parameters such as\u000a      demography, disease burden, vaccine costs, coverage, efficacy, health\u000a      service utilisation and costs, as well as data from international sources\u000a      (e.g. WHO and Centers for Disease Control and Prevention &#8212; CDC) were\u000a      assembled and loaded into the model. Data from published literature were\u000a      also used. The aim was to allow national policy-makers to estimate the\u000a      benefits of each new vaccine in terms of mortality, morbidity and\u000a      disability adjusted life-years (DALYs) based on national estimates of\u000a      disease burden and of vaccine coverage and timeliness, and regional\u000a      estimates of vaccine efficacy. Most of this work was done as part of the\u000a      Pan-American Health Organization's (PAHO) ProVac project, and TRIVAC was\u000a      launched at ProVac workshops in South and Central America in 2008.\u000a    Clark also developed the CERVIVAC model in 2011 using a similar interface\u000a      to TRIVAC to evaluate the impact and cost effectiveness of human papilloma\u000a      virus (HPV) vaccine &#8212; used to help protect against cervical cancer. This\u000a      incorporates results from the model developed by Susan Goldie's group at\u000a      Harvard to allow for different cervical cancer screening scenarios.\u000a    Between 2008 and 2012, LSHTM researchers developed a risk\/benefit model\u000a      for rotavirus to conduct scenario analyses assessing the potential\u000a      benefits of mortality reduction from rotavirus versus the risk of fatal\u000a      intussusception when the first dose of vaccine has to be administered by\u000a      15 weeks of age, compared with 1 year of age. They concluded that in\u000a      developing countries, the additional lives saved by broadening the age\u000a      restrictions for initiation of rotavirus vaccination would far outnumber\u000a      the hypothetical excess intussusception deaths that might accompany such\u000a      an approach.3.2\u000a    The schedules model was developed (2012-2013) to help evaluate the public\u000a      health impact of alternative Hib vaccine schedules. For this purpose LSHTM\u000a      researchers have re-analysed existing national and regional data about the\u000a      distribution of deaths among children from diseases that are preventable\u000a      by vaccination, and actual ages at each vaccine dose. Additional research\u000a      by Sanderson and Clark has involved assembling other data necessary for\u000a      these models, including a review of literature on the prevalence of\u000a      disabling sequelae after bacterial meningitis,3.3 analysis of\u000a      vaccination coverage at different ages in 45 low- and middle-income\u000a      countries,3.4 and reviews of data to determine variations in\u000a      vaccine efficacy measured against number of doses and region.3.5\u000a    "},{"CaseStudyId":"41798","Continent":[],"Country":[],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000aThe findings of the Marmot Review and subsequent work conducted through the Institute of Health\u000d\u000aEquity (IHE) have contributed to the shaping of England's health policy. Health inequalities\u000d\u000aare at the centre of the new health system in England. In December 2010, the government's White\u000d\u000aPaper \"Healthy Lives, Healthy People: Our strategy for public health in England\" stated that it\u000d\u000a\"responds to Professor Sir Michael Marmot's Fair Society, Healthy Lives report and adopts its life\u000d\u000acourse framework for tackling the wider determinants of health\" [a]. In 2011, the Department of\u000d\u000aHealth's Public Health Outcomes Framework set out the strategy for achieving this with the\u000d\u000aintention to follow the Review's life course framework for tackling the wider social determinants of\u000d\u000ahealth, stating that: \"In improving the wider determinants of health, we have included a range of\u000d\u000aindicators that reflect factors that can have a significant impact on our health and wellbeing. These\u000d\u000aindicators are in line with those recommended by Sir Michael Marmot in his report Fair Society,\u000d\u000aHealthy Lives in 2010, and focus on the \"causes of the causes\" of health inequalities. Wherever\u000d\u000apossible, the indicators will follow the formulation published by the Marmot Review team and the\u000d\u000aLondon Health Observatory\" [b]. The principles set out in these documents were then followed by\u000d\u000ainequalities duties - introduced for the first time by the Health and Social Care Act 2012. As part of\u000d\u000ademocratic scrutiny of these policies, members of the team have given oral and written evidence to\u000d\u000aseveral Select Committees [c].\u000d\u000aThe Institute has worked with the Department of Health and other national and local bodies,\u000d\u000aincluding NHS bodies and local government to help embed a social determinants approach to\u000d\u000ahealth inequalities throughout the health system in England, including advising and influencing\u000d\u000anational organisations such as the Department of Health, local authorities, Clinical Commissioning\u000d\u000aGroups, health sector and public health professionals. The IHE's work has had measureable and\u000d\u000aimportant impacts across England, including influencing national and local government, the NHS,\u000d\u000athird and private sector organisations.\u000d\u000aThe shape of national health services has been influenced by our work. Public Health England\u000d\u000a(PHE) was established in April 2013, bringing together specialists from more than 70 organisations\u000d\u000ainto a single public health service. The organisation reports that \"the recommendations of the\u000d\u000a[Marmot] report have informed the design of PHE in general, and the Health and Wellbeing\u000d\u000adirectorate in particular\" [d].\u000d\u000aOver 70% of local authorities are now working to embed `Marmot principles' in their approaches\u000d\u000ato improving health and reducing inequalities [e]. For example, Coventry Council describe its\u000d\u000aapproach as follows:\u000d\u000a\"Coventry is a Marmot City, and the aim of the Health and Well-being Board is to improve\u000d\u000ahealth and well-being levels in Coventry so they match the best in the Country. The Health\u000d\u000aand Well-being Strategy is based around the six Marmot Themes which were identified in\u000d\u000aFebruary 2010 by Professor Michael Marmot in his report \"Fair Society, Healthy Lives\" (link\u000d\u000abelow). These themes identify the wider social determinants of ill-health and have been\u000d\u000aadopted by the Coventry Health and Well-being Board\" [f].\u000d\u000aThe Institute is engaged in a high profile programme of activity to encourage and support health\u000d\u000aprofessionals to tackle health inequalities. The programme has been enthusiastically supported\u000d\u000aby Royal Colleges, the British Medical Association (BMA) and other relevant organisations who\u000d\u000ahave provided many practical ideas for action and made commitments to embed them over the\u000d\u000anext few years. For example, the Royal College of General Practitioners (RCGP) committed to:\u000d\u000a\"ensuring that health inequalities are taken into account across all areas of RCGP activity and\u000d\u000apolicy\" and the Royal College of Nursing committed to \"developing the workforce in terms of\u000d\u000aemphasis on the awareness of public health and social determinants of health in pre and post\u000d\u000aregistration training\" [g].\u000d\u000aWe have also been commissioned internationally to expand the impact of this work. The WHO\u000d\u000aRegional Office for Europe commissioned us to lead a review to support the development and\u000d\u000aimplementation of the new common health policy framework for Europe: Health 2020. It was\u000d\u000acarried out to answer demands from policy makers and public health advocates for practical\u000d\u000aguidance on identifying \"policies that work\" to reduce the inequities in health1 between and within\u000d\u000alow-, medium- and high-income European countries [h]. The European Commission awarded a\u000d\u000acontract for IHE to lead a consortium to review progress made by its Member States in reducing\u000d\u000ahealth inequalities action and recommend action by Governments and the EC [i]. IHE has\u000d\u000aestablished international partnerships to support implementation of work on social determinants,\u000d\u000aincluding a sub-network of WHO European Health Cities network [j]. IHE has also worked with the\u000d\u000aPan American Health Organisation (PAHO) to embed social determinants of health in its five year\u000d\u000astrategy, as shown in its recent update to Health in the Americas [k].\u000d\u000a","ImpactSummary":"\u000d\u000aIn November 2008, Professor Sir Michael Marmot and his team at UCL were asked by the\u000d\u000aSecretary of State for Health to chair an independent review to propose the most effective\u000d\u000aevidence-based strategies for reducing health inequalities in England. The Marmot Review,\u000d\u000apublished in 2010, has fundamentally shifted discourse on health inequalities in the UK and\u000d\u000ainternationally. It has shaped public health services across England and around the world, guided\u000d\u000agovernment and international policy, and has given rise to a new commitment from service\u000d\u000aproviders and health professionals to reducing health inequalities and addressing the social\u000d\u000adeterminants of health.\u000d\u000a","ImpactType":"Political","Institution":"\u000d\u000aUniversity College London\u000d\u000a","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a\u000a[1] Brunner EJ, Marmot MG, Nanchahal K, Shipley MJ, Stansfeld SA, Juneja M, Alberti KG. Social\u000d\u000ainequality in coronary risk: central obesity and the metabolic syndrome. Evidence from the\u000d\u000aWhitehall II study. Diabetologia. 1997 Nov;40(11):1341-9. http:\/\/doi.org\/b8xp5d\u000d\u000a\u000a\u000a[2] Stringhini S, Sabia S, Shipley M, Brunner E, Nabi H, Kivimaki M, Singh-Manoux A. Association\u000d\u000aof socioeconomic position with health behaviors and mortality. JAMA. 2010 Mar\u000d\u000a24;303(12):1159-66. http:\/\/dx.doi.org\/10.1001\/jama.2010.297\u000d\u000a\u000a\u000a[3] CSDH. Closing the gap in a generation: health equity through action on the social determinants\u000d\u000aof health. Final Report of the Commission on Social Determinants of Health. Geneva: World\u000d\u000aHealth Organization; 2008.\u000d\u000ahttp:\/\/whqlibdoc.who.int\/publications\/2008\/9789241563703_eng.pdf. Other publications from\u000d\u000athe commission can be found at:\u000d\u000ahttp:\/\/www.who.int\/social_determinants\/publications\/en\/index.html\u000d\u000a\u000a\u000a[4] Marmot, M. Fair society, healthy lives : the Marmot Review : strategic review of health\u000d\u000ainequalities in England post-2010. London: The Marmot Review; 2010. ISBN 9780956487001\u000d\u000ahttp:\/\/www.instituteofhealthequity.org\/projects\/fair-society-healthy-lives-the-marmot-review\u000d\u000aOverview published as: Marmot M, Bell R. Fair society, healthy lives. Public Health. 2012\u000d\u000aSep;126 Suppl 1:S4-10. http:\/\/dx.doi.org\/10.1016\/j.puhe.2012.05.014.\u000d\u000a\u000a[5] Publications from the Institute of Health Equity:\u000d\u000a&#8226; Early years: https:\/\/www.instituteofhealthequity.org\/projects\/an-equal-start-improving-\u000d\u000aoutcomes-in-childrens-centres\u000d\u000a&#8226; Fuel poverty: http:\/\/www.instituteofhealthequity.org\/projects\/the-health-impacts-of-cold-\u000d\u000ahomes-and-fuel-poverty\u000d\u000a&#8226; CVD: https:\/\/www.instituteofhealthequity.org\/projects\/a-social-determinants-based-\u000d\u000aapproach-to-cvd-prevention-in-england\u000d\u000a&#8226; Impact of the economic downturn:\u000d\u000ahttps:\/\/www.instituteofhealthequity.org\/projects\/demographics-finance-and-policy-london-\u000d\u000a2011-15-effects-on-housing-employment-and-income-and-strategies-to-reduce-health-\u000d\u000ainequalities\u000d\u000a&#8226; Healthy Hospitals: http:\/\/www.instituteofhealthequity.org\/projects\/barts-and-the-london-nhs-\u000d\u000atrust---health-promoting-hospitals-strategy\u000d\u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a[a]https:\/\/www.gov.uk\/government\/publications\/healthy-lives-healthy-people-our-strategy-for-\u000d\u000apublic-health-in-england\u000d\u000a[b] Public Health Outcomes Framework for England 2013 to 2016: Part 1A.\u000d\u000ahttps:\/\/www.gov.uk\/government\/publications\/healthy-lives-healthy-people-improving-outcomes-\u000d\u000aand-supporting-transparency\u000d\u000a[c] Health Select Committee corrected transcript of oral evidence, Session 2010-12:HC 1048-iii:\u000d\u000ahttp:\/\/www.publications.parliament.uk\/pa\/cm201012\/cmselect\/cmhealth\/c1048-iii\/c104801.htm\u000d\u000aPublic service and demographic change committee evidence volume 2 Pages 168-189:\u000d\u000ahttp:\/\/www.parliament.uk\/documents\/lords-\u000d\u000acommittees\/Demographicchange\/PublicServiceVol2.pdf\u000d\u000aCommunities and Local Government Committee - The role of local authorities in health issues:\u000d\u000aTackling the causes of the causes of poor health:\u000d\u000ahttp:\/\/www.publications.parliament.uk\/pa\/cm201213\/cmselect\/cmcomloc\/694\/69407.htm\u000d\u000a[d] Public Health England equality analysis https:\/\/www.gov.uk\/government\/publications\/equality-\u000d\u000aanalysis-public-health-england\u000d\u000a[e] The Joint Strategy Needs Analysis or Health and Wellbeing Strategy of every local authority in\u000d\u000aEngland was reviewed for alignment with the objectives of Fair Society, Healthy Lives. Only\u000d\u000athose local authorities specifically referencing the Marmot Review as underpinning their\u000d\u000aapproach are included in the figure of 70%. A copy of these data are available on request.\u000d\u000aExamples include:\u000d\u000a\u000d\u000ahttp:\/\/www.walthamforest.nhs.uk\/Global\/Team_folders\/communications_and_engagem\u000d\u000aent\/NHSWF_Health-Inequalities-strategy_2011-15.pdf\u000d\u000ahttp:\/\/www.marmotreview.org\/AssetLibrary\/local%20examples\/Sheffield%20Action%20\u000d\u000aPlan.pdf\u000d\u000ahttp:\/\/www.london.gov.uk\/sites\/default\/files\/LondonHealthInequalitiesStrategy.pdf\u000d\u000a\u000d\u000a[f] http:\/\/www.coventrypartnership.com\/group-members\/healthandwellbeing\u000d\u000a[g] Over 19 royal colleges and other professional organisations made commitments to action,\u000d\u000awhich are summarised here:\u000d\u000ahttps:\/\/www.instituteofhealthequity.org\/Content\/FileManager\/healthprofs\/all-commitments-by-\u000d\u000atheme.pdf\u000d\u000a[h] Review of social determinants and the health divide in the WHO European Region. Final report\u000d\u000ahttp:\/\/www.euro.who.int\/en\/publications\/abstracts\/review-of-social-determinants-and-the-health-\u000d\u000adivide-in-the-who-european-region.-final-report\u000d\u000a[i] Commission staff working document on \"Report on health inequalities in the European Union\"\u000d\u000ahttp:\/\/ec.europa.eu\/health\/social_determinants\/docs\/report_healthinequalities_swd_2013_328_\u000d\u000aen.pdf\u000d\u000a[j] Information on our networks is at: http:\/\/www.instituteofhealthequity.org\/Networks\u000d\u000a[k] See for example, the PAHO page on Determinants of Health, which references our work:\u000d\u000ahttp:\/\/www.paho.org\/hq\/index.php?option=com_content&amp;view=article&amp;id=5165&amp;Itemid=3822&amp;l\u000d\u000aang=en\u000d\u000a\u000a1 The term \"inequities in health\" is used to describe unfair systematic differences in health between social groups that are avoidable\u000d\u000aby reasonable means.\u000d\u000a\u000d\u000a","Title":"\u000d\u000aThe impact of the Marmot Review on national and local policies to redress\u000d\u000asocial inequalities in health\u000d\u000a","UKLocation":[{"GeoNamesId":"2652221","Name":"Coventry"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000aResearch by Professor Michael Marmot and colleagues over the last 20 years has investigated the\u000d\u000arole of social inequalities in health.\u000d\u000aThe Whitehall II study was established in 1985 by Marmot and his UCL team to investigate the\u000d\u000aimportance of social class for health by following a cohort of 10,308 working men and women.\u000d\u000aResearch on this cohort has continued throughout the period 1993-2013 with funding from the\u000d\u000aMRC, British Heart Foundation and NIH, and to date over 500 research papers have been\u000d\u000apublished based on data collected from the study. The initial aims were to investigate the causes of\u000d\u000ainequalities in disease during the working life, such as the inverse social gradient in cardiovascular\u000d\u000adisease in Britain. In addition to the contribution of unhealthy behaviours and traditional risk factors\u000d\u000a(such as high blood pressure) in heart disease and diabetes, the Whitehall II study showed the\u000d\u000aimportance of psychosocial factors such as work stress, unfairness, and work-family conflict to\u000d\u000asocio-economic inequalities [1, 2].\u000d\u000aMarmot was Chair of the Commission on Social Determinants of Health set up by the World Health\u000d\u000aOrganization in 2005 to support tackling the social causes of poor health and avoidable health\u000d\u000ainequalities. The final report, entitled Closing the Gap in a Generation was published in 2008 [3].\u000d\u000aAt the request of the British Government, Marmot then chaired an independent review to propose\u000d\u000athe most effective evidence-based strategies for reducing health inequalities in England. The\u000d\u000aReview was tasked with identifying relevant evidence, showing how this could be translated into\u000d\u000apolicy, and advising on indicators and targets. The UCL secretariat team set up nine task groups in\u000d\u000atopic areas relevant to the review (e.g. the built environment, early years, employment and work).\u000d\u000aEach was made up of academic and practitioner experts in their area. The task groups produced\u000d\u000aevidence-based reports and proposals for action. These reports provided a basis for the final\u000d\u000areport, which was also informed by focus groups, consultation responses, policy dialogues and\u000d\u000ameetings with professionals. The final report was therefore able to bring together and draw\u000d\u000aconclusions from a wide range of up-to-date, expert research and data. Fair Society, Healthy Lives:\u000d\u000aA Strategic Review of Health Inequalities in England Post-2010 was published in February 2010\u000d\u000a[4] and had six main policy objectives, based around the social determinants of health:\u000d\u000aA. Give every child the best start in life\u000d\u000aB. Enable all children, young people and adults to maximise their capabilities and have control\u000d\u000aover their lives\u000d\u000aC. Create fair employment and good work for all\u000d\u000aD. Ensure a healthy standard of living for all\u000d\u000aE. Create and develop healthy and sustainable places and communities\u000d\u000aF. Strengthen the role and impact of ill-health prevention.\u000d\u000aFollowing publication there has been an intensive phase of supporting implementation of the\u000d\u000aproposals at national and local level to ensure the review is built on and taken forward. In\u000d\u000aNovember 2011, the UCL Institute of Health Equity (www.instituteofhealthequity.org) was launched\u000d\u000ato support this phase. The new Institute is supported by the Department of Health, UCL and the\u000d\u000aBMA. The team have carried out further research work to implement the findings of the Marmot\u000d\u000aReview and have published on issues relating to the social determinants of health, continuing to\u000d\u000abuild the evidence base for practitioners and policy makers &#8212; for instance in relation to alcohol,\u000d\u000aobesity and smoking, the early years, fuel poverty, cardiovascular disease (CVD), the impact of the\u000d\u000aeconomic downturn, mental health, advice for local government, healthy hospitals, chronically\u000d\u000aexcluded groups [5].\u000d\u000a"},{"CaseStudyId":"41826","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Wellcome Trust","Medical Research Council"],"ImpactDetails":"\u000d\u000a    Our studies were initially established to understand the potential spread\u000d\u000a      of HIV, but have informed\u000d\u000a      many aspects of sexual health policy and practice over 20 years, becoming\u000d\u000a      a primary source of\u000d\u000a      information about sexual behaviour in Britain. They are used widely by\u000d\u000a      policy makers and service\u000d\u000a      planners in both setting and monitoring strategy. We provide key examples\u000d\u000a      of impact since 2008.\u000d\u000a    Impact on HIV service planning. Natsal data are used by the Health\u000d\u000a      Protection Agency (HPA)\u000d\u000a      (now Public Health England [PHE]) in their annual estimates of the\u000d\u000a      population burden of HIV,\u000d\u000a      combining anonymous prevalence surveillance data with Natsal estimates of\u000d\u000a      the size of the\u000d\u000a      population at risk, to estimate the number infected and the proportion who\u000d\u000a      remain undiagnosed [a].\u000d\u000a      These data have underpinned national campaigns to increase and expand HIV\u000d\u000a      testing, for example\u000d\u000a      those run by the Terence Higgins Trust [b], and to assess the\u000d\u000a      impact of these campaigns [c].\u000d\u000a      Estimates of HIV distribution and other Natsal data are used to plan HIV\u000d\u000a      services locally and\u000d\u000a      nationally, for example in a sexual health needs assessment for London in\u000d\u000a      2008 [d], enabling NHS\u000d\u000a      resource distribution for effective service delivery. Johnson served as a\u000d\u000a      Specialist Adviser to the\u000d\u000a      House of Lords Select Committee on HIV\/AIDS in the UK (2011; Chair Lord\u000d\u000a      Fowler) which\u000d\u000a      emphasised the need to re-invigorate HIV Prevention Services [e].\u000d\u000a      Among their recommendations,\u000d\u000a      the final report of the Select Committee argued for the ban on HIV\u000d\u000a      home-testing kits to be\u000d\u000a      repealed, an outcome which is being processed following announcement by\u000d\u000a      the Chief Medical\u000d\u000a      Officer in August 2013.\u000d\u000a    Impact on the National Chlamydia Screening Programme (NCSP)\u000d\u000a      Natsal-2 data were used in\u000d\u000a      mathematical models to assess the impact of a screening programme on\u000d\u000a      chlamydia prevalence in\u000d\u000a      men and women. This contributed to the evidence base for establishing the\u000d\u000a      NCSP [f], which has\u000d\u000a      opportunistically screened young people aged 15-24 for chlamydia since\u000d\u000a      2003. Our data showing\u000d\u000a      similar chlamydia prevalence in men and women were used to support\u000d\u000a      inclusion of men in the\u000d\u000a      programme, rather than women only, as originally recommended and cited as\u000d\u000a      evidence for the\u000d\u000a      importance of increasing testing in men in the NCSP strategy Men too.\u000d\u000a      To date, NCSP has\u000d\u000a      delivered around 7.5 million tests, diagnosing over 470,000 infections in\u000d\u000a      young adults aged 15-24\u000d\u000a      (The vast majority of this impact occurred within the REF period &#8212; the\u000d\u000a      2008 NCSP annual report\u000d\u000a      stated that by that time only 700,000 tests had been carried out).\u000d\u000a      Although both the design and\u000d\u000a      cost-effectiveness of the programme have been criticised [see case study\u000d\u000a        UCL02-STE], the NCSP\u000d\u000a      report that \"modelling suggests that the substantial increases in the\u000d\u000a        number of diagnoses made in\u000d\u000a        England between 2000 and 2010\/11 has probably decreased the prevalence\u000d\u000a        of chlamydia among\u000d\u000a      sexually active under 25 year olds\". In 2010, Natsal questions were\u000d\u000a      included for the first time in the\u000d\u000a      Health Survey for England, and this survey demonstrated a high uptake of\u000d\u000a      the programme (44% of\u000d\u000a      women and 27% of men aged 16-24), greatest in those at highest risk [g].\u000d\u000a    Impact on HPV vaccination policy: In 2008, Natsal-2 data on sexual\u000d\u000a      behaviour and age at first\u000d\u000a      intercourse were used by the Joint Committee on Vaccination and\u000d\u000a      Immunisation (JCVI) in models\u000d\u000a      which showed the cost effectiveness of introducing bivalent HPV vaccine in\u000d\u000a      Britain for girls aged 12\u000d\u000a      to 14 at 80% coverage with a catch-up to age 18 [h]. A vaccination\u000d\u000a      programme commenced in\u000d\u000a      2008 and by 2012, 6 million doses of the vaccine had been delivered in\u000d\u000a      schools [i]. It is estimated\u000d\u000a      that about 400 lives could be saved every year in the UK as a result of\u000d\u000a      vaccinating girls [j]. Data\u000d\u000a      from Natsal-3 show high uptake of the catch-up programme (61.5%). The JCVI\u000d\u000a      is undertaking an\u000d\u000a      HPV immunisation review and our data on prevalence of HPV vaccine and\u000d\u000a      non-vaccine subtypes\u000d\u000a      have been submitted as evidence which is under consideration (outcome\u000d\u000a      awaited).\u000d\u000a    Impact on young people's sexual health: Natsal-2 data on teenage\u000d\u000a      sexual partnerships and\u000d\u000a      contraceptive use were used in a modelling project for the Departments of\u000d\u000a      Health and Education in\u000d\u000a      2009 to contribute to a new approach to sexual health communications\u000d\u000a      recommended in the\u000d\u000a      Teenage Pregnancy and Sexual Health Marketing Strategy in 2009 [k].\u000d\u000a      It was implemented in the\u000d\u000a      2009 Sex: Worth Talking About campaign by NHS choices. This print,\u000d\u000a      radio, digital, and television\u000d\u000a      campaign was designed to help young people make more informed choices\u000d\u000a      about their sexual\u000d\u000a      health and contraception, and to promote honest discussions about sex,\u000d\u000a      relationships, and\u000d\u000a      contraception between 16 to 24 year olds and their parents [l].\u000d\u000a      Natsal data on early sexual\u000d\u000a      experiences have been used as part of the evidence base for improved\u000d\u000a      provision of sexual health\u000d\u000a      services in schools and further education settings, including a guidance\u000d\u000a      document produced by the\u000d\u000a      Sex Education Forum for commissioners and practitioners in 2010 [m].\u000d\u000a      Data from the survey are\u000d\u000a      used on a number of public information websites as a reliable source of\u000d\u000a      information about sex.\u000d\u000a      Examples include: NHS Choices sex myth buster; Brook; one-plus-one; the\u000d\u000a      Family Planning\u000d\u000a      Association [n].\u000d\u000a    Contributing to Health Technology Assessments: Natsal-2 data were\u000d\u000a      used in three Health\u000d\u000a      Technology Assessments in the period 2008-13 [o]: 1) Natsal data on\u000d\u000a      sexual behaviour were used\u000d\u000a      to set the parameters for economic evaluation models assessing behavioural\u000d\u000a      interventions for STI\u000d\u000a      prevention STIs in young people; 2) Natsal data on the age-specific\u000d\u000a      prevalence of men who have\u000d\u000a      sex with men (MSM) were used in models to assess the cost-effectiveness of\u000d\u000a      screening HIV\u000d\u000a      positive men and women, and MSM, for anal cancer; 3) Natsal data were\u000d\u000a      cited as part of the\u000d\u000a      existing evidence base for school-linked sexual health services.\u000d\u000a    Impact on the Diagnostic and Statistical manual of mental disorders:\u000d\u000a      Natsal data were used\u000d\u000a      to define the minimum duration for sexual dysfunction in the latest\u000d\u000a      American Psychiatric\u000d\u000a      Association Diagnostic and Statistical manual of mental disorders (DSM V)\u000d\u000a        [p].\u000d\u000a    Public Engagement: Our public engagement work from 2008-2013 has\u000d\u000a      included media\u000d\u000a      interviews, for example an interview by Johnson on Radio 4's Am I\u000d\u000a        Normal? (2011, Series 8,\u000d\u000a      Episode 1), in which the Natsal results on sexual behaviour were\u000d\u000a      contrasted to less reliable\u000d\u000a      impressions often given by the media. Natsal has been used in two public\u000d\u000a      lectures which are\u000d\u000a      available via YouTube: a mini-lecture on the Natsal study in 2010\u000d\u000a      (Johnson; over 4,400 views) and\u000d\u000a      a UCL lunchtime lecture in 2011 (Johnson; over 1,800 views). Johnson gave\u000d\u000a      a lecture about HIV at\u000d\u000a      the Cheltenham Science Festival in 2010. Natsal was included as one of 14\u000d\u000a      case studies for its\u000d\u000a      impact at the Wellcome Trust 75th anniversary celebrations (2011) [q],\u000d\u000a      and for an oral history\u000d\u000a      recorded and available on open access from Wellcome Trust Witness seminar\u000d\u000a      series [r].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The National Surveys of Sexual Attitudes and Lifestyles (Natsal) have\u000d\u000a      made major contributions to\u000d\u000a      sexual health policy in Britain, and are widely regarded as among the most\u000d\u000a      reliable sources of\u000d\u000a      scientific data in the field, not replicated with such frequency, detail\u000d\u000a      or sample size in a single\u000d\u000a      country anywhere in the world. Since 2008 they have influenced (amongst\u000d\u000a      other things) HIV\u000d\u000a      services, HPV vaccination policy, the national chlamydia screening\u000d\u000a      programme, teenage\u000d\u000a      pregnancy strategy and health education campaigns for young people and gay\u000d\u000a      men. Our data are\u000d\u000a      widely used in the NHS and third sector. We have disseminated the results\u000d\u000a      of our research through\u000d\u000a      public engagement activities including extensive media work, podcasts, and\u000d\u000a      science festivals.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University College London\u000d\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    The results of the first Natsal study have been widely disseminated\u000d\u000a      through publication of books\u000d\u000a      and papers, while the key findings from Natsal-2 were published as a\u000d\u000a      series of high-profile papers\u000d\u000a      in the Lancet and over 50 subsequent papers: see http:\/\/www.natsal.ac.uk\/natsals-12\/publications\u000d\u000a    \u000a[1] Johnson AM, Wadsworth J, Wellings K, Field J Sexual Attitudes and\u000d\u000a        Lifestyles. Blackwell, 1994\u000d\u000a    \u000a\u000a[2] Johnson AM, Mercer CH, Erens B et al Sexual behaviour in\u000d\u000a      Britain: partnerships, practices,\u000d\u000a      and HIV risk behaviours. Lancet, 2001, 358: 1835-1842.http:\/\/doi.org\/dwzhp5\u000d\u000a    \u000a\u000a[3] Fenton KA, Korovessis C, Johnson AM et al Sexual behaviour in\u000d\u000a      Britain: reported sexually\u000d\u000a      transmitted infections and prevalent genital Chlamydia Trachomatis\u000d\u000a      infection. Lancet, 2001,\u000d\u000a      358: 1851-1854.http:\/\/dx.doi.org\/10.1016\/S0140-6736(01)06886-6\u000d\u000a    \u000a\u000a[4] Wellings K, Nanchahal K, Macdowall W et al Sexual behaviour in\u000d\u000a      Britain: early heterosexual\u000d\u000a      experience. Lancet, 2001, 358: 1843-1850http:\/\/dx.doi.org\/10.1016\/S0140-6736(01)06885-4\u000d\u000a    \u000a\u000a[5] Johnson\u000d\u000a        AM, Mercer CH, Beddows S et al. Epidemiology of, and\u000d\u000a      behavioural risk factors for,\u000d\u000a      sexually transmitted human papillomavirus infection in men and women in\u000d\u000a      Britain.  Sex\u000d\u000a        Transm\u000d\u000a        Infect. 2012;88(3):212-7. http:\/\/dx.doi.org\/10.1136\/sextrans-2011-050306\u000d\u000a    \u000a\u000a[6] Mercer CH, Fenton KA, Johnson AM, et al. Sexual function\u000d\u000a      problems and help seeking\u000d\u000a      behaviour in Britain: national probability sample survey. BMJ. 2003 Aug\u000d\u000a      23;327(7412):426-7.\u000d\u000a      http:\/\/doi.org\/fjzxkw\u000d\u000a    \u000aFunding: Natsal 1, PI Johnson, Wellcome Trust &#163;960,000 1999-2004;\u000d\u000a      Natsal 2: PI Johnson,\u000d\u000a      funding MRC programme grant &#163;1.8 million 1998-2003; Natsal 3: PI Johnson,\u000d\u000a      Funding Wellcome\u000d\u000a      Trust\/MRC &#163;7.3 million.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [a] Natsal data are used in a model to estimate the population burden of\u000d\u000a      HIV in the annual HIV in\u000d\u000a        the United Kingdom report. See reference 1 in the latest report\u000d\u000a      (link below):\u000d\u000a      http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1317137200016\u000d\u000a    [b] http:\/\/www.tht.org.uk\/our-charity\/Campaign\/Our-health-policies\/Testing-for-HIV\u000d\u000a    [c] Time to test, a report by the HPA in 2011 (Natsal data used\u000d\u000a      on page 6):\u000d\u000a      http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1316424799217\u000d\u000a    [d] MedFASH report on London needs assessment (see section 8):\u000d\u000a      http:\/\/www.medfash.org.uk\/uploads\/files\/p17abkmkdk1eggac18ul18lpqo5h.pdf\u000d\u000a    [e] http:\/\/www.parliament.uk\/hivselect\u000d\u000a    [f] NCSP website: http:\/\/www.chlamydiascreening.nhs.uk\/ps\/index.asp.\u000d\u000a      A model using Natsal data\u000d\u000a      is cited under the `evidence' section of the NCSP website (REF 16, under\u000d\u000a      `mathematical\u000d\u000a      modelling'): http:\/\/www.chlamydiascreening.nhs.uk\/ps\/evidence.asp.\u000d\u000a      The Men too strategy can\u000d\u000a      be found at:\u000d\u000a    http:\/\/www.chlamydiascreening.nhs.uk\/ps\/resources\/guidelines\/NCSPMens\u000d\u000a        strat.pdf Numbers\u000d\u000a      of patients screened so far are on the front page. Numbers to 2008 are in\u000d\u000a      annual report for that\u000d\u000a      year: http:\/\/www.chlamydiascreening.nhs.uk\/ps\/resources\/annual-reports\/NCSPa-rprt-07\u000d\u000a        08.pdf\u000d\u000a    [g] Health Survey for England 2010: data on Chlamydia Screening uptake\u000d\u000a      can be found in tables\u000d\u000a      6.10-6.12: https:\/\/catalogue.ic.nhs.uk\/publications\/public-health\/surveys\/heal-surv-resp-heal-\u000d\u000a        eng-2010\/heal-surv-eng-2010-resp-heal-ch6-sex.pdf\u000d\u000a    [h] JCVI statement on HPV vaccines to protect against cervical cancer.\u000d\u000a      See page 6 for use of\u000d\u000a      Natsal data in modelling:\u000d\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@ab\/documents\/digitalasset\/dh_094739.pdf\u000d\u000a    [i] http:\/\/www.mhra.gov.uk\/home\/groups\/pl-p\/documents\/websiteresources\/con213228.pdf\u000d\u000a    [j] http:\/\/www.nhs.uk\/conditions\/vaccinations\/pages\/hpv-human-papillomavirus-vaccine.aspx\u000d\u000a    [k] Teenage Pregnancy &amp; Sexual Health Marketing Strategy:\u000d\u000a      http:\/\/www.nhs.uk\/sexualhealthprofessional\/Documents\/Sexual\u000d\u000a        Health Strategy 2009.pdf\u000d\u000a    [l] Sex: Worth Talking About (NHS choices):http:\/\/www.nhs.uk\/worthtalkingabout\/Pages\/sex-worth-talking-about.aspx\u000d\u000a    [m] Sex Education Forum Briefing Paper for sexual health service\u000d\u000a      commissioners, FE senior\u000d\u000a      leaders and professionals working in FE-based sexual health services.\u000d\u000a      http:\/\/www.ncb.org.uk\/media\/238893\/taking\u000d\u000a        a strategic approach to sexual health service\u000d\u000a        development in further education.pdf\u000d\u000a    [n] Public information sources:\u000d\u000a    \u000d\u000a       NHS Choices: http:\/\/www.nhs.uk\/Tools\/Pages\/sex-myths.aspx\u000a\u000d\u000a       Sex worth Talking about cmpaign: www.nhs.uk\/Livewell\/STIs\/Pages\/oral-sex-and-cancer.\u000d\u000a      \u000d\u000a       Brook: http:\/\/www.brook.org.uk\/index.php\/sex-and-relationship\/sex\/ready-for-sex\u000d\u000a      \u000d\u000a       One-plus-one: http:\/\/www.oneplusone.org.uk\/content\u000d\u000a          topic\/having-problems\/key-facts-on-having-problems\/\u000d\u000a      \u000d\u000a       Family Planning Association:http:\/\/www.fpa.org.uk\/factsheets\/teenagers-sexual-health-behaviour\u000d\u000a      \u000d\u000a    \u000d\u000a    [o] Health Technology Assessments available from the HTA website (www.hta.ac.uk)\u000d\u000a    \u000d\u000a       The effectiveness and cost-effectiveness of behavioural interventions\u000d\u000a        for the prevention of\u000d\u000a        STIs in young people aged 13-19 www.hta.ac.uk\/fullmono\/mon1407.pdf\u000d\u000a      \u000d\u000a       Cost-effectiveness of screening high-risk HIV-positive men who have\u000d\u000a        sex with men (MSM)\u000d\u000a        and HIV-positive women for anal cancer http:\/\/www.hta.ac.uk\/fullmono\/mon1453.pdf\u000d\u000a      \u000d\u000a       School-linked sexual health services for young people\u000d\u000a        www.hta.ac.uk\/fullmono\/mon1430.pdf\u000d\u000a      \u000d\u000a    \u000d\u000a    [p] Recommendation for minimum duration of six months for sexual\u000d\u000a      dysfunctions based on Mercer\u000d\u000a      et al (2003): Segraves RT. Considerations for Diagnostic Criteria for\u000d\u000a      Erectile Dysfunction in\u000d\u000a      DSM V. Journal of Sexual Medicine, 2010; 7:654-660, which was used in the\u000d\u000a      final DSM-V\u000d\u000a      criteria: http:\/\/www.dsm5.org\/Documents\/changes%20from%20dsm-iv-tr%20to%20dsm-5.pdf\u000d\u000a    [q] http:\/\/www.wellcome.ac.uk\/About-us\/75th-anniversary\/WTVM051253.htm\u000d\u000a    [r] http:\/\/www2.history.qmul.ac.uk\/research\/modbiomed\/wellcome\u000d\u000a        witnesses\/vol41 \/index.html\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    The National Surveys of Sexual Attitudes and Lifestyles (Natsal)\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The first National Survey of Sexual Attitudes and Lifestyles (Natsal-1)\u000d\u000a      was undertaken in 1990-1991\u000d\u000a      in response to the emerging HIV epidemic. It examined, through probability\u000d\u000a      samples of\u000d\u000a      18,876 men and women aged 16-59, the distribution of sexual behaviours to\u000d\u000a      determine the likely\u000d\u000a      spread of HIV in the population. Analysis work was undertaken in 1993, and\u000d\u000a      the results were\u000d\u000a      published in 1994 [1].\u000d\u000a    Natsal-2 was undertaken in 2000-1. It surveyed 12,110 men and women aged\u000d\u000a      16-44 and provided\u000d\u000a      extensive data in the broad context of sexual and reproductive health and\u000d\u000a      pioneered computer-assisted\u000d\u000a      methodologies that we demonstrated could produce more accurate reporting\u000d\u000a      of sexual\u000d\u000a      behaviours. Key findings from Natsal-2 included evidence of:\u000d\u000a    \u000d\u000a      increasing risk behaviour between 1990 and 2000 consistent with rising\u000d\u000a        incidence of sexually\u000d\u000a        transmitted infections (STIs) [2];\u000d\u000a      increases in both the proportion of men reporting same-sex activity\u000d\u000a        and their risk behaviours,\u000d\u000a        informing prevention for gay men and service planning for HIV [also\u000d\u000a          2];\u000d\u000a      similar prevalence of asymptomatic Chlamydia trachomatis\u000d\u000a        infection in men and women,\u000d\u000a        providing the first population-based estimates [3];\u000d\u000a      a strong relationship between age at onset of sex, competence at the\u000d\u000a        time, and poor sexual\u000d\u000a        health outcomes, informing education for young people and teenage\u000d\u000a        pregnancy strategy [4];\u000d\u000a      Population estimates of sexual behaviour and the distribution of\u000d\u000a        different human papillomavirus\u000d\u000a        subtypes to inform HPV vaccination programs [5];\u000d\u000a      Data on sexual function problems and their duration to inform the\u000d\u000a        DSM-V [6].\u000d\u000a    \u000d\u000a    Natsal-3 was undertaken in 2010 to 2012 interviewing 15,162 men and women\u000d\u000a      aged 16 to 74. Key\u000d\u000a      findings will be published in a series of papers in the Lancet in November\u000d\u000a      2013. While it is too early\u000d\u000a      to assess the impact on transmission, the papers provide population\u000d\u000a      estimates showing\u000d\u000a      considerable uptake of interventions including, HIV testing and HPV\u000d\u000a      vaccination and chlamydia\u000d\u000a      screening, interventions that were influenced by Natsal-2.\u000d\u000a    The Natsal surveys were undertaken in collaboration with colleagues at\u000d\u000a      the London School of\u000d\u000a      Hygiene and Tropical Medicine, and NatCen Social Research and the Health\u000d\u000a      Protection Agency\u000d\u000a      (Natsal-3). All three studies were led from UCL by Johnson as Principal\u000d\u000a      Investigator. UCL\u000d\u000a      scientists led in particular the epidemiological and STI analyses, with\u000d\u000a      all statistical analysis led by\u000d\u000a      Mercer with Copas.\u000d\u000a    "},{"CaseStudyId":"41839","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2186224","Name":"New Zealand"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Since their launch in the UK in 2009, the UK-WHO growth charts developed\u000d\u000a      by Cole and others are now used universally. They were introduced in\u000d\u000a      England in May 2009, in Wales and Scotland in January 2010 and in Northern\u000d\u000a      Ireland in October 2010 [a]. The charts are available in two\u000d\u000a      formats: A5 charts that are included in the personal child health record\u000d\u000a      (PCHR) known as the \"red book\", and A4 professional charts (0-4 years,\u000d\u000a      2-18 years, NICM). All new mothers receive a copy of the PCHR, [b]\u000d\u000a      so that in 2012, for example, the PCHR was distributed to all parents of\u000d\u000a      the 813,000 infants born in the four countries that year. The charts and\u000d\u000a      their interpretation were also discussed in the government's Birth to\u000d\u000a        Five book, produced by the Department of Health in 2009 and\u000d\u000a      distributed free to all new parents in England until 2011; in Wales a\u000d\u000a      bilingual edition is issued [c].\u000d\u000a    The A4 professional charts are used in primary, secondary and tertiary\u000d\u000a      care, and for the year to April 2013 the numbers sold by the publishers,\u000d\u000a      Harlow Printing Limited, for each chart were as follows:\u000d\u000a    \u000d\u000a      0-4 years - 400,000 copies\u000d\u000a      2-18 years - 287,000 copies\u000d\u000a      NICM - 95,000 copies [d]\u000a\u000d\u000a    \u000d\u000a    These numbers are impressive, not only in terms of their size, but also\u000d\u000a      because they show how rapidly the UK-WHO charts have superseded the\u000d\u000a      previous British 1990 charts (amounting to 90% of total growth chart\u000d\u000a      sales).\u000d\u000a    As they enable practitioners to recognise the range of normal\u000d\u000a      development, the UK-WHO charts are uniquely well designed to achieve UK\u000d\u000a      government policy aims in relation to child health, namely with regard to\u000d\u000a      early recognition of growth disorders and risk factors for obesity, as\u000d\u000a      defined in the Healthy Child Programme [b, e]. In June 2013, the\u000d\u000a      CPCM chart was released. This is a modification of the main school age\u000d\u000a      chart for use in children with growth or nutritional problems. It extends\u000d\u000a      to age 20 years and features a body mass index (BMI) chart; low and high\u000d\u000a      lines to monitor unusually short, thin or overweight children; puberty\u000d\u000a      phase specific thresholds to assess small children with late onset puberty\u000d\u000a      and tall children with early onset puberty [f].\u000d\u000a    The UK work has also had an impact internationally. For example, the 0-4\u000d\u000a      years and NICM charts have been adapted for use in New Zealand [g],\u000d\u000a      where they have been used since mid-2010. From January 2013, they have\u000d\u000a      also been in use in Ireland [h], where all newborn infants are\u000d\u000a      assessed using them. As an indication of reach, 72,000 babies were born in\u000d\u000a      Ireland in 2012 [i].\u000d\u000a    The guiding principles in the chart design were that the charts should be\u000d\u000a      evidence-based, useful and easy to use &#8212; and hence more likely to be\u000d\u000a      effective. Parents often claim to understand growth charts, yet they show\u000d\u000a      only limited comprehension when tested [j]. Therefore the charts\u000d\u000a      were developed with better layout than before, and with instructions for\u000d\u000a      the PCHR and A4 charts targeted at their respective audiences, parents and\u000d\u000a      professionals [k].\u000d\u000a    The new and improved elements on the charts also benefit both parents and\u000d\u000a      professionals. These include a reduced emphasis on the 50th\u000d\u000a      centile, as sometimes parents expect all `normal' children to grow along\u000d\u000a      the 50th centile line. On the new charts however, there are more centile\u000d\u000a      labels and the curve labels sit on the 50th centile to assist orientation\u000d\u000a      when plotting and interpreting [l]. A `dip' in weight between 2-4\u000d\u000a      weeks is no longer seen, as the charts have more information on weight\u000d\u000a      gain in the first few weeks, and they allow for the average tendency for\u000d\u000a      infants to show a slower net weight gain up to age 2 weeks [l].\u000d\u000a    The new adult height predictor tells parents how tall their child will\u000d\u000a      be, a matter of endless interest. It also allows professionals to compare\u000d\u000a      the prediction with the parents' heights, and hence detect a possible\u000d\u000a      growth disorder. For this a graphical parent height comparator is\u000d\u000a      provided, which improves on the British 1990 calculator by avoiding the\u000d\u000a      need for any calculations.\u000d\u000a    Child obesity is a considerable public health concern, and these charts\u000d\u000a      provide better tools for assessing possible weight problems in children.\u000d\u000a      In the past, BMI in children has been relatively little used as a\u000d\u000a      screening tool, due to the need for calculation and a separate BMI chart.\u000d\u000a      The new charts include a BMI look-up, which provides the BMI centile from\u000d\u000a      the height and weight centiles, avoiding both BMI calculation and a BMI\u000d\u000a      chart. This makes it easy to plot the child's BMI centile over time, and\u000d\u000a      it is likely to considerably increase parental and professional awareness\u000d\u000a      of a child's overweight, which parents are poor at recognising [m].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research at the UCL Institute of Child Health underpinned the update in\u000d\u000a      2009 of children's growth charts, which allow for more accurate\u000d\u000a      determination of a child's growth pattern and provide better tools for\u000d\u000a      assessing possible weight problems in children. The new charts are now in\u000d\u000a      universal use in the UK for children from birth to 18 years of age,\u000d\u000a      including preterm babies. Having been quickly adopted, they now account\u000d\u000a      for 90% of all growth chart sales. Modified versions of the charts are in\u000d\u000a      use in Ireland and New Zealand. In the UK they are provided to all new\u000d\u000a      parents as part of the Personal Child Health Record (PCHR) &#8212; known as the\u000d\u000a      \"red book\". They are used in general practice, community paediatrics,\u000d\u000a      general paediatrics and paediatric endocrinology. The most recent charts\u000d\u000a      are for use in children with growth or nutritional problems.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    University College London\u000d\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Wright CM, Williams AF, Elliman D, Bedford H, Birks E, Butler G, et\u000d\u000a      al. Using the new UK-WHO growth charts. BMJ 2010;340:c1140. http:\/\/dx.doi.org\/10.1136\/bmj.c1140\u000d\u000a    \u000a\u000a[2] Cole TJ, Williams AF, Wright CM, RCPCH Growth Chart Expert Group.\u000d\u000a      Revised birth centiles for weight, length and head circumference in the\u000d\u000a      UK-WHO growth charts. Ann Hum Biol 2011;38:7-11. http:\/\/dx.doi.org\/10.3109\/03014460.2011.544139\u000d\u000a    \u000a\u000a[3] Cole TJ, Wright CM, Williams AF, RCPCH Growth Chart Expert Group.\u000d\u000a      Designing the new UK-WHO growth charts to enhance assessment of growth\u000d\u000a      around birth. Arch Dis Child 2011;\u000d\u000a      http:\/\/dx.doi.org\/10.1136\/adc.2010.205864\u000d\u000a    \u000a\u000a[4] Cole TJ. A chart to link child centiles of body mass index, weight\u000d\u000a      and height. Eur J Clin Nutr 2002;56:1194-9. http:\/\/dx.doi.org\/10.1038\/sj.ejcn.1601473\u000d\u000a    \u000a\u000a[5] Cole TJ, Wright CM. A chart to predict adult height from a child's\u000d\u000a      current height. Ann Hum Biol 2011;38:662-8. http:\/\/dx.doi.org\/10.3109\/03014460.2011.598189\u000d\u000a    \u000aPeer-reviewed funding\u000d\u000a    Cole has held four successive MRC programme grants:\u000d\u000a\u0009\u000d\u000a    Mathematical methods in the assessment of human growth\u000d\u000a\u0009\u000d\u000a    Oct 1998 - Sep 2003, &#163;381,000\u000d\u000a    Oct 2003 - Sep 2008, &#163;380,000\u000d\u000a    Oct 2008 - Nov 2011, &#163;355,000\u000d\u000a\u0009\u000d\u000a    The SITAR method of growth curve analysis for growth assessment in\u000d\u000a      translational medicine and life course epidemiology\u000d\u000a\u0009  \u000d\u000a    Apr 2012 - Mar 2015, &#163;79,000.\u000d\u000a\u0009\u000d\u000a\u0009\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [a] Information accompanying the introduction of the new growth charts in\u000d\u000a      England in May 2009:\u000d\u000a      http:\/\/www.smahcp.co.uk\/professional-know-how\/growth-charts\/new-growth-charts\/information-771.aspx?catid=22\u000d\u000a      Introduction in Scotland: http:\/\/www.scotland.gov.uk\/Resource\/Doc\/337318\/0110676.pdf\u000d\u000a      See p6.\u000d\u000a    [b] Healthy Child Programme &#8212; Pregnancy and the first five years. English\u000d\u000a      Department of Health.\u000d\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consu\u000d\u000am_dh\/groups\/dh_digitalassets\/@dh\/@en\/@ps\/documents\/digitalasset\/dh_118525.pdf\u000d\u000a      See p 8 for policy aims; p 58 for details of the PCHR.\u000d\u000a    [c] Birth to Five book, Chapter 4, p. 66, http:\/\/www.publichealth.hscni.net\/publications\/birth-five;\u000d\u000a      Continued use in Wales\u000d\u000a      http:\/\/wales.gov.uk\/topics\/health\/improvement\/index\/earlyyears\/?lang=en\u000d\u000a    [d] Personal communication from Harlow Printing Limited (copy available\u000d\u000a      on request)\u000d\u000a    [e] Healthy Child Programme &#8212; From 5-19 years old. English Department of\u000d\u000a      Health.\u000d\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/+\/www.dh.gov.uk\/en\/publicationsandstatistics\/publications\/publicationspolicyandguidance\/dh_107566\u000d\u000a    [f] School age charts and resources, RCPCH, http:\/\/www.rcpch.ac.uk\/child-health\/research-projects\/uk-who-growth-charts\/uk-growth-chart-resources-2-18-years\/school-age\u000d\u000a    [g] Well Child growth charts. Ministry of Health, New Zealand. http:\/\/www.health.govt.nz\/our-work\/life-stages\/child-health\/well-child-tamariki-ora-services\/growth-charts\u000d\u000a    [h] UK-WHO-Ireland growth charts. Health Services Executive, Ireland.\u000d\u000a      http:\/\/www.hse.ie\/growthmonitoring\/\u000d\u000a    [i] Ireland Perinatal Statistics Report 2012:\u000d\u000a      http:\/\/www.esri.ie\/news_events\/latest_press_releases\/perinatal-statistics-repo-1\/index.xml\u000d\u000a    [j] Do Parents Understand Growth Charts? A National, Internet-Based\u000d\u000a      Survey; EP Ben-Joseph, SA Dowshen, N Izenberg, Pediatrics 124(4) Oct 2009;\u000d\u000a      pp. 1100 -1109\u000d\u000a      http:\/\/doi.org\/10.1542\/peds.2008-0797\u000d\u000a    [k] Sachs M, Sharp L, Bedford H, et al. 'Now I understand': consulting\u000d\u000a      parents on chart design and parental information for the UK-WHO child\u000d\u000a      growth charts. Child Care Health Dev 2012;38:435-40. http:\/\/doi.org\/10.1111\/j.1365-2214.2011.01256.x\u000d\u000a    [l] The UK-WHO Growth Charts: What is the difference?\u000d\u000a      http:\/\/www.rcpch.ac.uk\/sites\/default\/files\/asset_library\/Research\/Growth%20Charts\/Education\u000a        %20Materials%2001092010\/FS2_What%20is%20the%20differenceN.pdf\u000d\u000a    [m] Maternal and Child Awareness and Expectations of Child Overweight; A\u000d\u000a      Br&#248;dsgaard, L Wagner, B Peitersen, I Poulsen, T S&#248;rensen; Obesity Facts\u000d\u000a      2011;4:297-304;\u000d\u000a      http:\/\/doi.org\/10.1159\/000331012\u000d\u000a    ","Title":"\u000d\u000a    Redesigning children's growth charts\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2647461","Name":"Harlow"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Until 2009, growth charts used in the UK were based on the British 1990\u000d\u000a      reference. Following a recommendation by the English Department of Health\u000d\u000a      (DH) Scientific Advisory Committee on Nutrition (SACN), they were replaced\u000d\u000a      by new charts based on the World Health Organization (WHO) 2006 growth\u000d\u000a      standard. These new UK-WHO charts were designed by a Growth Chart Expert\u000d\u000a      Group commissioned through the Royal College of Paediatrics and Child\u000d\u000a      Health (RCPCH), which included Professors Tim Cole and Gary Butler, and Dr\u000d\u000a      Helen Bedford (all UCL Institute of Child Health). The Expert Group was\u000d\u000a      chaired by Professor Charlotte Wright (Glasgow University), who is using\u000d\u000a      her chart development work as a separate REF case study.\u000d\u000a    The charts for 0 to 4 year olds, launched in May 2009, used WHO growth\u000d\u000a      standard data from two weeks to four years, and reanalysed birth data from\u000d\u000a      the British 1990 reference [1]. Further charts extending the age\u000d\u000a      range to 18 years were launched in May 2012, based on the same British\u000d\u000a      1990 reference as before but to an improved design. In addition more\u000d\u000a      specialised \"close monitoring\" charts were developed for neonates and\u000d\u000a      infants (NICM) and childhood and puberty (CPCM). They incorporate a series\u000d\u000a      of innovative plotting aids devised by Professor Cole, who was thus\u000d\u000a      responsible for the following features:\u000d\u000a    \u000d\u000a      Centiles for birth weight, length and head circumference for 23-42\u000d\u000a        weeks of gestation constructed using Cole's LMS method [2, 3].\u000d\u000a        For this Cole used the LMS method to update pre-existing birth centiles\u000d\u000a        to augment the WHO growth standard (which lacked preterm data).\u000d\u000a      A Body Mass Index (BMI) look-up that converts height centile and\u000d\u000a        weight centile to a BMI centile [4]. Here Cole used the strong\u000d\u000a        relation between centiles of weight, height and BMI to predict BMI\u000d\u000a        centile. As a result, knowing centiles of weight and height, BMI centile\u000d\u000a        can be predicted to reasonable accuracy without having to calculate or\u000d\u000a        plot BMI on a centile chart.\u000d\u000a      An adult height predictor, a nomogram to convert the child's current\u000d\u000a        height centile (at any age) to a predicted adult height, adjusted for\u000d\u000a        regression to the mean [5]. This was joint work with Wright, and\u000d\u000a        a simplified version was included with the growth chart. As well as\u000d\u000a        being popular with parents and children, the height prediction is used\u000d\u000a        in conjunction with the parent height comparator (see below) to detect\u000d\u000a        growth disorders.\u000d\u000a      A parent height comparator, a nomogram to compare the child's height\u000d\u000a        centile to the mid-parent height centile adjusted for regression to the\u000d\u000a        mean. Again, in joint work with Wright, it provides a graphical method\u000d\u000a        to calculate an improved version of mid-parent height that, with the\u000d\u000a        height predictor (above), detects disordered growth where the two height\u000d\u000a        estimates are discordant.\u000d\u000a    \u000d\u000a    Centiles for height and weight for three phases of puberty were\u000d\u000a      constructed using the LMS method. This was joint work with Butler and\u000d\u000a      Wright, where the five Tanner pubertal stages were rationalised into three\u000d\u000a      pubertal phases, and reference centiles for height and weight were\u000d\u000a      constructed for children in each of the three phases separately. Elements\u000d\u000a      of these centiles were incorporated in the CPCM charts to monitor growth\u000d\u000a      in delayed puberty.\u000d\u000a    "},{"CaseStudyId":"41842","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"927384","Name":"Malawi"},{"GeoNamesId":"1210997","Name":"Bangladesh"},{"GeoNamesId":"337996","Name":"Ethiopia"},{"GeoNamesId":"226074","Name":"Uganda"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"1282988","Name":"Nepal"}],"Funders":[],"ImpactDetails":"\u000a    As a result of the underpinning research described above, scale-up of\u000a      participatory women's groups has begun in various parts of India. Our work\u000a      has also begun to influence policy in other low and middle-income\u000a      countries. The results of our meta-analysis influenced WHO's decision to\u000a      develop a training module on the intervention for global dissemination.\u000a    From 2008-13, UCL and Ekjut worked to scale up the intervention in the\u000a      high-mortality eastern Indian states of Jharkhand and Odisha. In total,\u000a      the project led to work with 4,676 women's groups across 17 districts in\u000a      four states, covering a population of over two million people [a].\u000a      In 2012, the Department of Health and Family Welfare in Jharkhand\u000a      incorporated the intervention into the curriculum of the Accredited Social\u000a      Health Activist, a cadre of community health volunteers working in the\u000a      country's poorest areas, and rolled out the intervention across the state\u000a      [b]. In 2013, the intervention was rolled out in the state of\u000a      Odisha in a collaboration between the Departments of Health, Women and\u000a      Child Development, and Rural Development, together with the UK Department\u000a      for International Development (DFID). DFID India made the decision to\u000a      promote the women's group intervention as a cost-effective strategy to\u000a      improve maternal and newborn health and to test its application to other\u000a      health issues, including maternal and child under-nutrition [c].\u000a      The roll-out in Odisha covers a population of over one million women [d].\u000a    The results of our work have received vast media coverage in India and\u000a      internationally. An article in The Hindu in 2010 interviewed\u000a      mothers who had benefited from the programme. One described the impact of\u000a      the programme as follows: \"Earlier, we didn't clean our hands before\u000a        cooking and eating. We'd just leave the baby and go off to work. Now we\u000a        clean and grow vegetables ourselves. We keep the water clean in the\u000a        house. Women in the village help one another and sometimes pool money to\u000a        transport someone to hospital for delivery and visits to the doctor.\"\u000a      Another said: \"Earlier, when a problem arose, we would pray. Now, I go\u000a        to a doctor at the slightest problem. I ate spinach, fish and vegetables\u000a        during and after my recent pregnancy. I breast-fed for six months from\u000a        the first day\" [e]. This story was also covered by the Guardian\u000a      and Time, as well as on Indian national television [f].\u000a      The New York Times also reported favourably on the publication of\u000a      our first Mumbai trial, where the results were less successful, reflecting\u000a      on the use of evidence in global policy and the political pressure to show\u000a      only positive findings [g].\u000a    In Malawi, the intervention has been adopted as a model for improving\u000a      maternal and newborn health by the Ministry of Health, UNFPA and the\u000a      Uchembere Network. Project team members participated in the development of\u000a      the Government of Malawi's plan for community interventions, part of the\u000a      Health Sector Strategic Plan (2011-6) and the Malawi Road Map for\u000a      Accelerating the Reduction of Maternal and Neonatal Mortality [h].\u000a      Further media coverage for MaiKhanda included an interview with Voice of\u000a      America in June 2013 [i].\u000a    Through the non-governmental organisation Women and Children First, we\u000a      are supporting further uptake of the women's group intervention in\u000a      Bangladesh, Malawi, Ethiopia and Uganda, using an implementation guide\u000a      developed jointly with UCL, the Perinatal Care Project of the Diabetic\u000a      Society of Bangladesh and Ekjut India [j]. The organisation aims\u000a      to extend the thematic content of the women's groups model to test its\u000a      effectiveness for addressing other maternal and child health issues,\u000a      including family planning, prevention of mother to child transmission of\u000a      HIV, and under- five's health and nutrition.\u000a    In December 2012, Costello and Prost participated in a World Health\u000a      Organisation (WHO) workshop to design a module on community mobilisation\u000a      with women's groups for maternal and newborn health, which will supplement\u000a      WHO's existing guidance on Caring for Newborns and Children in the\u000a      Community [k]. The results of our meta-analysis were also\u000a      presented to WHO in early 2013 and influenced their decision to develop a\u000a      training module for community health workers intended for global\u000a      dissemination; this will have an impact on developing country health\u000a      systems around the world [l]. The meta-analysis results were also\u000a      launched at a large event in the Houses of Parliament and at the Women\u000a      Deliver International Conference, both in May 2013.\u000a    ","ImpactSummary":"\u000a    UCL researchers and overseas partners have developed a successful\u000a      community intervention to improve maternal and newborn health, which is\u000a      now saving lives in India's poorest communities and is being taken up in\u000a      other low- and middle-income countries. The intervention involves village\u000a      women's groups working together to identify, prioritise and address common\u000a      problems during and after pregnancy using local resources. The process was\u000a      tested successfully in Nepal, led to a 45% reduction in newborn mortality\u000a      in an award-winning trial in rural India, demonstrated an impact on\u000a      maternal mortality in a meta-analysis of seven trials across four\u000a      countries, and has already been scaled up to a population of over 1.5\u000a      million in rural India's poorest communities.\u000a    ","ImpactType":"Health","Institution":"\u000a    University College London\u000a    ","Institutions":[{"AlternativeName":"University College London","InstitutionName":"University College London","PeerGroup":"A","Region":"London","UKPRN":10007784}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"1444365","Name":"State of Jharkhand"},{"GeoNamesId":"1275339","Name":"Mumbai"}],"References":"\u000a    \u000a[1] Manandhar DS, Osrin D, Shrestha BP, et al.; Members of the MIRA\u000a      Makwanpur trial team. Effect of a participatory intervention with women's\u000a      groups on birth outcomes in Nepal: cluster- randomised controlled trial.\u000a      Lancet. 2004 Sep 11-17;364(9438):970-9. http:\/\/doi.org\/fntgkw\u000a    \u000a\u000a[2] Tripathy P, Nair N, Barnett S, et al. Effect of a participatory\u000a      intervention with women's groups on birth outcomes and maternal depression\u000a      in Jharkhand and Orissa, India: a cluster- randomised controlled trial.\u000a      Lancet. 2010 Apr 3;375(9721):1182-92. http:\/\/doi.org\/bs583j\u000a    \u000a\u000a[3] Houweling TA, Tripathy P, Nair N, et al. The equity impact of\u000a      participatory women's groups to reduce neonatal mortality in India:\u000a      secondary analysis of a cluster-randomised trial. Int J Epidemiol. 2013\u000a      Apr;42(2):520-32. http:\/\/dx.doi.org\/10.1093\/ije\/dyt012.\u000a    \u000a\u000a[4] More NS, Bapat U, Das S, et al. Community mobilization in Mumbai\u000a      slums to improve perinatal care and outcomes: a cluster randomized\u000a      controlled trial. PLoS Med. 2012;9(7):e1001257. http:\/\/doi.org\/p5w\u000a    \u000a\u000a[5] Lewycka S, Mwansambo C, Rosato M, et al. Effect of women's groups and\u000a      volunteer peer counselling on rates of mortality, morbidity, and health\u000a      behaviours in mothers and children in rural Malawi (MaiMwana): a\u000a      factorial, cluster-randomised controlled trial. Lancet. 2013 May\u000a      18;381(9879):1721-35. http:\/\/dx.doi.org\/10.1016\/S0140-6736(12)61959-X.\u000a    \u000a\u000a[6] Colbourn T, Nambiar B, Bondo A, et al. Effects of quality improvement\u000a      in health facilities and community mobilization through women's groups on\u000a      maternal, neonatal and perinatal mortality in three districts of Malawi:\u000a      MaiKhanda, a cluster randomized controlled effectiveness trial. Int\u000a      Health. 2013 Sep;5(3):180-95. http:\/\/dx.doi.org\/10.1093\/inthealth\/iht011.\u000a    \u000a\u000a[7] Fottrell E, Azad K, Kuddus A, et al. The effect of increased coverage\u000a      of participatory women's groups on neonatal mortality in Bangladesh: A\u000a      cluster randomized trial. JAMA Pediatr. 2013 Sep;167(9):816-25. http:\/\/dx.doi.org\/10.1001\/jamapediatrics.2013.2534.\u000a    \u000a\u000a[8] Prost A, Colbourn T, Seward N, et al. Women's groups practising\u000a      participatory learning and action to improve maternal and newborn health\u000a      in low-resource settings: a systematic review and meta-analysis. Lancet.\u000a      2013 May 18;381(9879):1736-46. http:\/\/doi.org\/f2m7hq\u000a    \u000aSociety for Clinical Trials, Trial of the Year Awards 2011:\u000a      http:\/\/www.sctweb.org\/public\/about\/toty.cfm\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [a] Letter of support from the Funding Officer, Big Lottery Fund, who\u000a      provided a grant to support the roll-out. The letter confirms the\u000a      population coverage and numbers of groups, and writes that \"having\u000a      undertaken monitoring visits to project communities in both countries I am\u000a      aware of how well the portfolio was received by the project beneficiaries\u000a      and stakeholders and how successful it has been\". Copy available on\u000a      request.\u000a    [b] Letter from the Deputy Director of Health Services, Jharkhand Rural\u000a      Health Mission Society, Department of Health and Family Welfare,\u000a      Jharkhand. Corroborates incorporation into training modules. Copy\u000a      available on request. Copies of letters to Chief Medical Officers of\u000a      individual regions, confirming the roll-out, are also available.\u000a    [c] Corroboration of the influence of UCL and Ekjut's work on DFID in\u000a      India can be obtained from the Health Advisor for DFID. Contact details\u000a      provided.\u000a    [d] Odisha CM launches Shakti Varta- empowering women through\u000a      participatory learning and action on health, nutrition involving self help\u000a      groups\". Odisha Diary. April 30, 2013. http:\/\/www.orissadiary.com\/CurrentNews.asp?id=40992\u000a    [e] `Lessons from the Ekjut way.' The Hindu. September 15, 2010.\u000a      http:\/\/www.thehindu.com\/opinion\/op-ed\/lessons-from-the-ekjut-way\/article646019.ece\u000a    [f] Further media coverage:\u000a    \u000a      `Ekjut achieves dramatic success in cutting child deaths in India.'\u000a        The Guardian. September 10, 2010. http:\/\/www.guardian.co.uk\/global-development\/2010\/sep\/24\/child-mortality-cut-\u000a          india-ekjut\u000a\u000a      `In India, Getting Mothers Talking Saves Babies' Lives.' Time. April\u000a        6, 2010. http:\/\/www.time.com\/time\/world\/article\/0,8599,1978043,00.html\u000a\u000a      Indian national television coverage: http:\/\/www.youtube.com\/watch?v=fF-ebpLWNm8\u000a\u000a    \u000a    [g] `Learning From Failure.' The New York Times. February 1, 2013\u000a      http:\/\/www.nytimes.com\/2013\/02\/03\/opinion\/sunday\/learning-from-research-failure.html?_r=0\u000a    [h] Corroboration of the influence of UCL and MaiMwana's work on\u000a      strategies to scale up interventions with community groups in Malawi can\u000a      be obtained from the Principal Secretary, Ministry of Health, Government\u000a      of the Republic of Malawi. Contact details provided.\u000a    [i] `Better Maternal Care Reduces Newborn, Infant Mortality in Malawi.'\u000a      Voice of America. June 24, 2013. http:\/\/m.voanews.com\/a\/1688430.html\u000a    [j] http:\/\/www.womenandchildrenfirst.org.uk\/what-we-do\/international-programmes\/programme-\u000a        resources\u000a    [k] Film by Mikey Rosato which was presented as evidence: https:\/\/vimeo.com\/75751099\u000a    [l] Corroboration on plans for a WHO module on working with participatory\u000a      women's groups to improve maternal and newborn health can be obtained from\u000a      Technical Officer, Department of Maternal, Newborn, Child and Adolescent\u000a      Health, World Health Organisation. Contact details provided.\u000a    ","Title":"\u000a    Community intervention through women's groups improves maternal and\u000a      newborn survival and health in low-resource settings\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Nearly ninety-nine per cent of the world's maternal and newborn deaths\u000a      occur in low- and middle- income countries. South Asian and African\u000a      nations shoulder a substantial proportion of this burden.\u000a    From 2000 to 2004, Professor Anthony Costello and Dr David Osrin at the\u000a      UCL Institute for Global Health (IGH) worked with MIRA, an NGO in Nepal,\u000a      to develop and test a community intervention, which involved women's\u000a      groups in identifying, prioritising, and addressing common problems during\u000a      the perinatal period using participatory methods. The intervention was\u000a      tested in a large community cluster-randomised controlled trial (RCT) in\u000a      Nepal, where it led to a 30% reduction in neonatal mortality [1].\u000a      The intervention increased care-seeking during pregnancy and institutional\u000a      deliveries, and was also linked to improved newborn care practices in the\u000a      home.\u000a    From 2005 to 2012, Costello and Osrin, along with Dr Tim Colbourn, Dr\u000a      Edward Fottrell (both IGH) and Dr Audrey Prost (UCL Institute of Child\u000a      Health) worked with partner organisations in India, Malawi, Nepal and\u000a      Bangladesh to test the impact of the women's group intervention on\u000a      maternal and newborn health in other under-served communities.\u000a    In rural India, the trial of the women's group intervention led by our\u000a      partner, Ekjut, resulted in a 45% reduction in newborn deaths over two\u000a      years in rural, largely indigenous communities among the poorest in India\u000a      [2]. Further research also found that, in this rural trial,\u000a      mortality reduction was greatest among the poorest mothers, suggesting\u000a      that women's groups can be an effective way of targeting inequalities [3].\u000a      The intervention's evaluation won the Society for Clinical Trials' 2011 Trial\u000a        of the Year award.\u000a    The intervention was also tested in slum communities in Mumbai, India, in\u000a      a project led by local organisation SNEHA (Society for Nutrition,\u000a      Education &amp; Health Action) in collaboration with Osrin. In this\u000a      setting, the effects were not as great as for the rural population. One\u000a      reason for this was that newborn survival was already better than in the\u000a      other settings in which groups were implemented [4].\u000a    Research in Malawi has been ongoing since 2003, when the MaiMwana project\u000a      was set-up by UCL researchers Sonia Lewycka and Mikey Rosato to test the\u000a      effect of the women's group intervention in Africa for the first time. The\u000a      results of the MaiMwana women's group intervention were impressive: a 74%\u000a      reduction in maternal mortality, and a 41% reduction in newborn mortality\u000a      [5]. In 2007 another less-intensive women's group intervention,\u000a      MaiKhanda, was tested, also by cluster randomised trial, by UCL\u000a      researchers Tim Colbourn and Bejoy Nambiar. MaiKhanda also achieved\u000a      significant results: a 16% reduction in perinatal mortality (stillbirths\u000a      and deaths in the first week of life) and a 23% reduction in newborn\u000a      mortality in areas where the women's group intervention was combined with\u000a      a health facility quality improvement intervention [6].\u000a    The intervention did not have the same impact on mortality as observed in\u000a      Nepal and rural India when applied to a population of around 500,000 in\u000a      rural Bangladesh with partners BADAS-PCP between 2005 and 2007. This\u000a      caused us to question why the intervention had been so successful in some\u000a      settings but not in others and we concluded that population coverage of\u000a      the intervention was likely to be key (i.e. the ratio of community women's\u000a      group per population). We therefore decided to test the intervention at a\u000a      higher population coverage, increasing the number of groups from a\u000a      coverage of one per 1,400 to one per 300 population. The results showed\u000a      that when delivered at this higher population coverage and with greater\u000a      participation or pregnant women and women of reproductive age, the\u000a      intervention reduced newborn mortality by more than one third and was\u000a      highly cost-effective [7].\u000a    In 2013, a meta-analysis led by Prost and Colbourn collated data from\u000a      seven trials testing the impact of women's groups, and found that the\u000a      intervention reduced maternal mortality by around a third, or, in trials\u000a      where the groups had greater than 30% of pregnant women as members, by 55%\u000a      [8]. This is the first time that a community intervention other\u000a      than training Traditional Birth Attendants has demonstrated an impact on\u000a      maternal mortality at a population level.\u000a    Partner organisations:\u000a    \u000a      Ekjut, India: http:\/\/ekjutindia.org\u000a\u000a      SNEHA, India: http:\/\/www.snehamumbai.org\/\u000a\u000a      MaiMwana Project, Malawi: http:\/\/www.maimwana.malawi.net\/MaiMwana\/Home.html\u000a\u000a      Diabetic Association of Bangladesh: http:\/\/www.dab-bd.org\/pcp.php\u000a\u000a      MIRA, Nepal http:\/\/www.mira.org.np\/mira\/\u000a\u000a      MaiKhanda, Malawi http:\/\/www.maikhandatrust.org\/About_Us.html\u000a\u000a    \u000a    "},{"CaseStudyId":"42220","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1668284","Name":"Taiwan"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"1861060","Name":"Japan"},{"GeoNamesId":"2017370","Name":"Russia"},{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6251999","Name":"Canada"}],"Funders":[],"ImpactDetails":"\u000d\u000a    Impacts include: health and welfare; public policy and services;\u000d\u000a      practitioners and services Main beneficiaries include: patients; NICE;\u000d\u000a      health professionals; industry; international guideline bodies\u000d\u000a    The relatively healthy elderly aged 80 and over are one of the fastest\u000d\u000a      growing sectors of the population, both in the UK and globally (in both\u000d\u000a      developed and developing countries). Systolic blood pressure tends to rise\u000d\u000a      with age as does the risk of cardiovascular and cerebrovascular events and\u000d\u000a      dementia. The rise in blood pressure with ageing means that a substantial\u000d\u000a      proportion of those aged 80 and over suffer from hypertension, estimated\u000d\u000a      at ~70% in the UK (Health Survey for England 2009). The results of the\u000d\u000a      HYVET research not only show the reduction in risk of cardiovascular\u000d\u000a      events but the identification of a safe goal blood pressure in this group\u000d\u000a      and are applicable to a large and growing group. This Imperial-led study\u000d\u000a      was the first in this age group and has directly influenced hypertension\u000d\u000a      guidelines internationally.\u000d\u000a    The results from HYVET have shaped hypertension guidelines in the UK,\u000d\u000a      Europe, Canada, Japan, the USA, China, Russia, Latin America, and South\u000d\u000a      Africa. In the UK the NICE guidelines (2011) indicate that people aged &#8805;80\u000d\u000a      should be treated [1] and the consultation on new indicators for the UK\u000d\u000a      2013\/14 Quality and Outcomes Framework (QOF) proposes inclusion of new\u000d\u000a      indicators specifically for the over 80s, using the HYVET goal systolic\u000d\u000a      blood pressure [2].\u000d\u000a    The European guidelines (2009) now recommend that antihypertensive\u000d\u000a      treatment can be extended to help patients aged 80 years and above,\u000d\u000a      stating that `gap in the evidence has been filled with...the results of\u000d\u000a      HYVET' [3].\u000d\u000a    The Canadian Hypertension Education Program (2009) `specifically\u000d\u000a      recommends that age not be used as a factor in prescribing' based on HYVET\u000d\u000a      results [4]. The Japanese guidelines (2009) now specify that hypertension\u000d\u000a      should be treated in patients of all ages [5; chapter 3] and the adequate\u000d\u000a      antihypertensive treatment is recommended in elderly patients (chapter 8).\u000d\u000a      Guidelines on hypertension in China, Latin America, Russia [6-8] also\u000d\u000a      recommend treatment of high blood pressure in the elderly and cite HYVET.\u000d\u000a      Beyond the ten sources of evidence provided, we can also evidence changes\u000d\u000a      to guidelines in Taiwan and South Africa.\u000d\u000a    A consensus document in the US on hypertension in the elderly (American\u000d\u000a      College of Cardiology Foundation\/American Heart Foundation, 2011)\u000d\u000a      concludes that HYVET provides clear evidence that blood pressure lowering\u000d\u000a      drugs are associated with definite cardiovascular benefits in patients 80\u000d\u000a      years and over and US guidelines from the National Heart Lung and Blood\u000d\u000a      Institute (JNC8) are expected to include HYVET at their next update [9].\u000d\u000a    More generally, medical professionals globally have benefitted in terms\u000d\u000a      of receiving clearer guidance, elderly individuals benefit in health terms\u000d\u000a      and health service providers in economic terms. A Swiss group have\u000d\u000a      calculated that applying the results of HYVET means a lower total cost per\u000d\u000a      patient receiving antihypertensive treatment as compared to an untreated\u000d\u000a      group and that the additional medication cost is covered by the reduction\u000d\u000a      of costs related to the treatment of strokes, myocardial infarction and\u000d\u000a      heart failure. The potential decrease in incident dementia and fracture\u000d\u000a      suggests that this may be an underestimate [10].\u000d\u000a    The pharmaceutical company (Servier) that provided part of the funding\u000d\u000a      and the medication for HYVET report that in the company financial year\u000d\u000a      during which the HYVET results were published their own sales of\u000d\u000a      indapamide (the first line medication used in HYVET) rose by 4% across 11\u000d\u000a      countries. Data provided by Servier also show generic indapamide sales\u000d\u000a      increasing year on year from 2009 to 2012 with the largest increase in the\u000d\u000a      Sustained Release formulation as used in the trial.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Before the Hypertension in the Very Elderly Trial (HYVET) it was not\u000d\u000a      clear whether people aged 80 and over with hypertension should receive\u000d\u000a      antihypertensive treatment. The over 80s are one of the fastest growing\u000d\u000a      groups in society and are at high risk of hypertension and its sequelae\u000d\u000a      due to age. HYVET demonstrated benefit of treatment including reduced\u000d\u000a      mortality and cardiovascular comorbidity. Guidelines around the world for\u000d\u000a      the treatment of hypertension have changed as a result. In the UK it is\u000d\u000a      proposed that the Quality Outcomes Framework (QOF) for GPs now includes\u000d\u000a      those over 80 and uses the target blood pressure used in HYVET.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    Imperial College London\u000d\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a(1) Bulpitt, C., Beckett, N., Cooke, J., Dumitrascu, D., Gil-Extremera,\u000d\u000a      B., Nachev, C., Nunes, M., Peters, R., Staessen, J., Thijs, L., on behalf\u000d\u000a      of the HYVET-pilot investigators. (2003). Results of the pilot study for\u000d\u000a      the Hypertension in the Very Elderly Trial. Journal of Hypertension,\u000d\u000a      21 (12), 2409-2417. DOI.\u000d\u000a      Times cited: 140 (as of 4th November 2013 from ISI Web of\u000d\u000a      Science). Journal Impact Factor: 3.80\u000d\u000a    \u000a\u000a(2) Beckett, N., Peters, R., Fletcher, A.E., Staessen, J., Liu, L.S.,\u000d\u000a      Dumitrascu, D., Stoyanovsky, V., Antikainen, R., Nikitin, Y., Anderson,\u000d\u000a      C., Belhani, A., Forette, F., Rajkumar, C., Thijs, L., Banya, W., Bulpitt,\u000d\u000a      C., for the HYVET study group. (2008). Treatment of hypertension in\u000d\u000a      patients 80 years of age or older. New England Journal of Medicine,\u000d\u000a      358 (18), 1887-1898. DOI.\u000d\u000a      Times cited: 652 (as of 4th November 2013 from ISI Web of\u000d\u000a      Science). Journal Impact Factor: 51.65\u000d\u000a    \u000a\u000a(3) Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R.,\u000d\u000a      Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., Comsa, M.,\u000d\u000a      Burch, L., Fletcher, A., Bulpitt, C., for the HYVET investigators. (2008).\u000d\u000a      Incident dementia and blood pressure lowering in the Hypertension in the\u000d\u000a      Very Elderly Trial cognitive function assessment (HYVET-COG): a\u000d\u000a      double-blind, placebo controlled trial. Lancet Neurology, 7 (8),\u000d\u000a      683-689. DOI.\u000d\u000a      Times cited: 185 (as of 4th November 2013 from ISI Web of\u000d\u000a      Science). Journal Impact Factor: 23.91\u000d\u000a    \u000a\u000a(4) Peters, R., Beckett, N., Burch, L., Vernejoul, M., Liu, L., Duggan,\u000d\u000a      J., Swift, C., Gil-Extremera, B., Fletcher, A., Bulpitt, C. (2010). The\u000d\u000a      effect of treatment based on a diuretic (indapamide) {+\/-} ACE inhibitor\u000d\u000a      (perindopril) on fractures in the Hypertension in the Very Elderly Trial\u000d\u000a      (HYVET). Age and Ageing, 39 (5), 609-616. DOI.\u000d\u000a      Times cited: 9 (as of 4th November 2013 from ISI Web of\u000d\u000a      Science). Journal Impact Factor: 3.81\u000d\u000a    \u000a\u000a(5) Beckett, N., Peters, R., Tuomilehto, J., Swift, C., Sever, P.,\u000d\u000a      Potter, J., McCormack, T., Forette, F., Gil-Extremera, B., Dumitrascu, D.,\u000d\u000a      Staessen, J., Thijs, L., Fletcher, A., Bulpitt, C. (2012). Immediate and\u000d\u000a      late benefits of treating very elderly people with hypertension: results\u000d\u000a      from active treatment extension to Hypertension in the Very Elderly\u000d\u000a      randomised controlled trial. British Medical Journal, 344, d7541.\u000d\u000a      DOI. Times cited: 12 (as\u000d\u000a      of 4th November 2013 from ISI Web of Science). Journal Impact\u000d\u000a      Factor: 17.21.\u000d\u000a    \u000a\u000a(6) Bulpitt, C., Beckett, N., Peters, R., Staessen, J., Wang, J., Comsa,\u000d\u000a      M., Fagard, R., Dumitrascu, D., Gergova, V., Antikainen, R., Cheek, E.,\u000d\u000a      Rajkumar, C. (2013). Does white coat hypertension require treatment over\u000d\u000a      age 80? Results of the Hypertension in the Very Elderly Trial ambulatory\u000d\u000a      Blood Pressure side project. Hypertension, 61, 89 - 94. DOI.\u000d\u000a      Times cited: 2 (as of 4th November 2013 from ISI Web of\u000d\u000a      Science). Journal Impact Factor: 6.87\u000d\u000a    \u000aAwards:\u000d\u000a    &#8226; HYVET was unanimously voted as the 2008 Trial of the Year by the\u000d\u000a      prestigious Project ImpACT (Important Achievements of Clinical Trials) and\u000d\u000a      the Society for Clinical Trials and judged to have improved the lot of\u000d\u000a      mankind providing the basis for a substantial, beneficial change in health\u000d\u000a      care and to be a landmark clinical trial in terms of design, execution,\u000d\u000a      and results. http:\/\/www.sctweb.org\/public\/about\/toty.cfm\u000d\u000a    Key funding:\u000d\u000a    &#8226; British Heart Foundation (1998-2004; &#163;728,830), Principal Investigator\u000d\u000a      (PI) C. Bulpitt, Hypertension in the very elderly trial.\u000d\u000a    &#8226; Servier International Research (1999-2010; &#163;8,301,643), PI C. Bulpitt,\u000d\u000a      Hypertension in the very elderly trial.\u000d\u000a    &#8226; British Heart Foundation (2000-2005; &#163;143,141), PI C. Rajkumar, Effects\u000d\u000a      of arterial compliance, ambulatory blood pressure, blood pressure\u000d\u000a      variability on morbidity and mortality in hypertension subjects over 80\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"},{"Level1":"11","Level2":"9","Subject":"Neurosciences"}],"Sources":"\u000d\u000a    [1] NICE clinical guideline 127 Hypertension: clinical management of\u000d\u000a      primary hypertension http:\/\/www.nice.org.uk\/guidance\/CG127\u000d\u000a      (pages 136-140). Archived\u000d\u000a      on 4th November 2013. NCGE (Commissioned by NICE) Update of\u000d\u000a      Clinical Guidelines 18 &amp; 24. Hypertension: The Clinical Management of\u000d\u000a      Hypertension in adults. Clinical Guide 127: Methods, Guides and Clinical\u000d\u000a      Evidence August 2011 (refer to p.171).\u000d\u000a      http:\/\/www.nice.org.uk\/nicemedia\/live\/13561\/56007\/56007.pdf.\u000d\u000a      Archived\u000d\u000a      on 4th November 2013.\u000d\u000a    [2] National Institute for Health and Clinical Excellence. Consultation\u000d\u000a      on potential new indicators for the 2013\/14 Quality and Outcomes Framework\u000d\u000a      (QOF). Archived\u000d\u000a      on 4th November 2013.\u000d\u000a    [3] Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier,\u000d\u000a      M., Caulfield, M., et al. (2009). Reappraisal of European guidelines on\u000d\u000a      hypertension management: a European Society of Hypertension Task Force\u000d\u000a      document. Journal of Hypertension, 27, 2121 - 2153 (refer to pp.\u000d\u000a      2140-2142). DOI.\u000d\u000a    [4] 2009 Canadian Education Programme Recommendations. The Short Clinical\u000d\u000a      Summary: An Annual Update. 1-17 (refer to p.3). http:\/\/www.hypertension.ca\/images\/stories\/dls\/09-clinical-summary.pdf.\u000d\u000a      Archived\u000d\u000a      on 4th November 2013.\u000d\u000a    [5] Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J.,\u000d\u000a      Horiuchi, M., Imai, Y., et al, on behalf of The Japanese Society of\u000d\u000a      Hypertension Committee. The Japanese Society of Hypertension: Guidelines\u000d\u000a      for the Management of Hypertension. Chapter 3: Principles of Treatment. Hypertension\u000a        Research, 32 (1): 24 - 28 (refer to p. 26).\u000d\u000a      http:\/\/www.nature.com\/hr\/journal\/v32\/n1\/pdf\/hr20083a.pdf.\u000d\u000a      (archived\u000d\u000a      on 4th November 2013) Chapter 8, Hypertension in the elderly.\u000d\u000a      (2009). Hypertension Research 32, 57-62. (refer to p58). http:\/\/www.nature.com\/hr\/journal\/v32\/n1\/pdf\/hr20086a.pdf\u000d\u000a      (archived\u000d\u000a      on 4th November 2013)\u000d\u000a    [6] Liu L. \u000d\u000a\u0009\u000d\u000a\u00092010 Chinese guidelines for the management of\u000d\u000a      hypertension. (2011). Chinese Journal of Cardiology, 39(7): 579 - 616. Full copy of the guidelines available on request; refer to p.49 of\u000d\u000a      translated version.\u000d\u000a      http:\/\/so.med.wanfangdata.com.cn\/ViewHTML\/PeriodicalPaper_zhxxgb201107002.aspx.\u000d\u000a      Archived on 26th\u000d\u000a      November 2013.\u000d\u000a    [7] Ramiro, A., Sanchez, M. A., Baglivo, H., Velazquez, C., Burlando, G.,\u000d\u000a      Kohlmann, O., et al on behalf of the Latin America Expert Group. (2009).\u000d\u000a      Latin American guidelines on hypertension. Journal of Hypertension,\u000d\u000a      27, 905-922; refer to p.913.DOI.\u000d\u000a    [8] Diagnosis &amp; Treatment: Arterial Hypertension. Recommendations of\u000d\u000a      the Russian Medical Society on Arterial Hypertension and the Russian\u000d\u000a      Scientific Society of Cardiology Moscow. (2008); 7 (6), 3 - 32.\u000d\u000a      &#1044;&#1048;&#1040;&#1043;&#1053;&#1054;&#1057;&#1058;&#1048;&#1050;&#1040; &#1048; &#1051;&#1045;&#1063;&#1045;&#1053;&#1048;&#1045;&#1040;&#1056;&#1058;&#1045;&#1056;&#1048;&#1040;&#1051;&#1068;&#1053;&#1054;&#1049; &#1043;&#1048;&#1055;&#1045;&#1056;&#1058;&#1045;&#1053;&#1047;&#1048;&#1048; &#1055;&#1088;&#1080;&#1083;&#1086;&#1078;&#1077;&#1085;&#1080;&#1077; 2 &#1082; &#1078;&#1091;&#1088;&#1085;&#1072;&#1083;&#1091;\u000d\u000a      &#8220;&#1050;&#1072;&#1088;&#1076;&#1080;&#1086;&#1074;&#1072;&#1089;&#1082;&#1091;&#1083;&#1103;&#1088;&#1085;&#1072;&#1103; &#1090;&#1077;&#1088;&#1072;&#1087;&#1080;&#1103; &#1080; &#1087;&#1088;&#1086;&#1092;&#1080;&#1083;&#1072;&#1082;&#1090;&#1080;&#1082;&#1072;&#8221; (see page 21). Full copy of the\u000d\u000a      guidelines available on request.\u000d\u000a    [9] Aronow, W., Fleg, J., Pepine, C., Artinian, N., Bakris, G., Brown,\u000d\u000a      A., et al (2011). ACCF\/AHA 2011 Expert Consensus Document on\u000d\u000a      Hypertension in the Elderly. American College of Cardiology Foundation\u000d\u000a      Task Force on Clinical Expert Consensus Documents, American Academy of\u000d\u000a      Neurology, American Geriatrics Society, American Society for Preventive\u000d\u000a      Cardiology, American Society of Hypertension, American Society of\u000d\u000a      Nephrology, Association of Black Cardiologists, European Society of\u000d\u000a      Hypertension. Journal of the American College of Cardiology, 57\u000d\u000a      (20), 2037-2114. (refer to pp. 2074 - 2075). DOI.\u000d\u000a    [10] Szucs, T., Waeber, B., Tomonaga, Y. (2010). Cost-effectiveness of\u000d\u000a      antihypertensive treatment in patients 80 years of age or older in\u000d\u000a      Switzerland: an analysis of the HYVET study from a Swiss perspective. Journal\u000a        of Human Hypertension, 24, 117-123. DOI.\u000d\u000a    ","Title":"\u000d\u000a    Global Change in Guidelines Relating to Treatment of the Very Elderly\u000d\u000a      Resulting from HYVET (Hypertension in the Very Elderly Trial)\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Key Imperial College London researchers:\u000d\u000a      Professor Christopher Bulpitt, Professor of Geriatric Medicine\u000d\u000a      (1989-2005), now Emeritus Professor and Chief Investigator of HYVET\u000d\u000a      Dr Nigel Beckett, Clinical Research Fellow, Honorary Consultant Physician\u000d\u000a      and trial coordinator (1998-2010)\u000d\u000a      Dr Ruth Peters, Senior Researcher and deputy trial coordinator\u000d\u000a      (1997-present)\u000d\u000a    HYVET is the only multinational double blind randomised placebo\u000d\u000a      controlled trial of antihypertensives in those aged 80 and over. HYVET was\u000d\u000a      sponsored, directed, coordinated and managed by an Imperial team led by\u000d\u000a      Professor Bulpitt. Prior to HYVET the balance of risks and benefits from\u000d\u000a      antihypertensive treatment in this very elderly group were not clear and\u000d\u000a      guidelines were equivocal. A multinational open label pilot trial from the\u000d\u000a      same Imperial-led group (1) preceded the main HYVET trial allowing\u000d\u000a      piloting of methodology.\u000d\u000a    Professor Bulpitt and Imperial colleagues were responsible for securing\u000d\u000a      and managing the funding, design, data collection, processing, statistics,\u000d\u000a      pharmacovigilance, endpoint identification and, validation, quality\u000d\u000a      assurance, monitoring and day to day running of the trial in all\u000d\u000a      countries\/centres.\u000d\u000a    3845 Hypertensive participants (systolic blood pressure &#8805;160mmHg at trial\u000d\u000a      entry) aged 80 or over at time of randomisation were recruited from 195\u000d\u000a      centres in Eastern and Western Europe, China, Australasia and Tunisia and\u000d\u000a      randomised to antihypertensives, a thiazide like diuretic (Indapamide\u000d\u000a      sustained release 1.5mg) +\/-an angiotensin converting enzyme inhibitor\u000d\u000a      (perindopril 2-4mg) or matching placebos. Participants were seen every 3\u000d\u000a      months in the first year then 6 monthly thereafter. Mean follow up was 2.1\u000d\u000a      years when the trial was terminated early at the time of the second\u000d\u000a      interim analysis due to a significant reduction in total mortality in the\u000d\u000a      actively treated group.\u000d\u000a    Key results from the main trial indicated that antihypertensive use was\u000d\u000a      associated with a 21% reduction in total mortality, a 37% reduction in\u000d\u000a      stroke, a 34% reduction in cardiovascular events, a 64% reduction in\u000d\u000a      incident\/worsening heart failure, a 42% deceased risk of fracture and no\u000d\u000a      negative impact on cognitive decline\/dementia (2-4).\u000d\u000a    A one year open label extension followed, carried out by the same team.\u000d\u000a      It found that very elderly patients with hypertension may gain early\u000d\u000a      benefit from treatment in terms of stroke and cardiovascular events but\u000d\u000a      that treatment for more than 12 months may be needed to achieve reductions\u000d\u000a      of cardiovascular and total mortality. The results reinforce the benefits\u000d\u000a      from treatment and support the need for both early and long term treatment\u000d\u000a      (5).\u000d\u000a    Substudies included Ambulatory Blood Pressure Monitoring (ABPM; showing a\u000d\u000a      high prevalence of white coat hypertension and a potential gain from\u000d\u000a      treatment in this group) and Quality of Life (showing no detriment\u000d\u000a      associated with antihypertensive treatment) (6).\u000d\u000a    "},{"CaseStudyId":"42221","Continent":[{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"}],"Funders":[],"ImpactDetails":"\u000a    Impacts include: health and welfare, public policy and service\u000a      Main Beneficiaries include: public, government and public policy makers\u000a    Since the publication of WHO recommendations and guidelines on sodium\u000a      intake in 2003 (as part\u000a      of WHO Technical Report Series 916) and 2007 (Prevention of\u000a        Cardiovascular Disease), Imperial\u000a      College researchers and others have published a significant body of\u000a      scientific evidence concerning\u000a      sodium intakes in adults and children worldwide (research ref. 6), and the\u000a      associated risks of high\u000a      blood pressure and cardiovascular disease. In response to the new\u000a      research, Member States and\u000a      international partners requested WHO to review the guidelines on sodium\u000a      intake for adults, and\u000a      also for the first time to generate a guideline on sodium intake for\u000a      children. At the same time,\u000a      guidelines for potassium intakes for adults and children were requested as\u000a      there were none\u000a      previously.\u000a    The 2012 WHO guidelines [1, 2] have set the world standards on sodium and\u000a      potassium intakes in\u000a      both adults and children, and are a template being used by governments,\u000a      policy makers and\u000a      industry for reductions in sodium and increases in potassium intakes\u000a      worldwide [3, 4]. Both\u000a      guidelines cite Imperial College-led research. The guidelines recommend a\u000a      reduction in sodium\u000a      intake to &lt;2 g\/day sodium (5 g\/day salt) in adults to reduce the\u000a      worldwide burden of high blood\u000a      pressure, heart disease and stroke, and a reduction in sodium intake to\u000a      control blood pressure in\u000a      children (intake to be based on the energy requirements of children\u000a      relative to those of adults) [1].\u000a      For potassium, WHO recommends an increase in potassium intake from food to\u000a      reduce blood\u000a      pressure and risk of cardiovascular disease, stroke and coronary heart\u000a      disease in adults with a\u000a      suggested potassium intake of at least 90 mmol\/day (3510 mg\/day); and an\u000a      increase in potassium\u000a      intake from food to control blood pressure in children (intake to be based\u000a      on the energy\u000a      requirements of children relative to those of adults) [2].\u000a    As noted in section 2, the WHO guidelines were developed by the Nutrition\u000a      Guidance Expert\u000a      Advisory Group (NUGAG) Subgroup on Diet and Health (Geneva, March 2011 and\u000a      Seoul,\u000a      November 2011) with substantial intellectual input from Professor Elliott\u000a      and other subject-matter\u000a      experts, using the WHO evidence-informed guideline development procedures\u000a      and the Grading of\u000a      Recommendations Assessment, Development and Evaluation (GRADE) criteria.\u000a      The guidelines\u000a      drew on results of systematic reviews and meta-analyses undertaken by WHO\u000a      staff and their\u000a      consultants working with the subject matter experts, including Professor\u000a      Elliott. Meetings of\u000a      NUGAG and its subject-matter experts including Professor Elliott were held\u000a      to agree on study\u000a      design and inclusion\/exclusion criteria for the supporting meta-analyses,\u000a      which were subsequently\u000a      published in the peer-reviewed literature (research refs. 4, 5). These\u000a      publications in BMJ (2013)\u000a      provided the science-base for both guidelines; as noted in the BMJ\u000a      papers \"WHO agreed with the\u000a        publication of this systematic review in a scientific journal as it\u000a        serves as the background evidence\u000a        review for updating the WHO guideline on sodium intake for adults and\u000a        for the establishment of a\u000a        guideline on sodium intake in children [for establishing the WHO\u000a        guideline on potassium intake]\u000a        and should therefore be widely available.\" The author contributions\u000a      state that Professor Elliott and\u000a      colleagues \"provided substantial intellectual input on research methods\u000a        and interpretation of\u000a        results. All authors read, provided input on, and agreed the final draft\u000a        of the manuscripts\" (research\u000a      ref 4, p8; 5, p7).\u000a    WHO Member States have agreed a target 25% reduction in premature\u000a      mortality from Non-Communicable\u000a      Diseases (NCDs) by 2025 through enactment of 9 voluntary targets,\u000a      including a\u000a      global target of 30% relative reduction in mean population intake of\u000a      salt\/sodium by 2025. The\u000a      report adopting the Global Monitoring Framework and Voluntary Global\u000a        Targets for the Prevention\u000a        and Control of NCDs dated 27 May 2013, following the 2011\u000a        Political Declaration of the United\u000a        Nations High Level Meeting on NCDs, cites the WHO sodium guideline\u000a      [3; page 43] and both the\u000a      sodium and potassium guidelines as relevant WHO tools to achieve the\u000a      targets [3; page 47]. A joint\u000a      technical meeting convened by WHO and The George Institute for Global\u000a      Health was held in\u000a      Sydney, Australia, in March 2013 (attended by Professor Elliott as a\u000a      subject-matter expert and\u000a      Chair of session) to agree methods to take forward salt reduction and\u000a      iodine fortification strategies\u000a      in public health. The report of that meeting [4] cites both the WHO sodium\u000a      and potassium\u000a      guidelines, based on the work of WHO staff, Professor Elliott and\u000a      colleagues, as key documents\u000a      \"to help develop and guide national policies [on sodium and potassium]\u000a        and public health nutrition\u000a        programmes\".\u000a    Imperial College-led research has also influenced US CDC efforts\u000a      underpinning the US\u000a      government strategy for monitoring population-wide sodium intakes. Thus\u000a      our demonstration of the\u000a      use of spot urines as a valid, low-cost alternative to 24-hr urine\u000a      collections for monitoring\u000a      population sodium intakes (research ref. 6) has had impact on the US CDC\u000a      approach to use of\u000a      biomarkers for monitoring sodium intakes in the US population [5, page 13;\u000a      6]. INTERMAP and\u000a      INTERSALT are cited by CDC as being among the top ten resources on sodium\u000a      reduction and\u000a      biomarkers [5, page 14 and 15]. CDC's own research using INTERSALT\u000a      equations developed by\u000a      Imperial College (research ref. 6) concludes \"[INTERSALT] equations\u000a        could be used with a single\u000a        spot urine specimen to monitor temporal trends in population mean sodium\u000a        intake among young\u000a        US adults... as part of a national surveillance system critical to\u000a        evaluating US efforts to reduce\u000a        sodium intake\" [6]. CDC is now taking this forward in its approach\u000a      to evaluating sodium intakes in\u000a      the US population. Specifically it is using spot urines collected in the\u000a      National Health and Nutrition\u000a      Examination Survey (NHANES) to examine trends over time in sodium intakes\u000a      in the US adult\u000a      population [7].\u000a    ","ImpactSummary":"\u000a    Research by Professor Elliott and colleagues at Imperial College on\u000a      worldwide salt and potassium\u000a      intakes, their relationships to blood pressure, and co-authored systematic\u000a      reviews and meta-analyses\u000a      of their effects in adults and children on blood pressure and\u000a      cardiovascular disease &#8212; and\u000a      potential adverse effects &#8212; has played an instrumental role in developing\u000a      international\u000a      guidelines and public policy on sodium reduction strategies. Furthermore,\u000a      published primary\u000a      research has influenced US Centers for Disease Control and Prevention\u000a      (CDC) strategies for\u000a      population-wide monitoring of sodium intakes in the USA. This work has\u000a      thus had impact on\u000a      policies for sodium reduction and monitoring of sodium intakes worldwide.\u000a    ","ImpactType":"Health","Institution":"\u000a    Imperial College London\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2660646","Name":"Genve"},{"GeoNamesId":"1835848","Name":"Seoul"},{"GeoNamesId":"2147714","Name":"Sydney"}],"References":"\u000a    \u000a(1) Elliott, P., Stamler, J., Nichols, R., et al. for the INTERSALT\u000a      Cooperative Research Group.\u000a      (1996). INTERSALT revisited: further analyses of 24 hour sodium excretion\u000a      and blood pressure\u000a      within and across populations. BMJ, 312, 1249-53. DOI.\u000a      Times cited: 372 (as at 8th November\u000a      2013 on ISI Web of Science). Journal Impact Factor: 17.21.\u000a    \u000a\u000a(2) Stamler, J., Elliott, P., Dennis, B., et al. (2003). INTERMAP:\u000a      background, aims, design,\u000a      methods, and descriptive statistics (nondietary). Journal of Human\u000a        Hypertension, 17(9), 591-608.\u000a      DOI. Times cited:\u000a      112 (as at 7th November 2013 on ISI Web of Science). Journal Impact\u000a      Factor: 2.81.\u000a    \u000a\u000a(3) Brown, I.J., Tzoulaki, I., Candeias, V., Elliott, P. (2009). Salt\u000a      intakes around the world:\u000a      implications for public health. Int J Epidemiol, 38(3), 791-813. DOI. Times cited: 125\u000a      (as at 7th\u000a      November 2013 on ISI Web of Science). Journal Impact Factor: 6.98.\u000a    \u000a\u000a(4) Aburto, N.J., Ziolkovska, A., Hooper, L., Elliott, P., Cappuccio,\u000a      F.P., Meerpohl, J.J. (2013).\u000a      Effect of lower sodium intake on health: systematic review and\u000a      meta-analyses. BMJ, 346, f1326\u000a      DOI. Times cited: 8 (as\u000a      at 7th November 2013 on ISI Web of Science). Journal Impact\u000a      Factor:\u000a      17.21.\u000a    \u000a\u000a(5) Aburto, N.J., Hanson, S., Gutierrez, H., Hooper, L., Elliott, P.,\u000a      Cappuccio, F.P. (2013). Effect of\u000a      increased potassium intake on cardiovascular risk factors and disease:\u000a      systematic review and\u000a      meta-analyses. BMJ, 346, 1378. DOI.\u000a      Times cited: 2 (as at 7th November 2013 on ISI Web of\u000a      Science). Journal Impact Factor: 17.21.\u000a    \u000a\u000a(6) Brown, I.J., Dyer, A.R., Chan, Q., Cogswell, M.E., Ueshima, H.,\u000a      Stamler, J., Elliott, P., on behalf\u000a      of the INTERSALT Co-Operative Research Group.(2013). Estimating 24-Hour\u000a      Urinary Sodium\u000a      Excretion From Casual Urinary Sodium Concentrations in Western\u000a      Populations. The\u000a      INTERSALT Study. Am J Epidemiol, 177(11), 1180-1192. DOI.\u000a      Times cited: 3 (as at 7th\u000a      November 2013 on ISI Web of Science). Journal Impact Factor: 4.78.\u000a    \u000aKey funding:\u000a    &#8226; US National Institutes of Health (NIH)\/National Heart, Lung &amp; Blood\u000a      Institute (1995-2004,\u000a      &#163;986,500; 2004-2009, &#163;703,200; 2009-2014, &#163;1,573,034), Principal\u000a      Investigator (PI) P. Elliott\u000a      INTERMAP Study: international cooperative study of macronutrients and\u000a      blood pressure.\u000a    &#8226; US NIH\/National Heart, Lung &amp; Blood Institute (2007-2012,\u000a      &#163;1,079,810; 2012-2015, &#163;884,584),\u000a      PI, P Elliott, Metabolomics measured urinary metabolites, diet and blood\u000a      pressure, 17\u000a      population samples: INTERMAP.\u000a    &#8226; US CDC (2010-2011, &#163;77,158) PI P Elliott, Assessing the use of spot\u000a      (casual) urine specimens\u000a      to estimate population mean 24-hr sodium excretion: INTERSALT project.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"16","Subject":"Medical Physiology"},{"Level1":"11","Level2":"11","Subject":"Nutrition and Dietetics"}],"Sources":"\u000a    [1] WHO. Guideline: Sodium intake for adults and children (2012).\u000a      http:\/\/www.who.int\/nutrition\/publications\/guidelines\/sodium_intake_printversion.pdf\u000a      (archived\u000a      on 8th November 2013)\u000a    [2] WHO. Guideline: Potassium intake for adults and children\u000a      (2012).\u000a      http:\/\/www.who.int\/nutrition\/publications\/guidelines\/potassium_intake_printversion.pdf\u000a      (archived\u000a      on 8th November 2013)\u000a    [3] Sixty-sixth World Health Assembly. WHA66.10. Follow-up to the\u000a      Political Declaration of the\u000a      High-level Meeting of the General Assembly on the Prevention and Control\u000a      of Non-communicable\u000a      Diseases, 2013 http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA66\/A66_R10-en.pdf\u000a      (archived\u000a      on 8th November 2013)\u000a    [4] Salt reduction and iodine fortification strategies in public health.\u000a      Report of a joint technical\u000a      meeting convened by World Health Organization (WHO) and The George\u000a      Institute for Global\u000a      Health in collaboration with the International Council for the Control of\u000a      Iodine Deficiency\u000a      Disorders Global Network, Sydney, Australia, March 2013. Geneva, World\u000a      Health Organization\u000a      (WHO), 2013 (in press).\u000a    [5] U.S. CDC Sodium Reduction Toolkit: http:\/\/www.cdc.gov\/dhdsp\/toolkit\/Bio-Package\/data\/resources\/Biomarkers%20Transcript.pdf\u000a      (archived\u000a      on 8th November 2013)\u000a    [6] Cogswell, M.E., Wang, C.Y., Chen, T.C., Pfeiffer, C.M., Elliott, P.,\u000a      Gillespie, C.D., Carriquiry,\u000a      A.L., Sempos, C.T., Liu, K., Perrine, C.G., Swanson, C.A., Caldwell, K.L.,\u000a      Loria, C.M. (2013).\u000a      Validity of predictive equations for 24-h urinary sodium excretion in\u000a      adults aged 18-39 y. Am J\u000a        Clin Nutr, 98(6), 1502-1513. DOI.\u000a    Contact to corroborate impact on US CDC policy:\u000a    [7] Senior Scientist, Epidemiology &amp; Surveillance Branch, Division\u000a      for Heart Disease and Stroke\u000a      Prevention, National Center for Chronic Disease and Health Promotion, U.S.\u000a      Centers for Disease\u000a      Control and Prevention (CDC).\u000a    ","Title":"\u000a    Improving Cardiovascular Health through International Recommendations on\u000a      Population Intakes of Sodium and Potassium\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Key Imperial College London researchers:\u000a      Professor Paul Elliott, Professor of Epidemiology and Public Health\u000a      (1995-present)\u000a      Dr Ian Brown, PhD student, then Postdoctoral Researcher (2006-2011)\u000a      Dr Queenie Chan, Researcher (2000-present)\u000a      Dr Ioanna Tzoulaki, Lecturer (2006-present)\u000a    Professor Elliott and colleagues have provided long standing academic\u000a      leadership of INTERSALT\u000a      and INTERMAP studies (1, 2) examining the relationships of sodium and\u000a      potassium intakes (and\u000a      other nutrients) with blood pressure. In the INTERSALT study, 24 hour\u000a      urinary sodium collections\u000a      (the 'gold standard' measurement of sodium intake) were obtained from more\u000a      than 10,000 men-and\u000a      women aged 20 to 59 years from 52 different population groups across 32\u000a      countries. This\u000a      study created the largest set of standardized data on 24 hour urinary\u000a      sodium samples in the world.\u000a      The INTERMAP study obtained 24 hour urinary sodium collections from men\u000a      and women aged 40-to\u000a      59 years from 17 population groups in 4 countries: China, Japan, the\u000a      United Kingdom, and the\u000a      United States. Both studies were led jointly by Professor Elliott\u000a      (Imperial College London from\u000a      1995) and Northwestern University Chicago. In 1996 analyses of the\u000a      INTERSALT study, led by\u000a      Imperial College researchers, provided updated estimates of the size of\u000a      associations of sodium\u000a      intake to blood pressure both within and across the 52 populations\u000a      studied, including significant\u000a      associations of sodium intake with the rise of blood pressure with age\u000a      (key to determining the high\u000a      prevalence of raised blood pressure and hypertension at older ages) (1).\u000a      In addition to 24 hour\u000a      urine collections, the INTERMAP study collected blood pressure readings\u000a      and multiple 24 -hour\u000a      dietary recalls. Except in China, where sodium urine values were higher,\u000a      the INTERMAP study &#8212; reported,\u000a      in 2003, similar findings to that of the INTERSALT study with respect to\u000a      24 hour urinary\u000a      sodium excretions (Stamler J, Elliott P, Chan Q. INTERMAP Appendix Tables.\u000a      J Hum. Hypertens-.\u000a      2003; 17:759 -775). Results for US adults indicate that 24 hour urinary\u000a      sodium excretions were\u000a      well in excess of the limits recommended in the Dietary Guidelines for\u000a        Americans 2010, averaging-4.2\u000a      g of sodium per day in men and 3.3 g in women. In the UK, averages were\u000a      3.7 g of sodium per\u000a      day in men and 2.9 g in women.\u000a    Professor Elliott and Dr Brown drew heavily on this evidence in their\u000a      analysis of sodium intakes\u000a      worldwide (3) for the World Health Organization (WHO) Forum and Technical\u000a      Meeting on\u000a      Reducing Salt Intakes in Populations held in Paris, 2006\u000a      (http:\/\/www.who.int\/dietphysicalactivity\/reducingsaltintake_EN.pdf).\u000a      It showed that in the vast\u000a      majority of populations, salt intake is well above recommended levels; it\u000a      was argued that simple\u000a      and cost-effective public health initiatives, in tandem with efforts by\u000a      the food industry, have the\u000a      potential to lower salt consumption and consequently lower cardiovascular\u000a      disease burden and\u000a      increase life expectancy. The paper published in the peer-reviewed\u000a      literature in 2009 (3) was a\u000a      distillation of the original technical report for WHO presented at the WHO\u000a      meeting in 2006 by\u000a      Professor Elliott\u000a      (http:\/\/www.who.int\/dietphysicalactivity\/Elliot-brown-2007.pdf).\u000a    WHO published guidelines on sodium and potassium intakes in adults and\u000a      children in 2012,\u000a      according to procedures laid down in the WHO Handbook for guideline\u000a        development. This includes\u000a      identification of priority questions and outcomes, and retrieval,\u000a      assessment and synthesis of the\u000a      evidence according to the Grading of Recommendations Assessment,\u000a      Development and\u000a      Evaluation (GRADE) methodology. These systematic reviews were planned and\u000a      refined in\u000a      meetings of the Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup\u000a      on Diet and Health\u000a      (Geneva, March 2011 and Seoul, November 2011) including definition of the\u000a      scientific questions\u000a      and design of the supporting meta-analyses. Professor Elliott was an\u000a      invited expert at these\u000a      meetings providing specialist subject-matter knowledge and provided\u000a      substantial intellectual input\u000a      to, and co-authored, the subsequent peer-reviewed publications in BMJ\u000a      (4,5), the substance of\u000a      which formed the scientific basis of the guidelines.\u000a    Imperial College research, funded by the US CDC, has additionally\u000a      influenced work by CDC to\u000a      develop a national strategy for monitoring sodium intakes in the US\u000a      population. The 'gold standard'\u000a      for monitoring sodium intakes via biomonitoring of 24-hr urine collections\u000a      is expensive and\u000a      burdensome to participants. Imperial College-led research (in\u000a      collaboration with INTERSALT\u000a      investigators) has shown that analysis of spot (casual) urine may be a\u000a      viable low-cost and less\u000a      burdensome alternative to 24-hr urine collections (6).\u000a    "},{"CaseStudyId":"42222","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"2542007","Name":"Morocco"},{"GeoNamesId":"878675","Name":"Zimbabwe"},{"GeoNamesId":"3355338","Name":"Namibia"},{"GeoNamesId":"927384","Name":"Malawi"}],"Funders":[],"ImpactDetails":"\u000d\u000a    Impacts include: health and welfare, public policy and services,\u000d\u000a      international development Main beneficiaries include: UNAIDS,\u000d\u000a      International Government bodies, international donors\u000d\u000a    The methods developed at Imperial are used by UNAIDS, the UN agency with\u000d\u000a      responsibility to lead the international response to AIDS (www.unaids.org),\u000a      to generate AIDS statistics for almost every country in the world (http:\/\/www.unaids.org\/en\/dataanalysis\/).\u000a      These statistics are used by countries and international donors (e.g. the\u000d\u000a      Global Fund to Fight AIDS, Tuberculosis and Malaria) to track the epidemic\u000d\u000a      and determine funding and policy decisions for HIV prevention and\u000d\u000a      treatment interventions. These estimates have been crucial in describing\u000d\u000a      the scale and the nature of the HIV epidemic. Without this basic\u000d\u000a      information, effective and sustained action against the epidemic would not\u000d\u000a      have been possible. Furthermore, it would not be possible to detect\u000d\u000a      reductions in HIV prevalence that may be ascribed to programmes, which are\u000d\u000a      expected to be vital in strengthening the response to epidemics. Without\u000d\u000a      these estimates, neither the numbers in need of treatment nor the\u000d\u000a      potential impact of interventions would have been known, both of which\u000d\u000a      have been crucial in allowing major international and bilateral donors to\u000d\u000a      donate billions of dollars to tackling HIV.\u000d\u000a    The routine use and impact of these statistics are typified by citations\u000d\u000a      by President George W Bush as he announced the President's Plan for AIDS\u000d\u000a      Relief (PEPFAR, which continued between 2008 and 2013) and more recently\u000d\u000a      by President Barack Obama and Senator Hilary Clinton in public addresses\u000d\u000a      in 2009, 2011 and 2012. In his keynote speech in 2009, President Obama is\u000d\u000a      quoted as saying: \"Globally, there are over 33 million people living with\u000d\u000a      HIV. While millions have died from this disease, the death rate is slowly\u000d\u000a      declining due, in part, to our Nation's global effort through the\u000d\u000a      President's Emergency Plan for AIDS Relief (PEPFAR) program.\" [1]. In a\u000d\u000a      keynote speech (2012), Hilary Clinton cited the UNAIDS estimates of HIV\u000d\u000a      impact: \"Just last week, UNAIDS announced that, over the past decade, the\u000d\u000a      rate of new HIV infections has dropped by more than half in 25\u000d\u000a      low-and-middle-income countries, most of them in Sub-Saharan Africa. Just\u000d\u000a      listen to these numbers: In Zimbabwe, a 50% reduction; in Namibia, a 68%\u000d\u000a      reduction; and in Malawi, a 73% in the rate of new infections. So as we\u000d\u000a      continue to drive down the number of new infections and drive up the\u000d\u000a      number of people on treatment, eventually we will be able to treat more\u000d\u000a      people than become infected every year. That will be the tipping point. We\u000d\u000a      will then get ahead of the pandemic, and an AIDS-free generation will be\u000d\u000a      in our sight. Now, we don't know how long it will take to do this\u000d\u000a      everywhere...\" [2]. The only source for the statistics is the UNAIDS\u000d\u000a      reports that are developed using the Imperial methods.\u000d\u000a    For each country, UNAIDS also recommends application of the `Modes of\u000d\u000a      Transmission' model (research reference 4) as part of a UNAIDS-GAMET\u000d\u000a      (Global AIDS Monitoring and Evaluation Team) supported synthesis process,\u000d\u000a      a component of the UNAIDS `know your epidemic, know your response'\u000d\u000a      strategy, and the World Bank's Epidemic, Response and Policy Syntheses\u000d\u000a      [3]. Over 30 countries have completed, or are currently conducting,\u000d\u000a      analyses with the model [4, 5]. The results from these applications have\u000d\u000a      been used for the design of prevention programmes, for resource allocation\u000d\u000a      and prioritisation and to inform the development of national strategic\u000d\u000a      planning for HIV. In many cases, the findings have led to realignment of\u000d\u000a      funding, sometimes increasing the focus of intervention in key populations\u000d\u000a      that had been previously neglected. For example, in Morocco strategic\u000d\u000a      information has been used to optimize the allocation of resources [6]. The\u000d\u000a      distribution of the people newly infected with HIV according to the\u000d\u000a      Imperial-developed model was compared with recent spending patterns to\u000d\u000a      focus future prevention planning. As a result, the 2012-2016 National\u000d\u000a      Strategic Plan for Morocco proposed to allocate 63% of AIDS resources\u000d\u000a      towards prevention among key populations at higher risk, up from about 25%\u000d\u000a      according to the 2008 spending assessment, which the model indicated would\u000d\u000a      generate a far greater health impact in that setting.\u000d\u000a    Estimates of Mother-To-Child Transmission events and numbers in need of\u000d\u000a      Antiretroviral Therapy in every country in the world are used by WHO to\u000d\u000a      track progress toward their goals of eliminating mother-to-child\u000d\u000a      transmission and universal access to antiretroviral therapy [7]. The UN\u000d\u000a      methods of estimating child mortality were updated to correct for the bias\u000d\u000a      effects that our research demonstrated, and these estimates are now used\u000d\u000a      to measure progress against a key Millennium Development Goal [8]. Without\u000d\u000a      a demonstration of that effect, it is possible that child mortality could\u000d\u000a      have been substantially under-estimated which could have resulted in an\u000d\u000a      inappropriate reduction in focus on child mortality in post-2015 targets.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    The Joint United Nations Programme on HIV\/AIDS (UNAIDS) and World Health\u000d\u000a      Organisation (WHO) regularly report estimates for the prevalence of HIV\u000d\u000a      and associated metrics for almost every country in the world. These\u000d\u000a      statistics are essential for tracking the scale and the impact of HIV\u000d\u000a      epidemic and are used routinely in the policy decisions and funding\u000d\u000a      allocation decisions of national governments and international donors and\u000d\u000a      therefore have a major impact on international public health. The methods\u000d\u000a      underlying those estimates were originally developed, and continue to be\u000d\u000a      refined and updated, by an international group of researchers at Imperial\u000d\u000a      College London.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    Imperial College London\u000d\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a(1) Artzrouni, M., Brown,\u000a        T., Feeney,\u000a        G., Garnett,\u000a        G., Ghys,\u000a        P., Grassly, N., Schneider,\u000a        D., Stanecki,\u000a        K., Stover,\u000a        J., Schwartlander,\u000a        B., Walker,\u000a        N., Way,\u000a        P., Yan, P., Zaba,\u000a        B., Zlotnik,\u000a        H., Timaeus,\u000a        I., Walker,\u000a        N. (2002). UNAIDS Reference Group on Estimates Modelling and\u000d\u000a      Projections. Improved methods and assumptions for estimation of the\u000d\u000a      HIV\/AIDS epidemic and its impact: Recommendations of the UNAIDS Reference\u000d\u000a      Group on Estimates, Modelling and Projections. AIDS. 16(9), W1 -\u000d\u000a      14. DOI\u000d\u000a      Times cited: 99 (as at 4th Novemebr 2013 from ISI Web of\u000d\u000a      Science). Journal Impact Factor 6.4\u000d\u000a    \u000a\u000a(2) Grassly, N.C., Timaeus, I.M. (2005). Methods\u000a        to estimate the number of orphans as a result of AIDS and other causes\u000d\u000a        in Sub-Saharan Africa. Journal of Acquired Immune Deficiency\u000d\u000a        Syndromes, 39, 365 - 375. Times cited: 8 (as at 4th\u000d\u000a      November 2013 from ISI Web of Science). Journal Impact Factor 4.65\u000d\u000a    \u000a\u000a(3) Pisani, E., Garnett, G.P., Grassly, N.C., Brown, T., Stover, J.,\u000d\u000a      Hankins, C., Walker, N., &amp; Ghys, P. (2003). Back to basics in HIV\u000d\u000a      prevention: focus on exposure. BMJ, 326, 1384-1387. DOI.\u000d\u000a      Times cited: 75 (as at 4th November 2013 from ISI Web of\u000d\u000a      Science). Journal Impact Factor: 17.21\u000d\u000a    \u000a\u000a(4) Stover, J., Walker, N., Garnett, G.P., Salomon, J.A., Stanecki, K.A.,\u000d\u000a      Ghys, P.D., Grassly, N.C., Anderson, R.M., Schwartlander, B. (2002) Can we\u000d\u000a      reverse the HIV\/AIDS pandemic with an expanded response? Lancet,\u000d\u000a      360, 73-77. DOI.\u000d\u000a      Times cited: 100 (as at 4th November 2013 on ISI Web of\u000d\u000a      Science). Journal Impact Factor: 39.06\u000d\u000a    \u000a\u000a(5) Hallett, T.B., Zaba, B., Todd, J., Lopman, B., Mwita, W., Biraro, S.,\u000d\u000a      Gregson, S., Boerma, J.T.; ALPHA Network. (2008). Estimating incidence\u000d\u000a      from prevalence in generalised HIV epidemics: methods and validation. PLoS\u000a        Med, 5 (4), 611 - 622. DOI.\u000d\u000a      Times cited: 38 (as at 4th Novemebr 2013 from ISI Web of\u000d\u000a      Science). Journal Impact Factor: 15.25\u000d\u000a    \u000a\u000a(6) Hallett, T.B., Gregson, S., Kurwa, F., Garnett, G.P., Dube, S.,\u000d\u000a      Chawira, G., Mason, P.R., Nyamukapa, C.A. (2010). Measuring and correcting\u000d\u000a      biased child mortality statistics in countries with generalized epidemics\u000d\u000a      of HIV infection. Bull. World Health Organ., 88 (10), 761 -768. DOI. Times cited: 5\u000d\u000a      (as at 4th November 2013 from ISI Web of Science). Journal\u000d\u000a      Impact Factor: 5.25\u000d\u000a    \u000aKey funding:\u000d\u000a    &#8226; UNAIDS (2001-2003; &#163;49,104), Principal Investigator (PI) G. Garnett,\u000d\u000a      Estimating the present and future impact of HIV &#8212; the establishment of a\u000d\u000a      reference group.\u000d\u000a    &#8226; UNAIDS (2003-2010; &#163;576,742), PI G. Garnett, Secretariat for Global\u000d\u000a      Reference Group on HIV.\u000d\u000a    &#8226; UNAIDS (2009-2012; &#163;341,318), PI G. Garnett, Providing Academic\u000d\u000a      Leadership through a Secretariat for the UNAIDS Reference Group on\u000d\u000a      Estimates Modelling and Projections.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [1] In his keynote speech, President Obama, cites the UNAIDS statistics,\u000d\u000a      which are taken from the UNAIDS Global Reports November 25th, 2009\u000d\u000a      (paragraph 3): http:\/\/www.whitehouse.gov\/the-press-office\/presidential-proclamation-world-aids-day\u000d\u000a      Archived on\u000d\u000a      26th November 2013.\u000d\u000a    [2] In her keynote speech in November 29th 2012, the Secretary\u000d\u000a      Clinton cites the UNAIDS estimates of HIV impact: http:\/\/www.state.gov\/secretary\/rm\/2012\/11\/201198.htm\u000d\u000a      (refer to paragraph 12). Archived\u000d\u000a      on 26th November 2013.\u000d\u000a    [3] UNAIDS recommends the use of the `Modes of Transmission model' is\u000d\u000a      setting a country's priorities for spending: Modelling the expected\u000d\u000a      Short-term Distribution of new HIV Infections by Modes of transmission.\u000d\u000a      https:\/\/www.unaids.org\/en\/media\/unaids\/contentassets\/documents\/document\/2012\/guidelines\/JC2427_ModelingNewHIVInfectionsbyModesofTransmission_en.pdf\u000d\u000a      (refer to p.2). Archived\u000d\u000a      on 4th November 2013.\u000d\u000a    [4] The estimates produced by UNAIDS\/WHO are based on methods and\u000d\u000a      parameters that are informed by the UNAIDS Reference Group on HIV\/AIDS\u000d\u000a      Estimates (2010) Global Report http:\/\/www.unaids.org\/globalreport\/documents\/20101123_GlobalReport_full_en.pdf\u000d\u000a      (refer to page 8). Archived\u000d\u000a      on 4th November 2013.\u000d\u000a    [5] UNAIDS. New HIV infections by mode of transmission in West Africa: A\u000d\u000a      multi-country analysis. Dakar, Senegal: UNAIDS Regional Support Team for\u000d\u000a      West and Central Africa; 2010.\u000d\u000a      http:\/\/www.unaids.org\/en\/media\/unaids\/contentassets\/documents\/countryreport\/2010\/201003_MOT_West_Africa_en.pdf.\u000d\u000a      Archived\u000d\u000a      on 4th November 2013.\u000d\u000a    [6] HIV modes of transmission in Morocco and reallocation of resources:\u000d\u000a      http:\/\/www.unaids.org\/en\/media\/unaids\/contentassets\/documents\/epidemiology\/2012\/gr2012\/20121120_UNAIDS_Global_Report_2012_en.pdf\u000d\u000a      (see page 68). Archived\u000d\u000a      on 4th November 2013.\u000d\u000a    [7] Tracking Numbers on Antiretroviral Therapy. A key report provides the\u000d\u000a      statistics:\u000d\u000a      UNAIDS\/WHO. Monitoring the Declaration of Commitment on HIV\/AIDS:\u000d\u000a      Guidelines on construction of core indicators: 2010 Reporting. Geneva,\u000d\u000a      WHO.\u000d\u000a      http:\/\/data.unaids.org\/pub\/manual\/2009\/jc1676_core_indicators_2009_en.pdf\u000d\u000a      Archived\u000d\u000a      on 4th November 2013.\u000d\u000a    [8] UN methods for estimating Child Mortality Updated. A paper describing\u000d\u000a      the updates to the methods (Walker, N., Hill, K., Zhao, F. (2012). Child\u000d\u000a      Mortality Estimation: Methods Used to Adjust for Bias due to AIDS in\u000d\u000a      Estimating Trends in Under-Five Mortality. PLoS Med 9(8):\u000d\u000a      e1001298. DOI.\u000d\u000a      Provides a direct citation to our article 6 on page 2 as providing the\u000d\u000a      evidence for the need to change in the UN methods and guidance on the\u000d\u000a      correction. The following quotes are taken from that paper: \"To our\u000d\u000a        knowledge, only one analysis of the magnitude of bias in direct child\u000d\u000a        mortality estimates due to AIDS mortality has been carried out using\u000d\u000a        real data rather than simulations. Hallett et al. [8]\u000d\u000a        used data from a prospective open cohort in Manicaland, Zimbabwe, to\u000d\u000a        measure the bias introduced by deaths of HIV-positive mothers.... Based\u000d\u000a          on the findings of Hallett et al.,\u000d\u000a      UN IGME [United Nations Inter-agency Group for Child Mortality\u000d\u000a        Estimation] recently implemented an adjustment approach for use in\u000d\u000a        countries where prevalence of HIV\/AIDS has reached 5% or above in the\u000d\u000a        adult population (ages 15-49 years).\" \u000d\u000a    ","Title":"\u000d\u000a    Developing Methods for Monitoring Global HIV Epidemic Trends that have\u000d\u000a      Informed the Worldwide Response to the Pandemic\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Key Imperial College London researchers:\u000d\u000a      Professor Geoff Garnett, Professor of Microparasite Epidemiology\u000d\u000a      (2002-2012)\u000d\u000a      Professor Simon Gregson, Professor in Demography and Behavioural Science\u000d\u000a      (2001-present)\u000d\u000a      Professor Nicholas Grassly, Professor of Infectious Disease and Vaccine\u000d\u000a      Epidemiology (2001-present)\u000d\u000a      Dr Peter White, Senior Lecturer (2002-present)\u000d\u000a      Professor Timothy Hallett, Professor of Global Health (2004-present)\u000d\u000a    In 2002, the data that were available to generate international estimates\u000d\u000a      for HIV consisted of measurements of HIV prevalence among small samples of\u000d\u000a      pregnant women attending a non-random selection of antenatal-clinics in\u000d\u000a      each country. Methods developed by Professor Grassly and Professor Garnett\u000d\u000a      provided a way to integrate those sparse data points within a unified\u000d\u000a      theory for epidemiological dynamics so that reliable estimates of the\u000d\u000a      time-course of HIV prevalence could be generated (1). In 2005, Professor\u000d\u000a      Grassly and colleagues created a method to estimate the number of orphans\u000d\u000a      generated by the HIV epidemic (a key impact of HIV) (2), and, in 2003, the\u000d\u000a      group also invented a decision-making tool, the `Modes of Transmission'\u000d\u000a      model (3), and showed that it could be used to analyse surveillance data\u000d\u000a      and identify priority groups for HIV prevention interventions. These\u000d\u000a      estimates were then used in extended models to investigate the impact that\u000d\u000a      expanded responses to the HIV epidemic can generate (4).\u000d\u000a    The group has since led the continuous evaluation and development of the\u000d\u000a      estimation methods. The methods have been adapted to produce estimates of\u000d\u000a      mother-to-child transmission rates and the numbers in need of\u000d\u000a      antiretroviral therapy. Additional methods developed by the group\u000d\u000a      demonstrated that changes in sexual behaviour had led to a decline in the\u000d\u000a      HIV epidemic in Zimbabwe, at that time the largest epidemic for which such\u000d\u000a      a change had occurred. Methods developed in 2008 by Professor Hallett and\u000d\u000a      Professor Gregson allow for the sex-ratio and age-pattern of new HIV\u000d\u000a      infections to be estimated reliably from available data (5), allowing for\u000d\u000a      substantially refined estimates of demographic impact of HIV and\u000d\u000a      highlighting the burden of HIV among women. New analyses and data\u000d\u000a      collection by Professor's Hallett and Gregson in 2010, also demonstrated\u000d\u000a      that the way in which UN agencies track progress toward Millennium\u000d\u000a        Development Goal 5 (child mortality) could lead to significant\u000d\u000a      biases (6), which subsequently led to the official monitoring methods\u000d\u000a      being revised.\u000d\u000a    This body of work has had a clear and lasting impact on policy and\u000d\u000a      funding in the field of global health at the highest decision-making\u000d\u000a      levels.\u000d\u000a    "},{"CaseStudyId":"42223","Continent":[{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"3996063","Name":"Mexico"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    Impacts include: health and welfare, public policy and services,\u000a      international development\u000a      Main Beneficiaries include: Governments, WHO\u000a    Prior to the references 1 and 2 above, there was virtually no\u000a      quantitative evidence base for\u000a      planning for influenza pandemic containment or mitigation. The research of\u000a      Professor Ferguson\u000a      and colleagues at Imperial supported UK and international pandemic\u000a      preparedness policy, notably\u000a      in (a) influencing the size of antiviral stockpile purchased and policies\u000a      on treatment and\u000a      prophylaxis, (b) policies on the use of travel restrictions and school\u000a      closure for pandemic\u000a      mitigation. It also supported WHO planning for pandemic containment. Work\u000a      during the pandemic\u000a      provided estimates of pandemic severity and transmissibility and informed\u000a      government policies\u000a      about the appropriate level of interventions to introduce in the UK, US\u000a      and globally.\u000a    Impact on policy formulation for influenza pandemic planning:\u000a      The research showed that for containment of an emergent severe pandemic to\u000a      be feasible, the\u000a      outbreak would need to be detected when cases numbers were still limited\u000a      (&lt;~100). This research\u000a      finding directly influenced the 2009 WHO guidelines for pandemic\u000a      surveillance [1, page 3], building\u000a      on the earlier WHO protocol for pandemic containment [2, pages 2, 4, and\u000a      23]. Professor Ferguson\u000a      actively advised WHO directly during the formulation of these and other\u000a      guidelines.\u000a    Research on pandemic mitigation and the impact of travel restrictions\u000a      informed UK policy decisions\u000a      on pandemic planning &#8212; most notably, providing evidence to support\u000a      stockpiling antiviral drugs and\u000a      for their use for treatment and prophylaxis, in recommendations that\u000a      travel restrictions would have\u000a      a limited role in mitigation, and in recommendations around the potential\u000a      use of school closure as a\u000a      public health measure. Much of this evidence was synthesised via the Dept.\u000a      of Health (DH) UK\u000a      Scientific Pandemic Influenza Advisory Committee (SPI) Modelling subgroup\u000a      evidence summaries,\u000a      [3A cites research references 1 and 2, plus unpublished work for DH on\u000a      antiviral prophylaxis, while\u000a      source 3B cites most of the research listed above]. In turn, these\u000a      modelling evidence summaries\u000a      informed national planning assumptions and policy on travel restrictions,\u000a      antiviral stockpiling and\u000a      use and school closure. The recent (2011) UK Pandemic Preparedness\u000a      strategy [4] cites Imperial\u000a      College work on travel restrictions (page 38), work on the use of\u000a      antivirals for prophylaxis (page\u000a      41), and analysis of the 2009 pandemic (page 11). Additional corroboration\u000a      on the influence of the\u000a      MRC Centre's work is available from DH.\u000a    The research also informed pandemic planning in Europe (e.g. European\u000a      Centre for Disease\u000a      Prevention and Control [ECDC] 2009 antiviral recommendations [5; ref 19,\u000a      cited on pages 5, 11, 17\u000a      and 19]) and the United States (US Homeland Security Council Key Elements\u000a      of Departmental\u000a      Pandemic Influenza Operational Plans 2008 [6; references 31 and 32].\u000a      Interestingly, while plans in\u000a      Europe and the US were both heavily informed by Professor Ferguson's\u000a      research (and role on\u000a      multiple advisory panels), the resulting policies differed in emphasis: in\u000a      the EU, more focus was\u000a      placed on the stockpiling and use of antivirals, while in the US, emphasis\u000a      was placed on the\u000a      potential for intensive use of non-pharmaceutical interventions (e.g.\u000a      school closure) to achieve\u000a      pandemic mitigation. Additional corroboration on the impact of this work\u000a      on US policy is available\u000a      from DHHS in the US.\u000a    The work of the MRC Centre for Outbreak Analysis and modelling continues\u000a      to have a lasting\u000a      impact on policy for pandemic planning. The 2013 WHO guidance for Pandemic\u000a      Influenza Risk\u000a      Management cites 5 papers from Centre staff [7, reference 31, 32, 39, 40,\u000a      53 in References\u000a      section on page 34 and citations throughout text].\u000a    Impact on public policy-making in response to the 2009 H1N1 pandemic:\u000a      During the 2009 H1N1 pandemic, the MRC Centre at Imperial provided\u000a      real-time analyses for\u000a      WHO and multiple governments (notably the UK and US, but also including\u000a      Mexico and China).\u000a      Professor Ferguson acted as advisor to the WHO Emergency Committee\u000a      throughout the 2009\u000a      H1N1 pandemic, and was also a member of the WHO Ad Hoc Policy Strategic\u000a      Advisory Group of\u000a      Experts Working Group on influenza A (H1N1) vaccines. He was a member of\u000a      the UK Scientific\u000a      Advisory Group for Emergencies (SAGE; and the modelling subgroup) and the\u000a      US CDC's `Team B'\u000a      advisory group.\u000a    Much of the real-time research undertaken was published after the\u000a      pandemic, but influenced policy\u000a      formulation at the time. The single most influential piece of work was the\u000a      initial assessment of the\u000a      pandemic (research reference 6), which played a substantial role in (a)\u000a      informing the WHO\u000a      decision to move from pandemic phase 4 to 5; (b) reassuring policymakers\u000a      that the H1N1\u000a      pandemic was no `severe', and therefore default UK, US and WHO policy\u000a      which had been\u000a      formulated to mitigate a severe pandemic (e.g. arising from H5N1) could be\u000a      appropriately modified\u000a      (e.g. cessation of the UK `containment' phase and of using school closure\u000a      in the US, policies on\u000a      use of vaccines).\u000a    Much of the UK modelling advice was summarised in updates published\u000a      throughout the pandemic\u000a      by the `SPI-M-O' advisory group [8]: these summaries are referred to in\u000a      multiple UK SAGE and DH\u000a      policy documents, and in the `Lessons learned' inquiry reports following\u000a      the pandemic (e.g. the\u000a      Hine review). However, the nature of both research and policy-making in an\u000a      emergency means the\u000a      impact of the MRC Centre's research is most easily corroborated by the\u000a      individuals listed under\u000a      `Sources' below.\u000a    ","ImpactSummary":"\u000a    The work of Professor Ferguson and colleagues at Imperial College on\u000a      modelling the effect of\u000a      different intervention measures on the spread and health impact of a new\u000a      influenza pandemic has\u000a      substantially shaped UK and international public policy-making over the\u000a      last 7 years. Prior to 2009,\u000a      this work shaped UK policy on antiviral and pre-pandemic vaccine\u000a      stockpiling and use, and on the\u000a      potential use of school closure and border restrictions during a pandemic.\u000a      During the 2009 H1N1\u000a      pandemic, real-time research provided the first estimates of key\u000a      epidemiological parameters of the\u000a      new pandemic virus, demonstrating the low-to-moderate severity and lower\u000a      than typical\u000a      transmissibility. In the UK, US and other countries, these data informed\u000a      public policy decisions to\u000a      pull back from use of economically costly interventions (such as reactive\u000a      school closure or antiviral\u000a      prophylaxis) and focus on targeted use of vaccination as the principal\u000a      pandemic mitigation\u000a      measure.\u000a    ","ImpactType":"Political","Institution":"\u000a    Imperial College London\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a(1) Ferguson, N.M., Cummings, D.A., Cauchemez, S., Fraser, C., Riley, S.,\u000a      Meeyai, A.,\u000a      Iamsirithaworn, S., Burke, D.S. (2005). Strategies for containing an\u000a      emerging influenza\u000a      pandemic in Southeast Asia. Nature, 437, 209-214. DOI.\u000a      Times cited: 702 (as at 4th November\u000a      2013 on ISI Web of Science). Journal Impact Factor: 38.59\u000a    \u000a\u000a(2) Ferguson, N.M., Cummings, D.A., Fraser, C., Cajka, J.C., Cooley,\u000a      P.C., Burke, D.S. (2006).\u000a      Strategies for mitigating an influenza pandemic. Nature, 442,\u000a      448-452. DOI. Times\u000a      cited: 669\u000a      (as at 4th November 2013 on ISI Web of Science). Journal Impact\u000a      Factor: 38.59\u000a    \u000a\u000a(3) Hollingsworth, T.D., Ferguson, N.M., Anderson, R.M. (2006). Will\u000a      travel restrictions control the\u000a      international spread of pandemic influenza? Nat Med, 12, 497-499.\u000a      DOI. Times cited: 53\u000a      (as at\u000a      4th November 2013 on ISI Web of Science). Journal Impact\u000a      Factor: 24.3\u000a    \u000a\u000a(4) Bootsma, M.C.J., Ferguson, N.M. (2007). The effect of public health\u000a      measures on the 1918\u000a      influenza pandemic in US cities. PNAS, 104, 7588-7593. DOI.\u000a      Times cited: 123 (as at 4th\u000a      November 2013 on ISI Web of Science). Journal Impact Factor: 9.73\u000a    \u000a\u000a(5) Cauchemez, S., Valleron, A.J., Bo&#235;lle, P.Y., Flahault, A., Ferguson,\u000a      N.M. (2008). Estimating the\u000a      impact of school closure on influenza transmission from Sentinel data. Nature,\u000a      452, 750-754.\u000a      DOI. Times cited: 167\u000a      (as at 4th November 2013 on ISI Web of Science). Journal Impact\u000a      Factor:\u000a      38.59\u000a    \u000a\u000a(6) Fraser, C., Donnelly, C.A., Cauchemez, S., Hanage, W.P., Van\u000a      Kerkhove, M.D., Hollingsworth,\u000a      T.D., Griffin, J., Baggaley, R.F., et al. (2009). Pandemic Potential of a\u000a      Strain of Influenza A\u000a      (H1N1): Early Findings. Science, 324, 1557-1561. DOI.\u000a      Times cited: 714 (as at 4th November\u000a      2013 on ISI Web of Science). Journal Impact Factor: 31.02\u000a    \u000aKey funding:\u000a      &#8226; National Institutes of Health (NIGMS MIDAS initiative; 2004-2009;\u000a      $470,000). Principal\u000a      Investigator (PI), N. Ferguson, Mathematical Models in the study of\u000a      Infectious Disease spread\u000a      and control\u000a    &#8226; European Commission (FP6; 2005-2008; &#8364;1,400,000), PI N. Ferguson,\u000a      Mathematical modelling\u000a      of emerging and deliberately released pathogens (`INFTRANS')\u000a    &#8226; Bill &amp; Melinda Gates Foundation (2008-2013; &#163;2,400,000), PI N.\u000a      Ferguson, Vaccine Modelling\u000a      Initiative.\u000a    &#8226; Medical Research Council (MRC; 2008-2013; &#163;2,100,000), PI N. Ferguson,\u000a      MRC Centre for\u000a      Outbreak Analysis and Modelling.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"99","Subject":"Other Medical and Health Sciences"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    [1] WHO report \"Global\u000a        Surveillance during an Influenza Pandemic\" (2009). Archived\u000a      on 8\/11\/13\u000a    [2] A. WHO Interim Protocol: Rapid\u000a        operations to contain the initial emergence of pandemicinfluenza. Archived\u000a      on 8\/11\/13\u000a    [3] UK Scientific Pandemic Influenza Advisory Committee (SPI) Modelling\u000a      subgroup evidence\u000a      summaries. A. February 2008 version:\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/20080728093434\/http:\/\/advisorybodies.doh.gov.uk\/spi\/modelling.htm;\u000a      (archived\u000a      on 8\/11\/13) B. June 2013 version:\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/208264\/SPI-M_Modelling_Summary_13_06_13.pdf\u000a      (archived\u000a      on 8\/1\/13)\u000a    [4] UK Influenza Pandemic Preparedness Strategy 2011.\u000a      http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_131040.pdf.\u000a      Archived\u000a      on 8\/11\/13\u000a    [5] ECDC Interim Guidance (2009) on Public health use of influenza\u000a      antivirals during influenza\u000a      pandemics.\u000a      http:\/\/www.ecdc.europa.eu\/en\/publications\/publications\/0907_gui_public_health_use_of_influenza_antivirals_during_influenza_pandemic.pdf.\u000a      Archived\u000a      on 8\/11\/13\u000a    [6] US National Strategy for Pandemic Influenza Implementation Plan, Key\u000a      Elements of\u000a      Departmental Pandemic Influenza Operational Plans (2008). http:\/\/www.flu.gov\/planning-preparedness\/federal\/operationalplans.html#\u000a      Archived on\u000a      8\/11\/13\u000a    [7] Pandemic Influenza Risk Management: WHO Interim Guidance (2013).\u000a      http:\/\/www.who.int\/influenza\/preparedness\/pandemic\/GIP_PandemicInfluenzaRiskManagementInterimGuidance_Jun2013.pdf\u000a      Archived\u000a      on 8\/11\/13\u000a    [8] SPI-M-O and the 2009 H1N1 Pandemic - document archive.\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/+\/www.dh.gov.uk\/ab\/SPI\/DH_118862\u000a      (archived\u000a      8\/11\/13)\u000a    Contact to corroborate impact on UK policy: Senior Principal Analyst,\u000a      Department of Health, Health\u000a      Protection Analytical Team\u000a    Contact to corroborate impact on WHO policy: Assistant Director-General -\u000a      Health Security and\u000a      Environment, World Health Organisation\u000a    Contact to corroborate impact on US policy: Chief Medical Officer and\u000a      Deputy Director, Biomedical\u000a      Advanced Research and Development Authority (HHS\/ASPR\/BARDA)\u000a    \u000a    ","Title":"\u000a    Evidence to Inform Policy Formulation for Influenza Pandemic Planning and\u000a      Response\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Key Imperial College London researchers:\u000a      Professor Neil Ferguson, Professor of Mathematical Biology (2000-present)\u000a      Dr Simon Cauchemez, Reader in Statistical Infectious Disease Epidemiology\u000a      (2005-present)\u000a      Professor Christophe Fraser, Professor of Theoretical Epidemiology\u000a      (2000-present)\u000a    From 2004, and building on extensive experience in modelling both\u000a      seasonal influenza and\u000a      emerging infections (e.g. SARS and H5N1 avian flu), Professor Ferguson led\u000a      an extensive\u000a      research programme to improve understanding of the epidemiology of\u000a      pandemic influenza and the\u000a      evidence base for interventions to mitigate the impacts of influenza\u000a      pandemics. This research:\u000a    a) Analysed data collected in historical influenza pandemics (1-5) to\u000a      improve our epidemiological\u000a      understanding of pandemics and the effectiveness of interventions (notably\u000a      school closure [5]\u000a      and other non-pharmaceutical interventions [4]). This work, undertaken\u000a      from 2004-2009,\u000a      provided some of the first reliable estimates of the transmissibility of\u000a      pandemic influenza,\u000a      demonstrating that the reproduction number, R, of the 3 twentieth\u000a      century pandemics lay in the\u000a      range 1.6-2.0, and thus that control measures needed only to have\u000a      relatively moderate effects\u000a      to achieve substantial reductions in the rate of spread and overall impact\u000a      of a pandemic.\u000a      Analysis of historical records of the 1918 `Spanish flu' H1N1 pandemic in\u000a      the US highlighted\u000a      that public health measures could substantially slow spread (4), while\u000a      detailed statistical\u000a      analysis of seasonal influenza transmission patterns in contemporary\u000a      France (5) provided the\u000a      first quantitative estimates of the role of schools in both seasonal and\u000a      pandemic influenza\u000a      transmission, suggesting that school closure as a public health measure\u000a      might have a\u000a      substantial impact on peak incidence in a pandemic (and thus healthcare\u000a      demand) but more\u000a      moderate impacts on overall attack rates.\u000a    b) Developed, in 2004, the first continental-scale epidemic simulator to\u000a      examine the potential\u000a      impact of multiple interventions on the transmission of pandemic\u000a      influenza. The feasibility of\u000a      containing a lethal pandemic at source was examined (1), together with a\u000a      wide range of\u000a      potential mitigation strategies (2). This work highlighted that the\u000a      timescale of spread of a\u000a      pandemic would make it unlikely that pandemic vaccine would be available\u000a      in the first wave of\u000a      transmission, meaning it would be necessary to rely on layered\u000a      combinations of antiviral use\u000a      and non-pharmaceutical interventions to achieve substantial mitigation of\u000a      a severe influenza\u000a      pandemic. Professor Ferguson developed a simulation platform to inform\u000a      pandemic planning\u000a      which combined epidemiological information on influenza transmission\u000a      dynamics with data\u000a      derived from clinical trials and observational studies on the impact of\u000a      vaccines, antivirals and\u000a      public health measures on influenza disease burden and transmission. This\u000a      platform allowed\u000a      flexible modelling of the likely impacts of different combinations of\u000a      interventions on the speed\u000a      of spread and overall attack rate of an unfolding pandemic. Logistical\u000a      constraints could be\u000a      specified, and resource requirements (e.g. antiviral stockpile sizes)\u000a      assessed. The work\u000a      concluded that if a severe pandemic (e.g. caused by H5N1) was detected\u000a      within the first few\u000a      generations of human-to-human transmission, it might be feasible to\u000a      achieve containment of\u000a      spread through the intensive use of antiviral prophylaxis, quarantine,\u000a      school and workplace\u000a      closure and travel restrictions (1). However, once an outbreak exceeded a\u000a      few hundred cases,\u000a      containment was predicted to be very unlikely to succeed (1), and use of\u000a      more sustainable\u000a      layered interventions to mitigate pandemic impact was indicated (2).\u000a      Related work by\u000a      Professor Ferguson and colleagues demonstrated that the use of\u000a      international travel bans\u000a      would be unlikely to have a major impact on the global spread of a\u000a      pandemic (3).\u000a    c) Analysed surveillance data collected in the first few weeks of the\u000a      2009 H1N1 pandemic to\u000a      provide the first estimates of pandemic transmissibility and severity (6).\u000a      This work was\u000a      undertaken in collaboration with colleagues in the World Health\u000a      Organisation (WHO) and the\u000a      Mexican Ministry of Health. It concluded that the transmissibility of the\u000a      2009 pandemic was\u000a      less than the previous 3 pandemics, and that severity was at worst\u000a      moderate, with a 1918-like\u000a      high severity scenario being able to be excluded. Throughout the pandemic,\u000a      the MRC Centre\u000a      for Outbreak Analysis and Modelling at Imperial analysed surveillance data\u000a      for WHO and\u000a      multiple governments (notably UK, US and China), to improve situational\u000a      awareness and\u000a      decision-making.\u000a    "},{"CaseStudyId":"42224","Continent":[{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1168579","Name":"Pakistan"},{"GeoNamesId":"1269750","Name":"India"},{"GeoNamesId":"1149361","Name":"Afghanistan"}],"Funders":["Medical Research Council","Royal Society"],"ImpactDetails":"\u000a    Impacts include: health and welfare; public policy and services;\u000a      international development Main beneficiaries include: patients; WHO; GPEI\u000a    The Global Polio Eradication Initiative (GPEI) is the largest coordinated\u000a      public health effort in history, with an `endgame' budget during 2013-2018\u000a      of $5.5 billion. The four spearheading partners of the GPEI are the WHO,\u000a      US Centers for Disease Control (CDC), Rotary International and UNICEF. The\u000a      vaccine epidemiology research group at Imperial College London has\u000a      provided critical information that has driven strategy at the GPEI and\u000a      helped to support polio eradication. In 2013 we were formally recognised\u000a      as the WHO collaborating institute on polio data analysis and modelling.\u000a    Perhaps most significantly, our research has provided evidence that\u000a      contributed to changing polio immunisation strategies in India, which\u000a      resulted in the elimination of infection from that country in 2011. The\u000a      GPEI Strategic Plan 2010-12 [1] notes that `Compounding the problem of\u000a      achieving sufficiently high population immunity to stop transmission in\u000a      western Uttar Pradesh, and possibly in central Bihar, is the compromised\u000a      efficacy of OPV compared with the rest of India15' (see page\u000a      18); citing our work demonstrating OPV failure in northern India (research\u000a      reference 2). Our subsequent demonstration of the greater efficacy of\u000a      monovalent and bivalent vaccines licensed in 2005 and 2009 respectively,\u000a      together with the geographic and targeted approaches described in the\u000a      Strategic Plan for 2010-2012, led to the eradication of polio from India,\u000a      with the last case reported in January 2011 (www.polioeradication.org).\u000a      Only three countries remain endemic for polio, and the group at Imperial\u000a      works closely with government and WHO staff in these countries and in WHO\u000a      headquarters to analyse surveillance data and optimise vaccination\u000a      strategy and campaign quality. For example, Dr O'Reilly was in northern\u000a      Afghanistan and Pakistan in July 2012 to monitor programme performance,\u000a      drawing from her findings on vaccination coverage and efficacy.\u000a    In the GPEI Strategic Plan 2010-2012, the Executive Summary identifies at\u000a      the outset four `major lessons learned', which each led to major changes\u000a      in the eradication programme. Two of these lessons drew directly from our\u000a      research findings on immunity induced by newly licensed poliovirus\u000a      vaccines and the epidemiology of poliovirus in endemic and re-infected\u000a      countries.\u000a    The first lesson learnt was that immunity thresholds to stop polio\u000a      differ, being higher in Asia than Africa, leading to a `\"Geographic\"\u000a      strategy, with OPV campaign and monitoring strategy tailored to local\u000a      circumstances. This was based on our findings that \"The differential\u000a      progress by country towards polio eradication globally has long suggested\u000a      that the population immunity thresholds at which WPV transmission stops\u000a      can differ substantially between geographic areas, with implications for\u000a      programme strategy, planning, and prioritization\" [1; see page 12, where\u000a      research references 1 and 4 are the cited evidence]. The resulting\u000a      `process indicators' in the Strategic Plan include targets based on our\u000a      estimates of vaccine-induced immunity [1; see page 15]. Our work is\u000a      therefore central to this new strategy and we provide updated analysis\u000a      when requested by the GPEI. As a result of these targeted approaches to\u000a      polio eradication and efforts to improve vaccination campaign coverage,\u000a      the global incidence of poliomyelitis is at an all time low (just 223\u000a      cases in 2012).\u000a    The second lesson drawing from our work was that `Routes of poliovirus\u000a      spread &amp; outbreaks are now largely predictable', leading to, among\u000a      others, `Pre-planned, synchronized campaigns.' We had shown that polio\u000a      outbreaks in sub-Saharan Africa could be predicted with reasonable\u000a      accuracy 6 months ahead of time using a simple statistical (mathematical)\u000a      model (described in research reference 6 above). The Strategic Plan notes\u000a      that `In view of the substantial resource demands of implementing this\u000a      [pre-emptive vaccination campaign] strategy, a mathematical model has been\u000a      developed to help prioritize countries and areas based on the risk of both\u000a      an importation and a subsequent outbreak (Figure 4). Regular assessments\u000a      of polio immunity among the \"WPV importation belt\" countries using NP AFP\u000a      data, this model and other relevant information, will continue to inform\u000a      this prioritization.'; Figure 4 was provided by us, based on work\u000a      described in research reference 6 [1; see page 35]. We therefore continue\u000a      to provide assessments and forecasts of the risk of outbreaks in\u000a      sub-Saharan Africa to support immunization planning. These risk\u000a      assessments allow the programme to prioritize vaccination campaigns in a\u000a      time of serious resource constraints, maximising the cost-effectiveness of\u000a      the programme.\u000a    The World Health Assembly (May 2012) and WHO Strategic Advisory Group of\u000a      Experts (SAGE) recently recommended a switch from trivalent to bivalent\u000a      OPV during routine immunisation and global cessation of vaccination with\u000a      any serotype-2-containing OPV. The motivation for this switch came from\u000a      the recognition of the significant burden of vaccine-associated paralytic\u000a      poliomyelitis (VAPP) and vaccine-derived poliovirus outbreaks associated\u000a      with continued use of a serotype 2 OPV, when this serotype of\u000a      wild-poliovirus was eradicated over 10 years previously. Our work\u000a      demonstrating equivalent pathogenicity and transmissibility of serotype 2\u000a      vaccine-derived and wild-type poliovirus was an important piece of\u000a      evidence underlying this decision [2].\u000a    Our work demonstrating rapid waning of intestinal mucosal immunity\u000a      following vaccination with OPV and the detection of vaccine and wild-type\u000a      poliovirus in stool samples collected from OPV vaccinated children\u000a      provided motivation for two clinical trials on the use of inactivated\u000a      poliovirus vaccine (IPV) to boost intestinal immunity (Grassly et al. J\u000a      Infect Dis 2009, 2010, 2012). The first of these trials was led by WHO and\u000a      enrolled 990 children in northern India [3]. Results from this trial, for\u000a      which Professor Grassly is a co-investigator, were presented to WHO SAGE\u000a      in November 2012 for their consideration. They provided evidence for one\u000a      of the benefits of IPV that led to the WHO SAGE recommendation made in\u000a      January 2013 for universal vaccination with IPV at the time of the switch\u000a      from trivalent to bivalent OPV in routine programmes [4].\u000a    ","ImpactSummary":"\u000a    Research by Professor Grassly and colleagues at Imperial College on the\u000a      epidemiology of poliovirus and the efficacy of new vaccines has played a\u000a      critical role in the thinking and strategy of the Global Polio Eradication\u000a      Initiative (GPEI). This research has supported the introduction of new\u000a      vaccines, guided the timing and location of vaccination campaigns and\u000a      influenced polio `endgame' policy. This is documented in the GPEI\u000a        Strategic Plan 2010-2012, where Imperial research informed 2 of the\u000a      4 `major lessons' concerning poliovirus epidemiology described in the\u000a      executive summary that led to changes in the programme. The research has\u000a      also informed our understanding of mucosal immunity induced by oral\u000a      poliovirus vaccines, and led to two clinical trials of the potential role\u000a      of inactivated vaccine to boost mucosal immunity. Results from one of\u000a      these trials were used to support the recent World Health Organisations\u000a      (WHO) recommendation for universal vaccination with inactivated vaccine\u000a      following the switch to bivalent oral vaccine in routine programmes.\u000a    ","ImpactType":"Political","Institution":"\u000a    Imperial College London\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"1253626","Name":"State of Uttar Pradesh"},{"GeoNamesId":"1275715","Name":"State of Bihar"}],"References":"\u000a    \u000a(1) Grassly, N.C., Fraser, C., Wenger, J., Deshpande, J.M., Sutter, R.W.,\u000a      Heymann, D.L., &amp; Aylward, R.B. (2006). New strategies for the\u000a      elimination of polio from India. Science, 314 (5802), 1150-1153. DOI. Times cited:\u000a      90 (as at 4th November 2013 on ISI Web of Science). Journal\u000a      Impact Factor: 31.02\u000a    \u000a\u000a(2) Grassly, N. C., Wenger, J., Durrani, S., Bahl, S., Deshpande, J.M.,\u000a      Sutter, R.W., Heymann, D.L., &amp; Aylward, R.B. (2007). Protective\u000a      efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control\u000a      study. Lancet, 369, 1356-1362. DOI.\u000a      Times cited: 63 (as at 4th November 2013 on ISI Web of\u000a      Science). Journal Impact Factor: 39.06\u000a    \u000a\u000a(3) O'Reilly, K. M., Durry, E., Ul-Islam, O., Quddus, A., Abid, N., Mir,\u000a      T.P., Tangermann, R., Aylward, R.B., &amp; Grassly, N.C. (2012). The\u000a      effect of mass immunisation campaigns and new oral poliovirus vaccines on\u000a      the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-2011: a\u000a      retrospective analysis. Lancet, 380, 491-498. DOI.\u000a      Times cited: 6 (as at 4th November 2013 on ISI Web of Science).\u000a      Journal Impact Factor: 39.06\u000a    \u000a\u000a(4) Jenkins, H. E., Aylward, R.B., Gasasira, A., Donnelly, C.A., Mwanza,\u000a      M., Corander, J., Garnier, S., Chauvin, C., Abanida, E.A., Pate, M.A.,\u000a      Adu, F., Baba, M., &amp; Grassly, N.C. (2010). Implications of a\u000a      circulating vaccine-derived poliovirus in Nigeria. N Engl J Med,\u000a      362, 2360-2369. DOI.\u000a      Times cited: 36 (as at 4th November 2013 on ISI Web of\u000a      Science). Journal Impact Factor: 51.65\u000a    \u000a\u000a(5) Grassly, N. C., Jafari, H., Bahl, S., Sethi, R., Deshpande, J.M.,\u000a      Wolff, C., Sutter, R.W., &amp; Aylward, R.B. (2012). Waning intestinal\u000a      immunity after vaccination with oral poliovirus vaccines in India. J\u000a        Infect Dis, 205, 1554-1561. DOI.\u000a      Times cited: 5 (as at 4th November 2013 on ISI Web of Science).\u000a      Journal Impact Factor: 5.84\u000a    \u000a\u000a(6) O'Reilly, K. M., Chauvin, C., Aylward, R.B., Maher, C., Okiror, S.,\u000a      Wolff, C., Nshmirimana, D., Donnelly, C.A., &amp; Grassly, N.C. (2011). A\u000a      Statistical Model of the International Spread of Wild Poliovirus in Africa\u000a      Used to Predict and Prevent Outbreaks. PLoS Medicine, 8 (10),\u000a      e1001109. DOI.\u000a      Times cited: 5 (as at 4th November 2013 on ISI Web of Science).\u000a      Journal Impact Factor: 15.25\u000a    \u000aKey funding:\u000a    &#8226; Royal Society (2004-2012; &#163;625,000), Principal Investigator (PI) N.\u000a      Grassly, University Research Fellowship\u000a    &#8226; WHO (2008-2012; &#163;167,000), PI N. Grassly, Mathematical models of polio\u000a      immunisation.\u000a    &#8226; Medical Research Council (MRC; 2008-2013; &#163;2.1million), PI N. Ferguson,\u000a      MRC Centre for Outbreak Analysis and Modelling.\u000a    &#8226; Bill and Melinda Gates Foundation (2008-2013; &#163;2.4million), PI N.\u000a      Ferguson, Vaccine Modelling Initiative.\u000a    &#8226; WHO (2010-2013; &#163;100,000), PI N. Grassly, Gut mucosal immunity induced\u000a      by vaccine and wild-type poliovirus in India.\u000a    &#8226; Bill and Melinda Gates Foundation (2012-2014; &#163;1.25million), PI N.\u000a      Grassly, Clinical trial to treat children in India for enteric infections\u000a      to improve their response to oral poliovirus vaccine.\u000a    &#8226; MRC (2012-2016; &#163;509,000), PI K. O'Reilly, MRC Population Health\u000a      Fellowship\u000a    &#8226; WHO (2013-2015; &#163;218,000), PI N. Grassly, Statistical and mathematical\u000a      analysis of polio surveillance data to support the endgame\u000a    &#8226; Bill and Melinda Gates Foundation (2013-2016; &#163;461,000), PI N. Grassly,\u000a      Mathematical modelling of poliovirus transmission to support the endgame.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"7","Subject":"Immunology"}],"Sources":"\u000a    [1] Global Polio Eradication Initiative Strategic Plan 2010-2012. WHO,\u000a      Rotary International, US CDC &amp; UNICEF, 2010 (WHO\/Polio\/10.01).\u000a      Available at:\u000a      http:\/\/www.polioeradication.org\/Portals\/0\/Document\/StrategicPlan\/StratPlan2010_2012_ENG.pdf\u000a      Archived\u000a      on 4th November 2013.\u000a    [2] 65th World Health Assembly. Resolution A65\/55\u000a      Poliomyelitis: intensification of the global eradication initiative (May\u000a      2012) http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA65\/A65_55-en.pdf\u000a      (pg 7). Archived\u000a      on 4th November 2013.\u000a    [3] Mucosal immunity study - Moradabad, India. Online summary document. http:\/\/bit.ly\/MAxyhk,\u000a      polioeradication.org). Archived\u000a      on 4th November 2013.\u000a    [4] WHO (2013). \"Meeting of the Strategic Advisory Group of Experts on\u000a      immunization, November 2012 - conclusions and recommendations.\" Wkly\u000a      Epidemiol Rec 88: 1-16.\u000a      http:\/\/www.who.int\/wer\/2013\/wer8801.pdf\u000a      (page 6). Archived\u000a      on 4th November 2013.\u000a    ","Title":"\u000a    Evidence to Support Use of New Vaccines and Vaccination Strategies by the\u000a      Global Polio Eradication Initiative\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Key Imperial College London researchers:\u000a    Professor Nicholas Grassly, Chair in Vaccine Epidemiology (2000-present)\u000a    Professor Christophe Fraser, Chair in Theoretical Epidemiology\u000a      (2000-present)\u000a    Professor Christl Donnelly, Chair in Statistical Epidemiology\u000a      (2000-present)\u000a    Dr Kathleen O'Reilly, MRC Research Fellow (2009-present)\u000a    Dr Helen Jenkins, PhD student (2007-2010)\u000a    In 2004, Professors Grassly and Fraser at Imperial College London\u000a      initiated a research collaboration with the Global Polio Eradication\u000a      Initiative (GPEI), which is headquartered at the World Health Organisation\u000a      (WHO), Geneva. The original intention of the research was to maximise the\u000a      utility of routine poliovirus surveillance data by providing more\u000a      sophisticated statistical and mathematical model-based analyses than were\u000a      in use at the time. Over time a vaccine epidemiology research group was\u000a      established at Imperial by Professor Grassly and the research effort has\u000a      expanded beyond secondary analysis of data to include clinical trials of\u000a      poliovirus vaccines. The group collaborates closely with field and\u000a      laboratory staff in polio affected countries, and has strong international\u000a      links, particularly in India. During 2004-2013 several of our research\u000a      findings with a significant impact on the strategies and success of the\u000a      GPEI can be highlighted:\u000a    1) In 2005 we found that the standard trivalent oral poliovirus vaccine\u000a      (OPV) has extremely poor efficacy in northern India, explaining the\u000a      persistence of polio at that time in the country despite frequent\u000a      vaccination campaigns (1).\u000a    2) We provided the first estimate of the efficacy of serotype 1\u000a      monovalent OPV, which was licensed in 2005, showing that this vaccine was\u000a      three times more efficacious per dose compared with the standard trivalent\u000a      OPV in northern India (2). This finding supported the widespread use of\u000a      this vaccine by the GPEI, and we have recently used similar methods to\u000a      demonstrate efficacy of bivalent OPV that was licensed in 2009 (3).\u000a    3) The clinical characteristics and attack rate for a vaccine-derived\u000a      poliovirus circulating in Nigeria were shown to be equivalent to that for\u000a      wild-poliovirus, making it clear that vaccine-derived polioviruses can\u000a      fully revert to neurovirulent and transmissible phenotypes (4).\u000a    4) Intestinal (mucosal) immunity, important for preventing infection and\u000a      transmission of polioviruses, was shown for the first time to wane over\u000a      time since vaccination with OPV (5).\u000a    5) Outbreaks of polio were shown to be predictable on the basis of known\u000a      risk factors, allowing strategic planning of the timing and scale of\u000a      pre-emptive vaccination campaigns (6).\u000a    "},{"CaseStudyId":"42225","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    Impacts include: health and welfare; society; public policy and services;\u000a      environment; production Main beneficiaries include: UK and Welsh Assembly\u000a      Governments, Defra, cattle industry\u000a    Bovine TB in cattle remains a high priority for the Defra and one of the\u000a      key challenges facing cattle farmers, particularly in the west and south\u000a      west of England and in Wales. Although the Krebs Committee (of which\u000a      Professor Donnelly was a member) identified in 1997 \"compelling\" evidence\u000a      that badgers were involved in transmitting infection to cattle, it was the\u000a      Randomised Badger Culling Trial (RBCT, 1998-2006) which demonstrated\u000a      conclusively that badger transmission contributed significantly to the\u000a      incidence of bovine TB in cattle and that badger culling could\u000a      significantly decrease that incidence. Badger culling is a politically\u000a      sensitive issue, and the results of this trial have been critically\u000a      examined by various stakeholders. They have undoubtedly stimulated public\u000a      debate [1] and have informed Government policy.\u000a    In light of the trial results, Defra had considered Government-led (and\u000a      Government-funded) culling but their impact assessment showed that the\u000a      costs were \"too high to justify the benefits achieved in the RBCT\" (para\u000a      3.26 [2]). Instead the Government proposed that farmers apply for licences\u000a      to undertake farmer-led badger culling to control TB in cattle. The\u000a      Government [3, 4, 5] used scientific evidence published by Professor\u000a      Donnelly and colleagues as the basis for several of their proposed\u000a      criteria for culling licenses, including:\u000a    \u000a      that the culling areas were large (at least 150sq-km, based on\u000a        extrapolation of RBCT results);\u000a      that there is land access for culling for &gt;70% of the area (as in\u000a        the RBCT);\u000a      that culling in a licensed area would be carried out annually for at\u000a        least 4 years (as undertaken in the RBCT proactive areas).\u000a    \u000a    The Government stated that \"the RBCT provides the best scientific\u000a      evidence available from which to predict the effects of a future culling\u000a      policy\" [5; see page 1].\u000a    The research impacted upon the Welsh government, who similarly proposed\u000a      to undertake badger culling in a large area, again based on the RBCT\u000a      finding that the overall benefits were increased as the culling area\u000a      increased in absolute size (\"based on previous experience and studies of\u000a      badger culling strategies, including the latest published results of the\u000a      Randomised Badger Culling Trial (RBCT), reducing the reservoir of\u000a      infection in this way is expected to reduce the number of confirmed cattle\u000a      herd breakdowns in the area. There is evidence from the RBCT that 40-50%\u000a      of confirmed herd breakdowns in high incidence areas can be attributed to\u000a      a local badger source. Although the RBCT differs considerably from the\u000a      approach we are proposing for the Intensive Action Area, the analysis of\u000a      its results suggests that a sustained reduction in confirmed herd\u000a      breakdowns within the area following culling can be achieved.\") [6; see\u000a      page 5].\u000a    Furthermore, the Welsh government proposal followed the RBCT protocol of\u000a      culling using cage-trapping and shooting and used RBCT results to predict\u000a      the expected minimum impact: \"The data from the RBCT shows that there was\u000a      a benefit in the cull area but there was a short term increase in bovine\u000a      TB in cattle in the surrounding area. Accounting for this, at the end of a\u000a      cull and post cull period of 10 years, we expect to have reduced bovine TB\u000a      by approximately 22%, overall preventing an estimated 83 confirmed herd\u000a      breakdowns that would otherwise have occurred in the absence of culling\u000a      badgers in the area.\" [6; see page 5]\u000a    On 20 March 2012 the Welsh Government [7] announced it would launch a\u000a      badger vaccination project, rather than a badger culling programme, as\u000a      part of its work to eradicate cattle TB from Wales. This decision was\u000a      based on the judgement that the effects of culling, informed by RBCT\u000a      results, would be not sufficient \"to eliminate or substantially reduce the\u000a      incidence of bovine TB in cattle\" [7].\u000a    ","ImpactSummary":"\u000a    The bovine tuberculosis (TB) research programme led by Professor Donnelly\u000a      at Imperial College has been informing policymakers for over a decade.\u000a      Professor Donnelly played a leading role in the design, oversight,\u000a      analysis and interpretation of the &#163;50 million Randomised Badger Culling\u000a      Trial (RBCT, 1998-2006), overseeing a bovine-TB research team at Imperial\u000a      since 2001. The RBCT compared two candidate culling policies (large-scale\u000a      culling repeated annually and one-off small-scale culls near farms\u000a      affected by bovine TB) with areas in which no badger culling took place.\u000a      Informed by RBCT results (in which widespread culling decreased cattle\u000a      incidence inside the culling area but increased it on neighbouring farms),\u000a      the Secretary of State Hilary Benn ruled out badger culling as a control\u000a      measure in July 2008. However, the coalition government took a different\u000a      view and in December 2011 announced that farmers could apply for licences\u000a      to undertake farmer-led (and farmer-funded) badger culling to control TB\u000a      in cattle. Several of the government's licensing requirements for badger\u000a      culls in England were based on many of the team's results. In contrast,\u000a      having proposed in 2010 a large government-led cull, the Welsh government\u000a      chose in March 2012 to vaccinate, rather than cull, badgers informed by\u000a      the same set of results.\u000a    ","ImpactType":"Political","Institution":"\u000a    Imperial College London\u000a    ","Institutions":[{"AlternativeName":"Imperial College London","InstitutionName":"Imperial College London","PeerGroup":"A","Region":"London","UKPRN":10003270}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a(1) Donnelly, C.A., Woodroffe, R., Cox, D.R., Bourne, J., Gettinby, G.,\u000a      Le Fevre, A.M., McInerney, J.P., &amp; Morrison, W.I. (2003). Impact of\u000a      localized badger culling on tuberculosis incidence in British cattle. Nature,\u000a      426, 834-837. DOI.\u000a      Times cited: 136 (as at 30th October 2013 on ISI Web of\u000a      Science). Journal Impact Factor: 38.59\u000a    \u000a\u000a(2) Donnelly, C.A., Woodroffe, R., Cox, D.R., Bourne, F.J., Cheeseman,\u000a      C.L., Clifton-Hadley, R.S., Gao, Wei, Gettinby, G., Gilks, P., Jenkins,\u000a      H., Johnston, W.T., Le Fevre, A.M., McInerney, J.P. &amp; Morrison, W.I.\u000a      (2006). Positive and negative effects of widespread badger culling on\u000a      tuberculosis in cattle. Nature, 439, 843-846. DOI.\u000a      Times cited: 132 (as at 30th October 2013 on ISI Web of\u000a      Science). Journal Impact Factor: 38.59\u000a    \u000a\u000a(3) Woodroffe, R., Donnelly, C.A., Cox, D.R., Bourne, F.J., Cheeseman,\u000a      C.L., Delahay, R.J., Gettinby, G., McInerney, J.P., &amp; Morrison, W.I.\u000a      (2006). Effects of culling on badger Meles meles spatial\u000a      organization: implications for the control of bovine tuberculosis. Journal\u000a        of Applied Ecology 43, 1-10. DOI.\u000a      Times cited: 62 (as at 30th October 2013 on ISI Web of\u000a      Science). Journal Impact Factor: 4.74\u000a    \u000a\u000a(4) Woodroffe, R., Donnelly, C.A., Jenkins, H.E., Johnston, W.T., Cox,\u000a      D.R., Bourne, F.J., Cheeseman, C.L., Delahay, R.J., Clifton-Hadley, R.S.,\u000a      Gettinby, G., Gilks, P., Hewinson, R.G., McInerney, J.P., &amp; Morrison,\u000a      W.I. (2006). Culling and cattle controls influence tuberculosis risk for\u000a      badgers. Proceedings of the National Academy of Sciences 103,\u000a      14713-14717. DOI.\u000a      Times cited: 56 (as at 30th October 2013 on ISI Web of\u000a      Science). Journal Impact Factor: 9.6\u000a    \u000a\u000a(5) Bourne, J., Donnelly, C., Cox, D., Gettinby, G., McInerney, J.,\u000a      Morrison, I., &amp; Woodroffe, R. (2007). Bovine TB: the Scientific\u000a      Evidence. A Science Base for a Sustainable Policy to Control TB in Cattle.\u000a      Final Report of the Independent Scientific Group on Cattle TB\u000a      presented to the Secretary of State for Environment, Food and Rural\u000a      Affairs the Rt Hon David Miliband MP. 287pp.\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/20081107201922\/http:\/\/defra.gov.uk\/animalh\/tb\/isg\/pdf\/final_report.pdf\u000a    \u000a\u000a(6) Jenkins, H.E., Woodroffe, R., &amp; Donnelly, C.A. (2010). The\u000a      Duration of the Effects of Repeated Widespread Badger Culling on Cattle\u000a      Tuberculosis Following the Cessation of Culling. PLoS ONE 5(2):\u000a      e9090. DOI.\u000a      Times cited: 25 (as at 30th October 2013 on ISI Web of\u000a      Science). Journal Impact Factor: 3.73\u000a    \u000aKey funding:\u000a    &#8226; The Randomised Badger Culling Trial (RBCT) was funded by and\u000a      implemented directly by Defra and Defra staff, under advice from the\u000a      Independent Scientific Group on Cattle TB (of which Christl Donnelly was\u000a      Deputy Chair).\u000a    \"The RBCT represents nearly 10 years of work (1998-2007) and nearly &#163;50\u000a      million of taxpayer investment.\" according to Defra's Annex B for their\u000a      Consultation Document on Badger Culling http:\/\/webarchive.nationalarchives.gov.uk\/20120616115816\/http:\/archive.defra.gov.uk\/corporate\/consult\/tb-control-measures\/100915-tb-control-measures-annexb.pdf\u000a    &#8226; Ministry of Agriculture, Fisheries and Food (2002-2004; &#163;140,549),\u000a      Principal Investigator (PI) C. Donnelly, Bovine TB in Cattle and Badgers.\u000a    &#8226; Veterinary Laboratories Agency ( (2002-2004; &#163;124,957), PI C. Donnelly,\u000a      Analysis of data derived from Randomised Culling Trial\u000a    &#8226; Defra (2004-2007; &#163;880,315), PI C. Donnelly, Analysis of data derived\u000a      from Randomised Badger Culling Trial.\u000a    &#8226; Defra (2009-2011; &#163;379,625), PI C. Donnelly, Further analyses of\u000a      spatial and temporal trends in the cattle data associated with the\u000a      Randomised Badger Culling Trial\u000a    &#8226; Defra (2011-2014; &#163;481,855), PI C. Donnelly, Transmission modelling and\u000a      cost-effectiveness analysis of cattle vaccination at a herd level\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"}],"Sources":"\u000a    [1] Examples of public debate:\u000a    \u000a      \u000ahttp:\/\/www.teambadger.org.uk\/rbct_sm.html &#8212; Archived\u000a        on 1st November 2013\u000a      \u000ahttp:\/\/www.nfuonline.com\/tackling-tb-document--august-2013\/ &#8212; Archived\u000a        on 1st November 2013\u000a      \u000ahttp:\/\/www.theguardian.com\/environment\/2012\/sep\/18\/badger-cull-shot-in-the-dark\u000a        &#8212; Archived\u000a        on 1st November 2013\u000a      \u000ahttp:\/\/www.shropshirewildlifetrust.org.uk\/Badgers%20and%20bovine%20TB\/Bovine%20tb%20and%20badger%20culling\u000a        &#8212; Archived\u000a        on 1st November 2013\u000a    \u000a    [2] Defra. The\u000a        Government's policy on Bovine TB and badger control in England.\u000a      December 2011. (archived\u000a      01\/11\/2013)\u000a    [3] Defra. Bovine Tuberculosis: The Government's approach to tackling the\u000a      disease and consultation on a badger control policy. September 2010. 54pp\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/20120616115816\/http:\/\/archive.defra.gov.uk\/corporate\/consult\/tb-control-measures\/100915-tb-control-measures-condoc.pdf\u000a      (archived\u000a      on 01\/11\/2013) Also of particular interest is Annex B \"Scientific Evidence\u000a      on Culling\"\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/20120616115816\/http:\/archive.defra.gov.uk\/corporate\/consult\/tb-control-measures\/100915-tb-control-measures-annexb.pdf\u000a      (archived\u000a      on 01\/11\/2013)\u000a    [4] Bovine TB and Badgers &#8212; Commons Library Standard Notes. This\u000a      information is provided to Members of Parliament in support of their\u000a      parliamentary duties. Badgers and Bovine TB: Background. Standard Note\u000a      SN\/SC\/3751 Last updated: 15 February 2011 Author: Dr Elena Ares http:\/\/www.parliament.uk\/briefing-papers\/SN03751\u000a      (archived on\u000a      01\/11\/2013) Badger Culling. Standard Note SNSC-5873 Last updated: 16\u000a      February 2012 Author: Dr Elena Ares http:\/\/www.parliament.uk\/briefing-papers\/SN05873\u000a      (archived on\u000a      01\/11\/2013)\u000a    [5] Defra. Bovine TB &#8212; Key conclusions from the meeting of scientific\u000a      experts, held at Defra on 4th April 2011. From a meeting between Bob\u000a      Watson (Chief Scientific Adviser, Defra), Nigel Gibbens (Chief Veterinary\u000a      Officer, Defra), Professor Lord John Krebs, Professor Lord Robert May,\u000a      Prof Christl Donnelly and 6 other scientists.\u000a      http:\/\/archive.defra.gov.uk\/foodfarm\/farmanimal\/diseases\/atoz\/tb\/documents\/bovinetb-scientificexperts-110404.pdf\u000a      (archived\u000a      on 01\/11\/2013)\u000a    [6] Welsh Assembly Government. Consultation Document. Bovine TB\u000a      Eradication Programme: Consultation on Badger Control in the Intensive\u000a      Action Area. 20 September 2010. 14pp. http:\/\/wales.gov.uk\/docs\/drah\/consultation\/100921badgercontroliaaen.pdf\u000a      (archived\u000a      on 01\/11\/2013)\u000a    [7] Welsh\u000a        Assembly Government. Environment Minister announces programme of\u000a      badger vaccination. 20 March 2012. Archived\u000a      on 01\/11\/2013. \u000a    ","Title":"\u000a    TB in Cattle and Badgers: Improving Control of a Multi-species Disease\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Key Imperial College London researcher:\u000a      Professor Christl Donnelly, Professor of Statistical Epidemiology\u000a      (2000-present)\u000a    Professor Donnelly played a leading role in the design, oversight,\u000a      analysis and interpretation of the Department for Environment, Food and\u000a      Rural Affairs (Defra)-funded Randomised Badger Culling Trial (RBCT,\u000a      1998-2006) as deputy chair of the Independent Scientific Group on Cattle\u000a      TB (ISG). She joined Imperial College in October 2000 and between 2001 and\u000a      2007 she led a team of (two to four) government-grant-funded research\u000a      associates undertaking RBCT-related research within the Department of\u000a      Infectious Disease Epidemiology at Imperial.\u000a    The RBCT was very large in scope involving 30 areas of England each of\u000a      100sq-km. Each area was randomised to one of three study arms: no culling;\u000a      small-scale reactive culling undertaken in response to confirmed infection\u000a      found in a cattle herd within the area; and large-scale, annually\u000a      repeated, proactive culling which was carried out across the entire\u000a      100sq-km area. Badger culls were undertaken within the trial between 1998\u000a      and 2005.\u000a    The reactive culling strategy was suspended in 2003 when Professor\u000a      Donnelly and colleagues found it to be associated with increased TB\u000a      incidence in cattle herds (1). Proactive culling continued until 2005 and\u000a      in 2006 Professor Donnelly and colleagues found that proactive culling was\u000a      associated with significantly decreased TB incidence in cattle herds\u000a      within proactively culled trial areas, but significantly increased TB\u000a      incidence among cattle herds up to 2km outside proactively culled trial\u000a      areas (2, 6).\u000a    There were several other strands of complementary research being\u000a      undertaken as part of the bovine TB research programme, published in\u000a      peer-reviewed scientific journals but also summarised in the Final Report\u000a      of the ISG to Ministers (5). Of particular note was the baitmarking study\u000a      in which the ranging behaviour of badgers was compared in the three\u000a      different types of areas (no culling; reactive culling and proactive\u000a      culling). Badger densities were, as expected, highest in the unculled\u000a      areas and lowest in the proactive culled areas. Furthermore, badgers in\u000a      culled areas (reactive and proactive) and crucially up to 2km outside\u000a      proactively culled areas were found to range significantly more widely\u000a      than badgers in undisturbed unculled areas (3). Thus, it was hypothesized\u000a      that this social \"perturbation\" to badger populations was responsible for\u000a      the increased transmission risks to cattle within reactively culled areas\u000a      and up to 2km outside proactively culled areas.\u000a    Badgers culled in follow-up proactive culls (i.e. those after the initial\u000a      proactive cull) were found to be significantly more likely to be infected\u000a      with Mycobacterium bovis, the aetiological agent of bovine TB (4). This is\u000a      consistent with the social perturbation caused by recent culling\u000a      increasing the risk of badger-to-badger transmission, as well as the risk\u000a      of badger-to-cattle transmission.\u000a    Professor Donnelly's current TB research (with two post-doctoral\u000a      researchers) focuses on modelling and cost-effectiveness analysis of\u000a      cattle vaccination in the presence of transmission risks from both badgers\u000a      and bought-in cattle. She met with Defra officials in March 2013 to\u000a      discuss how the results of current work could inform the government's\u000a      planned field trial of a Bacillus Calmette-Gu&#233;rin (BCG) cattle vaccine.\u000a    "},{"CaseStudyId":"42580","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2361809","Name":"Burkina Faso"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"149590","Name":"Tanzania"}],"Funders":[],"ImpactDetails":"\u000a    Few strategies exist to control malaria, despite the fact that, every\u000a      year, it kills at least 600,000 people, predominantly very young children\u000a      in Africa. The trials and analyses of IPTi led by LSHTM staff made key\u000a      contributions to the WHO decision to recommend IPTi as policy.\u000a    The IPTi Consortium, developed by Prof. D Schellenberg at LSHTM in 2003,\u000a      brought together some of the leading centres of malaria research in\u000a      Africa, Europe and the USA, plus two UN agencies, to complete the\u000a      evaluation of IPTi. The Consortium generated key evidence to move beyond\u000a      the proof of concept towards a strategy for deployment as part of routine\u000a      immunisation programmes. At the time, the Consortium model was a novel\u000a      approach to generate all the critical information for policy\u000a      consideration. Under the Consortium, staff from all LSHTM faculties\u000a      generated information on issues surrounding the choice of drug for IPTi,\u000a      the relationship between IPTi and the development of drug resistance, and\u000a      the cost effectiveness, acceptability, mortality impact and community\u000a      effectiveness of IPTi.\u000a    School staff presented evidence to WHO technical expert groups in 2006\u000a      and 2007, but the WHO policy-making process became politicised and the US\u000a      Institute of Medicine (IOM) undertook its own review of the evidence.\u000a      Prof. D Schellenberg participated in the IOM committee meeting in January\u000a      2008,5.1 giving a two-hour presentation on the acceptability,\u000a      cost effectiveness and applicability of IPTi, plus an assessment of the\u000a      impact of IPTi on drug resistance. This was based primarily on data from\u000a      the pilot implementation study he led in southern Tanzania.\u000a    LSHTM staff presented to all three WHO technical review meetings,\u000a      including the key session in April 2009 which recommended IPTi as policy.5.2\u000a      At this meeting, the Consortium presented robust information on the\u000a      efficacy and safety of IPTi in different epidemiological settings and\u000a      excluded the possibility of adverse interactions between IPTi and the\u000a      serological response to EPI vaccinations. Prof. D Schellenberg presented\u000a      information on the safety of IPTi, its health impacts, effect on drug\u000a      resistance and the feasibility of large-scale deployment based on\u000a      experience in the southern Tanzania study.\u000a    In September 2009 another WHO expert committee was convened to consider\u000a      the relationship between IPTi and drug resistance.5.3 Dr Roper\u000a      presented her analyses of the molecular markers of resistance to sulfadoxine-pyrimethamine\u000a      and their relationship to IPTi efficacy in the Consortium's studies. Prof\u000a      D Schellenberg presented the evaluation of the impact of IPTi on the\u000a      spread of resistant parasites in the pilot implementation study in\u000a      southern Tanzania. This led to a key resistance-based criterion for\u000a      countries to consider prior to implementation.\u000a    The final step in the policy process was the endorsement in October 20095.4\u000a\u0009  of the Strategic Advisory Group of Experts (SAGE) for the WHO\u000a      Expanded Programme on Immunisation. Prof. D Schellenberg once more\u000a      presented information (on efficacy, coverage, effectiveness,\u000a      acceptability, cost effectiveness, implementation lessons and impact on\u000a      EPI time use) from the southern Tanzania project.\u000a    WHO recommended IPTi as a malaria control tool for implementation in\u000a      areas of moderate to high transmission in March 2010.5.5 This\u000a      recommendation was based on the findings of seven studies, including those\u000a      carried out by LSHTM staff, showing the benefits of IPTi in reducing\u000a      malaria, anaemia and hospital admissions. Joint WHO\/UNICEF implementation\u000a      guidelines5.6 were released in September 2011. These draw\u000a      heavily on the LSHTM-led southern Tanzanian pilot implementation study. At\u000a      the time of writing, IPTi has been adopted by the national malaria control\u000a      programme of Burkina Faso.5.7 In 2012 a further eight nations\u000a      met to discuss implementation.5.8 Unpublished estimates suggest\u000a      that up to a million malaria episodes could be prevented annually if IPTi\u000a      were rolled out in the countries where studies have been conducted.\u000a    LSHTM's work on IPTi produced a number of additional benefits. Firstly,\u000a      the Consortium model of malaria research has been adopted by others,\u000a      including the Artemisinin-based Combination Treatment (ACT) Consortium\u000a      funded in 2007 and led by Prof. D Schellenberg since 2009. Secondly, the\u000a      review and modelling-based exercise to understand the age-pattern of\u000a      malaria disease and death in different transmission settings, led by Dr\u000a      Ilona Carneiro, continues to inform discussions in WHO, regulators and\u000a      within industry, about the possible deployment and dose scheduling of new\u000a      tools to control malaria. For example, this work has been presented and\u000a      discussed at several meetings during the reporting period of WHO's Joint\u000a      Technical Expert Group on malaria vaccines in pivotal phase 3 evaluation.5.9\u000a      Finally, the complexities of the policy-making process provided a learning\u000a      opportunity, as captured by the LSHTM's Dr Cruz,5.10 helping\u000a      groups (including the ACT Consortium) to engage better with policy-makers.\u000a    ","ImpactSummary":"\u000a    LSHTM researchers carried out the initial trials of intermittent\u000a      preventive treatment in infants (IPTi), a strategy to improve malaria\u000a      control in very young children. LSHTM staff were active in setting up and\u000a      running a dedicated research consortium which developed and executed a\u000a      research agenda to provide data to inform policy. School staff presented\u000a      evidence to a series of WHO policy-making meetings which in 2009\u000a      recommended that IPTi should be included as part of routine malaria\u000a      control. This policy, which has been adopted in one country and discussed\u000a      by eight others, has the potential to benefit hundreds of millions of\u000a      lives.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1. Chandramohan, D, Owusu-Agyei, S, Carneiro, I, Awine, T,\u000a      Amponsa-Achiano, K, Mensah, N, Jaffar, S, Baiden, R, Hodgson, A, Binka, F\u000a      and Greenwood B (2005) Cluster randomised trial of intermittent preventive\u000a      treatment for malaria in infants in area of high, seasonal transmission in\u000a      Ghana, BMJ, 331(7519): 727-733, doi: 10.1136\/bmj.331.7519.727.\u000a      Citation count: 105\u000a    \u000a\u000a3.2. Gosling, RD, Gesase, S, Mosha, JF, Carneiro, I, Hashim, R, Lemnge,\u000a      M, Mosha, FW, Greenwood, B and Chandramohan, D (2009) Protective efficacy\u000a      and safety of three anti-malarial regimens for intermittent preventive\u000a      treatment for malaria in infants: a randomised, double-blind,\u000a      placebo-controlled trial, Lancet, (374): 9700: 1521-1532, doi:\u000a      10.1016\/S0140-6736(09)60997-1. Citation count:39\u000a    \u000a\u000a3.3. Manzi, F, Schellenberg, J, Hamis, Y, Mushi, AK, Shirima, K, Mwita,\u000a      A, Simba, A, Rusibamayila, N, Kitambi, M, Tanner, M, Alonso, P, Mshinda, H\u000a      and Schellenberg, D (2008) Intermittent preventive treatment for malaria\u000a      and anaemia control in Tanzanian infants: the development and\u000a      implementation of a public health strategy, Transactions of the Royal\u000a        Society of Tropical Medicine and Hygiene, 103(1): 79-86,\u000a      doi:10.1016\/j.trstmh.2008.08.014. Citation count: 12\u000a    \u000a\u000a3.4. Pearce, RJ, Ord, R, Kaur, H, Lupala, C, Schellenberg, J, Shirima, K,\u000a      Manzi, F, Alonso, P, Tanner, M, Mshinda, H, Roper, C and Schellenberg, D\u000a      (2013) A community-randomized evaluation of the effect of intermittent\u000a      preventive treatment in infants on antimalarial drug resistance in\u000a      southern Tanzania, Journal of Infectious Diseases, 207(5):\u000a      848-859, doi: 10.1093\/infdis\/jis742. Citation count: 1\u000a    \u000a\u000a3.5. Pool, R, Mushi, A, Armstrong Schellenberg J,\u000a      Mrisho, M, Alonso, P, Montgomery, C, Tanner, M, Mshinda, H\u000a      and Schellenberg, D (2008) The acceptability of intermittent preventive\u000a      treatment of malaria in infants (IPTi) delivered through the expanded\u000a      programme of immunization in southern Tanzania', Malaria Journal,\u000a      7(213), doi: 10.1186\/1475-2875-7-213. Citation count: 22\u000a    \u000a\u000a3.6. Aponte, JJ, Schellenberg, D, Egan, A, Breckenridge, A, Carneiro, I,\u000a      Critchley, J, Danquah, I, Dodoo, A, Kobbe, R, Lell, B, May, J, Premji, Z,\u000a      Sanz, S, Sevene, E, Soulaymani-Becheikh, R, Winstanley, P, Adjei, S,\u000a      Anemana, S, Chandramohan, D, Issifou, S, Mockenhaupt, F, Owusu-Agyei, S,\u000a      Greenwood, B, Grobusch, MP, Kremsner, PG, Macete, E, Mshinda, H, Newman,\u000a      RD, Slutsker, L, Tanner, M, Alonso, P and Menendez, C (2009) Efficacy and\u000a      safety of intermittent preventive treatment with sulfadoxine-pyrimethamine\u000a      for malaria in African infants: a pooled analysis of six randomised,\u000a      placebo-controlled trials, Lancet, 374(9700): 1533-1542, doi:\u000a      10.1016\/S0140-6736(09)61258-7. Citation count: 93\u000a    \u000aKey grants\u000a    Chandramohan, the second study of IPTi, EPI-Linked Intermittent\u000a      Preventive Treatment for Malaria in Infants, DFID, 1998-2003, &#163;330,000.\u000a    Schellenberg D joined LSHTM in 2003 and led the development of the $28\u000a      million IPTi Consortium proposal. Funding was approved by the Bill and\u000a      Melinda Gates Foundation, 2004-2009. This included funds for the following\u000a      projects, led by LSHTM PIs:\u000a    1 Chandramohan, Options of Drugs for Intermittent Preventive Treatment\u000a      for Malaria in Infants, 2003-2008, $1.8m.\u000a    2 Schellenberg D, Community Effectiveness of Intermittent Treatment (IPT)\u000a      Delivered through the Expanded Program of Immunisation for Malaria and\u000a      Anemia Control in Tanzanian Infants, 2004-2009, $6.8m.\u000a    3 Chandramohan, Gosling, Roper and Schellenberg D, The Measurement of\u000a      Antimalarial Drug Resistance Across the Trials in the Intermittent\u000a      Preventive Treatment in Infants (IPTi) Consortium, 2007-2008, $750,356.\u000a    4 Carneiro, Intermittent Preventive Treatment for African Children: Where\u000a      and How Should IPT be applied?, 2004-2007, $561,217.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"}],"Sources":"\u000a    5.1 Committee on the Perspectives on the Role of Intermittent Preventive\u000a      Treatment for Malaria in Infants (2008) Assessment of the Role of\u000a        Intermittent Preventive Treatment for Malaria in Infants: Letter Report.\u000a      Washington, DC: National Academies Press,\u000a\u0009  http:\/\/books.nap.edu\/openbook.php?record_id=12180\u000a      (accessed 16 October 2013).\u000a\u0009  Note references to work of IPTi Consortium\u000a      Appendix B, p. 69 and David Schellenberg's presentation on 9 January 2008,\u000a      2.30-4:30 p.m., Acceptability, Cost Effectiveness, Drug Resistance,\u000a        Applicability of IPTi-SP, Effectiveness study of IPTi-SP,\u000a\u0009\u0009http:\/\/www.iom.edu\/Activities\/Nutrition\/PrevMalariaTreatment\/2008-JAN-09.aspx.\u000a    5.2 WHO (2009) Report of the Technical Consultation on Intermittent\u000a        Preventive Treatment in Infants (IPTi), Technical Expert Group on\u000a        Chemotherapy, 23 -24 April. Geneva: WHO,\u000a\u0009\u0009http:\/\/www.who.int\/malaria\/publications\/atoz\/tegconsultiptiapr2009report.pdf\u000a      (accessed 16 October 2013) (note references 3, 6, 9-13, 15 and list of\u000a      participants\/observers).\u000a    5.3 WHO (2009) Defining and Validating a Measure of Parasite\u000a        Resistance to Sulfadoxine- pyrimethamine (SP) that would be Indicative\u000a        of the Protective Efficacy of SP for Intermittent Preventive Treatment\u000a        in Infancy (SP-IPTi): Report of the Technical Consultation, 10-11\u000a      September. Geneva: WHO,\u000a\u0009  http:\/\/www.who.int\/malaria\/publications\/atoz\/who_sp_ipti_resistance_march_2010.pdf\u000a      (accessed 16 October 2013) (note p. 6, list of participants).\u000a    5.4 WHO (2009) Reports from other immunization-related advisory\u000a      committees: Malaria: co-administration of intermittent preventive\u000a      treatment of infants (IPTi) for malaria at time of immunization, WHO\u000a        Weekly Epidemiological Record, 50(84): 529-530,\u000a\u0009\u0009http:\/\/www.who.int\/wer\/2009\/wer8450.pdf\u000a      (accessed 16 October 2013).\u000a    5.5 WHO (2010) WHO Policy Recommendation on Intermittent Preventive\u000a        Treatment During Infancy with Sulfadoxine-pyrimethamine (SP-IPTi) for\u000a        Plasmodium Falciparum Malaria Control in Africa. Geneva: WHO,\u000a\u0009\u0009http:\/\/www.who.int\/malaria\/news\/WHO_policy_recommendation_IPTi_032010.pdf\u000a      (accessed 16 October 2013) (note footnote 2 referencing the 2009 TEG\u000a      meeting).\u000a    5.6 WHO Global Malaria Programme (GMP), WHO Department of Immunization,\u000a      Vaccines &amp; Biologicals (IBV) and UNICEF (2011) Intermittent\u000a        Preventive Treatment for Infants Using Sulfadoxine-pyrimethamine\u000a        (SP-IPTi) for Malaria Control in Africa: Implementation Field Guide.\u000a      Geneva: WHO, http:\/\/whqlibdoc.who.int\/hq\/2011\/WHO_IVB_11.07_eng.pdf\u000a      (accessed 16 October 2013) (see footnotes on p. 9, contents of Chapters\u000a      4-6, e.g. Figure 6 on p. 32 and Figure 8 on p. 35, and key references on\u000a      p. 47).\u000a    5.7 WHO (2012) World Malaria Report 2012. Geneva: WHO,\u000a\u0009http:\/\/www.who.int\/malaria\/publications\/world_malaria_report_2012\/wmr2012_no_profiles.pdf\u000a      (accessed 16 October 2013) (see section 5.2.2, p. 32).\u000a    5.8. WHO (2011) World Malaria Report 2011. Geneva: WHO,\u000a\u0009\u000a        http:\/\/apps.who.int\/iris\/bitstream\/10665\/44792\/2\/9789241564403_eng_full.pdf\u000a        (accessed 16 October 2013) (see section 5.1.2, p. 36).\u000a    5.9. WHO-UNAIDS HIV Vaccine Initiative, WHO.\u000a    5.10. Cruz, VO and Walt, G (2013) Brokering the boundary between science\u000a      and advocacy: the case of intermittent preventive treatment among infants,\u000a      Health Policy and Planning, 28(6): 616-625, doi:\u000a      10.1093\/heapol\/czs101.\u000a    ","Title":"\u000a    Intermittent preventive treatment for malaria control\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Malaria remains one of the world's major killers. At the start of the\u000a      millennium it was responsible for a million deaths a year, most of the\u000a      victims being children in sub-Saharan Africa. In the late 1990s and early\u000a      2000s a new strategy, intermittent preventive treatment (IPT), was\u000a      evaluated. IPT involves the administration of a treatment dose of an\u000a      antimalarial drug at pre-specified times, irrespective of the presence of\u000a      malaria parasites.\u000a    Randomised, controlled trials (RCTs) of IPTi were led by LSHTM's\u000a      Professor Daniel Chandramohan in Ghana3.1 and northern\u000a      Tanzania.3.2 Both provided evidence of a beneficial effect of\u000a      IPTi, the Tanzanian study also providing insights into the drug\u000a      characteristics (for example, long half-life) required for efficacy of\u000a      IPTi. This study was undertaken under the auspices of the IPTi Consortium,\u000a      a research collaboration with partners across Europe, the USA and Africa,\u000a      set up in 2003 by David Schellenberg at LSHTM. In addition to evaluating\u000a      the safety and efficacy of IPTi with a number of antimalarial drugs across\u000a      a range of malaria transmission settings,3.2 the Consortium\u000a      generated operational experience of IPTi implementation3.3\u000a      through a large-scale pilot implementation study led by Professor David\u000a      Schellenberg. Additional in-depth studies led by LSHTM staff included\u000a      evaluations of the effect of the routine use of IPTi on the spread of drug\u000a      resistance,3.4 the cost effectiveness and acceptability3.5\u000a      of IPTi and an assessment &#8212; through a systematic review and modelling\u000a      exercise &#8212; of the potential impact of IPTi in a range of settings. A\u000a      pooled analysis with major contributions from LSHTM staff showed that IPTi\u000a      reduces clinical malaria by 30% and anaemia by 21% in the first year of\u000a      life.3.6 LSHTM staff presented evidence to a series of\u000a      policy-making meetings at WHO which recommended in 2009 the inclusion of\u000a      IPTi as part of the global malaria control recommendations.\u000a    Key academics involved in the underpinning research are D. Schellenberg\u000a      (role pre 2004 LSHTM\/Ifakara Health Institute, 2003-2007; Senior Lecturer,\u000a      LSHTM 2004-5 and Professor of Malaria and International Health, LSHTM,\u000a      2005-present); D. Chandramohan (Professor of Public Health, 2009-present,\u000a      LSHTM since 1992, then Research Fellow ); and B. Greenwood (LSHTM\u000a      Professor of Clinical Tropical Medicine 1996-present). Other involved\u000a      LSHTM staff include Dr I. Carneiro, who examined the potential health\u000a      impacts of IPTi in different settings and led the development of a web\u000a      tool (http:\/\/ipti.lshtm.ac.uk\/) to\u000a      support decision-making at country level (2004-2007, Lecturer); Dr L.\u000a      Conteh, who showed that IPTi costs only USD 1.36-4.03 per malaria episode\u000a      averted (2010, Senior Lecturer); Drs C. Roper and R. Pearce, who confirmed\u000a      the modest impact of IPTi on drug resistance (2004-2009, Senior Lecturer\u000a      and Research Fellow); Dr R. Pool, who confirmed the acceptability of IPTi\u000a      (2004-2008, Senior Lecturer); and Dr J. Schellenberg, who led the\u000a      development of a strategy for operationalisation of IPTi in Tanzania\u000a      (2004-2008 Senior Lecturer then Reader).\u000a    "},{"CaseStudyId":"43193","Continent":[{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"3686110","Name":"Colombia"},{"GeoNamesId":"3469034","Name":"Brazil"}],"Funders":["Economic and Social Research Council","Medical Research Council"],"ImpactDetails":"\u000a    The impact emanating from the research has been to:\u000a    \u000a      Enable NICE to employ a rigorous, fair and standardised methodology\u000a        with which medical devices and pharmaceuticals can be assessed, and\u000a        thus;\u000a      Support the selection of the most cost- and health-effective medical\u000a        devices and pharmaceuticals to be approved for public use;\u000a      Help pharmaceutical and device manufacturers seeking NICE approval to\u000a        implement processes and practices which are more efficient and\u000a        effective.\u000a    \u000a    Healthcare Decision Making in NHS for England &amp; Wales\u000a    The National Institute for health Care Excellence (NICE) was created in\u000a      1999 in order to make timely and equitable decisions regarding the\u000a      appropriate use of health technologies (medical devices and\u000a      pharmaceuticals) within the NHS for England and Wales thus improving\u000a      patient care. Since its inception NICE has radically changed the way in\u000a      which health technologies are assessed and appraised &#8212; using evidence on\u000a      both clinical and cost-effectiveness1,2. Evidence regarding\u000a      health technologies on both clinical and cost-effectiveness is identified,\u000a      collated and synthesised by both commissioned academic groups and the\u000a      pharmaceutical industry\/device manufacturers (often subcontracted to\u000a      specialist healthcare consultancy companies), and which is then appraised\u000a      by an independent technology appraisal committee at NICE. This comprises\u000a      NHS healthcare professionals, academics (including Abrams since\u000a      2006), industry representatives and lay members. The ensuing guidance\u000a      issued regarding the use of such health technologies is mandatory within\u000a      the NHS in England and Wales. In addition to the academic and\u000a      pharmaceutical\/device company submissions NICE may also call upon its own\u000a      Decision Support Unit (DSU), in which Leicester (Abrams, Cooper &amp;\u000a        Sutton) is a key member, to undertake ad hoc analyses and\u000a      bespoke methodological work,. For example, Abrams3 led\u000a      the NICE response to the judicial review of the NICE appraisal of\u000a      alendronate, etidronate, risedronate, raloxifene and strontium ranelate\u000a      for the primary (TA 160) and secondary (TA 161) prevention of osteoporotic\u000a      fragility fractures in post-menopausal women. In addition to appraising\u000a      health technologies, NICE also has a remit to undertaken the assessment of\u000a      public health interventions under the auspices of its Public Health\u000a      Guidance Committee (of which Jones is a member).\u000a    Methods Employed by NICE &amp; Pharmaceutical\/Device Industry for\u000a          Technology Appraisal &amp; Public Health Guidance\u000a    The methods to be employed by academic groups, DSU and industry in\u000a      undertaking submissions for NICE are set out in the NICE Methods Guide,\u000a      to which Abrams &amp; Sutton have contributed extensively\u000a      as members of Methods Task Forces ,and are specialist advisers on\u000a      evidence synthesis methodology1,2. In particular, Abrams,\u000a      Cooper and Sutton have pioneered at NICE, (through\u000a      membership of the Appraisal Committee, DSU and contributors to the Methods\u000a        Guide}, the use of indirect comparisons or network meta-analysis in\u000a      technology appraisals and this has led to an increase in its use, for\u000a      example all 10 of the 212 technology appraisals published to 2011 which\u000a      used indirect comparisons or network meta-analysis appeared after\u000a      publication of 2004 Methods Guide which approved its use4.\u000a      Abrams &amp; Sutton has further contributed extensively to a series\u000a      of NICE DSU Technical Support Documents which have further\u000a      articulated the rationale and use of network meta-analysis5. In\u000a      addition Abrams, Cooper &amp; Sutton have run\u000a      tailored bespoke courses for the pharmaceutical industry on network\u000a      meta-analysis, including courses for Novartis, Pfizer &amp; Roche (approx.\u000a      150 participants), as well as for NICE (approx. 50 participants) and\u000a      general courses (approx. 600 participants from consultancy companies,\u000a      industry and academia). Further, Abrams has provided\u000a      methodological consultancy services to both major pharmaceutical companies\u000a      (Bristol-Meyers-Squibb, GSK, Janssen, Novartis, &amp; Roche) and\u000a      healthcare consultancy companies (Amaris, OptumInsight, &amp; PRMA) on\u000a      network meta-analysis. Abrams, Bujkiewicz, Cooper\u000a      &amp; Sutton undertook implementation of comprehensive decision\u000a      model in user-friendly real-time software and piloted it in a NICE\u000a      Technology Appraisal Committee meeting in order to aid more timely\u000a      decision making on tumour necrosis factor-alpha inhibitors in psoriatic\u000a      arthritis6.\u000a    In addition to short courses and consultancy activities on evidence\u000a      synthesis, including network meta-analysis, Abrams &amp; Lambert\u000a      have delivered courses, provided consultancy and undertaken contract\u000a      research projects on methods for dealing with treatment switching in\u000a      oncology clinical trials to inform HTA for ABPI, Amaris, GSK,\u000a      OptumInsight, and Roche. For example, in the area of locally advanced or\u000a      metastatic BRAF V600 mutation-positive malignant melanoma Abrams\u000a      provided expert advice on most appropriate methods for adjusting for\u000a      treatment switching which led to an eventual positive decision by NICE\u000a      (subject to a patient access scheme) for Vemurafenib [Roche] which\u000a      represents an innovative therapy in this poor prognosis condition in which\u000a      80% die within 2 years of diagnosis7. Lambert has also\u000a      provided methodological advice as a member of the Academic Reference Group\u000a      to the International Cancer Benchmarking Partnership.\u000a    As a measure of contribution to UK economy, since 2010 the ability to Abrams\u000a      to provide expert methodological advice on methods for evidence synthesis\u000a      and treatment switching to Amaris (a health-care consultancy company) has\u000a      resulted in them being awarded projects with a combined revenue of [text\u000a      removed for publication], including them being awarded `preferred vendor\u000a      status' by Roche in 2013.\u000a    In terms of Public Health decision making, Cooper &amp; Sutton\u000a      undertook a network meta-analysis to evaluate the effectiveness of\u000a      interventions to increase the uptake of smoke alarms as part of a NIHR\u000a      Programme Grant and which has been included in an update to NICE Public\u000a      Health Guidance 29: Strategies to prevent unintentional injuries among\u000a        children and young people aged under158. Using\u000a      comprehensive decision modelling techniques pioneered at Leicester, Abrams\u000a      &amp; Gillies undertook further modelling for the Department of\u000a      Health to inform the UK Vascular Screening Programme9.\u000a    International Impact\u000a    As well as disseminating and promoting methodological developments in the\u000a      UK, Abrams, Cooper &amp; Sutton have delivered\u000a      short courses of evidence synthesis in the US to the Agency for Healthcare\u000a      Research and Quality (AHRQ) which have adopted some of these innovative\u000a      methods10. In addition Abrams has acted as an advisor\u000a      to both the Brazilian and Colombian Ministries of Health as regards\u000a      methods for HTA, whilst Lambert has delivered short courses on\u000a      advanced survival methodology, developed at Leicester, to the\u000a      International Association of Cancer Registries (approx. 60 individuals)\u000a      and North American Association of Central Cancer Registries (approx. 30\u000a      individuals).\u000a    This significant body of translational activity &#8212; delivered through\u000a      committee membership, contract research, consultancy and training\u000a      delivered by key academics &#8212; is fundamentally underpinned by research in Evidence\u000a        Synthesis and Decision Modelling Methodology and Survival\u000a        Analysis Methodology pioneered at Leicester.\u000a    ","ImpactSummary":"\u000a    The National Institute for health Care Excellence (NICE) in England and\u000a      Wales makes timely and equitable decisions regarding the use of health\u000a      technologies (medical devices and pharmaceuticals) within the NHS in order\u000a      to improve patient care. Such decisions are reliant on Health Technology\u000a      Assessment (HTA) &#8212; the processes of evidence generation and synthesis, and\u000a      the methods that underpin these. Methods pioneered and developed at\u000a      Leicester over the last 15 years are now used routinely in HTA both by\u000a      NICE and the pharmaceutical industry and healthcare consultancy companies\u000a      who make submissions to NICE. Internationally, these methods are also now\u000a      being adopted in the US by Agency for Healthcare Research and Quality\u000a      (AHRQ), as well as in rapidly developing countries such as Brazil and\u000a      Colombia.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Leicester\u000a    ","Institutions":[{"AlternativeName":"Leicester (University of)","InstitutionName":"University of Leicester","PeerGroup":"A","Region":"East Midlands","UKPRN":10007796}],"Panel":"A         ","PlaceName":[],"References":"\u000a    [Underlined authors were members of staff\/students at UoL at the time the\u000a      research was undertaken]\u000a    \u000aCooper NJ, Sutton AJ, Abrams KR, Turner D,\u000a      Wailoo A. Comprehensive decision analytical modelling in economic\u000a      evaluation: A Bayesian approach. Health Economics.\u000a      2004;13(3):203-226. [MRC funded]\u000a    \u000a\u000aCrowther MJ, Abrams KR, Lambert PC. Flexible\u000a      parametric joint modelling of longitudinal and survival data. Stat Med.\u000a      2012 Dec 30;31(30):4456-71. doi: 10.1002\/sim.5644. Epub 2012 Oct 4 [NIHR\u000a        funded]\u000a    \u000a\u000aGillies CL, Lambert PC, Abrams KR, Sutton AJ,\u000a      Cooper NJ, Hsu RT, Davies MJ, Khunti K.\u000a      Different strategies for screening and prevention of type 2 diabetes in\u000a      adults: cost effectiveness analysis. BMJ. 2008;336:1180-5. [ESRC-MRC\u000a        funded]\u000a    \u000a\u000aMorden JP, Lambert PC, Latimer N, Abrams KR,\u000a      Wailoo AJ. Assessing statistical methods for dealing with treatment\u000a      switching in randomised controlled trials: A simulation study. BMC\u000a      Methodology 2011;11(4). [NICE funded]\u000a    \u000a\u000aPrevost TC, Abrams KR, Jones DR. Hierarchical\u000a      models in generalized synthesis of evidence: an example based on studies\u000a      of breast cancer screening. Stat Med. 2000 Dec 30;19(24):3359-76. [NHS\u000a        funded]\u000a    \u000a\u000aSutton AJ, Cooper NJ, Abrams KR, Lambert PC,\u000a      Jones DR. A Bayesian approach to evaluating net clinical benefit\u000a      allowed for parameter uncertainty. Journal of Clinical Epidemiology.\u000a      2005;58(1):26-40.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"1","Level2":"4","Subject":"Statistics"},{"Level1":"14","Level2":"3","Subject":"Econometrics"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000a    Contactable individuals to corroborate impact:\u000a    \u000a      Director, Centre for Health Technology Evaluation, NICE (to\u000a        corroborate impact on NICE methodology)\u000a      Director, Health Economics and Outcomes Research, Amaris, UK (to\u000a        corroborate impact on healthcare consultancy companies)\u000a      Group Health Economics Manager, Roche Products Limited, UK (to\u000a        corroborate impact on pharmaceutical companies)\u000a      Executive Director, Instituto de Evaluaci&#243;n de Tecnolog&#237;as en Salud\u000a        (IETS) Bogota, Colombia (to corroborate international impact).\u000a    \u000a    Documents to corroborate impact\u000a    \u000a      http:\/\/www.nice.org.uk\/niceMedia\/pdf\/TAP_Methods.pdf\u000a      http:\/\/www.nice.org.uk\/media\/B52\/A7\/TAMethodsGuideUpdatedJune2008.pdf\u000a      http:\/\/www.nicedsu.org.uk\/PDFs%20of%20reports\/Final%20submitted%20to%20NICE%20\u000a          25%2009%2010.pdf\u000a      Tan SH, Bujkiewicz S, Sutton A, Dequen P, Cooper N. Presentational\u000a        approaches used in the UK for reporting evidence synthesis using\u000a        indirect and mixed treatment comparisons. J Health Serv Res Policy\u000a        Online First, published on August 14, 2013 as\u000a        doi:10.1177\/1355819613498379.\u000a      http:\/\/www.nicedsu.org.uk\/Technical-Support-Documents(1985314).htm\u000a      Bujkiewicz S, Jones HE, Lai MC, Cooper NJ, Hawkins N, Squires H,\u000a        Abrams KR, Spiegelhalter DJ, Sutton AJ. Development of a transparent\u000a        interactive decision interrogator to facilitate the decision-making\u000a        process in health care. Value Health. 2011 Jul-Aug;14(5):768-76.\u000a      Vemurafenib [Roche] for treating locally advanced or metastatic BRAF\u000a        V600 mutation-positive malignant melanoma [TA269] http:\/\/publications.nice.org.uk\/vemurafenib-for-\u000a        treating-locally-advanced-or-metastatic-braf-v600-mutation-positive-malignant-ta269\u000a\u000a      NICE public health guidance 29 `Strategies to prevent unintentional\u000a        injuries among children and young people aged under 15' (2010) &#8212; Updated\u000a        Feb 2013. http:\/\/arms.evidence.nhs.uk\/resources\/hub\/930820\/attachment\u000a\u000a      http:\/\/www.screening.nhs.uk\/vascularrisk\u000a      Agency for Healthcare Research and Quality (AHRQ) &#8212; Methods Guide\u000a        http:\/\/effectivehealthcare.ahrq.gov\/tasks\/sites\/ehc\/assets\/File\/MethodsGuide_ConductingQuantitati\u000a        veSynthesis.pdf\u000a\u000a    \u000a    ","Title":"\u000a    Development of methods to better inform healthcare decision making and\u000a      innovation\u000a    ","UKLocation":[{"GeoNamesId":"2644668","Name":"Leicester"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The underpinning research that this case study is based upon has two\u000a      inter-linked themes &#8212; Evidence Synthesis and Decision Modelling\u000a        Methodology and Survival Analysis Methodology. The\u000a      pioneering work that researchers in Biostatistics at Leicester have\u000a      undertaken over the last 15 years is briefly summarised below.\u000a    Evidence Synthesis &amp; Decision Modelling\u000a    In HTA the evidence on clinical effectiveness is often disparate and\u000a      heterogeneous in both source and nature. As such the methods that have to\u000a      used are by necessity flexible and often complex. Members of the\u000a      Biostatistics Group at Leicester have been at the forefront of developing\u000a      such methodology in the field of evidence synthesis over the last 15 years\u000a      funded by MRC, NIHR, and the pharmaceutical industry. Such methodological\u000a      developments have included: allowing for different types of evidence\u000a      within a generalised evidence synthesis framework, publication bias, and\u000a      network meta-analysis. Such syntheses are often undertaken in order to\u000a      inform either a clinical net benefit model or an economic decision model,\u000a      and it is important that the uncertainty (and correlation derived from the\u000a      same source informing a numbers of inputs into such models) is\u000a      appropriately accounted for. Many of these issues have been addressed\u000a      using Bayesian methods which both allow for the heterogeneous nature of\u000a      the evidence to be synthesised and the often complex structure, whilst\u000a      enabling appropriate inputs into the decision models to be obtained.\u000a    Survival Analysis\u000a    The Cox proportional hazards model is one of the most widely cited\u000a      methods in medical research and is used in wide variety of clinical\u000a      setting in which time to an event is the main outcome, e.g. mortality,\u000a      discharge, disease recurrence. However, the model makes a number of\u000a      assumptions that often do not hold and that hinder the complexity of data\u000a      that can be modelled, and hence the clinical questions that can be\u000a      answered. Extension of these regression based survival models to\u000a      accommodate more realistic aspects of the data is a key component of\u000a      research in Biostatistics at Leicester &#8212; often using flexible parametric\u000a      models. In HTA interest often focuses on differences in overall survival\u000a      for decision making, but this can be problematic when patients switch from\u000a      the treatment to which they have been randomised to in RCTs. Research at\u000a      Leicester has focused on the evaluation of a variety of different methods\u000a      that have been proposed for adjusting RCTs to account for treatment\u000a      switching, and this work has been funded by ABPI, NICE and NIHR. In both\u000a      HTA and other health-care policy contexts appropriate prediction of long\u000a      term patient outcomes (including death) is important in either the\u000a      evaluation of health technologies or the planning of patient services. The\u000a      methods developed at Leicester using flexible parametric models are\u000a      particularly suited to this aim of long term prediction.\u000a    The Biostatistics Group at Leicester comprises; Prof. Keith R Abrams, Dr\u000a      Sylwia Bujkiewicz (L), Prof. Nicola J Cooper, Dr Clare L Gillies (L), Dr\u000a      Laura Gray (L), Prof. David R Jones, Prof Paul C Lambert &amp; Prof. Alex\u000a      J Sutton.\u000a    "},{"CaseStudyId":"43267","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000d\u000a    The results of the research were submitted to the Scottish Cabinet in\u000d\u000a      early November 2004 and the main finding &#8212; a net economic benefit to\u000d\u000a      Scotland from banning smoking in public places &#8212; was cited in the First\u000d\u000a      Minister's speech to the Scottish Parliament on 10th November\u000d\u000a      2004 announcing the proposal to introduce the legislation [a].\u000d\u000a    The research underpinned the Regulatory Impact Assessment produced by\u000d\u000a      civil servants for the Committee stages of the Bill and the researchers\u000d\u000a      were able to defend their findings against evidence submissions made by\u000d\u000a      opponents of the proposed legislation [b].\u000d\u000a    The importance of the research in supporting the passage of the Smokefree\u000d\u000a      legislation has also been demonstrated by independent stakeholder evidence\u000d\u000a      from an independent review of the performance of the Health Economics\u000d\u000a      Research Unit for the Chief Scientist Office [c]. The research\u000d\u000a      was described as \"enormously influential\" and `the most\u000d\u000a        important piece of work of all' in relation to the Bill.\" The\u000d\u000a      legislation was passed by the Scottish Parliament and implemented in March\u000d\u000a      2006.\u000d\u000a    The legislation has resulted in significant health improvements for the\u000d\u000a      Scottish population, which would not have been achieved otherwise.\u000d\u000a      Specific improvements in public health have started to accrue from 2008\u000d\u000a      onwards, including:\u000d\u000a    \u000d\u000a      reductions in admissions for acute coronary syndrome were reported in\u000d\u000a        2008 [d];\u000d\u000a      reductions in admissions for childhood asthma were reported in 2010 [e];\u000d\u000a      reductions in complications of pregnancy were reported in 2012 [f];\u000a        and\u000d\u000a      health improvements for occupational groups previously exposed to high\u000d\u000a        levels of environmental tobacco smoke (bar workers) have also been\u000d\u000a        noted, with a first report in 2009 [g].\u000d\u000a    \u000d\u000a    These health benefits have been evidenced in post implementation studies\u000d\u000a      conducted by other research teams and are the result of the legislation\u000d\u000a      having been passed. Admissions for acute coronary syndrome fell by 17%,\u000d\u000a      compared with a previous mean annual decrease of 3%. The scale of\u000d\u000a      reduction in admissions for childhood asthma was similar at 18.2%. Reduced\u000d\u000a      use of health services, as a consequence of better health, also provides\u000d\u000a      an economic benefit.\u000d\u000a    The evidence review and the modelling methodology were also used by the\u000d\u000a      Welsh Assembly Government in deciding to introduce Smokefree legislation\u000d\u000a      in Wales.\u000d\u000a    The claimed impact, as defined by REF guidance, therefore includes: public\u000a        health and well-being has improved; disease prevention has\u000d\u000a      been enhanced by research; public behaviour has changed and awareness\u000a        of a health risk has been raised; costs of treatment and healthcare\u000d\u000a      have improved and policy debate has been stimulated by research.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    University of Aberdeen research had impact on public policy as it was\u000d\u000a      instrumental in the introduction of legislation in Scotland to restrict\u000d\u000a      smoking in public places. The implementation of the legislation has\u000d\u000a      impacted on the health of the public and benefited the economy through\u000d\u000a      reduced use of health services.\u000d\u000a    Exposure to environmental tobacco smoke (ETS) &#8212; passive smoking &#8212; had\u000d\u000a      been estimated to cause more than 1,000 deaths per year in Scotland and\u000d\u000a      significant morbidity. International evidence was used to model the health\u000d\u000a      and economic impacts of potential legislation to eliminate smoking in\u000d\u000a      public places in Scotland, under a range of scenarios. The net present\u000d\u000a      value of all the benefits and costs over 30 years was demonstrated to be\u000d\u000a      positive under all the scenarios examined, with a central estimate of\u000d\u000a      +&#163;4.6 billion (ranging from +&#163;0.056 billion to +&#163;7.4 billion).\u000d\u000a    The research results provided convincing evidence to support the passage\u000d\u000a      of legislation. Following the implementation of smokefree public places in\u000d\u000a      Scotland, evidence of the resulting health benefits have been accruing\u000d\u000a      from 2008. These include significant reductions in admissions for acute\u000d\u000a      coronary syndrome and for childhood asthma, reductions in complications of\u000d\u000a      pregnancy (pre-term delivery and small for gestational age) and\u000d\u000a      improvements in bar workers' health.\u000d\u000a    The claimed impact, as defined by REF guidance, therefore includes: public\u000a        health and welfare have improved; public behaviour and the control of\u000d\u000a        disease has changed.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of Aberdeen\u000d\u000a    ","Institutions":[{"AlternativeName":"Aberdeen (University of)","InstitutionName":"University of Aberdeen","PeerGroup":"B","Region":"Scotland","UKPRN":10007783}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Ludbrook, A, Bird, S and van Teijlingen, E. (2005). International\u000d\u000a      review of the health and economic impact of the regulation of smoking in\u000d\u000a      public places. Edinburgh. NHS Health Scotland. http:\/\/www.healthscotland.com\/documents\/451.aspx\u000d\u000a      (This report was submitted to rigorous peer review by four independent\u000d\u000a        international experts prior to publication)\u000d\u000a    \u000a\u000a[2] Ludbrook, A, Cohen, D, Bird, S and van Teijlingen, E. International\u000d\u000a      review of the health and economic impact of the regulation of smoking in\u000d\u000a      public places. Report submitted to the Committee on Smoking in Public\u000d\u000a        Places. National Assembly for Wales 2005\u000d\u000a    \u000aGrant funding for this research:\u000d\u000a    Ludbrook A, van Teijlingen E. International Review of the Health and\u000d\u000a        Economic Impact of the Regulation of Smoking in Public Places. NHS\u000d\u000a      Health Scotland on behalf of the Scottish Executive Health Department.\u000d\u000a      April 2004 &#8212; October 2004 &#163;46,873.\u000d\u000a    Ludbrook A, Cohen D. (University of Glamorgan) International review of\u000d\u000a        the health and economic impact of the regulation of smoking in public\u000d\u000a        places &#8212; extension to Wales. NHS Health Scotland on behalf of the\u000d\u000a      Welsh Assembly Government. &#163;16,167\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    References to confirm the impact of the research on the passage of\u000d\u000a        legislation:\u000d\u000a    [a] Scottish Parliament Official Report 10 November 2004 &#8212; demonstrates the results of the research being used to support the\u000d\u000a\u0009\u0009introduction of the legislation\u000d\u000a      http:\/\/www.scottish.parliament.uk\/Apps2\/business\/orsearch\/ReportView.aspx?r=4540\u000d\u000a    [b] Finance Committee papers &#8212; include the rebuttal of criticisms of\u000d\u000a        the research and further evidence the role of the research in supporting\u000d\u000a        the legislative decision-making.\u000d\u000a      http:\/\/archive.scottish.parliament.uk\/business\/committees\/finance\/reports-05\/fir05-smokingFMreport-00.htm\u000d\u000a    [c] Review of Health Economics Research Unit. Report of Stakeholder\u000d\u000a      Interviews 2005. This report provides independent views from\u000d\u000a        stakeholders on the contribution of the research to the passage of the\u000d\u000a        legislation\u000d\u000a    References relating to the health impacts achieved:\u000d\u000a    [d] Pell JP, Haw SJ, Cobbe S et al. (2008). Smoke-free legislation and\u000d\u000a      hospitalizations for acute coronary syndrome. New England Journal of\u000d\u000a        Medicine, 359: 482-91.\u000d\u000a    [e] Mackay D, Haw S, Ayres JG, et al. (2010). Smoke-free Legislation and\u000d\u000a      Hospitalizations for Childhood Asthma. New England Journal of Medicine,\u000d\u000a      363:1139-1145.\u000d\u000a    [f] Mackay DF, Nelson SM, Haw SJ, Pell JP. (2012). Impact of Scotland's\u000d\u000a      Smoke-Free Legislation on Pregnancy Complications: Retrospective Cohort\u000d\u000a      Study. PLoS Med, 9(3): e1001175.\u000d\u000a    [g] Ayres JG, Semple S, MacCalman L et al. (2009). Bar workers' Health\u000d\u000a      and Environmental Tobacco Smoke Exposure (BHETSE): Symptomatic improvement\u000d\u000a      in bar staff following smoke-free legislation in Scotland. Occupational\u000a        and Environmental Medicine, 66, 339-46.\u000d\u000a    [h] Testimonial from Head of the Evaluation Unit, NHS Health Scotland\u000d\u000a      which confirms the commissioning and peer review process for the research\u000d\u000a      and corroborates the use of the research findings and the health impacts\u000d\u000a      which have followed.\u000d\u000a    [i] Testimonial from a former MSP and member of the Scottish Government\u000d\u000a      in 2004, which corroborates the importance of the research findings for\u000d\u000a      the decision-making process within the Scottish Government.\u000d\u000a    ","Title":"\u000d\u000a    Improved public health through the impact of research underpinning the\u000d\u000a        introduction of Smokefree Legislation in Scotland\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2657832","Name":"Aberdeen"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The University of Aberdeen research, led by Professor Anne Ludbrook, was\u000d\u000a      commissioned by NHS Health Scotland on behalf of the Scottish Executive to\u000d\u000a      inform a decision to be taken by Scottish Ministers on whether or not to\u000d\u000a      introduce smokefree legislation to the Scottish Parliament.\u000d\u000a    Passive smoking was recognised to be an important component of tobacco\u000d\u000a      related health harms in the Scottish Executive's tobacco control action\u000d\u000a      plan, Clearing the Air. Deaths from passive smoking in Scotland\u000d\u000a      had been estimated to be in the region of 1000 to 1200 per year, which is\u000d\u000a      about 10% of the total deaths from smoking related diseases.\u000d\u000a    Passive smoking was known to increase risk of lung cancer and ischaemic\u000d\u000a      heart disease, with growing evidence of a causal effect for other\u000d\u000a      diseases. Passive smoking was also known to aggravate respiratory\u000d\u000a      diseases, such as asthma and chronic bronchitis. The costs of treating\u000d\u000a      smoking related diseases in Scotland was estimated at &#163;200 million in\u000d\u000a      2004; if the cost attributable to passive smoking were pro rata to the\u000d\u000a      share in mortality then this would be approximately &#163;20 million per year.\u000d\u000a      The Aberdeen team was approached because of its reputation for high\u000d\u000a      quality evidence reviews and economic modelling. The Scottish Executive\u000d\u000a      required a robust evidence base to underpin their decision-making. There\u000d\u000a      was particular controversy about the potential impact of smokefree\u000d\u000a      legislation on the hospitality sector (bars, restaurants and hotels), with\u000d\u000a      the industry claiming that there would be a significant negative effect on\u000d\u000a      this area of the Scottish economy. Despite the evidence from studies of\u000d\u000a      smoking restrictions in other jurisdictions, it was important to provide\u000d\u000a      results relevant to Scotland through the modelling process.\u000d\u000a    Systematic reviews were undertaken of evidence relating to the health\u000d\u000a      effects of exposure to ETS, the impact of restrictions on exposure levels\u000d\u000a      and on tobacco use behaviours and the economic impacts of restrictions on\u000d\u000a      workplaces, in general, and on the hospitality sector in particular.\u000d\u000a      Effect sizes from the reviews were used in the modelling. Specific health,\u000d\u000a      health service and economic information relating to the Scottish context\u000d\u000a      was also collected to assist in the modelling of impacts.\u000d\u000a    The model combined information relating to the main health and economic\u000d\u000a      impacts of smoking in public places and was estimated to show the impact\u000d\u000a      of moving from the existing situation, under a voluntary code of practice,\u000d\u000a      to a complete ban. The model provided a framework in which to compare the\u000d\u000a      expected benefits of smokefree legislation with the potential costs,\u000d\u000a      estimated on the basis of the best available evidence and using expert\u000d\u000a      judgement where evidence did not exist or was unclear. The model was\u000d\u000a      estimated across a range of assumptions to test its robustness and\u000d\u000a      demonstrated a positive net benefit under all assumptions. Key findings\u000d\u000a      [1,2] included:\u000d\u000a    \u000d\u000a      an annual reduction in deaths from lung cancer and CHD of 219, with a\u000d\u000a        possible additional reduction in deaths from stroke and respiratory\u000d\u000a        diseases of 187;\u000d\u000a      complete smoking bans were associated with greater reductions in\u000d\u000a        exposure to ETS and greater reductions in active smoking than other\u000d\u000a        forms of restrictions;\u000d\u000a      the annual effect on the hospitality sector (bars, restaurants and\u000d\u000a        hotels) in Scotland was estimated to lie in the range-&#163;104m to +&#163;299m\u000d\u000a        with a central estimate of +&#163;97m; and\u000d\u000a      the net present value of all the benefits and costs over 30 years was\u000d\u000a        positive under all the scenarios examined, with a central estimate of\u000d\u000a        +&#163;4.6 billion (range: +&#163;0.056 to +&#163;7.4).\u000d\u000a    \u000d\u000a    This research built on a strong but contested evidence base.\u000d\u000a    The researchers adopted a deliberately conservative approach in\u000d\u000a      estimating the benefits for Scotland to ensure the robustness of the\u000d\u000a      conclusions. In particular, the research included a wide range of\u000d\u000a      estimates relating to the impact on the hospitality sector. Although\u000d\u000a      previous studies using robust methods had found no significant effect, the\u000d\u000a      model scenarios included possible negative economic effects, using\u000d\u000a      confidence intervals from this literature. The research could then\u000d\u000a      demonstrate that, in the worst-case scenario, the scale of any negative\u000d\u000a      economic impact was outweighed by the value of the health benefits. This\u000d\u000a      provided a strong basis on which to counter criticisms of the research\u000d\u000a      during the legislative process, including the provision of a written\u000d\u000a      response to the Finance Committee of the Scottish Parliament. The quality\u000d\u000a      and robustness of the research contributed to the successful passage of\u000d\u000a      the legislation and the public health benefits which have accrued\u000d\u000a      thereafter.\u000d\u000a    All of the researchers on the project were from the University of\u000d\u000a      Aberdeen:\u000d\u000a    \u000d\u000a      Anne Ludbrook, Senior Research Fellow and Principal Investigator,\u000d\u000a        Health Economics Research Unit\u000d\u000a      Edwin van Teijlingen, Senior Lecturer, Department of Public Health\u000d\u000a        (now Professor of Reproductive Health Research at Bournemouth\u000d\u000a        University)\u000d\u000a      Sheona Bird, Research Assistant, Health Economics Research Unit\u000d\u000a    \u000d\u000a    All of the research was undertaken between April 2004 and October 2004\u000d\u000a      and all researchers were in post at the University of Aberdeen for the\u000d\u000a      whole period.\u000d\u000a    "},{"CaseStudyId":"43268","Continent":[{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2750405","Name":"Netherlands"}],"Funders":[],"ImpactDetails":"\u000a    The development of the AVVQ has had impact in a range of areas:\u000a    \u000a      \u000aNational and international adoption of the AVVQ as the measure of\u000a        choice in research studies. Varicose veins are a common medical\u000a      condition, with approximately 25% of women and 15% of men having some form\u000a      of visible varicose veins. The recently introduced minimally invasive\u000a      therapies for the treatment of varicose veins has led to their\u000a      effectiveness being assessed in a number of observational studies and\u000a      randomised controlled trials. The AVVQ has become the most commonly used\u000a      disease specific questionnaire in venous studies and has been used in all\u000a      of the large recent randomised controlled trials eg a review of published\u000a      venous studies in the Journal of Vascular Surgery, European Journal of\u000a        Vascular and Endovascular Surgery and Phlebology found that out of\u000a      60 studies assessed, 47 studies adopted the AVVQ as the gold standard\u000a      measure for assessment of disease-specific quality of life. The AVVQ has\u000a      also been translated into Dutch in 2009 [a] and Portuguese in 2012 [b] by\u000a      international groups in the Netherlands and Brazil and validated for use\u000a      in these countries.\u000a      \u000aRecommendation of the AVVQ as a preferred measurement tool by\u000a          international agencies: Reporting standards for the treatment of\u000a        varicose veins issued by the American Venous Forum and the\u000a          Society of Interventional Radiology recommended from 2007 that the\u000a        use of both generic and venous disease-specific measures to be the\u000a        accepted standard for studying quality-of-life (QOL) changes.\u000a        Specifically, it recommended the AVVQ as one of only three acceptable\u000a        disease-specific validated questionnaires worldwide. More recently in\u000a        2011, the clinical practice guidelines of the Society for Vascular\u000a        Surgery and the American Venous Forum strongly recommended that, as part\u000a        of the assessment of the outcome of treatment, a disease-specific\u000a        instrument (such as the AVVQ) be used to evaluate patient-reported\u000a        outcomes [c]. The current UK NICE guidelines [d] on the diagnosis and\u000a        treatment of varicose veins also highlights the key role\u000a        disease-specific quality of life measures, including the AVVQ,\u000a        contribute to the assessment of the effectiveness of different treatment\u000a        options and subsequent recommendations on their use in the NHS.\u000a      \u000aAdoption of the AVVQ as the mandated measurement of quality\u000a          of varicose vein treatment in the NHS in England to in form\u000a        NHS service planning: In 2008, Lord Darzi\u000a        published a review of the NHS in England entitled High Quality Care\u000a          for All. The review was commissioned by the Prime Minister, the\u000a        Chancellor and the Secretary of State for Health to develop a vision of\u000a        a health service fit for the 21st century. A core tenet of\u000a        this review was that \"quality should be at the heart of the NHS\" and a\u000a        recommendation made that the NHS should \"systematically measure and\u000a        publish information about the quality of care ... including patients'\u000a        own views on the success of their treatment and the quality of their\u000a        experiences\" &#8212; so called \"PROMs\", or Patient Reported Outcome Measures.\u000a        This information would then be used to assess the quality of services\u000a        provided across the NHS and inform service redesign [e]. To enable this,\u000a        the Standard NHS Contract for Acute Services, was revised to include a\u000a        requirement for all licensed providers of NHS-funded procedures\u000a        including varicose vein surgery to ask patients to complete PROM\u000a        questionnaires before and after surgery, from April 2009. The associated\u000a        guidance document produced by the Department of Health mandated the use\u000a        of the AVVQ as the disease-specific PROM for varicose vein surgery [f].\u000a        Since April 2009, all patients in England undergoing varicose vein\u000a        surgery now complete the AVVQ before and after their surgery. To date\u000a        over 27,000 patients have already completed these multiple assessments\u000a        using the AVVQ. Data from these measures are collated centrally by the\u000a        NHS Information Centre in England and reports produced quarterly to\u000a        allow the assessment of quality of service across the country and the\u000a        planning of service delivery nationwide [g]. Already the PROMs data for\u000a        varicose vein surgery &#8212; ie the AVVQ data &#8212; has shown that treatment in\u000a        England results in significant improvement in health for patients [h].\u000a        Patients with the lowest &#8212; less severe &#8212; pre-treatment scores have been\u000a        found to benefit least from surgery. These observations are now being\u000a        used by individual NHS providers to assess the quality of their care\u000a        (the NHS Information Centre provides data by provider) and to improve\u000a        their services in line with providers seen to provide high quality care.\u000a        Data is also being used for planning and commissioning of services\u000a        nationwide. Data is now also being linked routinely to national Hospital\u000a        Episode Statistics by the National Information Centre to allow long-term\u000a        tracking of outcomes.\u000a    \u000a    The claimed impact, as defined by REF guidance, therefore includes impact\u000a      on: public policy and services particularly through the\u000a      specification of AVVQ-reporting as part of the NHS contract;\u000a        practitioners and professional services through the widespread use\u000a      and adoption of the measure and health and welfare through its use\u000a      to plan NHS services.\u000a    ","ImpactSummary":"\u000a    University of Aberdeen research has directly impacted on clinical\u000a      practice with regard to the treatment of varicose veins. The University's\u000a      Health Services Research Unit (HSRU) developed and validated the Aberdeen\u000a      Varicose Vein Questionnaire (AVVQ), which allows patients to self-assess\u000a      the severity of their varicose veins. Current national and international\u000a      guidelines now recommend that as part of the assessment of outcome for\u000a      patients with varicose veins, patients' self-assessment of their veins be\u000a      routinely undertaken &#8212; with the AVVQ the most commonly recommended\u000a      measure. The Department of Health in England also mandated the use of the\u000a      AVVQ and all patients in England are now required to complete the AVVQ\u000a      before and after treatment. Results from these questionnaires are being\u000a      used by individual NHS providers to assess the quality of their care, to\u000a      improve their services, and for planning and commissioning of services\u000a      nationwide.\u000a    The claimed impact, as defined by REF guidance, therefore includes impact\u000a      upon public policy and services; practitioners and\u000a        professional services and health and welfare.\u000a    ","ImpactType":"Health","Institution":"\u000a    University of Aberdeen\u000a    ","Institutions":[{"AlternativeName":"Aberdeen (University of)","InstitutionName":"University of Aberdeen","PeerGroup":"B","Region":"Scotland","UKPRN":10007783}],"Panel":"A         ","PlaceName":[],"References":"\u000a    Research outputs\u000a    \u000a[1] Garratt AM, Macdonald LM, Ruta DA, Russell IT, Buckingham JK,\u000a      Krukowski ZH. Towards measurement of outcome for patients with\u000a        varicose veins. Qual Health Care. 1993 Mar; 2(1):5-10.\u000a    \u000aThis paper describes the development and validation of the original\u000a        Aberdeen Varicose Vein measure. The measure remains the accepted\u000a        standard in patient-reported measurement of varicose veins. (Cited 160\u000a        times as at 12\/8\/13, Google Scholar)\u000a    \u000a[2] Garratt AM, Ruta DA, Abdalla MI, Russell IT. Responsiveness of\u000a      the SF-36 and a condition-specific measure of health for patients with\u000a      varicose veins. Qual Life Res. 1996 Apr; 5(2):223-34\u000a    \u000aThis paper describes further research undertaken around the properties\u000a        of the AVVQ showing that it was more responsive to changes in patient\u000a        condition compared with the widely used generic measure of quality of\u000a        life &#8212; the SF36 measure. It also showed that the measure could easily be\u000a        used and adopted in routine health care. (Cited 80 times as at 12\/8\/13,\u000a        Google Scholar)\u000a    \u000a[3] Evaluating and improving health-related quality of life in\u000a        patients with varicose veins. Smith JJ, Garratt AM, Guest M,\u000a      Greenhalgh RM, Davies AH J Vasc Surg 1999; 30:710-719\u000a    \u000aThis paper describes the external testing of the AVVQ by a different\u000a        research group which confirmed the AVVQ to be a valid and specific\u000a        measure of varicose vein quality of life. (Cited 147 times as at\u000a        12\/8\/13, Google Scholar).\u000a    Key grant funding associated with the research\u000a    The development of the AVVQ was supported by a Chief Scientist Office,\u000a      Scottish Government competitively awarded grant:\u000a    Grampian Health Outcomes Study. Chief Scientist Office, March 1991\u000a      to Feb 1994, &#163;70,000\u000a    The wider methodology and outcomes development work was also supported by\u000a      a further grant from the Kings Fund:\u000a    Grampian Health Outcomes Study 2: implementing a package of outcome\u000a        measures in a service setting, Kings Fund Centre for Health Service\u000a      Development, October 1992 to Sept 1993, &#163;30,000\u000a    Both the research outputs and research grant award underwent rigorous\u000a      independent external peer review by the funding bodies.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [a] Klem TM, Sybrandy JE, Wittens CH. Measurement of health-related\u000a      quality of life with the Dutch translated Aberdeen Varicose Vein\u000a      Questionnaire before and after treatment. Eur J Vasc Endovasc Surg. 2009\u000a      Apr;37(4):470-6\u000a    This paper describes the translation and validation of the AVVQ into\u000a        Dutch for use in the Netherlands and other Dutch speaking contexts.\u000a    [b] Leal, Fl&#225;via de Jesus et al. Translation and cultural adaptation of\u000a      Aberdeen Varicose Veins Questionnaire (Tradu&#231;&#227;o e adapta&#231;&#227;o cultural do\u000a      Question&#225;rio Aberdeen para veias varicosas).  J. vasc. bras. 2012,\u000a      11, 34-42.\u000a    This paper describes the translation and validation of the AVVQ into\u000a        Portuguese for use in Brazilian populations.\u000a    [c] DGloviczki P, Comerota, Dalsing MC. The care of patients with\u000a      varicose veins and associated chronic venous diseases: Clinical practice\u000a      guidelines of the Society for Vascular Surgery and the American Venous\u000a      Forum. Journal of Vascular Surgery,53, 2S-48S, 2011\u000a    This paper describes the Society for Vascular Surgery and the American\u000a        Venous Forum guidelines on the management of varicose veins, and\u000a        identifies the importance of patient reported measures including the\u000a        AVVQ.\u000a    [d] NICE. Varicose veins in the leg: the diagnosis and management of\u000a      varicose veins. Clinical guidelines, methods and recommendations. July\u000a      2013.http:\/\/www.nice.org.uk\/nicemedia\/live\/\u000a        14226\/64567\/64567.pdf\u000a    This NICE guidance on the diagnosis and management of varicose veins\u000a        highlights the importance of quality of life measures including as the\u000a        AVVQ in the assessment of the effectiveness of different treatment\u000a        options.\u000a    [e] Department of Health (2008). High Quality Care For All. NHS Next\u000a      Stage Review Final Report.\u000a    This is Lord Darzi's report which was presented to Parliament and\u000a        which recommended the use of patient reported outcomes in the NHS for\u000a        specific treatments including varicose vein surgery.\u000a    [f] DH (2008). Guidance on the routine collection of Patient Reported\u000a      Outcome Measures (PROMs).\u000a    This document outlined the formal guidance from the Department of\u000a        Health on how patient reported measures should be collected by NHS\u000a        providers in England (in response to the Darzi report above) and\u000a        mandates the use of the AVVQ for the disease-specific measurement of\u000a        varicose vein surgery.\u000a    [g] NHS Information Centre. http:\/\/www.ic.nhs.uk\/proms\u000a    This is the website of the NHS Information Centre which collates all\u000a        the PROM data and produces reports of the service quality based on the\u000a        PROMs. The AVVQ data is presented in the reports related to varicose\u000a        vein surgery which are used by NHS providers for service planning.\u000a    [h] Nesbitt C, Wilson WR, Lees TA, Stansby G Interpretation of\u000a      patient-reported outcome measures for varicose vein surgery. Phlebology,\u000a      2012:27:173-8\u000a    This paper is one of the first analyses of the PROMs data to interpret\u000a        the quality of venous treatment in the UK.\u000a    ","Title":"\u000a    Development of an international standard measure for the reporting of\u000a        patients' assessment of their varicose veins\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    In the 1990s, a key strand of research at the University of Aberdeen's\u000a      Health Services Research Unit was the development, validation and\u000a      implementation of patient reported outcome measures &#8212; these are measures\u000a      by which patients rate their own health. This involved a rigorous\u000a      programme of research which incorporated state-of-the-art questionnaire\u000a      development and validation methods including health economic approaches.\u000a      The research led to the development of a suite of measures tailored to the\u000a      specific needs of patients with differing health conditions including the\u000a      development of measures for varicose veins, low back pain and dyspepsia.\u000a    One of the primary outcome measures developed and validated at that time\u000a      was the AVVQ (Aberdeen Varicose Vein Questionnaire) &#8212; a 13-item measure\u000a      which allowed patients to self-assess all aspects of their varicose veins\u000a      including physical symptoms such as pain, ankle oedema, ulcers, the effect\u000a      on daily activities, and cosmetic issues.\u000a    The researchers involved in the development and validation of the AVVQ\u000a      were:\u000a    \u000a      Andrew Garratt (Research Fellow, HSRU &amp; Dept of Public Health,\u000a        University of Aberdeen)\u000a      Danny Ruta (Lecturer, Dept of Public Health, University of Aberdeen)\u000a      Ian Russell (Director, HSRU, University of Aberdeen)\u000a      Ken Buckingham (Research Fellow HSRU, University of Aberdeen)\u000a      Mona Abdalla (Research Fellow HSRU, University of Aberdeen)\u000a      Clinical expertise was led by Zygmunt Krukowski, Consultant Surgeon,\u000a        Aberdeen Royal Infirmary (now honorary chair, University of Aberdeen)\u000a        and Lesley MacDonald, Department of Public Health Medicine, Grampian\u000a        Health Board (the local health board).\u000a    \u000a    The final validated version of the AVVQ was published in 1993 [1],\u000a      followed by further research exploring its properties in the clinical\u000a      setting, published in 1996 [2].\u000a    The AVVQ has also been subjected to external assessments of validity by\u000a      other groups [3] which have further confirmed the AVVQ to be a valid and\u000a      specific measure of varicose vein quality of life.\u000a    "},{"CaseStudyId":"43269","Continent":[],"Country":[],"Funders":["Economic and Social Research Council"],"ImpactDetails":"\u000a    Initial impact occurred when the randomised trial ended in 2005. The\u000a      study led to a direct change\u000a      in the Scottish Dental Contract in Nov 2005 with a new fee-for-service for\u000a      preventative sealant\u000a      application on child molars introduced. The revised contract stated...\u000a    \"5.2 Fissure Sealants\u000a    Lewis Macdonald, Deputy Minister for Health's, letter of 29 November\u000a      advised that, from 1 April\u000a      2006, a new item of service fee would be introduced for the application of\u000a      fissure sealants as a\u000a      primary preventive measure to pits and fissures in each permanent molar\u000a      tooth.\" [a]\u000a    Since its introduction, over 37,000 children per year in Scotland have\u000a      received fissure sealants.\u000a      This is double the number of children receiving sealants compared to\u000a      before the policy change and\u000a      equates to some 150,000 children receiving the sealants from January 2008\u000a      [b,c]\u000a    From 2008, guidance documents from the NHS Department of Health (England\u000a      and Wales) [d] and\u000a      the Scottish Dental Clinical Effectiveness Programme [e] have recommended\u000a      placement of fissure\u000a      sealants on children above 11-years-old. These guidance documents are\u000a      provided to some\u000a      10,000 dentists throughout the UK.\u000a    This work was also pivotal to demonstrating that a significant gap exists\u000a      between known evidence-based\u000a      practice and the implementation of that practice in dental primary care.\u000a      In November 2008,\u000a      it led to the setting up of an innovative programmatic approach to\u000a      knowledge translation research\u000a      in Scottish Dentistry (led jointly by Craig Ramsay, HSRU as principal\u000a      investigator for methodology,\u000a      and the Scottish Dental Clinical Effectiveness Programme) that informs\u000a      some 1000 dental services\u000a      practitioners, policy makers and patients on how best to translate\u000a      national recommendations into\u000a      routine clinical activities. The initial randomised study now provides an\u000a      exemplar for how\u000a      translational research in a dental setting can be performed and forms part\u000a      of the protocol [f] for the\u000a      Translation Research in a Dental Setting (TRiaDS) initiative (http:\/\/www.sdpbrn.org.uk\/index.aspx?o=2688). As\u000a      well as influencing practitioner services the TRiaDS programme impacts\u000a      on the broader research community through knowledge transfer initiatives\u000a      such as running national\u000a      conferences (http:\/\/www.sdpbrn.org.uk\/index.aspx?o=3113).\u000a    The claimed impact, as defined by REF guidance, is therefore on public\u000a        policy and services;\u000a      practitioners and professional services; society and economically.\u000a    ","ImpactSummary":"\u000a    University of Aberdeen research directly led to a change in the Scottish\u000a      Dental Contract which has\u000a      doubled the number of children receiving fissure sealants. The University\u000a      of Aberdeen's Health\u000a      Services Research Unit (HSRU) conducted a randomised trial looking at the\u000a      effectiveness of a\u000a      strategy to improve adoption of fissure sealants &#8212; known to reduce decay\u000a      in children's teeth but\u000a      which were rarely administered. The trial examined a fee-for-service\u000a      intervention in primary dental\u000a      care where each dentist received &#163;6.80 per tooth sealed. It demonstrated\u000a      that fee payment was\u000a      associated with an increase in fissure sealant placement in dental primary\u000a      care. This led to a\u000a      change in the Scottish Dental Contract which now includes a\u000a      fee-for-service for the placement in\u000a      fissure sealants in children over 11 years old. From 2008, guidance\u000a      documents from the NHS\u000a      Department of Health and the Scottish Dental Clinical Effectiveness\u000a      Programme have\u000a      recommended placement of fissure sealants on children above 11-years-old.\u000a      These guidance\u000a      documents are provided to some 10,000 dentists throughout the UK. Since\u000a      the introduction of the\u000a      fee, over 37,000 children per year in Scotland have received fissure\u000a      sealants. This is double the\u000a      number of children receiving sealants compared to before the policy change\u000a      and equates to some\u000a      150,000 children receiving the sealants since January 2008.\u000a    The claimed impact, as defined by REF guidance, is therefore on public\u000a        policy and services;\u000a      practitioners and professional services; society and economically.\u000a    ","ImpactType":"Political","Institution":"\u000a    University of Aberdeen\u000a    ","Institutions":[{"AlternativeName":"Aberdeen (University of)","InstitutionName":"University of Aberdeen","PeerGroup":"B","Region":"Scotland","UKPRN":10007783}],"Panel":"A         ","PlaceName":[],"References":"\u000a    Research outputs\u000a    \u000a[1] Grimshaw JM, Thomas RE, MacLennan GS, Fraser C, Ramsay CR, Vale L,\u000a      Whitty P, Eccles\u000a      MP, Matowe L, Shirran L, Wensing M, Dijkstra R, Donaldson C. (2004).\u000a      Effectiveness and\u000a      efficiency of guideline dissemination and implementation strategies. Health\u000a        Technol Assess\u000a      8(6):1-72.\u000a      This research, led from the University of Aberdeen's HSRU was, and\u000a        continues to be, the\u000a        most comprehensive review of guideline dissemination and implementation\u000a        strategies ever\u000a        undertaken and has been cited 1743 times, Google Scholar at 12\/8\/13. It\u000a        underpinned the\u000a        choice of implementation strategy for the ERUPT trial.\u000a    \u000a\u000a[2] Campbell MK, Mollison JM, Grimshaw JM (2001). Cluster trials in\u000a      implementation research:\u000a      estimation of intracluster correlation coefficients and sample size. Statistics\u000a        in Medicine\u000a      2001; 20: 391-399.\u000a      This paper is an example of the methodological advances being developed\u000a        by HSRU\u000a        researchers at the time in the field of implementation research, around\u000a        the development of\u000a        cluster trial methods in the field. The developments in this paper\u000a        informed the design of the\u000a        ERUPT trial discussed in this case study.\u000a    \u000a\u000a[3] Clarkson JE, Turner S, Grimshaw JM, Ramsay CR, Johnston M, Scott A,\u000a      Bonetti D, Tilley\u000a      CJ, Maclennan G, Ibbetson R, MacPherson L, Pitts NB. (2008). Changing\u000a      clinicians'\u000a      behavior: a randomized controlled trial of fees and education. J Dent\u000a        Res; 87(7):640-4.\u000a      This paper reports the ERUPT trial referred to in this case study. It\u000a        continues to be the\u000a        largest trial ever undertaken of a fee-for-service intervention in\u000a        primary dental care.\u000a    \u000aKey grant funding associated with the research\u000a    The project was conducted by a Chief Scientist Office (Scottish\u000a      Government) grant led by Jan\u000a      Clarkson of the University of Dundee as clinical lead with Craig Ramsay\u000a      (HSRU, University of\u000a      Aberdeen) as methodological lead. Details shown below:\u000a    Title: The effect of remuneration and education on the implementation\u000a        of research evidence to\u000a        reduce inequalities in oral health. Chief Scientist Office, Dec 2001\u000a      to Nov 2005, &#163;382,473.\u000a    The research outputs and research grant award underwent rigorous\u000a      independent external peer\u000a      review by the funding bodies.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"5","Subject":"Dentistry"}],"Sources":"\u000a    [a] Amendments to the statement of dental remuneration. Scottish\u000a        Executive Health\u000a        Department, 2006.\u000a      http:\/\/www.google.com\/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;cad=rja&amp;ved=0CCoQFjAA&amp;url=http%3A%2F%2Fwww.scottishdental.org%2Findex.aspx%3Fo%3D1495&amp;ei=7u9GUs65IKWy7Aa16IC4Aw&amp;usg=AFQjCNH9VwiBWn0e-Ka8cvt31_DjX0q9Ww&amp;bvm=bv.53217764,d.ZGU\u000a      This reference highlights the change in the Dental Contract to account\u000a        for remuneration of fissure\u000a        sealants on child molars.\u000a    [b] National Dental Inspection Programme of Scotland. Scottish Dental\u000a        Epidemiology Co-ordinating\u000a        Committee, 2005.\u000a      http:\/\/www.scottishdental.org\/index.aspx?o=2153&amp;record=73\u000a      Data on fissure sealant use are collected and reported at a national\u000a        level on an annual basis. This\u000a        report details the level of sealant use prior to 2005.\u000a    [c] National Dental Inspection Programme of Scotland. Scottish Dental\u000a        Epidemiology Co-ordinating\u000a        Committee, 2011.\u000a      http:\/\/www.isdscotland.org\/Health-Topics\/Dental-Care\/Publications\/2011-11-29\/2011-11-29-NDIP-Report.pdf\u000a      As with reference [b] above this report details the increased level of\u000a        fissure sealant use in 2011.\u000a    [d] NHS Department of Health. Delivering Better Oral Health: An\u000a      evidence-based toolkit for\u000a      prevention, April 2009.\u000a      http:\/\/www.google.com\/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;cad=rja&amp;ved=0CCoQFjAA&amp;url=http%3A%2F%2Fwww.oralhealthplatform.eu%2Fsites%2Fdefault%2Ffiles%2Ffield%2Fdocument%2FNHS_Delivering%2520Better%2520Oral%2520health.pdf&amp;ei=mPFGUvLZHMee7AaPsYGYDw&amp;usg=AFQjCNFOePeTk5uyxKOs84dHBpLyEQ9Enw&amp;bvm=bv.53217764,d.ZGU\u000a      This guidance document demonstrates that fissure sealant replacement in\u000a        11 years olds was being\u000a        recommended as optimal practice for dentists in England and Wales.\u000a    [e] Scottish Dental Clinical Effectiveness Programme. Prevention and\u000a      management of dental\u000a      caries in children, April 2010.\u000a      http:\/\/www.sdcep.org.uk\/index.aspx?o=2866\u000a      Similar to reference [d] above, this guidance document demonstrates\u000a        that fissure sealant\u000a        replacement in 11 years olds was being recommended as optimal practice\u000a        for dentists in Scotland.\u000a    [f] Clarkson JE, Ramsay CR, Eccles MP, et al. (2010). The\u000a      translation research in a dental\u000a      setting (TRiaDS) programme protocol. Implementation Science; 5:\u000a      57.\u000a      http:\/\/www.implementationscience.com\/content\/pdf\/1748-5908-5-57.pdf\u000a      This paper describes the TRiaDS programme and references the ERUPT\u000a        study as an exemplar of\u000a        a rigorous implementation study in dentistry.\u000a    [g] Testimonial from Postgraduate Dental Dean for Scotland\u000a      Letter from Postgraduate Dental Dean for Scotland (till 2011),\u000a        confirming the ERUPT trial directly\u000a        contributed to the decision to change in remuneration for dentists in\u000a        Scotland in respect of\u000a        placement of preventative fissure sealants and the impact it has had on\u000a        the thousands of children\u000a        who have now benefited from this policy.\u000a    ","Title":"\u000a    Aberdeen research prompts change in dental policy benefiting\u000a        thousands of Scottish children\u000a    ","UKLocation":[{"GeoNamesId":"2657832","Name":"Aberdeen"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"},{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"2634895","Name":"Wales"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    In the 1990s, a key focus of research at the University of Aberdeen's\u000a      HSRU was the development\u000a      of strategies to improve the implementation of research findings. Through\u000a      its Aberdeen Centre for\u000a      Implementation Research it provided international guidance on which\u000a      strategies were most\u000a      effective for improving implementation of research findings [1]. It also\u000a      undertook research into\u000a      specific trial methodology (especially cluster randomised trials) and\u000a      methods for designing and\u000a      conducting innovative national evaluations [2]. With this strong\u000a      reputation for innovation, clinical\u000a      collaborators routinely approached HSRU with possible clinical questions\u000a      and HSRU led the\u000a      translation into robust study designs. This trial related to dental\u000a      fissure sealants placement is one\u000a      such example of this practice.\u000a    Dental decay is very common in childhood. By age 15, 50% of UK children\u000a      have experienced\u000a      decay in their first permanent molars. Dental decay is closely linked to\u000a      social deprivation and, in\u000a      Scotland, 69% of five year olds in the least affluent areas have caries.\u000a      Methods of prevention are\u000a      well-known and placement of fissure sealants has been shown to reduce\u000a      decay in children's teeth\u000a      by up to 86% at 12 months. Adoption in Scotland was poor, however, with\u000a      only 15% of 11-year-olds\u000a      having any first molars sealed prior to 2005.\u000a    Reasons suggested for the poor adoption of the sealant method by dentists\u000a      included lack of\u000a      financial reimbursement for placing sealants on children over 11-years-old\u000a      and dentists' lack of\u000a      knowledge of the evidence base for the treatments in older children. To\u000a      address this adoption\u000a      problem, methodologists at the University of Aberdeen's HSRU worked with\u000a      clinical colleagues at\u000a      the University of Dundee, to design a national cluster randomised trial\u000a      (the ERUPT trial) to test\u000a      these implementation strategies. Aberdeen researchers led on the design\u000a      and implementation of\u000a      the trial interventions (HSRU researchers were the recognised\u000a      international experts in\u000a      implementation research interventions and had developed the evidence base\u000a      [1]) and on the\u000a      design and analysis of the trial (HSRU researchers were also the\u000a      international experts in cluster\u000a      trial methodology [2]).\u000a    University of Aberdeen researchers engaged directly in the ERUPT trial\u000a      were:\u000a    \u000a      Craig Ramsay, Senior Statistician, Aberdeen Centre for Implementation\u000a        Research\u000a      Jeremy Grimshaw, Director, Aberdeen Centre for Implementation Research\u000a      Graeme MacLennan, Statistician, HSRU,\u000a        together with clinical input from Jan Clarkson and Nigel Pitts, Dental\u000a        Health Services Research\u000a        Unit, Dundee.\u000a    \u000a    Additional University of Aberdeen researchers who were integral to the\u000a      development of the\u000a      evidence base and the cluster trial methodology underpinning the ERUPT\u000a      trial were:\u000a    \u000a      Ruth Thomas, Research Assistant, HSRU (implementation evidence base)\u000a      Liz Shirran, Research Assistant, HSRU (implementation evidence base)\u000a      Marion Campbell, Senior Statistician, HSRU (methodology of cluster\u000a        trials for implementation\u000a        research)\u000a      Jill Mollison, Statistician, Department of Public Health (methodology\u000a        of cluster trials for\u000a        implementation research)\u000a    \u000a    The ERUPT trial [3] was completed in 2005 and continues to be the largest\u000a      randomised trial\u000a      internationally of a fee-for-service intervention in primary dental care.\u000a      Some 140 dentists and 2833\u000a      high risk of caries children were randomised for the dentists to receive\u000a      either a fee for fissure\u000a      sealant placement (each dentist received &#163;6.80 per tooth sealed) or\u000a      training in evidence-based\u000a      practice. The trial demonstrated that placement of fissure sealants\u000a      increased by 10% (when a\u000a      small fee-for-service was offered). There was no effect of the education\u000a      intervention. The\u000a      economic evaluation conducted as part of the study clearly demonstrated\u000a      that the fee-for-service\u000a      was a cost-effective intervention.\u000a    At the completion of the trial in 2005, a dissemination conference was\u000a      organised by the trial team\u000a      to which service providers, national decision makers (such as the British\u000a      Dental Association) and\u000a      policy-makers including the Deputy Chief Dental Officer who was\u000a      responsible for recommending\u000a      any changes to the Scottish Dental Contract were invited. After the\u000a      conference, the Deputy Chief\u000a      Dental Officer recommended a change to the contract informed by the\u000a      findings of the trial. The\u000a      Scottish Dental Contract was amended in Nov 2005 to include a\u000a      fee-for-service for the placement\u000a      of fissure sealants in children over 11-years-old.\u000a    From 2008, guidance documents from the NHS Department of Health (England)\u000a      and the Scottish\u000a      Dental Clinical Effectiveness Programme have recommended placement of\u000a      fissure sealants on\u000a      children above 11-years-old. These guidance documents are provided to some\u000a      10,000 dentists\u000a      throughout the UK.\u000a    "},{"CaseStudyId":"43270","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Wellcome Trust"],"ImpactDetails":"\u000d\u000a    The results of this research programme have demonstrated that, in younger\u000d\u000a      women undergoing\u000d\u000a      IVF replacing one embryo at a time (ie. eSET), results in livebirth rates\u000d\u000a      are comparable to the usual\u000d\u000a      policy of double embryo transfer. This research also established that eSET\u000d\u000a      leads to higher rates of\u000d\u000a      term singleton liveborn babies i.e. healthy babies in comparison with\u000d\u000a      double embryo transfer.\u000d\u000a    The Aberdeen research group's Cochrane systematic review [2] and\u000d\u000a      subsequent print publication\u000d\u000a      [3] was influential in informing policy within the United Kingdom, where\u000d\u000a      the Human Fertilisation and\u000d\u000a      Embryology Authority (HFEA) &#8212; the IVF regulatory body for the UK &#8212; set up\u000d\u000a      an expert group to\u000d\u000a      advise on Multiple Births after IVF. This Group referenced the Aberdeen\u000d\u000a      review in its\u000d\u000a      recommendation, which advised eSET (with transfer of a second frozen\u000d\u000a      embryo) and set targets\u000d\u000a      for twin rates after IVF [a]. This resulted in an increase in the uptake\u000d\u000a      of eSET from 4.8% in 2008 to\u000d\u000a      14.7% in 2010 and a corresponding decrease in multiple pregnancy rates\u000d\u000a      [b]. The implementation\u000d\u000a      of eSET has been particularly noticeable in younger women who have the\u000d\u000a      best chance of\u000d\u000a      achieving a livebirth, but the overall success rate has not been affected\u000d\u000a      as a consequence of this\u000d\u000a      policy.\u000d\u000a    Although the results of the initial Cochrane systematic review led to a\u000d\u000a      degree of change in the IVF\u000d\u000a      sector, many practitioners remained unconvinced until the publication of\u000d\u000a      the individual patient data\u000d\u000a      meta-analysis of all relevant randomised trials [4]. This meta-analysis\u000d\u000a      showed that eSET in a fresh\u000d\u000a      IVF treatment cycle (without an additional frozen embryo replacement)\u000d\u000a      resulted in a higher chance\u000d\u000a      of a single healthy baby (live baby born at full term). This work was\u000d\u000a      widely publicised by the\u000d\u000a      national and international media, the NHS and the global professional\u000d\u000a      organisation for\u000d\u000a      Obstetricians and Gynaecologists [c,d,e] and highlighted by the HFEA on\u000d\u000a      its website [a]. It was\u000d\u000a      also promoted by the \"One at a time\" website &#8212; a professionally-led\u000d\u000a      website in the UK aimed at\u000d\u000a      reducing the risks of multiple pregnancies associated with fertility\u000d\u000a      treatment. This meta-analysis\u000d\u000a      was also cited in the updated NICE guideline [f] on infertility published\u000d\u000a      in 2013 as clear evidence of\u000d\u000a      the benefit of eSET to mothers and their babies. Along with the paper from\u000d\u000a      the Aberdeen group\u000d\u000a      on the cost effectiveness of alternative embryo transfer strategies (eSET\u000d\u000a      versus DET) in IVF in\u000d\u000a      women of different ages, it also served to inform NICE guidance on\u000d\u000a      selective use of eSET in\u000d\u000a      women of different ages [f]. In the UK, the impact of the research\u000d\u000a      directly and indirectly through\u000d\u000a      HFEA recommendations is evident from national data published by HFEA [b].\u000d\u000a      Between 2008 and\u000d\u000a      2011, HFEA data show that rates of eSET have increased from 4% to 18% (25%\u000d\u000a      in women aged\u000d\u000a      18-34 years) in all IVF cycles in the UK and twin rates have fallen from\u000d\u000a      27% to just under 20%\u000d\u000a      [a,b]. There is no evidence of any compromise in livebirth rates per IVF\u000d\u000a      treatment in the UK over\u000d\u000a      this period with perhaps even a modest increase from 26% to 32%.\u000d\u000a    Results of the Aberdeen research group's individual patient data\u000d\u000a      meta-analysis on eSET, which\u000d\u000a      included data from over 1300 women, has also informed clinical guidelines\u000d\u000a      on IVF embryo transfer\u000d\u000a      policies internationally in countries such as Canada and South Africa\u000d\u000a      [g,h]. Most recently, the\u000d\u000a      United States, which has also used our research as evidence to inform its\u000d\u000a      eSET policy [i] has also\u000d\u000a      witnessed an increase in eSET in women under 35 years of age &#8212; from 4.5%\u000d\u000a      in 2007 to 11.75% in\u000d\u000a      2011 [j].\u000d\u000a    In summary, the initial impact in the UK occurred just after the Cochrane\u000d\u000a      review and received a\u000d\u000a      further boost after the publication of the IPD meta-analysis and health\u000d\u000a      economic papers prompting\u000d\u000a      policy changes within the regulators, HFEA, [a] and NICE [f]. Countries\u000d\u000a      more initially resistant to\u000d\u000a      eSET (Canada, South Africa and USA) have now developed guidance [g,h,i]\u000d\u000a      and have cited the\u000d\u000a      Aberdeen work. The effects of these more recent changes on international\u000d\u000a      guidance on eSET are\u000d\u000a      already apparent with evidence continuing to accrue.\u000d\u000a    The claimed impact as defined by REF guidance is, therefore on public\u000d\u000a        policy and services;\u000d\u000a        practitioners and professional services and health and welfare\u000d\u000a      in the UK and internationally.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Multiple births following in-vitro fertilisation (IVF) treatment\u000d\u000a      leads to serious health risks in the\u000d\u000a      mother and offspring. It is caused by replacing multiple embryos within\u000d\u000a      the uterus. Concerns\u000d\u000a      about reduced success rates have deterred patients and practitioners from\u000d\u000a      transplanting a single\u000d\u000a      embryo. A programme of research led from the University of Aberdeen\u000d\u000a      established that a policy of\u000d\u000a      replacing one embryo at a time minimises the risk of twins without\u000d\u000a      compromising livebirth rates.\u000d\u000a      This work has received international media coverage, influenced clinical\u000d\u000a      guidance and resulted in\u000d\u000a      an increased uptake of single embryo transfer in the United Kingdom and\u000d\u000a      beyond.\u000d\u000a    The claimed impact, as defined by REF guidance, is therefore on public\u000d\u000a        policy and services;\u000d\u000a        practitioners and professional services and health and welfare.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of Aberdeen\u000d\u000a    ","Institutions":[{"AlternativeName":"Aberdeen (University of)","InstitutionName":"University of Aberdeen","PeerGroup":"B","Region":"Scotland","UKPRN":10007783}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Porter M, Bhattacharya S. Investigation of staff and patients'\u000d\u000a      opinions of a proposed trial of\u000d\u000a      elective single embryo transfer. Human Reproduction (2005); 20(9): 2523 -\u000d\u000a      2530.\u000d\u000a      Paper by two Aberdeen researchers exploring attitudes to single embryo\u000d\u000a        transfer and levels of\u000d\u000a        equipoise as regards a proposed randomised trial of this policy versus\u000d\u000a        double embryo transfer\u000d\u000a        in IVF.\u000d\u000a    \u000a\u000a[2] Pandian Z, Bhattacharya S, Ozturk O, Serour GI, Templeton A. Number\u000d\u000a        of embryos for\u000d\u000a        transfer following in-vitro fertilisation or intra-cytoplasmic sperm\u000d\u000a        injection. Cochrane Database\u000d\u000a      Syst Rev. 2004 Oct 18;(4):CD003416.\u000d\u000a      Initial Cochrane review of aggregated data from published trials\u000d\u000a        showing significantly lower twin\u000d\u000a        rate but also reduced livebirth rate after eSET. First, second, third\u000d\u000a        and last author are from\u000d\u000a        Aberdeen. (Cited 103 times, Google Scholar at 12\/8\/13).\u000d\u000a    \u000a\u000a[3] Pandian Z, Templeton A, Serour G, Bhattacharya, S. Number of embryos\u000d\u000a      for transfer after in-\u000d\u000a      vitro fertilisation and intra-cytoplasmic sperm injection: a systematic\u000d\u000a      review. Human\u000d\u000a      Reproduction (2005); 20 910): 2681 - 2687.\u000d\u000a      Paper publication based on updated Cochrane review by the same group of\u000d\u000a        authors, which\u000d\u000a        included a new trial showing that cumulative live birth rates following\u000d\u000a        fresh + frozen single\u000d\u000a        embryo transfer are similar to those after double embryo transfer.\u000d\u000a        (Cited 127 times, Google\u000d\u000a        Scholar at 12\/8\/13)\u000d\u000a    \u000a\u000a[4] McLernon DJ, Harrild K, Bergh C, Davies MJ, de Neubourg D, Dumoulin\u000d\u000a      JCM, Gerris J,\u000d\u000a      Kremer JAM, Martikainen H, Mol BW, Norman RJ, Thurin-Kjellberg A, Tiitinen\u000d\u000a      A, van Montfoort\u000d\u000a      APA, van Peperstraten AM, van Royen E, Bhattacharya S. Clinical\u000d\u000a      effectiveness of elective\u000d\u000a      single versus double embryo transfer: meta-analysis of individual patient\u000d\u000a      data from randomised\u000d\u000a      trials. BMJ. 2010;341:c6945.\u000d\u000a      Most comprehensive systematic review undertaken in the field to date.\u000d\u000a        The review included\u000d\u000a        individual data meta-analysis based on all published and unpublished\u000d\u000a        randomised trials. It\u000d\u000a        showed that eSET led to a fivefold increase in the odds of having a\u000d\u000a        single baby born at term.\u000d\u000a        The first and last authors from Aberdeen; the secretariat for handling\u000d\u000a        all data was based in\u000d\u000a        Aberdeen; and all methodological work was undertaken in Aberdeen. The\u000d\u000a        results were widely\u000d\u000a        publicised by the media \/professional organisations and were influential\u000d\u000a        in converting increased\u000d\u000a        numbers of stakeholders to eSET. (Cited 67 times, Google Scholar\u000d\u000a        at 12\/8\/13)\u000d\u000a    \u000a\u000a[5] Scotland G, McLernon D, Kurinczuk J, McNamee P, Harrild K, Lyall H,\u000d\u000a      Rajkhowa M, Hamilton\u000d\u000a      M, Bhattacharya S. Minimising twins in in-vitro fertilisation: a modelling\u000d\u000a      study assessing the\u000d\u000a      costs, consequences and cost-utility of elective single versus double\u000d\u000a      embryo transfer over a\u000d\u000a      20-year time horizon. BJOG. 2011; 118(9):1073-1083.\u000d\u000a      Study using Scottish IVF data to model cost effectiveness of single and\u000d\u000a        double embryo transfer\u000d\u000a        policies. First, second and last author (CI) were from Aberdeen, where\u000d\u000a        all the analysis and\u000d\u000a        methodological work was done. This was the first study to investigate\u000d\u000a        fertility outcomes in\u000d\u000a        different age groups of women in terms of QALYs. The study was quoted by\u000d\u000a        NICE in its fertility\u000d\u000a        guideline in the context of recommendations on number of embryos to\u000d\u000a        transfer in IVF.\u000d\u000a    \u000a\u000a[6] Maheshwari A, Griffiths S, Bhattacharya S. Global variations in the\u000d\u000a      update of single embryo\u000d\u000a      transfer. Human Reproduction Update. 2010; 17(1):107-120.\u000d\u000a      All authors based in Aberdeen. First and only study to describe global\u000d\u000a        uptake of eSET and\u000d\u000a        explored barriers to wider implementation of this strategy.\u000d\u000a    \u000aKey grant funding associated with the research (which all\u000d\u000a      underwent rigorous peer review):\u000d\u000a    &#8226; Effective treatment of Infertility. Research Leave Award. Bhattacharya\u000d\u000a      S. Wellcome Trust\u000d\u000a      (2002) &#163;775,757.\u000d\u000a    &#8226; ECOSSE: Efficacy and cost effectiveness of selective single embryo\u000d\u000a      transfer. Bhattacharya S,\u000d\u000a      Templeton A, Harrold, A, Lieberman B, Brison D, Gazvani R, Braude P.\u000d\u000a      Bertarelli Foundation.\u000d\u000a      CHF (2004) &#163;240,030.\u000d\u000a    &#8226; Clinical and Cost-Effectiveness of Elective Single Embryo versus Double\u000d\u000a      Embryo Transfer\u000d\u000a      Policy in Assisted Reproduction. Bhattacharya S, Scotland G, Harrild K,\u000d\u000a      Rajkhowa M, Harold\u000d\u000a      A, Lyall H. Chief Scientist Office for Scotland (2008-9) &#163;45,638.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"14","Subject":"Paediatrics and Reproductive Medicine"}],"Sources":"\u000d\u000a    [a] http:\/\/www.hfea.gov.uk\/6211.html\u000d\u000a      This is the Human Fertilisation Embryology Authority website which\u000d\u000a        highlights their expert\u000d\u000a        group on Multiple Births after IVF. This Group referenced the Aberdeen\u000d\u000a        review in their\u000d\u000a        recommendation, which advised elective single embryo transfer (with\u000d\u000a        transfer of a second\u000d\u000a        frozen embryo) and set targets for twin rates after IVF.\u000d\u000a    [b] http:\/\/www.hfea.gov.uk\/docs\/2011-12-01_-_Multiple_Births_Publication_2011_-_Rationalising_Register_Data_-_FINAL_1.2.DOC.pdf\u000d\u000a      This report shows the increase in the uptake of eSET from 4.8% in 2008\u000d\u000a        to 14.7% in 2010 and\u000d\u000a        the corresponding decrease in multiple pregnancy rates.\u000d\u000a\u0009\u0009The three references [c-e] below are examples of the extensive media\u000d\u000a        coverage of Aberdeen's\u000d\u000a        large individual data meta-analysis showing that single embryo transfer\u000d\u000a        led to a fivefold increase in\u000d\u000a        the odds of having a single baby born at term:\u000d\u000a    [c] http:\/\/www.guardian.co.uk\/society\/2010\/dec\/22\/ivf-researchers-single-embryo-treatment\u000d\u000a    [d] http:\/\/abcnews.go.com\/Health\/WomensHealth\/single-embryo-transfer-effective-safer-double-embryo-transfer\/story?id=12451473\u000d\u000a    [e] http:\/\/www.figo.org\/news\/single-embryo-transfer-ivf-increases-chance-delivering-full-term-baby-003151\u000d\u000a    [f] http:\/\/guidance.nice.org.uk\/CG156\/Guidance\u000d\u000a      This is the NICE guidance on the management of infertility, published\u000d\u000a        in 2013. It cites the\u000d\u000a        Aberdeen research as clear evidence of the benefit of eSET to mothers\u000d\u000a        and their babies.\u000d\u000a    [g] Min\u000d\u000a        JK, Hughes\u000d\u000a        E, Young\u000d\u000a        D, Gysler\u000d\u000a        M, Hemmings\u000d\u000a        R, Cheung\u000d\u000a        AP, Goodrow\u000d\u000a        GJ, Senikas\u000d\u000a        V,\u000d\u000a      Wong\u000d\u000a        BC, Sierra\u000d\u000a        S, Carranza-Mamane\u000d\u000a        B, Case\u000d\u000a        A, Dwyer\u000d\u000a        C, Graham\u000d\u000a        J, Havelock\u000d\u000a        J, Lee\u000d\u000a        F, Liu\u000d\u000a      , Vause\u000d\u000a        T; Joint\u000d\u000a        Society of Obstetricians and Gynaecologists of Canada-Canadian Fertility\u000d\u000a        and Andrology Society Clinical Practice Guidelines Committee.\u000d\u000a      Elective single embryo transfer\u000d\u000a      following in vitro fertilization. J\u000d\u000a        Obstet Gynaecol Can. 2010 Apr;32(4):363-77.\u000d\u000a      This summarises Canada's guidance on the management of infertility and\u000d\u000a        cites the Aberdeen\u000d\u000a        research as evidence of benefit of eSET.\u000d\u000a    [h] http:\/\/www.fertilitysa.org.za\/Guidelines\/ReproductiveMedicine\/SASREGEmbryoTransferRecommendations.asp\u000d\u000a      This summarises South Africa's guidance on the management of\u000d\u000a        infertility and cites the\u000d\u000a        Aberdeen research as evidence of benefit of eSET.\u000d\u000a    [i] Elective single embryo transfer. Practice Committee of the Society\u000d\u000a      for Assisted Reproduction\u000d\u000a      and Practice Committee of American Society for Reproductive Medicine.\u000d\u000a      Fertility and Sterility\u000d\u000a      2012; 97:835-42\u000d\u000a      This summarises the US guidance on the management of infertility and\u000d\u000a        cites the Aberdeen\u000d\u000a        research as evidence of benefit of eSET.\u000d\u000a    [j] http:\/\/www.sart.org\/frame\/detail.aspx?id=3893\u000d\u000a      This reports US registry data on eSET and shows an increase in eSET in\u000d\u000a        women under 35\u000d\u000a        years of age from 4.5% in 2007 to 11.75% in 2011.\u000d\u000a    ","Title":"\u000d\u000a    Making in-vitro fertilisation (IVF) safer: a\u000d\u000a        strategy of elective single\u000d\u000a        embryo transfer to minimise the risk of perinatal complications\u000d\u000a        associated with multiple\u000d\u000a        pregnancy\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2657832","Name":"Aberdeen"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Researchers from the University of Aberdeen have led a programme of\u000d\u000a      research on single embryo\u000d\u000a      transfer in IVF since 2002. The work has been led by Siladitya\u000d\u000a      Bhattacharya (Senior\u000d\u000a      Lecturer\/Professor from 2000) together with Zabeena Pandian (Research\u000d\u000a      Fellow, 2001-3), Allan\u000d\u000a      Templeton (Professor, 1985 - 2011), Graham Scotland (Senior Research\u000d\u000a      Fellow, 2004-date),\u000d\u000a      Abha Maheshwari (Clinical Senior Lecturer, 2010-13) and David McLernon\u000d\u000a      (Research Fellow,\u000d\u000a      2008-date). The research has been funded by Wellcome Trust and the Chief\u000d\u000a      Scientist Office for\u000d\u000a      Scotland. Initial work involved exploring patient and service providers'\u000d\u000a      views on risks of multiple\u000d\u000a      pregnancy in IVF and the level of equipoise regarding a strategy of\u000d\u000a      elective single (eSET) versus\u000d\u000a      double embryo transfer [1]. This was accompanied by a Cochrane review of\u000d\u000a      randomised trials of\u000d\u000a      eSET versus double embryo transfer in IVF [2] conducted by the Aberdeen\u000d\u000a      group and a widely\u000d\u000a      cited updated version of this review published in 2005 [3]. Pooled results\u000d\u000a      showed that multiple\u000d\u000a      pregnancy rates were significantly higher following transfer of two\u000d\u000a      embryos. Although double\u000d\u000a      embryo transfer led to a higher live birth rate in a single fresh IVF\u000d\u000a      treatment in a fresh IVF cycle,\u000d\u000a      comparable results were obtained by subsequent transfer of a frozen\u000d\u000a      embryo.\u000d\u000a    Dr McLernon and Professor Bhattacharya subsequently conducted an\u000d\u000a      individual patient data (IPD)\u000d\u000a      meta-analysis [4] of all randomised trials (including unpublished data\u000d\u000a      from two additional trials in\u000d\u000a      the United Kingdom and Australia). This individual patient meta-analysis\u000d\u000a      included data on more\u000d\u000a      than 1300 women. This study showed that eSET in a fresh IVF cycle (even\u000d\u000a      without the need for an\u000d\u000a      additional frozen embryo) resulted in a 5-fold increase in the odds of\u000d\u000a      having a healthy baby (i.e. a\u000d\u000a      singleton baby after 37 weeks) in comparison with double embryo transfer\u000d\u000a      (odds ratio 4.93, 95%\u000d\u000a      confidence intervals 2.98 to 8.18) [4].\u000d\u000a    Further research conducted by the Aberdeen researchers [5] used data from\u000d\u000a      Scottish IVF units to\u000d\u000a      model the cost effectiveness of eSET and double embryo transfer in women\u000d\u000a      of different age\u000d\u000a      groups with varying prognoses for livebirth. The results demonstrated that\u000d\u000a      eSET was particularly\u000d\u000a      useful in younger women but not in those who were older and\/or had a\u000d\u000a      poorer chance of achieving\u000d\u000a      pregnancy through IVF. Finally, a systematic review of worldwide\u000d\u000a      implementation of eSET\u000d\u000a      conducted by the Aberdeen researchers provided much needed data on why\u000d\u000a      certain countries\u000d\u000a      were able to use eSET successfully in order to reduce IVF risks without\u000d\u000a      compromising livebirth\u000d\u000a      rates [6] but not others. This study also identified the personal,\u000d\u000a      organisational and societal barriers\u000d\u000a      to the uptake of an eSET policy and provided information relevant to\u000d\u000a      patients, clinicians, regulators\u000d\u000a      and policy makers.\u000d\u000a    In summary, University of Aberdeen researchers led the first systematic\u000d\u000a      review and meta-analysis\u000d\u000a      of eSET versus double embryo transfer. They led the only individual\u000d\u000a      patient data meta-analysis\u000d\u000a      ever undertaken in this field. They were also the first and only group to\u000d\u000a      model the cost\u000d\u000a      effectiveness of an individualised age-based policy of eSET. Finally the\u000d\u000a      Aberdeen team have\u000d\u000a      explored factors affecting the global uptake of eSET &#8212; the output of which\u000d\u000a      has informed guideline\u000d\u000a      development groups in other countries.\u000d\u000a    "},{"CaseStudyId":"43271","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":[],"ImpactDetails":"\u000a    This University of Aberdeen research programme has had direct impact on\u000a      breastfeeding care worldwide.\u000a    In 1992 the children's charity UNICEF and the World Health Organization\u000a      (WHO) launched their worldwide Baby Friendly Hospital Initiative\u000a      [a]. The Initiative provided a framework for the implementation of\u000a      best practice by hospitals, other health-care facilities and higher\u000a      education institutions, with the aim of ensuring that all parents make\u000a      informed decisions about feeding their babies. Until 2012, best practice\u000a      was represented by UNICEFs evidence-based \"Ten Steps to Successful\u000a        Breastfeeding\". New standards were introduced in December 2012 which\u000a      adopt a more mother and parent centred approach. Hospitals can apply to be\u000a      a UNICEF \"Baby Friendly\" accredited hospital if they can show they\u000a      are implementing UNICEF guidance. Research has shown that implementation\u000a      of the Baby Friendly Hospital Initiative has led to increases in\u000a      breastfeeding rates and subsequent child health.\u000a    The results of the BIG trial directly influenced a change to Step 10 of\u000a      the UNICEF UK's Ten Step guidance. The 10 steps were the standard guidance\u000a      until December 2012, when new standards incorporating, updating and\u000a      expanding the 10 steps were published. Prior to the BIG trial results\u000a      being published, Step 10 read \"Step 10: Foster\u000a        the establishment of breastfeeding support groups and refer mothers to\u000a        them on discharge from the hospital or clinic.\" with the expectation\u000a      that hospitals routinely promote the establishment of breast feeding\u000a      support groups. Following publication of the BIG trial in 2009 which\u000a      showed no evidence that these peer-support groups improved breastfeeding\u000a      rates, Step 10 was reworded, after consultation with the trial team, to: \"Step\u000a          10 - Identify sources of national and local support for\u000a        breastfeeding and ensure that mothers know how to access these prior to\u000a        discharge from hospital\" thus removing the expectation that\u000a      hospitals should be routinely establishing these groups [b]. Clearly this\u000a      results in savings to national health services, as these groups are no\u000a      longer being routinely set up.\u000a    In the UK, the Baby Friendly Initiative also accredits maternity\u000a      and community facilities that adopt the UNICEF internationally recognised\u000a      standards. Hospitals undergo a structured assessment to attain the award\u000a      and achieve \"Baby Friendly\" accreditation if successful. The National\u000a      Institute of Health and Clinical Excellence (NICE) has, through its\u000a      guidance on standards of postnatal care in the UK, recommended that the Baby\u000a        Friendly Accreditation be the minimum standard for the care of all\u000a      mothers and babies [c]. Thus this research from the University of Aberdeen\u000a      has directly influenced the care of all new mothers and babies across the\u000a      UK.\u000a    In November 2011, the UNICEF UK Baby Friendly quality standards were\u000a      further revised both in the language used and their content (to reflect\u000a      more recent changes in evidence). Again, this revision drew directly on\u000a      the findings of this University of Aberdeen programme of research (in\u000a      particular, the in-depth qualitative study of disadvantaged families),\u000a      recommending a move away from a breastfeeding-centred towards a more\u000a      realistic woman, baby and family centred approach to feeding care [d]. In\u000a      particular, Standard 3 recommends a more mother and parent-centred\u000a      approach to discussing infant feeding antenatally, and references\u000a      Aberdeen's work as supporting evidence.\u000a    The Aberdeen research on coaching has also been integral to the policies\u000a      developed by the Baby Caf&#233; Charitable Trust. The Baby Caf&#233; Charitable\u000a      Trust is an independent charity dedicated to providing free, top-quality\u000a      support to breastfeeding mothers and runs a network of drop-in centres in\u000a      the UK and worldwide. There are currently 111 Baby Cafe centres in the UK\u000a      and a further 27 overseas (source: babycafe.org). Baby Caf&#233; drop-ins are\u000a      run by health professionals such as midwives, health visitors, or\u000a      lactation consultants and they also run so-called \"Baby Caf&#233; Local\"\u000a      drop-ins which are run by healthcare practitioners (e.g. maternity support\u000a      worker) or breastfeeding counsellors from voluntary breastfeeding\u000a      organisations. Help is available on all aspects of breastfeeding. Anyone\u000a      wishing to set up a Baby Caf&#233; drop-in centre must apply to be licensed by\u000a      the Charitable Trust and agree to run their drop-in centre according to\u000a      pre-specified procedures. These procedures are outlined in the Baby Caf&#233;\u000a      \"toolkit\". The Baby Caf&#233; Charitable Trust have sought to ensure that their\u000a      \"toolkit\" is evidence-based and have drawn on research to inform their\u000a      best practice. They explicitly reference the findings from the coaching\u000a      intervention and the BIG trial in their toolkit as providing evidence to\u000a      inform their procedures [e].\u000a    The claimed impact, as defined by REF guidance, is therefore on policy\u000a        and services; practitioners and professional services; society\u000a      and economically.\u000a    ","ImpactSummary":"\u000a    University of Aberdeen research has directly influenced worldwide\u000a      guidance for breastfeeding. A programme of research led by University\u000a      researchers set out to develop, design and evaluate interventions to\u000a      improve breastfeeding rates. Findings from the research directly led to a\u000a      change to UNICEF guidance on how to promote breastfeeding care. Hospitals\u000a      can apply to be UNICEF \"Baby Friendly\" accredited if they can demonstrate\u000a      implementation of the UNICEF guidance. The National Institute for Health\u000a      and Clinical Excellence has also indicated that all UK hospitals must\u000a      follow the UNICEF guidance. The research has also directly impacted on the\u000a      work of the Baby Caf&#233; Charitable Trust -a charity which runs accredited\u000a      drop-in centres to promote breastfeeding across in the UK and\u000a      internationally - with the findings from the Aberdeen research programme\u000a      directly influencing the Baby Caf&#233; \"toolkit\": the \"rule-book\" by which all\u000a      Baby Caf&#233; drop-in centres worldwide are run.\u000a    The claimed impact, as defined by REF guidance, is therefore on policy\u000a        and services; practitioners and professional services; society\u000a      and economically.\u000a    ","ImpactType":"Political","Institution":"\u000a    University of Aberdeen\u000a    ","Institutions":[{"AlternativeName":"Aberdeen (University of)","InstitutionName":"University of Aberdeen","PeerGroup":"B","Region":"Scotland","UKPRN":10007783}],"Panel":"A         ","PlaceName":[],"References":"\u000a    Research outputs:\u000a    \u000a[1] Hoddinott P, Chalmers M, Pill R. One-to-one or group based peer\u000a      support for breastfeeding? Women's perceptions of a breastfeeding peer\u000a      coaching intervention. Birth. 2006;33(2):139-146. (cited 26 times,\u000a      Google Scholar at 12\/8\/13)\u000a    \u000a\u000a[2] Hoddinott P, Lee AJ, Pill R. Effectiveness of a breastfeeding peer\u000a      coaching intervention on breastfeeding rates in rural Scotland. Birth.\u000a      2006;33(1):27-36. (cited 24 times, Google Scholar at 12\/8\/13)\u000a      These two papers describe the peer-support intervention study in rural\u000a        areas which concluded that group support for breastfeeding was likely to\u000a        be more acceptable to women than individual coaching. This study was\u000a        designed and led by Hoddinott from the University of Aberdeen. Lee is\u000a        also from the University of Aberdeen and led on the statistical\u000a        analysis.\u000a    \u000a\u000a[3] Hoddinott P, Britten J, Prescott G, Tappin D, Ludbrook A, Godden D.\u000a      Effectiveness of a policy to provide breastfeeding groups (BIG) for\u000a      pregnant and breastfeeding mothers in primary care. Brit Med J\u000a      2009;338:a3026. (cited 34 times, Google Scholar at 12\/8\/13)\u000a      This is the report of the breastfeeding groups trial (the BIG trial),\u000a        published in the British Medical Journal. It was the first and largest\u000a        cluster randomised trial in the field and was designed and led from the\u000a        University of Aberdeen (Hoddinott, Prescott, Ludbrook and Godden were\u000a        all University of Aberdeen researchers).\u000a    \u000a\u000a[4] Hoddinott P, Britten J, Pill R. Why do interventions work in some\u000a      places and not others: a breastfeeding support group trial. Social\u000a        Science and Medicine. 2010;70(5):769-778. (cited 13 times, Google\u000a      Scholar at 12\/8\/13)\u000a      This paper reports the qualitative process evaluation undertaken within\u000a        the BIG trial which explained why outcomes were favourable in some\u000a        locations but others weren't. This was led by Hoddinott from the\u000a        University of Aberdeen.\u000a    \u000a\u000a[5] Hoddinott P, Craig L, Britten J, McInnes R. A serial qualitative\u000a      study of infant feeding experiences: idealism meets realism. BMJ Open\u000a      2012;2:e000504. (cited 18 times, Google Scholar at 12\/8\/13)\u000a      This is the report of the serial qualitative interview study with\u000a        families recruited from more disadvantaged areas. It showed that the\u000a        need to move away from \"breastfeeding-centred\" care towards a mother,\u000a        baby and family centred approach. The study was led and designed by\u000a        Hoddinott with input from Craig from the University's Public Health\u000a        Nutrition Group.\u000a    \u000aResearch Grants:\u000a    All the research grants supporting these projects were led from the\u000a      University of Aberdeen with Hoddinott as Chief Investigator. All\u000a      University of Aberdeen grantholders are identified in bold.\u000a    &#8226; Hoddinott P, Britten J, Mollison J, Ludbrook\u000a      A, McInnes R, Tappin D, Godden D. The BIG (Breastfeeding in\u000a      Groups) trial: a randomised controlled trial to evaluate the clinical and\u000a      cost-effectiveness of breastfeeding peer support groups in improving\u000a      breastfeeding initiation, duration and satisfaction. Chief Scientist's\u000a      Office of the Scottish Government Health Directorate. Ref: CZH\/4\/156:\u000a      final report graded excellent. &#163;209,603. 01\/10\/04 - 30\/09\/07.\u000a    &#8226; Hoddinott P. How can breastfeeding initiation, duration and\u000a      maternal satisfaction with breastfeeding experience be improved in\u000a      Scotland? Chief Scientist's Office of the Scottish Government Health\u000a      Directorate. Primary Care Research Career Award. CZP\/4\/4. &#163;294,225.\u000a      01\/10\/03 - 30\/09\/08.\u000a    &#8226; Hoddinott P. An action research project to implement and\u000a      evaluate a breastfeeding coaching project in Banff and Buchan. Chief\u000a      Scientist's Office of the Scottish Government Health Directorate. Research\u000a      Practice Scheme. &#163;46,500. 01\/10\/00 - 30\/09\/03.\u000a    &#8226; Hoddinott P, Craig L, McInnes R. A prospective study\u000a      exploring the early infant feeding experiences of parents and their\u000a      significant others during the first 6 months of life. NHS Health Scotland\u000a      Research Grant. Ref: RE031. &#163;95,501. 01\/03\/09-31\/07\/10.\u000a    All research outputs and research grants underwent rigorous independent\u000a      external peer review.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"10","Subject":"Nursing"}],"Sources":"\u000a    [a] http:\/\/www.unicef.org\/nutrition\/index_24806.html\u000a      This is UNICEFs website which describes the Baby Friendly Hospital\u000a        Initiative and the number of Baby Friendly accredited facilities there\u000a        are worldwide.\u000a    [b] Entwistle FM. The evidence and rationale for the UNICEF Baby Friendly\u000a      Initiative standards, UNICEF UK, 2013.\u000a      This document describes the latest version of the Baby Friendly\u000a        Initiative standards and extensively references our research as\u000a        underpinning evidence.\u000a    [c] NICE. Clinical Guidance (CG037): Postnatal Care.\u000a       http:\/\/www.nice.org.uk\/cg037\u000a      This is the current NICE guidance document which outlines the UNICEF\u000a        Baby Friendly Initiative as the minimum standard for breastfeeding in\u000a        the UK.\u000a    [d]http:\/\/www.unicef.org.uk\/BabyFriendly\/News-and-Research\/Research\/Support-for-breastfeeding\/Feeding-support-needs-to-be-more-woman-centred\/\u000a      This is UNICEF'S commentary on the serial qualitative study. UNICEF\u000a        indicated that the research had raised important issues and they\u000a        recognised that whilst their Baby Friendly Initiative had gone some way\u000a        to addressing women-centredness, they required to promote this further.\u000a        This led to the changes in Standard 3 in the newly issued (2012) Baby\u000a        Friendly guidance.\u000a    [e] Pardoe C &amp; Williams J. Baby Caf&#233; Toolkit: all you need to know\u000a      about running a Baby Caf&#233; Drop in Centre. Baby Caf&#233; Charitable Trust,\u000a      2011.\u000a      This toolkit, which is issued to all registered Baby Caf&#233; licence\u000a        holders, outlines the guidance and standards of care which must be\u000a        followed under the Baby Caf&#233; licence. It explicitly references the\u000a        research on coaching and the process evaluation of the BIG trial as\u000a        evidence informing its guidance and standards.\u000a    ","Title":"\u000a    Influencing national and international breastfeeding care through the\u000a        generation of high quality evidence\u000a    ","UKLocation":[{"GeoNamesId":"2657832","Name":"Aberdeen"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Breastfeeding is known to provide considerable health benefits for both\u000a      mother and baby, with reduced risk of infections in babies and of breast\u000a      and ovarian cancer in mothers. The World Health Organization recommends\u000a      exclusive breastfeeding for the first 6 months of life. However\u000a      breastfeeding rates in Scotland and the rest of the UK are amongst the\u000a      lowest in the developed world, with only around 40% of babies receiving\u000a      any breast milk at 6-8 weeks. Recognising the importance of addressing\u000a      this significant health need, researchers in the University of Aberdeen - led by Pat Hoddinott, then Senior Lecturer in Primary Care at the\u000a      University - developed an extensive programme of research into the\u000a      barriers and facilitators to breastfeeding as well as a rigorous\u000a      evaluation of interventions to improve breast feeding rates. This research\u000a      programme included three substantive elements:\u000a    \u000a      \u000aThe evaluation of peer-support groups to promote breastfeeding\u000a            in rural areas with below average rates of breastfeeding\u000a        [1,2]. This study evaluated the effectiveness of peer support for new\u000a        mothers. Peer support was provided through midwife\/health visitor\u000a        facilitated groups where actively breastfeeding mothers supported or\u000a        \"coached\" other new mothers to breastfeed. One-to-one coaching could\u000a        also be provided. The study, which followed the feeding outcomes of\u000a        around 600 babies, showed that breastfeeding rates at two weeks in the\u000a        intervention area rose significantly by 34.3% to 41.1%. Breastfeeding\u000a        rates increased at all time points until 8 months. Groups were reported\u000a        to be more popular than one-to-one coaching.\u000a      \u000aA large-scale, pan-Scotland evaluation of a policy to routinely\u000a            establish breastfeeding groups for new mothers [3,4].\u000a        Insights from the peer-support study above, which showed that\u000a        peer support groups looked to be effective in rural areas, led to the\u000a        development a large-scale, pan-Scotland evaluation of a policy to\u000a        routinely establish breastfeeding groups for new mothers. This large\u000a        scale cluster randomised trial - called the \"BIG\" (Breastfeeding in\u000a        Groups) Trial - involved primary care organisations across Scotland\u000a        being randomised to either set up new breastfeeding support groups or to\u000a        not change their existing breastfeeding support provision. This trial,\u000a        which followed more than 18,000 babies, showed no significant change in\u000a        breastfeeding rates at 8 weeks after birth. In-depth qualitative data,\u000a        collected while the trial was ongoing, allowed a model to be developed\u000a        which highlighted the circumstances under which peer support groups\u000a        worked best - strong leadership, evidence of multidisciplinary working\u000a        etc. The report of this study was nominated for the Royal College\u000a        General Practitioners Research Paper of the Year Award.\u000a      \u000aIn-depth qualitative investigation of factors to improve\u000a            breastfeeding in disadvantaged area [5]. Following the\u000a        publication of the BIG trial, NHS Health Scotland commissioned the\u000a        University of Aberdeen group to design and undertake an in-depth\u000a        interview study with families from more disadvantaged areas. The aim was\u000a        to inform the design of future interventions to improve breastfeeding in\u000a        this population, not particularly likely to breastfeed. This rigorous\u000a        qualitative study, following families over time, showed a need to move\u000a        away from \"breastfeeding-centred\" care towards a mother, baby and family\u000a        centred approach.\u000a    \u000a    Led by Pat Hoddinott, the University of Aberdeen team also included:\u000a    \u000a      Dave Godden (Director, Centre for Rural Health, University of\u000a        Aberdeen),\u000a      Jane Britten (Research Fellow, Public Health Nutrition Group,\u000a        University of Aberdeen),\u000a      Jill Mollison (Senior Lecturer, Department of Public Health,\u000a        University of Aberdeen),\u000a      Amanda Lee (Reader, Department of Primary Care, University of\u000a        Aberdeen),\u000a      Gordon Prescott (Senior Lecturer, Department of Public Health,\u000a        University of Aberdeen); and\u000a      Anne Ludbrook (Senior Research Fellow, Health Economics Research Unit,\u000a        University of Aberdeen)\u000a    \u000a    "},{"CaseStudyId":"43272","Continent":[],"Country":[],"Funders":["Economic and Social Research Council","Royal Society"],"ImpactDetails":"\u000d\u000a    The research described has created a substantial body of evidence and has\u000d\u000a      influenced public policy and services in several ways. Geared towards\u000d\u000a      improving the quality, accessibility and cost-effectiveness of UK health\u000d\u000a      and education services, the work has advanced policy debate and has had a\u000d\u000a      major impact on the way hospitals and schools are allocated funding. The\u000d\u000a      research has produced impact in four main areas:\u000d\u000a     &#8226; Review of the Market Forces Factor (MFF)\u000d\u000a      The first phase of research into the MFF, commissioned in 2005,\u000d\u000a        recommended six major changes to the MFF formula. The report was\u000d\u000a        presented to policy makers within the Department of Health (DoH), the\u000d\u000a        Technical Advisory Group on Resource Allocation (TAGRA) and ACRA. The\u000d\u000a        recommendations were adopted by ACRA and formed part of their 2008\u000d\u000a        report to the DoH [a] which was implemented in 2009\/10. Recommendations\u000d\u000a        were geared towards a fairer distribution of funding and for the first\u000d\u000a        time took part-time NHS workers, as well as those working in the City of\u000d\u000a        London, into account. The second phase of the research resulted in\u000d\u000a        further changes to the formula and to the distribution of funding of\u000d\u000a        Primary Care Trusts which were recommended to the Secretary of State for\u000d\u000a        Health in 2010 and implemented from 2011\/12 onwards [b] funding totalled\u000d\u000a        &#163;89 billion for 2011\/12.\u000d\u000a      &#8226; Regional Pay for NHS Medical and Non-Medical Staff\u000d\u000a      Here, research findings were communicated to the DoH via a written\u000d\u000a        report and several presentations addressed to policy makers. The results\u000d\u000a        of the research formed a central part of the DoH's submissions to the\u000d\u000a        both the Nursing and other Health Professionals Review Body and\u000d\u000a        the Doctors and Dentists Review Body (DDRB) in 2006, as well as\u000d\u000a        the NHS Pay Review Body in 2011 [c,d]. In 2012 the NHS Pay\u000d\u000a        Review Body Report &#8212; Market Facing Pay \"recommend[ed] a fundamental\u000d\u000a          review of high cost area supplements, [and] appropriate use of local\u000d\u000a          recruitment and retention premia\" on the basis of the research\u000d\u000a        into how NHS labour markets are connected to the private sector\" [e]\u000d\u000a      &#8226; Review of Resource Allocation Adjustment for the Excess Costs of\u000d\u000a          Health Care Services\u000d\u000a      Having been commissioned by the NHS Scotland Resource Allocation\u000d\u000a        Committee (NRAC), impact resulted from production of a report to NRAC\u000d\u000a        and presentations of research to the NRAC Committee. The research formed\u000d\u000a        part of the evidence base for the recommendations in NRAC's 2007 final\u000d\u000a        report. It developed and applied a method for compensating Health Boards\u000d\u000a        in Scotland for local variations in the unavoidable excess costs of\u000d\u000a        delivering health services to different geographical areas. The report\u000d\u000a        was published in full by the Committee and was the basis of a full\u000d\u000a        consultation, after which further work was commissioned. Recommendations\u000d\u000a        by HERU on the hospital cost adjustment and that for travel-intensive\u000d\u000a        community health services were accepted by the Committee. The Committee\u000d\u000a        wrote: \"The new adjustment for unavoidable excess costs reflects a\u000d\u000a          rigorous programme of research...[which] provides a better reflection\u000d\u000a          of all unavoidable excess costs of supplying health services rather\u000d\u000a          than just remoteness.\" As a result of the research, the model used\u000d\u000a        to predict the costs of travelling to deliver services in the community\u000d\u000a        was updated to encompass the activities and travel times of a variety of\u000d\u000a        community staff. This adjustment in turn affects the formula which now\u000d\u000a        distributes funding for hospital and community services to Health Boards\u000d\u000a        in Scotland. [f], page 70.\u000d\u000a      &#8226; Local and Regional Pay Structures for Teachers in England and Wales\u000d\u000a      The research project focusing on school teachers in England and Wales\u000d\u000a        proposed and implemented a method for redesigning the regional and local\u000d\u000a        structure of pay, showing how the Review Body might allocate different\u000d\u000a        local authorities to different local pay bands. The research was\u000d\u000a        disseminated in 2009 via presentations to the Office for Manpower\u000d\u000a        Economics, Scottish Government Health Department, Department of Health,\u000d\u000a        HM Treasury, and Cabinet Office, as well as through frequent informal\u000d\u000a        and follow-up meetings and participation in a seminar at Number 11\u000d\u000a        Downing Street in 2012. As a result the findings form part of the\u000d\u000a        evidence base cited by the Chancellor of the Exchequer in his letter to\u000d\u000a        the Review Bodies in March 2012 [g].\u000d\u000a      In summary, the research has had impacts on public policy and services\u000d\u000a        in the following ways: policy debate has been stimulated and advanced by\u000d\u000a        research evidence; policy decisions have been informed by research\u000d\u000a        evidence; and the implementation of a policy for funding hospitals and\u000d\u000a        setting the pay of health service professionals and teachers or the\u000d\u000a        delivery of a public service has changed. The purpose of these policy\u000d\u000a        changes is to improve the quality, accessibility, acceptability or\u000d\u000a        cost-effectiveness of the health and education service.\u000d\u000a      The claimed impact, as defined by REF guidance, is therefore on: policy\u000a          debate and decisions, legislation and service delivery influenced by\u000d\u000a          research.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Researchers at the University of Aberdeen's Health Economics Research\u000d\u000a      Unit (HERU) have developed a theoretical model of the causes of local\u000d\u000a      variations in the competitiveness of pay in the public sector and shown\u000d\u000a      the impact of these variations on health and teaching services.\u000d\u000a      Recommendations arising from the research have changed the way funding is\u000d\u000a      distributed to: Primary Care Trusts in England and Wales; the adjustment\u000d\u000a      for excess costs in the resource allocation formula for health services in\u000d\u000a      Scotland; and the structure of regional pay for doctors in the UK. The\u000d\u000a      evidence also underpinned proposals by the Chancellor of the Exchequer in\u000d\u000a      2012 to introduce local pay for health service and teaching professionals\u000d\u000a      in England.\u000d\u000a    The claimed impact, as defined by REF guidance, is therefore on policy\u000a        debate and decisions, legislation and service delivery influenced by\u000d\u000a        research.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of Aberdeen\u000d\u000a    ","Institutions":[{"AlternativeName":"Aberdeen (University of)","InstitutionName":"University of Aberdeen","PeerGroup":"B","Region":"Scotland","UKPRN":10007783}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000aThe quality of the underpinning research and development of the main\u000d\u000a      theoretical and empirical methods is evidenced by the peer reviewed\u000d\u000a      articles listed below and the initial ESRC grant award which funded the\u000d\u000a      initial research. Researchers from the University of Aberdeen are shown in\u000d\u000a      bold text.\u000d\u000a    [1] Ma A, Elliott RF, Bell D, Scott A and Roberts E.\u000d\u000a      2006. Comparing the NES and LFS: An analysis of the differences between\u000d\u000a      the data sets and their implications for the pattern of geographical pay\u000d\u000a      in the UK. Regional Studies, 40 (6), 645-65\u000d\u000a      Reported and evaluated the secondary data sets available for empirical\u000d\u000a        research into local and regional pay\u000d\u000a    \u000a\u000a[2] Elliott RF, Bell D, Scott A, Ma A and Roberts\u000d\u000a      E. 2007. Geographically differentiated pay in the labour market for\u000d\u000a      nurses. Journal of Health Economics. 26, 190-212\u000d\u000a      Reported the underpinning theoretical model and econometric method in\u000d\u000a        an application to NHS nursing staff\u000d\u000a    \u000a\u000a[3] Elliott RF, Bell D, Scott A, Ma A, and\u000d\u000a      Roberts E. 2007. The pattern and evolution of geographic wage differences\u000d\u000a      in the public and private sectors in Britain. Manchester School\u000d\u000a      75(4), 386-421\u000d\u000a      Explored different econometric method and data and reported the\u000d\u000a        evolution of local pay differences\u000d\u000a    \u000a\u000a[4] Resource Allocation Working Paper 1 and Resource Allocation Research\u000d\u000a      Papers (RARP) 32 plus Technical Appendices, together with RARP 34a and\u000d\u000a      RARP 34b at\u000d\u000a      http:\/\/www.dh.gov.uk\/en\/Managingyourorganisation\/Financeandplanning\/Allocations\/index.htm\u000d\u000a      Reported the research undertaken for the Advisory Committee on Resource\u000d\u000a        Allocation between 2005 and 2010\u000d\u000a    [5] Morris S, Elliott R, Ma A, McConnachie A, Rice N, Sk&#229;tun\u000a        D and Sutton M. (2008). Analysis of consultants' NHS and\u000d\u000a      private incomes in England in 2003\/4. Journal of the Royal Society of\u000d\u000a        Medicine. 101: 372-380\u000d\u000a      Extended the analysis to provide the first detailed analysis of\u000d\u000a        regional variations in consultants earnings\u000d\u000a    \u000a[6] Elliott R, Sutton M, Ma A, McConnachie A,\u000d\u000a      Morris S, Rice N and Sk&#229;tun D. (2010). The role of the staff MFF\u000d\u000a      in distributing NHS funding: taking account of differences in local labour\u000d\u000a      market conditions. Health Economics: 19, 532-548\u000d\u000a      Reported the underlying theoretical model and its empirical application\u000d\u000a        to the issue of resource allocation to PCTs in the NHS in England.\u000d\u000a    The initial development of the theoretical model and empirical methods\u000d\u000a      was funded by the ESRC (Chief Investigator, Elliott, HERU):\u000d\u000a    &#8226; Competition and Reform: Devolved Government and Public Pay-Setting.\u000d\u000a      ESRC, July 2002 to June 2005 &#8212; &#163;141,775\u000d\u000a    Further funding (all led from the University of Aberdeen, with Elliott as\u000d\u000a      Chief Investigator) included:\u000d\u000a    &#8226; Regional Pay for NHS Medical and Non-Medical Staff, &#163;35,000 &#8212;\u000d\u000a      Department of Health, January 2005 &#8212; June 2005\u000d\u000a    &#8226; Adjusting the General Medical Services Allocation Formula to Reflect\u000d\u000a      Recruitment and Retention Difficulties, &#163;68,000 &#8212; Department of Health &#8212;\u000d\u000a      May 2005 &#8212; January 2006\u000d\u000a    &#8226; Review of the Market Forces Factor following the Introduction of\u000d\u000a      Payment-by-Results:\u000d\u000a      Improving the General Labour Market Method, &#163;96,932 &#8212; Department of Health\u000d\u000a      &#8212; November 2005 &#8212; July 2006\u000d\u000a    &#8226; Review of the Resource Allocation Adjustment for Excess Costs of Supply\u000d\u000a      of Healthcare Services in Scotland, &#163;51.344 &#8212; Scottish Executive &#8212;\u000d\u000a      November 2005 &#8212; June 2006\u000d\u000a    &#8226; Spatial Wage Variation for Teachers in the Public Sector in England and\u000d\u000a      Wales, &#163;25,000 &#8212; Office of Manpower Economics &#8212; February &#8212; August 2008\u000d\u000a    &#8226; The Staff Market Forces Factor Component of the Resource Allocation\u000d\u000a      Weighted Capitation Formula &#163;68,983 &#8212; Department of Health &#8212; January &#8212;\u000d\u000a      September 2010\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"},{"Level1":"15","Level2":"3","Subject":"Business and Management"}],"Sources":"\u000d\u000a    [a] Report of the Advisory Committee on Resource Allocation, Report\u000d\u000a      Section 5, December 2008. See:\u000d\u000a      http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_091484\u000d\u000a    [b] Letter dated 27 September 2010 from Chair ACRA to Secretary of State\u000d\u000a      for Health\u000d\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/147600\/dh_122685.pdf.pdf\u000d\u000a    [c] Thirty-Fifth Report of Doctors and Dentists Review Body, Cm\u000d\u000a      6733, 2006, Recommendation 1\u000d\u000a      http:\/\/www.ome.uk.com\/DDRB_Reports.aspx\u000d\u000a    [d] Twenty-First Report on Nursing and Other Health Professionals\u000d\u000a      Cm 6752, 2006 pp 43-45. See:\u000d\u000a      http:\/\/www.ome.uk.com\/NHSPRB_Reports.aspx\u000d\u000a    [e] NHS Pay Review Body &#8212; Market Facing Pay: Written Evidence from\u000d\u000a        the Health Department for England: pp 35,36,41 and 93-96. April 2012\u000d\u000a      http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_133505\u000d\u000a      and NHS Review Body: Market Facing Pay, p 13 and 48, Cm 8501,\u000d\u000a      December 2012 http:\/\/www.ome.uk.com\/NHSPRB_Reports.aspx\u000d\u000a    [f] Delivering Fair Shares for Health in Scotland: the report of the\u000d\u000a        NHSScotland Resource Allocation Committee, NRAC Final Report,\u000d\u000a      Chapter 6.3, September 2007. See\u000d\u000a      http:\/\/www.nrac.scot.nhs.ukhttps:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/147600\/dh_122685.pdf.pdf\/research.htm\u000d\u000a    [g] Chancellor of Exchequer, George Osborne, Letter to Review Bodies\u000d\u000a      dated 20th March 2012 and government economic evidence, in\u000d\u000a      particular paragraphs 1 and 28 for reference to research by Elliott et.al.\u000d\u000a      See:\u000d\u000a      http:\/\/www.ome.uk.com\/Search\/Default.aspx?q=Chancellor&amp;page_num=1\u000d\u000a    ","Title":"\u000d\u000a    Towards improved policies on public-sector pay: revising the way\u000d\u000a        government funding is allocated to hospitals, schools and public sector\u000d\u000a        pay structures\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2657832","Name":"Aberdeen"},{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Private sector pay in the UK, as elsewhere, is subject to regional\u000d\u000a      variations &#8212; reflecting differences in the cost of living as well as the\u000d\u000a      supply and demand for similarly skilled labour. This is not the case in\u000d\u000a      the public sector. As a result in important areas of the country, London\u000d\u000a      and the South east in particular, public sector pay is perceived as\u000d\u000a      uncompetitive and attracting and retaining staff becomes harder &#8212; leading\u000d\u000a      to higher recruitment and training costs, a less productive workforce and\u000d\u000a      disrupted services for the end user. Hence, creating efficient pay systems\u000d\u000a      that neither under-nor overpay public sector staff is crucial for the\u000d\u000a      provision of high-quality services.\u000d\u000a    Since 2002, a team at the University of Aberdeen's HERU, led by Professor\u000d\u000a      Robert Elliott (at Aberdeen since 2001) have investigated the determinants\u000d\u000a      and consequences of local and regional pay variations in the public\u000d\u000a      sector. The University of Aberdeen researchers integral to this research\u000d\u000a      were:\u000d\u000a    \u000d\u000a      Robert Elliott, Director, HERU\u000d\u000a      Ada Ma, Research Fellow, HERU\u000d\u000a      Anthony Scott, Reader, HERU (until 31.3.05)\u000d\u000a    \u000d\u000a    Collaborators from the Universities of Manchester, Stirling, York and\u000d\u000a      University College London also contributed to this Aberdeen-led research.\u000d\u000a    The underpinning methodology was developed between 2002 and 2005, led by\u000d\u000a      HERU, funded by a grant from the Economic and Social Research Council\u000d\u000a      (ESRC). The Aberdeen research team employed theories of compensating wage\u000d\u000a      variation and trade union wage bargaining, established in labour\u000d\u000a      economics, to model the determinants of local and regional variations in\u000d\u000a      the competitiveness of pay. [1,2,3]. These variations were then related to\u000d\u000a      recruitment and retention.\u000d\u000a    The methodology was then applied in a number of important policy relevant\u000d\u000a      areas:\u000d\u000a    \u000d\u000a      To develop a new method to calculate the Market Forces Factor (MFF).\u000d\u000a        The MFF compensates for unavoidable cost differences in different areas\u000d\u000a        and is a critical element of the formula used to distribute funding to\u000d\u000a        Primary Care Trusts (PCTs) in England and Wales. Here, research was\u000d\u000a        undertaken by a team at HERU, led by Elliott, in collaboration with\u000d\u000a        researchers at the universities of York and Glasgow and University\u000d\u000a        College, London. The first phase was carried out between November 2005\u000d\u000a        and December 2008 and was commissioned by the Advisory Committee on\u000d\u000a        Resource Allocation (ACRA) as part of a major review by the Department\u000d\u000a        of Health (DoH). The research recommended six major changes to the MFF\u000d\u000a        formula. A second phase was conducted between December 2009 and November\u000d\u000a        2010 and resulted in further changes [4, 5, 6]\u000d\u000a      To research regional pay of NHS medical and non-medical staff. With\u000d\u000a        Department of Health (England) funding, research was undertaken by\u000d\u000a        Elliott et al, with researchers from the University of Stirling, between\u000d\u000a        December 2004 and June 2005. It found that the existing structure of\u000d\u000a        regional payments produced substantial local variations in pay for NHS\u000d\u000a        hospital doctors and nurses and suggested this be addressed through a\u000d\u000a        change in pay structure.\u000d\u000a      To distinguish the magnitude of local variations in the unavoidable\u000d\u000a        excess costs of delivering health services in Scotland. Elliott et al\u000d\u000a        undertook research between December 2006 and June 2007 with funding from\u000d\u000a        the NHS Scotland Resource Allocation Committee (NRAC). The research\u000d\u000a        developed and applied a method for compensating Health Boards for local\u000d\u000a        variations.\u000d\u000a      To research links between local pay for teachers and school\u000d\u000a        performance in England and Wales. Research was conducted between\u000d\u000a        February 2008 and March 2009 by Elliott and Ma (from HERU) and Harminder\u000d\u000a        Battu (University of Aberdeen Business School) with funding from the\u000d\u000a        Office for Manpower Economics. Research proposed and implemented a\u000d\u000a        method for redesigning pay structures, showing how the review body might\u000d\u000a        allocate local authorities to different pay bands.\u000d\u000a    \u000d\u000a    "},{"CaseStudyId":"43410","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    By devising and refining the methods and undertaking the empirical\u000a      analysis on which formulae are based, York helped to ensure that the\u000a      organisations responsible for commissioning services receive a fairer\u000a      share of the NHS budget i.e. in proportion to the relative health care\u000a      needs of their constituent populations. The path-breaking nature of the\u000a      work was referred to in a review of Resource Allocation for the Secretary\u000a      of State in 2008:\"A team from York University were awarded the contract\u000a        ... and produced an impressive report based on state-of-the art\u000a        techniques to derive estimates from small-area variations in utilization\u000a        (Carr-Hill et al, 1994a): this was well described by Ken Judge, in\u000a        evidence to the Health Select Committee as being `widely acknowledged to\u000a        be the most impressive and sophisticated undertaken so far in this\u000a        field' (source 1).\u000a    The DoH has been utilising this body of research for the allocation of\u000a      resources for almost 20 years and in 2011-2012, weighted capitation\u000a      formulae informed recurrent allocations of &#163;85 billion to Primary Care\u000a      Trusts and thence via Practice Based Commissioning (PBRA) to General\u000a      Practices, directing resources according to relative population needs.\u000a      Revising the formulae to take account of unmet need, rather than\u000a      just reflecting current utilisation patterns, ensured that particular\u000a      groups in the population (e.g., ethnic minorities and the socially\u000a      disadvantaged) who were not utilising health care services at the same\u000a      level as other groups with similar health characteristics, were not\u000a      unfairly treated in terms of the resources allocated for their care. The\u000a      decisive impact of York's research on NHS resource allocation is\u000a      corroborated in the official history of resource allocation (source 2).\u000a      Research led by, or involving York researchers as co-authors, is\u000a      referenced throughout the account of how the formulae have been developed.\u000a      The appendix shows that York's research features in 18 of the 27\u000a      \"external\" reports to the Dept of Health, used in the development of the\u000a      formulae over several years (source 3).\u000a    Through successive re-organisations of the NHS, York research has defined\u000a      and under-pinned the development of allocation formulae in order to ensure\u000a      that a more equitable distribution of resources is achieved, regardless of\u000a      which organisations (District Health Authorities, PCTs, Clinical\u000a      Commissioning Groups) have had responsibility for the provision and\u000a      purchasing of health care services (source 2). Without the\u000a      research, the financial allocations made to these organisations would have\u000a      been made on a cruder basis, ignoring many of the sources of the relative\u000a      difference in the healthcare needs of local communities. The impact of the\u000a      formula can be illustrated by comparing the allocations to a hypothetical\u000a      benchmark: in 2011\/12, adjusting the allocations to reflect population\u000a      needs (as in the most recent formula) has the effect of re-distributing\u000a      approximately 10% of the total budget of over &#163;100 billion compared with a\u000a      benchmark scenario under which each area received a share based purely on\u000a      the size of their population. The use of the formula, compared to this\u000a      \"equal shares\" scenario, would increase health care budgets by up to &#163;571\u000a      per head of the population in 56% of PCTs and reduce allocations by up to\u000a      &#163;440 in the remaining 44% of PCTs, thus reflecting a re-distribution to\u000a      areas most in need.\u000a    The research undertaken on general practice General Medical Services\u000a      (references 3 and 4) and in particular the element of the research by\u000a      Carr-Hill (reference 3) became widely known as the \"Carr-Hill formula\",\u000a      and has underpinned the capitation payments &#8212; the \"global sum allocation\u000a      formula\" &#8212; since 2004. The BMA said \"The new Carr-Hill allocation\u000a        formula will provide equity, recognise casemix and practice\u000a        circumstances, and ensure money will flow according to patient need\"\u000a      (source 4). The lack of adjustment for factors influencing workload\u000a      and the cost of providing services were perceived as flaws and the new\u000a      contract stated \"The introduction of a global sum payment, combined\u000a        with new rewards for quality, will address these flaws. A new GMS\u000a        resource allocation formula, developed by Professor Roy Carr-Hill of\u000a        York University, will provide the basis for allocating funds for global\u000a        sum resources and for quality payments\" (source 5). The\u000a      formula and its adjusted versions (reference 5) continues to inform\u000a      capitation payments to general practices, involving around &#163;3 billion per\u000a      annum (source 5).\u000a    In addition to the research impacting on the main allocation formula,\u000a      other York research has also had a significant effect on allocations.\u000a      Research on the mental health formula led the DoH working group (ACRA) to\u000a      recommend to Ministers: \"One of two recommendations to have a\u000a        significant impact on PCT target allocations is that for mental health.\u000a        ACRA recommends a new approach to the mental health component of the\u000a        weighted capitation formula. The approach is a major step forward in how\u000a        funding is allocated for mental health services\" (source 6)\u000a      Hence improving the accuracy with which resources can be allocated to\u000a      reflect the relative mental health needs of the population and the costs\u000a      to commissioners of delivering those services.\u000a    The most recently developed Person Based Resource Allocation (PBRA)\u000a      mechanism was the basis of the \"toolkit\" to enable PCTs to compare actual\u000a      expenditure on acute care at practice level with a needs-based standard\u000a      allowing for the differences in needs amongst general practices. This can\u000a      promote an even fairer distribution of NHS funds, to the direct benefit of\u000a      society. This research is cited in the Department of Health's Guidance to\u000a      PCTs which also cites the role of research on mental health (covered in\u000a      reference 6): \" The 2011\/12 toolkit introduces new methodologies for\u000a        the Prescribing and Mental Health parts of the toolkit. This is based\u000a        upon the results of the Resource Allocation for Mental Health and\u000a        Prescribing (RAMP) project, which was developed as part of the\u000a        methodology for PCT allocations. In the 2010\/2011 toolkit we introduced\u000a        a new methodology for the Acute care component. This was based on\u000a        research that the Department of Health commissioned ... to develop an\u000a        acute formula based on the prediction of individual patient costs. We\u000a        have retained this methodology for the 2011\/12 toolkit and the data\u000a        underlying the formula have been updated.\" (source 7).\u000a    ","ImpactSummary":"\u000a    York research has, continuously since the early 1990's, underpinned the\u000a      methods by which a substantial proportion of the total NHS budget is\u000a      allocated by the Department of Health to the organisations providing or\u000a      arranging healthcare. Despite numerous NHS reforms, our research has\u000a      produced formulae appropriate to each new system. These formulae have\u000a      driven NHS policy on allocations across geographical areas and health care\u000a      administrative entities in England, thereby ensuring that the population\u000a      of approximately 55 million people receives a share of over &#163;90 billion of\u000a      healthcare resources that is fair and better reflects relative health care\u000a      needs.\u000a    ","ImpactType":"Economic","Institution":"\u000a    University of York\u000a    ","Institutions":[{"AlternativeName":"York (University of)","InstitutionName":"University of York","PeerGroup":"B","Region":"Yorkshire And Humberside","UKPRN":10007167}],"Panel":"A         ","PlaceName":[],"References":"\u000a    The research has been published either in top peer reviewed journals\u000a      (refs 1, 2, 7) or Resource Allocation Working Papers and reports to the\u000a      Dept of Health (refs 3, 4, 5, 6) which are reviewed rigorously by both the\u000a      Advisory Committee on Resource Allocation (ACRA) - an independent expert\u000a      body that advises the Secretary of State for Health on the weighted\u000a      capitation formula - and the Technical Advisory Group which supports ACRA.\u000a      All the research was funded by the Dept of Health either via a competitive\u000a      process or was subject to review by ACRA.\u000a    \u000a1. Carr-Hill R, Sheldon TA, Smith P, Martin S, Peacock S, Hardman G\u000a      (1994) Allocating resources to health authorities: development of method\u000a      for small area analysis of use of inpatient services. British Medical\u000a        Journal 1994 http:\/\/dx.doi.org\/10.1136\/bmj.309.6961.1046\u000a    \u000a\u000a2. Gravelle H, Sutton M, Morris S, Windmeijer F, Leyland A, Dibben C,\u000a      Muirhead M (2003) Modelling supply and demand influences on the use of\u000a      healthcare: implications for deriving a needs-based capitation formula. Health\u000a        Economics. 12: 985-1004. DOI:10.1002\/hec.830\u000a    \u000a\u000a3. Carr-Hill R (2003) Dept of Health Resource Allocation Research Paper\u000a      27 GMS Contract Workload Formula http:\/\/webarchive.nationalarchives.gov.uk\/20081211165009\/http:\/\/www.dh.gov.uk\/en\/Managingyourorganisation\/Financeandplanning\/Allocations\/DH_4108515?IdcService=GET_FILE&amp;dID=175473&amp;Rendition=Web\u000a    \u000a\u000a4. Morris S, Sutton M, Gravelle H. An analysis of the factors predicting\u000a      GP consultations: a small- area level analysis using Health Survey for\u000a      England data. Report to the DoH May 2003. Resource Allocation Research\u000a      Paper 28 http:\/\/webarchive.nationalarchives.gov.uk\/20110907135717\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_089608.pdf\u000a    \u000a\u000a5. Morris, S., Carr-Hill, R., Dixon, P., Law, M., Rice, N., Sutton, M.,\u000a      Vallejo-Torres, L. Combining Age Related and Additional Needs (CARAN)\u000a        Report. 2007 review of the needs formulae for hospital services and\u000a        prescribing activity in England. Final Report. DoH, 2007. http:\/\/webarchive.nationalarchives.gov.uk\/20110322043809\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_093169.pdf\u000a    \u000a\u000a6. Sutton M, Whittaker W, Morris S, Glover G, Dusheiko M, Wildman J,\u000a      Gravelle H, Burrows S, Simpson J, F&#233;-Rodr03afguez E, Birch, S, Smith PC.\u000a      Report of the resource allocation mental health and prescribing project\u000a      (RAMP). Dec 2010. Resource Allocation Research Paper 35 http:\/\/webarchive.nationalarchives.gov.uk\/20110907135717\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_122619.pdf\u000a    \u000a\u000a7. Dixon J, Smith P, Gravelle H, Martin S, Bardsley M, Rice N, Georghiou\u000a      T, Dusheiko M, Billings J, De Lorenzo M, Sanderson C A person based\u000a      formula for allocating commissioning funds to general practices in\u000a      England: development of a statistical model British Medical Journal\u000a      2011;343:d6608 http:\/\/dx.doi.org\/10.1136\/bmj.d6608\u000a    \u000aGrants (amount sub-contracted to York given, where contract held\u000a        elsewhere):\u000a    Research on resource allocation (Carr-Hill) was undertaken as part of\u000a      successive 5 year large programme contracts awarded to the Centre for\u000a      Health Economics by the DoH (Aug 1996-July 2001 &amp; Aug 2001-July 2006).\u000a    Carr-Hill R, Sheldon TA, Smith P. (1993) Small area study for the review\u000a      of weighted capitation. NHS Executive &#163;138,500.\u000a    Gravelle H (2002\/3) Small area study of supply and demand determinants of\u000a      healthcare resource use and estimation of relative needs for PCTS in\u000a      England. &#163;11, 653\u000a    Carr-Hill R (2007) Review of need formula. DoH (&#163;32,300)\u000a    Smith PC, Gravelle H (July 2008-Oct 2009) Developing a PBRA formula for\u000a      general practices in England. DoH (&#163;219,907)\u000a    Gravelle H (2009) Programme budget level PBRA. DoH &#163;11,500\u000a      [sub-contracted amount]\u000a    Gravelle H (2010) Resource Allocation for Mental Health and prescribing\u000a      (RAMP) DoH (&#163;26,340)\u000a    Gravelle H (Nov 2010-Dec 2012) Developing the mental health funding\u000a      formula for allocations to general practices. DoH &#163;35,312\u000a    Gravelle H, Rice N (Nov 2010-Sept 2011) Updating and enhancing a resource\u000a      allocation formula at general practice level based on individual patient\u000a      characteristics. DoH (&#163;39,800)\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000a    \u000a      Review of Weighted Capitation Formula, report submitted to the\u000a        Secretary of State for Health in June 2008 by Prof Gwyn Bevan http:\/\/webarchive.nationalarchives.gov.uk\/20110907135717\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_093167.pdf\u000a\u000a      Annual report by DoH on the formula used and the underpinning methods,\u000a        which also contains a history of resource allocation. Resource\u000a        Allocation: weighted capitation formula. 7th edn, 2011. www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/152060\/dh_124947.pdf.pdf.\u000a      List of major research and working papers commissioned on resource\u000a        allocation, also here: http:\/\/webarchive.nationalarchives.gov.uk\/+\/www.dh.gov.uk\/en\/Managingyourorganisation\/Financeandplanning\/Allocations\/DH_4108515#dhContent\u000a\u000a      Investing in General Practice: the new General Medical Services\u000a        Contract http:\/\/www.nhsemployers.org\/SiteCollectionDocuments\/gms_contract_cd_130209.pdf\u000a        This contains the quotations cited in the text as well as extensive\u000a        further references to the Carr-Hill formula and an Appendix D (Carr-Hill\u000a        resource allocation formula) explaining it in more detail. http:\/\/www.nhsemployers.org\/SiteCollectionDocuments\/gms_contract_annex_d_cd_130209.pdf\u000a\u000a      British Medical Association letter to GPs (2\/11\/11) explaining their\u000a        national 2012\/13 contract agreement with all the UK health departments,\u000a        referring to the use of the \"Carr-Hill formula\" and to the work\u000a        undertaken by Professor Roy Carr-Hill in 2001-03 http:\/\/bma.org.uk\/practical-support-at-work\/contracts\/independent-contractors\/contract-agreement\u000a\u000a      Letter to Andrew Lansley 27\/9\/10 from David Fillingham Chief Exec,\u000a        Advancing Quality Alliance (AQuA) North West &amp; Chair of ACRA: www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/147600\/dh_122685.pdf.pdf\u000a\u000a      Practice Based Commissioning Budget Guidance for 2011\/12. DoH March\u000a        2011 www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/153550\/dh_125566.pdf.pdf\u000a\u000a    \u000a    ","Title":"\u000a    Allocating Resources in the National Health Service\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The underlying principle of allocation formulae is to distribute\u000a      resources on the basis of the relative need for health care services of\u000a      the population. York has been at the forefront of developing methods for\u000a      designing these formulae across the spectrum of NHS activity, encompassing\u000a      primary and secondary care services. This dates back to seminal work in\u000a      1993 when research at York resulted in a step change in the methodology of\u000a      NHS allocation formulae by combining small area level information on\u000a      health care utilisation with small area census data to produce a more\u000a      robust method of modelling population need than hitherto (1). Used by the\u000a      Department of Health (DoH) to allocate resources in the English NHS, the\u000a      `York formula' set the precedent for research and policy over the\u000a      following 20 years and York researchers have made a regular, sustained\u000a      intellectual contribution to this area of research introducing major\u000a      methodological innovations. Research on resource allocation brings\u000a      together a range of researchers from different institutions. York's main\u000a      contributions have centred on devising modelling strategies, developing\u000a      methods, interpreting results and advising on datasets.\u000a    The AREA research (Gravelle; jointly led with the University of Glasgow),\u000a      formed the basis of allocations made from 2003\/04 to 2009\/10 and for the\u000a      first time devised formulae suitable for allocations to Primary Care\u000a      Trusts (2). Using newly assembled data for 8414 geographical areas, the\u000a      research estimated utilisation models that took into account unmet need,\u000a      in order to make the distribution of resources more equitable. It was\u000a      innovative in deriving measures of specifb01c morbidities (to measure\u000a      relative need) at small area level from individual level survey data.\u000a    Capitation payments to general practices since 2004\/05 have been based on\u000a      work by York researchers, producing what is generally referred to as the\u000a      \"Carr-Hill formula\". Carr-Hill led analysis of the impact on GP workload\u000a      (and hence on the costs of delivering care) of a range of factors\u000a      including rurality, age\/sex of practice population and practice turnover\u000a      (3). The research utilised novel data sources, including Inland Revenue\u000a      accounts to explore the expenses attributable to GPs operating in rural\u000a      areas and analysed 99 million computerised \"file openings\" recorded at GP\u000a      practices in order to explore workload. Additional analyses (Gravelle;\u000a      collaborating with Imperial College), used small area data from the Health\u000a      Survey for England for the first time, to allow for socio-economic patient\u000a      factors affecting consultation rates (4). Research by Carr-Hill, Dixon and\u000a      Rice (collaborating with Brunel University) refined the measurement of\u000a      health care needs, incorporating more sensitive age-specific needs\u000a      adjustment and, for the first time, included outpatient hospital activity,\u000a      producing the CARAN formula (5).\u000a    York researchers utilised new data sources in order to improve the way in\u000a      which the formulae take account of the need for mental health services\u000a      (Gravelle, Dusheiko, Smith, in collaboration with Manchester University)\u000a      (6). In particular, use of the Mental Health Minimum Dataset allowed the\u000a      formula to reflect a substantial amount of community-based activity\u000a      delivered to people with mental health conditions, previously excluded\u000a      from the formula.\u000a    A major recent development (Dusheiko, Gravelle, Rice; in collaboration\u000a      with Nuffield Trust) was the derivation of a formula to assist PCTs in\u000a      setting fair share indicative allocations to over 8000 general practices\u000a      within PCTs in England. The analysis involved innovative data linkage\u000a      methods to combine the 55 million patients registered with a general\u000a      practice with around 16 million annual hospital admissions and 84 million\u000a      annual outpatient visits, together with demographic and morbidity\u000a      characteristics, area measures of deprivation and practice and area supply\u000a      characteristics. This research represents a significant innovation in\u000a      several ways: analysis is conducted at the individual, rather than at the\u000a      area level (\"Person Based Resource Allocation\"); the model is prospective\u000a      (it predicts next year's expenditures based on current year's needs\u000a      characteristics); and it includes detailed individual morbidity\u000a      information (7).\u000a    Hugh Gravelle (Prof, August 1995-); Nigel Rice (Senior Research Fellow\u000a      (SRF), Prof 1994-); Roy Carr-Hill (SRF, Prof, 1983-Sept 2011); Mark\u000a      Dusheiko (Research Fellow (RF), SRF 1998-); Peter Smith (Reader, Prof,\u000a      1991-Sept 2009); Paul Dixon (SRF, 1989-April 2010), Trevor Sheldon (SRF,\u000a      Prof, 1992-); Geoff Hardman (RF, 1984-Sept 2005), Steve Martin (RF,\u000a      1989-).\u000a    "},{"CaseStudyId":"43411","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"3175395","Name":"Italy"}],"Funders":["Royal Society"],"ImpactDetails":"\u000d\u000a    York research has had an impact on policy and practice in relation to the\u000d\u000a      measurement of overall NHS productivity and the analysis of variations in\u000d\u000a      productivity at hospital and at consultant level.\u000d\u000a    National NHS productivity\u000d\u000a    The annual NHS budget is approximately &#163;106 billion, accounting for 8.2%\u000d\u000a      of gross national product. By developing improved methods of measuring NHS\u000d\u000a      productivity and providing methodologically robust evidence on annual NHS\u000d\u000a      productivity growth, York research has played a significant role in the\u000d\u000a      processes by which the size of the NHS budget is determined. The 2002\u000d\u000a      Spending Review committed the Government to a new Public Service Agreement\u000d\u000a      target of 2% improvements in productivity per year. The DoH turned to York\u000d\u000a      researchers to find a way to incorporate quality of care improvements into\u000d\u000a      the measurement of the output of the NHS. This had not previously been\u000d\u000a      attempted. The methods that York developed then were adopted as national\u000d\u000a      policy and have been used continuously. These methods are incorporated\u000d\u000a      into the Office for National Statistics (ONS) estimates of NHS\u000d\u000a      productivity, which feed into the annual UK National Accounts (source 1).\u000a      Every year since, the ONS has used the method developed by York as a key\u000d\u000a      element in their triangulation of evidence. The statement \"ONS would\u000d\u000a        like to thank Professor Andrew Street, Dr Adriana Castelli and the\u000d\u000a        Centre for Health Economics (CHE) team at the University of York for\u000d\u000a        their work on healthcare quality adjustments\" appears in all ONS\u000d\u000a      publications relating to NHS productivity. The ONS states that \"Estimates\u000a        of Health gain, Short-term survival and Waiting times are provided by\u000d\u000a        the Centre for Health Economics (CHE) at the University of York. These\u000d\u000a        are derived from patient-level records and offer detailed information at\u000d\u000a        the level of the individual procedure for Inpatients and Day-cases.\u000d\u000a        These are combined into a single measure of quality following the\u000d\u000a        guidance of CHE et al ....\" (source 2). These quality\u000d\u000a      adjustments have added an average of 0.5 percentage points to estimates of\u000d\u000a      annual output growth (source 2) and without York's research, NHS\u000d\u000a      productivity would have been underestimated with negative consequences for\u000d\u000a      the size of future budget settlements for the NHS and hence less\u000d\u000a      investment in NHS services.\u000d\u000a    Estimates of input, output and productivity growth, along with details\u000d\u000a      of the methodological issues that York research addresses, are produced\u000d\u000a      regularly for the DoH for use in their calculations of NHS productivity.\u000d\u000a      Researchers have produced a tool for DoH analysts to use in order to\u000d\u000a      explore in detail the productivity estimates and the impact of different\u000d\u000a      assumptions on future productivity estimates. The estimates provided by\u000d\u000a      York are vital for negotiations with ministers and with agencies that have\u000d\u000a      the power to influence the size of the NHS budget. The research has been\u000d\u000a      used directly to provide numerical answers and context for Health Select\u000d\u000a      Committees and Public Accounts Committees, and Hansard records show that\u000d\u000a      York is often cited by name (source 3). The National Audit Office\u000d\u000a      report on Agenda for Change raised the issue of how measures of NHS output\u000d\u000a      were quality adjusted and, at the Public Accounts Committee, the DoH\u000d\u000a      responded by referring to the research commissioned from York in order to\u000d\u000a      improve the method of adjustment (source 4). The 2008\/9 Public\u000d\u000a      Expenditure Inquiry asked for a progress report on the York work and in\u000d\u000a      answering the question the DoH cited the York study on inputs and also\u000d\u000a      indicated that York would be producing productivity estimates at a\u000d\u000a      Strategic Health Authority level (source 5).\u000d\u000a    York research has also been influential internationally. Representatives\u000d\u000a      from the Italian, Swedish and Japanese governments visited York in 2011,\u000d\u000a      2012 and 2013 respectively, to learn more about the methods used to\u000d\u000a      measure productivity in the UK. York researchers are working on\u000d\u000a      measurement of productivity for the Italian Ministry of Health (with\u000d\u000a      colleagues at the University of Rome Tor Vergata), replicating for Italy,\u000d\u000a      the methods used in England. York staff have run invited workshops on\u000d\u000a      methods of productivity measurement to policy makers, national\u000d\u000a      statisticians and academics nationally and internationally.\u000d\u000a    Specialist hospital care\u000d\u000a    Research on the costs of specialist care was commissioned from York as\u000d\u000a      part of \"a fundamental review of the current methodology\" used to\u000d\u000a      calculate specialised service top-ups for the Payment by Results tariff (source\u000a        6). Our research resulted in changes in policy in 2011\/12, including\u000d\u000a      the introduction of new top-ups for neurosciences and spinal surgery and\u000d\u000a      revision of the level of existing top-ups for children's services and\u000d\u000a      orthopaedics (source 6, paras 11 and 94-101). York's report is\u000d\u000a      included on the DoH website alongside the Payment by Results Guidance\u000d\u000a      documents.\u000d\u000a    Hospital consultant productivity\u000d\u000a    Staff costs are the largest single component of NHS expenditure. York\u000d\u000a      research into productivity at consultant level has had significant policy\u000d\u000a      impacts in three ways. Firstly, the method of describing and exploring\u000d\u000a      variation in consultant productivity was adopted as a benchmarking tool by\u000d\u000a      the DoH's Workforce Directorate and the NHS Institute of Innovation and\u000d\u000a      Improvement as part of their `Delivering Quality and Value' programme,\u000d\u000a      which in 2008 distributed comparative data on consultant clinical activity\u000d\u000a      to all hospital Trusts in England (source 7). This document states\u000d\u000a      that their process: \"uses the methodology outlined in York University's\u000d\u000a        report: Measuring Productivity of Hospital Consultants using Hospital\u000d\u000a        Episode Statistics in England\".\u000d\u000a    Second, this research influenced the recent review of clinical excellence\u000d\u000a      awards by the Doctors' and Dentists' Review Body (DDRB). In evidence to\u000d\u000a      the Review Body, Bloor and Maynard recommended \"introducing an extended\u000d\u000a      career structure for doctors, with earned increments and a senior\u000d\u000a      consultant grade\" and this recommendation was adopted by the DDRB in their\u000d\u000a      report (source 8), and a `principal consultant grade' is now under\u000d\u000a      negotiation with the British Medical Association (source 9). Our\u000d\u000a      work was also cited by the DoH in their submission to DDRB: \"research\u000d\u000a        by the University of York ... showed that consultants in surgical\u000d\u000a        specialties with local Clinical Excellence Awards were those who had the\u000d\u000a        highest levels of productivity\" (source 10). The DDRB review\u000d\u000a      team contacted York for supplementary evidence and further details, and\u000d\u000a      cited York research (references 6 and 7 above) in their final report (source\u000a        8).\u000d\u000a    Finally, the findings of our evaluation of the effect of the consultant\u000d\u000a      contract reform on consultant productivity (reference 8) informed the\u000d\u000a      recent National Audit Office review of the management of NHS consultants:\u000d\u000a      \"recent work by York University shows a downwards trend in finished\u000d\u000a        episodes per consultant ... [the researchers] concluded that the\u000d\u000a        contract had no or a negative impact on the declining trend in the ten\u000d\u000a        specialty areas analysed\" (source 11).\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Methods developed at the University of York for measuring NHS\u000d\u000a      productivity have changed how the Office of National Statistics values the\u000d\u000a      NHS in the national accounts. Our methods, which take into account\u000d\u000a      improvements in the quality of care, have been incorporated into\u000d\u000a      submissions to the Comprehensive Spending Reviews that determine the NHS\u000d\u000a      budget and are internationally influential. Research on productivity at\u000d\u000a      hospital level has influenced the tariffs set by the Department of Health\u000d\u000a      for reimbursement of specialist hospital care. Research on the\u000d\u000a      productivity of hospital consultants influenced the reviews of doctors'\u000d\u000a      pay and rewards by the Doctors' and Dentists' Pay Review Body and the\u000d\u000a      National Audit Office and formed the basis of benchmarking tools\u000d\u000a      distributed for use in the NHS.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of York\u000d\u000a    ","Institutions":[{"AlternativeName":"York (University of)","InstitutionName":"University of York","PeerGroup":"B","Region":"Yorkshire And Humberside","UKPRN":10007167}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"3169070","Name":"Rome"}],"References":"\u000d\u000a    All outputs are in high quality peer-reviewed journals except (5), which\u000d\u000a      is a peer reviewed report. All research funding was competitively awarded\u000d\u000a      or subject to peer review for scientific quality.\u000d\u000a    \u000a1. Castelli, A., Dawson, D., Gravelle, H., &amp; Street, A. Improving the\u000d\u000a      measurement of health system output growth. Health Economics, 2007,16(10),\u000a      1091-1107. DOI: 10.1002\/hec.1211\u000d\u000a    \u000a\u000a2. Castelli A, Laudicella M, Street A, Ward P. Getting out what we put\u000d\u000a      in: productivity of the English NHS. Health Economics, Policy and Law\u000d\u000a      2011;6:313-335. DOI: 10.1017\/S1744133110000307\u000d\u000a    \u000a\u000a3. Bojke C, Castelli A, Laudicella M, Street A, Ward P. Regional\u000d\u000a      variation in the productivity of the English National Health Service. Health\u000a        Economics 2013;22(2):194-211. DOI: 10.1002\/hec.2794\u000d\u000a    \u000a\u000a4. Daidone S, Street A. How much should be paid for specialised\u000d\u000a      treatment? Social Science and Medicine 2013;84:110-8. DOI:\u000d\u000a      10.1016\/j.socscimed.2013.02.005\u000d\u000a    \u000a\u000a5. Bloor K, Maynard A. Measuring productivity of hospital consultants\u000d\u000a      using Hospital Episode Statistics for England. http:\/\/collections.europarchive.org\/tna\/20080102105757\/http:\/www.york\u000a        .ac.uk\/healthsciences\/research\/bloormaynardexecsum07.pdf\u000d\u000a    \u000a\u000a6. Bloor KE, Maynard A, Freemantle N 2004. Variation in activity rates of\u000d\u000a      consultant surgeons, and the influence of reward structures in the English\u000d\u000a      NHS: descriptive analysis and a multi-level model. Journal of Health\u000d\u000a        Services Research and Policy 2004: 9(2): 76-84. DOI:\u000d\u000a      10.1258\/135581904322987481\u000d\u000a    \u000a\u000a7. Bloor K, Freemantle N, Maynard A. Gender and variation in activity\u000d\u000a      rates of hospital consultants. Journal of the Royal Society of\u000d\u000a        Medicine. 2008 101: 27-33. doi: 10.1258\/jrsm.2007.070424.\u000d\u000a    \u000a\u000a8. Bloor K, Freemantle N, Maynard A (2012) Trends in consultant clinical\u000d\u000a      activity and the effect of the 2003 contract change: retrospective\u000d\u000a      analysis of secondary data. Journal of the Royal Society of Medicine\u000d\u000a      2012; 105:472-479. DOI: 10.1258\/jrsm.2012.120130\u000d\u000a    \u000aGrants:\u000d\u000a    Dawson et al. 2004-5 Dept of Health. Developing new approaches to\u000d\u000a      measuring NHS outputs and productivity; &#163;169,130\u000d\u000a    Street A. 2008-10 Measuring productivity in the NHS: updates and\u000d\u000a      methodological improvement. Dept of Health Policy Research Programme;\u000d\u000a      &#163;155,310\u000d\u000a    Street A, Bojke C, Castelli A. 2011-14 The productivity of the NHS:\u000d\u000a      national, geographical and organisational analyses. Department of Health\u000d\u000a      Central Commissioning Facility; &#163;823,611\u000d\u000a    Research on specialised costs and some national productivity work was\u000d\u000a      undertaken within a CHE programme grant (2006-11): DoH Policy Research\u000d\u000a      Programme grant; &#163;2,304,205\u000d\u000a    Bloor K, Maynard A. 2002-2006 Department of Health Policy Research\u000d\u000a      Programme. Measuring productivity of hospital consultants using Hospital\u000d\u000a      Episode Statistics for England; &#163;340,000\u000d\u000a    Bloor K. 2008-2012 NIHR Career Development Fellowship. Exploring and\u000d\u000a      explaining variations in consultant clinical activity; &#163;407,000\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000d\u000a    \u000d\u000a      Public service outputs, inputs and productivity: healthcare. Edition\u000d\u000a        5, March 2011 ONS:\u000d\u000a        http:\/\/www.ons.gov.uk\/ons\/rel\/psa\/public-service-productivity\/healthcare-2011\/public-service-output--input-and-productivity.pdf\u000a\u000d\u000a      Sources and methods: public service productivity estimates:healthcare.\u000d\u000a        December 2012 ONS:\u000d\u000a        http:\/\/www.ons.gov.uk\/ons\/dcp171766_289768.pdf\u000a\u000d\u000a      See, for example, Hansard HC Deb 17 May Col WA307; Hansard HL Deb 24\u000d\u000a        March 11, col WA254; House of Commons Public Accounts Committee 29th\u000d\u000a        Report of session 2008-09 (HC 310, 18 June 2009); House of Commons\u000d\u000a        Public Accounts Committee 26th Report of session 2010-11 (HC\u000d\u000a        512, 9 Mar 2011); House of Commons Health Committee Second Report of\u000d\u000a        Session 2011-11 Volume 1 (HC 741, 14 Dec 2010).\u000d\u000a      House of Commons. Public Accounts Committee NHS Pay Modernisation in\u000d\u000a        England: Agenda for Change Twenty-ninth Report of Session 2008-09 Report,\u000a          together with formal minutes, oral and written evidence 18 June\u000d\u000a        2009\u000d\u000a        http:\/\/www.publications.parliament.uk\/pa\/cm200809\/cmselect\/cmpubacc\/310\/310.pdf\u000a\u000d\u000a      House of Commons Public Accounts Committee. NHS Pay Modernisation in\u000d\u000a        England. Further supplementary memorandum from the Chief Executive, NHS\u000d\u000a        DoH; April 2009.\u000d\u000a        http:\/\/www.publications.parliament.uk\/pa\/cm200809\/cmselect\/cmpubacc\/310\/09030209.htm\u000a\u000d\u000a      Department of Health. Payment by Results Guidance for 2011\/12. Feb\u000d\u000a        2011.\u000d\u000a        http:\/\/webarchive.nationalarchives.gov.uk\/20130507170152\/https:\/\/www.gov.uk\/government\/up\u000a          loads\/system\/uploads\/attachment_data\/file\/151911\/dh_126157.pdf.pdf\u000d\u000a        And DOH note on CHE research: http:\/\/webarchive.nationalarchives.gov.uk\/20130507170152\/https:\/\/www.\u000d\u000agov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/151916\/dh_124454.pdf.pdf\u000a\u000d\u000a      Department of Health (2008) Delivering Quality and Value: Consultant\u000d\u000a        Clinical Activity http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consu\u000d\u000am_dh\/groups\/dh_digitalassets\/@dh\/@en\/documents\/digitalasset\/dh_082902.pdf\u000a\u000d\u000a      Evidence to review body (see \"evidence submitted by individuals\" http:\/\/tinyurl.com\/evidence-individuals):\u000a        http:\/\/www.ome.uk.com\/DDRB_CEA_review.aspx.\u000d\u000a        Review body report: Review Body on Doctors' and Dentists' Remuneration.\u000d\u000a        Review of compensation levels, incentives and the Clinical Excellence\u000d\u000a        and Distinction Award schemes for NHS consultants. Cm 8518; London: The\u000d\u000a        Stationery Office; December 2012.\u000d\u000a      British Medical Association. BMA engages members on consultant\u000d\u000a        contract proposals (press release): http:\/\/tinyurl.com\/bma-news-consultant\u000a\u000d\u000a      Department of Health. UK wide review of compensation levels and\u000d\u000a        incentives for NHS consultants: Evidence to the Review Body on Doctors'\u000d\u000a        and Dentists' Remuneration by the Department of Health:\u000d\u000a        http:\/\/webarchive.nationalarchives.gov.uk\/20130106083031\/http:\/\/www.ome.uk.com\/Document\/\u000a          Default.aspx?DocumentUid=7A282E6C-6C9B-489C-9366-6E8DDD49FFCC\u000a\u000d\u000a      National Audit Office. Managing NHS Hospital Consultants. Report by\u000d\u000a        the Comptroller and Auditor General; HC 885, session 2012-2013; 6\u000d\u000a        February 2013. http:\/\/www.nao.org.uk\/wp-content\/uploads\/2013\/03\/Hospital-consultants-full-report.pdf\u000a\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Measuring health service productivity\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Productivity is a key indicator of efficiency and competitiveness.\u000d\u000a      Measures of public service output and productivity are important elements\u000d\u000a      of public accountability for how the &#163;106 billion annual NHS budget is\u000d\u000a      spent. York researchers have conducted a programme of research to improve\u000d\u000a      the measurement of NHS productivity at macro, meso and micro levels.\u000d\u000a      Methods developed at York have been used to seek explanations for\u000d\u000a      variations in productivity.\u000d\u000a    National NHS productivity\u000d\u000a    In 2005, a York team (Street, Castelli, Gravelle, Dawson) developed novel\u000d\u000a      and substantially improved methods to measure the productivity of the NHS\u000d\u000a      in England (1). This was followed by an ongoing research programme which\u000d\u000a      has continuously refined and improved the methods over the subsequent 8\u000d\u000a      years.\u000d\u000a    The productivity estimates that researchers at York developed were\u000d\u000a      derived from detailed secondary analysis of routinely collected NHS data.\u000d\u000a      They represented an advance on standard practice in other sectors and\u000d\u000a      internationally in three important ways (1). Firstly, the index of outputs\u000d\u000a      was comprehensive, capturing activities in 5,381 healthcare\u000d\u000a      categories for all NHS patients treated by either NHS or non-NHS\u000d\u000a      providers, incorporating information about every patient treated in\u000d\u000a      hospital including outpatient and accident and emergency departments,\u000d\u000a      mental health and community care settings, diagnostic facilities, and\u000d\u000a      primary care. Second, the quality of output was assessed by\u000d\u000a      including indicators such as health outcomes, patient satisfaction,\u000d\u000a      waiting times and readmissions. Third, better measures of NHS input,\u000d\u000a      particularly labour and capital, were compiled. Annual estimates of NHS\u000d\u000a      input, output and productivity growth are now produced by York researchers\u000d\u000a      for the Department of Health (DoH) (2), incorporating updated methods and\u000d\u000a      new data each year. They include a range of sensitivity analyses to ensure\u000d\u000a      robust estimates. Methods to analyse regional productivity have also been\u000d\u000a      developed, with estimates showing significant variation across the country\u000d\u000a      which indicate potential savings of &#163;3.2bn (3).\u000d\u000a    Specialist hospital care\u000d\u000a    Research on specialist hospital care, undertaken by Street and Daidone in\u000d\u000a      2010 and 2011, applied advanced econometric methods to hospital data for\u000d\u000a      over 26 million patients. They isolated the extra costs associated with\u000d\u000a      the provision of specialist care, accounting for a range of other factors\u000d\u000a      that may also influence hospital costs. Results showed that higher costs\u000d\u000a      were legitimately associated with the provision of specialised care only\u000d\u000a      for a small number of conditions and groups, including cancer, cystic\u000d\u000a      fibrosis and children's care (4).\u000d\u000a    Hospital consultant productivity\u000d\u000a    Bloor and Maynard developed and applied methods of measuring the\u000d\u000a      productivity of individual hospital consultants (5). Linking NHS data with\u000d\u000a      information about consultants from the Medical Workforce Census for the\u000d\u000a      first time, datasets of inpatient activity were derived for all\u000d\u000a      consultants in ten specialties in England. Using multi-level modelling,\u000d\u000a      factors were identified that predict consultant productivity. Consultants\u000d\u000a      with a `maximum part-time contract' (permitting substantial private\u000d\u000a      practice) were found to treat more NHS patients on average than their\u000d\u000a      full-time NHS colleagues, as did those with clinical excellence awards\u000d\u000a      (bonus payments) (6). This finding was reinforced in a later study which\u000d\u000a      included exploration of associations between clinical excellence awards\u000d\u000a      and consultant productivity (7). Finally, using interrupted time series,\u000d\u000a      it was shown that reform of the consultant contract in 2003 failed to\u000d\u000a      improve consultant productivity, and indeed in some specialties such as\u000d\u000a      trauma and orthopaedic surgery, the effect was negative (8).\u000d\u000a    Contributors to the research:\u000d\u000a    Karen Bloor, (Senior Research Fellow (SRF), Prof, 1991-); Chris Bojke\u000d\u000a      (SRF 2009-); Adriana Castelli (Research Fellow (RF), SRF 2004-); Silvio\u000d\u000a      Daidone (RF, 2010); Diane Dawson (SRF 1997-2005; Nick Freemantle\u000d\u000a      (SRF,1993- 2000); Rosalind Goudie, (RF, 2011); Hugh Gravelle (Prof,\u000d\u000a      1995-); Mauro Laudicella (RF 2007-10); Alan Maynard (Prof 1971-); Andrew\u000d\u000a      Street (1999-SRF, Prof); Padraic Ward (RF 2008-12).\u000d\u000a    "},{"CaseStudyId":"43412","Continent":[{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"2802361","Name":"Belgium"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"1605651","Name":"Thailand"},{"GeoNamesId":"453733","Name":"Estonia"},{"GeoNamesId":"3686110","Name":"Colombia"},{"GeoNamesId":"298795","Name":"Turkey"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"1814991","Name":"China"},{"GeoNamesId":"6290252","Name":"Serbia"}],"Funders":["Wellcome Trust","Medical Research Council"],"ImpactDetails":"\u000d\u000a    The research undertaken at York underpins NICE technology appraisal\u000d\u000a      methods. NICE's 2008 \"Guide to the Methods of Technology Appraisal\" (source\u000d\u000a        1) describes the key principles of appraisal methodology which must\u000d\u000a      be adhered to by all organisations submitting evidence to the technology\u000d\u000a      appraisal programme. The guidance was shaped by the York research and York\u000d\u000a      researchers involved in: the NICE Decision Support Unit (Palmer); the\u000d\u000a      Methodology Working Party (Sculpher); the Methods Guide Review Workshops\u000d\u000a      (Sculpher, Griffin); producing 3 briefing papers (source 2). The\u000d\u000a      Guide drew on York research showing the need to consider the uncertainty\u000d\u000a      and limitations of the evidence base and a requirement for rigorous\u000d\u000a      methods \"to assess the implications of uncertainty, including the\u000d\u000a        uncertainty around the appropriate structure of the economic model, the\u000d\u000a        choice of sources and analyses to inform the estimates of costs and\u000d\u000a        health effects, and the precision with which these are known.\" (para\u000d\u000a      5.1.11).\u000d\u000a    This Guide (and the 2013 version) has governed the methods used to\u000d\u000a      generate each of the 161 pieces of Technology Guidance issued by NICE\u000d\u000a      since 2008. These are relevant to clinical practice in conditions that are\u000d\u000a      major causes of mortality and morbidity which also place significant\u000d\u000a      demands on NHS resources. Over half of NICE guidance has been in the areas\u000d\u000a      of cancer, cardiovascular and respiratory heath, which, in 2008, were\u000d\u000a      responsible for almost 350,000 deaths (associated with over 2m years of\u000d\u000a      life lost) and accounted for over &#163;16bn of NHS spending. York research on\u000d\u000a      methods for evidence synthesis was cited extensively in four NICE Decision\u000d\u000a      Support Unit Technical guidance documents in 2011 (source 3). NICE\u000d\u000a      has reviewed the Methods Guide (2013) and York staff have been heavily\u000d\u000a      involved as members and facilitators of the Methods Guide Review Workshops\u000d\u000a      (Griffin, McKenna, Palmer, Sculpher, Spackman, Walker) and have produced a\u000d\u000a      briefing paper on the appropriate cost perspective for NICE appraisals to\u000d\u000a      adopt (ie, whether evaluation of healthcare interventions should include\u000d\u000a      costs that fall on non-health sectors) (source 4). Sculpher\u000d\u000a      participated in the decision-making meetings on perspective and the\u000d\u000a      revised Guide follows York recommendations in terms of limiting the\u000d\u000a      perspective to the NHS and personal social services, unless NICE\u000d\u000a      specifically requests a broader scope (source 5).\u000d\u000a    The Department of Health's consultation document on value based pricing\u000d\u000a      referred to the need to establish the evidence base for an appropriate\u000d\u000a      cost-effectiveness threshold, saying that \"Work is already in hand with\u000d\u000a        external experts to achieve this\", citing Sculpher's research as the\u000d\u000a      source of that evidence (source 6). The value and appropriateness\u000d\u000a      of NICE processes were reviewed by the House of Commons Health Select\u000d\u000a      Committee. Oral and written evidence was presented by York on the cost\u000d\u000a      effectiveness threshold used by NICE and expenditure decisions by Primary\u000d\u000a      Care Trusts. The Select Committee advocated that further research -\u000d\u000a      similar to that undertaken by York - takes place on the cost effectiveness\u000d\u000a      thresholds used by NICE. The Government endorsed the Committee's\u000d\u000a      expression of support for NICE's programmes and commended the processes by\u000d\u000a      which it discharges its responsibilities (source 7).\u000d\u000a    The York contribution to economic evaluation methods used by NICE is\u000d\u000a      internationally influential. Countries that have developed\/are developing\u000d\u000a      decision-making institutions like NICE are listed by NICE International\u000d\u000a      and the methods adopted are based on those developed by York (source\u000d\u000a        8). York researchers have been involved in directly advising other\u000d\u000a      health systems about their methods and processes of technology assessment,\u000d\u000a      for example, in Ireland: \"The guidelines for evaluating clinical\u000d\u000a        effectiveness have been developed in consultation with the Scientific\u000d\u000a        Advisory Group of the Authority... this group includes methodological\u000d\u000a        experts from the field of HTA.\" Drummond and Sculpher are listed in\u000d\u000a      the Scientific Group as the only non-Irish members (source 9). The\u000d\u000a      Belgian Guidelines external expert group lists York's Claxton and Gravelle\u000d\u000a      as the only UK experts (source 10) and Sculpher is the only\u000d\u000a      non-North American on the USA Cost-effectiveness Panel (source 11).\u000d\u000a      The establishment and\/or development of approaches to technology appraisal\u000d\u000a      in countries such as Brazil, USA, China, Colombia, Estonia, Serbia,\u000d\u000a      Thailand and Turkey are influenced by the methods and processes developed\u000d\u000a      by York and employed by NICE: eg, the Brazilian guidelines: \"The entire\u000d\u000a        methodology pointed out in the following topics is based on\u000d\u000a        internationally published methodological guidelines\" &#8212; and cites\u000d\u000a      NICE as one of the sources (source 12); the US Wellpoint HTA\u000d\u000a      Guidelines: \"The US Panel on Cost-Effectiveness and the latest NICE\u000d\u000a        Guide to the Methods of Technology Appraisal argue for the pivotal role\u000d\u000a        of a reference case in driving resource allocation decisions within\u000d\u000a        health care systems. This position is also taken by WP ...\" (source\u000d\u000a        13).\u000d\u000a    Our research has impacted on major NHS policy initiatives and has had a\u000d\u000a      wider impact on the health care system. York research on the Quality and\u000d\u000a      Outcomes Framework (QOF), whereby GPs are paid for achieving quality, has\u000d\u000a      informed the approach taken by NICE. Since 2009 NICE has been responsible\u000d\u000a      for producing an annual `menu' of new, evidence-based cost-effective\u000d\u000a      clinical and health improvement indicators. The methods used by NICE to\u000d\u000a      assess the value for money of potential QOF indicators are taken directly\u000d\u000a      from York's research: \"this appendix presents the underpinning\u000d\u000a        assumptions and data requirements that will be used to determine cost\u000d\u000a        effectiveness by the York Health Economics Consortium. The work has been\u000d\u000a        informed by research undertaken by York University and University of\u000d\u000a        East Anglia ...\" (source 14). By ensuring that QOF payments\u000d\u000a      reflect the value of the indicators in terms of the health benefit\u000d\u000a      produced, our research helps to ensure maximum health gain is achieved for\u000d\u000a      money spent on rewarding high quality care. The QOF indicators cover a\u000d\u000a      range of conditions and activities for the population of 54 million\u000d\u000a      registered patients in England served by over 8,000 GP practices, thus the\u000d\u000a      impact on quality is considerable.\u000d\u000a    Professor Sir Michael Rawlins, chair of NICE until 2012, supporting our\u000d\u000a      successful application for a Queen's Anniversary Prize, described York's\u000d\u000a      impact: \"The centre [CHE, Uni of York] has made extraordinary\u000d\u000a        contributions both nationally and internationally to the development of\u000d\u000a        health economics. It has done so from both a theoretical and practical\u000d\u000a        standpoint. In particular, its contributions to the work of NICE have\u000d\u000a        been so very important that I doubt if we would have achieved anything\u000d\u000a        without the rigour and expertise provided by the Centre and many of its\u000d\u000a        staff.\"\u000d\u000a    ","ImpactSummary":"\u000d\u000a    A programme of methodological research undertaken by the University of\u000d\u000a      York has shaped the economic evaluation methods used by the National\u000d\u000a      Institute for Health and Care Excellence (NICE) since its inception, to\u000d\u000a      assess the cost-effectiveness of healthcare interventions. Therefore the\u000d\u000a      methods developed by York underpin many of the healthcare decisions by\u000d\u000a      NICE on which new and existing interventions and programmes should be\u000d\u000a      funded and used in the NHS. The methods used by NICE have also had a major\u000d\u000a      influence on the approach taken to technology assessment internationally\u000d\u000a      and so York's underpinning research has had wide impact beyond the UK.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of York\u000d\u000a    ","Institutions":[{"AlternativeName":"York (University of)","InstitutionName":"University of York","PeerGroup":"B","Region":"Yorkshire And Humberside","UKPRN":10007167}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    Most of the research has been published in high quality peer reviewed\u000d\u000a      journals and was supported primarily by competitively awarded grants.\u000d\u000a    \u000a1. Claxton K., Sculpher MJ., and Drummond M. A rational framework for\u000d\u000a      decision making by the National Institute for Clinical Excellence. Lancet,\u000d\u000a      2002; 360: 711-715. DOI: 10.1016\/S0140-6736(02)09832-X\u000d\u000a    \u000a\u000a2. Griffin S, Claxton K, Hawkins N, Sculpher MJ. Probabilistic analysis\u000d\u000a      and computationally expensive models: necessary and required? Value in\u000d\u000a        Health 2006; 9: 244-252. DOI: 10.1111\/j.1524-4733.2006.00107.x\u000d\u000a    \u000a\u000a3. Claxton K., Sculpher MJ., McCabe C., Briggs A., Akehurst R., Buxton\u000d\u000a      M., Brazier J. and O'Hagan A. Probabilistic sensitivity analysis for NICE\u000d\u000a      technology assessment: not an optional extra. Health Economics,\u000d\u000a      2005; 14: 339-347. DOI: 10.1002\/hec.985\u000d\u000a    \u000a\u000a4. Ades AE, Sculpher MJ, Sutton A, Abrams K, Cooper N, Welton. Bayesian\u000d\u000a      methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics\u000d\u000a        2006 ;24:1-19. DOI: 10.2165\/00019053-200624010-00001\u000d\u000a    \u000a\u000a5. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R ,\u000d\u000a      Bradburn M and Eastwood AJ. Indirect comparisons of competing\u000d\u000a      interventions Health Tech Assess; 2005; 9(26).\u000d\u000a    \u000a\u000a6. Sculpher MJ. Subgroups and heterogeneity in cost-effectiveness\u000d\u000a      analysis Pharmacoeconomics. 2008;26:799-806. DOI:\u000d\u000a      10.2165\/00019053-200826090-00009\u000d\u000a    \u000a\u000a7. Fenwick E, Claxton K, Sculpher M. The value of implementation and the\u000d\u000a      value of information: combined and uneven development. Medical\u000d\u000a        Decision Making 2008;28:21-32. DOI: 10.1177\/0272989X07308751\u000d\u000a    \u000a\u000a8. Walker S, Mason A, Claxton K, Cookson R, Fenwick E, Fleetcroft\u000d\u000a      R, Sculpher M. Value for money and the quality and outcomes framework in\u000d\u000a      primary care in the NHS. British Journal of General Practice\u000d\u000a      2010;60(574):213-20. DOI: 10.3399\/bjgp10X501859\u000d\u000a    \u000a\u000a9. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N,\u000d\u000a      Smith P, Sculpher MJ. (2013) Methods for the estimation of the NICE\u000d\u000a      cost-effectiveness threshold. CHE Research Paper http:\/\/www.york.ac.uk\/media\/che\/documents\/papers\/researchpapers\/CHERP81_Methods_estimation_NICE_costeffectiveness_threshold.pdf\u000d\u000a    \u000aGrants supporting the research\u000d\u000a      Sculpher MJ, Claxton K. Methodological issues relating to decision\u000d\u000a      analysis for resource allocation in healthcare. MRC HSRC Programme Grant\u000d\u000a      1.4.04-31.3.09. &#163;437,281 (York element)\u000d\u000a      Sculpher MJ. National Public Health Career Scientist. 1.7.01-30.6.06.\u000d\u000a      NHSR&amp;D &#163;304,826. Manca A. Issues in generalisibility by location of\u000d\u000a      results in economic evaluation. Wellcome Fellowship 1.9.04-31.8.07. The\u000d\u000a      Wellcome Trust &#163;131,552.\u000d\u000a      Ginnelly L. Use of decision analysis for evidence synthesis\u000d\u000a      1.10.04-30.9.07. NCCRCD &#163;150,446.\u000d\u000a      Sculpher MJ, Claxton K, et al. Economic Evaluation of Healthcare\u000d\u000a      Interventions DH Policy Research Programme (with Sheffield) 2011-2016.\u000d\u000a      &#163;1,891,841 (York element).\u000d\u000a      Sculpher MJ, Claxton K, Palmer S. NICE Decision Support Unit (with\u000d\u000a      Sheffield) 1.4.03-31.3.12 &#163;116,615; and Palmer SJ 1.4.12-31.3.17 &#163;87,615.\u000d\u000a      Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing\u000d\u000a      interventions 1999.\u000d\u000a      NIHR HTA &#163;37,385 (with Oxford).\u000d\u000a      Sculpher MJ. Are the quality &amp; outcomes framework (QOF) indicators a\u000d\u000a      cost-effective use of NHS\u000d\u000a      resources? 1.1.07-30.6.07. Department of Health Policy Research Programme\u000d\u000a      &#163;69,536.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"14","Level2":"2","Subject":"Applied Economics"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    \u000d\u000a      National Institute for Health and Clinical Excellence (NICE). Guide\u000a          to the Methods of Technology Appraisal. London: NICE, 2008.\u000d\u000a        http:\/\/www.nice.org.uk\/media\/B52\/A7\/TAMethodsGuideUpdatedJune2008.pdf\u000a\u000d\u000a      A Special issue of Pharmacoeconomics 2008 volume 26, issue 9 published\u000d\u000a        all the briefing papers produced as part of the development of the NICE\u000d\u000a        Methods Guidance, including 4 involving authors from York. http:\/\/link.springer.com\/journal\/40273\/26\/9\/page\/1\u000a\u000d\u000a      NICE Decision Support Unit Technical Documents 1-4. Dias S et al 2011\u000d\u000a        http:\/\/www.nicedsu.org.uk\/Technical-Support-Documents(1985314).htm\u000a\u000d\u000a      Centre for Health Economics Research paper 54 http:\/\/www.york.ac.uk\/media\/che\/documents\/papers\/researchpapers\/rp54_appropriate_perspectives_for_health_care_decisions.pdf\u000a\u000d\u000a      Guide to the methods of technology appraisal 2013. NICE, April 2013\u000d\u000a        http:\/\/publications.nice.org.uk\/guide-to-the-methods-of-technology-appraisal-2013-pmg9\u000a\u000d\u000a      Dept of Health A new value-based approach to the pricing of branded\u000d\u000a        medicines, 2010\u000d\u000a        http:\/\/webarchive.nationalarchives.gov.uk\/20110322002013\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@en\/documents\/digitalasset\/dh_122793.pdf\u000a\u000d\u000a      House of Commons Health Committee. National Institute for Health and\u000d\u000a        Clinical Excellence: First report of the Health Committee 2007-08.\u000d\u000a        HC550. London: Stationery Office, 2008.\u000d\u000a        http:\/\/www.publications.parliament.uk\/pa\/cm200708\/cmselect\/cmhealth\/27\/27.pdf\u000a\u000d\u000a    \u000d\u000a    House of Commons Health Committee. National Institute for Health and\u000d\u000a      Clinical Excellence: NICE's response to the Health Select Committee's\u000d\u000a      first report of session 2007-08. HC550; 2008.\u000d\u000a      http:\/\/www.publications.parliament.uk\/pa\/cm200708\/cmselect\/cmhealth\/550\/550.pdf\u000d\u000a    The Government's Response to the Health Select Committee's first report\u000d\u000a      of session 2007-08 on the NICE. CM7331; 2008.\u000d\u000a      http:\/\/webarchive.nationalarchives.gov.uk\/20080817152455\/http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Legislation\/DH_083348?IdcService=GET_FILE&amp;dID=161359&amp;Rendition=Web\u000d\u000a    \u000d\u000a      NICE International Review 2011\u000d\u000a        http:\/\/www.nice.org.uk\/media\/5F8\/F8\/NICEInternationalReview2011.pdf\u000a\u000d\u000a      Health Information and Quality Authority. Guidelines for Evaluating\u000d\u000a        the Clinical Effectiveness of Health Technologies in Ireland.\u000d\u000a        Dublin: Health Information and Quality Authority; 2011.\u000d\u000a        http:\/\/www.hiqa.ie\/healthcare\/health-technology-assessment\/guidelines\u000a\u000d\u000a      Guidelines for pharmacoeconomic evaluations in Belgium. KCE Report\u000d\u000a        78C. Belgium Healthcare Knowledge Centre, 2008. Updated in 2011 (KCE\u000d\u000a        report 103) with similar citation.\u000d\u000a        https:\/\/kce.fgov.be\/sites\/default\/files\/page_documents\/d20081027327.pdf\u000a\u000d\u000a      Second panel on cost-effectiveness in health and medicine, USA http:\/\/2ndcep.hsrc.ucsd.edu\/\u000a\u000d\u000a      Methodological Guidelines for Appraisals on HTA for the Ministry of\u000d\u000a        Health of Brazil. Department of Science and Technology, 2007. Section\u000d\u000a        2.2:\u000d\u000a        http:\/\/200.214.130.94\/rebrats\/publicacoes\/diretrizes_ptc.pdf\u000a\u000d\u000a      Wellpoint HTA Guidelines The Wellpoint Outcomes based\u000d\u000a        formulary 2008\u000d\u000a        http:\/\/www.elsevierbi.com\/~\/media\/Images\/Publications\/Archive\/The%20Pink%20Sheet\/70\/043\/00700430001\/wellpoint_formulary_guidelines.pdf\u000a\u000d\u000a      NICE Developing clinical and health improvement indicators for the\u000d\u000a          Quality and Outcomes Framework: Interim process guide. May 2009,\u000d\u000a        Appendix A.\u000d\u000a        http:\/\/www.nice.org.uk\/media\/742\/32\/QOFProcessGuide.pdf\u000a\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Methods development in economic evaluation to support decision making\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    The University of York has been providing the evidence to support the\u000d\u000a      NICE technology appraisal process since its inception in 1999. The process\u000d\u000a      entails assessment of the benefits, harms and cost-effectiveness of\u000d\u000a      healthcare interventions. Given the nature of NICE's decision-making\u000d\u000a      responsibilities, the methods used for cost effectiveness analysis (CEA)\u000d\u000a      required further development. York research addressed important\u000d\u000a      methodological issues and has therefore shaped the methods adopted by NICE\u000d\u000a      in key areas (listed below). Developing methods for evaluation of\u000d\u000a      healthcare technologies brings together a range of research skills from\u000d\u000a      different institutions. Much of the work described was led by York whose\u000d\u000a      researchers have made a sustained intellectual contribution throughout the\u000d\u000a      period, centred on methods of cost effectiveness analysis to support\u000d\u000a      health system decision making; characterising and reflecting evidential\u000d\u000a      uncertainty and heterogeneity; and value of information analysis to\u000d\u000a      prioritise and design research. Much of the research was led by York or,\u000d\u000a      where undertaken in collaboration with other institutions, York\u000d\u000a      researchers made significant intellectual contributions focusing on the\u000d\u000a      economic issues.\u000d\u000a    (1) Approaches to dealing with decision uncertainty\u000d\u000a      We demonstrated: the sensitivity of evaluation results to key parameter\u000d\u000a      estimates and the centrality of handling uncertainty appropriately in\u000d\u000a      decision making; the importance of dealing with uncertainty in all sources\u000d\u000a      of evidence simultaneously using probabilistic methods; the need to link parameter\u000d\u000a      uncertainty to decision uncertainty and to the value of additional\u000d\u000a      research; the potential need to tie access to new technologies to\u000d\u000a      requirements for more data collection (1-3).\u000d\u000a    (2) Methods for evidence synthesis for use in economic evaluation\u000d\u000a      Research with the Bristol University (York co-investigators) considered\u000d\u000a      appropriate methods for evidence synthesis to support decisions by NICE\u000d\u000a      and similar organisations. We demonstrated how to estimate the\u000d\u000a      effectiveness of an intervention relative to policy relevant comparators\u000d\u000a      where no head-to-head comparison was available (4), building on earlier\u000d\u000a      York research (5).\u000d\u000a    (3) Approaches to dealing with heterogeneity\u000d\u000a      We showed the importance of exploring variation in both the effects and\u000d\u000a      the costs of health technologies according to patient clinical and\u000d\u000a      socio-demographic characteristics. The research can inform decisions on\u000d\u000a      which interventions should be recommended for which patients. We also\u000d\u000a      explored the methodological issues raised by undertaking sub-group\u000d\u000a      analysis in CEA (6).\u000d\u000a    (4) Methods to estimate the cost-effectiveness of increasing NHS\u000d\u000a        uptake of innovation\u000d\u000a      A major challenge for most healthcare systems is how to ensure the\u000d\u000a      adoption of cost-effective interventions. Value of implementation\u000d\u000a      analysis, which estimates the level of investment justified for\u000d\u000a      implementation activities was developed in York (7). With clinical input\u000d\u000a      from East Anglia, we proposed that the Quality and Outcomes Framework\u000d\u000a      performance indicators should use value of implementation analysis,\u000d\u000a      applying the same evidential standards as those used by NICE (8).\u000d\u000a    (5) Estimating the cost-effectiveness threshold\u000d\u000a      CEA assesses whether the expected health gain from the use of a new\u000d\u000a      medical technology exceeds the health likely to be forgone as other NHS\u000d\u000a      activities are displaced to cover the additional costs of the new\u000d\u000a      technology. The cost-effectiveness threshold represents an estimate of the\u000d\u000a      health forgone as services are displaced. York researchers developed\u000d\u000a      appropriate methods for threshold estimation to be used in decisions about\u000d\u000a      the use of NHS resources (9).\u000d\u000a    Researchers: Mark Sculpher (Prof Nov 1997-); Susan Griffin (Research\u000d\u000a      Fellow (RF) &amp; Senior Research Fellow (SRF) Oct 2002-) Richard Cookson\u000d\u000a      (Reader Aug 2006-); Simon Walker (RF Oct 2006-); Karl Claxton (SRF &amp;\u000d\u000a      Prof Oct 1989-); Anne Mason (RF &amp; SRF June 1998-); Stephen Palmer (SRF\u000d\u000a      &amp; Prof April 1995-); Mike Drummond (Prof May 1990-); Fuijan Song (SRF\u000d\u000a      July 1993-Oct 2000); Alison Eastwood (RF &amp; SRF Sept 1994-); Anne-Marie\u000d\u000a      Glenny (RF Oct 1995-April 1999); Elizabeth Fenwick (RF Oct 1999-Dec 2005);\u000d\u000a      Marta Soares (RF 2007); Seb Hind (RF Oct 2010-); Eldon Spackman (RF Feb\u000d\u000a      2010-)\u000d\u000a    "},{"CaseStudyId":"43413","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"6251999","Name":"Canada"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    (a) Screening for depression in primary care\u000d\u000a    Prior to the conduct and dissemination of our work, guidance issued by\u000d\u000a      NICE (source 1) and international bodies such as the US Agency for\u000d\u000a      Healthcare Research and Quality (AHRQ) (source 2) had been\u000d\u000a      supportive of screening for depression. In the UK, since 2005 General\u000d\u000a      Practitioners were paid to screen for depression in certain populations\u000d\u000a      under the Quality and Outcomes Framework (QoF) (the `DEP 1 indicator').\u000d\u000a      Our research showed that this strategy was ineffective and inefficient.\u000d\u000a      Our outputs generated debate both nationally and internationally,\u000d\u000a      prompting editorials in the BMJ (source 3) and the Canadian Medical\u000d\u000a      Association Journal (source 4).\u000d\u000a    National impact\u000d\u000a    (i) The National Screening Committee (NSC), which oversees screening\u000d\u000a      programmes in the NHS, reversed its policy recommendations on the\u000d\u000a      effectiveness of screening for depression in primary care using our work\u000d\u000a      as the primary source of evidence (source 5). The 2010 NSC\u000d\u000a      evidence-based policy cites and updates our work: \"This paper uses\u000d\u000a        evidence published up to June 2009 to update the review by Gilbody et al\u000d\u000a        of the performance of screening for depression....Routine screening of\u000d\u000a        the population or subsets of the population for depression is now not\u000d\u000a        recommended by the UK NSC.\" (source 5);\u000d\u000a    (ii) NICE's 2009 guidelines for depression (CG90) now recommend against\u000d\u000a      routine screening and cite our Cochrane reviews as the main source of\u000d\u000a      evidence (source 6), reversing previous policy;\u000d\u000a    (iii) In 2011 the body which oversees the Quality and Outcomes Framework\u000d\u000a      (QOF) ceased to incentivise screening for depression, and `retired' and\u000d\u000a      `revised' the QOF DEP indicators, citing York-led research to conclude `case-finding\u000a        for depression as a routine strategy has not been shown to improve\u000d\u000a        outcomes, or process measures, based on high quality evidence' (source\u000a        7). The annual costs of supporting the QOF DEP indicators were &#163;8.4M\u000d\u000a      (source 8).The revision of QOF indicators has improved the use of\u000d\u000a      NHS resources.\u000d\u000a    International impact\u000d\u000a      Our reviews are also cited in evidence summaries in other healthcare\u000d\u000a      systems, demonstrating the international reach of our work. The Agency for\u000d\u000a      Healthcare Research and Quality and the US Preventative Services Task\u000d\u000a      Force (two of the most influential and respected federally-funded\u000d\u000a      organisations in the USA) refer to our research in their 2009 revision of\u000d\u000a      depression guidelines, where a reversal of policy is made on the basis of\u000d\u000a      our reviews (source 9).\u000d\u000a    (b) Effective and efficient strategies to manage depression in primary\u000d\u000a        care\u000d\u000a    National impact\u000d\u000a      The first iteration of guidance from the National Institute of Health and\u000d\u000a      Care Excellence (NICE) in 2004 did not mention collaborative care. Our\u000d\u000a      research helped produce a wholesale shift in emphasis towards primary care\u000d\u000a      led strategies with improved access to more effective care and improved\u000d\u000a      outcomes for the substantial section of the population who suffer from\u000d\u000a      depression.\u000d\u000a    (i) NICE revised its guidelines on the management of depression in 2009\u000d\u000a      and 2011 and our research is cited (47 times in the most recent guidance)\u000d\u000a      as evidence of the effectiveness of collaborative care as an\u000d\u000a      organisational model (sources 6 &amp; 10).\u000d\u000a    (ii) Our research also formed the evidential basis for an influential\u000d\u000a      handbook for NHS commissioners on the configuration\/specification of\u000d\u000a      primary care for depression which helped to change practice over the REF\u000d\u000a      period (source 11) `This handbook seeks to provide guidance on\u000d\u000a        a model of care for depression in line with the current evidence\u000d\u000a      (cites Gilbody's reviews).'\u000d\u000a    (iii) There has been NHS-wide improved access to psychological therapies\u000d\u000a      (IAPT) for depression as a result of a major UK policy shift and\u000d\u000a      investment initiated in 2006. York's research was directly cited as the\u000d\u000a      evidence underpinning the first `demonstration sites' in Doncaster (source\u000a        12). Due to the success of field trials this programme was scaled up\u000d\u000a      and one million NHS patients received new episodes of care under the IAPT\u000d\u000a      by 2013 (source 13).\u000d\u000a    (iv) York developed a secure and responsive computer support system to\u000d\u000a      record treatments and track patient progress over time (Primary Care\u000d\u000a      Management Information System &#8212; PC-MIS&#169;). This formed the\u000d\u000a      central I support for our collaborative care trials (www.pc-mis.co.uk\/).\u000a      PC-MIS&#169;has been widely adopted; it is being used in 69 NHS\u000d\u000a      trusts and has recorded the outcome of over one million patient episodes\u000d\u000a      (over six million individual patient contacts) since roll out in 2006 (source\u000a        14).\u000d\u000a    (v) We pioneered the analysis of PC-MIS IAPT clinical outcome data to\u000d\u000a      'benchmark' local clinical performance against national standards. This\u000d\u000a      system of service-level evaluations was adopted nationally and forms a\u000d\u000a      national template to allow mental health services to engage in `Payment by\u000d\u000a      Results' based on reliable and statistically significant measures of\u000d\u000a      clinical change (source 15). The metrics of treatment success which\u000d\u000a      York researchers developed though PC-MIS&#169; are now the `gold\u000d\u000a      standard outcome' for IAP `Payment by Results' (source 16), which\u000d\u000a      is being rolled out across the NHS, having initially been piloted in 23\u000d\u000a      sites in the UK.\u000d\u000a    International impact\u000d\u000a      Our research is cited in international guidelines in the US, Canada,\u000d\u000a      Europe and Australia. York's evidence synthesis, for example, formed an\u000d\u000a      organising principle in the US Veterans Affairs services for depression (source\u000a        17) and influenced (and was cited in) the 2009 revision of\u000d\u000a      depression guidelines by the Agency for Healthcare Research and Quality\u000d\u000a      &amp; US Preventative Services Task Force (source 9). York's 2006\u000d\u000a      review is cited as the evidential basis for a US-wide training programme\u000d\u000a      led from the University of Washington (the IMPACT evidence based\u000d\u000a        depression care programme www.impact-uw.org).\u000a      (`A meta-analysis of the evidence for collaborative depression care was\u000d\u000a        published by Gilbody, et al ...concluded that sufficient randomized\u000d\u000a        evidence had emerged by 2000 to demonstrate the effectiveness of\u000d\u000a        collaborative care beyond conventional levels of statistical\u000d\u000a        significance. ...and it is unlikely that further randomized evidence\u000d\u000a        will overturn this result.' (Source 18). This programme of\u000d\u000a      training and organisational enhancement for depression has now been\u000d\u000a      implemented in 31 states in the USA, and has been adopted by a number of\u000d\u000a      US healthcare providers, including Kaiser Permanente (serving over 3\u000d\u000a      million people) and the Institute for Urban Family Health) (source 18).\u000d\u000a    ","ImpactSummary":"\u000d\u000a    York research showing that a) screening for depression in primary\u000d\u000a        care is ineffective and b) collaborative and stepped care\u000d\u000a      improves outcomes for depression in primary care, has changed national and\u000d\u000a      international policy. The National Institute for Health and Care\u000d\u000a      Excellence (NICE) revised its guidelines, the National Screening Committee\u000d\u000a      altered its recommendations, and money has been saved by no longer paying\u000d\u000a      GPs to screen for depression under the Quality and Outcomes Framework. US\u000d\u000a      advisory bodies have also shifted away from recommending routine screening\u000d\u000a      for depression. Treatment guidelines\/programmes in the USA, Europe and\u000d\u000a      Australia now recommend collaborative care for the management of\u000d\u000a      depression. Our research has also resulted in an expansion of the NHS\u000d\u000a      Improving Access to Psychological Therapies programme, with many patients\u000d\u000a      benefitting from improved care. The computer support system (PC-MIS&#169;)\u000d\u000a      we developed to record treatments and to track patient progress over time\u000d\u000a      is the most widely used in the NHS. The clinical performance benchmarks we\u000d\u000a      derived from this form the basis of metrics used for NHS-wide performance\u000d\u000a      management of depression services.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of York\u000d\u000a    ","Institutions":[{"AlternativeName":"York (University of)","InstitutionName":"University of York","PeerGroup":"B","Region":"Yorkshire And Humberside","UKPRN":10007167}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    The research findings have been published in high quality peer-reviewed\u000d\u000a      journals. All the research was funded by competitive, peer-reviewed grants\u000d\u000a      from the MRC.\u000d\u000a    \u000a1. Gilbody, SM, House, AO, Sheldon, TA (2008) Routine screening\/case\u000d\u000a      finding for depression (Cochrane Review). The Cochrane Library\u000d\u000a      Wiley. DOI: 10.1002\/14651858.CD002792.pub2\u000d\u000a    \u000a\u000a2. Gilbody, SM, House, AO, Sheldon, TA (2008) Routine screening\/case\u000d\u000a      finding for depression. Canadian Medical Association Journal\u000d\u000a      178(8):997-1003 DOI: 10.1503\/cmaj.070281\u000d\u000a    \u000a\u000a3. Thombs, B., J. Coyne, P. Cuijpers, P. de Jonge, S. Gilbody, J.\u000d\u000a      Ioannidis, B. Johnson, S. Patten, E. Turner and R. Ziegelstein (2011).\u000d\u000a      \"Rethinking recommendations for screening for depression in primary care.\"\u000d\u000a      Canadian Medical Association Journal 184: 413-418. DOI:\u000d\u000a      10.1503\/cmaj.111035\u000d\u000a    \u000a\u000a4. Gilbody, S., P. Bower, J. Fletcher, D. Richards and A. J.\u000d\u000a      Sutton (2006). \"Collaborative care for depression: a cumulative\u000d\u000a      meta-analysis and review of longer-term outcomes.\" Archives of\u000d\u000a        Internal Medicine 166: 2314-2321. 410 citations, Scopus,\u000d\u000a      July 2013. DOI: 10.1001\/archinte.166.21.2314\u000d\u000a    \u000a\u000a5. Richards, D. A., K. Lovell, S. Gilbody, L. Gask, D. Torgerson, M.\u000d\u000a      Barkham, M. Bland, P. Bower, L. A., A. Simpson, J. Fletcher, D. Escott, S.\u000d\u000a      Hennessy and R. Richardson (2008).\u000d\u000a      \"Collaborative care for depression in UK primary care: a randomized\u000d\u000a      controlled trial.\"\u000d\u000a      Psychological Medicine 38: 279-287. DOI: 10.1017\/S0033291707001365\u000d\u000a    \u000aGrants:\u000d\u000a      Gilbody conducted the early work on screening for depression whilst funded\u000d\u000a      by a MRC fellowship in health services research at the University of York\u000d\u000a      (1996-2000). The subsequent Cochrane reviews on screening were conducted\u000d\u000a      whilst Gilbody was a senior lecturer\/Professor at the University of York\u000d\u000a      (2005-).\u000d\u000a    RCT of collaborative care for depression in adults &#8212; MRC grant G03000677\u000d\u000a      (&#163;167,000 2004-2007) Chief investigator Richards and co-investigators\u000d\u000a      Gilbody and Bland.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    1. National Institute for Clinical Excellence (2004). Depression:\u000d\u000a        core interventions in the management of depression in primary and\u000d\u000a        secondary care. London, HMSO.\u000d\u000a    2. Pignone, M. P., B. N. Gaynes, et al. (2002). \"Screening for depression\u000d\u000a      in adults: a summary of the evidence for the U.S. Preventive Services Task\u000d\u000a      Force.\" Ann Intern Med 136: 765-776.\u000d\u000a      http:\/\/annals.org\/article.aspx?articleid=715293\u000d\u000a    3. Scott, J. (2006). \"Depression should be managed like a chronic\u000d\u000a      disease: Clinicians need to move beyond ad hoc approaches to isolated\u000d\u000a      acute episodes.\" BMJ 332(7548): 985. DOI:\u000d\u000a      10.1136\/bmj.332.7548.985\u000d\u000a    4. Stewart, D. E. (2008). \"Battling depression.\" Canadian Med Assoc J\u000d\u000a      178(8): 1023-1024.\u000d\u000a    5. National Screening Committee (2010). An evaluation of screening\u000d\u000a        for depression against NSC criteria. London, HMSO.\u000d\u000a    6. National Institute for Clinical Excellence (2009). Depression:\u000d\u000a        core interventions in the management of depression in primary and\u000d\u000a        secondary care. London, HMSO.\u000d\u000a    7. Primary Care Quality and Outcomes Framework Indicator Advisory\u000d\u000a      Committee Wednesday 8th June 2011 Agenda Item 9.1: Review of Depression\u000d\u000a      indicators &#8212; recommendations on DEP01\u000d\u000a      http:\/\/www.nice.org.uk\/media\/E19\/EA\/NICEIndependentPrimaryCareQOFAdvisoryCommittee080611ConfirmedMinutes.pdf\u000d\u000a    8. Doran, T., et al. (2012). \"Exempting dissenting patients from pay for\u000d\u000a      performance schemes: retrospective analysis of exception reporting in the\u000d\u000a      UK Quality and Outcomes Framework.\" BMJ 344. DOI:10.1136\/bmj.e2405\u000d\u000a    9. US Preventive Services Task Force (2009). \"Screening for depression in\u000d\u000a      adults: US Preventive Services Task Force recommendation statement.\" Annal\u000a        Int Med 151:784-792.\u000d\u000a      DOI:10.7326\/0003-4819-151-11-200912010-00006\u000d\u000a    10. British Psychological Association and the Royal College of\u000d\u000a      Psychiatrists (on behalf of NICE) (2011) Common Mental Health\u000d\u000a        Disorders: Identification and pathways to care. National Clinical\u000d\u000a      Guideline Number 123. http:\/\/guidance.nice.org.uk\/CG123\/Guidance\/pdf\u000d\u000a    11. National Institute for Mental Health in England (NIMHE) (2004). Enhanced\u000a        services specification for depression under the new GP contract.\u000d\u000a      Manchester, NIMHE North West.\u000d\u000a      http:\/\/www.personalitydisorder.org.uk\/assets\/resources\/113.pdf\u000d\u000a    12. National Institute for Mental Health in England (NIMHE) (2005). Improving\u000a        Access to Psychological Therapies.\u000d\u000a    13. Department of Health and IAPT (2012). IAPT three-year report: The\u000d\u000a        first million patients. DoH: http:\/\/www.iapt.nhs.uk\/silo\/files\/iapt-3-year-report.pdf\u000d\u000a    14. The Primary Care Management Information System (PC-MIS)\u000d\u000a      http:\/\/php.york.ac.uk\/healthsciences\/spip.php?rubrique2\u000d\u000a    15. Delgadillo, J., D. McMillan, et al. (2012). \"Benchmarking routine\u000d\u000a      psychological services: a discussion of challenges and methods.\" Behavioural\u000a        &amp; Cognitive Psychotherapy 1(1): 1-15. DOI:\u000d\u000a      10.1017\/S135246581200080X\u000d\u000a    16. The Improving Access to Psychological Therapies Programme &#8212; Defining\u000d\u000a      good clinical outcomes http:\/\/www.iapt.nhs.uk\/good-clinical-outcomes\/\u000d\u000a    17. Chang, E. T., K. B. Wells, E. P. Post and L. V. Rubenstein (2013).\u000d\u000a      \"Determinants of readiness for primary care-mental health integration\u000d\u000a      (PC-MHI) in the VA health care system.\" Journal of General Internal\u000d\u000a        Medicine 28(3): 353-362. doi: 10.1007\/s11606-012-2217-z\u000d\u000a    18. IMPACT Evidence Based Depression Care program: http:\/\/impact-uw.org\/about\/research.html\u000d\u000a      and http:\/\/impact-uw.org\/stories\/implementation.html\u000d\u000a    ","Title":"\u000d\u000a    Improving primary care for depression\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2651123","Name":"Doncaster"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Depression is the most common mental disorder and is the second most\u000d\u000a      common cause for consultation in primary care (where 90% of care is\u000d\u000a      delivered). Estimates of the incidence of depression within the population\u000d\u000a      range from 3-6% of adults. Our programme of research addressed two major\u000d\u000a      issues: (a) screening for depression and (b) organisation and delivery of\u000d\u000a      primary care for management of depression.\u000d\u000a    a) Screening for depression in primary care\u000d\u000a\u0009Our Cochrane\u000d\u000a      review, which pooled data from 16 randomised controlled trials (RCTs)\u000d\u000a      including 5996 patients, reported that screening had no clinical impact on\u000d\u000a      quality of care (RR 1.03; 95% CI: 0.85 to 1.24) or depression outcomes\u000d\u000a      (standardized mean difference -0.02; 95% CI: -0.25 to 0.20).1\u000d\u000a      On the basis of these meta-analyses we, (with international collaborators\u000d\u000a      from McGill, Stanford and Pennsylvania Universities), concluded that the\u000d\u000a      policy of screening for depression did not meet international criteria.2,3\u000d\u000a    b) Organisation and delivery of primary care for management of\u000d\u000a          depression\u000d\u000a    Systematic reviews to evaluate the\u000d\u000a        effectiveness of collaborative care: A meta-analysis in 2006 led by\u000d\u000a      Gilbody (36 RCTs, 12,355 participants) found that average depression\u000d\u000a      outcomes in primary care improved (standardised effect size = 0.26; 95%CI:\u000d\u000a      0.18 - 0.32) when services were managed in a `collaborative' fashion by\u000d\u000a      the use of trained case managers who deliver evidence-based psychological\u000d\u000a      and pharmacological treatments'.4 The greatest improvement in\u000d\u000a      depression outcomes was found where case managers received rigorous\u000d\u000a      training and supervision and used computer-decision support systems\u000d\u000a      (p=0.03).\u000d\u000a    RCT to evaluate clinical and cost effectiveness of collaborative care\u000d\u000a        in the NHS: From 2006 onwards we adapted a model of collaborative\u000d\u000a      care for the NHS (writing treatment manuals, developing a computer support\u000d\u000a      system (PC-MIS&#169;) and training a cohort of case managers to\u000d\u000a      deliver telephone support) using the MRC complex interventions framework.5\u000d\u000a      York researchers then conducted the first UK multi-centre trial of\u000d\u000a      collaborative\/stepped care in adults. This confirmed the model's\u000d\u000a      effectiveness in improving depression outcomes compared to usual care in\u000d\u000a      working age adults (standardised effect size = 0.63 95% CI 0.18-1.07).5\u000d\u000a    University of York Staff\u000d\u000a      Staff: Gilbody (MRC Fellow 1996-2000 &amp; 2005-present as Senior Lecturer\u000d\u000a      and then Professor); Richards (2004-2009 Professor of Mental Health &#8212;\u000d\u000a      academic lead for PC-MIS and lead for IAPT demonstration sites; chief\u000d\u000a      investigator on MRC trials); Sheldon (1992 - present, Senior Research\u000d\u000a      Fellow (SRF) and Professor); Bland (2004-present Professor and lead\u000d\u000a      statistician on MRC trials); Torgerson (1996-present Senior Research\u000d\u000a      Fellow and Professor).\u000d\u000a    "},{"CaseStudyId":"43414","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2635167","Name":"United Kingdom"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Active dissemination of the research as a pathway to impact\u000d\u000a    We planned a targeted dissemination and implementation strategy to\u000d\u000a      promote the adoption of our research findings into practice in health\u000d\u000a      services across England. This included distribution of 60,000 copies of an\u000d\u000a      Effective Health Care bulletin (http:\/\/www.york.ac.uk\/inst\/crd\/EHC\/ehc62.pdf), which\u000a      summarised the findings of our systematic review of interventions to\u000d\u000a      promote the initiation of breastfeeding, to NHS practitioners and\u000d\u000a      service-users and supported this with a targeted media campaign. Second,\u000d\u000a      we produced a NICE `Evidence into Practice' briefing based on our\u000d\u000a      systematic reviews of interventions to promote breastfeeding. Finally we\u000d\u000a      conducted a national consultation with health professionals and\u000d\u000a      management, government, service user and voluntary organisations which\u000d\u000a      highlighted that the routine implementation of multifaceted, local\u000d\u000a      packages of breastfeeding services and the UNICEF UK BFI standards for\u000d\u000a      maternity services should be priorities for action (nice.org.uk\/aboutnice\/whoweare\/aboutthehda\/hdapublications\/promotion_of_breastfeeding_initiati\u000a        on_and_duration_evidence_into_practice_briefing.jsp). Our\u000d\u000a      dissemination and implementation strategy has helped our research have a\u000d\u000a      significant impact on national and international health policy, clinical\u000d\u000a      guidelines, staff education, practice, and infant feeding behaviour as\u000d\u000a      outlined below.\u000d\u000a    Impact on policy statements, guidelines, toolkits and care pathways\u000d\u000a    Our work has directly contributed to the development of national and\u000d\u000a      international policy, including NICE Clinical Guidelines (CG) which UK\u000d\u000a      healthcare professionals are expected to follow.\u000d\u000a    --Initiation and maintenance of breastfeeding\u000d\u000a    \u000d\u000a      The NICE `Evidence into Practice' briefing which we produced was\u000d\u000a        referenced explicitly for its specific contribution to formulating\u000d\u000a        recommendations in the full NICE Clinical Guidance on postnatal care (in\u000d\u000a        2006 and updated in 2012) as well as being cited 16 times in the text.\u000d\u000a        This included the priority recommendation that all maternity care\u000d\u000a        providers in acute and primary settings should implement care using the\u000d\u000a        UNICEF UK BFI as a minimum standard (source 1).\u000d\u000a      Our reviews and evidence summary documents were incorporated into the\u000d\u000a        NICE Maternal and Child Nutrition Public Health Guidance CG 037 (source\u000a          2) and the 2008 NICE CG on antenatal care (source 3). Both\u000d\u000a        NICE documents cited the reviews as evidence to support specific\u000d\u000a        recommendations for \"interactive antenatal breastfeeding education\" and\u000d\u000a        \"one-to-one counselling and peer support\", using the UK UNICEF BFI as a\u000d\u000a        minimum standard.\u000d\u000a      The recent evidence document underpinning the 2013 revision of the UK\u000d\u000a        UNICEF BFI standards cited our reviews and evidence summary documents\u000d\u000a        more than 20 times (source 4).\u000d\u000a      Our systematic reviews are cited in guidelines in Australia and the\u000d\u000a        USA:\u000d\u000a      \u000d\u000a        The Australian National Health &amp; Medical Research Council\u000d\u000a          (NHMRC) Infant Feeding Guideline cites reference 3 in recommending\u000d\u000a          \"evidence-based actions for promoting the initiation and duration of\u000d\u000a          exclusive breastfeeding\" (source 5).\u000d\u000a        The US Surgeon General's Call to Action to Support Breastfeeding\u000d\u000a          cites our research (refs 1 and 3) as the basis for recommending\u000d\u000a          \"professional and lay support [.] to increase the duration of\u000d\u000a          breastfeeding\", and for adoption of UNICEF-BFI training (source 6).\u000d\u000a      \u000d\u000a    \u000d\u000a    --Breastfeeding in neonatal units\u000d\u000a    \u000d\u000a      The systematic reviews of interventions to promote breast (milk)\u000d\u000a        feeding for infants in neonatal units (refs 4, 6) informed the\u000d\u000a        development of the NICE CG on donor breast milk banks (source 7),\u000d\u000a        the Department of Health toolkit for high-quality neonatal services (source\u000a          8), and the UNICEF-BFI guideline for neonatal units (source 9).\u000d\u000a      The Australian NHMRC Infant Feeding Guideline cites ref 4 as providing\u000d\u000a        evidence that \"expressed breast milk reduces the incidence of\u000d\u000a        necrotising enterocolitis\" among preterm infants (source 5).\u000d\u000a      WHO Guidelines on optimal feeding of LBW infants in low\/middle-income\u000d\u000a        countries cites our review (ref 6) as evidence to recommend feeding\u000d\u000a        infants based on hunger cues (source 10).\u000d\u000a    \u000d\u000a    Impact on education and training\u000d\u000a    Our work has had a direct influence on staff education and training. It\u000d\u000a      has formed the basis for the three modules on infant feeding of the\u000d\u000a      Department of Health-funded Royal College of Paediatrics and Child Health\u000d\u000a      e-learning programme on early years, freely available since 2009 to all\u000d\u000a      health professionals in the UK [www.rcpch.ac.uk\/hcp].\u000a      Prof Renfrew worked closely with the charity \"Best Beginnings\" to produce\u000d\u000a      a DVD ('From Bump to Breastfeeding') www.bestbeginnings.org.uk\/fbtb\u000d\u000a      which promotes and supports breastfeeding based on evidence from our\u000d\u000a      systematic reviews. 1.5million copies have been distributed free to\u000d\u000a      pregnant women throughout the UK since 2008.\u000d\u000a    Impact on behaviour and outcomes\u000d\u000a    -- Initiation of breastfeeding\u000d\u000a    Data from the Infant Feeding Survey, collected every 5 years since 1990\u000d\u000a      and standardised for factors associated with breastfeeding (age, education\u000d\u000a      and social class), show that breastfeeding initiation remained static at\u000d\u000a      62% of all women in England &amp; Wales between 1990 and 2000. Comparable\u000d\u000a      data in 2005 and 2010, however, show a 5% point increase at each time\u000d\u000a      point in the number of women starting to breastfeed since the start of the\u000d\u000a      York research programme, from 62% in 2000 to 72% in 2010 (source 11).\u000d\u000a    Standardised data are not available by socio-economic group, but non-\u000d\u000a      standardised data (see graph) indicate relatively larger and sustained\u000d\u000a      increases in the proportion of women from lower socio economic groups\u000d\u000a      starting to breastfeed in England &amp; Wales from 2000 to 2010. This is\u000d\u000a      consistent with York's research (source 11). Changes in the\u000d\u000a      definitions used to categorize \"socio-economic status\" limit the direct\u000d\u000a      comparability of data from the IFS prior to 2000. However, no increases in\u000d\u000a      breastfeeding initiation rates were observed between 1995 and 2000 for\u000d\u000a      both \"non-manual\" (81%) and \"manual\" occupation households (61% ) before\u000d\u000a      this research was carried out.\u000d\u000a    \u000d\u000a   \u000d\u000a   \u000d\u000a   -- Maintenance of breastfeeding\u000d\u000a    The 2010 UK Infant Feeding Survey found that the proportion of women\u000d\u000a      maintaining breast-feeding has continually increased from 2005. The\u000d\u000a      prevalence of breastfeeding at six weeks was static at 45% between 1995\u000d\u000a      and 2000, but then rose to 48% in 2005 and 55% in 2010. Six months rates\u000d\u000a      were 21% in both 1995 and 2000, but then rose to 25% in 2005 and 34% in\u000d\u000a      2010. Exclusive breast-feeding rates have also increased (at three months\u000d\u000a      they were 17% in 2010 compared with 13% in 2005, and at four months they\u000d\u000a      were 12% in 2010 compared with 7% in 2005). Rates of increase were highest\u000d\u000a      in low income women, reflecting our research recommendations to focus on\u000d\u000a      those where the potential to impact on important health outcomes is\u000d\u000a      greatest (source 11).\u000d\u000a    -- Health outcomes\u000d\u000a    Increased rates of breastfeeding, particularly amongst those at higher\u000d\u000a      risk improves health outcomes in infants in the short and long term. The\u000d\u000a      UNICEF report, Preventing\u000a          Disease and Saving Resources, estimates that even\u000d\u000a      moderate increases in breastfeeding could see millions in potential annual\u000d\u000a      savings to the NHS from improved health outcomes (source 12).\u000d\u000a    --Breastfeeding in neonatal units\u000d\u000a    In 2010, as part of the DH-funded regional Health Innovation and\u000d\u000a      Education Cluster (HIEC), York developed educational packages to support\u000d\u000a      quality-improvement initiatives to promote bonding, attachment and\u000d\u000a      breastfeeding in neonatal units based on our research. Following\u000d\u000a      implementation of recommendations from our reviews, the prevalence of\u000d\u000a      skin-to-skin care in neonatal units across Yorkshire &amp; the Humber\u000d\u000a      increased from 20% in 2010 to &gt;40% in 2012 and receipt of breast milk\u000d\u000a      on discharge from 40% to 52% (source 13). This has resulted in all\u000d\u000a      UK units now collecting breast (milk) feeding outcomes within the UK\u000d\u000a      national routine audit systems and the RCPCH National Neonatal Audit\u000d\u000a      Programme. This national audit found that the proportion of very preterm\u000d\u000a      infants receiving any breast milk at discharge rose from 54% in 2011 to\u000d\u000a      58% in 2012, which will reduce mortality and morbidity associated with\u000d\u000a      diseases such as necrotising enterocolitis (source 14).\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Our research, which identified effective and cost-effective interventions\u000d\u000a      to help women, particularly those in low income groups, make informed\u000d\u000a      choices and establish and maintain breastfeeding for newborn infants, has\u000d\u000a      changed health policy and practice nationally and internationally. The\u000d\u000a      findings have been included in national and international practice\u000d\u000a      recommendations including National Institute for Health and Care\u000d\u000a      Excellence guidelines. Active dissemination of our research outputs and\u000d\u000a      adoption of their recommendations have been associated with stepwise\u000d\u000a      increases in breastfeeding rates in the UK, particularly for socially\u000d\u000a      disadvantaged women who typically have low breastfeeding rates, and is\u000d\u000a      likely to be associated with improved health of infants.\u000d\u000a    ","ImpactType":"Societal","Institution":"\u000d\u000a    University of York\u000d\u000a    ","Institutions":[{"AlternativeName":"York (University of)","InstitutionName":"University of York","PeerGroup":"B","Region":"Yorkshire And Humberside","UKPRN":10007167}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a1. Fairbank (Dyson) L, O'Meara S, Renfrew MJ, Woolridge M, Sowden AJ,\u000d\u000a      Lister-Sharp D. Systematic review to evaluate the effectiveness of\u000d\u000a      interventions to promote the uptake of breastfeeding. Health Technol\u000d\u000a        Assess 2000;4(25):1-171. DOI: 10.3310\/hta4250\u000d\u000a    \u000a\u000a2. Dyson L, McCormick FM, Renfrew MJ. Interventions for promoting the\u000d\u000a      initiation of breastfeeding. Cochrane Database Syst Rev\u000d\u000a      2005;(2):CD001688. DOI: 10.1002\/14651858.CD001688\u000d\u000a    \u000a\u000a3. Britton C, McCormick FM, Renfrew MJ, Wade A, King SE. Support for\u000d\u000a      breastfeeding mothers. Cochrane Database Syst Rev\u000d\u000a      2007;(1):CD001141 DOI: 10.1002\/14651858.CD001141.pub3 [updated 2012]. DOI:\u000d\u000a      10.1002\/14651858.CD001141.pub4\u000d\u000a    \u000a\u000a4. Renfrew MJ, Craig D, Dyson L, McCormick F, Rice S, King SE, et al.\u000d\u000a      Breastfeeding promotion for infants in neonatal units: a systematic review\u000d\u000a      and economic analysis. Health Technol Assess 2009;13(40):1-146.\u000d\u000a      DOI: 10.3310\/hta13400\u000d\u000a    \u000a\u000a5. Rice SJ, Craig D, McCormick F, Renfrew MJ, Williams AF. Economic\u000d\u000a      evaluation of enhanced staff contact for the promotion of breastfeeding\u000d\u000a      for low birth weight infants. Int J Technol Assess Health Care\u000d\u000a      2010;26:133-40. DOI: 10.1017\/S0266462310000115\u000d\u000a    \u000a\u000a6. McCormick FM, Tosh K, McGuire W. Ad libitum or demand\/semi-demand\u000d\u000a      feeding versus scheduled interval feeding for preterm infants. Cochrane\u000a        Database Syst Rev 2010;(2):CD005255. DOI:\u000d\u000a      10.1002\/14651858.CD005255.pub3.\u000d\u000a    \u000aThis research was funded from the following competitive grants:\u000d\u000a    &#8226; Systematic review of factors which promote or inhibit the initiation of\u000d\u000a      breastfeeding. NHS R&amp;D HTA programme. &#163;56,000; 1998-9 (Lister-Sharp).\u000d\u000a    &#8226; Systematic review of interventions to promote the initiation of\u000d\u000a      breastfeeding. Canadian Child Health Field Bursary, Cochrane\u000d\u000a      Collaboration. &#163;3304; 2002-3 (Dyson).\u000d\u000a    &#8226; NICE Public Health Collaborating Centre for Maternal and Child\u000d\u000a      Nutrition. &#163;446,000; 2004-7 (Renfrew, Dyson).\u000d\u000a    &#8226; Infant feeding for babies in Special and Intensive Care Units. NIHR HTA\u000d\u000a      programme: &#163;204,000; 2007-8 (Craig, Renfrew).\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"10","Subject":"Nursing"},{"Level1":"11","Level2":"14","Subject":"Paediatrics and Reproductive Medicine"}],"Sources":"\u000d\u000a    \u000d\u000a      Routine postnatal care of women and their babies. NICE guideline\u000d\u000a        (2006) www.nice.org.uk\/CG037\u000a\u000d\u000a      Maternal and child nutrition: NICE public health guidance 11 (2008) www.nice.org.uk\/PH11\u000a\u000d\u000a      Routine care for the healthy pregnant woman. NICE guideline 62 (2008).\u000d\u000a        www.nice.org.uk\/CG062\u000a\u000d\u000a      Entwistle FM (2013) The evidence and rationale for the UNICEF UK\u000d\u000a          Baby Friendly Initiative standards. UNICEF UK.\u000d\u000a      Infant Feeding Guidelines. National Health and Medical Research\u000d\u000a        Council (2012). www.nhmrc.gov.au\/guidelines\/publications\/n56\u000a\u000d\u000a      US Department of Health and Human Services. The Surgeon General's Call\u000d\u000a        to Action to Support Breastfeeding. Department of Health and Human\u000d\u000a        Services, Office of the Surgeon General (2011).\u000d\u000a      Donor breast milk banks. NICE clinical guideline 93 (2010). www.nice.org.uk\/CG093\u000a\u000d\u000a      Department of Health. Commissioning local breastfeeding support\u000d\u000a        services (2009). http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_106497.pdf\u000a\u000d\u000a      Nyqvist KH et al. Expansion of the Baby-Friendly Hospital Initiative\u000d\u000a        ten steps to successful breast-feeding into neonatal intensive care:\u000d\u000a        expert group recommendations. J Hum Lact 2013;29:300-309. DOI:\u000d\u000a        10.1177\/0890334413489775\u000d\u000a      Guidelines on optimal feeding of low birth weight infants in low-and\u000d\u000a        middle-income countries. World Health Organization (2011). Available\u000d\u000a        from: www.who.int\/maternal_child_adolescent\/documents\/infant_feeding_low_bw\/en\/\u000a\u000d\u000a      McAndrew F, et al. Infant Feeding Survey 2010 www.esds.ac.uk\/doc\/7281\/mrdoc\/pdf\/7281_ifs-uk-2010_report.pdf\u000a\u000d\u000a      Preventing disease and saving resources: the potential of increasing\u000d\u000a        breastfeeding in the UK unicef.org.uk\/Documents\/Baby_Friendly\/Research\/Preventing_disease_saving_resources.pdf\u000a\u000d\u000a      Yorkshire &amp; Humber HIEC. Turning best practice into common\u000d\u000a        practice. Final report (2013) yhhiec.org.uk\/wp-content\/uploads\/2013\/07\/12120503_HIEC_Report_2012_2013_PRINT-FINAL.pdf\u000a\u000d\u000a      National Neonatal Audit Programme, Annual Report 2012. www.rcpch.ac.uk\/system\/files\/protected\/page\/RCPCH_NNAP_Report%202012%20(2).pdf\u000a\u000d\u000a    \u000d\u000a    ","Title":"\u000d\u000a    Promotion and support of breastfeeding for newborn infants\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2634895","Name":"Wales"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Breastfeeding improves important outcomes for mothers and infants.\u000d\u000a      Initiation and maintenance of breastfeeding in the UK have historically\u000d\u000a      been low, particularly in socially disadvantaged young women.\u000d\u000a      Breastfeeding is particularly important for the 10% of infants born\u000d\u000a      preterm or with low birth weight (LBW). York researchers conducted seminal\u000d\u000a      systematic reviews which identified effective and cost-effective\u000d\u000a      interventions to increase rates of initiation and maintenance of\u000d\u000a      breastfeeding.\u000d\u000a    (i) Initiation of breastfeeding: Our systematic review of 59\u000d\u000a      studies evaluating a range of policy, supportive and educational\u000d\u000a      interventions showed the effectiveness of multi-faceted packages of\u000d\u000a      interventions including: targeted, small group, interactive education\u000d\u000a      programmes and peer support for women with low incomes (1). Our Cochrane\u000d\u000a      review of randomised controlled trials (RCTs) identified the substantial\u000d\u000a      benefits of interactive health education interventions. For every 100\u000d\u000a      women receiving education, 20 extra initiated breastfeeding (2).\u000d\u000a    (ii) Maintenance of breastfeeding: Our Cochrane review of 34 RCTs\u000d\u000a      involving ~30000 mother-infant pairs in 14 countries showed that extra\u000d\u000a      support for women (particularly integrated lay and professional support)\u000d\u000a      increased the duration of breastfeeding. For every 100 women receiving\u000d\u000a      extra support, 5 more continued to breastfeed up to six months (3).\u000d\u000a    (iii) Breastfeeding infants in neonatal units: Our systematic\u000d\u000a      review of the effectiveness of interventions to promote breastfeeding or\u000d\u000a      feeding with expressed breast milk for infants admitted to neonatal units\u000d\u000a      (4) included 8 studies from 17 countries. We reported strong evidence for\u000d\u000a      the effectiveness of parent-baby \"skin-to-skin\" contact and UNICEF Baby\u000d\u000a      Friendly Initiative (BFI) accreditation. Our cost-effectiveness analysis\u000d\u000a      found that enhanced contact and support reduced overall costs and\u000d\u000a      increased \"quality adjusted life years\" for preterm or LBW infants,\u000d\u000a      especially those with very low birth weight (5). Our Cochrane review found\u000d\u000a      that feeding preterm or LBW infants in response to hunger and satiation\u000d\u000a      cues rather than a caregiver-led regimen shortened both transition to oral\u000d\u000a      feeding and hospital stay (6).\u000d\u000a    Researchers: Britton (Lecturer, Nov 1996 - present); Craig\u000d\u000a      (Research fellow, Nov 2004 - present); Dyson (Research fellow, Feb 2005 -\u000d\u000a      present); Lister-Sharp (Research fellow June 1996 - June 2002); McCormick\u000d\u000a      (Research fellow, Nov 2004 - Dec 2012); McFadden (Research fellow, Nov\u000d\u000a      2004 - Dec 2012); McGuire (Professor, Dec 2008 - present); O'Meara\u000d\u000a      (Research fellow, Nov 1995 - June 2013); Renfrew (Professor, Nov 2004 -\u000d\u000a      July 2012); Rice (Research fellow, Mar 2003 - present); Sowden (Senior\u000d\u000a      Researcher, Feb 1994 - present).\u000d\u000a    "},{"CaseStudyId":"43415","Continent":[{"GeoNamesId":"6255150","Name":"South America"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"3469034","Name":"Brazil"},{"GeoNamesId":"2562770","Name":"Malta"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"2623032","Name":"Denmark"},{"GeoNamesId":"2658434","Name":"Switzerland"},{"GeoNamesId":"3077311","Name":"Czech Republic"},{"GeoNamesId":"2782113","Name":"Austria"},{"GeoNamesId":"2186224","Name":"New Zealand"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2802361","Name":"Belgium"},{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"3144096","Name":"Norway"},{"GeoNamesId":"2629691","Name":"Iceland"},{"GeoNamesId":"3175395","Name":"Italy"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"2510769","Name":"Spain"}],"Funders":["Economic and Social Research Council"],"ImpactDetails":"\u000a    Improving Public Understanding of Social Issues\u000a    In order to increase awareness of the research findings and the\u000a      consequences of inequality and to\u000a      campaign for change, in 2009 Pickett and Wilkinson established The\u000a        Equality Trust (TET). This\u000a      is a not-for-profit educational and campaigning organisation\u000a      (www.equalitytrust.org.uk) with core\u000a      funding from the Joseph Rowntree Charitable Trust. Through this they\u000a      created the One Society\u000a      campaign to work with policy-makers, employers, other decision-makers and\u000a      influencers who have\u000a      significant power to affect rates of income inequality\u000a      (www.onesociety.org.uk). TET produces\u000a      research digests and updates that are widely cited in the media and has 23\u000a      UK local groups and\u000a      28 international groups, including 8 in the USA. The Trust also has 8000+\u000a      followers on Twitter and\u000a      7000+ on Facebook. Pickett and Wilkinson, through TET, have directly\u000a      contributed to public\u000a      understanding and debate through more than 600, predominantly\u000a      non-academic, conferences\u000a      keynotes and seminars, including national, foreign and international\u000a      government ministries and\u000a      agencies, the UK Cabinet Office, health authorities, political party\u000a      conferences, universities, trade\u000a      unions, faith groups, NGOs, think tanks and charities (e.g., the United\u000a      Nations, Canadian\u000a      parliament, US Congress, and the OECD &#8212; in the UK, USA, Australia, New\u000a      Zealand, Bhutan,\u000a      Czech Republic, Spain, Sweden, Norway, Austria, Belgium, Ireland, Turkey,\u000a      Italy, Denmark,\u000a      Belgium, Iceland, Canada, Germany, Singapore, Switzerland, Brazil and\u000a      Malta). They have also\u000a      been invited to disseminate their research in magazines, newspapers, and\u000a      popular journals.1\u000a    Shaping and Informing Political Debate\u000a    In the lead up to the last General Election, TET asked parliamentary\u000a      candidates to sign the\u000a      Equality Pledge, which described Pickett and Wilkinson's research, and\u000a      asked them to \"actively\u000a      support the case for policies designed to narrow the gap between rich and\u000a      poor\" &#8212; it was signed by\u000a      75 MPs who entered the new parliament, including 11 Conservatives, 18\u000a      Liberal Democrats\u000a      (including 2 cabinet ministers), 1 Green and 45 Labour MPs. Pickett &amp;\u000a      Wilkinson were consulted\u000a      by the Liberal Democrat's Policy Consultation on Inequality and by the\u000a      Green Party Strategy group,\u000a      each of which was developing manifesto commitments to greater equality and\u000a      fairness. Prime\u000a      Minister David Cameron In his Hugo Young lecture, prior to the election,\u000a      said \"Research by\u000a        Richard Wilkinson and Katie Pickett has shown that among the richest\u000a        countries, it's the more\u000a        unequal ones that do worse according to almost every quality of life\u000a        indicator\".2 Ed Milliband wrote\u000a      about the importance of academic research for changing politics in The New\u000a      Statesman, saying\u000a      \"The Spirit Level by Richard Wilkinson and Kate Pickett is a book in\u000a        the best of that tradition.\"3\u000a      Following the election, BBC 4 journalist Mukul Devichand said \"Both\u000a        Prime Minister David\u000a        Cameron and Labour leader Ed Milliband appear to be disciples of The\u000a        Spirit Level.\"4\u000a    Contributing to Campaigns for Change\u000a    Local Equality Trust groups are active in campaigning, using the research\u000a      base as evidence. For\u000a      example, the London branch, My Fair London, developed a pledge for\u000a      candidates in the London\u000a      Mayoral election, stating \"we draw heavily on The Spirit Level\".5\u000a      Equality Bristol produced an\u000a      `Equality Declaration' for local election candidates to sign. The Newport\u000a      group successfully\u000a      campaigned for the setting up of a local Fairness Commission.\u000a    The Spirit Level has been extensively reviewed, discussed, and referred\u000a      to by commentators,\u000a      politicians and others in the international printed media (from the\u000a      Financial Times and The\u000a      Economist to The New York Times; quotes are available at:\u000a      www.equalitytrust.org.uk\/node\/200),\u000a      on radio, television (including the BBC and CNN), the internet, and in\u000a      legislative assemblies\u000a      including both Houses of Parliament in England, the Scottish Parliament,\u000a      the Welsh Assembly, the\u000a      New Zealand, Australian and Canadian parliaments.6\u000a    Inspiring the Production of Cultural Artefacts\u000a    A Spirit Level Documentary is in production by award-winning independent\u000a      documentary maker\u000a      Christopher Hird of Dartmouth Films and directed by Kathryn Round. The\u000a      film raised $70,000 in 40\u000a      days through crowd sourcing and has received grants from the Tudor Trust\u000a      and the City of Sydney.\u000a    The ESRC funded Pickett, through its Follow-On Fund, to produce The Young\u000a      Persons Guide to\u000a      Inequality, educational materials for 16-19 year olds, based on The\u000a        Spirit Level. These include: a\u000a      Theatre in Education Learning Module, Kuan's Wonderland (a novel with\u000a      study guide), a statistics\u000a      learning module, Economicum, a game for learning about economics and\u000a      inequality, collections of\u000a      videos and other art based on The Spirit Level. All free online:www.equalitytrustr.org.uk\/education.\u000a    Influencing policy\u000a    There is growing international recognition of The Spirit Level\u000a      research: head of the International\u000a      Monetary Fund, Christine Lagarde, said \"Now all of us have a better\u000a        understanding that a more\u000a        equal distribution of income allows for more economic stability, more\u000a        sustained economic growth,\u000a        and healthier societies with stronger bonds of cohesion and trust.\"7\u000a      United Nations Secretary\u000a      General, Ban Ki-Moon, quoting from The Spirit Level said \"Social\u000a        and economic inequalities can\u000a        tear the social fabric, undermine social cohesion and prevent nations\u000a        from thriving. Inequality can\u000a        breed crime, disease and environmental degradation and hamper economic\u000a        growth.\"8 Nobel Prize\u000a      winning economist, Paul Krugman, wrote, \"Wilkinson-type views about the\u000a        corrosive effects of\u000a        inequality are going seriously mainstream.\"9 Wilkinson\u000a      was a keynote speaker at the High Level\u000a      Meeting on Wellbeing and Happiness at the UN in New York in April 2011,\u000a      which resulted in UN\u000a      resolution 65\/309 Happiness: towards a holistic approach to development,\u000a      which recognised that\u000a      \"gross domestic product...does not adequately reflect the...wellbeing\u000a        of people in a country\"\u000a    In terms of UK policy impact, The Spirit Level has perhaps been most\u000a      influential in the\u000a      establishment and outcomes of local Fairness Commissions.10\u000a      Since 2010, twelve Local\u000a      Authorities, (Birmingham, Blackpool, Islington, Leicester, Liverpool,\u000a      Newcastle, Newport,\u000a      Portsmouth, Sheffield, Southampton, Tower Hamlets, York) have established\u000a      `Fairness\u000a      Commissions', to investigate and implement ways of reducing inequality in\u000a      their areas such as\u000a      recommending and campaigning for, the payment of a Living Wage.\u000a      Wilkinson was a\u000a      Commissioner for Islington and York, and Pickett for York. All Fairness\u000a      Commissions cite The\u000a      Spirit Level as inspiration for their formation and objectives and all\u000a      that have reported so far\u000a      support the implementation of a Living Wage and pay ratios. Pickett was\u000a      appointed in July 2013 to\u000a      the independent Living Wage Commission. The Spirit Level also\u000a      influenced the High Pay\u000a      Commission,11 and the UK Drug Policy Commission.12\u000a    The Equality Act which received Royal Assent in 2010 included a duty that\u000a      local and national public\u000a      bodies must `have regard to the desirability of reducing socio-economic\u000a      inequalities' in their\u000a      decision-making. The Spirit Level was cited in the Lords debate.13\u000a      Introducing the Equality Bill, the\u000a      then Labour Government's Equalities Office quoted The Spirit Level\u000a      in support of the socio-economic\u000a      duty.14\u000a    In addition, The Spirit Level has been cited in numerous policy\u000a      documents, including: Fair Society,\u000a      Healthy Lives: The Marmot Review http:\/\/www.ghwatch.org\/;\u000a      Global Health Watch 3\u000a      http:\/\/www.ghwatch.org; Action\u000a        for Children, Backing the Future: Why Investing in Children if\u000a      Good for Us All http:\/\/www.ncw.gc.ca\/l.3bd.2t.1ils%40-eng.jsp?lid=433;\u000a      WHO Europe, Mental Health and Resilience in Europe www.mentalhealth.org.uk\/publications\/mh-\u000a        resilience-inequalities\/; WHO Europe, Addressing the Social\u000a      Determinants of Health: the Urban\u000a      Dimension and the Role of Local Government.\u000a      http:\/\/www.euro.who.int\/data\/assets\/pdf_file\/0003\/145686\/HCP_Liege_09-\u000a        SocDem_government.pdf ; Canadian National Council of Welfare,\u000a      The Dollars and Sense of\u000a      Solving Poverty http:\/\/www.ncw.gc.ca\/l.3bd.2t.1ils%40-eng.jsp?lid=433;TUC,\u000a      Fairness and\u000a      Prosperity https:\/\/www.tuc.org.uk\/tucfiles\/49\/FairnessandProsperity.pdf; New Economics\u000a        Foundation, The Great Transition http:\/\/www.neweconomics.org\/publications\/great-transition\u000a      Demos, Reinventing the Firm http:\/\/www.demos.co.uk\/publications\/reinventing-the-firm\u000a      The Children's Society The Good Childhood Report http:\/\/www.childrenssociety.org.uk\/what-\u000a        wedo\/research\/initiatives\/good-childhood-inquiry\/buy-book\u000a    ","ImpactSummary":"\u000a    Pickett and Wilkinson's research, summarised in The Spirit Level\u000a      (Penguin), argued that the level\u000a      of income inequality in rich, developed market democracies strongly\u000a      influences their performance\u000a      on a wide range of health and social indicators. Since 2009, the book has\u000a      contributed to a\u000a      significant shift in public debate across the world &#8212; at grassroots level,\u000a      in the media and in\u000a      legislative assemblies &#8212; and has shaped political thinking, legislation\u000a      and policy making.\u000a    ","ImpactType":"Societal","Institution":"\u000a    University of York\u000a    ","Institutions":[{"AlternativeName":"York (University of)","InstitutionName":"University of York","PeerGroup":"B","Region":"Yorkshire And Humberside","UKPRN":10007167}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2641598","Name":"Newport"},{"GeoNamesId":"5128638","Name":"New York"}],"References":"\u000a    \u000a1. Wilkinson R and Pickett K. The Spirit Level: Why Equality is\u000a        Better for Everybody. London:\u000a      Penguin (2009). The Spirit Level has sold more than 150,000 copies\u000a      in its English edition and\u000a      is published in 23 foreign editions. The book was awarded the 2010 Bristol\u000a      Festival of Ideas\u000a      Book Prize and the 2011 Political Studies Association Publication of the\u000a      Year Award. The New\u000a      Statesman named it one of the Top Ten Books of the Decade. (UK edition\u000a      1559 citations,\u000a      according to Google Scholar).\u000a    \u000a\u000a2. Wilkinson RG, Pickett KE. Income inequality and health: A review and\u000a      explanation of the\u000a      evidence. Social Science and Medicine 2006; 62:1768-1784. DOI:\u000a      10.1016\/j.socscimed.2005.08.036 (705 citations).\u000a    \u000a\u000a3. Wilkinson RG, Pickett KE. The problems of relative deprivation: why\u000a      some societies do better\u000a      than others. Social Science &amp; Medicine. 2005;65:1965-1978. DOI:\u000a      10.1016\/j.socscimed.2007.05.041 (184 citations).\u000a    \u000a\u000a4. Pickett KE, Wilkinson RG. Child well-being and income inequality in\u000a      rich societies: Ecological\u000a      cross sectional study. BMJ 2007; 335(7629):1080-1086.\u000a      DOI:10.1136\/bmj.39377.580162.55\u000a      (100 citations).\u000a    \u000a\u000a5. Wilkinson RG, Pickett KE. Income inequality and social dysfunction.\u000a      Annual Review of\u000a      Sociology, 2009; 35:493-511. DOI: 10.1146\/annurev-soc-070308-115926 (81\u000a      citations).\u000a    \u000a\u000a6. Wilkinson RG, Pickett KE. Income inequality and social gradients in\u000a      mortality. American\u000a      Journal of Public Health 2008 98: 699-704. DOI: 10.2105\/AJPH.2007.109637\u000a      (81 citations).\u000a    \u000aRelated grants: Pickett KE. 2007-2012. Deprivation, difference and early\u000a      development:\u000a      Healthy societies for healthy families, Career Scientist Award, NIHR,\u000a      &#163;318,953.\u000a    Pickett K, Wilkinson R. 2012-2013. Discussing Inequality: Materials for\u000a      the classroom and beyond.\u000a      ESRC, &#163;92,846.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"14","Level2":"2","Subject":"Applied Economics"}],"Sources":"\u000a    \u000a      See for example: Wilkinson R, Pickett K. Inequality: it's not the\u000a        politics of envy. The Common\u000a        Good, Summer 2008, issue 198, page 12. Pickett K, Wilkinson R.\u000a        Inequality rise is to blame\u000a        for `broken society.' Yorkshire Post, 12 Mar 2009. Wilkinson R, Pickett\u000a        K. Poverty is not the\u000a        problem. Church Times, 27 Mar 2009. Pickett K, Wilkinson R. Child\u000a        wellbeing and income\u000a        inequality in rich countries. Poverty 2009; 133:6-9. Wilkinson R,\u000a        Pickett K. Equality of what?\u000a        Runneymede Quarterly Bulletin, June 2009; 358: 5. Pickett KE. Health and\u000a        wellbeing. In:\u000a        Deprivation and Risk: The Case for Early Intervention. Action for\u000a        Children, London, 2010.\u000a        Pickett KE, Wilkinson RG. The Spirit Level: Why The American Service\u000a        Sector Is All About\u000a        Servitude. Huffington Post, 2010. http:\/\/www.huffingtonpost.com\/kate-pickett\/the-spirit-level-\u000a          why-the_b_478313.html. Wilkinson R, Pickett K. In defence of\u000a        equality. Prospect, 2010. Kate\u000a        Pickett on the nation's health &#8212; why can't we close the gap between rich\u000a        and poor?\u000a        http:\/\/scienceblog.cancerresearchuk.org\/2010\/09\/21\/kate-pickett-on-the-nations-healt-why-\u000a          cant-we-close-the-gap-between-rich-and-poor\/. Wilkinson R, Pickett\u000a        K. Mind the many gaps...\u000a        New Scientist 16 April 2011.\u000a      Cameron D. Hugo Young Lecture. 2009 10 Nov.\u000a        http:\/\/www.respublica.org.uk\/item\/ResPublica-mentioned-in-Camerons-speech-ggtc\u000a\u000a      Milliband E. What this country needs is Labour with a new vision. New\u000a          Statesman 2010 Aug\u000a        26. http:\/\/www.newstatesman.com\/uk-politics\/2010\/08\/labour-movement-society-party\u000a\u000a      Devichand M. The Spirit Level: Britain's new theory of everything? BBC\u000a          News Radio 4 2010\u000a        12 Oct. http:\/\/www.bbc.co.uk\/programmes\/b00v6lkp\u000a\u000a      My Fair London. Plan of Action for a Fairer London: A challenge to\u000a        candidates for Mayor of\u000a        London from London Equality Group. www.myfairlondon.org.uk\/plan-of-action\/2012\u000a\u000a      House of Commons Debates Hansard 19 Oct 2009 (pt 0012), 6 Apr 2010 (pt\u000a        0005), Lords\u000a        Hansard text 5 Jan 2010 (pt 0011), 2 Jun 2010 (p t0007). www.publications.parliament.uk\/\u000a\u000a      Lagarde C. Speech at World Economic Forum, Davos. 2013 23 Jan.\u000a        http:\/\/www.imf.org\/external\/np\/speeches\/2013\/012313.htm\u000a\u000a      Moon B-K. Remarks at informal General Assembly Thematic Debate on\u000a        Inequality.\u000a        http:\/\/www.un.org\/apps\/news\/infocus\/sgspeeches\/statments_full.asp?statID=1918#.UfDb943E\u000a        PO4: United Nations, 2013.\u000a      Krugman P. Economics of marginalization and hopelessness. New York\u000a          Times 2012; 12 May.\u000a      Sillett J, O'Donnell C. Fairness Commissions. Policy Briefing.\u000a        London: Local Government\u000a        Information Unit, 2013.\u000a      High Pay Commission. Cheques with balances: why tackling high pay is\u000a        in the national\u000a        interest. London: High Pay Commission, 2011.\u000a      UK Drug Policy Commission. A fresh approach to drugs. London: UK Drugs\u000a        Policy\u000a        Commission, 2012: www.ukdpc.org.uk\/publication\/a-fresh-approach\u000a\u000a      The Lord Bishop of Chester. Speech in House of Lord's debate. Lords\u000a        Hansard 15 Dec\u000a        2009, col 1449.\u000a      Department for Culture, Media &amp; Sport and Government Equalities\u000a        Office. Creating a fairer\u000a        and equal society. https:\/\/www.gov.uk\/government\/policies\/creating-a-fairer-and-more-equal-society,\u000a        30 Apr 2013\u000a    \u000a    ","Title":"\u000a    The Impact of Social Inequality: changing the public and policy debate\u000a    ","UKLocation":[{"GeoNamesId":"2637487","Name":"Southampton"},{"GeoNamesId":"2646003","Name":"Islington"},{"GeoNamesId":"2641673","Name":"Newcastle-upon-Tyne"},{"GeoNamesId":"2655459","Name":"Blackpool"},{"GeoNamesId":"2655603","Name":"Birmingham"},{"GeoNamesId":"2643743","Name":"London"},{"GeoNamesId":"2639996","Name":"Portsmouth"},{"GeoNamesId":"2654675","Name":"Bristol"},{"GeoNamesId":"2638077","Name":"Sheffield"},{"GeoNamesId":"2644210","Name":"Liverpool"},{"GeoNamesId":"2644668","Name":"Leicester"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    The Spirit Level (1) was based on a programme of research jointly\u000a      conducted by Pickett and\u000a      Wilkinson and published in 16 widely cited articles in peer-reviewed\u000a      journals.\u000a    Using both ecological and multi-level cross-national comparisons, the\u000a      research compared life\u000a      expectancy, infant mortality, mental health, levels of violence, teenage\u000a      birth rates, drug abuse,\u000a      child wellbeing, obesity rates, levels of trust, the educational\u000a      performance of school children,\u000a      imprisonment and social mobility, and found that societies with lower\u000a      levels of income inequality\u000a      perform consistently better (2 - 5). The picture is consistent whether\u000a      comparing rich countries or\u000a      the 50 states of the USA, and the magnitude of the effect is very large:\u000a      for example, there are ten-fold\u000a      differences in teenage birth rates, three-fold differences in rates of\u000a      mental illness and two-fold\u000a      differences in infant mortality between more and less equal societies.\u000a    The York-based research by Pickett and Wilkinson which underpins The\u000a        Spirit Level established\u000a      that levels of absolute standards of living, measured as Gross National\u000a      Income per capita are\u000a      unrelated to levels of health and wellbeing in rich nations, whereas\u000a      income differences are key. It is\u000a      relative income, one's status within the social hierarchy of a society,\u000a      which matters more than\u000a      absolute income. Importantly, greater inequality seems to produce worse\u000a      outcomes for the vast\u000a      majority of the population (6). Analyses comparing people in more equal\u000a      societies with their\u000a      counterparts at the same socioeconomic position in less equal societies\u000a      showed that whilst those\u000a      lower down the social hierarchy benefit most from greater equality; even\u000a      those near the top benefit.\u000a    The pathways linking inequality to health and social problems are\u000a      psychosocial. Foremost among\u000a      the psychosocial risk factors for poor health are three intensely social\u000a      factors: low social status,\u000a      weak social support, and a poor quality of early childhood experience. To\u000a      improve the quality of\u000a      life, The Spirit Level suggests that attention must be paid to the\u000a      social environment and the quality\u000a      of social relations, and that reducing material inequality will improve\u000a      the psychosocial wellbeing\u000a      and social functioning of whole societies.\u000a    Pickett (L, then SL, then Prof; 2003 -) and Wilkinson (Prof at the\u000a      University of Nottingham until\u000a      retirement in 2008 and Honorary Visiting Professor at York, 2005 &#8212;\u000a      present).\u000a    "},{"CaseStudyId":"43526","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"895949","Name":"Zambia"},{"GeoNamesId":"192950","Name":"Kenya"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Work by LSHTM researchers into TB prevention among people with HIV has\u000d\u000a      directly informed the evolution of WHO guidelines on IPT since 1998,\u000d\u000a      including the most recent update in 2011, and updated guidance on TB and\u000d\u000a      HIV collaborative activities in 2012. It has also provided evidence for\u000d\u000a      key stakeholders to adopt IPT.\u000d\u000a    Drawing directly on Porter's Kenyan and Zambian trials, IPT became one of\u000d\u000a      the key interventions recommended by WHO in 19985.1 to reduce\u000d\u000a      the burden of TB in people living with HIV &#8212; yet implementation of IPT was\u000d\u000a      initially very slow. In 2005 only 25,000 people living with HIV worldwide\u000d\u000a      were reported to have received it.\u000d\u000a    A series of research articles about IPT, including Grant and\u000d\u000a      Godfrey-Faussett as co-authors, was published in 2010 in AIDS,5.2,\u000d\u000a        5.3 the International AIDS Society's official journal, made\u000d\u000a      publicly available, open access, via their website to 16,000 members from\u000d\u000a      196 countries including clinicians, public health and community\u000d\u000a      practitioners, policy and programme planners. The same edition also\u000d\u000a      contains an opinion piece that heavily draws on LSHTM research.5.4\u000d\u000a    At the AIDS 2012 Conference in Washington, Grant was invited to present\u000d\u000a      her research regarding new approaches for TB prevention.5.5\u000d\u000a      This was reported, among others, by HIV &amp; AIDS Treatment in\u000d\u000a        Practice, a widely read email newsletter distributed to\u000d\u000a      practitioners worldwide.5.6\u000d\u000a    As part of Grant's `Thibela TB' trial (ended 2012), over 24,000 miners\u000d\u000a      started IPT, the largest number in any clinical trial. Beyond the health\u000d\u000a      benefit experienced by those participating in the trial, the results, in\u000d\u000a      combination with Grant's data from the meta-analyses about drug resistance\u000d\u000a      after IPT, and on how to screen for active TB prior to IPT, were directly\u000d\u000a      fed into the revision of WHO guidelines on IPT. In 2010 Grant and\u000d\u000a      Godfrey-Faussett were invited to join the WHO Guidelines Group, reviewing\u000d\u000a      new scientific evidence and contributing LSHTM research into the process\u000d\u000a      which led to a revision of WHO guidelines.5.7 As a direct\u000d\u000a      result of LSHTM research, new recommendations included that isoniazid\u000d\u000a      should be offered to individuals regardless of previous tuberculosis\u000d\u000a      history,3.2 and that people living with HIV should be screened\u000d\u000a      for active TB using a tool derived largely from LSHTM research. The\u000d\u000a      guidelines also draw directly on the LSHTM research in addressing the\u000d\u000a      misconceptions that may contribute to the low uptake of isoniazid therapy\u000d\u000a      &#8212; for example the concern that using isoniazid without other TB\u000d\u000a      medications promotes drug resistance.\u000d\u000a    The following year (2011) Godfrey-Faussett was a member of WHO's policy\u000d\u000a      updating group, responsible for advising WHO concerning collaborative\u000d\u000a      TB\/HIV activities in response to demand from countries for guidance on\u000d\u000a      actions to decrease the dual burden of TB and HIV. Drawing on LSHTM\u000d\u000a      research,3.5 the updated policy emphasised the need to\u000d\u000a      establish mechanisms for integrated TB and HIV services, preferably at the\u000d\u000a      same time and location.5.8\u000d\u000a    Grant's Thibela TB research has been particularly influential in\u000d\u000a      promoting IPT use in South Africa. Through work with key collaborators\u000d\u000a      such as the Aurum Institute, greater stakeholder and political awareness\u000d\u000a      of the efficacy of IPT was raised. In 2009, the South African Minister of\u000d\u000a      Health said of the Thibela TB study: `your research on the community-wide\u000d\u000a      use of isoniazid has that ground-breaking feel'.5.9 In his\u000d\u000a      opening speech at the South African AIDS Conference (Durban, June 2013),\u000d\u000a      the Minister of Health, Dr Aaron Motsoaledi, referred directly to LSHTM\u000d\u000a      research when he said: `This decline [in TB deaths] has been attributed by\u000d\u000a      researchers to the increased number of HIV positive patients on ARVs as\u000d\u000a      well as the screening for TB and putting eligible patients on IPT... This\u000d\u000a      is very good news!'5.10\u000d\u000a    ","ImpactSummary":"\u000d\u000a    LSHTM research has resulted in isoniazid preventive therapy (IPT)\u000d\u000a      becoming one of the key interventions recommended by WHO to reduce the\u000d\u000a      impact of tuberculosis (TB) among HIV-positive people. As a direct result\u000d\u000a      of the research findings, WHO recommendations now promote wider use of\u000d\u000a      IPT. In addition, barriers to implementation have been overcome, leading\u000d\u000a      to increasing worldwide use of IPT for TB prevention among people with\u000d\u000a      HIV. A companion case study addresses impact on screening for TB amongst\u000d\u000a      such people.\u000d\u000a    ","ImpactType":"Health","Institution":"\u000d\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000d\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"1007311","Name":"Durban"}],"References":"\u000d\u000a    \u000a3.1 Mwinga, A, Hosp, M, Godfrey-Faussett, P, Quigley, M, Mwaba, P,\u000d\u000a      Mugala, BN, Nyirenda, O, Luo, N, Pobee, J, Elliott, AM, McAdam, KPWJ and\u000d\u000a      Porter, JDH (1998) Twice weekly tuberculosis preventive therapy in HIV\u000d\u000a      infection in Zambia, AIDS, 12(18): 2447-2457, doi:\u000d\u000a      10.1097\/00002030-199818000-00014. Citation count: 158.\u000d\u000a    \u000a\u000a3.2 Churchyard, GJ, Fielding, K, Charalambous, S, Day, JH, Corbett, EL,\u000d\u000a      Hayes, RJ, Chaisson, RE, De Cock, KM, Samb, B and Grant, AD (2003)\u000d\u000a      Efficacy of secondary isoniazid preventive therapy among HIV-infected\u000d\u000a      Southern Africans: time to change policy? AIDS, 17(14): 2063-2070,\u000d\u000a      http:\/\/journals.lww.com\/aidsonline\/Fulltext\/2003\/09260\/Efficacy_of_secondary_isoniazid_preventive_therapy.7.aspx\u000d\u000a      (accessed 14th November 2013). Citation count: 59.\u000d\u000a    \u000a\u000a3.3 Grant, AD, Charalambous, S, Fielding, KL, Day, JH, Corbett, EL,\u000d\u000a      Chaisson, RE, De Cock, KM, Hayes, RJ and Churchyard, GJ (2005) Effect of\u000d\u000a      routine isoniazid preventive therapy on tuberculosis incidence among\u000d\u000a      HIV-infected men in South Africa: a novel randomized incremental\u000d\u000a      recruitment study, JAMA-Journal of the American Medical Association,\u000d\u000a      293(22): 2719-2725, doi: 10.1001\/jama.293.22.2719. Citation count: 69.\u000d\u000a    \u000a\u000a3.4 Balcells, ME, Thomas, SL, Godfrey-Faussett, P and Grant, AD (2006)\u000d\u000a      Isoniazid preventive therapy and risk for resistant tuberculosis, Emerging\u000d\u000a        Infectious Diseases, 12(5): 744-7451,\u000d\u000a      http:\/\/wwwnc.cdc.gov\/eid\/article\/12\/5\/pdfs\/05-0681.pdf\u000d\u000a      (accessed 14 November 2013). Citation count: 70.\u000d\u000a    \u000a\u000a3.5 Legido-Quigley, H, Montgomery, CM, Khan, P, Atun, R, Fakoya, A,\u000d\u000a      Getahun, H and Grant, AD (2013) Integrating tuberculosis and HIV services\u000d\u000a      in low- and middle-income countries: a systematic review, Tropical\u000d\u000a        Medicine &amp; International Health, 18(2): 199-211, doi:\u000d\u000a      10.1111\/tmi.12029. Citation count: 0\u000d\u000a    \u000a\u000a3.6 Grant, AD, Mngadi, KT, van Halsema, CL, Luttig, MM, Fielding, KL and\u000d\u000a      Churchyard, GJ (2010) Adverse events with isoniazid preventive therapy:\u000d\u000a      experience from a large trial, AIDS, 24(Suppl. 5): s29-36, doi:\u000d\u000a      10.1097\/01.aids.0000391019.10661.66. Citation count: 7.\u000d\u000a    \u000aKey grants\u000d\u000a    Award to Aurum Institute, South Africa, co-PI Grant, Effect of\u000d\u000a      Community-wide Isoniazid Preventive Therapy on Tuberculosis Among South\u000d\u000a      African Gold Miners, Bill and Melinda Gates Foundation, 2004-2013, US$27m.\u000d\u000a      Grant, National Public Health Career Scientist Award, UK Department of\u000d\u000a      Health, 2003-2008, &#163;688,000 (portfolio including work on Thibela TB).\u000d\u000a      Godfrey-Faussett, Innovations Programme, The Zambian ProTEST Project,\u000d\u000a      Department for International Development, 1999-2001, &#163;192,900.\u000d\u000a      Porter, Prevention of HIV-related TB in Zambia, WHO, 1992-1997, $521,000.\u000d\u000a      Porter, Prevention of HIV-related TB in Zambia, 1992-1997, Overseas\u000d\u000a      Development Association, &#163;447,000.\u000d\u000a      Porter, Prevention of HIV-related TB in Kenya, MRC, 1990-1994. &#163;250,000.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    5.1 WHO, Global Tuberculosis Programme, UNAIDS (1998) Policy\u000d\u000a        Statement on Preventive Therapy Against Tuberculosis in People Living\u000d\u000a        with HIV: Report of a Meeting Held in Geneva 18-20 February 1998,\u000d\u000a      WHO\/TB\/98.255; UNAIDS\/98.34. Geneva: WHO,\u000d\u000a      http:\/\/whqlibdoc.who.int\/hq\/1998\/WHO_TB_98.255.pdf\u000d\u000a      (accessed 14 November 2013).\u000d\u000a    5.2 Eldred, LJ, Churchyard, G, Durovni, B, Godfrey-Faussett, P, Grant,\u000d\u000a      AD, Getahun, H and Chaisson, RE (2010) Isoniazid preventive therapy for\u000d\u000a      HIV-infected people: evidence to support implementation, AIDS,\u000d\u000a      24(Suppl. 5): s1-3, doi: 10.1097\/01.aids.0000391009.95149.ec.\u000d\u000a    5.3 Chaisson, RE, Grant, A, Getahun, H and Glynn, JR (eds) (2010)\u000d\u000a      Implementation of isoniazid preventive therapy to control HIV-related\u000d\u000a      tuberculosis: evidence, challenges and policy, AIDS, 24(Suppl. 5),\u000d\u000a      http:\/\/journals.lww.com\/aidsonline\/toc\/2010\/11005\u000d\u000a      (accessed 14 November 2013) (supplement of the journal AIDS devoted to\u000d\u000a      IPT).\u000d\u000a    5.4 Getahun, H, Granich, R, Sculier, D, Gunneberg, C, Blanc, L, Nunn, P\u000d\u000a      and Raviglione, M (2010) Implementation of isoniazid preventive therapy\u000d\u000a      for people living with HIV worldwide: barriers and solutions, AIDS,\u000d\u000a      24(Suppl. 5): s57-65,\u000d\u000a      http:\/\/journals.lww.com\/aidsonline\/Fulltext\/2010\/11005\/Implementation_of_isoniazid_preventive_therapy_for.9.aspx\u000d\u000a      (accessed 14 November 2013).\u000d\u000a    5.5 XIX International AIDS Conference 22-27 July, Washington DC\u000d\u000a      Grant, A (2012) TB prevention: new data, new approaches, new challenges,\u000d\u000a      paper presented at the XIX International AIDS Conference, 22-27 July,\u000d\u000a      Washington DC,\u000d\u000a      http:\/\/pag.aids2012.org\/session.aspx?s=651\u000d\u000a      (accessed 14 November 2013).\u000d\u000a      Stop TB Partnership (2012) Whoopi Goldberg calls for action on childhood\u000d\u000a      TB at International AIDS Conference, press release, 27 July. Geneva: WHO,\u000d\u000a      http:\/\/www.stoptb.org\/news\/stories\/2012\/ns12_049.asp\u000d\u000a      (accessed 14 November 2013) (includes reference to Grant).\u000d\u000a    5.6 TB and HIV news from the 19th International AIDS Conference (2012) HATiP:\u000a        HIV &amp; AIDS Treatment in Practice, 198: 5-11, http:\/\/www.aidsmap.com\/pdf\/HATIP-198-August-6th-2012\/page\/2468298\/\u000d\u000a      (accessed 14 November 2013).\u000d\u000a    5.7 WHO (2011) Guidelines for Intensified Tuberculosis Case-finding\u000d\u000a        and Isoniazid Preventive Therapy for People Living with HIV in\u000d\u000a        Resource-constrained Settings. Geneva: WHO,\u000d\u000a      http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241500708_eng.pdf\u000d\u000a      (accessed 14 November 2013) (2011 guidelines on IPT: multiple items of\u000d\u000a      LSHTM research are cited, particularly references 5, 15 - LSHTM provided\u000d\u000a      most of the data and multiple staff are authors - 27, 38, 39 - Grant's\u000d\u000a      work - 42, 43 &#8212; trials mentioned in this case study).\u000d\u000a    5.8 WHO (2012) WHO policy on Collaborative TV\/HIV Activities:\u000d\u000a        Guidelines for National Programmes and Other Stakeholders. Geneva:\u000d\u000a      WHO,\u000d\u000a      http:\/\/www.who.int\/tb\/publications\/2012\/tb_hiv_policy_9789241503006\/en\/\u000d\u000a      (accessed 14\u000d\u000a      November 2013) (updated policy on TB HIV collaborative activities, which\u000d\u000a      draws directly on 3.4 and 3.5).\u000d\u000a    5.9 The Aurum Institute A Prospectus for Victory. Johannesburg:\u000d\u000a      The Aurum Institute,\u000d\u000a      https:\/\/sitefinder.tghn.org\/site_media\/media\/site_finder\/sites\/documents\/Aurum_Prospectus.pdf\u000d\u000a      (accessed 14 November 2013) (p. 7).\u000d\u000a    5.10 Motsoaledi, A (2013) Opening speech by the Minister of Health,\u000d\u000a      delivered at the South African AIDS Conference, 18 June, Durban,\u000d\u000a      transcript, http:\/\/www.doh.gov.za\/show.php?id=4305\u000d\u000a      (accessed 14 November 2013) (refers to LSHTM work on the effect of IPT on\u000d\u000a      mortality).\u000d\u000a    ","Title":"\u000d\u000a    Isoniazid preventive therapy for people with HIV\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    TB is a major cause of death among HIV-positive people. In the pre-HIV\u000d\u000a      era, IPT was an important intervention for preventing TB, but its efficacy\u000d\u000a      among people with HIV was unknown. This has been the focus of work for\u000d\u000a      researchers at LSHTM including Professors of International Health Alison\u000d\u000a      Grant (LSHTM since 1994, MRC Training Fellow 1994-7), John Porter (LSHTM\u000d\u000a      since 1990, then Senior Clinical Lecturer) and Peter Godfrey-Faussett\u000d\u000a      (LSHTM since 1989, then Clinical Research Fellow).\u000d\u000a    Between 1992 and 1998, Porter led randomised trials to determine the\u000d\u000a      efficacy of isoniazid in preventing TB among HIV-positive adults in Kenya\u000d\u000a      (N=684) and Zambia (N=1053), the latter with Godfrey-Faussett.3.1\u000d\u000a      The results of the Kenyan trial were inconclusive, but the Zambian trial\u000d\u000a      demonstrated that preventive therapy with twice-weekly isoniazid for six\u000d\u000a      months reduced the incidence of TB among people with HIV.\u000d\u000a    Based on these findings, Godfrey-Faussett, currently on secondment to\u000d\u000a      WHO, led the development of new WHO guidelines on IPT use. With WHO\u000d\u000a      support, Godfrey-Faussett undertook pioneering research between 1999 and\u000d\u000a      2004, integrating TB and HIV care at primary care level, featuring IPT as\u000d\u000a      a key intervention.\u000d\u000a    Starting in 1999, Grant undertook a series of studies addressing\u000d\u000a      obstacles to IPT implementation, collaborating with South African\u000d\u000a      researchers, in the setting of the intense TB epidemic in South African\u000d\u000a      gold mines. An observational cohort study demonstrated effectiveness of\u000d\u000a      IPT among people with HIV and a past history of TB (for whom IPT was not\u000d\u000a      previously recommended in WHO guidelines).3.2 Using an\u000d\u000a      innovative study design, 1,655 HIV-positive male employees of a South\u000d\u000a      African gold-mining company were offered enrolment in HIV care, in a\u000d\u000a      randomly-allocated sequence. Key findings were that enrolment in a clinic\u000d\u000a      offering IPT (300mg daily for six months, self-administered) to these gold\u000d\u000a      miners reduced TB incidence by 38% overall, and by 46% among individuals\u000d\u000a      with no prior history of TB, although post-IPT TB incidence in this\u000d\u000a      setting remained unacceptably high.3.3\u000d\u000a    Further work led by Grant included a meta-analysis showing that the risk\u000d\u000a      of developing isoniazid resistance after IPT was small.3.4\u000d\u000a      Qualitative work in South Africa identified that health care worker\u000d\u000a      perceptions were a major barriers to IPT use. In 2010 Grant was\u000d\u000a      commissioned by WHO to produce a systematic review of TB\/HIV integration\u000d\u000a      which directly informed updated WHO guidelines on TB\/HIV collaborative\u000d\u000a      activities.3.5\u000d\u000a    In the `Thibela TB' trial (2004-12) Grant, with colleagues in South\u000d\u000a      Africa, led a cluster-randomised study of community-wide IPT among gold\u000d\u000a      miners in South Africa, as a population-level strategy to control the TB\u000d\u000a      epidemic. This study enrolled 24,221 miners to start IPT &#8212; the largest\u000d\u000a      number of people ever to receive IPT in a clinical trial. Prior to\u000d\u000a      enrolment, nurses used clinical criteria to screen participants for active\u000d\u000a      TB and increased risk of isoniazid toxicity using a questionnaire and\u000d\u000a      chest radiograph. Study-defined IPT-related adverse events were checked at\u000d\u000a      each study visit. Key findings were that adverse events were extremely\u000d\u000a      rare, and IPT could be safely implemented by nurses using clinical\u000d\u000a      criteria.3.6 The main study results are currently in press.\u000d\u000a    "},{"CaseStudyId":"43528","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"1036973","Name":"Mozambique"}],"Funders":["Wellcome Trust","Medical Research Council"],"ImpactDetails":"\u000a    Data and new algorithms developed by LSHTM researchers are fundamental to\u000a      ongoing global\u000a      strategies to combat TB. As a direct result of their research and case\u000a      findings, and their wide\u000a      experience in the field and in terms of TB service provision at community\u000a      level, LSHTM has been\u000a      called upon to advise policy-makers at the highest level.\u000a    The impact of LSHTM research is clearly evidenced by current WHO guidance\u000a      promoting the\u000a      integration of HIV and TB services. This guidance is based on LSHTM's\u000a      ProTEST research where\u000a      the case-finding approach was first formally articulated and recommended\u000a      in 20045.1 but has had\u000a      ongoing impact. WHO guidelines re-issued in 2012 stated: \"The [2004]\u000a      policy, which provided\u000a      guidance for Member States and other partners on how to address the\u000a      HIV-related TB burden, has\u000a        been one of the most widely accepted policies issued by both departments\u000a      ... more than 170\u000a      countries had reported implementing its components by the end of 2010.\"5.2\u000a    In 2010-2011, Ayles, Corbett and Grant undertook meta-analyses of data\u000a      from LSHTM's African\u000a      population surveys in collaboration with WHO and Centres for Disease\u000a      Control and Prevention\u000a      (CDC) and developed a simplified symptom-based screening algorithm that\u000a      relies on the absence\u000a      of all four clinical symptoms (current cough, night sweats, fever and\u000a      weight loss) to identify PWLH\u000a      who have less likelihood of active TB and hence are eligible for isoniazid\u000a      preventive therapy to\u000a      prevent latent TB infection. Use of this algorithm is included in WHO's\u000a      2010 revision of TB\u000a      guidelines. Wide dissemination through WHO and aimed at health care\u000a      workers, policy-makers\u000a      and health programme managers working in the field of HIV\/AIDS and TB\u000a      means the algorithms\u000a      now form a standard part of global diagnostic practice.5.3\u000a    The impact of LSHTM population surveys is demonstrated through WHO's\u000a      promotion, since 2011,\u000a      of prevalence surveys modelled after those developed by LSHTM as a key\u000a      measure to understand\u000a      the progress of TB control throughout the world. This guidance is included\u000a      in the new WHO\u000a      handbook published in 2011 designed for TB experts, survey investigators,\u000a      researchers and\u000a      advisors at national and international level. WHO says it has ensured the\u000a      standardisation of\u000a      methods across multiple surveys in more than 20 countries in African,\u000a      Eastern Mediterranean,\u000a      South-East Asian and Western Pacific regions. Ayles was lead author of\u000a      Chapter 6 which covers,\u000a      among other things, the purpose of interviews in a TB prevalence survey\u000a      and guidance on how to\u000a      design questionnaires. Findings and methods used in the ZAMSTAR project\u000a      are also heavily cited\u000a      in the workbook where it is featured as a full case study. LSHTM\u000a      approaches to design, sampling,\u000a      microbiology, data collection and analysis are offered as a template for\u000a      new studies.5.4\u000a    In 2012, Godfrey-Faussett chaired the WHO review of evidence that saw\u000a      LSHTM equivocal results\u000a      for the impacts of case-finding at a community level incorporated into new\u000a      guidelines on systematic\u000a      screening for TB. Based on LSHTM research, the resulting document sets out\u000a      basic principles for\u000a      prioritising risk groups and choosing a screening approach at community\u000a      level.5.5 Ayles and Corbett\u000a      were also members of the Guideline Development Group.\u000a    Also in 2012, WHO issued a new updated policy on collaborative TB\/HIV\u000a      activities for national\u000a      programmes and other stakeholders.5.2 Godfrey-Faussett was an\u000a      active member of WHO's Policy\u000a      Updating Group and Ayles acted as an external peer reviewer in the\u000a      preparation of this new policy\u000a      aimed at establishing and strengthening mechanisms for integrated delivery\u000a      of TB and HIV\u000a      services internationally. LSHTM findings and experience on the integration\u000a      of services for TB with\u000a      those for HIV through community-based organisations from the DetecTB\u000a      project are referenced\u000a      under the section on carrying out joint planning to integrate services.\u000a    Further impact has been made through LSHTM researcher participation in\u000a      international workshops\u000a      and meetings such as the Regional TB\/HIV Implementation Workshop and Core\u000a      Group Meeting of\u000a      the Global TB\/HIV Working Group held in Maputo, Mozambique, 10-12 April\u000a      2013. Ayles provided\u000a      an official commentary on the latest in TB diagnostic technologies to an\u000a      audience of &gt;120\u000a      participants, comprising key international partners (e.g. The President's\u000a      Emergency Plan for AIDS\u000a      Relief, Global Fund) and community and civil society representatives from\u000a      14 African countries\u000a      representing 70% of the TB\/HIV burden worldwide.5.6\u000a    WHO estimates that through the LSHTM-influenced collaborative TB-HIV\u000a      activities, more than\u000a      400,000 lives have been saved since 2005, and more than 3m PLWH are now\u000a      screened for TB\u000a      each year.5.7\u000a    ","ImpactSummary":"\u000a    Research carried out by LSHTM has had a major influence on the\u000a      development of international\u000a      strategies to screen for tuberculosis (TB) in HIV positive patients. Data\u000a      from these studies has led\u000a      directly to new screening algorithms promoted by WHO and other major\u000a      policy-makers as a key\u000a      entry point for TB-HIV collaborative activities. Results from these\u000a      studies have been incorporated\u000a      into new international guidelines on systematic screening for TB and\u000a      collaborative TB-HIV\u000a      activities, resulting in more than 0.5m lives saved and a rapid rise in TB\u000a      screening for people living\u000a      with HIV. A companion case study addresses impact on use of isoniazid\u000a      preventive therapy.\u000a    ","ImpactType":"Political","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"1105845","Name":"Cidade de Maputo"}],"References":"\u000a    \u000a3.1 Godfrey-Faussett, P, Sonnenberg, P, Shearer, SC, Bruce, MC, Mee, C,\u000a      Morris, L and Murray, J\u000a      (2000) Tuberculosis control and molecular epidemiology in a South African\u000a      gold-mining communit',\u000a      Lancet, 356(9235): 1066-1071, doi: 10.1016\/S0140-6736(00)02730-6.\u000a      Citation count: 92\u000a    \u000a\u000a3.2 Corbett, EL, Charalambous, S, Moloi, VM, Fielding, K, Grant, AD, Dye,\u000a      C, De Cock, KM,\u000a      Hayes, RJ, Williams, BG and Churchyard, GJ (2004) Human immunodeficiency\u000a      virus and the\u000a      prevalence of undiagnosed tuberculosis in African gold miners, American\u000a        Journal of Respiratory\u000a        and Critical Care Medicine, 170(6): 673-679, doi:\u000a      10.1164\/rccm.200405-590OC. Citation count: 89\u000a    \u000a\u000a3.3 Ayles, H, Schaap, A, Nota, A, Sismanidis, C, Tembwe, R, De Haas, P,\u000a      Muyoyeta, M, Beyers, N\u000a      and Godfrey-Faussett, P for the ZAMSTAR Study Team (2009) Prevalence of\u000a      tuberculosis, HIV\u000a      and respiratory symptoms in two Zambian communities: implications for\u000a      tuberculosis control in the\u000a      era of HI', PLoS One, 4(5): e5602, doi:\u000a      10.1371\/journal.pone.0005602. Citation count: 40\u000a    \u000a\u000a3.4 Corbett, EL, Bandason, T, Cheung, YB, Munyati, S, Godfrey-Faussett,\u000a      P, Hayes, R,\u000a      Churchyard, G, Butterworth, A and Mason, P (2007) Epidemiology of\u000a      tuberculosis in a high HIV\u000a      prevalence population provided with enhanced diagnosis of symptomatic\u000a      disease, PLoS Medicine,\u000a      4(1): e22, doi: 10.1371\/journal.pmed.0040022. Citation count: 70\u000a    \u000a\u000a3.5 Corbett, EL, Bandason, T, Duong, T, Dauya, E, Makamure, B,\u000a      Churchyard, GJ, Williams, BG,\u000a      Munyati, SS, Butterworth, AE, Mason, PR, Mungofa, S and Hayes, RJ (2010)\u000a      Comparison of two\u000a      active case-finding strategies for community-based diagnosis of\u000a      symptomatic smear-positive\u000a      tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe\u000a      (DETECTB): a cluster-\u000a      randomised trial, Lancet, 376(9748):1244-1253, doi:\u000a      10.1016\/S0140-6736(10)61425-0. Citation\u000a      count: 45\u000a    \u000a\u000a3.6 Ayles, H, Muyoyeta, M, Du Toit, E, Schaap, A, Floyd, S, Simwinga, M,\u000a      Shanaube, K,\u000a      Chishinga, N, Bond, V, Dunbar, R, De Haas, P, James, A, Gey van Pittius,\u000a      NC, Claassens, M,\u000a      Fielding, K, Fenty, J, Sismanidis, C, Hayes, RJ, Beyers, N and\u000a      Godfrey-Faussett P, the ZAMSTAR\u000a      Team (2013) Effect of household and community interventions on the burden\u000a      of tuberculosis in\u000a      southern Africa: the ZAMSTAR community-randomised trial, Lancet,\u000a      382(9899): 1183-1194, doi:\u000a      10.1016\/S0140-6736(13)61131-9. Citation count: 0\u000a    \u000aKey grants\u000a    Godfrey-Faussett, TB Knowledge Programmes, DFID, 1995-2001, &#163;1,4m;\u000a      2001-2006, &#163;2.9m.\u000a    Godfrey-Faussett, Zamstar: Zambia &amp; South Africa TB and AIDS\u000a      Reduction Study, Bill &amp; Melinda\u000a    Gates Foundation, 2004-2014, &#163;17m.\u000a    Corbett, Senior Clinical Research Fellowship (supplemented by an\u000a      extension), Wellcome Trust,\u000a      3\/2005-11\/2010, &#163;2m.\u000a    Porter, TARGETS Consortium, DFID, 2006-10, &#163;5.1m.\u000a    Other funding from EU, WHO, Beit, Colt Foundation.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"}],"Sources":"\u000a    5.1 WHO (2004) Interim Policy on Collaborative TB\/HIV Activities,\u000a      WHO\/HTM\/TB\/2004.330,\u000a      WHO\/HTM\/HIV\/2004.1. Geneva: WHO,\u000a      http:\/\/whqlibdoc.who.int\/hq\/2004\/who_htm_tb_2004.330.pdf\u000a      (accessed 11 November 2013)\u000a      (guidelines for national programmes and other stakeholders. LSHTM\/ProTEST\u000a      references 7 and\u000a      8).\u000a    5.2 WHO (2012) WHO Policy on Collaborative TB\/HIV Activities:\u000a        Guidelines for National\u000a        Programmes and Other Stakeholders. Geneva: WHO,\u000a      http:\/\/www.who.int\/tb\/publications\/2012\/tb_hiv_policy_9789241503006\/en\/index.html\u000a      (accessed 11\u000a      November 2013) (DetecTB is referenced in Chapter 3:A.3.3, Involving\u000a      nongovernmental and other\u000a      civil society organisations and communities. p. 19).\u000a    5.3 WHO (2011) Guidelines for Intensified Tuberculosis Case-finding\u000a        and Isoniazid Preventive\u000a        Therapy for People Living with HIV in Resource-constrained Settings.\u000a      Geneva: WHO,\u000a      http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241500708_eng.pdf\u000a      (accessed 11 November 2013)\u000a      (Ayles, Grant and Godfrey Faussett are among those named as WHO Guidelines\u000a      Group; p. 8,\u000a      algorithm for TB screening in adults and adolescents living with HIV in\u000a      HIV-prevalent and resource-\u000a      constrained settings; Ayles and Corbett's research is further cited in\u000a      GRADE profile table 1, p. 20).\u000a    5.4 WHO (2011) Tuberculosis Prevalence Surveys: A Handbook (The Lime\u000a        Book). Geneva: WHO,\u000a      http:\/\/www.who.int\/tb\/advisory_bodies\/impact_measurement_taskforce\/resources_documents\/thelimebook\/en\/\u000a      (accessed 11 November 2013) (p. 81, Chapter 6, Interviews, data collection\u000a      tools and\u000a      informed consent, lead author Helen Ayles; ZAMSTAR findings and research\u000a      featured in Chapters\u000a      4, 6, 8, 15, including on p. 87; case studies for symptom screening: Case\u000a      1: Zambia &#8212; the\u000a      ZAMSTAR Pilot prevalence survey).\u000a    5.5 WHO (2013) Systematic Screening for Active Tuberculosis:\u000a        Principles and Recommendations.\u000a      Geneva: WHO, http:\/\/www.who.int\/tb\/tbscreening\/en\/index.html\u000a      (accessed 11 November 2013) (for\u000a      the critical outcomes of increased case-finding and community impact, the\u000a      ZAMSTAR data was the\u000a      highest quality evidence available; see GRADE tables on p. 94ff in\u000a      guidelines document).\u000a    5.6 WHO (2013) Report of the 18th Core Group Meeting of the TB\/HIV\u000a        Working Group, Regional\u000a        TB\/HIV Implementation Workshop &amp; 18th Core Group Meeting\u000a        of the Global TB\/HIV Working\u000a        Group, 10-12 April, Maputo, Mozambique. Geneva: WHO,\u000a      http:\/\/www.who.int\/tb\/challenges\/hiv\/report_of_the_18th_tb-hiv_core_group_meeting.pdf\u000a      (accessed\u000a      11 November 2013) (reference to Ayles is made on pp. 2-3 of the report;\u000a      see also\u000a      http:\/\/www.who.int\/tb\/challenges\/hiv\/maputo_main\/en\/index.html).\u000a    5.7 Personal reference: WHO Director, Stop TB Department, WHO. To\u000a      corroborate health\u000a      consequences of research impact on WHO guidelines, principles and\u000a      recommendations.\u000a    ","Title":"\u000a    Screening for TB in people living with HIV\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    TB is a curable and preventable disease. Despite this, in 2011, 8.7m\u000a      people fell ill with TB and\u000a      1.4m died. WHO has estimated in 2013 that among people living with HIV, TB\u000a      caused a quarter of\u000a      all deaths. Research conducted by Peter Godfrey-Faussett, Professor of\u000a      International Health\u000a      (joined LSHTM as MRC Training Fellow in 1989, Professor since 2005), Liz\u000a      Corbett (joined as\u000a      Wellcome Trust Clinical Training Fellow in 2000, Professor of Tropical\u000a      Epidemiology since 2012),\u000a      Helen Ayles (joined as Wellcome fellow in Tropical Medicine in 1998,\u000a      Senior Lecturer since 2007)\u000a      and other Department of Clinical Research researchers at LSHTM has been\u000a      responsible for\u000a      establishing the first clinical cohorts of HIV-infected and uninfected TB\u000a      patients in Africa, identifying\u000a      difficulties in diagnosis, and researching and developing effective new\u000a      strategies for screening and\u000a      treatment.\u000a    LSHTM researchers launched the ProTEST Initiative (1999-2004) to\u000a      demonstrate the feasibility of\u000a      providing collaborative TB\/HIV care for people living with HIV (PLWH) in\u000a      poor settings. ProTEST\u000a      facilitated collaboration between service providers. Voluntary counselling\u000a      and testing (VCT) acted\u000a      as the entry point for services including TB screening and preventative\u000a      therapy, clinical treatment\u000a      for HIV-related disease, and home-based and hospice care, in Zambia,\u000a      Malawi and South Africa.\u000a      Findings demonstrated that coordinating an integrated and comprehensive\u000a      package of services for\u000a      PLWH was relatively inexpensive.\u000a    Previous research by Godfrey-Faussett among Kenyan sex workers and South\u000a      African gold miners\u000a      (1995-1999) used molecular and conventional epidemiology to demonstrate\u000a      that most of the HIV-\u000a      related TB in these communities was due to ongoing transmission rather\u000a      than reactivation. Further\u000a      findings were that for PLWH, recurrent TB was more likely to be the result\u000a      of reinfection; recurrent\u000a      TB for HIV-uninfected patients was the result of relapse.3.1\u000a      These conclusions were reinforced by\u000a      similar findings from work by other LSHTM researchers working in other\u000a      South African goldmines\u000a      and in Malawi.\u000a    Population-based HIV and TB disease surveys conducted by Ayles and\u000a      Godfrey-Faussett (in\u000a      Zambia and South Africa, 2006), and occupational health surveys in mines\u000a      and factories by\u000a      Corbett (in South Africa 2001-2003 and Zimbabwe, 2004-2006), found\u000a      significant numbers of\u000a      undiagnosed TB cases, demonstrating that DOTS (the global control strategy\u000a      aimed at controlling\u000a      TB transmission through prompt diagnosis of symptomatic smear-positive\u000a      disease developed in\u000a      the 1990s) had failed to prevent rising TB incidence rates in Africa\u000a      brought about by the HIV\u000a      epidemic. The researchers concluded that new approaches were needed in\u000a      order to reach\u000a      international targets for reducing TB, and that epidemiological studies\u000a      could inform screening\u000a      algorithms for both detection and prevention of active TB.3.2-3.4\u000a    For case-finding strategies, LSHTM researchers administered two\u000a      large-scale community\u000a      randomised trials: DetecTB (in Harare, 2006-2009) and ZAMSTAR (in Zambia\u000a      and the Western\u000a      Cape Province, 2006-2010). DetecTB demonstrated that wide implementation\u000a      of active case-finding,\u000a      particularly with a mobile van approach, could have rapid effects on TB\u000a      transmission and\u000a      disease.3.5 In ZAMSTAR, two interventions (community-level\u000a      enhanced TB case-finding and\u000a      household level TB-HIV care) were implemented. Researchers found plausible\u000a      evidence of a\u000a      reduction in TB among communities receiving the household intervention.3.6\u000a    "},{"CaseStudyId":"43529","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000a    CSG research has been central to how UK government and the NHS have\u000a      targeted investment in cancer services and devised strategies to improve\u000a      cancer survival and reduce inequalities.\u000a    In the period since 2008, CSG members have frequently and on an ongoing\u000a      basis been called upon to advise the DH on cancer policy. This included\u000a      working closely with Professor Sir Mike Richards, the government's first\u000a      National Cancer Director, mainly through policy-influencing initiatives\u000a      such as the National Cancer Action Team (2008-2013), the National Cancer\u000a      Policy Team, the Cancer Reform Strategy Advisory Board (April 2010) and\u000a      the National Cancer Intelligence Network (Scientific Advisory Panel\u000a      2010-2013).5.1\u000a    The CSG has also been responsible for producing the UK's annual official\u000a      national statistics on cancer survival since 1999, both nationally,\u000a      for various NHS geographies,5.2 and for the UK.5.3\u000a      Since 2008, this has included close collaboration with the Office for\u000a      National Statistics (ONS) analysing and publishing trends and\u000a      sociodemographic patterns in cancer survival for major cancers by age, sex\u000a      and socioeconomic status in England. These statistics and research are\u000a      used by policy-makers and key stakeholders at national and local levels to\u000a      evaluate and update cancer policy.\u000a    CSG research estimating the number of avoidable premature deaths arising\u000a      from the UK cancer survival deficit relative to Europe featured heavily in\u000a      the evidence underpinning the DH's National Awareness and Early\u000a        Diagnosis Initiative (NAEDI), launched in November 2008. Established\u000a      as part of the government's strategy to improve cancer outcomes, NAEDI\u000a      draws on CSG findings to support its key hypothesis that delays in cancer\u000a      diagnosis are linked to poor survival and avoidable deaths in the UK. As a\u000a      result, the government has focused its entire cancer strategy around\u000a      `halving the gap' in avoidable premature cancer deaths identified in LSHTM\u000a      research.5.4 In its 2011 assessment of NAEDI's impact on NHS\u000a      costs and public benefits, the DH found that `earlier diagnosis is\u000a      generally cost-effective, but not cost-saving. If people are diagnosed\u000a      earlier ... the benefit is a substantial improvement in health outcomes'.\u000a    Building on NAEDI, in 2010, the DH commissioned the CSG to design and\u000a      execute survival comparisons for the International Cancer Benchmarking\u000a        Partnership, a global partnership aimed at improving cancer survival\u000a      outcomes by optimising cancer polices and services, intended to feed\u000a      directly into England's national cancer strategy for 2011. The results of\u000a      CSG research were considered so important by the DH that publication of\u000a      the government's plans to reform health and care services, Improving\u000a          Outcomes: a Strategy for Cancer5.5 was delayed\u000a      until the LSHTM-authored article in The Lancet3.4 was\u000a      accepted for publication and could be cited in the new strategy. This\u000a      article is the first one listed under `New evidence supporting the\u000a      development of this strategy', where it is described thus: `We now have\u000a      internationally comparable data which is more robust and up-to-date than\u000a      has been possible before'.\u000a    The 2010 Beral\/Peto criticism of the international survival comparisons,\u000a      upon which the government's cancer strategy is based, threatened to\u000a      undermine both official and public confidence. The CSG's independently\u000a      initiated research, published in rebuttal in 2011, provided policy-makers\u000a      with evidence of the robustness of comparisons derived from the national\u000a      cancer registration data for England.3.3 The DH initiated its\u000a      own review of the cancer registration scheme, but considered the CSG's\u000a      peer-reviewed research as the strongest plank of evidence for the\u000a      strategic utility of cancer registration in cancer control policy.5.1\u000a    In January 2013, the CSG was commissioned by the DH to develop interim\u000a      metrics to evaluate progress toward the central target in national cancer\u000a      control policy (i.e. to `save 5,000 lives' a year by 2014-2015.) CSG\u000a      researchers developed several such metrics, and wrote Annex C of the\u000a      second annual report of the DH's 2012 report, Improving Outcomes: A\u000a          Strategy for Cancer.5.6 The DH then commissioned\u000a      the CSG to update these estimates with the results of the EUROCARE-5 study\u000a      in 2013, to assess progress in reducing the survival deficit.\u000a    Additional commissions from the DH during the REF's impact period include\u000a      the production of the indicators of cancer survival specified for the NHS\u000a      Outcomes Framework5.7 and the indicators of cancer survival for\u000a      the Clinical Commissioning Groups Outcome Indicator Set;5.8\u000a      both in January 2013.\u000a    Such has been the relevance of CSG's cancer survival research that during\u000a      the REF's impact period, Coleman has delivered invited presentations or\u000a      keynote lectures at more than 50 major national and international\u000a      conferences and meetings for policy-makers and stakeholders at the highest\u000a      levels.5.9 He has also been regularly called upon by national\u000a      and international media to provide expert information based on the CSG's\u000a      research.5.10\u000a    ","ImpactSummary":"\u000a    The core target in the government's national strategy for cancer control\u000a      in England is to `save 5,000 lives a year by 2015'. This target was taken\u000a      directly from research done by LSHTM showing that 10,000 cancer-related\u000a      deaths per annum would be avoidable if five-year relative survival were as\u000a      high as the highest levels observed in Europe. Current government strategy\u000a      is entirely focused around `halving the gap' in avoidable premature cancer\u000a      deaths identified in this research, which also forms the basis for\u000a      England's National Awareness and Early Diagnosis Initiative.\u000a    ","ImpactType":"Political","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1 Rachet, B, Maringe, C, Nur, U, Quaresma, M, Shah, A, Woods, LM,\u000a      Ellis, L, Walters, S, Forman, D, Steward, JA and Coleman, MP (2009)\u000a      Population-based cancer survival trends in England and Wales up to 2007:\u000a      an assessment of the NHS cancer plan for England, Lancet Oncology,\u000a      10(4): 351-369, doi: 10.1016\/S1470-2045(09)70028-2. Citation count: 59.\u000a    \u000a\u000a3.2 Abdel-Rahman, MA, Stockton, DL, Rachet, B, Hakulinen T and Coleman,\u000a      MP (2009) What if cancer survival in Britain were the same as in Europe:\u000a      how many deaths are avoidable?, British Journal of Cancer,\u000a      101(Suppl. 2): s115-124, doi: 10.1038\/sj.bjc.6605401. Citation count: 39.\u000a    \u000a\u000a3.3 Woods, LM, Coleman, MP, Lawrence, G, Rashbass, J, Berrino, F and\u000a      Rachet, B (2011) Evidence against the proposition that `UK cancer survival\u000a      statistics are misleading': simulation study with National Cancer Registry\u000a      data', BMJ, 324(d3399), doi: 10.1136\/bmj.d3399. Citation count: 9.\u000a    \u000a\u000a3.4 Coleman, MP, Forman, D, Bryant, H, Butler, J, Rachet, B, Maringe, C,\u000a      Nur, U, Tracey, E, Coory, M, Hatcher, J, McGahan, CE, Turner D, Marrett,\u000a      L, Gjerstorff, ML, Johannesen, TB, Adolfsson, J, Lambe, M, Lawrence, G,\u000a      Meechan, D, Morris, EJ, Middleton, R, Steward, J, Richards MA and ICBP\u000a      Module 1 Working Group (2011) Cancer survival in Australia, Canada,\u000a      Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer\u000a      Benchmarking Partnership): an analysis of population-based cancer registry\u000a      data, Lancet, 377(9760): 127-138, doi:\u000a      10.1016\/S0140-6736(10)62231-3. Citation count: 149.\u000a    \u000a\u000a3.5 Walters, S, Maringe, C, Butler, J, Rachet, B, Barrett-Lee, P, Bergh,\u000a      J, Boyages, J, Christiansen, P, Lee, M, W&#228;rnberg, F, Allemani, C, Engholm,\u000a      G, Fornander, T, Gjerstorff, ML, Johannesen, TB, Lawrence, G, McGahan, CE,\u000a      Middleton, R, Steward, J, Tracey, E, Turner, D, Richards, MA, Coleman, MP\u000a      and ICBP Module 1 Working Group (2013) Breast cancer survival and stage at\u000a      diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK,\u000a      2000-2007: a population-based study, British Journal of Cancer,\u000a      108(5): 1195-1208, doi: 10.1038\/bjc.2013.6. Citation count: 2.\u000a    \u000a\u000a3.6 Maringe, C, Walters, S, Rachet, B, Butler, J, Fields, T, Finan, PJ,\u000a      Maxwell, R, Nedreb&#248;, B, P&#229;hlman, L, Sj&#246;vall, A, Spigelman, A, Engholm, G,\u000a      Gavin, A, Gjerstorff, ML, Hatcher, J, Johannesen, TB, Morris, EJ, McGahan,\u000a      CE, Tracey, E, Turner, D, Richards, MA, Coleman, MP and ICBP Module 1\u000a      Working Group (2013) Stage at diagnosis and colorectal cancer survival in\u000a      six high-income countries: a population-based study of patients diagnosed\u000a      during 2000-2007, Acta Oncologica, 52(5): 919-932, doi:\u000a      10.3109\/0284186X.2013.764008. Citation count: 3.\u000a    \u000aKey grants (all to Coleman)\u000a    1. Cancer survival programme, Cancer Research UK, 4\/2005-3\/2010,\u000a      &#163;1,984,261.\u000a    2. Post-doc fellowship for Laura Woods (part-time), Cancer Research UK,\u000a      10\/2006-6\/2017, &#163;239,159.\u000a    3. International Cancer Benchmarking Partnership, DH via McKinsey\u000a      Consultants, 1\/2010-12\/2011, &#163;162,583.\u000a    4. Cancer Survival Programme, Cancer Research UK, 4\/2010-3\/2015,\u000a      &#163;1,185,330.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    5.1 National Cancer Director, England (until March 2013), DH, to\u000a      corroborate the impact of the CSG's research on cancer control policy in\u000a      England.\u000a    5.2 Quaresma, M, Whitehead, S, Coleman, MP and Rachet B (2012) Combined\u000a        Cancer Survival by Primary Care Trusts, Patients Diagnosed 1996-2010,\u000a        Followed Up to 2011. London: ONS, http:\/\/www.ons.gov.uk\/ons\/rel\/cancer-unit\/combined-cancer-survival-by-primary-care-\u000a        trusts\/patients-diagnosed-1996-2010--followed-up-to-2011\/index.html\u000a      (accessed 14 November 2013).\u000a    5.3 OECD (2011) Health At a Glance 2011: OECD Indicators. Paris:\u000a      OECD Publishing, doi: 10.1787\/health_glance-2011-en.\u000a    5.4 Richards, MA (2009) The National Awareness and Early Diagnosis\u000a      Initiative in England: assembling the evidence, British Journal of\u000a        Cancer, 101(Suppl. 2): s1-4, doi: 10.1038\/sj.bjc.6605382.\u000a    5.5 DH (2011) Improving Outcomes: A Strategy for Cancer &#8212; January\u000a        2011. London: DH, https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/213785\/dh_123394.pdf\u000a      (accessed 14 November 2014).\u000a    5.6 DH (2012) Improving Outcomes: A Strategy for Cancer &#8212; Second\u000a        Annual Report 2012. London: DH,\u000a      https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/136551\/Improving_o\u000a        utcomes_second_annual_report.pdf\u000a      (accessed 14 November 2014).\u000a    5.7 DH (2011) The NHS Outcomes Framework 2012\/13: Technical Appendix.\u000a      London: DH, https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/213713\/dh_131721.pdf\u000a      (accessed 14 November 2014).\u000a    5.8 Health and Social Care Information Centre (2013) CCG OIS\u000a      (Clinical Commissioning Groups Outcome Indicator Set) Planned\u000a      Publication Schedule. London: Health and Social Care Information\u000a      Centre, http:\/\/www.hscic.gov.uk\/media\/11813\/Clinical-Commissioning-Groups-OIS-\u000a      Publication-Schedule\/pdf\/CCG_OIS_publication_schedule_14_Jun.pdf\u000a      (accessed 14 November 2013).\u000a    5.9 List of conferences, seminars and other events for policy-makers,\u000a      practitioners and\/or stakeholders featuring invited presentations or\u000a      keynote lectures delivered by Professor Michel Coleman between 1 January\u000a      2008 and 31 July 2013 is available upon request.\u000a    5.10 Michel Coleman's many media engagements include a two-part cancer\u000a      documentary series, Catching Up With Cancer, broadcast on BBC\u000a      Radio 4, February-April 2008,\u000a\u0009  http:\/\/www.bbc.co.uk\/programmes\/b008vt6c\u000a      http:\/\/www.bbc.co.uk\/programmes\/b008vzdq\u000a      (accessed 14 November 2013). International media coverage includes Canada\u000a      TV News 16 July 2008,\u000a      http:\/\/www.ctvnews.ca\/canada-gets-high-ranking-for-cancer-survival-rates-1.309105\u000a      (accessed 14 November 2013). A full list of media engagements 1 January\u000a      2008-31 July 2013 available here: http:\/\/www.lshtm.ac.uk\/eph\/ncde\/cancersurvival\/research\/media_engagements_since_2008.pdf\u000a      (accessed 15 November 2013).\u000a    ","Title":"\u000a    Cancer survival: impact on cancer control policy in England\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    In August 2003, EUROCARE-3, an EU-funded study, published data confirming\u000a      that cancer survival five years after diagnosis in the UK was below the\u000a      European average for most cancers. LSHTM's Cancer Survival Group (CSG),\u000a      led by Michel Coleman (Professor of Epidemiology and Vital Statistics at\u000a      LSHTM since 1995) and Bernard Rachet (Clinical Reader in Cancer\u000a      Epidemiology, at LSHTM since 2002, then Clinical Lecturer), and employing\u000a      three Research Fellows, was formed in 2005 (grants 1, 2, 4). Its goal has\u000a      been to identify, quantify and explain inequalities in survival,\u000a      specifically to inform health policy for improved cancer control. The\u000a      Cancer Survival Group now has more than 20 scientific staff, with\u000a      worldwide collaborations in cancer survival research and methodological\u000a      development.\u000a    Early work involved the evaluation of the effectiveness of the NHS Cancer\u000a      Plan (2000) in improving one-year survival in England, by explicitly\u000a      seeking acceleration in the underlying trends before (1995-1999), during\u000a      (2000-2003) and after (2004-2006) implementation of the Plan. The Group\u000a      took advantage of a natural experiment in that, despite NHS similarities\u000a      in England and Wales, Wales did not have a formal cancer plan until 2006.\u000a      They found that survival increased more quickly during 2004-2006 in\u000a      England than in Wales for about half the cancers examined. 3.1\u000a    The research underpinning the core target in the current national cancer\u000a      strategy in England (Improving Outcomes: A Strategy for Cancer, 2011)\u000a      was initiated by the Group in 2008, in collaboration with Professor Timo\u000a      Hakulinen (University of Helsinki) and Dr Manar Abdel-Rahman (University\u000a      of Khartoum). The Group developed a method to estimate the annual number\u000a      of cancer-related deaths within five years of diagnosis in Britain that\u000a      would not be expected to occur if relative survival were as high as the\u000a      highest levels observed in Europe.3.2 International comparisons\u000a      of survival from the EUROCARE programme were used to estimate trends in\u000a      `avoidable premature mortality' over the previous 15 years. This was done\u000a      as the product of the number of five-year survivors expected from life\u000a      tables and the difference in relative survival between each country in\u000a      Britain and the highest survival in Europe, summed across age group, sex,\u000a      type of cancer and country.\u000a    In August 2010, in a BMJ editorial, two eminent cancer\u000a      specialists, Valerie Beral and Richard Peto, dismissed international\u000a      comparisons of cancer survival involving the UK as `unreliable', on the\u000a      basis of two proposed errors in national cancer registry data. In\u000a      response, the Cancer Survival Group rapidly performed a full-scale\u000a      simulation of the proposed errors. This provided firm evidence to refute\u000a      the critique.3.3\u000a    In 2010, the Department of Health (DH) commissioned the Group to perform\u000a      a major international comparison of cancer survival involving six\u000a      high-income countries as part of the International Cancer Benchmarking\u000a      Partnership (ICBP). It showed that UK survival up to 2007 improved faster\u000a      than comparator countries for breast cancer, but not for cancers of the\u000a      bowel, lung or ovary.3.4 Subsequent analyses indicated that the\u000a      UK survival deficits are partly explained by later diagnosis and partly by\u000a      lower stage-specific survival.3.5, 3.6\u000a    "},{"CaseStudyId":"43532","Continent":[{"GeoNamesId":"6255146","Name":"Africa"}],"Country":[{"GeoNamesId":"149590","Name":"Tanzania"},{"GeoNamesId":"2245662","Name":"Senegal"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    To address the problem of overdiagnosis of malaria and convince\u000d\u000a      practitioners, national and\u000d\u000a      international policy-makers and aid donors of the value of change required\u000d\u000a      a multidisciplinary\u000d\u000a      approach of coordinated research, which LSHTM helped to provide as\u000d\u000a      summarised above. The\u000d\u000a      impacts have been in terms of policy change at international and national\u000d\u000a      levels, changes in clinical\u000d\u000a      practice and cost savings. Health benefits should emerge, though are\u000d\u000a      difficult to quantify at this\u000d\u000a      point.\u000d\u000a    LSHTM staff were involved in the technical discussions at national,\u000d\u000a      regional, international and\u000d\u000a      donor levels to explain their research findings and set the research in\u000d\u000a      context. At national level,\u000d\u000a      Reyburn was a member of the Tanzanian malaria diagnostic working group\u000d\u000a      which met between\u000d\u000a      2007 and 2010.5.1 At international level, Reyburn (and eight\u000d\u000a      other LSHTM malaria researchers)\u000d\u000a      also participated in the Technical Consultation on Parasitological\u000d\u000a      Confirmation of Malaria\u000d\u000a      Diagnosis (6-8 October 2009, Geneva), which was convened by WHO.5.2\u000d\u000a      To influence the main\u000d\u000a      funder of supplies for malaria diagnosis and treatment, the GFATM, LSHTM\u000d\u000a      provided the\u000d\u000a      background briefing for the Global Fund decisions and co-chairmanship of a\u000d\u000a      key consultation (31\u000d\u000a      May-1 June 2010) on the economics and financing of universal access to\u000d\u000a      parasitological\u000d\u000a      confirmation of malaria.5.3\u000d\u000a    In 2010 WHO changed its policy from one of treating all fevers in Africa\u000d\u000a      as malaria, to one where\u000d\u000a      only parasite-test positive cases were treated, recommending RDTs as a\u000d\u000a      good way to do this.5.4\u000d\u000a      The related BMJ editorial by Dr Rob Newman, Director of WHO's\u000d\u000a      Global Malaria Programme,\u000d\u000a      explaining this policy change5.5 cited three studies in support\u000d\u000a      of it, two of which3.1, 3.3 were from\u000d\u000a      LSHTM research and the third was influenced by LSHTM research.\u000d\u000a    With this change in policy, the Global Fund is financing RDT roll-out in\u000d\u000a      Africa (including with\u000d\u000a      significant UK government funds). Many countries have rapidly changed\u000d\u000a      policy &#8212; for example, in\u000d\u000a      Tanzania, roll-out of RDTs nationwide was completed by end 20115.6\u000d\u000a      (see also 5.1 who is the\u000d\u000a      person giving the presentation in 5.6).\u000d\u000a    LSHTM researchers have also engaged with other funders beyond the GFATM.\u000d\u000a      For example, their\u000d\u000a      advice is acknowledged in a recent National Audit Office report in the UK\u000d\u000a      which concentrated\u000d\u000a      heavily on the potential waste of resources if antimalarial drugs financed\u000d\u000a      by UK aid go to children\u000d\u000a      without malaria.5.7 The report acknowledged progress in\u000d\u000a      introducing testing for malaria but argued\u000d\u000a      this should go further, recommending on p. 12: `Specify milestones and\u000d\u000a      targets to reduce\u000d\u000a      unnecessary treatment by focusing drug consumption on positively tested\u000d\u000a      cases, in public and\u000d\u000a      private sectors,' reflecting the key message of LSHTM research.\u000d\u000a    Other LSHTM malaria experts have helped to spread the findings of the\u000d\u000a      research by Reyburn and\u000d\u000a      Whitty through their engagement activities with relevant stakeholders. For\u000d\u000a      example, Schellenberg\u000d\u000a      (Professor of Malaria and International Health, since 2005) included the\u000d\u000a      role of RDTs in reports\u000d\u000a      authored for the UK All Party Parliamentary Group on Malaria in 2011, 2012\u000d\u000a      and 2013.5.8 School\u000d\u000a      staff have also worked with the media to raise awareness and understanding\u000d\u000a      of the importance of\u000d\u000a      RDTs, for example Schellenberg's interview with the BBC World Service's Focus\u000d\u000a        on Africa\u000d\u000a      programme (September 2011), where he stated that testing is\u000d\u000a      `revolutionising malaria control'. This\u000d\u000a      interview attracted 10m listeners in Africa.5.9\u000d\u000a    The impact of the WHO policy change and subsequent national programme\u000d\u000a      changes has already\u000d\u000a      been considerable. A study in Senegal (which cited LSHTM work) found that\u000d\u000a      the change to pre-treatment\u000d\u000a      parasitological confirmation reduced ACT prescriptions from 72.9% of\u000d\u000a      malaria-like febrile\u000d\u000a      illness to 31.5%, reaching close equivalence to confirmed malaria (29.9%\u000d\u000a      of 584,873 suspect fever\u000d\u000a      cases). An estimated 516,576 courses of inappropriate ACT prescription\u000d\u000a      were averted, worth in\u000d\u000a      excess of $1m.5.10\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Malaria in Africa, traditionally diagnosed from fever symptoms, has been\u000d\u000a      massively overdiagnosed,\u000d\u000a      and other causes of fever missed. This research demonstrated the magnitude\u000d\u000a      of overdiagnosis,\u000d\u000a      undertook trials of rapid diagnostic tests, identified alternative\u000d\u000a      bacterial diagnoses, completed\u000d\u000a      economic appraisals and studied prescriber behaviour. The research\u000d\u000a      underpinned a major change\u000d\u000a      in policy by WHO (2010), substantial investments by the Global Fund to\u000d\u000a      fight HIV, TB and Malaria\u000d\u000a      (GFATM), and changed clinical practice, to direct antimalarials to malaria\u000d\u000a      patients only. In one\u000d\u000a      country alone, 516,576 courses of inappropriate artemisinin-based\u000d\u000a      combination therapy (ACT)\u000d\u000a      were averted, worth in excess of $1m.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000d\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2660646","Name":"Genve"}],"References":"\u000d\u000a    \u000a3.1 Reyburn, HR, Mbatia, R, Drakeley, C, Carneiro, I, Mwakasungula, E,\u000d\u000a      Mwerine, O, Saganda, K,\u000d\u000a      Shao, J, Kitua, A, Olomi, R, Greenwood, BM and Whitty, CJM (2004)\u000d\u000a      Overdiagnosis of malaria in\u000d\u000a      patients with severe febrile illness in Tanzania: a prospective study, BMJ,\u000d\u000a      329(7476): 1212-1215,\u000d\u000a      doi: 10.1136\/bmj.38251.658229.55. Citation count: 243.\u000d\u000a    \u000a\u000a3.2 Reyburn, H, Mbakilwa, H, Mwangi, R, Mwerinde, M, Olomi, R, Drakeley,\u000d\u000a      C, and Whitty, CJM\u000d\u000a      (2007) Rapid diagnostic tests compared with malaria microscopy for guiding\u000d\u000a      outpatient treatment\u000d\u000a      of febrile illness in Tanzania: randomised trial, BMJ, 334(7590):\u000d\u000a      403-406A, doi:\u000d\u000a      10.1136\/bmj.39073.496829.AE. Citation count: 172.\u000d\u000a    \u000a\u000a3.3 Ansah, EK, Narh-Bana, S, Epokor, M, Akanpigbiam, S, Quartey, AA,\u000d\u000a      Gyapong, J and Whitty,\u000d\u000a      CJM (2010) Rapid testing for malaria in settings where microscopy is\u000d\u000a      available and peripheral\u000d\u000a      clinics where only presumptive treatment is available: a randomised\u000d\u000a      controlled trial in Ghana, BMJ,\u000d\u000a      340(c930), doi: 10.1136\/bmj.c930. Citation count: 36.\u000d\u000a    \u000a\u000a3.4 Lubell, Y, Reyburn, H, Mbakilwa, H, Mwangi, R, Chonya, S, Whitty, CJM\u000d\u000a      and Mills, A (2008)\u000d\u000a      The impact of response to the results of diagnostic tests for malaria:\u000d\u000a      cost-benefit analysis, BMJ,\u000d\u000a      336(7637): 202-205, doi: 10.1136\/bmj.39395.696065.47. Citation count: 66.\u000d\u000a    \u000a\u000a3.5 Chandler, CIR, Jones, C, Boniface, G, Juma, K, Reyburn, H and Whitty,\u000d\u000a      CJM (2008)\u000d\u000a      Guidelines and mindlines: why do clinical staff over-diagnose malaria in\u000d\u000a      Tanzania? A qualitative\u000d\u000a      study, Malaria Journal, 7(53), doi: 10.1186\/1475-2875-7-53.\u000d\u000a      Citation count: 58.\u000d\u000a    \u000a\u000a3.6 Nadjm, B, Amos, B, Mtove, G, Ostermann, J, Chonya, S, Wangai, H,\u000d\u000a      Kimera, J, Msuya, W,\u000d\u000a      Mtei, F, Dekker, D, Malahiyo, R, Olomi, R, Crump, JA, Whitty, CJM and\u000d\u000a      Reyburn, H (2010) WHO\u000d\u000a      guidelines for antimicrobial treatment in children admitted to hospital in\u000d\u000a      an area of intense\u000d\u000a      Plasmodium falciparum transmission: prospective study, BMJ,\u000d\u000a      340(c1350), doi:\u000d\u000a      10.1136\/bmj.c1350. Citation count: 43.\u000d\u000a    \u000aKey grants\u000d\u000a      Greenwood (LSHTM PI), The Effects of the Level of Plasmodium\u000d\u000a        falciparum Transmission on the\u000d\u000a      Pattern of Malaria in north-eastern Tanzania, MRC, 2000-2002, &#163;1.36m.\u000d\u000a      (funded 2004 Reyburn\u000d\u000a      and Whitty study)\u000d\u000a      Reyburn and Bygbjorg, Improving the Quality, Effectiveness and Access to\u000d\u000a      Basic Treatment for\u000d\u000a      Severe Febrile Illness and Chronic Anaemia Caused by Malaria and Other\u000d\u000a      Common Infections,\u000d\u000a      European Commision EU SANTE, 2004\/078-607, 1\/4\/2005-6\/4\/2009, &#163;403,934.\u000d\u000a      Mills, Methods for Economic Evaluation of New Malaria Control Technologies\u000d\u000a      and Delivery\u000d\u000a      Strategies, MRC Studentship, 2004-2008, &#163;17,240 (plus stipend).\u000d\u000a      Ansah, supervised by Whitty. An Individually Randomised Trial of Rapid\u000d\u000a      Diagnostic Tests in Rural\u000d\u000a      Ghana, Gates Malaria Partnership Re-entry (postdoctoral) grant, Bill &amp;\u000d\u000a      Melinda Gates Foundation,\u000d\u000a      1\/12\/2006-30\/11\/2008, $149,219.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"8","Subject":"Medical Microbiology"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    5.1 Deputy Manager of the National Malaria Control Programme, Tanzania.\u000d\u000a    5.2 WHO (2010) Parasitological Confirmation of Malaria Diagnosis:\u000d\u000a        Report of a WHO Technical\u000d\u000a        Consultation Geneva, 6-8 October 2009. Geneva: WHO,\u000d\u000a      http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241599412_eng.pdf\u000d\u000a      (accessed 15 November 2013)\u000d\u000a      (Reyburn is acknowledged for his help in preparing the proceedings; eight\u000d\u000a      LSHTM staff are\u000d\u000a      acknowledged for their contributions discussed at the meeting).\u000d\u000a    5.3 The Global Fund &amp; WHO (2010) Consultation on the Economics\u000d\u000a        and Financing of Universal\u000d\u000a        Access to Parasitological Confirmation of Malaria, May 31-June 1 2010:\u000d\u000a        Meeting Report. Geneva:\u000d\u000a      The Global Fund,\u000d\u000a      http:\/\/www.theglobalfund.org\/documents\/amfm\/AMFm_EconFinanceDiagnostics_Report_en\/\u000d\u000a      (accessed 15 November 2013) (includes presentations from LSHTM staff;\u000d\u000a      names co-chairs, p. 16;\u000d\u000a      WHO pre-read includes LSHTM authorship:\u000d\u000a      Schellenberg, D, Reyburn, H, Yeung, S, Bosman, A,\u000d\u000a      Snow, R, Lansang, MA, Gelband, H,\u000d\u000a      Newman, R, Jamison, D and Adeyi, O, (2010) Consultation on the\u000d\u000a        Economics and Financing of\u000d\u000a        Universal Access to Parasitological Confirmation of Malaria, Pre-read,\u000d\u000a      draft, Appendix 2, Geneva:\u000d\u000a      The Global Fund,\u000d\u000a      http:\/\/www.theglobalfund.org\/documents\/amfm\/AMFm_EconFinancePreread_Appendix02_en\/,\u000d\u000a      accessed 15 November 2013).\u000d\u000a    5.4 WHO (2010) Guidelines for the Treatment of Malaria, 2nd edn.\u000d\u000a      Geneva: WHO,\u000d\u000a      http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241547925_eng.pdf\u000d\u000a      (accessed 15 November\u000d\u000a      2013).\u000d\u000a    5.5 Newman, RD (2010) Malaria control beyond 2010', BMJ,\u000d\u000a      340(c2714), doi: 10.1136\/bmj.c2714.\u000d\u000a    5.6 Mandike, R (2011) Recent developments and achievements in malaria\u000d\u000a      control in Tanzania\u000d\u000a      (mainland), presentation given at the DPG-Health Meeting, 4 May. Tanzania:\u000d\u000a      DPG (Development\u000d\u000a      Partners Group),\u000d\u000a      http:\/\/www.tzdpg.or.tz\/fileadmin\/documents\/dpg_internal\/dpg_working_groups_clusters\/cluster_2\/health\/DPGH_Meeting_Documents_2011\/National_Malaria_Control_Program-Tanzania_Mainland.pdf\u000d\u000a      (accessed 15 November 2013).\u000d\u000a    5.7 National Audit Office (2013) Malaria, HC534. London: The\u000d\u000a      Stationery Office,\u000d\u000a      http:\/\/www.nao.org.uk\/wp-content\/uploads\/2013\/07\/10181-001-Malaria-Book.pdf\u000d\u000a      (accessed 15\u000d\u000a      November 2013).\u000d\u000a    5.8 All-Parliamentary Group on Malaria and Neglected Tropical Diseases\u000d\u000a      (2011) The Control of\u000d\u000a        Malaria 2005-15: Progress and Priorities Towards Eradication, the Sixth\u000d\u000a        Report of the All-party\u000d\u000a        Parliamentary Group on Malaria and Neglected Tropical Diseases.\u000d\u000a      London: House of Commons,\u000d\u000a      http:\/\/healthmarketinnovations.org\/sites\/default\/files\/The%20Control%20of%20Malaria%202005-2015%202010.pdf\u000d\u000a      (accessed 15 November 2013) (pp. 16-19).\u000d\u000a    All-Parliamentary Group on Malaria and Neglected Tropical Diseases (2012)\u000d\u000a      Targeting Zero:\u000d\u000a        Sustaining Success in Malaria Control: All-parliamentary Group on\u000d\u000a        Malaria and Neglected Tropical\u000d\u000a        Diseases Report 2010-2011. London: House of Commons,\u000d\u000a      http:\/\/malaria.lshtm.ac.uk\/sites\/default\/files\/uploads\/docs\/APPMG_7th_Annual_Report_11th_July_2011.pdf\u000d\u000a      (accessed 15 November 2013)(pp. 6-7).\u000d\u000a    All-Parliamentary Group on Malaria and Neglected Tropical Diseases (2013)\u000d\u000a      Malaria:\u000d\u000a        Consolidating the Gains: Report for the All-parliamentary Group on\u000d\u000a        Malaria and Neglected Tropical\u000d\u000a        Diseases 2011-2012. London: House of Commons, http:\/\/redballoonhosting.com\/appmg\/wp-content\/uploads\/2013\/04\/APPMG-Malaria-Report-Consolidating-the-Gains.pdf\u000d\u000a      (accessed 15 November 2013) (p. 2).\u000d\u000a    5.9 Malaria No More (2011) Listen to Professor David Schellenberg on BBC\u000d\u000a      World Service, news\u000d\u000a      briefing, 21 September, http:\/\/malarianomore.org.uk\/news\/listen-to-professor-david-schellenberg-on-bbc-world-service\u000d\u000a      (accessed 15 November 2013).\u000d\u000a    5.10 Thiam, S, Thior, M, Faye, B, Ndiop, M, Diouf, ML, Diouf, MB, Diallo,\u000d\u000a      I, Fall, FB, Ndiaye, JL,\u000d\u000a      Albertini, A, Lee, E, Jorgensen, P, Gaye, O and Bell, D (2011) Major\u000d\u000a      reduction in anti-malarial drug\u000d\u000a      consumption in Senegal after nationwide introduction of malaria rapid\u000d\u000a      diagnostic tests, PLoS ONE,\u000d\u000a      6(4): e18419, doi:10.1371\/journal.pone.0018419.\u000d\u000a    ","Title":"\u000d\u000a    Reducing the overdiagnosis of malaria and improving case management of\u000d\u000a      fever in East and West Africa\u000d\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Malaria has been routinely diagnosed from fever symptoms alone in Africa,\u000d\u000a      producing massive\u000d\u000a      overdiagnosis and treatment, and inappropriate treatment for other causes\u000d\u000a      of fever. Until 2010, it\u000d\u000a      was WHO policy to treat all children with fever in sub-Saharan Africa as\u000d\u000a      malaria, unless there was\u000d\u000a      an obvious alternative cause, leading to both unnecessary expenditure on\u000d\u000a      antimalarials and health\u000d\u000a      consequences for children with other causes of fever.\u000d\u000a    The scale of the problem of overdiagnosis of malaria was demonstrated by\u000d\u000a      a widely cited study in\u000d\u000a      2004 of over 17,000 patients in 13 Tanzanian hospitals led by Hugh Reyburn\u000d\u000a      (Senior Lecturer,\u000d\u000a      LSHTM since 2001) and Professor Chris Whitty (LSHTM since 2001, then\u000d\u000a      Senior Lecturer).3.1 This\u000d\u000a      showed that only 46% of the 2,062 people treated for severe malaria had Plasmodium\u000d\u000a        falciparum\u000d\u000a      parasites. Among patients aged &#8805; 5 years in medium transmission areas,\u000d\u000a      only 31.1% treated for\u000d\u000a      malaria had malaria. Of the patients with severe febrile illness\u000d\u000a      incorrectly treated for malaria, 66%\u000d\u000a      were given no antibiotics and 7.6% died. This paper alerted the public\u000d\u000a      health community to a major\u000d\u000a      preventable problem.\u000d\u000a    Reyburn and Whitty followed this with collaborative studies in East\u000d\u000a      (2004) and West (2009, 2010)\u000d\u000a      Africa showing that overdiagnosis of malaria in febrile patients was even\u000d\u000a      greater in outpatient\u000d\u000a      settings, where malaria is the commonest diagnosis and fever the commonest\u000d\u000a      presenting\u000d\u000a      syndrome. To address this they undertook trials of the effect of providing\u000d\u000a      rapid diagnostic tests\u000d\u000a      (RDTs) for malaria in outpatients in East Africa3.2 and\u000d\u000a      outpatients and peripheral clinics in West\u000d\u000a      Africa (several settings).3.3 In outpatients in both settings,\u000d\u000a      RDTs were sensitive and specific under\u000d\u000a      operational conditions, but clinicians ignored negative test results and\u000d\u000a      prescribed antimalarial\u000d\u000a      drugs in about half the cases. Where microscopic diagnosis of malaria was\u000d\u000a      present, RDTs had no\u000d\u000a      significant impact.\u000d\u000a    Economic analyses of the cost effectiveness and cost benefit of\u000d\u000a      introducing RDTs in a variety of\u000d\u000a      epidemiological settings, including modelling the reality that clinicians\u000d\u000a      often ignore test results,3.4\u000d\u000a      showed that except at the extremes of epidemiological malaria\u000d\u000a      transmission, introducing RDTs is\u000d\u000a      cost effective, but that this is very sensitive to assumptions on changes\u000d\u000a      in prescriber behaviour.\u000d\u000a      These analyses were done by PhD student Yoel Lubell, supervised by\u000d\u000a      Professor Anne Mills\u000d\u000a      (LSHTM since 1979), Whitty and Reyburn.\u000d\u000a    To understand clinician behaviour and its drivers, Clare Chandler (then\u000d\u000a      Research Fellow, LSHTM\u000d\u000a      since 2008) undertook a series of anthropological studies (2008-2013) on\u000d\u000a      clinicians' diagnostic\u000d\u000a      behaviour with respect to fever in East and West Africa.3.5\u000d\u000a      These showed that prescriber behaviour\u000d\u000a      was influenced by multiple factors, including peer opinion, and provided\u000d\u000a      the formative research\u000d\u000a      behind behavioural interventions. A barrier to clinicians reducing\u000d\u000a      overprescribing of antimalarials is\u000d\u000a      lack of alternative diagnoses. There is also a need to ensure\u000d\u000a      overtreatment with antibiotics does\u000d\u000a      not substitute for overprescribing antimalarials. Reyburn and Whitty\u000d\u000a      therefore undertook clinical\u000d\u000a      and microbiological studies of febrile children and adults who tested\u000d\u000a      negative for malaria. These\u000d\u000a      demonstrated a significant burden of bacterial diseases in severe cases,\u000d\u000a      but much lower in\u000d\u000a      outpatient cases, providing the data for guidelines on what to do when\u000d\u000a      patients were malaria-negative.3.6\u000d\u000a    "},{"CaseStudyId":"43612","Continent":[],"Country":[],"Funders":["Medical Research Council","Royal Society"],"ImpactDetails":"\u000a    Two decades of research at LSHTM have made a vital contribution to\u000a      successful efforts to reduce\u000a      the number of deaths from malaria. Using WHO methods of estimation, it can\u000a      be estimated that\u000a      approximately 1m malaria-related deaths were prevented by LLINs between\u000a      2008 and 2013,\u000a      mostly among African children.5.1, 5.2 Although it is clearly\u000a      impossible to quantify the contribution of\u000a      LSHTM research to this development with precision, the leading role LSHTM\u000a      has played in this\u000a      field gives an indication of its key role in achieving this impact.\u000a    LSHTM research involving experimental huts has made a direct impact on\u000a      the WHO Pesticide\u000a      Evaluation Scheme (WHOPES) whose authority in terms of the standardisation\u000a      and quality control\u000a      of ITNs is accepted by industry and donors. The experimental hut\u000a        methods and methods of ITN\u000a      field evaluation developed by LSHTM are described in WHO's Guidelines\u000a        for Laboratory and Field\u000a        Testing of Long-lasting Insecticidal Nets (2013).5.3, 5.4\u000a      On account of his research expertise,\u000a      Rowland played a leading role in drafting these guidelines5.4\u000a      and most of the techniques are now\u000a      too standardised for this second version to cite their origins. LSHTM's\u000a      influence is still visible\u000a      however, in the guidelines' use of Curtis' diagram of an experimental hut\u000a      (p.17) and LSHTM's\u000a      washing, field testing and quality control methodologies.\u000a    Much of WHOPES's work on ITNs prior to producing these guidelines\u000a      involved evaluating a large\u000a      number of datasets from field research in Africa, most of them produced by\u000a      LSHTM and\/or the\u000a      French IRD (Institut de recherche pour le d&#233;veloppement). Overall, LSHTM\u000a      contributed to the data\u000a      portfolio of 9 out of 11 LLIN products evaluated by WHOPES.5.3\u000a      The key role of the WHOPES\u000a      process is that it provides donors with a guarantee of product quality and\u000a      reliability; without this\u000a      guarantee, the very rapid scaling-up of LLIN procurement in the 2007&#8212;2010\u000a      period (&gt;140m nets\u000a      procured in 2010) would not have been possible. The importance of this\u000a      guarantee is illustrated by\u000a      the fact that the Global Fund will not allow its funds to be used to buy\u000a      nets not recommended by\u000a      WHOPES.\u000a    The risk assessment carried out by Lines and collaborators3.3\u000a      highlighted the fact that WHO was\u000a      still lacking a formal and documented position on the safety of ITNs. The\u000a      LSHTM work prompted\u000a      WHO to publish a general review of safety aspects and then to employ the\u000a      same team of\u000a      toxicologists who had worked with Lines to develop an extended generic set\u000a      of risk assessment\u000a      methods (revised edition 2012), using the same approach and format as in\u000a      the published paper.\u000a      This document (which also cites the original 2001 paper) gives\u000a      manufacturers of ITNs a protocol to\u000a      follow with regard to toxicology and safety.5.5\u000a    WHO's Global Plan for Insecticide Resistance Management in Malaria\u000a        Vectors (GPIRM), published\u000a      in 2012,5.6 represents a radical shift in technical strategies\u000a      for malaria vector control, and its\u000a      implications will take many years to implement. The plan quotes very\u000a      little actual data, but in\u000a      arguing that resistance can reduce effectiveness of vector\u000a      control, it relies heavily on 3.4, and\u000a      reproduces a figure from that article.\u000a    WHO's technical recommendations for insecticide resistance management\u000a        strategies, which\u000a      form the technical basis of the GPIRM implementation plan, were agreed by\u000a      a group of experts\u000a      convened by WHO in 2010, including Lines and Rowland. The meeting report5.7\u000a      quotes 3.4 as a\u000a      basic source. The meeting concluded that the use of mixtures of dissimilar\u000a      insecticides was one\u000a      of the most promising possible methods of resistance management, as had\u000a      been shown to be the\u000a      case by LSHTM research, and that manufacturers should be encouraged to\u000a      develop such\u000a      products. This recommendation was then included in the GPIRM plan5.7\u000a      and several manufacturers\u000a      have since started developing such `mixture' products, for example\u000a      Japan-based Sumitomo\u000a      Chemical5.8 and Swiss-headquartered Vestergaard Frandsen,\u000a      makers of Permanet 3.0.5.9 In 2010,\u000a      German chemical giant BASF announced an agreement with LSHTM and the\u000a      Innovative Vector\u000a      Control Consortium to develop a new generation of malaria prevention\u000a      products based on the\u000a      BASF insecticide chlorfenapyr, including a new LLIN;5.10 this\u000a      decision drew on formative work by\u000a      Rowland's group since 2003. Although these products are not yet in public\u000a      health use, they have\u000a      entered the WHOPES evaluation process and this manufacturers' investment\u000a      represents a\u000a      substantial commercial impact in itself, and clearly indicates that\u000a      manufacturers expect these to\u000a      gain significant market share in the next generation of vector control\u000a      products.\u000a    ","ImpactSummary":"\u000a    Twenty years of comprehensive research into long-lasting insecticidal\u000a      nets (LLINs) by LSHTM\u000a      have contributed substantially to the prevention of around 1m deaths from\u000a      malaria between 2008\u000a      and 2013. The research made a direct impact on guidelines and strategies\u000a      issued by WHO as well\u000a      as driving new technologies for insecticide-treated nets (ITNs), with\u000a      downstream commercial\u000a      benefits. Without the evolution of LLIN technology driven by LSHTM\u000a      research, the large-scale roll-out\u000a      of the new generation of nets (described in more detail in the other LSHTM\u000a      impact case study\u000a      on this body of research) would not have been possible.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1 Kolaczinski, JH, Fanello, C, Herv&#233;, JP, Conway, DJ, Carnevale, P and\u000a      Curtis, CF (2000)\u000a      Experimental and molecular genetic analysis of the impact of pyrethroid\u000a      and non-pyrethroid\u000a      insecticide impregnated bednets for mosquito control in an area of\u000a      pyrethroid resistance, Bulletin of\u000a        Entomological Research, 90(2): 125-132, doi: 10.1017\/S0007485300000237.\u000a      Citation count: 70\u000a    \u000a\u000a3.2 Graham, K, Kayedi, MH, Maxwell, C, Kaur, H, Rehman, H, Malima, R,\u000a      Curtis, CF, Lines, JD\u000a      and Rowland, MW (2005) Multi-country field trials comparing\u000a      wash-resistance of PermaNet&#8482; and\u000a      conventional insecticide-treated nets against anopheline and culicine\u000a      mosquitoes, Medical and\u000a        Veterinary Entomology, 19(1): 72-83, doi:\u000a      10.1111\/j.0269-283X.2005.00543.x. Citation count: 55\u000a    \u000a\u000a3.3 Barlow, SM, Sullivan, FM and Lines, J (2001) Risk assessment of the\u000a      use of deltamethrin on\u000a      bednets for the prevention of malaria, Food and Chemical Toxicology,\u000a      39(5): 407&#8212;422, doi:\u000a      10.1016\/S0278-6915(00)00152-6. Citation count: 44\u000a    \u000a\u000a3.4 N'Guessan, R, Corbel, V, Akogb&#233;to, M and Rowland, M (2007) Reduced\u000a      efficacy of insecticide-treated\u000a      nets and indoor residual spraying for malaria control in pyrethroid\u000a      resistance area, Benin,\u000a      Emerging Infectious Diseases, 13(2): 199-206, doi: 10.3201\/eid1302.060631.\u000a      Citation count: 159\u000a    \u000a\u000a3.5 Curtis, CF, Miller, JE, Hodjati, MH, Kolaczinski, JH and Kasumba, I\u000a      (1998) Can anything be\u000a      done to maintain the effectiveness of pyrethroid-impregnated bednets\u000a      against malaria vectors?,\u000a      Philosophical Transactions of the Royal Society of London, Series B,\u000a        Biological Sciences,\u000a      353(1376):1769-1775, doi: 10.1098\/rstb.1998.0329. Citation count: 50\u000a    \u000a\u000a3.6 N'Guessan, R, Boko, P, Odjo, A, Akogbeto, M, Yates, A and Rowland, M\u000a      (2007) Chlorfenapyr:\u000a      a pyrrole insecticide for the control of pyrethroid or DDT resistant Anopheles\u000a        gambiae (Diptera:\u000a      Culicidae) mosquitoes, Acta Tropica, 102(1): 69-78, doi:\u000a      10.1016\/j.actatropica.2007.03.003.\u000a      Citation count: 13.\u000a    \u000aKey grants\u000a    3.1 Curtis, Sustainability of Malaria Control with Impregnated Bednets,\u000a      MRC, 1998&#8212;2004, &#163;1,272,640.\u000a    3.3 Lines, Malaria Knowledge Programme, DFID, 1998&#8212;2003, &#163;2.5m.\u000a    3.4 Rowland, Gates Malaria Partnership Vector Control Research Project,\u000a      Bill &amp; Melinda Gates Foundation, 2001&#8212;2006, &#163;600,000.\u000a    3.5 Curtis, Application of Genetics and Etiology of Mosquitoes, MRC,\u000a      1993&#8212;1998, &#163;450,795.\u000a    3.6 Rowland, IVCC Field Site Studies, Bill &amp; Melinda Gates\u000a      Foundation, 2007&#8212;2010, &#163;513,349.\u000a    ","ResearchSubjectAreas":[{"Level1":"6","Level2":"4","Subject":"Genetics"},{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"7","Level2":"3","Subject":"Crop and Pasture Production"}],"Sources":"\u000a    5.1 WHO (2012) World Malaria Report 2012. Geneva: WHO,\u000a      http:\/\/www.who.int\/malaria\/publications\/world_malaria_report_2012\/en\/\u000a      (accessed 11 November\u000a      2013) (see pp. 59-61).\u000a    5.2 Roll Back Malaria Partnership (2011) A Decade of Partnership and\u000a        Results, Progress &amp; Impact\u000a      Series, no. 7, September. Geneva: WHO,\u000a      http:\/\/www.rbm.who.int\/ProgressImpactSeries\/docs\/report8-en.pdf\u000a      (accessed 11 November 2013)\u000a      (pp. 18, 68-69); Roll Back Malaria (2010) World Malaria Day 2010:\u000a        Africa Update, Progress &amp;\u000a      Impact Series, no. 2, April. Geneva: WHO\u000a      http:\/\/www.rbm.who.int\/ProgressImpactSeries\/docs\/wmd2010report-en.pdf\u000a      (accessed 11\u000a      November 2013) (p. 38).\u000a    5.3 See paragraphs 2 and 3 of letter from Coordinator of the Vector\u000a      Control Unit at the Global\u000a      Malaria Programme, WHO. Available on request.\u000a    5.4 WHO (2013) Guidelines for Laboratory and Field-testing of\u000a        Long-lasting Insecticidal Nets.\u000a      Geneva: WHO, http:\/\/apps.who.int\/iris\/bitstream\/10665\/80270\/1\/9789241505277_eng.pdf\u000a      (accessed 11 November 2013).\u000a    5.5 WHO (2012) A Generic Risk Assessment Model for\u000a        Insecticide-treated Nets: Revised Edition.\u000a      Geneva: WHO, http:\/\/apps.who.int\/iris\/bitstream\/10665\/44862\/1\/9789241503419_eng.pdf\u000a      (accessed 12 November 2013) (the second paragraph, p. 2, of the Background\u000a      section of this\u000a      document refers to work led by Lines &#8212; Barlow et al. 2001, Food Chem\u000a        Toxicol, 39: 407-422 &#8212; as\u000a      the first `detailed risk assessment' of a pyrethroid on nets).\u000a    5.6 WHO (2012) Global Plan for Insecticide Resistance Management in\u000a        Malaria Vectors (GPIRM).\u000a      Geneva: WHO, http:\/\/www.who.int\/malaria\/vector_control\/ivm\/gpirm\/en\/index.html\u000a      (accessed 12\u000a      November 2013).\u000a    5.7 WHO (2011) The Technical Basis for Coordinated Action Against\u000a        Insecticide Resistance:\u000a        Preserving the Effectiveness of Modern Malaria Vector Control,\u000a      meeting report, 4-6 May 2010,.\u000a      Geneva: WHO, http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241501095\/en\/index.html\u000a      (accessed 12 November 2013) (IM6 is the implementation plan, less\u000a      technical and IM7 the\u000a      technical foundation).\u000a    5.8 Sumitomo Chemical (2010) Sumitomo Chemical launches `Olyset&#174; Plus',\u000a      press release,\u000a      http:\/\/www.olyset.net\/resourcecenter\/news\/20120711_1\/\u000a      (accessed 12 November 2013).\u000a    5.9 Vestergaard (2013) Permanet&#174; 3.0: First Insecticide-Synergist\u000a        Combination Net. Technical\u000a        Basis for Deployment in Areas with Pyrethroid-Resistant Malaria Vectors.\u000a      Lausanne: Vestergaard\u000a      Frandsen S.A., http:\/\/www.vestergaard.com\/images\/pdf\/PN3-TechEng_latest.pdf\u000a      (accessed 14\u000a      November 2013).\u000a    5.10 BASF (2010) News release: next-generation malaria control, press\u000a      release, 21 April,\u000a      http:\/\/www.agro.basf.com\/agr\/AP-Internet\/en\/content\/news_room\/news\/next-generation-malaria-control\u000a      (accessed 12 November 2013).\u000a    ","Title":"\u000a    The technology of insecticide treated nets for malaria control\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Insecticide-treated nets (ITNs) have played an important part in recent\u000a      reductions in malaria\u000a      incidence and deaths. This case study describes LSHTM research into the\u000a      technical characteristics\u000a      required to make nets as effective as possible. Lead researchers were Dr\u000a      Jo Lines, Reader in\u000a      Malaria Control and Vector Biology, at LSHTM since 1984 (seconded to WHO\u000a      2008&#8212;2011); Mark\u000a      Rowland, Professor of Medical Entomology, at LSHTM since 2000; and Chris\u000a      Curtis, Professor of\u000a      Medical Entomology, at LSHTM from 1976 until his death in 2008. As so many\u000a      LSHTM\u000a      researchers made a contribution to research in this field, work\u000a      contributing to introducing and\u000a      distributing ITNs is described in a separate case study.\u000a    By 1993, LSHTM was already established as a leading player in developing\u000a      LLINs and work in this\u000a      area continued throughout the research assessment period.\u000a    LSHTM made numerous contributions to methods currently used for product\u000a      development testing,\u000a      epidemiological research and standardisation and quality control of ITNs\u000a      and LLINs. One major\u000a      contribution was the development and modernisation of experimental hut\u000a        methods. Experimental\u000a      huts were first used to evaluate insecticide treatments in the 1960s, but\u000a      LSHTM work introduced\u000a      more rigorous and innovative methods including Latin Square designs and\u000a      the genotyping of wild\u000a      mosquitoes after capture to measure the impact of insecticide resistance,3.1\u000a      carried out in 1999.\u000a    In 2001-2004, LSHTM researchers undertook a multicentre study that\u000a      compared various methods\u000a      of washing LLINs and testing their performance in three contrasting\u000a      settings.3.2 Other studies\u000a      investigated various non-pyrethroid insecticides, and found some to be\u000a      promising alternative\u000a      insecticides for bed nets.\u000a    During 1994-1996, when LSHTM was developing the first home treatment kits\u000a      for bed nets\u000a      (enabling users to re-treat nets with insecticide during washing) WHO\u000a      stated that ITNs were\u000a      considered safe, but did not provide supporting evidence. In 1999, LSHTM\u000a      employed two external\u000a      consultant toxicologists to carry out and publish a formal risk\u000a        assessment, together with Lines;3.3\u000a      the findings confirmed that the benefits of using ITNs in reducing\u000a      morbidity and mortality from\u000a      malaria were considerable and that the risk-benefit ratio was very\u000a      favourable.\u000a    In 2007\/2008, Rowland's group carried out further experimental hut\u000a      research in West Africa, in\u000a      response to the discovery that insecticide resistance genes in\u000a        mosquito vectors were\u000a      spreading rapidly. This research was the first to provide clear and\u000a      conclusive evidence that\u000a      resistance does reduce the effectiveness of ITNs.3.4\u000a    In 1993-1997, Curtis had studied methods of responding to or preventing\u000a        the emergence of\u000a        pyrethroid resistance in Anopheles vectors. He concluded\u000a      that there was no easy solution to the\u000a      problem of resistance management,3.5 but that deploying\u000a      mixtures of dissimilar insecticides was\u000a      among the most promising strategies. Investigation of various\u000a      non-pyrethroid insecticides found\u000a      some to be promising alternatives for bed nets.3.1\u000a    Recognising the grave threat that resistance presented to the future of\u000a      pyrethroid LLIN and the\u000a      long lead time required to develop new safe and effective alternatives,\u000a      LSHTM joined in strategic\u000a      partnership with WHOPES and pesticide and textile industry from 2002 to\u000a      identify and test new\u000a      active ingredients. Thus when WHO called in 2008 for the development\u000a        of products containing\u000a        new active ingredients, insecticide mixtures and combinations,\u000a      studies evaluating several\u000a      new products were already well advanced, including one formulation using a\u000a      synergist which has\u000a      since been marketed (as Permanet 3.0) and another more effective and\u000a      soon-to-be launched\u000a      product using the insecticide chlorfenapyr, which is new in public health\u000a      but has a long history of\u000a      use in agriculture.3.6\u000a    "},{"CaseStudyId":"43698","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"226074","Name":"Uganda"},{"GeoNamesId":"149590","Name":"Tanzania"},{"GeoNamesId":"1168579","Name":"Pakistan"},{"GeoNamesId":"2300660","Name":"Ghana"},{"GeoNamesId":"1149361","Name":"Afghanistan"},{"GeoNamesId":"192950","Name":"Kenya"}],"Funders":[],"ImpactDetails":"\u000a    The research carried out by LSHTM has made an important contribution\u000a      towards reducing the number of deaths from malaria. Using WHO methods of\u000a      estimation, it can be estimated that approximately 1m malaria-related\u000a      deaths were prevented by LLINs between 2008 and 2013, mostly among African\u000a      children.5.1 This impact was brought about by net distribution\u000a      operations and investment decisions during the impact assessment period\u000a      (mostly in 2009-2010). The WHO policy that led to these operations, which\u000a      explicitly cites LSHTM research as supporting evidence, was first drafted\u000a      and announced shortly before the impact assessment period (in 2007).\u000a      Nevertheless, it is clear that the operations putting this policy into\u000a      practice did take place during the assessment period, and were equally\u000a      influenced and justified by the same research, as were the subsequent WHO\u000a      statements repeating and amplifying the initial policy announcement.\u000a    Following a very limited emphasis on vector control by WHO and leading\u000a      agencies in the 1990s, the late 2000s marked a strategic sea change. Since\u000a      2006, and supported by the evidence accumulated through the research, WHO\u000a      has been recommending ITNs\/LLINs as the default vector control\u000a        intervention for Africa, with indoor residual spraying (IRS) as a\u000a      possible alternative that might be preferable in some settings. The\u000a      relevant WHO report, Malaria Vector Control and Personal Protection5.2\u000a      acknowledges Curtis' work on the Study Group that produced it, as well as\u000a      Rowland's written contribution. It also cites numerous relevant LSHTM\u000a      outputs. This document set the scene for further strategic emphasis on\u000a      malaria prevention through ITNs\/LLINs.\u000a    In 2008, The Roll Back Malaria partnership (RBM) &#8212; the global framework\u000a      for coordinated action against malaria &#8212; made ITNs and LLINs the lead\u000a        intervention in its Global Malaria Action Plan.5.3 The\u000a      plan acknowledges the contributions of no fewer than six LSHTM researchers\u000a      and quotes a December 2007 briefing produced by Lines and colleagues for\u000a      the Department for International Development (DFID), which was based on\u000a      3.1 and 3.3 and itself highlighted LLINs as a central plank in the quest\u000a      to eradicate malaria.5.4 As part of the 2008 Global Malaria\u000a      Action Plan, `SUFI' (Scaling-Up For Impact) was proclaimed as a goal &#8212;\u000a      aiming to rapidly reach universal coverage for all populations at risk\u000a      with locally appropriate malaria control interventions, with 730m\u000a        LLINs to be distributed globally (about 350m in Africa) (5.3, p.\u000a      14). The impact paper in Pakistan and the implementation research that\u000a      followed led to the LLIN strategy adopted by the Global Fund for South\u000a      Asia (e.g. Pakistan and Afghanistan) 5.3 and by WHO for\u000a      conflict induced emergencies 5.5.\u000a    In 2008, following a series of publications arguing that the impact of\u000a      ITNs would be maximised only if they were given free to everyone in the\u000a      community (because of the `mass effect' demonstrated by Lines et al.3.3,\u000a        3.4), the UN Secretary-General announced a vision of universal\u000a        coverage to end malaria deaths.5.6 His message was that\u000a      LLINs, along with indoor residual spraying, would be made available to all\u000a      people at risk, especially women and children in Africa. It was based on a\u000a      WHO position statement on Insecticide-Treated Mosquito Nets which\u000a      was first published in 2007 and remained the standard WHO policy position\u000a      throughout the 2008-2013 period.5.7 The position statement\u000a      explains the reasons for this shift to universal coverage through the use\u000a      of ITNs, citing several LSHTM outputs as well as Lengeler's Cochrane\u000a      review of the earlier mortality trials. Subsequently, and following these\u000a      WHO recommendations, ITN distribution campaigns have mostly been\u000a      standalone and designed to provide nets for entire populations, with one\u000a      net provided for every two people (eg Uganda). The contributions of LSHTM\u000a      research and staff are acknowledged by the WHO unit responsible for global\u000a      WHO policy on this topic.5.8\u000a    Largely as a result of the strategic initiatives described, expenditure\u000a      on malaria control as a whole is expected to exceed $1bn throughout\u000a      2008-20135.1, 5.2 with some 40% to 60% of this being spent on\u000a      vector control (mostly nets).\u000a    Not all countries wish to rely on externally funded and free distribution\u000a      of all nets, and some prefer to develop approaches more readily\u000a      sustainable over the longer term. LSHTM research findings on the public\u000a      health value of commercial markets as a distribution mechanism for\u000a      ITNs, and their importance in achieving overall coverage levels,\u000a      encouraged several countries to promote a diverse and complementary\u000a      mixture of distribution channels. Examples include Kenya, Ghana, Tanzania,\u000a      Pakistan and Afghanistan, who are encouraging mixed distribution\u000a        systems operating in parallel, including not only mass campaigns but\u000a      also distribution of free nets through routine public health systems\u000a      (especially antenatal and immunisation services) and unsubsidised\u000a      commercial markets.5.9, 5.10\u000a    ","ImpactSummary":"\u000a    A comprehensive body of research into the effectiveness, cost and\u000a      distribution of long-lasting insecticidal nets (LLINs) by LSHTM has made a\u000a      major contribution to the reduction of malaria-related mortality between\u000a      2008 and 2013, especially among children in Africa. The research formed\u000a      the basis of a radically altered strategic approach to combating malaria\u000a      by WHO and other agencies, and led to the roll-out of malaria campaigns\u000a      based around LLINs in several African countries. LSHTM research into the\u000a      technology of LLINs, which also contributed to these developments, is\u000a      described in a separate case study.\u000a    ","ImpactType":"Health","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1 Binka, FN, Kubaje, A, Adjuik, M, Williams, LA, Lengeler, C, Maude,\u000a      GH, Armah, GE, Kajihara, B, Adiamah, JH and Smith, PG (1996) Impact of\u000a      permethrin impregnated bednets on child mortality in Kassena-Nankana\u000a      district, Ghana: a randomized controlled trial, Tropical Medicine\u000a        &amp; International Health, 1(2): 147-154, doi:\u000a      10.1111\/j.1365-3156.1996.tb00020.x. Citation count: 241.\u000a    \u000a\u000a3.2 Goodman, C, Coleman, P and Mills, A (1999) Cost-effectiveness of\u000a      malaria control in sub-Saharan Africa, Lancet, 354(9176): 378-385,\u000a      doi: 10.1016\/S0140-6736(99)02141-8. Citation count: 138.\u000a    \u000a\u000a3.3 Hill, J, Lines, J and Rowland, M (2006) Insecticide-treated nets, Advances\u000a        in Parasitology, 61: 77-128, doi: 10.1016\/S0065-308X(05)61003-2.\u000a      Citation count: 40.\u000a    \u000a\u000a3.4 Curtis, C, Maxwell, C, Lemnge, M, Kilama, WL, Steketee, RW, Hawley,\u000a      WA, Bergevin, Y, Campbell CC, Sachs, J, Teklehaimanot, A, Ochola, S,\u000a      Guyatt, H and Snow, RW (2003) Scaling-up coverage with insecticide-treated\u000a      nets against malaria in Africa: who should pay?, Lancet Infectious\u000a        Diseases, 3(5): 304-307, doi: 10.1016\/S1473-3099(03)00612-1.\u000a      Citation count: 81.\u000a    \u000a\u000a3.5 Webster, J, Lines, J, Bruce, J, Schellenberg, JRA and Hanson, K\u000a      (2005) Which delivery systems reach the poor? A review of equity of\u000a      coverage of ever-treated nets, never-treated nets, and immunisation to\u000a      reduce child mortality in Africa, Lancet Infectious Diseases,\u000a      5(11): 709-717, doi: 10.1016\/S1473-3099(05)70269-3. Citation count: 32.\u000a    \u000a\u000a3.6 Okell, LC, Paintain, LS, Webster, J, Hanson, K and Lines, J (2012)\u000a      From intervention to impact: modelling the potential mortality impact\u000a      achievable by different long-lasting, insecticide-treated net delivery\u000a      strategies, Malaria Journal, 11(327), doi:\u000a      10.1186\/1475-2875-11-327. Citation count: 3.\u000a    \u000aKey grants\u000a    Mills, Economic Evaluation of National Impregnated Bednet Programme, The\u000a      Gambia, WHO-TDR, 1992-1994, $275,000.\u000a    Mills, Workshop on Cost-effectiveness Analysis of Impregnated bednets,\u000a      WHO-TDR, 1996, $7,500.\u000a    Mills, Lines, Hanson, Scaling Up ITN Coverage in Tanzania, Understanding\u000a      the Contribution and Limitations of the Private Sector, Gates Malaria\u000a      Partnership, 2002-2005, &#163;366,833.\u000a    Porter, Lines, Godfrey-Faussett, TARGETS: Team for Applied Research\u000a      Generating Effective Tools and Strategies: Proposal for a Research\u000a      Programme Consortium in Communicable Diseases, DFID, 1\/4\/2005-31\/3\/2010,\u000a      &#163;5,082,631.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    5.1 Number of deaths prevented 2008-13 calculated from: WHO (2012) World\u000a        Malaria Report. Geneva: WHO, http:\/\/www.who.int\/malaria\/publications\/world_malaria_report_2012\/en\/\u000a      (accessed 14 November 2013) (pp. 59-61); Roll Back Malaria Partnership\u000a      (2011) A Decade of Partnership and Results, Progress &amp; Impact\u000a      Series, no. 7, September. Geneva: WHO,? http:\/\/www.rbm.who.int\/ProgressImpactSeries\/docs\/report8-en.pdf\u000a      (accessed 11 November 2013) (pp. 18, 68-69); Roll Back Malaria (2010) World\u000a        Malaria Day 2010: Africa Update, Progress &amp; Impact Series, no.\u000a      2, April. Geneva: WHO,\u000a\u0009  http:\/\/www.rbm.who.int\/ProgressImpactSeries\/docs\/wmd2010report-en.pdf\u000a      (accessed 11 November 2013) (p. 38).\u000a    5.2 WHO (2006) Malaria Vector Control and Personal Protection: Report\u000a        of a WHO Study Group, WHO Technical Report Series, no. 936, http:\/\/whqlibdoc.who.int\/trs\/WHO_TRS_936_eng.pdf\u000a      (accessed 14 November 2013).\u000a    5.3 Roll Back Malaria (2008) The Global Malaria Action Plan: For a\u000a        Malaria-free World. Geneva: WHO, http:\/\/www.rbm.who.int\/gmap\/gmap.pdf\u000a      (accessed 14 November 2013).\u000a    5.4 Lines, J, Whitty, CJM and Hanson, K (2007) Prospects for\u000a      Eradication and Elimination of Malaria: A Technical Briefing for DFID.\u000a      London: DFID Health Resource Centre, http:\/\/r4d.dfid.gov.uk\/PDF\/Outputs\/Targets_RPC\/HD205-DFID-final-2007-20_2_.pdf\u000a      (accessed 14 November 2013).\u000a    5.5 WHO (2013) Malaria control in humanitarian emergencies: an\u000a        inter-agency field handbook, 2nd edition, WHO, Geneva, http:\/\/apps.who.int\/iris\/bitstream\/10665\/90556\/1\/9789241548656_eng.pdf\u000a      (accessed 25 November 2013).\u000a    5.6 Ki-moon, B (2008) UN Secretary-General's video message on World\u000a      Malaria Day &#8212; announcing vision for universal coverage to end malaria\u000a      deaths, statement, 25 April. New York: UN, http:\/\/www.un.org\/sg\/statements\/index.asp?nid=3118\u000a      (accessed 14 November 2014).\u000a    5.7 WHO (2007) Insecticide-treated Mosquito Nets: a WHO Position\u000a        Statement. Geneva: WHO, http:\/\/www.who.int\/malaria\/publications\/atoz\/itnspospaperfinal\/en\/index.html\u000a      (accessed 14 November 2014) (remains the primary WHO policy document on\u000a      this issue).\u000a    5.8 See paragraph 4 of letter from Coordinator of the Vector Control Unit\u000a      at the Global Malaria Programme, WHO. Available upon request.\u000a    5.9 Njau, RJA, de Savigny, D, Gilson, L, Mwageni, E and Mosha, FW (2009)\u000a      Implementation of an insecticide-treated net subsidy scheme under a\u000a      public-private partnership for malaria control in Tanzania &#8212; challenges in\u000a      implementation, Malaria Journal, 8(201), doi:\u000a      10.1186\/1475-2875-8-201.\u000a    5.10 Kolaczinski, JH, Muhammad, N, Khan, QS, Jan, Z, Rehman, N, Leslie,\u000a      TJ and Rowland, M (2004) Subsidized sales of insecticide-treated nets in\u000a      Afghan refugee camps demonstrate the feasibility of a transition from\u000a      humanitarian aid towards sustainability, Malaria Journal, 3(15),\u000a      doi: 10.1186\/1475-2875-3-15\u000a    ","Title":"\u000a    Scaling up insecticide treated net coverage: evidence to support\u000a      strategic policy decisions and investment\u000a    ","UKLocation":[],"UKRegion":[],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    This case study traces LSHTM contributions to the evidence that justified\u000a      the scaling-up of investment and large-scale distribution of\u000a      insecticide-treated nets (ITNs) to control malaria. Lead researchers\u000a      included Jo Lines, Reader in Malaria Control and Vector Biology, at LSHTM\u000a      since 1984 (seconded to WHO 2008-2011); Christian Lengeler, LSHTM Trial\u000a      Coordinator and Research Fellow 1992-1995; Peter Smith, Professor of\u000a      Tropical Epidemiology, at LSHTM since 1979; Chris Curtis, Professor of\u000a      Medical Entomology, at LSHTM from 1976 until his death in 2008; Mark\u000a      Rowland, Professor of Medical Entomology, at LSHTM since 2000, and Anne\u000a      Mills and Kara Hanson, Professors of Health Economics, at LSHTM since 1979\u000a      and 1990. Due to the number of LSHTM researchers contributing to research\u000a      into ITNs, work contributing to the technological development of LLINs is\u000a      described in a separate case study.\u000a    By 1993, the first major field trial of insecticide-treated nets (ITNs)\u000a      in Africa (in The Gambia) had shown a remarkably large reduction in\u000a      all-cause child mortality. However, to justify large-scale roll-out of\u000a      nets, replication across the range of eco-epidemiological conditions in\u000a      the region was needed. Lengeler, Smith and country researchers carried out\u000a      a series of field trials (in Burkina Faso, Kenya, The Gambia and Ghana)\u000a      between 1993 and 1996. The Ghana findings &#8212; similar to those in the other\u000a      countries &#8212; showed a reduction in all-cause child mortality of 17%.3.1\u000a      Supporting evidence on cost-effectiveness gathered by Mills and country\u000a      economists showed that ITNs were extremely cost-effective.3.2\u000a    A subsequent influential 2004 Cochrane review and meta-analysis by\u000a      Lengeler concluded that ITN coverage for a cohort of 1,000 children will\u000a      on average prevent 5.5 deaths per year across a wide range of\u000a      epidemiological settings in rural Africa. Further LSHTM epidemiological\u000a      trials conducted between 1995 and 2005 and included in the Cochrane review\u000a      confirmed that ITNs are effective against both falciparum and vivax\u000a      malaria in regions where the vector mosquito species are different (e.g.\u000a      the Amazon Basin and South Asia) but where mortality rates are lower, and\u000a      when deployed through other methods of implementation.\u000a    Also during 1993 and 1998, small-scale Tanzanian trials by Lines and\u000a      Curtis confirmed the entomological mode of action of ITNs, by recording\u000a      reductions in sporozoite rates in mosquitoes. This confirmed the\u000a      underlying mechanism of the `mass effect',3.3 which occurs when\u000a      the insecticide kills so many of the mosquitoes trying to feed through the\u000a      net that the transmission capacity of the local mosquito population as a\u000a      whole is reduced, protecting the whole community rather than just the\u000a      individual sleeper. The researchers argued that in order to obtain the\u000a      necessary levels of coverage, nets should be distributed free of charge to\u000a      everyone.3.4\u000a    In 2001-2005, LSHTM researchers conducted a series of detailed studies to\u000a      examine the role of local commercial markets in delivering mosquito nets\u000a      to end users, and showed that the coverage achieved by commercial markets\u000a      in nets is more equitable than that achieved by the sale of subsidised\u000a      nets by public health systems and projects.3.5 Further work in\u000a      2010-2011 demonstrated the epidemiological advantages of free distribution\u000a      of nets directly to pregnant women and infants through routine antenatal\u000a      and immunisation services.3.6\u000a    "},{"CaseStudyId":"43699","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"1733045","Name":"Malaysia"},{"GeoNamesId":"1643084","Name":"Indonesia"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"298795","Name":"Turkey"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"1168579","Name":"Pakistan"},{"GeoNamesId":"294640","Name":"Israel"},{"GeoNamesId":"1562822","Name":"Vietnam"},{"GeoNamesId":"453733","Name":"Estonia"},{"GeoNamesId":"1605651","Name":"Thailand"},{"GeoNamesId":"1210997","Name":"Bangladesh"},{"GeoNamesId":"1820814","Name":"Brunei"},{"GeoNamesId":"1668284","Name":"Taiwan"},{"GeoNamesId":"1269750","Name":"India"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    The research directly resulted in a new smoking cessation support service\u000a      in England delivered by\u000a      text message, with tens of thousands of smokers signing up, as well as\u000a      considerable national and\u000a      international public interest in the txt2stop trial findings. Similar\u000a      schemes are in the early stages of\u000a      roll-out in several other countries.\u000a    Following the publication of the paper in The Lancet3.3\u000a      in 2011, the Tobacco Control Marketing\u000a      Team for the Department of Health (DH) in England approached Free to help\u000a      them develop a new\u000a      text messaging service. Free advised the DH regarding the text message\u000a      content for the\u000a      intervention and provided extensive feedback on the messages written. She\u000a      also gave advice\u000a      regarding the design of the intervention covering the delivery system\u000a      requirements, message\u000a      frequency and the interactive features required.5.1 The service\u000a      was made available free at the point\u000a      of delivery from the NHS Stop Smoking website in January 2012.5.2\u000a      By the end of March 2013,\u000a      over 34,000 smokers had joined the programme. The DH Senior Campaigns\u000a      Manager states that\u000a      the service `continues to be a great success' and that `we look forward to\u000a      continuing to work with\u000a      you, and particularly on the academic evaluation to compare the success\u000a      rates of the 12 week\u000a      programme to the 28 day programme'.5.3\u000a    Free was invited to present her research findings to the European Society\u000a      for Research on\u000a      Nicotine and Tobacco in Helsinki in 2012; around 100 delegates listened to\u000a      her presentation.5.4\u000a      She was also asked to present her findings at the Royal College of General\u000a      Practitioners\u000a      conference in the UK twice, in 2011 and 2012,5.5, 5.6 with\u000a      around 100 GPs attending the first time.\u000a      The second time it was a plenary presentation at a conference attracting\u000a      over 4,000 GPs. Her\u000a      paper was voted the research paper of the year by the Royal College of\u000a      General Practitioners in\u000a      the primary care category. The research and the new service also received\u000a      the BUPA Healthy\u000a      Lives Prize 2012, an award which honours research enabling sustained\u000a      behaviour changes\u000a      towards a healthy lifestyle.5.7\u000a    As a result of presenting her findings, Free received a number of\u000a      enquiries from international\u000a      organisations. WHO used the txt2stop campaign in a presentation and panel\u000a      discussion for\u000a      member states focused on mHealth (health-related messages delivered by\u000a      mobile phone) in\u000a      Geneva in May 2013. The event was hosted by Costa Rica, which in April\u000a      2013 had become the\u000a      first to roll out its own equivalent of the txt2stop campaign. At least\u000a      175 delegates from WHO\u000a      member states, civil society, private sector representatives and the media\u000a      attended; Turkey, Israel\u000a      and Estonia were shown to have taken steps to introduce mHealth campaigns\u000a      to help people stop\u000a      smoking. WHO invited Free to be a member of the WHO informal working group\u000a      on m-cessation in\u000a      recognition of her `leadership and experience in m-cessation'.5.8\u000a    In the USA, Agile Health &#8212; a commercial provider of mobile health care\u000a      engagement solutions &#8212;\u000a      based their Kick Buts programme, launched in 2012, on the LSHTM and STOMP\u000a      trials.5.9 A\u000a      technologically improved version, Kick Buts 2.0, offering Facebook\u000a      integration and a Spanish\u000a      language version among other things, was launched in January 2013. By the\u000a      middle of 2013, 1,000\u000a      people had signed up to Kick Buts.\u000a    The research received extensive media coverage in June 2011, appearing in\u000a      national and\u000a      international newspapers, on radio, television and the internet. Examples\u000a      include a live interview\u000a      Free gave on the Today programme on BBC Radio 4; an interview for\u000a      SKY News radio, syndicated\u000a      for 300+ UK commercial radio stations; and interviews on three major local\u000a      BBC radio stations\u000a      (London, Sheffield, Three Counties). There was also extensive coverage in\u000a      the print media,\u000a      including the Daily Mail and local papers. Examples of online\u000a      coverage included Bloomberg, BBC\u000a      News online and Guardian online. The research findings were also picked up\u000a      by news agencies\u000a      such as Reuters and the Press Association. Put together, the coverage in\u000a      June 2011 would have\u000a      reached millions of people in the UK, widely raising awareness and\u000a      understanding of the\u000a      effectiveness of text messaging for people trying to quit smoking.5.10\u000a    Internationally, too, the research findings were very widely reported.\u000a      Numerous TV outlets in\u000a      Bangladesh, Brunei, India, Hong Kong, Indonesia, Malaysia, Pakistan,\u000a      Taiwan, Thailand and\u000a      Vietnam picked up a newsreel produced by AP in 2011, featuring Free\u000a      talking about her findings.\u000a      Free was also interviewed by USA Today (June 2011), and a video\u000a      release made available by\u000a      LSHTM was widely used.5.10\u000a    ","ImpactSummary":"\u000a    The txt2stop trial, led by LSHTM, provided robust evidence that smoking\u000a      cessation support\u000a      delivered by text messaging doubles biochemically verified quitting at six\u000a      months and is highly\u000a      cost-effective. The research resulted in a new smoking cessation service\u000a      delivered by text\u000a      message in England, with over 34,000 smokers having joined the programme\u000a      by the end of March\u000a      2013. The research was noted in international forums and used by WHO in a\u000a      presentation to\u000a      member countries; at least four countries have taken steps to roll out\u000a      their own programmes. The\u000a      trial findings received exceptionally wide media coverage in 2011.\u000a    ","ImpactType":"Societal","Institution":"\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"658225","Name":"Helsinki"},{"GeoNamesId":"1819729","Name":"Hong Kong"},{"GeoNamesId":"2660646","Name":"Genve"}],"References":"\u000a    \u000a3.1 Free, C (2012) Developing and adapting a text messaging intervention\u000a      for smoking cessation\u000a      from New Zealand for the United Kingdom, in J Donner and P Mechael (eds),\u000a      mHealth in Practice:\u000a        Mobile technology for Health Promotion in the Developing World.\u000a      London: Bloomsbury Academic,\u000a      pp. 46-61. No citation information available for book chapter\u000a    \u000a\u000a3.2 Free, C, Whittaker, R, Knight, R, Abramsky, T, Rodgers A and Roberts,\u000a      IG (2009) Txt2stop: a\u000a      pilot randomised controlled trial of mobile phone-based smoking cessation\u000a      support, Tobacco\u000a        Control, 18(2): 88-91, doi: 10.1136\/tc.2008.026146. Citation count:\u000a      25\u000a    \u000a\u000a3.3 Free, C, Knight, R, Robertson, S, Whittaker, R, Edwards, P, Zhou, W,\u000a      Rodgers, A, Cairns, J,\u000a      Kenward, MG and Roberts, I (2011) Smoking cessation support delivered via\u000a      mobile phone text\u000a      messaging (txt2stop): a single-blind, randomised trial, Lancet,\u000a      378(9785): 49-55, doi:\u000a      10.1016\/S0140-6736(11)60701-0. Citation count: 68\u000a    \u000a\u000a3.4 Guerriera, C, Cairns, J, Roberts, I, Rodgers, A, Whittaker, R and\u000a      Free, C (2013) The cost-effectiveness\u000a      of smoking cessation support delivered by mobile phone messaging:\u000a      txt2stop,\u000a      European Journal of Health Economics, 4(5): 789-797, doi:\u000a      10.1007\/s10198-012-0424-5. Citation\u000a      count: 1\u000a    \u000a\u000a3.5 Bodurtha Smith, AJ, Tennison, I, Roberts, I, Cairns J and Free, C\u000a        (2013) The carbon footprint\u000a      of behavioural support services for smoking cessation, Tobacco Control,\u000a      22(5): 302-307, doi:\u000a      10.1136\/tobaccocontrol-2012-050672. Citation count: 1\u000a    \u000aKey grants\u000a    Free, Roberts, Cairns, Edwards, Knight, Rodgers, Whittaker, Txt2stop: A\u000a      Trial of Mobile Phone-\u000a      based Smoking Cessation Support, UK MRC, 4\/2007-11\/2010, &#163;1,458,261, UK\u000a      MRC grant\u000a      supplement, 4\/2007-11\/2010, &#163;240,000.\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    5.1 Head of CRM, Department of Health regarding Dr Free's input in\u000a      developing the new service.\u000a      5.2 Department of Health (2013) Smokefree: support straight to you,\u000a      wherever you are, viewed 30\u000a      October 2013, http:\/\/smokefree.nhs.uk\/ways-to-quit\/support-on-your-mobile\/\u000a      (accessed 30 October\u000a      2013) (citing our involvement in the development of the programme).\u000a    5.3 Senior Campaigns Manager, Tobacco Control Marketing Team,\u000a      Department of Health, regarding the number of smokers using the programme\u000a      and the DH\u000a      evaluation of the new service.\u000a    5.4 Free, C (2012) Smoking cessation support delivered via mobile phone\u000a      text messaging\u000a      (txt2Stop), paper presented at the 14th Annual Meeting of the Society for\u000a      Research on Nicotine\u000a      and Tobacco (SNRT) Europe, 30 August-2 September, Helsinki, Finland, 2013,\u000a      http:\/\/www.srnteurope.org\/assets\/Abstract-Book-Final.pdf\u000a      (accessed 30 October 2013) (see pp. 9,\u000a      13, 30, 49).\u000a    5.5 Society for Academic Primary Care, invitation letter to present the\u000a      txt2stop trial results at the\u000a      RCGP conference 2011.\u000a    5.6 Royal College of General Practitioners (2012) Innovative quit smoking\u000a      programme wins\u000a      national award (press release, 19 June 2012), http:\/\/www.rcgp.org.uk\/news\/2012\/june\/innovative-\u000a        quit-smoking-programme-wins-national-award.aspx (accessed 30 October\u000a      2013).\u000a    5.7 BUPA Foundation (2012) Healthy Lives Prize, http:\/\/www.bupafoundation.co.uk\/research-\u000a        prizes\/2012-healthy-lives-prize (accessed 30 October 2013).\u000a    5.8 WHO, copy of emails outlining the influence of the txt2stop trial on\u000a      the WHO m-health smoking\u000a      cessation programme and inviting Free to be a member of the WHO informal\u000a      working group on m-\u000a      cessation.\u000a    5.9 Agile Health Inc, Kick Buts, http:\/\/www.agilehealth.com\/#!services\/ca4p\u000a      (accessed 30 October\u000a      2013).\u000a    5.10\u000a      http:\/\/www.lshtm.ac.uk\/research\/publicationsandimpact\/casestudies\/carolinefree_txt2stop.html\u000a    \u000a    ","Title":"\u000a    Smoking cessation support by text message: the impact of the txt2stop\u000a      trial\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Smoking continues to cause more preventable deaths than anything else in\u000a      the UK and worldwide\u000a      &#8212; nearly 80,000 in England alone during 2011, according to government\u000a      figures. Around half of\u000a      current smokers will be killed by their habit if they continue to smoke.\u000a      The UK government aims to\u000a      reduce the number of smokers in England by around 210,000 each year, with\u000a      campaigns to help\u000a      people stop smoking being an important plank in its strategy.\u000a    Dr Caroline Free, Senior Lecturer (at LSHTM since 2003, then Lecturer),\u000a      led the txt2stop trial, a\u000a      single blind randomised controlled trial evaluating the effect of smoking\u000a      cessation support delivered\u000a      by text message on biochemically verified continuous abstinence at six\u000a      months. The trial was\u000a      undertaken between October 2007 and October 2010. The academic\u000a      co-investigators included\u000a      Professor Ian Roberts (LSHTM), Professor John Cairns (LSHTM), Dr Robyn\u000a      Whittaker (University\u000a      of Auckland), Professor Anthony Rodgers (The George Institute, Sydney,\u000a      Australia), Dr Phil\u000a      Edwards (LSHTM) and Professor Mike Kenward (LSHTM). The LSHTM team were\u000a      all based at the\u000a      School throughout the trial. A previous New Zealand based trial (the STOMP\u000a      trial) had suggested\u000a      that smoking cessation support delivered by text messaging was effective\u000a      in the short term; Free\u000a      and her team modified and developed STOMP's approach and were the first to\u000a      reliably report the\u000a      long-term effects of the intervention.\u000a    As part of the research, smoking cessation counsellors, cognitive\u000a      behavioural therapists and 62\u000a      potential participants reviewed all text messages from STOMP in a series\u000a      of focus groups, and\u000a      modifications were made based on their input. The LSHTM team added\u000a      additional content to the\u000a      intervention, employing a wider range of behaviour change techniques\u000a      including feedback\u000a      regarding the physical benefits achieved, advice and support in using\u000a      nicotine replacement therapy\u000a      and specific content designed to reduce relapse.3.1, 3.2\u000a    5,800 smokers who were willing to make an attempt to quit were randomly\u000a      allocated to txt2stop,\u000a      comprising motivational messages and behavioural change support, or to a\u000a      control group that\u000a      received text messages unrelated to quitting.3.3 Outcome\u000a      assessors were masked to treatment\u000a      allocation. The primary outcome was self-reported continuous abstinence\u000a      biochemically verified at\u000a      six months. All analyses were by intention to treat.\u000a    Biochemically verified continuous abstinence at six months was\u000a      significantly increased in the\u000a      txt2stop group, with txt2stop proving successful in 10.7% of cases versus\u000a      4.9% in the control\u000a      group. The study found that txt2stop worked well for all ages and across\u000a      all social groups.3.3\u000a    Free and colleagues thus demonstrated that the txt2stop mobile phone text\u000a      messaging smoking\u000a      cessation programme substantially increased quit rates at six months.3.3\u000a    The cost-effectiveness analysis demonstrated that the intervention was\u000a      cost-effective and cost-saving\u000a      when the future NHS costs saved (as a result of reduced smoking) are\u000a      included.3.4 Free\u000a      and colleagues also conducted a carbon footprint analysis of the smoking\u000a      cessation support\u000a      delivered by text message and demonstrated that carbon emissions were low\u000a      in comparison with\u000a      the health gains produced.3.5\u000a    "},{"CaseStudyId":"43730","Continent":[{"GeoNamesId":"6255148","Name":"Europe"}],"Country":[{"GeoNamesId":"2510769","Name":"Spain"},{"GeoNamesId":"3175395","Name":"Italy"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2802361","Name":"Belgium"},{"GeoNamesId":"2661886","Name":"Sweden"},{"GeoNamesId":"2782113","Name":"Austria"},{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"3190538","Name":"Slovenia"}],"Funders":[],"ImpactDetails":"\u000d\u000a    The research was highly influential in informing the consultations and\u000d\u000a      legislative process leading to the adoption of the EU Directive on\u000d\u000a      Patients' Rights to Healthcare in Other European Countries. McKee and\u000d\u000a      colleagues have also advised individual governments and health care\u000d\u000a      professionals on cross-border patient mobility.\u000d\u000a    The European Parliament and the Council of Ministers adopted EU Directive\u000d\u000a      2011\/24\/EU in 2011. For the LSHTM team, this marked a milestone in a\u000d\u000a      period of intensive consultation work which resulted in their findings\u000d\u000a      being used in several European Commission and Parliamentary consultative\u000d\u000a      and working papers. Patient Mobility in the European Union: Study on\u000d\u000a        Legislative Proposals on Patients' Rights in Cross-Border Health Care\u000d\u000a      (2008)5.1 uses McKee's findings on the slow emergence of\u000d\u000a      patient mobility on the European health policy agenda, on controversial\u000d\u000a      court rulings, and his work for the European Observatory. A Commission\u000d\u000a      staff working document accompanying the Directive proposal (2008) uses his\u000d\u000a      findings on cross-border care in Slovenia, Austria and Italy.5.2\u000d\u000a      A consultation paper from the EU Commission, published in 2006 but\u000d\u000a      directly relevant to the eventual shape of the 2011 Directive, quotes\u000d\u000a      McKee's findings on problems in cross-border health care due to\u000d\u000a      incompatible rules between the countries concerned.5.3 The\u000d\u000a      quotes below amplify these uses.\u000d\u000a    The importance of McKee's work for the European Commission was underlined\u000d\u000a      by Nick Fahy, former head of the Unit for Health Information at the\u000d\u000a      Commission and former Deputy Head of the unit responsible for health\u000d\u000a      systems and cross-border health care. In 2013 he commented that McKee's\u000d\u000a      work had `been particularly influential ... His analysis has helped to\u000d\u000a      shape the debate on issues such as cross-border health care and the\u000d\u000a      emerging debate on a European health care policy ... and has been a\u000d\u000a      reference point during legislative processes including the adoption of\u000d\u000a      directive 2011\/24\/EU'. 5.4 Bernard Merkel, former head of the\u000d\u000a      Commission's health strategy and health systems unit, responsible for the\u000d\u000a      proposals for the Directive, added that McKee's work had made an\u000d\u000a      `invaluable contribution' to providing answers to complex questions: `It\u000d\u000a      was regarded by policy-makers as an authoritative source and thus had a\u000d\u000a      significant influence both on the Commission's proposals as they evolved\u000d\u000a      and on the political process of consideration by the European Parliament\u000d\u000a      and the EU member states.'5.5 Isabel de la Mata, Principal\u000d\u000a      Advisor to the Directorate-General for Health and Consumers of the\u000d\u000a      European Commission, stated that, `This work has been very important and\u000d\u000a      influential to help us to develop the initial proposal for a Directive ...\u000d\u000a      LSHTM work has always been a basic tool to support our actions.'5.6\u000d\u000a      Throughout the impact assessment period, McKee held meetings with European\u000d\u000a      Commission staff every six months and maintained fortnightly contact.\u000d\u000a    Between 2008 and July 2013, McKee advised individual governments on\u000d\u000a      cross-border patient mobility, including those of Slovenia, Belgium,\u000d\u000a      Sweden, the Netherlands, Spain, Ireland and Austria &#8212; in most cases at\u000d\u000a      regular intervals. Regional governments in Italy also sought his advice &#8212;\u000d\u000a      and a former EU health policy advisor for the Veneto Regional Government,\u000d\u000a      Ilaria Passarani, praised the fact that, `he successfully reached the very\u000d\u000a      difficult goal of bridging the gap between research and policy'.5.7\u000d\u000a      In the UK, McKee's work was used by stakeholders preparing submissions to\u000d\u000a      the consultation on the adoption of the Directive, including for the\u000d\u000a      Scottish government (2008)5.8 and the Northern Ireland\u000d\u000a      Assembly.\u000d\u000a    At UK and international level, McKee also communicated his findings to\u000d\u000a      health care stakeholders. In January 2009, he gave a presentation at the\u000d\u000a      Royal College of Physicians (RCP) to an audience of RCP experts,\u000d\u000a      government representatives and UK and EU stakeholder organisations. A\u000d\u000a      similar audience was reached by his editorial in the BMJ\u000d\u000a      (co-authored with Paul Belcher of the RCP) in July 2008.5.9\u000d\u000a      Belcher, in his role as senior EU advisor to the RCP and board member of\u000d\u000a      the European Public Health Alliance, commented that McKee's work had\u000d\u000a      proved `invaluable ... Without this evidence base, our ability to\u000d\u000a      influence political developments in Brussels would have been greatly\u000d\u000a      weakened'.5.10\u000d\u000a    McKee and Legido-Quigley advised the General Medical Council on patient\u000d\u000a      mobility and the Directive throughout the impact assessment period,\u000d\u000a      feeding into the Council's thinking on ways to respond to concerns about\u000d\u000a      the mobility of medical professionals. At international level, McKee\u000d\u000a      advised the European Union of Medical Specialists, a professional\u000d\u000a      organisation of EU doctors. For the European Health Forum based in\u000d\u000a      Gastein, Austria, McKee presented insights into the effects of the\u000d\u000a      economic crisis on European health policy in May 2013.\u000d\u000a    EU countries have until 25 October 2013 to implement the Directive. Its\u000d\u000a      full health benefits for the EU's citizens are just around the corner.\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Research into cross-border patient care in Europe carried out by LSHTM\u000d\u000a      has contributed substantially to shaping the 2011 EU Directive on\u000d\u000a      Patients' Rights in cross-border health care. The research was cited in\u000d\u000a      numerous policy documents and used extensively in consultations at EU and\u000d\u000a      national level, feeding into the legislative process. Influential EU\u000d\u000a      officials have explicitly acknowledged the importance of the research in\u000d\u000a      the political process. The research team has also advised professional\u000d\u000a      bodies in the health care sector as part of the consultation process.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    London School of Hygiene &amp; Tropical Medicine (LSHTM)\u000d\u000a    ","Institutions":[{"AlternativeName":"London School of Hygiene & Tropical Medicine","InstitutionName":"London School of Hygiene & Tropical Medicine","PeerGroup":"A","Region":"London","UKPRN":10007771}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"2800867","Name":"Bruxelles-Capitale"}],"References":"\u000d\u000a    \u000a3.1 Legido-Quigley, H, Panteli, D, Brusamento, S, Knai, C, Saliba, V,\u000d\u000a      Turk, E, Sol&#233;, M, Augustin, U, Car, J, McKee, M and Busse, R (2012)\u000d\u000a      Clinical guidelines in the European Union: mapping the regulatory basis,\u000d\u000a      development, quality control, implementation and evaluation across member\u000d\u000a      states, Health Policy, 107(2-3): 146-156, doi:\u000d\u000a      10.1016\/j.healthpol.2012.08.004.\u000d\u000a    \u000a\u000a3.2 Rosenm&#246;ller, M, McKee, M and Baeten, R (eds) (2006) Patient\u000d\u000a        Mobility in the European Union: Learning from Experience.\u000d\u000a      Copenhagen: WHO on behalf of the Europe 4 Patients project and the\u000d\u000a      European Observatory on Health Systems and Policies,*\u000d\u000a      http:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0005\/98420\/Patient_Mobility.pdf\u000d\u000a      (accessed 30 September 2013).\u000d\u000a    \u000a\u000a3.3 Legido-Quigley, H, Nolte, E, Green, J, la Parra, D and McKee M (2012)\u000d\u000a      The health care experiences of British pensioners migrating to Spain: a\u000d\u000a      qualitative study, Health Policy, 105(1): 46-54, doi:\u000d\u000a      10.1016\/j.healthpol.2012.02.002.\u000d\u000a    \u000a\u000a3.4 Legido-Quigley H, Glinos, I, Baeten, R and McKee M (2007) Patient\u000d\u000a      mobility in the European Union, British Medical Journal,\u000d\u000a      334(7586): 188-190, doi: 10.1136\/bmj.39086.497639.68.\u000d\u000a    \u000a\u000a3.5 Legido-Quigley, H, McKee, M, Nolte, E and Glinos, I (2008) Assuring\u000a        the Quality of Health Care in the European Union: A Case for Action,\u000d\u000a      Observatory Studies Series no. 12*. Copenhagen: WHO on behalf of the\u000d\u000a      European Observatory on Health Systems and Policies, http:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0007\/98233\/E91397.pdf\u000d\u000a      (accessed 30 September 2013).\u000d\u000a    \u000a\u000a3.6 Legido-Quigley, H, McKee, M, Walshe, K, Su&#241;ol, R, Nolte, E and\u000d\u000a      Klazinga, N (2008) How can quality of health care be safeguarded across\u000d\u000a      the European Union?, British Medical Journal, 336(7650): 920-923,\u000d\u000a      doi: 10.1136\/bmj.39538.584190.47.\u000d\u000a    \u000a* All European Observatory publications are peer reviewed.\u000d\u000a    Key grants\u000d\u000a    LSHTM PI, McKee, Europe4Patients: The Future for Patients in Europe,\u000d\u000a      European Commission FP6, 2\/2004-1\/2007, &#8364;1,499,136 (coordinator: IESE,\u000d\u000a      Barcelona).\u000d\u000a    LSHTM PI, McKee, Health Research for Europe, European Commission, 6th\u000d\u000a      Framework Programme, 5\/2007-4\/2009, &#8364;699,797 (coordinator: IESE,\u000d\u000a      Barcelona).\u000d\u000a    LSHTM PI, McKee, EU Cross Border Care Collaboration (ECAB), European\u000d\u000a      Commission (FP7), 3\/2010-4\/2013, &#8364;4,500,000 (coordinator LSE).\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    5.1 European Parliament Policy Department: Economic and Scientific Policy\u000d\u000a      (2008) Patient Mobility in the European Union: Study on Legislative\u000d\u000a        Proposals on Patients' Rights in Cross-Border Health Care,\u000d\u000a      IP\/A\/ENVI\/ST\/2008-16, PE 408.577, requested by the Committee on the\u000d\u000a      Environment, Public Health and Food Safety, European Parliament. Brussels,\u000d\u000a      Belgium, http:\/\/www.europarl.europa.eu\/document\/activities\/cont\/201107\/20110718ATT24286\/20110718ATT24286EN.pdf\u000d\u000a      (accessed 30 September 2013).\u000d\u000a    5.2 Commission of the European Communities (2008) Commission Staff\u000d\u000a        Working Document: Accompanying Document to the proposal for a Directive\u000d\u000a        of the European Parliament and of the Council on the Application of\u000d\u000a        Patients' Rights in Cross-border Healthcare: Impact Assessment,\u000d\u000a      COM(2008)414 final, SEC(2008)2164. Brussels: Commission of the European\u000d\u000a      Communities, Brussels, Belgium,\u000d\u000a      http:\/\/ec.europa.eu\/health\/archive\/ph_overview\/co_operation\/healthcare\/docs\/impact_assessment_en.pdf\u000d\u000a      (accessed 30 September 2013).\u000d\u000a    5.3 Commission of the European Communities (2006) Communication from\u000d\u000a        the Commission: Consultation Regarding Community Action on Health\u000d\u000a        Services, SEC (2006) 1195\/4 Brussels: Commission of the European\u000d\u000a      Communities,\u000d\u000a      http:\/\/ec.europa.eu\/health\/ph_overview\/co_operation\/mobility\/docs\/comm_health_services_comm\u000d\u000a        2006_en.pdf (accessed 30 September 2013).\u000d\u000a    5.4-5.6 European Commission.\u000d\u000a    5.7 Veneto Regional Government, Italy.\u000d\u000a    5.8 Centre for International Public Health Policy (CIHP) (2008) Response\u000a        to the Scottish Government's Consultation on the European Commission's\u000d\u000a        Proposals for a Directive on the Application of Patients' rights in\u000d\u000a        Cross-border Healthcare. Edinburgh:\u000d\u000a      CIHP,http:\/\/www.scotland.gov.uk\/Resource\/Doc\/256823\/0076235.pdf\u000d\u000a      (accessed 30 September 2013).\u000d\u000a    5.9 McKee, M and Belcher, P (2008) Cross border health care in Europe, BMJ,\u000d\u000a      337(7662): 124-125, doi: 10.1136\/bmj.39398.456493.80 (editorial).\u000d\u000a    5.10 Royal College of Physicians. \u000d\u000a    ","Title":"\u000d\u000a    Influencing EU and national policy on patient mobility within Europe\u000d\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2641364","Name":"Northern Ireland"},{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    EU citizens move across Europe with greater ease than ever before. Across\u000d\u000a      much of the continent, border checks have been abolished. Budget travel,\u000d\u000a      cross-border working and retirement all have implications for individual\u000d\u000a      countries' health systems.\u000d\u000a    Questions around the impact of an increasingly integrated Europe on\u000d\u000a      patients, providers and health systems were the focus of research carried\u000d\u000a      out at LSHTM within the framework of three projects: the EU-funded Europe\u000d\u000a      for Patients (e4p, 2004-2007), a multidisciplinary project involving\u000d\u000a      universities in Spain, Belgium and other EU countries together with LSHTM\u000d\u000a      and the London School of Economics and Political Science (LSE); the\u000d\u000a      European Union Cross Border Care Collaboration (ECAB); and specific\u000d\u000a      projects within the European Observatory on Health Systems and Policies, a\u000d\u000a      partnership which includes EU governments as well as WHO, the European\u000d\u000a      Commission, LSHTM and LSE. Key LSHTM researchers included Martin McKee,\u000d\u000a      Professor of European Public Health (LSHTM since 1995, then Senior\u000d\u000a      Lecturer) together with Helena Legido-Quigley and Cecile Knai (appointed\u000d\u000a      Research Fellows 2010 and 2007 respectively).\u000d\u000a    Research was conducted at two levels: Europe-wide initiatives and\u000d\u000a      in-depth case studies of national and cross-border policies. Findings\u000d\u000a      clarified various aspects of cross-border care, including the practical\u000d\u000a      implications of the legal framework at EU and national level; patterns of\u000d\u000a      patient mobility, contracting arrangements, patient orientation and\u000d\u000a      information, and communication between professionals; arrangements for\u000d\u000a      cross-border collaboration, purchase of care abroad, and care of long-term\u000d\u000a      residents; and the identification of options for primary legislation and\u000d\u000a      implementation.\u000d\u000a    In 2005, McKee and colleagues comprehensively reviewed current\u000d\u000a      information and issues relating to cross-border health care in Europe,\u000d\u000a      including patterns of patient mobility, legal frameworks, financial\u000d\u000a      implications, etc. They concluded that public authorities needed to act to\u000d\u000a      put a legal and institutional framework for cross-border health care in\u000d\u000a      place.3.1\u000d\u000a    In a 2006 European Observatory output, McKee (together with co-editors\u000d\u000a      from Spain and Belgium) collated practical experience of patient mobility\u000d\u000a      from across Europe. Together with Legido-Quigley, he contributed a study\u000d\u000a      on Ireland, using interviews with health officials on both sides of the\u000d\u000a      border, which found that although there was a general presumption that\u000d\u000a      people on both sides suffered from an unmet need for hospital services,\u000d\u000a      mortality and utilisation data failed to confirm this.3.2\u000d\u000a    A subsequent study (2012) found that the special needs of people retiring\u000d\u000a      to other European countries were not being adequately met.3.3\u000d\u000a      It and other work by the team concluded that a compromise was needed to\u000d\u000a      ensure access to care without damaging the sustainability and integrity of\u000d\u000a      national health systems.3.4 A further European Observatory\u000d\u000a      output (2008)3.5 using a variety of methods including\u000d\u000a      literature reviews, patient surveys and interviews, highlighted the need\u000d\u000a      for national and European commitment to patient safety.\u000d\u000a    Drawing on evidence collected from two major projects, in 2008\u000d\u000a      Legido-Quigley and colleagues examined how quality of health care can be\u000d\u000a      safeguarded across the EU.3.6 They found that given the\u000d\u000a      enormous diversity of health systems in member states, Europe-wide\u000d\u000a      legislation to mandate a single approach was not realistic, and that the\u000d\u000a      proposed Directive was likely to leave details of possible mechanisms to\u000d\u000a      national governments.\u000d\u000a    "},{"CaseStudyId":"44153","Continent":[{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"}],"Country":[{"GeoNamesId":"294640","Name":"Israel"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000a    UK antibiotic prescribing rose progressively until 1997 then fell\u000a      markedly until 2000 since when it has risen slowly. There is a link\u000a      between the use of delayed prescriptions and the fall in prescriptions\u000a      that can be traced to the first Southampton study (1997) of delayed\u000a      prescribing for acute infections. Sharland et al reported (in 2005) an 18%\u000a      reduction in national antibiotic prescribing for children in the five\u000a      years after 1997 due to a progressive divergence between antibiotics\u000a      prescribed and antibiotics used. The authors concluded that GPs were\u000a      adopting delayed prescribing, \"introduced after widespread dissemination\u000a      of trial results supporting this practice\". This impact continued through\u000a      the REF assessment period, demonstrated by an Ipsos MORI household\u000a      questionnaire survey in January 2011 which showed that 14.2% of adults in\u000a      England had been offered a delayed prescription for antibiotics [5.1],\u000a      and the recent national MRC-funded DESCARTE study - that showed delayed\u000a      prescribing was used in 18% of sore throat consultations, reducing\u000a      complications and reconsultations as effectively as immediate antibiotics.\u000a    The rise in antibiotic prescribing highlights the importance of\u000a      guidelines for primary care that, influenced by our research, discourage\u000a      the immediate prescription of antibiotics and advocate delayed\u000a      prescribing. The long-term impact is in reducing the risk of antibiotic\u000a      resistance and saving NHS resources due to fewer antibiotic prescriptions\u000a      and repeat consultations.\u000a    The wealth of research, and recognition of antibiotic resistance as a\u000a      public health priority, spurred NICE to commission guidance for managing\u000a      RTIs focusing on novel prescribing strategies. The recognition of\u000a      Southampton's central role in generating the evidence led to Little being\u000a      invited to chair the NICE guideline group [5.2]. Integral to the\u000a      formulation of this guidance - and referenced in it - were the Southampton\u000a      trials for sore throat, chest infection and otitis media. The guidance\u000a      (CG69, 2008) endorsed delayed prescribing or no offer of antibiotics for\u000a      all acute RTIs by GPs, emergency departments and walk-in centres. NICE\u000a      made conservative assumptions that the guidance would save &#163;3.7 million\u000a      annually [5.2].\u000a    Building on the NICE guidance, the Health Protection Agency published its\u000a      Management of Infection Guidance for Primary Care in the UK (2010) [5.3].\u000a      Referencing the Southampton trials, the guidance advises delayed\u000a      prescription for otitis media, sinusitis and bronchitis and also uses and\u000a      references Southampton's UTI diagnostic work. Williamson and Everitt, on\u000a      the strength of their research, were asked to draft two Drug and\u000a      Therapeutics Bulletins (DTB) for sinusitis (2009) [5.4] and\u000a      conjunctivitis (2011) [5.5]. DTB is owned by BMJ Group, provides\u000a      independent advice for doctors, pharmacists and healthcare professionals,\u000a      and is described as essential reading for practising doctors by the House\u000a      of Commons Health Select Committee.\u000a    The research also informed Scottish Intercollegiate Guidelines Network\u000a      (SIGN) guidance on sore throats (guideline 117, 2010) for the NHS in\u000a      Scotland [5.6], and has been central to guidance bulletins\u000a      published by the Medicine Resource Centre, which is attached to the\u000a      National Prescribing Centre, and read by GPs across the UK. It is also\u000a      forming the basis of online training for existing and future GPs. The\u000a      Royal College of General Practitioners appointed Moore as its Antibiotic\u000a      Resistance champion in 2011, and has developed online modules on treatment\u000a      of RTIs and UTIs (with input from Little and Moore), with one module based\u000a      on delayed prescribing [5.7].\u000a    The impact is felt internationally with guidelines that remain in force.\u000a      Southampton studies laid the foundations for a change in policy of the\u000a      American Academy of Paediatrics which updated its Guideline for the\u000a      Diagnosis and Management of Acute Otitis Media in 2013 [5.8]. It\u000a      generated controversy in the United States, representing the first time a\u000a      US health organisation had advised a wait-and-see approach in the form of\u000a      delayed prescription.\u000a    The European Society of Clinical Microbiology and Infectious Diseases\u000a      issued guidance on the management of sore throats (2012), referencing the\u000a      Southampton trials and the University's research on sore throats [5.9].\u000a      The guidelines are read by GPs and doctors in emergency departments around\u000a      the EU. The research on delayed prescribing has also been used as the\u000a      central recommendation in Israeli guidance on managing otitis media in\u000a      Israel, in force throughout the REF assessment period [5.10].\u000a    ","ImpactSummary":"\u000a    Research by the University of Southampton has contributed significantly\u000a      to reducing the global threat of antibiotic resistance. A series of both\u000a      conventional placebo-controlled and novel open design trials has\u000a      influenced a number of important national clinical guidelines for\u000a      Respiratory Tract Infections (RTIs) and the implementation of novel\u000a      prescribing strategies that discourage unnecessary antibiotic\u000a      prescription. As a direct result of the research, delayed prescribing for\u000a      all acute respiratory infections is a tool in the everyday practice of the\u000a      UK's GPs. Southampton's work in this field has informed international\u000a      guidelines currently in place in the United States, Israel and the\u000a      European Union.\u000a    ","ImpactType":"Political","Institution":"\u000a    University of Southampton\u000a    ","Institutions":[{"AlternativeName":"Southampton (University of)","InstitutionName":"University of Southampton","PeerGroup":"A","Region":"South East","UKPRN":10007158}],"Panel":"A         ","PlaceName":[],"References":"\u000a    \u000a3.1 Little PS, Williamson I, Warner G, Gould C, Gantley M,\u000a      Kinmonth AL. An open randomised trial of prescribing strategies for sore\u000a      throat. BMJ 1997; 314:722-727.\u000a    \u000aFunded by NHS South and West Region Research and Development, to\u000a      Little and Williamson, 1993-5, &#163;49,000)\u000a    \u000a3.2 Little P, Gould C, Williamson I, Moore M, Warner G, Dunleavey\u000a      J. Pragmatic randomised controlled trial of two prescribing strategies for\u000a      childhood acute otitis media. BMJ 2001; 322:336-342.\u000a    \u000aFunded by NHS South and West Region Reseach and Development, to\u000a      Little, Williamson and Moore, 1996-2000, &#163;94,000\u000a    \u000a3.3 Little P, Rumsby K, Kelly J, Watson L, Moore M, Warner G et\u000a      al. Information leaflet and antibiotic prescribing strategies for acute\u000a      lower respiratory tract infection: a randomised controlled trial. JAMA\u000a      2005; 293:3029-3035.\u000a    \u000aFunded by MRC, Clinician Scientist Fellowship for Little,\u000a      1998-2003, &#163;416,000\u000a    \u000a3.4 Williamson IG, Rumsby K, Benge S, Moore M, Smith PW, Cross M,\u000a      Little P. Antibiotics and Topical Nasal Steroid for Treatment of Acute\u000a      Maxillary Sinusitis: A Randomized Controlled Trial. JAMA 2007;\u000a      298(21): 2487-2496.\u000a    \u000aFunded by NHS South and West Region Research and Development, to\u000a      Little, Williamson and Moore, 2001-2006, &#163;140,000\u000a    \u000a3.5 Everitt HA, Little PS, Smith PWF. A randomised controlled\u000a      trial of management strategies for acute infective conjunctivitis in\u000a      general practice. BMJ 2006; 333:321.\u000a    \u000aFunded as part of MRC HSR training fellowship for Everitt,\u000a      2003-2006 &#163;87,000\u000a    \u000a3.6 Little P, Turner S, Rumsby K, Warner G, Moore M, Lowes JA et\u000a      al. Dipsticks and diagnostic algorithms in urinary tract infection:\u000a      development and validation, randomised trial, economic analysis,\u000a      observational cohort and qualitative study. Health Technol Assess\u000a      2009; 13: No 19.\u000a    \u000aFunded by NHS Health Technology Assessment Board, 2001-2007\u000a      &#163;326,000\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000a    Examples of national and international Guidelines that have been in\u000a        force throughout the REF assessment period, that have provided\u000a        recommendations based on our research and which advocate delayed\u000a        prescribing as a strategy [5.2-5.10].\u000a    5.1 McNulty CAM, Nichols T, French DP, Joshi P, Butler CC.\u000a      Expectations for consultations and antibiotics for respiratory tract\u000a      infection in primary care: the RTI clinical iceberg. Br J Gen Pract\u000a      2013; 63(612):e429-36.\u000a    5.2 NICE guidance 2008. Prescribing of antibiotics for\u000a      self-limiting respiratory tract infections in adults and children in\u000a      primary care. http:\/\/guidance.nice.org.uk\/CG69\/NICEGuidance\/pdf\/English\u000a      Central to the formulation of this guidance (chaired by Little) were\u000a        our trials for acute sore throat, acute cough and otitis media. The\u000a        guidance advocates delayed prescribing as one option,and references the\u000a        respiratory trials. The sore throat trial was the basis of NICE's\u000a        economic modelling.\u000a    5.3 Health Protection Agency. Management of Infection Guidance for\u000a      Primary Care. HPA 2010;\u000a      http:\/\/www.hpa.org.uk\/Topics\/InfectiousDiseases\/InfectionsAZ\/PrimaryCareGuidance\/\u000a      This guidance advises delayed prescription for otitis media, sinusitis,\u000a        bronchitis, references the NICE guidance above which our group was\u000a        formative in developing, and also directly references our trials. The\u000a        guidance on diagnosis also uses and references our diagnostic work in\u000a        UTI.\u000a    5.4 Drug and Therapeutics Bulletin. The management of acute\u000a      sinusitis. DTB 2009 47: 26-30. This guidance was drafted by\u000a        Williamson and references both the JAMA trial [3.4] and\u000a        the Lancet individual patient data meta-analysis by Young et al.,\u000a        co-authored by Williamson\u000a    5.5 Drug and Therapeutics Bulletin The management of acute\u000a      infective conjunctivitis DTB 2011 49: 78-81. This guidance was\u000a        drafted by Everitt and both references her research [3.5]\u000a      and advises delayed prescribing as a reasonable option.\u000a    5.6 SIGN guidance on sore throat (guideline 117, 2010). http:\/\/www.sign.ac.uk\/pdf\/sign117.pdf\u000a      This refers to our trials and provides guidance about antibiotic\u000a        prescribing strategies.\u000a    5.7 The Royal College of General Practitioners' (RCGP, 2011)\u000a      e-learning modules on respiratory tract infections: Managing Acute\u000a      Respiratory Tract Infections - www.elearning.rcgp.org.uk\u000a    5.8 American Academy of Paediatrics Guideline in the Diagnosis and\u000a      Management of Acute Otitis Media. Pediatrics 2004; 113:1451-65,\u000a      updated 2013 (Pediatrics 2013;131:e964-e999). This guidance was\u000a        very controversial and, for the first time in the US, advocates a wait\u000a        and see approach trialled by Little, Williamson, Moore, Everitt and team.\u000a    5.9 European Society of Clinical Microbiology and Infectious\u000a      Diseases Sore Throat Guideline Group, Pelucchi C, Grigoryan L, Galeone C,\u000a      Esposito S, Huovinen P, Little P, Verheij T. Clin Microbiol Infect\u000a      2012; Apr; 18 Suppl 1:1-28. Doi: 10.1111\/j.1469-0691.2012.03766. This\u000a        guidance uses and references our trials and other research on sore\u000a        throat.\u000a    5.10 Clinical guidelines: diagnosis and treatment of acute otitis\u000a      media in children. Israel Medical Association 2004, updated in a new\u000a      edition in 2010. This guideline references our trial [3.2],\u000a        and provides guidance on using the delayed prescribing approach. N.B.\u000a        Document available from Southampton (in Hebrew).\u000a    ","Title":"\u000a    02-11 Fighting Antibiotic Resistance: Changing International Prescribing\u000a      Policies\u000a    ","UKLocation":[{"GeoNamesId":"2637487","Name":"Southampton"}],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"},{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Unnecessary antibiotic prescriptions in primary care are a key driver for\u000a      antibiotic resistance, which is recognised as a global health threat.\u000a      Several campaigns by the UK Department of Health (DH) have discouraged\u000a      overuse and overprescription of antibiotics by patients and doctors. A\u000a      recent major effort to raise awareness of antibiotic resistance commenced\u000a      with a 1998 report The Path of Least Resistance by the Standing\u000a      Medical Advisory Committee, which advised DH. Highlighting that 80% of UK\u000a      human prescribing occurs in primary care, the report recommended the\u000a      National Institute for Health and Clinical Excellence (NICE) develop new\u000a      guidelines on antibiotic prescribing by medical practitioners. In 2008\u000a      NICE reported that 25% of the UK population visited their GP with RTIs\u000a      each year, costing &#163;24.3 million and accounting for 60% of GP antibiotic\u000a      prescribing.\u000a    Starting in the mid-1990s, and continuing currently, a research group at\u000a      the University of Southampton's Faculty of Medicine embarked on a series\u000a      of trials to assess the effectiveness of different antibiotic prescribing\u000a      strategies for acute infections. The key team members are Paul Little,\u000a      Professor of Primary Care Research (employed at Southampton since 1993),\u000a      Ian Williamson, Senior Lecturer in Primary Care (since 1987), Michael\u000a      Moore, Reader in Primary Care Research (since 2004), and Hazel Everitt,\u000a      Clinical Lecturer in General Practice (since 1999).\u000a    In the first trial, funded by DH and published in the British Medical\u000a        Journal in 1997 [3.1], 700 patients with sore throats\u000a      received one of three antibiotic prescribing strategies: immediate\u000a      prescription, no prescription and, if symptoms did not settle after three\u000a      days, delayed prescription. The research represented a novel approach in\u000a      developing open designs, allowing them to assess not only the\u000a      effectiveness of the different strategies but, crucially, the\u000a      `medicalisation' of illness - that is, the effect of prescription on\u000a      patients' belief in the power of antibiotics and their intention to\u000a      reconsult their GP.\u000a    The research found that prescribing antibiotics for sore throats - one of\u000a      the most common respiratory illnesses for which people consult GPs - does\u000a      not reduce the extent and duration of symptoms. However, the strategies of\u000a      offering no antibiotics or delayed prescribing significantly reduce\u000a      patients' use of antibiotics, their belief in antibiotics and their\u000a      intention to consult and reconsult their GP in future.\u000a    Similar findings of the limited benefit and medicalising effect of\u000a      immediate prescriptions followed in DH-funded studies of antibiotic\u000a      prescribing strategies for acute otitis media (2001) and sinusitis (2007)\u000a      and Medical Research Council-funded studies of lower respiratory tract\u000a      infections (RTIs) (2005) and conjunctivitis (2006) [3.2-3.5].This\u000a      led to substantial further funding to the group for RTI research,\u000a      including the NIHR-funded PRIME Programme (2008-13, &#163;1,999,000) and the\u000a      MRC PRIMIT trial (2007-2013, &#163;1,282,000).\u000a    In the case of lower RTIs, the academics showed a delayed prescribing\u000a      strategy is preferable to no offer of a prescription in limiting\u000a      reconsultations [3.3]. In further DH-funded research, similar\u000a      trials involving urinary tract infection (UTI) concluded antibiotic use\u000a      can be reduced by either a 48-hour delayed prescription or by offering\u000a      delayed prescription if results of diagnostic dipsticks are negative [3.6].\u000a      All the trials resulted in the same key recommendation to GPs: avoid or\u000a      delay prescribing antibiotics as part of a national strategy to reduce the\u000a      risk of antibiotic resistance.\u000a    "},{"CaseStudyId":"44154","Continent":[{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"}],"Country":[{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"6252001","Name":"United States"}],"Funders":["Medical Research Council"],"ImpactDetails":"\u000d\u000a    Southampton research into depression assessment has had significant\u000d\u000a      impacts on UK healthcare\u000d\u000a      guidelines, on GP practice, and &#8212; the trial evidence suggests &#8212; on patient\u000d\u000a      well-being.\u000d\u000a    The 2009 NICE depression guideline CG90 made direct reference to\u000d\u000a      Thompson, Kinmonth and\u000d\u000a      Kendrick's findings that attempts to improve the rate of recognition of\u000d\u000a      depression by GPs using\u000d\u000a      education had not improved recognition or outcomes [5.1]. It also\u000d\u000a      referred to Kendrick's (2005)\u000d\u000a      finding that, while the probability of prescribing antidepressants was\u000d\u000a      associated with GPs' ratings\u000d\u000a      of severity of depression, almost half of the people offered\u000d\u000a      antidepressants were not depressed\u000d\u000a      according to a validated measure [3.3]. Following Kendrick, the\u000d\u000a      guideline recommended (page\u000d\u000a      118): \"When assessing a person with suspected depression, consider\u000d\u000a        using a validated measure\u000d\u000a        (for example, for symptoms, functions and\/or disability) to inform and\u000d\u000a        evaluate treatment\"\u000d\u000a      (Recommendation 5.2.13.4) [5.1]. The subsequent NICE quality\u000d\u000a      standard on the assessment of\u000d\u000a      depression issued in March 2011 recommended the use of a formal rating\u000d\u000a      scale for symptom\u000d\u000a      severity, and was endorsed by the British Association for\u000d\u000a      Psychopharmacology, the British\u000d\u000a      Psychological Society, the College of Mental Health Pharmacy, the College\u000d\u000a      of Occupational\u000d\u000a      Therapists, Depression Alliance, MIND, the Royal College of Nursing, and\u000d\u000a      the Royal College of\u000d\u000a      Psychiatrists [5.2].\u000d\u000a    A performance indicator for assessment of depression was introduced into\u000d\u000a      the QOF in April 2006\u000d\u000a      which had a sustained impact on care through to 2013. This made direct\u000d\u000a      reference to the findings\u000d\u000a      of Kendrick and colleagues, stating (page 141): \"GP global assessment\u000d\u000a        of severity does not accord\u000d\u000a        closely with more structured assessment of symptoms (Kendrick et al.\u000d\u000a        British Journal of General\u000d\u000a        Practice 2005; 55:280-286). Assessment of severity is essential to\u000d\u000a        decide on appropriate\u000d\u000a        interventions and improve the quality of care\" [5.3]. Thus,\u000d\u000a      QOF points (giving increased funding)\u000d\u000a      were awarded for the assessment of depression at diagnosis using validated\u000d\u000a      symptom\u000d\u000a      questionnaires. Other researchers, including David Goldberg (at the\u000d\u000a      Institute of Psychiatry), Linda\u000d\u000a      Gask (University of Manchester) and Christopher Dowrick (University of\u000d\u000a      Liverpool) had shown that\u000d\u000a      global GP assessment was inaccurate, but it was Kendrick and colleagues\u000d\u000a      who demonstrated that\u000d\u000a      GP treatment with antidepressants was poorly targeted as a result.\u000d\u000a      Kendrick, Gask and Dowrick\u000d\u000a      were members of the mental health expert advisory group for the QOF.\u000d\u000a    The impact was immediate, widespread and sustained throughout the REF\u000d\u000a      assessment period.\u000d\u000a      NHS data from all UK general practices show that a total of 2,402,400 new\u000d\u000a      episodes of depression\u000d\u000a      were diagnosed and recorded by GPs between April 2008 and March 2013\u000d\u000a      inclusively, of which\u000d\u000a      2,213,485 (92.1%) were assessed using symptom questionnaires [5.4].\u000d\u000a    In 2009 another indicator was added to the QOF, promoting follow-up\u000d\u000a      assessment of depression\u000d\u000a      with symptom questionnaires 5 to 12 weeks after diagnosis. The QOF\u000d\u000a      guidance reminded\u000d\u000a      practitioners of the importance of follow-up [5.5], citing the\u000d\u000a      Southampton analysis of the GP\u000d\u000a      research database [3.5] (on page 110): \"Analysis of the GPRD\u000d\u000a        from 1993 to 2005 found that more\u000d\u000a        than half of patients treated with antidepressants only received\u000d\u000a        prescriptions for one or two months\u000d\u000a        of treatment\" [5.5].\u000d\u000a    Between April 2009 and March 2013, UK GPs reported completing a total of\u000d\u000a      1,109,284 follow-up\u000d\u000a      assessments using validated severity measures (74.0% of 1,497,914 eligible\u000d\u000a      cases) [5.4].\u000d\u000a    The Southampton group's observational research indicates that\u000d\u000a      questionnaire assessment has\u000d\u000a      improved the targeting of treatment for patients compared to the situation\u000d\u000a      prior to its introduction in\u000d\u000a      the QOF [3.4, 3.6]. GPs' decisions to start or change treatment,\u000d\u000a      or refer patients, became much\u000d\u000a      more in line with NICE guidance than before the introduction of the\u000d\u000a      indicators. There is also trial\u000d\u000a      evidence of benefit on patient outcomes of symptom questionnaire\u000d\u000a      assessment and monitoring. A\u000d\u000a      2012 primary care trial in the USA found that questionnaire feedback led\u000d\u000a      to increased remission\u000d\u000a      and response rates among patients with depression [5.6]. This is\u000d\u000a      consistent with systematic review\u000d\u000a      evidence of clear benefit of monitoring in terms of patient outcomes from\u000d\u000a      research in psychological\u000d\u000a      and psychiatric practice [5.7].\u000d\u000a    Patient experience of the use of questionnaires has been positive, as was\u000d\u000a      shown by qualitative\u000d\u000a      interviews in 2007-8 led by Geraldine Leydon (Reader, at Southampton since\u000d\u000a      2005) in\u000d\u000a      collaboration with Dowrick (Liverpool) and Amanda Howe (East Anglia).\u000d\u000a      Patients said they saw the\u000d\u000a      questionnaires as helpful adjuncts to medical judgment, and their use as\u000d\u000a      an indication that their\u000d\u000a      depressive symptoms were taken seriously [5.8]. The requirement to\u000d\u000a      use symptom questionnaires\u000d\u000a      has been somewhat controversial, however. Some GPs complained that\u000d\u000a      questionnaires cannot be\u000d\u000a      used with patients with language or literacy difficulties, are sometimes\u000d\u000a      inaccurate, and may be\u000d\u000a      intrusive in sensitive consultations. Research led by Leydon showed some\u000d\u000a      GPs considered their\u000d\u000a      clinical judgment more important than questionnaires, and were concerned\u000d\u000a      that questionnaires\u000d\u000a      reduced the human element of the consultation and were a threat to their\u000d\u000a      professionalism [5.9].\u000d\u000a      Symptom questionnaires are now an optional component, rather than a\u000d\u000a      requirement, of the\u000d\u000a      structured assessment of depression promoted by indicators in the QOF\u000d\u000a      (2013) [5.5]. However, an\u000d\u000a      email survey in October 2013 of Hampshire general practices asking about\u000d\u000a      their use of depression\u000d\u000a      symptom questionnaires since these became optional showed that more than\u000d\u000a      half of practices\u000d\u000a      were still using questionnaires to aid the assessment of selected patients\u000d\u000a      [5.10].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    Southampton's research into the management of depression highlighted\u000d\u000a      deficits in the way GPs\u000d\u000a      were assessing and treating depression, and demonstrated failure to\u000d\u000a      improve their performance\u000d\u000a      through education alone. The findings were included in guidelines drawn up\u000d\u000a      by the National\u000d\u000a      Institute for Health and Care Excellence (NICE) and led to incentives for\u000d\u000a      questionnaire\u000d\u000a      assessments of depression being introduced into the GP contract Quality\u000d\u000a      Outcomes Framework\u000d\u000a      (QOF). UK-wide QOF data from 2008-2013 demonstrated questionnaire\u000d\u000a      assessments in 2.2 million\u000d\u000a      cases of depression. Subsequent Southampton-led research showed that\u000d\u000a      improved targeting of\u000d\u000a      treatment resulted from questionnaire assessments, and trial evidence\u000d\u000a      shows such assessments\u000d\u000a      improve patient outcomes.\u000d\u000a    ","ImpactType":"Political","Institution":"\u000d\u000a    University of Southampton\u000d\u000a    ","Institutions":[{"AlternativeName":"Southampton (University of)","InstitutionName":"University of Southampton","PeerGroup":"A","Region":"South East","UKPRN":10007158}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a3.1 Thompson C, Kinmonth AL, Stevens L, Peveler RC, Stevens A,\u000d\u000a      Ostler KJ, Pickering RM, Baker\u000d\u000a      NG, Henson A, Preece J, Cooper D, Campbell MJ. Effects of a\u000d\u000a      clinical-practice guideline and\u000d\u000a      practice-based education on detection and outcome of depression in primary\u000d\u000a      care: Hampshire\u000d\u000a      Depression Project randomised controlled trial. Lancet.\u000d\u000a      2000;355:185-91.\u000d\u000a    \u000aFunding: MRC project grant: Evaluation of the impact of an\u000d\u000a      educational package on recognition\u000d\u000a      and management of depression. &#163;412,847 to Christopher Thompson, Ann Louise\u000d\u000a      Kinmonth,\u000d\u000a      Robert Peveler &amp; Lesley Stevens, 01.10.94 to 30.09.97.\u000d\u000a    \u000a3.2 Kendrick T, Stevens L, Bryant A, Goddard J, Stevens A, Raftery\u000d\u000a      J and Thompson C.\u000d\u000a      Hampshire Depression Project: changes in the process of care and cost\u000d\u000a      consequences. British\u000d\u000a        Journal of General Practice 2001;51:911-913.\u000d\u000a    \u000aFunding: South &amp; West Regional Health Authority NHS R&amp;D\u000d\u000a      project grant: The Hampshire\u000d\u000a      Depression Project: a randomised controlled trial of education on\u000d\u000a      depression for primary care\u000d\u000a      workers. &#163;133,188 to Christopher Thompson, Ann Louise Kinmonth &amp;\u000d\u000a      Robert Peveler, 01.01.95 to\u000d\u000a      31.12.97.\u000d\u000a    \u000a3.3 Kendrick T, King F, Albertella L, Smith P. GP treatment\u000d\u000a      decisions for patients with depression:\u000d\u000a      an observational study. British Journal of General Practice\u000d\u000a      2005;55:280-286.\u000d\u000a    \u000aFunding: supported by NIHR infrastructure funding to Primary\u000d\u000a      Medical Care, Southampton.\u000d\u000a    \u000a3.4 Kendrick T, Dowrick C, McBride A, Howe A, Clarke P, Maisey S,\u000d\u000a      Moore M, Smith PW.\u000d\u000a      Management of depression in UK general practice in relation to scores on\u000d\u000a      depression severity\u000d\u000a      questionnaires: analysis of medical record data. British Medical\u000d\u000a        Journal 2009; 338: b750. doi:\u000d\u000a      10.1136\/bmj.b750.\u000d\u000a    \u000aFunding: Lilly, Lundbeck, Servier, and Wyeth Pharmaceutical\u000d\u000a      Companies unrestricted educational\u000d\u000a      grant: Observational study of GP treatment of depression following the\u000d\u000a      introduction of quality\u000d\u000a      indicators in the new GP contract. &#163;70,000 to Tony Kendrick, Christopher\u000d\u000a      Dowrick, Michael Moore,\u000d\u000a      and Amanda Howe, 1.10.06 to 28.2.08.\u000d\u000a    \u000a3.5 Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T.\u000d\u000a      Explaining the rise in\u000d\u000a      antidepressant prescribing: a descriptive study using the general practice\u000d\u000a      research database.\u000d\u000a      British Medical Journal 2009; 339;b3999 doi:10.1136\/bmj.b3999.\u000d\u000a    \u000aFunding: supported by NIHR infrastructure funding to Primary\u000d\u000a      Medical Care, Southampton.\u000d\u000a    \u000a3.6 Moore M, Ali S, Stuart B, Leydon GM, Ovens J, Goodall C,\u000d\u000a      Kendrick T. Depression\u000d\u000a      management in primary care: an observational study of management changes\u000d\u000a      related to PHQ-9\u000d\u000a      score for depression monitoring. British Journal of General Practice\u000d\u000a      2012;62:310-311.\u000d\u000a    \u000aFunding: NIHR National School for Primary Care Research project\u000d\u000a      grant: Effects of monitoring\u000d\u000a      depression in primary care. &#163;123,971 to Tony Kendrick, Michael Moore and\u000d\u000a      Geraldine Leydon,\u000d\u000a      1.1.10-30.6.11.\u000d\u000a    ","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"},{"Level1":"11","Level2":"3","Subject":"Clinical Sciences"}],"Sources":"\u000d\u000a    5.1 National Institute for Health and Clinical Excellence.\u000d\u000a      National Collaborating Centre for Mental\u000d\u000a      Health. Depression. The treatment and management of depression in adults.\u000d\u000a      NICE Clinical\u000d\u000a      Guideline 90. London: 2009 (page 29 refers to Thompson et al., 2000 and\u000d\u000a      Kendrick et al., 2001,\u000d\u000a      and page 98 to Kendrick et al., 2005).\u000d\u000a      http:\/\/www.nice.org.uk\/nicemedia\/live\/12329\/45896\/45896.pdf\u000d\u000a      (Accessed 22nd August 2013).\u000d\u000a    5.2 NICE Quality Standards for the Management of Depression in\u000d\u000a      Adults, NICE, London, 2011.\u000d\u000a      http:\/\/publications.nice.org.uk\/depression-in-adults-quality-standard-qs8\/quality-statement-1-assessment\u000d\u000a      (Accessed 22nd august 2013).\u000d\u000a    5.3 BMA, NHS Employers. Revisions to the GMS contract 2006\/07.\u000d\u000a      Delivering investment in\u000d\u000a      general practice. London: 2006 (page 141 refers to Kendrick et al., 2005).\u000d\u000a      (This guidance was in\u000d\u000a      place from 2006 until 2013, throughout most of the REF assessment period).\u000d\u000a      http:\/\/www.nhsemployers.org\/SiteCollectionDocuments\/Revisions_to_the_GMS_contract_-_full_CD_120209.pdf\u000d\u000a      (Accessed 22nd August 2013).\u000d\u000a    5.4 UK level data for Quality and Outcomes Framework 2008-2013\u000d\u000a      depression indicators:\u000d\u000a      http:\/\/www.gpcontract.co.uk\/browse\/UK\/Depression\/13\u000d\u000a      (accessed 21st November 2013).\u000d\u000a    5.5 BMA, NHS Commissioning Board, NHS Employers. Quality and\u000d\u000a      Outcomes Framework\u000d\u000a      guidance for GMS contract 2013\/14. London: 2013 (page 111 refers to Moore\u000d\u000a      et al., 2009).\u000d\u000a      http:\/\/www.nhsemployers.org\/Aboutus\/Publications\/Documents\/qof-2013-14.pdf\u000d\u000a      (Accessed 22nd\u000d\u000a      August 2013).\u000d\u000a    5.6 Yeung AS, Jing Y, Brenneman SK, Chang TE, Baer L, Hebden T,\u000d\u000a      Kalsekar I, McQuade RD,\u000d\u000a      Kurlander J, Siebenaler J, Fava, M. Clinical Outcomes in Measurement based\u000d\u000a      Treatment\u000d\u000a      (COMET): a trial of depression monitoring and feedback to primary care\u000d\u000a      physicians. Depression\u000d\u000a        and Anxiety 2012; 29(10):865-873.\u000d\u000a    5.7 Knaup C, Koesters M, Schoefer D, et al. Effect of feedback of\u000d\u000a      treatment outcome in specialist\u000d\u000a      mental healthcare: meta-analysis. British Journal of Psychiatry\u000d\u000a      2009; 195:15-22\u000d\u000a    5.8 Dowrick C, Leydon GM, McBride A, Howe A, Burgess H, Clarke P,\u000d\u000a      Maisey S, Kendrick T.\u000d\u000a      Patients' and doctors' views on depression severity questionnaires\u000d\u000a      incentivised in UK quality and\u000d\u000a      outcomes framework: qualitative study. British Medical Journal\u000d\u000a      2009; 338:b663\u000d\u000a    5.9 Leydon GM, Dowrick CF, McBride A, Burgess H, Howe AC, Moore M,\u000d\u000a      Clarke PD, Maisey, SP,\u000d\u000a      Kendrick, T on behalf of the QOF Depression Study Team. Questionnaire\u000d\u000a      severity measures for\u000d\u000a      depression: a threat to the doctor-patient relationship? British\u000d\u000a        Journal of General Practice 2011;\u000d\u000a      61:117-123.\u000d\u000a    5.10 Email survey of Hampshire general practices asking about\u000d\u000a      their use of symptom\u000d\u000a      questionnaires since these became an optional component, rather than a\u000d\u000a      requirement, of the\u000d\u000a      structured assessment of depression promoted by indicators in the GP\u000d\u000a      contract QOF (confidential:\u000d\u000a      data available from Southampton).\u000d\u000a    ","Title":"\u000d\u000a    02-12 Impact on assessment of depression\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2637487","Name":"Southampton"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    Depression is common, disabling and costly. More than 80% of cases are\u000d\u000a      managed in primary\u000d\u000a      care, so effective management in primary care is crucial. However, in the\u000d\u000a      1990s management of\u000d\u000a      depression by GPs was found to be poor. GPs failed to recognise around\u000d\u000a      one-third of cases, and\u000d\u000a      most patients received either no treatment, or their treatment was\u000d\u000a      inadequate.\u000d\u000a    A study on the Swedish island of Gotland suggested education was the way\u000d\u000a      to improve GP\u000d\u000a      management of depression, so Southampton researchers tested that\u000d\u000a      proposition in the UK. The\u000d\u000a      Hampshire Depression Project (HDP) was a randomised controlled trial\u000d\u000a      (RCT), carried out\u000d\u000a      between 1994 and 1998, funded by the Medical Research Council (MRC) and\u000d\u000a      led by Chris\u000d\u000a      Thompson (Professor of Psychiatry, left 2003) and Ann Louise Kinmonth\u000d\u000a      (Professor of Primary\u000d\u000a      Care, left 1996). This trial (21,409 patients, 60 practices) was\u000d\u000a      ground-breaking in showing that\u000d\u000a      guideline-based education of GPs alone did not improve recognition of\u000d\u000a      depression or patient\u000d\u000a      outcomes [3.1]. From 1998 to 1999, Tony Kendrick (Professor of\u000d\u000a      Primary Care from April 1998 to\u000d\u000a      August 2010 and again since May 2013) led a new analysis of the trial's\u000d\u000a      findings, showing a lack of\u000d\u000a      impact on appropriate targeting of treatment. Only 15% of those with\u000d\u000a      possible, and 26% of those\u000d\u000a      with probable, major depression were prescribed the doses and duration of\u000d\u000a      antidepressants\u000d\u000a      recommended by guidelines [3.2].\u000d\u000a    Subsequent research led by Kendrick (694 patients, seven practices,\u000d\u000a      between 1999 and 2003)\u000d\u000a      showed that this poor targeting was due to inaccurate GP assessment. GPs\u000d\u000a      tried to follow\u000d\u000a      guidance to offer antidepressants to patients with more severe depression,\u000d\u000a      but their ratings of\u000d\u000a      severity were inaccurate when compared with the Hospital Anxiety and\u000d\u000a      Depression Scale validated\u000d\u000a      severity measure, and almost half of the patients offered antidepressants\u000d\u000a      did not have major\u000d\u000a      depression according to that measure [3.3].\u000d\u000a    Subsequently, NICE depression guidelines (2004) recommended symptom\u000d\u000a      questionnaires be\u000d\u000a      considered to aid assessment at diagnosis, and an indicator was introduced\u000d\u000a      into the GP contract\u000d\u000a      QOF (2006) to promote their use. Following this, Kendrick led further\u000d\u000a      research (2,294 patients, 38\u000d\u000a      practices in 2007-8) with Dowrick (Liverpool) and Howe (East Anglia),\u000d\u000a      which showed that decisions\u000d\u000a      to prescribe antidepressants, or refer for therapy, were significantly\u000d\u000a      associated with higher severity\u000d\u000a      scores on symptom questionnaires at diagnosis (p&lt;0.001) [3.4].\u000d\u000a    In 2007-8, Michael Moore (Reader, at Southampton since 2005) led an\u000d\u000a      analysis of the General\u000d\u000a      Practice Research Database (153,931 patients, 170 practices) showing that\u000d\u000a      more than half of\u000d\u000a      patients treated with antidepressants between 1993 and 2005 received\u000d\u000a      prescriptions for only one\u000d\u000a      or two months [3.5]. This contributed to the introduction of a\u000d\u000a      second indicator in the QOF (2009)\u000d\u000a      promoting follow-up questionnaire assessments 5-12 weeks after diagnosis.\u000d\u000a    Following the introduction of the follow-up indicator, Moore led further\u000d\u000a      research (604 patients, 13\u000d\u000a      practices, in 2010-11) showing that follow-up scores appeared to influence\u000d\u000a      decisions to change\u000d\u000a      treatment. After controlling for confounders, patients who showed an\u000d\u000a      inadequate response in\u000d\u000a      questionnaire score change at follow-up were nearly five times more likely\u000d\u000a      to experience a\u000d\u000a      subsequent change in treatment compared to those with an adequate response\u000d\u000a      (odds ratio 4.72,\u000d\u000a      95% confidence interval 2.83 to 7.86) [3.6].\u000d\u000a    "},{"CaseStudyId":"44466","Continent":[{"GeoNamesId":"6255146","Name":"Africa"},{"GeoNamesId":"6255148","Name":"Europe"},{"GeoNamesId":"6255149","Name":"North America"},{"GeoNamesId":"6255147","Name":"Asia"},{"GeoNamesId":"6255151","Name":"Oceania"}],"Country":[{"GeoNamesId":"1668284","Name":"Taiwan"},{"GeoNamesId":"2750405","Name":"Netherlands"},{"GeoNamesId":"6252001","Name":"United States"},{"GeoNamesId":"290291","Name":"Bahrain"},{"GeoNamesId":"146669","Name":"Cyprus"},{"GeoNamesId":"953987","Name":"South Africa"},{"GeoNamesId":"934292","Name":"Mauritius"},{"GeoNamesId":"2077456","Name":"Australia"},{"GeoNamesId":"290557","Name":"United Arab Emirates"},{"GeoNamesId":"2963597","Name":"Ireland"},{"GeoNamesId":"2635167","Name":"United Kingdom"},{"GeoNamesId":"660013","Name":"Finland"},{"GeoNamesId":"6251999","Name":"Canada"},{"GeoNamesId":"294640","Name":"Israel"}],"Funders":[],"ImpactDetails":"\u000a    The evidence we published in 1997-1999 was reported to the UK Department\u000a      of Health's Standing Committee on Tobacco and Health (SCOTH) and\u000a      contributed, with similar evidence from studies of adults, to the growing\u000a      prominence of environmental tobacco smoke (or secondhand smoke) in health\u000a      policy during the past decade. The Thorax reviews were cited (on\u000a      screen) as the principal source of evidence underlying the UK Department\u000a      of Health's \"smoking babies\" TV advertisement campaign in 2003 (evaluated\u000a      in reference [A]). Before this campaign, 48% of adults spontaneously\u000a      mentioned second-hand smoke as an environmental risk to children's health\u000a      and this increased to 54% after the advertisements were broadcast.\u000a    The US Surgeon-General's 2006 report [B] and particularly our chapter\u000a      within it (chapter 6, reference 5 above) has been influential in\u000a      development of public campaigns to reduce exposure of children to parental\u000a      smoking, particularly in the United States. The US Environmental\u000a      Protection Agency's initiative on smoke-free homes and cars [C] refers\u000a      specifically to the Surgeon-General's report as evidence of adverse health\u000a      effects [D] and has prepared a multilingual brochure, available in\u000a      hardcopy and online [E], explaining the effects of secondhand smoke on the\u000a      health of young families.\u000a    Since 2008, legislation to ban smoking in private vehicles when children\u000a      are passengers has been introduced in several states of the USA: Arkansas,\u000a      California, Hawaii, Louisiana, Maine, Maryland, Utah and most recently\u000a      (June 2013) in Oregon. Similar bans exist in Australia, Bahrain, Canada,\u000a      Cyprus, Mauritius, South Africa, and United Arab Emirates. Legislation is\u000a      under consideration in Finland, Ireland, Israel, the Netherlands and\u000a      Taiwan [F].\u000a    The UK has been slower to develop similar initiatives, but the Action on\u000a      Smoking and Health (ASH) policy briefing in 2009 [G] built upon our\u000a      1997-1999 publications. Following the publication of the Royal College of\u000a      Physicians (RCP) Report in 2010 [H] (which was based in part on our\u000a      updated review of health effects in younger children [reference 6 above]),\u000a      a revised ASH briefing paper cited both the Surgeon-General's and Royal\u000a      College of Physicians' reports as evidence on parental smoking and\u000a      ill-health among children [I], and a January 2012 ASH factsheet on smoking\u000a      in cars refers to both the SCOTH and RCP reports as evidence of risks to\u000a      children [J]. At the time of writing (July 2013), political pressure is\u000a      building within the UK, particularly in Scotland [K], for legislation to\u000a      outlaw smoking in cars when children are present.\u000a    Online NHS guidance [L] specifically refers to the adverse effects of\u000a      parental smoking on the health of young children and advises: \"One of\u000a        the best things you can do to protect other people and children is to\u000a        keep your home and car smoke-free by smoking outside, as smoke can\u000a        linger for up to two-and-a-half-hours.\"\u000a    Thus, our work has had demonstrable impact on the direction of public\u000a      policy and publicity campaigns, both in the UK and overseas. We also note,\u000a      with amusement, that in 2012 a new Canadian version of Clement C Moore's\u000a      classic poem Twas the Night Before Christmas was published with\u000a      two lines (referring to Santa Claus's pipe) removed in an attempt to limit\u000a      children's exposure to images of smoking [M]. This must be a rare example\u000a      of epidemiological research having a cultural impact on the fictional\u000a      literature, but we hesitate to suggest that there will be any resulting\u000a      health benefits, except, perhaps, north of the Arctic Circle..!\u000a    ","ImpactSummary":"\u000a    Systematic quantitative reviews of epidemiological evidence linking\u000a      parental smoking with adverse respiratory health effects in childhood were\u000a      published in 1997-1999 in Thorax. These meta-analyses were\u000a      updated as a contribution to the US Surgeon-General's report on Secondhand\u000a      Smoking, published in 2006, and the UK Royal College of Physicians' report\u000a      on Passive Smoking and Children, published in 2010.\u000a    Over this period the adverse health effects of environmental tobacco\u000a      smoke achieved prominence in public health policy, through campaigns for\u000a      smoke-free workplaces (including pubs and restaurants) and publicity\u000a      against parental smoking in the presence of children, both in cars and in\u000a      the home.\u000a    ","ImpactType":"Health","Institution":"\u000a    St George's, University of London\u000a    ","Institutions":[{"AlternativeName":"St George's Hospital Medical School","InstitutionName":"St George's, University of London","PeerGroup":"A","Region":"London","UKPRN":10007782}],"Panel":"A         ","PlaceName":[{"GeoNamesId":"5744337","Name":"Oregon"},{"GeoNamesId":"4099753","Name":"Arkansas"},{"GeoNamesId":"5549030","Name":"Utah"},{"GeoNamesId":"5855797","Name":"Hawaii"},{"GeoNamesId":"4361885","Name":"Maryland"},{"GeoNamesId":"5332921","Name":"California"},{"GeoNamesId":"4331987","Name":"Louisiana"}],"References":"\u000a    \u000a[1] Strachan DP, Cook DG. Parental smoking and lower respiratory illness\u000a      in infancy and early childhood. Thorax 1997;52:905-914. PMID:\u000a      9404380 DOI - 10.1136\/thx.52.10.905.\u000a    \u000a\u000a[2] Anderson HR, Cook DG. Passive smoking and sudden infant death\u000a      syndrome: review of the epidemiological evidence. Thorax\u000a      1997;52:1003-9. PMID: 9487351 No DOI available.\u000a    \u000a\u000a[3] Cook DG, Strachan DP. Parental smoking and prevalence of respiratory\u000a      symptoms and asthma in school age children. Thorax\u000a      1997;52:1081-1094. PMID: 951690 No DOI available\u000a    \u000a\u000a[4] Cook DG, Strachan DP. Summary of effects of parental smoking on the\u000a      respiratory health of children and implications for research. Thorax\u000a      1999;54:357-366. PMID: 10092699 No DOI available.\u000a    \u000a\u000a[5] U.S. Department of Health and Human Services. The Health\u000a        Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the\u000a        Surgeon General. Atlanta, GA: U.S. Department of Health and Human\u000a      Services, Centers for Disease Control and Prevention, Coordinating Center\u000a      for Health Promotion, National Center for Chronic Disease Prevention and\u000a      Health Promotion, Office on Smoking and Health, 2006. ISBN 0-16-076152-2.\u000a      (Chapter 6: pages 261-420. Cook DG, Strachan DP, Weiss ST, DeMeo D.\u000a      Respiratory Effects in Children from Exposure to Secondhand Smoke.\u000a      http:\/\/www.surgeongeneral.gov\/library\/secondhandsmoke\/report\/chapter6.pdf)\u000a    \u000a\u000a[6] Jones LL, Hashim A, McKeever T, Cook DG, Britton J, Leonardi-Bee J.\u000a      Parental and household smoking and the increased risk of bronchitis,\u000a      bronchiolitis and other lower respiratory infections in infancy:\u000a      systematic review and meta-analysis. Respir Res.2011;12:5. PMID:\u000a      21219618 DOI 10.1186\/1465-9921-12-5.\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000a    [A] DH evaluation of \"Smoking Kids\" TV campaigns 2003-2005:\u000a      http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@en\/@ps\/@freofinf\/@clainf\/documents\/digitalasset\/dh_073864.pdf [downloaded October\u000a      2011]\u000a    [B] U.S. Department of Health and Human Services. The Health\u000a        Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the\u000a        Surgeon General. Atlanta, GA: U.S. Department of Health and Human\u000a      Services, Centers for Disease Control and Prevention, Coordinating Center\u000a      for Health Promotion, National Center for Chronic Disease Prevention and\u000a      Health Promotion, Office on Smoking and Health, 2006. ISBN 0-16-076152-2.\u000a      http:\/\/www.surgeongeneral.gov\/library\/secondhandsmoke\/report\/\u000a    [C] http:\/\/www.epa.gov\/smokefree\/\u000a      [accessed and screen-dumped to PDF October 2011]\u000a    [D] http:\/\/www.epa.gov\/smokefree\/healtheffects.html\u000a      [screen-dumped to PDF October 2011]\u000a    [E] U.S. Environmental Protection Agency. Secondhand Tobacco Smoke\u000a        and the Health of Your Family. EPA 402\/F\/09\/004. U.S.E.P.A,\u000a      September 2009.\u000a      http:\/\/www.epa.gov\/smokefree\/pdfs\/trifold_brochure.pdf [downloaded\u000a      October 2011]\u000a    [F] http:\/\/en.wikipedia.org\/wiki\/Smoking_bans_in_private_vehicles\u000a      [accessed 12 July 2013].\u000a    [G] UK campaigns for smoke-free cars and homes: ASH briefing, August 2009\u000a      www.smokefreenorthwest.org\/pdf\/Smoking_in_Cars.pdf\u000a      [downloaded October 2011]\u000a    [H] Royal College of Physicians. Passive smoking and children: A report\u000a      of the Tobacco Advisory Group of the Royal College of Physicians. London:\u000a      RCP, 2010. 200 pages. ISBN: 9781860163753.\u000a    [I] ASH research report. Secondhand smoke: the impact on children,\u000a      June 2011. www.ash.org.uk\/files\/documents\/ASH_596.pdf [downloaded October 2011]\u000a    [J] ASH factsheet. Smoking in cars, January 2012. www.ash.org.uk\/files\/documents\/ASH_714.pdf\u000a      [downloaded 12 July 2013]\u000a    [K] BBC News 28 May 2013. MSP wants ban on smoking in cars carrying\u000a        children.\u000a\u0009\u0009http:\/\/www.bbc.co.uk\/news\/uk-scotland-scotland-politics-22684036\u000a      [accessed and screen-dumped to PDF 12 July 2013]\u000a    [L] NHS Smokefree website (tab for non-smokers and children), 2011\u000a\u0009http:\/\/smokefree.nhs.uk\/why-quit\/non-smokers-and-children\/ [screen-dumped October 2011]\u000a    [M] The Guardian, 24 October 2012. Santa's pipe put out in new\u000a        edition of children's classic. http:\/\/www.guardian.co.uk\/books\/2012\/oct\/24\/santa-pipe-new-night-before-christmas [accessed and screen-dumped October 2012 - still available online 12 July 2013]\u000a    ","Title":"\u000a    Effects of parental smoking on respiratory health among children\u000a    ","UKLocation":[],"UKRegion":[{"GeoNamesId":"2638360","Name":"Scotland"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000a    Systematic quantitative reviews of the epidemiological evidence linking\u000a      parental smoking with adverse respiratory health effects in infancy and\u000a      childhood were carried out in the late 1990s under commission from the UK\u000a      Department of Health, and published as a series of 9 peer-reviewed papers\u000a      in Thorax during 1997-1999 (see references [1-3] for examples).\u000a    At this time, Cook was senior lecturer in epidemiology, later promoted to\u000a      professor. Anderson and Strachan were professors of epidemiology\u000a      throughout. All three have been in continuous employment at St George's\u000a      since 1993.\u000a    Although there had been a number of previous narrative reviews, our\u000a      papers were the first attempt at a quantitative meta-analysis of this\u000a      rapidly expanding evidence base. For this work, Cook and Strachan were\u000a      jointly awarded the 1999 European Respiratory Society \/ Astra Zeneca Prize\u000a      for Paediatric Respiratory Research in Europe.\u000a    The findings were summarised in a final review of the Thorax\u000a      series [4]. This described a consistent pattern for respiratory illnesses\u000a      and symptoms and middle ear disease with odds ratios of between 1.2 and\u000a      1.6 for either parent smoking, the risks usually being higher in\u000a      pre-school than in school aged children. For sudden infant death syndrome\u000a      the odds ratio for maternal smoking was higher at about 2.0. The results\u000a      appeared robust to adjustment for a range of potential confounding\u000a      variables. Significant adverse effects from paternal smoking even in\u000a      countries where few mothers smoked suggested a causal role for postnatal\u000a      exposure to environmental tobacco smoke, independent of any prenatal\u000a      effects of maternal smoking in pregnancy.\u000a    These meta-analyses were updated as a contribution to the US\u000a      Surgeon-General's report on Secondhand Smoking, published in 2006 [5], and\u000a      updated again in 2010 [6], as preparation for the UK Royal College of\u000a      Physicians' report on Passive Smoking and Children. The latest review [6],\u000a      focussing on respiratory illness in infancy, included 60 studies: twice as\u000a      many as had been considered in the original 1997 review of these outcomes\u000a      [1]. Despite this expanded evidence base, the conclusions of the original\u000a      reviews were sustained.\u000a    The original review series concluded [4] that \"substantial benefits\u000a        to children would arise if parents stopped smoking after birth, even if\u000a        the mother smoked during pregnancy. Policies need to be developed which\u000a        reduce smoking amongst parents and protect infants and young children\u000a        from exposure to environmental tobacco smoke.\"\u000a    This was endorsed 12 years later [6]: \"Passive smoking in the family\u000a        home is a major influence on the risk of lower respiratory\u000a        illness in infants, and ... is particularly strong in relation to\u000a        post-natal maternal smoking. Strategies to prevent passive smoke\u000a        exposure in young children are an urgent public and child health\u000a        priority.\"\u000a    Over the intervening period, the adverse health effects of environmental\u000a      tobacco smoke achieved prominence in public health policy, through the\u000a      successful campaigns for smoke-free workplaces (including pubs and\u000a      restaurants) in many countries. Currently, the evidence that we assembled\u000a      in relation to risks to young children is being used to argue the case\u000a      against parental smoking in the presence of children, both in cars and in\u000a      the home.\u000a    "},{"CaseStudyId":"44467","Continent":[],"Country":[],"Funders":[],"ImpactDetails":"\u000d\u000a    The European Union (EU) has designated 2013 to be the \"Year of Air\"\u000d\u000a      during which a comprehensive review of the air quality policies has been\u000d\u000a      undertaken. To inform this review, the REVIHAAP (Review of Evidence on\u000d\u000a      Health Aspects of Air Pollution) project was co-funded by the EU DG\u000d\u000a      ENVIRONMENT and WHO Regional Office for Europe, to answer 24\u000d\u000a      policy-related questions about air pollution and health. Included in this\u000d\u000a      review was consideration of whether new evidence was sufficient to revise\u000d\u000a      the WHO 2005 Air Quality Guidelines, published in 2006 [A]. Anderson was a\u000d\u000a      member of the REVIHAAP Scientific Advisory Committee and Atkinson was an\u000d\u000a      expert advisor and contributor to the report, especially sections on\u000d\u000a      ozone.\u000d\u000a    The following sections of the REVIHAAP July 2013 report [B] refer to the\u000d\u000a      Air Pollution Epidemiology Database (APED) which is a systematic review\u000d\u000a      facility established at St George's to provide continuously updated\u000d\u000a      meta-analyses of time-series evidence, as described in document REF3a.\u000d\u000a      APED incorporated the results of the underpinning time-series studies into\u000d\u000a      a cumulative meta-analysis, commissioned specifically for the REVIHAAP\u000d\u000a      report:\u000d\u000a    \u000d\u000a      Pages 52-55 &amp; table 2: Use of ozone coefficients from APED,\u000d\u000a        including APHENA [4]\u000d\u000a      Pages 74-76 &amp; table 5: Use of NO2 coefficients from APED\u000d\u000a      Pages 145-149 &amp; table 11: Use of SO2 coefficients from APED\u000d\u000a      Pages 217-218: References (APED cited as Anderson HR et al.\u000d\u000a        2007, but see REF3a.)\u000d\u000a    \u000d\u000a    Linked with REVIHAAP, and extending from it, the HRAPIE (Health Risks of\u000d\u000a      Air Pollution in Europe) review [C] recommends concentration-response\u000d\u000a      functions for cost-benefit analysis to guide future policies for air\u000d\u000a      pollutant control. Anderson is a member of the Scientific Advisory\u000d\u000a      Committee and Atkinson is an advisor and contributor of evidence to\u000d\u000a      HRAPIE. Coefficients from time-series studies provide the key evidence\u000d\u000a      base for estimating response functions and cost-benefit analyses for all\u000d\u000a      gaseous pollutants.\u000d\u000a    Also, the observation that time-series analyses show similar effects of\u000d\u000a      short-term fluctuations in PM on health outcomes worldwide [D] buttresses\u000d\u000a      the argument that there is a causal association between respirable\u000d\u000a      particulate exposures and diverse health outcomes, including\u000d\u000a      non-respiratory mortality. This conclusion, linking time-series work with\u000d\u000a      chronic effects of PM, was also reached by the UK Department of Health\u000d\u000a      COMEAP in 2010 [E].\u000d\u000a    Results from time-series studies also underpin the 2011 COMEAP subgroup\u000d\u000a      report on UK Air Quality Standards, on which Anderson was a committee\u000d\u000a      member [F]. This used APED to update the WHO 2005 Air Quality Guidelines\u000d\u000a      [A] from which was developed a Daily Air Quality Index (DAQI) with\u000d\u000a      bandings indicating likely short-term health effects. The DAQI is now\u000d\u000a      implemented as a public information system online [G] and during periods\u000d\u000a      of high air pollutant levels, health warnings are incorporated into\u000d\u000a      national weather forecasts for the UK.\u000d\u000a    Time-series methods have been extended to studies of the effects of heat\u000d\u000a      waves and climate change. Although sulphate is a cooling agent, black\u000d\u000a      carbon and ozone could together exert nearly half as much global warming\u000d\u000a      as carbon dioxide. The complexity of these health and climate effects of\u000d\u000a      shorter-lived greenhouse pollutants needs to be recognised in mitigation\u000d\u000a      policies. Links between strategies to reduce greenhouse gases and public\u000d\u000a      health outcomes were reviewed in 2009 by a consortium in which Anderson\u000d\u000a      and Atkinson were involved [H].\u000d\u000a    Assessment of the relative importance of 67 risk factors, worldwide and\u000d\u000a      by region, formed part of the Global Burden of Disease 2010 project (GBD).\u000d\u000a      Anderson co-chaired the GBD subgroup assessing health effects of outdoor\u000d\u000a      air pollution, which evaluated both ambient particulate pollution and\u000d\u000a      ambient ozone [I]. An analysis of burden of disease due to air pollution\u000d\u000a      in the UK found that this had fallen by over 50% between 1990 and 2010,\u000d\u000a      reflecting mainly improvements in air quality over this time resulting\u000d\u000a      from effective environmental policies [J].\u000d\u000a    ","ImpactSummary":"\u000d\u000a    A sustained programme of epidemiological research at St George's,\u000d\u000a      spanning 20 years, has informed air pollution control policies in the UK\u000d\u000a      and internationally. Time-series studies of the acute health effects of\u000d\u000a      daily fluctuations in air pollutants, initially in London, were extended\u000d\u000a      to Europe-wide collaborations, trans-Atlantic comparisons and studies in\u000d\u000a      Asian cities. Publication bias has been explored systematically in\u000d\u000a      meta-analyses of published time-series results, and the adverse effects of\u000d\u000a      different particulate fractions compared in a UK setting. This evidence\u000d\u000a      base has contributed substantially to the current UK Air Quality Strategy\u000d\u000a      and informs ongoing debates about health impacts of shorter-lived\u000d\u000a      \"greenhouse\" pollutants.\u000d\u000a    ","ImpactType":"Environmental","Institution":"\u000d\u000a    St George's, University of London\u000d\u000a    ","Institutions":[{"AlternativeName":"St George's Hospital Medical School","InstitutionName":"St George's, University of London","PeerGroup":"A","Region":"London","UKPRN":10007782}],"Panel":"A         ","PlaceName":[],"References":"\u000d\u000a    \u000a[1] Anderson HR, Ponce de Leon A, Bland JM, Bower JS, Strachan DP. Air\u000d\u000a      pollution and daily mortality in London: 1987-92. Br Med J\u000d\u000a      1996;312:665-9. PMID:8597732. doi:\u000d\u000a        http:\/\/dx.doi.org\/10.1136\/bmj.312.7032.665\u000d\u000a    \u000a\u000a[2] Katsouyanni K, Touloumi G, Spix C, Schwartz J, Balducci F, Medina S,\u000d\u000a      Rossi G, Wojtyniak B, Sunyer J, Bacharova L, Schouten JP, Ponka A,\u000d\u000a      Anderson HR. Short-term effects of ambient sulphur dioxide and particulate\u000d\u000a      matter on mortality in 12 European cities: results from time series data\u000d\u000a      from the APHEA project. Air Pollution and Health: a European Approach. Br\u000a        Med J 1997;314:1658-63. PMID:9180068. doi: http:\/\/dx.doi.org\/10.1136\/bmj.314.7095.1658\u000d\u000a    \u000a\u000a[3] Atkinson RW, Anderson HR, Sunyer J, Ayres J, Baccini M, Vonk JM,\u000d\u000a      Boumghar A, Forastiere F, Forsberg B, Touloumi G, Schwartz J, Katsouyanni\u000d\u000a      K. Acute effects of particulate air pollution on respiratory admissions:\u000d\u000a      results from APHEA 2 project. Air Pollution and Health: a European\u000d\u000a      Approach. Am J Respir Crit Care Med 2001;164:1860-6.\u000d\u000a      PMID:11734437. doi: 10.1164\/ajrccm.164.10.2010138\u000d\u000a    \u000a\u000a[4] Katsouyanni K, Samet JM, Anderson HR, Atkinson R, Le Tertre A, Medina\u000d\u000a      S, Samoli E, Touloumi G, Burnett RT, Krewski D, Ramsay T, Dominici F, Peng\u000d\u000a      RD, Schwartz J, Zanobetti A; HEI Health Review Committee. Air pollution\u000d\u000a      and health: a European and North American approach (APHENA). Res Rep\u000d\u000a        Health Eff Inst 2009;142:5-90. PMID: 20073322. No DOI available.\u000d\u000a    \u000a\u000a[5] Anderson HR, Atkinson RW, Peacock JL, Sweeting MJ, Marston L. Ambient\u000d\u000a      particulate matter and health effects: publication bias in studies of\u000d\u000a      short-term associations. Epidemiology 2005;16:155-63.\u000d\u000a      PMID:15703529. DOI: 10.1097\/01.ede.0000152528.22746.0f\u000d\u000a    \u000a\u000a[6] Atkinson RW, Fuller GW, Anderson HR, Harrison RM, Armstrong B. Urban\u000d\u000a      ambient particle metrics and health: a time-series analysis. Epidemiology\u000d\u000a      2010;21:501-11. PMID: 20502338. doi: 10.1097\/EDE.0b013e3181debc88\u000d\u000a    \u000a","ResearchSubjectAreas":[{"Level1":"11","Level2":"17","Subject":"Public Health and Health Services"}],"Sources":"\u000d\u000a    [A] WHO. Air Quality Guidelines, Global Update 2005. Particulate\u000d\u000a        Matter, Ozone, Nitrogen Dioxide and Sulfur Dioxide. World Health\u000d\u000a      Organization, Copenhagen, 2006. ISBN: 92-890-2192-6.\u000d\u000a    [B] REVIHAAP report (2013).\u000d\u000a      http:\/\/www.euro.who.int\/en\/what-we-do\/health-topics\/environment-and-health\/air-quality\/publications\/2013\/review-of-evidence-on-health-aspects-of-air-pollution-revihaap\u000d\u000a      [Downloaded to PDF 11 July 2013]\u000d\u000a    [C] HRAPIE report (2013). http:\/\/www.euro.who.int\/en\/health-topics\/environment-and-health\/air-quality\/publications\/2013\/health-risks-of-air-pollution-in-europe-hrapie-project.-new-emerging-risks-to-health-from-air-pollution-results-from-the-survey-of-experts\u000d\u000a      [Downloaded to PDF 15 November 2013]\u000d\u000a    [D] Atkinson RW, Cohen A, Mehta S, Anderson HR. Systematic review and\u000d\u000a      meta-analysis of epidemiological time-series studies on outdoor air\u000d\u000a      pollution and health in Asia. Air Quality Atmosphere and Health\u000d\u000a      2012;5:383-91. doi:10.1007\/s11869-010-0123-2.\u000d\u000a    [E] Committee on the Medical Effects of Air Pollutants. The Mortality\u000d\u000a        Effects of Long-Term Exposure to Particulate Air Pollution in the United\u000d\u000a        Kingdom. Health Protection Agency, 2010. ISBN 978-0-85951-685-3.\u000d\u000a    [F] Committee on the Medical Effects of Air Pollutants Standards Advisory\u000d\u000a      Subgroup. Review of the UK Air Quality Index. Health Protection\u000d\u000a      Agency, 2011. [PDF downloaded 11 July 2013]\u000d\u000a      http:\/\/www.comeap.org.uk\/images\/stories\/Documents\/Reports\/comeap%20review%20of%20the%20uk%20air%20quality%20index.pdf\u000d\u000a    [G] http:\/\/uk-air.defra.gov.uk\/air-pollution\/daqi\u000d\u000a      [Downloaded to PDF 11 July 2013]\u000d\u000a    [H] Smith KR, Jerrett M, Anderson HR, Burnett RT, Stone V, Derwent R,\u000d\u000a      Atkinson RW, Cohen A, Shonkoff SB, Krewski D, Pope CA 3rd, Thun MJ,\u000d\u000a      Thurston G. Public health benefits of strategies to reduce greenhouse-gas\u000d\u000a      emissions: health implications of short-lived greenhouse pollutants. Lancet\u000d\u000a      2009;374:2091-103. PMID: 19942276.\u000d\u000a    [I] Lim SS, Vos T, Flaxman AD, ... Anderson HR, ... Lopez AD, Murray CJ,\u000d\u000a      Ezzati M. A comparative risk assessment of burden of disease and injury\u000d\u000a      attributable to 67 risk factors and risk factor clusters in 21 regions,\u000d\u000a      1990-2010: a systematic analysis for the Global Burden of Disease Study\u000d\u000a      2010. Lancet 2012;380:2224-60. PMID: 23245609.\u000d\u000a    [J] Murray CJ, Richards MA, Newton JN, Fenton KA, Anderson HR, Atkinson C\u000d\u000a      et al. UK health performance: findings of the Global Burden of\u000d\u000a      Disease Study 2010. Lancet 2013;381:997-1020 PMID: 23668584.\u000d\u000a    ","Title":"\u000d\u000a    Effects of outdoor air pollutants on human health\u000d\u000a    ","UKLocation":[{"GeoNamesId":"2643743","Name":"London"}],"UKRegion":[{"GeoNamesId":"6269131","Name":"England"}],"UOA":"Public Health, Health Services and Primary Care","UnderpinningResearch":"\u000d\u000a    In the early 1990s, the UK Department of Health convened an expert panel\u000d\u000a      which developed into the Committee on the Medical Effects of Air Pollution\u000d\u000a      (COMEAP). Three epidemiologists from St George's (Anderson, Atkinson and\u000d\u000a      Strachan) have served at length on COMEAP and associated committees over\u000d\u000a      the past two decades, a period which has seen outdoor air pollution\u000d\u000a      re-emerge as a public health concern.\u000d\u000a    All three have been in continuous employment at St George's since 1993.\u000d\u000a      Anderson has been professor of epidemiology and public health throughout.\u000d\u000a      Atkinson was initially a research fellow working with Anderson and was\u000d\u000a      promoted to senior lecturer in epidemiology in 2009. Strachan was\u000d\u000a      initially senior lecturer in epidemiology and was promoted to professor in\u000d\u000a      1997.\u000d\u000a    An early stimulus to this renewed interest in air pollution was the\u000d\u000a      observation that daily fluctuations in ambient levels of several\u000d\u000a      pollutants were associated with short-term variations in both fatal and\u000d\u000a      non-fatal health events at concentrations well below air quality standards\u000d\u000a      of the time. Our studies of daily mortality in London during 1987-1992 [1]\u000d\u000a      showed that ozone levels were associated with a significant increase in\u000d\u000a      all cause mortality on the same day; black smoke concentrations on the\u000d\u000a      previous day were significantly associated with all cause mortality; and\u000d\u000a      significant but smaller adverse effects were observed for fluctuations in\u000d\u000a      nitrogen dioxide and sulphur dioxide.\u000d\u000a    Embellishment of this approach and its extension to 12 European cities as\u000d\u000a      part of the APHEA collaboration confirmed that, even at historically low\u000d\u000a      ambient levels, airborne particles had detectable short term effects on\u000d\u000a      mortality [2] and respiratory hospital admissions [3]. The consistency of\u000d\u000a      the results across cities with wide differences in climate and\u000d\u000a      environmental conditions suggested that these associations may be causal.\u000d\u000a      As published evidence accumulated to support short-term associations\u000d\u000a      between air pollution levels and adverse health effects, three\u000d\u000a      methodological issues required investigation:\u000d\u000a    Firstly, whether developments of the time-series methodology through the\u000d\u000a      1990s could explain differences in the results obtained from various\u000d\u000a      studies. This was addressed by the APHENA project which re-analysed, using\u000d\u000a      a standardized methodology, the largest time-series studies of mortality\u000d\u000a      from Europe and North America [4]. The findings obtained with the new\u000d\u000a      standardized analysis were generally comparable to those obtained in the\u000d\u000a      earlier studies, and were relatively robust to the data analysis method\u000d\u000a      used. This led to greater confidence in their relevance to public policy\u000d\u000a      on both sides of the Atlantic.\u000d\u000a    A second issue was whether selective publication and citation of\u000d\u000a      \"positive\" results, or undue focus on the most statistically significant\u000d\u000a      lag period between pollution measurement and health outcome, could have\u000d\u000a      overstated the epidemiological evidence. Our review of time series\u000d\u000a      analyses published up to 2002 [5] concluded that publication bias is\u000d\u000a      present in single-city time-series studies of ambient particles, and that\u000d\u000a      differential selection of positive lags may also inflate estimates.\u000d\u000a      However, short-term associations between particles and adverse health\u000d\u000a      effects remained positive and significant after correcting statistically\u000d\u000a      for publication bias.\u000d\u000a    A third issue of policy relevance was which components of the particulate\u000d\u000a      mixture (size, number, source, toxicity) are most relevant to health. We\u000d\u000a      investigated associations of a range of particle metrics with daily deaths\u000d\u000a      and hospital admissions in London [6]. This is one of few studies to\u000d\u000a      investigate particle numbers, rather than mass concentration, and found\u000d\u000a      that particle numbers were associated with daily mortality and admissions,\u000d\u000a      particularly for cardiovascular diseases whereas fluctuations in secondary\u000d\u000a      particles (nitrate and sulphate) were more important for respiratory\u000d\u000a      outcomes.\u000d\u000a    "}]